Date,Article_title,Stock_symbol,Url,Publisher,Author,Article,Lsa_summary,Summarized,Sentiment_score,UUID
2023-12-17T04:00:00.000+08:00,Eli Lilly (LLY) Rises Yet Lags Behind Market: Some Facts Worth Knowing,LLY,https://www.nasdaq.com/articles/eli-lilly-lly-rises-yet-lags-behind-market%3A-some-facts-worth-knowing,,,"Eli Lilly (LLY) closed the most recent trading day at $572, moving +0.31% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 1.03%. Meanwhile, the Dow gained 0.87%, and the Nasdaq, a tech-heavy index, added 1.26%.",,0,0,629f61da-d2f3-4933-a5dc-3838b4100cd7
2023-12-16T20:00:00.000+08:00,Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry,LLY,https://www.nasdaq.com/articles/weighing-their-chances%3A-5-leading-healthcare-companies-fight-for-market-share-in-the-%24100,,,"The anti-obesity drug market could be worth $100 billion by 2030, according to analysts from Goldman Sachs. It's a mammoth market and one that looks to be heating up with a growing number of large healthcare companies showing interest in the space. Below, I'll look at some of the top names in the weight-loss market today, and others you may not have realized could be potential rivals in the future.",,0,0,72d93d69-9205-4f4a-8a8b-08f16f74bb5b
2023-12-16T19:00:00.000+08:00,3 Cancer-Focused Biotechs That Appear Promising Bets for 2024,LLY,https://www.nasdaq.com/articles/3-cancer-focused-biotechs-that-appear-promising-bets-for-2024,,,"Oncology treatments have been at the forefront this year, with biotech companies looking to capitalize on advancements in technology in this challenging but lucrative space. This has put the spotlight on companies with a solid portfolio of cancer treatments and/or a promising pipeline.",,0,0,37e26e65-5ae5-4755-9cb9-f62659be2581
2023-12-16T18:00:00.000+08:00,Guru Fundamental Report for LLY,LLY,https://www.nasdaq.com/articles/guru-fundamental-report-for-lly-78,,,"Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout yields.",,0,0,f75608ea-b808-4be9-80e0-5944f3d0ff13
2023-12-16T16:00:00.000+08:00,Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?,LLY,https://www.nasdaq.com/articles/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now-0,,,"The Invesco Pharmaceuticals ETF (PJP) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.",,0,0,fa8b3939-23f5-4864-b516-1497056336c2
2023-12-16T08:00:00.000+08:00,"SOFTS-Arabica, robusta coffee ease off peaks, raw sugar consolidates",LLY,https://www.nasdaq.com/articles/softs-arabica-robusta-coffee-ease-off-peaks-raw-sugar-consolidates,,,Updates prices,,0,0,dd9978f8-80f3-4e31-a1f8-217cd9113522
2023-12-16T08:00:00.000+08:00,2 Unstoppable Growth Stocks to Buy in 2024,LLY,https://www.nasdaq.com/articles/2-unstoppable-growth-stocks-to-buy-in-2024,,,"Growth stocks have done well this year, but heading into 2024, many of them could start to lose steam, especially amid rising valuations. Yet, some businesses still look poised for much more growth in the years ahead, and are likely to continue rising in value next year, regardless of their high prices tags.",,0,0,d7162927-37c2-4392-a64c-9966c2a177af
2020-06-11T09:40:14.000+08:00,Lilly's Chief Scientist Says Co's COVID-19 Treatment Could be Authorized for Use by September,LLY,https://www.benzinga.com/news/20/06/16229931/lillys-chief-scientist-says-cos-covid-19-treatment-could-be-authorized-for-use-by-september,Charles Gross,,,,0,0,e1f79566-cb04-4b05-a28b-91e2f6d2177c
2020-06-11T09:40:14.000+08:00,Lilly's Chief Scientist Says Co's COVID-19 Treatment Could be Authorized for Use by September,LLY,https://www.benzinga.com/news/20/06/16229931/lillys-chief-scientist-says-cos-covid-19-treatment-could-be-authorized-for-use-by-september,Charles Gross,,,,0,0,1e8727d6-838c-4609-b5e5-cae086084f63
2020-06-10T19:40:33.000+08:00,"Eli Lilly Shares Spike To Session High, Up 1.7%, Following Report Co. Chief Scientist Has Said One Of Co.'s Antibodies Could Be Authorized As Coronavirus Treatment As Early As Sept.",LLY,https://www.benzinga.com/news/20/06/16225883/eli-lilly-shares-spike-to-session-high-up-1-7-following-report-co-chief-scientist-has-said-one-of-co,Benzinga Newsdesk,,,,0,0,624c50ee-9359-483a-9fc6-a22153cecba4
2020-06-10T19:40:33.000+08:00,"Eli Lilly Shares Spike To Session High, Up 1.7%, Following Report Co. Chief Scientist Has Said One Of Co.'s Antibodies Could Be Authorized As Coronavirus Treatment As Early As Sept.",LLY,https://www.benzinga.com/news/20/06/16225883/eli-lilly-shares-spike-to-session-high-up-1-7-following-report-co-chief-scientist-has-said-one-of-co,Benzinga Newsdesk,,,,0,0,19a4f0e2-078f-4a3f-a0e9-298ab6d8b510
2020-06-09T13:49:09.000+08:00,Travel Stocks Lose Momentum In Pre-Market After Leading Yesterday's Sharp Rally,LLY,https://www.benzinga.com/news/20/06/16212137/travel-stocks-lose-momentum-in-pre-market-after-leading-yesterdays-sharp-rally,JJ Kinahan,,,,0,0,f83687bd-70fa-49c8-be54-999f4ab9497f
2020-06-09T13:49:09.000+08:00,Travel Stocks Lose Momentum In Pre-Market After Leading Yesterday's Sharp Rally,LLY,https://www.benzinga.com/news/20/06/16212137/travel-stocks-lose-momentum-in-pre-market-after-leading-yesterdays-sharp-rally,JJ Kinahan,,,,0,0,ca5db735-8a32-4876-8b38-193e236b9755
2020-06-09T10:47:38.000+08:00,First Patient Dose Delivered For Lilly's Tirzepatide Cardiovascular Outcomes Trial,LLY,https://www.benzinga.com/general/biotech/20/06/16209618/first-patient-dose-delivered-for-lillys-tirzepatide-cardiovascular-outcomes-trial,Benzinga Newsdesk,,,,0,0,7253f349-03fd-4162-ab35-fc674fbcd412
2020-06-09T10:47:38.000+08:00,First Patient Dose Delivered For Lilly's Tirzepatide Cardiovascular Outcomes Trial,LLY,https://www.benzinga.com/general/biotech/20/06/16209618/first-patient-dose-delivered-for-lillys-tirzepatide-cardiovascular-outcomes-trial,Benzinga Newsdesk,,,,0,0,95af3434-87fb-45bc-a790-56b50660d124
2020-06-08T11:18:03.000+08:00,"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment, Doses First Patient",LLY,https://www.benzinga.com/news/20/06/16199696/lilly-announces-start-of-a-phase-1-study-for-its-second-potential-covid-19-antibody-treatment-doses,Luke J Jacobi,,,,0,0,f8551b85-c84e-4b04-ac47-45498092340a
2020-06-08T11:18:03.000+08:00,"Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment, Doses First Patient",LLY,https://www.benzinga.com/news/20/06/16199696/lilly-announces-start-of-a-phase-1-study-for-its-second-potential-covid-19-antibody-treatment-doses,Luke J Jacobi,,,,0,0,5c197486-a380-4b7c-af56-7202e45e7c30
2020-06-05T16:36:32.000+08:00,"Fauci: Need To 'Definitively Show' Treatments Are Effective, On Eli Lilly's Recent Human Trials",LLY,https://www.benzinga.com/news/20/06/16191947/fauci-need-to-definitively-show-treatments-are-effective-on-eli-lillys-recent-human-trials,Benzinga Newsdesk,,,,0,0,d7ac087f-03cd-4a82-8924-e524f4c6fa80
2020-06-05T16:36:32.000+08:00,"Fauci: Need To 'Definitively Show' Treatments Are Effective, On Eli Lilly's Recent Human Trials",LLY,https://www.benzinga.com/news/20/06/16191947/fauci-need-to-definitively-show-treatments-are-effective-on-eli-lillys-recent-human-trials,Benzinga Newsdesk,,,,0,0,0b7d4d5e-91db-4136-88d1-75ec84a6ddd1
2020-06-03T11:39:19.000+08:00,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",LLY,https://www.benzinga.com/general/biotech/20/06/16167710/the-daily-biotech-pulse-regulatory-delay-for-novartis-multiple-sclerosis-drug-fsd-gets-nod-for-co,Shanthi Rexaline,,,,0,0,48937aec-f65e-4f2c-b59f-faf969d61afd
2020-06-03T11:39:19.000+08:00,"The Daily Biotech Pulse: Regulatory Delay For Novartis' Multiple Sclerosis Drug, FSD Gets Nod For COVID-19 Study",LLY,https://www.benzinga.com/general/biotech/20/06/16167710/the-daily-biotech-pulse-regulatory-delay-for-novartis-multiple-sclerosis-drug-fsd-gets-nod-for-co,Shanthi Rexaline,,,,0,0,dbae739f-badd-4a11-a8ea-bb4139ef93d9
2020-06-03T08:00:00.000+08:00,EULAR —…—…: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent ...,LLY,http://www.gurufocus.com/news/1154415/eular-2020-lillys-taltz-ixekizumab-continues-to-show-robust-and-consistent-efficacy-in-psoriatic-arthritis,GuruFocus,,,,0,0,aea9ea99-8e37-4a24-ab59-80df9f26e6b1
2020-06-03T08:00:00.000+08:00,EULAR —…—…: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent ...,LLY,http://www.gurufocus.com/news/1154415/eular-2020-lillys-taltz-ixekizumab-continues-to-show-robust-and-consistent-efficacy-in-psoriatic-arthritis,GuruFocus,,,,0,0,8187f386-0e1c-40de-8d62-fddb1210d69a
2020-06-02T08:00:00.000+08:00,"AstraZeneca Ranked Most Inventive, Roche Most Innovative",LLY,http://www.gurufocus.com/news/1153150/astrazeneca-ranked-most-inventive-roche-most-innovative,GuruFocus,,,,0,0,b9185c8e-cb48-45e9-8849-9d1489ebf128
2020-06-02T08:00:00.000+08:00,"AstraZeneca Ranked Most Inventive, Roche Most Innovative",LLY,http://www.gurufocus.com/news/1153150/astrazeneca-ranked-most-inventive-roche-most-innovative,GuruFocus,,,,0,0,bf09f9b2-a50e-4060-b2d7-7e0b102479cb
2020-06-01T19:40:17.000+08:00,Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy',LLY,https://www.benzinga.com/general/biotech/20/06/16151876/eli-lilly-ceo-talks-coronavirus-treatment-progress-this-is-an-important-bridge-therapy,Jayson Derrick,,,,0,0,f5b86921-3ca0-46f0-8246-35c4eaeb5267
2020-06-01T19:40:17.000+08:00,Eli Lilly CEO Talks Coronavirus Treatment Progress: 'This Is An Important Bridge Therapy',LLY,https://www.benzinga.com/general/biotech/20/06/16151876/eli-lilly-ceo-talks-coronavirus-treatment-progress-this-is-an-important-bridge-therapy,Jayson Derrick,,,,0,0,5b75b628-7cbc-4928-b166-b97630c8d9e1
2020-06-01T10:49:07.000+08:00,Eli Lilly's Supplemental Biologics License Application for Taltz for the Treatment of Active Non-Radiographic Axial Spondyloarthritis Approved by the FDA,LLY,https://www.benzinga.com/news/20/06/16147522/eli-lillys-supplemental-biologics-license-application-for-taltz-for-the-treatment-of-active-non-radi,Luke J Jacobi,,,,0,0,1d048a1e-b0ca-4b42-9ea3-924a78a5a6a0
2020-06-01T10:49:07.000+08:00,Eli Lilly's Supplemental Biologics License Application for Taltz for the Treatment of Active Non-Radiographic Axial Spondyloarthritis Approved by the FDA,LLY,https://www.benzinga.com/news/20/06/16147522/eli-lillys-supplemental-biologics-license-application-for-taltz-for-the-treatment-of-active-non-radi,Luke J Jacobi,,,,0,0,07e7ea0b-62b2-4f43-a87d-59f797920cbd
2020-06-01T10:31:40.000+08:00,Eli Lilly Doses Patients in its Phase 1 Coronavirus Antibody Treatment,LLY,https://www.benzinga.com/news/20/06/16147397/eli-lilly-doses-patients-in-its-phase-1-coronavirus-antibody-treatment,Luke J Jacobi,,,,0,0,461cb1ca-f997-4854-8fd3-f4edb9b7b3d8
2020-06-01T10:31:40.000+08:00,Eli Lilly Doses Patients in its Phase 1 Coronavirus Antibody Treatment,LLY,https://www.benzinga.com/news/20/06/16147397/eli-lilly-doses-patients-in-its-phase-1-coronavirus-antibody-treatment,Luke J Jacobi,,,,0,0,b0ae92ee-624e-4c7d-8cd0-3596363e690e
2020-06-01T08:00:00.000+08:00,Lilly Begins World's First Study of a Potential COVID-–9 Antibody Treatment in Humans,LLY,http://www.gurufocus.com/news/1152544/lilly-begins-worlds-first-study-of-a-potential-covid19-antibody-treatment-in-humans,GuruFocus,,,,0,0,14accc72-81ac-4f98-a0ef-cca08a328248
2020-06-01T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) is the First IL-–7A Antagonist to Receive U.S. ...,LLY,http://www.gurufocus.com/news/1152576/lillys-taltz-ixekizumab-is-the-first-il17a-antagonist-to-receive-us-fda-approval-for-the-treatment-of-nonradiographic-axial-spondyloarthritis-nraxspa,GuruFocus,,,,0,0,42426eb0-911f-4361-9027-44006978ce41
2020-06-01T08:00:00.000+08:00,Lilly Begins World's First Study of a Potential COVID-–9 Antibody Treatment in Humans,LLY,http://www.gurufocus.com/news/1152544/lilly-begins-worlds-first-study-of-a-potential-covid19-antibody-treatment-in-humans,GuruFocus,,,,0,0,723d57d6-11f9-407f-b66a-46a62e48c95e
2020-06-01T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) is the First IL-–7A Antagonist to Receive U.S. ...,LLY,http://www.gurufocus.com/news/1152576/lillys-taltz-ixekizumab-is-the-first-il17a-antagonist-to-receive-us-fda-approval-for-the-treatment-of-nonradiographic-axial-spondyloarthritis-nraxspa,GuruFocus,,,,0,0,bb89723a-4615-49c9-ab51-a5d348895bb9
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma at ASCO,LLY,https://www.benzinga.com/news/20/05/16146249/innovent-biologics-and-lilly-jointly-announced-the-long-term-follow-up-results-of-tyvyt-sintilimab-i,Charles Gross,,,,0,0,69f8b20d-4f2d-4b59-b9db-aed43834917f
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® ...,LLY,http://www.gurufocus.com/news/1152283/innovent-biologics-and-lilly-jointly-announced-the-longterm-followup-results-of-tyvyt-sintilimab-injection-in-the-treatment-of-patients-with-relapsedrefractory-classic-hodgkins-lymphoma,GuruFocus,,,,0,0,a5c9ab2e-f7e8-434f-8930-4460bf55527f
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® ...,LLY,http://www.gurufocus.com/news/1152284/innovent-biologics-and-lilly-jointly-announced-the-pivotal-clinical-study-results-of-tyvyt-sintilimab-injection-in-the-secondline-treatment-of-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carc,GuruFocus,,,,0,0,385dca6e-dea0-458c-9896-b56ac6c3de78
2020-05-31T08:00:00.000+08:00,Bristol-Myers Deserves Better Than a Single-Digit Multiple,LLY,http://www.gurufocus.com/news/1151961/bristolmyers-deserves-better-than-a-singledigit-multiple,GuruFocus,,,,0,0,2ea05178-90f0-49d7-9f6d-54c816803749
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma at ASCO,LLY,https://www.benzinga.com/news/20/05/16146249/innovent-biologics-and-lilly-jointly-announced-the-long-term-follow-up-results-of-tyvyt-sintilimab-i,Charles Gross,,,,0,0,59c837a7-1a0d-4ba1-8ebd-8c7281e2e6d4
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® ...,LLY,http://www.gurufocus.com/news/1152283/innovent-biologics-and-lilly-jointly-announced-the-longterm-followup-results-of-tyvyt-sintilimab-injection-in-the-treatment-of-patients-with-relapsedrefractory-classic-hodgkins-lymphoma,GuruFocus,,,,0,0,8e96b082-0931-430a-88e6-2e41915320b7
2020-05-31T08:00:00.000+08:00,Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® ...,LLY,http://www.gurufocus.com/news/1152284/innovent-biologics-and-lilly-jointly-announced-the-pivotal-clinical-study-results-of-tyvyt-sintilimab-injection-in-the-secondline-treatment-of-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carc,GuruFocus,,,,0,0,249813de-1e59-4753-9052-f7d37e860e80
2020-05-31T08:00:00.000+08:00,Bristol-Myers Deserves Better Than a Single-Digit Multiple,LLY,http://www.gurufocus.com/news/1151961/bristolmyers-deserves-better-than-a-singledigit-multiple,GuruFocus,,,,0,0,d00c4ddc-513d-4ff3-8023-db8ff8ab436e
2020-05-29T08:00:00.000+08:00,Lilly Yesterday Received U.S. FDA Approval of TAUVID for Use in Patients Being Evaluated for Alzheimer's Disease,LLY,https://www.benzinga.com/general/biotech/20/05/16138311/lilly-yesterday-received-u-s-fda-approval-of-tauvid-for-use-in-patients-being-evaluated-for-alzhe,Benzinga Newsdesk,,,,0,0,41aa8ba4-b91c-4bf0-a0bc-6552b7c68d54
2020-05-29T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic ...,LLY,http://www.gurufocus.com/news/1151826/lillys-cyramza-ramucirumab-receives-fda-approval-as-firstline-treatment-for-metastatic-egfrmutated-nonsmall-cell-lung-cancer,GuruFocus,,,,0,0,1255d6fb-ef38-4d8d-b691-397b50de6b2c
2020-05-29T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN",LLY,http://www.zacks.com/stock/news/951712/pharma-stock-roundup-mrk-rhhby-give-coronavirus-updatessny-to-sell-stake-in-regn?cid=CS-BENZ-FT-analyst_blog|stock_roundup-951712,Zacks,,,,0,0,9d3acd53-6e02-404e-8d37-87329bc97467
2020-05-29T08:00:00.000+08:00,Lilly Yesterday Received U.S. FDA Approval of TAUVID for Use in Patients Being Evaluated for Alzheimer's Disease,LLY,https://www.benzinga.com/general/biotech/20/05/16138311/lilly-yesterday-received-u-s-fda-approval-of-tauvid-for-use-in-patients-being-evaluated-for-alzhe,Benzinga Newsdesk,,,,0,0,b889f2e6-3575-41a3-8282-1799e9ac0b86
2020-05-29T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic ...,LLY,http://www.gurufocus.com/news/1151826/lillys-cyramza-ramucirumab-receives-fda-approval-as-firstline-treatment-for-metastatic-egfrmutated-nonsmall-cell-lung-cancer,GuruFocus,,,,0,0,cd8f3d9f-9216-431b-aef0-c510860f7984
2020-05-29T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN",LLY,http://www.zacks.com/stock/news/951712/pharma-stock-roundup-mrk-rhhby-give-coronavirus-updatessny-to-sell-stake-in-regn?cid=CS-BENZ-FT-analyst_blog|stock_roundup-951712,Zacks,,,,0,0,16731e53-a3d6-4ef9-90ce-a7981311eead
2020-05-28T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",LLY,https://www.benzinga.com/wiim/20/05/16129874/shares-of-several-healthcare-companies-are-trading-higher-amid-market-strength-strength-potentially,Benzinga Newsdesk,,,,0,0,9a3d116f-b018-4d35-8714-9f30cf6f3106
2020-05-28T08:00:00.000+08:00,Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F –8 injection) for Use in ...,LLY,http://www.gurufocus.com/news/1150170/lilly-receives-us-fda-approval-of-tauvid-flortaucipir-f-18-injection-for-use-in-patients-being-evaluated-for-alzheimers-disease,GuruFocus,,,,0,0,d4c2606a-cc41-47b0-b964-6be70b5fe873
2020-05-28T08:00:00.000+08:00,Thursday Morning Market Highlights,LLY,http://www.gurufocus.com/news/1149518/thursday-morning-market-highlights,GuruFocus,,,,0,0,b059af77-d6a8-4ad6-864c-8e163582b673
2020-05-28T08:00:00.000+08:00,"3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020",LLY,http://www.zacks.com/stock/news/949284/3-investing-facts-about-required-minimum-distributions-you-need-to-know-may-28-2020?cid=CS-BENZ-FT-retirement_ideas|required_minimum_distribution-949284,Zacks,,,,0,0,c301274b-7e0c-405e-ad26-01546fc747fe
2020-05-28T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.",LLY,https://www.benzinga.com/wiim/20/05/16129874/shares-of-several-healthcare-companies-are-trading-higher-amid-market-strength-strength-potentially,Benzinga Newsdesk,,,,0,0,4196cc66-3e1c-4593-98bf-9ebc2f86396f
2020-05-28T08:00:00.000+08:00,Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F –8 injection) for Use in ...,LLY,http://www.gurufocus.com/news/1150170/lilly-receives-us-fda-approval-of-tauvid-flortaucipir-f-18-injection-for-use-in-patients-being-evaluated-for-alzheimers-disease,GuruFocus,,,,0,0,11d1be7b-097b-4083-be1e-bcd9b6735b97
2020-05-28T08:00:00.000+08:00,Thursday Morning Market Highlights,LLY,http://www.gurufocus.com/news/1149518/thursday-morning-market-highlights,GuruFocus,,,,0,0,58a0f49a-39cf-4d5c-ab02-9f2c6b995c2c
2020-05-28T08:00:00.000+08:00,"3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020",LLY,http://www.zacks.com/stock/news/949284/3-investing-facts-about-required-minimum-distributions-you-need-to-know-may-28-2020?cid=CS-BENZ-FT-retirement_ideas|required_minimum_distribution-949284,Zacks,,,,0,0,54bc207b-14f1-4563-a2cb-2d51923538b8
2020-05-27T08:00:00.000+08:00,"\"Trumpdesivir: Operation Warp Speed, \"\"Engage.\"\"\"",LLY,https://talkmarkets.com/content/trumpdesivir-operation-warp-speed-engage?post=263499,TalkMarkets,,,,0,0,372bd925-27f7-456c-a534-509ff9471f2b
2020-05-27T08:00:00.000+08:00,"\"Trumpdesivir: Operation Warp Speed, \"\"Engage.\"\"\"",LLY,https://talkmarkets.com/content/trumpdesivir-operation-warp-speed-engage?post=263499,TalkMarkets,,,,0,0,a8913caa-aa77-4576-8c7d-2f03ad6edff4
2020-05-26T08:00:00.000+08:00,'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet,LLY,https://www.benzinga.com/news/20/05/16110564/list-of-external-participants-expected-at-rose-garden-event-starting-momentarily-where-potus-will-an,Benzinga Newsdesk,,,,0,0,abdea272-b4a1-4a79-9dcd-4b2834dae124
2020-05-26T08:00:00.000+08:00,"Eli Lilly Intend To File An IND, Initiate Clinical Trials In U.S. & China In Q2 2020 For Company's COVID-19 Neutralizing Antibodies",LLY,https://www.benzinga.com/news/20/05/16105875/eli-lilly-intend-to-file-an-ind-initiate-clinical-trials-in-u-s-china-in-q2-2020-for-companys-covid,Benzinga Newsdesk,,,,0,0,29e035d9-c36d-4775-b0a2-9714418ea174
2020-05-26T08:00:00.000+08:00,Boehringer Ingelheim And Lilly To Collaborate With Duke Clinical Research Institute On A Pragmatic Trial Examining Jardiance's Effects Following An Acute Myocardial Infarction,LLY,https://www.benzinga.com/general/biotech/20/05/16104895/boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-pragmati,Benzinga Newsdesk,,,,0,0,46b8d421-6647-4317-81b2-e00b29d70818
2020-05-26T08:00:00.000+08:00,Eli Lilly Announces Emgality 'significantly improved work productivity and reduced interictal burden' In Migraine Patients,LLY,https://www.benzinga.com/general/biotech/20/05/16104029/eli-lilly-announces-emgality-significantly-improved-work-productivity-and-reduced-interictal-burd,Benzinga Newsdesk,,,,0,0,f65dbca4-7df2-455a-8747-b9af6308bb70
2020-05-26T08:00:00.000+08:00,Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model,LLY,http://www.gurufocus.com/news/1147739/statement-from-lilly-chairman-and-ceo-dave-ricks-on-new-part-d-senior-savings-model,GuruFocus,,,,0,0,f0978d2e-c4ed-4614-9b9b-253e223b5284
2020-05-26T08:00:00.000+08:00,"GCIC Ltd. Buys Amazon.com Inc, Brookfield Asset Management Inc, Eli Lilly and Co, Sells Bank of ...",LLY,http://www.gurufocus.com/news/1147522/gcic-ltd-buys-amazoncom-inc-brookfield-asset-management-inc-eli-lilly-and-co-sells-bank-of-america-corp-jpmorgan-chase-nike-inc,GuruFocus,,,,0,0,51d64642-6e90-43d5-a389-b68e0654b346
2020-05-26T08:00:00.000+08:00,CanSino Biologics' Covid-–9 Vaccine Shows Early Promise,LLY,http://www.gurufocus.com/news/1147372/cansino-biologics-covid19-vaccine-shows-early-promise-,GuruFocus,,,,0,0,884194d5-3903-464e-9b6d-0e3f740f7138
2020-05-26T08:00:00.000+08:00,Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi ...,LLY,http://www.gurufocus.com/news/1147266/nature-publishes-preclinical-characterization-and-primate-efficacy-data-on-junshi-biosciences-covid19-neutralizing-antibodies,GuruFocus,,,,0,0,d449243a-2a31-437d-8439-3b3d2d4cca9a
2020-05-26T08:00:00.000+08:00,Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in ...,LLY,http://www.gurufocus.com/news/1147282/emgality-shows-improvement-in-work-productivity-and-health-and-wellbeing-between-attacks-in-patients-with-migraine-and-a-history-of-preventive-treatment-failure,GuruFocus,,,,0,0,ba977753-eb03-4574-8733-1883d611c734
2020-05-26T08:00:00.000+08:00,Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a ...,LLY,http://www.gurufocus.com/news/1146886/boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-pragmatic-trial-examining-jardiances-effects-following-an-acute-myocardial-infarction,GuruFocus,,,,0,0,002124c4-126b-455c-8da1-f899016dbec5
2020-05-26T08:00:00.000+08:00,'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than $35 for a month's supply.' -Steve Herman Tweet,LLY,https://www.benzinga.com/news/20/05/16110564/list-of-external-participants-expected-at-rose-garden-event-starting-momentarily-where-potus-will-an,Benzinga Newsdesk,,,,0,0,58a94271-263f-4171-a370-ecc6a80e6024
2020-05-26T08:00:00.000+08:00,"Eli Lilly Intend To File An IND, Initiate Clinical Trials In U.S. & China In Q2 2020 For Company's COVID-19 Neutralizing Antibodies",LLY,https://www.benzinga.com/news/20/05/16105875/eli-lilly-intend-to-file-an-ind-initiate-clinical-trials-in-u-s-china-in-q2-2020-for-companys-covid,Benzinga Newsdesk,,,,0,0,4b294ccd-fe45-409b-bcaf-36808e1bede4
2020-05-26T08:00:00.000+08:00,Boehringer Ingelheim And Lilly To Collaborate With Duke Clinical Research Institute On A Pragmatic Trial Examining Jardiance's Effects Following An Acute Myocardial Infarction,LLY,https://www.benzinga.com/general/biotech/20/05/16104895/boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-pragmati,Benzinga Newsdesk,,,,0,0,f9e4f638-d1b2-4bed-84d4-b6c10f7de5c2
2020-05-26T08:00:00.000+08:00,Eli Lilly Announces Emgality 'significantly improved work productivity and reduced interictal burden' In Migraine Patients,LLY,https://www.benzinga.com/general/biotech/20/05/16104029/eli-lilly-announces-emgality-significantly-improved-work-productivity-and-reduced-interictal-burd,Benzinga Newsdesk,,,,0,0,c41b3508-b1f5-460d-8783-ad4464d183dd
2020-05-26T08:00:00.000+08:00,Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model,LLY,http://www.gurufocus.com/news/1147739/statement-from-lilly-chairman-and-ceo-dave-ricks-on-new-part-d-senior-savings-model,GuruFocus,,,,0,0,de70c130-dccb-4de6-9fca-8412ca17a245
2020-05-26T08:00:00.000+08:00,"GCIC Ltd. Buys Amazon.com Inc, Brookfield Asset Management Inc, Eli Lilly and Co, Sells Bank of ...",LLY,http://www.gurufocus.com/news/1147522/gcic-ltd-buys-amazoncom-inc-brookfield-asset-management-inc-eli-lilly-and-co-sells-bank-of-america-corp-jpmorgan-chase-nike-inc,GuruFocus,,,,0,0,a416ac14-5bd5-4f6e-b78c-d8bc12ec4de9
2020-05-26T08:00:00.000+08:00,CanSino Biologics' Covid-–9 Vaccine Shows Early Promise,LLY,http://www.gurufocus.com/news/1147372/cansino-biologics-covid19-vaccine-shows-early-promise-,GuruFocus,,,,0,0,9329b1d4-746e-4a2c-b0de-30e3f477b737
2020-05-26T08:00:00.000+08:00,Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi ...,LLY,http://www.gurufocus.com/news/1147266/nature-publishes-preclinical-characterization-and-primate-efficacy-data-on-junshi-biosciences-covid19-neutralizing-antibodies,GuruFocus,,,,0,0,c07b21d3-f7cd-4195-b382-94fd9485d731
2020-05-26T08:00:00.000+08:00,Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in ...,LLY,http://www.gurufocus.com/news/1147282/emgality-shows-improvement-in-work-productivity-and-health-and-wellbeing-between-attacks-in-patients-with-migraine-and-a-history-of-preventive-treatment-failure,GuruFocus,,,,0,0,b558f0ab-9670-4184-984c-45d161779666
2020-05-26T08:00:00.000+08:00,Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a ...,LLY,http://www.gurufocus.com/news/1146886/boehringer-ingelheim-and-lilly-to-collaborate-with-duke-clinical-research-institute-on-a-pragmatic-trial-examining-jardiances-effects-following-an-acute-myocardial-infarction,GuruFocus,,,,0,0,4a56525d-cc57-4f4b-ad42-c1448882b9da
2020-05-23T08:00:00.000+08:00,Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?,LLY,http://www.zacks.com/stock/news/940216/why-is-lilly-lly-down-55-since-last-earnings-report?cid=CS-BENZ-FT-realtime_blog-940216,Zacks,,,,0,0,ff6283c1-47e3-4771-90a4-d795abe3b483
2020-05-23T08:00:00.000+08:00,Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?,LLY,http://www.zacks.com/stock/news/940216/why-is-lilly-lly-down-55-since-last-earnings-report?cid=CS-BENZ-FT-realtime_blog-940216,Zacks,,,,0,0,e0246ff3-e68b-4451-8130-930bb7ea25e1
2020-05-21T08:00:00.000+08:00,Clovis Oncology Needs a Savior,LLY,http://www.gurufocus.com/news/1144188/clovis-oncology-needs-a-savior,GuruFocus,,,,0,0,1a90c91a-d87f-4ab2-9fac-1ac690d6af4e
2020-05-21T08:00:00.000+08:00,Clovis Oncology Needs a Savior,LLY,http://www.gurufocus.com/news/1144188/clovis-oncology-needs-a-savior,GuruFocus,,,,0,0,e046012c-0621-4163-9976-ade0d63fe132
2020-05-20T08:00:00.000+08:00,J&J to Stop Sale of Talc-Based Baby Powder in North America,LLY,http://www.zacks.com/stock/news/934832/jj-to-stop-sale-of-talc-based-baby-powder-in-north-america?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-934832,Zacks,,,,0,0,575f898c-e39e-4e73-95da-2238aff78e74
2020-05-20T08:00:00.000+08:00,J&J to Stop Sale of Talc-Based Baby Powder in North America,LLY,http://www.zacks.com/stock/news/934832/jj-to-stop-sale-of-talc-based-baby-powder-in-north-america?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-934832,Zacks,,,,0,0,7ed81aed-6f8d-42be-94ba-12c99a4421e7
2020-05-19T08:00:00.000+08:00,"Eli Lilly Reports Results Of GERAS-US Study Showed Societal Cost Burden For Patients, Caregivers During Early Stages Of Alzheimer's Disease",LLY,https://www.benzinga.com/news/20/05/16064469/eli-lilly-reports-results-of-geras-us-study-showed-societal-cost-burden-for-patients-caregivers-duri,Benzinga Newsdesk,,,,0,0,aaea577a-79b8-4339-8583-2f9ee065e1df
2020-05-19T08:00:00.000+08:00,Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During ...,LLY,http://www.gurufocus.com/news/1141850/results-of-gerasus-study-demonstrate-societal-cost-burden-for-patients-and-caregivers-during-early-stages-of-alzheimers-disease,GuruFocus,,,,0,0,0536574a-de88-480a-90aa-4a5bb77867a5
2020-05-19T08:00:00.000+08:00,"Eli Lilly Reports Results Of GERAS-US Study Showed Societal Cost Burden For Patients, Caregivers During Early Stages Of Alzheimer's Disease",LLY,https://www.benzinga.com/news/20/05/16064469/eli-lilly-reports-results-of-geras-us-study-showed-societal-cost-burden-for-patients-caregivers-duri,Benzinga Newsdesk,,,,0,0,16ffa43e-11a5-4985-a5ce-3bbda0324404
2020-05-19T08:00:00.000+08:00,Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During ...,LLY,http://www.gurufocus.com/news/1141850/results-of-gerasus-study-demonstrate-societal-cost-burden-for-patients-and-caregivers-during-early-stages-of-alzheimers-disease,GuruFocus,,,,0,0,3a7f19b5-b5b9-4f59-88e1-ab8eeb6fe826
2020-05-15T08:00:00.000+08:00,"Asahi Life Asset Management Co., Ltd. Buys Facebook Inc, Alibaba Group Holding, Amazon. ...",LLY,http://www.gurufocus.com/news/1138088/asahi-life-asset-management-co-ltd-buys-facebook-inc-alibaba-group-holding-amazoncom-inc-sells-gilead-sciences-inc-texas-instruments-inc-qualcomm-inc,GuruFocus,,,,0,0,5830b7af-76d8-4ebf-a6a5-0df7f7da4f8b
2020-05-15T08:00:00.000+08:00,"UBP Investment Advisors SA Buys iShares Short Maturity Bond, iShares MSCI China ETF, Eli Lilly ...",LLY,http://www.gurufocus.com/news/1137997/ubp-investment-advisors-sa-buys-ishares-short-maturity-bond-ishares-msci-china-etf-eli-lilly-and-co-sells-vanguard-shortterm-government-bond-etf-exact-sciences-corp-the-walt-disney-co,GuruFocus,,,,0,0,f63f21c0-a2c4-4a8e-ab88-ca2876d072ac
2020-05-15T08:00:00.000+08:00,"Asahi Life Asset Management Co., Ltd. Buys Facebook Inc, Alibaba Group Holding, Amazon. ...",LLY,http://www.gurufocus.com/news/1138088/asahi-life-asset-management-co-ltd-buys-facebook-inc-alibaba-group-holding-amazoncom-inc-sells-gilead-sciences-inc-texas-instruments-inc-qualcomm-inc,GuruFocus,,,,0,0,cfcc2750-4129-4c20-8c63-62e84b89680a
2020-05-15T08:00:00.000+08:00,"UBP Investment Advisors SA Buys iShares Short Maturity Bond, iShares MSCI China ETF, Eli Lilly ...",LLY,http://www.gurufocus.com/news/1137997/ubp-investment-advisors-sa-buys-ishares-short-maturity-bond-ishares-msci-china-etf-eli-lilly-and-co-sells-vanguard-shortterm-government-bond-etf-exact-sciences-corp-the-walt-disney-co,GuruFocus,,,,0,0,de466877-b867-4c59-8232-c3fee34c9fa0
2020-05-14T08:00:00.000+08:00,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",LLY,https://www.benzinga.com/general/biotech/20/05/16029961/the-daily-biotech-pulse-asco-abstracts-create-stock-ripples-applied-dnas-coronavirus-test-receive,Shanthi Rexaline,,,,0,0,2a0a9e38-6697-4435-937d-7b9aa2ab43e6
2020-05-14T08:00:00.000+08:00,"Summit Global Investments Buys Amazon.com Inc, Clorox Co, Adobe Inc, Sells NVR Inc, TJX Inc, ...",LLY,http://www.gurufocus.com/news/1137307/summit-global-investments-buys-amazoncom-inc-clorox-co-adobe-inc-sells-nvr-inc-tjx-inc-sysco-corp,GuruFocus,,,,0,0,ad475160-0b3e-44b8-add4-816502d19fe6
2020-05-14T08:00:00.000+08:00,"GCIC Ltd. Buys Brookfield Asset Management Inc, Eli Lilly and Co, Stryker Corp, Sells Bank of ...",LLY,http://www.gurufocus.com/news/1136972/gcic-ltd-buys-brookfield-asset-management-inc-eli-lilly-and-co-stryker-corp-sells-bank-of-nova-scotia-visa-inc-enbridge-inc,GuruFocus,,,,0,0,77318ef1-7a41-4930-9bf6-6b0fe10628d6
2020-05-14T08:00:00.000+08:00,"Tekla Capital Management LLC Buys Centene Corp, Moderna Inc, Eli Lilly and Co, Sells Anthem ...",LLY,http://www.gurufocus.com/news/1136990/tekla-capital-management-llc-buys-centene-corp-moderna-inc-eli-lilly-and-co-sells-anthem-inc-the-medicines-co-esperion-therapeutics-inc,GuruFocus,,,,0,0,4c32b30c-e86e-4fc1-9838-29724ecec830
2020-05-14T08:00:00.000+08:00,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",LLY,https://www.benzinga.com/general/biotech/20/05/16029961/the-daily-biotech-pulse-asco-abstracts-create-stock-ripples-applied-dnas-coronavirus-test-receive,Shanthi Rexaline,,,,0,0,469fbd44-e2ab-4697-adb3-2a39a3a45e3f
2020-05-14T08:00:00.000+08:00,"Summit Global Investments Buys Amazon.com Inc, Clorox Co, Adobe Inc, Sells NVR Inc, TJX Inc, ...",LLY,http://www.gurufocus.com/news/1137307/summit-global-investments-buys-amazoncom-inc-clorox-co-adobe-inc-sells-nvr-inc-tjx-inc-sysco-corp,GuruFocus,,,,0,0,1af7858d-363d-411c-aa09-a1e05591a0d3
2020-05-14T08:00:00.000+08:00,"GCIC Ltd. Buys Brookfield Asset Management Inc, Eli Lilly and Co, Stryker Corp, Sells Bank of ...",LLY,http://www.gurufocus.com/news/1136972/gcic-ltd-buys-brookfield-asset-management-inc-eli-lilly-and-co-stryker-corp-sells-bank-of-nova-scotia-visa-inc-enbridge-inc,GuruFocus,,,,0,0,db49c2f0-1d9b-48a3-9cac-d6b074509a49
2020-05-14T08:00:00.000+08:00,"Tekla Capital Management LLC Buys Centene Corp, Moderna Inc, Eli Lilly and Co, Sells Anthem ...",LLY,http://www.gurufocus.com/news/1136990/tekla-capital-management-llc-buys-centene-corp-moderna-inc-eli-lilly-and-co-sells-anthem-inc-the-medicines-co-esperion-therapeutics-inc,GuruFocus,,,,0,0,39ddece2-d742-4200-b2b6-53fcb00dfe0c
2020-05-13T08:00:00.000+08:00,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16022153/abbvies-potential-is-underappreciated-says-morgan-stanley-analyst,Shanthi Rexaline,,,,0,0,e0c35aa9-945d-4dd9-8abd-b16f4d5096d9
2020-05-13T08:00:00.000+08:00,"'6– Capital Llc Buys Spire Inc, McKesson Corp, Berry Global Group Inc, Sells Jazz ...",LLY,http://www.gurufocus.com/news/1135880/361-capital-llc-buys-spire-inc-mckesson-corp-berry-global-group-inc-sells-jazz-pharmaceuticals-plc-paccar-inc-spotify-technology-sa,GuruFocus,,,,0,0,a0614b2a-70d3-4a12-95e3-3f4352740349
2020-05-13T08:00:00.000+08:00,"AlphaCrest Capital Management LLC Buys AT&T Inc, Eli Lilly and Co, Apple Inc, Sells The ...",LLY,http://www.gurufocus.com/news/1135824/alphacrest-capital-management-llc-buys-att-inc-eli-lilly-and-co-apple-inc-sells-the-torontodominion-bank-oracle-corp-charles-schwab-corp,GuruFocus,,,,0,0,dfc3dd7c-ec31-419a-8561-281108400683
2020-05-13T08:00:00.000+08:00,"Pitcairn Co Buys Mastercard Inc, Eli Lilly and Co, Seagate Technology PLC, Sells IQ Hedge ...",LLY,http://www.gurufocus.com/news/1135209/pitcairn-co-buys-mastercard-inc-eli-lilly-and-co-seagate-technology-plc-sells-iq-hedge-multiiq-hedge-multistrategy-tracker-visa-inc-bwx-technologies-inc,GuruFocus,,,,0,0,c67e6f70-3ee1-4832-ba4c-8c95ac70ecf6
2020-05-13T08:00:00.000+08:00,"Skandinaviska Enskilda Banken AB (publ) Buys Align Technology Inc, Eli Lilly and Co, Alibaba ...",LLY,http://www.gurufocus.com/news/1135118/skandinaviska-enskilda-banken-ab-publ-buys-align-technology-inc-eli-lilly-and-co-alibaba-group-holding-sells-hewlett-packard-enterprise-co-gilead-sciences-inc-target-corp,GuruFocus,,,,0,0,83da3ad3-1fa6-439e-ba80-1ba5098dd3cd
2020-05-13T08:00:00.000+08:00,"AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16022153/abbvies-potential-is-underappreciated-says-morgan-stanley-analyst,Shanthi Rexaline,,,,0,0,be3adc7e-6300-45ef-bc53-05e5f9808ff8
2020-05-13T08:00:00.000+08:00,"'6– Capital Llc Buys Spire Inc, McKesson Corp, Berry Global Group Inc, Sells Jazz ...",LLY,http://www.gurufocus.com/news/1135880/361-capital-llc-buys-spire-inc-mckesson-corp-berry-global-group-inc-sells-jazz-pharmaceuticals-plc-paccar-inc-spotify-technology-sa,GuruFocus,,,,0,0,ca269ca7-9b98-4b7a-896a-af6eb272148a
2020-05-13T08:00:00.000+08:00,"AlphaCrest Capital Management LLC Buys AT&T Inc, Eli Lilly and Co, Apple Inc, Sells The ...",LLY,http://www.gurufocus.com/news/1135824/alphacrest-capital-management-llc-buys-att-inc-eli-lilly-and-co-apple-inc-sells-the-torontodominion-bank-oracle-corp-charles-schwab-corp,GuruFocus,,,,0,0,a363d54a-9e7b-4c92-aa25-7c727b1c967d
2020-05-13T08:00:00.000+08:00,"Pitcairn Co Buys Mastercard Inc, Eli Lilly and Co, Seagate Technology PLC, Sells IQ Hedge ...",LLY,http://www.gurufocus.com/news/1135209/pitcairn-co-buys-mastercard-inc-eli-lilly-and-co-seagate-technology-plc-sells-iq-hedge-multiiq-hedge-multistrategy-tracker-visa-inc-bwx-technologies-inc,GuruFocus,,,,0,0,cbd468e7-c1f5-4f9c-9b22-3aed3cda5d19
2020-05-13T08:00:00.000+08:00,"Skandinaviska Enskilda Banken AB (publ) Buys Align Technology Inc, Eli Lilly and Co, Alibaba ...",LLY,http://www.gurufocus.com/news/1135118/skandinaviska-enskilda-banken-ab-publ-buys-align-technology-inc-eli-lilly-and-co-alibaba-group-holding-sells-hewlett-packard-enterprise-co-gilead-sciences-inc-target-corp,GuruFocus,,,,0,0,566edbb7-b833-4d75-8f9a-d65b2613fc0d
2020-05-12T08:00:00.000+08:00,"Oxford Financial Group Ltd Buys Intuitive Surgical Inc, Eli Lilly and Co, Vanguard Value, Sells ...",LLY,http://www.gurufocus.com/news/1134552/oxford-financial-group-ltd-buys-intuitive-surgical-inc-eli-lilly-and-co-vanguard-value-sells-ishares-core-msci-emerging-markets-vanguard-real-estate-ishares-north-american-natural-resources,GuruFocus,,,,0,0,e9ac1655-e658-463a-879f-33a0968e2053
2020-05-12T08:00:00.000+08:00,Smith Asset Management Group LP Buys Amazon. ...,LLY,http://www.gurufocus.com/news/1134321/smith-asset-management-group-lp-buys-amazoncom-inc-nvidia-corp-jpmorgan-chase-sells-facebook-inc-vf-corp-varian-medical-systems-inc,GuruFocus,,,,0,0,a4f4b191-c72a-489e-8514-58fb59da4d60
2020-05-12T08:00:00.000+08:00,"Oxford Financial Group Ltd Buys Intuitive Surgical Inc, Eli Lilly and Co, Vanguard Value, Sells ...",LLY,http://www.gurufocus.com/news/1134552/oxford-financial-group-ltd-buys-intuitive-surgical-inc-eli-lilly-and-co-vanguard-value-sells-ishares-core-msci-emerging-markets-vanguard-real-estate-ishares-north-american-natural-resources,GuruFocus,,,,0,0,9fe719f8-7ee0-4432-9ca8-8f7c9f3ce30f
2020-05-12T08:00:00.000+08:00,Smith Asset Management Group LP Buys Amazon. ...,LLY,http://www.gurufocus.com/news/1134321/smith-asset-management-group-lp-buys-amazoncom-inc-nvidia-corp-jpmorgan-chase-sells-facebook-inc-vf-corp-varian-medical-systems-inc,GuruFocus,,,,0,0,d453d96c-f530-41a5-b8b7-31d6567de798
2020-05-11T08:00:00.000+08:00,Why Eli Lilly's Stock Is Trading Higher Today,LLY,https://www.benzinga.com/news/20/05/16003134/why-eli-lillys-stock-is-trading-higher-today,Tanzeel Akhtar,,,,0,0,2efdeafd-d393-4dd6-9ed2-b64f6a08b7db
2020-05-11T08:00:00.000+08:00,Eli Lilly shares are trading higher amid strength in the healthcare sector. The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.,LLY,https://www.benzinga.com/wiim/20/05/16002972/eli-lilly-shares-are-trading-higher-amid-strength-in-the-healthcare-sector-the-company-late-friday-a,Benzinga Newsdesk,,,,0,0,0a6ed6a1-b192-4ff7-9042-7af0e8623744
2020-05-11T08:00:00.000+08:00,"Lilly Late Friday Announced Co. Received U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers",LLY,https://www.benzinga.com/news/20/05/16001162/lilly-late-friday-announced-co-received-u-s-fda-approval-for-retevmo-selpercatinib-the-first-therapy,Benzinga Newsdesk,,,,0,0,80fd753b-5558-4d17-838d-60fe68463d05
2020-05-11T08:00:00.000+08:00,LLY Stock Approaching Support: Here Are Two Option Trade Ideas,LLY,http://www.investors.com/research/options/lly-stock-approaching-support-here-are-two-option-trade-ideas/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,394efff0-0982-4b10-be16-06effbede0d0
2020-05-11T08:00:00.000+08:00,"Varma Mutual Pension Insurance Co Buys PowerShares QQQ Trust Ser –, iShares MSCI China ETF, ...",LLY,http://www.gurufocus.com/news/1133017/varma-mutual-pension-insurance-co-buys-powershares-qqq-trust-ser-1-ishares-msci-china-etf-kraneshares-trust-csi-china-internet-sells-ishares-core-sp-500-ishares-core-msci-emerging-markets-vanguard-sp-500,GuruFocus,,,,0,0,a3e6e0f8-e10a-4bb6-9724-2e1f94c101e0
2020-05-11T08:00:00.000+08:00,Health Care's Market-Beating Performance,LLY,https://talkmarkets.com/content/health-cares-market-beating-performance?post=261681,TalkMarkets,,,,0,0,a18693d0-addc-4402-b34a-0c8be1c274c3
2020-05-11T08:00:00.000+08:00,Why Eli Lilly's Stock Is Trading Higher Today,LLY,https://www.benzinga.com/news/20/05/16003134/why-eli-lillys-stock-is-trading-higher-today,Tanzeel Akhtar,,,,0,0,231728c8-2dd4-41e1-8b92-d0433269c7a1
2020-05-11T08:00:00.000+08:00,Eli Lilly shares are trading higher amid strength in the healthcare sector. The company late Friday announced FDA approval for Retevmo in patients with advanced RET-driven lung and thyroid cancers.,LLY,https://www.benzinga.com/wiim/20/05/16002972/eli-lilly-shares-are-trading-higher-amid-strength-in-the-healthcare-sector-the-company-late-friday-a,Benzinga Newsdesk,,,,0,0,57daf949-7347-4b7d-930a-8111ba7865b5
2020-05-11T08:00:00.000+08:00,"Lilly Late Friday Announced Co. Received U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers",LLY,https://www.benzinga.com/news/20/05/16001162/lilly-late-friday-announced-co-received-u-s-fda-approval-for-retevmo-selpercatinib-the-first-therapy,Benzinga Newsdesk,,,,0,0,66137bd8-5033-4c5d-b267-133cb8db2eb4
2020-05-11T08:00:00.000+08:00,LLY Stock Approaching Support: Here Are Two Option Trade Ideas,LLY,http://www.investors.com/research/options/lly-stock-approaching-support-here-are-two-option-trade-ideas/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,9a2b9899-877a-42e6-bc92-90c3d58670d5
2020-05-11T08:00:00.000+08:00,"Varma Mutual Pension Insurance Co Buys PowerShares QQQ Trust Ser –, iShares MSCI China ETF, ...",LLY,http://www.gurufocus.com/news/1133017/varma-mutual-pension-insurance-co-buys-powershares-qqq-trust-ser-1-ishares-msci-china-etf-kraneshares-trust-csi-china-internet-sells-ishares-core-sp-500-ishares-core-msci-emerging-markets-vanguard-sp-500,GuruFocus,,,,0,0,9043d0fa-ebf9-4ebf-8e1e-310d309044e2
2020-05-11T08:00:00.000+08:00,Health Care's Market-Beating Performance,LLY,https://talkmarkets.com/content/health-cares-market-beating-performance?post=261681,TalkMarkets,,,,0,0,28692fd2-138f-4eb3-9969-3f1cde74788b
2020-05-10T08:00:00.000+08:00,8 Monster Stock Market Predictions For The Week Of May 11,LLY,https://talkmarkets.com/content/8-monster-stock-market-predictions-for-the-week-of-may-11?post=261550,TalkMarkets,,,,0,0,385fbfda-ba07-4bb6-8965-013fa577e8f2
2020-05-10T08:00:00.000+08:00,8 Monster Stock Market Predictions For The Week Of May 11,LLY,https://talkmarkets.com/content/8-monster-stock-market-predictions-for-the-week-of-may-11?post=261550,TalkMarkets,,,,0,0,e5c82654-311a-4109-98af-e27f75ac7616
2020-05-09T08:00:00.000+08:00,Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly,LLY,https://talkmarkets.com/content/week-in-review-junshi-out-licenses-ex-china-rights-for-covid-19-therapeutic-to-lilly?post=261491,TalkMarkets,,,,0,0,fcfdd827-f268-4591-b514-7e7a6d62a83e
2020-05-09T08:00:00.000+08:00,Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly,LLY,https://talkmarkets.com/content/week-in-review-junshi-out-licenses-ex-china-rights-for-covid-19-therapeutic-to-lilly?post=261491,TalkMarkets,,,,0,0,9a815347-566f-431b-a0d8-728f921bb8da
2020-05-08T08:00:00.000+08:00,Eli Lilly Press Release Highlights 'Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes',LLY,https://www.benzinga.com/news/20/05/15992034/eli-lilly-press-release-highlights-higher-investigational-doses-of-trulicity-dulaglutide-meaningfull,Benzinga Newsdesk,,,,0,0,6cf51beb-5a66-415e-8035-450010d9cfb0
2020-05-08T08:00:00.000+08:00,5 Biopharmas Where BofA Would Put Its Money To Work,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/15989612/5-biopharmas-where-bofa-would-put-its-money-to-work,Shanthi Rexaline,,,,0,0,e848f27a-2a12-434e-b855-0b9011fae266
2020-05-08T08:00:00.000+08:00,"Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically ...",LLY,http://www.gurufocus.com/news/1131696/lilly-receives-us-fda-approval-for-retevmo-selpercatinib-the-first-therapy-specifically-for-patients-with-advanced-retdriven-lung-and-thyroid-cancers,GuruFocus,,,,0,0,37463995-3945-4d81-a028-c79e2b505a4d
2020-05-08T08:00:00.000+08:00,"Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass",LLY,http://www.zacks.com/stock/news/918318/radius-rdus-q1-earnings-miss-estimates-sales-surpass?cid=CS-BENZ-FT-analyst_blog|earnings_article-918318,Zacks,,,,0,0,dfd37118-e55e-49de-a3fa-2705b32f6228
2020-05-08T08:00:00.000+08:00,Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A–C and body ...,LLY,http://www.gurufocus.com/news/1131363/higher-investigational-doses-of-trulicity-dulaglutide-meaningfully-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes,GuruFocus,,,,0,0,78136897-6629-4ada-a5e6-59666fcc2f4a
2020-05-08T08:00:00.000+08:00,"Sustainable Insight Capital Management, LLC Buys Apple Inc, Eli Lilly and Co, Truist Financial ...",LLY,http://www.gurufocus.com/news/1131193/sustainable-insight-capital-management-llc-buys-apple-inc-eli-lilly-and-co-truist-financial-corp-sells-citigroup-inc-simon-property-group-inc-becton-dickinson-and-co,GuruFocus,,,,0,0,23d707b7-f2d9-430b-bcf9-f11ebc5e2c87
2020-05-08T08:00:00.000+08:00,"Mastrapasqua Asset Management Inc Buys II-VI Inc, Ciena Corp, Skyworks Solutions Inc, Sells ...",LLY,http://www.gurufocus.com/news/1131220/mastrapasqua-asset-management-inc-buys-iivi-inc-ciena-corp-skyworks-solutions-inc-sells-aramark-air-lease-corp-sealed-air-corp,GuruFocus,,,,0,0,2fe465b9-09b0-467b-b870-0e1a78ac4e7f
2020-05-08T08:00:00.000+08:00,"Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY",LLY,http://www.zacks.com/stock/news/918157/pharma-stock-roundup-q1-earnings-of-bmy-nvo-coronavirus-update-from-pfe-rhhby?cid=CS-BENZ-FT-analyst_blog|stock_roundup-918157,Zacks,,,,0,0,e07fae25-1ec4-462b-806a-644dabc14ffb
2020-05-08T08:00:00.000+08:00,"OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates",LLY,http://www.zacks.com/stock/news/918074/opko-health-opk-reports-q1-loss-lags-revenue-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-918074,Zacks,,,,0,0,bb3aa73e-7579-4e66-9b27-a647aeffd90c
2020-05-08T08:00:00.000+08:00,Globus Medical (GMED) Misses on Q1 Earnings and Revenues,LLY,http://www.zacks.com/stock/news/918003/globus-medical-gmed-misses-on-q1-earnings-and-revenues?cid=CS-BENZ-FT-analyst_blog|earnings_article-918003,Zacks,,,,0,0,40a65209-0f11-489e-bfee-26e3745f2e14
2020-05-08T08:00:00.000+08:00,"Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises",LLY,http://www.zacks.com/stock/news/917984/omnicell-omcl-q1-earnings-top-operating-margin-rises?cid=CS-BENZ-FT-analyst_blog|earnings_article-917984,Zacks,,,,0,0,73d0df75-98f8-4e73-b44e-395349286f80
2020-05-08T08:00:00.000+08:00,"Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top",LLY,http://www.zacks.com/stock/news/917867/avanos-medical-avns-q1-earnings-lag-estimates-revenues-top?cid=CS-BENZ-FT-analyst_blog|earnings_article-917867,Zacks,,,,0,0,1e26bc93-ae03-4034-8aa3-826df0055b2a
2020-05-08T08:00:00.000+08:00,DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results,LLY,http://www.zacks.com/stock/news/917851/dentsply-sirona-xray-posts-weak-q1-preliminary-results?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-917851,Zacks,,,,0,0,dda0e0f0-1e07-4137-ba32-86ed46cec12e
2020-05-08T08:00:00.000+08:00,Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates,LLY,http://www.zacks.com/stock/news/917857/glaukos-gkos-q1-earnings-and-revenues-miss-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-917857,Zacks,,,,0,0,2377c5c1-b554-4708-91a6-48986d7335c3
2020-05-08T08:00:00.000+08:00,"Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook",LLY,http://www.zacks.com/stock/news/917856/integra-iart-lags-q1-earnings-estimates-withdraws-outlook?cid=CS-BENZ-FT-analyst_blog|earnings_article-917856,Zacks,,,,0,0,e4b673cd-819f-4817-b8b4-3e926c9d04eb
2020-05-08T08:00:00.000+08:00,"Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended",LLY,http://www.zacks.com/stock/news/917849/bruker-brkr-q1-earnings-miss-estimates-guidance-suspended?cid=CS-BENZ-FT-analyst_blog|earnings_article-917849,Zacks,,,,0,0,f8404b7a-5fa6-4169-bcdb-949be3e5234f
2020-05-08T08:00:00.000+08:00,Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates,LLY,http://www.zacks.com/stock/news/917790/pacific-biosciences-pacb-q1-earnings-surpass-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-917790,Zacks,,,,0,0,c3de5621-7ee2-4692-88a4-57ab2f6fc5d6
2020-05-08T08:00:00.000+08:00,Eli Lilly Press Release Highlights 'Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A1C and body weight in people with type 2 diabetes',LLY,https://www.benzinga.com/news/20/05/15992034/eli-lilly-press-release-highlights-higher-investigational-doses-of-trulicity-dulaglutide-meaningfull,Benzinga Newsdesk,,,,0,0,47825f4d-7bb5-49e2-929a-25a8765511bb
2020-05-08T08:00:00.000+08:00,5 Biopharmas Where BofA Would Put Its Money To Work,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/15989612/5-biopharmas-where-bofa-would-put-its-money-to-work,Shanthi Rexaline,,,,0,0,9ae439fb-38f8-4e57-ad7d-efd1fa103624
2020-05-08T08:00:00.000+08:00,"Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically ...",LLY,http://www.gurufocus.com/news/1131696/lilly-receives-us-fda-approval-for-retevmo-selpercatinib-the-first-therapy-specifically-for-patients-with-advanced-retdriven-lung-and-thyroid-cancers,GuruFocus,,,,0,0,13d98f4d-7a80-4bd9-9a6f-75f4282963f3
2020-05-08T08:00:00.000+08:00,"Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass",LLY,http://www.zacks.com/stock/news/918318/radius-rdus-q1-earnings-miss-estimates-sales-surpass?cid=CS-BENZ-FT-analyst_blog|earnings_article-918318,Zacks,,,,0,0,7f29bbb8-2d29-4f5f-858b-b139d1909e18
2020-05-08T08:00:00.000+08:00,Higher investigational doses of Trulicity® (dulaglutide) meaningfully reduced A–C and body ...,LLY,http://www.gurufocus.com/news/1131363/higher-investigational-doses-of-trulicity-dulaglutide-meaningfully-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes,GuruFocus,,,,0,0,3bf1b968-64ce-4b00-a836-f5fd6633b62b
2020-05-08T08:00:00.000+08:00,"Sustainable Insight Capital Management, LLC Buys Apple Inc, Eli Lilly and Co, Truist Financial ...",LLY,http://www.gurufocus.com/news/1131193/sustainable-insight-capital-management-llc-buys-apple-inc-eli-lilly-and-co-truist-financial-corp-sells-citigroup-inc-simon-property-group-inc-becton-dickinson-and-co,GuruFocus,,,,0,0,b7e97d53-0a3a-41eb-a854-5375175527d8
2020-05-08T08:00:00.000+08:00,"Mastrapasqua Asset Management Inc Buys II-VI Inc, Ciena Corp, Skyworks Solutions Inc, Sells ...",LLY,http://www.gurufocus.com/news/1131220/mastrapasqua-asset-management-inc-buys-iivi-inc-ciena-corp-skyworks-solutions-inc-sells-aramark-air-lease-corp-sealed-air-corp,GuruFocus,,,,0,0,0fce5543-a739-444e-a64b-d8e4fba4cb45
2020-05-08T08:00:00.000+08:00,"Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY",LLY,http://www.zacks.com/stock/news/918157/pharma-stock-roundup-q1-earnings-of-bmy-nvo-coronavirus-update-from-pfe-rhhby?cid=CS-BENZ-FT-analyst_blog|stock_roundup-918157,Zacks,,,,0,0,ac1de9e5-e11c-4863-95a0-51aab36afe13
2020-05-08T08:00:00.000+08:00,"OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates",LLY,http://www.zacks.com/stock/news/918074/opko-health-opk-reports-q1-loss-lags-revenue-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-918074,Zacks,,,,0,0,aa07fecc-a233-4d2b-9ead-02637518e92c
2020-05-08T08:00:00.000+08:00,Globus Medical (GMED) Misses on Q1 Earnings and Revenues,LLY,http://www.zacks.com/stock/news/918003/globus-medical-gmed-misses-on-q1-earnings-and-revenues?cid=CS-BENZ-FT-analyst_blog|earnings_article-918003,Zacks,,,,0,0,0d3ff15b-860a-41fb-86c6-d32607516f65
2020-05-08T08:00:00.000+08:00,"Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises",LLY,http://www.zacks.com/stock/news/917984/omnicell-omcl-q1-earnings-top-operating-margin-rises?cid=CS-BENZ-FT-analyst_blog|earnings_article-917984,Zacks,,,,0,0,e6c0ab1f-8038-4db9-a4a3-6917ce952041
2020-05-08T08:00:00.000+08:00,"Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top",LLY,http://www.zacks.com/stock/news/917867/avanos-medical-avns-q1-earnings-lag-estimates-revenues-top?cid=CS-BENZ-FT-analyst_blog|earnings_article-917867,Zacks,,,,0,0,4f91220e-84ae-42e7-b8d2-ff8ed8a2d915
2020-05-08T08:00:00.000+08:00,DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results,LLY,http://www.zacks.com/stock/news/917851/dentsply-sirona-xray-posts-weak-q1-preliminary-results?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-917851,Zacks,,,,0,0,03418e8a-e805-482d-a073-4875e1ac29a9
2020-05-08T08:00:00.000+08:00,Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates,LLY,http://www.zacks.com/stock/news/917857/glaukos-gkos-q1-earnings-and-revenues-miss-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-917857,Zacks,,,,0,0,10bbfc6a-5b14-438a-8274-791a32ffb30c
2020-05-08T08:00:00.000+08:00,"Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook",LLY,http://www.zacks.com/stock/news/917856/integra-iart-lags-q1-earnings-estimates-withdraws-outlook?cid=CS-BENZ-FT-analyst_blog|earnings_article-917856,Zacks,,,,0,0,8bb2df14-eeb2-4175-88a0-3d8a72493120
2020-05-08T08:00:00.000+08:00,"Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended",LLY,http://www.zacks.com/stock/news/917849/bruker-brkr-q1-earnings-miss-estimates-guidance-suspended?cid=CS-BENZ-FT-analyst_blog|earnings_article-917849,Zacks,,,,0,0,16996e98-2b61-4526-a72e-bdc9accfc425
2020-05-08T08:00:00.000+08:00,Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates,LLY,http://www.zacks.com/stock/news/917790/pacific-biosciences-pacb-q1-earnings-surpass-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-917790,Zacks,,,,0,0,607db8dd-5c7e-4b55-98f2-3df1ea788c65
2020-05-06T08:00:00.000+08:00,Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum ...,LLY,http://www.gurufocus.com/news/1128601/tyvyt-sintilimab-injection-combined-with-gemzar-gemcitabine-for-injection-and-platinum-chemotherapy-met-the-predefined-primary-endpoint-in-the-phase-3-orient12-study-as-firstline-therapy-in-patients-with-locally-advan,GuruFocus,,,,0,0,fc3cd6fc-44ca-4af6-98f8-d500eb6479c1
2020-05-06T08:00:00.000+08:00,"Mengis Capital Management, Inc. Buys 'M Co, SPDR S&P 5……, Eli Lilly and Co, Sells ...",LLY,http://www.gurufocus.com/news/1128307/mengis-capital-management-inc-buys-3m-co-spdr-sp-500-eli-lilly-and-co-sells-williams-inc-nuveen-energy-mlp-total-return-fund-allegheny-technologies-inc,GuruFocus,,,,0,0,48566d95-3d81-40eb-acc8-c12e42b3db28
2020-05-06T08:00:00.000+08:00,"Jennison Associates Llc Buys Eli Lilly and Co, Uber Technologies Inc, Goldman Sachs Group Inc, ...",LLY,http://www.gurufocus.com/news/1127973/jennison-associates-llc-buys-eli-lilly-and-co-uber-technologies-inc-goldman-sachs-group-inc-sells-the-walt-disney-co-intuitive-surgical-inc-nike-inc,GuruFocus,,,,0,0,048dd6c1-a665-419e-a4d1-f108879ae700
2020-05-06T08:00:00.000+08:00,"Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View",LLY,http://www.zacks.com/stock/news/915656/myriad-genetics-mygn-lags-q3-earnings-estimates-cancels-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-915656,Zacks,,,,0,0,7400ffe8-6540-4163-9b7b-91250909eb25
2020-05-06T08:00:00.000+08:00,"Pearl River Capital, LLC Buys American Electric Power Co Inc, Goldman Sachs Group Inc, ...",LLY,http://www.gurufocus.com/news/1127563/pearl-river-capital-llc-buys-american-electric-power-co-inc-goldman-sachs-group-inc-electronic-arts-inc-sells-honeywell-international-inc-sp-global-inc-northern-trust-corp,GuruFocus,,,,0,0,2c7863fd-dd2a-4b5c-a71e-56d2da70c111
2020-05-06T08:00:00.000+08:00,"CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate",LLY,http://www.zacks.com/stock/news/915641/cvs-health-cvs-q1-earnings-top-estimates-costs-escalate?cid=CS-BENZ-FT-analyst_blog|earnings_article-915641,Zacks,,,,0,0,ca30fe82-8cd7-41d8-8ff8-fb904848cfa6
2020-05-06T08:00:00.000+08:00,Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates,LLY,http://www.zacks.com/stock/news/915493/inogens-ingn-q1-earnings-and-revenues-beat-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-915493,Zacks,,,,0,0,0ce2063a-77d6-44b6-809a-c816c8c8d031
2020-05-06T08:00:00.000+08:00,DaVita (DVA) Earnings and Revenues Beat Estimates in Q1,LLY,http://www.zacks.com/stock/news/915484/davita-dva-earnings-and-revenues-beat-estimates-in-q1?cid=CS-BENZ-FT-analyst_blog|earnings_article-915484,Zacks,,,,0,0,33e8337b-a07b-44c7-8b0a-432aaad3c6be
2020-05-06T08:00:00.000+08:00,"Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin",LLY,http://www.zacks.com/stock/news/915230/cardiovascular-systems-csii-reports-q3-loss-lower-margin?cid=CS-BENZ-FT-analyst_blog|earnings_article-915230,Zacks,,,,0,0,062ea4d9-8c9f-4005-99e1-bb61eeec3cc0
2020-05-06T08:00:00.000+08:00,PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates,LLY,http://www.zacks.com/stock/news/915190/perkinelmer-pki-q1-earnings-and-revenues-surpass-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-915190,Zacks,,,,0,0,dfde1bf5-8a72-4fca-b095-fcdcaab91533
2020-05-06T08:00:00.000+08:00,"NN Investment Partners Holdings N.V. Buys Mastercard Inc, Apple Inc, The Estee Lauder Inc, ...",LLY,http://www.gurufocus.com/news/1127520/nn-investment-partners-holdings-nv-buys-mastercard-inc-apple-inc-the-estee-lauder-inc-sells-cigna-corp-simon-property-group-inc-merck-inc,GuruFocus,,,,0,0,132f05ca-347f-46ad-b2bd-8c24bdb34721
2020-05-06T08:00:00.000+08:00,Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum ...,LLY,http://www.gurufocus.com/news/1128601/tyvyt-sintilimab-injection-combined-with-gemzar-gemcitabine-for-injection-and-platinum-chemotherapy-met-the-predefined-primary-endpoint-in-the-phase-3-orient12-study-as-firstline-therapy-in-patients-with-locally-advan,GuruFocus,,,,0,0,6fe3c93f-90cf-432a-9819-96be7953d732
2020-05-06T08:00:00.000+08:00,"Mengis Capital Management, Inc. Buys 'M Co, SPDR S&P 5……, Eli Lilly and Co, Sells ...",LLY,http://www.gurufocus.com/news/1128307/mengis-capital-management-inc-buys-3m-co-spdr-sp-500-eli-lilly-and-co-sells-williams-inc-nuveen-energy-mlp-total-return-fund-allegheny-technologies-inc,GuruFocus,,,,0,0,5a184a36-2644-4181-8ee5-6fdd546e3b85
2020-05-06T08:00:00.000+08:00,"Jennison Associates Llc Buys Eli Lilly and Co, Uber Technologies Inc, Goldman Sachs Group Inc, ...",LLY,http://www.gurufocus.com/news/1127973/jennison-associates-llc-buys-eli-lilly-and-co-uber-technologies-inc-goldman-sachs-group-inc-sells-the-walt-disney-co-intuitive-surgical-inc-nike-inc,GuruFocus,,,,0,0,d8508d2e-3288-47d7-a38d-c70721f1ab8e
2020-05-06T08:00:00.000+08:00,"Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View",LLY,http://www.zacks.com/stock/news/915656/myriad-genetics-mygn-lags-q3-earnings-estimates-cancels-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-915656,Zacks,,,,0,0,0a454181-b5b3-46c9-8399-01a1b7ead425
2020-05-06T08:00:00.000+08:00,"Pearl River Capital, LLC Buys American Electric Power Co Inc, Goldman Sachs Group Inc, ...",LLY,http://www.gurufocus.com/news/1127563/pearl-river-capital-llc-buys-american-electric-power-co-inc-goldman-sachs-group-inc-electronic-arts-inc-sells-honeywell-international-inc-sp-global-inc-northern-trust-corp,GuruFocus,,,,0,0,effe4e60-26bc-4e28-8567-5105bc8efcd9
2020-05-06T08:00:00.000+08:00,"CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate",LLY,http://www.zacks.com/stock/news/915641/cvs-health-cvs-q1-earnings-top-estimates-costs-escalate?cid=CS-BENZ-FT-analyst_blog|earnings_article-915641,Zacks,,,,0,0,3ad35e11-bb7f-438a-ba9e-acdffcee099f
2020-05-06T08:00:00.000+08:00,Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates,LLY,http://www.zacks.com/stock/news/915493/inogens-ingn-q1-earnings-and-revenues-beat-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-915493,Zacks,,,,0,0,2e799701-9c99-47c3-8ca4-8e32d0701c7c
2020-05-06T08:00:00.000+08:00,DaVita (DVA) Earnings and Revenues Beat Estimates in Q1,LLY,http://www.zacks.com/stock/news/915484/davita-dva-earnings-and-revenues-beat-estimates-in-q1?cid=CS-BENZ-FT-analyst_blog|earnings_article-915484,Zacks,,,,0,0,e70e12b7-541a-4c35-87f9-3a36112ccf60
2020-05-06T08:00:00.000+08:00,"Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin",LLY,http://www.zacks.com/stock/news/915230/cardiovascular-systems-csii-reports-q3-loss-lower-margin?cid=CS-BENZ-FT-analyst_blog|earnings_article-915230,Zacks,,,,0,0,b91aa3b0-81b1-41e0-878d-abac1778028f
2020-05-06T08:00:00.000+08:00,PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates,LLY,http://www.zacks.com/stock/news/915190/perkinelmer-pki-q1-earnings-and-revenues-surpass-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-915190,Zacks,,,,0,0,f06f00f3-5537-46d2-9ce2-7533542c00f7
2020-05-06T08:00:00.000+08:00,"NN Investment Partners Holdings N.V. Buys Mastercard Inc, Apple Inc, The Estee Lauder Inc, ...",LLY,http://www.gurufocus.com/news/1127520/nn-investment-partners-holdings-nv-buys-mastercard-inc-apple-inc-the-estee-lauder-inc-sells-cigna-corp-simon-property-group-inc-merck-inc,GuruFocus,,,,0,0,b0607e6d-5ac0-4367-891a-4213a4aa210b
2020-05-05T08:00:00.000+08:00,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,LLY,https://www.benzinga.com/wiim/20/05/15957697/shares-of-several-healthcare-companies-are-trading-higher-amid-positive-investor-sentiment-as-some-u,Benzinga Newsdesk,,,,0,0,a68e303d-1d79-4860-b7c1-ad65a66f30a5
2020-05-05T08:00:00.000+08:00,Lilly to Participate in UBS Virtual Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1127200/lilly-to-participate-in-ubs-virtual-global-healthcare-conference,GuruFocus,,,,0,0,94a266d3-4a3f-4bb3-88f4-0c9447f0b3f0
2020-05-05T08:00:00.000+08:00,"The Vanguard Health Care Fund Exits CVS Health, Teva Pharmaceutical",LLY,http://www.gurufocus.com/news/1126786/the-vanguard-health-care-fund-exits-cvs-health-teva-pharmaceutical,GuruFocus,,,,0,0,e58cc262-3bca-40fa-89d8-b09886206962
2020-05-05T08:00:00.000+08:00,"Highland Capital Management, Llc Buys Johnson & Johnson, Truist Financial Corp, Honeywell ...",LLY,http://www.gurufocus.com/news/1126269/highland-capital-management-llc-buys-johnson--johnson-truist-financial-corp-honeywell-international-inc-sells-boeing-co-ishares-core-msci-eafe-delta-air-lines-inc,GuruFocus,,,,0,0,fb409e74-e19c-401c-921f-71b65fca3cfc
2020-05-05T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/914066/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-914066,Zacks,,,,0,0,129b6af5-0ec4-4674-a68a-edfd8a9bf6f5
2020-05-05T08:00:00.000+08:00,"Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues",LLY,http://www.zacks.com/stock/news/914228/incyte-incy-misses-q1-earnings-estimates-beats-on-revenues?cid=CS-BENZ-FT-analyst_blog|earnings_article-914228,Zacks,,,,0,0,0d54b17a-8efd-48e8-a7ee-a58d88c3651d
2020-05-05T08:00:00.000+08:00,Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates,LLY,http://www.zacks.com/stock/news/914225/henry-schein-hsic-q1-earnings-and-revenues-top-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-914225,Zacks,,,,0,0,e111b0ef-cb30-4d6b-9ae6-a40585e53591
2020-05-05T08:00:00.000+08:00,"Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates",LLY,http://www.zacks.com/stock/news/914196/tandem-diabetes-tndm-q1-loss-widens-revenues-top-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-914196,Zacks,,,,0,0,0b358823-9f92-4af7-b9f0-0ca5fc38200f
2020-05-05T08:00:00.000+08:00,"First Quadrant L P Buys UnitedHealth Group Inc, Eli Lilly and Co, Sanmina Corp, Sells Vanguard ...",LLY,http://www.gurufocus.com/news/1126066/first-quadrant-l-p-buys-unitedhealth-group-inc-eli-lilly-and-co-sanmina-corp-sells-vanguard-real-estate-vanguard-global-exus-real-estate-etf-ishares-iboxx--high-yield-corporate-bond,GuruFocus,,,,0,0,05e56069-0220-4dce-939b-a6c6597c98d5
2020-05-05T08:00:00.000+08:00,Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.,LLY,https://www.benzinga.com/wiim/20/05/15957697/shares-of-several-healthcare-companies-are-trading-higher-amid-positive-investor-sentiment-as-some-u,Benzinga Newsdesk,,,,0,0,f2c1f448-3c1e-4b6d-9063-8b941be6ca38
2020-05-05T08:00:00.000+08:00,Lilly to Participate in UBS Virtual Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1127200/lilly-to-participate-in-ubs-virtual-global-healthcare-conference,GuruFocus,,,,0,0,8f8a6873-b455-4c88-a165-31798eb7728c
2020-05-05T08:00:00.000+08:00,"The Vanguard Health Care Fund Exits CVS Health, Teva Pharmaceutical",LLY,http://www.gurufocus.com/news/1126786/the-vanguard-health-care-fund-exits-cvs-health-teva-pharmaceutical,GuruFocus,,,,0,0,f5a0c9a0-8428-48d6-aead-b67d4b7722df
2020-05-05T08:00:00.000+08:00,"Highland Capital Management, Llc Buys Johnson & Johnson, Truist Financial Corp, Honeywell ...",LLY,http://www.gurufocus.com/news/1126269/highland-capital-management-llc-buys-johnson--johnson-truist-financial-corp-honeywell-international-inc-sells-boeing-co-ishares-core-msci-eafe-delta-air-lines-inc,GuruFocus,,,,0,0,332138e4-728f-4bad-95b1-e906006f4e63
2020-05-05T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/914066/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-914066,Zacks,,,,0,0,64d4a415-6bfd-4e90-8c29-ea2b05fa6d4d
2020-05-05T08:00:00.000+08:00,"Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues",LLY,http://www.zacks.com/stock/news/914228/incyte-incy-misses-q1-earnings-estimates-beats-on-revenues?cid=CS-BENZ-FT-analyst_blog|earnings_article-914228,Zacks,,,,0,0,fddf6d05-33a2-4993-b1f2-041710405988
2020-05-05T08:00:00.000+08:00,Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates,LLY,http://www.zacks.com/stock/news/914225/henry-schein-hsic-q1-earnings-and-revenues-top-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-914225,Zacks,,,,0,0,0eeccb5d-91d3-4e98-aabe-d7af3d586295
2020-05-05T08:00:00.000+08:00,"Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates",LLY,http://www.zacks.com/stock/news/914196/tandem-diabetes-tndm-q1-loss-widens-revenues-top-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-914196,Zacks,,,,0,0,4dc08216-eba9-419b-bb1a-b9d1522eba4e
2020-05-05T08:00:00.000+08:00,"First Quadrant L P Buys UnitedHealth Group Inc, Eli Lilly and Co, Sanmina Corp, Sells Vanguard ...",LLY,http://www.gurufocus.com/news/1126066/first-quadrant-l-p-buys-unitedhealth-group-inc-eli-lilly-and-co-sanmina-corp-sells-vanguard-real-estate-vanguard-global-exus-real-estate-etf-ishares-iboxx--high-yield-corporate-bond,GuruFocus,,,,0,0,313c1540-8332-49a3-9ceb-ae9b370d7c51
2020-05-04T08:00:00.000+08:00,Lilly And Junshi Biosciences To Co-Develop Antibody Therapies For The Prevention And Treatment Of COVID-19,LLY,https://www.benzinga.com/general/biotech/20/05/15943172/lilly-and-junshi-biosciences-to-co-develop-antibody-therapies-for-the-prevention-and-treatment-of,Benzinga Newsdesk,,,,0,0,58b98df5-8dcc-4d76-8eee-42003fe926a1
2020-05-04T08:00:00.000+08:00,Lilly Declares Second-Quarter —…—… Dividend,LLY,http://www.gurufocus.com/news/1125493/lilly-declares-secondquarter-2020-dividend,GuruFocus,,,,0,0,ae031487-6dad-487e-94ab-5145b6603337
2020-05-04T08:00:00.000+08:00,"Cookson Peirce & Co Inc Buys Eli Lilly and Co, Vertex Pharmaceuticals Inc, Netflix Inc, ...",LLY,http://www.gurufocus.com/news/1125063/cookson-peirce--co-inc-buys-eli-lilly-and-co-vertex-pharmaceuticals-inc-netflix-inc-sells-hilton-worldwide-holdings-inc-transdigm-group-inc-abbott-laboratories,GuruFocus,,,,0,0,562923dd-a0f5-45e4-b07e-df5831b9a755
2020-05-04T08:00:00.000+08:00,"Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand",LLY,http://www.zacks.com/stock/news/913172/hill-roms-hrc-q2-earnings-top-estimates-margins-expand?cid=CS-BENZ-FT-analyst_blog|earnings_article-913172,Zacks,,,,0,0,9a3dd4fb-4e9e-41e7-aa4b-0fd716e79a2c
2020-05-04T08:00:00.000+08:00,Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1,LLY,http://www.zacks.com/stock/news/913170/teleflex-tfx-earnings-and-revenues-beat-estimates-in-q1?cid=CS-BENZ-FT-analyst_blog|earnings_article-913170,Zacks,,,,0,0,f041c49f-6f86-4b14-ac48-2acf3c689070
2020-05-04T08:00:00.000+08:00,"Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down",LLY,http://www.zacks.com/stock/news/913095/syneos-health-synh-tops-q1-earnings-estimates-margins-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-913095,Zacks,,,,0,0,d7c876d0-a617-4302-ad33-2f75aa2ef306
2020-05-04T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/912721/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-sector_etf-912721,Zacks,,,,0,0,e5e77af7-c915-4a11-ac93-a3b79adec451
2020-05-04T08:00:00.000+08:00,Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment ...,LLY,http://www.gurufocus.com/news/1124937/lilly-and-junshi-biosciences-to-codevelop-antibody-therapies-for-the-prevention-and-treatment-of-covid19,GuruFocus,,,,0,0,18149272-6681-4311-b997-e5a8cd13b163
2020-05-04T08:00:00.000+08:00,Lilly And Junshi Biosciences To Co-Develop Antibody Therapies For The Prevention And Treatment Of COVID-19,LLY,https://www.benzinga.com/general/biotech/20/05/15943172/lilly-and-junshi-biosciences-to-co-develop-antibody-therapies-for-the-prevention-and-treatment-of,Benzinga Newsdesk,,,,0,0,1c836cc4-1608-4509-b9d9-8e0806fb323d
2020-05-04T08:00:00.000+08:00,Lilly Declares Second-Quarter —…—… Dividend,LLY,http://www.gurufocus.com/news/1125493/lilly-declares-secondquarter-2020-dividend,GuruFocus,,,,0,0,df7cf466-eaed-4def-b7f0-2a19d78b32e3
2020-05-04T08:00:00.000+08:00,"Cookson Peirce & Co Inc Buys Eli Lilly and Co, Vertex Pharmaceuticals Inc, Netflix Inc, ...",LLY,http://www.gurufocus.com/news/1125063/cookson-peirce--co-inc-buys-eli-lilly-and-co-vertex-pharmaceuticals-inc-netflix-inc-sells-hilton-worldwide-holdings-inc-transdigm-group-inc-abbott-laboratories,GuruFocus,,,,0,0,d5498d42-c599-4235-9c0a-8162ea4ea36c
2020-05-04T08:00:00.000+08:00,"Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand",LLY,http://www.zacks.com/stock/news/913172/hill-roms-hrc-q2-earnings-top-estimates-margins-expand?cid=CS-BENZ-FT-analyst_blog|earnings_article-913172,Zacks,,,,0,0,8084d8b7-e365-4318-99e3-9b05ee76e0d2
2020-05-04T08:00:00.000+08:00,Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1,LLY,http://www.zacks.com/stock/news/913170/teleflex-tfx-earnings-and-revenues-beat-estimates-in-q1?cid=CS-BENZ-FT-analyst_blog|earnings_article-913170,Zacks,,,,0,0,5a83a7a2-32e9-494d-b702-8caacb2d0b0a
2020-05-04T08:00:00.000+08:00,"Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down",LLY,http://www.zacks.com/stock/news/913095/syneos-health-synh-tops-q1-earnings-estimates-margins-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-913095,Zacks,,,,0,0,51f903b4-7c10-46c8-96eb-1ac56c27f6dd
2020-05-04T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/912721/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-sector_etf-912721,Zacks,,,,0,0,33086211-b167-4c4e-a584-11b6ce2932dd
2020-05-04T08:00:00.000+08:00,Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment ...,LLY,http://www.gurufocus.com/news/1124937/lilly-and-junshi-biosciences-to-codevelop-antibody-therapies-for-the-prevention-and-treatment-of-covid19,GuruFocus,,,,0,0,c58dfeb8-b752-42be-a652-0e06ab127121
2020-05-03T08:00:00.000+08:00,Shanghai Junshi Biosciences Says Entered Research Collaboration and License Agreement With Eli Lilly; Says Parties Will Collaborate in Research Relating to Sars-cov-2 Neutralizing Antibodies,LLY,https://www.benzinga.com/news/20/05/15941096/shanghai-junshi-biosciences-says-entered-research-collaboration-and-license-agreement-with-eli-lilly,Charles Gross,,,,0,0,1c257faa-ae8a-493a-a659-88c2c5968c3c
2020-05-03T08:00:00.000+08:00,Shanghai Junshi Biosciences Says Entered Research Collaboration and License Agreement With Eli Lilly; Says Parties Will Collaborate in Research Relating to Sars-cov-2 Neutralizing Antibodies,LLY,https://www.benzinga.com/news/20/05/15941096/shanghai-junshi-biosciences-says-entered-research-collaboration-and-license-agreement-with-eli-lilly,Charles Gross,,,,0,0,f97872ef-e15c-4b8b-bab8-1a08e03bb087
2020-05-01T08:00:00.000+08:00,"Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View",LLY,http://www.zacks.com/stock/news/910477/illumina-ilmn-beats-q1-earnings-estimates-withdraws-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-910477,Zacks,,,,0,0,a5299b1f-24b3-486e-8e87-6b873211e836
2020-05-01T08:00:00.000+08:00,"Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View",LLY,http://www.zacks.com/stock/news/910477/illumina-ilmn-beats-q1-earnings-estimates-withdraws-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-910477,Zacks,,,,0,0,28652225-77e0-4d94-b90c-f2b8dbc8d2d3
2020-04-30T08:00:00.000+08:00,Lilly to Participate in Bank of America Securities Health Care Conference,LLY,http://www.gurufocus.com/news/1122780/lilly-to-participate-in-bank-of-america-securities-health-care-conference,GuruFocus,,,,0,0,7edeb6db-f753-439e-8099-0012a30aee98
2020-04-30T08:00:00.000+08:00,"Chartwell Investment Partners, Inc. Buys Allison Transmission Holdings Inc, Truist Financial ...",LLY,http://www.gurufocus.com/news/1121910/chartwell-investment-partners-inc-buys-allison-transmission-holdings-inc-truist-financial-corp-amdocs-sells-duke-realty-corp-mantech-international-corp-truist-financial-corp,GuruFocus,,,,0,0,49279789-fa61-4161-88bf-ecd91a2c09b7
2020-04-30T08:00:00.000+08:00,"Moody Lynn & Lieberson, Inc. Buys ishares Gold Trust, Eli Lilly and Co, ServiceNow Inc, ...",LLY,http://www.gurufocus.com/news/1121851/moody-lynn--lieberson-inc-buys-ishares-gold-trust-eli-lilly-and-co-servicenow-inc-sells-sysco-corp-chevron-corp-trane-technologies-plc,GuruFocus,,,,0,0,93a05348-9a77-4b60-a31b-d33a8a8da7f1
2020-04-30T08:00:00.000+08:00,"Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View",LLY,http://www.zacks.com/stock/news/901586/hologic-holx-beats-q2-earnings-estimates-withdraws-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-901586,Zacks,,,,0,0,80ee1874-c7c0-47ed-be4c-0687f96b0729
2020-04-30T08:00:00.000+08:00,Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat,LLY,http://www.zacks.com/stock/news/900034/remdesivir-progresses-on-coronavirus-trial-pharma-upbeat?cid=CS-BENZ-FT-analyst_blog|industry_focus-900034,Zacks,,,,0,0,1f89dfa3-b600-4ae0-bf7d-773cd37e862c
2020-04-30T08:00:00.000+08:00,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat,LLY,http://www.zacks.com/stock/news/899914/united-therapeutics-uthr-down-despite-q1-earnings-beat?cid=CS-BENZ-FT-analyst_blog|earnings_article-899914,Zacks,,,,0,0,27ac9d7a-25e0-46ca-a3d4-7b2930385eba
2020-04-30T08:00:00.000+08:00,Lilly to Participate in Bank of America Securities Health Care Conference,LLY,http://www.gurufocus.com/news/1122780/lilly-to-participate-in-bank-of-america-securities-health-care-conference,GuruFocus,,,,0,0,4ce11c87-df72-413e-9d9d-661cfbd060cf
2020-04-30T08:00:00.000+08:00,"Chartwell Investment Partners, Inc. Buys Allison Transmission Holdings Inc, Truist Financial ...",LLY,http://www.gurufocus.com/news/1121910/chartwell-investment-partners-inc-buys-allison-transmission-holdings-inc-truist-financial-corp-amdocs-sells-duke-realty-corp-mantech-international-corp-truist-financial-corp,GuruFocus,,,,0,0,63d05b79-5b93-49b0-b6c6-ef800ff6ad1b
2020-04-30T08:00:00.000+08:00,"Moody Lynn & Lieberson, Inc. Buys ishares Gold Trust, Eli Lilly and Co, ServiceNow Inc, ...",LLY,http://www.gurufocus.com/news/1121851/moody-lynn--lieberson-inc-buys-ishares-gold-trust-eli-lilly-and-co-servicenow-inc-sells-sysco-corp-chevron-corp-trane-technologies-plc,GuruFocus,,,,0,0,39a97f72-5d79-4516-935c-6c5185472420
2020-04-30T08:00:00.000+08:00,"Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View",LLY,http://www.zacks.com/stock/news/901586/hologic-holx-beats-q2-earnings-estimates-withdraws-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-901586,Zacks,,,,0,0,9b9a23c1-3961-4580-9250-da33f5092194
2020-04-30T08:00:00.000+08:00,Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat,LLY,http://www.zacks.com/stock/news/900034/remdesivir-progresses-on-coronavirus-trial-pharma-upbeat?cid=CS-BENZ-FT-analyst_blog|industry_focus-900034,Zacks,,,,0,0,8e3bb1d3-add5-4c01-ab09-24054271572e
2020-04-30T08:00:00.000+08:00,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat,LLY,http://www.zacks.com/stock/news/899914/united-therapeutics-uthr-down-despite-q1-earnings-beat?cid=CS-BENZ-FT-analyst_blog|earnings_article-899914,Zacks,,,,0,0,c7bc0665-6f0e-464a-8d13-68ebb603ca5e
2020-04-29T08:00:00.000+08:00,"Chronos Wealth Management, LLC Buys Illinois Tool Works Inc, Facebook Inc, iShares U.S. ...",LLY,http://www.gurufocus.com/news/1120767/chronos-wealth-management-llc-buys-illinois-tool-works-inc-facebook-inc-ishares-us-preferred-stock-sells-constellation-brands-inc-alibaba-group-holding-3m-co,GuruFocus,,,,0,0,f03e7bc2-e351-4726-9a4a-bb071cc109ee
2020-04-29T08:00:00.000+08:00,Bull of the Day: Eli Lilly (LLY),LLY,http://www.zacks.com/commentary/897187/bull-of-the-day-eli-lilly-lly?cid=CS-BENZ-FT-bull_of_the_day-897187,Zacks,,,,0,0,808e5824-e569-46a4-a09a-4473d968cf7d
2020-04-29T08:00:00.000+08:00,"Chronos Wealth Management, LLC Buys Illinois Tool Works Inc, Facebook Inc, iShares U.S. ...",LLY,http://www.gurufocus.com/news/1120767/chronos-wealth-management-llc-buys-illinois-tool-works-inc-facebook-inc-ishares-us-preferred-stock-sells-constellation-brands-inc-alibaba-group-holding-3m-co,GuruFocus,,,,0,0,1213f736-7544-4158-9cb2-83cf062bffc5
2020-04-29T08:00:00.000+08:00,Bull of the Day: Eli Lilly (LLY),LLY,http://www.zacks.com/commentary/897187/bull-of-the-day-eli-lilly-lly?cid=CS-BENZ-FT-bull_of_the_day-897187,Zacks,,,,0,0,b07fe5af-92d5-433e-944c-b0090a1702d5
2020-04-28T08:00:00.000+08:00,"Sym Financial Corporation Buys Vanguard Total World Stock Index, Schwab Short-Term U.S. ...",LLY,http://www.gurufocus.com/news/1118941/sym-financial-corporation-buys-vanguard-total-world-stock-index-schwab-shortterm-us-treasury-lincoln-national-corp-sells-vanguard-total-stock-market-corteva-inc-ishares-edge-msci-min-vol-usa,GuruFocus,,,,0,0,d4bea2db-ac03-4c54-b9f1-8d6c16014105
2020-04-28T08:00:00.000+08:00,Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates,LLY,http://www.zacks.com/stock/news/894178/merck-mrk-surpasses-q1-earnings-and-revenue-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-894178,Zacks,,,,0,0,d728f53e-9cf7-4bc4-b127-7e5b3664fbcf
2020-04-28T08:00:00.000+08:00,Axsome Shares Jump —5% on Alzheimer's Study Results,LLY,http://www.gurufocus.com/news/1118254/axsome-shares-jump-25-on-alzheimers-study-results,GuruFocus,,,,0,0,191170d1-b1c8-4835-a7b3-acd7a7935477
2020-04-28T08:00:00.000+08:00,Solid Rally Kicks Off Tech Week,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-25159,Zacks,,,,0,0,28590109-7c52-4487-9165-c3438bd832bc
2020-04-28T08:00:00.000+08:00,"Sym Financial Corporation Buys Vanguard Total World Stock Index, Schwab Short-Term U.S. ...",LLY,http://www.gurufocus.com/news/1118941/sym-financial-corporation-buys-vanguard-total-world-stock-index-schwab-shortterm-us-treasury-lincoln-national-corp-sells-vanguard-total-stock-market-corteva-inc-ishares-edge-msci-min-vol-usa,GuruFocus,,,,0,0,56eb8b36-8e8a-4231-8429-8bd7118c2106
2020-04-28T08:00:00.000+08:00,Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates,LLY,http://www.zacks.com/stock/news/894178/merck-mrk-surpasses-q1-earnings-and-revenue-estimates?cid=CS-BENZ-FT-analyst_blog|earnings_article-894178,Zacks,,,,0,0,565703ac-0f8e-4141-b1ac-41a788c397d8
2020-04-28T08:00:00.000+08:00,Axsome Shares Jump —5% on Alzheimer's Study Results,LLY,http://www.gurufocus.com/news/1118254/axsome-shares-jump-25-on-alzheimers-study-results,GuruFocus,,,,0,0,7f7bb064-640c-476f-a266-1558eba7e4c2
2020-04-28T08:00:00.000+08:00,Solid Rally Kicks Off Tech Week,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-25159,Zacks,,,,0,0,18684b55-d9dd-4140-a4e5-4be2fe6b10f3
2020-04-27T08:00:00.000+08:00,"Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead",LLY,https://www.benzinga.com/news/earnings/20/04/15884587/apple-and-amazon-earnings-fed-meeting-among-highlights-in-busy-week-ahead,JJ Kinahan,,,,0,0,aabe4a90-4e63-421c-b090-7ecfe7ef7e07
2020-04-27T08:00:00.000+08:00,"Geneva Partners, LLC Buys Eli Lilly and Co, Netflix Inc, Veeva Systems Inc, Sells Vanguard High ...",LLY,http://www.gurufocus.com/news/1118071/geneva-partners-llc-buys-eli-lilly-and-co-netflix-inc-veeva-systems-inc-sells-vanguard-high-dividend-yield-the-walt-disney-co-jpmorgan-chase,GuruFocus,,,,0,0,dbd701eb-da71-485e-905b-f305baeb0638
2020-04-27T08:00:00.000+08:00,"Huntington National Bank Buys Apple Inc, NVIDIA Corp, Fidelity Total Bond, Sells iShares Core ...",LLY,http://www.gurufocus.com/news/1118091/huntington-national-bank-buys-apple-inc-nvidia-corp-fidelity-total-bond-sells-ishares-core-sp-midcap-dollar-tree-inc-constellation-brands-inc,GuruFocus,,,,0,0,25cd8cb5-e31a-4e55-9fa4-9d4ff3a41d79
2020-04-27T08:00:00.000+08:00,"Apple And Amazon Earnings, Fed Meeting Among Highlights In Busy Week Ahead",LLY,https://www.benzinga.com/news/earnings/20/04/15884587/apple-and-amazon-earnings-fed-meeting-among-highlights-in-busy-week-ahead,JJ Kinahan,,,,0,0,984ef1a5-cb33-4739-8f9e-dfcf2ba3f269
2020-04-27T08:00:00.000+08:00,"Geneva Partners, LLC Buys Eli Lilly and Co, Netflix Inc, Veeva Systems Inc, Sells Vanguard High ...",LLY,http://www.gurufocus.com/news/1118071/geneva-partners-llc-buys-eli-lilly-and-co-netflix-inc-veeva-systems-inc-sells-vanguard-high-dividend-yield-the-walt-disney-co-jpmorgan-chase,GuruFocus,,,,0,0,2a0675fd-d5ad-4a3f-b868-2c24cf711420
2020-04-27T08:00:00.000+08:00,"Huntington National Bank Buys Apple Inc, NVIDIA Corp, Fidelity Total Bond, Sells iShares Core ...",LLY,http://www.gurufocus.com/news/1118091/huntington-national-bank-buys-apple-inc-nvidia-corp-fidelity-total-bond-sells-ishares-core-sp-midcap-dollar-tree-inc-constellation-brands-inc,GuruFocus,,,,0,0,5956dc5d-ac18-499e-b0c4-b39de03d0dea
2020-04-24T08:00:00.000+08:00,"CFRA Maintains Hold on Eli Lilly, Raises Price Target to $167",LLY,https://www.benzinga.com/news/20/04/15875697/cfra-maintains-hold-on-eli-lilly-raises-price-target-to-167,Vick Meyer,,,,0,0,04fc6038-85b9-4c80-aa03-3f31d3c0c8de
2020-04-24T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company announced the NMPA has of China has accepted the supplemental NDA for Sintilimab in combination with ALIMTA and Platinum as first-line therapy in non-squamous non-small cell lung cancer.,LLY,https://www.benzinga.com/wiim/20/04/15874985/eli-lilly-shares-are-trading-higher-after-the-company-announced-the-nmpa-has-of-china-has-accepted-t,Benzinga Newsdesk,,,,0,0,ddc20d3f-3dca-4a7f-800b-798b7e9f6b61
2020-04-24T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/04/15874963/stocks-that-hit-52-week-highs-on-friday,Benzinga Insights,,,,0,0,e25760e5-5a48-410f-8417-471b449c4c82
2020-04-24T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",LLY,https://www.benzinga.com/general/biotech/20/04/15873096/the-daily-biotech-pulse-fda-approves-sanofis-meningococcal-vaccine-pluristem-secures-54m-in-fundi,Shanthi Rexaline,,,,0,0,c579158a-1921-46b4-b0a0-09b6769b1d8c
2020-04-24T08:00:00.000+08:00,Eli Lilly Stock Joins IBD's Long-Term Leaders Portfolio,LLY,http://www.investors.com/research/eli-lilly-stock-joins-ibds-long-term-leaders-portfolio/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,5ba818fb-4827-4cfa-92ef-1f621f6c7b9e
2020-04-24T08:00:00.000+08:00,"Thinking about trading options or stock in Eli Lilly, Square, Tesla, UnitedHealth Group, or ...",LLY,http://www.gurufocus.com/news/1115456/thinking-about-trading-options-or-stock-in-eli-lilly-square-tesla-unitedhealth-group-or-zoom-video-communications,GuruFocus,,,,0,0,bf50cb9a-9e23-4c54-99d5-ffcfeefbb325
2020-04-24T08:00:00.000+08:00,Will Eli Lilly and Company Continue to Surge Higher?,LLY,http://www.zacks.com/stock/news/887487/will-eli-lilly-and-company-continue-to-surge-higher?cid=CS-BENZ-FT-tale_of_the_tape|20_day_moving_average-887487,Zacks,,,,0,0,d523108e-20e1-40bc-b356-46a56f24fd88
2020-04-24T08:00:00.000+08:00,"Company News for Apr 24, 2020",LLY,http://www.zacks.com/stock/news/887485/company-news-for-apr-24-2020?cid=CS-BENZ-FT-corporate_summary-887485,Zacks,,,,0,0,9aeacb01-e00a-4aff-84ad-f0f8043e10ee
2020-04-24T08:00:00.000+08:00,S&P 500 Stocks That Rose In The Crisis: It's A Market Of Stocks - Part 2,LLY,https://talkmarkets.com/content/sp-500-stocks-that-rose-in-the-crisis-its-a-market-of-stocks-part-2?post=259792,TalkMarkets,,,,0,0,80d1bec3-a1dc-4fcb-b53f-5542d25ecd59
2020-04-24T08:00:00.000+08:00,"Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN",LLY,http://www.zacks.com/stock/news/887364/pharma-stock-roundup-q1-earnings-of-lly-coronavirus-update-from-pfe-nvs-azn?cid=CS-BENZ-FT-analyst_blog|stock_roundup-887364,Zacks,,,,0,0,351b1f39-1fe8-40b4-a41f-59a85f9e8ffa
2020-04-24T08:00:00.000+08:00,"CFRA Maintains Hold on Eli Lilly, Raises Price Target to $167",LLY,https://www.benzinga.com/news/20/04/15875697/cfra-maintains-hold-on-eli-lilly-raises-price-target-to-167,Vick Meyer,,,,0,0,1c71c0ec-646d-4805-a54e-363a8c4923dc
2020-04-24T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company announced the NMPA has of China has accepted the supplemental NDA for Sintilimab in combination with ALIMTA and Platinum as first-line therapy in non-squamous non-small cell lung cancer.,LLY,https://www.benzinga.com/wiim/20/04/15874985/eli-lilly-shares-are-trading-higher-after-the-company-announced-the-nmpa-has-of-china-has-accepted-t,Benzinga Newsdesk,,,,0,0,9411c6b3-04af-4243-b4d9-94f052b95e9a
2020-04-24T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/04/15874963/stocks-that-hit-52-week-highs-on-friday,Benzinga Insights,,,,0,0,4640cd8c-4ecf-43a3-b49a-4b7246c1820c
2020-04-24T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",LLY,https://www.benzinga.com/general/biotech/20/04/15873096/the-daily-biotech-pulse-fda-approves-sanofis-meningococcal-vaccine-pluristem-secures-54m-in-fundi,Shanthi Rexaline,,,,0,0,21ea200e-41d1-4971-abd8-501c5fa1875d
2020-04-24T08:00:00.000+08:00,Eli Lilly Stock Joins IBD's Long-Term Leaders Portfolio,LLY,http://www.investors.com/research/eli-lilly-stock-joins-ibds-long-term-leaders-portfolio/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,a76a4c77-4ad7-4917-8e6a-116d35e0b9ba
2020-04-24T08:00:00.000+08:00,"Thinking about trading options or stock in Eli Lilly, Square, Tesla, UnitedHealth Group, or ...",LLY,http://www.gurufocus.com/news/1115456/thinking-about-trading-options-or-stock-in-eli-lilly-square-tesla-unitedhealth-group-or-zoom-video-communications,GuruFocus,,,,0,0,060a4d2f-76b6-4aa5-b716-4c76fa7c7532
2020-04-24T08:00:00.000+08:00,Will Eli Lilly and Company Continue to Surge Higher?,LLY,http://www.zacks.com/stock/news/887487/will-eli-lilly-and-company-continue-to-surge-higher?cid=CS-BENZ-FT-tale_of_the_tape|20_day_moving_average-887487,Zacks,,,,0,0,1c7657df-2ed2-40b9-8410-d52f8545842f
2020-04-24T08:00:00.000+08:00,"Company News for Apr 24, 2020",LLY,http://www.zacks.com/stock/news/887485/company-news-for-apr-24-2020?cid=CS-BENZ-FT-corporate_summary-887485,Zacks,,,,0,0,f41d7d0e-52e0-44b7-acaa-3d83e2c2cc00
2020-04-24T08:00:00.000+08:00,S&P 500 Stocks That Rose In The Crisis: It's A Market Of Stocks - Part 2,LLY,https://talkmarkets.com/content/sp-500-stocks-that-rose-in-the-crisis-its-a-market-of-stocks-part-2?post=259792,TalkMarkets,,,,0,0,0ce26f77-aff3-4063-9a25-26fc8c63b869
2020-04-24T08:00:00.000+08:00,"Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN",LLY,http://www.zacks.com/stock/news/887364/pharma-stock-roundup-q1-earnings-of-lly-coronavirus-update-from-pfe-nvs-azn?cid=CS-BENZ-FT-analyst_blog|stock_roundup-887364,Zacks,,,,0,0,8a1d8bf2-7efc-4773-bf42-a2ffa48e169d
2020-04-23T08:00:00.000+08:00,Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop,LLY,https://www.benzinga.com/news/earnings/20/04/15868998/mid-afternoon-market-update-sleep-number-surges-on-strong-q1-results-netgear-shares-drop,Lisa Levin,,,,0,0,18a925f7-c51b-420c-b63c-bf531e05bb81
2020-04-23T08:00:00.000+08:00,Afternoon Market Stats in 5 Minutes,LLY,https://www.benzinga.com/intraday-update/20/04/15867187/afternoon-market-stats-in-5-minutes,Benzinga Insights,,,,0,0,32f24d65-5149-41c8-ae5d-19bbed897cc8
2020-04-23T08:00:00.000+08:00,Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings,LLY,https://www.benzinga.com/news/earnings/20/04/15867563/mid-day-market-update-crude-oil-jumps-31-invesco-shares-slide-on-downbeat-earnings,Lisa Levin,,,,0,0,596c5193-eed1-4214-918d-8fde83555bf4
2020-04-23T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/04/15866414/stocks-that-hit-52-week-highs-on-thursday,Benzinga Insights,,,,0,0,1a427a9f-9428-4815-947b-961c2e4081e9
2020-04-23T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views,LLY,https://www.benzinga.com/news/earnings/20/04/15866179/mid-morning-market-update-markets-open-higher-eli-lilly-beats-q1-views,Lisa Levin,,,,0,0,22dac53f-82a5-42c0-aa98-9f3b4578c739
2020-04-23T08:00:00.000+08:00,Eli Lilly Kicks Off Earnings Day With A Beat And Investors Prepare For Intel After Close,LLY,https://www.benzinga.com/news/earnings/20/04/15865752/eli-lilly-kicks-off-earnings-day-with-a-beat-and-investors-prepare-for-intel-after-close,JJ Kinahan,,,,0,0,39cc01a5-700b-4f0d-bb1b-87e06ccdf149
2020-04-23T08:00:00.000+08:00,"From Eli Lilly Earnings Conference Call: CFO Says Expecting Muted Impact From Unemployment In 2020, Sees A Bigger Impact In 2021",LLY,https://www.benzinga.com/news/20/04/15865645/from-eli-lilly-earnings-conference-call-cfo-says-expecting-muted-impact-from-unemployment-in-2020-se,Benzinga Newsdesk,,,,0,0,f9c6f1f5-06f0-41d2-b610-52076ae57dbc
2020-04-23T08:00:00.000+08:00,Eli Lilly And Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued FY20 EPS and sales guidance above analyst estimates.,LLY,https://www.benzinga.com/wiim/20/04/15864917/eli-lilly-and-co-shares-are-trading-higher-after-the-company-reported-better-than-expected-q1-eps-an,Benzinga Newsdesk,,,,0,0,954eea97-8403-4b8e-858f-90f4d84f075c
2020-04-23T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",LLY,https://www.benzinga.com/general/biotech/20/04/15863794/the-daily-biotech-pulse-fda-nod-for-immunomedics-lillys-solid-q1-beat-predictive-oncology-restruc,Shanthi Rexaline,,,,0,0,7f76b617-03d6-4831-a9c5-2e48d9b10ad9
2020-04-23T08:00:00.000+08:00,"UPDATE: Eli Lilly FY20 Adj. EPS Guidance Raised, Widened From $6.70-$6.80 To $6.70-$6.90",LLY,https://www.benzinga.com/news/20/04/15863392/update-eli-lilly-fy20-adj-eps-guidance-raised-widened-from-6-70-6-80-to-6-70-6-90,Benzinga Newsdesk,,,,0,0,0347c7ff-3505-44cd-9b19-9ff5710f89e4
2020-04-23T08:00:00.000+08:00,"Eli Lilly Sees FY20 Adj. EPS $6.70-$6.90 vs $6.73 Estimate, Sales $23.7B-$24.2B vs $23.84B Est.",LLY,https://www.benzinga.com/news/20/04/15863388/eli-lilly-sees-fy20-adj-eps-6-70-6-90-vs-6-73-estimate-sales-23-7b-24-2b-vs-23-84b-est,Benzinga Newsdesk,,,,0,0,53fba134-1a09-44a2-95a0-3a21f3234891
2020-04-23T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.750 Beats $1.480 Estimate, Sales $5.860B Beat $5.510B Estimate",LLY,https://www.benzinga.com/news/earnings/20/04/15863376/eli-lilly-q1-adj-eps-1-750-beats-1-480-estimate-sales-5-860b-beat-5-510b-estimate,Benzinga Newsdesk,,,,0,0,6c923d39-f936-420b-b82e-c94a297fa7dd
2020-04-23T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports",LLY,https://www.benzinga.com/news/earnings/20/04/15863165/a-peek-into-the-markets-us-stock-futures-flat-ahead-of-earnings-economic-reports,Lisa Levin,,,,0,0,ba307427-b971-4172-8aae-5f3706be9fc3
2020-04-23T08:00:00.000+08:00,"8 Stocks To Watch For April 23, 2020",LLY,https://www.benzinga.com/news/earnings/20/04/15862800/8-stocks-to-watch-for-april-23-2020,Lisa Levin,,,,0,0,8129b957-61e0-46b0-80d2-2157807aaf06
2020-04-23T08:00:00.000+08:00,"Earnings Scheduled For April 23, 2020",LLY,https://www.benzinga.com/news/earnings/20/04/15862746/earnings-scheduled-for-april-23-2020,Lisa Levin,,,,0,0,43009d12-f564-41d3-8498-205ba7e661a9
2020-04-23T08:00:00.000+08:00,Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for ...,LLY,http://www.gurufocus.com/news/1114896/innovent-and-eli-lilly-announce-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-alimta-pemetrexed-and-platinum-as-firstline-therapy-in-nonsquamous-nsclc,GuruFocus,,,,0,0,2e8933df-4cc9-4169-909b-93115e2242a3
2020-04-23T08:00:00.000+08:00,"Van Leeuwen & Company, LLC Buys UnitedHealth Group Inc, Microsoft Corp, SPDR S&P ...",LLY,http://www.gurufocus.com/news/1114596/van-leeuwen--company-llc-buys-unitedhealth-group-inc-microsoft-corp-spdr-sp-500-sells-allstate-corp-boeing-co-first-trust-vl-dividend,GuruFocus,,,,0,0,82ef43d5-1ce0-469a-9ae6-0eb42efe86b0
2020-04-23T08:00:00.000+08:00,Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know,LLY,http://www.zacks.com/stock/news/885692/eli-lilly-lly-is-up-793-in-one-week-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-885692,Zacks,,,,0,0,99f3fbb9-bd29-44a7-a72b-762b01e3ad1e
2020-04-23T08:00:00.000+08:00,Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates,LLY,http://www.zacks.com/stock/news/885139/eli-lilly-lly-surpasses-q1-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-885139,Zacks,,,,0,0,f50545a2-cb3f-4897-93d4-78cd7af854c8
2020-04-23T08:00:00.000+08:00,Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop,LLY,https://www.benzinga.com/news/earnings/20/04/15868998/mid-afternoon-market-update-sleep-number-surges-on-strong-q1-results-netgear-shares-drop,Lisa Levin,,,,0,0,b9ec1159-c611-4674-abab-6b911918610d
2020-04-23T08:00:00.000+08:00,Afternoon Market Stats in 5 Minutes,LLY,https://www.benzinga.com/intraday-update/20/04/15867187/afternoon-market-stats-in-5-minutes,Benzinga Insights,,,,0,0,7c4ed4dd-7bbe-443b-b4e0-addb579ce175
2020-04-23T08:00:00.000+08:00,Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings,LLY,https://www.benzinga.com/news/earnings/20/04/15867563/mid-day-market-update-crude-oil-jumps-31-invesco-shares-slide-on-downbeat-earnings,Lisa Levin,,,,0,0,85cacbdc-096e-406f-b9d8-ad370fbcdd29
2020-04-23T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/04/15866414/stocks-that-hit-52-week-highs-on-thursday,Benzinga Insights,,,,0,0,8e15083a-7f84-4186-854d-454a21b22173
2020-04-23T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views,LLY,https://www.benzinga.com/news/earnings/20/04/15866179/mid-morning-market-update-markets-open-higher-eli-lilly-beats-q1-views,Lisa Levin,,,,0,0,56558e64-a28a-4d68-90ac-1ac03794097f
2020-04-23T08:00:00.000+08:00,Eli Lilly Kicks Off Earnings Day With A Beat And Investors Prepare For Intel After Close,LLY,https://www.benzinga.com/news/earnings/20/04/15865752/eli-lilly-kicks-off-earnings-day-with-a-beat-and-investors-prepare-for-intel-after-close,JJ Kinahan,,,,0,0,d2ed2401-8c02-45e8-b534-9c8b8b49fcd3
2020-04-23T08:00:00.000+08:00,"From Eli Lilly Earnings Conference Call: CFO Says Expecting Muted Impact From Unemployment In 2020, Sees A Bigger Impact In 2021",LLY,https://www.benzinga.com/news/20/04/15865645/from-eli-lilly-earnings-conference-call-cfo-says-expecting-muted-impact-from-unemployment-in-2020-se,Benzinga Newsdesk,,,,0,0,e07d43d4-8ac1-4de6-b515-f785c03a7863
2020-04-23T08:00:00.000+08:00,Eli Lilly And Co shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued FY20 EPS and sales guidance above analyst estimates.,LLY,https://www.benzinga.com/wiim/20/04/15864917/eli-lilly-and-co-shares-are-trading-higher-after-the-company-reported-better-than-expected-q1-eps-an,Benzinga Newsdesk,,,,0,0,44a6660f-5d71-4f8b-bda8-5e2288f6bab5
2020-04-23T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",LLY,https://www.benzinga.com/general/biotech/20/04/15863794/the-daily-biotech-pulse-fda-nod-for-immunomedics-lillys-solid-q1-beat-predictive-oncology-restruc,Shanthi Rexaline,,,,0,0,49d74e6b-d960-49f4-ab56-173739ac045d
2020-04-23T08:00:00.000+08:00,"UPDATE: Eli Lilly FY20 Adj. EPS Guidance Raised, Widened From $6.70-$6.80 To $6.70-$6.90",LLY,https://www.benzinga.com/news/20/04/15863392/update-eli-lilly-fy20-adj-eps-guidance-raised-widened-from-6-70-6-80-to-6-70-6-90,Benzinga Newsdesk,,,,0,0,d54c99f7-4742-4280-bd91-0c3ee780997b
2020-04-23T08:00:00.000+08:00,"Eli Lilly Sees FY20 Adj. EPS $6.70-$6.90 vs $6.73 Estimate, Sales $23.7B-$24.2B vs $23.84B Est.",LLY,https://www.benzinga.com/news/20/04/15863388/eli-lilly-sees-fy20-adj-eps-6-70-6-90-vs-6-73-estimate-sales-23-7b-24-2b-vs-23-84b-est,Benzinga Newsdesk,,,,0,0,13949d0c-48d3-445e-b3bd-002df9c23e15
2020-04-23T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.750 Beats $1.480 Estimate, Sales $5.860B Beat $5.510B Estimate",LLY,https://www.benzinga.com/news/earnings/20/04/15863376/eli-lilly-q1-adj-eps-1-750-beats-1-480-estimate-sales-5-860b-beat-5-510b-estimate,Benzinga Newsdesk,,,,0,0,40f2e37b-220e-4000-84a4-1b973c6cd726
2020-04-23T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports",LLY,https://www.benzinga.com/news/earnings/20/04/15863165/a-peek-into-the-markets-us-stock-futures-flat-ahead-of-earnings-economic-reports,Lisa Levin,,,,0,0,5f96c9cf-9c0a-468d-b5c7-9ed1fec03540
2020-04-23T08:00:00.000+08:00,"8 Stocks To Watch For April 23, 2020",LLY,https://www.benzinga.com/news/earnings/20/04/15862800/8-stocks-to-watch-for-april-23-2020,Lisa Levin,,,,0,0,4cefabd7-7ad0-48cd-979c-102bf09304e2
2020-04-23T08:00:00.000+08:00,"Earnings Scheduled For April 23, 2020",LLY,https://www.benzinga.com/news/earnings/20/04/15862746/earnings-scheduled-for-april-23-2020,Lisa Levin,,,,0,0,38efd92b-1bc1-4f89-b9e2-752fa216eec6
2020-04-23T08:00:00.000+08:00,Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for ...,LLY,http://www.gurufocus.com/news/1114896/innovent-and-eli-lilly-announce-nmpa-acceptance-of-a-supplemental-new-drug-application-for-sintilimab-in-combination-with-alimta-pemetrexed-and-platinum-as-firstline-therapy-in-nonsquamous-nsclc,GuruFocus,,,,0,0,a7bf7fe1-98dc-4ac9-93a7-d824b0f4d4b4
2020-04-23T08:00:00.000+08:00,"Van Leeuwen & Company, LLC Buys UnitedHealth Group Inc, Microsoft Corp, SPDR S&P ...",LLY,http://www.gurufocus.com/news/1114596/van-leeuwen--company-llc-buys-unitedhealth-group-inc-microsoft-corp-spdr-sp-500-sells-allstate-corp-boeing-co-first-trust-vl-dividend,GuruFocus,,,,0,0,e5ed01ce-610a-43d6-af15-41dd9e9830e3
2020-04-23T08:00:00.000+08:00,Eli Lilly (LLY) Is Up 7.93% in One Week: What You Should Know,LLY,http://www.zacks.com/stock/news/885692/eli-lilly-lly-is-up-793-in-one-week-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-885692,Zacks,,,,0,0,27529cfc-ea97-429f-aeb7-f7c7eefe303a
2020-04-23T08:00:00.000+08:00,Eli Lilly (LLY) Surpasses Q1 Earnings and Revenue Estimates,LLY,http://www.zacks.com/stock/news/885139/eli-lilly-lly-surpasses-q1-earnings-and-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-885139,Zacks,,,,0,0,c3f0d7e0-62ab-41a4-af84-fe38571ebc59
2020-04-22T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Rally Powers Back; Apple, AMD, Tesla, Intel, Microsoft Near Buy Points, But Watch Out For This",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-rally-apple-tesla-intel-buy-points/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,6cfeb8d3-72b2-4283-8f05-33c4242b54e2
2020-04-22T08:00:00.000+08:00,"Anderson Fisher Llc Buys Kulicke & Soffa Industries Inc, Bloomin Brands Inc, ...",LLY,http://www.gurufocus.com/news/1113183/anderson-fisher-llc-buys-kulicke--soffa-industries-inc-bloomin-brands-inc-louisianapacific-corp-sells-cms-energy-corp-allegiant-travel-co-lyondellbasell-industries-nv,GuruFocus,,,,0,0,9f9387d1-ceb6-4365-b095-f8d8ce4497f4
2020-04-22T08:00:00.000+08:00,Chip Earnings To Continue With Intel Stock Near Buy Point; Domino's Due: Investing Action Plan,LLY,http://www.investors.com/research/investing-action-plan/chip-earnings-continue-intel-stock-near-buy-point-dominos-pizza-due/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,8da44ac7-5976-4ac6-86f1-9bf0291b0f40
2020-04-22T08:00:00.000+08:00,"Railway Pension Investments Ltd Buys AbbVie Inc, Intel Corp, Eli Lilly and Co, Sells iShares ...",LLY,http://www.gurufocus.com/news/1112498/railway-pension-investments-ltd-buys-abbvie-inc-intel-corp-eli-lilly-and-co-sells-ishares-iboxx--high-yield-corporate-bond-walmart-inc-comcast-corp,GuruFocus,,,,0,0,c442fc01-059c-4cea-a90e-5f99f5e22ee2
2020-04-22T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke",LLY,http://www.zacks.com/stock/news/883863/the-zacks-analyst-blog-highlights-exxon-mobil-oracle-eli-lilly-and-coke?cid=CS-BENZ-FT-press_releases-883863,Zacks,,,,0,0,dd33224a-bbd0-4da5-9fc6-70f8757b21a9
2020-04-22T08:00:00.000+08:00,Is a Surprise Coming for Lilly (LLY) This Earnings Season?,LLY,http://www.zacks.com/stock/news/883574/is-a-surprise-coming-for-lilly-lly-this-earnings-season?cid=CS-BENZ-FT-tale_of_the_tape|earnings_surprise-883574,Zacks,,,,0,0,62257219-0192-4f36-9241-c24d9c3effc5
2020-04-22T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Rally Powers Back; Apple, AMD, Tesla, Intel, Microsoft Near Buy Points, But Watch Out For This",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-rally-apple-tesla-intel-buy-points/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,1dc7beec-52c8-455a-8122-5f8e872c6b49
2020-04-22T08:00:00.000+08:00,"Anderson Fisher Llc Buys Kulicke & Soffa Industries Inc, Bloomin Brands Inc, ...",LLY,http://www.gurufocus.com/news/1113183/anderson-fisher-llc-buys-kulicke--soffa-industries-inc-bloomin-brands-inc-louisianapacific-corp-sells-cms-energy-corp-allegiant-travel-co-lyondellbasell-industries-nv,GuruFocus,,,,0,0,1fad33ef-a548-4004-be28-1b0de9de6ddf
2020-04-22T08:00:00.000+08:00,Chip Earnings To Continue With Intel Stock Near Buy Point; Domino's Due: Investing Action Plan,LLY,http://www.investors.com/research/investing-action-plan/chip-earnings-continue-intel-stock-near-buy-point-dominos-pizza-due/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,b6168f78-0fee-4f74-8256-989662f00433
2020-04-22T08:00:00.000+08:00,"Railway Pension Investments Ltd Buys AbbVie Inc, Intel Corp, Eli Lilly and Co, Sells iShares ...",LLY,http://www.gurufocus.com/news/1112498/railway-pension-investments-ltd-buys-abbvie-inc-intel-corp-eli-lilly-and-co-sells-ishares-iboxx--high-yield-corporate-bond-walmart-inc-comcast-corp,GuruFocus,,,,0,0,4920e898-bda9-4f6c-a17c-6d1f68842c61
2020-04-22T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Exxon Mobil, Oracle, Eli Lilly and Coke",LLY,http://www.zacks.com/stock/news/883863/the-zacks-analyst-blog-highlights-exxon-mobil-oracle-eli-lilly-and-coke?cid=CS-BENZ-FT-press_releases-883863,Zacks,,,,0,0,5b722d2e-4f5c-4992-870d-a1670959ceb5
2020-04-22T08:00:00.000+08:00,Is a Surprise Coming for Lilly (LLY) This Earnings Season?,LLY,http://www.zacks.com/stock/news/883574/is-a-surprise-coming-for-lilly-lly-this-earnings-season?cid=CS-BENZ-FT-tale_of_the_tape|earnings_surprise-883574,Zacks,,,,0,0,c5a00672-f8d9-4c8a-ad33-0787e1608e3c
2020-04-21T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",LLY,https://www.benzinga.com/wiim/20/04/15849176/shares-of-several-healthcare-companies-are-trading-lower-with-the-overall-market-on-continued-downwa,Benzinga Newsdesk,,,,0,0,4dc35400-676c-49a9-8f82-d1989254fc28
2020-04-21T08:00:00.000+08:00,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",LLY,https://www.benzinga.com/general/biotech/20/04/15846249/the-daily-biotech-pulse-applied-dna-begins-validating-covid-19-test-caras-positive-readout-novan-,Shanthi Rexaline,,,,0,0,242b2c64-ecf1-484f-aa10-9d9200bb7443
2020-04-21T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Fall Ahead Of Coca-Cola, Lockheed Martin Earnings",LLY,https://www.benzinga.com/news/earnings/20/04/15845466/a-peek-into-the-markets-us-stock-futures-fall-ahead-of-coca-cola-lockheed-martin-earnings,Lisa Levin,,,,0,0,242458b0-ba3c-4a26-a52e-83d5a7feba34
2020-04-21T08:00:00.000+08:00,"UBS Downgrades Eli Lilly to Neutral, Raises Price Target to $158",LLY,https://www.benzinga.com/news/20/04/15845335/ubs-downgrades-eli-lilly-to-neutral-raises-price-target-to-158,Vick Meyer,,,,0,0,910fd6b6-d2f0-4267-94a7-59a08a6c7b7c
2020-04-21T08:00:00.000+08:00,"Cordatus Wealth Management LLC Buys Apple Inc, Eli Lilly and Co, Netflix Inc, Sells Danaher ...",LLY,http://www.gurufocus.com/news/1111561/cordatus-wealth-management-llc-buys-apple-inc-eli-lilly-and-co-netflix-inc-sells-danaher-corp-moodys-corporation-zoetis-inc,GuruFocus,,,,0,0,e1a7d4e8-3f52-4829-a312-a75c5d858edf
2020-04-21T08:00:00.000+08:00,"VeraBank, N.A. Buys Vanguard High Dividend Yield, Exxon Mobil Corp, Chevron Corp, Sells Wells ...",LLY,http://www.gurufocus.com/news/1111569/verabank-na-buys-vanguard-high-dividend-yield-exxon-mobil-corp-chevron-corp-sells-wells-fargo-metlife-inc-valero-energy-corp,GuruFocus,,,,0,0,ff18d625-9b51-450d-8495-ea9d3a1fb409
2020-04-21T08:00:00.000+08:00,Health Care Leading In New Highs,LLY,https://talkmarkets.com/content/health-care-leading-in-new-highs?post=259318,TalkMarkets,,,,0,0,71fd6558-fe83-4062-806a-dd31208d1489
2020-04-21T08:00:00.000+08:00,Stocks Drop as May Oil Contract Goes Negative,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-25078,Zacks,,,,0,0,0108c99b-9efa-4134-8df8-754d64853559
2020-04-21T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",LLY,https://www.benzinga.com/wiim/20/04/15849176/shares-of-several-healthcare-companies-are-trading-lower-with-the-overall-market-on-continued-downwa,Benzinga Newsdesk,,,,0,0,65ae6237-001b-4026-970f-5fbd8802d303
2020-04-21T08:00:00.000+08:00,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",LLY,https://www.benzinga.com/general/biotech/20/04/15846249/the-daily-biotech-pulse-applied-dna-begins-validating-covid-19-test-caras-positive-readout-novan-,Shanthi Rexaline,,,,0,0,b9f3714d-4feb-45a7-be75-567ecd700c62
2020-04-21T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Fall Ahead Of Coca-Cola, Lockheed Martin Earnings",LLY,https://www.benzinga.com/news/earnings/20/04/15845466/a-peek-into-the-markets-us-stock-futures-fall-ahead-of-coca-cola-lockheed-martin-earnings,Lisa Levin,,,,0,0,5d8dfaca-4996-4985-832c-ee45b432be8c
2020-04-21T08:00:00.000+08:00,"UBS Downgrades Eli Lilly to Neutral, Raises Price Target to $158",LLY,https://www.benzinga.com/news/20/04/15845335/ubs-downgrades-eli-lilly-to-neutral-raises-price-target-to-158,Vick Meyer,,,,0,0,cefa75b0-01f1-4838-b5e4-a2d5e7d2401c
2020-04-21T08:00:00.000+08:00,"Cordatus Wealth Management LLC Buys Apple Inc, Eli Lilly and Co, Netflix Inc, Sells Danaher ...",LLY,http://www.gurufocus.com/news/1111561/cordatus-wealth-management-llc-buys-apple-inc-eli-lilly-and-co-netflix-inc-sells-danaher-corp-moodys-corporation-zoetis-inc,GuruFocus,,,,0,0,26263d08-96bb-45ae-b7dd-01a1565546cb
2020-04-21T08:00:00.000+08:00,"VeraBank, N.A. Buys Vanguard High Dividend Yield, Exxon Mobil Corp, Chevron Corp, Sells Wells ...",LLY,http://www.gurufocus.com/news/1111569/verabank-na-buys-vanguard-high-dividend-yield-exxon-mobil-corp-chevron-corp-sells-wells-fargo-metlife-inc-valero-energy-corp,GuruFocus,,,,0,0,95737863-92a9-48bf-b1ce-afd457ca6190
2020-04-21T08:00:00.000+08:00,Health Care Leading In New Highs,LLY,https://talkmarkets.com/content/health-care-leading-in-new-highs?post=259318,TalkMarkets,,,,0,0,8f7f66ac-a205-4263-b649-2a5c846c5b99
2020-04-21T08:00:00.000+08:00,Stocks Drop as May Oil Contract Goes Negative,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-25078,Zacks,,,,0,0,0222185f-eec9-4903-8bdb-a9f5b8717dd6
2020-04-20T08:00:00.000+08:00,Will Lower WarnerMedia Margins Hurt AT&T's (T) Q1 Earnings?,LLY,http://www.zacks.com/stock/news/880332/will-lower-warnermedia-margins-hurt-atts-t-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880332,Zacks,,,,0,0,ce557aa7-6934-4c1b-a0cd-9b965822ece9
2020-04-20T08:00:00.000+08:00,Will Communications Segment Buoy AT&T's (T) Q1 Earnings?,LLY,http://www.zacks.com/stock/news/880327/will-communications-segment-buoy-atts-t-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880327,Zacks,,,,0,0,23743602-0b73-495c-a71a-8acb1246edff
2020-04-20T08:00:00.000+08:00,Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing?,LLY,http://www.zacks.com/stock/news/880321/ericsson-eric-to-report-q1-earnings-whats-in-the-offing?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880321,Zacks,,,,0,0,47b5ad66-10fb-4bdf-98b0-1a67cf47e1c8
2020-04-20T08:00:00.000+08:00,"Steigerwald, Gordon & Koch Inc. Buys Adobe Inc, The Walt Disney Co, ViacomCBS Inc, Sells T. ...",LLY,http://www.gurufocus.com/news/1109977/steigerwald-gordon--koch-inc-buys-adobe-inc-the-walt-disney-co-viacomcbs-inc-sells-t-rowe-price-group-inc-viacomcbs-inc-exxon-mobil-corp,GuruFocus,,,,0,0,f1dcf6b1-8884-4c08-a806-7a14cc027587
2020-04-20T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly",LLY,http://www.zacks.com/stock/news/880271/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-moderna-sanofi-vaxart-and-eli-lilly?cid=CS-BENZ-FT-press_releases-880271,Zacks,,,,0,0,c54a35b0-daf0-4c29-a777-ad78774addb4
2020-04-20T08:00:00.000+08:00,Will Lower WarnerMedia Margins Hurt AT&T's (T) Q1 Earnings?,LLY,http://www.zacks.com/stock/news/880332/will-lower-warnermedia-margins-hurt-atts-t-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880332,Zacks,,,,0,0,c416874b-84d1-4e4e-a790-9e2838540a75
2020-04-20T08:00:00.000+08:00,Will Communications Segment Buoy AT&T's (T) Q1 Earnings?,LLY,http://www.zacks.com/stock/news/880327/will-communications-segment-buoy-atts-t-q1-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880327,Zacks,,,,0,0,40a76416-7990-4861-a6e0-9b9a1612d969
2020-04-20T08:00:00.000+08:00,Ericsson (ERIC) to Report Q1 Earnings: What's in the Offing?,LLY,http://www.zacks.com/stock/news/880321/ericsson-eric-to-report-q1-earnings-whats-in-the-offing?cid=CS-BENZ-FT-analyst_blog|earnings_preview-880321,Zacks,,,,0,0,96221d55-1a1d-4cc1-973f-dad93374963e
2020-04-20T08:00:00.000+08:00,"Steigerwald, Gordon & Koch Inc. Buys Adobe Inc, The Walt Disney Co, ViacomCBS Inc, Sells T. ...",LLY,http://www.gurufocus.com/news/1109977/steigerwald-gordon--koch-inc-buys-adobe-inc-the-walt-disney-co-viacomcbs-inc-sells-t-rowe-price-group-inc-viacomcbs-inc-exxon-mobil-corp,GuruFocus,,,,0,0,020bae1f-fdd6-40f3-a99d-cf1835b5f78a
2020-04-20T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly",LLY,http://www.zacks.com/stock/news/880271/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-moderna-sanofi-vaxart-and-eli-lilly?cid=CS-BENZ-FT-press_releases-880271,Zacks,,,,0,0,78adf5bd-185e-4035-8751-13c64c4e4468
2020-04-19T08:00:00.000+08:00,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision",LLY,https://www.benzinga.com/general/biotech/20/04/15833296/the-week-ahead-in-biotech-april-19-25-eli-lilly-biogen-earnings-on-tap-sanofi-awaits-fda-decision,Shanthi Rexaline,,,,0,0,a14b49d4-975f-4c00-bb76-9db450be974b
2020-04-19T08:00:00.000+08:00,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision",LLY,https://www.benzinga.com/general/biotech/20/04/15833296/the-week-ahead-in-biotech-april-19-25-eli-lilly-biogen-earnings-on-tap-sanofi-awaits-fda-decision,Shanthi Rexaline,,,,0,0,d9a2316e-4767-43e2-9a93-86959e68353f
2020-04-17T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/04/15830602/stocks-that-hit-52-week-highs-on-friday,Benzinga Insights,,,,0,0,ba068034-f126-4f1f-ab4e-5c008f6fcf46
2020-04-17T08:00:00.000+08:00,"Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting",LLY,https://www.benzinga.com/news/earnings/20/04/15830154/big-earnings-day-as-honeywell-procter-gamble-schlumberger-among-those-reporting,JJ Kinahan,,,,0,0,e7e832ae-a95a-41c7-a6f3-266045444830
2020-04-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",LLY,https://www.benzinga.com/general/biotech/20/04/15828432/the-daily-biotech-pulse-moderna-secures-483m-in-barda-funding-gilead-remdesivir-data-veracytes-po,Shanthi Rexaline,,,,0,0,dd05f906-196d-4279-9ec2-d96c22deb6b6
2020-04-17T08:00:00.000+08:00,Coronavirus Stocks Hitting New Highs This Week In Current Stock Market Rally Include Eli Lilly,LLY,http://www.investors.com/stock-lists/new-highs/coronavirus-stocks-new-highs-bio-rad-eli-lilly-breakouts-buy-points/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,af2c7494-fded-4abf-8071-30089fbbf14f
2020-04-17T08:00:00.000+08:00,"Netflix Stock Rallies Bullishly Ahead Of Earnings, But Is All The Good News Priced In?",LLY,http://www.investors.com/research/earnings-preview/netflix-stock-rallies-bullishly-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,f69ec60d-e649-4b2f-ab36-a72179978f3b
2020-04-17T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts",LLY,http://www.zacks.com/stock/news/876163/pharma-stock-roundup-jnjs-q1-earnings-coronavirus-product-development-efforts?cid=CS-BENZ-FT-analyst_blog|stock_roundup-876163,Zacks,,,,0,0,e7d8b788-6797-46ad-b79a-ae0313757474
2020-04-17T08:00:00.000+08:00,"Bremer Bank National Association Buys Xilinx Inc, iShares Cohen & Steers REIT, Eli Lilly ...",LLY,http://www.gurufocus.com/news/1107689/bremer-bank-national-association-buys-xilinx-inc-ishares-cohen--steers-reit-eli-lilly-and-co-sells-ishares-core-msci-eafe-microchip-technology-inc-phillips-66,GuruFocus,,,,0,0,b2e42988-a67a-4c62-93e6-ad3a679bbf7f
2020-04-17T08:00:00.000+08:00,Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results,LLY,http://www.zacks.com/stock/news/875830/buy-5-top-medical-stocks-on-coronavirus-drug-trial-results?cid=CS-BENZ-FT-analyst_blog|investment_ideas-875830,Zacks,,,,0,0,51aad97f-5146-41d7-b4f7-e8f3b46fa102
2020-04-17T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/04/15830602/stocks-that-hit-52-week-highs-on-friday,Benzinga Insights,,,,0,0,08b959f1-c108-415a-ab5e-deb11dc9cf77
2020-04-17T08:00:00.000+08:00,"Big Earnings Day As Honeywell, Procter & Gamble, Schlumberger Among Those Reporting",LLY,https://www.benzinga.com/news/earnings/20/04/15830154/big-earnings-day-as-honeywell-procter-gamble-schlumberger-among-those-reporting,JJ Kinahan,,,,0,0,add8d597-e03d-4ff0-9099-f5d5d84f0782
2020-04-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement",LLY,https://www.benzinga.com/general/biotech/20/04/15828432/the-daily-biotech-pulse-moderna-secures-483m-in-barda-funding-gilead-remdesivir-data-veracytes-po,Shanthi Rexaline,,,,0,0,21016b98-aeb6-4a6d-9e0e-fdabb2b83692
2020-04-17T08:00:00.000+08:00,Coronavirus Stocks Hitting New Highs This Week In Current Stock Market Rally Include Eli Lilly,LLY,http://www.investors.com/stock-lists/new-highs/coronavirus-stocks-new-highs-bio-rad-eli-lilly-breakouts-buy-points/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,3b083d4f-461b-49e0-b653-54e51bace706
2020-04-17T08:00:00.000+08:00,"Netflix Stock Rallies Bullishly Ahead Of Earnings, But Is All The Good News Priced In?",LLY,http://www.investors.com/research/earnings-preview/netflix-stock-rallies-bullishly-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,121dba6c-1c82-4dea-9ea2-8a4430ae194d
2020-04-17T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ's Q1 Earnings, Coronavirus Product Development Efforts",LLY,http://www.zacks.com/stock/news/876163/pharma-stock-roundup-jnjs-q1-earnings-coronavirus-product-development-efforts?cid=CS-BENZ-FT-analyst_blog|stock_roundup-876163,Zacks,,,,0,0,5a9ad7d6-cbb5-49c1-a454-04f3d055a1e5
2020-04-17T08:00:00.000+08:00,"Bremer Bank National Association Buys Xilinx Inc, iShares Cohen & Steers REIT, Eli Lilly ...",LLY,http://www.gurufocus.com/news/1107689/bremer-bank-national-association-buys-xilinx-inc-ishares-cohen--steers-reit-eli-lilly-and-co-sells-ishares-core-msci-eafe-microchip-technology-inc-phillips-66,GuruFocus,,,,0,0,bb9861c1-769e-4bd2-8d20-135ab94f5c71
2020-04-17T08:00:00.000+08:00,Buy 5 Top Medical Stocks on Coronavirus Drug Trial Results,LLY,http://www.zacks.com/stock/news/875830/buy-5-top-medical-stocks-on-coronavirus-drug-trial-results?cid=CS-BENZ-FT-analyst_blog|investment_ideas-875830,Zacks,,,,0,0,f83616aa-912e-4f64-b52f-c8b23a639156
2020-04-16T08:00:00.000+08:00,10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic,LLY,https://www.benzinga.com/general/education/20/04/15822818/10-stocks-hitting-all-time-highs-amid-the-covid-19-pandemic,Tyree Gorges,,,,0,0,c8b741ab-3515-4917-89f0-7c15c4278b73
2020-04-16T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/04/15820155/stocks-that-hit-52-week-highs-on-thursday,Benzinga Insights,,,,0,0,374fed76-d772-4244-810e-a5348346885c
2020-04-16T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",LLY,https://www.benzinga.com/general/biotech/20/04/15817454/the-daily-biotech-pulse-fda-nod-for-urogen-novavax-coronavirus-vaccine-to-enter-clinics-soligenix,Shanthi Rexaline,,,,0,0,dfb0fe08-8347-42c6-ac92-513c9ec0defc
2020-04-16T08:00:00.000+08:00,"Eli Lilly Reports Non-Branded Versions Of Humalog KwikPen, Humalog Junior KwikPen Now Available For Order By US Pharmacies",LLY,https://www.benzinga.com/news/20/04/15816917/eli-lilly-reports-non-branded-versions-of-humalog-kwikpen-humalog-junior-kwikpen-now-available-for-o,Benzinga Newsdesk,,,,0,0,2aa75f7f-77b2-401c-8ab2-7d4b0d24103c
2020-04-16T08:00:00.000+08:00,"Are These 5 Stocks Coronavirus-Proof? What Fortinet, Veeva, Eli Lilly Charts Say Now",LLY,http://www.investors.com/stock-lists/ibd-big-cap-20/top-stocks-to-watch-are-these-5-growth-stocks-coronavirus-proof-what-fortinet-veeva-eli-lilly-charts/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,5fbfbeb6-efa2-4996-906a-3aefd4a74f25
2020-04-16T08:00:00.000+08:00,Eli Lilly Just Within Buy Range As Quarterly Report Nears,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-just-within-buy-range-as-quarterly-report-nears/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,0de29d6b-1e3b-4aa6-b2c4-9a296c0d5057
2020-04-16T08:00:00.000+08:00,Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?,LLY,http://www.zacks.com/stock/news/874609/eli-lilly-lly-earnings-expected-to-grow-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-874609,Zacks,,,,0,0,e8330ce4-983b-46c6-8f69-8f95682bd5ed
2020-04-16T08:00:00.000+08:00,"Roche Most Innovative, Astra Zeneca Most Inventive",LLY,http://www.gurufocus.com/news/1106135/roche-most-innovative-astra-zeneca-most-inventive,GuruFocus,,,,0,0,66358f63-dd15-4b5b-be17-0f48d0a15edf
2020-04-16T08:00:00.000+08:00,Lower-priced versions of Humalog® Mix75/—5™ KwikPen® and Humalog® Junior KwikPen® now ...,LLY,http://www.gurufocus.com/news/1106532/lowerpriced-versions-of-humalog-mix7525-kwikpen-and-humalog-junior-kwikpen-now-available,GuruFocus,,,,0,0,32b9b6eb-2f83-4575-956a-f5cc106b1f7c
2020-04-16T08:00:00.000+08:00,10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic,LLY,https://www.benzinga.com/general/education/20/04/15822818/10-stocks-hitting-all-time-highs-amid-the-covid-19-pandemic,Tyree Gorges,,,,0,0,dcffb49d-7a8b-4c3f-bb92-dadc835b92da
2020-04-16T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/04/15820155/stocks-that-hit-52-week-highs-on-thursday,Benzinga Insights,,,,0,0,0384ecbb-64f4-4b5f-afea-da58580d24de
2020-04-16T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",LLY,https://www.benzinga.com/general/biotech/20/04/15817454/the-daily-biotech-pulse-fda-nod-for-urogen-novavax-coronavirus-vaccine-to-enter-clinics-soligenix,Shanthi Rexaline,,,,0,0,6ca9005e-1081-4458-8144-5154c95f7587
2020-04-16T08:00:00.000+08:00,"Eli Lilly Reports Non-Branded Versions Of Humalog KwikPen, Humalog Junior KwikPen Now Available For Order By US Pharmacies",LLY,https://www.benzinga.com/news/20/04/15816917/eli-lilly-reports-non-branded-versions-of-humalog-kwikpen-humalog-junior-kwikpen-now-available-for-o,Benzinga Newsdesk,,,,0,0,bb902ccb-fe84-4233-8343-cc90e7db1865
2020-04-16T08:00:00.000+08:00,"Are These 5 Stocks Coronavirus-Proof? What Fortinet, Veeva, Eli Lilly Charts Say Now",LLY,http://www.investors.com/stock-lists/ibd-big-cap-20/top-stocks-to-watch-are-these-5-growth-stocks-coronavirus-proof-what-fortinet-veeva-eli-lilly-charts/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,85938a55-ec66-4c8a-a99a-408d685a1604
2020-04-16T08:00:00.000+08:00,Eli Lilly Just Within Buy Range As Quarterly Report Nears,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-just-within-buy-range-as-quarterly-report-nears/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,82cf79c2-5f2c-4be1-8daf-060ba8ceebf4
2020-04-16T08:00:00.000+08:00,Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?,LLY,http://www.zacks.com/stock/news/874609/eli-lilly-lly-earnings-expected-to-grow-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-874609,Zacks,,,,0,0,906da430-1602-4daa-9538-0a0e4ab5dbee
2020-04-16T08:00:00.000+08:00,"Roche Most Innovative, Astra Zeneca Most Inventive",LLY,http://www.gurufocus.com/news/1106135/roche-most-innovative-astra-zeneca-most-inventive,GuruFocus,,,,0,0,dd3852d5-2e70-4878-b598-a8972754789e
2020-04-16T08:00:00.000+08:00,Lower-priced versions of Humalog® Mix75/—5™ KwikPen® and Humalog® Junior KwikPen® now ...,LLY,http://www.gurufocus.com/news/1106532/lowerpriced-versions-of-humalog-mix7525-kwikpen-and-humalog-junior-kwikpen-now-available,GuruFocus,,,,0,0,879f76ee-2ec8-44d3-a716-50454d631a37
2020-04-15T08:00:00.000+08:00,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,LLY,https://www.benzinga.com/news/20/04/15808727/every-member-of-trumps-great-american-economic-revival-industry-groups,Tanzeel Akhtar,,,,0,0,f3ccf24c-b559-4a4f-92bb-56eed34b2687
2020-04-15T08:00:00.000+08:00,"Cowen & Co. Maintains Outperform on Eli Lilly, Raises Price Target to $160",LLY,https://www.benzinga.com/news/20/04/15807720/cowen-co-maintains-outperform-on-eli-lilly-raises-price-target-to-160,Benzinga_Newsdesk,,,,0,0,c3989536-6567-40e4-9348-9f184c424eda
2020-04-15T08:00:00.000+08:00,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",LLY,https://www.benzinga.com/general/biotech/20/04/15806223/the-daily-biotech-pulse-applied-dna-ships-vaccine-constructs-for-animal-testing-herceptin-biosimi,Shanthi Rexaline,,,,0,0,1fc0d2ee-1dbd-4387-bf62-a6cf7e8cd9e5
2020-04-15T08:00:00.000+08:00,AstraZeneca to Begin Calquence Study for Coronavirus Treatment,LLY,http://www.zacks.com/stock/news/872061/astrazeneca-to-begin-calquence-study-for-coronavirus-treatment?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-872061,Zacks,,,,0,0,52ed04dd-8309-4583-9aad-c84ccad608a0
2020-04-15T08:00:00.000+08:00,Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month,LLY,http://www.zacks.com/stock/news/871880/buy-5-top-stocks-set-to-beat-on-q1-earnings-this-month?cid=CS-BENZ-FT-analyst_blog|investment_ideas-871880,Zacks,,,,0,0,e2d29990-be22-4d89-a490-d46f52631b23
2020-04-15T08:00:00.000+08:00,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,LLY,https://www.benzinga.com/news/20/04/15808727/every-member-of-trumps-great-american-economic-revival-industry-groups,Tanzeel Akhtar,,,,0,0,c21adfcc-d632-460d-b73d-8f181117af65
2020-04-15T08:00:00.000+08:00,"Cowen & Co. Maintains Outperform on Eli Lilly, Raises Price Target to $160",LLY,https://www.benzinga.com/news/20/04/15807720/cowen-co-maintains-outperform-on-eli-lilly-raises-price-target-to-160,Benzinga_Newsdesk,,,,0,0,e8c5a64d-e7a0-42e7-bc75-c411a8439854
2020-04-15T08:00:00.000+08:00,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",LLY,https://www.benzinga.com/general/biotech/20/04/15806223/the-daily-biotech-pulse-applied-dna-ships-vaccine-constructs-for-animal-testing-herceptin-biosimi,Shanthi Rexaline,,,,0,0,96bc408b-695e-4f7b-aa96-74768d824948
2020-04-15T08:00:00.000+08:00,AstraZeneca to Begin Calquence Study for Coronavirus Treatment,LLY,http://www.zacks.com/stock/news/872061/astrazeneca-to-begin-calquence-study-for-coronavirus-treatment?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-872061,Zacks,,,,0,0,85a1b865-7bc4-4e3b-8e53-e485119482ba
2020-04-15T08:00:00.000+08:00,Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month,LLY,http://www.zacks.com/stock/news/871880/buy-5-top-stocks-set-to-beat-on-q1-earnings-this-month?cid=CS-BENZ-FT-analyst_blog|investment_ideas-871880,Zacks,,,,0,0,a43e1c77-3eaf-491e-a8a8-0c10112d8a82
2020-04-14T08:00:00.000+08:00,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,LLY,https://www.benzinga.com/wiim/20/04/15798567/shares-of-several-healthcare-companies-are-trading-higher-as-markets-gain-on-positive-coronavirus-ou,Benzinga Newsdesk,,,,0,0,afecb248-62d3-459f-8a1f-dc6ed2363440
2020-04-14T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Tuesday,LLY,https://www.benzinga.com/news/20/04/15798317/stocks-that-hit-52-week-highs-on-tuesday,Benzinga Insights,,,,0,0,7b28c185-fc3e-4511-b0f2-0b24e9e4a596
2020-04-14T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Rally Soars As Two Wrongs Go Right; Amazon, Nvidia Lead New Breakouts",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-rally-soars-amazon-microsoft-nvidia-apple-lead/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,7aa5b26e-caf2-4c54-a7a8-5ff8d74f9f24
2020-04-14T08:00:00.000+08:00,Indexes Near Session Highs As These Top Stocks Finally Clear Buy Points,LLY,http://www.investors.com/market-trend/stock-market-today/stock-market-near-session-highs-techs-lead/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,bb531f7a-c715-4754-a00c-ef205fe868fc
2020-04-14T08:00:00.000+08:00,"Six Surprising Stocks Making New Highs Today, One Especially",LLY,https://talkmarkets.com/content/six-surprising-stocks-making-new-highs-today-one-especially?post=258512,TalkMarkets,,,,0,0,8d0797b9-f622-46f0-946d-d0ea1aecb645
2020-04-14T08:00:00.000+08:00,SNY vs. LLY: Which Stock Is the Better Value Option?,LLY,http://www.zacks.com/stock/news/870517/sny-vs-lly-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-870517,Zacks,,,,0,0,36605909-2b16-4942-a5d5-7b6056db3924
2020-04-14T08:00:00.000+08:00,"OneAscent Financial Services LLC Buys S&P Global Inc, Eli Lilly and Co, Brookfield ...",LLY,http://www.gurufocus.com/news/1104035/oneascent-financial-services-llc-buys-sp-global-inc-eli-lilly-and-co-brookfield-renewable-partners-lp-sells-vanguard-intermediateterm-government-bond-etf-vanguard-mortgagebacked-securities-etf-phillips-66,GuruFocus,,,,0,0,1398ac57-c273-4d6c-9c29-f2bc78ed6ff2
2020-04-14T08:00:00.000+08:00,"J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact",LLY,http://www.zacks.com/stock/news/870325/jj-jnj-beats-on-q1-earnings-cuts-view-on-coronavirus-impact?cid=CS-BENZ-FT-analyst_blog|earnings_article-870325,Zacks,,,,0,0,8d5b6f5f-b654-49a6-896c-e4310b42fcd3
2020-04-14T08:00:00.000+08:00,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,LLY,https://www.benzinga.com/wiim/20/04/15798567/shares-of-several-healthcare-companies-are-trading-higher-as-markets-gain-on-positive-coronavirus-ou,Benzinga Newsdesk,,,,0,0,db679564-654b-4ba4-9b47-534a86bba5e9
2020-04-14T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Tuesday,LLY,https://www.benzinga.com/news/20/04/15798317/stocks-that-hit-52-week-highs-on-tuesday,Benzinga Insights,,,,0,0,cbecff0e-50a3-4dbe-b231-295802980398
2020-04-14T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Rally Soars As Two Wrongs Go Right; Amazon, Nvidia Lead New Breakouts",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-rally-soars-amazon-microsoft-nvidia-apple-lead/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,7d144419-9688-4c30-adcf-5f38030229ee
2020-04-14T08:00:00.000+08:00,Indexes Near Session Highs As These Top Stocks Finally Clear Buy Points,LLY,http://www.investors.com/market-trend/stock-market-today/stock-market-near-session-highs-techs-lead/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,c6e7d64e-8be4-4c60-bcdf-1afef7332792
2020-04-14T08:00:00.000+08:00,"Six Surprising Stocks Making New Highs Today, One Especially",LLY,https://talkmarkets.com/content/six-surprising-stocks-making-new-highs-today-one-especially?post=258512,TalkMarkets,,,,0,0,808be2f5-3392-45e2-b9a7-2afbba7845f7
2020-04-14T08:00:00.000+08:00,SNY vs. LLY: Which Stock Is the Better Value Option?,LLY,http://www.zacks.com/stock/news/870517/sny-vs-lly-which-stock-is-the-better-value-option?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-870517,Zacks,,,,0,0,5f0df933-61ab-4532-a86e-289b6a6e9f6c
2020-04-14T08:00:00.000+08:00,"OneAscent Financial Services LLC Buys S&P Global Inc, Eli Lilly and Co, Brookfield ...",LLY,http://www.gurufocus.com/news/1104035/oneascent-financial-services-llc-buys-sp-global-inc-eli-lilly-and-co-brookfield-renewable-partners-lp-sells-vanguard-intermediateterm-government-bond-etf-vanguard-mortgagebacked-securities-etf-phillips-66,GuruFocus,,,,0,0,1f314658-3c79-4490-8100-7a288f834f32
2020-04-14T08:00:00.000+08:00,"J&J (JNJ) Beats on Q1 Earnings, Cuts View on Coronavirus Impact",LLY,http://www.zacks.com/stock/news/870325/jj-jnj-beats-on-q1-earnings-cuts-view-on-coronavirus-impact?cid=CS-BENZ-FT-analyst_blog|earnings_article-870325,Zacks,,,,0,0,d5eea007-040f-424f-852d-f22c96145eb2
2020-04-13T08:00:00.000+08:00,Lilly On Friday Anounced It Has Begun Clinical Testing of Therapies for Coronavirus,LLY,https://www.benzinga.com/news/20/04/15789003/lilly-on-friday-anounced-it-has-begun-clinical-testing-of-therapies-for-coronavirus,Benzinga Newsdesk,,,,0,0,1c62bff4-37d1-4bc6-b460-098a4d3f7a03
2020-04-13T08:00:00.000+08:00,"Norman Fields, Gottscho Capital Management, LLC Buys Amazon.com Inc, Liberty Global PLC, D.R. ...",LLY,http://www.gurufocus.com/news/1103317/norman-fields-gottscho-capital-management-llc-buys-amazoncom-inc-liberty-global-plc-dr-horton-inc-sells-delta-air-lines-inc-southwest-airlines-co-carmax-inc,GuruFocus,,,,0,0,d1dbff81-e979-4734-90e4-fe3e1c26163f
2020-04-13T08:00:00.000+08:00,"Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo",LLY,http://www.zacks.com/stock/news/868599/zackscom-featured-highlights-include-electromed-novagold-resources-fti-consulting-eli-lilly-and-masimo?cid=CS-BENZ-FT-press_releases-868599,Zacks,,,,0,0,f9f89718-21e4-4dfe-b918-533bca9182f8
2020-04-13T08:00:00.000+08:00,Lilly Announces Clinical Study Plans for Coronavirus Disease,LLY,http://www.zacks.com/stock/news/868591/lilly-announces-clinical-study-plans-for-coronavirus-disease?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-868591,Zacks,,,,0,0,5f286c77-dc36-4002-992e-aab6ebc47cbf
2020-04-13T08:00:00.000+08:00,Lilly On Friday Anounced It Has Begun Clinical Testing of Therapies for Coronavirus,LLY,https://www.benzinga.com/news/20/04/15789003/lilly-on-friday-anounced-it-has-begun-clinical-testing-of-therapies-for-coronavirus,Benzinga Newsdesk,,,,0,0,32b86b3a-e1fc-4ac4-ada0-a9600bb51e8f
2020-04-13T08:00:00.000+08:00,"Norman Fields, Gottscho Capital Management, LLC Buys Amazon.com Inc, Liberty Global PLC, D.R. ...",LLY,http://www.gurufocus.com/news/1103317/norman-fields-gottscho-capital-management-llc-buys-amazoncom-inc-liberty-global-plc-dr-horton-inc-sells-delta-air-lines-inc-southwest-airlines-co-carmax-inc,GuruFocus,,,,0,0,06532db5-bed7-4bc1-8e43-4f7fce319aad
2020-04-13T08:00:00.000+08:00,"Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo",LLY,http://www.zacks.com/stock/news/868599/zackscom-featured-highlights-include-electromed-novagold-resources-fti-consulting-eli-lilly-and-masimo?cid=CS-BENZ-FT-press_releases-868599,Zacks,,,,0,0,ba59dddf-fc9a-4b73-9f7a-a779cb1597cb
2020-04-13T08:00:00.000+08:00,Lilly Announces Clinical Study Plans for Coronavirus Disease,LLY,http://www.zacks.com/stock/news/868591/lilly-announces-clinical-study-plans-for-coronavirus-disease?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-868591,Zacks,,,,0,0,3b4f30d3-ef2e-4c34-89f5-5f9f0bde06d8
2020-04-12T08:00:00.000+08:00,This Trio of Strong Performers Is Predicted to Outperform,LLY,http://www.gurufocus.com/news/1102568/this-trio-of-strong-performers-is-predicted-to-outperform-,GuruFocus,,,,0,0,373dde5d-c75d-4daf-aa7d-e650940a4e67
2020-04-12T08:00:00.000+08:00,This Trio of Strong Performers Is Predicted to Outperform,LLY,http://www.gurufocus.com/news/1102568/this-trio-of-strong-performers-is-predicted-to-outperform-,GuruFocus,,,,0,0,bf889341-38eb-400a-b17a-1f1af9f9f4a4
2020-04-11T08:00:00.000+08:00,"Benzinga's Bulls And Bears Of The Week: Apple, Disney, Intel And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/20/04/15784941/benzingas-bulls-and-bears-of-the-week-apple-disney-intel-and-more,Nelson Hem,,,,0,0,18a9d0b4-5cf7-4f36-adae-bd982d16dc8b
2020-04-11T08:00:00.000+08:00,"Benzinga's Bulls And Bears Of The Week: Apple, Disney, Intel And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/20/04/15784941/benzingas-bulls-and-bears-of-the-week-apple-disney-intel-and-more,Nelson Hem,,,,0,0,cd0eb59e-8ad8-406c-9904-b448833566a0
2020-04-10T08:00:00.000+08:00,Lilly Begins Clinical Testing of Therapies for COVID-–9,LLY,http://www.gurufocus.com/news/1102076/lilly-begins-clinical-testing-of-therapies-for-covid19,GuruFocus,,,,0,0,e12f28b3-5d40-448a-9e23-038312c16d18
2020-04-10T08:00:00.000+08:00,"Perkins Coie Trust Co Buys First Financial Corp, Truist Financial Corp, Vanguard Mid-Cap, Sells ...",LLY,http://www.gurufocus.com/news/1101996/perkins-coie-trust-co-buys-first-financial-corp-truist-financial-corp-vanguard-midcap-sells-truist-financial-corp-ishares-gold-trust-spdr-midcap-trust-series-i,GuruFocus,,,,0,0,c3cec752-0160-46c1-a360-0f68974c411a
2020-04-10T08:00:00.000+08:00,Lilly Begins Clinical Testing of Therapies for COVID-–9,LLY,http://www.gurufocus.com/news/1102076/lilly-begins-clinical-testing-of-therapies-for-covid19,GuruFocus,,,,0,0,9d471d57-e8eb-4821-86b0-e0148b0c715c
2020-04-10T08:00:00.000+08:00,"Perkins Coie Trust Co Buys First Financial Corp, Truist Financial Corp, Vanguard Mid-Cap, Sells ...",LLY,http://www.gurufocus.com/news/1101996/perkins-coie-trust-co-buys-first-financial-corp-truist-financial-corp-vanguard-midcap-sells-truist-financial-corp-ishares-gold-trust-spdr-midcap-trust-series-i,GuruFocus,,,,0,0,b4df5eab-731b-4cb6-a5b9-63cef54dd101
2020-04-09T08:00:00.000+08:00,"Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/04/15775641/bofa-downgrades-lilly-on-valuation-says-growth-pipeline-potential-balanced-by-stock,Shanthi Rexaline,,,,0,0,c0fdb7ea-c801-4f27-947c-3240a1ce4957
2020-04-09T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 9, 2020",LLY,https://www.benzinga.com/analyst-ratings/upgrades/20/04/15775842/benzingas-top-upgrades-downgrades-for-april-9-2020,Lisa Levin,,,,0,0,dbffe749-5f31-4d91-bfe1-6edc2663849e
2020-04-09T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.,LLY,https://www.benzinga.com/wiim/20/04/15774537/eli-lilly-and-co-shares-are-trading-lower-after-morgan-stanley-downgraded-the-stock-from-overweight,Benzinga Newsdesk,,,,0,0,02c9e6c5-99e3-428d-ba7b-a9fa2e5a83ef
2020-04-09T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,LLY,https://www.benzinga.com/news/20/04/15773342/morgan-stanley-downgrades-eli-lilly-to-equal-weight,Vick Meyer,,,,0,0,d5623011-a4ae-4482-878c-5f85410a1123
2020-04-09T08:00:00.000+08:00,"Nadler Financial Group, Inc. Buys PIMCO Corporate & Income Opportunity Fds, Eli Lilly and ...",LLY,http://www.gurufocus.com/news/1100943/nadler-financial-group-inc-buys-pimco-corporate--income-opportunity-fds-eli-lilly-and-co-netflix-inc-sells-copart-inc-philip-morris-international-inc-ishares-msci-india,GuruFocus,,,,0,0,d0b47636-4970-428f-9a49-221d0c024dc2
2020-04-09T08:00:00.000+08:00,Highly Rated Eli Lilly Near Buy Zone Ahead Of Earnings,LLY,http://www.investors.com/ibd-data-stories/highly-rated-eli-lilly-near-buy-zone-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,91d5f000-723c-42d6-b2e2-cb80dbb8d03d
2020-04-09T08:00:00.000+08:00,Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer,LLY,http://www.zacks.com/stock/news/863161/pfizers-braftovi-combo-gets-fda-nod-for-colorectal-cancer?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-863161,Zacks,,,,0,0,78042e32-3910-4394-b7d3-e4bca9e6716a
2020-04-09T08:00:00.000+08:00,J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma,LLY,http://www.zacks.com/stock/news/862892/jj-jnj-q1-earnings-may-indicate-coronavirus-impact-on-pharma?cid=CS-BENZ-FT-analyst_blog|earnings_preview-862892,Zacks,,,,0,0,1c1ab1e2-9a30-4c32-86cd-a7f30711761e
2020-04-09T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo",LLY,http://www.zacks.com/stock/news/862816/the-zacks-analyst-blog-highlights-a10-networks-chemed-core-mark-eli-lilly-and-masimo?cid=CS-BENZ-FT-press_releases-862816,Zacks,,,,0,0,bf81f31a-cf47-497f-8c26-feea13e6b940
2020-04-09T08:00:00.000+08:00,"Morgan Stanley Downgrades Lilly On Valuation, Says Growth, Pipeline Potential Balanced By Stock Premium",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/04/15775641/bofa-downgrades-lilly-on-valuation-says-growth-pipeline-potential-balanced-by-stock,Shanthi Rexaline,,,,0,0,67cac7c0-9547-42ec-b7f4-a80f5640ab96
2020-04-09T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 9, 2020",LLY,https://www.benzinga.com/analyst-ratings/upgrades/20/04/15775842/benzingas-top-upgrades-downgrades-for-april-9-2020,Lisa Levin,,,,0,0,49513878-bb5c-468f-8cd5-c4b18e7a9551
2020-04-09T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight.,LLY,https://www.benzinga.com/wiim/20/04/15774537/eli-lilly-and-co-shares-are-trading-lower-after-morgan-stanley-downgraded-the-stock-from-overweight,Benzinga Newsdesk,,,,0,0,ddedb6c5-4bea-4ca1-93c5-37afcd559b07
2020-04-09T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,LLY,https://www.benzinga.com/news/20/04/15773342/morgan-stanley-downgrades-eli-lilly-to-equal-weight,Vick Meyer,,,,0,0,2a29545c-071f-45c1-9c1d-44c7da131c16
2020-04-09T08:00:00.000+08:00,"Nadler Financial Group, Inc. Buys PIMCO Corporate & Income Opportunity Fds, Eli Lilly and ...",LLY,http://www.gurufocus.com/news/1100943/nadler-financial-group-inc-buys-pimco-corporate--income-opportunity-fds-eli-lilly-and-co-netflix-inc-sells-copart-inc-philip-morris-international-inc-ishares-msci-india,GuruFocus,,,,0,0,2e552ab9-565a-44b1-b86c-a85fdfa38f01
2020-04-09T08:00:00.000+08:00,Highly Rated Eli Lilly Near Buy Zone Ahead Of Earnings,LLY,http://www.investors.com/ibd-data-stories/highly-rated-eli-lilly-near-buy-zone-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,39171f04-4dfc-409d-a20b-7f2a1372bdc6
2020-04-09T08:00:00.000+08:00,Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer,LLY,http://www.zacks.com/stock/news/863161/pfizers-braftovi-combo-gets-fda-nod-for-colorectal-cancer?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-863161,Zacks,,,,0,0,cd580ce3-7731-44b1-9fe6-abc86a9cbb5e
2020-04-09T08:00:00.000+08:00,J&J (JNJ) Q1 Earnings May Indicate Coronavirus Impact on Pharma,LLY,http://www.zacks.com/stock/news/862892/jj-jnj-q1-earnings-may-indicate-coronavirus-impact-on-pharma?cid=CS-BENZ-FT-analyst_blog|earnings_preview-862892,Zacks,,,,0,0,e4681082-0a87-469c-9730-f1f9cd923873
2020-04-09T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: A10 Networks, Chemed, Core-Mark, Eli Lilly and Masimo",LLY,http://www.zacks.com/stock/news/862816/the-zacks-analyst-blog-highlights-a10-networks-chemed-core-mark-eli-lilly-and-masimo?cid=CS-BENZ-FT-press_releases-862816,Zacks,,,,0,0,e885be0d-c9bf-4d06-8844-ca91692597b7
2020-04-08T08:00:00.000+08:00,"Eli Lilly shares are trading higher, not seeing company-specific news from the session. NOTE: The healthcare sector has been strong this week amid positive market sentiment as well as increased demand for therapies and medical supplies due to coronavirus.",LLY,https://www.benzinga.com/wiim/20/04/15766253/eli-lilly-shares-are-trading-higher-not-seeing-company-specific-news-from-the-session-note-the-healt,Benzinga Newsdesk,,,,0,0,1e9580bd-1e15-4893-b362-54155545c739
2020-04-08T08:00:00.000+08:00,Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market,LLY,http://www.zacks.com/commentary/860406/large-cap-pharma-stocks-to-benefit-in-post-pandemic-market?cid=CS-BENZ-FT-industry_outlook-860406,Zacks,,,,0,0,1ee2778e-a9f8-4eed-b896-29957fa5cb7a
2020-04-08T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for First-Quarter —…—… Financial Results ...,LLY,http://www.gurufocus.com/news/1099259/lilly-confirms-date-and-conference-call-for-firstquarter-2020-financial-results-announcement,GuruFocus,,,,0,0,fd8bd970-ab5b-488b-9263-011308b8aa8b
2020-04-08T08:00:00.000+08:00,"Eli Lilly shares are trading higher, not seeing company-specific news from the session. NOTE: The healthcare sector has been strong this week amid positive market sentiment as well as increased demand for therapies and medical supplies due to coronavirus.",LLY,https://www.benzinga.com/wiim/20/04/15766253/eli-lilly-shares-are-trading-higher-not-seeing-company-specific-news-from-the-session-note-the-healt,Benzinga Newsdesk,,,,0,0,0c25a15c-928c-4892-ab54-e1fce29f7385
2020-04-08T08:00:00.000+08:00,Large-Cap Pharma Stocks to Benefit in Post-Pandemic Market,LLY,http://www.zacks.com/commentary/860406/large-cap-pharma-stocks-to-benefit-in-post-pandemic-market?cid=CS-BENZ-FT-industry_outlook-860406,Zacks,,,,0,0,9262e1e3-834f-45ad-811d-85efdef97603
2020-04-08T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for First-Quarter —…—… Financial Results ...,LLY,http://www.gurufocus.com/news/1099259/lilly-confirms-date-and-conference-call-for-firstquarter-2020-financial-results-announcement,GuruFocus,,,,0,0,646eb489-cde3-4e1c-aada-e517e6015908
2020-04-07T08:00:00.000+08:00,Eli Lilly And Co Says New $35 Co-Pay Now Available Through Lilly Insulin Value Program In Response To Coronavirus Crisus,LLY,https://www.benzinga.com/general/health-care/20/04/15755030/eli-lilly-and-co-says-new-35-co-pay-now-available-through-lilly-insulin-value-program-in-resp,Benzinga Newsdesk,,,,0,0,6755c55d-67d2-4d1d-a25e-c0086957abb0
2020-04-07T08:00:00.000+08:00,Eli Lilly and Company to Hold —…—… Annual Meeting of Shareholders Virtually,LLY,http://www.gurufocus.com/news/1098422/eli-lilly-and-company-to-hold-2020-annual-meeting-of-shareholders-virtually,GuruFocus,,,,0,0,e1661972-d96d-4f2a-94a0-38a7247ec30c
2020-04-07T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Qualcomm and Electronic Arts",LLY,http://www.zacks.com/stock/news/858933/the-zacks-analyst-blog-highlights-eli-lilly-qualcomm-and-electronic-arts?cid=CS-BENZ-FT-press_releases-858933,Zacks,,,,0,0,34ff9df2-b757-4986-b611-c8b18344494a
2020-04-07T08:00:00.000+08:00,"Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day",LLY,http://www.zacks.com/stock/news/858915/agilysys-manpower-eli-lilly-and-company-innoviva-and-abbvie-highlighted-as-zacks-bull-and-bear-of-the-day?cid=CS-BENZ-FT-press_releases-858915,Zacks,,,,0,0,db978451-ad05-4d86-9857-11f6b8446e3e
2020-04-07T08:00:00.000+08:00,New $'5 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-–9 ...,LLY,http://www.gurufocus.com/news/1098140/new-35-copay-now-available-through-lilly-insulin-value-program-in-response-to-covid19-crisis-in-us,GuruFocus,,,,0,0,8e1f913b-3db5-4d99-8ead-7c58a3ceec9c
2020-04-07T08:00:00.000+08:00,Eli Lilly And Co Says New $35 Co-Pay Now Available Through Lilly Insulin Value Program In Response To Coronavirus Crisus,LLY,https://www.benzinga.com/general/health-care/20/04/15755030/eli-lilly-and-co-says-new-35-co-pay-now-available-through-lilly-insulin-value-program-in-resp,Benzinga Newsdesk,,,,0,0,8841667b-e6aa-40b7-9f51-ce461b305929
2020-04-07T08:00:00.000+08:00,Eli Lilly and Company to Hold —…—… Annual Meeting of Shareholders Virtually,LLY,http://www.gurufocus.com/news/1098422/eli-lilly-and-company-to-hold-2020-annual-meeting-of-shareholders-virtually,GuruFocus,,,,0,0,1830384b-dcb4-45cd-aca2-222b1274bc89
2020-04-07T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Qualcomm and Electronic Arts",LLY,http://www.zacks.com/stock/news/858933/the-zacks-analyst-blog-highlights-eli-lilly-qualcomm-and-electronic-arts?cid=CS-BENZ-FT-press_releases-858933,Zacks,,,,0,0,cac187e2-93ef-4ad4-a363-a5d4cbb49128
2020-04-07T08:00:00.000+08:00,"Agilysys, Manpower, Eli Lilly and Company, Innoviva and AbbVie highlighted as Zacks Bull and Bear of the Day",LLY,http://www.zacks.com/stock/news/858915/agilysys-manpower-eli-lilly-and-company-innoviva-and-abbvie-highlighted-as-zacks-bull-and-bear-of-the-day?cid=CS-BENZ-FT-press_releases-858915,Zacks,,,,0,0,8b7bd533-1b27-4d9b-9114-adcc7de1ff72
2020-04-07T08:00:00.000+08:00,New $'5 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-–9 ...,LLY,http://www.gurufocus.com/news/1098140/new-35-copay-now-available-through-lilly-insulin-value-program-in-response-to-covid19-crisis-in-us,GuruFocus,,,,0,0,522d95fa-6d89-4b74-ab4a-fa7ef701879a
2020-04-06T08:00:00.000+08:00,"'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb",LLY,https://www.benzinga.com/news/20/04/15749782/there-are-four-main-antibody-programs-underway-in-u-s-by-lilly-regeneron-vir-and-amgen-regeneron-may,Benzinga Newsdesk,,,,0,0,85f433f8-d10c-485f-9e2c-921a3e36b532
2020-04-06T08:00:00.000+08:00,Another Drug to Fight Coronavirus & 3 Picks,LLY,http://www.zacks.com/stock/news/857483/another-drug-to-fight-coronavirus-3-picks?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-857483,Zacks,,,,0,0,66488057-fe11-4160-ac16-2ace6988c4e7
2020-04-06T08:00:00.000+08:00,Why the Earnings Surprise Streak Could Continue for Lilly (LLY),LLY,http://www.zacks.com/stock/news/857355/why-the-earnings-surprise-streak-could-continue-for-lilly-lly?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_7-857355,Zacks,,,,0,0,87cef95b-119b-481a-9c35-281da5193446
2020-04-06T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck",LLY,http://www.zacks.com/stock/news/857136/the-zacks-analyst-blog-highlights-jj-sanofi-astrazeneca-lilly-and-merck?cid=CS-BENZ-FT-press_releases-857136,Zacks,,,,0,0,05027109-d43b-4901-bac2-16245206f68b
2020-04-06T08:00:00.000+08:00,"'There are four main antibody programs underway in U.S. by Lilly, Regeneron, Vir, and Amgen. Regeneron may be furthest along and have the best chance of doing this at the scale required...' -Weekend Tweet From Former FDA Commish Gottlieb",LLY,https://www.benzinga.com/news/20/04/15749782/there-are-four-main-antibody-programs-underway-in-u-s-by-lilly-regeneron-vir-and-amgen-regeneron-may,Benzinga Newsdesk,,,,0,0,b9205b5a-4c99-41fd-8698-eaaecf233413
2020-04-06T08:00:00.000+08:00,Another Drug to Fight Coronavirus & 3 Picks,LLY,http://www.zacks.com/stock/news/857483/another-drug-to-fight-coronavirus-3-picks?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-857483,Zacks,,,,0,0,91cd3a7e-0897-4db8-b373-41156b73f35e
2020-04-06T08:00:00.000+08:00,Why the Earnings Surprise Streak Could Continue for Lilly (LLY),LLY,http://www.zacks.com/stock/news/857355/why-the-earnings-surprise-streak-could-continue-for-lilly-lly?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_7-857355,Zacks,,,,0,0,07388489-b3e1-41f0-8abc-2ed488f0876e
2020-04-06T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Sanofi, AstraZeneca, Lilly and Merck",LLY,http://www.zacks.com/stock/news/857136/the-zacks-analyst-blog-highlights-jj-sanofi-astrazeneca-lilly-and-merck?cid=CS-BENZ-FT-press_releases-857136,Zacks,,,,0,0,d57ec201-658c-4006-a858-94102b641786
2020-04-04T08:00:00.000+08:00,Stocks Move Lower but Stay Calm After Dreary Jobs Report,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-24917,Zacks,,,,0,0,dba85591-e383-41ad-86ef-7743e8a8fda0
2020-04-04T08:00:00.000+08:00,Stocks Move Lower but Stay Calm After Dreary Jobs Report,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-24917,Zacks,,,,0,0,0cbf6178-f4ac-4a50-8525-562e354672eb
2020-04-03T08:00:00.000+08:00,IBD Stock Of The Day: Why Eli Lilly Is Outplaying Its Pharma Giant Peers,LLY,http://www.investors.com/research/ibd-stock-of-the-day/lly-stock-pharma-giant-winning-despite-coronavirus-pandemic/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,4ea4ca76-56d3-4674-9d5e-1c6bab0048ae
2020-04-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor",LLY,http://www.zacks.com/stock/news/853139/the-zacks-analyst-blog-highlights-eli-lilly-charter-eaton-autodesk-and-cypress-semiconductor?cid=CS-BENZ-FT-press_releases-853139,Zacks,,,,0,0,8fe6a67c-cfa8-4a36-b4a7-e9e8ee3d9e5b
2020-04-03T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/852982/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-852982,Zacks,,,,0,0,0bd79c54-96bd-43be-a031-894ac0464de7
2020-04-03T08:00:00.000+08:00,IBD Stock Of The Day: Why Eli Lilly Is Outplaying Its Pharma Giant Peers,LLY,http://www.investors.com/research/ibd-stock-of-the-day/lly-stock-pharma-giant-winning-despite-coronavirus-pandemic/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,c3f92a65-0d37-4426-a5d1-e34995d5cf62
2020-04-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Charter, Eaton, Autodesk and Cypress Semiconductor",LLY,http://www.zacks.com/stock/news/853139/the-zacks-analyst-blog-highlights-eli-lilly-charter-eaton-autodesk-and-cypress-semiconductor?cid=CS-BENZ-FT-press_releases-853139,Zacks,,,,0,0,05c1922e-46d7-4b84-9ebb-2dcaf7248155
2020-04-03T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/852982/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-852982,Zacks,,,,0,0,d3bb04a8-75c3-4397-ad6f-51a4a7c5e326
2020-04-02T08:00:00.000+08:00,"Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $148",LLY,https://www.benzinga.com/news/20/04/15727486/morgan-stanley-maintains-overweight-on-eli-lilly-lowers-price-target-to-148,Vick Meyer,,,,0,0,279e4968-ec52-4854-ab6d-e8f5aef68387
2020-04-02T08:00:00.000+08:00,Stock Indexes Jump As Jobless Claims Soar Again,LLY,http://www.investors.com/videos/stock-indexes-jump-as-jobless-claims-soar-again/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,1751a84b-d273-4302-b6f8-bc14e13e3c11
2020-04-02T08:00:00.000+08:00,"Top Analyst Reports for Eli Lilly, Charter Communications & Eaton",LLY,http://www.zacks.com/research-daily/851105/top-analyst-reports-for-eli-lilly-charter-communications-eaton?cid=CS-BENZ-FT-research_daily-851105,Zacks,,,,0,0,c778094a-6088-423c-970d-98a25c641c3c
2020-04-02T08:00:00.000+08:00,Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis,LLY,http://www.zacks.com/stock/news/851267/heres-why-you-should-buy-lilly-stock-amid-coronavirus-crisis?cid=CS-BENZ-FT-analyst_blog|rank_focused-851267,Zacks,,,,0,0,8f32ebb7-5a23-404b-9fbf-bd6eab23fa20
2020-04-02T08:00:00.000+08:00,Bull of the Day: Eli Lilly (LLY),LLY,http://www.zacks.com/commentary/849904/bull-of-the-day-eli-lilly-lly?cid=CS-BENZ-FT-bull_of_the_day-849904,Zacks,,,,0,0,00d8fef0-bf4c-43af-bd57-027eef11aab9
2020-04-02T08:00:00.000+08:00,"Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $148",LLY,https://www.benzinga.com/news/20/04/15727486/morgan-stanley-maintains-overweight-on-eli-lilly-lowers-price-target-to-148,Vick Meyer,,,,0,0,963e5b1e-3c87-4abd-9cad-12dd63bce6b6
2020-04-02T08:00:00.000+08:00,Stock Indexes Jump As Jobless Claims Soar Again,LLY,http://www.investors.com/videos/stock-indexes-jump-as-jobless-claims-soar-again/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,3cb00419-0b01-4164-b3c3-8b2ed1486276
2020-04-02T08:00:00.000+08:00,"Top Analyst Reports for Eli Lilly, Charter Communications & Eaton",LLY,http://www.zacks.com/research-daily/851105/top-analyst-reports-for-eli-lilly-charter-communications-eaton?cid=CS-BENZ-FT-research_daily-851105,Zacks,,,,0,0,770c7275-f33d-4056-9e40-2fea2cb4b0c0
2020-04-02T08:00:00.000+08:00,Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis,LLY,http://www.zacks.com/stock/news/851267/heres-why-you-should-buy-lilly-stock-amid-coronavirus-crisis?cid=CS-BENZ-FT-analyst_blog|rank_focused-851267,Zacks,,,,0,0,74504dad-cb88-4766-9fde-46659a7877cc
2020-04-02T08:00:00.000+08:00,Bull of the Day: Eli Lilly (LLY),LLY,http://www.zacks.com/commentary/849904/bull-of-the-day-eli-lilly-lly?cid=CS-BENZ-FT-bull_of_the_day-849904,Zacks,,,,0,0,ea4e3451-82ee-4a6a-8d07-cf42a43b715a
2020-04-01T08:00:00.000+08:00,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,LLY,https://www.benzinga.com/wiim/20/04/15717065/shares-of-several-healthcare-companies-are-trading-lower-amid-market-weakness-as-growing-coronavirus,Benzinga Newsdesk,,,,0,0,ae8d6c87-86f5-4b24-b3e2-28a8027a8a13
2020-04-01T08:00:00.000+08:00,Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy,LLY,http://www.zacks.com/stock/news/849899/pharma-giant-eli-lilly-lly-stock-is-a-buy-during-the-coronavirus-economy?cid=CS-BENZ-FT-stocks_in_the_news|investment_ideas-849899,Zacks,,,,0,0,6726d63c-2a83-4d97-90d8-3d68117c50d0
2020-04-01T08:00:00.000+08:00,"Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA",LLY,http://www.zacks.com/stock/news/849395/bristol-myers-bluebird-submit-bla-for-myeloma-drug-to-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-849395,Zacks,,,,0,0,024740fb-3d3d-4858-aa07-2deae44d6440
2020-04-01T08:00:00.000+08:00,Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/849155/is-eli-lilly-and-lly-outperforming-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-849155,Zacks,,,,0,0,2c2de7ee-f0be-4d29-9816-fa8f6d094eca
2020-04-01T08:00:00.000+08:00,3 Drugmakers Still Worth Betting on Amid Coronavirus Woes,LLY,http://www.zacks.com/stock/news/849056/3-drugmakers-still-worth-betting-on-amid-coronavirus-woes?cid=CS-BENZ-FT-analyst_blog|investment_ideas-849056,Zacks,,,,0,0,0f63bcaa-0ed0-410f-a309-ad2f23738b73
2020-04-01T08:00:00.000+08:00,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,LLY,https://www.benzinga.com/wiim/20/04/15717065/shares-of-several-healthcare-companies-are-trading-lower-amid-market-weakness-as-growing-coronavirus,Benzinga Newsdesk,,,,0,0,2750f588-8e44-4df8-9e83-4dd629d579b6
2020-04-01T08:00:00.000+08:00,Pharma Giant Eli Lilly (LLY) Stock is a Buy During the Coronavirus Economy,LLY,http://www.zacks.com/stock/news/849899/pharma-giant-eli-lilly-lly-stock-is-a-buy-during-the-coronavirus-economy?cid=CS-BENZ-FT-stocks_in_the_news|investment_ideas-849899,Zacks,,,,0,0,ca4b0bc5-19b1-42a9-8483-0950a0e35a4f
2020-04-01T08:00:00.000+08:00,"Bristol Myers, bluebird Submit BLA for Myeloma Drug to FDA",LLY,http://www.zacks.com/stock/news/849395/bristol-myers-bluebird-submit-bla-for-myeloma-drug-to-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-849395,Zacks,,,,0,0,bede8fba-ba06-457d-875a-7222f10fe09e
2020-04-01T08:00:00.000+08:00,Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/849155/is-eli-lilly-and-lly-outperforming-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-849155,Zacks,,,,0,0,07aa778e-78fc-4916-9ef4-5122cf8745f1
2020-04-01T08:00:00.000+08:00,3 Drugmakers Still Worth Betting on Amid Coronavirus Woes,LLY,http://www.zacks.com/stock/news/849056/3-drugmakers-still-worth-betting-on-amid-coronavirus-woes?cid=CS-BENZ-FT-analyst_blog|investment_ideas-849056,Zacks,,,,0,0,bf7281d7-1e4e-4348-bf32-eea3c99450fb
2020-03-31T08:00:00.000+08:00,Patent Court Rejects Eli Lilly Challenge To Teva Patents On Migraine Drug Ajovy,LLY,https://www.benzinga.com/news/20/03/15708775/patent-court-rejects-eli-lilly-challenge-to-teva-patents-on-migraine-drug-ajovy,Benzinga Newsdesk,,,,0,0,40ec70fd-da12-47fc-9feb-127c66446209
2020-03-31T08:00:00.000+08:00,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions",LLY,https://www.benzinga.com/general/biotech/20/03/15704595/the-daily-biotech-pulse-amarin-faces-legal-setback-milestone-payment-kicks-in-for-cytomx-savara-r,Shanthi Rexaline,,,,0,0,c591d722-22ac-4bcf-b764-e935720b3a55
2020-03-31T08:00:00.000+08:00,Lilly And Sitryx Announce Licensing And Research Collaboration To Discover And Develop New Immunometabolic Medicines,LLY,https://www.benzinga.com/general/biotech/20/03/15703815/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immuno,Benzinga Newsdesk,,,,0,0,cf76bbfe-64d1-4b80-92d6-e7cc2bbdc933
2020-03-31T08:00:00.000+08:00,Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus,LLY,http://www.zacks.com/stock/news/847731/buy-this-high-yield-large-cap-pharma-stock-for-income-amid-coronavirus?cid=CS-BENZ-FT-video_blog-847731,Zacks,,,,0,0,813333d1-f6e2-4eb5-9e6f-35da78a4bdda
2020-03-31T08:00:00.000+08:00,Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children,LLY,http://www.zacks.com/stock/news/847430/lillys-taltz-gets-fda-nod-for-plaque-psoriasis-in-children?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-847430,Zacks,,,,0,0,46950875-1d68-4317-93dc-3abaf8097b52
2020-03-31T08:00:00.000+08:00,Patent Court Rejects Eli Lilly Challenge To Teva Patents On Migraine Drug Ajovy,LLY,https://www.benzinga.com/news/20/03/15708775/patent-court-rejects-eli-lilly-challenge-to-teva-patents-on-migraine-drug-ajovy,Benzinga Newsdesk,,,,0,0,0d1aae0c-c6f7-4298-9038-a16250079cc6
2020-03-31T08:00:00.000+08:00,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions",LLY,https://www.benzinga.com/general/biotech/20/03/15704595/the-daily-biotech-pulse-amarin-faces-legal-setback-milestone-payment-kicks-in-for-cytomx-savara-r,Shanthi Rexaline,,,,0,0,f7bd9789-d009-493d-ab11-2ed6b124bf0d
2020-03-31T08:00:00.000+08:00,Lilly And Sitryx Announce Licensing And Research Collaboration To Discover And Develop New Immunometabolic Medicines,LLY,https://www.benzinga.com/general/biotech/20/03/15703815/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immuno,Benzinga Newsdesk,,,,0,0,a2137d6a-e995-41c4-8a3a-22d4f91112c6
2020-03-31T08:00:00.000+08:00,Buy this High-Yield Large Cap Pharma Stock for Income Amid Coronavirus,LLY,http://www.zacks.com/stock/news/847731/buy-this-high-yield-large-cap-pharma-stock-for-income-amid-coronavirus?cid=CS-BENZ-FT-video_blog-847731,Zacks,,,,0,0,63412230-1e85-438a-b985-22820c237c16
2020-03-31T08:00:00.000+08:00,Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children,LLY,http://www.zacks.com/stock/news/847430/lillys-taltz-gets-fda-nod-for-plaque-psoriasis-in-children?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-847430,Zacks,,,,0,0,f125beab-87b7-4c94-a90f-3ea9e2d0c3d7
2020-03-30T08:00:00.000+08:00,Why Eli Lilly's Stock Is Trading Higher Today,LLY,https://www.benzinga.com/news/20/03/15695621/why-eli-lillys-stock-is-trading-higher-today,Tanzeel Akhtar,,,,0,0,7e54301b-1810-4493-9b60-3866af1dd6ab
2020-03-30T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company received FDA approval for Taltz for treatment of pediatric patients with moderate to severe plaque psoriasis.,LLY,https://www.benzinga.com/wiim/20/03/15694884/eli-lilly-shares-are-trading-higher-after-the-company-received-fda-approval-for-taltz-for-treatment,Benzinga Newsdesk,,,,0,0,15055dd2-9743-4f1f-8a54-fd0159f562bc
2020-03-30T08:00:00.000+08:00,Eli Lilly's Taltz Receives FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/20/03/15692388/eli-lillys-taltz-receives-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-seve,luke@benzinga.com,,,,0,0,9a776a18-f25e-4eda-8622-1706f4ed8ca8
2020-03-30T08:00:00.000+08:00,"Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View",LLY,http://www.zacks.com/stock/news/845617/vertex-to-halt-enrollment-due-to-coronavirus-keeps-sales-view?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-845617,Zacks,,,,0,0,db638934-4cd4-45e3-a0f0-f778b2219209
2020-03-30T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) Receives U.S. ...,LLY,http://www.gurufocus.com/news/1089445/lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-severe-plaque-psoriasis,GuruFocus,,,,0,0,d16222e8-d043-45b5-be73-deb0a8ae657a
2020-03-30T08:00:00.000+08:00,Why Eli Lilly's Stock Is Trading Higher Today,LLY,https://www.benzinga.com/news/20/03/15695621/why-eli-lillys-stock-is-trading-higher-today,Tanzeel Akhtar,,,,0,0,8e0d0269-5e60-4f52-8d30-1b45e7fbacd3
2020-03-30T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company received FDA approval for Taltz for treatment of pediatric patients with moderate to severe plaque psoriasis.,LLY,https://www.benzinga.com/wiim/20/03/15694884/eli-lilly-shares-are-trading-higher-after-the-company-received-fda-approval-for-taltz-for-treatment,Benzinga Newsdesk,,,,0,0,c77f1864-1c1e-4812-b808-b7af584750ee
2020-03-30T08:00:00.000+08:00,Eli Lilly's Taltz Receives FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/20/03/15692388/eli-lillys-taltz-receives-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-seve,luke@benzinga.com,,,,0,0,f28fbe8b-7138-4d90-8b6a-35fbebdc82be
2020-03-30T08:00:00.000+08:00,"Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View",LLY,http://www.zacks.com/stock/news/845617/vertex-to-halt-enrollment-due-to-coronavirus-keeps-sales-view?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-845617,Zacks,,,,0,0,80fb4dcc-0d42-4f2f-a021-a22e64f78ed9
2020-03-30T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) Receives U.S. ...,LLY,http://www.gurufocus.com/news/1089445/lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment-of-pediatric-patients-with-moderate-to-severe-plaque-psoriasis,GuruFocus,,,,0,0,35daf613-fd8c-4fc2-a831-dd615ffdecf2
2020-03-27T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",LLY,https://www.benzinga.com/wiim/20/03/15682782/shares-of-several-healthcare-companies-are-trading-lower-selling-off-from-this-weeks-strength-while,Benzinga Newsdesk,,,,0,0,cbf71d9f-6b93-4504-9839-9cefd95d3838
2020-03-27T08:00:00.000+08:00,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic,LLY,https://www.benzinga.com/news/20/03/15679170/veeva-systems-crm-product-is-seeing-ten-times-more-usage-during-coronavirus-pandemic,Neer Varshney,,,,0,0,06447f9e-78be-425a-884a-8e55c819f930
2020-03-27T08:00:00.000+08:00,Spiros Segalas Starts the New Year Adding 5 Stocks to Portfolio,LLY,http://www.gurufocus.com/news/1087247/spiros-segalas-starts-the-new-year-adding-5-stocks-to-portfolio-,GuruFocus,,,,0,0,a28abe07-85c2-4c2e-96f2-be5a46bd4693
2020-03-27T08:00:00.000+08:00,Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia,LLY,http://www.zacks.com/stock/news/838749/bristol-myers-bmy-clinches-fda-nod-for-ms-drug-zeposia?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-838749,Zacks,,,,0,0,8840baba-b0aa-41dd-af1a-acf7d5ecd7bb
2020-03-27T08:00:00.000+08:00,"Eli Lilly Clears Key Benchmark, Hitting 90-Plus RS Rating",LLY,http://www.investors.com/ibd-data-stories/eli-lilly-clears-key-benchmark-hitting-90-plus-rs-rating/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,2eea5e7f-e8ef-42fe-8d45-7079934f85df
2020-03-27T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",LLY,https://www.benzinga.com/wiim/20/03/15682782/shares-of-several-healthcare-companies-are-trading-lower-selling-off-from-this-weeks-strength-while,Benzinga Newsdesk,,,,0,0,98d19d1c-eb42-450f-8233-ece494e2586c
2020-03-27T08:00:00.000+08:00,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic,LLY,https://www.benzinga.com/news/20/03/15679170/veeva-systems-crm-product-is-seeing-ten-times-more-usage-during-coronavirus-pandemic,Neer Varshney,,,,0,0,299fec74-fd64-4302-a3a4-a3d7f9422497
2020-03-27T08:00:00.000+08:00,Spiros Segalas Starts the New Year Adding 5 Stocks to Portfolio,LLY,http://www.gurufocus.com/news/1087247/spiros-segalas-starts-the-new-year-adding-5-stocks-to-portfolio-,GuruFocus,,,,0,0,41eb09c2-19a2-4a29-957c-7760e23fa523
2020-03-27T08:00:00.000+08:00,Bristol Myers (BMY) Clinches FDA Nod for MS Drug Zeposia,LLY,http://www.zacks.com/stock/news/838749/bristol-myers-bmy-clinches-fda-nod-for-ms-drug-zeposia?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-838749,Zacks,,,,0,0,f311814f-e1aa-4b25-b8f7-6bd5cac78236
2020-03-27T08:00:00.000+08:00,"Eli Lilly Clears Key Benchmark, Hitting 90-Plus RS Rating",LLY,http://www.investors.com/ibd-data-stories/eli-lilly-clears-key-benchmark-hitting-90-plus-rs-rating/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,ba8310ac-d2b3-4002-88c4-20f4cb895088
2020-03-26T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",LLY,https://www.benzinga.com/wiim/20/03/15674560/shares-of-several-healthcare-companies-are-trading-higher-following-senate-passage-of-a-2-trillion-e,Benzinga Newsdesk,,,,0,0,9b437164-47bb-4fa4-93c4-ebccaad61fc2
2020-03-26T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",LLY,https://www.benzinga.com/wiim/20/03/15674560/shares-of-several-healthcare-companies-are-trading-higher-following-senate-passage-of-a-2-trillion-e,Benzinga Newsdesk,,,,0,0,a9d0fbe6-dd49-4e26-94e2-4c4b51711f07
2020-03-24T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.",LLY,https://www.benzinga.com/wiim/20/03/15653267/shares-of-several-healthcare-companies-are-trading-higher-as-equities-gain-amid-hopes-of-a-us-stimul,Benzinga Newsdesk,,,,0,0,0e59dc06-66b2-46df-9224-a1e116212eb4
2020-03-24T08:00:00.000+08:00,"Eli Lilly Offers Update On Insulin Supply, Affordability, Says Does Not Source Active Pharma Ingredients From China, Says US Pharmacies Temporarily Unavailable For Co. Medicines Can Order From Wholesalers",LLY,https://www.benzinga.com/news/20/03/15649668/eli-lilly-offers-update-on-insulin-supply-affordability-says-does-not-source-active-pharma-ingredien,Benzinga Newsdesk,,,,0,0,fa672b69-e65c-49fa-b8c9-ca26c2e70b69
2020-03-24T08:00:00.000+08:00,Agios' IND for PKR Activator AG-946 Gets FDA Clearance,LLY,http://www.zacks.com/stock/news/832392/agios-ind-for-pkr-activator-ag-946-gets-fda-clearance?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-832392,Zacks,,,,0,0,8e21e38e-7691-4dac-a08b-682e9d7a2b1b
2020-03-24T08:00:00.000+08:00,"Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure",LLY,http://www.zacks.com/stock/news/831913/lilly-halts-enrollment-biotechs-focus-to-find-coronavirus-cure?cid=CS-BENZ-FT-analyst_blog|industry_focus-831913,Zacks,,,,0,0,5eb2e9eb-4174-4dc0-970c-bc42c1a400d6
2020-03-24T08:00:00.000+08:00,Updates from Lilly about insulin supply and affordability,LLY,http://www.gurufocus.com/news/1083554/updates-from-lilly-about-insulin-supply-and-affordability,GuruFocus,,,,0,0,7fb089ab-b38c-4d8b-9f74-3104798965c8
2020-03-24T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher as equities gain amid hopes of a US stimulus agreement. Additionally, the coronavirus outbreak has increased demand for certain medical supplies.",LLY,https://www.benzinga.com/wiim/20/03/15653267/shares-of-several-healthcare-companies-are-trading-higher-as-equities-gain-amid-hopes-of-a-us-stimul,Benzinga Newsdesk,,,,0,0,d340bf8c-61b5-473b-85f6-9757b3ee6d56
2020-03-24T08:00:00.000+08:00,"Eli Lilly Offers Update On Insulin Supply, Affordability, Says Does Not Source Active Pharma Ingredients From China, Says US Pharmacies Temporarily Unavailable For Co. Medicines Can Order From Wholesalers",LLY,https://www.benzinga.com/news/20/03/15649668/eli-lilly-offers-update-on-insulin-supply-affordability-says-does-not-source-active-pharma-ingredien,Benzinga Newsdesk,,,,0,0,3a12fd21-1d45-475c-bd7e-e79697ec63c7
2020-03-24T08:00:00.000+08:00,Agios' IND for PKR Activator AG-946 Gets FDA Clearance,LLY,http://www.zacks.com/stock/news/832392/agios-ind-for-pkr-activator-ag-946-gets-fda-clearance?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-832392,Zacks,,,,0,0,b8fb5d14-4683-4c39-aed4-16c74085ef60
2020-03-24T08:00:00.000+08:00,"Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure",LLY,http://www.zacks.com/stock/news/831913/lilly-halts-enrollment-biotechs-focus-to-find-coronavirus-cure?cid=CS-BENZ-FT-analyst_blog|industry_focus-831913,Zacks,,,,0,0,daa4abbc-b614-4aa8-b3db-738f17364a4c
2020-03-24T08:00:00.000+08:00,Updates from Lilly about insulin supply and affordability,LLY,http://www.gurufocus.com/news/1083554/updates-from-lilly-about-insulin-supply-and-affordability,GuruFocus,,,,0,0,8a3a86da-943c-4598-9eaa-04fe006589b7
2020-03-23T08:00:00.000+08:00,Eli Lilly Delays New Study Starts,LLY,https://www.benzinga.com/news/20/03/15635955/eli-lilly-delays-new-study-starts,Tanzeel Akhtar,,,,0,0,aa2c7041-b072-4e00-871d-b7002dace96e
2020-03-23T08:00:00.000+08:00,Eli Lilly and Co. shares are trading lower after the company announced it will delay most of the new study starts and pause enrollment in most of the ongoing studies amid Coronavirus.,LLY,https://www.benzinga.com/wiim/20/03/15632908/eli-lilly-and-co-shares-are-trading-lower-after-the-company-announced-it-will-delay-most-of-the-new,Benzinga Newsdesk,,,,0,0,f2dd7717-700f-4779-8594-f73a0fe958f2
2020-03-23T08:00:00.000+08:00,AC Immune Receives a Second Milestone Payment of CHF 10M From Eli Lilly,LLY,https://www.benzinga.com/news/20/03/15632092/ac-immune-receives-a-second-milestone-payment-of-chf-10m-from-eli-lilly,luke@benzinga.com,,,,0,0,9aafcd00-a700-4757-b4b3-459022588c55
2020-03-23T08:00:00.000+08:00,Eli Lilly Says it Will Delay Most New Trial Starts and Pause Enrollment in Ongoing Studies Amid Coronavirus,LLY,https://www.benzinga.com/news/20/03/15631606/eli-lilly-says-it-will-delay-most-new-trial-starts-and-pause-enrollment-in-ongoing-studies-amid-coro,luke@benzinga.com,,,,0,0,7d65dcd3-80e1-4f9b-a106-ea7bac7c1bbd
2020-03-23T08:00:00.000+08:00,Lilly Gets CRL for Jardiance in Type I Diabetes Indication,LLY,http://www.zacks.com/stock/news/829757/lilly-gets-crl-for-jardiance-in-type-i-diabetes-indication?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-829757,Zacks,,,,0,0,b3f29606-8f61-465b-9a48-e20106a15818
2020-03-23T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck",LLY,http://www.zacks.com/stock/news/829731/the-zacks-analyst-blog-highlights-pfizer-roche-sanofi-lilly-and-merck?cid=CS-BENZ-FT-press_releases-829731,Zacks,,,,0,0,46b9d7ff-ca8f-4a24-9b40-af19521bdd41
2020-03-23T08:00:00.000+08:00,Lilly Provides Update on Clinical Trial Activities During COVID-–9 Pandemic,LLY,http://www.gurufocus.com/news/1082320/lilly-provides-update-on-clinical-trial-activities-during-covid19-pandemic,GuruFocus,,,,0,0,6b23a17f-fefd-4781-a145-0a79e217cc32
2020-03-23T08:00:00.000+08:00,Eli Lilly Delays New Study Starts,LLY,https://www.benzinga.com/news/20/03/15635955/eli-lilly-delays-new-study-starts,Tanzeel Akhtar,,,,0,0,b1887c34-dcaa-4953-833b-96c3719bbcf5
2020-03-23T08:00:00.000+08:00,Eli Lilly and Co. shares are trading lower after the company announced it will delay most of the new study starts and pause enrollment in most of the ongoing studies amid Coronavirus.,LLY,https://www.benzinga.com/wiim/20/03/15632908/eli-lilly-and-co-shares-are-trading-lower-after-the-company-announced-it-will-delay-most-of-the-new,Benzinga Newsdesk,,,,0,0,ade791d0-851b-43fc-84da-343cfd5e20be
2020-03-23T08:00:00.000+08:00,AC Immune Receives a Second Milestone Payment of CHF 10M From Eli Lilly,LLY,https://www.benzinga.com/news/20/03/15632092/ac-immune-receives-a-second-milestone-payment-of-chf-10m-from-eli-lilly,luke@benzinga.com,,,,0,0,c6a6fc29-b9f0-4d14-96f9-df24a4c25707
2020-03-23T08:00:00.000+08:00,Eli Lilly Says it Will Delay Most New Trial Starts and Pause Enrollment in Ongoing Studies Amid Coronavirus,LLY,https://www.benzinga.com/news/20/03/15631606/eli-lilly-says-it-will-delay-most-new-trial-starts-and-pause-enrollment-in-ongoing-studies-amid-coro,luke@benzinga.com,,,,0,0,69819cfd-8022-4d45-a5cf-a033b870df76
2020-03-23T08:00:00.000+08:00,Lilly Gets CRL for Jardiance in Type I Diabetes Indication,LLY,http://www.zacks.com/stock/news/829757/lilly-gets-crl-for-jardiance-in-type-i-diabetes-indication?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-829757,Zacks,,,,0,0,477547ea-e279-478b-a153-aa49d9a9c2eb
2020-03-23T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Pfizer, Roche, Sanofi, Lilly and Merck",LLY,http://www.zacks.com/stock/news/829731/the-zacks-analyst-blog-highlights-pfizer-roche-sanofi-lilly-and-merck?cid=CS-BENZ-FT-press_releases-829731,Zacks,,,,0,0,a24f176b-8d9b-4b93-b65c-04c26efe33ca
2020-03-23T08:00:00.000+08:00,Lilly Provides Update on Clinical Trial Activities During COVID-–9 Pandemic,LLY,http://www.gurufocus.com/news/1082320/lilly-provides-update-on-clinical-trial-activities-during-covid19-pandemic,GuruFocus,,,,0,0,7c18a49c-ec17-4270-8dcc-1650895c31fc
2020-03-22T08:00:00.000+08:00,Lilly to Provide Drive-Through COVID-–9 Testing for Indianapolis Health Care Workers,LLY,http://www.gurufocus.com/news/1082072/lilly-to-provide-drivethrough-covid19-testing-for-indianapolis-health-care-workers,GuruFocus,,,,0,0,726bb828-8442-45bb-b205-9fb0d9165182
2020-03-22T08:00:00.000+08:00,Lilly to Provide Drive-Through COVID-–9 Testing for Indianapolis Health Care Workers,LLY,http://www.gurufocus.com/news/1082072/lilly-to-provide-drivethrough-covid19-testing-for-indianapolis-health-care-workers,GuruFocus,,,,0,0,207fb464-ccc3-479b-a346-627d43170aa5
2020-03-20T08:00:00.000+08:00,"FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes, Indicates FDA Is Unable To Approve Application In Current Form; Empagliflozin 2.5 Mg Is Being Developed By Boehringer Ingelheim & Lilly",LLY,https://www.benzinga.com/news/20/03/15621263/fda-issues-complete-response-letter-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-t,Benzinga Newsdesk,,,,0,0,27efda26-cdb2-40b9-ba64-935219675d8e
2020-03-20T08:00:00.000+08:00,US FDA issues complete response letter for empagliflozin —. ...,LLY,http://www.gurufocus.com/news/1081165/us-fda-issues-complete-response-letter-for-empagliflozin-25-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes,GuruFocus,,,,0,0,251562b5-1eb7-4ead-ac07-1b079a2a02b9
2020-03-20T08:00:00.000+08:00,"Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates",LLY,http://www.zacks.com/stock/news/825091/pharma-stock-roundup-sny-rhhby-pfes-coronavirus-product-development-other-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-825091,Zacks,,,,0,0,196c81ee-1674-41d3-995f-e2eb784d3f4d
2020-03-20T08:00:00.000+08:00,"FDA Issues Complete Response Letter For Empagliflozin 2.5 Mg As Adjunct To Insulin For Adults With Type 1 Diabetes, Indicates FDA Is Unable To Approve Application In Current Form; Empagliflozin 2.5 Mg Is Being Developed By Boehringer Ingelheim & Lilly",LLY,https://www.benzinga.com/news/20/03/15621263/fda-issues-complete-response-letter-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-t,Benzinga Newsdesk,,,,0,0,36c50fab-8b80-4ad3-b97b-72b9dfb69e82
2020-03-20T08:00:00.000+08:00,US FDA issues complete response letter for empagliflozin —. ...,LLY,http://www.gurufocus.com/news/1081165/us-fda-issues-complete-response-letter-for-empagliflozin-25-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes,GuruFocus,,,,0,0,4d81a4a8-76b1-44ce-bfbc-e19f7f78ec54
2020-03-20T08:00:00.000+08:00,"Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates",LLY,http://www.zacks.com/stock/news/825091/pharma-stock-roundup-sny-rhhby-pfes-coronavirus-product-development-other-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-825091,Zacks,,,,0,0,67484605-0d09-4a99-804b-29c499bd13b3
2020-03-19T08:00:00.000+08:00,"Thinking about trading options or stock in Akamai Technologies, Citrix Systems, Eli Lilly, ...",LLY,http://www.gurufocus.com/news/1079527/thinking-about-trading-options-or-stock-in-akamai-technologies-citrix-systems-eli-lilly-veeva-systems-or-walmart,GuruFocus,,,,0,0,d77777f5-5093-440c-abc6-74979a915983
2020-03-19T08:00:00.000+08:00,"Thinking about trading options or stock in Akamai Technologies, Citrix Systems, Eli Lilly, ...",LLY,http://www.gurufocus.com/news/1079527/thinking-about-trading-options-or-stock-in-akamai-technologies-citrix-systems-eli-lilly-veeva-systems-or-walmart,GuruFocus,,,,0,0,090eea41-dd72-4c8a-b637-f7b23a7a1dfb
2020-03-18T08:00:00.000+08:00,Eli Lilly Reports Partnership With Indiana State Dept. Of Health With Support From FDA To Accelerate Testing For Coronavirus In Indiana,LLY,https://www.benzinga.com/news/20/03/15583777/eli-lilly-reports-partnership-with-indiana-state-dept-of-health-with-support-from-fda-to-accelerate,Benzinga Newsdesk,,,,0,0,67a72af6-243c-491e-8bbe-e19eb7480a98
2020-03-18T08:00:00.000+08:00,"Lilly, Indiana State Department of Health Partner to Accelerate COVID-–9 Testing Using Lilly ...",LLY,http://www.gurufocus.com/news/1078652/lilly-indiana-state-department-of-health-partner-to-accelerate-covid19-testing-using-lilly-research-laboratories,GuruFocus,,,,0,0,837a09a4-f747-4d6e-a2bb-474fdfdaba64
2020-03-18T08:00:00.000+08:00,Eli Lilly Reports Partnership With Indiana State Dept. Of Health With Support From FDA To Accelerate Testing For Coronavirus In Indiana,LLY,https://www.benzinga.com/news/20/03/15583777/eli-lilly-reports-partnership-with-indiana-state-dept-of-health-with-support-from-fda-to-accelerate,Benzinga Newsdesk,,,,0,0,db3719df-06a5-4417-bf32-1f59c22c76f4
2020-03-18T08:00:00.000+08:00,"Lilly, Indiana State Department of Health Partner to Accelerate COVID-–9 Testing Using Lilly ...",LLY,http://www.gurufocus.com/news/1078652/lilly-indiana-state-department-of-health-partner-to-accelerate-covid19-testing-using-lilly-research-laboratories,GuruFocus,,,,0,0,96481dc5-cb20-4aee-8483-79de5ba9c889
2020-03-17T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.",LLY,https://www.benzinga.com/wiim/20/03/15568177/shares-of-several-healthcare-companies-are-trading-higher-rebounding-from-mondays-crash-stocks-may-a,Benzinga Newsdesk,,,,0,0,f8b3e8b0-c626-4358-8ce6-fc8c4059b648
2020-03-17T08:00:00.000+08:00,Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss,LLY,http://www.zacks.com/stock/news/818757/lillys-olumiant-gets-breakthrough-therapy-tag-for-hair-loss?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-818757,Zacks,,,,0,0,445c9f55-9dfa-475f-84fe-79e64d71d76b
2020-03-17T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher, rebounding from Monday's crash. Stocks may also potentially be getting a boost from expectations of further stimulus proposals.",LLY,https://www.benzinga.com/wiim/20/03/15568177/shares-of-several-healthcare-companies-are-trading-higher-rebounding-from-mondays-crash-stocks-may-a,Benzinga Newsdesk,,,,0,0,5cd6f35c-af88-4269-bf11-a153dd667725
2020-03-17T08:00:00.000+08:00,Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss,LLY,http://www.zacks.com/stock/news/818757/lillys-olumiant-gets-breakthrough-therapy-tag-for-hair-loss?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-818757,Zacks,,,,0,0,d381acd9-1a59-456e-a349-a10f9df9414a
2020-03-16T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.",LLY,https://www.benzinga.com/wiim/20/03/15559452/shares-of-several-healthcare-companies-are-trading-lower-as-the-coronavirus-outbreak-continues-to-ca,Benzinga Newsdesk,,,,0,0,d2f8dad8-b8a0-4f58-b54f-425f2d868c8d
2020-03-16T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata,LLY,https://www.benzinga.com/news/20/03/15556180/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-ar,luke@benzinga.com,,,,0,0,37683cc8-eceb-42d2-8a7a-82a341cc4948
2020-03-16T08:00:00.000+08:00,"Coronavirus Correction: Eli Lilly Stock Shows Strength Amid Accelerating Earnings, Sales",LLY,http://www.investors.com/stock-lists/stock-spotlight/eli-lilly-stock-shows-strength-during-coronavirus-stock-market-correction/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,888187a9-243b-4622-aef3-62522b21c15c
2020-03-16T08:00:00.000+08:00,4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy,LLY,http://www.zacks.com/stock/news/816672/4-big-drug-biotech-stocks-up-in-coronavirus-hit-economy?cid=CS-BENZ-FT-analyst_blog|investment_ideas-816672,Zacks,,,,0,0,28ace1df-29dd-4f58-8f9a-58ab12256b71
2020-03-16T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of ...,LLY,http://www.gurufocus.com/news/1074543/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-areata,GuruFocus,,,,0,0,dc78595f-4c57-41d6-93b7-444096590755
2020-03-16T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.",LLY,https://www.benzinga.com/wiim/20/03/15559452/shares-of-several-healthcare-companies-are-trading-lower-as-the-coronavirus-outbreak-continues-to-ca,Benzinga Newsdesk,,,,0,0,e7ac06bc-2223-4b42-a743-8a6a7fa5e3a8
2020-03-16T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata,LLY,https://www.benzinga.com/news/20/03/15556180/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-ar,luke@benzinga.com,,,,0,0,381807ef-b7b3-4f01-975e-a3943fa10bf7
2020-03-16T08:00:00.000+08:00,"Coronavirus Correction: Eli Lilly Stock Shows Strength Amid Accelerating Earnings, Sales",LLY,http://www.investors.com/stock-lists/stock-spotlight/eli-lilly-stock-shows-strength-during-coronavirus-stock-market-correction/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,28af1505-5333-4565-97c3-4db209e08a01
2020-03-16T08:00:00.000+08:00,4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy,LLY,http://www.zacks.com/stock/news/816672/4-big-drug-biotech-stocks-up-in-coronavirus-hit-economy?cid=CS-BENZ-FT-analyst_blog|investment_ideas-816672,Zacks,,,,0,0,af3e5da0-a0b7-485c-84ad-a39110ea7228
2020-03-16T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of ...,LLY,http://www.gurufocus.com/news/1074543/lilly-receives-fda-breakthrough-therapy-designation-for-baricitinib-for-the-treatment-of-alopecia-areata,GuruFocus,,,,0,0,3adb01b7-5f91-4b66-ae74-ee1c0b42e541
2020-03-13T08:00:00.000+08:00,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals",LLY,https://www.benzinga.com/general/biotech/20/03/15546603/the-latest-coronavirus-developments-from-biotechs-la-jolla-provides-giapreza-in-italy-enanta-rese,Shanthi Rexaline,,,,0,0,f54be27d-8dbe-40d0-adfb-012be703c043
2020-03-13T08:00:00.000+08:00,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,LLY,https://www.benzinga.com/wiim/20/03/15546640/shares-of-several-healthcare-companies-are-trading-higher-as-the-market-rebounds-following-thursdays,Benzinga Newsdesk,,,,0,0,8c2b85d9-9e32-4e63-8d96-34c662af00d8
2020-03-13T08:00:00.000+08:00,"Thinking about trading options or stock in Alphabet, Eli Lilly, Microsoft, Procter & ...",LLY,http://www.gurufocus.com/news/1072825/thinking-about-trading-options-or-stock-in-alphabet-eli-lilly-microsoft-procter--gamble-or-roku,GuruFocus,,,,0,0,cce0cb16-c928-4086-a52c-955592651d07
2020-03-13T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates",LLY,http://www.zacks.com/stock/news/811614/pharma-stock-roundup-abbv-lly-coronavirus-product-development-efforts-fda-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-811614,Zacks,,,,0,0,5986cbbd-ead2-4943-8a44-685c884238d1
2020-03-13T08:00:00.000+08:00,Weekly Biotech Update After WHO Declares Coronavirus a Pandemic,LLY,http://www.zacks.com/stock/news/811616/weekly-biotech-update-after-who-declares-coronavirus-a-pandemic?cid=CS-BENZ-FT-analyst_blog|industry_focus-811616,Zacks,,,,0,0,228f2cf0-59bb-4ee6-a51d-551fc55ff505
2020-03-13T08:00:00.000+08:00,Coronavirus Drug Development Efforts Pick Up Amid Sell-Off,LLY,http://www.zacks.com/stock/news/811498/coronavirus-drug-development-efforts-pick-up-amid-sell-off?cid=CS-BENZ-FT-analyst_blog|industry_focus-811498,Zacks,,,,0,0,d13d4f58-ac26-4707-b340-2a6a5640ada9
2020-03-13T08:00:00.000+08:00,When To Buy Large Cap Stocks During A Stock Market Crash: These 2 Sectors Offer Clues,LLY,http://www.investors.com/stock-lists/ibd-big-cap-20/when-to-buy-large-cap-stocks-during-a-stock-market-crash-these-2-sectors-offer-clues/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,94257769-561d-4b9b-91ef-fbf9f2ac25b9
2020-03-13T08:00:00.000+08:00,"The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals",LLY,https://www.benzinga.com/general/biotech/20/03/15546603/the-latest-coronavirus-developments-from-biotechs-la-jolla-provides-giapreza-in-italy-enanta-rese,Shanthi Rexaline,,,,0,0,3d618b82-6c9d-4e5f-aee4-20e2e1467a63
2020-03-13T08:00:00.000+08:00,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,LLY,https://www.benzinga.com/wiim/20/03/15546640/shares-of-several-healthcare-companies-are-trading-higher-as-the-market-rebounds-following-thursdays,Benzinga Newsdesk,,,,0,0,3b32a389-110a-4ea6-a8c2-a05d9323ff0e
2020-03-13T08:00:00.000+08:00,"Thinking about trading options or stock in Alphabet, Eli Lilly, Microsoft, Procter & ...",LLY,http://www.gurufocus.com/news/1072825/thinking-about-trading-options-or-stock-in-alphabet-eli-lilly-microsoft-procter--gamble-or-roku,GuruFocus,,,,0,0,b2f1f03c-c951-4984-8c1d-3c20f36628e7
2020-03-13T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates",LLY,http://www.zacks.com/stock/news/811614/pharma-stock-roundup-abbv-lly-coronavirus-product-development-efforts-fda-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-811614,Zacks,,,,0,0,30f2846a-0fe3-4860-a31d-8fc6b34f7fff
2020-03-13T08:00:00.000+08:00,Weekly Biotech Update After WHO Declares Coronavirus a Pandemic,LLY,http://www.zacks.com/stock/news/811616/weekly-biotech-update-after-who-declares-coronavirus-a-pandemic?cid=CS-BENZ-FT-analyst_blog|industry_focus-811616,Zacks,,,,0,0,5d254b42-af0c-49eb-8eee-a7924287ec7b
2020-03-13T08:00:00.000+08:00,Coronavirus Drug Development Efforts Pick Up Amid Sell-Off,LLY,http://www.zacks.com/stock/news/811498/coronavirus-drug-development-efforts-pick-up-amid-sell-off?cid=CS-BENZ-FT-analyst_blog|industry_focus-811498,Zacks,,,,0,0,16e758b2-5808-4ed6-9a27-b43fac386706
2020-03-13T08:00:00.000+08:00,When To Buy Large Cap Stocks During A Stock Market Crash: These 2 Sectors Offer Clues,LLY,http://www.investors.com/stock-lists/ibd-big-cap-20/when-to-buy-large-cap-stocks-during-a-stock-market-crash-these-2-sectors-offer-clues/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,a182aac2-7307-4461-a464-89f2e14ed651
2020-03-12T08:00:00.000+08:00,"Eli Lilly Shares Make Parabolic Move, Spike Higher Then Sell Off; Hearing Co. Said To Join Race To Develop Coronavirus Treatment",LLY,https://www.benzinga.com/news/20/03/15539101/eli-lilly-shares-make-parabolic-move-spike-higher-then-sell-off-hearing-co-said-to-join-race-to-deve,Benzinga Newsdesk,,,,0,0,267c29c4-11ed-48b1-a0a9-77a2fa19dab0
2020-03-12T08:00:00.000+08:00,Eli Lilly & Co shares are trading lower despite receiving fast track designation to Jardiance by the FDA for the treatment of chronic kidney diseases. NOTE: Markets continue to drop amid the global coronavirus outbreak.,LLY,https://www.benzinga.com/wiim/20/03/15536434/eli-lilly-co-shares-are-trading-lower-despite-receiving-fast-track-designation-to-jardiance-by-the-f,Benzinga Newsdesk,,,,0,0,45686936-b8e7-4e1d-8c29-095fe1e3717f
2020-03-12T08:00:00.000+08:00,US FDA Grants Fast Track Designation to Jardiance® for The Treatment of Chronic Kidney Disease,LLY,https://www.benzinga.com/news/20/03/15534998/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease,Benzinga Newsdesk,,,,0,0,853ab277-23e9-4541-a5dc-6bc7d2d60a42
2020-03-12T08:00:00.000+08:00,AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-–9,LLY,http://www.gurufocus.com/news/1072123/abcellera-and-lilly-to-codevelop-antibody-therapies-for-the-treatment-of-covid19,GuruFocus,,,,0,0,1f00f87a-5b21-44e4-9c3b-9df14818a964
2020-03-12T08:00:00.000+08:00,US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease,LLY,http://www.gurufocus.com/news/1071067/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease,GuruFocus,,,,0,0,2a76976e-5309-4518-97dd-2611ff1e7249
2020-03-12T08:00:00.000+08:00,"Eli Lilly Shares Make Parabolic Move, Spike Higher Then Sell Off; Hearing Co. Said To Join Race To Develop Coronavirus Treatment",LLY,https://www.benzinga.com/news/20/03/15539101/eli-lilly-shares-make-parabolic-move-spike-higher-then-sell-off-hearing-co-said-to-join-race-to-deve,Benzinga Newsdesk,,,,0,0,19c97191-091f-4234-857a-2cd3d967fd2f
2020-03-12T08:00:00.000+08:00,Eli Lilly & Co shares are trading lower despite receiving fast track designation to Jardiance by the FDA for the treatment of chronic kidney diseases. NOTE: Markets continue to drop amid the global coronavirus outbreak.,LLY,https://www.benzinga.com/wiim/20/03/15536434/eli-lilly-co-shares-are-trading-lower-despite-receiving-fast-track-designation-to-jardiance-by-the-f,Benzinga Newsdesk,,,,0,0,a9fc1c43-a451-4c35-9e51-38899ebcc8dd
2020-03-12T08:00:00.000+08:00,US FDA Grants Fast Track Designation to Jardiance® for The Treatment of Chronic Kidney Disease,LLY,https://www.benzinga.com/news/20/03/15534998/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease,Benzinga Newsdesk,,,,0,0,6ca9f8b0-b618-4946-bbf5-dfeb0e662e60
2020-03-12T08:00:00.000+08:00,AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-–9,LLY,http://www.gurufocus.com/news/1072123/abcellera-and-lilly-to-codevelop-antibody-therapies-for-the-treatment-of-covid19,GuruFocus,,,,0,0,3afb6649-f6d6-4f04-9793-717e11b7969c
2020-03-12T08:00:00.000+08:00,US FDA grants Fast Track designation to Jardiance® for the treatment of chronic kidney disease,LLY,http://www.gurufocus.com/news/1071067/us-fda-grants-fast-track-designation-to-jardiance-for-the-treatment-of-chronic-kidney-disease,GuruFocus,,,,0,0,5119cb60-27a2-4293-9b02-08f993ec83c6
2020-03-11T08:00:00.000+08:00,Lilly To Participate In New Model Designed To Make Insulins More Affordable For Seniors In Medicare Part D,LLY,https://www.benzinga.com/general/health-care/20/03/15528798/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-me,luke@benzinga.com,,,,0,0,7ff6c24b-46af-4a69-9506-995a19015779
2020-03-11T08:00:00.000+08:00,"Goldman Sachs Maintains Buy on Eli Lilly, Announces $168 Price Target; Adds To Conviction Buy List",LLY,https://www.benzinga.com/news/20/03/15525286/goldman-sachs-maintains-buy-on-eli-lilly-announces-168-price-target-adds-to-conviction-buy-list,Benzinga_Newsdesk,,,,0,0,e87bb4d2-e34a-4272-9306-9945aa921d06
2020-03-11T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Correction Is A Bear; Apple, Tesla, AMD Show Strength",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-correction-is-bear-market-apple-tesla-show-strength/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,c62f259b-9f91-4b7a-b61a-5735226a3fd2
2020-03-11T08:00:00.000+08:00,Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in ...,LLY,http://www.gurufocus.com/news/1070532/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-medicare-part-d,GuruFocus,,,,0,0,c76b9f7b-ad41-4b0d-8450-dea4523b17c9
2020-03-11T08:00:00.000+08:00,Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4,LLY,http://www.zacks.com/stock/news/808270/aduros-adro-earnings-revenues-miss-estimates-in-q4?cid=CS-BENZ-FT-analyst_blog|earnings_article-808270,Zacks,,,,0,0,d320bc4d-ee76-4f35-9053-7e695c90fc76
2020-03-11T08:00:00.000+08:00,"\"Dow Jones Slammed 1,151 Points On Coronavirus Fears; Will \"\"Stay At Home\"\" Stocks Win Big In 2020?\"",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-slammed-1151-points-on-coronavirus-fears-will-stay-at-home-stocks-win-big-in-2020/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,4b6a8d03-bdec-449b-b4fc-1ab39e8dd50a
2020-03-11T08:00:00.000+08:00,Pharma M&A Has Slowed to a Crawl,LLY,http://www.gurufocus.com/news/1069653/pharma-ma-has-slowed-to-a-crawl,GuruFocus,,,,0,0,055882fc-d099-499d-8f8d-8e38d1bc6af3
2020-03-11T08:00:00.000+08:00,Lilly To Participate In New Model Designed To Make Insulins More Affordable For Seniors In Medicare Part D,LLY,https://www.benzinga.com/general/health-care/20/03/15528798/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-me,luke@benzinga.com,,,,0,0,62177142-3e3b-439a-85d5-5926f9a77842
2020-03-11T08:00:00.000+08:00,"Goldman Sachs Maintains Buy on Eli Lilly, Announces $168 Price Target; Adds To Conviction Buy List",LLY,https://www.benzinga.com/news/20/03/15525286/goldman-sachs-maintains-buy-on-eli-lilly-announces-168-price-target-adds-to-conviction-buy-list,Benzinga_Newsdesk,,,,0,0,bc6ed62d-2ccc-42eb-af6e-786e0264748a
2020-03-11T08:00:00.000+08:00,"Dow Jones Futures: Coronavirus Stock Market Correction Is A Bear; Apple, Tesla, AMD Show Strength",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-coronavirus-stock-market-correction-is-bear-market-apple-tesla-show-strength/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,ee518e85-037b-42f3-b8b6-96fd3e983a11
2020-03-11T08:00:00.000+08:00,Lilly to Participate in New Model Designed to Make Insulins More Affordable for Seniors in ...,LLY,http://www.gurufocus.com/news/1070532/lilly-to-participate-in-new-model-designed-to-make-insulins-more-affordable-for-seniors-in-medicare-part-d,GuruFocus,,,,0,0,0d5fe3fa-f8ba-43a3-97f8-da76005d417b
2020-03-11T08:00:00.000+08:00,Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4,LLY,http://www.zacks.com/stock/news/808270/aduros-adro-earnings-revenues-miss-estimates-in-q4?cid=CS-BENZ-FT-analyst_blog|earnings_article-808270,Zacks,,,,0,0,e57e1c3a-785c-441a-b664-aca1dc775930
2020-03-11T08:00:00.000+08:00,"\"Dow Jones Slammed 1,151 Points On Coronavirus Fears; Will \"\"Stay At Home\"\" Stocks Win Big In 2020?\"",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-slammed-1151-points-on-coronavirus-fears-will-stay-at-home-stocks-win-big-in-2020/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,8dba8d63-7665-4223-969c-a14692d0eb2a
2020-03-11T08:00:00.000+08:00,Pharma M&A Has Slowed to a Crawl,LLY,http://www.gurufocus.com/news/1069653/pharma-ma-has-slowed-to-a-crawl,GuruFocus,,,,0,0,179af4d0-4ef2-4335-bcd2-332637e9987d
2020-03-09T08:00:00.000+08:00,Lilly to Participate in Barclays Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1068579/lilly-to-participate-in-barclays-global-healthcare-conference,GuruFocus,,,,0,0,edf3f4b3-b6d5-4058-b793-a96e1f8781ed
2020-03-09T08:00:00.000+08:00,"Thinking about trading options or stock in Dollar General, Eli Lilly, 'M, Regeneron ...",LLY,http://www.gurufocus.com/news/1068401/thinking-about-trading-options-or-stock-in-dollar-general-eli-lilly-3m-regeneron-pharmaceuticals-or-slack-technologies,GuruFocus,,,,0,0,786e1e21-9c0f-4399-b84d-9b4c7e17adc3
2020-03-09T08:00:00.000+08:00,Lilly to Participate in Barclays Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1068579/lilly-to-participate-in-barclays-global-healthcare-conference,GuruFocus,,,,0,0,bdcbc614-3e6f-4589-8af3-bae39cf62b34
2020-03-09T08:00:00.000+08:00,"Thinking about trading options or stock in Dollar General, Eli Lilly, 'M, Regeneron ...",LLY,http://www.gurufocus.com/news/1068401/thinking-about-trading-options-or-stock-in-dollar-general-eli-lilly-3m-regeneron-pharmaceuticals-or-slack-technologies,GuruFocus,,,,0,0,90cb9a4b-adc4-439a-90ce-6c7bfdc63e56
2020-03-07T08:00:00.000+08:00,Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics,LLY,https://talkmarkets.com/content/week-in-review-abpro-bio-signs-11-billion-deal-for-china-asian-rights-to-two-bi-specifics?post=253730,TalkMarkets,,,,0,0,ca4c0bcf-8b8d-477b-bede-4dbea8b0714d
2020-03-07T08:00:00.000+08:00,Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics,LLY,https://talkmarkets.com/content/week-in-review-abpro-bio-signs-11-billion-deal-for-china-asian-rights-to-two-bi-specifics?post=253730,TalkMarkets,,,,0,0,d20ee971-2771-44ab-8171-2840b6a23d99
2020-03-06T08:00:00.000+08:00,"Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates",LLY,http://www.zacks.com/stock/news/799956/pharma-stock-roundup-trump-pharma-executives-meeting-on-coronavirus-fda-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-799956,Zacks,,,,0,0,63577eae-5f95-48b7-8fd6-508135d47d8d
2020-03-06T08:00:00.000+08:00,"Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates",LLY,http://www.zacks.com/stock/news/799956/pharma-stock-roundup-trump-pharma-executives-meeting-on-coronavirus-fda-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-799956,Zacks,,,,0,0,a440e9f9-db56-4c22-9e86-77c07b6fc109
2020-03-04T08:00:00.000+08:00,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,LLY,https://www.benzinga.com/wiim/20/03/15477290/shares-of-several-drugmakers-and-healthcare-companies-are-trading-higher-following-us-super-tuesday,luke@benzinga.com,,,,0,0,b3438728-fec4-4e17-a012-b88c55aa053f
2020-03-04T08:00:00.000+08:00,Lilly Expects No Drug Supply Shortages Due to Coronavirus,LLY,http://www.zacks.com/stock/news/796161/lilly-expects-no-drug-supply-shortages-due-to-coronavirus?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-796161,Zacks,,,,0,0,0ac77bc7-df64-4285-812b-28932de952ef
2020-03-04T08:00:00.000+08:00,Shares of several drugmakers and healthcare companies are trading higher following US Super Tuesday results in which Joe Biden won the highest number of delegates. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,LLY,https://www.benzinga.com/wiim/20/03/15477290/shares-of-several-drugmakers-and-healthcare-companies-are-trading-higher-following-us-super-tuesday,luke@benzinga.com,,,,0,0,ba8279d8-db16-495e-8cf6-12c3b695003c
2020-03-04T08:00:00.000+08:00,Lilly Expects No Drug Supply Shortages Due to Coronavirus,LLY,http://www.zacks.com/stock/news/796161/lilly-expects-no-drug-supply-shortages-due-to-coronavirus?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-796161,Zacks,,,,0,0,f3c0fd54-cd74-4ae5-bb1b-ebb188a2f08d
2020-03-03T08:00:00.000+08:00,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",LLY,https://www.benzinga.com/general/biotech/20/03/15463518/the-daily-biotech-pulse-genmark-diagnostics-ships-covid-19-test-kits-karyopharm-to-offer-shares-a,Shanthi Rexaline,,,,0,0,993dbf02-bc53-416a-815e-914bd42ce98c
2020-03-03T08:00:00.000+08:00,"Lilly Issued A Statement On Coronavirus And The Reliable Syooly Of The Company's Medicines; The Company Does Not Anticioae Shortage For Any Of Its Products, Including All Forms Of Insulin",LLY,https://www.benzinga.com/news/20/03/15464651/lilly-issued-a-statement-on-coronavirus-and-the-reliable-syooly-of-the-companys-medicines-the-compan,Benzinga Newsdesk,,,,0,0,6c4b4fb6-d6c5-4054-b14a-e3cd68ed97e4
2020-03-03T08:00:00.000+08:00,Sometimes The Best Trade Is No Trade,LLY,https://talkmarkets.com/content/sometimes-the-best-trade-is-no-trade?post=253102,TalkMarkets,,,,0,0,1612c752-a6fb-4ddd-b61b-064d7b649e87
2020-03-03T08:00:00.000+08:00,"Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA",LLY,http://www.zacks.com/stock/news/794372/pfizer-plans-coronavirus-therapy-progresses-with-tanezumab-bla?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-794372,Zacks,,,,0,0,4ad00473-811e-4fa5-b215-f944aeec76e0
2020-03-03T08:00:00.000+08:00,Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines,LLY,http://www.gurufocus.com/news/1063461/lilly-statement-on-novel-coronavirus-and-the-reliable-supply-of-the-companys-medicines,GuruFocus,,,,0,0,fecb14ab-b764-43c3-94eb-4dfb1c74ff6a
2020-03-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Union Pacific, Lockheed Martin, Bayer and Prologis",LLY,http://www.zacks.com/stock/news/794092/the-zacks-analyst-blog-highlights-eli-lilly-union-pacific-lockheed-martin-bayer-and-prologis?cid=CS-BENZ-FT-press_releases-794092,Zacks,,,,0,0,fa0a908f-b224-468b-a614-2e87c02295e7
2020-03-03T08:00:00.000+08:00,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",LLY,https://www.benzinga.com/general/biotech/20/03/15463518/the-daily-biotech-pulse-genmark-diagnostics-ships-covid-19-test-kits-karyopharm-to-offer-shares-a,Shanthi Rexaline,,,,0,0,da01d061-1fb8-485c-99b6-3e7aa007ad77
2020-03-03T08:00:00.000+08:00,"Lilly Issued A Statement On Coronavirus And The Reliable Syooly Of The Company's Medicines; The Company Does Not Anticioae Shortage For Any Of Its Products, Including All Forms Of Insulin",LLY,https://www.benzinga.com/news/20/03/15464651/lilly-issued-a-statement-on-coronavirus-and-the-reliable-syooly-of-the-companys-medicines-the-compan,Benzinga Newsdesk,,,,0,0,39c04d2d-0a6a-435b-88a3-019b0cd9dcd5
2020-03-03T08:00:00.000+08:00,Sometimes The Best Trade Is No Trade,LLY,https://talkmarkets.com/content/sometimes-the-best-trade-is-no-trade?post=253102,TalkMarkets,,,,0,0,854293ff-d9cf-43eb-98d0-e17869f11a56
2020-03-03T08:00:00.000+08:00,"Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA",LLY,http://www.zacks.com/stock/news/794372/pfizer-plans-coronavirus-therapy-progresses-with-tanezumab-bla?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-794372,Zacks,,,,0,0,1f9c9ceb-1c21-4a15-9be2-53756a9caa00
2020-03-03T08:00:00.000+08:00,Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines,LLY,http://www.gurufocus.com/news/1063461/lilly-statement-on-novel-coronavirus-and-the-reliable-supply-of-the-companys-medicines,GuruFocus,,,,0,0,a955f436-c630-4466-af2d-503821e8c86f
2020-03-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Union Pacific, Lockheed Martin, Bayer and Prologis",LLY,http://www.zacks.com/stock/news/794092/the-zacks-analyst-blog-highlights-eli-lilly-union-pacific-lockheed-martin-bayer-and-prologis?cid=CS-BENZ-FT-press_releases-794092,Zacks,,,,0,0,3f3d1a6f-e8e1-48b8-bbaf-2899406382fd
2020-03-02T08:00:00.000+08:00,Pfizer's Biologics License Application for Tanezumab Accepted for Review by the FDA,LLY,https://www.benzinga.com/news/20/03/15452717/pfizers-biologics-license-application-for-tanezumab-accepted-for-review-by-the-fda,Benzinga Newsdesk,,,,0,0,43b38b8f-6ba9-4e09-9e9a-f78e6eee9ac2
2020-03-02T08:00:00.000+08:00,"Top Stock Reports for Eli Lilly, Union Pacific & Lockheed",LLY,http://www.zacks.com/research-daily/792580/top-stock-reports-for-eli-lilly-union-pacific-lockheed?cid=CS-BENZ-FT-research_daily-792580,Zacks,,,,0,0,58ae6de2-4de5-49db-8a6c-76944dc45a96
2020-03-02T08:00:00.000+08:00,This is Why Eli Lilly (LLY) is a Great Dividend Stock,LLY,http://www.zacks.com/stock/news/792843/this-is-why-eli-lilly-lly-is-a-great-dividend-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-792843,Zacks,,,,0,0,f71cfaf1-d107-4ded-9f39-ba8a3ec4d4de
2020-03-02T08:00:00.000+08:00,"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for ...",LLY,http://www.gurufocus.com/news/1061635/us-fda-accepts-regulatory-submission-for-tanezumab-a-potential-firstinclass-treatment-for-patients-with-chronic-pain-due-to-moderatetosevere-osteoarthritis,GuruFocus,,,,0,0,1e926a85-a297-4f84-b064-a15c09e58aea
2020-03-02T08:00:00.000+08:00,Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength,LLY,http://www.zacks.com/stock/news/792360/radius-rdus-q4-earnings-beat-estimates-on-tymlos-strength?cid=CS-BENZ-FT-analyst_blog|earnings_article-792360,Zacks,,,,0,0,ae22aef5-aaf5-463b-b458-37f80fc4090d
2020-03-02T08:00:00.000+08:00,Pfizer's Biologics License Application for Tanezumab Accepted for Review by the FDA,LLY,https://www.benzinga.com/news/20/03/15452717/pfizers-biologics-license-application-for-tanezumab-accepted-for-review-by-the-fda,Benzinga Newsdesk,,,,0,0,fd461be3-f58f-4ebc-99b7-2b62698ac5ad
2020-03-02T08:00:00.000+08:00,"Top Stock Reports for Eli Lilly, Union Pacific & Lockheed",LLY,http://www.zacks.com/research-daily/792580/top-stock-reports-for-eli-lilly-union-pacific-lockheed?cid=CS-BENZ-FT-research_daily-792580,Zacks,,,,0,0,c8f914f5-11af-4f00-8a7b-4144b513cc5b
2020-03-02T08:00:00.000+08:00,This is Why Eli Lilly (LLY) is a Great Dividend Stock,LLY,http://www.zacks.com/stock/news/792843/this-is-why-eli-lilly-lly-is-a-great-dividend-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-792843,Zacks,,,,0,0,38decf4c-7364-4583-b58e-de25f02848d6
2020-03-02T08:00:00.000+08:00,"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for ...",LLY,http://www.gurufocus.com/news/1061635/us-fda-accepts-regulatory-submission-for-tanezumab-a-potential-firstinclass-treatment-for-patients-with-chronic-pain-due-to-moderatetosevere-osteoarthritis,GuruFocus,,,,0,0,0c3bdbc5-dedf-4d0b-a065-8206d699f69c
2020-03-02T08:00:00.000+08:00,Radius (RDUS) Q4 Earnings Beat Estimates on Tymlos Strength,LLY,http://www.zacks.com/stock/news/792360/radius-rdus-q4-earnings-beat-estimates-on-tymlos-strength?cid=CS-BENZ-FT-analyst_blog|earnings_article-792360,Zacks,,,,0,0,8571ce2e-1a88-461d-b1e5-4c1e70fc6ae5
2020-02-29T08:00:00.000+08:00,Lilly (LLY) Down 11.6% Since Last Earnings Report: Can It Rebound?,LLY,http://www.zacks.com/stock/news/790111/lilly-lly-down-116-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-realtime_blog-790111,Zacks,,,,0,0,203fc1ef-c3d1-446d-bc14-6f12f185984d
2020-02-29T08:00:00.000+08:00,Lilly (LLY) Down 11.6% Since Last Earnings Report: Can It Rebound?,LLY,http://www.zacks.com/stock/news/790111/lilly-lly-down-116-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-realtime_blog-790111,Zacks,,,,0,0,cc69cc29-8d99-4b42-ba48-f7c873fd108f
2020-02-28T08:00:00.000+08:00,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,LLY,https://www.benzinga.com/wiim/20/02/15440922/shares-of-several-healthcare-companies-are-trading-lower-as-the-global-coronavirus-spread-continues,Benzinga Newsdesk,,,,0,0,e839450e-6c1d-49e1-93c0-b8d781e8b5f8
2020-02-28T08:00:00.000+08:00,EMA Says Adopted Negative Opinion For Eli Lilly's Indication Extension For Emgality To Add Prevention Of Attacks In Adults With Episodic Cluster Headache,LLY,https://www.benzinga.com/news/20/02/15439219/ema-says-adopted-negative-opinion-for-eli-lillys-indication-extension-for-emgality-to-add-prevention,Benzinga Newsdesk,,,,0,0,36df7bdd-c5c4-4bf6-8665-60884a224751
2020-02-28T08:00:00.000+08:00,"Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit",LLY,http://www.zacks.com/stock/news/788467/pharma-stock-roundup-fda-updates-from-lly-gsk-nvs-sny-to-spin-off-api-unit?cid=CS-BENZ-FT-analyst_blog|stock_roundup-788467,Zacks,,,,0,0,139867e0-ffd9-47b5-8d56-cd6a088299c7
2020-02-28T08:00:00.000+08:00,"Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/788298/nektar-nktr-q4-earnings-revenues-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-788298,Zacks,,,,0,0,a0399c4f-1805-42a3-9c0d-42c34019b72d
2020-02-28T08:00:00.000+08:00,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,LLY,https://www.benzinga.com/wiim/20/02/15440922/shares-of-several-healthcare-companies-are-trading-lower-as-the-global-coronavirus-spread-continues,Benzinga Newsdesk,,,,0,0,7c2b2afc-22ac-4365-bf29-8fa1b7b86be2
2020-02-28T08:00:00.000+08:00,EMA Says Adopted Negative Opinion For Eli Lilly's Indication Extension For Emgality To Add Prevention Of Attacks In Adults With Episodic Cluster Headache,LLY,https://www.benzinga.com/news/20/02/15439219/ema-says-adopted-negative-opinion-for-eli-lillys-indication-extension-for-emgality-to-add-prevention,Benzinga Newsdesk,,,,0,0,0f7f2f00-d5f3-4c14-87a8-fda555cd49bc
2020-02-28T08:00:00.000+08:00,"Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit",LLY,http://www.zacks.com/stock/news/788467/pharma-stock-roundup-fda-updates-from-lly-gsk-nvs-sny-to-spin-off-api-unit?cid=CS-BENZ-FT-analyst_blog|stock_roundup-788467,Zacks,,,,0,0,69941f7e-c75c-4b3c-bc7b-2327b70cb80b
2020-02-28T08:00:00.000+08:00,"Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/788298/nektar-nktr-q4-earnings-revenues-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-788298,Zacks,,,,0,0,8ea48a59-08ac-484f-a845-4b3fa0454216
2020-02-27T08:00:00.000+08:00,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",LLY,https://www.benzinga.com/general/biotech/20/02/15425291/the-daily-biotech-pulse-gilead-kicks-off-coronavirus-drug-trials-adcom-nod-for-lily-fda-approves-,Shanthi Rexaline,,,,0,0,69000353-5503-4838-831c-009d7a96652f
2020-02-27T08:00:00.000+08:00,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/news/20/02/15425380/fda-advisory-committee-votes-in-favor-of-lillys-cyramza-as-first-line-treatment-for-metastatic-egfr,Charles Gross,,,,0,0,cbb50e04-124d-4999-952b-c1f81aa0fd49
2020-02-27T08:00:00.000+08:00,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?,LLY,http://www.zacks.com/stock/news/786342/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe?cid=CS-BENZ-FT-sector_etf-786342,Zacks,,,,0,0,76451737-b478-49b3-977c-7a797926078d
2020-02-27T08:00:00.000+08:00,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",LLY,https://www.benzinga.com/general/biotech/20/02/15425291/the-daily-biotech-pulse-gilead-kicks-off-coronavirus-drug-trials-adcom-nod-for-lily-fda-approves-,Shanthi Rexaline,,,,0,0,8924a1cb-4843-413a-902b-6085285d7238
2020-02-27T08:00:00.000+08:00,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/news/20/02/15425380/fda-advisory-committee-votes-in-favor-of-lillys-cyramza-as-first-line-treatment-for-metastatic-egfr,Charles Gross,,,,0,0,05f1a52b-ac2f-455a-a05d-9f4da3102f48
2020-02-27T08:00:00.000+08:00,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?,LLY,http://www.zacks.com/stock/news/786342/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe?cid=CS-BENZ-FT-sector_etf-786342,Zacks,,,,0,0,90f518b3-8ad5-48b8-95fd-1b887af6278d
2020-02-26T08:00:00.000+08:00,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",LLY,https://www.benzinga.com/general/biotech/20/02/15415577/the-daily-biotech-pulse-menlo-flunks-midstage-trial-gw-pharmas-earnings-covid-19-updates,Shanthi Rexaline,,,,0,0,ef5ef71c-6d4d-4439-bd26-f884b77ee70b
2020-02-26T08:00:00.000+08:00,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line ...,LLY,http://www.gurufocus.com/news/1054936/fda-advisory-committee-votes-in-favor-of-lillys-cyramza-ramucirumab-as-firstline-treatment-for-metastatic-egfrmutated-nonsmall-cell-lung-cancer,GuruFocus,,,,0,0,2e3b8ab6-ea82-4c6a-b926-089ac72584e4
2020-02-26T08:00:00.000+08:00,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",LLY,https://www.benzinga.com/general/biotech/20/02/15415577/the-daily-biotech-pulse-menlo-flunks-midstage-trial-gw-pharmas-earnings-covid-19-updates,Shanthi Rexaline,,,,0,0,9a0650cf-c471-4245-ba0f-6323840f37f1
2020-02-26T08:00:00.000+08:00,FDA Advisory Committee Votes in Favor of Lilly's CYRAMZA® (ramucirumab) as First-Line ...,LLY,http://www.gurufocus.com/news/1054936/fda-advisory-committee-votes-in-favor-of-lillys-cyramza-ramucirumab-as-firstline-treatment-for-metastatic-egfrmutated-nonsmall-cell-lung-cancer,GuruFocus,,,,0,0,30eaf215-53e7-415e-8584-42b7d85d308c
2020-02-24T08:00:00.000+08:00,"Eli Lilly Earlier Announced It Has Received FDA Approval For Trulicity, The First And Only Type 2 Diabetes Medicine Approved To Reduce Cardiovascular Events In Adults With And Without Established Cardiovascular Disease",LLY,https://www.benzinga.com/news/20/02/15393466/eli-lilly-yesterday-announced-it-has-received-fda-approval-for-trulicity-the-first-and-only-type-2-d,Benzinga Newsdesk,,,,0,0,12f21b34-fcb0-4d89-8fbb-c786b6b608b5
2020-02-24T08:00:00.000+08:00,Weekly Trades With Yields Up To 165%,LLY,https://talkmarkets.com/content/weekly-trades-with-yields-up-to-165?post=252194,TalkMarkets,,,,0,0,67a9e64f-233e-40df-9440-c17f8be4dc97
2020-02-24T08:00:00.000+08:00,"Eli Lilly Earlier Announced It Has Received FDA Approval For Trulicity, The First And Only Type 2 Diabetes Medicine Approved To Reduce Cardiovascular Events In Adults With And Without Established Cardiovascular Disease",LLY,https://www.benzinga.com/news/20/02/15393466/eli-lilly-yesterday-announced-it-has-received-fda-approval-for-trulicity-the-first-and-only-type-2-d,Benzinga Newsdesk,,,,0,0,236a698b-c8c5-473a-88d9-06bede9af103
2020-02-24T08:00:00.000+08:00,Weekly Trades With Yields Up To 165%,LLY,https://talkmarkets.com/content/weekly-trades-with-yields-up-to-165?post=252194,TalkMarkets,,,,0,0,ef6d4ead-8b81-49ca-aae8-651cccd4c058
2020-02-23T08:00:00.000+08:00,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,LLY,https://www.benzinga.com/general/biotech/20/02/15384645/the-week-ahead-in-biotech-biopharma-earnings-pick-up-pace,Shanthi Rexaline,,,,0,0,1c55a037-b06d-4edd-b8b3-d4dcaf3390cd
2020-02-23T08:00:00.000+08:00,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,LLY,https://www.benzinga.com/general/biotech/20/02/15384645/the-week-ahead-in-biotech-biopharma-earnings-pick-up-pace,Shanthi Rexaline,,,,0,0,7d4e16aa-4ba4-4ab7-8369-f09becd96f0f
2020-02-21T08:00:00.000+08:00,Trulicity® (dulaglutide) is the first and only type — diabetes medicine approved to reduce ...,LLY,http://www.gurufocus.com/news/1047429/trulicity-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease,GuruFocus,,,,0,0,00cd927c-06c1-4128-a652-667da00126da
2020-02-21T08:00:00.000+08:00,Mairs and Power: Top 4th-Quarter Trades,LLY,http://www.gurufocus.com/news/1047325/mairs-and-power-top-4thquarter-trades,GuruFocus,,,,0,0,db718531-8fbe-4ac8-9d9b-06800a8c3d24
2020-02-21T08:00:00.000+08:00,Lilly To Participate in SVB Leerink Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1047212/lilly-to-participate-in-svb-leerink-global-healthcare-conference,GuruFocus,,,,0,0,93b58e5a-e6a9-4abb-a4eb-a9ca7f6cc689
2020-02-21T08:00:00.000+08:00,Lilly to Participate in Cowen Health Care Conference,LLY,http://www.gurufocus.com/news/1047207/lilly-to-participate-in-cowen-health-care-conference,GuruFocus,,,,0,0,6c2d1d8e-70ab-4622-a4f2-da1023e34210
2020-02-21T08:00:00.000+08:00,Trulicity® (dulaglutide) is the first and only type — diabetes medicine approved to reduce ...,LLY,http://www.gurufocus.com/news/1047429/trulicity-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease,GuruFocus,,,,0,0,ff20b6a7-f324-46f2-af59-2a04e5959975
2020-02-21T08:00:00.000+08:00,Mairs and Power: Top 4th-Quarter Trades,LLY,http://www.gurufocus.com/news/1047325/mairs-and-power-top-4thquarter-trades,GuruFocus,,,,0,0,31159cfd-a9cc-4beb-abf2-d16d870e4eb7
2020-02-21T08:00:00.000+08:00,Lilly To Participate in SVB Leerink Global Healthcare Conference,LLY,http://www.gurufocus.com/news/1047212/lilly-to-participate-in-svb-leerink-global-healthcare-conference,GuruFocus,,,,0,0,764af556-bed6-46d4-a593-a79aa10afd7b
2020-02-21T08:00:00.000+08:00,Lilly to Participate in Cowen Health Care Conference,LLY,http://www.gurufocus.com/news/1047207/lilly-to-participate-in-cowen-health-care-conference,GuruFocus,,,,0,0,d470db35-3ba0-483d-981a-7d7844c5e429
2020-02-20T08:00:00.000+08:00,"Watching Sanofi Shares As Hearing Co., Eli Lilly Will Face Claims Of Violation Of RICO Act Related To Pricing Of Insulin",LLY,https://www.benzinga.com/news/20/02/15376985/watching-sanofi-shares-as-hearing-co-eli-lilly-will-face-claims-of-violation-of-rico-act-related-to,Benzinga Newsdesk,,,,0,0,9477818f-d394-4987-8842-95850a06c027
2020-02-20T08:00:00.000+08:00,"North Point Portfolio Managers Corp Buys Church & Dwight Co Inc, Gildan Activewear Inc, Eli ...",LLY,http://www.gurufocus.com/news/1045945/north-point-portfolio-managers-corp-buys-church--dwight-co-inc-gildan-activewear-inc-eli-lilly-and-co-sells-signature-bank-matson-inc-boeing-co,GuruFocus,,,,0,0,fe9915e2-5ce0-4733-9173-c988411a7704
2020-02-20T08:00:00.000+08:00,"Watching Sanofi Shares As Hearing Co., Eli Lilly Will Face Claims Of Violation Of RICO Act Related To Pricing Of Insulin",LLY,https://www.benzinga.com/news/20/02/15376985/watching-sanofi-shares-as-hearing-co-eli-lilly-will-face-claims-of-violation-of-rico-act-related-to,Benzinga Newsdesk,,,,0,0,4529d18f-6116-420a-b102-57a68702089a
2020-02-20T08:00:00.000+08:00,"North Point Portfolio Managers Corp Buys Church & Dwight Co Inc, Gildan Activewear Inc, Eli ...",LLY,http://www.gurufocus.com/news/1045945/north-point-portfolio-managers-corp-buys-church--dwight-co-inc-gildan-activewear-inc-eli-lilly-and-co-sells-signature-bank-matson-inc-boeing-co,GuruFocus,,,,0,0,afbe468d-07ba-4fdd-8be4-d654f374b29f
2020-02-17T08:00:00.000+08:00,"Mirova Buys First Solar Inc, Air Products & Chemicals Inc, Waste Management Inc, Sells ...",LLY,http://www.gurufocus.com/news/1041503/mirova-buys-first-solar-inc-air-products--chemicals-inc-waste-management-inc-sells-microsoft-corp-mastercard-inc-thermo-fisher-scientific-inc,GuruFocus,,,,0,0,f6903d55-261c-4b1c-a27d-80731c230502
2020-02-17T08:00:00.000+08:00,"Woodley Farra Manion Portfolio Management Inc Buys Comcast Corp, JPMorgan Chase, iShares Core ...",LLY,http://www.gurufocus.com/news/1041489/woodley-farra-manion-portfolio-management-inc-buys-comcast-corp-jpmorgan-chase-ishares-core-sp-500-sells-fortive-corp-alcon-inc-nestle-sa,GuruFocus,,,,0,0,04fc3a9b-cacb-4bda-9b99-4cc332ed07b2
2020-02-17T08:00:00.000+08:00,"Reynders McVeigh Capital Management, LLC Buys Becton, Dickinson and Co, Envista Holdings Corp, ...",LLY,http://www.gurufocus.com/news/1041416/reynders-mcveigh-capital-management-llc-buys-becton-dickinson-and-co-envista-holdings-corp-tjx-inc-sells-american-eagle-outfitters-inc-alcon-inc-zuora-inc,GuruFocus,,,,0,0,3abe4f53-27ca-4e04-808d-c57c911ba3b5
2020-02-17T08:00:00.000+08:00,"Mirova Buys First Solar Inc, Air Products & Chemicals Inc, Waste Management Inc, Sells ...",LLY,http://www.gurufocus.com/news/1041503/mirova-buys-first-solar-inc-air-products--chemicals-inc-waste-management-inc-sells-microsoft-corp-mastercard-inc-thermo-fisher-scientific-inc,GuruFocus,,,,0,0,6f6388b1-5dea-4a51-b05b-d929b93392fa
2020-02-17T08:00:00.000+08:00,"Woodley Farra Manion Portfolio Management Inc Buys Comcast Corp, JPMorgan Chase, iShares Core ...",LLY,http://www.gurufocus.com/news/1041489/woodley-farra-manion-portfolio-management-inc-buys-comcast-corp-jpmorgan-chase-ishares-core-sp-500-sells-fortive-corp-alcon-inc-nestle-sa,GuruFocus,,,,0,0,3b44129f-2fd1-415d-9051-e3b884724fce
2020-02-17T08:00:00.000+08:00,"Reynders McVeigh Capital Management, LLC Buys Becton, Dickinson and Co, Envista Holdings Corp, ...",LLY,http://www.gurufocus.com/news/1041416/reynders-mcveigh-capital-management-llc-buys-becton-dickinson-and-co-envista-holdings-corp-tjx-inc-sells-american-eagle-outfitters-inc-alcon-inc-zuora-inc,GuruFocus,,,,0,0,69520eb2-875f-4729-b64b-b90520135b35
2020-02-16T08:00:00.000+08:00,Healthcare (Top 30 Weights) Earnings Estimates And Revisions,LLY,https://talkmarkets.com/content/healthcare-top-30-weights-earnings-estimates-and-revisions?post=251191,TalkMarkets,,,,0,0,61bb1f8a-a513-465b-893e-a5d7b856aa8b
2020-02-16T08:00:00.000+08:00,Healthcare (Top 30 Weights) Earnings Estimates And Revisions,LLY,https://talkmarkets.com/content/healthcare-top-30-weights-earnings-estimates-and-revisions?post=251191,TalkMarkets,,,,0,0,e627e414-3b6f-4c0d-8a5b-a78d36941c48
2020-02-14T08:00:00.000+08:00,"Fayez Sarofim & Co Buys Progressive Corp, Booking Holdings Inc, Blackstone Group Inc, Sells ...",LLY,http://www.gurufocus.com/news/1039999/fayez-sarofim--co-buys-progressive-corp-booking-holdings-inc-blackstone-group-inc-sells-anheuserbusch-inbev-sanv-total-sa-constellation-brands-inc,GuruFocus,,,,0,0,a47c40ce-dabd-4ab3-9273-8a7fda37b3ff
2020-02-14T08:00:00.000+08:00,"Buckingham Capital Management, Inc. Buys iShares Short Maturity Bond, TJX Inc, Bristol-Myers ...",LLY,http://www.gurufocus.com/news/1039548/buckingham-capital-management-inc-buys-ishares-short-maturity-bond-tjx-inc-bristolmyers-squibb-company-sells-total-sa-celgene-corp-the-travelers-inc,GuruFocus,,,,0,0,2da09530-e9a2-4091-922c-2319c6927a7e
2020-02-14T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails",LLY,http://www.zacks.com/stock/news/765605/pharma-stock-roundup-abbv-agn-post-q4-results-another-alzheimers-study-fails?cid=CS-BENZ-FT-analyst_blog|stock_roundup-765605,Zacks,,,,0,0,bb2c61b3-3da4-43f1-847f-294731ea27c0
2020-02-14T08:00:00.000+08:00,Stocks Stay Resilient Amid New Coronavirus Cases,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-24304,Zacks,,,,0,0,03ea1f8d-9ef1-45c6-be29-97607f9c3725
2020-02-14T08:00:00.000+08:00,"Fayez Sarofim & Co Buys Progressive Corp, Booking Holdings Inc, Blackstone Group Inc, Sells ...",LLY,http://www.gurufocus.com/news/1039999/fayez-sarofim--co-buys-progressive-corp-booking-holdings-inc-blackstone-group-inc-sells-anheuserbusch-inbev-sanv-total-sa-constellation-brands-inc,GuruFocus,,,,0,0,301f8af5-77ca-4208-bad7-a05000246533
2020-02-14T08:00:00.000+08:00,"Buckingham Capital Management, Inc. Buys iShares Short Maturity Bond, TJX Inc, Bristol-Myers ...",LLY,http://www.gurufocus.com/news/1039548/buckingham-capital-management-inc-buys-ishares-short-maturity-bond-tjx-inc-bristolmyers-squibb-company-sells-total-sa-celgene-corp-the-travelers-inc,GuruFocus,,,,0,0,673bc40d-f3a4-42cc-9bcf-c86701a162d6
2020-02-14T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails",LLY,http://www.zacks.com/stock/news/765605/pharma-stock-roundup-abbv-agn-post-q4-results-another-alzheimers-study-fails?cid=CS-BENZ-FT-analyst_blog|stock_roundup-765605,Zacks,,,,0,0,ce6010fc-64b3-41b0-b908-91ab9bb37758
2020-02-14T08:00:00.000+08:00,Stocks Stay Resilient Amid New Coronavirus Cases,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-24304,Zacks,,,,0,0,4cd40fad-b1bd-4a4e-9dd1-188f9a5ecc6a
2020-02-13T08:00:00.000+08:00,"Greenwood Capital Associates Llc Buys iShares Core MSCI Emerging Markets, Vanguard ...",LLY,http://www.gurufocus.com/news/1038613/greenwood-capital-associates-llc-buys-ishares-core-msci-emerging-markets-vanguard-ftseeuropean-spdr-select-sector-fund--health-care-sells-ishares-core-msci-total-international-stock-etf-walmart-inc-ishares-us-aerospac,GuruFocus,,,,0,0,3ff7f914-8f81-409a-88ad-2eab4600cba5
2020-02-13T08:00:00.000+08:00,"Leaner, More Agile Teva Has Brighter Days Ahead",LLY,http://www.gurufocus.com/news/1038203/leaner-more-agile-teva-has-brighter-days-ahead,GuruFocus,,,,0,0,54d11e22-e5b9-4d75-a597-8e916bf389f6
2020-02-13T08:00:00.000+08:00,"Leaner, More Agile Teva Sees Brighter Days Ahead",LLY,http://www.gurufocus.com/news/1038203/leaner-more-agile-teva-sees-brighter-days-ahead,GuruFocus,,,,0,0,a27247e4-36e7-40ee-890e-6e11e3b5dbd6
2020-02-13T08:00:00.000+08:00,Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales,LLY,http://www.zacks.com/stock/news/763949/incyte-incy-q4-earnings-top-estimates-on-solid-jakafi-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-763949,Zacks,,,,0,0,51c8e1a3-636c-4e4d-93c0-615aa5ebc748
2020-02-13T08:00:00.000+08:00,"Hudson Canyon Investment Counselors Llc Buys The Walt Disney Co, Zscaler Inc, Incyte Corp, ...",LLY,http://www.gurufocus.com/news/1037879/hudson-canyon-investment-counselors-llc-buys-the-walt-disney-co-zscaler-inc-incyte-corp-sells-acacia-communications-inc-summit-materials-inc-dycom-industries-inc,GuruFocus,,,,0,0,9c40d997-5148-4d15-97d4-4f628cf9231e
2020-02-13T08:00:00.000+08:00,"Greenwood Capital Associates Llc Buys iShares Core MSCI Emerging Markets, Vanguard ...",LLY,http://www.gurufocus.com/news/1038613/greenwood-capital-associates-llc-buys-ishares-core-msci-emerging-markets-vanguard-ftseeuropean-spdr-select-sector-fund--health-care-sells-ishares-core-msci-total-international-stock-etf-walmart-inc-ishares-us-aerospac,GuruFocus,,,,0,0,aa868765-ea74-4d2a-ac7a-d2831f9ec807
2020-02-13T08:00:00.000+08:00,"Leaner, More Agile Teva Has Brighter Days Ahead",LLY,http://www.gurufocus.com/news/1038203/leaner-more-agile-teva-has-brighter-days-ahead,GuruFocus,,,,0,0,d69515f3-f34a-4c92-bab2-c00618e316e8
2020-02-13T08:00:00.000+08:00,"Leaner, More Agile Teva Sees Brighter Days Ahead",LLY,http://www.gurufocus.com/news/1038203/leaner-more-agile-teva-sees-brighter-days-ahead,GuruFocus,,,,0,0,c39d60c0-1bbc-4c17-a99e-b4605949c16a
2020-02-13T08:00:00.000+08:00,Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales,LLY,http://www.zacks.com/stock/news/763949/incyte-incy-q4-earnings-top-estimates-on-solid-jakafi-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-763949,Zacks,,,,0,0,80905dd5-9b85-475e-982a-ab7b45024179
2020-02-13T08:00:00.000+08:00,"Hudson Canyon Investment Counselors Llc Buys The Walt Disney Co, Zscaler Inc, Incyte Corp, ...",LLY,http://www.gurufocus.com/news/1037879/hudson-canyon-investment-counselors-llc-buys-the-walt-disney-co-zscaler-inc-incyte-corp-sells-acacia-communications-inc-summit-materials-inc-dycom-industries-inc,GuruFocus,,,,0,0,1cd61483-9bf9-4298-825f-1e9facc21d3f
2020-02-12T08:00:00.000+08:00,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",LLY,https://www.benzinga.com/general/biotech/20/02/15308201/the-daily-biotech-pulse-j-j-intensifies-efforts-on-covid-19-cure-adamas-reports-positive-long-ter,Shanthi Rexaline,,,,0,0,4ee81fd0-5222-4bba-8103-0e9bf27d8e00
2020-02-12T08:00:00.000+08:00,Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/20/02/15307648/lilly-and-incyte-announce-positive-top-line-results-from-the-north-american-phase-3-study-breeze-ad5,Charles Gross,,,,0,0,1fc3ef8e-4d2a-4857-9157-81c6ed033ec9
2020-02-12T08:00:00.000+08:00,"Halbert, Hargrove Buys iShares ESG USD Corporate Bond ETF, Bristol-Myers Squibb Company, ...",LLY,http://www.gurufocus.com/news/1036711/halbert-hargrove-buys-ishares-esg-usd-corporate-bond-etf-bristolmyers-squibb-company-ishares-core-us-reit-etf-sells-ishares-msci-emerging-markets-etf-ishares-core-msci-eafe-etf-procter--gamble-co,GuruFocus,,,,0,0,6b47b662-3640-4e65-a9f2-c3db43c552cf
2020-02-12T08:00:00.000+08:00,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",LLY,https://www.benzinga.com/general/biotech/20/02/15308201/the-daily-biotech-pulse-j-j-intensifies-efforts-on-covid-19-cure-adamas-reports-positive-long-ter,Shanthi Rexaline,,,,0,0,3e3087dd-7645-4528-b4e4-3b5f1a49c8d1
2020-02-12T08:00:00.000+08:00,Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/20/02/15307648/lilly-and-incyte-announce-positive-top-line-results-from-the-north-american-phase-3-study-breeze-ad5,Charles Gross,,,,0,0,c8572f28-32e0-4240-9823-bd33cb4c6ff7
2020-02-12T08:00:00.000+08:00,"Halbert, Hargrove Buys iShares ESG USD Corporate Bond ETF, Bristol-Myers Squibb Company, ...",LLY,http://www.gurufocus.com/news/1036711/halbert-hargrove-buys-ishares-esg-usd-corporate-bond-etf-bristolmyers-squibb-company-ishares-core-us-reit-etf-sells-ishares-msci-emerging-markets-etf-ishares-core-msci-eafe-etf-procter--gamble-co,GuruFocus,,,,0,0,ebe73347-8b0b-44f6-a0af-9159e0a5f5cf
2020-02-11T08:00:00.000+08:00,Citizens & Northern Corp Buys iShares J.P. ...,LLY,http://www.gurufocus.com/news/1036136/citizens--northern-corp-buys-ishares-jp-morgan-usd-emerging-markets-bond-etf-energy-select-sector-spdr-fund-ishares-nasdaq-biotechnology-index-fund-sells-celgene-corp-alexion-pharmaceuticals-inc-exxon-mobil-corp,GuruFocus,,,,0,0,8d6b8d49-4575-4210-a004-e1363a40533a
2020-02-11T08:00:00.000+08:00,"Ci Investments Inc. Buys Berry Global Group Inc, DuPont de Nemours Inc, iShares Core MSCI EAFE ...",LLY,http://www.gurufocus.com/news/1035896/ci-investments-inc-buys-berry-global-group-inc-dupont-de-nemours-inc-ishares-core-msci-eafe-etf-sells-spdr-gold-trust-verizon-communications-inc-pattern-energy-group-inc,GuruFocus,,,,0,0,ed7d5fd4-ff75-4d95-bd47-6605d432be7b
2020-02-11T08:00:00.000+08:00,Lilly Reports Disappointing Data on Alzheimer's Candidate,LLY,http://www.zacks.com/stock/news/760082/lilly-reports-disappointing-data-on-alzheimers-candidate?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-760082,Zacks,,,,0,0,31f9e78d-101f-4749-aec7-2ccd71437961
2020-02-11T08:00:00.000+08:00,Citizens & Northern Corp Buys iShares J.P. ...,LLY,http://www.gurufocus.com/news/1036136/citizens--northern-corp-buys-ishares-jp-morgan-usd-emerging-markets-bond-etf-energy-select-sector-spdr-fund-ishares-nasdaq-biotechnology-index-fund-sells-celgene-corp-alexion-pharmaceuticals-inc-exxon-mobil-corp,GuruFocus,,,,0,0,5359462e-2fbc-4650-8865-b8b933eaa979
2020-02-11T08:00:00.000+08:00,"Ci Investments Inc. Buys Berry Global Group Inc, DuPont de Nemours Inc, iShares Core MSCI EAFE ...",LLY,http://www.gurufocus.com/news/1035896/ci-investments-inc-buys-berry-global-group-inc-dupont-de-nemours-inc-ishares-core-msci-eafe-etf-sells-spdr-gold-trust-verizon-communications-inc-pattern-energy-group-inc,GuruFocus,,,,0,0,34c15413-48e9-44dd-af71-41a528ce90b9
2020-02-11T08:00:00.000+08:00,Lilly Reports Disappointing Data on Alzheimer's Candidate,LLY,http://www.zacks.com/stock/news/760082/lilly-reports-disappointing-data-on-alzheimers-candidate?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-760082,Zacks,,,,0,0,8c202647-5edb-4bc7-b077-c76a5fa9e35f
2020-02-10T08:00:00.000+08:00,Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint,LLY,https://www.benzinga.com/general/biotech/20/02/15290344/eli-lilly-suffers-setback-as-alzheimers-study-fails-to-meet-primary-endpoint,Shanthi Rexaline,,,,0,0,4473af1d-7445-4bf9-bef8-619fb5d07772
2020-02-10T08:00:00.000+08:00,12 Healthcare Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/pre-market-outlook/20/02/15287557/12-healthcare-stocks-moving-in-mondays-pre-market-session,Benzinga Newsdesk,,,,0,0,d5defcce-3b3c-47bf-a6f0-959c2825c0dd
2020-02-10T08:00:00.000+08:00,30 Stocks Moving in Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/20/02/15287528/30-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,ae493cd1-f9a1-4589-8a08-49f33d1ad2f4
2020-02-10T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported the results for Solanezumba from the Alzheimer's study did not meet its primary endpoint.,LLY,https://www.benzinga.com/wiim/20/02/15287485/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-the-results-for-solanezumba-fro,Benzinga Newsdesk,,,,0,0,d3ed9da7-eaf3-475d-bcee-ed6b23ea608d
2020-02-10T08:00:00.000+08:00,Lilly Announces Alzheimer's Study Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/20/02/15286645/lilly-announces-alzheimers-study-did-not-meet-primary-endpoint,Charles Gross,,,,0,0,08fb3531-2230-4bc6-80b3-2e5ad4806a75
2020-02-10T08:00:00.000+08:00,"Lcnb Corp Buys Eli Lilly and Co, Bank of America Corp, Carnival Corp, Sells iShares Core MSCI ...",LLY,http://www.gurufocus.com/news/1034543/lcnb-corp-buys-eli-lilly-and-co-bank-of-america-corp-carnival-corp-sells-ishares-core-msci-emerging-markets-etf-ishares-13-year-credit-bond-etf-wisdomtree-total-dividend-fund,GuruFocus,,,,0,0,197abebb-d5e8-4dd6-ba49-0f007684900a
2020-02-10T08:00:00.000+08:00,"Compton Capital Management Inc Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Truist ...",LLY,http://www.gurufocus.com/news/1034459/compton-capital-management-inc-buys-bristolmyers-squibb-company-eli-lilly-and-co-truist-financial-corp-sells-celgene-corp-cognizant-technology-solutions-corp-suntrust-banks-inc,GuruFocus,,,,0,0,8eff5284-30cb-45c5-95ce-367ae1ce1643
2020-02-10T08:00:00.000+08:00,Spiros Segalas Comments on Eli Lilly,LLY,http://www.gurufocus.com/news/1034323/spiros-segalas-comments-on-eli-lilly,GuruFocus,,,,0,0,696f7497-9e52-47e2-99d0-20435f22de5b
2020-02-10T08:00:00.000+08:00,Spiros Segalas' Harbor Capital Appreciation Fund 4th-Quarter Commentary,LLY,http://www.gurufocus.com/news/1034315/spiros-segalas-harbor-capital-appreciation-fund-4thquarter-commentary,GuruFocus,,,,0,0,1c928933-c361-4b24-bdf0-32de7f04f8b3
2020-02-10T08:00:00.000+08:00,"Thinking about buying stock in L Brands, Eli Lilly, Netflix, Tesla, or Xylem?",LLY,http://www.gurufocus.com/news/1034234/thinking-about-buying-stock-in-l-brands-eli-lilly-netflix-tesla-or-xylem,GuruFocus,,,,0,0,65ea892c-f3dd-41c1-b0d6-8d55f358c5a3
2020-02-10T08:00:00.000+08:00,Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network ...,LLY,http://www.gurufocus.com/news/1033506/lilly-announces-topline-results-for-solanezumab-from-the-dominantly-inherited-alzheimer-network-trials-unit-diantu-study,GuruFocus,,,,0,0,9494cb49-b2df-418e-875f-d07821112870
2020-02-10T08:00:00.000+08:00,Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint,LLY,https://www.benzinga.com/general/biotech/20/02/15290344/eli-lilly-suffers-setback-as-alzheimers-study-fails-to-meet-primary-endpoint,Shanthi Rexaline,,,,0,0,9ad3e99b-2693-4bc9-9319-b9a76145644e
2020-02-10T08:00:00.000+08:00,12 Healthcare Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/pre-market-outlook/20/02/15287557/12-healthcare-stocks-moving-in-mondays-pre-market-session,Benzinga Newsdesk,,,,0,0,9e96d4c6-478c-4f40-a52c-9b59f8a7face
2020-02-10T08:00:00.000+08:00,30 Stocks Moving in Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/20/02/15287528/30-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,3240c301-fa3c-4593-a86e-ac6589153325
2020-02-10T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported the results for Solanezumba from the Alzheimer's study did not meet its primary endpoint.,LLY,https://www.benzinga.com/wiim/20/02/15287485/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-the-results-for-solanezumba-fro,Benzinga Newsdesk,,,,0,0,cb689a9c-d483-4a59-b588-9308a78bb6d5
2020-02-10T08:00:00.000+08:00,Lilly Announces Alzheimer's Study Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/20/02/15286645/lilly-announces-alzheimers-study-did-not-meet-primary-endpoint,Charles Gross,,,,0,0,09fa46d4-352d-45d0-9d3f-14f45045f7a2
2020-02-10T08:00:00.000+08:00,"Lcnb Corp Buys Eli Lilly and Co, Bank of America Corp, Carnival Corp, Sells iShares Core MSCI ...",LLY,http://www.gurufocus.com/news/1034543/lcnb-corp-buys-eli-lilly-and-co-bank-of-america-corp-carnival-corp-sells-ishares-core-msci-emerging-markets-etf-ishares-13-year-credit-bond-etf-wisdomtree-total-dividend-fund,GuruFocus,,,,0,0,bf28092a-1c1b-450b-a000-c0c601d396ad
2020-02-10T08:00:00.000+08:00,"Compton Capital Management Inc Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Truist ...",LLY,http://www.gurufocus.com/news/1034459/compton-capital-management-inc-buys-bristolmyers-squibb-company-eli-lilly-and-co-truist-financial-corp-sells-celgene-corp-cognizant-technology-solutions-corp-suntrust-banks-inc,GuruFocus,,,,0,0,5b870725-2390-4d2e-bb19-b19e81c22de8
2020-02-10T08:00:00.000+08:00,Spiros Segalas Comments on Eli Lilly,LLY,http://www.gurufocus.com/news/1034323/spiros-segalas-comments-on-eli-lilly,GuruFocus,,,,0,0,a107ac14-fce3-4709-9d1f-e6401f61811d
2020-02-10T08:00:00.000+08:00,Spiros Segalas' Harbor Capital Appreciation Fund 4th-Quarter Commentary,LLY,http://www.gurufocus.com/news/1034315/spiros-segalas-harbor-capital-appreciation-fund-4thquarter-commentary,GuruFocus,,,,0,0,4b6ab131-7f2f-4bac-b64f-8cc0972204e3
2020-02-10T08:00:00.000+08:00,"Thinking about buying stock in L Brands, Eli Lilly, Netflix, Tesla, or Xylem?",LLY,http://www.gurufocus.com/news/1034234/thinking-about-buying-stock-in-l-brands-eli-lilly-netflix-tesla-or-xylem,GuruFocus,,,,0,0,c70b328c-da32-4943-b342-69c8c63ef6fe
2020-02-10T08:00:00.000+08:00,Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network ...,LLY,http://www.gurufocus.com/news/1033506/lilly-announces-topline-results-for-solanezumab-from-the-dominantly-inherited-alzheimer-network-trials-unit-diantu-study,GuruFocus,,,,0,0,883ef15a-e3b1-46ef-899f-d79cad9d25e6
2020-02-07T08:00:00.000+08:00,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",LLY,https://www.benzinga.com/general/biotech/20/02/15277159/the-daily-biotech-pulse-assertio-to-sell-opioid-pain-drug-milestone-payment-for-aduro-myriad-gene,Shanthi Rexaline,,,,0,0,f0d897b8-5f7a-4815-8f09-2852e5f06983
2020-02-07T08:00:00.000+08:00,"Smith, Moore & Co. Buys Vanguard Dividend Appreciation ETF, MPLX LP, Becton, Dickinson and ...",LLY,http://www.gurufocus.com/news/1032407/smith-moore--co-buys-vanguard-dividend-appreciation-etf-mplx-lp-becton-dickinson-and-co-sells-ishares-core-high-dividend-etf-blackrock-science-and-technology-trust-canadian-national-railway-co,GuruFocus,,,,0,0,947705b9-a0d4-454f-8fc8-8b828615b37d
2020-02-07T08:00:00.000+08:00,Med Stock Dexcom In Buy Range Ahead Of Earnings,LLY,http://www.investors.com/stock-lists/stock-spotlight/med-stock-dexcom-in-buy-range-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,ad2236ae-9506-4fe6-8af4-fca089eb9983
2020-02-07T08:00:00.000+08:00,Lilly to Participate in Guggenheim Healthcare Talks Idea Forum,LLY,http://www.gurufocus.com/news/1032277/lilly-to-participate-in-guggenheim-healthcare-talks-idea-forum,GuruFocus,,,,0,0,aacaa63d-6cff-4c0f-8edd-058aab6995db
2020-02-07T08:00:00.000+08:00,"Jennison Associates Llc Buys Coupa Software Inc, Boston Scientific Corp, Eli Lilly and Co, ...",LLY,http://www.gurufocus.com/news/1032228/jennison-associates-llc-buys-coupa-software-inc-boston-scientific-corp-eli-lilly-and-co-sells-boeing-co-american-tower-corp-vertex-pharmaceuticals-inc,GuruFocus,,,,0,0,d74f5c1b-47bd-4b43-bbf8-7da94be94906
2020-02-07T08:00:00.000+08:00,Teva (TEVA) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-754447,Zacks,,,,0,0,2da0fed1-4522-4097-8ed3-0e4ad42d4df6
2020-02-07T08:00:00.000+08:00,Incyte (INCY) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/754325/incyte-incy-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-754325,Zacks,,,,0,0,40d0a062-6668-4e83-87f6-0626cbc48e6c
2020-02-07T08:00:00.000+08:00,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",LLY,https://www.benzinga.com/general/biotech/20/02/15277159/the-daily-biotech-pulse-assertio-to-sell-opioid-pain-drug-milestone-payment-for-aduro-myriad-gene,Shanthi Rexaline,,,,0,0,b35d8a23-02d5-4224-b08d-922f3ccf3abd
2020-02-07T08:00:00.000+08:00,"Smith, Moore & Co. Buys Vanguard Dividend Appreciation ETF, MPLX LP, Becton, Dickinson and ...",LLY,http://www.gurufocus.com/news/1032407/smith-moore--co-buys-vanguard-dividend-appreciation-etf-mplx-lp-becton-dickinson-and-co-sells-ishares-core-high-dividend-etf-blackrock-science-and-technology-trust-canadian-national-railway-co,GuruFocus,,,,0,0,d95ed3da-5e94-4efe-9df6-aab8d1c0af62
2020-02-07T08:00:00.000+08:00,Med Stock Dexcom In Buy Range Ahead Of Earnings,LLY,http://www.investors.com/stock-lists/stock-spotlight/med-stock-dexcom-in-buy-range-ahead-of-earnings/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,5e94f32d-81b6-452e-92f9-d1d13ac71bc1
2020-02-07T08:00:00.000+08:00,Lilly to Participate in Guggenheim Healthcare Talks Idea Forum,LLY,http://www.gurufocus.com/news/1032277/lilly-to-participate-in-guggenheim-healthcare-talks-idea-forum,GuruFocus,,,,0,0,af3ff905-9f7d-4fac-83d3-c0a60a54600e
2020-02-07T08:00:00.000+08:00,"Jennison Associates Llc Buys Coupa Software Inc, Boston Scientific Corp, Eli Lilly and Co, ...",LLY,http://www.gurufocus.com/news/1032228/jennison-associates-llc-buys-coupa-software-inc-boston-scientific-corp-eli-lilly-and-co-sells-boeing-co-american-tower-corp-vertex-pharmaceuticals-inc,GuruFocus,,,,0,0,0f554a99-9637-42b5-8ff6-49204208ee76
2020-02-07T08:00:00.000+08:00,Teva (TEVA) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-754447,Zacks,,,,0,0,3ea73cac-5e01-463e-baaa-dfe7f409bbc8
2020-02-07T08:00:00.000+08:00,Incyte (INCY) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/754325/incyte-incy-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-754325,Zacks,,,,0,0,9c0dddf8-8f2e-49d1-9d8b-4af27628e43f
2020-02-06T08:00:00.000+08:00,"UPDATE: Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target Notes 'we expect Verzenio's impact to increase following recent positive data releases and see the Loxo acquisition providing additional mid-term growth drivers.'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/02/15270875/mizuho-initiates-coverage-on-eli-lilly-with-neutral-rating-announces-148-price-targ,Benzinga Newsdesk,,,,0,0,84457a66-06db-42ad-bc21-c44a4e5a08b7
2020-02-06T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/02/15270346/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,,,,0,0,1cf390ff-b2a8-4fbb-bd07-91481d6f59f3
2020-02-06T08:00:00.000+08:00,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",LLY,https://www.benzinga.com/general/biotech/20/02/15266453/the-daily-biotech-pulse-tonix-slumps-on-failed-study-applied-genetic-announces-offering-beam-ther,Shanthi Rexaline,,,,0,0,45c2b34a-fc88-4f5b-ae5e-bd3350c277d9
2020-02-06T08:00:00.000+08:00,"Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target",LLY,https://www.benzinga.com/news/20/02/15266407/mizuho-initiates-coverage-on-eli-lilly-with-neutral-rating-announces-148-price-target,Vick Meyer,,,,0,0,e304b3e5-0a60-4e19-81f5-54bd1f870ce3
2020-02-06T08:00:00.000+08:00,Paragon Capital Management Ltd Buys Vanguard Global ex-U.S. ...,LLY,http://www.gurufocus.com/news/1030331/paragon-capital-management-ltd-buys-vanguard-global-exus-real-estate-etf-vanguard-taxexempt-bond-etf-spdr-gold-trust-sells-suntrust-banks-inc-united-technologies-corp,GuruFocus,,,,0,0,bf57b5bf-6617-4082-a7d3-66324179d793
2020-02-06T08:00:00.000+08:00,"Thinking about trading options or stock in Apple, Eli Lilly, Microchip Technology, Tesla, or ...",LLY,http://www.gurufocus.com/news/1029944/thinking-about-trading-options-or-stock-in-apple-eli-lilly-microchip-technology-tesla-or-unitedhealth-group,GuruFocus,,,,0,0,d703cc89-14e8-4c20-9190-ccf5eb7bc0a1
2020-02-06T08:00:00.000+08:00,"UPDATE: Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target Notes 'we expect Verzenio's impact to increase following recent positive data releases and see the Loxo acquisition providing additional mid-term growth drivers.'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/02/15270875/mizuho-initiates-coverage-on-eli-lilly-with-neutral-rating-announces-148-price-targ,Benzinga Newsdesk,,,,0,0,c469aab8-bda5-4fe4-af7e-b6dad44ed682
2020-02-06T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/02/15270346/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,,,,0,0,8c7850b5-6897-423b-81e5-1587a5f0188a
2020-02-06T08:00:00.000+08:00,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",LLY,https://www.benzinga.com/general/biotech/20/02/15266453/the-daily-biotech-pulse-tonix-slumps-on-failed-study-applied-genetic-announces-offering-beam-ther,Shanthi Rexaline,,,,0,0,76821bb0-26b9-4848-a937-bce3049f29ca
2020-02-06T08:00:00.000+08:00,"Mizuho Initiates Coverage On Eli Lilly with Neutral Rating, Announces $148 Price Target",LLY,https://www.benzinga.com/news/20/02/15266407/mizuho-initiates-coverage-on-eli-lilly-with-neutral-rating-announces-148-price-target,Vick Meyer,,,,0,0,850f07c9-0e37-49b8-abb4-b00db2d97c5e
2020-02-06T08:00:00.000+08:00,Paragon Capital Management Ltd Buys Vanguard Global ex-U.S. ...,LLY,http://www.gurufocus.com/news/1030331/paragon-capital-management-ltd-buys-vanguard-global-exus-real-estate-etf-vanguard-taxexempt-bond-etf-spdr-gold-trust-sells-suntrust-banks-inc-united-technologies-corp,GuruFocus,,,,0,0,141ac2af-838a-40f6-8e98-38552b21c2bd
2020-02-06T08:00:00.000+08:00,"Thinking about trading options or stock in Apple, Eli Lilly, Microchip Technology, Tesla, or ...",LLY,http://www.gurufocus.com/news/1029944/thinking-about-trading-options-or-stock-in-apple-eli-lilly-microchip-technology-tesla-or-unitedhealth-group,GuruFocus,,,,0,0,e91c886b-6d1e-44e4-9ee7-fc6c440cb2eb
2020-02-05T08:00:00.000+08:00,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings",LLY,https://www.benzinga.com/news/20/02/15264057/mizuho-initiates-abbvie-biohaven-with-buy-ratings-eli-lilly-alkermes-with-neutral-ratings,Benzinga Newsdesk,,,,0,0,c8b8b2c8-485f-4ff2-9019-9445c646a6b6
2020-02-05T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Wednesday,LLY,https://www.benzinga.com/news/20/02/15259090/stocks-that-hit-52-week-highs-on-wednesday,Lisa Levin,,,,0,0,c751b609-b2ec-4c83-a696-b39ac492f4a8
2020-02-05T08:00:00.000+08:00,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,LLY,https://www.benzinga.com/wiim/20/02/15258715/shares-of-several-healthcare-and-biotech-companies-are-trading-higher-as-unconfirmed-reports-of-prog,Benzinga Newsdesk,,,,0,0,cd47801e-acf5-444a-a9a2-6bfb26650a25
2020-02-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",LLY,https://www.benzinga.com/general/biotech/20/02/15256778/the-daily-biotech-pulse-merck-spins-off-slow-growth-businesses-ziopharm-announces-offering-phaseb,Shanthi Rexaline,,,,0,0,d5f192a0-7aa3-4b63-8395-8d5a6d097593
2020-02-05T08:00:00.000+08:00,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?,LLY,http://www.zacks.com/stock/news/750129/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe?cid=CS-BENZ-FT-sector_etf-750129,Zacks,,,,0,0,248d6303-1b93-4412-ac9e-e99106fa5e24
2020-02-05T08:00:00.000+08:00,"Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings",LLY,https://www.benzinga.com/news/20/02/15264057/mizuho-initiates-abbvie-biohaven-with-buy-ratings-eli-lilly-alkermes-with-neutral-ratings,Benzinga Newsdesk,,,,0,0,0d5696f5-f9e1-4e2b-ab55-ec25184c6b9f
2020-02-05T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Wednesday,LLY,https://www.benzinga.com/news/20/02/15259090/stocks-that-hit-52-week-highs-on-wednesday,Lisa Levin,,,,0,0,db97365a-756c-4ad3-bdec-1dc851b2256c
2020-02-05T08:00:00.000+08:00,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,LLY,https://www.benzinga.com/wiim/20/02/15258715/shares-of-several-healthcare-and-biotech-companies-are-trading-higher-as-unconfirmed-reports-of-prog,Benzinga Newsdesk,,,,0,0,d0446b6c-a5d8-4a4b-a42c-8d84bdd8b60e
2020-02-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",LLY,https://www.benzinga.com/general/biotech/20/02/15256778/the-daily-biotech-pulse-merck-spins-off-slow-growth-businesses-ziopharm-announces-offering-phaseb,Shanthi Rexaline,,,,0,0,dbdd757a-90e9-4dd7-b5fc-970a692ce768
2020-02-05T08:00:00.000+08:00,Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?,LLY,http://www.zacks.com/stock/news/750129/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe?cid=CS-BENZ-FT-sector_etf-750129,Zacks,,,,0,0,345ff803-36d6-4be2-b368-c4693d999ac5
2020-02-04T08:00:00.000+08:00,A Pick and Shovel Strategy to Avoid Competition and Speculation,LLY,http://www.gurufocus.com/news/1027985/a-pick-and-shovel-strategy-to-avoid-competition-and-speculation,GuruFocus,,,,0,0,91d82176-a0bc-4304-aa39-980b3ba2aaa6
2020-02-04T08:00:00.000+08:00,Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal,LLY,http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-748888,Zacks,,,,0,0,9728b1bc-3621-4338-8169-c4e86c99f30d
2020-02-04T08:00:00.000+08:00,Foster Dykema Cabot & Co Inc Buys iShares Core U.S. ...,LLY,http://www.gurufocus.com/news/1027979/foster-dykema-cabot--co-inc-buys-ishares-core-us-value-etf-amphenol-corp-jpmorgan-chase-sells-ishares-sp-500-growth-etf-verisk-analytics-inc-msci-inc,GuruFocus,,,,0,0,824d9f4f-9bbb-4b62-b5c5-6d3834604d89
2020-02-04T08:00:00.000+08:00,"Analysts Forecast Huge Upsides for Aimmune, Biohaven",LLY,http://www.gurufocus.com/news/1027390/analysts-forecast-huge-upsides-for-aimmune-biohaven,GuruFocus,,,,0,0,4fb0cb7f-1940-4811-86e4-3f77f5837c88
2020-02-04T08:00:00.000+08:00,A Pick and Shovel Strategy to Avoid Competition and Speculation,LLY,http://www.gurufocus.com/news/1027985/a-pick-and-shovel-strategy-to-avoid-competition-and-speculation,GuruFocus,,,,0,0,80e5b4ab-db42-4dd0-9c2e-2c2e3a870a02
2020-02-04T08:00:00.000+08:00,Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal,LLY,http://www.zacks.com/stock/news/748888/tevas-two-pivotal-studies-on-ajovy-in-japan-meet-goal?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-748888,Zacks,,,,0,0,6c81250a-5a82-42c6-9e73-d0849256bebd
2020-02-04T08:00:00.000+08:00,Foster Dykema Cabot & Co Inc Buys iShares Core U.S. ...,LLY,http://www.gurufocus.com/news/1027979/foster-dykema-cabot--co-inc-buys-ishares-core-us-value-etf-amphenol-corp-jpmorgan-chase-sells-ishares-sp-500-growth-etf-verisk-analytics-inc-msci-inc,GuruFocus,,,,0,0,8bedc393-e5fd-4df6-8dfe-5db9a88ec72d
2020-02-04T08:00:00.000+08:00,"Analysts Forecast Huge Upsides for Aimmune, Biohaven",LLY,http://www.gurufocus.com/news/1027390/analysts-forecast-huge-upsides-for-aimmune-biohaven,GuruFocus,,,,0,0,ad05bf84-fa61-467b-b584-8171603e0992
2020-02-03T08:00:00.000+08:00,3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty,LLY,http://www.zacks.com/stock/news/747608/3-dividend-paying-stocks-for-investors-to-buy-to-fight-off-market-uncertainty?cid=CS-BENZ-FT-stocks_in_the_news|major_headlines-747608,Zacks,,,,0,0,c141f136-0150-4e2a-9672-711d8167b237
2020-02-03T08:00:00.000+08:00,"Miller Investment Management, LP Buys Comcast Corp, Tortoise Pipeline & Energy Fund Inc, ...",LLY,http://www.gurufocus.com/news/1027358/miller-investment-management-lp-buys-comcast-corp-tortoise-pipeline--energy-fund-inc-eli-lilly-and-co-sells-jpmorgan-ultrashort-income-etf-centene-corp-lowes-inc,GuruFocus,,,,0,0,a1aff3bb-077c-4f8b-87de-4c3b8563cc4c
2020-02-03T08:00:00.000+08:00,"United Bank Buys iShares Global Infrastructure ETF, Southern Co, Truist Financial Corp, Sells ...",LLY,http://www.gurufocus.com/news/1026995/united-bank-buys-ishares-global-infrastructure-etf-southern-co-truist-financial-corp-sells-celgene-corp-etrade-financial-corp-alexion-pharmaceuticals-inc,GuruFocus,,,,0,0,1d574caf-42c6-4f66-bc0c-fcde7ed710da
2020-02-03T08:00:00.000+08:00,Amarillo National Bank Buys iShares Core U.S. ...,LLY,http://www.gurufocus.com/news/1026853/amarillo-national-bank-buys-ishares-core-us-aggregate-bond-etf-eli-lilly-and-co-conocophillips-sells-berkshire-hathaway-inc,GuruFocus,,,,0,0,06990197-54ee-4b40-bba6-ed847b101619
2020-02-03T08:00:00.000+08:00,3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty,LLY,http://www.zacks.com/stock/news/747608/3-dividend-paying-stocks-for-investors-to-buy-to-fight-off-market-uncertainty?cid=CS-BENZ-FT-stocks_in_the_news|major_headlines-747608,Zacks,,,,0,0,9f41045b-b7a6-4c62-801c-f0ef3fe2642f
2020-02-03T08:00:00.000+08:00,"Miller Investment Management, LP Buys Comcast Corp, Tortoise Pipeline & Energy Fund Inc, ...",LLY,http://www.gurufocus.com/news/1027358/miller-investment-management-lp-buys-comcast-corp-tortoise-pipeline--energy-fund-inc-eli-lilly-and-co-sells-jpmorgan-ultrashort-income-etf-centene-corp-lowes-inc,GuruFocus,,,,0,0,002d19ee-7dc9-420b-9edc-5083594d2c98
2020-02-03T08:00:00.000+08:00,"United Bank Buys iShares Global Infrastructure ETF, Southern Co, Truist Financial Corp, Sells ...",LLY,http://www.gurufocus.com/news/1026995/united-bank-buys-ishares-global-infrastructure-etf-southern-co-truist-financial-corp-sells-celgene-corp-etrade-financial-corp-alexion-pharmaceuticals-inc,GuruFocus,,,,0,0,f836d69d-740b-4d97-8687-8b74fb7ebd37
2020-02-03T08:00:00.000+08:00,Amarillo National Bank Buys iShares Core U.S. ...,LLY,http://www.gurufocus.com/news/1026853/amarillo-national-bank-buys-ishares-core-us-aggregate-bond-etf-eli-lilly-and-co-conocophillips-sells-berkshire-hathaway-inc,GuruFocus,,,,0,0,da18e9fe-29e7-41a6-a50b-86f67b565ac4
2020-02-02T08:00:00.000+08:00,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",LLY,https://www.benzinga.com/general/biotech/20/02/15229115/the-week-ahead-in-biotech-merck-bristol-myers-earnings-conference-presentations-in-focus,Shanthi Rexaline,,,,0,0,6b390fba-e20c-45fc-915b-7e14038e6900
2020-02-02T08:00:00.000+08:00,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",LLY,https://www.benzinga.com/general/biotech/20/02/15229115/the-week-ahead-in-biotech-merck-bristol-myers-earnings-conference-presentations-in-focus,Shanthi Rexaline,,,,0,0,17946c5a-cefb-44ff-a5c0-481182ab8ec9
2020-01-31T08:00:00.000+08:00,Lilly's Announces That Its REYVOW C-V Is The First And Only Medicine In a New Class Of Acute Treatment For Migraine,LLY,https://www.benzinga.com/news/20/01/15227875/lillys-announces-that-its-reyvow-c-v-is-the-first-and-only-medicine-in-a-new-class-of-acute-treatmen,Benzinga Newsdesk,,,,0,0,309a925f-2fc0-429e-b953-4fa3dc181d2f
2020-01-31T08:00:00.000+08:00,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",LLY,https://www.benzinga.com/general/biotech/20/01/15224639/the-daily-biotech-pulse-amgen-hurt-by-generic-competition-nanoviricides-confirms-working-on-wuhan,Shanthi Rexaline,,,,0,0,d85f96ee-ff09-4bff-a0e4-75ec7e838aee
2020-01-31T08:00:00.000+08:00,Eli Lilly Reports Its Liumjev Receives Positive CHMP Opinion,LLY,https://www.benzinga.com/news/20/01/15225310/eli-lillys-liumjev-receives-positive-chmp-opinion,Benzinga Newsdesk,,,,0,0,3580198e-e30a-4a39-ad3f-952fade44542
2020-01-31T08:00:00.000+08:00,"Opus Capital Group, LLC Buys iShares Short Treasury Bond ETF, Truist Financial Corp, SPDR ...",LLY,http://www.gurufocus.com/news/1026062/opus-capital-group-llc-buys-ishares-short-treasury-bond-etf-truist-financial-corp-spdr-portfolio-world-ex-us-etf-sells-vanguard-shortterm-corporate-bond-etf-schwab-intermediateterm-us-treasury-etf-hp-inc,GuruFocus,,,,0,0,62720f96-d078-43ff-8f69-9c300bd93e4d
2020-01-31T08:00:00.000+08:00,"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute ...",LLY,http://www.gurufocus.com/news/1025829/lillys-reyvow-lasmiditan-cv-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription,GuruFocus,,,,0,0,9b259a4c-3e8b-4de9-9a26-c8d110a0ca63
2020-01-31T08:00:00.000+08:00,Bayer Seeks FDA Approval for New Formulation of Nifurtimox,LLY,http://www.zacks.com/stock/news/742609/bayer-seeks-fda-approval-for-new-formulation-of-nifurtimox?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-742609,Zacks,,,,0,0,5d69a73d-3cfc-4972-9e8a-e9004a9f5551
2020-01-31T08:00:00.000+08:00,Lilly's Announces That Its REYVOW C-V Is The First And Only Medicine In a New Class Of Acute Treatment For Migraine,LLY,https://www.benzinga.com/news/20/01/15227875/lillys-announces-that-its-reyvow-c-v-is-the-first-and-only-medicine-in-a-new-class-of-acute-treatmen,Benzinga Newsdesk,,,,0,0,2e8d118b-3340-435c-bfe6-952ceba0cc4a
2020-01-31T08:00:00.000+08:00,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",LLY,https://www.benzinga.com/general/biotech/20/01/15224639/the-daily-biotech-pulse-amgen-hurt-by-generic-competition-nanoviricides-confirms-working-on-wuhan,Shanthi Rexaline,,,,0,0,35354f9f-2382-46bc-99b5-69c1d784edbf
2020-01-31T08:00:00.000+08:00,Eli Lilly Reports Its Liumjev Receives Positive CHMP Opinion,LLY,https://www.benzinga.com/news/20/01/15225310/eli-lillys-liumjev-receives-positive-chmp-opinion,Benzinga Newsdesk,,,,0,0,7545abe8-d32e-49c6-b2f4-c52bb3f4cca0
2020-01-31T08:00:00.000+08:00,"Opus Capital Group, LLC Buys iShares Short Treasury Bond ETF, Truist Financial Corp, SPDR ...",LLY,http://www.gurufocus.com/news/1026062/opus-capital-group-llc-buys-ishares-short-treasury-bond-etf-truist-financial-corp-spdr-portfolio-world-ex-us-etf-sells-vanguard-shortterm-corporate-bond-etf-schwab-intermediateterm-us-treasury-etf-hp-inc,GuruFocus,,,,0,0,dc7e1419-bbec-4ba7-9b91-3a73db899eff
2020-01-31T08:00:00.000+08:00,"Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute ...",LLY,http://www.gurufocus.com/news/1025829/lillys-reyvow-lasmiditan-cv-the-first-and-only-medicine-in-a-new-class-of-acute-treatment-for-migraine-ditan-now-available-for-prescription,GuruFocus,,,,0,0,0403b250-ce00-467b-985e-e1e0ceff197b
2020-01-31T08:00:00.000+08:00,Bayer Seeks FDA Approval for New Formulation of Nifurtimox,LLY,http://www.zacks.com/stock/news/742609/bayer-seeks-fda-approval-for-new-formulation-of-nifurtimox?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-742609,Zacks,,,,0,0,128466a6-30f4-48ef-9fe1-fedc57364e55
2020-01-30T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,LLY,https://www.benzinga.com/wiim/20/01/15220945/eli-lilly-shares-are-trading-higher-after-the-company-reported-better-than-expected-q4-eps-and-sales,Benzinga Newsdesk,,,,0,0,63f5b569-b506-4b4e-978d-7daf29de5e19
2020-01-30T08:00:00.000+08:00,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",LLY,https://www.benzinga.com/general/biotech/20/01/15215233/the-daily-biotech-pulse-sanofi-reports-positive-readout-tonix-vaccine-candidate-aces-animal-study,Shanthi Rexaline,,,,0,0,a2db78b9-e3c3-40f6-9162-3f112a16007e
2020-01-30T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings, GDP Data",LLY,https://www.benzinga.com/news/earnings/20/01/15215756/a-peek-into-the-markets-us-stock-futures-tumble-ahead-of-earnings-gdp-data,Lisa Levin,,,,0,0,ac5ead59-1cec-4798-a857-ff4a62dfca2e
2020-01-30T08:00:00.000+08:00,Eli Lilly Reaffirms FY20 Adj. EPS Guidance $6.70-$6.80,LLY,https://www.benzinga.com/news/20/01/15215575/eli-lilly-reaffirms-fy20-adj-eps-guidance-6-70-6-80,Benzinga Newsdesk,,,,0,0,0c87fe30-c163-4cfe-8536-5f2b58ca59cd
2020-01-30T08:00:00.000+08:00,"Eli Lilly Q4 Adj. EPS $1.73 Beats $1.51 Estimate, Sales $6.114B Beat $5.9B Estimate",LLY,https://www.benzinga.com/news/earnings/20/01/15215574/eli-lilly-q4-adj-eps-1-73-beats-1-51-estimate-sales-6-114b-beat-5-9b-estimate,Benzinga Newsdesk,,,,0,0,0efce7b4-0c1d-44b8-9483-c483629c5306
2020-01-30T08:00:00.000+08:00,Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/20/01/15215540/eli-lilly-reports-top-line-results-from-breeze-ad5-phase-3-study-of-oral-selective-jak-inhibitor-in,Benzinga Newsdesk,,,,0,0,3620c428-e393-4d67-bb84-b866bf3364ab
2020-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2020",LLY,https://www.benzinga.com/news/earnings/20/01/15215156/earnings-scheduled-for-january-30-2020,Lisa Levin,,,,0,0,f7a4f102-cf98-4a60-a918-8050fb5dece9
2020-01-30T08:00:00.000+08:00,"14 Stocks To Watch For January 30, 2020",LLY,https://www.benzinga.com/news/earnings/20/01/15215081/14-stocks-to-watch-for-january-30-2020,Lisa Levin,,,,0,0,30bdb4ad-725f-4138-9489-f3656b3c5799
2020-01-30T08:00:00.000+08:00,"Thinking about buying stock in Applied Materials, General Electric, Eli Lilly, Qorvo, or Tesla?",LLY,http://www.gurufocus.com/news/1024833/thinking-about-buying-stock-in-applied-materials-general-electric-eli-lilly-qorvo-or-tesla,GuruFocus,,,,0,0,24ebbf45-cbf8-4ad0-aa1a-5f8c821034a6
2020-01-30T08:00:00.000+08:00,Lilly's NDA for Selpercatinib Gets FDA's Priority Review,LLY,http://www.zacks.com/stock/news/740824/lillys-nda-for-selpercatinib-gets-fdas-priority-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-740824,Zacks,,,,0,0,845e3519-e10b-4441-b530-77a9f7b32182
2020-01-30T08:00:00.000+08:00,"Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/740768/lilly-lly-q4-earnings-and-sales-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-740768,Zacks,,,,0,0,82e5f47f-0da3-45fe-9c53-eac847f8b5c1
2020-01-30T08:00:00.000+08:00,Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase ...,LLY,http://www.gurufocus.com/news/1024618/lilly-and-incyte-announce-positive-topline-results-from-the-north-american-breezead5-phase-3-study-of-oral-selective-jak-inhibitor-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis,GuruFocus,,,,0,0,2e1551ea-b27b-40a1-8083-e4be8e9b3acf
2020-01-30T08:00:00.000+08:00,"Tesla soars on upbeat earnings, Facebook struggles with expenses",LLY,https://talkmarkets.com/content/tesla-soars-on-upbeat-earnings-facebook-struggles-with-expenses?post=249049,TalkMarkets,,,,0,0,80bdae87-0f4b-4722-b6f6-27f354bb8f9b
2020-01-30T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company reported better-than-expected Q4 EPS and sales results.,LLY,https://www.benzinga.com/wiim/20/01/15220945/eli-lilly-shares-are-trading-higher-after-the-company-reported-better-than-expected-q4-eps-and-sales,Benzinga Newsdesk,,,,0,0,82963082-d39a-4442-9a9f-ec55ca2e950e
2020-01-30T08:00:00.000+08:00,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",LLY,https://www.benzinga.com/general/biotech/20/01/15215233/the-daily-biotech-pulse-sanofi-reports-positive-readout-tonix-vaccine-candidate-aces-animal-study,Shanthi Rexaline,,,,0,0,66cb9cff-a906-4fba-960f-14ed57bc0d69
2020-01-30T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings, GDP Data",LLY,https://www.benzinga.com/news/earnings/20/01/15215756/a-peek-into-the-markets-us-stock-futures-tumble-ahead-of-earnings-gdp-data,Lisa Levin,,,,0,0,5fec56f9-0888-4d47-961e-49adb8eaa1bd
2020-01-30T08:00:00.000+08:00,Eli Lilly Reaffirms FY20 Adj. EPS Guidance $6.70-$6.80,LLY,https://www.benzinga.com/news/20/01/15215575/eli-lilly-reaffirms-fy20-adj-eps-guidance-6-70-6-80,Benzinga Newsdesk,,,,0,0,2ac9f4e3-4c37-4639-9622-1d04a96d7e85
2020-01-30T08:00:00.000+08:00,"Eli Lilly Q4 Adj. EPS $1.73 Beats $1.51 Estimate, Sales $6.114B Beat $5.9B Estimate",LLY,https://www.benzinga.com/news/earnings/20/01/15215574/eli-lilly-q4-adj-eps-1-73-beats-1-51-estimate-sales-6-114b-beat-5-9b-estimate,Benzinga Newsdesk,,,,0,0,8097f6cb-3f9c-4fc9-979e-7817c21517e2
2020-01-30T08:00:00.000+08:00,Eli Lilly Reports Top-Line Results From BREEZE-AD5 Phase 3 Study Of Oral Selective JAK Inhibitor In Patients With Moderate To Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/20/01/15215540/eli-lilly-reports-top-line-results-from-breeze-ad5-phase-3-study-of-oral-selective-jak-inhibitor-in,Benzinga Newsdesk,,,,0,0,0769ff10-0894-4c64-871f-f4b055b61f7c
2020-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2020",LLY,https://www.benzinga.com/news/earnings/20/01/15215156/earnings-scheduled-for-january-30-2020,Lisa Levin,,,,0,0,f50c919b-4063-44a8-b6c6-9681f4c6c237
2020-01-30T08:00:00.000+08:00,"14 Stocks To Watch For January 30, 2020",LLY,https://www.benzinga.com/news/earnings/20/01/15215081/14-stocks-to-watch-for-january-30-2020,Lisa Levin,,,,0,0,99b7941a-a227-44b7-8b37-3e35e950fbd1
2020-01-30T08:00:00.000+08:00,"Thinking about buying stock in Applied Materials, General Electric, Eli Lilly, Qorvo, or Tesla?",LLY,http://www.gurufocus.com/news/1024833/thinking-about-buying-stock-in-applied-materials-general-electric-eli-lilly-qorvo-or-tesla,GuruFocus,,,,0,0,ece54560-4a7f-49fd-a8a8-6ed2fcaa0f16
2020-01-30T08:00:00.000+08:00,Lilly's NDA for Selpercatinib Gets FDA's Priority Review,LLY,http://www.zacks.com/stock/news/740824/lillys-nda-for-selpercatinib-gets-fdas-priority-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-740824,Zacks,,,,0,0,807025f7-93c7-452a-b237-05a1af737dd2
2020-01-30T08:00:00.000+08:00,"Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/740768/lilly-lly-q4-earnings-and-sales-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-740768,Zacks,,,,0,0,cbc7e049-01eb-41d4-a82b-f129c81d34da
2020-01-30T08:00:00.000+08:00,Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase ...,LLY,http://www.gurufocus.com/news/1024618/lilly-and-incyte-announce-positive-topline-results-from-the-north-american-breezead5-phase-3-study-of-oral-selective-jak-inhibitor-baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis,GuruFocus,,,,0,0,1616dae9-5526-4f51-bf08-41496c999eb7
2020-01-30T08:00:00.000+08:00,"Tesla soars on upbeat earnings, Facebook struggles with expenses",LLY,https://talkmarkets.com/content/tesla-soars-on-upbeat-earnings-facebook-struggles-with-expenses?post=249049,TalkMarkets,,,,0,0,7549c67b-48bc-4043-a7de-ce805671736b
2020-01-29T08:00:00.000+08:00,Lilly Receives FDA Priority Review For Selpercatinib New Drug Application,LLY,https://www.benzinga.com/news/20/01/15206768/lilly-receives-fda-priority-review-for-selpercatinib-new-drug-application,Benzinga Newsdesk,,,,0,0,fcf43df9-2755-42d8-ae88-0acdf6d2b6ac
2020-01-29T08:00:00.000+08:00,5 Top Non-Tech Earnings Charts,LLY,http://www.zacks.com/stock/news/739543/5-top-non-tech-earnings-charts?cid=CS-BENZ-FT-video_blog-739543,Zacks,,,,0,0,364933fe-1ef8-473d-9a64-5fafe9fca71e
2020-01-29T08:00:00.000+08:00,"Amazon Earnings, Q4 GDP Report Lead Investing Action Plan",LLY,http://www.investors.com/research/investing-action-plan/amazon-earnings-stock-eyes-buy-point-q4-2019-gdp-growth-estimate-due/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,ac4e32c8-04e9-4bc3-bf1b-4dd5d1ea2a0f
2020-01-29T08:00:00.000+08:00,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...,LLY,http://www.gurufocus.com/news/1022161/lilly-and-incyte-announce-topline-results-from-phase-3-study-breezead4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-,GuruFocus,,,,0,0,4b45228d-d54a-46ae-8209-cce3e0177f22
2020-01-29T08:00:00.000+08:00,Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review,LLY,http://www.zacks.com/stock/news/738792/alkermes-alks-nda-for-alks-3831-accepted-by-fda-for-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-738792,Zacks,,,,0,0,77c3054a-5d19-4f62-910f-acf473be8be2
2020-01-29T08:00:00.000+08:00,"Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More",LLY,http://www.zacks.com/stock/news/738675/big-drug-biotech-stock-earnings-on-jan-30-biib-alxn-more?cid=CS-BENZ-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-738675,Zacks,,,,0,0,e10b777b-2731-4229-b6e6-8e351ba8e2b5
2020-01-29T08:00:00.000+08:00,Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application,LLY,http://www.gurufocus.com/news/1023784/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application,GuruFocus,,,,0,0,fd465477-7c91-4fe6-a646-6693cfa74d25
2020-01-29T08:00:00.000+08:00,Lilly Receives FDA Priority Review For Selpercatinib New Drug Application,LLY,https://www.benzinga.com/news/20/01/15206768/lilly-receives-fda-priority-review-for-selpercatinib-new-drug-application,Benzinga Newsdesk,,,,0,0,c6681f51-daa4-4dce-8a69-e3bd66bd4c25
2020-01-29T08:00:00.000+08:00,5 Top Non-Tech Earnings Charts,LLY,http://www.zacks.com/stock/news/739543/5-top-non-tech-earnings-charts?cid=CS-BENZ-FT-video_blog-739543,Zacks,,,,0,0,7bccec49-e992-4af3-9e68-a72d5b9cc033
2020-01-29T08:00:00.000+08:00,"Amazon Earnings, Q4 GDP Report Lead Investing Action Plan",LLY,http://www.investors.com/research/investing-action-plan/amazon-earnings-stock-eyes-buy-point-q4-2019-gdp-growth-estimate-due/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,0cb6c80a-68f1-44fa-a211-4d8ca781e03c
2020-01-29T08:00:00.000+08:00,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...,LLY,http://www.gurufocus.com/news/1022161/lilly-and-incyte-announce-topline-results-from-phase-3-study-breezead4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-,GuruFocus,,,,0,0,c0e3df03-9278-4120-b50a-781c020ceb8a
2020-01-29T08:00:00.000+08:00,Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review,LLY,http://www.zacks.com/stock/news/738792/alkermes-alks-nda-for-alks-3831-accepted-by-fda-for-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-738792,Zacks,,,,0,0,8adc8459-36dd-41e8-8c5f-698d788c1dff
2020-01-29T08:00:00.000+08:00,"Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More",LLY,http://www.zacks.com/stock/news/738675/big-drug-biotech-stock-earnings-on-jan-30-biib-alxn-more?cid=CS-BENZ-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-738675,Zacks,,,,0,0,d30ef537-207f-4032-a806-e973743ceb76
2020-01-29T08:00:00.000+08:00,Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application,LLY,http://www.gurufocus.com/news/1023784/lilly-receives-fda-priority-review-for-the-selpercatinib-new-drug-application,GuruFocus,,,,0,0,4e6aeeea-6243-48f4-b966-a0c3d6644949
2020-01-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",LLY,https://www.benzinga.com/general/biotech/20/01/15195781/the-daily-biotech-pulse-accelerons-positive-data-readout-surface-oncology-gets-nod-for-pushing-2-,Shanthi Rexaline,,,,0,0,ed07dabe-7cf9-4b7f-adef-3f124b763544
2020-01-28T08:00:00.000+08:00,AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study,LLY,http://www.zacks.com/stock/news/736760/aveo-posts-data-on-ficlatuzumab-from-pancreatic-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-736760,Zacks,,,,0,0,25c3508f-26ab-4ab4-abf8-c349c2c18d80
2020-01-28T08:00:00.000+08:00,Lilly's Olumiant Meets Primary Goal in Dermatitis Study,LLY,http://www.zacks.com/stock/news/736741/lillys-olumiant-meets-primary-goal-in-dermatitis-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-736741,Zacks,,,,0,0,02e972c0-52c8-41e5-bd29-e038db4086c1
2020-01-28T08:00:00.000+08:00,"Lilly plans donation of —……,……… insulin KwikPens over next three years to support ...",LLY,http://www.gurufocus.com/news/1022897/lilly-plans-donation-of-200000-insulin-kwikpens-over-next-three-years-to-support-lowerincome-communities,GuruFocus,,,,0,0,83d97ae5-bafa-42a6-a33d-44a37fe83c02
2020-01-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics",LLY,https://www.benzinga.com/general/biotech/20/01/15195781/the-daily-biotech-pulse-accelerons-positive-data-readout-surface-oncology-gets-nod-for-pushing-2-,Shanthi Rexaline,,,,0,0,2b8563fa-159e-4563-b1e3-e26d6aa77d6d
2020-01-28T08:00:00.000+08:00,AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study,LLY,http://www.zacks.com/stock/news/736760/aveo-posts-data-on-ficlatuzumab-from-pancreatic-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-736760,Zacks,,,,0,0,4419e8dc-3f06-42bb-8165-fffddaade964
2020-01-28T08:00:00.000+08:00,Lilly's Olumiant Meets Primary Goal in Dermatitis Study,LLY,http://www.zacks.com/stock/news/736741/lillys-olumiant-meets-primary-goal-in-dermatitis-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-736741,Zacks,,,,0,0,24487004-380e-42da-b9b4-c1ccb70b0c49
2020-01-28T08:00:00.000+08:00,"Lilly plans donation of —……,……… insulin KwikPens over next three years to support ...",LLY,http://www.gurufocus.com/news/1022897/lilly-plans-donation-of-200000-insulin-kwikpens-over-next-three-years-to-support-lowerincome-communities,GuruFocus,,,,0,0,5fd7a65f-45e1-49a5-8122-3f33879cabf6
2020-01-27T08:00:00.000+08:00,FDA Approves Lilly's Trijardy,LLY,https://www.benzinga.com/general/biotech/20/01/15194253/fda-approves-lillys-trijardy,Benzinga Newsdesk,,,,0,0,74f2cc79-1e4f-4157-b5cc-e662835cd804
2020-01-27T08:00:00.000+08:00,Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint,LLY,https://www.benzinga.com/news/20/01/15187132/eli-lilly-and-incytes-phase-3-breeze-ad4-study-met-its-primary-endpoint,Benzinga Newsdesk,,,,0,0,15eaa3c6-0b7f-41fa-a7d4-cfb03ba908ce
2020-01-27T08:00:00.000+08:00,US FDA approves only triple-combination tablet with Jardiance® for adults with type — diabetes,LLY,http://www.gurufocus.com/news/1022645/us-fda-approves-only-triplecombination-tablet-with-jardiance-for-adults-with-type-2-diabetes,GuruFocus,,,,0,0,97e4f11c-7092-4976-a774-f04e93969e34
2020-01-27T08:00:00.000+08:00,"Bremer Bank National Association Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Marsh ...",LLY,http://www.gurufocus.com/news/1022412/bremer-bank-national-association-buys-bristolmyers-squibb-company-eli-lilly-and-co-marsh--mclennan-inc-sells-powershares-qqq-trust-ser-1-celgene-corp-ishares-russell-1000-growth-etf,GuruFocus,,,,0,0,00492fde-9a72-42c5-b2c0-4427c7368c2d
2020-01-27T08:00:00.000+08:00,"British Airways Pensions Investment Management Ltd Buys Bristol-Myers Squibb Company, Zimmer ...",LLY,http://www.gurufocus.com/news/1022404/british-airways-pensions-investment-management-ltd-buys-bristolmyers-squibb-company-zimmer-biomet-holdings-inc-sysco-corp-sells-spdr-sp-500-etf-trust-stryker-corp-dr-horton-inc,GuruFocus,,,,0,0,a2dbed0f-5ed9-4790-8798-57c8bc6179a4
2020-01-27T08:00:00.000+08:00,Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-trading-near-top-of-buy-zone-with-earnings-on-tap/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,1c18d3d0-15cb-4441-a7fa-e86812a9670e
2020-01-27T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/734952/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-734952,Zacks,,,,0,0,51394c57-d405-4506-9061-c8687e985ec2
2020-01-27T08:00:00.000+08:00,Lilly (LLY) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/734541/lilly-lly-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-734541,Zacks,,,,0,0,99aded02-0a3c-4ee5-acb1-db7894a57170
2020-01-27T08:00:00.000+08:00,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...,LLY,http://www.gurufocus.com/news/1022161/lilly-and-incyte-announce-topline-results-from-phase-3-study-breezead4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-,GuruFocus,,,,0,0,f956c1af-7ef7-42a8-b667-dc462b40b87e
2020-01-27T08:00:00.000+08:00,FDA Approves Lilly's Trijardy,LLY,https://www.benzinga.com/general/biotech/20/01/15194253/fda-approves-lillys-trijardy,Benzinga Newsdesk,,,,0,0,3ff1ae74-dedb-4ea2-93e9-f1be3d5d9624
2020-01-27T08:00:00.000+08:00,Eli Lilly and Incyte's Phase 3 BREEZE-AD4 Study Met its Primary Endpoint,LLY,https://www.benzinga.com/news/20/01/15187132/eli-lilly-and-incytes-phase-3-breeze-ad4-study-met-its-primary-endpoint,Benzinga Newsdesk,,,,0,0,73dbfeec-d628-44aa-8418-4e972f2e9b57
2020-01-27T08:00:00.000+08:00,US FDA approves only triple-combination tablet with Jardiance® for adults with type — diabetes,LLY,http://www.gurufocus.com/news/1022645/us-fda-approves-only-triplecombination-tablet-with-jardiance-for-adults-with-type-2-diabetes,GuruFocus,,,,0,0,e2c70d63-554e-498e-ae99-9de49c35ad72
2020-01-27T08:00:00.000+08:00,"Bremer Bank National Association Buys Bristol-Myers Squibb Company, Eli Lilly and Co, Marsh ...",LLY,http://www.gurufocus.com/news/1022412/bremer-bank-national-association-buys-bristolmyers-squibb-company-eli-lilly-and-co-marsh--mclennan-inc-sells-powershares-qqq-trust-ser-1-celgene-corp-ishares-russell-1000-growth-etf,GuruFocus,,,,0,0,b0ccaa7d-2faa-4e32-ba90-3340dd866308
2020-01-27T08:00:00.000+08:00,"British Airways Pensions Investment Management Ltd Buys Bristol-Myers Squibb Company, Zimmer ...",LLY,http://www.gurufocus.com/news/1022404/british-airways-pensions-investment-management-ltd-buys-bristolmyers-squibb-company-zimmer-biomet-holdings-inc-sysco-corp-sells-spdr-sp-500-etf-trust-stryker-corp-dr-horton-inc,GuruFocus,,,,0,0,484e2880-6dfd-4c70-bfd7-c922b120d6c2
2020-01-27T08:00:00.000+08:00,Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-trading-near-top-of-buy-zone-with-earnings-on-tap/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,8614fc32-8352-4589-8263-39797e2b386b
2020-01-27T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/734952/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-734952,Zacks,,,,0,0,9b44e564-dc58-45a2-bf4e-06d2233c4fde
2020-01-27T08:00:00.000+08:00,Lilly (LLY) to Report Q4 Earnings: What's in the Cards?,LLY,http://www.zacks.com/stock/news/734541/lilly-lly-to-report-q4-earnings-whats-in-the-cards?cid=CS-BENZ-FT-analyst_blog|earnings_preview-734541,Zacks,,,,0,0,171a7b65-c182-4b63-850e-7c1e9ea6a00b
2020-01-27T08:00:00.000+08:00,Lilly and Incyte Announce Top-Line Results from Phase ' Study (BREEZE-AD4) of Oral Selective ...,LLY,http://www.gurufocus.com/news/1022161/lilly-and-incyte-announce-topline-results-from-phase-3-study-breezead4-of-oral-selective-jak-inhibitor-baricitinib-in-combination-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-,GuruFocus,,,,0,0,6eb902c0-dc1e-49ed-9eaf-b2d36223ae88
2020-01-26T08:00:00.000+08:00,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes",LLY,https://www.benzinga.com/general/biotech/20/01/15181472/the-week-ahead-in-biotech-amgen-eli-lilly-pfizer-in-earnings-mix-ipo-flow-resumes,Shanthi Rexaline,,,,0,0,e57b97f9-e830-4cec-b79d-c29eee9d0854
2020-01-26T08:00:00.000+08:00,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes",LLY,https://www.benzinga.com/general/biotech/20/01/15181472/the-week-ahead-in-biotech-amgen-eli-lilly-pfizer-in-earnings-mix-ipo-flow-resumes,Shanthi Rexaline,,,,0,0,20bc94ee-76a2-401a-80cc-51851cb7b738
2020-01-24T08:00:00.000+08:00,J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children,LLY,http://www.zacks.com/stock/news/731608/jjs-stelara-gets-eu-nod-for-plaque-psoriasis-in-children?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-731608,Zacks,,,,0,0,bfd3fdb5-636c-4d74-ac6d-ebd6fdcbb367
2020-01-24T08:00:00.000+08:00,Anat Hakim to join Lilly as General Counsel,LLY,http://www.gurufocus.com/news/1021273/anat-hakim-to-join-lilly-as-general-counsel,GuruFocus,,,,0,0,c78389da-cc0f-4ced-b77c-33df852bc6ca
2020-01-24T08:00:00.000+08:00,"Acima Private Wealth, Llc Buys SPDR Barclays Short Term Corporate Bond ETF, iShares MSCI ...",LLY,http://www.gurufocus.com/news/1021233/acima-private-wealth-llc-buys-spdr-barclays-short-term-corporate-bond-etf-ishares-msci-frontier-100-etf-ishares-msci-china-etf-sells-celgene-corp-vaneck-vectors-etf-trust--vaneck-vectors-vietnam--jpmorgan-ultrashort-i,GuruFocus,,,,0,0,7759074c-fa78-480b-80f2-1dfd70f0b170
2020-01-24T08:00:00.000+08:00,J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children,LLY,http://www.zacks.com/stock/news/731608/jjs-stelara-gets-eu-nod-for-plaque-psoriasis-in-children?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-731608,Zacks,,,,0,0,a5911646-2f01-44a6-9438-4efa7683815c
2020-01-24T08:00:00.000+08:00,Anat Hakim to join Lilly as General Counsel,LLY,http://www.gurufocus.com/news/1021273/anat-hakim-to-join-lilly-as-general-counsel,GuruFocus,,,,0,0,0a2e0303-421d-4d61-a278-fff4d446b47f
2020-01-24T08:00:00.000+08:00,"Acima Private Wealth, Llc Buys SPDR Barclays Short Term Corporate Bond ETF, iShares MSCI ...",LLY,http://www.gurufocus.com/news/1021233/acima-private-wealth-llc-buys-spdr-barclays-short-term-corporate-bond-etf-ishares-msci-frontier-100-etf-ishares-msci-china-etf-sells-celgene-corp-vaneck-vectors-etf-trust--vaneck-vectors-vietnam--jpmorgan-ultrashort-i,GuruFocus,,,,0,0,844ac409-cbfd-4783-bf68-914a6bd69c70
2020-01-23T08:00:00.000+08:00,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",LLY,https://www.benzinga.com/general/biotech/20/01/15169823/the-daily-biotech-pulse-roche-reports-positive-sma-data-readout-vir-biotech-to-work-on-virus-trea,Shanthi Rexaline,,,,0,0,5bcfdd23-a446-4982-8f3b-a6f30287a519
2020-01-23T08:00:00.000+08:00,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",LLY,https://www.benzinga.com/general/biotech/20/01/15169823/the-daily-biotech-pulse-roche-reports-positive-sma-data-readout-vir-biotech-to-work-on-virus-trea,Shanthi Rexaline,,,,0,0,56d3bca6-4edf-4b4e-98d3-2b945484000c
2020-01-22T08:00:00.000+08:00,Steven Cohen's Point7— Piles Into Menlo Therapeutics,LLY,http://www.gurufocus.com/news/1020274/steven-cohens-point72-piles-into-menlo-therapeutics,GuruFocus,,,,0,0,8217b1aa-577e-46bb-8333-def1fa61fe10
2020-01-22T08:00:00.000+08:00,"Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP",LLY,http://www.zacks.com/research-daily/729250/top-stock-analyst-reports-for-pfizer-wells-fargo-sap?cid=CS-BENZ-FT-research_daily-729250,Zacks,,,,0,0,b17d59f3-1220-4de1-873f-f28c2c35ee4b
2020-01-22T08:00:00.000+08:00,Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review,LLY,http://www.zacks.com/stock/news/729106/glaxos-multiple-myeloma-candidate-gets-fdas-priority-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-729106,Zacks,,,,0,0,865b3771-8b1e-4060-aacc-df7b5cce89a1
2020-01-22T08:00:00.000+08:00,Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?,LLY,http://www.zacks.com/stock/news/729079/should-first-trust-capital-strength-etf-ftcs-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-729079,Zacks,,,,0,0,0c64c0a0-4895-406f-bcb5-2a120b53ec4e
2020-01-22T08:00:00.000+08:00,Steven Cohen's Point7— Piles Into Menlo Therapeutics,LLY,http://www.gurufocus.com/news/1020274/steven-cohens-point72-piles-into-menlo-therapeutics,GuruFocus,,,,0,0,f37ce6f0-02cf-4481-b469-f18540f26560
2020-01-22T08:00:00.000+08:00,"Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP",LLY,http://www.zacks.com/research-daily/729250/top-stock-analyst-reports-for-pfizer-wells-fargo-sap?cid=CS-BENZ-FT-research_daily-729250,Zacks,,,,0,0,c11f5ea4-038f-492e-a87d-6af79f3fc19c
2020-01-22T08:00:00.000+08:00,Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review,LLY,http://www.zacks.com/stock/news/729106/glaxos-multiple-myeloma-candidate-gets-fdas-priority-review?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-729106,Zacks,,,,0,0,35a671ef-b9a0-4aee-aa9e-7f9ac284cfe0
2020-01-22T08:00:00.000+08:00,Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?,LLY,http://www.zacks.com/stock/news/729079/should-first-trust-capital-strength-etf-ftcs-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-729079,Zacks,,,,0,0,7cb039c0-ea68-45da-b9f2-19a5c10c0e6a
2020-01-21T08:00:00.000+08:00,Pharma Company Buybacks: Do They Really Benefit Shareholders?,LLY,http://www.gurufocus.com/news/1019458/pharma-company-buybacks-do-they-really-benefit-shareholders,GuruFocus,,,,0,0,657ec45d-6a78-47f5-8f34-2f8bf1f9d149
2020-01-21T08:00:00.000+08:00,Governor Cooper Announces over 46… Jobs in Durham as Eli Lilly and Company Selects North ...,LLY,http://www.gurufocus.com/news/1019448/governor-cooper-announces-over-460-jobs-in-durham-as-eli-lilly-and-company-selects-north-carolina-for-major-pharmaceutical-plant,GuruFocus,,,,0,0,e1608c41-2457-489b-94b2-8744da392ab2
2020-01-21T08:00:00.000+08:00,Pharma Company Buybacks: Do They Really Benefit Shareholders?,LLY,http://www.gurufocus.com/news/1019458/pharma-company-buybacks-do-they-really-benefit-shareholders,GuruFocus,,,,0,0,9bb2087e-ac07-4e5f-979d-3b5f905f6688
2020-01-21T08:00:00.000+08:00,Governor Cooper Announces over 46… Jobs in Durham as Eli Lilly and Company Selects North ...,LLY,http://www.gurufocus.com/news/1019448/governor-cooper-announces-over-460-jobs-in-durham-as-eli-lilly-and-company-selects-north-carolina-for-major-pharmaceutical-plant,GuruFocus,,,,0,0,f593ad71-f59f-4414-8228-04a4be51a8ac
2020-01-17T08:00:00.000+08:00,9 Takeaways From The JPMorgan Healthcare Conference,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/01/15144617/9-takeaways-from-the-jpmorgan-healthcare-conference,Shanthi Rexaline,,,,0,0,6976dbba-7dc7-4025-b549-3cd38ef13f05
2020-01-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",LLY,https://www.benzinga.com/general/biotech/20/01/15141617/the-daily-biotech-pulse-novo-nordisks-ozempic-receives-label-expansion-for-cardiovascular-events-,Shanthi Rexaline,,,,0,0,715b2385-4889-4849-9e5c-abf032f1a93b
2020-01-17T08:00:00.000+08:00,Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction,LLY,http://www.zacks.com/stock/news/722212/novo-nordisks-ozempic-gets-fda-nod-for-cv-risk-reduction?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-722212,Zacks,,,,0,0,e27b4e9c-3867-4eb3-bc31-46de287eb3a7
2020-01-17T08:00:00.000+08:00,Castle Could Crumble When IPO Lockup Expires,LLY,https://talkmarkets.com/content/castle-could-crumble-when-ipo-lockup-expires?post=247483,TalkMarkets,,,,0,0,5c5c847c-aeea-44c2-a207-69a0a24e68ef
2020-01-17T08:00:00.000+08:00,9 Takeaways From The JPMorgan Healthcare Conference,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/20/01/15144617/9-takeaways-from-the-jpmorgan-healthcare-conference,Shanthi Rexaline,,,,0,0,e75da93d-d4cb-45ed-8ea2-e04ca9d77f82
2020-01-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",LLY,https://www.benzinga.com/general/biotech/20/01/15141617/the-daily-biotech-pulse-novo-nordisks-ozempic-receives-label-expansion-for-cardiovascular-events-,Shanthi Rexaline,,,,0,0,2cf93779-ac5a-4673-afae-8dbe2b7d0b42
2020-01-17T08:00:00.000+08:00,Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction,LLY,http://www.zacks.com/stock/news/722212/novo-nordisks-ozempic-gets-fda-nod-for-cv-risk-reduction?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-722212,Zacks,,,,0,0,ec26c4e5-9696-4660-a151-9af6920c69a8
2020-01-17T08:00:00.000+08:00,Castle Could Crumble When IPO Lockup Expires,LLY,https://talkmarkets.com/content/castle-could-crumble-when-ipo-lockup-expires?post=247483,TalkMarkets,,,,0,0,f973a88e-85ce-4e97-86b9-50fb036e36d1
2020-01-16T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/01/15135505/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,,,,0,0,c8bc37ab-fae6-440e-98f7-d50eabcea8bd
2020-01-16T08:00:00.000+08:00,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",LLY,https://www.benzinga.com/general/biotech/20/01/15133299/the-daily-biotech-pulse-osmotica-soars-on-insider-buys-ultragenyxs-partnered-rare-disease-drug-mo,Shanthi Rexaline,,,,0,0,1cb1a907-d664-47a6-972e-b88cdd2fdab0
2020-01-16T08:00:00.000+08:00,Eli Lilly (LLY) Gains But Lags Market: What You Should Know,LLY,http://www.zacks.com/stock/news/721414/eli-lilly-lly-gains-but-lags-market-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v1-721414,Zacks,,,,0,0,5ad8c6b9-8803-4bd1-a09a-7f8ee5415eab
2020-01-16T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for Fourth-Quarter —…–9 Financial Results Announcement,LLY,http://www.gurufocus.com/news/1016786/lilly-confirms-date-and-conference-call-for-fourthquarter-2019-financial-results-announcement,GuruFocus,,,,0,0,55e52d92-dd82-4659-9247-11e6d9f40382
2020-01-16T08:00:00.000+08:00,Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA,LLY,http://www.zacks.com/stock/news/720624/bristol-myers-opdivo-yervoy-sbla-for-nsclc-accepted-by-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-720624,Zacks,,,,0,0,931aa300-39ef-4762-b75b-21bd3c95562d
2020-01-16T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Thursday,LLY,https://www.benzinga.com/news/20/01/15135505/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,,,,0,0,8a9a2506-2c97-4e3f-95b9-70e50bb4339f
2020-01-16T08:00:00.000+08:00,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",LLY,https://www.benzinga.com/general/biotech/20/01/15133299/the-daily-biotech-pulse-osmotica-soars-on-insider-buys-ultragenyxs-partnered-rare-disease-drug-mo,Shanthi Rexaline,,,,0,0,aa10ab7a-1499-4493-a6a6-65ea8d26ef0b
2020-01-16T08:00:00.000+08:00,Eli Lilly (LLY) Gains But Lags Market: What You Should Know,LLY,http://www.zacks.com/stock/news/721414/eli-lilly-lly-gains-but-lags-market-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v1-721414,Zacks,,,,0,0,10f04cdd-7f4c-422e-bbc4-42cbb6acd24b
2020-01-16T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for Fourth-Quarter —…–9 Financial Results Announcement,LLY,http://www.gurufocus.com/news/1016786/lilly-confirms-date-and-conference-call-for-fourthquarter-2019-financial-results-announcement,GuruFocus,,,,0,0,7187bccc-290a-446f-913a-01595ac3401e
2020-01-16T08:00:00.000+08:00,Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA,LLY,http://www.zacks.com/stock/news/720624/bristol-myers-opdivo-yervoy-sbla-for-nsclc-accepted-by-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-720624,Zacks,,,,0,0,ec8be218-bc65-4e1e-b438-e68d056ef8ce
2020-01-15T08:00:00.000+08:00,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",LLY,https://www.benzinga.com/general/biotech/20/01/15125323/the-daily-biotech-pulse-nektar-withdraws-opioid-pain-drug-nda-galapagos-takes-stake-in-fibrocor-i,Shanthi Rexaline,,,,0,0,a9b00663-2e3a-4361-9d1a-5f2060d0a0d6
2020-01-15T08:00:00.000+08:00,Which Stocks Join Market For Another New High?,LLY,https://talkmarkets.com/content/which-stocks-join-market-for-another-new-high?post=247244,TalkMarkets,,,,0,0,fec10b8f-68a5-4401-bbb4-750b552aadb3
2020-01-15T08:00:00.000+08:00,Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins,LLY,http://www.zacks.com/stock/news/719140/lilly-to-launch-cheaper-versions-of-humalog-kwikpen-insulins?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-719140,Zacks,,,,0,0,82956529-60bf-4db2-a47f-091f1102a299
2020-01-15T08:00:00.000+08:00,"Lilly, Anna Kaiser Launch ''…-Day Thriver Challenge' to Increase Awareness of Daily Stress ...",LLY,http://www.gurufocus.com/news/1015662/lilly-anna-kaiser-launch-30day-thriver-challenge-to-increase-awareness-of-daily-stress-of-living-with-metastatic-breast-cancer-elevate-support-for-women-and-men-living-with-the-disease,GuruFocus,,,,0,0,fe172a9d-05fc-479b-962a-777fa5edfc43
2020-01-15T08:00:00.000+08:00,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",LLY,https://www.benzinga.com/general/biotech/20/01/15125323/the-daily-biotech-pulse-nektar-withdraws-opioid-pain-drug-nda-galapagos-takes-stake-in-fibrocor-i,Shanthi Rexaline,,,,0,0,8509268f-c257-41b8-85c1-cc050f397b86
2020-01-15T08:00:00.000+08:00,Which Stocks Join Market For Another New High?,LLY,https://talkmarkets.com/content/which-stocks-join-market-for-another-new-high?post=247244,TalkMarkets,,,,0,0,99706f57-a0da-4c22-ab07-9dd4184ab200
2020-01-15T08:00:00.000+08:00,Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins,LLY,http://www.zacks.com/stock/news/719140/lilly-to-launch-cheaper-versions-of-humalog-kwikpen-insulins?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-719140,Zacks,,,,0,0,d0392793-01b8-4638-9caa-1ddc64fb0fba
2020-01-15T08:00:00.000+08:00,"Lilly, Anna Kaiser Launch ''…-Day Thriver Challenge' to Increase Awareness of Daily Stress ...",LLY,http://www.gurufocus.com/news/1015662/lilly-anna-kaiser-launch-30day-thriver-challenge-to-increase-awareness-of-daily-stress-of-living-with-metastatic-breast-cancer-elevate-support-for-women-and-men-living-with-the-disease,GuruFocus,,,,0,0,cfd477a9-f20b-4030-9a27-00b1763ac560
2020-01-14T08:00:00.000+08:00,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",LLY,https://www.benzinga.com/general/biotech/20/01/15117688/the-daily-biotech-pulse-phasebio-to-buy-hypertension-asset-stemline-falls-on-q4-pre-announcement-,Shanthi Rexaline,,,,0,0,7beb5727-9355-4b76-b56a-ec06cd54d1d6
2020-01-14T08:00:00.000+08:00,"Lilly Announces Insulin Cost-Saving Options; Lower-Priced Versions Of Humalog Junior KwikPen And Humalog Mix75/25 KwikPen To Have 50% Lower List Price Than Branded Versions, Will Be Available By Mid April",LLY,https://www.benzinga.com/general/health-care/20/01/15117761/lilly-announces-insulin-cost-saving-options-lower-priced-versions-of-humalog-junior-kwikpen-a,Benzinga Newsdesk,,,,0,0,892c0b45-8513-471d-8c7e-ada1ed92885b
2020-01-14T08:00:00.000+08:00,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",LLY,https://www.benzinga.com/general/biotech/20/01/15117688/the-daily-biotech-pulse-phasebio-to-buy-hypertension-asset-stemline-falls-on-q4-pre-announcement-,Shanthi Rexaline,,,,0,0,8decebce-a4a2-4277-aa47-b466d8f44ddb
2020-01-14T08:00:00.000+08:00,"Lilly Announces Insulin Cost-Saving Options; Lower-Priced Versions Of Humalog Junior KwikPen And Humalog Mix75/25 KwikPen To Have 50% Lower List Price Than Branded Versions, Will Be Available By Mid April",LLY,https://www.benzinga.com/general/health-care/20/01/15117761/lilly-announces-insulin-cost-saving-options-lower-priced-versions-of-humalog-junior-kwikpen-a,Benzinga Newsdesk,,,,0,0,0b13e5f1-962b-4a62-a81d-f1721ff280f1
2020-01-13T08:00:00.000+08:00,Eli Lilly's Phase 3 ORIENT-11 Study of Tyvyt Combined with ALIMTA Met its Primary Endpoint,LLY,https://www.benzinga.com/news/20/01/15110468/eli-lillys-phase-3-orient-11-study-of-tyvyt-combined-with-alimta-met-its-primary-endpoint,Benzinga Newsdesk,,,,0,0,4fe2b39d-4a96-48bf-be7c-23fe03a50e7c
2020-01-13T08:00:00.000+08:00,Glaxo Files Marketing Application for Fostemsavir in Europe,LLY,http://www.zacks.com/stock/news/715692/glaxo-files-marketing-application-for-fostemsavir-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-715692,Zacks,,,,0,0,ef82f50e-2ce4-4fe9-8970-1d2b57f8702d
2020-01-13T08:00:00.000+08:00,"Company News for Jan 13, 2020",LLY,http://www.zacks.com/stock/news/715585/company-news-for-jan-13-2020?cid=CS-BENZ-FT-corporate_summary-715585,Zacks,,,,0,0,eff1701d-c3c1-4bf7-96cf-06ca462708af
2020-01-13T08:00:00.000+08:00,Eli Lilly's Phase 3 ORIENT-11 Study of Tyvyt Combined with ALIMTA Met its Primary Endpoint,LLY,https://www.benzinga.com/news/20/01/15110468/eli-lillys-phase-3-orient-11-study-of-tyvyt-combined-with-alimta-met-its-primary-endpoint,Benzinga Newsdesk,,,,0,0,a7015a83-5ef5-4f62-babe-734116d1b28e
2020-01-13T08:00:00.000+08:00,Glaxo Files Marketing Application for Fostemsavir in Europe,LLY,http://www.zacks.com/stock/news/715692/glaxo-files-marketing-application-for-fostemsavir-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-715692,Zacks,,,,0,0,072da151-8f89-4e85-af9d-016f659b1974
2020-01-13T08:00:00.000+08:00,"Company News for Jan 13, 2020",LLY,http://www.zacks.com/stock/news/715585/company-news-for-jan-13-2020?cid=CS-BENZ-FT-corporate_summary-715585,Zacks,,,,0,0,0e429ce6-5344-41c2-aeed-f1b7cf0e2548
2020-01-11T08:00:00.000+08:00,Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020,LLY,https://talkmarkets.com/content/week-in-review-four-china-biopharmas-announce-100-million-deals-in-first-week-of-2020?post=246706,TalkMarkets,,,,0,0,19f7ac27-5533-4db1-b9d0-d6d92ec270dd
2020-01-11T08:00:00.000+08:00,Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020,LLY,https://talkmarkets.com/content/week-in-review-four-china-biopharmas-announce-100-million-deals-in-first-week-of-2020?post=246706,TalkMarkets,,,,0,0,608be065-ef3b-440c-8d2d-eccf98c4b41c
2020-01-10T08:00:00.000+08:00,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet,LLY,https://www.benzinga.com/news/20/01/15107226/mid-afternoon-market-update-dow-falls-90-points-rumbleon-shares-plummet,Lisa Levin,,,,0,0,134c335e-2408-4b46-b07b-4d7ea48c0c8f
2020-01-10T08:00:00.000+08:00,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier",LLY,https://www.benzinga.com/general/biotech/20/01/15106641/california-gov-gavin-newsom-wants-the-state-to-become-the-first-to-create-its-own-generic-drug-la,Benzinga Newsdesk,,,,0,0,6751133f-9f2a-411d-8ed0-8ad659f73073
2020-01-10T08:00:00.000+08:00,40 Stocks Moving In Friday's Mid-Day Session,LLY,https://www.benzinga.com/news/20/01/15106445/40-stocks-moving-in-fridays-mid-day-session,Lisa Levin,,,,0,0,2f541903-fed8-4354-b668-40238ef3c77d
2020-01-10T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/01/15106362/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,,,,0,0,8027159e-9aa4-4798-a94a-9a7321401b41
2020-01-10T08:00:00.000+08:00,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump,LLY,https://www.benzinga.com/news/20/01/15106324/mid-day-market-update-crude-oil-down-over-1-ultragenyx-pharmaceutical-shares-jump,Lisa Levin,,,,0,0,c83050b6-ad04-4aaf-a4c9-3cfce06df6ff
2020-01-10T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share,LLY,https://www.benzinga.com/news/earnings/20/01/15105179/mid-morning-market-update-markets-open-higher-eli-lilly-to-buy-dermira-for-18-75share,Lisa Levin,,,,0,0,55cf507e-18e9-411e-8564-24a62efbea81
2020-01-10T08:00:00.000+08:00,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR",LLY,https://www.benzinga.com/pre-market-outlook/20/01/15104511/benzinga-pros-top-5-stocks-to-watch-for-fri-jan-10-2020-lly-jpm-srne-elan-twtr,Benzinga Newsdesk,,,,0,0,fb60c015-4b95-4098-951d-d548edb924ef
2020-01-10T08:00:00.000+08:00,Eli Lilly Reports Deal To Buy Dermira For $1.1B,LLY,https://www.benzinga.com/general/biotech/20/01/15103879/eli-lilly-reports-deal-to-buy-dermira-for-1-1b,Tanzeel Akhtar,,,,0,0,ae7b3d53-1d4b-4f26-b923-a0e69cc89daa
2020-01-10T08:00:00.000+08:00,33 Stocks Moving in Friday's Pre-Market Session,LLY,https://www.benzinga.com/news/20/01/15103893/33-stocks-moving-in-fridays-pre-market-session,Lisa Levin,,,,0,0,57231f34-2f28-4642-9348-d3190fe9a18b
2020-01-10T08:00:00.000+08:00,Eli Lilly Reports Deal To Buy Dermira For $18.75/Share In Cash,LLY,https://www.benzinga.com/m-a/20/01/15103620/eli-lilly-reports-deal-to-buy-dermira-for-18-75share-in-cash,Benzinga Newsdesk,,,,0,0,b47983e7-f109-4e29-a501-beafa6b6425d
2020-01-10T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/711690/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-711690,Zacks,,,,0,0,4f82ea2a-571a-4d11-b5ec-de62398cf7d9
2020-01-10T08:00:00.000+08:00,Mid-Afternoon Market Update: Dow Falls 90 Points; RumbleON Shares Plummet,LLY,https://www.benzinga.com/news/20/01/15107226/mid-afternoon-market-update-dow-falls-90-points-rumbleon-shares-plummet,Lisa Levin,,,,0,0,5354556d-5561-4303-a0dc-5ad2750b13ef
2020-01-10T08:00:00.000+08:00,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier",LLY,https://www.benzinga.com/general/biotech/20/01/15106641/california-gov-gavin-newsom-wants-the-state-to-become-the-first-to-create-its-own-generic-drug-la,Benzinga Newsdesk,,,,0,0,0f90a323-cc5d-49bc-a1fb-4c02d7ef782c
2020-01-10T08:00:00.000+08:00,40 Stocks Moving In Friday's Mid-Day Session,LLY,https://www.benzinga.com/news/20/01/15106445/40-stocks-moving-in-fridays-mid-day-session,Lisa Levin,,,,0,0,941571df-bd54-48a0-88a0-276ef34fd4a0
2020-01-10T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/20/01/15106362/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,,,,0,0,5fc7fbc1-ac76-47c4-a62e-49c48d791dc2
2020-01-10T08:00:00.000+08:00,Mid-Day Market Update: Crude Oil Down Over 1%; Ultragenyx Pharmaceutical Shares Jump,LLY,https://www.benzinga.com/news/20/01/15106324/mid-day-market-update-crude-oil-down-over-1-ultragenyx-pharmaceutical-shares-jump,Lisa Levin,,,,0,0,56e6085b-cd72-444e-b30f-4f0ff832993c
2020-01-10T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Eli Lilly To Buy Dermira For $18.75/Share,LLY,https://www.benzinga.com/news/earnings/20/01/15105179/mid-morning-market-update-markets-open-higher-eli-lilly-to-buy-dermira-for-18-75share,Lisa Levin,,,,0,0,776be0f9-990b-42a0-a73e-1aeef03e5a6c
2020-01-10T08:00:00.000+08:00,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR",LLY,https://www.benzinga.com/pre-market-outlook/20/01/15104511/benzinga-pros-top-5-stocks-to-watch-for-fri-jan-10-2020-lly-jpm-srne-elan-twtr,Benzinga Newsdesk,,,,0,0,6919c0e4-9c5b-467f-aad5-a08812f5715a
2020-01-10T08:00:00.000+08:00,Eli Lilly Reports Deal To Buy Dermira For $1.1B,LLY,https://www.benzinga.com/general/biotech/20/01/15103879/eli-lilly-reports-deal-to-buy-dermira-for-1-1b,Tanzeel Akhtar,,,,0,0,79c66ecd-55f0-4b03-878f-76b74bee1b84
2020-01-10T08:00:00.000+08:00,33 Stocks Moving in Friday's Pre-Market Session,LLY,https://www.benzinga.com/news/20/01/15103893/33-stocks-moving-in-fridays-pre-market-session,Lisa Levin,,,,0,0,d55d6b8f-801f-472e-99a3-134e53345258
2020-01-10T08:00:00.000+08:00,Eli Lilly Reports Deal To Buy Dermira For $18.75/Share In Cash,LLY,https://www.benzinga.com/m-a/20/01/15103620/eli-lilly-reports-deal-to-buy-dermira-for-18-75share-in-cash,Benzinga Newsdesk,,,,0,0,ab6ea3a5-3a9b-479f-85ae-1dd36d16ed81
2020-01-10T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/711690/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_1-711690,Zacks,,,,0,0,9821eb39-e404-4701-9608-4dc24ac78def
2020-01-09T08:00:00.000+08:00,"Eli Lilly, In Collaboration With Strateos, Inc. Launches Remote-Controlled Robotic Cloud Lab",LLY,https://www.benzinga.com/general/biotech/20/01/15097676/eli-lilly-in-collaboration-with-strateos-inc-launches-remote-controlled-robotic-cloud-lab,Benzinga Newsdesk,,,,0,0,9e326c71-cb23-4469-88c9-39709382c1cd
2020-01-09T08:00:00.000+08:00,Stocks With Rising Composite Ratings: Eli Lilly,LLY,http://www.investors.com/ibd-data-stories/stocks-with-rising-composite-ratings-eli-lilly/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,11f409e7-715b-44a7-8fe2-e4f7ad56e3b7
2020-01-09T08:00:00.000+08:00,"Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up",LLY,http://www.zacks.com/stock/news/709682/verastem-in-licenses-kras-focused-drug-from-chugai-stock-up?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-709682,Zacks,,,,0,0,8ee4cbd1-7ff7-4986-a232-395df15e0f89
2020-01-09T08:00:00.000+08:00,"Eli Lilly, In Collaboration With Strateos, Inc. Launches Remote-Controlled Robotic Cloud Lab",LLY,https://www.benzinga.com/general/biotech/20/01/15097676/eli-lilly-in-collaboration-with-strateos-inc-launches-remote-controlled-robotic-cloud-lab,Benzinga Newsdesk,,,,0,0,921a04a1-d4e5-46c1-a734-97d602f7831e
2020-01-09T08:00:00.000+08:00,Stocks With Rising Composite Ratings: Eli Lilly,LLY,http://www.investors.com/ibd-data-stories/stocks-with-rising-composite-ratings-eli-lilly/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,c42c4350-b2d4-484c-bf3d-809c5f0c7094
2020-01-09T08:00:00.000+08:00,"Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up",LLY,http://www.zacks.com/stock/news/709682/verastem-in-licenses-kras-focused-drug-from-chugai-stock-up?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-709682,Zacks,,,,0,0,048a9e0a-e123-4eb6-a5eb-9d7e24508b65
2020-01-08T08:00:00.000+08:00,"Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company",LLY,http://www.zacks.com/stock/news/708231/zackscom-featured-highlights-include-ruths-hospitality-cadence-design-system-toro-company-and-eli-lilly-and-company?cid=CS-BENZ-FT-press_releases-708231,Zacks,,,,0,0,c10d1980-8ff9-4ade-abf7-7758d4a48ebd
2020-01-08T08:00:00.000+08:00,"Zacks.com featured highlights include: Ruth's Hospitality, Cadence Design System, Toro Company and Eli Lilly and Company",LLY,http://www.zacks.com/stock/news/708231/zackscom-featured-highlights-include-ruths-hospitality-cadence-design-system-toro-company-and-eli-lilly-and-company?cid=CS-BENZ-FT-press_releases-708231,Zacks,,,,0,0,209a7b39-dff6-438c-a549-2826107ab59d
2020-01-06T08:00:00.000+08:00,AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA,LLY,http://www.zacks.com/stock/news/704636/astrazenecas-farxiga-snda-gets-priority-review-status-by-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-704636,Zacks,,,,0,0,d9f2d2dc-134c-4dc3-b9cf-f9ce22666bf0
2020-01-06T08:00:00.000+08:00,AstraZeneca's Farxiga sNDA Gets Priority Review Status by FDA,LLY,http://www.zacks.com/stock/news/704636/astrazenecas-farxiga-snda-gets-priority-review-status-by-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-704636,Zacks,,,,0,0,aea0aadc-0e3f-49eb-9af4-70b630af433c
2020-01-02T08:00:00.000+08:00,3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020,LLY,http://www.zacks.com/stock/news/698989/3-reasons-why-you-should-buy-eli-lilly-lly-stock-in-2020?cid=CS-BENZ-FT-analyst_blog|rank_focused-698989,Zacks,,,,0,0,fe8ff3b5-d2e2-4b51-8cbc-0a46a993f8fe
2020-01-02T08:00:00.000+08:00,3 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2020,LLY,http://www.zacks.com/stock/news/698989/3-reasons-why-you-should-buy-eli-lilly-lly-stock-in-2020?cid=CS-BENZ-FT-analyst_blog|rank_focused-698989,Zacks,,,,0,0,f236454a-53c6-4e89-990a-2255f34aa186
2019-12-31T08:00:00.000+08:00,Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study,LLY,http://www.zacks.com/stock/news/696056/axsomes-axsm-migraine-drug-meets-goals-in-late-stage-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-696056,Zacks,,,,0,0,2f1c7acc-804b-4894-b3e8-85a6e1423f1a
2019-12-31T08:00:00.000+08:00,Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study,LLY,http://www.zacks.com/stock/news/696056/axsomes-axsm-migraine-drug-meets-goals-in-late-stage-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-696056,Zacks,,,,0,0,f73779d6-ad92-474c-9e62-5b9578088580
2019-12-30T08:00:00.000+08:00,U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/19/12/15052912/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Benzinga Newsdesk,,,,0,0,c992a545-ea3e-4975-bafc-d0fa57d409e8
2019-12-30T08:00:00.000+08:00,"UPDATE: Argus Maintains Buy On Eli Lilly, Raises Target To $165 Notes 'We see increased volume and expanded indications for existing drugs, along with potential regulatory approvals, as cat-alysts for growth in 2020'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15051790/update-argus-maintains-buy-on-eli-lilly-raises-target-to-165-notes-we-see-increased,Benzinga_Newsdesk,,,,0,0,bd3ec2d4-a469-461e-8d21-b074e582936e
2019-12-30T08:00:00.000+08:00,10 Biggest Price Target Changes For Monday,LLY,https://www.benzinga.com/analyst-ratings/price-target/19/12/15051040/10-biggest-price-target-changes-for-monday,Lisa Levin,,,,0,0,3d5b6b58-cc63-4590-a65f-b67bc412664f
2019-12-30T08:00:00.000+08:00,"Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $165",LLY,https://www.benzinga.com/news/19/12/15050619/argus-research-maintains-buy-on-eli-lilly-raises-price-target-to-165,Vick Meyer,,,,0,0,1b06c57d-f2ea-4e79-af05-a258327c72de
2019-12-30T08:00:00.000+08:00,Lilly Opens Phase 3 Clinical Trial In RET-Mutant Medullary Thyroid Cancer,LLY,https://www.benzinga.com/general/biotech/19/12/15050433/lilly-opens-phase-3-clinical-trial-in-ret-mutant-medullary-thyroid-cancer,Benzinga Newsdesk,,,,0,0,bbcb89c0-ee04-43bf-a9e7-e2527c0d51e5
2019-12-30T08:00:00.000+08:00,U.S. District Court Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/19/12/15052912/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Benzinga Newsdesk,,,,0,0,3f0e3c75-3034-4c93-8d68-c8d5e5f52728
2019-12-30T08:00:00.000+08:00,"UPDATE: Argus Maintains Buy On Eli Lilly, Raises Target To $165 Notes 'We see increased volume and expanded indications for existing drugs, along with potential regulatory approvals, as cat-alysts for growth in 2020'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15051790/update-argus-maintains-buy-on-eli-lilly-raises-target-to-165-notes-we-see-increased,Benzinga_Newsdesk,,,,0,0,59eb5bc0-3ef3-4df7-9c54-a40ee270a9f7
2019-12-30T08:00:00.000+08:00,10 Biggest Price Target Changes For Monday,LLY,https://www.benzinga.com/analyst-ratings/price-target/19/12/15051040/10-biggest-price-target-changes-for-monday,Lisa Levin,,,,0,0,399fe3eb-d1cf-42c5-bc8f-1c90c54aa85e
2019-12-30T08:00:00.000+08:00,"Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $165",LLY,https://www.benzinga.com/news/19/12/15050619/argus-research-maintains-buy-on-eli-lilly-raises-price-target-to-165,Vick Meyer,,,,0,0,51562c83-cf6f-4454-ad92-221ae18cdefe
2019-12-30T08:00:00.000+08:00,Lilly Opens Phase 3 Clinical Trial In RET-Mutant Medullary Thyroid Cancer,LLY,https://www.benzinga.com/general/biotech/19/12/15050433/lilly-opens-phase-3-clinical-trial-in-ret-mutant-medullary-thyroid-cancer,Benzinga Newsdesk,,,,0,0,3280a2bb-6c28-4a76-97d8-d64f6d2d69d8
2019-12-29T08:00:00.000+08:00,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",LLY,https://www.benzinga.com/general/biotech/19/12/15047719/week-ahead-in-biotech-pdufa-date-ahead-for-astra-zeneca-mercks-lynparza-pending-clinical-readouts,Shanthi Rexaline,,,,0,0,0b9fcc0d-281a-4522-a45c-9aac7055f1e7
2019-12-29T08:00:00.000+08:00,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",LLY,https://www.benzinga.com/general/biotech/19/12/15047719/week-ahead-in-biotech-pdufa-date-ahead-for-astra-zeneca-mercks-lynparza-pending-clinical-readouts,Shanthi Rexaline,,,,0,0,df57e3b4-3a74-4c4b-81cc-130a9f156428
2019-12-26T08:00:00.000+08:00,Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance,LLY,http://www.zacks.com/stock/news/688652/incyte-incy-surges-44-ytd-on-jakafis-strong-performance?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-688652,Zacks,,,,0,0,8089d329-1315-4e40-9bd2-e1017531d09c
2019-12-26T08:00:00.000+08:00,Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance,LLY,http://www.zacks.com/stock/news/688652/incyte-incy-surges-44-ytd-on-jakafis-strong-performance?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-688652,Zacks,,,,0,0,f4e72073-135b-4259-a4c9-149aed03cd9b
2019-12-24T08:00:00.000+08:00,Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy,LLY,http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-685884,Zacks,,,,0,0,59294394-0ee0-4787-89a1-ba00abbe6719
2019-12-24T08:00:00.000+08:00,Buy These 5 Low-Beta Stocks to Counter Market Volatility,LLY,http://www.zacks.com/stock/news/685699/buy-these-5-low-beta-stocks-to-counter-market-volatility?cid=CS-BENZ-FT-analyst_blog|rw-685699,Zacks,,,,0,0,4318390b-098c-4652-a88f-cf913d1207ba
2019-12-24T08:00:00.000+08:00,Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy,LLY,http://www.zacks.com/stock/news/685884/allergan-agn-gets-fda-approval-for-migraine-drug-ubrelvy?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-685884,Zacks,,,,0,0,e1a5e4f2-3979-45fe-aba8-c5d4c1eff343
2019-12-24T08:00:00.000+08:00,Buy These 5 Low-Beta Stocks to Counter Market Volatility,LLY,http://www.zacks.com/stock/news/685699/buy-these-5-low-beta-stocks-to-counter-market-volatility?cid=CS-BENZ-FT-analyst_blog|rw-685699,Zacks,,,,0,0,eaf94b37-2a1a-45a5-9157-8f4581eb8080
2019-12-23T08:00:00.000+08:00,A Perspective On Biopharma's Record M&A Run In 2019,LLY,https://www.benzinga.com/general/biotech/19/12/14981726/a-perspective-on-biopharmas-record-m-a-run-in-2019,Shanthi Rexaline,,,,0,0,40d19431-e520-4b2b-973a-424924e3238a
2019-12-23T08:00:00.000+08:00,"PreMarket Prep Recap: $TSLAQ Crowd Continues To Be Punished, Eli Lilly's Incredible Friday Open",LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/12/15034287/premarket-prep-recap-tslaq-crowd-continues-to-be-punished-eli-lillys-incredible-friday-o,Joel Elconin,,,,0,0,bdafd7c3-f3b4-4b32-b642-a48fdaa992bf
2019-12-23T08:00:00.000+08:00,"Top Stock Reports for SAP, AbbVie & Sinopec",LLY,http://www.zacks.com/research-daily/684233/top-stock-reports-for-sap-abbvie-sinopec?cid=CS-BENZ-FT-research_daily-684233,Zacks,,,,0,0,2df9e07c-a27c-4103-b1f6-ebe1bd52dfa1
2019-12-23T08:00:00.000+08:00,A Perspective On Biopharma's Record M&A Run In 2019,LLY,https://www.benzinga.com/general/biotech/19/12/14981726/a-perspective-on-biopharmas-record-m-a-run-in-2019,Shanthi Rexaline,,,,0,0,1bcfdee5-51b9-42db-9486-123d2e4cf114
2019-12-23T08:00:00.000+08:00,"PreMarket Prep Recap: $TSLAQ Crowd Continues To Be Punished, Eli Lilly's Incredible Friday Open",LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/12/15034287/premarket-prep-recap-tslaq-crowd-continues-to-be-punished-eli-lillys-incredible-friday-o,Joel Elconin,,,,0,0,2a0e6088-af80-4d06-b04f-4fd906666311
2019-12-23T08:00:00.000+08:00,"Top Stock Reports for SAP, AbbVie & Sinopec",LLY,http://www.zacks.com/research-daily/684233/top-stock-reports-for-sap-abbvie-sinopec?cid=CS-BENZ-FT-research_daily-684233,Zacks,,,,0,0,8fe2cd74-6d58-4af6-ad68-09f20b216a17
2019-12-20T08:00:00.000+08:00,PreMarket Prep Recap: Buyers And More Buyers On Quadruple Witch Expiration,LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/12/15027267/premarket-prep-recap-buyers-and-more-buyers-on-quadruple-witch-expiration,Joel Elconin,,,,0,0,875aff6a-ff0f-4746-9398-a6a723b83876
2019-12-20T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/19/12/15026655/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,,,,0,0,c33fa7bb-c37c-4e0b-8444-95c3c1d03de7
2019-12-20T08:00:00.000+08:00,"S&P 500, Transports Lead Market; These 2 Stocks Drag The IBD 50",LLY,http://www.investors.com/market-trend/stock-market-today/sp-500-today-leads-stock-market-ibd-50/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,fb9d2af7-3abc-4d69-80f5-91e1e1939fd2
2019-12-20T08:00:00.000+08:00,"Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs",LLY,http://www.zacks.com/stock/news/679924/pharma-stock-roundup-lillys-upbeat-2020-outlook-fda-nod-for-pfe-mrks-drugs?cid=CS-BENZ-FT-analyst_blog|stock_roundup-679924,Zacks,,,,0,0,8f319481-ee9b-49c5-94c8-f7d7bedf4c4e
2019-12-20T08:00:00.000+08:00,Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib,LLY,http://www.zacks.com/stock/news/679808/gilead-gild-files-nda-with-fda-for-ra-candidate-filgotinib?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-679808,Zacks,,,,0,0,c5bcdcc2-0fb6-40fd-b3cb-c2a22aadef42
2019-12-20T08:00:00.000+08:00,PreMarket Prep Recap: Buyers And More Buyers On Quadruple Witch Expiration,LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/12/15027267/premarket-prep-recap-buyers-and-more-buyers-on-quadruple-witch-expiration,Joel Elconin,,,,0,0,f1a9c58d-744f-4b52-aecf-f232f5b84313
2019-12-20T08:00:00.000+08:00,Stocks That Hit 52-Week Highs On Friday,LLY,https://www.benzinga.com/news/19/12/15026655/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,,,,0,0,967c7a3d-c336-47ce-b3bb-5591e0eb09c1
2019-12-20T08:00:00.000+08:00,"S&P 500, Transports Lead Market; These 2 Stocks Drag The IBD 50",LLY,http://www.investors.com/market-trend/stock-market-today/sp-500-today-leads-stock-market-ibd-50/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,57f684d7-c9bf-4271-8375-960b1914434f
2019-12-20T08:00:00.000+08:00,"Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs",LLY,http://www.zacks.com/stock/news/679924/pharma-stock-roundup-lillys-upbeat-2020-outlook-fda-nod-for-pfe-mrks-drugs?cid=CS-BENZ-FT-analyst_blog|stock_roundup-679924,Zacks,,,,0,0,bd70a7dd-33af-42ae-9df9-32c400edfae3
2019-12-20T08:00:00.000+08:00,Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib,LLY,http://www.zacks.com/stock/news/679808/gilead-gild-files-nda-with-fda-for-ra-candidate-filgotinib?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-679808,Zacks,,,,0,0,546cdc0c-1017-4803-8630-29b2ea975aa4
2019-12-19T08:00:00.000+08:00,Eli Lilly Sees IBD RS Rating Climb To 72,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-sees-ibd-rs-rating-climb-to-72/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,c1f08a11-446a-4a69-869e-36dd40b9efc7
2019-12-19T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland",LLY,http://www.zacks.com/stock/news/678361/the-zacks-analyst-blog-highlights-johnson-johnson-eli-lilly-pnc-financial-eog-resources-and-archer-daniels-midland?cid=CS-BENZ-FT-press_releases-678361,Zacks,,,,0,0,c917c347-5298-4dcc-a643-00776891962e
2019-12-19T08:00:00.000+08:00,Eli Lilly Sees IBD RS Rating Climb To 72,LLY,http://www.investors.com/ibd-data-stories/eli-lilly-sees-ibd-rs-rating-climb-to-72/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,7dd6ffad-b9d4-4a2e-b37a-7da0907fc88e
2019-12-19T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland",LLY,http://www.zacks.com/stock/news/678361/the-zacks-analyst-blog-highlights-johnson-johnson-eli-lilly-pnc-financial-eog-resources-and-archer-daniels-midland?cid=CS-BENZ-FT-press_releases-678361,Zacks,,,,0,0,dacb3ed3-547d-402e-80da-63f1bb2ace33
2019-12-18T08:00:00.000+08:00,"UPDATE: Morgan Stanley On Eli Lilly Notes 'While Novo appears set to win market share in diabetes, we still expect strong and durable Lilly franchise growth, including benefits from initial high-dose Trulicity sales in 2021 and tirzepatide in 2022'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15012286/update-morgan-stanley-on-eli-lilly-notes-while-novo-appears-set-to-win-market-share,Benzinga_Newsdesk,,,,0,0,a62d06fa-686b-4523-af08-1d2e209e0dc5
2019-12-18T08:00:00.000+08:00,"UPDATE: Morgan Stanley Upgrades Eli Lilly To Overweight, Raises Target To $150 Notes 'We expect LLY shares to outperform, driven by strong growth and pipeline optionality'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15012285/update-morgan-stanley-upgrades-eli-lilly-to-overweight-raises-target-to-150-notes-w,Benzinga_Newsdesk,,,,0,0,2505b9cc-200a-434d-9ca7-42cc7aab0165
2019-12-18T08:00:00.000+08:00,"Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15010335/eli-lilly-ceo-hits-back-at-elizabeth-warren-blames-pbms-insurance-for-blocking-affo,Elizabeth Balboa,,,,0,0,a5f07017-e371-4bd6-b156-68067227fba6
2019-12-18T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For December 18, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/12/15011287/benzingas-top-upgrades-downgrades-for-december-18-2019,Lisa Levin,,,,0,0,f1c47af5-4c59-4550-a943-91831c25c2e5
2019-12-18T08:00:00.000+08:00,Eli Lilly And Co shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from $116 to $150 per share.,LLY,https://www.benzinga.com/wiim/19/12/15010613/eli-lilly-and-co-shares-are-trading-higher-after-morgan-stanley-upgraded-the-stock-from-equal-weight,Benzinga Newsdesk,,,,0,0,12f388b8-428f-4499-b7d7-2eeb8f83f7b5
2019-12-18T08:00:00.000+08:00,"JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $150",LLY,https://www.benzinga.com/news/19/12/15010028/jp-morgan-maintains-overweight-on-eli-lilly-raises-price-target-to-150,Vick Meyer,,,,0,0,f2370b48-c9b7-4d9d-8d77-dfec4f0c30d6
2019-12-18T08:00:00.000+08:00,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/12/15009648/30-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,410fb371-ff44-4f6a-975d-5a2770455dca
2019-12-18T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Price Target to $150",LLY,https://www.benzinga.com/news/19/12/15009322/morgan-stanley-upgrades-eli-lilly-to-overweight-raises-price-target-to-150,Benzinga_Newsdesk,,,,0,0,fd3a471f-4ac2-458e-bade-981c6774fcfe
2019-12-18T08:00:00.000+08:00,Lilly Announces Launch Of TRIUMPH Real-World Evidence Study Of Emgality For Migraine Prevention,LLY,https://www.benzinga.com/general/biotech/19/12/15009001/lilly-announces-launch-of-triumph-real-world-evidence-study-of-emgality-for-migraine-prevention,Benzinga Newsdesk,,,,0,0,8ba35b42-2fe5-42c9-b583-fdaf9af89e35
2019-12-18T08:00:00.000+08:00,"Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial",LLY,http://www.zacks.com/research-daily/676738/top-stock-reports-for-johnson-johnson-eli-lilly-pnc-financial?cid=CS-BENZ-FT-research_daily-676738,Zacks,,,,0,0,efa529b8-8fc7-41f6-bda4-19a121be36c2
2019-12-18T08:00:00.000+08:00,Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU,LLY,http://www.zacks.com/stock/news/676816/dicernas-drna-a1at-candidate-gets-orphan-drug-tag-in-eu?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-676816,Zacks,,,,0,0,dee9af17-33b2-4c4c-882f-dda3c9d0dae8
2019-12-18T08:00:00.000+08:00,Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020,LLY,http://www.zacks.com/stock/news/676513/lillys-stock-up-on-upbeat-sales-profit-outlook-for-2020?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-676513,Zacks,,,,0,0,e25ce336-e762-4ede-88d5-29eab7bdd6ed
2019-12-18T08:00:00.000+08:00,"UPDATE: Morgan Stanley On Eli Lilly Notes 'While Novo appears set to win market share in diabetes, we still expect strong and durable Lilly franchise growth, including benefits from initial high-dose Trulicity sales in 2021 and tirzepatide in 2022'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15012286/update-morgan-stanley-on-eli-lilly-notes-while-novo-appears-set-to-win-market-share,Benzinga_Newsdesk,,,,0,0,bd228875-e49d-4d82-84bb-56aeddcc86c1
2019-12-18T08:00:00.000+08:00,"UPDATE: Morgan Stanley Upgrades Eli Lilly To Overweight, Raises Target To $150 Notes 'We expect LLY shares to outperform, driven by strong growth and pipeline optionality'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15012285/update-morgan-stanley-upgrades-eli-lilly-to-overweight-raises-target-to-150-notes-w,Benzinga_Newsdesk,,,,0,0,5b194b83-8ef7-4a58-888b-f9be76d7ab9e
2019-12-18T08:00:00.000+08:00,"Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/15010335/eli-lilly-ceo-hits-back-at-elizabeth-warren-blames-pbms-insurance-for-blocking-affo,Elizabeth Balboa,,,,0,0,8d53cc5a-5f58-4084-bc42-2e7b076881c7
2019-12-18T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For December 18, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/12/15011287/benzingas-top-upgrades-downgrades-for-december-18-2019,Lisa Levin,,,,0,0,482e16a8-b1f6-4bf1-ac8c-ea977264a54b
2019-12-18T08:00:00.000+08:00,Eli Lilly And Co shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised the price target from $116 to $150 per share.,LLY,https://www.benzinga.com/wiim/19/12/15010613/eli-lilly-and-co-shares-are-trading-higher-after-morgan-stanley-upgraded-the-stock-from-equal-weight,Benzinga Newsdesk,,,,0,0,9992fee2-1745-4039-8cee-f31f92ef41de
2019-12-18T08:00:00.000+08:00,"JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $150",LLY,https://www.benzinga.com/news/19/12/15010028/jp-morgan-maintains-overweight-on-eli-lilly-raises-price-target-to-150,Vick Meyer,,,,0,0,8f70d343-80fd-453c-ac3d-83f36230a7bb
2019-12-18T08:00:00.000+08:00,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/12/15009648/30-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,838ddbdb-5caf-4137-9704-532a6c17ffb4
2019-12-18T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Price Target to $150",LLY,https://www.benzinga.com/news/19/12/15009322/morgan-stanley-upgrades-eli-lilly-to-overweight-raises-price-target-to-150,Benzinga_Newsdesk,,,,0,0,8081a1e4-4cbb-4d09-8ea1-6bc8e95a910a
2019-12-18T08:00:00.000+08:00,Lilly Announces Launch Of TRIUMPH Real-World Evidence Study Of Emgality For Migraine Prevention,LLY,https://www.benzinga.com/general/biotech/19/12/15009001/lilly-announces-launch-of-triumph-real-world-evidence-study-of-emgality-for-migraine-prevention,Benzinga Newsdesk,,,,0,0,9675bb5f-c2f8-4856-beaf-5dd709b7ab8d
2019-12-18T08:00:00.000+08:00,"Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial",LLY,http://www.zacks.com/research-daily/676738/top-stock-reports-for-johnson-johnson-eli-lilly-pnc-financial?cid=CS-BENZ-FT-research_daily-676738,Zacks,,,,0,0,3ca90d99-0be2-432a-bf2a-bd96995cb0e3
2019-12-18T08:00:00.000+08:00,Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU,LLY,http://www.zacks.com/stock/news/676816/dicernas-drna-a1at-candidate-gets-orphan-drug-tag-in-eu?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-676816,Zacks,,,,0,0,44182615-8d48-49b7-99da-4ba125d51aa4
2019-12-18T08:00:00.000+08:00,Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020,LLY,http://www.zacks.com/stock/news/676513/lillys-stock-up-on-upbeat-sales-profit-outlook-for-2020?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-676513,Zacks,,,,0,0,b2280f5c-f518-432d-8a5e-c680560e48a9
2019-12-17T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company issued upbeat FY20 guidance.,LLY,https://www.benzinga.com/wiim/19/12/15004129/eli-lilly-shares-are-trading-higher-after-the-company-issued-upbeat-fy20-guidance,Benzinga Newsdesk,,,,0,0,5260deb4-3ae3-4aaa-86a5-8a6ead04af7e
2019-12-17T08:00:00.000+08:00,Eli Lilly Executive Says Reasonable To Expect Net Price Declines In The Low Single-Digit Level Going Forward,LLY,https://www.benzinga.com/news/19/12/15003142/eli-lilly-executive-says-reasonable-to-expect-net-price-declines-in-the-low-single-digit-level-going,Benzinga Newsdesk,,,,0,0,8649ab47-cc7d-4a41-96b5-1fbb426ebaee
2019-12-17T08:00:00.000+08:00,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 17, 2019: BA, AAPL, BLPH, JNJ, LLY",LLY,https://www.benzinga.com/pre-market-outlook/19/12/15002311/benzinga-pros-top-5-stocks-to-watch-for-tues-dec-17-2019-ba-aapl-blph-jnj-lly,Benzinga Newsdesk,,,,0,0,c157a2d2-ae04-4544-92e8-8dbc0df1244c
2019-12-17T08:00:00.000+08:00,"Lilly Reaffirms Prelim. FY19 Adj. EPS Guidance $5.75-$5.85 vs $5.81 Est., Sales Guidance $22B-$22.5B vs $22.16B Est.",LLY,https://www.benzinga.com/news/19/12/15001141/lilly-reaffirms-prelim-fy19-adj-eps-guidance-5-75-5-85-vs-5-81-est-sales-guidance-22b-22-5b-vs-22-16,Benzinga Newsdesk,,,,0,0,7e06b43d-6151-40e7-b5ec-a5cb0a23e2ed
2019-12-17T08:00:00.000+08:00,"Lilly Sees FY20 Adj. EPS $6.70-$6.80 vs $6.61 Est., Sales $23.6B-$24.1B vs $23.52B Est.",LLY,https://www.benzinga.com/news/19/12/15001136/lilly-sees-fy20-adj-eps-6-70-6-80-vs-6-61-est-sales-23-6b-24-1b-vs-23-52b-est,Benzinga Newsdesk,,,,0,0,a1fcd08e-5ec9-4f21-8102-a3ffd7a030cc
2019-12-17T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company issued upbeat FY20 guidance.,LLY,https://www.benzinga.com/wiim/19/12/15004129/eli-lilly-shares-are-trading-higher-after-the-company-issued-upbeat-fy20-guidance,Benzinga Newsdesk,,,,0,0,36c91239-d422-4f20-a9ad-5f9d16fd28de
2019-12-17T08:00:00.000+08:00,Eli Lilly Executive Says Reasonable To Expect Net Price Declines In The Low Single-Digit Level Going Forward,LLY,https://www.benzinga.com/news/19/12/15003142/eli-lilly-executive-says-reasonable-to-expect-net-price-declines-in-the-low-single-digit-level-going,Benzinga Newsdesk,,,,0,0,f55d61d3-dbaf-4a1a-b10e-e83c1a66fae7
2019-12-17T08:00:00.000+08:00,"Benzinga Pro's Top 5 Stocks To Watch For Tues., Dec. 17, 2019: BA, AAPL, BLPH, JNJ, LLY",LLY,https://www.benzinga.com/pre-market-outlook/19/12/15002311/benzinga-pros-top-5-stocks-to-watch-for-tues-dec-17-2019-ba-aapl-blph-jnj-lly,Benzinga Newsdesk,,,,0,0,74e3bc92-a5e3-4356-99e8-b01b533e8c1a
2019-12-17T08:00:00.000+08:00,"Lilly Reaffirms Prelim. FY19 Adj. EPS Guidance $5.75-$5.85 vs $5.81 Est., Sales Guidance $22B-$22.5B vs $22.16B Est.",LLY,https://www.benzinga.com/news/19/12/15001141/lilly-reaffirms-prelim-fy19-adj-eps-guidance-5-75-5-85-vs-5-81-est-sales-guidance-22b-22-5b-vs-22-16,Benzinga Newsdesk,,,,0,0,f9177e94-1580-4657-8001-b0fa28cb1592
2019-12-17T08:00:00.000+08:00,"Lilly Sees FY20 Adj. EPS $6.70-$6.80 vs $6.61 Est., Sales $23.6B-$24.1B vs $23.52B Est.",LLY,https://www.benzinga.com/news/19/12/15001136/lilly-sees-fy20-adj-eps-6-70-6-80-vs-6-61-est-sales-23-6b-24-1b-vs-23-52b-est,Benzinga Newsdesk,,,,0,0,40333d11-0dc6-431f-9dbc-aafe7a3535e4
2019-12-16T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.645 To $0.74/Share,LLY,https://www.benzinga.com/news/19/12/14998960/eli-lilly-raises-qtr-dividend-from-0-645-to-0-74share,Benzinga Newsdesk,,,,0,0,03055bcf-47e6-4dbe-84d5-3f4c56c5f1bc
2019-12-16T08:00:00.000+08:00,DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System,LLY,https://www.benzinga.com/node/14993782,Benzinga Newsdesk,,,,0,0,24dc0f3e-5e63-428f-8d1c-acbcaa645dd0
2019-12-16T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.645 To $0.74/Share,LLY,https://www.benzinga.com/news/19/12/14998960/eli-lilly-raises-qtr-dividend-from-0-645-to-0-74share,Benzinga Newsdesk,,,,0,0,b7617e9a-fa6e-42db-ace7-e98d7de448e4
2019-12-16T08:00:00.000+08:00,DexCom Says Eli Lilly Will Integrate its Continuous Glucose Monitoring into Lilly's Personalized Diabetes Management System,LLY,https://www.benzinga.com/node/14993782,Benzinga Newsdesk,,,,0,0,e1b10542-c44d-464a-b94a-0662249b1f3d
2019-12-15T08:00:00.000+08:00,Boris Bounce; Trump Tripwire,LLY,https://www.benzinga.com/node/14992968,TalkMarkets,,,,0,0,406be083-8e55-4251-9d80-788138496a21
2019-12-15T08:00:00.000+08:00,Investors Dig Into Trade War Halt (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4312534-investors-dig-trade-war-halt-stocks-to-watch-podcast?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,df13d186-0346-4a47-86d0-b80d41171e6b
2019-12-15T08:00:00.000+08:00,Boris Bounce; Trump Tripwire,LLY,https://www.benzinga.com/node/14992968,TalkMarkets,,,,0,0,0f309516-792b-4b97-88bc-4f91c3d2268d
2019-12-15T08:00:00.000+08:00,Investors Dig Into Trade War Halt (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4312534-investors-dig-trade-war-halt-stocks-to-watch-podcast?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,c49db21b-0654-41b4-bc7e-dba458651e27
2019-12-14T08:00:00.000+08:00,Stocks To Watch: Investors Dig Into Trade War Halt,LLY,https://seekingalpha.com/article/4312511-stocks-to-watch-investors-dig-trade-war-halt?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,d092e49a-e02c-45cd-87da-394c14484dbf
2019-12-14T08:00:00.000+08:00,Stocks To Watch: Investors Dig Into Trade War Halt,LLY,https://seekingalpha.com/article/4312511-stocks-to-watch-investors-dig-trade-war-halt?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,4a246296-f8ab-4bac-963f-4d8e66caad58
2019-12-13T08:00:00.000+08:00,'Fast Money' Picks For December 13,LLY,https://www.benzinga.com/media/19/12/14988782/fast-money-picks-for-december-13,Craig Jones,,,,0,0,491be742-7a94-4345-b208-ed3c7d63ef98
2019-12-13T08:00:00.000+08:00,"Boehringer Ingelheim, Lilly Offer Update On Jardiance Phase 3 Exercise Ability Studies In Chronic Heart Failure",LLY,https://www.benzinga.com/news/19/12/14986985/boehringer-ingelheim-lilly-offer-update-on-jardiance-phase-3-exercise-ability-studies-in-chronic-hea,Benzinga Newsdesk,,,,0,0,2c792133-aec0-483b-80b1-83a4dcfad607
2019-12-13T08:00:00.000+08:00,Lilly Reports CHMP Issues Positive Opinion Related To Expanded Label Of CYRAMZA To Include Results From RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/news/19/12/14986467/lilly-reports-chmp-issues-positive-opinion-related-to-expanded-label-of-cyramza-to-include-results-f,Benzinga Newsdesk,,,,0,0,0452fda3-c9fe-413e-842d-a13784202eba
2019-12-13T08:00:00.000+08:00,"Merger Mating Dance: We Explore Who Gets The Rose Next - Sectors And Targets, Part I",LLY,https://seekingalpha.com/article/4312437-merger-mating-dance-explore-who-gets-rose-next-sectors-and-targets-part-i?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,9e18b12f-dbac-4b9f-97c5-9af457b46f6d
2019-12-13T08:00:00.000+08:00,Eagle Pharma on go to launch Alimta alternative in early 2022,LLY,https://seekingalpha.com/news/3526258-eagle-pharma-on-go-to-launch-alimta-alternative-in-early-2022?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,56489da9-c03c-486f-81c4-232542dfaf98
2019-12-13T08:00:00.000+08:00,Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies ...,LLY,https://www.benzinga.com/node/14989381,GuruFocus,,,,0,0,5cd7e0a3-eb3b-40df-a9c7-c6603482588d
2019-12-13T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study",LLY,http://www.zacks.com/stock/news/668756/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study?cid=CS-BENZ-FT-analyst_blog|stock_roundup-668756,Zacks,,,,0,0,d1a14cb6-cfe4-490e-bbbe-6fb9fbed307b
2019-12-13T08:00:00.000+08:00,CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from ...,LLY,https://www.benzinga.com/node/14987060,GuruFocus,,,,0,0,12282c19-43d0-49e5-8e18-69ab5f6c8e87
2019-12-13T08:00:00.000+08:00,European advisory group backs expanded use of Lilly's Cyramza,LLY,https://seekingalpha.com/news/3526129-european-advisory-group-backs-expanded-use-of-lillys-cyramza?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,377dda7f-cf14-4d85-96e6-f81e21321838
2019-12-13T08:00:00.000+08:00,'Fast Money' Picks For December 13,LLY,https://www.benzinga.com/media/19/12/14988782/fast-money-picks-for-december-13,Craig Jones,,,,0,0,ca85f67d-28e6-40ef-8764-aea84874c3f4
2019-12-13T08:00:00.000+08:00,"Boehringer Ingelheim, Lilly Offer Update On Jardiance Phase 3 Exercise Ability Studies In Chronic Heart Failure",LLY,https://www.benzinga.com/news/19/12/14986985/boehringer-ingelheim-lilly-offer-update-on-jardiance-phase-3-exercise-ability-studies-in-chronic-hea,Benzinga Newsdesk,,,,0,0,9a2218b2-203a-4fa1-a5a7-c989812e8222
2019-12-13T08:00:00.000+08:00,Lilly Reports CHMP Issues Positive Opinion Related To Expanded Label Of CYRAMZA To Include Results From RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/news/19/12/14986467/lilly-reports-chmp-issues-positive-opinion-related-to-expanded-label-of-cyramza-to-include-results-f,Benzinga Newsdesk,,,,0,0,04f73b0e-8083-4dc4-b424-7953c05a5453
2019-12-13T08:00:00.000+08:00,"Merger Mating Dance: We Explore Who Gets The Rose Next - Sectors And Targets, Part I",LLY,https://seekingalpha.com/article/4312437-merger-mating-dance-explore-who-gets-rose-next-sectors-and-targets-part-i?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,57b3bf21-2ae9-4e1f-968a-d56985af448f
2019-12-13T08:00:00.000+08:00,Eagle Pharma on go to launch Alimta alternative in early 2022,LLY,https://seekingalpha.com/news/3526258-eagle-pharma-on-go-to-launch-alimta-alternative-in-early-2022?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,2ab18875-51d1-42d4-95b3-752cf65bdf85
2019-12-13T08:00:00.000+08:00,Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies ...,LLY,https://www.benzinga.com/node/14989381,GuruFocus,,,,0,0,b247b46e-ce40-4156-8d4a-ee610d159251
2019-12-13T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study",LLY,http://www.zacks.com/stock/news/668756/pharma-stock-roundup-mrk-sny-to-buy-cancer-firms-lly-starts-new-lung-cancer-study?cid=CS-BENZ-FT-analyst_blog|stock_roundup-668756,Zacks,,,,0,0,058bd519-31de-47cf-8dba-edd6d506a8db
2019-12-13T08:00:00.000+08:00,CHMP Issues Positive Opinion to Expand CYRAMZA® (ramucirumab) Label to Include Results from ...,LLY,https://www.benzinga.com/node/14987060,GuruFocus,,,,0,0,b2879586-c911-44fb-9742-b3feb363ea23
2019-12-13T08:00:00.000+08:00,European advisory group backs expanded use of Lilly's Cyramza,LLY,https://seekingalpha.com/news/3526129-european-advisory-group-backs-expanded-use-of-lillys-cyramza?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,4161bed3-c951-403b-910b-43a0d336f48f
2019-12-12T08:00:00.000+08:00,Elanco Animal Health: Still Not Very Healthy,LLY,https://seekingalpha.com/article/4312269-elanco-animal-health-still-not-healthy?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,efe17711-0dd4-490c-992f-01145b81bc8d
2019-12-12T08:00:00.000+08:00,"House passes drug pricing bill, Senate unlikely to support",LLY,https://seekingalpha.com/news/3526005-house-passes-drug-pricing-bill-senate-unlikely-to-support?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,fc721d96-ffaa-4711-9494-8d4ef5a3fb7d
2019-12-12T08:00:00.000+08:00,Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor,LLY,http://www.zacks.com/stock/news/667111/lilly-initiates-phase-iii-lung-cancer-study-on-ret-inhibitor?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-667111,Zacks,,,,0,0,26949d14-9db3-4690-aeab-34db77343287
2019-12-12T08:00:00.000+08:00,Elanco Animal Health: Still Not Very Healthy,LLY,https://seekingalpha.com/article/4312269-elanco-animal-health-still-not-healthy?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,b8a4bfe0-ef99-469c-ab3d-3bb70d86618b
2019-12-12T08:00:00.000+08:00,"House passes drug pricing bill, Senate unlikely to support",LLY,https://seekingalpha.com/news/3526005-house-passes-drug-pricing-bill-senate-unlikely-to-support?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,3461abf9-d229-4bcd-8795-a9b174e7a911
2019-12-12T08:00:00.000+08:00,Lilly Initiates Phase III Lung Cancer Study on RET Inhibitor,LLY,http://www.zacks.com/stock/news/667111/lilly-initiates-phase-iii-lung-cancer-study-on-ret-inhibitor?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-667111,Zacks,,,,0,0,7622053c-ff81-4e61-9e4c-7de8bb9c8019
2019-12-11T08:00:00.000+08:00,Lilly Opens Randomized Phase 3 Clinical Trial Of LOXO-292 In Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/general/biotech/19/12/14969892/lilly-opens-randomized-phase-3-clinical-trial-of-loxo-292-in-treatment-na-ve-ret-fusion-positive-,Benzinga Newsdesk,,,,0,0,e006face-b157-4139-8a5e-d47ab5593412
2019-12-11T08:00:00.000+08:00,Lilly Opens First Ever Randomized Phase ' Clinical Trial in Treatment-Naïve RET ...,LLY,https://www.benzinga.com/node/14970681,GuruFocus,,,,0,0,a7a8b9d6-9e12-4d46-b0a5-8958a1bfa1d5
2019-12-11T08:00:00.000+08:00,Lilly opens late-stage RET fusion-positive NSCLC study,LLY,https://seekingalpha.com/news/3525422-lilly-opens-late-stage-ret-fusion-positive-nsclc-study?source=partner_benzinga,Seeking Alpha,,,,0,0,d9a992a6-0650-42e7-a605-ec3de5351aff
2019-12-11T08:00:00.000+08:00,Lilly Opens Randomized Phase 3 Clinical Trial Of LOXO-292 In Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/general/biotech/19/12/14969892/lilly-opens-randomized-phase-3-clinical-trial-of-loxo-292-in-treatment-na-ve-ret-fusion-positive-,Benzinga Newsdesk,,,,0,0,addfda05-47d4-4843-858a-b3e43d5339b1
2019-12-11T08:00:00.000+08:00,Lilly Opens First Ever Randomized Phase ' Clinical Trial in Treatment-Naïve RET ...,LLY,https://www.benzinga.com/node/14970681,GuruFocus,,,,0,0,3da55e30-813f-4969-ba4e-aedb1b6f3ac2
2019-12-11T08:00:00.000+08:00,Lilly opens late-stage RET fusion-positive NSCLC study,LLY,https://seekingalpha.com/news/3525422-lilly-opens-late-stage-ret-fusion-positive-nsclc-study?source=partner_benzinga,Seeking Alpha,,,,0,0,faf7abd6-5e31-4fdc-abed-8d2ac1665220
2019-12-10T08:00:00.000+08:00,Aptose Shoots Up As Investors Focus On Reversible BTK Inhibitors,LLY,https://seekingalpha.com/article/4311702-aptose-shoots-up-investors-focus-on-reversible-btk-inhibitors?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,b0b0ee66-eba1-4de5-b0d2-6eb0720f1bf5
2019-12-10T08:00:00.000+08:00,Sanofi to exit diabetes research; shares up 4% premarket,LLY,https://seekingalpha.com/news/3525050-sanofi-to-exit-diabetes-research-shares-up-4-premarket?source=partner_benzinga,Seeking Alpha,,,,0,0,87c0243e-150b-4f5a-bd71-9f29abe854c7
2019-12-10T08:00:00.000+08:00,Aptose Shoots Up As Investors Focus On Reversible BTK Inhibitors,LLY,https://seekingalpha.com/article/4311702-aptose-shoots-up-investors-focus-on-reversible-btk-inhibitors?utm_source=partner_&utm_medium=referralbenzinga,Seeking Alpha,,,,0,0,8aef5063-1518-4299-b698-dd0cd25af7c1
2019-12-10T08:00:00.000+08:00,Sanofi to exit diabetes research; shares up 4% premarket,LLY,https://seekingalpha.com/news/3525050-sanofi-to-exit-diabetes-research-shares-up-4-premarket?source=partner_benzinga,Seeking Alpha,,,,0,0,4ba044a1-ded9-46f8-b30a-cbbbb36e0650
2019-12-09T08:00:00.000+08:00,Highlights From The Deutsche Bank ADR Virtual Investor Conference,LLY,https://www.benzinga.com/news/19/12/14923069/highlights-from-the-deutsche-bank-adr-virtual-investor-conference,Spencer Israel,,,,0,0,cd40f86e-21d4-41bc-84eb-78a9fc70ae96
2019-12-09T08:00:00.000+08:00,Kinase inhibitors in focus after Merck bid for ArQule,LLY,https://seekingalpha.com/news/3524810-kinase-inhibitors-in-focus-after-merck-bid-for-arqule?source=partner_benzinga,Seeking Alpha,,,,0,0,143fdadf-a514-43d6-83d7-fa38b46a0531
2019-12-09T08:00:00.000+08:00,Highlights From The Deutsche Bank ADR Virtual Investor Conference,LLY,https://www.benzinga.com/news/19/12/14923069/highlights-from-the-deutsche-bank-adr-virtual-investor-conference,Spencer Israel,,,,0,0,6e20593b-18db-4485-9e2d-a1284ffa4e2d
2019-12-09T08:00:00.000+08:00,Kinase inhibitors in focus after Merck bid for ArQule,LLY,https://seekingalpha.com/news/3524810-kinase-inhibitors-in-focus-after-merck-bid-for-arqule?source=partner_benzinga,Seeking Alpha,,,,0,0,0243e558-2424-4d60-9bb9-b9b5d858ebcc
2019-12-08T08:00:00.000+08:00,Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at ASH 2019,LLY,https://www.benzinga.com/news/19/12/14951584/lilly-presents-interim-clinical-data-from-loxo-305-dose-escalation-trial-in-b-cell-leukemias-and-lym,Charles Gross,,,,0,0,e21d0368-fcb8-4fce-9e05-f1030454b607
2019-12-08T08:00:00.000+08:00,Lilly Presents Interim Clinical Data from LOXO-'…5 Dose Escalation Trial in B-Cell ...,LLY,https://www.benzinga.com/node/14951639,GuruFocus,,,,0,0,458a8f68-6330-48f7-a7fb-799aaf52bacc
2019-12-08T08:00:00.000+08:00,"Netflix, Cisco And Chewy On The Marquee (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4311222-netflix-cisco-and-chewy-on-marquee-stocks-to-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,78f6557a-381d-422a-97f0-425bd7432b75
2019-12-08T08:00:00.000+08:00,Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at ASH 2019,LLY,https://www.benzinga.com/news/19/12/14951584/lilly-presents-interim-clinical-data-from-loxo-305-dose-escalation-trial-in-b-cell-leukemias-and-lym,Charles Gross,,,,0,0,fd6c5ea1-8653-46aa-aa67-eb4206d96756
2019-12-08T08:00:00.000+08:00,Lilly Presents Interim Clinical Data from LOXO-'…5 Dose Escalation Trial in B-Cell ...,LLY,https://www.benzinga.com/node/14951639,GuruFocus,,,,0,0,9a16ba13-af74-4f20-9f9f-6c5c6d8b820b
2019-12-08T08:00:00.000+08:00,"Netflix, Cisco And Chewy On The Marquee (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4311222-netflix-cisco-and-chewy-on-marquee-stocks-to-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,0db3e31b-2487-4868-98ee-ea6a45a9012f
2019-12-07T08:00:00.000+08:00,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",LLY,https://www.benzinga.com/general/biotech/19/12/14947992/the-week-ahead-in-biotech-ash-presentations-pick-up-steam-correvio-awaits-adcom-ruling,Shanthi Rexaline,,,,0,0,6bf54801-b104-4eec-bd00-b40f149feb1d
2019-12-07T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of December 8,LLY,https://seekingalpha.com/article/4311216-dividend-challenger-highlights-week-of-december-8?source=partner_benzinga,Seeking Alpha,,,,0,0,c9b78c5d-a254-41b8-8152-bb2a84a4bd38
2019-12-07T08:00:00.000+08:00,"Stocks To Watch: Netflix, Cisco And Chewy On The Marquee",LLY,https://seekingalpha.com/article/4311202-stocks-to-watch-netflix-cisco-and-chewy-on-marquee?source=partner_benzinga,Seeking Alpha,,,,0,0,cc02b321-d2fb-4558-acd4-6bbbafe5e34a
2019-12-07T08:00:00.000+08:00,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",LLY,https://www.benzinga.com/general/biotech/19/12/14947992/the-week-ahead-in-biotech-ash-presentations-pick-up-steam-correvio-awaits-adcom-ruling,Shanthi Rexaline,,,,0,0,e7a723b1-a690-41d7-8bef-bdd445ac0304
2019-12-07T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of December 8,LLY,https://seekingalpha.com/article/4311216-dividend-challenger-highlights-week-of-december-8?source=partner_benzinga,Seeking Alpha,,,,0,0,0a2e2e63-b198-4b56-a17c-985441950057
2019-12-07T08:00:00.000+08:00,"Stocks To Watch: Netflix, Cisco And Chewy On The Marquee",LLY,https://seekingalpha.com/article/4311202-stocks-to-watch-netflix-cisco-and-chewy-on-marquee?source=partner_benzinga,Seeking Alpha,,,,0,0,f79db19c-aad7-4ba9-9909-9ef07bbf3c26
2019-12-06T08:00:00.000+08:00,Dicerna Pharmaceuticals: A Solid Pick For 2020,LLY,https://seekingalpha.com/article/4311121-dicerna-pharmaceuticals-solid-pick-for-2020?source=partner_benzinga,Seeking Alpha,,,,0,0,0d70e312-c1b9-404b-bda2-f35fffa1803b
2019-12-06T08:00:00.000+08:00,Dicerna Pharmaceuticals: A Solid Pick For 2020,LLY,https://seekingalpha.com/article/4311121-dicerna-pharmaceuticals-solid-pick-for-2020?source=partner_benzinga,Seeking Alpha,,,,0,0,b787916d-5d1f-47ec-bc54-0ef57bad69da
2019-12-05T08:00:00.000+08:00,Health Care Select Sector SPDR Fund: Long-Term Growth Outlook Remains Intact,LLY,https://seekingalpha.com/article/4310774-health-care-select-sector-spdr-fund-long-term-growth-outlook-remains-intact?source=partner_benzinga,Seeking Alpha,,,,0,0,96cecb3b-10c9-4ef1-8af3-195b0ab9b463
2019-12-05T08:00:00.000+08:00,Lilly to combine Loxo with oncology research group,LLY,https://seekingalpha.com/news/3523979-lilly-to-combine-loxo-oncology-research-group?source=partner_benzinga,Seeking Alpha,,,,0,0,896aedd4-f740-4079-afd1-5179d32921ac
2019-12-05T08:00:00.000+08:00,Lilly Announces New Leadership and Strategy in Oncology Research and Development,LLY,https://www.benzinga.com/node/14936990,GuruFocus,,,,0,0,33915f2f-382b-4e75-b75c-566d5945a8b3
2019-12-05T08:00:00.000+08:00,Health Care Select Sector SPDR Fund: Long-Term Growth Outlook Remains Intact,LLY,https://seekingalpha.com/article/4310774-health-care-select-sector-spdr-fund-long-term-growth-outlook-remains-intact?source=partner_benzinga,Seeking Alpha,,,,0,0,40983796-e088-4150-942f-5d64d0c0d4c3
2019-12-05T08:00:00.000+08:00,Lilly to combine Loxo with oncology research group,LLY,https://seekingalpha.com/news/3523979-lilly-to-combine-loxo-oncology-research-group?source=partner_benzinga,Seeking Alpha,,,,0,0,8e8620ca-2c74-4da0-bba3-e51d11079d1e
2019-12-05T08:00:00.000+08:00,Lilly Announces New Leadership and Strategy in Oncology Research and Development,LLY,https://www.benzinga.com/node/14936990,GuruFocus,,,,0,0,128a1e89-1138-46db-8ab8-ac8e6aa6061e
2019-12-02T08:00:00.000+08:00,U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada,LLY,https://www.benzinga.com/general/biotech/19/12/14915526/u-s-considers-scaling-back-ip-protections-for-big-drugmakers-to-help-win-democratic-support-for-n,Benzinga Newsdesk,,,,0,0,28b9461d-de5b-4277-a3fc-f53671a6dffa
2019-12-02T08:00:00.000+08:00,"Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/14913226/biogens-alzheimers-drug-falls-far-short-of-compelling-argument-for-approval-baird-s,Shanthi Rexaline,,,,0,0,dac3be54-c5b6-44a8-ada1-9a5ecd997c98
2019-12-02T08:00:00.000+08:00,Lilly to Participate in Evercore ISI —nd Annual HealthCONx Conference,LLY,https://www.benzinga.com/node/14917145,GuruFocus,,,,0,0,a36310fc-6feb-44c8-8c2e-9e93db834003
2019-12-02T08:00:00.000+08:00,Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco,LLY,https://www.benzinga.com/node/14913666,GuruFocus,,,,0,0,7c9b134b-a4c6-46a1-bb68-d94e732fa489
2019-12-02T08:00:00.000+08:00,Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory ...,LLY,https://www.benzinga.com/node/14911109,GuruFocus,,,,0,0,40e23c53-2161-49d3-ab51-f1881c563901
2019-12-02T08:00:00.000+08:00,Now Is A Good Time To Buy XLV,LLY,https://seekingalpha.com/article/4309959-now-good-time-buy-xlv?source=partner_benzinga,Seeking Alpha,,,,0,0,237fc475-0180-4792-a36f-203493b9c65b
2019-12-02T08:00:00.000+08:00,U.S. Considers Scaling Back IP Protections For Big Drugmakers To Help Win Democratic Support For New Trade Pact With Mexico And Canada,LLY,https://www.benzinga.com/general/biotech/19/12/14915526/u-s-considers-scaling-back-ip-protections-for-big-drugmakers-to-help-win-democratic-support-for-n,Benzinga Newsdesk,,,,0,0,3bacfc5b-5daa-4656-95a4-50386ebe8790
2019-12-02T08:00:00.000+08:00,"Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/14913226/biogens-alzheimers-drug-falls-far-short-of-compelling-argument-for-approval-baird-s,Shanthi Rexaline,,,,0,0,e7379b60-623e-4fc0-bf4d-c1ef41c14677
2019-12-02T08:00:00.000+08:00,Lilly to Participate in Evercore ISI —nd Annual HealthCONx Conference,LLY,https://www.benzinga.com/node/14917145,GuruFocus,,,,0,0,e76a5841-aa4a-49b4-b163-82d6a41d7066
2019-12-02T08:00:00.000+08:00,Eli Lilly and Company Unveils Shared Innovation Laboratory in South San Francisco,LLY,https://www.benzinga.com/node/14913666,GuruFocus,,,,0,0,cbc7c597-a85f-4e33-ae97-f5a952e55de6
2019-12-02T08:00:00.000+08:00,Lilly Names HealthVoyager as Winner of Digital Health Innovation Challenge for Inflammatory ...,LLY,https://www.benzinga.com/node/14911109,GuruFocus,,,,0,0,2b397239-d296-480c-84f5-a75888fc9a4a
2019-12-02T08:00:00.000+08:00,Now Is A Good Time To Buy XLV,LLY,https://seekingalpha.com/article/4309959-now-good-time-buy-xlv?source=partner_benzinga,Seeking Alpha,,,,0,0,5204e6c1-fed8-4f05-8085-97f10f1a6f1c
2019-11-27T08:00:00.000+08:00,"Top Research Reports for Merck, Eli Lilly & Charter Communications",LLY,http://www.zacks.com/research-daily/643445/top-research-reports-for-merck-eli-lilly-charter-communications?cid=CS-BENZ-FT-research_daily-643445,Zacks,,,,0,0,817dd9e3-f765-4876-8d3e-2c173b2db667
2019-11-27T08:00:00.000+08:00,"Top Research Reports for Merck, Eli Lilly & Charter Communications",LLY,http://www.zacks.com/research-daily/643445/top-research-reports-for-merck-eli-lilly-charter-communications?cid=CS-BENZ-FT-research_daily-643445,Zacks,,,,0,0,f6375f4d-912a-4a25-8418-a5b4d3f71f99
2019-11-24T08:00:00.000+08:00,Acreage Holdings: The Best Investment In The Cannabis Space,LLY,https://seekingalpha.com/article/4308875-acreage-holdings-best-investment-cannabis-space?source=partner_benzinga,Seeking Alpha,,,,0,0,b63ce3aa-72f1-4a1e-b2b6-90067bbc9f28
2019-11-24T08:00:00.000+08:00,Acreage Holdings: The Best Investment In The Cannabis Space,LLY,https://seekingalpha.com/article/4308875-acreage-holdings-best-investment-cannabis-space?source=partner_benzinga,Seeking Alpha,,,,0,0,6079fcdb-656a-4745-90f6-7ca57457f1ea
2019-11-22T08:00:00.000+08:00,"\"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are \"\"MUCH CHEAPER\"\"\"",LLY,https://www.benzinga.com/general/politics/19/11/14868610/trump-says-he-will-release-a-plan-to-let-states-import-prescription-drugs-which-are-much-cheaper,Benzinga Newsdesk,,,,0,0,b08be62e-2690-449b-9089-484c2d449893
2019-11-22T08:00:00.000+08:00,"\"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are \"\"MUCH CHEAPER\"\"\"",LLY,https://www.benzinga.com/general/politics/19/11/14868610/trump-says-he-will-release-a-plan-to-let-states-import-prescription-drugs-which-are-much-cheaper,Benzinga Newsdesk,,,,0,0,6614bbca-b275-4ece-b80f-06a182088641
2019-11-21T08:00:00.000+08:00,Why Eli Lilly Can't Match Novo Nordisk,LLY,https://seekingalpha.com/article/4308457-eli-lilly-match-novo-nordisk?source=partner_benzinga,Seeking Alpha,,,,0,0,cfe2330a-767b-4572-b1c4-c22e990a3549
2019-11-21T08:00:00.000+08:00,Why Eli Lilly Can't Match Novo Nordisk,LLY,https://seekingalpha.com/article/4308457-eli-lilly-match-novo-nordisk?source=partner_benzinga,Seeking Alpha,,,,0,0,b289763b-fbd3-48f7-bef5-2ef6af3e728a
2019-11-20T08:00:00.000+08:00,Lilly Announces $400M Capital Investment In Manufacturing Facilities In Indianapolis,LLY,https://www.benzinga.com/news/19/11/14846669/lilly-announces-400m-capital-investment-in-manufacturing-facilities-in-indianapolis,Benzinga Newsdesk,,,,0,0,026dab1d-f446-4783-bfbb-7542a376044a
2019-11-20T08:00:00.000+08:00,Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug,LLY,http://www.zacks.com/stock/news/629205/alkermes-submits-nda-to-fda-for-schizophrenia-bipolar-i-drug?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-629205,Zacks,,,,0,0,264d9d1b-3ff1-484a-8eed-5314b912c641
2019-11-20T08:00:00.000+08:00,Lilly announces $4…… million capital investment in manufacturing facilities in Indianapolis,LLY,https://www.benzinga.com/node/14847656,GuruFocus,,,,0,0,fcdcbf6b-628a-4f7a-b614-1f152d3169a1
2019-11-20T08:00:00.000+08:00,Launch of new generic drugs in U.S. still lags - WSJ,LLY,https://seekingalpha.com/news/3520772-launch-new-generic-drugs-u-s-still-lags-wsj?source=partner_benzinga,Seeking Alpha,,,,0,0,99959fa0-370b-4df5-911f-73103a9d55d6
2019-11-20T08:00:00.000+08:00,Lilly to invest $400M in Indianapolis manufacturing facilities,LLY,https://seekingalpha.com/news/3520758-lilly-invest-400m-indianapolis-manufacturing-facilities?source=partner_benzinga,Seeking Alpha,,,,0,0,5cd42029-9616-4f42-857c-023c65936558
2019-11-20T08:00:00.000+08:00,Lilly Announces $400M Capital Investment In Manufacturing Facilities In Indianapolis,LLY,https://www.benzinga.com/news/19/11/14846669/lilly-announces-400m-capital-investment-in-manufacturing-facilities-in-indianapolis,Benzinga Newsdesk,,,,0,0,0d290e42-f385-4080-ae11-46e858c678d5
2019-11-20T08:00:00.000+08:00,Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug,LLY,http://www.zacks.com/stock/news/629205/alkermes-submits-nda-to-fda-for-schizophrenia-bipolar-i-drug?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-629205,Zacks,,,,0,0,79c46552-2a10-433a-9b4b-46ce804b6835
2019-11-20T08:00:00.000+08:00,Lilly announces $4…… million capital investment in manufacturing facilities in Indianapolis,LLY,https://www.benzinga.com/node/14847656,GuruFocus,,,,0,0,89ffc6fb-4e57-4a72-926b-379b26324c1d
2019-11-20T08:00:00.000+08:00,Launch of new generic drugs in U.S. still lags - WSJ,LLY,https://seekingalpha.com/news/3520772-launch-new-generic-drugs-u-s-still-lags-wsj?source=partner_benzinga,Seeking Alpha,,,,0,0,ba3bd283-db04-413b-9db7-8cd18ffa1ae6
2019-11-20T08:00:00.000+08:00,Lilly to invest $400M in Indianapolis manufacturing facilities,LLY,https://seekingalpha.com/news/3520758-lilly-invest-400m-indianapolis-manufacturing-facilities?source=partner_benzinga,Seeking Alpha,,,,0,0,7d3e5460-af35-40cd-ab4b-22fd9abd7d61
2019-11-19T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for —…—… Financial Guidance Announcement,LLY,https://www.benzinga.com/node/14845243,GuruFocus,,,,0,0,44e62e02-63b0-4107-bc0b-550c1b238ae7
2019-11-19T08:00:00.000+08:00,"Ccm Investment Advisers Llc Buys MDU Resources Group Inc, Gilead Sciences Inc, Automatic Data ...",LLY,https://www.benzinga.com/node/14842904,GuruFocus,,,,0,0,c0cfab6d-b6c6-4187-898c-dba2fb830aba
2019-11-19T08:00:00.000+08:00,Steven Cohen's Top 5 Buys in the 'rd Quarter,LLY,https://www.benzinga.com/node/14842459,GuruFocus,,,,0,0,b17d3b1c-aaf4-43d7-a150-3a23871dd6ea
2019-11-19T08:00:00.000+08:00,Drug Legislation Likely to Dry Up Biotech Funding,LLY,https://www.benzinga.com/node/14839953,GuruFocus,,,,0,0,900d9cac-1463-4a2a-93fe-55a88e89e539
2019-11-19T08:00:00.000+08:00,Nektar: Poised For A Rebound,LLY,https://seekingalpha.com/article/4307652-nektar-poised-rebound?source=partner_benzinga,Seeking Alpha,,,,0,0,c29ae146-0180-4d4f-9870-b6468eef1d6a
2019-11-19T08:00:00.000+08:00,Lilly Confirms Date and Conference Call for —…—… Financial Guidance Announcement,LLY,https://www.benzinga.com/node/14845243,GuruFocus,,,,0,0,9b764301-b312-45c8-828b-a6b60e759edb
2019-11-19T08:00:00.000+08:00,"Ccm Investment Advisers Llc Buys MDU Resources Group Inc, Gilead Sciences Inc, Automatic Data ...",LLY,https://www.benzinga.com/node/14842904,GuruFocus,,,,0,0,faf0df8b-af35-4cd6-baf6-faae98be4ef5
2019-11-19T08:00:00.000+08:00,Steven Cohen's Top 5 Buys in the 'rd Quarter,LLY,https://www.benzinga.com/node/14842459,GuruFocus,,,,0,0,5c93c194-c8db-4298-8ee3-9021f7be5ec5
2019-11-19T08:00:00.000+08:00,Drug Legislation Likely to Dry Up Biotech Funding,LLY,https://www.benzinga.com/node/14839953,GuruFocus,,,,0,0,ca58f074-83bb-4520-9694-828d9edc37ee
2019-11-19T08:00:00.000+08:00,Nektar: Poised For A Rebound,LLY,https://seekingalpha.com/article/4307652-nektar-poised-rebound?source=partner_benzinga,Seeking Alpha,,,,0,0,bf5ff2d2-0bfa-45a0-b5f2-8b2d65773096
2019-11-17T08:00:00.000+08:00,Interim Analysis From Emprise Real-world Study Shows Lilly's Jardiance Decreased Risk of Hospitalization for Heart Failure vs Dpp-4 Inhibitors and Glp-1 Receptor Agonists,LLY,https://www.benzinga.com/news/19/11/14826392/interim-analysis-from-emprise-real-world-study-shows-lillys-jardiance-decreased-risk-of-hospitalizat,Charles Gross,,,,0,0,507b3ad4-d8b1-4bb8-9e1d-6a359937800f
2019-11-17T08:00:00.000+08:00,Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of ...,LLY,https://www.benzinga.com/node/14826196,GuruFocus,,,,0,0,bdd362f7-505c-489b-b900-0326597b3983
2019-11-17T08:00:00.000+08:00,Interim Analysis From Emprise Real-world Study Shows Lilly's Jardiance Decreased Risk of Hospitalization for Heart Failure vs Dpp-4 Inhibitors and Glp-1 Receptor Agonists,LLY,https://www.benzinga.com/news/19/11/14826392/interim-analysis-from-emprise-real-world-study-shows-lillys-jardiance-decreased-risk-of-hospitalizat,Charles Gross,,,,0,0,06dcbad0-a543-451f-9046-bc1fee6d45a2
2019-11-17T08:00:00.000+08:00,Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of ...,LLY,https://www.benzinga.com/node/14826196,GuruFocus,,,,0,0,52c1a38a-9282-457b-8fba-40dcd6208d6a
2019-11-15T08:00:00.000+08:00,"Willis Investment Counsel Buys Paychex Inc, Eli Lilly and Co, Pfizer Inc, Sells United Parcel ...",LLY,https://www.benzinga.com/node/14823641,GuruFocus,,,,0,0,f6f14674-a4a5-450e-907f-6cd39e47f971
2019-11-15T08:00:00.000+08:00,UCB's bimekizumab success in second late-stage psoriasis study,LLY,https://seekingalpha.com/news/3519817-ucbs-bimekizumab-success-second-late-stage-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,00154b31-c1e9-4e10-bf2a-6f51ebf9fd56
2019-11-15T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates",LLY,http://www.zacks.com/stock/news/621121/pharma-stock-roundup-mrk-gsk-abbv-llys-pipeline-regulatory-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-621121,Zacks,,,,0,0,727b7e57-88b7-4d09-aa08-f3d5876ab0aa
2019-11-15T08:00:00.000+08:00,"Willis Investment Counsel Buys Paychex Inc, Eli Lilly and Co, Pfizer Inc, Sells United Parcel ...",LLY,https://www.benzinga.com/node/14823641,GuruFocus,,,,0,0,d7aa2937-178c-445e-81df-71f963501383
2019-11-15T08:00:00.000+08:00,UCB's bimekizumab success in second late-stage psoriasis study,LLY,https://seekingalpha.com/news/3519817-ucbs-bimekizumab-success-second-late-stage-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,97632ce1-c9d3-4176-920f-bd007cc9df2b
2019-11-15T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates",LLY,http://www.zacks.com/stock/news/621121/pharma-stock-roundup-mrk-gsk-abbv-llys-pipeline-regulatory-updates?cid=CS-BENZ-FT-analyst_blog|stock_roundup-621121,Zacks,,,,0,0,c72b5632-60d5-4347-bb7d-9a6aa22067a8
2019-11-14T08:00:00.000+08:00,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",LLY,https://www.benzinga.com/general/biotech/19/11/14805285/the-daily-biotech-pulse-amarin-braces-for-vascepa-adcom-verdict-biotechs-on-a-fundraising-spree-z,Shanthi Rexaline,,,,0,0,cc092234-aadf-41ca-a3c0-f713210b42e0
2019-11-14T08:00:00.000+08:00,"HBK Sorce Advisory LLC Buys Global Payments Inc, SPDR Barclays Convertible Securities ETF, ...",LLY,https://www.benzinga.com/node/14817345,GuruFocus,,,,0,0,2ea58230-5282-4ad4-babf-f6081e1b87c3
2019-11-14T08:00:00.000+08:00,Livongo Bounces Back After Revenue Guidance Boost,LLY,https://www.benzinga.com/node/14816034,GuruFocus,,,,0,0,74c38551-da9b-4f8d-8fc9-86d8cf04cfee
2019-11-14T08:00:00.000+08:00,"Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss",LLY,http://www.zacks.com/stock/news/619674/celldex-cldx-q3-loss-narrower-than-expected-revenues-miss?cid=CS-BENZ-FT-analyst_blog|earnings_article-619674,Zacks,,,,0,0,030d4292-5c9d-4996-8778-687fab39f72f
2019-11-14T08:00:00.000+08:00,FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes,LLY,http://www.zacks.com/stock/news/619673/fda-panel-votes-against-lillys-jardiance-for-type-i-diabetes?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-619673,Zacks,,,,0,0,86ebe372-c0cd-441b-a3b1-a90abd7ce21f
2019-11-14T08:00:00.000+08:00,FDA Ad Com thumbs down on BI and Lilly's empagliflozin for T1D,LLY,https://seekingalpha.com/news/3519118-fda-ad-com-thumbs-bi-lillys-empagliflozin-t1d?source=partner_benzinga,Seeking Alpha,,,,0,0,0b3d6c2b-6b64-4506-afd2-587cc11bfde6
2019-11-14T08:00:00.000+08:00,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",LLY,https://www.benzinga.com/general/biotech/19/11/14805285/the-daily-biotech-pulse-amarin-braces-for-vascepa-adcom-verdict-biotechs-on-a-fundraising-spree-z,Shanthi Rexaline,,,,0,0,c1df9e1a-b079-4941-8b23-05e7109fb472
2019-11-14T08:00:00.000+08:00,"HBK Sorce Advisory LLC Buys Global Payments Inc, SPDR Barclays Convertible Securities ETF, ...",LLY,https://www.benzinga.com/node/14817345,GuruFocus,,,,0,0,f96f9fe2-32f9-49aa-b969-88e33e5c5695
2019-11-14T08:00:00.000+08:00,Livongo Bounces Back After Revenue Guidance Boost,LLY,https://www.benzinga.com/node/14816034,GuruFocus,,,,0,0,a18e88b3-cff0-4680-9f14-a68d26ab4d02
2019-11-14T08:00:00.000+08:00,"Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss",LLY,http://www.zacks.com/stock/news/619674/celldex-cldx-q3-loss-narrower-than-expected-revenues-miss?cid=CS-BENZ-FT-analyst_blog|earnings_article-619674,Zacks,,,,0,0,0e411053-ad5f-412e-9d79-07a1763205b1
2019-11-14T08:00:00.000+08:00,FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes,LLY,http://www.zacks.com/stock/news/619673/fda-panel-votes-against-lillys-jardiance-for-type-i-diabetes?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-619673,Zacks,,,,0,0,3fe94ad2-af52-4dee-94d9-c9edc553b5b3
2019-11-14T08:00:00.000+08:00,FDA Ad Com thumbs down on BI and Lilly's empagliflozin for T1D,LLY,https://seekingalpha.com/news/3519118-fda-ad-com-thumbs-bi-lillys-empagliflozin-t1d?source=partner_benzinga,Seeking Alpha,,,,0,0,199d7580-450d-4aee-a74d-4332ade8a991
2019-11-13T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks",LLY,https://www.benzinga.com/news/19/11/14803368/eli-lilly-boehringer-ingleheim-report-fda-endocrinologic-and-metabolic-drugs-advisory-committee-vote,Benzinga Newsdesk,,,,0,0,6947b1e3-425b-41cd-b06f-f5845668391d
2019-11-13T08:00:00.000+08:00,FDA Panel Votes 14-2 Against Approval Of Eli Lilly And Boehringer Ingelheim's Empagliflozin As An Add On To Insulin Therapy For Type 1 Diabetes,LLY,https://www.benzinga.com/general/biotech/19/11/14801622/fda-panel-votes-14-2-against-approval-of-eli-lilly-and-boehringer-ingelheims-empagliflozin-as-an-,Benzinga Newsdesk,,,,0,0,c2f14d61-2754-45a2-9228-e8a5ce36ea5b
2019-11-13T08:00:00.000+08:00,Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for ...,LLY,https://www.benzinga.com/node/14804357,GuruFocus,,,,0,0,bf006193-feb1-49fe-b8a6-703aa51b2011
2019-11-13T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks",LLY,https://www.benzinga.com/news/19/11/14803368/eli-lilly-boehringer-ingleheim-report-fda-endocrinologic-and-metabolic-drugs-advisory-committee-vote,Benzinga Newsdesk,,,,0,0,a0cde436-8649-45d1-942a-d9781fe492c7
2019-11-13T08:00:00.000+08:00,FDA Panel Votes 14-2 Against Approval Of Eli Lilly And Boehringer Ingelheim's Empagliflozin As An Add On To Insulin Therapy For Type 1 Diabetes,LLY,https://www.benzinga.com/general/biotech/19/11/14801622/fda-panel-votes-14-2-against-approval-of-eli-lilly-and-boehringer-ingelheims-empagliflozin-as-an-,Benzinga Newsdesk,,,,0,0,106eceeb-c662-4829-8837-6d2cf56c1016
2019-11-13T08:00:00.000+08:00,Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for ...,LLY,https://www.benzinga.com/node/14804357,GuruFocus,,,,0,0,551d54c6-ffe6-4808-8201-e2321d908eea
2019-11-12T08:00:00.000+08:00,Boehringer Ingelheim And Lilly Initiate Study To Assess Jardiance In People Hospitalized For Acute Heart Failure Who Have Been Stabilized,LLY,https://www.benzinga.com/general/biotech/19/11/14784437/boehringer-ingelheim-and-lilly-initiate-study-to-assess-jardiance-in-people-hospitalized-for-acut,Benzinga Newsdesk,,,,0,0,4e89f34c-6b97-44a2-8a2e-b9e7375ea3c5
2019-11-12T08:00:00.000+08:00,Eli Lilly And Co Announces 52-Week Head-To-Head Data From Taltz Versus Humira Trial In Psoriatic Arthritis Met The Primary And All Major Secondary Endpoints Of The Study,LLY,https://www.benzinga.com/general/biotech/19/11/14783146/eli-lilly-and-co-announces-52-week-head-to-head-data-from-taltz-versus-humira-trial-in-psoriatic-,Benzinga Newsdesk,,,,0,0,975a73da-2c4b-4855-ae94-fb8b085407d6
2019-11-12T08:00:00.000+08:00,"Diversified Portfolios, Inc. Buys Schwab Intermediate-Term U.S. ...",LLY,https://www.benzinga.com/node/14789886,GuruFocus,,,,0,0,e2aaf8a5-dc0a-4b8c-b33d-5eff3884ade2
2019-11-12T08:00:00.000+08:00,"Palladium Partners Llc Buys iShares Edge MSCI USA Value Factor ETF, Facebook Inc, Eli Lilly and ...",LLY,https://www.benzinga.com/node/14789912,GuruFocus,,,,0,0,4d72cc53-0fd6-4a55-8c8e-e52f443ea881
2019-11-12T08:00:00.000+08:00,Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people ...,LLY,https://www.benzinga.com/node/14788008,GuruFocus,,,,0,0,149b3865-e90e-44f0-ad91-40531e3069a7
2019-11-12T08:00:00.000+08:00,"Buckingham Capital Management, Inc. Buys Schwab Intermediate-Term U.S. ...",LLY,https://www.benzinga.com/node/14785635,GuruFocus,,,,0,0,ea2d2f6f-c788-4286-b73a-3f4571e0fd55
2019-11-12T08:00:00.000+08:00,Lilly's Taltz tops Humira in psoriatic arthritis study,LLY,https://seekingalpha.com/news/3517948-lillys-taltz-tops-humira-psoriatic-arthritis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,0cb4c07a-a207-47d0-ac9f-72a3056aeff6
2019-11-12T08:00:00.000+08:00,ACR —…–9: Lilly Presents 5—-Week Head-to-Head (SPIRIT-H—H) Data from Taltz® ...,LLY,https://www.benzinga.com/node/14783804,GuruFocus,,,,0,0,b4a6fddc-ac77-4912-9cc8-2448a03a3202
2019-11-12T08:00:00.000+08:00,"ACR —…–9: Lilly Presents Positive New Data from COAST-X, a Phase ' Study of Taltz® ...",LLY,https://www.benzinga.com/node/14783852,GuruFocus,,,,0,0,9d572cea-b4cd-405b-89e3-2e3ea2a8104c
2019-11-12T08:00:00.000+08:00,Boehringer Ingelheim And Lilly Initiate Study To Assess Jardiance In People Hospitalized For Acute Heart Failure Who Have Been Stabilized,LLY,https://www.benzinga.com/general/biotech/19/11/14784437/boehringer-ingelheim-and-lilly-initiate-study-to-assess-jardiance-in-people-hospitalized-for-acut,Benzinga Newsdesk,,,,0,0,3642ce1f-1c10-442c-8dbe-a3cd08022e81
2019-11-12T08:00:00.000+08:00,Eli Lilly And Co Announces 52-Week Head-To-Head Data From Taltz Versus Humira Trial In Psoriatic Arthritis Met The Primary And All Major Secondary Endpoints Of The Study,LLY,https://www.benzinga.com/general/biotech/19/11/14783146/eli-lilly-and-co-announces-52-week-head-to-head-data-from-taltz-versus-humira-trial-in-psoriatic-,Benzinga Newsdesk,,,,0,0,84b580ba-40ac-4c34-9018-05f58d742e7f
2019-11-12T08:00:00.000+08:00,"Diversified Portfolios, Inc. Buys Schwab Intermediate-Term U.S. ...",LLY,https://www.benzinga.com/node/14789886,GuruFocus,,,,0,0,435b17a0-d853-420c-8a19-eea7c47bf5da
2019-11-12T08:00:00.000+08:00,"Palladium Partners Llc Buys iShares Edge MSCI USA Value Factor ETF, Facebook Inc, Eli Lilly and ...",LLY,https://www.benzinga.com/node/14789912,GuruFocus,,,,0,0,e9058e4a-a45a-4b86-9abe-30973333ccb5
2019-11-12T08:00:00.000+08:00,Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people ...,LLY,https://www.benzinga.com/node/14788008,GuruFocus,,,,0,0,efb2e470-2fc3-4396-900d-515df5761c68
2019-11-12T08:00:00.000+08:00,"Buckingham Capital Management, Inc. Buys Schwab Intermediate-Term U.S. ...",LLY,https://www.benzinga.com/node/14785635,GuruFocus,,,,0,0,26699e95-f6f1-4624-8665-a574a1b1b49e
2019-11-12T08:00:00.000+08:00,Lilly's Taltz tops Humira in psoriatic arthritis study,LLY,https://seekingalpha.com/news/3517948-lillys-taltz-tops-humira-psoriatic-arthritis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,90ffe39d-57fc-4e25-82ab-240d74dc7a36
2019-11-12T08:00:00.000+08:00,ACR —…–9: Lilly Presents 5—-Week Head-to-Head (SPIRIT-H—H) Data from Taltz® ...,LLY,https://www.benzinga.com/node/14783804,GuruFocus,,,,0,0,0dee0bc8-b21a-49b1-bc02-0d2a0cbada9f
2019-11-12T08:00:00.000+08:00,"ACR —…–9: Lilly Presents Positive New Data from COAST-X, a Phase ' Study of Taltz® ...",LLY,https://www.benzinga.com/node/14783852,GuruFocus,,,,0,0,2db23b21-51d2-4970-bf4d-1c0af1f3a208
2019-11-11T08:00:00.000+08:00,ImmunoGen: Profiting And Turning Around,LLY,https://seekingalpha.com/article/4305416-immunogen-profiting-turning-around?source=partner_benzinga,Seeking Alpha,,,,0,0,cfe0cace-7866-46ad-aa71-8a411d7e9c84
2019-11-11T08:00:00.000+08:00,4 Biotech Stocks That Could Keep Beating Wall Street,LLY,http://www.zacks.com/stock/news/614227/4-biotech-stocks-that-could-keep-beating-wall-street?cid=CS-BENZ-FT-analyst_blog|investment_ideas-614227,Zacks,,,,0,0,cec3dec3-8808-409c-b7c2-9192335dbc4d
2019-11-11T08:00:00.000+08:00,Nektar up 5% premarket on encouraging NKTR-358 data,LLY,https://seekingalpha.com/news/3517501-nektar-5-percent-premarket-encouraging-nktrminus-358-data?source=partner_benzinga,Seeking Alpha,,,,0,0,1c9e0e94-78ce-4a1a-a9eb-52638236e569
2019-11-11T08:00:00.000+08:00,ImmunoGen: Profiting And Turning Around,LLY,https://seekingalpha.com/article/4305416-immunogen-profiting-turning-around?source=partner_benzinga,Seeking Alpha,,,,0,0,45c55658-34d5-4325-acff-a984a36e86b1
2019-11-11T08:00:00.000+08:00,4 Biotech Stocks That Could Keep Beating Wall Street,LLY,http://www.zacks.com/stock/news/614227/4-biotech-stocks-that-could-keep-beating-wall-street?cid=CS-BENZ-FT-analyst_blog|investment_ideas-614227,Zacks,,,,0,0,b12523ff-cd6f-4f2f-94a0-e2d412edb52e
2019-11-11T08:00:00.000+08:00,Nektar up 5% premarket on encouraging NKTR-358 data,LLY,https://seekingalpha.com/news/3517501-nektar-5-percent-premarket-encouraging-nktrminus-358-data?source=partner_benzinga,Seeking Alpha,,,,0,0,522c96d3-bdc9-4015-95eb-53cc74653a03
2019-11-09T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of November 10,LLY,https://seekingalpha.com/article/4304895-dividend-challenger-highlights-week-november-10?source=partner_benzinga,Seeking Alpha,,,,0,0,b7fe42fd-7a87-408a-9223-f8a39be00198
2019-11-09T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of November 10,LLY,https://seekingalpha.com/article/4304895-dividend-challenger-highlights-week-november-10?source=partner_benzinga,Seeking Alpha,,,,0,0,72f9bdbd-ea8d-4dce-93c6-f68746af1e16
2019-11-08T08:00:00.000+08:00,Ad Com on Lilly and BI's Jardiance for T1D,LLY,https://seekingalpha.com/news/3517323-ad-com-lilly-bis-jardiance-t1d?source=partner_benzinga,Seeking Alpha,,,,0,0,81d25d61-8eb0-4968-95af-a199af7a1048
2019-11-08T08:00:00.000+08:00,"Andesa Financial Management Inc. Buys Comcast Corp, Texas Instruments Inc, First Trust Value ...",LLY,https://www.benzinga.com/node/14769530,GuruFocus,,,,0,0,9fa4a61f-1bb2-408f-bdbf-9b84a0f9adc5
2019-11-08T08:00:00.000+08:00,"Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales",LLY,http://www.zacks.com/stock/news/610314/corcept-cort-earnings-beat-in-q3-korlym-boosts-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-610314,Zacks,,,,0,0,48614b39-f868-4605-8e09-01808f683b4d
2019-11-08T08:00:00.000+08:00,Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting,LLY,https://www.benzinga.com/node/14766998,GuruFocus,,,,0,0,e796b5f9-daa5-490d-9844-86acb5302d9a
2019-11-08T08:00:00.000+08:00,Ad Com on Lilly and BI's Jardiance for T1D,LLY,https://seekingalpha.com/news/3517323-ad-com-lilly-bis-jardiance-t1d?source=partner_benzinga,Seeking Alpha,,,,0,0,99a3e268-fa24-4d8c-8edd-60963b7511f0
2019-11-08T08:00:00.000+08:00,"Andesa Financial Management Inc. Buys Comcast Corp, Texas Instruments Inc, First Trust Value ...",LLY,https://www.benzinga.com/node/14769530,GuruFocus,,,,0,0,89bee4dc-9d47-4801-a9ec-3d7f68b663f0
2019-11-08T08:00:00.000+08:00,"Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales",LLY,http://www.zacks.com/stock/news/610314/corcept-cort-earnings-beat-in-q3-korlym-boosts-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-610314,Zacks,,,,0,0,68a6f1dd-86d2-4e00-abb5-3b05d54b689e
2019-11-08T08:00:00.000+08:00,Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting,LLY,https://www.benzinga.com/node/14766998,GuruFocus,,,,0,0,d8834aa5-329f-400f-a89e-323784facce0
2019-11-07T08:00:00.000+08:00,Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up to $2B Aggregate Principal Amount Of Its Outstanding Debt Securities,LLY,https://www.benzinga.com/news/19/11/14759390/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-2b-aggregate-principal-amount-o,Benzinga Newsdesk,,,,0,0,01fefe29-22f1-4f00-94ea-f88ab5dea523
2019-11-07T08:00:00.000+08:00,"Abbrea Capital, LLC Buys JPMorgan Ultra-Short Income ETF, Vanguard Short-Term ...",LLY,https://www.benzinga.com/node/14763934,GuruFocus,,,,0,0,06a69540-9bc2-4ad8-977b-0eb5a88e67c4
2019-11-07T08:00:00.000+08:00,Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to ...,LLY,https://www.benzinga.com/node/14761665,GuruFocus,,,,0,0,ca1cb3fd-ac58-4633-9a97-095958a5ad84
2019-11-07T08:00:00.000+08:00,4 RNA Therapy Stocks For A Biotech Portfolio,LLY,https://seekingalpha.com/article/4303833-4-rna-therapy-stocks-biotech-portfolio?source=partner_benzinga,Seeking Alpha,,,,0,0,01d7f18c-13cb-4832-8c42-d3155f8d8deb
2019-11-07T08:00:00.000+08:00,"Holistic Financial Partners Buys Eli Lilly and Co, Schwab Emerging Markets Equity ETF, Schwab ...",LLY,https://www.benzinga.com/node/14759889,GuruFocus,,,,0,0,5a630a1e-e45c-4906-b54e-9fc72cb2395b
2019-11-07T08:00:00.000+08:00,Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to ...,LLY,https://www.benzinga.com/node/14758867,GuruFocus,,,,0,0,282c5bd5-d1b2-4e02-a628-88ecbe495bfa
2019-11-07T08:00:00.000+08:00,"Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/608635/nektar-nktr-q3-earnings-revenues-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-608635,Zacks,,,,0,0,57da959b-a074-4828-9b45-2be1676a0eb5
2019-11-07T08:00:00.000+08:00,Fidelity MSCI Health Care Index ETF Is Undervalued,LLY,https://seekingalpha.com/article/4303596-fidelity-msci-health-care-index-etf-undervalued?source=partner_benzinga,Seeking Alpha,,,,0,0,0d4b6dbf-6161-491b-a4c5-22bab7d552c1
2019-11-07T08:00:00.000+08:00,Lilly Announces The Pricing Terms Of Its Cash Tender Offer For Up to $2B Aggregate Principal Amount Of Its Outstanding Debt Securities,LLY,https://www.benzinga.com/news/19/11/14759390/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-2b-aggregate-principal-amount-o,Benzinga Newsdesk,,,,0,0,ba63b6f7-3269-4ead-a5b4-2e72da42a4d0
2019-11-07T08:00:00.000+08:00,"Abbrea Capital, LLC Buys JPMorgan Ultra-Short Income ETF, Vanguard Short-Term ...",LLY,https://www.benzinga.com/node/14763934,GuruFocus,,,,0,0,b5c63ae0-b78e-49ad-a509-013c4e1575de
2019-11-07T08:00:00.000+08:00,Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to ...,LLY,https://www.benzinga.com/node/14761665,GuruFocus,,,,0,0,d0625ad8-df04-4fc2-8e4a-17f6727183a2
2019-11-07T08:00:00.000+08:00,4 RNA Therapy Stocks For A Biotech Portfolio,LLY,https://seekingalpha.com/article/4303833-4-rna-therapy-stocks-biotech-portfolio?source=partner_benzinga,Seeking Alpha,,,,0,0,80e25f71-2788-4c60-8d7f-0701a3ba3605
2019-11-07T08:00:00.000+08:00,"Holistic Financial Partners Buys Eli Lilly and Co, Schwab Emerging Markets Equity ETF, Schwab ...",LLY,https://www.benzinga.com/node/14759889,GuruFocus,,,,0,0,6da849b6-e77c-4427-be95-0f125cb4cc6a
2019-11-07T08:00:00.000+08:00,Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to ...,LLY,https://www.benzinga.com/node/14758867,GuruFocus,,,,0,0,9640110f-4723-4de2-a2df-681133c018c8
2019-11-07T08:00:00.000+08:00,"Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up",LLY,http://www.zacks.com/stock/news/608635/nektar-nktr-q3-earnings-revenues-top-estimates-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-608635,Zacks,,,,0,0,dfc98f59-fd11-4fd8-b34b-e83c905bd587
2019-11-07T08:00:00.000+08:00,Fidelity MSCI Health Care Index ETF Is Undervalued,LLY,https://seekingalpha.com/article/4303596-fidelity-msci-health-care-index-etf-undervalued?source=partner_benzinga,Seeking Alpha,,,,0,0,4e646c03-42d9-4484-af69-4a9cb1b586a7
2019-11-06T08:00:00.000+08:00,Eli Lilly shares are trading higher. Not seeing any news to justify the price action.,LLY,https://www.benzinga.com/markets/wiim/19/11/14747724/eli-lilly-shares-are-trading-higher-not-seeing-any-news-to-justify-the-price-action,Benzinga Newsdesk,,,,0,0,a65cc292-66b9-4771-84f1-7722e9feb6eb
2019-11-06T08:00:00.000+08:00,AstraZeneca Named The Most Innovative Global Pharma Company,LLY,https://www.benzinga.com/general/biotech/19/11/14734171/astrazeneca-named-the-most-innovative-global-pharma-company,Shanthi Rexaline,,,,0,0,74dca360-90df-4c9f-937d-49d8941524ed
2019-11-06T08:00:00.000+08:00,Eli Lilly To Present Multiple Abstracts For LOXO-305 At ASH 2019 Dec. 7-10,LLY,https://www.benzinga.com/general/biotech/19/11/14744185/eli-lilly-to-present-multiple-abstracts-for-loxo-305-at-ash-2019-dec-7-10,luke@benzinga.com,,,,0,0,e70c0176-b67a-480d-8606-1ac2a3656238
2019-11-06T08:00:00.000+08:00,US Indexes Close Mostly Flat Wednesday,LLY,https://www.benzinga.com/node/14750420,GuruFocus,,,,0,0,52428008-641b-4d06-9d8f-f9c40f5e55ee
2019-11-06T08:00:00.000+08:00,Eli Lilly and Company to Present Multiple Abstracts for LOXO-'…5 at ASH —…–9,LLY,https://www.benzinga.com/node/14746448,GuruFocus,,,,0,0,74f115c1-a1f6-4a3e-8363-546c0f82b967
2019-11-06T08:00:00.000+08:00,Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength,LLY,http://www.zacks.com/stock/news/606644/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength?cid=CS-BENZ-FT-analyst_blog|earnings_article-606644,Zacks,,,,0,0,7d1bb69d-e88d-46d4-9c51-87ece61c6a61
2019-11-06T08:00:00.000+08:00,ArQule down 17% on early-stage data on ARQ 531,LLY,https://seekingalpha.com/news/3515381-arqule-17-percent-early-stage-data-arq-531?source=partner_benzinga,Seeking Alpha,,,,0,0,f89c073d-584d-49a9-ab9d-5f33b0fa0d11
2019-11-06T08:00:00.000+08:00,Eli Lilly shares are trading higher. Not seeing any news to justify the price action.,LLY,https://www.benzinga.com/markets/wiim/19/11/14747724/eli-lilly-shares-are-trading-higher-not-seeing-any-news-to-justify-the-price-action,Benzinga Newsdesk,,,,0,0,610d26f8-6750-4b17-97b3-c923cb8054a1
2019-11-06T08:00:00.000+08:00,AstraZeneca Named The Most Innovative Global Pharma Company,LLY,https://www.benzinga.com/general/biotech/19/11/14734171/astrazeneca-named-the-most-innovative-global-pharma-company,Shanthi Rexaline,,,,0,0,dcdbaa82-6dba-4cc1-9f50-d09800a22b1f
2019-11-06T08:00:00.000+08:00,Eli Lilly To Present Multiple Abstracts For LOXO-305 At ASH 2019 Dec. 7-10,LLY,https://www.benzinga.com/general/biotech/19/11/14744185/eli-lilly-to-present-multiple-abstracts-for-loxo-305-at-ash-2019-dec-7-10,luke@benzinga.com,,,,0,0,dc9aa460-4f62-48ef-9165-f546eba4836b
2019-11-06T08:00:00.000+08:00,US Indexes Close Mostly Flat Wednesday,LLY,https://www.benzinga.com/node/14750420,GuruFocus,,,,0,0,d28df7a7-46b4-4e54-a242-6a3d91d1d153
2019-11-06T08:00:00.000+08:00,Eli Lilly and Company to Present Multiple Abstracts for LOXO-'…5 at ASH —…–9,LLY,https://www.benzinga.com/node/14746448,GuruFocus,,,,0,0,755ae085-a3df-49fd-978a-15b8606e9992
2019-11-06T08:00:00.000+08:00,Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength,LLY,http://www.zacks.com/stock/news/606644/radius-rdus-q3-earnings-beat-estimates-on-tymlos-strength?cid=CS-BENZ-FT-analyst_blog|earnings_article-606644,Zacks,,,,0,0,79f4bad1-d460-466e-95d3-c905738f9130
2019-11-06T08:00:00.000+08:00,ArQule down 17% on early-stage data on ARQ 531,LLY,https://seekingalpha.com/news/3515381-arqule-17-percent-early-stage-data-arq-531?source=partner_benzinga,Seeking Alpha,,,,0,0,e4e81a5e-85a9-4bbf-8f86-2ac259501a4b
2019-11-05T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2019 Update,LLY,https://seekingalpha.com/article/4302912-tracking-ken-fishers-fisher-asset-management-portfolio-q3-2019-update?source=partner_benzinga,Seeking Alpha,,,,0,0,e696dbc4-2848-4265-8871-c1b8a6ac6851
2019-11-05T08:00:00.000+08:00,"Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View",LLY,http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-604652,Zacks,,,,0,0,0a69e344-5c84-43ec-9242-4b288b00b27b
2019-11-05T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2019 Update,LLY,https://seekingalpha.com/article/4302912-tracking-ken-fishers-fisher-asset-management-portfolio-q3-2019-update?source=partner_benzinga,Seeking Alpha,,,,0,0,ca671261-b23f-41a5-883e-2f40484ece69
2019-11-05T08:00:00.000+08:00,"Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View",LLY,http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-604652,Zacks,,,,0,0,5162485e-a7c9-4ca8-bbd2-dd6f79ff470d
2019-11-04T08:00:00.000+08:00,"Boehringer Ingelheim, Eli Lilly Report Modernization Of Alliance To Focus Full Expertise On Jardiance",LLY,https://www.benzinga.com/news/19/11/14720748/boehringer-ingelheim-eli-lilly-report-modernization-of-alliance-to-focus-full-expertise-on-jardiance,Benzinga Newsdesk,,,,0,0,c123ca72-a768-4798-92e0-60c8b2ee42a1
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513849-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,cc87072e-8373-4382-a43f-e57a517c0fb2
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513847-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,ad7f6f69-68a4-4b13-b150-b9f3eb31e26e
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513846-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,9b6a0697-af7a-4f64-b1d2-0e6b0ecfcadd
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513845-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,3c1032cc-c8c3-4419-9317-d712713db36e
2019-11-04T08:00:00.000+08:00,Value Biotech ETFs & Stocks to Buy Now,LLY,http://www.zacks.com/stock/news/602866/value-biotech-etfs-stocks-to-buy-now?cid=CS-BENZ-FT-etf_news_and_commentary-602866,Zacks,,,,0,0,f13706e5-739d-465c-86a8-df0fdc8404cf
2019-11-04T08:00:00.000+08:00,What's in the Cards for Teva (TEVA) This Earnings Season?,LLY,http://www.zacks.com/stock/news/602734/whats-in-the-cards-for-teva-teva-this-earnings-season?cid=CS-BENZ-FT-analyst_blog|earnings_preview-602734,Zacks,,,,0,0,ef3bd042-7200-4f40-90c5-2c6d57a67fbd
2019-11-04T08:00:00.000+08:00,Incyte: An Undervalued Biotech With Catalysts,LLY,https://seekingalpha.com/article/4302109-incyte-undervalued-biotech-catalysts?source=partner_benzinga,Seeking Alpha,,,,0,0,51aaae08-fb77-4c93-b911-be4080d486ec
2019-11-04T08:00:00.000+08:00,Incyte: An Undervalued Biotech With Catalysts,LLY,https://seekingalpha.com/article/4302109-incyte-undervalued-biotech-catalysts?source=partner_benzinga,Seeking Alpha,,,,0,0,212ee5d3-f970-4105-b93b-0f109b09c6d4
2019-11-04T08:00:00.000+08:00,"Boehringer Ingelheim, Eli Lilly Report Modernization Of Alliance To Focus Full Expertise On Jardiance",LLY,https://www.benzinga.com/news/19/11/14720748/boehringer-ingelheim-eli-lilly-report-modernization-of-alliance-to-focus-full-expertise-on-jardiance,Benzinga Newsdesk,,,,0,0,558c1795-7243-40e3-a35f-96aa162fa8e8
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513849-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,ec83c6db-47dd-481d-b278-c459dd0357c1
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513847-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,4072115c-4a8a-418d-8b35-0821a75c37e5
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513846-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,a943551e-bf91-4adf-9589-16cdb9752113
2019-11-04T08:00:00.000+08:00,Boston nonprofit playing big role in drug pricing,LLY,https://seekingalpha.com/news/3513845-boston-nonprofit-playing-big-role-drug-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,dee59271-939b-4f32-818c-bad7f5b551fe
2019-11-04T08:00:00.000+08:00,Value Biotech ETFs & Stocks to Buy Now,LLY,http://www.zacks.com/stock/news/602866/value-biotech-etfs-stocks-to-buy-now?cid=CS-BENZ-FT-etf_news_and_commentary-602866,Zacks,,,,0,0,8a3b86a6-3785-4f23-93b8-6bc6d7b9bb6d
2019-11-04T08:00:00.000+08:00,What's in the Cards for Teva (TEVA) This Earnings Season?,LLY,http://www.zacks.com/stock/news/602734/whats-in-the-cards-for-teva-teva-this-earnings-season?cid=CS-BENZ-FT-analyst_blog|earnings_preview-602734,Zacks,,,,0,0,535274aa-7935-483b-b3e7-105e86710c01
2019-11-04T08:00:00.000+08:00,Incyte: An Undervalued Biotech With Catalysts,LLY,https://seekingalpha.com/article/4302109-incyte-undervalued-biotech-catalysts?source=partner_benzinga,Seeking Alpha,,,,0,0,2ae54611-6e05-4be7-9b9b-e27a81132a4e
2019-11-04T08:00:00.000+08:00,Incyte: An Undervalued Biotech With Catalysts,LLY,https://seekingalpha.com/article/4302109-incyte-undervalued-biotech-catalysts?source=partner_benzinga,Seeking Alpha,,,,0,0,f1034548-dfe5-442e-95f1-61b93697a593
2019-11-03T08:00:00.000+08:00,Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen,LLY,https://seekingalpha.com/article/4301966-week-review-beigene-forms-blockbuster-2_7-billion-collaboration-amgen?source=partner_benzinga,Seeking Alpha,,,,0,0,8c5c9367-f694-4538-b1cf-6a549c60cd23
2019-11-03T08:00:00.000+08:00,Week In Review: BeiGene Forms Blockbuster $2.7 Billion Collaboration With Amgen,LLY,https://seekingalpha.com/article/4301966-week-review-beigene-forms-blockbuster-2_7-billion-collaboration-amgen?source=partner_benzinga,Seeking Alpha,,,,0,0,71b4a35a-0393-4d50-a498-25bca7825487
2019-11-01T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/11/14674520/attention-biotech-investors-mark-your-calendar-for-these-november-pdufa-dates,Shanthi Rexaline,,,,0,0,b89dd364-f8b8-4595-b313-b941b11a25b5
2019-11-01T08:00:00.000+08:00,"Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss",LLY,http://www.zacks.com/stock/news/598502/agios-agio-q3-loss-narrower-than-expected-revenues-miss?cid=CS-BENZ-FT-analyst_blog|earnings_article-598502,Zacks,,,,0,0,310dba03-2f0d-4024-b6ba-ac82e472e003
2019-11-01T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/11/14674520/attention-biotech-investors-mark-your-calendar-for-these-november-pdufa-dates,Shanthi Rexaline,,,,0,0,6960440d-b9ef-462f-984f-a65c87769ecc
2019-11-01T08:00:00.000+08:00,"Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss",LLY,http://www.zacks.com/stock/news/598502/agios-agio-q3-loss-narrower-than-expected-revenues-miss?cid=CS-BENZ-FT-analyst_blog|earnings_article-598502,Zacks,,,,0,0,ff22386c-7632-41dd-a6bd-db0463090948
2019-10-31T08:00:00.000+08:00,"United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up",LLY,http://www.zacks.com/stock/news/596339/united-therapeutics-uthr-q3-earnings-sales-top-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-596339,Zacks,,,,0,0,e3790268-ba4c-4a0b-a939-9a98432eeecb
2019-10-31T08:00:00.000+08:00,"Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales",LLY,http://www.zacks.com/stock/news/596377/sanofi-sny-q3-earnings-beat-vaccines-chc-units-hurt-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-596377,Zacks,,,,0,0,2ad8bfd2-a151-47d8-af06-7aabaecd44e2
2019-10-31T08:00:00.000+08:00,"United Therapeutics (UTHR) Q3 Earnings & Sales Top, Stock Up",LLY,http://www.zacks.com/stock/news/596339/united-therapeutics-uthr-q3-earnings-sales-top-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-596339,Zacks,,,,0,0,070fc39e-c35b-4919-83f0-cf9d84299179
2019-10-31T08:00:00.000+08:00,"Sanofi (SNY) Q3 Earnings Beat, Vaccines/CHC Units Hurt Sales",LLY,http://www.zacks.com/stock/news/596377/sanofi-sny-q3-earnings-beat-vaccines-chc-units-hurt-sales?cid=CS-BENZ-FT-analyst_blog|earnings_article-596377,Zacks,,,,0,0,94b8124d-b540-4298-b216-3f74a237a1f1
2019-10-30T08:00:00.000+08:00,Daily Insider Ratings Round Up 10/28/19,LLY,https://seekingalpha.com/article/4300437-daily-insider-ratings-round-10-28-19?source=partner_benzinga,Seeking Alpha,,,,0,0,cc683692-876f-4d3e-b49f-9b64d25885f9
2019-10-30T08:00:00.000+08:00,Eli Lilly's Approval For Migraine Drug Provides A Unique Treatment Option,LLY,https://seekingalpha.com/article/4300401-eli-lillys-approval-migraine-drug-provides-unique-treatment-option?source=partner_benzinga,Seeking Alpha,,,,0,0,86e09ea5-3e64-4c03-895f-a86c72d6d1a1
2019-10-30T08:00:00.000+08:00,Daily Insider Ratings Round Up 10/28/19,LLY,https://seekingalpha.com/article/4300437-daily-insider-ratings-round-10-28-19?source=partner_benzinga,Seeking Alpha,,,,0,0,45bea7ec-e599-419d-b518-8981318500ef
2019-10-30T08:00:00.000+08:00,Eli Lilly's Approval For Migraine Drug Provides A Unique Treatment Option,LLY,https://seekingalpha.com/article/4300401-eli-lillys-approval-migraine-drug-provides-unique-treatment-option?source=partner_benzinga,Seeking Alpha,,,,0,0,0397575b-49e7-431e-9db4-693fb47c7504
2019-10-29T08:00:00.000+08:00,"\"Drug shortages reflect \"\"broken market\"\" - FDA\"",LLY,https://seekingalpha.com/news/3510787-drug-shortages-reflect-broken-market-fda?source=partner_benzinga,Seeking Alpha,,,,0,0,5decc4a1-a681-4ca8-a241-d4424f37bdcd
2019-10-29T08:00:00.000+08:00,"Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View",LLY,http://www.zacks.com/stock/news/590995/incyte-incy-beats-on-q3-earnings-sales-ups-jakafi-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-590995,Zacks,,,,0,0,516e1338-a33a-493a-b8dc-403f42c39f93
2019-10-29T08:00:00.000+08:00,S&P Goes Where It's Never Gone Before,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-23210,Zacks,,,,0,0,6f93b948-be3c-4d7a-bd8c-03672245b5f4
2019-10-29T08:00:00.000+08:00,"\"Drug shortages reflect \"\"broken market\"\" - FDA\"",LLY,https://seekingalpha.com/news/3510787-drug-shortages-reflect-broken-market-fda?source=partner_benzinga,Seeking Alpha,,,,0,0,a805cc9e-3d18-45a6-927b-e6d77e162945
2019-10-29T08:00:00.000+08:00,"Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View",LLY,http://www.zacks.com/stock/news/590995/incyte-incy-beats-on-q3-earnings-sales-ups-jakafi-view?cid=CS-BENZ-FT-analyst_blog|earnings_article-590995,Zacks,,,,0,0,1a6d24df-7aa8-43bf-9054-93230140c1b1
2019-10-29T08:00:00.000+08:00,S&P Goes Where It's Never Gone Before,LLY,https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/30c3?adid=ZU_CONTENT_SYND&cid=CS-BENZ-FT-zucommentary-23210,Zacks,,,,0,0,2e3ff54c-77ec-4884-b353-2514b2e6ae1c
2019-10-28T08:00:00.000+08:00,"Eli Lilly Reports Results For Taltz In Pediatric Patients With Moderate To Severe Plaque Psoriasis, Met Co-Primary Endpoints; Co. To Submit For US Regulatory Approval",LLY,https://www.benzinga.com/news/19/10/14672812/eli-lilly-reports-results-for-taltz-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-m,Benzinga Newsdesk,,,,0,0,e1177161-7d3e-495e-9694-ecfb13adac48
2019-10-28T08:00:00.000+08:00,Daily Insider Ratings Round Up 10/25/19,LLY,https://seekingalpha.com/article/4299646-daily-insider-ratings-round-10-25-19?source=partner_benzinga,Seeking Alpha,,,,0,0,55bd952c-4810-42b3-bf98-a41999ced276
2019-10-28T08:00:00.000+08:00,Lilly's Taltz successful in pediatric psoriasis study; shares up 2%,LLY,https://seekingalpha.com/news/3510163-lillys-taltz-successful-pediatric-psoriasis-study-shares-2-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,0b236ac7-98a8-41f0-8fb6-ef188106ac2c
2019-10-28T08:00:00.000+08:00,"Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More",LLY,http://www.zacks.com/stock/news/588895/drug-biotech-stock-q3-earnings-due-on-oct-29-mrk-pfe-more?cid=CS-BENZ-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-588895,Zacks,,,,0,0,034467e8-e0dd-4f89-aba6-c047cb7b3a18
2019-10-28T08:00:00.000+08:00,"Eli Lilly Reports Results For Taltz In Pediatric Patients With Moderate To Severe Plaque Psoriasis, Met Co-Primary Endpoints; Co. To Submit For US Regulatory Approval",LLY,https://www.benzinga.com/news/19/10/14672812/eli-lilly-reports-results-for-taltz-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-m,Benzinga Newsdesk,,,,0,0,91ba064b-ffff-4eb9-902d-f9a12c93ace8
2019-10-28T08:00:00.000+08:00,Daily Insider Ratings Round Up 10/25/19,LLY,https://seekingalpha.com/article/4299646-daily-insider-ratings-round-10-25-19?source=partner_benzinga,Seeking Alpha,,,,0,0,1ca2a3dc-b067-4d60-b627-c87c8e617931
2019-10-28T08:00:00.000+08:00,Lilly's Taltz successful in pediatric psoriasis study; shares up 2%,LLY,https://seekingalpha.com/news/3510163-lillys-taltz-successful-pediatric-psoriasis-study-shares-2-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,6d238559-5aa4-480c-86f6-7be34882e7ea
2019-10-28T08:00:00.000+08:00,"Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More",LLY,http://www.zacks.com/stock/news/588895/drug-biotech-stock-q3-earnings-due-on-oct-29-mrk-pfe-more?cid=CS-BENZ-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-588895,Zacks,,,,0,0,33f48b32-0f82-47c0-b244-0faffcb691ef
2019-10-27T08:00:00.000+08:00,3 Stocks Seeing Notable Insider Buying,LLY,https://seekingalpha.com/article/4299479-3-stocks-seeing-notable-insider-buying?source=partner_benzinga,Seeking Alpha,,,,0,0,5f31b515-db25-4fdc-b457-37e8d135892d
2019-10-27T08:00:00.000+08:00,Top Insider Buys Highlight for the Week of Oct. —5,LLY,https://www.benzinga.com/node/14669347,GuruFocus,,,,0,0,c177d5ab-8b54-46ce-a789-d40ef0f61c19
2019-10-27T08:00:00.000+08:00,"FOMC, Streaming Wars And JEDI In Focus (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4299416-fomc-streaming-wars-jedi-focus-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,26a265af-2f9e-43cd-a2a0-35605a8e7c12
2019-10-27T08:00:00.000+08:00,3 Stocks Seeing Notable Insider Buying,LLY,https://seekingalpha.com/article/4299479-3-stocks-seeing-notable-insider-buying?source=partner_benzinga,Seeking Alpha,,,,0,0,0d2503bc-7cf2-4a45-b9af-e9f0797ae38c
2019-10-27T08:00:00.000+08:00,Top Insider Buys Highlight for the Week of Oct. —5,LLY,https://www.benzinga.com/node/14669347,GuruFocus,,,,0,0,5d5ce9a1-b36e-4bd0-bfb3-d268ee49579a
2019-10-27T08:00:00.000+08:00,"FOMC, Streaming Wars And JEDI In Focus (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4299416-fomc-streaming-wars-jedi-focus-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,f5ea0b66-6dad-45fc-9e3a-454d52d4ed2b
2019-10-26T08:00:00.000+08:00,"Notable Insider Buys In The Past Week: Eli Lilly, JPMorgan, Thor Industries",LLY,https://www.benzinga.com/news/19/10/14668908/notable-insider-buys-in-the-past-week-eli-lilly-jpmorgan-thor-industries,Nelson Hem,,,,0,0,3b5e9cdb-f18f-48f8-9ae9-f4be586f5b2b
2019-10-26T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - October 26, 2019",LLY,https://www.benzinga.com/node/14669017,TalkMarkets,,,,0,0,1e3a96e3-c2a0-4a1a-b21e-0247e3676235
2019-10-26T08:00:00.000+08:00,"Stocks To Watch: FOMC, Streaming Wars And JEDI In Focus",LLY,https://seekingalpha.com/article/4299364-stocks-watch-fomc-streaming-wars-jedi-focus?source=partner_benzinga,Seeking Alpha,,,,0,0,11c40b26-dc6a-4ed9-a41e-37886ab7c53f
2019-10-26T08:00:00.000+08:00,"Notable Insider Buys In The Past Week: Eli Lilly, JPMorgan, Thor Industries",LLY,https://www.benzinga.com/news/19/10/14668908/notable-insider-buys-in-the-past-week-eli-lilly-jpmorgan-thor-industries,Nelson Hem,,,,0,0,e9222af7-6bdf-40af-ac8f-f812dbc22899
2019-10-26T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - October 26, 2019",LLY,https://www.benzinga.com/node/14669017,TalkMarkets,,,,0,0,11df1159-d79b-417d-a168-339f6bdd845c
2019-10-26T08:00:00.000+08:00,"Stocks To Watch: FOMC, Streaming Wars And JEDI In Focus",LLY,https://seekingalpha.com/article/4299364-stocks-watch-fomc-streaming-wars-jedi-focus?source=partner_benzinga,Seeking Alpha,,,,0,0,07d7d794-838b-4847-9bc0-d615e3d7510e
2019-10-25T08:00:00.000+08:00,"Eli Lilly And Co (LLY) President & CEO David A Ricks Bought $5……,–74 of Shares",LLY,https://www.benzinga.com/node/14665857,GuruFocus,,,,0,0,a97557b2-72ae-428c-acca-c55f43bd7820
2019-10-25T08:00:00.000+08:00,"Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA",LLY,http://www.zacks.com/stock/news/584115/pharma-stock-roundup-lly-nvs-azns-q3-earnings-updates-from-fda?cid=CS-BENZ-FT-analyst_blog|stock_roundup-584115,Zacks,,,,0,0,c5169abf-68b0-49a8-b5e0-ab7ced88dea7
2019-10-25T08:00:00.000+08:00,"Eli Lilly And Co (LLY) President & CEO David A Ricks Bought $5……,–74 of Shares",LLY,https://www.benzinga.com/node/14665857,GuruFocus,,,,0,0,50a8200d-823c-4283-921f-991ecf673c4a
2019-10-25T08:00:00.000+08:00,"Pharma Stock Roundup: LLY, NVS, AZN's Q3 Earnings, Updates From FDA",LLY,http://www.zacks.com/stock/news/584115/pharma-stock-roundup-lly-nvs-azns-q3-earnings-updates-from-fda?cid=CS-BENZ-FT-analyst_blog|stock_roundup-584115,Zacks,,,,0,0,64a230f6-9ed6-46c4-b440-021dedef0f1f
2019-10-24T08:00:00.000+08:00,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",LLY,https://www.benzinga.com/general/biotech/19/10/14651754/the-daily-biotech-pulse-acorda-to-trim-jobs-glaxosmithkline-gets-fda-nod-edward-lifesciences-post,Shanthi Rexaline,,,,0,0,4c997d19-83d0-4314-b357-162a0754bd99
2019-10-24T08:00:00.000+08:00,Lilly Announces Cash Tender Offer for Up to $—. ...,LLY,https://www.benzinga.com/node/14656996,GuruFocus,,,,0,0,08e064e5-f25a-44d0-98a3-e1316c2dc66e
2019-10-24T08:00:00.000+08:00,"The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise",LLY,https://www.benzinga.com/general/biotech/19/10/14651754/the-daily-biotech-pulse-acorda-to-trim-jobs-glaxosmithkline-gets-fda-nod-edward-lifesciences-post,Shanthi Rexaline,,,,0,0,a8355b54-95d2-4a98-a54f-7237b3dfc5b7
2019-10-24T08:00:00.000+08:00,Lilly Announces Cash Tender Offer for Up to $—. ...,LLY,https://www.benzinga.com/node/14656996,GuruFocus,,,,0,0,a985718b-b745-4148-abfc-1f45719d92c0
2019-10-23T08:00:00.000+08:00,Stocks That Hit 52-Week Lows On Wednesday,LLY,https://www.benzinga.com/news/19/10/14646280/stocks-that-hit-52-week-lows-on-wednesday,Lisa Levin,,,,0,0,96ba8972-cc9f-4373-a35f-a1cd4f2f8077
2019-10-23T08:00:00.000+08:00,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/10/14644456/33-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,7528cfc8-0edf-4239-9d48-08990d9f64b0
2019-10-23T08:00:00.000+08:00,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",LLY,https://www.benzinga.com/general/biotech/19/10/14643503/the-daily-biotech-pulse-eli-lily-revenues-trail-estimates-moderna-gets-fast-track-designation-mac,Shanthi Rexaline,,,,0,0,722815bd-5ed7-474d-a77e-1d7a409b689d
2019-10-23T08:00:00.000+08:00,"Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance",LLY,https://www.benzinga.com/news/earnings/19/10/14643457/eli-lilly-reports-mixed-q3-earnings-raises-guidance,Tanzeel Akhtar,,,,0,0,b7224c3b-64b4-40af-b8b1-bdbabe8a73ec
2019-10-23T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported worse-than-expected Q3 sales results.,LLY,https://www.benzinga.com/markets/wiim/19/10/14643410/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-worse-than-expected-q3-sales-re,Benzinga Newsdesk,,,,0,0,e7d6c45c-1c1e-4443-bbee-b29e89a80e1f
2019-10-23T08:00:00.000+08:00,"Lilly Raises FY19 Adj. EPS Guidance From $5.67-$5.77 To $5.75-$5.85 vs $5.72 Est., Sees Sales $22B-$22.5B vs $22.23B Est.",LLY,https://www.benzinga.com/news/19/10/14642841/lilly-raises-fy19-adj-eps-guidance-from-5-67-5-77-to-5-75-5-85-vs-5-72-est-sees-sales-22b-22-5b-vs-2,Benzinga Newsdesk,,,,0,0,b5e60b68-4115-44fa-8b7c-d5f725a39612
2019-10-23T08:00:00.000+08:00,"Eli Lilly Q3 Adj. EPS $1.48 Beats $1.4 Estimate, Sales $5.48B Miss $5.5B Estimate",LLY,https://www.benzinga.com/news/earnings/19/10/14642837/eli-lilly-q3-adj-eps-1-48-beats-1-4-estimate-sales-5-48b-miss-5-5b-estimate,Benzinga Newsdesk,,,,0,0,a5dab8b4-0820-48f6-9d12-79571a95d6a3
2019-10-23T08:00:00.000+08:00,"12 Stocks To Watch For October 23, 2019",LLY,https://www.benzinga.com/news/earnings/19/10/14642240/12-stocks-to-watch-for-october-23-2019,Lisa Levin,,,,0,0,8f14060a-8ca5-4ca6-a60f-4613481ec2bd
2019-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2019",LLY,https://www.benzinga.com/news/earnings/19/10/14642223/earnings-scheduled-for-october-23-2019,Lisa Levin,,,,0,0,d583f32c-5532-429b-abd0-337a0a95805d
2019-10-23T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4298376-eli-lilly-company-lly-ceo-dave-ricks-q3-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,00d58465-e8fa-4b78-b209-ffd975003b68
2019-10-23T08:00:00.000+08:00,Biogen: A Trading Strategy,LLY,https://seekingalpha.com/article/4298175-biogen-trading-strategy?source=partner_benzinga,Seeking Alpha,,,,0,0,91502467-6e75-4503-b262-5dd21ce5dbf3
2019-10-23T08:00:00.000+08:00,"Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down",LLY,http://www.zacks.com/stock/news/578857/lilly-lly-q3-earnings-top-estimates-sales-lag-stock-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-578857,Zacks,,,,0,0,72c1a802-4ee3-44e0-bb02-0678e3ed1759
2019-10-23T08:00:00.000+08:00,Lilly down 3% as sales lag expectations,LLY,https://seekingalpha.com/news/3508322-lilly-3-percent-sales-lag-expectations?source=partner_benzinga,Seeking Alpha,,,,0,0,2dca69ee-0d59-4202-9ca5-2baeec08e67b
2019-10-23T08:00:00.000+08:00,"Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to ...",LLY,https://www.benzinga.com/node/14643872,GuruFocus,,,,0,0,8b10af6d-a86f-4548-a505-80c8bd49f79f
2019-10-23T08:00:00.000+08:00,Eli Lilly (LLY) Surpasses Q3 Earnings Estimates,LLY,http://www.zacks.com/stock/news/578512/eli-lilly-lly-surpasses-q3-earnings-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-578512,Zacks,,,,0,0,d23add37-383e-479a-9437-dc3786e8de7e
2019-10-23T08:00:00.000+08:00,Eli Lilly raises EPS guidance after Q3 earnings beat,LLY,https://seekingalpha.com/news/3508263-eli-lilly-raises-eps-guidance-q3-earnings-beat?source=partner_benzinga,Seeking Alpha,,,,0,0,acebeb94-5a89-46a3-b596-d65e8fd19e2e
2019-10-23T08:00:00.000+08:00,"Eli Lilly EPS beats by $0.07, misses on revenue",LLY,https://seekingalpha.com/news/3508202-eli-lilly-eps-beats-0_07-misses-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,a4a8d1f4-d608-4cc7-9059-63ebcd498ef7
2019-10-23T08:00:00.000+08:00,Stocks That Hit 52-Week Lows On Wednesday,LLY,https://www.benzinga.com/news/19/10/14646280/stocks-that-hit-52-week-lows-on-wednesday,Lisa Levin,,,,0,0,7b5ab94d-91d1-4b25-b740-fd9bdafa369a
2019-10-23T08:00:00.000+08:00,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/10/14644456/33-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,9433d425-f574-4860-90f7-3fab6967b1b1
2019-10-23T08:00:00.000+08:00,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",LLY,https://www.benzinga.com/general/biotech/19/10/14643503/the-daily-biotech-pulse-eli-lily-revenues-trail-estimates-moderna-gets-fast-track-designation-mac,Shanthi Rexaline,,,,0,0,dc76991d-d3c0-47a8-92c7-34194c930bbe
2019-10-23T08:00:00.000+08:00,"Eli Lilly Reports Mixed Q3 Earnings, Raises Guidance",LLY,https://www.benzinga.com/news/earnings/19/10/14643457/eli-lilly-reports-mixed-q3-earnings-raises-guidance,Tanzeel Akhtar,,,,0,0,4a324f8e-b75b-421a-ac83-a0b3be3c69fa
2019-10-23T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported worse-than-expected Q3 sales results.,LLY,https://www.benzinga.com/markets/wiim/19/10/14643410/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-worse-than-expected-q3-sales-re,Benzinga Newsdesk,,,,0,0,b1249034-5460-4979-9ed8-6de82b87c543
2019-10-23T08:00:00.000+08:00,"Lilly Raises FY19 Adj. EPS Guidance From $5.67-$5.77 To $5.75-$5.85 vs $5.72 Est., Sees Sales $22B-$22.5B vs $22.23B Est.",LLY,https://www.benzinga.com/news/19/10/14642841/lilly-raises-fy19-adj-eps-guidance-from-5-67-5-77-to-5-75-5-85-vs-5-72-est-sees-sales-22b-22-5b-vs-2,Benzinga Newsdesk,,,,0,0,ebd4ea04-146c-4cf2-93c0-6c6d41963924
2019-10-23T08:00:00.000+08:00,"Eli Lilly Q3 Adj. EPS $1.48 Beats $1.4 Estimate, Sales $5.48B Miss $5.5B Estimate",LLY,https://www.benzinga.com/news/earnings/19/10/14642837/eli-lilly-q3-adj-eps-1-48-beats-1-4-estimate-sales-5-48b-miss-5-5b-estimate,Benzinga Newsdesk,,,,0,0,57ab3bc2-f613-4d09-8219-45751ff65e5f
2019-10-23T08:00:00.000+08:00,"12 Stocks To Watch For October 23, 2019",LLY,https://www.benzinga.com/news/earnings/19/10/14642240/12-stocks-to-watch-for-october-23-2019,Lisa Levin,,,,0,0,19cffc7a-74f8-4a0a-95ac-46b5384a0b75
2019-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2019",LLY,https://www.benzinga.com/news/earnings/19/10/14642223/earnings-scheduled-for-october-23-2019,Lisa Levin,,,,0,0,08a2c5ff-cf59-4bc3-b632-f3dbcfb7ff84
2019-10-23T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO Dave Ricks on Q3 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4298376-eli-lilly-company-lly-ceo-dave-ricks-q3-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,15a54d73-2283-4662-babb-36ec55c9142c
2019-10-23T08:00:00.000+08:00,Biogen: A Trading Strategy,LLY,https://seekingalpha.com/article/4298175-biogen-trading-strategy?source=partner_benzinga,Seeking Alpha,,,,0,0,f79c0bb5-b48f-468c-80d0-3fad036467be
2019-10-23T08:00:00.000+08:00,"Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down",LLY,http://www.zacks.com/stock/news/578857/lilly-lly-q3-earnings-top-estimates-sales-lag-stock-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-578857,Zacks,,,,0,0,16036777-1c90-4ad4-a2d2-0976c8bfdf26
2019-10-23T08:00:00.000+08:00,Lilly down 3% as sales lag expectations,LLY,https://seekingalpha.com/news/3508322-lilly-3-percent-sales-lag-expectations?source=partner_benzinga,Seeking Alpha,,,,0,0,e1803401-d129-4eaf-851b-4745807ff4a3
2019-10-23T08:00:00.000+08:00,"Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to ...",LLY,https://www.benzinga.com/node/14643872,GuruFocus,,,,0,0,730c4ac1-605d-46c4-aedf-63c70e2ebf1d
2019-10-23T08:00:00.000+08:00,Eli Lilly (LLY) Surpasses Q3 Earnings Estimates,LLY,http://www.zacks.com/stock/news/578512/eli-lilly-lly-surpasses-q3-earnings-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-578512,Zacks,,,,0,0,1fde8657-853e-47cb-a13e-dad51f7b6677
2019-10-23T08:00:00.000+08:00,Eli Lilly raises EPS guidance after Q3 earnings beat,LLY,https://seekingalpha.com/news/3508263-eli-lilly-raises-eps-guidance-q3-earnings-beat?source=partner_benzinga,Seeking Alpha,,,,0,0,bc1277fe-38f2-40aa-b52a-20bc6f9e266e
2019-10-23T08:00:00.000+08:00,"Eli Lilly EPS beats by $0.07, misses on revenue",LLY,https://seekingalpha.com/news/3508202-eli-lilly-eps-beats-0_07-misses-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,8606fac6-a022-426c-b644-13299ea7fd43
2019-10-22T08:00:00.000+08:00,"Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses",LLY,https://www.benzinga.com/news/earnings/19/10/14636560/mixed-bag-better-outlooks-from-lockheed-united-technologies-but-mcdonalds-misses,JJ Kinahan,,,,0,0,36324271-db94-44b2-a07c-deec673dbb54
2019-10-22T08:00:00.000+08:00,Notable earnings before Wednesday's open,LLY,https://seekingalpha.com/news/3507808-notable-earnings-wednesday-s-open?source=partner_benzinga,Seeking Alpha,,,,0,0,6fba7577-c546-47c9-9374-d66c5b5064de
2019-10-22T08:00:00.000+08:00,— Large-Cap Stocks Announce Dividends,LLY,https://www.benzinga.com/node/14637510,GuruFocus,,,,0,0,ef1c7acb-5a64-41c8-9a67-85f6f5f3d52f
2019-10-22T08:00:00.000+08:00,"Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses",LLY,https://www.benzinga.com/news/earnings/19/10/14636560/mixed-bag-better-outlooks-from-lockheed-united-technologies-but-mcdonalds-misses,JJ Kinahan,,,,0,0,44092dfa-5b99-4ad2-804d-ba2f105456cf
2019-10-22T08:00:00.000+08:00,Notable earnings before Wednesday's open,LLY,https://seekingalpha.com/news/3507808-notable-earnings-wednesday-s-open?source=partner_benzinga,Seeking Alpha,,,,0,0,221f8bd9-0c36-4c02-b579-819e9d09bc11
2019-10-22T08:00:00.000+08:00,— Large-Cap Stocks Announce Dividends,LLY,https://www.benzinga.com/node/14637510,GuruFocus,,,,0,0,d4021b27-6f34-4d92-98c3-ca6b1b6c4517
2019-10-21T08:00:00.000+08:00,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,LLY,https://www.benzinga.com/news/earnings/19/10/14628501/earnings-season-kicks-into-full-gear-in-round-3-of-the-wetrader-competition,Chris Dier-Scalise,,,,0,0,17269a29-3ef6-47ab-9b56-1291c68074a4
2019-10-21T08:00:00.000+08:00,Lilly Declares Fourth-Quarter —…–9 Dividend,LLY,https://www.benzinga.com/node/14630613,GuruFocus,,,,0,0,89db2401-bfe6-4421-bccc-3c1556be32a6
2019-10-21T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3507409-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,0,0,bc99bc5a-e170-4db2-a522-d3394660694e
2019-10-21T08:00:00.000+08:00,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,LLY,https://www.benzinga.com/news/earnings/19/10/14628501/earnings-season-kicks-into-full-gear-in-round-3-of-the-wetrader-competition,Chris Dier-Scalise,,,,0,0,845304a9-20d7-40e9-9323-aef8ed6ca50b
2019-10-21T08:00:00.000+08:00,Lilly Declares Fourth-Quarter —…–9 Dividend,LLY,https://www.benzinga.com/node/14630613,GuruFocus,,,,0,0,97ae1b5b-346a-4383-9f21-8d2b0346447b
2019-10-21T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3507409-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,0,0,dbcc36cb-d817-4955-a1a7-95ee0edc965d
2019-10-20T08:00:00.000+08:00,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",LLY,https://www.benzinga.com/general/biotech/19/10/14614270/the-week-ahead-in-biotech-earnings-trickle-in-while-glaxo-melinta-foamix-and-eton-await-fda-verdi,Shanthi Rexaline,,,,0,0,c5841ea4-1227-41a4-bf36-6e5a0c83afde
2019-10-20T08:00:00.000+08:00,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",LLY,https://www.benzinga.com/general/biotech/19/10/14614270/the-week-ahead-in-biotech-earnings-trickle-in-while-glaxo-melinta-foamix-and-eton-await-fda-verdi,Shanthi Rexaline,,,,0,0,6eb0acc9-40be-40dc-a21f-902a72c3a958
2019-10-18T08:00:00.000+08:00,European Medicines Agency Says CHMP Recommended Granting A Marketing Authorization For Eli Lilly's BAQSIMI,LLY,https://www.benzinga.com/news/19/10/14618168/european-medicines-agency-says-chmp-recommended-granting-a-marketing-authorization-for-eli-lillys-ba,Benzinga Newsdesk,,,,0,0,f32affbf-e0be-4b41-8423-06087facc304
2019-10-18T08:00:00.000+08:00,"Supplemental Annuity Collective Trust of NJ Buys Mastercard Inc, L'Harris Technologies Inc, ...",LLY,https://www.benzinga.com/node/14622509,GuruFocus,,,,0,0,82061cc5-dd84-4e65-9e42-65d4ade185ac
2019-10-18T08:00:00.000+08:00,"Hills Bank & Trust Co Buys Mastercard Inc, Alexion Pharmaceuticals Inc, NextEra Energy Inc, ...",LLY,https://www.benzinga.com/node/14621686,GuruFocus,,,,0,0,9912a7ae-af7f-4444-9846-61a00b088039
2019-10-18T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow",LLY,http://www.zacks.com/stock/news/571300/pharma-stock-roundup-jnjs-q3-earnings-rhhbys-sales-fda-nod-to-lillys-reyvow?cid=CS-BENZ-FT-analyst_blog|stock_roundup-571300,Zacks,,,,0,0,d1d06503-e222-4fda-9537-efdeb641d8ef
2019-10-18T08:00:00.000+08:00,New Gilead CFO: Let's Make A Deal,LLY,https://www.benzinga.com/node/14620155,GuruFocus,,,,0,0,ca4e12ca-2425-4bf8-8024-7668a0ced72e
2019-10-18T08:00:00.000+08:00,European advisory group backs Lilly's nasally administered glucagon,LLY,https://seekingalpha.com/news/3506826-european-advisory-group-backs-lillys-nasally-administered-glucagon?source=partner_benzinga,Seeking Alpha,,,,0,0,05a03542-d1cd-4c38-a0a6-4135c20fc73b
2019-10-18T08:00:00.000+08:00,European Medicines Agency Says CHMP Recommended Granting A Marketing Authorization For Eli Lilly's BAQSIMI,LLY,https://www.benzinga.com/news/19/10/14618168/european-medicines-agency-says-chmp-recommended-granting-a-marketing-authorization-for-eli-lillys-ba,Benzinga Newsdesk,,,,0,0,18ece381-5f13-4d2e-ad01-a5e60952cf03
2019-10-18T08:00:00.000+08:00,"Supplemental Annuity Collective Trust of NJ Buys Mastercard Inc, L'Harris Technologies Inc, ...",LLY,https://www.benzinga.com/node/14622509,GuruFocus,,,,0,0,8776fbc7-6ddd-4ea1-a597-674569a9eb0d
2019-10-18T08:00:00.000+08:00,"Hills Bank & Trust Co Buys Mastercard Inc, Alexion Pharmaceuticals Inc, NextEra Energy Inc, ...",LLY,https://www.benzinga.com/node/14621686,GuruFocus,,,,0,0,7375730f-f228-4bd1-9e70-176f89824c7c
2019-10-18T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ's Q3 Earnings, RHHBY's Sales, FDA Nod to Lilly's Reyvow",LLY,http://www.zacks.com/stock/news/571300/pharma-stock-roundup-jnjs-q3-earnings-rhhbys-sales-fda-nod-to-lillys-reyvow?cid=CS-BENZ-FT-analyst_blog|stock_roundup-571300,Zacks,,,,0,0,457a0b90-f029-4670-9806-320fe34b9173
2019-10-18T08:00:00.000+08:00,New Gilead CFO: Let's Make A Deal,LLY,https://www.benzinga.com/node/14620155,GuruFocus,,,,0,0,e4f5f064-b20e-4d97-a071-2230ccacc093
2019-10-18T08:00:00.000+08:00,European advisory group backs Lilly's nasally administered glucagon,LLY,https://seekingalpha.com/news/3506826-european-advisory-group-backs-lillys-nasally-administered-glucagon?source=partner_benzinga,Seeking Alpha,,,,0,0,505537ab-7c10-4f8d-8be2-81a1b254339e
2019-10-17T08:00:00.000+08:00,"UBS Maintains Buy on Eli Lilly, Lowers Price Target to $133",LLY,https://www.benzinga.com/news/19/10/14611009/ubs-maintains-buy-on-eli-lilly-lowers-price-target-to-133,Vick Meyer,,,,0,0,6802f4db-24aa-46d7-8505-a767db279a65
2019-10-17T08:00:00.000+08:00,"Bank of America Reinstates Buy on Eli Lilly, Announces $133 Price Target",LLY,https://www.benzinga.com/news/19/10/14609995/bank-of-america-reinstates-buy-on-eli-lilly-announces-133-price-target,Benzinga_Newsdesk,,,,0,0,b8867436-8bf0-4a1c-8085-36eec049e06a
2019-10-17T08:00:00.000+08:00,Pelosi drug bill passes first House committee,LLY,https://seekingalpha.com/news/3506633-pelosi-drug-bill-passes-first-house-committee?source=partner_benzinga,Seeking Alpha,,,,0,0,871ea44a-9fdc-4fc0-8f4b-356509908ee3
2019-10-17T08:00:00.000+08:00,Lilly's Pancreatic Cancer Candidate Fails in Phase III Study,LLY,http://www.zacks.com/stock/news/569619/lillys-pancreatic-cancer-candidate-fails-in-phase-iii-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-569619,Zacks,,,,0,0,db8b5d7c-ed3c-4066-8b58-9c56290284c9
2019-10-17T08:00:00.000+08:00,Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?,LLY,http://www.zacks.com/stock/news/569574/can-new-drugs-help-lilly-lly-to-deliver-solid-q3-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-569574,Zacks,,,,0,0,e4e97a24-38b6-45b1-b0b4-0130654b77aa
2019-10-17T08:00:00.000+08:00,"UBS Maintains Buy on Eli Lilly, Lowers Price Target to $133",LLY,https://www.benzinga.com/news/19/10/14611009/ubs-maintains-buy-on-eli-lilly-lowers-price-target-to-133,Vick Meyer,,,,0,0,48854900-04aa-46da-a73a-cfedb559c2e7
2019-10-17T08:00:00.000+08:00,"Bank of America Reinstates Buy on Eli Lilly, Announces $133 Price Target",LLY,https://www.benzinga.com/news/19/10/14609995/bank-of-america-reinstates-buy-on-eli-lilly-announces-133-price-target,Benzinga_Newsdesk,,,,0,0,7fff5ac6-8a6e-4b55-9197-a5434c77de6c
2019-10-17T08:00:00.000+08:00,Pelosi drug bill passes first House committee,LLY,https://seekingalpha.com/news/3506633-pelosi-drug-bill-passes-first-house-committee?source=partner_benzinga,Seeking Alpha,,,,0,0,b5d3a7bc-119b-42a4-b517-ac065b66b110
2019-10-17T08:00:00.000+08:00,Lilly's Pancreatic Cancer Candidate Fails in Phase III Study,LLY,http://www.zacks.com/stock/news/569619/lillys-pancreatic-cancer-candidate-fails-in-phase-iii-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-569619,Zacks,,,,0,0,730c7027-a713-471c-be87-fef45367f7e0
2019-10-17T08:00:00.000+08:00,Can New Drugs Help Lilly (LLY) to Deliver Solid Q3 Earnings?,LLY,http://www.zacks.com/stock/news/569574/can-new-drugs-help-lilly-lly-to-deliver-solid-q3-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-569574,Zacks,,,,0,0,8486f77e-290c-42c9-8519-4e5dff5ee971
2019-10-16T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported that its Phase 3 study in patients with Metastatic pancreatic cancer did not meet its primary endpoint.,LLY,https://www.benzinga.com/markets/wiim/19/10/14602350/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-that-its-phase-3-study-in-patie,Benzinga Newsdesk,,,,0,0,a931afc4-245c-4ad1-9a2b-19e4022c20c1
2019-10-16T08:00:00.000+08:00,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/10/14601880/17-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,86f62aca-d7bf-416d-b706-f86f1c595de7
2019-10-16T08:00:00.000+08:00,Eli Lilly Reports Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/19/10/14601445/eli-lilly-reports-phase-3-study-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-primary-e,Benzinga Newsdesk,,,,0,0,6cfc428d-efd6-4e37-8f91-e05f2dfb6964
2019-10-16T08:00:00.000+08:00,BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action,LLY,https://seekingalpha.com/news/3506336-bofa-merrill-lynch-sees-25-percent-upside-vertex-hours-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,906520ac-65a9-42a4-8bc3-092bb5d1d73d
2019-10-16T08:00:00.000+08:00,Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth,LLY,http://www.zacks.com/stock/news/567502/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-567502,Zacks,,,,0,0,13941f36-b0cf-4d5a-910e-18fe557433e8
2019-10-16T08:00:00.000+08:00,Lilly Announces Phase ' Study in Patients with Metastatic Pancreatic Cancer Did Not Meet ...,LLY,https://www.benzinga.com/node/14602124,GuruFocus,,,,0,0,0bf80ef4-c866-4c34-9aa1-41c5f952e817
2019-10-16T08:00:00.000+08:00,Lilly's pegilodecakin flunks late-stage study; shares down 2% premarket,LLY,https://seekingalpha.com/news/3506048-lillys-pegilodecakin-flunks-late-stage-study-shares-2-percent-premarket?source=partner_benzinga,Seeking Alpha,,,,0,0,eb0037c8-d63b-4697-9138-1bf41059cce7
2019-10-16T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the company reported that its Phase 3 study in patients with Metastatic pancreatic cancer did not meet its primary endpoint.,LLY,https://www.benzinga.com/markets/wiim/19/10/14602350/eli-lilly-and-co-shares-are-trading-lower-after-the-company-reported-that-its-phase-3-study-in-patie,Benzinga Newsdesk,,,,0,0,e19e3a71-e2c7-4deb-9451-4024b5300ea2
2019-10-16T08:00:00.000+08:00,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/10/14601880/17-healthcare-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,f0bf1917-34ea-4448-9857-eae4aa745cd4
2019-10-16T08:00:00.000+08:00,Eli Lilly Reports Phase 3 Study In Patients With Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/19/10/14601445/eli-lilly-reports-phase-3-study-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-primary-e,Benzinga Newsdesk,,,,0,0,3060f8ee-303a-4397-b4db-0939cc65e32b
2019-10-16T08:00:00.000+08:00,BofA Merrill Lynch sees 25% upside in Vertex in after-hours analyst action,LLY,https://seekingalpha.com/news/3506336-bofa-merrill-lynch-sees-25-percent-upside-vertex-hours-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,8b2ca10a-9627-4688-b4b4-4d6116e4850b
2019-10-16T08:00:00.000+08:00,Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth,LLY,http://www.zacks.com/stock/news/567502/eli-lilly-lly-reports-next-week-wall-street-expects-earnings-growth?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-567502,Zacks,,,,0,0,2ff93f32-a97f-46c7-aa4a-e83392da750e
2019-10-16T08:00:00.000+08:00,Lilly Announces Phase ' Study in Patients with Metastatic Pancreatic Cancer Did Not Meet ...,LLY,https://www.benzinga.com/node/14602124,GuruFocus,,,,0,0,431c4780-bca4-4b0b-8ecf-61ada2015253
2019-10-16T08:00:00.000+08:00,Lilly's pegilodecakin flunks late-stage study; shares down 2% premarket,LLY,https://seekingalpha.com/news/3506048-lillys-pegilodecakin-flunks-late-stage-study-shares-2-percent-premarket?source=partner_benzinga,Seeking Alpha,,,,0,0,578fa87a-be61-43b8-8ac7-7be9fea0cfb8
2019-10-15T08:00:00.000+08:00,Pelosi drug bill would save $345B - CBO,LLY,https://seekingalpha.com/news/3505888-pelosi-drug-bill-save-345b-cbo?source=partner_benzinga,Seeking Alpha,,,,0,0,1a34e2e5-c919-43e8-917f-f86b0e0685ae
2019-10-15T08:00:00.000+08:00,Lilly to close UK research facility,LLY,https://seekingalpha.com/news/3505700-lilly-close-uk-research-facility?source=partner_benzinga,Seeking Alpha,,,,0,0,cf3039d9-3057-46ca-80c4-b0fec78c5d65
2019-10-15T08:00:00.000+08:00,Pelosi drug bill would save $345B - CBO,LLY,https://seekingalpha.com/news/3505888-pelosi-drug-bill-save-345b-cbo?source=partner_benzinga,Seeking Alpha,,,,0,0,ccffc9e4-539c-46b9-8a33-2af00f7ef677
2019-10-15T08:00:00.000+08:00,Lilly to close UK research facility,LLY,https://seekingalpha.com/news/3505700-lilly-close-uk-research-facility?source=partner_benzinga,Seeking Alpha,,,,0,0,d3051462-4b81-47b2-a5a5-223783cf6746
2019-10-14T08:00:00.000+08:00,5—-Week Company Lows,LLY,https://www.benzinga.com/node/14588565,GuruFocus,,,,0,0,deee1747-8f5b-4716-90f1-fc40642d5540
2019-10-14T08:00:00.000+08:00,Pfenex up 2% premarket on positive human factor data on PF708,LLY,https://seekingalpha.com/news/3505486-pfenex-2-percent-premarket-positive-human-factor-data-pf708?source=partner_benzinga,Seeking Alpha,,,,0,0,23637852-bcaa-4a4c-80b4-b5b144ce372e
2019-10-14T08:00:00.000+08:00,Lilly's Taltz successful in late-stage pediatric psoriasis study,LLY,https://seekingalpha.com/news/3505416-lillys-taltz-successful-late-stage-pediatric-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,fb0fcbfa-d269-4a7e-8bb4-bb5cdce606be
2019-10-14T08:00:00.000+08:00,5—-Week Company Lows,LLY,https://www.benzinga.com/node/14588565,GuruFocus,,,,0,0,d1349287-86c6-410b-9a2f-08f1874bc308
2019-10-14T08:00:00.000+08:00,Pfenex up 2% premarket on positive human factor data on PF708,LLY,https://seekingalpha.com/news/3505486-pfenex-2-percent-premarket-positive-human-factor-data-pf708?source=partner_benzinga,Seeking Alpha,,,,0,0,4d7f7a1f-9522-44ed-bf06-506dd39be6c9
2019-10-14T08:00:00.000+08:00,Lilly's Taltz successful in late-stage pediatric psoriasis study,LLY,https://seekingalpha.com/news/3505416-lillys-taltz-successful-late-stage-pediatric-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,79ae5499-f163-42a2-9c03-6e5b098fdc9d
2019-10-13T08:00:00.000+08:00,New Sanofi CEO Looks to Shake Things Up,LLY,https://www.benzinga.com/node/14585932,GuruFocus,,,,0,0,5918fbbb-7717-4f27-a523-13476559b029
2019-10-13T08:00:00.000+08:00,New Sanofi CEO Looks to Shake Things Up,LLY,https://www.benzinga.com/node/14585932,GuruFocus,,,,0,0,eec55958-5671-4417-8ae1-d2ce3db1fba2
2019-10-12T08:00:00.000+08:00,Lilly Presents Positive Results for Taltz in Pediatric Patients with Moderate to Severe Plaque Psoriasis at EADV 2019,LLY,https://www.benzinga.com/news/19/10/14585556/lilly-presents-positive-results-for-taltz-in-pediatric-patients-with-moderate-to-severe-plaque-psori,Charles Gross,,,,0,0,c63312a1-d289-4cd6-a4bf-b4ba5c72465c
2019-10-12T08:00:00.000+08:00,Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to ...,LLY,https://www.benzinga.com/node/14585425,GuruFocus,,,,0,0,b52e4ff2-bc05-47b3-81c0-498d0ca0d94a
2019-10-12T08:00:00.000+08:00,Lilly Presents Positive Results for Taltz in Pediatric Patients with Moderate to Severe Plaque Psoriasis at EADV 2019,LLY,https://www.benzinga.com/news/19/10/14585556/lilly-presents-positive-results-for-taltz-in-pediatric-patients-with-moderate-to-severe-plaque-psori,Charles Gross,,,,0,0,50370bf3-45c6-4b04-9d0a-902b865839e0
2019-10-12T08:00:00.000+08:00,Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to ...,LLY,https://www.benzinga.com/node/14585425,GuruFocus,,,,0,0,0e0a9554-8965-4bb3-ab16-84218685584d
2019-10-11T08:00:00.000+08:00,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,LLY,https://www.benzinga.com/markets/wiim/19/10/14582266/shares-of-several-healthcare-companies-are-trading-higher-after-president-trump-made-positive-remark,Benzinga Newsdesk,,,,0,0,b04cd6a7-f4bb-4eb3-9f81-c553917d5bce
2019-10-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",LLY,https://www.benzinga.com/general/biotech/19/10/14579916/the-daily-biotech-pulse-therapix-extends-merger-deadline-five-prime-restructures-gilead-galapagos,Shanthi Rexaline,,,,0,0,0da2b4d9-c520-4a91-a276-ea909e117219
2019-10-11T08:00:00.000+08:00,FDA OKs Lilly's lasmiditan for migraine,LLY,https://seekingalpha.com/news/3505358-fda-oks-lillys-lasmiditan-migraine?source=partner_benzinga,Seeking Alpha,,,,0,0,7dfb5d6d-5caf-4b6a-8401-959392659102
2019-10-11T08:00:00.000+08:00,"Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment ...",LLY,https://www.benzinga.com/node/14584173,GuruFocus,,,,0,0,652ec82b-b8d9-441d-830a-579e1c5946c3
2019-10-11T08:00:00.000+08:00,Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study,LLY,https://seekingalpha.com/article/4296113-eli-lilly-shows-strength-taltz-positive-head-head-study?source=partner_benzinga,Seeking Alpha,,,,0,0,b398d70d-05ea-4823-af2f-94559ee7176e
2019-10-11T08:00:00.000+08:00,"Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals",LLY,http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-BENZ-FT-analyst_blog|stock_roundup-559573,Zacks,,,,0,0,06066b09-935c-46dd-8e46-0cd496303235
2019-10-11T08:00:00.000+08:00,Gilead-Galapagos Report Efficacy & Safety Results on RA Drug,LLY,http://www.zacks.com/stock/news/559457/gilead-galapagos-report-efficacy-safety-results-on-ra-drug?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-559457,Zacks,,,,0,0,b56d26b4-9f81-491c-b883-0064e35e9748
2019-10-11T08:00:00.000+08:00,"Affiance Financial, LLC Buys Eli Lilly and Co, Mondelez International Inc, U.S. ...",LLY,https://www.benzinga.com/node/14580643,GuruFocus,,,,0,0,bcdee371-86e9-4423-9412-12e5771a9f03
2019-10-11T08:00:00.000+08:00,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,LLY,https://www.benzinga.com/markets/wiim/19/10/14582266/shares-of-several-healthcare-companies-are-trading-higher-after-president-trump-made-positive-remark,Benzinga Newsdesk,,,,0,0,888d3247-8c5b-411f-ad42-c7e4974ab929
2019-10-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",LLY,https://www.benzinga.com/general/biotech/19/10/14579916/the-daily-biotech-pulse-therapix-extends-merger-deadline-five-prime-restructures-gilead-galapagos,Shanthi Rexaline,,,,0,0,87b87cef-fc76-4eb5-b01c-84b03a9ddf4c
2019-10-11T08:00:00.000+08:00,FDA OKs Lilly's lasmiditan for migraine,LLY,https://seekingalpha.com/news/3505358-fda-oks-lillys-lasmiditan-migraine?source=partner_benzinga,Seeking Alpha,,,,0,0,9681b12a-8607-4cb6-b019-e8b34a076bb7
2019-10-11T08:00:00.000+08:00,"Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment ...",LLY,https://www.benzinga.com/node/14584173,GuruFocus,,,,0,0,32f32c90-fbef-44cc-a31a-7ca8a0a1724d
2019-10-11T08:00:00.000+08:00,Eli Lilly Shows Its Strength With Taltz In Positive Head To Head Study,LLY,https://seekingalpha.com/article/4296113-eli-lilly-shows-strength-taltz-positive-head-head-study?source=partner_benzinga,Seeking Alpha,,,,0,0,00105e0f-d7a0-4c74-a448-ee1fa3e2c5e7
2019-10-11T08:00:00.000+08:00,"Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals",LLY,http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-BENZ-FT-analyst_blog|stock_roundup-559573,Zacks,,,,0,0,8cecee45-946f-4f98-b899-7985fe2dfc6b
2019-10-11T08:00:00.000+08:00,Gilead-Galapagos Report Efficacy & Safety Results on RA Drug,LLY,http://www.zacks.com/stock/news/559457/gilead-galapagos-report-efficacy-safety-results-on-ra-drug?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-559457,Zacks,,,,0,0,1a38f9d2-a2e6-4801-b806-f5a02c99c78e
2019-10-11T08:00:00.000+08:00,"Affiance Financial, LLC Buys Eli Lilly and Co, Mondelez International Inc, U.S. ...",LLY,https://www.benzinga.com/node/14580643,GuruFocus,,,,0,0,54a4afae-1c15-4626-b7ce-af007310368d
2019-10-10T08:00:00.000+08:00,"Lilly Says Taltz Met Primary, Secondary Endpoints of Ixora-R Study in People With Moderate to Severe Plaque Psoriasis",LLY,https://www.benzinga.com/news/19/10/14578853/lilly-says-taltz-met-primary-secondary-endpoints-of-ixora-r-study-in-people-with-moderate-to-severe,Charles Gross,,,,0,0,2b7f61c7-304e-4d95-8d63-c35ba513fbb1
2019-10-10T08:00:00.000+08:00,"Country Trust Bank Buys Ingersoll-Rand PLC, PepsiCo Inc, NVIDIA Corp, Sells The Walt Disney Co, ...",LLY,https://www.benzinga.com/node/14577820,GuruFocus,,,,0,0,fcc7dd4e-6306-4385-8b7b-9606f6440b99
2019-10-10T08:00:00.000+08:00,Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study,LLY,http://www.zacks.com/stock/news/557899/dermira-starts-lebrikizumab-dosing-in-late-stage-eczema-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-557899,Zacks,,,,0,0,39021c35-c2f1-4449-a021-cf08f0bedc10
2019-10-10T08:00:00.000+08:00,"Lilly Says Taltz Met Primary, Secondary Endpoints of Ixora-R Study in People With Moderate to Severe Plaque Psoriasis",LLY,https://www.benzinga.com/news/19/10/14578853/lilly-says-taltz-met-primary-secondary-endpoints-of-ixora-r-study-in-people-with-moderate-to-severe,Charles Gross,,,,0,0,0b2d76db-c3d1-4925-b244-74f893303dbe
2019-10-10T08:00:00.000+08:00,"Country Trust Bank Buys Ingersoll-Rand PLC, PepsiCo Inc, NVIDIA Corp, Sells The Walt Disney Co, ...",LLY,https://www.benzinga.com/node/14577820,GuruFocus,,,,0,0,a0bf690b-2670-46d6-af59-e50fc5eb8d2b
2019-10-10T08:00:00.000+08:00,Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study,LLY,http://www.zacks.com/stock/news/557899/dermira-starts-lebrikizumab-dosing-in-late-stage-eczema-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-557899,Zacks,,,,0,0,1d89d6f7-2e3b-46e1-adc8-3bf32a78cc5d
2019-10-09T08:00:00.000+08:00,"Novartis Delivers In Breast Cancer Study, Could Lead To A Major Battle With Competitors",LLY,https://seekingalpha.com/article/4295800-novartis-delivers-breast-cancer-study-lead-major-battle-competitors?source=partner_benzinga,Seeking Alpha,,,,0,0,ea637ef0-4138-4969-a70a-ddfada41f1ce
2019-10-09T08:00:00.000+08:00,Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan,LLY,http://www.zacks.com/stock/news/556224/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-556224,Zacks,,,,0,0,2a68f6f2-f805-41a2-b821-b51c2ef05717
2019-10-09T08:00:00.000+08:00,"First National Bank of Mount Dora, Trust Investmen Buys Eli Lilly and Co, TJX Inc, The Hartford ...",LLY,https://www.benzinga.com/node/14567666,GuruFocus,,,,0,0,72d386c5-748f-46ae-bd08-f902edc1b14a
2019-10-09T08:00:00.000+08:00,"Novartis Delivers In Breast Cancer Study, Could Lead To A Major Battle With Competitors",LLY,https://seekingalpha.com/article/4295800-novartis-delivers-breast-cancer-study-lead-major-battle-competitors?source=partner_benzinga,Seeking Alpha,,,,0,0,97b99baa-af1b-459c-8e54-38c6765e0db9
2019-10-09T08:00:00.000+08:00,Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan,LLY,http://www.zacks.com/stock/news/556224/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-556224,Zacks,,,,0,0,c0231329-ce54-448a-8858-14bf0780b8d3
2019-10-09T08:00:00.000+08:00,"First National Bank of Mount Dora, Trust Investmen Buys Eli Lilly and Co, TJX Inc, The Hartford ...",LLY,https://www.benzinga.com/node/14567666,GuruFocus,,,,0,0,3e26d0c2-8676-4f2c-b6bc-36d91f4ee301
2019-10-08T08:00:00.000+08:00,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,LLY,https://www.benzinga.com/markets/wiim/19/10/14561148/shares-of-several-healthcare-companies-are-trading-lower-with-the-broader-market-after-the-us-expand,Benzinga Newsdesk,,,,0,0,6e2bd548-035e-4dc9-bb63-9328f12e8307
2019-10-08T08:00:00.000+08:00,BioNTech IPO: What You Need To Know,LLY,https://www.benzinga.com/news/19/10/14555357/biontech-ipo-what-you-need-to-know,Shanthi Rexaline,,,,0,0,bcd0bd67-a64a-4b4f-9b00-ce715bb3af2f
2019-10-08T08:00:00.000+08:00,Lilly To Present New Data For Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology and Venereology Congress Ot. 9-13,LLY,https://www.benzinga.com/general/biotech/19/10/14558613/lilly-to-present-new-data-for-treatments-of-complex-dermatological-conditions-at-the-28th-annual-,Benzinga Newsdesk,,,,0,0,603a108d-8c70-4eaf-97de-80b9838cfb2e
2019-10-08T08:00:00.000+08:00,AbbVie and Roche price hike leaders past two years,LLY,https://seekingalpha.com/news/3504522-abbvie-roche-price-hike-leaders-past-two-years?source=partner_benzinga,Seeking Alpha,,,,0,0,d02c38ea-c25c-4cc7-8aff-71ff2d429d56
2019-10-08T08:00:00.000+08:00,"A Look At Merck's Keytruda And Other Headlines: The Good, Bad, And Ugly Of Biopharma",LLY,https://seekingalpha.com/article/4295583-look-mercks-keytruda-headlines-good-bad-ugly-biopharma?source=partner_benzinga,Seeking Alpha,,,,0,0,3c0061b7-44f9-4d91-b2b0-78d66f03695b
2019-10-08T08:00:00.000+08:00,Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the —8th ...,LLY,https://www.benzinga.com/node/14559287,GuruFocus,,,,0,0,63c18ced-d1e3-48b6-9f5c-f4f92b8720fb
2019-10-08T08:00:00.000+08:00,MannKind: Q3 Afrezza Sales In The Books - Brazil Launch Pending,LLY,https://seekingalpha.com/article/4295537-mannkind-q3-afrezza-sales-books-brazil-launch-pending?source=partner_benzinga,Seeking Alpha,,,,0,0,7f93253e-0647-468b-9649-44ae7e24b01d
2019-10-08T08:00:00.000+08:00,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,LLY,https://www.benzinga.com/markets/wiim/19/10/14561148/shares-of-several-healthcare-companies-are-trading-lower-with-the-broader-market-after-the-us-expand,Benzinga Newsdesk,,,,0,0,f73c3739-aed2-4242-aed2-52f89d0410c4
2019-10-08T08:00:00.000+08:00,BioNTech IPO: What You Need To Know,LLY,https://www.benzinga.com/news/19/10/14555357/biontech-ipo-what-you-need-to-know,Shanthi Rexaline,,,,0,0,314aa2fb-79e7-4a06-b25d-a2308fda660d
2019-10-08T08:00:00.000+08:00,Lilly To Present New Data For Treatments Of Complex Dermatological Conditions At The 28th Annual European Academy Of Dermatology and Venereology Congress Ot. 9-13,LLY,https://www.benzinga.com/general/biotech/19/10/14558613/lilly-to-present-new-data-for-treatments-of-complex-dermatological-conditions-at-the-28th-annual-,Benzinga Newsdesk,,,,0,0,f701d5ec-90c7-440f-a69f-855180458c52
2019-10-08T08:00:00.000+08:00,AbbVie and Roche price hike leaders past two years,LLY,https://seekingalpha.com/news/3504522-abbvie-roche-price-hike-leaders-past-two-years?source=partner_benzinga,Seeking Alpha,,,,0,0,5ea18378-ffad-4609-9a5a-8e3074b3f7c4
2019-10-08T08:00:00.000+08:00,"A Look At Merck's Keytruda And Other Headlines: The Good, Bad, And Ugly Of Biopharma",LLY,https://seekingalpha.com/article/4295583-look-mercks-keytruda-headlines-good-bad-ugly-biopharma?source=partner_benzinga,Seeking Alpha,,,,0,0,ab2efe23-c10b-458b-8c2b-0275faa2100d
2019-10-08T08:00:00.000+08:00,Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the —8th ...,LLY,https://www.benzinga.com/node/14559287,GuruFocus,,,,0,0,4f50ec3a-1615-42e7-b585-4cca2dd2abea
2019-10-08T08:00:00.000+08:00,MannKind: Q3 Afrezza Sales In The Books - Brazil Launch Pending,LLY,https://seekingalpha.com/article/4295537-mannkind-q3-afrezza-sales-books-brazil-launch-pending?source=partner_benzinga,Seeking Alpha,,,,0,0,99ffcae8-9945-43ac-8c04-0b54ff438914
2019-10-07T08:00:00.000+08:00,Eli Lilly Announces that Phase 3 CYRAMZA Results Were Published in the Journal Lancet Oncology,LLY,https://www.benzinga.com/news/19/10/14551487/eli-lilly-announces-that-phase-3-cyramza-results-were-published-in-the-journal-lancet-oncology,Benzinga Newsdesk,,,,0,0,d32e0da8-d724-46f5-9f9a-17d4be520095
2019-10-07T08:00:00.000+08:00,IPO Update: Innate Pharma Readies Plan For U.S. IPO,LLY,https://seekingalpha.com/article/4295471-ipo-update-innate-pharma-readies-plan-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,2edfca27-929e-4004-b5a0-dd791cc917f6
2019-10-07T08:00:00.000+08:00,"Enterprise Bank & Trust Co Buys Intercontinental Exchange Inc, Eli Lilly and Co, JPMorgan ...",LLY,https://www.benzinga.com/node/14555422,GuruFocus,,,,0,0,e04ed653-1b9a-45e1-a253-c674b5030611
2019-10-07T08:00:00.000+08:00,UCB challenges Roche patent covering IL-17-targeting antibodies,LLY,https://seekingalpha.com/news/3504267-ucb-challenges-roche-patent-covering-ilminus-17-targeting-antibodies?source=partner_benzinga,Seeking Alpha,,,,0,0,c14fb701-9264-4685-9733-af2e064fb99d
2019-10-07T08:00:00.000+08:00,5—-Week Company Lows,LLY,https://www.benzinga.com/node/14554389,GuruFocus,,,,0,0,8b1e1b2d-3e47-4a2d-b560-d57c482d7873
2019-10-07T08:00:00.000+08:00,Novo Nordisk Focuses on Pipeline Development Amid Competition,LLY,http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-552953,Zacks,,,,0,0,a921bf3e-ea5e-4d76-a72e-c363fcf7b178
2019-10-07T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Phase ' Data in First-Line EGFR-Mutated Non-Small Cell Lung ...,LLY,https://www.benzinga.com/node/14552200,GuruFocus,,,,0,0,1cad75fc-7c4b-4163-bd30-c3d366dcc0e5
2019-10-07T08:00:00.000+08:00,FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket,LLY,https://seekingalpha.com/news/3504130-fda-oks-pfenex-forteo-biosimilar-shares-9-percent-premarket?source=partner_benzinga,Seeking Alpha,,,,0,0,fe3f2366-1b8c-481b-ba27-98994927be98
2019-10-07T08:00:00.000+08:00,Eli Lilly Announces that Phase 3 CYRAMZA Results Were Published in the Journal Lancet Oncology,LLY,https://www.benzinga.com/news/19/10/14551487/eli-lilly-announces-that-phase-3-cyramza-results-were-published-in-the-journal-lancet-oncology,Benzinga Newsdesk,,,,0,0,b959a6f9-2360-4cf5-b808-148fd511af33
2019-10-07T08:00:00.000+08:00,IPO Update: Innate Pharma Readies Plan For U.S. IPO,LLY,https://seekingalpha.com/article/4295471-ipo-update-innate-pharma-readies-plan-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,80feb83a-8061-4b2f-a11e-725a5ed54da0
2019-10-07T08:00:00.000+08:00,"Enterprise Bank & Trust Co Buys Intercontinental Exchange Inc, Eli Lilly and Co, JPMorgan ...",LLY,https://www.benzinga.com/node/14555422,GuruFocus,,,,0,0,29f58330-6e9e-4ba4-a367-f35e2d6781cf
2019-10-07T08:00:00.000+08:00,UCB challenges Roche patent covering IL-17-targeting antibodies,LLY,https://seekingalpha.com/news/3504267-ucb-challenges-roche-patent-covering-ilminus-17-targeting-antibodies?source=partner_benzinga,Seeking Alpha,,,,0,0,44b60288-a19b-459e-a0c0-0ae01e85a2df
2019-10-07T08:00:00.000+08:00,5—-Week Company Lows,LLY,https://www.benzinga.com/node/14554389,GuruFocus,,,,0,0,df41afb9-8af2-4d1c-af0d-24eb2b073c6c
2019-10-07T08:00:00.000+08:00,Novo Nordisk Focuses on Pipeline Development Amid Competition,LLY,http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-552953,Zacks,,,,0,0,8c913ac2-9dac-4f2f-8026-273460ba869d
2019-10-07T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Phase ' Data in First-Line EGFR-Mutated Non-Small Cell Lung ...,LLY,https://www.benzinga.com/node/14552200,GuruFocus,,,,0,0,20c66ae4-1237-44e9-a450-11621d48f2f4
2019-10-07T08:00:00.000+08:00,FDA OKs Pfenex Forteo biosimilar; shares up 9% premarket,LLY,https://seekingalpha.com/news/3504130-fda-oks-pfenex-forteo-biosimilar-shares-9-percent-premarket?source=partner_benzinga,Seeking Alpha,,,,0,0,f394d083-779e-4818-9510-ed939c612b8a
2019-10-06T08:00:00.000+08:00,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck",LLY,https://www.benzinga.com/general/biotech/19/10/14541123/the-week-ahead-in-biotech-pfenex-and-clinuvel-on-the-radar-ahead-of-fda-decisions-2-ipos-on-deck,Shanthi Rexaline,,,,0,0,5cdbac3f-4b1a-4b92-9f0d-92fd1a8708aa
2019-10-06T08:00:00.000+08:00,"The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck",LLY,https://www.benzinga.com/general/biotech/19/10/14541123/the-week-ahead-in-biotech-pfenex-and-clinuvel-on-the-radar-ahead-of-fda-decisions-2-ipos-on-deck,Shanthi Rexaline,,,,0,0,6b776a14-aa3a-44df-9af8-5c461f8942cc
2019-10-04T08:00:00.000+08:00,"Keytruda on path to become world's no. 1 selling drug, research firm says",LLY,https://seekingalpha.com/news/3504108-keytruda-path-become-worlds-1-selling-drug-research-firm-says?source=partner_benzinga,Seeking Alpha,,,,0,0,06c7f730-e092-49f3-92ec-fbf7876fd709
2019-10-04T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly",LLY,http://www.zacks.com/stock/news/548879/the-zacks-analyst-blog-highlights-bank-of-america-home-depot-philip-morris-nextera-and-eli-lilly?cid=CS-BENZ-FT-press_releases-548879,Zacks,,,,0,0,8ed084e8-7a18-47be-bfb2-53cecde7baaa
2019-10-04T08:00:00.000+08:00,"Keytruda on path to become world's no. 1 selling drug, research firm says",LLY,https://seekingalpha.com/news/3504108-keytruda-path-become-worlds-1-selling-drug-research-firm-says?source=partner_benzinga,Seeking Alpha,,,,0,0,ad141083-cd72-4c2c-83f8-fd559f8ea7af
2019-10-04T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly",LLY,http://www.zacks.com/stock/news/548879/the-zacks-analyst-blog-highlights-bank-of-america-home-depot-philip-morris-nextera-and-eli-lilly?cid=CS-BENZ-FT-press_releases-548879,Zacks,,,,0,0,67f81915-3385-4a44-8c3a-537e111ada91
2019-10-03T08:00:00.000+08:00,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar,LLY,https://www.benzinga.com/general/biotech/19/10/14527152/biotech-stock-on-the-radar-fda-comes-calling-for-pfenex-osteoporosis-biosimilar,Shanthi Rexaline,,,,0,0,24b307c5-8d5c-430f-88b9-8f3e09748e13
2019-10-03T08:00:00.000+08:00,Eli Lilly Highlights Head-To-Head Data Showed Taltz Superiority Vs. TREMFYA In People with Moderate to Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/19/10/14536755/eli-lilly-highlights-head-to-head-data-showed-taltz-superiority-vs-tremfya-in-people-with-moderate-t,Benzinga Newsdesk,,,,0,0,b531aafb-82eb-4cd4-91fa-f331e7a7a4ad
2019-10-03T08:00:00.000+08:00,"Top Research Reports for Bank of America, Home Depot & Philip Morris",LLY,http://www.zacks.com/research-daily/547512/top-research-reports-for-bank-of-america-home-depot-philip-morris?cid=CS-BENZ-FT-research_daily-547512,Zacks,,,,0,0,247c6ae9-6137-4641-929e-9281122b0c09
2019-10-03T08:00:00.000+08:00,Why Lilly (LLY) Could Beat Earnings Estimates Again,LLY,http://www.zacks.com/stock/news/547471/why-lilly-lly-could-beat-earnings-estimates-again?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_7-547471,Zacks,,,,0,0,aa246df5-e62a-4b1b-b124-7802dadaeed7
2019-10-03T08:00:00.000+08:00,Novartis Reports Additional Data on Spondylitis Drug Cosentyx,LLY,http://www.zacks.com/stock/news/547460/novartis-reports-additional-data-on-spondylitis-drug-cosentyx?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-547460,Zacks,,,,0,0,decf35a6-7993-4bd7-ac79-cf3664a15715
2019-10-03T08:00:00.000+08:00,Here's Why You Should Add Thermo Fisher to Your Portfolio,LLY,http://www.zacks.com/stock/news/547523/heres-why-you-should-add-thermo-fisher-to-your-portfolio?cid=CS-BENZ-FT-analyst_blog|rank_focused-547523,Zacks,,,,0,0,58b61f35-1800-45e8-984a-40a294e98bbd
2019-10-03T08:00:00.000+08:00,Eli Lilly issues positive update on Taltz,LLY,https://seekingalpha.com/news/3503655-eli-lilly-issues-positive-update-taltz?source=partner_benzinga,Seeking Alpha,,,,0,0,139763d0-7612-490b-9f7c-89f6958e4b01
2019-10-03T08:00:00.000+08:00,Biotech Stock On The Radar: FDA Verdict Ahead For Pfenex's Osteoporosis Biosimilar,LLY,https://www.benzinga.com/general/biotech/19/10/14527152/biotech-stock-on-the-radar-fda-comes-calling-for-pfenex-osteoporosis-biosimilar,Shanthi Rexaline,,,,0,0,d64d3929-4c89-44eb-acfb-35c76bc03b26
2019-10-03T08:00:00.000+08:00,Eli Lilly Highlights Head-To-Head Data Showed Taltz Superiority Vs. TREMFYA In People with Moderate to Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/19/10/14536755/eli-lilly-highlights-head-to-head-data-showed-taltz-superiority-vs-tremfya-in-people-with-moderate-t,Benzinga Newsdesk,,,,0,0,c61909e7-0302-4b22-a85e-c397558b97f8
2019-10-03T08:00:00.000+08:00,"Top Research Reports for Bank of America, Home Depot & Philip Morris",LLY,http://www.zacks.com/research-daily/547512/top-research-reports-for-bank-of-america-home-depot-philip-morris?cid=CS-BENZ-FT-research_daily-547512,Zacks,,,,0,0,8ea20837-c483-4cbf-8c61-99f6cb8f22ff
2019-10-03T08:00:00.000+08:00,Why Lilly (LLY) Could Beat Earnings Estimates Again,LLY,http://www.zacks.com/stock/news/547471/why-lilly-lly-could-beat-earnings-estimates-again?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_7-547471,Zacks,,,,0,0,f5f83ed6-b812-47b1-a74e-a4bc67acf995
2019-10-03T08:00:00.000+08:00,Novartis Reports Additional Data on Spondylitis Drug Cosentyx,LLY,http://www.zacks.com/stock/news/547460/novartis-reports-additional-data-on-spondylitis-drug-cosentyx?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-547460,Zacks,,,,0,0,9e79a660-aa6a-4d53-975a-026ec731c1a3
2019-10-03T08:00:00.000+08:00,Here's Why You Should Add Thermo Fisher to Your Portfolio,LLY,http://www.zacks.com/stock/news/547523/heres-why-you-should-add-thermo-fisher-to-your-portfolio?cid=CS-BENZ-FT-analyst_blog|rank_focused-547523,Zacks,,,,0,0,080f6adc-2df9-4c05-98b3-fd3791de1157
2019-10-03T08:00:00.000+08:00,Eli Lilly issues positive update on Taltz,LLY,https://seekingalpha.com/news/3503655-eli-lilly-issues-positive-update-taltz?source=partner_benzinga,Seeking Alpha,,,,0,0,47f911b0-0d48-4905-a960-66553da5a7bb
2019-10-02T08:00:00.000+08:00,Eli Lilly Highlights Availability Of Emgality In Canada,LLY,https://www.benzinga.com/news/19/10/14531514/eli-lilly-highlights-availability-of-emgality-in-canada,Benzinga Newsdesk,,,,0,0,6097dc6a-3458-40f7-9e89-d68800a92ed7
2019-10-02T08:00:00.000+08:00,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,LLY,https://www.benzinga.com/markets/wiim/19/10/14530664/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-on-cont,Benzinga Newsdesk,,,,0,0,bc76dad3-1d23-42c8-b105-0ce62e04bbcd
2019-10-02T08:00:00.000+08:00,Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 Conference (Transcript),LLY,https://seekingalpha.com/article/4294651-eli-lilly-companys-lly-management-presents-lilly-oncology-update-esmo-2019-conference?source=partner_benzinga,Seeking Alpha,,,,0,0,22fdfcde-4352-4adc-8672-ba6d500eb98a
2019-10-02T08:00:00.000+08:00,Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study,LLY,http://www.zacks.com/stock/news/546049/agios-tibsovo-improves-survival-in-cholangiocarcinoma-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-546049,Zacks,,,,0,0,70452db5-94db-4a94-8296-6e3ea46092ba
2019-10-02T08:00:00.000+08:00,Novartis (NVS) Announces Data on Asthma Drugs & Kisqali,LLY,http://www.zacks.com/stock/news/545899/novartis-nvs-announces-data-on-asthma-drugs-kisqali?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-545899,Zacks,,,,0,0,ad131395-662b-45aa-91ba-371165922cb9
2019-10-02T08:00:00.000+08:00,Lilly Oncology Update at ESMO,LLY,https://seekingalpha.com/article/4294544-lilly-oncology-update-esmo?source=partner_benzinga,Seeking Alpha,,,,0,0,d67b8760-d903-489d-b1ff-59a0112024be
2019-10-02T08:00:00.000+08:00,Eli Lilly Highlights Availability Of Emgality In Canada,LLY,https://www.benzinga.com/news/19/10/14531514/eli-lilly-highlights-availability-of-emgality-in-canada,Benzinga Newsdesk,,,,0,0,5d6f40cd-ee53-41e1-8f6c-d506d49cabfa
2019-10-02T08:00:00.000+08:00,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,LLY,https://www.benzinga.com/markets/wiim/19/10/14530664/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-on-cont,Benzinga Newsdesk,,,,0,0,f9094a2d-e72e-4e5d-97be-e42609f80bae
2019-10-02T08:00:00.000+08:00,Eli Lilly and Company's (LLY) Management Presents at Lilly Oncology Update at ESMO 2019 Conference (Transcript),LLY,https://seekingalpha.com/article/4294651-eli-lilly-companys-lly-management-presents-lilly-oncology-update-esmo-2019-conference?source=partner_benzinga,Seeking Alpha,,,,0,0,d0e03f31-6c9d-4455-875d-41920357d0c5
2019-10-02T08:00:00.000+08:00,Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study,LLY,http://www.zacks.com/stock/news/546049/agios-tibsovo-improves-survival-in-cholangiocarcinoma-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-546049,Zacks,,,,0,0,35d626af-1900-4d84-a497-899e43dc6a3a
2019-10-02T08:00:00.000+08:00,Novartis (NVS) Announces Data on Asthma Drugs & Kisqali,LLY,http://www.zacks.com/stock/news/545899/novartis-nvs-announces-data-on-asthma-drugs-kisqali?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-545899,Zacks,,,,0,0,2e72f86f-13b5-4a24-a81c-809609b145c0
2019-10-02T08:00:00.000+08:00,Lilly Oncology Update at ESMO,LLY,https://seekingalpha.com/article/4294544-lilly-oncology-update-esmo?source=partner_benzinga,Seeking Alpha,,,,0,0,c15eae55-bd25-45f8-82d2-ecf423a90c2b
2019-09-30T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/09/14491876/attention-biotech-investors-mark-your-calendar-for-these-october-pdufa-dates,Shanthi Rexaline,,,,0,0,f3056164-6084-46e7-a929-b04d00867828
2019-09-30T08:00:00.000+08:00,IPO Update: Annovis Bio Readies $10 Million IPO,LLY,https://seekingalpha.com/article/4294246-ipo-update-annovis-bio-readies-10-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,827c1ad7-11cf-423f-8939-48b845aa917c
2019-09-30T08:00:00.000+08:00,Earnings Estimates/Revisions - Healthcare,LLY,https://www.benzinga.com/node/14513590,TalkMarkets,,,,0,0,515b45df-12e3-46a0-9bca-cbb40b55c5df
2019-09-30T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/09/14491876/attention-biotech-investors-mark-your-calendar-for-these-october-pdufa-dates,Shanthi Rexaline,,,,0,0,be14e2ae-f807-482f-98d6-23e46b553e43
2019-09-30T08:00:00.000+08:00,IPO Update: Annovis Bio Readies $10 Million IPO,LLY,https://seekingalpha.com/article/4294246-ipo-update-annovis-bio-readies-10-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,585246ca-a562-41e1-ab69-b80549c01e75
2019-09-30T08:00:00.000+08:00,Earnings Estimates/Revisions - Healthcare,LLY,https://www.benzinga.com/node/14513590,TalkMarkets,,,,0,0,df280d7a-091a-4475-82ec-b6879eb9d09c
2019-09-29T08:00:00.000+08:00,"Spotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4294031-spotlight-microsoft-tesla-xilinx-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,7f56755c-9550-4d76-ac1c-1756e94b28e1
2019-09-29T08:00:00.000+08:00,"Spotlight On Microsoft, Tesla And Xilinx (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4294031-spotlight-microsoft-tesla-xilinx-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,328011f9-9a65-46bf-9f5b-a9c58fd94bc3
2019-09-28T08:00:00.000+08:00,"Stocks To Watch: Spotlight On Microsoft, Tesla And Xilinx",LLY,https://seekingalpha.com/article/4293999-stocks-watch-spotlight-microsoft-tesla-xilinx?source=partner_benzinga,Seeking Alpha,,,,0,0,4f84cd1c-4cd9-415e-9f3c-0c252deecba5
2019-09-28T08:00:00.000+08:00,Daily Insider Ratings Round Up 9/23/19,LLY,https://seekingalpha.com/article/4293985-daily-insider-ratings-round-9-23-19?source=partner_benzinga,Seeking Alpha,,,,0,0,a3e1f4c1-eb1d-4bf0-852e-57cd2b89ba19
2019-09-28T08:00:00.000+08:00,"Stocks To Watch: Spotlight On Microsoft, Tesla And Xilinx",LLY,https://seekingalpha.com/article/4293999-stocks-watch-spotlight-microsoft-tesla-xilinx?source=partner_benzinga,Seeking Alpha,,,,0,0,b98484dd-687b-4ab3-be1a-7975d34ea11a
2019-09-28T08:00:00.000+08:00,Daily Insider Ratings Round Up 9/23/19,LLY,https://seekingalpha.com/article/4293985-daily-insider-ratings-round-9-23-19?source=partner_benzinga,Seeking Alpha,,,,0,0,823db157-dd92-4c9b-81f6-3f9b1ba89da7
2019-09-27T08:00:00.000+08:00,IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA,LLY,http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-539102,Zacks,,,,0,0,fa9d5fef-d693-43fe-87c2-e70ec3d3112e
2019-09-27T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3500469-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,557124b8-d169-485f-b9e5-0601e448147d
2019-09-27T08:00:00.000+08:00,IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA,LLY,http://www.zacks.com/stock/news/539102/intelgenx-igxt-resubmits-nda-for-migraine-candidate-to-fda?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-539102,Zacks,,,,0,0,6b1cdd34-9b91-41cf-bea2-9581598b1b6b
2019-09-27T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3500469-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,73363152-7e6e-4557-bc3c-43f9ff9d9718
2019-09-26T08:00:00.000+08:00,Immuno-Oncology Firm Innate Pharma Files For U.S. IPO,LLY,https://seekingalpha.com/article/4293772-immuno-oncology-firm-innate-pharma-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,4d61449c-267e-40ec-83c3-b40c0708602c
2019-09-26T08:00:00.000+08:00,6 Declining Stocks in Gurus' Portfolios,LLY,https://www.benzinga.com/node/14499201,GuruFocus,,,,0,0,6385d634-68ad-4099-845c-6e861935fc95
2019-09-26T08:00:00.000+08:00,IPO Update: ADC Therapeutics Readies $200 Million IPO,LLY,https://seekingalpha.com/article/4293669-ipo-update-adc-therapeutics-readies-200-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,cf299110-05aa-483b-9651-50fc7cd449ba
2019-09-26T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/536794/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-536794,Zacks,,,,0,0,d2568d76-f2ff-42a3-9584-a64331862021
2019-09-26T08:00:00.000+08:00,Immuno-Oncology Firm Innate Pharma Files For U.S. IPO,LLY,https://seekingalpha.com/article/4293772-immuno-oncology-firm-innate-pharma-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,a1b920d3-b207-45b4-be8a-a54eb4279081
2019-09-26T08:00:00.000+08:00,6 Declining Stocks in Gurus' Portfolios,LLY,https://www.benzinga.com/node/14499201,GuruFocus,,,,0,0,ba900a59-91e3-4086-a8c8-2fe6be5d0fae
2019-09-26T08:00:00.000+08:00,IPO Update: ADC Therapeutics Readies $200 Million IPO,LLY,https://seekingalpha.com/article/4293669-ipo-update-adc-therapeutics-readies-200-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,8f186b50-f2b7-4a6c-8f17-54bad0d972cc
2019-09-26T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/536794/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-536794,Zacks,,,,0,0,9251de1f-90a7-47d9-a395-3484243dcb02
2019-09-25T08:00:00.000+08:00,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/09/14475189/biotech-stock-on-the-radar-anavex-a-neurology-focused-precision-medicine-company,Shanthi Rexaline,,,,0,0,44cb1734-fc9c-4baa-991c-fb8f63ae4753
2019-09-25T08:00:00.000+08:00,"Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach",LLY,https://seekingalpha.com/article/4293545-eli-lilly-throws-hat-ring-lung-cancer-space-takes-targeted-treatment-approach?source=partner_benzinga,Seeking Alpha,,,,0,0,d6e5fdfa-2ae6-40bc-a537-ccb507051d3e
2019-09-25T08:00:00.000+08:00,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/09/14475189/biotech-stock-on-the-radar-anavex-a-neurology-focused-precision-medicine-company,Shanthi Rexaline,,,,0,0,8af4245c-84ae-4f05-81fb-6606373e8442
2019-09-25T08:00:00.000+08:00,"Eli Lilly Throws Hat In The Ring For Lung Cancer Space, Takes Targeted Treatment Approach",LLY,https://seekingalpha.com/article/4293545-eli-lilly-throws-hat-ring-lung-cancer-space-takes-targeted-treatment-approach?source=partner_benzinga,Seeking Alpha,,,,0,0,785c61aa-115d-4bfb-8c11-29ddf9eba7d4
2019-09-23T08:00:00.000+08:00,Eli Lilly to Present Data at the European Society for Medical Oncology,LLY,https://www.benzinga.com/news/19/09/14470457/eli-lilly-to-present-data-at-the-european-society-for-medical-oncology,Benzinga Newsdesk,,,,0,0,eb81a80b-a0fc-482e-ad42-305a45811d71
2019-09-23T08:00:00.000+08:00,Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids,LLY,http://www.zacks.com/stock/news/532006/glaxos-benlysta-gets-positive-chmp-opinion-for-use-in-kids?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-532006,Zacks,,,,0,0,eaf17dc3-5a6f-4502-813d-c798b3aa72b7
2019-09-23T08:00:00.000+08:00,Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label,LLY,http://www.zacks.com/stock/news/531931/lilly-gets-chmp-nod-to-add-heart-indication-to-trulicity-label?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-531931,Zacks,,,,0,0,14a12a29-b80f-42b3-908f-e02750e54b2c
2019-09-23T08:00:00.000+08:00,Eli Lilly to Present Data at the European Society for Medical Oncology,LLY,https://www.benzinga.com/news/19/09/14470457/eli-lilly-to-present-data-at-the-european-society-for-medical-oncology,Benzinga Newsdesk,,,,0,0,b518b0a1-273a-4900-8dd5-ad5269fe54c7
2019-09-23T08:00:00.000+08:00,Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids,LLY,http://www.zacks.com/stock/news/532006/glaxos-benlysta-gets-positive-chmp-opinion-for-use-in-kids?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-532006,Zacks,,,,0,0,c4e69440-fe2e-423e-b258-49fdb821ef95
2019-09-23T08:00:00.000+08:00,Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label,LLY,http://www.zacks.com/stock/news/531931/lilly-gets-chmp-nod-to-add-heart-indication-to-trulicity-label?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-531931,Zacks,,,,0,0,221c21ad-f87c-42cc-acd6-26c61d0fe9a8
2019-09-20T08:00:00.000+08:00,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,LLY,https://www.benzinga.com/markets/wiim/19/09/14466308/shares-of-several-drug-companies-are-trading-higher-after-senate-majority-leader-mcconnell-suggested,Benzinga Newsdesk,,,,0,0,da839b61-de35-4493-8513-4f93cb52b42e
2019-09-20T08:00:00.000+08:00,AC Immune Receives First Milestone Payment From Lilly In Small Molecule Tau Morphomer Program,LLY,https://www.benzinga.com/general/biotech/19/09/14463538/ac-immune-receives-first-milestone-payment-from-lilly-in-small-molecule-tau-morphomer-program,Benzinga Newsdesk,,,,0,0,b0320680-ff63-4352-b1ea-eadd5233a844
2019-09-20T08:00:00.000+08:00,CHMP Issues Positive Opinion To Expand Lilly's Trulicity Label To Include Results From REWIND Cardiovascular Outcomes Trial,LLY,https://www.benzinga.com/general/biotech/19/09/14463459/chmp-issues-positive-opinion-to-expand-lillys-trulicity-label-to-include-results-from-rewind-card,Benzinga Newsdesk,,,,0,0,0041bce1-6558-4d8d-8463-c182a8acf338
2019-09-20T08:00:00.000+08:00,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices,LLY,http://www.gurufocus.com/news/950178/3-pharmaceutical-companies-to-consider-as-lawmakers-continue-to-fight-for-lower-drug-prices,GuruFocus,,,,0,0,6f68a416-4c25-4811-936a-26141e1c8fa7
2019-09-20T08:00:00.000+08:00,Nektar Hammered On Multiple Setbacks; Core Efficacy Questions Remain Open,LLY,https://seekingalpha.com/article/4292757-nektar-hammered-multiple-setbacks-core-efficacy-questions-remain-open?source=partner_benzinga,Seeking Alpha,,,,0,0,9e336f8f-8010-4022-8421-9ec668b94768
2019-09-20T08:00:00.000+08:00,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices,LLY,https://www.benzinga.com/node/14468003,GuruFocus,,,,0,0,3a96d980-2076-4a84-83bb-0e94f162a057
2019-09-20T08:00:00.000+08:00,Drug makers up after McConnell thumbs down on Pelosi price pricing plan,LLY,https://seekingalpha.com/news/3500811-drug-makers-mcconnell-thumbs-pelosi-price-pricing-plan?source=partner_benzinga,Seeking Alpha,,,,0,0,e93ef177-907f-47ca-967c-bf24efce04d5
2019-09-20T08:00:00.000+08:00,CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from ...,LLY,https://www.benzinga.com/node/14464594,GuruFocus,,,,0,0,939f0d68-3841-4e43-8b87-79134a88ae74
2019-09-20T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3498627-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,41fc06f3-ae26-4a2a-967b-888df97b9c5a
2019-09-20T08:00:00.000+08:00,European advisory group backs label update to Lilly's Trulicity,LLY,https://seekingalpha.com/news/3500736-european-advisory-group-backs-label-update-lillys-trulicity?source=partner_benzinga,Seeking Alpha,,,,0,0,47cf05d9-6cfc-4e60-bfb2-2686dbfaf147
2019-09-20T08:00:00.000+08:00,AC Immune earns CHF30M milestone from Eli Lilly,LLY,https://seekingalpha.com/news/3500733-ac-immune-earns-chf30m-milestone-eli-lilly?source=partner_benzinga,Seeking Alpha,,,,0,0,8d81e632-dfd6-45d7-94d6-d43a227012a4
2019-09-20T08:00:00.000+08:00,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,LLY,https://www.benzinga.com/markets/wiim/19/09/14466308/shares-of-several-drug-companies-are-trading-higher-after-senate-majority-leader-mcconnell-suggested,Benzinga Newsdesk,,,,0,0,166910a3-d1ee-40d1-9ddd-3027c9a58b3e
2019-09-20T08:00:00.000+08:00,AC Immune Receives First Milestone Payment From Lilly In Small Molecule Tau Morphomer Program,LLY,https://www.benzinga.com/general/biotech/19/09/14463538/ac-immune-receives-first-milestone-payment-from-lilly-in-small-molecule-tau-morphomer-program,Benzinga Newsdesk,,,,0,0,193c79a5-be18-435c-966c-9441a66d603a
2019-09-20T08:00:00.000+08:00,CHMP Issues Positive Opinion To Expand Lilly's Trulicity Label To Include Results From REWIND Cardiovascular Outcomes Trial,LLY,https://www.benzinga.com/general/biotech/19/09/14463459/chmp-issues-positive-opinion-to-expand-lillys-trulicity-label-to-include-results-from-rewind-card,Benzinga Newsdesk,,,,0,0,d0f118c9-3e2f-49cf-9663-b4390cad2dcf
2019-09-20T08:00:00.000+08:00,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices,LLY,http://www.gurufocus.com/news/950178/3-pharmaceutical-companies-to-consider-as-lawmakers-continue-to-fight-for-lower-drug-prices,GuruFocus,,,,0,0,96181a31-a900-4410-afaf-17517c4ccb0d
2019-09-20T08:00:00.000+08:00,Nektar Hammered On Multiple Setbacks; Core Efficacy Questions Remain Open,LLY,https://seekingalpha.com/article/4292757-nektar-hammered-multiple-setbacks-core-efficacy-questions-remain-open?source=partner_benzinga,Seeking Alpha,,,,0,0,2e00f86d-06ea-4b85-ba85-5710e7298316
2019-09-20T08:00:00.000+08:00,' Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices,LLY,https://www.benzinga.com/node/14468003,GuruFocus,,,,0,0,67ee759e-9e15-466a-aa20-73ed92b11559
2019-09-20T08:00:00.000+08:00,Drug makers up after McConnell thumbs down on Pelosi price pricing plan,LLY,https://seekingalpha.com/news/3500811-drug-makers-mcconnell-thumbs-pelosi-price-pricing-plan?source=partner_benzinga,Seeking Alpha,,,,0,0,a3c33e8f-2bad-497c-8025-e0124aa34dba
2019-09-20T08:00:00.000+08:00,CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from ...,LLY,https://www.benzinga.com/node/14464594,GuruFocus,,,,0,0,e75a2845-fe7f-4e84-a796-8c507472bc96
2019-09-20T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3498627-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,e82d641b-b6cc-494d-b486-90d35093391e
2019-09-20T08:00:00.000+08:00,European advisory group backs label update to Lilly's Trulicity,LLY,https://seekingalpha.com/news/3500736-european-advisory-group-backs-label-update-lillys-trulicity?source=partner_benzinga,Seeking Alpha,,,,0,0,3327d32c-c915-418b-a4d9-d37022b58f5a
2019-09-20T08:00:00.000+08:00,AC Immune earns CHF30M milestone from Eli Lilly,LLY,https://seekingalpha.com/news/3500733-ac-immune-earns-chf30m-milestone-eli-lilly?source=partner_benzinga,Seeking Alpha,,,,0,0,f2d3b187-e48f-431a-b0ed-2e14ad4e6bb6
2019-09-17T08:00:00.000+08:00,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline,LLY,https://www.benzinga.com/general/biotech/19/09/14433747/biotech-stock-on-the-radar-vtv-therapeutics-diabetes-pipeline,Shanthi Rexaline,,,,0,0,ef4bcdaf-7e80-4ac7-ad39-5e32cd11f4c4
2019-09-17T08:00:00.000+08:00,Kitov Pharma: NT-219 Data Reveals Ability To Reverse Pancreatic Cancer Drugs Resistance And The Market Doesn't Care,LLY,https://seekingalpha.com/article/4292021-kitov-pharma-ntminus-219-data-reveals-ability-reverse-pancreatic-cancer-drugs-resistance?source=partner_benzinga,Seeking Alpha,,,,0,0,d93cb1c7-bfba-4f8d-bc59-61556bcf483d
2019-09-17T08:00:00.000+08:00,Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck,LLY,http://www.zacks.com/stock/news/522796/alder-aldr-stock-up-on-acquisition-agreement-with-lundbeck?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-522796,Zacks,,,,0,0,1aee0d70-bbdd-4901-a8b1-07f654611938
2019-09-17T08:00:00.000+08:00,"Lundbeck Makes A Large M&A Move, But The Target Will Be Somewhat Controversial",LLY,https://seekingalpha.com/article/4292001-lundbeck-makes-large-m-move-target-will-somewhat-controversial?source=partner_benzinga,Seeking Alpha,,,,0,0,aa9518de-e500-4fac-a308-bac4afc500b9
2019-09-17T08:00:00.000+08:00,Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline,LLY,https://www.benzinga.com/general/biotech/19/09/14433747/biotech-stock-on-the-radar-vtv-therapeutics-diabetes-pipeline,Shanthi Rexaline,,,,0,0,ce65b220-9d44-4d1a-892c-c00f078877a6
2019-09-17T08:00:00.000+08:00,Kitov Pharma: NT-219 Data Reveals Ability To Reverse Pancreatic Cancer Drugs Resistance And The Market Doesn't Care,LLY,https://seekingalpha.com/article/4292021-kitov-pharma-ntminus-219-data-reveals-ability-reverse-pancreatic-cancer-drugs-resistance?source=partner_benzinga,Seeking Alpha,,,,0,0,2af6b966-e652-4b6d-979f-26b9d10f24e0
2019-09-17T08:00:00.000+08:00,Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck,LLY,http://www.zacks.com/stock/news/522796/alder-aldr-stock-up-on-acquisition-agreement-with-lundbeck?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-522796,Zacks,,,,0,0,bd7efbc9-5849-4452-b37d-c46a2036be36
2019-09-17T08:00:00.000+08:00,"Lundbeck Makes A Large M&A Move, But The Target Will Be Somewhat Controversial",LLY,https://seekingalpha.com/article/4292001-lundbeck-makes-large-m-move-target-will-somewhat-controversial?source=partner_benzinga,Seeking Alpha,,,,0,0,010f1d40-7b3e-4f93-8fed-6b70357acbee
2019-09-16T08:00:00.000+08:00,Fitch Planning To Withdraw Ratings For Eli Lilly,LLY,https://www.benzinga.com/news/19/09/14436109/fitch-planning-to-withdraw-ratings-for-eli-lilly,Benzinga Newsdesk,,,,0,0,d4c54078-9bf4-4ba4-b571-6a00cea7b38a
2019-09-16T08:00:00.000+08:00,ADC Therapeutics Begins U.S. IPO Process,LLY,https://seekingalpha.com/article/4291811-adc-therapeutics-begins-u-s-ipo-process?source=partner_benzinga,Seeking Alpha,,,,0,0,d6488efa-ee09-4ccb-8066-245ece916872
2019-09-16T08:00:00.000+08:00,Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert,LLY,http://www.zacks.com/stock/news/520833/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert?cid=CS-BENZ-FT-analyst_blog|industry_focus-520833,Zacks,,,,0,0,7cd2717d-06a5-402c-ad72-b18311d9b438
2019-09-16T08:00:00.000+08:00,Fitch Planning To Withdraw Ratings For Eli Lilly,LLY,https://www.benzinga.com/news/19/09/14436109/fitch-planning-to-withdraw-ratings-for-eli-lilly,Benzinga Newsdesk,,,,0,0,b5176c1f-c7d1-41d9-869a-a05f01d5cb5e
2019-09-16T08:00:00.000+08:00,ADC Therapeutics Begins U.S. IPO Process,LLY,https://seekingalpha.com/article/4291811-adc-therapeutics-begins-u-s-ipo-process?source=partner_benzinga,Seeking Alpha,,,,0,0,dd41b781-83b6-4c6c-b8b2-1c7fecbc7968
2019-09-16T08:00:00.000+08:00,Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert,LLY,http://www.zacks.com/stock/news/520833/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert?cid=CS-BENZ-FT-analyst_blog|industry_focus-520833,Zacks,,,,0,0,b5d3c25c-22c5-4abe-b2b7-1c65337f4da0
2019-09-13T08:00:00.000+08:00,FDA warns on rare side effect of breast cancer meds,LLY,https://seekingalpha.com/news/3499244-fda-warns-rare-side-effect-breast-cancer-meds?source=partner_benzinga,Seeking Alpha,,,,0,0,45ce92b0-de0e-4941-b9a6-7717598ba7e4
2019-09-13T08:00:00.000+08:00,"Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival",LLY,http://www.zacks.com/stock/news/516999/zackscom-featured-highlights-include-columbia-sportswear-fossil-group-alexion-and-shoe-carnival?cid=CS-BENZ-FT-press_releases-516999,Zacks,,,,0,0,3c584402-f759-4d59-8622-424e821b753c
2019-09-13T08:00:00.000+08:00,"Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others",LLY,http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-BENZ-FT-analyst_blog|stock_roundup-516828,Zacks,,,,0,0,b14382f0-2123-4433-8874-ced3a5142bf0
2019-09-13T08:00:00.000+08:00,FDA warns on rare side effect of breast cancer meds,LLY,https://seekingalpha.com/news/3499244-fda-warns-rare-side-effect-breast-cancer-meds?source=partner_benzinga,Seeking Alpha,,,,0,0,9c949f33-b129-42d3-8f96-eb99aaca780d
2019-09-13T08:00:00.000+08:00,"Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival",LLY,http://www.zacks.com/stock/news/516999/zackscom-featured-highlights-include-columbia-sportswear-fossil-group-alexion-and-shoe-carnival?cid=CS-BENZ-FT-press_releases-516999,Zacks,,,,0,0,2a07b50b-a777-4b71-ac18-4fa11f06e3f7
2019-09-13T08:00:00.000+08:00,"Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others",LLY,http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-BENZ-FT-analyst_blog|stock_roundup-516828,Zacks,,,,0,0,82ab29ab-4fc5-43eb-98d1-03870d6a77e3
2019-09-12T08:00:00.000+08:00,Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks,LLY,http://www.zacks.com/stock/news/514650/rising-p-e-an-often-ignored-trick-to-pick-5-winning-stocks?cid=CS-BENZ-FT-analyst_blog|rw-514650,Zacks,,,,0,0,0214ef5a-0747-49cc-993a-c0d54cb508a0
2019-09-12T08:00:00.000+08:00,Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks,LLY,http://www.zacks.com/stock/news/514650/rising-p-e-an-often-ignored-trick-to-pick-5-winning-stocks?cid=CS-BENZ-FT-analyst_blog|rw-514650,Zacks,,,,0,0,16cd3681-c151-4409-b81b-a1342c465378
2019-09-10T08:00:00.000+08:00,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,LLY,https://www.benzinga.com/markets/wiim/19/09/14407152/shares-of-several-drugmakers-are-trading-lower-on-news-of-a-drug-pricing-bill-being-developed-by-hou,Benzinga Newsdesk,,,,0,0,de057eb5-70fd-4a37-92a7-3ec8742c949a
2019-09-10T08:00:00.000+08:00,"Bank of America Reiterates Neutral on Eli Lilly, Raises Price Target to $120",LLY,https://www.benzinga.com/news/19/09/14406163/bank-of-america-reiterates-neutral-on-eli-lilly-raises-price-target-to-120,Vick Meyer,,,,0,0,abddc037-0259-45e2-bead-41465b5884f3
2019-09-10T08:00:00.000+08:00,Pfizer's Pneumococcal Vaccine Shows Potential in Infants,LLY,http://www.zacks.com/stock/news/511848/pfizers-pneumococcal-vaccine-shows-potential-in-infants?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-511848,Zacks,,,,0,0,adf3317a-e8ae-47f5-81b6-d3cac3cc25f3
2019-09-10T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/510993/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-510993,Zacks,,,,0,0,42b035da-49ad-452d-876a-0dfc752a47cd
2019-09-10T08:00:00.000+08:00,"Novo Nordisk Joins Insulin Discount Party, But Prices Still Unlikely To Fall",LLY,https://seekingalpha.com/article/4290590-novo-nordisk-joins-insulin-discount-party-prices-still-unlikely-fall?source=partner_benzinga,Seeking Alpha,,,,0,0,bde90416-c16c-49a9-a41c-a8f43fbf096d
2019-09-10T08:00:00.000+08:00,Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.,LLY,https://www.benzinga.com/markets/wiim/19/09/14407152/shares-of-several-drugmakers-are-trading-lower-on-news-of-a-drug-pricing-bill-being-developed-by-hou,Benzinga Newsdesk,,,,0,0,05e765b3-b425-44f6-b9c0-7d9e263f0c34
2019-09-10T08:00:00.000+08:00,"Bank of America Reiterates Neutral on Eli Lilly, Raises Price Target to $120",LLY,https://www.benzinga.com/news/19/09/14406163/bank-of-america-reiterates-neutral-on-eli-lilly-raises-price-target-to-120,Vick Meyer,,,,0,0,abfd4b3f-a024-4577-9fb5-6a2407b36b71
2019-09-10T08:00:00.000+08:00,Pfizer's Pneumococcal Vaccine Shows Potential in Infants,LLY,http://www.zacks.com/stock/news/511848/pfizers-pneumococcal-vaccine-shows-potential-in-infants?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-511848,Zacks,,,,0,0,d78865f1-3638-44e6-86c4-ed8b3a762013
2019-09-10T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/510993/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-510993,Zacks,,,,0,0,5885d0b1-a8ac-42bd-ac62-1155532f8341
2019-09-10T08:00:00.000+08:00,"Novo Nordisk Joins Insulin Discount Party, But Prices Still Unlikely To Fall",LLY,https://seekingalpha.com/article/4290590-novo-nordisk-joins-insulin-discount-party-prices-still-unlikely-fall?source=partner_benzinga,Seeking Alpha,,,,0,0,2300e58d-69ac-4337-b3c9-c49adb833885
2019-09-09T08:00:00.000+08:00,Eli Lilly shares are trading lower. Shares traded higher on light volume in Monday's pre-market session after the company reported results from its clinical trial of LOXO-292 and have since reversed.,LLY,https://www.benzinga.com/markets/wiim/19/09/14398697/eli-lilly-shares-are-trading-lower-shares-traded-higher-in-mondays-pre-market-session-after-the-comp,Benzinga Newsdesk,,,,0,0,c31c2eb3-6220-4cbb-90ec-5cbe06f29429
2019-09-09T08:00:00.000+08:00,30 Stocks Moving in Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/09/14396544/30-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,d06f8655-6487-4218-b5d3-999367316455
2019-09-09T08:00:00.000+08:00,"Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",LLY,https://www.benzinga.com/news/19/09/14395555/lilly-announces-positive-results-for-selpercatinib-loxo-292-demonstrating-a-68-percent-objective-res,Charles Gross,,,,0,0,02e37b4f-80a0-46b6-a341-50674e851dd2
2019-09-09T08:00:00.000+08:00,"Wall Street's Top Stories For Monday, September 9, 2019",LLY,https://www.benzinga.com/node/14401753,TalkMarkets,,,,0,0,d60f8e9e-2ab4-42fc-934d-89f80e849bac
2019-09-09T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow,LLY,https://seekingalpha.com/article/4290610-eli-lilly-company-lly-presents-iaslc-2019-world-conference-lung-cancer-slideshow?source=partner_benzinga,Seeking Alpha,,,,0,0,5fa3a39c-2615-4c0a-8694-71921a7fb68c
2019-09-09T08:00:00.000+08:00,Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study,LLY,http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-509890,Zacks,,,,0,0,bb30062a-8a5f-468e-be8c-2e1886d8b02d
2019-09-09T08:00:00.000+08:00,Thermo Fisher to develop companion diagnostic for Lilly's selpercatinib,LLY,https://seekingalpha.com/news/3497898-thermo-fisher-develop-companion-diagnostic-lillys-selpercatinib?source=partner_benzinga,Seeking Alpha,,,,0,0,c1a832db-53e6-49b0-b749-dfa674d4b42a
2019-09-09T08:00:00.000+08:00,Eli Lilly up 3% premarket on positive selpercatinib data,LLY,https://seekingalpha.com/news/3497844-eli-lilly-3-percent-premarket-positive-selpercatinib-data?source=partner_benzinga,Seeking Alpha,,,,0,0,980fbc2f-073a-424d-9e4d-feb73f51a180
2019-09-09T08:00:00.000+08:00,Eli Lilly shares are trading lower. Shares traded higher on light volume in Monday's pre-market session after the company reported results from its clinical trial of LOXO-292 and have since reversed.,LLY,https://www.benzinga.com/markets/wiim/19/09/14398697/eli-lilly-shares-are-trading-lower-shares-traded-higher-in-mondays-pre-market-session-after-the-comp,Benzinga Newsdesk,,,,0,0,b4836495-9605-4ffa-bc99-1c9e39cc64b0
2019-09-09T08:00:00.000+08:00,30 Stocks Moving in Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/09/14396544/30-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,30ba2138-ce67-469f-9e17-cc4bfbd092ab
2019-09-09T08:00:00.000+08:00,"Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer",LLY,https://www.benzinga.com/news/19/09/14395555/lilly-announces-positive-results-for-selpercatinib-loxo-292-demonstrating-a-68-percent-objective-res,Charles Gross,,,,0,0,250ecdc5-f6c6-4bb2-9258-2370f178b463
2019-09-09T08:00:00.000+08:00,"Wall Street's Top Stories For Monday, September 9, 2019",LLY,https://www.benzinga.com/node/14401753,TalkMarkets,,,,0,0,f0925d5c-e0c3-4abd-b7cc-382f7edae703
2019-09-09T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents At IASLC 2019 World Conference On Lung Cancer - Slideshow,LLY,https://seekingalpha.com/article/4290610-eli-lilly-company-lly-presents-iaslc-2019-world-conference-lung-cancer-slideshow?source=partner_benzinga,Seeking Alpha,,,,0,0,b001ee23-d167-460b-acd8-db681457dd9a
2019-09-09T08:00:00.000+08:00,Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study,LLY,http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-509890,Zacks,,,,0,0,5c754fb8-405f-447f-aea4-b16404a4ee7a
2019-09-09T08:00:00.000+08:00,Thermo Fisher to develop companion diagnostic for Lilly's selpercatinib,LLY,https://seekingalpha.com/news/3497898-thermo-fisher-develop-companion-diagnostic-lillys-selpercatinib?source=partner_benzinga,Seeking Alpha,,,,0,0,4575eacb-de01-4401-ae70-981d153919d1
2019-09-09T08:00:00.000+08:00,Eli Lilly up 3% premarket on positive selpercatinib data,LLY,https://seekingalpha.com/news/3497844-eli-lilly-3-percent-premarket-positive-selpercatinib-data?source=partner_benzinga,Seeking Alpha,,,,0,0,4647d155-fbbb-4c1c-90c1-8ceb655df83d
2019-09-08T08:00:00.000+08:00,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",LLY,https://www.benzinga.com/general/biotech/19/09/14385354/the-week-ahead-in-biotech-conference-presentations-ipo-news-flow-take-the-spotlight,Shanthi Rexaline,,,,0,0,dac0b4b4-074c-4c99-bb93-c105c1ff890e
2019-09-08T08:00:00.000+08:00,"Apple, IPOs And German Auto (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4290354-apple-ipos-german-auto-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,4efc9d3e-161a-491c-809c-dea1852ef578
2019-09-08T08:00:00.000+08:00,"The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight",LLY,https://www.benzinga.com/general/biotech/19/09/14385354/the-week-ahead-in-biotech-conference-presentations-ipo-news-flow-take-the-spotlight,Shanthi Rexaline,,,,0,0,2fb4dc18-1c4e-426d-b4ea-5fb7ac761b7e
2019-09-08T08:00:00.000+08:00,"Apple, IPOs And German Auto (Stocks To Watch Podcast)",LLY,https://seekingalpha.com/article/4290354-apple-ipos-german-auto-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,5f8dce26-c29b-4c87-b309-4f8246685b6c
2019-09-07T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of September 8,LLY,https://seekingalpha.com/article/4290338-dividend-challenger-highlights-week-september-8?source=partner_benzinga,Seeking Alpha,,,,0,0,523ed9ef-9470-4bde-8f51-cfed7d785183
2019-09-07T08:00:00.000+08:00,Vanguard Health Care ETF: A Good Fund To Benefit From An Ageing Demographic Trend,LLY,https://seekingalpha.com/article/4290324-vanguard-health-care-etf-good-fund-benefit-ageing-demographic-trend?source=partner_benzinga,Seeking Alpha,,,,0,0,5ca18493-475c-40c5-adea-1efa856a423f
2019-09-07T08:00:00.000+08:00,"Stocks To Watch: Apple, IPOs And German Auto",LLY,https://seekingalpha.com/article/4290308-stocks-watch-apple-ipos-german-auto?source=partner_benzinga,Seeking Alpha,,,,0,0,59f61ea8-a99d-4476-83ac-54dc51a07d9d
2019-09-07T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of September 8,LLY,https://seekingalpha.com/article/4290338-dividend-challenger-highlights-week-september-8?source=partner_benzinga,Seeking Alpha,,,,0,0,b3dbd709-b489-4e06-bea0-6c79e010e9ba
2019-09-07T08:00:00.000+08:00,Vanguard Health Care ETF: A Good Fund To Benefit From An Ageing Demographic Trend,LLY,https://seekingalpha.com/article/4290324-vanguard-health-care-etf-good-fund-benefit-ageing-demographic-trend?source=partner_benzinga,Seeking Alpha,,,,0,0,c0b6c550-d03a-4c47-ae54-ef47652886b5
2019-09-07T08:00:00.000+08:00,"Stocks To Watch: Apple, IPOs And German Auto",LLY,https://seekingalpha.com/article/4290308-stocks-watch-apple-ipos-german-auto?source=partner_benzinga,Seeking Alpha,,,,0,0,4df01459-192b-48d7-a0cd-b066d089a173
2019-09-06T08:00:00.000+08:00,"Xeris Pharma's Gvoke: Strong Approval Chances, But This Is A Highly Competitive Space",LLY,https://seekingalpha.com/article/4289833-xeris-pharmas-gvoke-strong-approval-chances-highly-competitive-space?source=partner_benzinga,Seeking Alpha,,,,0,0,ad9accb5-16b4-44f6-a12f-b0d966825e76
2019-09-06T08:00:00.000+08:00,"Xeris Pharma's Gvoke: Strong Approval Chances, But This Is A Highly Competitive Space",LLY,https://seekingalpha.com/article/4289833-xeris-pharmas-gvoke-strong-approval-chances-highly-competitive-space?source=partner_benzinga,Seeking Alpha,,,,0,0,c1bcaeb1-8779-45a4-837e-3c7ee5866558
2019-09-05T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted Application To Enter Complex Innovative Trial Designs Pilot Meeting Program,LLY,https://www.benzinga.com/news/19/09/14385756/eli-lilly-reports-fda-accepted-application-to-enter-complex-innovative-trial-designs-pilot-meeting-p,Benzinga Newsdesk,,,,0,0,e0623f1b-4f98-499d-9a62-d17b12690169
2019-09-05T08:00:00.000+08:00,Xeris: Preparing For The Gvoke PDUFA,LLY,https://seekingalpha.com/article/4290076-xeris-preparing-gvoke-pdufa?source=partner_benzinga,Seeking Alpha,,,,0,0,2c6f4ab8-7134-4b61-8c82-22dd99738a5b
2019-09-05T08:00:00.000+08:00,Lilly into FDA pilot program to modernize drug development,LLY,https://seekingalpha.com/news/3497458-lilly-fda-pilot-program-modernize-drug-development?source=partner_benzinga,Seeking Alpha,,,,0,0,e7e4f043-a125-4699-92fb-0e6f98134fc0
2019-09-05T08:00:00.000+08:00,AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC,LLY,http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-503575,Zacks,,,,0,0,ce52ddd1-fa7b-411e-8f23-4b92671aaf9d
2019-09-05T08:00:00.000+08:00,J&J's Stelara Gets Approval in EU for Ulcerative Colitis,LLY,http://www.zacks.com/stock/news/503348/jjs-stelara-gets-approval-in-eu-for-ulcerative-colitis?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-503348,Zacks,,,,0,0,0ab484b3-5e47-40a1-988e-e35817459491
2019-09-05T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted Application To Enter Complex Innovative Trial Designs Pilot Meeting Program,LLY,https://www.benzinga.com/news/19/09/14385756/eli-lilly-reports-fda-accepted-application-to-enter-complex-innovative-trial-designs-pilot-meeting-p,Benzinga Newsdesk,,,,0,0,d3211ed7-b5a2-40f2-8138-41a5182866a9
2019-09-05T08:00:00.000+08:00,Xeris: Preparing For The Gvoke PDUFA,LLY,https://seekingalpha.com/article/4290076-xeris-preparing-gvoke-pdufa?source=partner_benzinga,Seeking Alpha,,,,0,0,ea06f6f4-d231-4304-9aaa-9afa69bb2ad1
2019-09-05T08:00:00.000+08:00,Lilly into FDA pilot program to modernize drug development,LLY,https://seekingalpha.com/news/3497458-lilly-fda-pilot-program-modernize-drug-development?source=partner_benzinga,Seeking Alpha,,,,0,0,da9a061a-ee4d-486d-a616-fa3cc48cac0d
2019-09-05T08:00:00.000+08:00,AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC,LLY,http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-503575,Zacks,,,,0,0,dfbb5e36-1816-40fd-8f3b-bc37e4334392
2019-09-05T08:00:00.000+08:00,J&J's Stelara Gets Approval in EU for Ulcerative Colitis,LLY,http://www.zacks.com/stock/news/503348/jjs-stelara-gets-approval-in-eu-for-ulcerative-colitis?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-503348,Zacks,,,,0,0,01739405-3b68-4d4d-9800-cbe9dabc822f
2019-09-04T08:00:00.000+08:00,Satsuma IPO: At Phase 3 Of Development,LLY,https://seekingalpha.com/article/4289688-satsuma-ipo-phase-3-development?source=partner_benzinga,Seeking Alpha,,,,0,0,6de424a9-b196-4927-9b19-ba4d6fc8a818
2019-09-04T08:00:00.000+08:00,Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M,LLY,http://www.zacks.com/stock/news/501399/vertex-vrtx-inks-all-cash-deal-to-acquire-semma-for-%24950m?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-501399,Zacks,,,,0,0,d0963e78-adfe-4796-a24b-3de80c9ed7e0
2019-09-04T08:00:00.000+08:00,Satsuma IPO: At Phase 3 Of Development,LLY,https://seekingalpha.com/article/4289688-satsuma-ipo-phase-3-development?source=partner_benzinga,Seeking Alpha,,,,0,0,8669ce69-e085-49f1-88a5-ce556e549dfe
2019-09-04T08:00:00.000+08:00,Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M,LLY,http://www.zacks.com/stock/news/501399/vertex-vrtx-inks-all-cash-deal-to-acquire-semma-for-%24950m?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-501399,Zacks,,,,0,0,caabb39b-f44f-4314-ab3b-65b59c677abd
2019-09-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie",LLY,http://www.zacks.com/stock/news/499580/the-zacks-analyst-blog-highlights-jj-eli-lilly-bristol-myers-roche-and-abbvie?cid=CS-BENZ-FT-press_releases-499580,Zacks,,,,0,0,901c3409-1232-4cdb-90a3-57cd03824e0a
2019-09-03T08:00:00.000+08:00,5 Cancer-Fighting Stocks to Add to Your Portfolio,LLY,http://www.zacks.com/stock/news/499386/5-cancer-fighting-stocks-to-add-to-your-portfolio?cid=CS-BENZ-FT-analyst_blog|investment_ideas-499386,Zacks,,,,0,0,db2bd011-c8b4-45cd-8680-fb8e2c039c9e
2019-09-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie",LLY,http://www.zacks.com/stock/news/499580/the-zacks-analyst-blog-highlights-jj-eli-lilly-bristol-myers-roche-and-abbvie?cid=CS-BENZ-FT-press_releases-499580,Zacks,,,,0,0,62c8d02c-5653-4671-881a-0fed7e47fc38
2019-09-03T08:00:00.000+08:00,5 Cancer-Fighting Stocks to Add to Your Portfolio,LLY,http://www.zacks.com/stock/news/499386/5-cancer-fighting-stocks-to-add-to-your-portfolio?cid=CS-BENZ-FT-analyst_blog|investment_ideas-499386,Zacks,,,,0,0,f6338723-1842-4732-a55b-b848039fe4e0
2019-08-31T08:00:00.000+08:00,"Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More",LLY,https://www.benzinga.com/media/19/08/14361134/barrons-picks-and-pans-activision-blizzard-best-buy-coca-cola-microsoft-and-more,Nelson Hem,,,,0,0,c8a16ade-d666-4e8a-8b54-be58cbf232b5
2019-08-31T08:00:00.000+08:00,Week In Review: HiFiBiO Raises $67 Million For Immune Modulator Portfolio,LLY,https://www.benzinga.com/node/14361212,TalkMarkets,,,,0,0,e6fe01c8-0d40-401c-bd84-7200c0519303
2019-08-31T08:00:00.000+08:00,"Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More",LLY,https://www.benzinga.com/media/19/08/14361134/barrons-picks-and-pans-activision-blizzard-best-buy-coca-cola-microsoft-and-more,Nelson Hem,,,,0,0,caef0bda-17e0-4a85-8039-a9301723d838
2019-08-31T08:00:00.000+08:00,Week In Review: HiFiBiO Raises $67 Million For Immune Modulator Portfolio,LLY,https://www.benzinga.com/node/14361212,TalkMarkets,,,,0,0,4365bf75-fd0d-4d0c-b587-1c22a8fe6dcd
2019-08-30T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3492969-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,81f06a9d-acaf-484c-a39c-eaaaf220df5f
2019-08-30T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3492969-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,a8ff1a93-55e1-4eaf-826d-683721e8540d
2019-08-29T08:00:00.000+08:00,FDA tentatively OK's Mylan's pemetrexed; shares up 4%,LLY,https://seekingalpha.com/news/3495779-fda-tentatively-oks-mylans-pemetrexed-shares-4-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,91364218-02b7-47c8-b5fd-a7c3fb31600f
2019-08-29T08:00:00.000+08:00,Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?,LLY,http://www.zacks.com/stock/news/494219/lilly-lly-up-19-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-realtime_blog-494219,Zacks,,,,0,0,e1b36de1-8c48-4254-85e0-4cf96219c226
2019-08-29T08:00:00.000+08:00,FDA tentatively OK's Mylan's pemetrexed; shares up 4%,LLY,https://seekingalpha.com/news/3495779-fda-tentatively-oks-mylans-pemetrexed-shares-4-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,74602cf6-1591-4bda-9915-29deab860035
2019-08-29T08:00:00.000+08:00,Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?,LLY,http://www.zacks.com/stock/news/494219/lilly-lly-up-19-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-realtime_blog-494219,Zacks,,,,0,0,6fd3daf1-2a01-457f-92fb-cfd2d615f84f
2019-08-28T08:00:00.000+08:00,Eli Lilly's Latest Approval Adds To An Ever-Growing Market For Taltz,LLY,https://seekingalpha.com/article/4288535-eli-lillys-latest-approval-adds-ever-growing-market-taltz?source=partner_benzinga,Seeking Alpha,,,,0,0,2f64bc9f-8f65-4861-9fc8-cb2555fbc419
2019-08-28T08:00:00.000+08:00,J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?,LLY,http://www.zacks.com/stock/news/493075/jj-jnj-loses-landmark-opioid-case-whats-next-for-pharmaceuticals?cid=CS-BENZ-FT-stocks_in_the_news|investment_ideas-493075,Zacks,,,,0,0,251b8de0-d6ad-41c1-944d-54540e8c0f54
2019-08-28T08:00:00.000+08:00,Eli Lilly's Latest Approval Adds To An Ever-Growing Market For Taltz,LLY,https://seekingalpha.com/article/4288535-eli-lillys-latest-approval-adds-ever-growing-market-taltz?source=partner_benzinga,Seeking Alpha,,,,0,0,bb2622c9-1ce3-4aaf-a2d7-a4bf5617a7c0
2019-08-28T08:00:00.000+08:00,J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?,LLY,http://www.zacks.com/stock/news/493075/jj-jnj-loses-landmark-opioid-case-whats-next-for-pharmaceuticals?cid=CS-BENZ-FT-stocks_in_the_news|investment_ideas-493075,Zacks,,,,0,0,d4062be1-c0db-4605-a127-0becbc3d45f4
2019-08-26T08:00:00.000+08:00,Lilly Receives FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis,LLY,https://www.benzinga.com/news/19/08/14324889/lilly-receives-fda-approval-for-taltz-for-the-treatment-of-active-ankylosing-spondylitis,Charles Gross,,,,0,0,4cc4f2bd-946e-4117-9211-355af2e5f3bf
2019-08-26T08:00:00.000+08:00,TFF Pharmaceuticals Readies $22 Million IPO,LLY,https://seekingalpha.com/article/4287981-tff-pharmaceuticals-readies-22-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,fbf837c9-46ac-421e-abe1-d8a5d46c7cac
2019-08-26T08:00:00.000+08:00,Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study,LLY,http://www.zacks.com/stock/news/489424/lillys-olumiant-meets-primary-endpoint-in-3rd-eczema-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-489424,Zacks,,,,0,0,cf60cc84-6e2f-457b-a008-2c792012a24b
2019-08-26T08:00:00.000+08:00,FDA OKs expanded use of Lilly's Taltz,LLY,https://seekingalpha.com/news/3494506-fda-oks-expanded-use-lillys-taltz?source=partner_benzinga,Seeking Alpha,,,,0,0,cdd7c315-1374-4cc8-a5d8-114373aa4ed0
2019-08-26T08:00:00.000+08:00,Lilly Receives FDA Approval for Taltz for the Treatment of Active Ankylosing Spondylitis,LLY,https://www.benzinga.com/news/19/08/14324889/lilly-receives-fda-approval-for-taltz-for-the-treatment-of-active-ankylosing-spondylitis,Charles Gross,,,,0,0,3fe7cd0b-9a34-4c98-a979-5fe8a55f4186
2019-08-26T08:00:00.000+08:00,TFF Pharmaceuticals Readies $22 Million IPO,LLY,https://seekingalpha.com/article/4287981-tff-pharmaceuticals-readies-22-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,414b3bf3-7155-4da8-97aa-1d469366e1a3
2019-08-26T08:00:00.000+08:00,Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study,LLY,http://www.zacks.com/stock/news/489424/lillys-olumiant-meets-primary-endpoint-in-3rd-eczema-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-489424,Zacks,,,,0,0,242f2b02-3fa8-4d5b-a9a4-ba53dede3276
2019-08-26T08:00:00.000+08:00,FDA OKs expanded use of Lilly's Taltz,LLY,https://seekingalpha.com/news/3494506-fda-oks-expanded-use-lillys-taltz?source=partner_benzinga,Seeking Alpha,,,,0,0,6e89516f-0155-4fc9-9988-d79fb517b065
2019-08-25T08:00:00.000+08:00,Week In Review: Biotheus Acquires China Rights To 3 Bi-Specifics In $142 Million Deal,LLY,https://seekingalpha.com/article/4287759-week-review-biotheus-acquires-china-rights-3-bi-specifics-142-million-deal?source=partner_benzinga,Seeking Alpha,,,,0,0,2848fe58-0554-4583-aa8d-287509e0fa86
2019-08-25T08:00:00.000+08:00,Week In Review: Biotheus Acquires China Rights To 3 Bi-Specifics In $142 Million Deal,LLY,https://seekingalpha.com/article/4287759-week-review-biotheus-acquires-china-rights-3-bi-specifics-142-million-deal?source=partner_benzinga,Seeking Alpha,,,,0,0,49e48948-446c-4705-ac79-b034f539f5c2
2019-08-24T08:00:00.000+08:00,Week In Review: Biotheus Acquires China Rights To Three Bi-specifics In $142 Million Deal,LLY,https://www.benzinga.com/node/14323616,TalkMarkets,,,,0,0,d49cd0c0-a4d9-4563-ba9f-d517110ef887
2019-08-24T08:00:00.000+08:00,Elanco: Greater Risks And Rewards Following The Bayer Deal,LLY,https://seekingalpha.com/article/4287727-elanco-greater-risks-rewards-following-bayer-deal?source=partner_benzinga,Seeking Alpha,,,,0,0,4492b44e-a1d6-4de4-ab03-4b1e26f75b55
2019-08-24T08:00:00.000+08:00,Week In Review: Biotheus Acquires China Rights To Three Bi-specifics In $142 Million Deal,LLY,https://www.benzinga.com/node/14323616,TalkMarkets,,,,0,0,bea9f566-c380-49f9-8646-3636270dedf9
2019-08-24T08:00:00.000+08:00,Elanco: Greater Risks And Rewards Following The Bayer Deal,LLY,https://seekingalpha.com/article/4287727-elanco-greater-risks-rewards-following-bayer-deal?source=partner_benzinga,Seeking Alpha,,,,0,0,f2c6a0e3-ce69-4c08-9576-fe6b00900828
2019-08-23T08:00:00.000+08:00,"Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019",LLY,https://www.benzinga.com/general/biotech/19/08/14321502/eli-lilly-reports-baricitinib-met-primary-endpoint-in-breeze-ad7-third-pivotal-phase-3-trial-in-b,Benzinga Newsdesk,,,,0,0,a6dbafde-4aff-47f6-bcbe-6317d020e063
2019-08-23T08:00:00.000+08:00,Lilly's baricitinib successful in third late-stage dermatitis study,LLY,https://seekingalpha.com/news/3494415-lillys-baricitinib-successful-third-late-stage-dermatitis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,81a4a29d-c329-4bd8-a141-66626fc7cf7b
2019-08-23T08:00:00.000+08:00,Arbitration panel backs Lilly in dispute with former collaboration partner Adocia,LLY,https://seekingalpha.com/news/3494272-arbitration-panel-backs-lilly-dispute-former-collaboration-partner-adocia?source=partner_benzinga,Seeking Alpha,,,,0,0,3f766b5c-a30f-4bdd-aad3-44a75714d8d3
2019-08-23T08:00:00.000+08:00,"Eli Lilly Reports Baricitinib Met Primary Endpoint In Breeze-AD7, Third Pivotal Phase 3 Trial In Breeze-AD Program To Be Completed In 2019",LLY,https://www.benzinga.com/general/biotech/19/08/14321502/eli-lilly-reports-baricitinib-met-primary-endpoint-in-breeze-ad7-third-pivotal-phase-3-trial-in-b,Benzinga Newsdesk,,,,0,0,647d84a0-d84b-4133-8bea-5287ee2ddead
2019-08-23T08:00:00.000+08:00,Lilly's baricitinib successful in third late-stage dermatitis study,LLY,https://seekingalpha.com/news/3494415-lillys-baricitinib-successful-third-late-stage-dermatitis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,6bb534f8-e2b2-4626-8ea3-decfd79d7fa0
2019-08-23T08:00:00.000+08:00,Arbitration panel backs Lilly in dispute with former collaboration partner Adocia,LLY,https://seekingalpha.com/news/3494272-arbitration-panel-backs-lilly-dispute-former-collaboration-partner-adocia?source=partner_benzinga,Seeking Alpha,,,,0,0,91ae129a-a6c5-4b1d-a826-80c2a7e94774
2019-08-22T08:00:00.000+08:00,AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China,LLY,http://www.zacks.com/stock/news/483440/astrazenecas-kidney-drug-roxadustat-gets-second-nod-in-china?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-483440,Zacks,,,,0,0,4c4511fa-3ba1-44f9-b709-e756e7956aea
2019-08-22T08:00:00.000+08:00,Novo Nordisk: A Secular Growth Engine,LLY,https://seekingalpha.com/article/4287453-novo-nordisk-secular-growth-engine?source=partner_benzinga,Seeking Alpha,,,,0,0,a424c778-ea36-4f51-81da-ba021338261c
2019-08-22T08:00:00.000+08:00,Satsuma Pharmaceuticals Files For U.S. IPO,LLY,https://seekingalpha.com/article/4287341-satsuma-pharmaceuticals-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,34b68f80-f39f-44c3-bd63-624b3bae7dec
2019-08-22T08:00:00.000+08:00,MannKind - 'Fireside' Chat With CEO Mike Castagna,LLY,https://seekingalpha.com/article/4287312-mannkind-fireside-chat-ceo-mike-castagna?source=partner_benzinga,Seeking Alpha,,,,0,0,ce88b3ad-845e-4efd-820b-cb65d3221e31
2019-08-22T08:00:00.000+08:00,AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China,LLY,http://www.zacks.com/stock/news/483440/astrazenecas-kidney-drug-roxadustat-gets-second-nod-in-china?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-483440,Zacks,,,,0,0,fb59af51-5e53-48dd-89da-d8e666d5d825
2019-08-22T08:00:00.000+08:00,Novo Nordisk: A Secular Growth Engine,LLY,https://seekingalpha.com/article/4287453-novo-nordisk-secular-growth-engine?source=partner_benzinga,Seeking Alpha,,,,0,0,afea05f5-05e3-4723-92bb-7738c92cca30
2019-08-22T08:00:00.000+08:00,Satsuma Pharmaceuticals Files For U.S. IPO,LLY,https://seekingalpha.com/article/4287341-satsuma-pharmaceuticals-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,2845cdde-e633-4a1d-ac7c-d3784ce04b90
2019-08-22T08:00:00.000+08:00,MannKind - 'Fireside' Chat With CEO Mike Castagna,LLY,https://seekingalpha.com/article/4287312-mannkind-fireside-chat-ceo-mike-castagna?source=partner_benzinga,Seeking Alpha,,,,0,0,b8003601-9369-4566-ae51-42504bd73cc1
2019-08-21T08:00:00.000+08:00,NuCana Stops Patient Enrollment in Pancreatic Cancer Study,LLY,http://www.zacks.com/stock/news/481254/nucana-stops-patient-enrollment-in-pancreatic-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-481254,Zacks,,,,0,0,81199f3f-39e4-4a2c-a32e-2110592e5f8b
2019-08-21T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/480986/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-480986,Zacks,,,,0,0,8a8b4f2c-8dad-495d-899e-1f2ff7ca4dce
2019-08-21T08:00:00.000+08:00,NuCana Stops Patient Enrollment in Pancreatic Cancer Study,LLY,http://www.zacks.com/stock/news/481254/nucana-stops-patient-enrollment-in-pancreatic-cancer-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-481254,Zacks,,,,0,0,c96bb144-8034-4d44-832e-ce1c13dde4f3
2019-08-21T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/480986/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-480986,Zacks,,,,0,0,09fe0000-dbb2-4d11-8956-28aa6d9a03a9
2019-08-19T08:00:00.000+08:00,Eli Lilly Taltz Data Points To A Solid Push Into The Psoriasis Space,LLY,https://seekingalpha.com/article/4286654-eli-lilly-taltz-data-points-solid-push-psoriasis-space?source=partner_benzinga,Seeking Alpha,,,,0,0,0a5fa693-ba9c-4a5e-9854-95279c47fee2
2019-08-19T08:00:00.000+08:00,Roche prices Rozlytrek below Bayer & Lilly's Vitrakvi,LLY,https://seekingalpha.com/news/3492803-roche-prices-rozlytrek-bayer-and-lillys-vitrakvi?source=partner_benzinga,Seeking Alpha,,,,0,0,ce98f544-20bb-4c81-b709-6a07ccdc91e3
2019-08-19T08:00:00.000+08:00,High-Quality Dividend Stocks,LLY,https://seekingalpha.com/article/4286474-high-quality-dividend-stocks?source=partner_benzinga,Seeking Alpha,,,,0,0,576f1776-ffe9-4ef1-8c41-3dbd8675fed5
2019-08-19T08:00:00.000+08:00,Eli Lilly Taltz Data Points To A Solid Push Into The Psoriasis Space,LLY,https://seekingalpha.com/article/4286654-eli-lilly-taltz-data-points-solid-push-psoriasis-space?source=partner_benzinga,Seeking Alpha,,,,0,0,d1a7b8fb-f9f3-49ad-b9c5-ce2778506b29
2019-08-19T08:00:00.000+08:00,Roche prices Rozlytrek below Bayer & Lilly's Vitrakvi,LLY,https://seekingalpha.com/news/3492803-roche-prices-rozlytrek-bayer-and-lillys-vitrakvi?source=partner_benzinga,Seeking Alpha,,,,0,0,83f5791e-eab0-4ebb-a8f7-17c823b2af28
2019-08-19T08:00:00.000+08:00,High-Quality Dividend Stocks,LLY,https://seekingalpha.com/article/4286474-high-quality-dividend-stocks?source=partner_benzinga,Seeking Alpha,,,,0,0,f070e46d-ed24-4c1b-a2c7-65f02263ed50
2019-08-18T08:00:00.000+08:00,AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira Issue,LLY,https://seekingalpha.com/article/4286448-abbvies-fda-approval-rinvoq-sets-first-phase-deployment-plan-counter-humira-issue?source=partner_benzinga,Seeking Alpha,,,,0,0,69c755b1-096d-4a22-bd6d-34a4382b1d06
2019-08-18T08:00:00.000+08:00,AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira Issue,LLY,https://seekingalpha.com/article/4286448-abbvies-fda-approval-rinvoq-sets-first-phase-deployment-plan-counter-humira-issue?source=partner_benzinga,Seeking Alpha,,,,0,0,c606f607-3420-40cc-ab68-c1304888f2a6
2019-08-16T08:00:00.000+08:00,FDA OKs AbbVie's Rinvoq rheumatoid arthritis; shares up 2%,LLY,https://seekingalpha.com/news/3492652-fda-oks-abbvies-rinvoq-rheumatoid-arthritis-shares-2-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,72edbca2-20af-4c16-9781-82edc5947e55
2019-08-16T08:00:00.000+08:00,Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe,LLY,http://www.zacks.com/stock/news/473330/gileads-gild-filgotinib-maa-for-ra-accepted-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-473330,Zacks,,,,0,0,a28800d5-f953-4d5c-a074-db213dda26e5
2019-08-16T08:00:00.000+08:00,FDA OKs AbbVie's Rinvoq rheumatoid arthritis; shares up 2%,LLY,https://seekingalpha.com/news/3492652-fda-oks-abbvies-rinvoq-rheumatoid-arthritis-shares-2-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,b9a41d9f-f746-477d-94b3-47b9547b0822
2019-08-16T08:00:00.000+08:00,Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe,LLY,http://www.zacks.com/stock/news/473330/gileads-gild-filgotinib-maa-for-ra-accepted-in-europe?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-473330,Zacks,,,,0,0,af1c8b83-d433-4cf8-bfc4-16cd950aa0ad
2019-08-15T08:00:00.000+08:00,"Gotham Asset Management, LLC Buys Intuit Inc, Oracle Corp, Cisco Systems Inc, Sells PayPal ...",LLY,http://www.gurufocus.com/news/929108/gotham-asset-management-llc-buys-intuit-inc-oracle-corp-cisco-systems-inc-sells-paypal-holdings-inc-wells-fargo-the-chemours-co,GuruFocus,,,,0,0,92b02cdf-d3e9-4174-9d4c-43550b51901a
2019-08-15T08:00:00.000+08:00,Agios Rides High on Tibsovo Sales Amid Acute Competition,LLY,http://www.zacks.com/stock/news/471900/agios-rides-high-on-tibsovo-sales-amid-acute-competition?cid=CS-BENZ-FT-analyst_blog|zer_report_update-471900,Zacks,,,,0,0,3707cc94-2975-43a7-a7a4-520896d7ee7f
2019-08-15T08:00:00.000+08:00,"Gotham Asset Management, LLC Buys Intuit Inc, Oracle Corp, Cisco Systems Inc, Sells PayPal ...",LLY,http://www.gurufocus.com/news/929108/gotham-asset-management-llc-buys-intuit-inc-oracle-corp-cisco-systems-inc-sells-paypal-holdings-inc-wells-fargo-the-chemours-co,GuruFocus,,,,0,0,0da185db-6c9b-49c2-b90b-a80d2f3a36a4
2019-08-15T08:00:00.000+08:00,Agios Rides High on Tibsovo Sales Amid Acute Competition,LLY,http://www.zacks.com/stock/news/471900/agios-rides-high-on-tibsovo-sales-amid-acute-competition?cid=CS-BENZ-FT-analyst_blog|zer_report_update-471900,Zacks,,,,0,0,4ffe39df-56c7-4bb7-a7bb-16d9223e1ae4
2019-08-14T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.",LLY,https://www.benzinga.com/markets/wiim/19/08/14267484/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-after-t,Benzinga Newsdesk,,,,0,0,91e4ae5a-b6f2-4eec-9c28-84a06dd86b3e
2019-08-14T08:00:00.000+08:00,Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study,LLY,http://www.zacks.com/stock/news/470170/lillys-taltz-outshines-jjs-tremfya-in-psoriasis-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-470170,Zacks,,,,0,0,58c4b535-59a9-40e0-bf7b-5fbe77aff03f
2019-08-14T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.",LLY,https://www.benzinga.com/markets/wiim/19/08/14267484/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-after-t,Benzinga Newsdesk,,,,0,0,49c4b0bf-fa67-46cc-88df-1b39d97483c3
2019-08-14T08:00:00.000+08:00,Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study,LLY,http://www.zacks.com/stock/news/470170/lillys-taltz-outshines-jjs-tremfya-in-psoriasis-study?cid=CS-BENZ-FT-analyst_blog|company_news_-_medical_sector-470170,Zacks,,,,0,0,b59b396d-8c63-4d55-b713-18b9f8defa2a
2019-08-13T08:00:00.000+08:00,Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study,LLY,https://www.benzinga.com/general/biotech/19/08/14256933/lillys-psoriasis-drug-found-superior-to-j-js-tremfya-in-phase-4-study,Shanthi Rexaline,,,,0,0,b8ee0f1a-47d5-4921-b2e2-5cf8315f6b14
2019-08-13T08:00:00.000+08:00,Lilly Announces Taltz Met Primary And All Major Secondary Endpoints In Phase 4 IXORA-R Study,LLY,https://www.benzinga.com/general/biotech/19/08/14254207/lilly-announces-taltz-met-primary-and-all-major-secondary-endpoints-in-phase-4-ixora-r-study,Benzinga Newsdesk,,,,0,0,ca16cd0b-8eb5-4df3-86e6-358a5c8e0892
2019-08-13T08:00:00.000+08:00,Lilly's Taltz beats J&J's Tremfya in post-market psoriasis study,LLY,https://seekingalpha.com/news/3490959-lillys-taltz-beats-j-and-js-tremfya-post-market-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,fe07bd34-497b-4666-bd86-e59f6c91b68b
2019-08-13T08:00:00.000+08:00,Lilly's Psoriasis Drug Found Superior To J&J's Tremfya In Phase 4 Study,LLY,https://www.benzinga.com/general/biotech/19/08/14256933/lillys-psoriasis-drug-found-superior-to-j-js-tremfya-in-phase-4-study,Shanthi Rexaline,,,,0,0,40148f74-d98f-47f8-bb51-6614ea8f98bb
2019-08-13T08:00:00.000+08:00,Lilly Announces Taltz Met Primary And All Major Secondary Endpoints In Phase 4 IXORA-R Study,LLY,https://www.benzinga.com/general/biotech/19/08/14254207/lilly-announces-taltz-met-primary-and-all-major-secondary-endpoints-in-phase-4-ixora-r-study,Benzinga Newsdesk,,,,0,0,bcdad2c7-0580-40f2-bf4a-818046363735
2019-08-13T08:00:00.000+08:00,Lilly's Taltz beats J&J's Tremfya in post-market psoriasis study,LLY,https://seekingalpha.com/news/3490959-lillys-taltz-beats-j-and-js-tremfya-post-market-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,76582c8c-1137-4ab9-b5de-54195bf0603c
2019-08-12T08:00:00.000+08:00,Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality,LLY,https://seekingalpha.com/article/4285002-eli-lilly-looks-positive-data-expand-market-opportunity-emgality?source=partner_benzinga,Seeking Alpha,,,,0,0,2cc15d42-dcfb-470e-95b4-225adea1f771
2019-08-12T08:00:00.000+08:00,Q2 Biotech Updates,LLY,https://seekingalpha.com/article/4284783-q2-biotech-updates?source=partner_benzinga,Seeking Alpha,,,,0,0,c90d1da2-d31b-4799-ac44-75ddbf9b1ca3
2019-08-12T08:00:00.000+08:00,Eli Lilly Looks To Positive Data To Expand Its Market Opportunity For Emgality,LLY,https://seekingalpha.com/article/4285002-eli-lilly-looks-positive-data-expand-market-opportunity-emgality?source=partner_benzinga,Seeking Alpha,,,,0,0,92086437-7be5-41a3-84e0-186a22560a9c
2019-08-12T08:00:00.000+08:00,Q2 Biotech Updates,LLY,https://seekingalpha.com/article/4284783-q2-biotech-updates?source=partner_benzinga,Seeking Alpha,,,,0,0,add336b6-6b43-454c-8d0e-6070f678831d
2019-08-10T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of August 11,LLY,https://seekingalpha.com/article/4284406-dividend-challenger-highlights-week-august-11?source=partner_benzinga,Seeking Alpha,,,,0,0,5d314ea3-a844-485c-9b50-d34eabb03617
2019-08-10T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of August 11,LLY,https://seekingalpha.com/article/4284406-dividend-challenger-highlights-week-august-11?source=partner_benzinga,Seeking Alpha,,,,0,0,16a9d243-e041-478c-8885-91cce65e6666
2019-08-09T08:00:00.000+08:00,Eli Lilly Shares Unaffected As Hearing US Appeals Court Ruled In Favor Of Co. In Alimta Alternate Salt Form Patent Suit,LLY,https://www.benzinga.com/news/19/08/14241295/eli-lilly-shares-unaffected-as-hearing-us-appeals-court-ruled-in-favor-of-co-in-alimta-alternate-sal,Benzinga Newsdesk,,,,0,0,c4bf0e2a-aa07-428e-aa39-98a08c90af6b
2019-08-09T08:00:00.000+08:00,"Intersect Capital LLC Buys Lockheed Martin Corp, Vornado Realty Trust, Berkshire Hathaway Inc, ...",LLY,http://www.gurufocus.com/news/925859/intersect-capital-llc-buys-lockheed-martin-corp-vornado-realty-trust-berkshire-hathaway-inc-sells-source-capital-inc-dupont-de-nemours-inc-amerigas-partners-lp,GuruFocus,,,,0,0,a5aa59c5-4f67-47da-9771-55a12eb6ff4e
2019-08-09T08:00:00.000+08:00,Lilly prevails in Alimta patent challenge,LLY,https://seekingalpha.com/news/3490347-lilly-prevails-alimta-patent-challenge?source=partner_benzinga,Seeking Alpha,,,,0,0,a005f855-4d0b-47c3-a545-a47dd47ada51
2019-08-09T08:00:00.000+08:00,Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2,LLY,http://www.zacks.com/stock/news/462902/intrexon-xon-reports-narrower-than-expected-loss-in-q2?cid=CS-BENZ-FT-analyst_blog|earnings_article-462902,Zacks,,,,0,0,b13b59ef-5f0c-451a-9fb6-11f536fbebf7
2019-08-09T08:00:00.000+08:00,"Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients",LLY,http://www.zacks.com/stock/news/462666/pharma-stock-roundup-agn-nvo-earnings-eu-nod-to-sny-abbv-drugs-for-new-patients?cid=CS-BENZ-FT-analyst_blog|stock_roundup-462666,Zacks,,,,0,0,cc2be48c-c6a5-4cff-8249-0ab2789ce416
2019-08-09T08:00:00.000+08:00,Eli Lilly Shares Unaffected As Hearing US Appeals Court Ruled In Favor Of Co. In Alimta Alternate Salt Form Patent Suit,LLY,https://www.benzinga.com/news/19/08/14241295/eli-lilly-shares-unaffected-as-hearing-us-appeals-court-ruled-in-favor-of-co-in-alimta-alternate-sal,Benzinga Newsdesk,,,,0,0,4ce5ada9-689a-4e87-8be7-844fccaa4d41
2019-08-09T08:00:00.000+08:00,"Intersect Capital LLC Buys Lockheed Martin Corp, Vornado Realty Trust, Berkshire Hathaway Inc, ...",LLY,http://www.gurufocus.com/news/925859/intersect-capital-llc-buys-lockheed-martin-corp-vornado-realty-trust-berkshire-hathaway-inc-sells-source-capital-inc-dupont-de-nemours-inc-amerigas-partners-lp,GuruFocus,,,,0,0,b7f98e13-34bf-4a4b-95eb-ed94f5093e0d
2019-08-09T08:00:00.000+08:00,Lilly prevails in Alimta patent challenge,LLY,https://seekingalpha.com/news/3490347-lilly-prevails-alimta-patent-challenge?source=partner_benzinga,Seeking Alpha,,,,0,0,14a8a9ce-c7e6-469e-b0ac-167d776b741c
2019-08-09T08:00:00.000+08:00,Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2,LLY,http://www.zacks.com/stock/news/462902/intrexon-xon-reports-narrower-than-expected-loss-in-q2?cid=CS-BENZ-FT-analyst_blog|earnings_article-462902,Zacks,,,,0,0,c42dab3a-08fd-4344-81fc-e5707d827359
2019-08-09T08:00:00.000+08:00,"Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients",LLY,http://www.zacks.com/stock/news/462666/pharma-stock-roundup-agn-nvo-earnings-eu-nod-to-sny-abbv-drugs-for-new-patients?cid=CS-BENZ-FT-analyst_blog|stock_roundup-462666,Zacks,,,,0,0,7e233ed7-f100-4d33-a565-3c19e3de80fc
2019-08-08T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company announced positive results for Emgality from the CONQUER study.,LLY,https://www.benzinga.com/markets/wiim/19/08/14232030/eli-lilly-shares-are-trading-higher-after-the-company-announced-positive-results-for-emgality-from-t,Benzinga Newsdesk,,,,0,0,27925e2b-b0ff-4753-afd8-4fd5ea5a3722
2019-08-08T08:00:00.000+08:00,"Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia",LLY,https://www.benzinga.com/news/19/08/14228163/lilly-evidation-health-and-apple-study-shows-personal-digital-devices-may-help-in-the-identification,Charles Gross,,,,0,0,d010d816-58f6-4abf-8c9d-5ddf551b70d8
2019-08-08T08:00:00.000+08:00,"Top Stock Reports: Disney, Eli Lilly, ADP & More",LLY,http://www.zacks.com/research-daily/461336/top-stock-reports-disney-eli-lilly-adp-more?cid=CS-BENZ-FT-research_daily-461336,Zacks,,,,0,0,0d8622b0-ccd4-4be6-a7ed-35518f66926e
2019-08-08T08:00:00.000+08:00,"Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid",LLY,http://www.zacks.com/stock/news/461339/radius-rdus-q2-earnings-beat-estimates-tymlos-sales-solid?cid=CS-BENZ-FT-analyst_blog|earnings_article-461339,Zacks,,,,0,0,5057879b-0924-4b43-a1ea-e2a03794a6b5
2019-08-08T08:00:00.000+08:00,"Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down",LLY,http://www.zacks.com/stock/news/461108/teva-teva-q2-earnings-sales-top-estimates-cfo-steps-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-461108,Zacks,,,,0,0,9ec49aaf-97d9-497a-ab8d-27bec9937844
2019-08-08T08:00:00.000+08:00,Apple devices + mobile apps show potential to screen for Alzheimer's,LLY,https://seekingalpha.com/news/3489350-apple-devices-mobile-apps-show-potential-screen-alzheimers?source=partner_benzinga,Seeking Alpha,,,,0,0,d38f788b-073c-408a-9e97-7af04e2765d4
2019-08-08T08:00:00.000+08:00,Eli Lilly shares are trading higher after the company announced positive results for Emgality from the CONQUER study.,LLY,https://www.benzinga.com/markets/wiim/19/08/14232030/eli-lilly-shares-are-trading-higher-after-the-company-announced-positive-results-for-emgality-from-t,Benzinga Newsdesk,,,,0,0,6e63add6-039e-433a-abb1-f3731e1043f2
2019-08-08T08:00:00.000+08:00,"Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia",LLY,https://www.benzinga.com/news/19/08/14228163/lilly-evidation-health-and-apple-study-shows-personal-digital-devices-may-help-in-the-identification,Charles Gross,,,,0,0,d29658e3-c728-4529-aa12-a0d8859df2f2
2019-08-08T08:00:00.000+08:00,"Top Stock Reports: Disney, Eli Lilly, ADP & More",LLY,http://www.zacks.com/research-daily/461336/top-stock-reports-disney-eli-lilly-adp-more?cid=CS-BENZ-FT-research_daily-461336,Zacks,,,,0,0,0211e309-839d-485b-86ef-4246b5772ab6
2019-08-08T08:00:00.000+08:00,"Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid",LLY,http://www.zacks.com/stock/news/461339/radius-rdus-q2-earnings-beat-estimates-tymlos-sales-solid?cid=CS-BENZ-FT-analyst_blog|earnings_article-461339,Zacks,,,,0,0,05466ae3-4458-4d3c-89e6-e74fd20b3855
2019-08-08T08:00:00.000+08:00,"Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down",LLY,http://www.zacks.com/stock/news/461108/teva-teva-q2-earnings-sales-top-estimates-cfo-steps-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-461108,Zacks,,,,0,0,cc62fcae-5154-4e86-b997-e9cc5374679f
2019-08-08T08:00:00.000+08:00,Apple devices + mobile apps show potential to screen for Alzheimer's,LLY,https://seekingalpha.com/news/3489350-apple-devices-mobile-apps-show-potential-screen-alzheimers?source=partner_benzinga,Seeking Alpha,,,,0,0,4d119371-593a-49d2-930c-8bfa3859dcd9
2019-08-07T08:00:00.000+08:00,"Trellis Advisors, LLC Buys Amgen Inc, Eli Lilly and Co, Laboratory Corp of America Holdings",LLY,http://www.gurufocus.com/news/923921/trellis-advisors-llc-buys-amgen-inc-eli-lilly-and-co-laboratory-corp-of-america-holdings,GuruFocus,,,,0,0,c027a71e-cad0-4b6c-b055-f44d291c06da
2019-08-07T08:00:00.000+08:00,Companies In The Healthcare Sector To Consider/Avoid Taking Into Account Patent Activity,LLY,https://seekingalpha.com/article/4282760-companies-healthcare-sector-consider-avoid-taking-account-patent-activity?source=partner_benzinga,Seeking Alpha,,,,0,0,4b217e6f-5391-4f4e-9f1e-022e3216ee06
2019-08-07T08:00:00.000+08:00,Execs on the move at Eli Lilly,LLY,https://seekingalpha.com/news/3488482-execs-move-eli-lilly?source=partner_benzinga,Seeking Alpha,,,,0,0,7f3ffd9a-9ce4-4fc8-9f3e-d16ac368f5b0
2019-08-07T08:00:00.000+08:00,"Trellis Advisors, LLC Buys Amgen Inc, Eli Lilly and Co, Laboratory Corp of America Holdings",LLY,http://www.gurufocus.com/news/923921/trellis-advisors-llc-buys-amgen-inc-eli-lilly-and-co-laboratory-corp-of-america-holdings,GuruFocus,,,,0,0,073d2a03-6c7d-4bab-8776-28589d65d0e4
2019-08-07T08:00:00.000+08:00,Companies In The Healthcare Sector To Consider/Avoid Taking Into Account Patent Activity,LLY,https://seekingalpha.com/article/4282760-companies-healthcare-sector-consider-avoid-taking-account-patent-activity?source=partner_benzinga,Seeking Alpha,,,,0,0,7d97c016-3a14-494e-9fdd-6cca4b32e9cd
2019-08-07T08:00:00.000+08:00,Execs on the move at Eli Lilly,LLY,https://seekingalpha.com/news/3488482-execs-move-eli-lilly?source=partner_benzinga,Seeking Alpha,,,,0,0,2e63206b-8440-481e-a184-e220fc30def2
2019-08-06T08:00:00.000+08:00,"Eli Lilly shares trading higher, rebounding following a more than 3% decline on Monday. Not seeing company-specific news to justify the rebound today.",LLY,https://www.benzinga.com/markets/wiim/19/08/14211788/eli-lilly-shares-trading-higher-rebounding-following-a-more-than-3-decline-on-monday-not-seeing-comp,Benzinga Newsdesk,,,,0,0,a37445f9-614b-4914-bdfa-371848d72532
2019-08-06T08:00:00.000+08:00,"Eli Lilly shares trading higher, rebounding following a more than 3% decline on Monday. Not seeing company-specific news to justify the rebound today.",LLY,https://www.benzinga.com/markets/wiim/19/08/14211788/eli-lilly-shares-trading-higher-rebounding-following-a-more-than-3-decline-on-monday-not-seeing-comp,Benzinga Newsdesk,,,,0,0,42261309-4b08-4f75-8112-9fae9a500311
2019-08-05T08:00:00.000+08:00,Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.,LLY,https://www.benzinga.com/markets/wiim/19/08/14202009/shares-of-several-drugpharma-companies-trading-lower-given-weakness-in-broader-stock-market-followin,Benzinga Newsdesk,,,,0,0,d1ea2380-5cac-42b6-8f17-79d12af09ceb
2019-08-05T08:00:00.000+08:00,Eli Lilly Announces Positive Results For Emgality,LLY,https://www.benzinga.com/news/19/08/14198981/eli-lilly-announces-positive-results-for-emgality,Tanzeel Akhtar,,,,0,0,e28d436a-45e1-45e7-b4e3-42e3f143ae12
2019-08-05T08:00:00.000+08:00,Lilly Announces 'Positive' Results for Emgality from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments,LLY,https://www.benzinga.com/news/19/08/14198592/lilly-announces-positive-results-for-emgality-from-the-conquer-study-in-patients-who-failed-previous,Benzinga Newsdesk,,,,0,0,11e33599-eea3-43e7-b4fb-01986869cd0c
2019-08-05T08:00:00.000+08:00,Lexicon Pharmaceuticals Now Walking A Fine Line,LLY,https://seekingalpha.com/article/4281646-lexicon-pharmaceuticals-now-walking-fine-line?source=partner_benzinga,Seeking Alpha,,,,0,0,ba94af89-cccc-425f-a5cb-5b11710341eb
2019-08-05T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2019 Update,LLY,https://seekingalpha.com/article/4281629-tracking-ken-fishers-fisher-asset-management-portfolio-q2-2019-update?source=partner_benzinga,Seeking Alpha,,,,0,0,5962bd10-2a83-4723-8686-da8f990a148e
2019-08-05T08:00:00.000+08:00,Lilly's Emgality successful in late-stage study in treatment-resistant migraine,LLY,https://seekingalpha.com/news/3486658-lillys-emgality-successful-late-stage-study-treatment-resistant-migraine?source=partner_benzinga,Seeking Alpha,,,,0,0,440bb6da-c409-4917-8659-db888808ff2b
2019-08-05T08:00:00.000+08:00,Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions.,LLY,https://www.benzinga.com/markets/wiim/19/08/14202009/shares-of-several-drugpharma-companies-trading-lower-given-weakness-in-broader-stock-market-followin,Benzinga Newsdesk,,,,0,0,f3636c17-515b-4c6d-b685-6dbe3f843178
2019-08-05T08:00:00.000+08:00,Eli Lilly Announces Positive Results For Emgality,LLY,https://www.benzinga.com/news/19/08/14198981/eli-lilly-announces-positive-results-for-emgality,Tanzeel Akhtar,,,,0,0,d41d0c25-b581-4c9c-9a71-251add30942c
2019-08-05T08:00:00.000+08:00,Lilly Announces 'Positive' Results for Emgality from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments,LLY,https://www.benzinga.com/news/19/08/14198592/lilly-announces-positive-results-for-emgality-from-the-conquer-study-in-patients-who-failed-previous,Benzinga Newsdesk,,,,0,0,7d7a3001-f345-46fb-a9ca-0f733853ee74
2019-08-05T08:00:00.000+08:00,Lexicon Pharmaceuticals Now Walking A Fine Line,LLY,https://seekingalpha.com/article/4281646-lexicon-pharmaceuticals-now-walking-fine-line?source=partner_benzinga,Seeking Alpha,,,,0,0,c3102c0c-9bef-47ad-bd23-5774e26c6367
2019-08-05T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2019 Update,LLY,https://seekingalpha.com/article/4281629-tracking-ken-fishers-fisher-asset-management-portfolio-q2-2019-update?source=partner_benzinga,Seeking Alpha,,,,0,0,53f0656f-ec32-423a-8523-6be7a25455dc
2019-08-05T08:00:00.000+08:00,Lilly's Emgality successful in late-stage study in treatment-resistant migraine,LLY,https://seekingalpha.com/news/3486658-lillys-emgality-successful-late-stage-study-treatment-resistant-migraine?source=partner_benzinga,Seeking Alpha,,,,0,0,83bb9b5e-fdcd-4b00-b1fd-af9e153b8943
2019-08-02T08:00:00.000+08:00,"Eli Lilly 10-Q Shows Co. Received Subpoena From New York Attorney General's Office, Civil Investigative Demands From Washing, New Mexico AG's Related To Pricing, Sale Of Its Insulin Products",LLY,https://www.benzinga.com/news/19/08/14193688/eli-lilly-10-q-shows-co-received-subpoena-from-new-york-attorney-generals-office-civil-investigative,Benzinga Newsdesk,,,,0,0,ac2826db-8e63-484f-946e-a5e229d9648f
2019-08-02T08:00:00.000+08:00,Lilly subpoenaed over insulin pricing,LLY,https://seekingalpha.com/news/3486445-lilly-subpoenaed-insulin-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,ebf00cd0-b317-4176-8d9d-bac6348e6fba
2019-08-02T08:00:00.000+08:00,"Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger",LLY,http://www.zacks.com/stock/news/457515/pharma-stock-roundup-pfe-mrk-lly-q2-earnings-upjohn-myl-merger?cid=CS-BENZ-FT-analyst_blog|stock_roundup-457515,Zacks,,,,0,0,0cbb8dc0-37eb-4696-a6a5-ebb7323e85e8
2019-08-02T08:00:00.000+08:00,"Eli Lilly 10-Q Shows Co. Received Subpoena From New York Attorney General's Office, Civil Investigative Demands From Washing, New Mexico AG's Related To Pricing, Sale Of Its Insulin Products",LLY,https://www.benzinga.com/news/19/08/14193688/eli-lilly-10-q-shows-co-received-subpoena-from-new-york-attorney-generals-office-civil-investigative,Benzinga Newsdesk,,,,0,0,20b2f46e-2bc6-4a1d-9563-ddaca92aea2e
2019-08-02T08:00:00.000+08:00,Lilly subpoenaed over insulin pricing,LLY,https://seekingalpha.com/news/3486445-lilly-subpoenaed-insulin-pricing?source=partner_benzinga,Seeking Alpha,,,,0,0,a1042b78-83cf-42c6-bded-8b0c55e6c6ea
2019-08-02T08:00:00.000+08:00,"Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger",LLY,http://www.zacks.com/stock/news/457515/pharma-stock-roundup-pfe-mrk-lly-q2-earnings-upjohn-myl-merger?cid=CS-BENZ-FT-analyst_blog|stock_roundup-457515,Zacks,,,,0,0,f8626163-0932-4275-9c32-19c35b3cefad
2019-07-31T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/07/14151998/attention-biotech-investors-mark-your-calendar-for-these-august-pdufa-dates,Shanthi Rexaline,,,,0,0,b2ea037e-db47-4bef-adf7-34491e9629fe
2019-07-31T08:00:00.000+08:00,"Stevens Capital Management Lp Buys Merck Inc, Eli Lilly and Co, Morgan Stanley, Sells Duke ...",LLY,http://www.gurufocus.com/news/919699/stevens-capital-management-lp-buys-merck-inc-eli-lilly-and-co-morgan-stanley-sells-duke-energy-corp-cme-group-inc-cognizant-technology-solutions-corp,GuruFocus,,,,0,0,64388efe-5447-4da7-8fed-9102670e5036
2019-07-31T08:00:00.000+08:00,Wall Street Breakfast: First Rate Cut Since The Financial Crisis,LLY,https://seekingalpha.com/article/4279398-wall-street-breakfast-first-rate-cut-since-financial-crisis?source=partner_benzinga,Seeking Alpha,,,,0,0,96c92c20-9acb-4d5d-8352-7538a3523a08
2019-07-31T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/19/07/14151998/attention-biotech-investors-mark-your-calendar-for-these-august-pdufa-dates,Shanthi Rexaline,,,,0,0,d638b678-1914-46e2-a3f7-9ceb587ae02d
2019-07-31T08:00:00.000+08:00,"Stevens Capital Management Lp Buys Merck Inc, Eli Lilly and Co, Morgan Stanley, Sells Duke ...",LLY,http://www.gurufocus.com/news/919699/stevens-capital-management-lp-buys-merck-inc-eli-lilly-and-co-morgan-stanley-sells-duke-energy-corp-cme-group-inc-cognizant-technology-solutions-corp,GuruFocus,,,,0,0,35a8a29c-ef6d-41cf-b66b-4eca5d4672a7
2019-07-31T08:00:00.000+08:00,Wall Street Breakfast: First Rate Cut Since The Financial Crisis,LLY,https://seekingalpha.com/article/4279398-wall-street-breakfast-first-rate-cut-since-financial-crisis?source=partner_benzinga,Seeking Alpha,,,,0,0,9d05e3cb-f092-439c-9d26-2019f04f417b
2019-07-30T08:00:00.000+08:00,"Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting",LLY,https://www.benzinga.com/news/earnings/19/07/14160136/apple-on-todays-menu-with-starring-roles-from-china-talks-fed-meeting,JJ Kinahan,,,,0,0,fe19f31f-06c0-4249-a042-bc319591a576
2019-07-30T08:00:00.000+08:00,Eli Lilly Reports Q2 Earnings Beat,LLY,https://www.benzinga.com/news/earnings/19/07/14158268/eli-lilly-reports-q2-earnings-beat,Tanzeel Akhtar,,,,0,0,237e3e34-f11e-41d8-b931-90f5b589ca6b
2019-07-30T08:00:00.000+08:00,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",LLY,https://www.benzinga.com/general/biotech/19/07/14156757/the-daily-biotech-pulse-european-cheer-for-merck-legal-victory-for-coherus-medpace-picks-up-on-ea,Shanthi Rexaline,,,,0,0,c6f80666-5367-4921-8ec8-1fe88eb52740
2019-07-30T08:00:00.000+08:00,Eli Lilly Sees FY19 Adj. EPS $5.67-$5.77 vs $5.66 Est.,LLY,https://www.benzinga.com/news/19/07/14157310/eli-lilly-sees-fy19-adj-eps-5-67-5-77-vs-5-66-est,Benzinga Newsdesk,,,,0,0,1666d030-bd2d-4d22-bd0b-7d2e2d1544dd
2019-07-30T08:00:00.000+08:00,"Eli Lilly Q2 Adj. EPS $1.5 Beats $1.45 Estimate, Sales $5.637B Beat $5.59B Estimate",LLY,https://www.benzinga.com/news/earnings/19/07/14157307/eli-lilly-q2-adj-eps-1-5-beats-1-45-estimate-sales-5-637b-beat-5-59b-estimate,Benzinga Newsdesk,,,,0,0,a6eba86f-008a-42c3-afc9-599c5233f901
2019-07-30T08:00:00.000+08:00,Lilly Announces Verzenio Demonstrated Significant Improvement In Overall Survival In Phase 3 MONARCH 2 The Clinical Trial,LLY,https://www.benzinga.com/general/biotech/19/07/14157155/lilly-announces-verzenio-demonstrated-significant-improvement-in-overall-survival-in-phase-3-mona,Benzinga Newsdesk,,,,0,0,b2f9aa61-6026-48f0-9349-5c377c47d196
2019-07-30T08:00:00.000+08:00,"15 Stocks To Watch For July 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/07/14156849/15-stocks-to-watch-for-july-30-2019,Lisa Levin,,,,0,0,f5f58ba4-4a67-4189-aab6-bd02ac86c3f2
2019-07-30T08:00:00.000+08:00,"Earnings Scheduled For July 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/07/14156797/earnings-scheduled-for-july-30-2019,Lisa Levin,,,,0,0,ab82f5b3-f073-4f53-b135-c03983a93a54
2019-07-30T08:00:00.000+08:00,Flexion: The Time To Buy Is Now,LLY,https://seekingalpha.com/article/4279278-flexion-time-buy-now?source=partner_benzinga,Seeking Alpha,,,,0,0,b534a099-6be7-42af-b112-24c104550208
2019-07-30T08:00:00.000+08:00,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q2 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4279204-eli-lilly-companys-lly-ceo-dave-ricks-q2-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,ee31c881-1a66-4d0c-96fb-ff28c34aea8b
2019-07-30T08:00:00.000+08:00,"Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y",LLY,http://www.zacks.com/stock/news/453958/incyte-incy-q2-earnings-beat-estimates-revenues-up-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-453958,Zacks,,,,0,0,81d663de-f5d0-4731-8438-9283f114982c
2019-07-30T08:00:00.000+08:00,"Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up",LLY,http://www.zacks.com/stock/news/453957/lilly-lly-q2-earnings-beat-new-drugs-drive-sales-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-453957,Zacks,,,,0,0,0a71cff0-a667-4cb7-b298-9f26ab6746bb
2019-07-30T08:00:00.000+08:00,"Svenska Handelsbanken AB (publ) Buys Welbilt Inc, Eli Lilly and Co, Service Corp International, ...",LLY,http://www.gurufocus.com/news/918292/svenska-handelsbanken-ab-publ-buys-welbilt-inc-eli-lilly-and-co-service-corp-international-sells-worldpay-inc-svb-financial-group-facebook-inc,GuruFocus,,,,0,0,084f146d-6551-4e66-b80a-dd7218740a7c
2019-07-30T08:00:00.000+08:00,Economic and Earnings Date Deluge,LLY,http://www.zacks.com/stock/news/453798/economic-and-earnings-date-deluge?cid=CS-BENZ-FT-economic_highlights-453798,Zacks,,,,0,0,8041a8cb-16da-478d-91f2-6c4b5bc973a7
2019-07-30T08:00:00.000+08:00,"Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More",LLY,http://www.zacks.com/stock/news/453588/busy-morning-for-investors-trade-data-earnings-for-pfe-mrk-cop-more?cid=CS-BENZ-FT-ahead_of_wall_street-453588,Zacks,,,,0,0,1f53352a-13f5-4f98-bef2-fe5d3bdd7f95
2019-07-30T08:00:00.000+08:00,Eli Lilly and Company 2019 Q2 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4278944-eli-lilly-company-2019-q2-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,0,0,ebcf0e00-1f19-48ae-b64f-d73b00c22e32
2019-07-30T08:00:00.000+08:00,5 Monster Stocks To Watch For the July 30 Trading Session,LLY,https://www.benzinga.com/node/14159964,TalkMarkets,,,,0,0,dbba861c-40ba-4534-8170-de85938064f9
2019-07-30T08:00:00.000+08:00,Trump readies plan allow drug imports from Canada,LLY,https://seekingalpha.com/news/3483442-trump-readies-plan-allow-drug-imports-canada?source=partner_benzinga,Seeking Alpha,,,,0,0,e3dd5e85-f961-4457-abbf-29e40afff6c7
2019-07-30T08:00:00.000+08:00,Eli Lilly (LLY) Tops Q2 Earnings Estimates,LLY,http://www.zacks.com/stock/news/453335/eli-lilly-lly-tops-q2-earnings-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-453335,Zacks,,,,0,0,8dae247c-d156-440b-b7b3-b84be9dffada
2019-07-30T08:00:00.000+08:00,Eli Lilly up 1% premarket on Q2 beat,LLY,https://seekingalpha.com/news/3483330-eli-lilly-1-percent-premarket-q2-beat?source=partner_benzinga,Seeking Alpha,,,,0,0,59f61f8d-76ce-4b14-8523-65b1e42a364f
2019-07-30T08:00:00.000+08:00,Lilly's abemaciclib extends survival in late-stage breast cancer study,LLY,https://seekingalpha.com/news/3483290-lillys-abemaciclib-extends-survival-late-stage-breast-cancer-study?source=partner_benzinga,Seeking Alpha,,,,0,0,317f4252-eb33-40a4-a6ed-b0b052ff7ee6
2019-07-30T08:00:00.000+08:00,"Eli Lilly EPS beats by $0.05, beats on revenue",LLY,https://seekingalpha.com/news/3483225-eli-lilly-eps-beats-0_05-beats-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,68e6ef82-ddb8-4d11-9a88-b6c1d68cf0e2
2019-07-30T08:00:00.000+08:00,"Apple On Today's Menu, With Starring Roles From China Talks, Fed Meeting",LLY,https://www.benzinga.com/news/earnings/19/07/14160136/apple-on-todays-menu-with-starring-roles-from-china-talks-fed-meeting,JJ Kinahan,,,,0,0,80d7d066-9e69-41b7-abc9-69e4e2676ace
2019-07-30T08:00:00.000+08:00,Eli Lilly Reports Q2 Earnings Beat,LLY,https://www.benzinga.com/news/earnings/19/07/14158268/eli-lilly-reports-q2-earnings-beat,Tanzeel Akhtar,,,,0,0,38f8af9e-c5ae-4eb6-a706-7041ff208b83
2019-07-30T08:00:00.000+08:00,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",LLY,https://www.benzinga.com/general/biotech/19/07/14156757/the-daily-biotech-pulse-european-cheer-for-merck-legal-victory-for-coherus-medpace-picks-up-on-ea,Shanthi Rexaline,,,,0,0,10afee00-5133-4717-b7eb-aed604d713af
2019-07-30T08:00:00.000+08:00,Eli Lilly Sees FY19 Adj. EPS $5.67-$5.77 vs $5.66 Est.,LLY,https://www.benzinga.com/news/19/07/14157310/eli-lilly-sees-fy19-adj-eps-5-67-5-77-vs-5-66-est,Benzinga Newsdesk,,,,0,0,1223f08b-1971-4d89-a222-105f51579531
2019-07-30T08:00:00.000+08:00,"Eli Lilly Q2 Adj. EPS $1.5 Beats $1.45 Estimate, Sales $5.637B Beat $5.59B Estimate",LLY,https://www.benzinga.com/news/earnings/19/07/14157307/eli-lilly-q2-adj-eps-1-5-beats-1-45-estimate-sales-5-637b-beat-5-59b-estimate,Benzinga Newsdesk,,,,0,0,4310a083-905d-4488-b391-35ee83688846
2019-07-30T08:00:00.000+08:00,Lilly Announces Verzenio Demonstrated Significant Improvement In Overall Survival In Phase 3 MONARCH 2 The Clinical Trial,LLY,https://www.benzinga.com/general/biotech/19/07/14157155/lilly-announces-verzenio-demonstrated-significant-improvement-in-overall-survival-in-phase-3-mona,Benzinga Newsdesk,,,,0,0,47d411f9-c609-4b4c-8ff7-58e60a0fc888
2019-07-30T08:00:00.000+08:00,"15 Stocks To Watch For July 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/07/14156849/15-stocks-to-watch-for-july-30-2019,Lisa Levin,,,,0,0,3b68ed43-ac8e-4fc6-98da-f4a1dee9b7c3
2019-07-30T08:00:00.000+08:00,"Earnings Scheduled For July 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/07/14156797/earnings-scheduled-for-july-30-2019,Lisa Levin,,,,0,0,7b37c163-5abe-4845-a359-96f08a7a77e8
2019-07-30T08:00:00.000+08:00,Flexion: The Time To Buy Is Now,LLY,https://seekingalpha.com/article/4279278-flexion-time-buy-now?source=partner_benzinga,Seeking Alpha,,,,0,0,be1e96cd-1522-42c2-9966-4deea46167b7
2019-07-30T08:00:00.000+08:00,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q2 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4279204-eli-lilly-companys-lly-ceo-dave-ricks-q2-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,af3521ed-b390-4743-8698-386c99a33356
2019-07-30T08:00:00.000+08:00,"Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y",LLY,http://www.zacks.com/stock/news/453958/incyte-incy-q2-earnings-beat-estimates-revenues-up-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-453958,Zacks,,,,0,0,5867dae6-757d-49ea-afc6-90c90f48a352
2019-07-30T08:00:00.000+08:00,"Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up",LLY,http://www.zacks.com/stock/news/453957/lilly-lly-q2-earnings-beat-new-drugs-drive-sales-stock-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-453957,Zacks,,,,0,0,dff66198-5944-4f51-bee4-eb190e0dc208
2019-07-30T08:00:00.000+08:00,"Svenska Handelsbanken AB (publ) Buys Welbilt Inc, Eli Lilly and Co, Service Corp International, ...",LLY,http://www.gurufocus.com/news/918292/svenska-handelsbanken-ab-publ-buys-welbilt-inc-eli-lilly-and-co-service-corp-international-sells-worldpay-inc-svb-financial-group-facebook-inc,GuruFocus,,,,0,0,d65524d3-6777-441d-853e-dd2c34e2d86f
2019-07-30T08:00:00.000+08:00,Economic and Earnings Date Deluge,LLY,http://www.zacks.com/stock/news/453798/economic-and-earnings-date-deluge?cid=CS-BENZ-FT-economic_highlights-453798,Zacks,,,,0,0,e9aaf70a-ca2b-4a27-b6bb-2ef2ddb814ed
2019-07-30T08:00:00.000+08:00,"Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More",LLY,http://www.zacks.com/stock/news/453588/busy-morning-for-investors-trade-data-earnings-for-pfe-mrk-cop-more?cid=CS-BENZ-FT-ahead_of_wall_street-453588,Zacks,,,,0,0,64b708ff-54da-40f0-b1fb-ba9a69007d7a
2019-07-30T08:00:00.000+08:00,Eli Lilly and Company 2019 Q2 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4278944-eli-lilly-company-2019-q2-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,0,0,92ca08db-a7f9-4e91-a420-dffacaa03398
2019-07-30T08:00:00.000+08:00,5 Monster Stocks To Watch For the July 30 Trading Session,LLY,https://www.benzinga.com/node/14159964,TalkMarkets,,,,0,0,b166fd1d-a847-427d-882a-8e39be7b2d6f
2019-07-30T08:00:00.000+08:00,Trump readies plan allow drug imports from Canada,LLY,https://seekingalpha.com/news/3483442-trump-readies-plan-allow-drug-imports-canada?source=partner_benzinga,Seeking Alpha,,,,0,0,9560d290-f848-4eae-858e-3e9daa62cb3d
2019-07-30T08:00:00.000+08:00,Eli Lilly (LLY) Tops Q2 Earnings Estimates,LLY,http://www.zacks.com/stock/news/453335/eli-lilly-lly-tops-q2-earnings-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-453335,Zacks,,,,0,0,2237749b-cff0-40e6-ad0f-a0942e4752c8
2019-07-30T08:00:00.000+08:00,Eli Lilly up 1% premarket on Q2 beat,LLY,https://seekingalpha.com/news/3483330-eli-lilly-1-percent-premarket-q2-beat?source=partner_benzinga,Seeking Alpha,,,,0,0,37467e20-956b-49d9-b4eb-02de96d5ec57
2019-07-30T08:00:00.000+08:00,Lilly's abemaciclib extends survival in late-stage breast cancer study,LLY,https://seekingalpha.com/news/3483290-lillys-abemaciclib-extends-survival-late-stage-breast-cancer-study?source=partner_benzinga,Seeking Alpha,,,,0,0,c110c266-3ba3-4633-9c6c-06eee7a54d32
2019-07-30T08:00:00.000+08:00,"Eli Lilly EPS beats by $0.05, beats on revenue",LLY,https://seekingalpha.com/news/3483225-eli-lilly-eps-beats-0_05-beats-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,62290c5f-b975-475c-9197-2fa9188c4a9e
2019-07-29T08:00:00.000+08:00,Q2 Earnings Preview For Eli Lilly,LLY,https://www.benzinga.com/news/earnings-previews/19/07/14153044/earnings-preview-eli-lilly,Benzinga Newsdesk,,,,0,0,d614c1eb-eb70-425a-91a5-cbee0727af38
2019-07-29T08:00:00.000+08:00,"Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up",LLY,http://www.zacks.com/stock/news/452891/sanofi-sny-q2-earnings-top-dupixent-shines-eps-view-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-452891,Zacks,,,,0,0,3d5d7234-379f-4ad4-b722-1ac3594e6666
2019-07-29T08:00:00.000+08:00,What's in Store for Array BioPharma (ARRY) in Q4 Earnings?,LLY,http://www.zacks.com/stock/news/452742/whats-in-store-for-array-biopharma-arry-in-q4-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-452742,Zacks,,,,0,0,7181126b-df40-48ab-82a9-c82056f4cf03
2019-07-29T08:00:00.000+08:00,DivGro Stocks Ranked By Quality Score,LLY,https://seekingalpha.com/article/4278548-divgro-stocks-ranked-quality-score?source=partner_benzinga,Seeking Alpha,,,,0,0,35dfd682-51dc-4f76-b39e-7304cc82aa2e
2019-07-29T08:00:00.000+08:00,Q2 Earnings Preview For Eli Lilly,LLY,https://www.benzinga.com/news/earnings-previews/19/07/14153044/earnings-preview-eli-lilly,Benzinga Newsdesk,,,,0,0,1ef46a2a-ebe3-4e5c-829d-19d7efe4a27b
2019-07-29T08:00:00.000+08:00,"Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up",LLY,http://www.zacks.com/stock/news/452891/sanofi-sny-q2-earnings-top-dupixent-shines-eps-view-up?cid=CS-BENZ-FT-analyst_blog|earnings_article-452891,Zacks,,,,0,0,bc1809ba-b0b7-4b2c-895f-2158ccdff417
2019-07-29T08:00:00.000+08:00,What's in Store for Array BioPharma (ARRY) in Q4 Earnings?,LLY,http://www.zacks.com/stock/news/452742/whats-in-store-for-array-biopharma-arry-in-q4-earnings?cid=CS-BENZ-FT-analyst_blog|earnings_preview-452742,Zacks,,,,0,0,7e4effb6-77ed-4060-9ef0-d8ff7508e2a8
2019-07-29T08:00:00.000+08:00,DivGro Stocks Ranked By Quality Score,LLY,https://seekingalpha.com/article/4278548-divgro-stocks-ranked-quality-score?source=partner_benzinga,Seeking Alpha,,,,0,0,e51e7db9-b261-477d-b6c2-689e3b68b61b
2019-07-28T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 28th, 2019",LLY,https://www.benzinga.com/node/14147979,TalkMarkets,,,,0,0,9d47333a-b05b-4c71-8934-4933833bd4dc
2019-07-28T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 28th, 2019",LLY,https://www.benzinga.com/node/14147979,TalkMarkets,,,,0,0,490fd7f9-66a8-4ab2-b11d-a063ca8b5a5c
2019-07-27T08:00:00.000+08:00,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",LLY,https://www.benzinga.com/general/biotech/19/07/14136579/the-week-ahead-in-biotech-pending-clinical-readouts-earnings-dominate,Shanthi Rexaline,,,,0,0,c0f1f4bf-d85c-409b-9737-38963e63aa76
2019-07-27T08:00:00.000+08:00,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",LLY,https://www.benzinga.com/general/biotech/19/07/14136579/the-week-ahead-in-biotech-pending-clinical-readouts-earnings-dominate,Shanthi Rexaline,,,,0,0,1259295c-953a-40ac-907a-f3978885d419
2019-07-26T08:00:00.000+08:00,Drug pricing bill passes Senate committee,LLY,https://seekingalpha.com/news/3482384-drug-pricing-bill-passes-senate-committee?source=partner_benzinga,Seeking Alpha,,,,0,0,d584799a-2af7-4ba9-9527-f2c825f62ccb
2019-07-26T08:00:00.000+08:00,"Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment",LLY,http://www.zacks.com/stock/news/450794/pharma-stock-roundup-gsk-bmy-q2-earnings-fda-nod-to-llys-hypoglycemia-treatment?cid=CS-BENZ-FT-analyst_blog|stock_roundup-450794,Zacks,,,,0,0,c07197aa-8bb1-4d1a-9872-ad71095ddccd
2019-07-26T08:00:00.000+08:00,Drug pricing bill passes Senate committee,LLY,https://seekingalpha.com/news/3482384-drug-pricing-bill-passes-senate-committee?source=partner_benzinga,Seeking Alpha,,,,0,0,1e9d06e7-3e48-478e-be8c-cc9cc0c362ed
2019-07-26T08:00:00.000+08:00,"Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment",LLY,http://www.zacks.com/stock/news/450794/pharma-stock-roundup-gsk-bmy-q2-earnings-fda-nod-to-llys-hypoglycemia-treatment?cid=CS-BENZ-FT-analyst_blog|stock_roundup-450794,Zacks,,,,0,0,57db4ec3-b5bd-4e8c-9ade-fb62c5fe06f4
2019-07-25T08:00:00.000+08:00,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",LLY,https://www.benzinga.com/general/biotech/19/07/14130982/the-daily-biotech-pulse-setback-for-bristol-myers-squibb-gemphire-explodes-lillys-nasal-low-blood,Shanthi Rexaline,,,,0,0,12fdf679-9d01-4382-b4f1-113c25e65fe9
2019-07-25T08:00:00.000+08:00,Lilly Announces FDA Approval of BAQSIMI to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older,LLY,https://www.benzinga.com/news/19/07/14130965/lilly-announces-fda-approval-of-baqsimi-to-treat-severe-hypoglycemia-in-adults-and-children-with-dia,Charles Gross,,,,0,0,e0296a06-98e0-40cd-8745-47c54f2055cb
2019-07-25T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 87,LLY,https://seekingalpha.com/article/4277815-bulletproof-investing-performance-update-week-87?source=partner_benzinga,Seeking Alpha,,,,0,0,f67b499e-eb52-4b1b-a7a1-82e2b2edfa1a
2019-07-25T08:00:00.000+08:00,FDA OKs Lilly's glucagon nasal powder for severe low blood sugar,LLY,https://seekingalpha.com/news/3481457-fda-oks-lillys-glucagon-nasal-powder-severe-low-blood-sugar?source=partner_benzinga,Seeking Alpha,,,,0,0,a3e75a6e-b721-4a23-90cc-73d7c5f1684d
2019-07-25T08:00:00.000+08:00,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",LLY,https://www.benzinga.com/general/biotech/19/07/14130982/the-daily-biotech-pulse-setback-for-bristol-myers-squibb-gemphire-explodes-lillys-nasal-low-blood,Shanthi Rexaline,,,,0,0,92463d4b-1d8b-4cf2-a5e3-b05210de5a50
2019-07-25T08:00:00.000+08:00,Lilly Announces FDA Approval of BAQSIMI to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older,LLY,https://www.benzinga.com/news/19/07/14130965/lilly-announces-fda-approval-of-baqsimi-to-treat-severe-hypoglycemia-in-adults-and-children-with-dia,Charles Gross,,,,0,0,baf6edd5-e5bd-493a-821b-d58f963876d7
2019-07-25T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 87,LLY,https://seekingalpha.com/article/4277815-bulletproof-investing-performance-update-week-87?source=partner_benzinga,Seeking Alpha,,,,0,0,3afdd15e-5659-458c-a6e7-bef92fe98f84
2019-07-25T08:00:00.000+08:00,FDA OKs Lilly's glucagon nasal powder for severe low blood sugar,LLY,https://seekingalpha.com/news/3481457-fda-oks-lillys-glucagon-nasal-powder-severe-low-blood-sugar?source=partner_benzinga,Seeking Alpha,,,,0,0,bfbe20a0-60e0-4ebb-8ed3-c97c1b4b51df
2019-07-24T08:00:00.000+08:00,Johnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate World,LLY,https://seekingalpha.com/article/4277125-johnson-and-johnsons-stock-may-cheap-low-interest-rate-world?source=partner_benzinga,Seeking Alpha,,,,0,0,d07c6e0e-f484-4874-9bd2-a79c13c44477
2019-07-24T08:00:00.000+08:00,Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?,LLY,http://www.zacks.com/stock/news/448183/eli-lilly-lly-to-report-q2-earnings-whats-in-store?cid=CS-BENZ-FT-analyst_blog|earnings_preview-448183,Zacks,,,,0,0,ca5cae74-3378-4378-9b04-8f96b2fb7f2c
2019-07-24T08:00:00.000+08:00,Johnson & Johnson's Stock May Be Too Cheap In A Low Interest Rate World,LLY,https://seekingalpha.com/article/4277125-johnson-and-johnsons-stock-may-cheap-low-interest-rate-world?source=partner_benzinga,Seeking Alpha,,,,0,0,dc5d1be1-7343-4a8c-b018-b9387162bfaf
2019-07-24T08:00:00.000+08:00,Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?,LLY,http://www.zacks.com/stock/news/448183/eli-lilly-lly-to-report-q2-earnings-whats-in-store?cid=CS-BENZ-FT-analyst_blog|earnings_preview-448183,Zacks,,,,0,0,4d34b87d-7207-4177-8bdd-aa3dfeea229d
2019-07-23T08:00:00.000+08:00,Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline,LLY,http://www.zacks.com/stock/news/447593/earnings-preview-eli-lilly-lly-q2-earnings-expected-to-decline?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-447593,Zacks,,,,0,0,a68cda77-0194-47ea-9ef6-b44b1cb2d476
2019-07-23T08:00:00.000+08:00,Earnings Preview: Eli Lilly (LLY) Q2 Earnings Expected to Decline,LLY,http://www.zacks.com/stock/news/447593/earnings-preview-eli-lilly-lly-q2-earnings-expected-to-decline?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_9-447593,Zacks,,,,0,0,bfa435cc-6ddc-4234-92fe-99cb10dba995
2019-07-22T08:00:00.000+08:00,U.S. Senator introduces bill to cut insulin prices,LLY,https://seekingalpha.com/news/3479829-u-s-senator-introduces-bill-cut-insulin-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,6eeaaeaa-4895-43c8-8cb8-64ffe887294f
2019-07-22T08:00:00.000+08:00,Annovis Bio Begins U.S. IPO Effort,LLY,https://seekingalpha.com/article/4276487-annovis-bio-begins-u-s-ipo-effort?source=partner_benzinga,Seeking Alpha,,,,0,0,dccfd5ed-21fc-4114-b7d2-c09bef8c6108
2019-07-22T08:00:00.000+08:00,U.S. Senator introduces bill to cut insulin prices,LLY,https://seekingalpha.com/news/3479829-u-s-senator-introduces-bill-cut-insulin-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,f8dcefa3-23b2-4844-91ac-0f3af966fc0f
2019-07-22T08:00:00.000+08:00,Annovis Bio Begins U.S. IPO Effort,LLY,https://seekingalpha.com/article/4276487-annovis-bio-begins-u-s-ipo-effort?source=partner_benzinga,Seeking Alpha,,,,0,0,a72feafd-1a7d-4beb-87e8-68b0554e1549
2019-07-21T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 21, 2019",LLY,https://www.benzinga.com/node/14106904,TalkMarkets,,,,0,0,23accded-5cb6-44d9-bb00-6654a33b4ba8
2019-07-21T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 21, 2019",LLY,https://www.benzinga.com/node/14106904,TalkMarkets,,,,0,0,de08a4d2-918c-469b-be9b-dede5f5be61a
2019-07-19T08:00:00.000+08:00,"Bessemer Securities Llc Buys Kirkland Lake Gold, Eli Lilly and Co, Capri Holdings, Sells ...",LLY,http://www.gurufocus.com/news/912068/bessemer-securities-llc-buys-kirkland-lake-gold-eli-lilly-and-co-capri-holdings-sells-ishares-msci-pacific-exjapan-index-fund-green-plains-inc-unitedhealth-group-inc,GuruFocus,,,,0,0,a8a6893c-5619-4572-b433-6c2c044f882c
2019-07-19T08:00:00.000+08:00,Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?,LLY,http://www.zacks.com/stock/news/445359/eli-lilly-lly-is-a-top-dividend-stock-right-now-should-you-buy?cid=CS-BENZ-FT-445359,Zacks,,,,0,0,0254424d-3a7c-463c-b8db-15ffe53c1205
2019-07-19T08:00:00.000+08:00,"Bessemer Securities Llc Buys Kirkland Lake Gold, Eli Lilly and Co, Capri Holdings, Sells ...",LLY,http://www.gurufocus.com/news/912068/bessemer-securities-llc-buys-kirkland-lake-gold-eli-lilly-and-co-capri-holdings-sells-ishares-msci-pacific-exjapan-index-fund-green-plains-inc-unitedhealth-group-inc,GuruFocus,,,,0,0,ff8403f6-cf69-4999-a4ce-6420b58939ed
2019-07-19T08:00:00.000+08:00,Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?,LLY,http://www.zacks.com/stock/news/445359/eli-lilly-lly-is-a-top-dividend-stock-right-now-should-you-buy?cid=CS-BENZ-FT-445359,Zacks,,,,0,0,59f2bd37-655d-41d1-9fb0-c3b721904948
2019-07-18T08:00:00.000+08:00,"The Pharma Scoop: Vanda Meets Endpoints, Aratana To Be Acquired, Einhorn Invests In NeuBase",LLY,https://seekingalpha.com/article/4275850-pharma-scoop-vanda-meets-endpoints-aratana-acquired-einhorn-invests-neubase?source=partner_benzinga,Seeking Alpha,,,,0,0,f4927f80-cbad-4a44-b194-593982c40784
2019-07-18T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 86,LLY,https://seekingalpha.com/article/4275730-bulletproof-investing-performance-update-week-86?source=partner_benzinga,Seeking Alpha,,,,0,0,08645c61-b468-4027-a78c-828ac4c795ea
2019-07-18T08:00:00.000+08:00,NuCana Initiates Dosing in Phase I Study for Solid Tumors,LLY,http://www.zacks.com/stock/news/444911/nucana-initiates-dosing-in-phase-i-study-for-solid-tumors?cid=CS-BENZ-FT-444911,Zacks,,,,0,0,9c95e609-cc0e-4586-9fbd-61d8a1f38226
2019-07-18T08:00:00.000+08:00,AC Immune Initiates Phase I Study for Alzheimer's Disease,LLY,http://www.zacks.com/stock/news/444451/ac-immune-initiates-phase-i-study-for-alzheimers-disease?cid=CS-BENZ-FT-444451,Zacks,,,,0,0,9cc0e0d0-2b38-4bb3-aaf7-ac1545d38ec6
2019-07-18T08:00:00.000+08:00,Healthcare Sector Innovation: How Biopharma Scientists Save Lives Globally,LLY,https://seekingalpha.com/article/4275627-healthcare-sector-innovation-biopharma-scientists-save-lives-globally?source=partner_benzinga,Seeking Alpha,,,,0,0,7d19d1e8-dee4-4cb7-a82f-fc1e0582249b
2019-07-18T08:00:00.000+08:00,"The Pharma Scoop: Vanda Meets Endpoints, Aratana To Be Acquired, Einhorn Invests In NeuBase",LLY,https://seekingalpha.com/article/4275850-pharma-scoop-vanda-meets-endpoints-aratana-acquired-einhorn-invests-neubase?source=partner_benzinga,Seeking Alpha,,,,0,0,e7f90e75-aedd-4bf0-a762-2ac635610274
2019-07-18T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 86,LLY,https://seekingalpha.com/article/4275730-bulletproof-investing-performance-update-week-86?source=partner_benzinga,Seeking Alpha,,,,0,0,ee63b585-f69b-4ef0-823e-ae8af7c1a751
2019-07-18T08:00:00.000+08:00,NuCana Initiates Dosing in Phase I Study for Solid Tumors,LLY,http://www.zacks.com/stock/news/444911/nucana-initiates-dosing-in-phase-i-study-for-solid-tumors?cid=CS-BENZ-FT-444911,Zacks,,,,0,0,ee665d3a-88af-4c26-88d5-63d7f59593f6
2019-07-18T08:00:00.000+08:00,AC Immune Initiates Phase I Study for Alzheimer's Disease,LLY,http://www.zacks.com/stock/news/444451/ac-immune-initiates-phase-i-study-for-alzheimers-disease?cid=CS-BENZ-FT-444451,Zacks,,,,0,0,a2ab10a8-dfc1-4137-a41e-8cd026cbbd1e
2019-07-18T08:00:00.000+08:00,Healthcare Sector Innovation: How Biopharma Scientists Save Lives Globally,LLY,https://seekingalpha.com/article/4275627-healthcare-sector-innovation-biopharma-scientists-save-lives-globally?source=partner_benzinga,Seeking Alpha,,,,0,0,3a3def84-e7b0-41eb-8b10-5033ec4b7b6b
2019-07-17T08:00:00.000+08:00,"AC Immune Initiates Phase 1 Study Of ACI-3024 Small Molecule Tau Morphomer, An Investigational Treatment For Alzheimer's Disease",LLY,https://www.benzinga.com/general/biotech/19/07/14086535/ac-immune-initiates-phase-1-study-of-aci-3024-small-molecule-tau-morphomer-an-investigational-tre,Benzinga Newsdesk,,,,0,0,f0266884-0a0f-4fcf-a03f-46035e6049c2
2019-07-17T08:00:00.000+08:00,"AC Immune Initiates Phase – Study of ACI-'…—4 Small Molecule Tau Morphomer™, an ...",LLY,http://www.gurufocus.com/news/910181/ac-immune-initiates-phase-1-study-of-aci3024-small-molecule-tau-morphomer-an-investigational-treatment-for-alzheimers-disease,GuruFocus,,,,0,0,7015254d-62bc-4ebd-8276-f7a3ccc03cca
2019-07-17T08:00:00.000+08:00,"AC Immune Initiates Phase 1 Study Of ACI-3024 Small Molecule Tau Morphomer, An Investigational Treatment For Alzheimer's Disease",LLY,https://www.benzinga.com/general/biotech/19/07/14086535/ac-immune-initiates-phase-1-study-of-aci-3024-small-molecule-tau-morphomer-an-investigational-tre,Benzinga Newsdesk,,,,0,0,5c76b762-2a5a-4e88-a015-99b067744815
2019-07-17T08:00:00.000+08:00,"AC Immune Initiates Phase – Study of ACI-'…—4 Small Molecule Tau Morphomer™, an ...",LLY,http://www.gurufocus.com/news/910181/ac-immune-initiates-phase-1-study-of-aci3024-small-molecule-tau-morphomer-an-investigational-treatment-for-alzheimers-disease,GuruFocus,,,,0,0,a08cd210-23a2-456e-866f-f3f37196ac47
2019-07-16T08:00:00.000+08:00,"Jim Cramer Weighs In On Marvell, General Motors And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/07/14078178/jim-cramer-weighs-in-on-marvell-general-motors-and-more,Brett Hershman,,,,0,0,97574085-4943-4a29-ba25-64186af1ff3d
2019-07-16T08:00:00.000+08:00,Recent Progress With Filgotinib Plus Latest Partnership Expansion Points To Gilead's New Solid Path,LLY,https://seekingalpha.com/article/4275289-recent-progress-filgotinib-plus-latest-partnership-expansion-points-gileads-new-solid-path?source=partner_benzinga,Seeking Alpha,,,,0,0,4688460e-8b8c-4f69-8dd9-b52ec698f83c
2019-07-16T08:00:00.000+08:00,"Gradient Investments LLC Buys SPDR Portfolio Short Term Corporate Bond, iShares MBS ETF, ...",LLY,http://www.gurufocus.com/news/909658/gradient-investments-llc-buys-spdr-portfolio-short-term-corporate-bond-ishares-mbs-etf-ishares-sp-500-value-sells-vanguard-intermediateterm-corporate-bond-etf-spdr-wells-fargo-preferred-stock-paychex-inc,GuruFocus,,,,0,0,52a5af27-5302-456b-9d64-bb57c02d2f75
2019-07-16T08:00:00.000+08:00,"Whitnell & Co. Buys iShares Russell –……… Value, DuPont de Nemours Inc, Fastenal Co, ...",LLY,http://www.gurufocus.com/news/909659/whitnell--co-buys-ishares-russell-1000-value-dupont-de-nemours-inc-fastenal-co-sells-invesco-db-commodity-index-tracking-fund-ishares-russell-1000-growth-bank-of-america-corporation,GuruFocus,,,,0,0,936e73b3-2d24-4f65-bcfa-a88440cf3fed
2019-07-16T08:00:00.000+08:00,ImmunoGen: Bold Move To Position A Comeback,LLY,https://seekingalpha.com/article/4275227-immunogen-bold-move-position-comeback?source=partner_benzinga,Seeking Alpha,,,,0,0,685febf7-7145-4e32-b6d7-dbd95fc99c86
2019-07-16T08:00:00.000+08:00,"Jim Cramer Weighs In On Marvell, General Motors And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/19/07/14078178/jim-cramer-weighs-in-on-marvell-general-motors-and-more,Brett Hershman,,,,0,0,385809fc-fa9f-4000-8985-8f0e0b547b1c
2019-07-16T08:00:00.000+08:00,Recent Progress With Filgotinib Plus Latest Partnership Expansion Points To Gilead's New Solid Path,LLY,https://seekingalpha.com/article/4275289-recent-progress-filgotinib-plus-latest-partnership-expansion-points-gileads-new-solid-path?source=partner_benzinga,Seeking Alpha,,,,0,0,28ccd24a-97a8-47a7-aefb-a7ff66911cef
2019-07-16T08:00:00.000+08:00,"Gradient Investments LLC Buys SPDR Portfolio Short Term Corporate Bond, iShares MBS ETF, ...",LLY,http://www.gurufocus.com/news/909658/gradient-investments-llc-buys-spdr-portfolio-short-term-corporate-bond-ishares-mbs-etf-ishares-sp-500-value-sells-vanguard-intermediateterm-corporate-bond-etf-spdr-wells-fargo-preferred-stock-paychex-inc,GuruFocus,,,,0,0,3fbab41b-d448-4b9b-a5ac-22281cc3c3bd
2019-07-16T08:00:00.000+08:00,"Whitnell & Co. Buys iShares Russell –……… Value, DuPont de Nemours Inc, Fastenal Co, ...",LLY,http://www.gurufocus.com/news/909659/whitnell--co-buys-ishares-russell-1000-value-dupont-de-nemours-inc-fastenal-co-sells-invesco-db-commodity-index-tracking-fund-ishares-russell-1000-growth-bank-of-america-corporation,GuruFocus,,,,0,0,46d75609-ff7f-4cf3-b529-2097b6b193c2
2019-07-16T08:00:00.000+08:00,ImmunoGen: Bold Move To Position A Comeback,LLY,https://seekingalpha.com/article/4275227-immunogen-bold-move-position-comeback?source=partner_benzinga,Seeking Alpha,,,,0,0,c326899c-02a6-4a50-893d-3f441861c245
2019-07-15T08:00:00.000+08:00,"Legacy Advisors, LLC Buys DuPont de Nemours Inc, PNC Financial Services Group Inc, Wells Fargo, ...",LLY,http://www.gurufocus.com/news/908995/legacy-advisors-llc-buys-dupont-de-nemours-inc-pnc-financial-services-group-inc-wells-fargo-sells-spdr-midcap-trust-series-i-spdr-sp-500-ishares-core-sp-500,GuruFocus,,,,0,0,3e7d554b-5ab6-4641-b6b1-696f788d0c24
2019-07-15T08:00:00.000+08:00,AbbVie enters STING field with Mavupharma buy,LLY,https://seekingalpha.com/news/3477651-abbvie-enters-sting-field-mavupharma-buy?source=partner_benzinga,Seeking Alpha,,,,0,0,4e404d6f-208c-4f6c-b2ad-bb8efb417734
2019-07-15T08:00:00.000+08:00,"Legacy Advisors, LLC Buys DuPont de Nemours Inc, PNC Financial Services Group Inc, Wells Fargo, ...",LLY,http://www.gurufocus.com/news/908995/legacy-advisors-llc-buys-dupont-de-nemours-inc-pnc-financial-services-group-inc-wells-fargo-sells-spdr-midcap-trust-series-i-spdr-sp-500-ishares-core-sp-500,GuruFocus,,,,0,0,b45307a4-1a5a-49f3-856f-6b0d5c5807c6
2019-07-15T08:00:00.000+08:00,AbbVie enters STING field with Mavupharma buy,LLY,https://seekingalpha.com/news/3477651-abbvie-enters-sting-field-mavupharma-buy?source=partner_benzinga,Seeking Alpha,,,,0,0,752b104a-c72f-4f88-95dd-9aa764eac985
2019-07-14T08:00:00.000+08:00,45 Fortune 500 Stocks Projected Top Total Returns To Investors To July 2020,LLY,https://seekingalpha.com/article/4274872-45-fortune-500-stocks-projected-top-total-returns-investors-july-2020?source=partner_benzinga,Seeking Alpha,,,,0,0,5dc8c9f0-6f74-4b48-9bbd-da6e62234d22
2019-07-14T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 14, 2019",LLY,https://www.benzinga.com/node/14071181,TalkMarkets,,,,0,0,b285d3ad-ce1d-40a0-a084-0e6c002a5ca9
2019-07-14T08:00:00.000+08:00,45 Fortune 500 Stocks Projected Top Total Returns To Investors To July 2020,LLY,https://seekingalpha.com/article/4274872-45-fortune-500-stocks-projected-top-total-returns-investors-july-2020?source=partner_benzinga,Seeking Alpha,,,,0,0,0fbc4244-ded2-41b7-8a1d-0c6757641638
2019-07-14T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - July 14, 2019",LLY,https://www.benzinga.com/node/14071181,TalkMarkets,,,,0,0,9600b824-5618-47a3-bece-32a82fed2b72
2019-07-13T08:00:00.000+08:00,"Barron's Picks And Pans: Dollar Tree, Expedia, Nvidia, Prudential And More",LLY,https://www.benzinga.com/media/19/07/14070792/barrons-picks-and-pans-dollar-tree-expedia-nvidia-prudential-and-more,Nelson Hem,,,,0,0,a42a81fd-0389-4240-8b50-e9bc34ecab54
2019-07-13T08:00:00.000+08:00,Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study,LLY,https://www.benzinga.com/news/19/07/14070774/lilly-presents-new-findings-on-stigma-faced-by-people-with-migraine-based-on-interim-results-from-th,Charles Gross,,,,0,0,7d854d07-e298-4621-b0b2-7b4a7523c3dc
2019-07-13T08:00:00.000+08:00,"Barron's Picks And Pans: Dollar Tree, Expedia, Nvidia, Prudential And More",LLY,https://www.benzinga.com/media/19/07/14070792/barrons-picks-and-pans-dollar-tree-expedia-nvidia-prudential-and-more,Nelson Hem,,,,0,0,576b6b6c-e178-4b53-9964-5a07c0f52dac
2019-07-13T08:00:00.000+08:00,Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study,LLY,https://www.benzinga.com/news/19/07/14070774/lilly-presents-new-findings-on-stigma-faced-by-people-with-migraine-based-on-interim-results-from-th,Charles Gross,,,,0,0,6e50ab99-b5f4-44df-b552-05d9b4ca344d
2019-07-12T08:00:00.000+08:00,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug",LLY,https://www.benzinga.com/general/biotech/19/07/14067050/novartis-amgen-scrap-pivotal-study-of-alzheimers-prevention-drug,Shanthi Rexaline,,,,0,0,057c177c-cd12-43ea-9c95-5e6ece0fa594
2019-07-12T08:00:00.000+08:00,Stock Market Eyes Records On Dovish Commentary From Federal Reserve,LLY,https://www.benzinga.com/news/19/07/14067261/stock-market-eyes-records-on-dovish-commentary-from-federal-reserve,JJ Kinahan,,,,0,0,353f5bac-8c6c-46c6-b7ff-1548623a48e4
2019-07-12T08:00:00.000+08:00,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.",LLY,https://www.benzinga.com/markets/wiim/19/07/14067031/shares-of-several-drug-manufacturing-companies-are-trading-lower-potentially-on-continued-weakness-a,Benzinga Newsdesk,,,,0,0,e2b62c01-91f6-496d-95f4-af14b89d5276
2019-07-12T08:00:00.000+08:00,Eli Lilly Highlights Upcoming Presentation Of Data From OVERCOME Study,LLY,https://www.benzinga.com/news/19/07/14066258/eli-lilly-highlights-upcoming-presentation-of-data-from-overcome-study,Benzinga Newsdesk,,,,0,0,3f387bc8-6565-40db-be09-9d7d0e89cc3a
2019-07-12T08:00:00.000+08:00,"Univest Corp Of Pennsylvania Buys Monster Beverage Corp, Vanguard Total Bond Market ETF, ...",LLY,http://www.gurufocus.com/news/908234/univest-corp-of-pennsylvania-buys-monster-beverage-corp-vanguard-total-bond-market-etf-fastenal-co-sells-ugi-corp-spdr-select-sector-fund--consumer-staples-eli-lilly-and-co,GuruFocus,,,,0,0,d090658d-c1cc-4ea0-9e84-47650634e3da
2019-07-12T08:00:00.000+08:00,Drug Pricing Woes Linger on Repealing Drug Rebate Proposal,LLY,http://www.zacks.com/stock/news/441711/drug-pricing-woes-linger-on-repealing-drug-rebate-proposal?cid=CS-BENZ-FT-441711,Zacks,,,,0,0,572fed13-9cf4-45e7-b875-d247e9a28a3e
2019-07-12T08:00:00.000+08:00,"Handelsbanken Fonder AB Buys AbbVie Inc, Columbia Sportswear Co, Boingo Wireless Inc, Sells ...",LLY,http://www.gurufocus.com/news/907957/handelsbanken-fonder-ab-buys-abbvie-inc-columbia-sportswear-co-boingo-wireless-inc-sells-johnson--johnson-apple-inc-mellanox-technologies,GuruFocus,,,,0,0,9034b880-ee0a-4ce3-b048-2bf97344e134
2019-07-12T08:00:00.000+08:00,Pooled post-hoc data support efficacy of Lilly's migraine med Emaglity,LLY,https://seekingalpha.com/news/3477375-pooled-post-hoc-data-support-efficacy-lillys-migraine-med-emaglity?source=partner_benzinga,Seeking Alpha,,,,0,0,f954dbca-4b67-4962-bc86-22dc868a7459
2019-07-12T08:00:00.000+08:00,"Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug",LLY,https://www.benzinga.com/general/biotech/19/07/14067050/novartis-amgen-scrap-pivotal-study-of-alzheimers-prevention-drug,Shanthi Rexaline,,,,0,0,6410788d-166e-4ed3-8fdc-b4b142770e22
2019-07-12T08:00:00.000+08:00,Stock Market Eyes Records On Dovish Commentary From Federal Reserve,LLY,https://www.benzinga.com/news/19/07/14067261/stock-market-eyes-records-on-dovish-commentary-from-federal-reserve,JJ Kinahan,,,,0,0,831cfe66-28c7-423a-a162-3d3f9c0ffcb3
2019-07-12T08:00:00.000+08:00,"Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.",LLY,https://www.benzinga.com/markets/wiim/19/07/14067031/shares-of-several-drug-manufacturing-companies-are-trading-lower-potentially-on-continued-weakness-a,Benzinga Newsdesk,,,,0,0,982ae3da-bf2f-4324-b8db-501aea90d8eb
2019-07-12T08:00:00.000+08:00,Eli Lilly Highlights Upcoming Presentation Of Data From OVERCOME Study,LLY,https://www.benzinga.com/news/19/07/14066258/eli-lilly-highlights-upcoming-presentation-of-data-from-overcome-study,Benzinga Newsdesk,,,,0,0,392de5ba-badc-4ec4-a910-9bde4d22cba1
2019-07-12T08:00:00.000+08:00,"Univest Corp Of Pennsylvania Buys Monster Beverage Corp, Vanguard Total Bond Market ETF, ...",LLY,http://www.gurufocus.com/news/908234/univest-corp-of-pennsylvania-buys-monster-beverage-corp-vanguard-total-bond-market-etf-fastenal-co-sells-ugi-corp-spdr-select-sector-fund--consumer-staples-eli-lilly-and-co,GuruFocus,,,,0,0,9bc36452-c502-4768-9890-d8b16754630d
2019-07-12T08:00:00.000+08:00,Drug Pricing Woes Linger on Repealing Drug Rebate Proposal,LLY,http://www.zacks.com/stock/news/441711/drug-pricing-woes-linger-on-repealing-drug-rebate-proposal?cid=CS-BENZ-FT-441711,Zacks,,,,0,0,af4b4623-770c-416b-9887-174f319c5030
2019-07-12T08:00:00.000+08:00,"Handelsbanken Fonder AB Buys AbbVie Inc, Columbia Sportswear Co, Boingo Wireless Inc, Sells ...",LLY,http://www.gurufocus.com/news/907957/handelsbanken-fonder-ab-buys-abbvie-inc-columbia-sportswear-co-boingo-wireless-inc-sells-johnson--johnson-apple-inc-mellanox-technologies,GuruFocus,,,,0,0,57a501b2-07ce-41d3-ba36-a41c69ba87a3
2019-07-12T08:00:00.000+08:00,Pooled post-hoc data support efficacy of Lilly's migraine med Emaglity,LLY,https://seekingalpha.com/news/3477375-pooled-post-hoc-data-support-efficacy-lillys-migraine-med-emaglity?source=partner_benzinga,Seeking Alpha,,,,0,0,62087519-8951-4d99-8d5e-0db3e9379ef5
2019-07-11T08:00:00.000+08:00,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,LLY,https://www.benzinga.com/markets/wiim/19/07/14061352/shares-of-several-drug-manufacturing-companies-are-trading-lower-the-trump-administration-earlier-ro,Hal Lindon,,,,0,0,ae82ac38-1d57-4c8c-a779-a808826ca245
2019-07-11T08:00:00.000+08:00,Eli Lilly Names Mike Harrington New General Counsel,LLY,https://www.benzinga.com/news/19/07/14059758/eli-lilly-names-mike-harrington-new-general-counsel,Benzinga Newsdesk,,,,0,0,465a5fce-7ccd-4d3f-97c7-36ec1d29ee12
2019-07-11T08:00:00.000+08:00,Eli Lilly Highlights Phase 3 Study Results Of Emgality For Treatment Of Episodic Cluster Headache Published In 'New England Journal Of Medicine',LLY,https://www.benzinga.com/news/19/07/14058909/eli-lilly-highlights-phase-3-study-results-of-emgality-for-treatment-of-episodic-cluster-headache-pu,Benzinga Newsdesk,,,,0,0,8f0cbbaf-8ae2-4ccd-80b1-b07b88091242
2019-07-11T08:00:00.000+08:00,Here's Why The Stock Market May Make Its Next Move Higher On July 12,LLY,https://www.benzinga.com/node/14064708,TalkMarkets,,,,0,0,84900dfb-17c6-47f7-8da8-ab5b97c669f6
2019-07-11T08:00:00.000+08:00,Big Biopharma in the red as investors wait for Trump's drug price plan,LLY,https://seekingalpha.com/news/3477237-big-biopharma-red-investors-wait-trumps-drug-price-plan?source=partner_benzinga,Seeking Alpha,,,,0,0,2b8419e6-a47a-4833-9f35-fa5248b153f3
2019-07-11T08:00:00.000+08:00,4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal,LLY,http://www.zacks.com/stock/news/441257/4-medical-stocks-to-consider-after-federal-judge-blocks-trump-proposal?cid=CS-BENZ-FT-441257,Zacks,,,,0,0,ac342694-e5c1-40e9-a34c-efea65ba4319
2019-07-11T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 85,LLY,https://seekingalpha.com/article/4274520-bulletproof-investing-performance-update-week-85?source=partner_benzinga,Seeking Alpha,,,,0,0,cc8e92ac-9998-430e-9655-3e9a91803f2e
2019-07-11T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices",LLY,http://www.zacks.com/stock/news/441141/the-zacks-analyst-blog-highlights-bank-of-america-eli-lilly-boston-scientific-schwab-and-advanced-micro-devices?cid=CS-BENZ-FT-441141,Zacks,,,,0,0,2d8a0d18-4975-4c1e-990b-e336016ff080
2019-07-11T08:00:00.000+08:00,Lilly Bio-Medicines chief to depart next month; shares down 3%,LLY,https://seekingalpha.com/news/3477097-lilly-bio-medicines-chief-depart-next-month-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,9f3fdd29-bfbb-4fa2-a0bc-264e32e4db25
2019-07-11T08:00:00.000+08:00,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,LLY,https://www.benzinga.com/markets/wiim/19/07/14061352/shares-of-several-drug-manufacturing-companies-are-trading-lower-the-trump-administration-earlier-ro,Hal Lindon,,,,0,0,a66cda5a-0f11-4c14-9507-a4641b925ec5
2019-07-11T08:00:00.000+08:00,Eli Lilly Names Mike Harrington New General Counsel,LLY,https://www.benzinga.com/news/19/07/14059758/eli-lilly-names-mike-harrington-new-general-counsel,Benzinga Newsdesk,,,,0,0,75bd546b-5af4-475c-972e-98748279dacf
2019-07-11T08:00:00.000+08:00,Eli Lilly Highlights Phase 3 Study Results Of Emgality For Treatment Of Episodic Cluster Headache Published In 'New England Journal Of Medicine',LLY,https://www.benzinga.com/news/19/07/14058909/eli-lilly-highlights-phase-3-study-results-of-emgality-for-treatment-of-episodic-cluster-headache-pu,Benzinga Newsdesk,,,,0,0,d1415742-8c97-4bc2-a230-9e72924faa31
2019-07-11T08:00:00.000+08:00,Here's Why The Stock Market May Make Its Next Move Higher On July 12,LLY,https://www.benzinga.com/node/14064708,TalkMarkets,,,,0,0,66ba54f6-7042-452a-82ad-408631b86793
2019-07-11T08:00:00.000+08:00,Big Biopharma in the red as investors wait for Trump's drug price plan,LLY,https://seekingalpha.com/news/3477237-big-biopharma-red-investors-wait-trumps-drug-price-plan?source=partner_benzinga,Seeking Alpha,,,,0,0,98fc55f2-9abb-4874-950a-1fb8a413416f
2019-07-11T08:00:00.000+08:00,4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal,LLY,http://www.zacks.com/stock/news/441257/4-medical-stocks-to-consider-after-federal-judge-blocks-trump-proposal?cid=CS-BENZ-FT-441257,Zacks,,,,0,0,048158ca-a16c-4731-921d-32911b829d30
2019-07-11T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 85,LLY,https://seekingalpha.com/article/4274520-bulletproof-investing-performance-update-week-85?source=partner_benzinga,Seeking Alpha,,,,0,0,7511712d-7e87-4d3c-847f-4f9fa889fea5
2019-07-11T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices",LLY,http://www.zacks.com/stock/news/441141/the-zacks-analyst-blog-highlights-bank-of-america-eli-lilly-boston-scientific-schwab-and-advanced-micro-devices?cid=CS-BENZ-FT-441141,Zacks,,,,0,0,9cff2337-d9cf-4cb1-a2ba-50449f8c9f5b
2019-07-11T08:00:00.000+08:00,Lilly Bio-Medicines chief to depart next month; shares down 3%,LLY,https://seekingalpha.com/news/3477097-lilly-bio-medicines-chief-depart-next-month-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,a0d16e8d-f55a-45dc-a8ad-b19b4b5a4fc3
2019-07-10T08:00:00.000+08:00,Enbridge Portfolio: Final Performance,LLY,https://seekingalpha.com/article/4274346-enbridge-portfolio-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,64fd0577-1073-4ae2-b1c2-2c08be437a19
2019-07-10T08:00:00.000+08:00,Eli Lilly And Baricitinib In PBC: What's The Story?,LLY,https://seekingalpha.com/article/4274342-eli-lilly-baricitinib-pbc-story?source=partner_benzinga,Seeking Alpha,,,,0,0,3582c100-e9f3-4b33-bd74-b326f2df72c1
2019-07-10T08:00:00.000+08:00,"Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific",LLY,http://www.zacks.com/research-daily/440507/top-stock-reports-for-bank-of-america-eli-lilly-boston-scientific?cid=CS-BENZ-FT-440507,Zacks,,,,0,0,eb2b6132-c52c-4d10-bdc4-c4083e9baa00
2019-07-10T08:00:00.000+08:00,"Court Ruling Topples Trump Order, No Price Display in TV Ads",LLY,http://www.zacks.com/stock/news/440524/court-ruling-topples-trump-order-no-price-display-in-tv-ads?cid=CS-BENZ-FT-440524,Zacks,,,,0,0,8c28d857-5b59-4f52-8cd9-62d2c19b5c80
2019-07-10T08:00:00.000+08:00,Enbridge Portfolio: Final Performance,LLY,https://seekingalpha.com/article/4274346-enbridge-portfolio-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,27001754-8786-4891-bbc5-85a9e4f74b94
2019-07-10T08:00:00.000+08:00,Eli Lilly And Baricitinib In PBC: What's The Story?,LLY,https://seekingalpha.com/article/4274342-eli-lilly-baricitinib-pbc-story?source=partner_benzinga,Seeking Alpha,,,,0,0,6527926e-bc26-42fd-ac70-1bf4d625cf7f
2019-07-10T08:00:00.000+08:00,"Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific",LLY,http://www.zacks.com/research-daily/440507/top-stock-reports-for-bank-of-america-eli-lilly-boston-scientific?cid=CS-BENZ-FT-440507,Zacks,,,,0,0,b2375ca1-ba78-40ba-965a-bb8ebcedd39d
2019-07-10T08:00:00.000+08:00,"Court Ruling Topples Trump Order, No Price Display in TV Ads",LLY,http://www.zacks.com/stock/news/440524/court-ruling-topples-trump-order-no-price-display-in-tv-ads?cid=CS-BENZ-FT-440524,Zacks,,,,0,0,901a7782-0688-4e3f-b978-62d2b97aee64
2019-07-09T08:00:00.000+08:00,Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials,LLY,https://www.benzinga.com/government/19/07/14045927/judge-rules-against-trump-proposal-forcing-pharma-companies-to-disclose-drug-prices-in-commercials,Jayson Derrick,,,,0,0,d53e0b7a-68d4-4457-be27-b7bc9c924f32
2019-07-09T08:00:00.000+08:00,"Ready, Set, Fedspeak (Wall Street Breakfast Podcast)",LLY,https://seekingalpha.com/article/4274018-ready-set-fedspeak-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,d54589f6-9ad9-4e30-8fc1-69e3f0e74513
2019-07-09T08:00:00.000+08:00,"Wall Street Breakfast: Ready, Set, Fedspeak",LLY,https://seekingalpha.com/article/4274002-wall-street-breakfast-ready-set-fedspeak?source=partner_benzinga,Seeking Alpha,,,,0,0,0dafbb17-dd21-4123-b939-bd2f363da485
2019-07-09T08:00:00.000+08:00,Rule requiring drug prices in TV ads blocked,LLY,https://seekingalpha.com/news/3476378-rule-requiring-drug-prices-tv-ads-blocked?source=partner_benzinga,Seeking Alpha,,,,0,0,c10bc51a-63c8-42d8-b7de-efc027c4010f
2019-07-09T08:00:00.000+08:00,Judge Rules Against Trump Proposal Forcing Pharma Companies To Disclose Drug Prices In Commercials,LLY,https://www.benzinga.com/government/19/07/14045927/judge-rules-against-trump-proposal-forcing-pharma-companies-to-disclose-drug-prices-in-commercials,Jayson Derrick,,,,0,0,cab62a07-62da-489e-856f-1731ac363e0c
2019-07-09T08:00:00.000+08:00,"Ready, Set, Fedspeak (Wall Street Breakfast Podcast)",LLY,https://seekingalpha.com/article/4274018-ready-set-fedspeak-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,6e9c7d13-c4be-47f8-8b3c-0b6ef79ede47
2019-07-09T08:00:00.000+08:00,"Wall Street Breakfast: Ready, Set, Fedspeak",LLY,https://seekingalpha.com/article/4274002-wall-street-breakfast-ready-set-fedspeak?source=partner_benzinga,Seeking Alpha,,,,0,0,44b41c6e-07c8-4c53-b378-d5d9433e9b1d
2019-07-09T08:00:00.000+08:00,Rule requiring drug prices in TV ads blocked,LLY,https://seekingalpha.com/news/3476378-rule-requiring-drug-prices-tv-ads-blocked?source=partner_benzinga,Seeking Alpha,,,,0,0,753aec15-a5ef-4537-a67e-8b69785c224c
2019-07-08T08:00:00.000+08:00,U.S. Judge Halts Trump Administration Rule Requiring Drug Prices in TV Ads,LLY,https://www.benzinga.com/news/19/07/14043197/u-s-judge-halts-trump-administration-rule-requiring-drug-prices-in-tv-ads,Charles Gross,,,,0,0,8195d6f5-0e78-476d-bc31-c5dec5200d55
2019-07-08T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",LLY,https://www.benzinga.com/markets/wiim/19/07/14041064/shares-of-several-healthcare-companies-are-trading-lower-after-trump-on-friday-said-he-was-preparing,Benzinga Newsdesk,,,,0,0,5bb940e6-932e-4f37-8eb8-a66bb3af9cbc
2019-07-08T08:00:00.000+08:00,Biophytis files for 8.75M-share U.S. IPO at $7-$9/ADS,LLY,https://seekingalpha.com/news/3476366-biophytis-files-8_75m-share-u-s-ipo-7-9-ads?source=partner_benzinga,Seeking Alpha,,,,0,0,020e1388-b154-4982-8064-efe01fb344a8
2019-07-08T08:00:00.000+08:00,Biotechs and biopharmas under pressure ahead of Trump order on drug prices,LLY,https://seekingalpha.com/news/3476265-biotechs-biopharmas-pressure-ahead-trump-order-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,82b180ec-ad7a-45ee-9944-39ddbfb3cf28
2019-07-08T08:00:00.000+08:00,U.S. Judge Halts Trump Administration Rule Requiring Drug Prices in TV Ads,LLY,https://www.benzinga.com/news/19/07/14043197/u-s-judge-halts-trump-administration-rule-requiring-drug-prices-in-tv-ads,Charles Gross,,,,0,0,11c79b09-837d-4f03-8256-49cad91958a6
2019-07-08T08:00:00.000+08:00,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",LLY,https://www.benzinga.com/markets/wiim/19/07/14041064/shares-of-several-healthcare-companies-are-trading-lower-after-trump-on-friday-said-he-was-preparing,Benzinga Newsdesk,,,,0,0,992dd8e9-afe4-40b5-b934-9f56489702ad
2019-07-08T08:00:00.000+08:00,Biophytis files for 8.75M-share U.S. IPO at $7-$9/ADS,LLY,https://seekingalpha.com/news/3476366-biophytis-files-8_75m-share-u-s-ipo-7-9-ads?source=partner_benzinga,Seeking Alpha,,,,0,0,a64d703d-bb82-4012-8df3-5deb6d2054a7
2019-07-08T08:00:00.000+08:00,Biotechs and biopharmas under pressure ahead of Trump order on drug prices,LLY,https://seekingalpha.com/news/3476265-biotechs-biopharmas-pressure-ahead-trump-order-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,410dd90e-a2f8-44d5-b045-2d614464fda6
2019-07-06T08:00:00.000+08:00,Most Favored Nation Protection For Abbott Laboratories,LLY,https://seekingalpha.com/article/4273686-favored-nation-protection-abbott-laboratories?source=partner_benzinga,Seeking Alpha,,,,0,0,0d2d9ea0-065b-4ad3-8d19-1dc510fca2ab
2019-07-06T08:00:00.000+08:00,Most Favored Nation Protection For Abbott Laboratories,LLY,https://seekingalpha.com/article/4273686-favored-nation-protection-abbott-laboratories?source=partner_benzinga,Seeking Alpha,,,,0,0,d8ade2de-d4d0-42f4-aabb-cc822ed278c8
2019-07-05T08:00:00.000+08:00,"Verde Servicos Internacionais S.A. Buys iShares Inc MSCI Brazil, NXP Semiconductors NV, ...",LLY,http://www.gurufocus.com/news/904387/verde-servicos-internacionais-sa-buys-ishares-inc-msci-brazil-nxp-semiconductors-nv-dominos-pizza-inc-sells-pagseguro-digital-visa-inc-microsoft-corp,GuruFocus,,,,0,0,b2bda464-5877-4d79-a3a8-743dcdd04557
2019-07-05T08:00:00.000+08:00,Drug stocks slip after Trump talks up 'favored nations' plan,LLY,https://seekingalpha.com/news/3475917-drug-stocks-slip-trump-talks-favored-nations-plan?source=partner_benzinga,Seeking Alpha,,,,0,0,34868c6f-a99c-4402-a681-fa62f5f30a84
2019-07-05T08:00:00.000+08:00,A First-Half Review Of The Markets,LLY,https://seekingalpha.com/article/4273561-first-half-review-markets?source=partner_benzinga,Seeking Alpha,,,,0,0,750cb03e-bce3-4dea-ab5b-9645984a7bb3
2019-07-05T08:00:00.000+08:00,"Verde Servicos Internacionais S.A. Buys iShares Inc MSCI Brazil, NXP Semiconductors NV, ...",LLY,http://www.gurufocus.com/news/904387/verde-servicos-internacionais-sa-buys-ishares-inc-msci-brazil-nxp-semiconductors-nv-dominos-pizza-inc-sells-pagseguro-digital-visa-inc-microsoft-corp,GuruFocus,,,,0,0,16cdc4af-a4db-48eb-b18c-ffe9814706cf
2019-07-05T08:00:00.000+08:00,Drug stocks slip after Trump talks up 'favored nations' plan,LLY,https://seekingalpha.com/news/3475917-drug-stocks-slip-trump-talks-favored-nations-plan?source=partner_benzinga,Seeking Alpha,,,,0,0,555b6053-0a93-4544-90c7-9fc469cf2152
2019-07-05T08:00:00.000+08:00,A First-Half Review Of The Markets,LLY,https://seekingalpha.com/article/4273561-first-half-review-markets?source=partner_benzinga,Seeking Alpha,,,,0,0,6939f82a-0ea4-4085-af9f-df74ec498f29
2019-07-04T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 84,LLY,https://seekingalpha.com/article/4273467-bulletproof-investing-performance-update-week-84?source=partner_benzinga,Seeking Alpha,,,,0,0,a4965b69-291c-473c-8004-894a55a00cfa
2019-07-04T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 84,LLY,https://seekingalpha.com/article/4273467-bulletproof-investing-performance-update-week-84?source=partner_benzinga,Seeking Alpha,,,,0,0,fb32b3ff-6b4c-4ebe-aa62-74b5bde2644f
2019-07-03T08:00:00.000+08:00,Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab,LLY,http://www.zacks.com/stock/news/437675/incyte-out-licenses-incmga0012-rights-in-china-to-zai-lab?cid=CS-BENZ-FT-437675,Zacks,,,,0,0,1bfd17d3-229b-4bf5-9022-9968822bfc2e
2019-07-03T08:00:00.000+08:00,Will the Pharma Space Witness More Mega-Merger Deals in 2H?,LLY,http://www.zacks.com/stock/news/437588/will-the-pharma-space-witness-more-mega-merger-deals-in-2h?cid=CS-BENZ-FT-437588,Zacks,,,,0,0,9f773dfa-d2e3-4e6b-a5fd-f0c3136cd8c8
2019-07-03T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/437556/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-437556,Zacks,,,,0,0,110a5404-2a86-4a97-b27e-7cfce67b3013
2019-07-03T08:00:00.000+08:00,Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab,LLY,http://www.zacks.com/stock/news/437675/incyte-out-licenses-incmga0012-rights-in-china-to-zai-lab?cid=CS-BENZ-FT-437675,Zacks,,,,0,0,820abc1a-2113-4e5d-b435-c1f3d8e55735
2019-07-03T08:00:00.000+08:00,Will the Pharma Space Witness More Mega-Merger Deals in 2H?,LLY,http://www.zacks.com/stock/news/437588/will-the-pharma-space-witness-more-mega-merger-deals-in-2h?cid=CS-BENZ-FT-437588,Zacks,,,,0,0,8dbe1e81-9979-4eac-852d-b4a3e36de299
2019-07-03T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/437556/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-437556,Zacks,,,,0,0,f76b2b17-148f-4901-95fe-4995b5e0ecde
2019-07-02T08:00:00.000+08:00,Entera Announces Initiation Of Phase 2 Dose Ranging Study For Oral PTH,LLY,https://www.benzinga.com/general/biotech/19/07/14016302/entera-announces-initiation-of-phase-2-dose-ranging-study-for-oral-pth,Benzinga Newsdesk,,,,0,0,9cff1f5f-703a-426a-ac11-34458e81efb2
2019-07-02T08:00:00.000+08:00,Bristol-Myers: Otezla Divestiture Highlights Compelling Opportunity,LLY,https://seekingalpha.com/article/4273141-bristol-myers-otezla-divestiture-highlights-compelling-opportunity?source=partner_benzinga,Seeking Alpha,,,,0,0,215acbe7-668a-4c04-863d-e95eebdb3a12
2019-07-02T08:00:00.000+08:00,U.S. drugmakers institute new round of increases,LLY,https://seekingalpha.com/news/3475290-u-s-drugmakers-institute-new-round-increases?source=partner_benzinga,Seeking Alpha,,,,0,0,a9d87af3-cb9d-49e1-ad1c-07010875ffc0
2019-07-02T08:00:00.000+08:00,Gilead to Submit NDA for Inflammation Drug Filgotinib in '19,LLY,http://www.zacks.com/stock/news/437135/gilead-to-submit-nda-for-inflammation-drug-filgotinib-in-19?cid=CS-BENZ-FT-437135,Zacks,,,,0,0,206b73f8-793b-45a5-b0a9-ed77335bea60
2019-07-02T08:00:00.000+08:00,M&A Activity A Favored Prescription For Biopharmaceutical Companies,LLY,https://seekingalpha.com/article/4273095-m-activity-favored-prescription-biopharmaceutical-companies?source=partner_benzinga,Seeking Alpha,,,,0,0,7b48bf8e-eed7-4e38-b5af-e0614f07a2f8
2019-07-02T08:00:00.000+08:00,Entera Announces Initiation Of Phase 2 Dose Ranging Study For Oral PTH,LLY,https://www.benzinga.com/general/biotech/19/07/14016302/entera-announces-initiation-of-phase-2-dose-ranging-study-for-oral-pth,Benzinga Newsdesk,,,,0,0,c125a4bc-b0a5-4bbb-a9cc-abcfe5485da2
2019-07-02T08:00:00.000+08:00,Bristol-Myers: Otezla Divestiture Highlights Compelling Opportunity,LLY,https://seekingalpha.com/article/4273141-bristol-myers-otezla-divestiture-highlights-compelling-opportunity?source=partner_benzinga,Seeking Alpha,,,,0,0,fcd25dfd-fce0-4417-aa5c-9e2c0ea855cc
2019-07-02T08:00:00.000+08:00,U.S. drugmakers institute new round of increases,LLY,https://seekingalpha.com/news/3475290-u-s-drugmakers-institute-new-round-increases?source=partner_benzinga,Seeking Alpha,,,,0,0,8e99c504-4b07-4fd1-870f-b6a1baa812c5
2019-07-02T08:00:00.000+08:00,Gilead to Submit NDA for Inflammation Drug Filgotinib in '19,LLY,http://www.zacks.com/stock/news/437135/gilead-to-submit-nda-for-inflammation-drug-filgotinib-in-19?cid=CS-BENZ-FT-437135,Zacks,,,,0,0,67d3a485-5738-4cee-914d-54bb35013713
2019-07-02T08:00:00.000+08:00,M&A Activity A Favored Prescription For Biopharmaceutical Companies,LLY,https://seekingalpha.com/article/4273095-m-activity-favored-prescription-biopharmaceutical-companies?source=partner_benzinga,Seeking Alpha,,,,0,0,1e32bf26-1344-4184-8424-53f82d16dd64
2019-07-01T08:00:00.000+08:00,"Cox Capital Co LLC Buys Digital Realty Trust Inc, AbbVie Inc, CVS Health Corp, Sells SPDR ...",LLY,http://www.gurufocus.com/news/902416/cox-capital-co-llc-buys-digital-realty-trust-inc-abbvie-inc-cvs-health-corp-sells-spdr-sp-500-royal-bank-of-canada-stock-yards-bancorp-inc,GuruFocus,,,,0,0,adef5be0-da61-479f-93ea-a78c97bfb0b3
2019-07-01T08:00:00.000+08:00,"Cox Capital Co LLC Buys Digital Realty Trust Inc, AbbVie Inc, CVS Health Corp, Sells SPDR ...",LLY,http://www.gurufocus.com/news/902416/cox-capital-co-llc-buys-digital-realty-trust-inc-abbvie-inc-cvs-health-corp-sells-spdr-sp-500-royal-bank-of-canada-stock-yards-bancorp-inc,GuruFocus,,,,0,0,0c8b0f43-f30e-4184-894b-1d2ffe5ac0b8
2019-06-28T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 83,LLY,https://seekingalpha.com/article/4272709-bulletproof-investing-performance-update-week-83?source=partner_benzinga,Seeking Alpha,,,,0,0,1ef1d4db-70fd-43fd-ba35-5da69d920b7c
2019-06-28T08:00:00.000+08:00,5 Stocks With Low Price-Sales Ratios,LLY,http://www.gurufocus.com/news/901562/5-stocks-with-low-pricesales-ratios,GuruFocus,,,,0,0,3cb0d601-d03f-48de-9630-513cff76cda0
2019-06-28T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger",LLY,http://www.zacks.com/stock/news/435476/pharma-stock-roundup-abbv-to-buy-agn-bmy-to-sell-celgs-otezla-to-close-merger?cid=CS-BENZ-FT-435476,Zacks,,,,0,0,20efd7cc-197e-47ce-97e1-f333dd558ab7
2019-06-28T08:00:00.000+08:00,European advisory group backs Lilly's Cyramza for liver cancer,LLY,https://seekingalpha.com/news/3474546-european-advisory-group-backs-lillys-cyramza-liver-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,a890c322-e81d-4e6d-bfee-c4d7a18deb84
2019-06-28T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 83,LLY,https://seekingalpha.com/article/4272709-bulletproof-investing-performance-update-week-83?source=partner_benzinga,Seeking Alpha,,,,0,0,d02d0ecb-3dfa-46ce-b1c3-e27556649d12
2019-06-28T08:00:00.000+08:00,5 Stocks With Low Price-Sales Ratios,LLY,http://www.gurufocus.com/news/901562/5-stocks-with-low-pricesales-ratios,GuruFocus,,,,0,0,40f96565-23e8-40bc-9ec2-244c7cd198ba
2019-06-28T08:00:00.000+08:00,"Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger",LLY,http://www.zacks.com/stock/news/435476/pharma-stock-roundup-abbv-to-buy-agn-bmy-to-sell-celgs-otezla-to-close-merger?cid=CS-BENZ-FT-435476,Zacks,,,,0,0,a50e1c36-4910-43a1-9da5-b382c67e898b
2019-06-28T08:00:00.000+08:00,European advisory group backs Lilly's Cyramza for liver cancer,LLY,https://seekingalpha.com/news/3474546-european-advisory-group-backs-lillys-cyramza-liver-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,3f0a53ff-665d-483f-89cf-e9123bcc915a
2019-06-26T08:00:00.000+08:00,Eli Lilly shares trading lower with the other major drugmakers. The downside comes despite news empagliflozin was granted Fast Track Designation by the FDA. The company also announced a Type-2 diabetes drug trial met endpoints.,LLY,https://www.benzinga.com/markets/wiim/19/06/13987215/eli-lilly-shares-trading-lower-with-the-other-major-drugmakers-the-downside-comes-despite-news-empag,Benzinga Newsdesk,,,,0,0,bbe35c28-89da-4709-87ad-dfe9600dbd66
2019-06-26T08:00:00.000+08:00,Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses,LLY,https://www.benzinga.com/general/biotech/19/06/13984718/lillys-heart-drug-snags-fast-track-designation-type-2-diabetes-drug-found-effective-at-higher-dos,Shanthi Rexaline,,,,0,0,482c7d51-6ede-4799-94fb-a36d9fe2e683
2019-06-26T08:00:00.000+08:00,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",LLY,https://www.benzinga.com/general/biotech/19/06/13983221/the-daily-biotech-pulse-decision-day-for-regeneron-sanofi-vermillion-offering-pdl-biopharma-cfo-t,Shanthi Rexaline,,,,0,0,a9536849-55c9-4ddc-bc31-0a82ed9aa3a5
2019-06-26T08:00:00.000+08:00,Lilly Announces AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/19/06/13983619/lilly-announces-award-11-trial-studying-higher-investigational-doses-of-trulicity-demonstrated-su,Benzinga Newsdesk,,,,0,0,0f714bef-6207-4533-8f66-2868cb21de9b
2019-06-26T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce FDA Grants Fast Track Designation To Empagliflozin For The Reduction Of The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In People With Chronic Heart Failure",LLY,https://www.benzinga.com/news/19/06/13983427/eli-lilly-announce-and-boehringer-ingelheim-announce-the-fda-grants-fast-track-designation-to-empagl,Benzinga_Newsdesk,,,,0,0,e49107be-bffa-4c11-abbb-65b83b66c361
2019-06-26T08:00:00.000+08:00,Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate,LLY,http://www.investors.com/research/ibd-industry-themes/health-care-stocks-dive-before-presidential-debate-democrats-drug-prices/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,01d35839-de5e-46a0-ba10-d96c3dc99aa5
2019-06-26T08:00:00.000+08:00,Healthcare stocks under pressure ahead of Dem debate,LLY,https://seekingalpha.com/news/3473947-healthcare-stocks-pressure-ahead-dem-debate?source=partner_benzinga,Seeking Alpha,,,,0,0,3158b931-4b65-48f1-901a-0a0462d6c8d6
2019-06-26T08:00:00.000+08:00,Higher doses of Lilly's Trulicity successful in late-stage T2D study,LLY,https://seekingalpha.com/news/3473804-higher-doses-lillys-trulicity-successful-late-stage-t2d-study?source=partner_benzinga,Seeking Alpha,,,,0,0,75ace089-f247-478e-a700-09bfccb6d69a
2019-06-26T08:00:00.000+08:00,Lilly's empagliflozin Fast Track'd for CV benefit claim in heart failure patients,LLY,https://seekingalpha.com/news/3473799-lillys-empagliflozin-fast-trackd-cv-benefit-claim-heart-failure-patients?source=partner_benzinga,Seeking Alpha,,,,0,0,36b33b4a-4816-4eaa-9da3-d5e8a23d5662
2019-06-26T08:00:00.000+08:00,Eli Lilly shares trading lower with the other major drugmakers. The downside comes despite news empagliflozin was granted Fast Track Designation by the FDA. The company also announced a Type-2 diabetes drug trial met endpoints.,LLY,https://www.benzinga.com/markets/wiim/19/06/13987215/eli-lilly-shares-trading-lower-with-the-other-major-drugmakers-the-downside-comes-despite-news-empag,Benzinga Newsdesk,,,,0,0,b34867b6-c8fa-4bb0-9aa4-cd4eb7400e35
2019-06-26T08:00:00.000+08:00,Lilly's Heart Drug Snags Fast Track Designation; Type 2 Diabetes Drug Found Effective At Higher Doses,LLY,https://www.benzinga.com/general/biotech/19/06/13984718/lillys-heart-drug-snags-fast-track-designation-type-2-diabetes-drug-found-effective-at-higher-dos,Shanthi Rexaline,,,,0,0,9750549f-7d6b-42dd-9237-50e1b032aac0
2019-06-26T08:00:00.000+08:00,"The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart",LLY,https://www.benzinga.com/general/biotech/19/06/13983221/the-daily-biotech-pulse-decision-day-for-regeneron-sanofi-vermillion-offering-pdl-biopharma-cfo-t,Shanthi Rexaline,,,,0,0,57e2d21c-84de-42bd-8729-827fd5f3278e
2019-06-26T08:00:00.000+08:00,Lilly Announces AWARD-11 Trial Studying Higher Investigational Doses Of Trulicity Demonstrated Superiority In A1C Reduction In People With Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/19/06/13983619/lilly-announces-award-11-trial-studying-higher-investigational-doses-of-trulicity-demonstrated-su,Benzinga Newsdesk,,,,0,0,449ea264-01c1-4529-8b44-48b9fec04e70
2019-06-26T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce FDA Grants Fast Track Designation To Empagliflozin For The Reduction Of The Risk Of Cardiovascular Death And Hospitalization For Heart Failure In People With Chronic Heart Failure",LLY,https://www.benzinga.com/news/19/06/13983427/eli-lilly-announce-and-boehringer-ingelheim-announce-the-fda-grants-fast-track-designation-to-empagl,Benzinga_Newsdesk,,,,0,0,52175e58-1854-43e0-85d9-0e00e4c701d5
2019-06-26T08:00:00.000+08:00,Will Democrats Slam Drug Prices? Health Care Stocks Dive Ahead Of Debate,LLY,http://www.investors.com/research/ibd-industry-themes/health-care-stocks-dive-before-presidential-debate-democrats-drug-prices/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,55b05fda-92b5-4204-952d-5907ba044472
2019-06-26T08:00:00.000+08:00,Healthcare stocks under pressure ahead of Dem debate,LLY,https://seekingalpha.com/news/3473947-healthcare-stocks-pressure-ahead-dem-debate?source=partner_benzinga,Seeking Alpha,,,,0,0,985bdd52-f43d-43c8-8613-d31db44015b7
2019-06-26T08:00:00.000+08:00,Higher doses of Lilly's Trulicity successful in late-stage T2D study,LLY,https://seekingalpha.com/news/3473804-higher-doses-lillys-trulicity-successful-late-stage-t2d-study?source=partner_benzinga,Seeking Alpha,,,,0,0,a2d26977-c7a0-452d-b12b-dba8609b24b4
2019-06-26T08:00:00.000+08:00,Lilly's empagliflozin Fast Track'd for CV benefit claim in heart failure patients,LLY,https://seekingalpha.com/news/3473799-lillys-empagliflozin-fast-trackd-cv-benefit-claim-heart-failure-patients?source=partner_benzinga,Seeking Alpha,,,,0,0,7f82232f-e358-411b-a9ed-b8d6be860143
2019-06-25T08:00:00.000+08:00,Axsome Initiates Phase III Study on Depression Candidate,LLY,http://www.zacks.com/stock/news/434234/axsome-initiates-phase-iii-study-on-depression-candidate?cid=CS-BENZ-FT-434234,Zacks,,,,0,0,e482e76d-8bfb-4d05-871b-eec63c685f52
2019-06-25T08:00:00.000+08:00,Key Factors Aligning To Short Pharmaceuticals,LLY,https://seekingalpha.com/article/4272056-key-factors-aligning-short-pharmaceuticals?source=partner_benzinga,Seeking Alpha,,,,0,0,97a8b367-b022-4760-89e9-92f698d4b72f
2019-06-25T08:00:00.000+08:00,Pharma players in green on AbbVie/Allergan deal,LLY,https://seekingalpha.com/news/3473634-pharma-players-green-abbvie-allergan-deal?source=partner_benzinga,Seeking Alpha,,,,0,0,8062496f-2575-46b1-bd27-15b136a59977
2019-06-25T08:00:00.000+08:00,Axsome Initiates Phase III Study on Depression Candidate,LLY,http://www.zacks.com/stock/news/434234/axsome-initiates-phase-iii-study-on-depression-candidate?cid=CS-BENZ-FT-434234,Zacks,,,,0,0,5c8c5bfd-c91d-47b3-a161-0591cfe3b276
2019-06-25T08:00:00.000+08:00,Key Factors Aligning To Short Pharmaceuticals,LLY,https://seekingalpha.com/article/4272056-key-factors-aligning-short-pharmaceuticals?source=partner_benzinga,Seeking Alpha,,,,0,0,6963ac96-e79a-48d7-80db-ec5b12f4922b
2019-06-25T08:00:00.000+08:00,Pharma players in green on AbbVie/Allergan deal,LLY,https://seekingalpha.com/news/3473634-pharma-players-green-abbvie-allergan-deal?source=partner_benzinga,Seeking Alpha,,,,0,0,4975be50-58a9-4079-8694-006de18c4ba5
2019-06-22T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 82,LLY,https://seekingalpha.com/article/4271593-bulletproof-investing-performance-update-week-82?source=partner_benzinga,Seeking Alpha,,,,0,0,8cba00d0-cf64-4b7a-b373-90f0730d5c0e
2019-06-22T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 82,LLY,https://seekingalpha.com/article/4271593-bulletproof-investing-performance-update-week-82?source=partner_benzinga,Seeking Alpha,,,,0,0,87662008-1f65-4ebc-8264-d101ab202669
2019-06-21T08:00:00.000+08:00,Karuna Therapeutics Readies Plan For $70 Million IPO,LLY,https://seekingalpha.com/article/4271532-karuna-therapeutics-readies-plan-70-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,741bd9f8-8101-475e-9f6f-186e2fac5f14
2019-06-21T08:00:00.000+08:00,Karuna Therapeutics Readies Plan For $70 Million IPO,LLY,https://seekingalpha.com/article/4271532-karuna-therapeutics-readies-plan-70-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,4a38e4f9-0c78-4da2-8c3f-9e3f0ba39ab9
2019-06-19T08:00:00.000+08:00,NASH And Diabetes Markets Could Soon Be Disrupted,LLY,https://seekingalpha.com/article/4271140-nash-diabetes-markets-soon-disrupted?source=partner_benzinga,Seeking Alpha,,,,0,0,5c58980d-9070-4133-8ea4-c4391faaea3f
2019-06-19T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3472440-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,0,0,883b22e0-6106-4877-8a1f-7a926ef6688d
2019-06-19T08:00:00.000+08:00,Eli Lilly Looks Into The Foray Of Developing Its Own NASH Drug,LLY,https://seekingalpha.com/article/4270974-eli-lilly-looks-foray-developing-nash-drug?source=partner_benzinga,Seeking Alpha,,,,0,0,4d9c4d4e-2cfc-4be4-a2e6-e922c7198f40
2019-06-19T08:00:00.000+08:00,Zai Lab: A Pearl In The Healthcare Market,LLY,https://seekingalpha.com/article/4270950-zai-lab-pearl-healthcare-market?source=partner_benzinga,Seeking Alpha,,,,0,0,4b51d6cc-0aa9-40af-8bbb-cfaee1d23e49
2019-06-19T08:00:00.000+08:00,NASH And Diabetes Markets Could Soon Be Disrupted,LLY,https://seekingalpha.com/article/4271140-nash-diabetes-markets-soon-disrupted?source=partner_benzinga,Seeking Alpha,,,,0,0,82a7fba9-95ac-4906-af74-486f949618d7
2019-06-19T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3472440-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,0,0,1fc886c1-e4b0-46ec-a301-39aca24f16cd
2019-06-19T08:00:00.000+08:00,Eli Lilly Looks Into The Foray Of Developing Its Own NASH Drug,LLY,https://seekingalpha.com/article/4270974-eli-lilly-looks-foray-developing-nash-drug?source=partner_benzinga,Seeking Alpha,,,,0,0,9ec3d379-3685-4e8c-b2d9-2760c5138d8e
2019-06-19T08:00:00.000+08:00,Zai Lab: A Pearl In The Healthcare Market,LLY,https://seekingalpha.com/article/4270950-zai-lab-pearl-healthcare-market?source=partner_benzinga,Seeking Alpha,,,,0,0,07995b40-f9c9-4b2b-bda4-8a43913f3a60
2019-06-18T08:00:00.000+08:00,Stock Spotlight: A New Lifesaving Drug Is Reviving This Drugmaker's Stock,LLY,http://www.investors.com/stock-lists/stock-spotlight/incyte-stock-gets-boost-lifesaving-drug/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,0ecffbac-58c9-407a-9515-107737e660f8
2019-06-18T08:00:00.000+08:00,The Best Places To Work: Delivering Strong Results Compared To The S&P 500 Over 10 Years,LLY,https://seekingalpha.com/article/4270853-best-places-work-delivering-strong-results-compared-s-and-p-500-10-years?source=partner_benzinga,Seeking Alpha,,,,0,0,b8f522b4-1c71-4f30-9af6-932d67d63d36
2019-06-18T08:00:00.000+08:00,Stock Upgrades: Eli Lilly Shows Rising Relative Strength,LLY,http://www.investors.com/ibd-data-stories/stock-upgrades-eli-lilly-shows-rising-relative-strength/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,88e225a2-8f59-43e5-8ad0-b1eee1c42666
2019-06-18T08:00:00.000+08:00,"Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio",LLY,http://www.zacks.com/stock/news/431106/pfizer-to-buy-array-biopharma-broaden-cancer-portfolio?cid=CS-BENZ-FT-431106,Zacks,,,,0,0,7771772b-c891-42db-851e-3caadd7624d5
2019-06-18T08:00:00.000+08:00,Microsoft: Final Performance,LLY,https://seekingalpha.com/article/4270801-microsoft-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,fc7c5d30-ed19-4763-b16d-7e8664463047
2019-06-18T08:00:00.000+08:00,Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients,LLY,http://www.zacks.com/stock/news/431041/novo-nordisks-victoza-gets-fda-nod-for-pediatric-patients?cid=CS-BENZ-FT-431041,Zacks,,,,0,0,5ce23253-8a8c-4017-a0d8-4e82c55ea2f6
2019-06-18T08:00:00.000+08:00,Stock Spotlight: A New Lifesaving Drug Is Reviving This Drugmaker's Stock,LLY,http://www.investors.com/stock-lists/stock-spotlight/incyte-stock-gets-boost-lifesaving-drug/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,89f972f3-e261-41f5-8c7c-bf641db1e6ee
2019-06-18T08:00:00.000+08:00,The Best Places To Work: Delivering Strong Results Compared To The S&P 500 Over 10 Years,LLY,https://seekingalpha.com/article/4270853-best-places-work-delivering-strong-results-compared-s-and-p-500-10-years?source=partner_benzinga,Seeking Alpha,,,,0,0,116f99e8-8456-48c1-ae5c-65e27a1cbd5b
2019-06-18T08:00:00.000+08:00,Stock Upgrades: Eli Lilly Shows Rising Relative Strength,LLY,http://www.investors.com/ibd-data-stories/stock-upgrades-eli-lilly-shows-rising-relative-strength/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,e4d91f31-b094-4702-8b16-815f8033cd54
2019-06-18T08:00:00.000+08:00,"Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio",LLY,http://www.zacks.com/stock/news/431106/pfizer-to-buy-array-biopharma-broaden-cancer-portfolio?cid=CS-BENZ-FT-431106,Zacks,,,,0,0,7206c764-220c-49df-89a3-ec8992fd09c9
2019-06-18T08:00:00.000+08:00,Microsoft: Final Performance,LLY,https://seekingalpha.com/article/4270801-microsoft-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,85054525-a904-48db-a6b5-72d465a7bb40
2019-06-18T08:00:00.000+08:00,Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients,LLY,http://www.zacks.com/stock/news/431041/novo-nordisks-victoza-gets-fda-nod-for-pediatric-patients?cid=CS-BENZ-FT-431041,Zacks,,,,0,0,99c40bdf-0870-4873-833e-55395cbaf54d
2019-06-17T08:00:00.000+08:00,How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers,LLY,http://www.investors.com/research/the-income-investor/biotech-company-array-acquired-pfizer-deal-cancer-treatments/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,db08ba5d-a61f-4575-8282-076da7532afb
2019-06-17T08:00:00.000+08:00,How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers,LLY,http://www.investors.com/research/the-income-investor/biotech-company-array-acquired-pfizer-deal-cancer-treatments/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,1e13bf79-935b-4a43-9539-be6d9e74afc8
2019-06-14T08:00:00.000+08:00,"From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'",LLY,https://www.benzinga.com/news/19/06/13924153/from-earlier-drug-makers-amgen-merck-lilly-and-the-association-of-national-advertisers-file-suit-to,Benzinga Newsdesk,,,,0,0,01f45edd-0a2a-4c85-a732-a669437b99a4
2019-06-14T08:00:00.000+08:00,Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthiritis at the European Congress of Rheumatology,LLY,https://www.benzinga.com/news/19/06/13921087/eli-lilly-presents-data-on-its-taltz-versus-abbvies-humira-in-patients-with-active-psoriatic-arthiri,Benzinga Newsdesk,,,,0,0,06c81603-a421-45e7-9443-8b9f2588b6f7
2019-06-14T08:00:00.000+08:00,Drug companies file suit to block disclosure of drug prices in TV ads,LLY,https://seekingalpha.com/news/3471595-drug-companies-file-suit-block-disclosure-drug-prices-tv-ads?source=partner_benzinga,Seeking Alpha,,,,0,0,cce48108-51b8-47cd-9eac-9463d6526b2d
2019-06-14T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 81,LLY,https://seekingalpha.com/article/4270327-bulletproof-investing-performance-update-week-81?source=partner_benzinga,Seeking Alpha,,,,0,0,64aa6ef7-d46d-41ce-8d11-54e2bffa7da4
2019-06-14T08:00:00.000+08:00,"Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod",LLY,http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-BENZ-FT-429560,Zacks,,,,0,0,041ba957-a438-478a-9946-b39d0763c7d9
2019-06-14T08:00:00.000+08:00,"From Earlier: 'Drug makers Amgen, Merck, Lilly and the Association of National Advertisers file suit to prevent the disclosure of drug prices in television ads.'",LLY,https://www.benzinga.com/news/19/06/13924153/from-earlier-drug-makers-amgen-merck-lilly-and-the-association-of-national-advertisers-file-suit-to,Benzinga Newsdesk,,,,0,0,dfeb14c3-098d-4b63-906d-e9d4d4dfe9ee
2019-06-14T08:00:00.000+08:00,Eli Lilly Presents Data on its Taltz Versus AbbVie's Humira in Patients With Active Psoriatic Arthiritis at the European Congress of Rheumatology,LLY,https://www.benzinga.com/news/19/06/13921087/eli-lilly-presents-data-on-its-taltz-versus-abbvies-humira-in-patients-with-active-psoriatic-arthiri,Benzinga Newsdesk,,,,0,0,8df57186-16d5-4cc3-a8d7-2c87bb6bf3a9
2019-06-14T08:00:00.000+08:00,Drug companies file suit to block disclosure of drug prices in TV ads,LLY,https://seekingalpha.com/news/3471595-drug-companies-file-suit-block-disclosure-drug-prices-tv-ads?source=partner_benzinga,Seeking Alpha,,,,0,0,1525950b-edeb-49e2-ad0d-7aac3424bf38
2019-06-14T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 81,LLY,https://seekingalpha.com/article/4270327-bulletproof-investing-performance-update-week-81?source=partner_benzinga,Seeking Alpha,,,,0,0,6241f36a-2b2a-4678-becd-ef3ad939b1fd
2019-06-14T08:00:00.000+08:00,"Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod",LLY,http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-BENZ-FT-429560,Zacks,,,,0,0,28fbb40f-4bd1-4877-b77a-c1bbbbb2d05a
2019-06-13T08:00:00.000+08:00,Akero Therapeutics Readies $75 Million IPO,LLY,https://seekingalpha.com/article/4270108-akero-therapeutics-readies-75-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,fcc7f9be-1caf-494e-86cf-7830ffd28375
2019-06-13T08:00:00.000+08:00,NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag,LLY,http://www.zacks.com/stock/news/429173/nucanas-biliary-tract-cancer-candidate-gets-orphan-drug-tag?cid=CS-BENZ-FT-429173,Zacks,,,,0,0,eb749be5-985c-4e55-a2d4-80f68cc23e93
2019-06-13T08:00:00.000+08:00,Akero Therapeutics Readies $75 Million IPO,LLY,https://seekingalpha.com/article/4270108-akero-therapeutics-readies-75-million-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,2cab2c47-c672-494e-afd2-be8c8d1a1448
2019-06-13T08:00:00.000+08:00,NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag,LLY,http://www.zacks.com/stock/news/429173/nucanas-biliary-tract-cancer-candidate-gets-orphan-drug-tag?cid=CS-BENZ-FT-429173,Zacks,,,,0,0,9a3f96e8-ca71-448f-8a5d-0ade1ba9193f
2019-06-12T08:00:00.000+08:00,Eli Lilly and Company's (LLY) Management Presents at Goldman Sachs 40th Annual Global Helathcare Conference (Transcript),LLY,https://seekingalpha.com/article/4269972-eli-lilly-companys-lly-management-presents-goldman-sachs-40th-annual-global-helathcare?source=partner_benzinga,Seeking Alpha,,,,0,0,98964757-4c76-4b90-8b06-11d5cb82d008
2019-06-12T08:00:00.000+08:00,Boost Your Portfolio's Health With These 3 Big Drug Stocks,LLY,http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-BENZ-FT-428332,Zacks,,,,0,0,e6e42cf9-f3a6-4202-8cb6-b87af4a2b79c
2019-06-12T08:00:00.000+08:00,Eli Lilly and Company's (LLY) Management Presents at Goldman Sachs 40th Annual Global Helathcare Conference (Transcript),LLY,https://seekingalpha.com/article/4269972-eli-lilly-companys-lly-management-presents-goldman-sachs-40th-annual-global-helathcare?source=partner_benzinga,Seeking Alpha,,,,0,0,3a56e3cd-11ca-4071-a4bd-14829bbd7707
2019-06-12T08:00:00.000+08:00,Boost Your Portfolio's Health With These 3 Big Drug Stocks,LLY,http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-BENZ-FT-428332,Zacks,,,,0,0,f0738401-27f4-4e71-9631-9d8a236903fe
2019-06-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering",LLY,https://www.benzinga.com/general/biotech/19/06/13900223/the-daily-biotech-pulse-lilly-reports-positive-long-term-efficacy-data-for-psoriasis-drug-provent,Shanthi Rexaline,,,,0,0,ae89c02b-c537-4851-a73d-4dcd595f0847
2019-06-11T08:00:00.000+08:00,These 27 Fortune 500 Dividend Stocks Made The Best Total Returns To Investors,LLY,https://seekingalpha.com/article/4269682-27-fortune-500-dividend-stocks-made-best-total-returns-investors?source=partner_benzinga,Seeking Alpha,,,,0,0,89b62bb0-44a3-400a-85b3-9a59ae559917
2019-06-11T08:00:00.000+08:00,Lilly's Taltz shows long-term benefit in psoriasis study,LLY,https://seekingalpha.com/news/3470448-lillys-taltz-shows-long-term-benefit-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,964e77a8-d005-463d-936a-46bd1e734e8a
2019-06-11T08:00:00.000+08:00,Lilly Announces Tradjenta Cardiovascular Outcome Study Data,LLY,http://www.zacks.com/stock/news/427738/lilly-announces-tradjenta-cardiovascular-outcome-study-data?cid=CS-BENZ-FT-427738,Zacks,,,,0,0,a53f4d31-86ff-495b-ae98-8d468619a2c9
2019-06-11T08:00:00.000+08:00,Zymeworks: Leader In Bispecifics Space Makes Substantial Headway,LLY,https://seekingalpha.com/article/4269567-zymeworks-leader-bispecifics-space-makes-substantial-headway?source=partner_benzinga,Seeking Alpha,,,,0,0,cf8bee49-5ea2-4f02-984c-3b57d256736c
2019-06-11T08:00:00.000+08:00,Antares Pharma: What The Market Is Missing,LLY,https://seekingalpha.com/article/4269562-antares-pharma-market-missing?source=partner_benzinga,Seeking Alpha,,,,0,0,59eee562-7c2f-4ea4-8365-0aecfe5209cb
2019-06-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering",LLY,https://www.benzinga.com/general/biotech/19/06/13900223/the-daily-biotech-pulse-lilly-reports-positive-long-term-efficacy-data-for-psoriasis-drug-provent,Shanthi Rexaline,,,,0,0,f86fe0cf-d06b-4c05-902e-a274dfeea896
2019-06-11T08:00:00.000+08:00,These 27 Fortune 500 Dividend Stocks Made The Best Total Returns To Investors,LLY,https://seekingalpha.com/article/4269682-27-fortune-500-dividend-stocks-made-best-total-returns-investors?source=partner_benzinga,Seeking Alpha,,,,0,0,100550a0-da33-45e0-9324-2fc3680df390
2019-06-11T08:00:00.000+08:00,Lilly's Taltz shows long-term benefit in psoriasis study,LLY,https://seekingalpha.com/news/3470448-lillys-taltz-shows-long-term-benefit-psoriasis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,d5bb486d-4ba1-4899-a274-f6b4bfe76e1a
2019-06-11T08:00:00.000+08:00,Lilly Announces Tradjenta Cardiovascular Outcome Study Data,LLY,http://www.zacks.com/stock/news/427738/lilly-announces-tradjenta-cardiovascular-outcome-study-data?cid=CS-BENZ-FT-427738,Zacks,,,,0,0,970053b5-665a-411b-89d2-33cb9f97da59
2019-06-11T08:00:00.000+08:00,Zymeworks: Leader In Bispecifics Space Makes Substantial Headway,LLY,https://seekingalpha.com/article/4269567-zymeworks-leader-bispecifics-space-makes-substantial-headway?source=partner_benzinga,Seeking Alpha,,,,0,0,92756269-64ce-45ed-931d-008d7a77c3e3
2019-06-11T08:00:00.000+08:00,Antares Pharma: What The Market Is Missing,LLY,https://seekingalpha.com/article/4269562-antares-pharma-market-missing?source=partner_benzinga,Seeking Alpha,,,,0,0,e3749c8f-9926-440c-b2af-ee83711fcfc3
2019-06-10T08:00:00.000+08:00,Eli Lilly shares are trading lower after the company announced disappointing data for the treatment of type 2 diabetes.,LLY,https://www.benzinga.com/markets/wiim/19/06/13896019/eli-lilly-shares-are-trading-lower-after-the-company-announced-disappointing-data-for-the-treatment,Benzinga Newsdesk,,,,0,0,c4830d40-a3c0-4ea7-aa50-2f8f4e7aa060
2019-06-10T08:00:00.000+08:00,Xeris: Gvoke PDUFA Gets Delayed And Creates Buying Opportunity,LLY,https://seekingalpha.com/article/4269514-xeris-gvoke-pdufa-gets-delayed-creates-buying-opportunity?source=partner_benzinga,Seeking Alpha,,,,0,0,43d2cb30-0bb0-4ece-a914-ca9de64db07e
2019-06-10T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents Webcast to Discuss ADA Presentations and Diabetes Portfolio Conference (Transcript),LLY,https://seekingalpha.com/article/4269487-eli-lilly-company-lly-presents-webcast-discuss-ada-presentations-diabetes-portfolio?source=partner_benzinga,Seeking Alpha,,,,0,0,d04e9a9a-b399-4123-bb4d-fb565a7a4647
2019-06-10T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca",LLY,http://www.zacks.com/stock/news/427178/the-zacks-analyst-blog-highlights-bristol-myers-merck-roche-lilly-and-astrazeneca?cid=CS-BENZ-FT-427178,Zacks,,,,0,0,1455816b-f0ec-4502-ac31-65fbc72aa770
2019-06-10T08:00:00.000+08:00,ADA Presentations and Diabetes Portfolio,LLY,https://seekingalpha.com/article/4269399-ada-presentations-diabetes-portfolio?source=partner_benzinga,Seeking Alpha,,,,0,0,c45dc8e1-67fd-4143-bdaf-60cbbb441b7a
2019-06-10T08:00:00.000+08:00,Lilly's Trulicity reduced CV risk in large-scale T2D study,LLY,https://seekingalpha.com/news/3470092-lillys-trulicity-reduced-cv-risk-large-scale-t2d-study?source=partner_benzinga,Seeking Alpha,,,,0,0,85970f99-5489-4353-88e5-d7e5f7ac1399
2019-06-10T08:00:00.000+08:00,Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet,LLY,http://www.zacks.com/stock/news/427034/lilly-lly-presents-data-from-diabetes-studies-at-ada-meet?cid=CS-BENZ-FT-427034,Zacks,,,,0,0,412aabcf-0310-475a-ac0f-3576399d7484
2019-06-10T08:00:00.000+08:00,"Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO",LLY,https://seekingalpha.com/article/4269341-week-review-frontage-u-s-china-cro-stages-205-million-hong-kong-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,f1606911-8c6d-4c81-86bd-cedf86958b89
2019-06-10T08:00:00.000+08:00,Eli Lilly shares are trading lower after the company announced disappointing data for the treatment of type 2 diabetes.,LLY,https://www.benzinga.com/markets/wiim/19/06/13896019/eli-lilly-shares-are-trading-lower-after-the-company-announced-disappointing-data-for-the-treatment,Benzinga Newsdesk,,,,0,0,9d330767-5648-4854-901d-207fc96e8ff3
2019-06-10T08:00:00.000+08:00,Xeris: Gvoke PDUFA Gets Delayed And Creates Buying Opportunity,LLY,https://seekingalpha.com/article/4269514-xeris-gvoke-pdufa-gets-delayed-creates-buying-opportunity?source=partner_benzinga,Seeking Alpha,,,,0,0,9785ca61-3b64-441b-b10b-4b154ecf114f
2019-06-10T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents Webcast to Discuss ADA Presentations and Diabetes Portfolio Conference (Transcript),LLY,https://seekingalpha.com/article/4269487-eli-lilly-company-lly-presents-webcast-discuss-ada-presentations-diabetes-portfolio?source=partner_benzinga,Seeking Alpha,,,,0,0,ae035aee-a8af-4634-9fa3-3a1145d717d5
2019-06-10T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca",LLY,http://www.zacks.com/stock/news/427178/the-zacks-analyst-blog-highlights-bristol-myers-merck-roche-lilly-and-astrazeneca?cid=CS-BENZ-FT-427178,Zacks,,,,0,0,13dfca99-935c-428d-996b-0b08b7fd1e92
2019-06-10T08:00:00.000+08:00,ADA Presentations and Diabetes Portfolio,LLY,https://seekingalpha.com/article/4269399-ada-presentations-diabetes-portfolio?source=partner_benzinga,Seeking Alpha,,,,0,0,6c0caacc-6a99-4860-b0be-5cf7e910be3a
2019-06-10T08:00:00.000+08:00,Lilly's Trulicity reduced CV risk in large-scale T2D study,LLY,https://seekingalpha.com/news/3470092-lillys-trulicity-reduced-cv-risk-large-scale-t2d-study?source=partner_benzinga,Seeking Alpha,,,,0,0,a41d1b26-2d18-4e12-bea8-d7e21c747139
2019-06-10T08:00:00.000+08:00,Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet,LLY,http://www.zacks.com/stock/news/427034/lilly-lly-presents-data-from-diabetes-studies-at-ada-meet?cid=CS-BENZ-FT-427034,Zacks,,,,0,0,9f58121b-5ba2-4b22-859b-99a062e7a553
2019-06-10T08:00:00.000+08:00,"Week In Review: Frontage, A U.S.-China CRO, Stages $205 Million Hong Kong IPO",LLY,https://seekingalpha.com/article/4269341-week-review-frontage-u-s-china-cro-stages-205-million-hong-kong-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,f1d8ef81-cd52-463c-8cff-7a549e7f8b3e
2019-06-09T08:00:00.000+08:00,Lilly Announces Trulicity Significantly Reduced Major Cardiovascular Events for Broad Range of People With Type 2 Diabetes,LLY,https://www.benzinga.com/news/19/06/13892707/lilly-announces-trulicity-significantly-reduced-major-cardiovascular-events-for-broad-range-of-peopl,Charles Gross,,,,0,0,3defe0cb-80cf-4d11-a913-ce0f7f8f316b
2019-06-09T08:00:00.000+08:00,Lilly Announces Tirzepatide Demonstrates Benefits in Data Presented at American Diabetes Association's Scientific Sessions,LLY,https://www.benzinga.com/news/19/06/13892625/lilly-announces-tirzepatide-demonstrates-benefits-in-data-presented-at-american-diabetes-association,Charles Gross,,,,0,0,68bdb8e2-355f-448c-a939-9cd32c23c5ec
2019-06-09T08:00:00.000+08:00,"Lilly Announces Ultra Rapid Lispro Provided Similar A1C Reductions vs Humalog, With Superior Post-meal Blood Glucose Reductions at ADA Scientific Sessions",LLY,https://www.benzinga.com/news/19/06/13892620/lilly-announces-ultra-rapid-lispro-provided-similar-a1c-reductions-vs-humalog-with-superior-post-mea,Charles Gross,,,,0,0,3904a3e4-5f59-4ede-9a4f-f8c8d39ffa39
2019-06-09T08:00:00.000+08:00,Lilly Announces Trulicity Significantly Reduced Major Cardiovascular Events for Broad Range of People With Type 2 Diabetes,LLY,https://www.benzinga.com/news/19/06/13892707/lilly-announces-trulicity-significantly-reduced-major-cardiovascular-events-for-broad-range-of-peopl,Charles Gross,,,,0,0,be4cac0a-04f7-48cc-ae53-f2416948c3e6
2019-06-09T08:00:00.000+08:00,Lilly Announces Tirzepatide Demonstrates Benefits in Data Presented at American Diabetes Association's Scientific Sessions,LLY,https://www.benzinga.com/news/19/06/13892625/lilly-announces-tirzepatide-demonstrates-benefits-in-data-presented-at-american-diabetes-association,Charles Gross,,,,0,0,b8c4f2de-e6b0-403c-a12c-2b8de8513eec
2019-06-09T08:00:00.000+08:00,"Lilly Announces Ultra Rapid Lispro Provided Similar A1C Reductions vs Humalog, With Superior Post-meal Blood Glucose Reductions at ADA Scientific Sessions",LLY,https://www.benzinga.com/news/19/06/13892620/lilly-announces-ultra-rapid-lispro-provided-similar-a1c-reductions-vs-humalog-with-superior-post-mea,Charles Gross,,,,0,0,8a9993bf-323e-4cc9-9211-4148716ec1df
2019-06-08T08:00:00.000+08:00,Novo's oral semaglutide successful in two late-stage T2D studies,LLY,https://seekingalpha.com/news/3469971-novos-oral-semaglutide-successful-two-late-stage-t2d-studies?source=partner_benzinga,Seeking Alpha,,,,0,0,649d02fa-859e-45aa-9455-3544c03e979e
2019-06-08T08:00:00.000+08:00,Novo's oral semaglutide successful in two late-stage T2D studies,LLY,https://seekingalpha.com/news/3469971-novos-oral-semaglutide-successful-two-late-stage-t2d-studies?source=partner_benzinga,Seeking Alpha,,,,0,0,1483ccf2-d65b-4194-bf50-6d061951f204
2019-06-07T08:00:00.000+08:00,Primecap Management Buys More Albemarle Corp,LLY,http://www.gurufocus.com/news/891292/primecap-management-buys-more-albemarle-corp,GuruFocus,,,,0,0,bc30aa63-0163-4b50-8978-208c75fc32a6
2019-06-07T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 80,LLY,https://seekingalpha.com/article/4269191-bulletproof-investing-performance-update-week-80?source=partner_benzinga,Seeking Alpha,,,,0,0,b8e8f3d8-17b1-43c9-bf39-1f65e69e9161
2019-06-07T08:00:00.000+08:00,Lilly petitions Supreme Court to protect Cialis BPH patent,LLY,https://seekingalpha.com/news/3469894-lilly-petitions-supreme-court-protect-cialis-bph-patent?source=partner_benzinga,Seeking Alpha,,,,0,0,cc61062c-5b90-4a51-9d30-2061b612c923
2019-06-07T08:00:00.000+08:00,"Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache",LLY,http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-BENZ-FT-426292,Zacks,,,,0,0,2f7b83ec-1eb4-4e0d-b3b1-491bb9e15d6f
2019-06-07T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3468331-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,35ce917f-883d-4a73-bf65-a8872884fcb4
2019-06-07T08:00:00.000+08:00,Primecap Management Buys More Albemarle Corp,LLY,http://www.gurufocus.com/news/891292/primecap-management-buys-more-albemarle-corp,GuruFocus,,,,0,0,cc60fa73-f67d-4352-95fc-417db19aa096
2019-06-07T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 80,LLY,https://seekingalpha.com/article/4269191-bulletproof-investing-performance-update-week-80?source=partner_benzinga,Seeking Alpha,,,,0,0,655ba581-6eb3-4c05-b067-7f64981bb75b
2019-06-07T08:00:00.000+08:00,Lilly petitions Supreme Court to protect Cialis BPH patent,LLY,https://seekingalpha.com/news/3469894-lilly-petitions-supreme-court-protect-cialis-bph-patent?source=partner_benzinga,Seeking Alpha,,,,0,0,76062b66-5240-4841-acae-c801aa3e35a7
2019-06-07T08:00:00.000+08:00,"Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache",LLY,http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-BENZ-FT-426292,Zacks,,,,0,0,befda8f3-3c33-411f-adc0-72338ed4cf09
2019-06-07T08:00:00.000+08:00,Key events next week - healthcare,LLY,https://seekingalpha.com/news/3468331-key-events-next-week-healthcare?source=partner_benzinga,Seeking Alpha,,,,0,0,234940d1-7257-47ed-8298-b599c27e0c00
2019-06-06T08:00:00.000+08:00,"Eli Lilly Highlights Will Present Data For Taltz, Olumiant At EULAR 2019 Jun. 12-15, 2019",LLY,https://www.benzinga.com/news/19/06/13872547/eli-lilly-highlights-will-present-data-for-taltz-olumiant-at-eular-2019-jun-12-15-2019,Benzinga Newsdesk,,,,0,0,33d46bda-339a-435d-8b28-6e399da77208
2019-06-06T08:00:00.000+08:00,Incyte Begins Phase III Study for Treatment of Duct Cancer,LLY,http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-BENZ-FT-425849,Zacks,,,,0,0,234006f4-5dd7-4440-a10c-4042fa8a1015
2019-06-06T08:00:00.000+08:00,Lilly's Emgality Gets FDA Approval for Cluster Headache,LLY,http://www.zacks.com/stock/news/425463/lillys-emgality-gets-fda-approval-for-cluster-headache?cid=CS-BENZ-FT-425463,Zacks,,,,0,0,ef282db6-4e4e-4f61-bb7b-c83cff756b7e
2019-06-06T08:00:00.000+08:00,"Eli Lilly Highlights Will Present Data For Taltz, Olumiant At EULAR 2019 Jun. 12-15, 2019",LLY,https://www.benzinga.com/news/19/06/13872547/eli-lilly-highlights-will-present-data-for-taltz-olumiant-at-eular-2019-jun-12-15-2019,Benzinga Newsdesk,,,,0,0,a75097b3-92be-45e8-891e-3233eb7159e0
2019-06-06T08:00:00.000+08:00,Incyte Begins Phase III Study for Treatment of Duct Cancer,LLY,http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-BENZ-FT-425849,Zacks,,,,0,0,d1c370c9-78e6-4541-8609-aacab20cc4be
2019-06-06T08:00:00.000+08:00,Lilly's Emgality Gets FDA Approval for Cluster Headache,LLY,http://www.zacks.com/stock/news/425463/lillys-emgality-gets-fda-approval-for-cluster-headache?cid=CS-BENZ-FT-425463,Zacks,,,,0,0,73def677-327a-4c5b-9df8-50c5fe5890fc
2019-06-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",LLY,https://www.benzinga.com/general/biotech/19/06/13864534/the-daily-biotech-pulse-curtains-down-on-asco-rewalk-flies-eli-lillys-migraine-drug-approved-for-,Shanthi Rexaline,,,,0,0,82c39ee5-e9d8-46b9-b021-2cc20dc18ed7
2019-06-05T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On AMD, CME Group, Microsoft And More",LLY,https://www.benzinga.com/media/19/06/13864062/jim-cramer-shares-his-thoughts-on-amd-cme-group-microsoft-and-more,Craig Jones,,,,0,0,ed90c0e6-d778-42ef-9b6d-56c589282390
2019-06-05T08:00:00.000+08:00,Lilly To Present Data From Dermatology Portfolio At 24th World Congress Of Dermatology,LLY,https://www.benzinga.com/general/biotech/19/06/13864598/lilly-to-present-data-from-dermatology-portfolio-at-24th-world-congress-of-dermatology,Benzinga Newsdesk,,,,0,0,f1e5b230-2a18-4d16-a05e-0d0e3feae1de
2019-06-05T08:00:00.000+08:00,EliLilly Announces FDA Approval of Emgality as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks,LLY,https://www.benzinga.com/news/19/06/13864224/elililly-announces-fda-approval-of-emgality-as-the-first-and-only-medication-for-the-treatment-of-ep,Charles Gross,,,,0,0,6e70e4df-e287-421b-bc94-04b8075f04be
2019-06-05T08:00:00.000+08:00,FDA OKs expanded label for Lilly's migraine med Emgality,LLY,https://seekingalpha.com/news/3469110-fda-oks-expanded-label-lillys-migraine-med-emgality?source=partner_benzinga,Seeking Alpha,,,,0,0,4a6876d1-e6bd-4dbf-936f-d44623d396f5
2019-06-05T08:00:00.000+08:00,"Credit Ratings And Quality Indicators For Dividend Champions, Contenders And Challengers",LLY,https://seekingalpha.com/article/4268351-credit-ratings-quality-indicators-dividend-champions-contenders-challengers?source=partner_benzinga,Seeking Alpha,,,,0,0,076a0aa4-4a1c-48f4-8c04-31c810207492
2019-06-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache",LLY,https://www.benzinga.com/general/biotech/19/06/13864534/the-daily-biotech-pulse-curtains-down-on-asco-rewalk-flies-eli-lillys-migraine-drug-approved-for-,Shanthi Rexaline,,,,0,0,4a0cbae3-045a-4f69-a318-6dbeb7d1df08
2019-06-05T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On AMD, CME Group, Microsoft And More",LLY,https://www.benzinga.com/media/19/06/13864062/jim-cramer-shares-his-thoughts-on-amd-cme-group-microsoft-and-more,Craig Jones,,,,0,0,1ea5c7cb-530d-48cb-bb78-a4e07e27efb3
2019-06-05T08:00:00.000+08:00,Lilly To Present Data From Dermatology Portfolio At 24th World Congress Of Dermatology,LLY,https://www.benzinga.com/general/biotech/19/06/13864598/lilly-to-present-data-from-dermatology-portfolio-at-24th-world-congress-of-dermatology,Benzinga Newsdesk,,,,0,0,85bfca31-9cc2-4c0b-bfbc-d88d541dd7d7
2019-06-05T08:00:00.000+08:00,EliLilly Announces FDA Approval of Emgality as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks,LLY,https://www.benzinga.com/news/19/06/13864224/elililly-announces-fda-approval-of-emgality-as-the-first-and-only-medication-for-the-treatment-of-ep,Charles Gross,,,,0,0,d92bee12-4f6b-431a-83b4-e8348ad02627
2019-06-05T08:00:00.000+08:00,FDA OKs expanded label for Lilly's migraine med Emgality,LLY,https://seekingalpha.com/news/3469110-fda-oks-expanded-label-lillys-migraine-med-emgality?source=partner_benzinga,Seeking Alpha,,,,0,0,f24746e5-c16f-4826-802b-6078ed8612e2
2019-06-05T08:00:00.000+08:00,"Credit Ratings And Quality Indicators For Dividend Champions, Contenders And Challengers",LLY,https://seekingalpha.com/article/4268351-credit-ratings-quality-indicators-dividend-champions-contenders-challengers?source=partner_benzinga,Seeking Alpha,,,,0,0,1f3f8788-408e-4cc0-b681-72b66867bf40
2019-06-04T08:00:00.000+08:00,FDA Approves Eli Lilly's Emgality For Injection For Treatment Of Episodic Cluster Headache In Adults,LLY,https://www.benzinga.com/news/19/06/13862233/fda-approves-eli-lillys-emgality-for-injection-for-treatment-of-episodic-cluster-headache-in-adults,Benzinga Newsdesk,,,,0,0,60e94601-327a-40b6-888c-bf76cf85b5e0
2019-06-04T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted New Drug Application For Triple Combo Tablet For Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/19/06/13856380/eli-lilly-reports-fda-accepted-new-drug-application-for-triple-combo-tablet-for-adults-with-type-2-d,Benzinga Newsdesk,,,,0,0,6f3eb482-58d2-4fee-84c0-7ac25ae473d4
2019-06-04T08:00:00.000+08:00,FDA accepts Eli Lilly's NDA for triple combination tablet for adults with type 2 diabetes,LLY,https://seekingalpha.com/news/3468865-fda-accepts-eli-lillys-nda-triple-combination-tablet-adults-type-2-diabetes?source=partner_benzinga,Seeking Alpha,,,,0,0,a445dd02-4a63-416a-9b82-b2e68dcc13f4
2019-06-04T08:00:00.000+08:00,FDA Approves Eli Lilly's Emgality For Injection For Treatment Of Episodic Cluster Headache In Adults,LLY,https://www.benzinga.com/news/19/06/13862233/fda-approves-eli-lillys-emgality-for-injection-for-treatment-of-episodic-cluster-headache-in-adults,Benzinga Newsdesk,,,,0,0,0482aad3-3c70-4581-9244-e69a6d6580e3
2019-06-04T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted New Drug Application For Triple Combo Tablet For Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/19/06/13856380/eli-lilly-reports-fda-accepted-new-drug-application-for-triple-combo-tablet-for-adults-with-type-2-d,Benzinga Newsdesk,,,,0,0,6a0eff90-9227-4827-a5c3-28ae4313c813
2019-06-04T08:00:00.000+08:00,FDA accepts Eli Lilly's NDA for triple combination tablet for adults with type 2 diabetes,LLY,https://seekingalpha.com/news/3468865-fda-accepts-eli-lillys-nda-triple-combination-tablet-adults-type-2-diabetes?source=partner_benzinga,Seeking Alpha,,,,0,0,eb57d916-c58c-448b-83ab-7da6b84f7d70
2019-06-03T08:00:00.000+08:00,"Atomwise Announces Multi-Year, Multi-Target Agreement With Lilly For AI-Driven Drug Discovery Program",LLY,https://www.benzinga.com/general/biotech/19/06/13849115/atomwise-announces-multi-year-multi-target-agreement-with-lilly-for-ai-driven-drug-discovery-prog,Benzinga Newsdesk,,,,0,0,f9a73c90-b85d-49f7-a21e-0b742e27e085
2019-06-03T08:00:00.000+08:00,Merck's Keytruda Improves 5-Year Survival in Lung Cancer,LLY,http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-BENZ-FT-423872,Zacks,,,,0,0,664edff8-670c-42c3-8f32-2d72fdc8b3be
2019-06-03T08:00:00.000+08:00,XBI: Biotech Performance And Valuation Update - June 2019,LLY,https://seekingalpha.com/article/4267925-xbi-biotech-performance-valuation-update-june-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,fb136048-759d-47ce-8504-b7465c00db72
2019-06-03T08:00:00.000+08:00,"Atomwise Announces Multi-Year, Multi-Target Agreement With Lilly For AI-Driven Drug Discovery Program",LLY,https://www.benzinga.com/general/biotech/19/06/13849115/atomwise-announces-multi-year-multi-target-agreement-with-lilly-for-ai-driven-drug-discovery-prog,Benzinga Newsdesk,,,,0,0,4c2376ed-a44f-44ef-9af5-0193da2476bc
2019-06-03T08:00:00.000+08:00,Merck's Keytruda Improves 5-Year Survival in Lung Cancer,LLY,http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-BENZ-FT-423872,Zacks,,,,0,0,a1b69315-a3ea-4303-ac0f-06039ed1ece5
2019-06-03T08:00:00.000+08:00,XBI: Biotech Performance And Valuation Update - June 2019,LLY,https://seekingalpha.com/article/4267925-xbi-biotech-performance-valuation-update-june-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,db3f6577-e556-4f75-9c4e-ffe832eaf030
2019-06-02T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of June 2,LLY,https://seekingalpha.com/article/4267811-dividend-challenger-highlights-week-june-2?source=partner_benzinga,Seeking Alpha,,,,0,0,22e97d4f-d9df-4412-8a3d-d085f69c2dbf
2019-06-02T08:00:00.000+08:00,Dividend Challenger Highlights: Week Of June 2,LLY,https://seekingalpha.com/article/4267811-dividend-challenger-highlights-week-june-2?source=partner_benzinga,Seeking Alpha,,,,0,0,275e845b-e874-4a92-ada7-2182017f5135
2019-05-30T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 79,LLY,https://seekingalpha.com/article/4267280-bulletproof-investing-performance-update-week-79?source=partner_benzinga,Seeking Alpha,,,,0,0,7a5230c9-1e16-4056-a737-031f72bbf3ea
2019-05-30T08:00:00.000+08:00,Lilly (LLY) Down 2.3% Since Last Earnings Report: Can It Rebound?,LLY,http://www.zacks.com/stock/news/422212/lilly-lly-down-23-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-422212,Zacks,,,,0,0,eb25fae2-6c2c-43ba-af0b-11df123bb909
2019-05-30T08:00:00.000+08:00,Mereo Bio's setrusumab shows encouraging action in mid-stage bone disorder study,LLY,https://seekingalpha.com/news/3467821-mereo-bios-setrusumab-shows-encouraging-action-mid-stage-bone-disorder-study?source=partner_benzinga,Seeking Alpha,,,,0,0,18923f53-3fa2-43d0-8af9-9e27e28d31d5
2019-05-30T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 79,LLY,https://seekingalpha.com/article/4267280-bulletproof-investing-performance-update-week-79?source=partner_benzinga,Seeking Alpha,,,,0,0,f53095e5-753e-48f7-a05a-fa791533afd2
2019-05-30T08:00:00.000+08:00,Lilly (LLY) Down 2.3% Since Last Earnings Report: Can It Rebound?,LLY,http://www.zacks.com/stock/news/422212/lilly-lly-down-23-since-last-earnings-report-can-it-rebound?cid=CS-BENZ-FT-422212,Zacks,,,,0,0,f4f82761-e4d6-4d8e-bb06-cc8f830730a1
2019-05-30T08:00:00.000+08:00,Mereo Bio's setrusumab shows encouraging action in mid-stage bone disorder study,LLY,https://seekingalpha.com/news/3467821-mereo-bios-setrusumab-shows-encouraging-action-mid-stage-bone-disorder-study?source=partner_benzinga,Seeking Alpha,,,,0,0,ff9b5079-567b-45fb-b231-c4357b4a1cf8
2019-05-29T08:00:00.000+08:00,Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate,LLY,http://www.zacks.com/stock/news/421715/lilly-in-licenses-private-biotechs-non-opoid-pain-candidate?cid=CS-BENZ-FT-421715,Zacks,,,,0,0,70b0fe37-cd1c-46bb-8f2e-c26e1f35ef9a
2019-05-29T08:00:00.000+08:00,Here's Why Eli Lilly Is Cutting The Price Of Humalog,LLY,https://seekingalpha.com/article/4266973-eli-lilly-cutting-price-humalog?source=partner_benzinga,Seeking Alpha,,,,0,0,e59b71a2-54d3-4bfb-ad07-b5e2b3af64f7
2019-05-29T08:00:00.000+08:00,Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate,LLY,http://www.zacks.com/stock/news/421715/lilly-in-licenses-private-biotechs-non-opoid-pain-candidate?cid=CS-BENZ-FT-421715,Zacks,,,,0,0,5619c4e6-b38d-4c36-a301-32cbad2fadfa
2019-05-29T08:00:00.000+08:00,Here's Why Eli Lilly Is Cutting The Price Of Humalog,LLY,https://seekingalpha.com/article/4266973-eli-lilly-cutting-price-humalog?source=partner_benzinga,Seeking Alpha,,,,0,0,d0a1cd23-8c39-48b5-ae1a-73561a6f124e
2019-05-28T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For May 28, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/05/13813592/benzingas-top-upgrades-downgrades-for-may-28-2019,Lisa Levin,,,,0,0,18911cd1-c3bc-43cf-85c0-a40ce5bc3fdb
2019-05-28T08:00:00.000+08:00,Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics; Lilly To Pay Centrexion $47.5M Up Front And Up To $575M In Potential Development Milestones,LLY,https://www.benzinga.com/general/biotech/19/05/13812619/lilly-announces-licensing-agreement-for-non-opioid-pain-asset-from-centrexion-therapeutics-lilly-,Benzinga Newsdesk,,,,0,0,efbbf9ba-6e95-4353-9935-87718ae3390a
2019-05-28T08:00:00.000+08:00,"Goldman Sachs Initiates Coverage On Eli Lilly with Buy Rating, Announces $135 Price Target",LLY,https://www.benzinga.com/news/19/05/13812492/goldman-sachs-initiates-coverage-on-eli-lilly-with-buy-rating-announces-135-price-target,Benzinga_Newsdesk,,,,0,0,288efa69-795d-41b2-805e-1c20464b84ed
2019-05-28T08:00:00.000+08:00,Lilly in-licenses non-opioid pain candidate from Centrexion for up ~$1B,LLY,https://seekingalpha.com/news/3467132-lilly-licenses-non-opioid-pain-candidate-centrexion-1b?source=partner_benzinga,Seeking Alpha,,,,0,0,41a0ffc0-696a-4c63-852a-617bab055245
2019-05-28T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For May 28, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/05/13813592/benzingas-top-upgrades-downgrades-for-may-28-2019,Lisa Levin,,,,0,0,6be4a01e-d105-4b7e-807b-28a93f79c07e
2019-05-28T08:00:00.000+08:00,Lilly Announces Licensing Agreement For Non-Opioid Pain Asset From Centrexion Therapeutics; Lilly To Pay Centrexion $47.5M Up Front And Up To $575M In Potential Development Milestones,LLY,https://www.benzinga.com/general/biotech/19/05/13812619/lilly-announces-licensing-agreement-for-non-opioid-pain-asset-from-centrexion-therapeutics-lilly-,Benzinga Newsdesk,,,,0,0,4a5570e8-18cd-424c-a2d2-0aa0810f10d9
2019-05-28T08:00:00.000+08:00,"Goldman Sachs Initiates Coverage On Eli Lilly with Buy Rating, Announces $135 Price Target",LLY,https://www.benzinga.com/news/19/05/13812492/goldman-sachs-initiates-coverage-on-eli-lilly-with-buy-rating-announces-135-price-target,Benzinga_Newsdesk,,,,0,0,dc6e0d21-0772-4d2f-9f77-5b10cd6834b9
2019-05-28T08:00:00.000+08:00,Lilly in-licenses non-opioid pain candidate from Centrexion for up ~$1B,LLY,https://seekingalpha.com/news/3467132-lilly-licenses-non-opioid-pain-candidate-centrexion-1b?source=partner_benzinga,Seeking Alpha,,,,0,0,055bb621-cdf2-4366-8770-ac6cc0f0fd52
2019-05-27T08:00:00.000+08:00,Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi,LLY,http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-BENZ-FT-420060,Zacks,,,,0,0,b4e1d716-3198-45e5-af37-a4c862a48f05
2019-05-27T08:00:00.000+08:00,Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi,LLY,http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-BENZ-FT-420060,Zacks,,,,0,0,8a7a5edf-8bf3-4e4e-9310-cf7948025140
2019-05-24T08:00:00.000+08:00,"Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates",LLY,http://www.zacks.com/stock/news/419108/pharma-stock-roundup-mrks-cancer-biotech-buyout-abbv-llys-pipeline-updates?cid=CS-BENZ-FT-419108,Zacks,,,,0,0,1b0eace6-b9a6-4070-bb69-c571558d9d0b
2019-05-24T08:00:00.000+08:00,"Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates",LLY,http://www.zacks.com/stock/news/419108/pharma-stock-roundup-mrks-cancer-biotech-buyout-abbv-llys-pipeline-updates?cid=CS-BENZ-FT-419108,Zacks,,,,0,0,638020a3-53dc-4165-be27-ebfee9c78040
2019-05-23T08:00:00.000+08:00,FDA OKs Novocure's TTF for mesothelioma under HDE status; shares up 4% after hours,LLY,https://seekingalpha.com/news/3466629-fda-oks-novocures-ttf-mesothelioma-hde-status-shares-4-percent-hours?source=partner_benzinga,Seeking Alpha,,,,0,0,d6298ae1-e447-4373-93f8-5d97c743d0f3
2019-05-23T08:00:00.000+08:00,"Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)",LLY,http://www.zacks.com/stock/news/418682/earnings-preview-veeva-veev-palo-alto-networks-panw-workday-wday?cid=CS-BENZ-FT-418682,Zacks,,,,0,0,cba24c9a-6f9a-4271-9f5f-dbbb74f01c37
2019-05-23T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 78,LLY,https://seekingalpha.com/article/4266153-bulletproof-investing-performance-update-week-78?source=partner_benzinga,Seeking Alpha,,,,0,0,e2a85751-039a-4e3e-afbe-f86a01f4d4f4
2019-05-23T08:00:00.000+08:00,Lilly (LLY) Launches Half-Priced Version of Humalog Insulin,LLY,http://www.zacks.com/stock/news/418337/lilly-lly-launches-half-priced-version-of-humalog-insulin?cid=CS-BENZ-FT-418337,Zacks,,,,0,0,d4a373fd-c9b2-433b-b8a8-8fda228e3ddf
2019-05-23T08:00:00.000+08:00,FDA OKs Novocure's TTF for mesothelioma under HDE status; shares up 4% after hours,LLY,https://seekingalpha.com/news/3466629-fda-oks-novocures-ttf-mesothelioma-hde-status-shares-4-percent-hours?source=partner_benzinga,Seeking Alpha,,,,0,0,ec73b5e4-d2bf-4b87-b784-c4675d4eec56
2019-05-23T08:00:00.000+08:00,"Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)",LLY,http://www.zacks.com/stock/news/418682/earnings-preview-veeva-veev-palo-alto-networks-panw-workday-wday?cid=CS-BENZ-FT-418682,Zacks,,,,0,0,e7c89508-89e0-42e3-9421-f03f3d416693
2019-05-23T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 78,LLY,https://seekingalpha.com/article/4266153-bulletproof-investing-performance-update-week-78?source=partner_benzinga,Seeking Alpha,,,,0,0,4e79085b-d993-486f-9514-783c1d55d3db
2019-05-23T08:00:00.000+08:00,Lilly (LLY) Launches Half-Priced Version of Humalog Insulin,LLY,http://www.zacks.com/stock/news/418337/lilly-lly-launches-half-priced-version-of-humalog-insulin?cid=CS-BENZ-FT-418337,Zacks,,,,0,0,8bf8dfce-12bd-4f00-bc4d-3b116a4b46a3
2019-05-22T08:00:00.000+08:00,"Eli Lilly Reports Insulin Lispro Injection Now Available For Order In Pharmacies For People Who Use Co.'s Rapid-Acting Insulin, Need For Lower-Cost Option",LLY,https://www.benzinga.com/news/19/05/13786675/eli-lilly-reports-insulin-lispro-injection-now-available-for-order-in-pharmacies-for-people-who-use,Benzinga Newsdesk,,,,0,0,0ec345b2-40b5-4f21-9e49-f299f00c485b
2019-05-22T08:00:00.000+08:00,Array BioPharma Gains on Colorectal Cancer Study Success,LLY,http://www.zacks.com/stock/news/418133/array-biopharma-gains-on-colorectal-cancer-study-success?cid=CS-BENZ-FT-418133,Zacks,,,,0,0,6812b432-f37c-4cab-bdf4-4e0a94ce8fa7
2019-05-22T08:00:00.000+08:00,3 Tech Stocks for Growth Investors to Buy Right Now,LLY,http://www.zacks.com/stock/news/418127/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-BENZ-FT-418127,Zacks,,,,0,0,dd6a8e04-c43c-4a40-a80b-f4a494524783
2019-05-22T08:00:00.000+08:00,Philip Morris International: Final Performance,LLY,https://seekingalpha.com/article/4265763-philip-morris-international-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,c04f6112-a4cf-4a84-b285-16b88e0bee6a
2019-05-22T08:00:00.000+08:00,Lilly's Crohn's Disease Candidate Meets Phase II Study Goals,LLY,http://www.zacks.com/stock/news/417952/lillys-crohns-disease-candidate-meets-phase-ii-study-goals?cid=CS-BENZ-FT-417952,Zacks,,,,0,0,ded139d4-ec82-4b6e-8882-dd511a03e1e3
2019-05-22T08:00:00.000+08:00,Merck to Buy Private Cancer Drugmaker Peloton Therapeutics,LLY,http://www.zacks.com/stock/news/417898/merck-to-buy-private-cancer-drugmaker-peloton-therapeutics?cid=CS-BENZ-FT-417898,Zacks,,,,0,0,4402fbc0-c006-400f-b875-92e9607c263b
2019-05-22T08:00:00.000+08:00,"Eli Lilly Reports Insulin Lispro Injection Now Available For Order In Pharmacies For People Who Use Co.'s Rapid-Acting Insulin, Need For Lower-Cost Option",LLY,https://www.benzinga.com/news/19/05/13786675/eli-lilly-reports-insulin-lispro-injection-now-available-for-order-in-pharmacies-for-people-who-use,Benzinga Newsdesk,,,,0,0,8c4e5660-3520-47d5-9bb4-1f92bee07471
2019-05-22T08:00:00.000+08:00,Array BioPharma Gains on Colorectal Cancer Study Success,LLY,http://www.zacks.com/stock/news/418133/array-biopharma-gains-on-colorectal-cancer-study-success?cid=CS-BENZ-FT-418133,Zacks,,,,0,0,b3b4de1e-b155-45ce-950d-3858600085f7
2019-05-22T08:00:00.000+08:00,3 Tech Stocks for Growth Investors to Buy Right Now,LLY,http://www.zacks.com/stock/news/418127/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-BENZ-FT-418127,Zacks,,,,0,0,23705264-2de5-44d2-8736-09d805d286c6
2019-05-22T08:00:00.000+08:00,Philip Morris International: Final Performance,LLY,https://seekingalpha.com/article/4265763-philip-morris-international-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,5a85dc87-405d-4233-86d5-6afdeaba7b2a
2019-05-22T08:00:00.000+08:00,Lilly's Crohn's Disease Candidate Meets Phase II Study Goals,LLY,http://www.zacks.com/stock/news/417952/lillys-crohns-disease-candidate-meets-phase-ii-study-goals?cid=CS-BENZ-FT-417952,Zacks,,,,0,0,e71634eb-05fa-432c-ba79-4123ec92bffe
2019-05-22T08:00:00.000+08:00,Merck to Buy Private Cancer Drugmaker Peloton Therapeutics,LLY,http://www.zacks.com/stock/news/417898/merck-to-buy-private-cancer-drugmaker-peloton-therapeutics?cid=CS-BENZ-FT-417898,Zacks,,,,0,0,3e41328d-5de7-4466-ac96-2bb62175b7db
2019-05-21T08:00:00.000+08:00,"Eli Lilly Reports Mirikizumab Met Primary, Key Secondary Endpoints",LLY,https://www.benzinga.com/news/19/05/13782648/eli-lilly-reports-mirikizumab-met-primary-key-secondary-endpoints,Benzinga Newsdesk,,,,0,0,d1fa00d3-fabb-45ab-a441-1cd1fad5a802
2019-05-21T08:00:00.000+08:00,An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market,LLY,https://seekingalpha.com/article/4265645-fda-win-astrazeneca-shifts-expanded-label-type-2-diabetes-market?source=partner_benzinga,Seeking Alpha,,,,0,0,e515ca2b-e593-4af3-a26a-05af02806e9c
2019-05-21T08:00:00.000+08:00,Lilly's mirikizumab shows positive effect in mid-stage Crohn's study,LLY,https://seekingalpha.com/news/3465778-lillys-mirikizumab-shows-positive-effect-mid-stage-crohns-study?source=partner_benzinga,Seeking Alpha,,,,0,0,12d9ff9b-9dbe-4166-ba56-8a7f95769708
2019-05-21T08:00:00.000+08:00,Array Bio down 5% premarket on uneven results for Braftovi/Mektovi in CRC,LLY,https://seekingalpha.com/news/3465641-array-bio-5-percent-premarket-uneven-results-braftovi-mektovi-crc?source=partner_benzinga,Seeking Alpha,,,,0,0,931682e9-03f9-427d-826c-ccb29d082b67
2019-05-21T08:00:00.000+08:00,"Eli Lilly Reports Mirikizumab Met Primary, Key Secondary Endpoints",LLY,https://www.benzinga.com/news/19/05/13782648/eli-lilly-reports-mirikizumab-met-primary-key-secondary-endpoints,Benzinga Newsdesk,,,,0,0,1b225fd9-fa56-4f3f-a4f1-8cbac66c98b4
2019-05-21T08:00:00.000+08:00,An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market,LLY,https://seekingalpha.com/article/4265645-fda-win-astrazeneca-shifts-expanded-label-type-2-diabetes-market?source=partner_benzinga,Seeking Alpha,,,,0,0,9ae2da54-f7fe-4e44-84a1-91c0bfc33ea1
2019-05-21T08:00:00.000+08:00,Lilly's mirikizumab shows positive effect in mid-stage Crohn's study,LLY,https://seekingalpha.com/news/3465778-lillys-mirikizumab-shows-positive-effect-mid-stage-crohns-study?source=partner_benzinga,Seeking Alpha,,,,0,0,740317f8-184b-4c4c-b7e8-c299603f995e
2019-05-21T08:00:00.000+08:00,Array Bio down 5% premarket on uneven results for Braftovi/Mektovi in CRC,LLY,https://seekingalpha.com/news/3465641-array-bio-5-percent-premarket-uneven-results-braftovi-mektovi-crc?source=partner_benzinga,Seeking Alpha,,,,0,0,bda8ea88-da84-464c-865d-2714de4161e0
2019-05-20T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/416747/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-416747,Zacks,,,,0,0,e0813686-5d4a-4a8c-8558-7e6ad2c671d5
2019-05-20T08:00:00.000+08:00,Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio,LLY,http://www.zacks.com/stock/news/416747/why-eli-lilly-lly-is-a-top-dividend-stock-for-your-portfolio?cid=CS-BENZ-FT-416747,Zacks,,,,0,0,13babe89-7c35-481a-a184-30e5a390c9b1
2019-05-19T08:00:00.000+08:00,6 Stock That May Drop During the Week of May 20,LLY,https://www.benzinga.com/node/13769693,TalkMarkets,,,,0,0,c819ad6f-e7a4-47c1-b303-76433ef737e8
2019-05-19T08:00:00.000+08:00,6 Stock That May Drop During the Week of May 20,LLY,https://www.benzinga.com/node/13769693,TalkMarkets,,,,0,0,83edb598-def7-49d9-85bf-3462754e0986
2019-05-18T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",LLY,https://www.benzinga.com/general/biotech/19/05/13747491/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-readouts-and-ipos,Shanthi Rexaline,,,,0,0,af504ece-577b-45e4-b969-2ea13413eb1a
2019-05-18T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",LLY,https://www.benzinga.com/general/biotech/19/05/13747491/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-readouts-and-ipos,Shanthi Rexaline,,,,0,0,7b8af170-129c-41cd-a34a-b4f5a0066798
2019-05-17T08:00:00.000+08:00,ImmunoGen: Assessing The Possibility Of A Turnaround,LLY,https://seekingalpha.com/article/4265020-immunogen-assessing-possibility-turnaround?source=partner_benzinga,Seeking Alpha,,,,0,0,96d24ec2-55ce-4ffd-97dd-c5d023f353aa
2019-05-17T08:00:00.000+08:00,ImmunoGen: Assessing The Possibility Of A Turnaround,LLY,https://seekingalpha.com/article/4265020-immunogen-assessing-possibility-turnaround?source=partner_benzinga,Seeking Alpha,,,,0,0,93ad9d34-43f5-426e-a4b8-1dcc205cd8a0
2019-05-16T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 77,LLY,https://seekingalpha.com/article/4264627-bulletproof-investing-performance-update-week-77?source=partner_benzinga,Seeking Alpha,,,,0,0,cf17be13-a732-4910-843c-55ca8587b0dc
2019-05-16T08:00:00.000+08:00,"Citadel Advisors LLC Buys Eli Lilly and Co, McDonald's Corp, The Walt Disney Co, Sells Amazon. ...",LLY,http://www.gurufocus.com/news/879131/citadel-advisors-llc-buys-eli-lilly-and-co-mcdonalds-corp-the-walt-disney-co-sells-amazoncom-inc-spdr-sp-500-att-inc,GuruFocus,,,,0,0,a72ee127-74a0-4b67-b12e-ac609b568135
2019-05-16T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 77,LLY,https://seekingalpha.com/article/4264627-bulletproof-investing-performance-update-week-77?source=partner_benzinga,Seeking Alpha,,,,0,0,38ea59eb-ad63-4833-a0c4-904b620c261a
2019-05-16T08:00:00.000+08:00,"Citadel Advisors LLC Buys Eli Lilly and Co, McDonald's Corp, The Walt Disney Co, Sells Amazon. ...",LLY,http://www.gurufocus.com/news/879131/citadel-advisors-llc-buys-eli-lilly-and-co-mcdonalds-corp-the-walt-disney-co-sells-amazoncom-inc-spdr-sp-500-att-inc,GuruFocus,,,,0,0,d551eeb7-8b7a-40b0-a860-8212647f81b0
2019-05-15T08:00:00.000+08:00,"Hunting Hill Global Capital, LLC Buys Red Hat Inc, Celgene Corp, iShares China Large-Cap, Sells ...",LLY,http://www.gurufocus.com/news/878607/hunting-hill-global-capital-llc-buys-red-hat-inc-celgene-corp-ishares-china-largecap-sells-shire-plc-spdr-bloomberg-barclays-high-yield-bond-dominion-energy-inc,GuruFocus,,,,0,0,50c6af09-fbea-4cdc-baf1-302ee8c70815
2019-05-15T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS",LLY,http://www.zacks.com/stock/news/414358/the-zacks-analyst-blog-highlights-alphabet-eli-lilly-cvs-marriott-and-telus?cid=CS-BENZ-FT-414358,Zacks,,,,0,0,eec03d69-e070-4508-930f-50363d09b305
2019-05-15T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2019 Update,LLY,https://seekingalpha.com/article/4264177-tracking-ken-fishers-fisher-asset-management-portfolio-q1-2019-update?source=partner_benzinga,Seeking Alpha,,,,0,0,8bf1fbfe-8811-423b-8cc8-d2b6c8c3cc97
2019-05-15T08:00:00.000+08:00,"Hunting Hill Global Capital, LLC Buys Red Hat Inc, Celgene Corp, iShares China Large-Cap, Sells ...",LLY,http://www.gurufocus.com/news/878607/hunting-hill-global-capital-llc-buys-red-hat-inc-celgene-corp-ishares-china-largecap-sells-shire-plc-spdr-bloomberg-barclays-high-yield-bond-dominion-energy-inc,GuruFocus,,,,0,0,54675471-b547-40ea-a5e3-860e422445e2
2019-05-15T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, CVS, Marriott and TELUS",LLY,http://www.zacks.com/stock/news/414358/the-zacks-analyst-blog-highlights-alphabet-eli-lilly-cvs-marriott-and-telus?cid=CS-BENZ-FT-414358,Zacks,,,,0,0,6ccdb720-c720-4261-9578-141910e8a9a8
2019-05-15T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2019 Update,LLY,https://seekingalpha.com/article/4264177-tracking-ken-fishers-fisher-asset-management-portfolio-q1-2019-update?source=partner_benzinga,Seeking Alpha,,,,0,0,99987dbe-3783-4d41-822d-d20083f00228
2019-05-14T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",LLY,https://www.benzinga.com/markets/wiim/19/05/13736459/shares-of-several-healthcare-companies-are-trading-higher-as-the-us-market-rebounds-from-recent-weak,Benzinga Newsdesk,,,,0,0,571ec556-3e8d-45db-8d3b-3cc4f8cb9ec3
2019-05-14T08:00:00.000+08:00,"Top Research Reports for Alphabet, Eli Lilly & CVS Health",LLY,http://www.zacks.com/research-daily/413862/top-research-reports-for-alphabet-eli-lilly-cvs-health?cid=CS-BENZ-FT-413862,Zacks,,,,0,0,319e37c8-589c-4996-add0-9151f864a5ff
2019-05-14T08:00:00.000+08:00,Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer,LLY,http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-BENZ-FT-413860,Zacks,,,,0,0,4ed75b3f-8d36-4e77-b163-6d5f4f81f74e
2019-05-14T08:00:00.000+08:00,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",LLY,https://www.benzinga.com/markets/wiim/19/05/13736459/shares-of-several-healthcare-companies-are-trading-higher-as-the-us-market-rebounds-from-recent-weak,Benzinga Newsdesk,,,,0,0,81719783-2d49-4fed-a343-122a7236bc10
2019-05-14T08:00:00.000+08:00,"Top Research Reports for Alphabet, Eli Lilly & CVS Health",LLY,http://www.zacks.com/research-daily/413862/top-research-reports-for-alphabet-eli-lilly-cvs-health?cid=CS-BENZ-FT-413862,Zacks,,,,0,0,708685ef-0f76-4bb9-a090-65039c76814d
2019-05-14T08:00:00.000+08:00,Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer,LLY,http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-BENZ-FT-413860,Zacks,,,,0,0,1a7bf057-917c-4c75-ac15-765258840295
2019-05-13T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 300 Points,LLY,https://www.benzinga.com/news/19/05/13723083/a-peek-into-the-markets-us-stock-futures-tumble-dow-futures-down-over-300-points,Lisa Levin,,,,0,0,d3252c2f-8ada-4cd6-a14f-8f67352188d8
2019-05-13T08:00:00.000+08:00,Eli Lilly Announces FDA Approval for its CYRAMZA for the Treatment of Patients with Hepatocellular Carcinoma,LLY,https://www.benzinga.com/news/19/05/13723042/eli-lilly-announces-fda-approval-for-its-cyramza-for-the-treatment-of-patients-with-hepatocellular-c,Benzinga Newsdesk,,,,0,0,a5db26ac-1537-4edc-87dc-62c108ed14e6
2019-05-13T08:00:00.000+08:00,"Hyman Charles D Buys International Business Machines Corp, Merck Inc, Cisco Systems Inc, Sells ...",LLY,http://www.gurufocus.com/news/876666/hyman-charles-d-buys-international-business-machines-corp-merck-inc-cisco-systems-inc-sells-blackrock-inc,GuruFocus,,,,0,0,0fd35067-187a-4ce3-a4f7-49b8642cf5ea
2019-05-13T08:00:00.000+08:00,FDA finalizes guidance on interchangeable biosimilars,LLY,https://seekingalpha.com/news/3462874-fda-finalizes-guidance-interchangeable-biosimilars?source=partner_benzinga,Seeking Alpha,,,,0,0,dd46756f-7c6e-4bdb-a840-928ce4b1e975
2019-05-13T08:00:00.000+08:00,FDA OK's Lilly's CYRAMZA for liver cancer,LLY,https://seekingalpha.com/news/3462858-fda-oks-lillys-cyramza-liver-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,cfa05abb-96aa-4de7-afdc-aa6483c39564
2019-05-13T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Tumble; Dow Futures Down Over 300 Points,LLY,https://www.benzinga.com/news/19/05/13723083/a-peek-into-the-markets-us-stock-futures-tumble-dow-futures-down-over-300-points,Lisa Levin,,,,0,0,57e47483-43a6-4ac3-acba-48d1887d6599
2019-05-13T08:00:00.000+08:00,Eli Lilly Announces FDA Approval for its CYRAMZA for the Treatment of Patients with Hepatocellular Carcinoma,LLY,https://www.benzinga.com/news/19/05/13723042/eli-lilly-announces-fda-approval-for-its-cyramza-for-the-treatment-of-patients-with-hepatocellular-c,Benzinga Newsdesk,,,,0,0,1e8b9a72-ece4-499b-b106-3946dcb44003
2019-05-13T08:00:00.000+08:00,"Hyman Charles D Buys International Business Machines Corp, Merck Inc, Cisco Systems Inc, Sells ...",LLY,http://www.gurufocus.com/news/876666/hyman-charles-d-buys-international-business-machines-corp-merck-inc-cisco-systems-inc-sells-blackrock-inc,GuruFocus,,,,0,0,7f2290b0-7276-4571-974d-e42a32126714
2019-05-13T08:00:00.000+08:00,FDA finalizes guidance on interchangeable biosimilars,LLY,https://seekingalpha.com/news/3462874-fda-finalizes-guidance-interchangeable-biosimilars?source=partner_benzinga,Seeking Alpha,,,,0,0,3ec20c31-36b4-41b8-81e4-97bfd607b057
2019-05-13T08:00:00.000+08:00,FDA OK's Lilly's CYRAMZA for liver cancer,LLY,https://seekingalpha.com/news/3462858-fda-oks-lillys-cyramza-liver-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,107103de-1988-43ee-beb6-163d4b784f11
2019-05-12T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - May 12, 2019",LLY,https://www.benzinga.com/node/13721692,TalkMarkets,,,,0,0,062dda02-2593-4006-a95e-bc632656c826
2019-05-12T08:00:00.000+08:00,"Week In Review: How Trump's Policies Moved Stocks - May 12, 2019",LLY,https://www.benzinga.com/node/13721692,TalkMarkets,,,,0,0,abe081d8-938b-4d68-9afd-18199e963a7e
2019-05-10T08:00:00.000+08:00,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., May 10, 2019",LLY,https://www.benzinga.com/news/19/05/13716417/top-10-most-oversold-stocks-via-benzinga-pros-radar-tool-for-fri-may-10-2019,Benzinga Newsdesk,,,,0,0,f74aea4e-c023-47b5-87d1-63804c064259
2019-05-10T08:00:00.000+08:00,"Bluestein R H & Co Buys Deere, Palo Alto Networks Inc, Delta Air Lines Inc, Sells ...",LLY,http://www.gurufocus.com/news/875529/bluestein-r-h--co-buys-deere-palo-alto-networks-inc-delta-air-lines-inc-sells-unitedhealth-group-inc-international-business-machines-corp-tesla-inc,GuruFocus,,,,0,0,fc71c8a3-4763-45f9-8325-835632f5697f
2019-05-10T08:00:00.000+08:00,Nektar: Undervalued And A Tremendous Prospect,LLY,https://seekingalpha.com/article/4262507-nektar-undervalued-tremendous-prospect?source=partner_benzinga,Seeking Alpha,,,,0,0,8711f87e-77e5-4b12-9477-8decfb4d01ca
2019-05-10T08:00:00.000+08:00,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., May 10, 2019",LLY,https://www.benzinga.com/news/19/05/13716417/top-10-most-oversold-stocks-via-benzinga-pros-radar-tool-for-fri-may-10-2019,Benzinga Newsdesk,,,,0,0,8b6114fa-0f8e-4fb3-9434-99d6e8eae895
2019-05-10T08:00:00.000+08:00,"Bluestein R H & Co Buys Deere, Palo Alto Networks Inc, Delta Air Lines Inc, Sells ...",LLY,http://www.gurufocus.com/news/875529/bluestein-r-h--co-buys-deere-palo-alto-networks-inc-delta-air-lines-inc-sells-unitedhealth-group-inc-international-business-machines-corp-tesla-inc,GuruFocus,,,,0,0,51df6942-de0b-46a4-9650-c642fe68d0aa
2019-05-10T08:00:00.000+08:00,Nektar: Undervalued And A Tremendous Prospect,LLY,https://seekingalpha.com/article/4262507-nektar-undervalued-tremendous-prospect?source=partner_benzinga,Seeking Alpha,,,,0,0,3960f36b-0040-46af-bc58-9b975186b224
2019-05-09T08:00:00.000+08:00,"Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues",LLY,http://www.zacks.com/stock/news/412113/radius-rdus-posts-narrower-q1-loss-misses-on-revenues?cid=CS-BENZ-FT-412113,Zacks,,,,0,0,608f2830-fafe-4837-b21f-bd7a7e07f3c5
2019-05-09T08:00:00.000+08:00,TV ad disclosures to affect small group of drug makers,LLY,https://seekingalpha.com/news/3461894-tv-ad-disclosures-affect-small-group-drug-makers?source=partner_benzinga,Seeking Alpha,,,,0,0,73a92e90-e676-4432-8c42-d35683095b13
2019-05-09T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 76,LLY,https://seekingalpha.com/article/4261929-bulletproof-investing-performance-update-week-76?source=partner_benzinga,Seeking Alpha,,,,0,0,6c42bd1d-18e9-4d59-b00b-407fa656e511
2019-05-09T08:00:00.000+08:00,"Radius (RDUS) Posts Narrower Q1 Loss, Misses on Revenues",LLY,http://www.zacks.com/stock/news/412113/radius-rdus-posts-narrower-q1-loss-misses-on-revenues?cid=CS-BENZ-FT-412113,Zacks,,,,0,0,ff5b4244-68c6-41e7-bb9e-30e70264b98d
2019-05-09T08:00:00.000+08:00,TV ad disclosures to affect small group of drug makers,LLY,https://seekingalpha.com/news/3461894-tv-ad-disclosures-affect-small-group-drug-makers?source=partner_benzinga,Seeking Alpha,,,,0,0,5e35703d-82bd-4da9-825b-d5d53c5a027f
2019-05-09T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 76,LLY,https://seekingalpha.com/article/4261929-bulletproof-investing-performance-update-week-76?source=partner_benzinga,Seeking Alpha,,,,0,0,1731e096-4f3b-4ea2-ab18-3f47f1c54265
2019-05-08T08:00:00.000+08:00,The Nextcure IPO: What You Need To Know,LLY,https://www.benzinga.com/general/biotech/19/05/13673725/the-nextcure-ipo-what-you-need-to-know,Elizabeth Balboa,,,,0,0,69d357cb-ef84-497c-aac6-190323652c9b
2019-05-08T08:00:00.000+08:00,Drug makers to disclose prices in TV ads as early as this summer,LLY,https://seekingalpha.com/news/3460803-drug-makers-disclose-prices-tv-ads-early-summer?source=partner_benzinga,Seeking Alpha,,,,0,0,feda0628-deb3-4798-900f-87968e54b186
2019-05-08T08:00:00.000+08:00,The Nextcure IPO: What You Need To Know,LLY,https://www.benzinga.com/general/biotech/19/05/13673725/the-nextcure-ipo-what-you-need-to-know,Elizabeth Balboa,,,,0,0,7c9a333e-d88c-4cfc-9f1b-6bb3e2e85982
2019-05-08T08:00:00.000+08:00,Drug makers to disclose prices in TV ads as early as this summer,LLY,https://seekingalpha.com/news/3460803-drug-makers-disclose-prices-tv-ads-early-summer?source=partner_benzinga,Seeking Alpha,,,,0,0,80926e32-0f8a-4492-93bc-437d0ee5ee5f
2019-05-07T08:00:00.000+08:00,NextCure IPO: The Enterprise Value Could Increase In 2020,LLY,https://seekingalpha.com/article/4261011-nextcure-ipo-enterprise-value-increase-2020?source=partner_benzinga,Seeking Alpha,,,,0,0,1993c6a8-60e0-43f8-ae03-c0e70291ceb1
2019-05-07T08:00:00.000+08:00,"Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View",LLY,http://www.zacks.com/stock/news/410272/allergan-agn-beats-on-q1-earnings-sales-raises-19-view?cid=CS-BENZ-FT-410272,Zacks,,,,0,0,b8a0e1e2-52b4-437a-86c0-c95e9194519e
2019-05-07T08:00:00.000+08:00,NextCure IPO: The Enterprise Value Could Increase In 2020,LLY,https://seekingalpha.com/article/4261011-nextcure-ipo-enterprise-value-increase-2020?source=partner_benzinga,Seeking Alpha,,,,0,0,f9aacfbd-29af-402e-9584-5370bc20f237
2019-05-07T08:00:00.000+08:00,"Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View",LLY,http://www.zacks.com/stock/news/410272/allergan-agn-beats-on-q1-earnings-sales-raises-19-view?cid=CS-BENZ-FT-410272,Zacks,,,,0,0,80754178-bef3-4dba-af2b-25a3329b99a9
2019-05-06T08:00:00.000+08:00,"Eli Lilly Highlights Upcoming Presentation Of Results From Pooled Subgroup Analyses Of Efficacy Data From Phase 3 EVOLVE-1, EVOLVE-2 Studies",LLY,https://www.benzinga.com/news/19/05/13670541/eli-lilly-highlights-upcoming-presentation-of-results-from-pooled-subgroup-analyses-of-efficacy-data,Benzinga Newsdesk,,,,0,0,c854807e-d15d-49e3-8c0b-a880ce8bbb8d
2019-05-06T08:00:00.000+08:00,"Oral Ozempic: Finally, An Alpha Catalyst For Novo Nordisk?",LLY,https://seekingalpha.com/article/4260690-oral-ozempic-finally-alpha-catalyst-novo-nordisk?source=partner_benzinga,Seeking Alpha,,,,0,0,f63f03e9-a244-4d40-8075-f7fc0396b05b
2019-05-06T08:00:00.000+08:00,Cortexyme IPO Isn't Cheap,LLY,https://seekingalpha.com/article/4260662-cortexyme-ipo-cheap?source=partner_benzinga,Seeking Alpha,,,,0,0,1d0a9535-c61a-414c-b38a-2754aaeae756
2019-05-06T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3459324-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,0,0,81333c04-6d7c-414f-ae4f-e8baf9bddf86
2019-05-06T08:00:00.000+08:00,"Eli Lilly Highlights Upcoming Presentation Of Results From Pooled Subgroup Analyses Of Efficacy Data From Phase 3 EVOLVE-1, EVOLVE-2 Studies",LLY,https://www.benzinga.com/news/19/05/13670541/eli-lilly-highlights-upcoming-presentation-of-results-from-pooled-subgroup-analyses-of-efficacy-data,Benzinga Newsdesk,,,,0,0,77318982-d080-4b1f-ba1b-86b90acc5002
2019-05-06T08:00:00.000+08:00,"Oral Ozempic: Finally, An Alpha Catalyst For Novo Nordisk?",LLY,https://seekingalpha.com/article/4260690-oral-ozempic-finally-alpha-catalyst-novo-nordisk?source=partner_benzinga,Seeking Alpha,,,,0,0,189c4ac9-5dc3-48e6-8307-9edacdfd5d1d
2019-05-06T08:00:00.000+08:00,Cortexyme IPO Isn't Cheap,LLY,https://seekingalpha.com/article/4260662-cortexyme-ipo-cheap?source=partner_benzinga,Seeking Alpha,,,,0,0,c823df08-2e1b-4514-90e9-b133c62a214f
2019-05-06T08:00:00.000+08:00,Eli Lilly declares $0.645 dividend,LLY,https://seekingalpha.com/news/3459324-eli-lilly-declares-0_645-dividend?source=partner_benzinga,Seeking Alpha,,,,0,0,0d5a6cad-6f65-4d2b-b6a0-ed0c39990349
2019-05-05T08:00:00.000+08:00,Dogs Of The Champions: An Improvement Over The Dogs Of The Dow,LLY,https://seekingalpha.com/article/4260285-dogs-champions-improvement-dogs-dow?source=partner_benzinga,Seeking Alpha,,,,0,0,fc121df8-ff4d-49b1-af5e-e098ca868665
2019-05-05T08:00:00.000+08:00,Uber Time (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4260203-uber-time-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,a1b28ad4-e543-4d17-9c68-8b0116cbf148
2019-05-05T08:00:00.000+08:00,Dogs Of The Champions: An Improvement Over The Dogs Of The Dow,LLY,https://seekingalpha.com/article/4260285-dogs-champions-improvement-dogs-dow?source=partner_benzinga,Seeking Alpha,,,,0,0,72b37b21-77e9-4b60-b70e-b68cf3900c93
2019-05-05T08:00:00.000+08:00,Uber Time (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4260203-uber-time-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,fa757829-64d2-4a81-afb1-9fbd64718dd3
2019-05-04T08:00:00.000+08:00,Stocks To Watch: Uber Time,LLY,https://seekingalpha.com/article/4260001-stocks-watch-uber-time?source=partner_benzinga,Seeking Alpha,,,,0,0,ef5a704e-e741-4dd3-bff6-f17dabf4214c
2019-05-04T08:00:00.000+08:00,Stocks To Watch: Uber Time,LLY,https://seekingalpha.com/article/4260001-stocks-watch-uber-time?source=partner_benzinga,Seeking Alpha,,,,0,0,eba36d98-b4c0-4ebb-80e3-9f9f3362aeb2
2019-05-03T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 75,LLY,https://seekingalpha.com/article/4259943-bulletproof-investing-performance-update-week-75?source=partner_benzinga,Seeking Alpha,,,,0,0,44d98b75-8f93-48cb-b261-1320519fe52f
2019-05-03T08:00:00.000+08:00,Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates,LLY,http://www.zacks.com/stock/news/408654/novo-nordisk-nvo-q1-earnings-and-revenues-miss-estimates?cid=CS-BENZ-FT-408654,Zacks,,,,0,0,182d61b6-3d89-4767-965e-b2fadebe4bbc
2019-05-03T08:00:00.000+08:00,FDA OKs AstraZeneca's combo pill for T2D,LLY,https://seekingalpha.com/news/3458570-fda-oks-astrazenecas-combo-pill-t2d?source=partner_benzinga,Seeking Alpha,,,,0,0,f54e3796-ed7c-471a-b73a-a88ba51e27be
2019-05-03T08:00:00.000+08:00,"Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down",LLY,http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-BENZ-FT-408333,Zacks,,,,0,0,b657696c-5eea-4766-a47e-08ee3c7401f3
2019-05-03T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod",LLY,http://www.zacks.com/stock/news/408311/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv-drugs-get-eu-nod?cid=CS-BENZ-FT-408311,Zacks,,,,0,0,a0bae209-8eca-43c2-94ef-65cf7371a1a6
2019-05-03T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 75,LLY,https://seekingalpha.com/article/4259943-bulletproof-investing-performance-update-week-75?source=partner_benzinga,Seeking Alpha,,,,0,0,c9155154-b173-412b-8e79-481e8bfa4412
2019-05-03T08:00:00.000+08:00,Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates,LLY,http://www.zacks.com/stock/news/408654/novo-nordisk-nvo-q1-earnings-and-revenues-miss-estimates?cid=CS-BENZ-FT-408654,Zacks,,,,0,0,8182cc0c-c79c-48e2-bd69-c84b7a929a4e
2019-05-03T08:00:00.000+08:00,FDA OKs AstraZeneca's combo pill for T2D,LLY,https://seekingalpha.com/news/3458570-fda-oks-astrazenecas-combo-pill-t2d?source=partner_benzinga,Seeking Alpha,,,,0,0,577f05db-0194-431e-91a6-d414c6b3c40d
2019-05-03T08:00:00.000+08:00,"Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down",LLY,http://www.zacks.com/stock/news/408333/teva-teva-q1-earnings-beat-copaxone-drags-sales-down?cid=CS-BENZ-FT-408333,Zacks,,,,0,0,d81a3c21-33a7-4537-9a95-a5d29df91a18
2019-05-03T08:00:00.000+08:00,"Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod",LLY,http://www.zacks.com/stock/news/408311/pharma-stock-roundup-mrk-lly-pfe-report-q1-earnings-sny-abbv-drugs-get-eu-nod?cid=CS-BENZ-FT-408311,Zacks,,,,0,0,f2b4da2d-5be7-4b0f-8b4d-2d3890a70488
2019-05-02T08:00:00.000+08:00,Eli Lilly Announces It Will Present 19 Scientific Abstracts For Emgality (Galcanezumab-Gnlm) And Lasmiditan At The 71St Annual Meeting Of The American Academy Of Neurology Taking Place In Philadelphia From May 4-10,LLY,https://www.benzinga.com/news/19/05/13650889/eli-lilly-announces-it-will-present-19-scientific-abstracts-for-emgality-galcanezumab-gnlm-and-lasmi,Benzinga_Newsdesk,,,,0,0,63fef11f-2b1d-456e-914b-8826f4b3d3de
2019-05-02T08:00:00.000+08:00,"Newport Trust Co Buys Westinghouse Air Brake Technologies Corp, LiveRamp Holdings Inc, Eli ...",LLY,http://www.gurufocus.com/news/869682/newport-trust-co-buys-westinghouse-air-brake-technologies-corp-liveramp-holdings-inc-eli-lilly-and-co-sells-liveramp-holdings-inc-tcg-bdc-inc,GuruFocus,,,,0,0,7c7bf9ea-666a-4369-ab6c-89cff245efec
2019-05-02T08:00:00.000+08:00,"German American Bancorp, Inc. Buys Vanguard Real Estate, Morgan Stanley, General Electric Co, ...",LLY,http://www.gurufocus.com/news/869324/german-american-bancorp-inc-buys-vanguard-real-estate-morgan-stanley-general-electric-co-sells-spdr-select-sector-fund--financial-spdr-select-sector-fund--industrial-vectren-corp,GuruFocus,,,,0,0,0098e67d-88c1-4c13-b0a1-458db1776eb1
2019-05-02T08:00:00.000+08:00,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat,LLY,http://www.zacks.com/stock/news/407647/united-therapeutics-uthr-down-despite-q1-earnings-beat?cid=CS-BENZ-FT-407647,Zacks,,,,0,0,b43b773e-eb13-4015-a71a-eda183279719
2019-05-02T08:00:00.000+08:00,Eli Lilly Announces It Will Present 19 Scientific Abstracts For Emgality (Galcanezumab-Gnlm) And Lasmiditan At The 71St Annual Meeting Of The American Academy Of Neurology Taking Place In Philadelphia From May 4-10,LLY,https://www.benzinga.com/news/19/05/13650889/eli-lilly-announces-it-will-present-19-scientific-abstracts-for-emgality-galcanezumab-gnlm-and-lasmi,Benzinga_Newsdesk,,,,0,0,85695fc9-716e-4904-84c0-5b696cc225d3
2019-05-02T08:00:00.000+08:00,"Newport Trust Co Buys Westinghouse Air Brake Technologies Corp, LiveRamp Holdings Inc, Eli ...",LLY,http://www.gurufocus.com/news/869682/newport-trust-co-buys-westinghouse-air-brake-technologies-corp-liveramp-holdings-inc-eli-lilly-and-co-sells-liveramp-holdings-inc-tcg-bdc-inc,GuruFocus,,,,0,0,6c63291b-9ff0-4211-b816-29a60d19b750
2019-05-02T08:00:00.000+08:00,"German American Bancorp, Inc. Buys Vanguard Real Estate, Morgan Stanley, General Electric Co, ...",LLY,http://www.gurufocus.com/news/869324/german-american-bancorp-inc-buys-vanguard-real-estate-morgan-stanley-general-electric-co-sells-spdr-select-sector-fund--financial-spdr-select-sector-fund--industrial-vectren-corp,GuruFocus,,,,0,0,ae43a10d-d2aa-43f1-9a3d-2f7b05921a6a
2019-05-02T08:00:00.000+08:00,United Therapeutics (UTHR) Down Despite Q1 Earnings Beat,LLY,http://www.zacks.com/stock/news/407647/united-therapeutics-uthr-down-despite-q1-earnings-beat?cid=CS-BENZ-FT-407647,Zacks,,,,0,0,8ddd54c6-174f-4e05-a1df-5205408abc8b
2019-05-01T08:00:00.000+08:00,"BMO Capital Maintains Outperform on Eli Lilly and Company Common Stock, Raises Price Target to $133",LLY,https://www.benzinga.com/news/19/05/13639759/bmo-capital-maintains-outperform-on-eli-lilly-and-company-common-stock-raises-price-target-to-133,Vick Meyer,,,,0,0,67f6164c-f374-4c4a-9cb9-97070d2f0408
2019-05-01T08:00:00.000+08:00,"Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure",LLY,http://www.zacks.com/stock/news/406447/amgen-amgn-q1-earnings-top-sales-hurt-by-pricing-pressure?cid=CS-BENZ-FT-406447,Zacks,,,,0,0,db0c9ed5-c4d3-4628-bc6f-389da47c9cce
2019-05-01T08:00:00.000+08:00,"BMO Capital Maintains Outperform on Eli Lilly and Company Common Stock, Raises Price Target to $133",LLY,https://www.benzinga.com/news/19/05/13639759/bmo-capital-maintains-outperform-on-eli-lilly-and-company-common-stock-raises-price-target-to-133,Vick Meyer,,,,0,0,638f7457-7b6e-48f3-91b4-0149f59e6bf5
2019-05-01T08:00:00.000+08:00,"Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure",LLY,http://www.zacks.com/stock/news/406447/amgen-amgn-q1-earnings-top-sales-hurt-by-pricing-pressure?cid=CS-BENZ-FT-406447,Zacks,,,,0,0,ecc3c2bb-ba65-44de-9751-e0ea6024434b
2019-04-30T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the the company reported mixed Q1 results and FY19 guidance which was slightly below the consensus estimate.,LLY,https://www.benzinga.com/markets/wiim/19/04/13626512/eli-lilly-and-co-shares-are-trading-lower-after-the-the-company-reported-mixed-q1-results-and-fy19-g,Benzinga Newsdesk,,,,0,0,d704a8cc-1ead-4372-84ed-4a5a67ca585d
2019-04-30T08:00:00.000+08:00,30 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/04/13625331/30-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,0,0,ef4ad11b-1bfa-4ec5-ac94-11c3dcec0a55
2019-04-30T08:00:00.000+08:00,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",LLY,https://www.benzinga.com/general/biotech/19/04/13623920/the-daily-biotech-pulse-earnings-deluge-g1-therapeutics-positive-fda-meeting-mustang-bio-offering,Shanthi Rexaline,,,,0,0,a1d527d3-51b3-4280-809a-f9b9f120f7ef
2019-04-30T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting",LLY,https://www.benzinga.com/news/19/04/13624641/a-peek-into-the-markets-us-stock-futures-mixed-ahead-of-earnings-fed-meeting,Lisa Levin,,,,0,0,4bbc3464-967e-4258-8fe6-c134087a61f7
2019-04-30T08:00:00.000+08:00,"15 Stocks To Watch For April 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/04/13623749/15-stocks-to-watch-for-april-30-2019,Lisa Levin,,,,0,0,4e9c7668-2e0e-4c97-aa28-87c790e2ea21
2019-04-30T08:00:00.000+08:00,Eli Lilly Sees FY19 EPS $5.60-$5.70 vs $5.64 Est.,LLY,https://www.benzinga.com/news/19/04/13623520/eli-lilly-sees-fy19-eps-5-60-5-70-vs-5-64-est,Benzinga Newsdesk,,,,0,0,cbd8032f-d845-4dd9-9222-0822797459cb
2019-04-30T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.33 Beats $1.26 Estimate, Sales $5.09B Miss $5.11B Estimate",LLY,https://www.benzinga.com/news/earnings/19/04/13623489/eli-lilly-q1-adj-eps-1-33-beats-1-26-estimate-sales-5-09b-miss-5-11b-estimate,Benzinga Newsdesk,,,,0,0,1276094b-4aa2-4b41-8b51-44cee21c6d8e
2019-04-30T08:00:00.000+08:00,"Earnings Scheduled For April 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/04/13623421/earnings-scheduled-for-april-30-2019,Lisa Levin,,,,0,0,28e3d3d6-f908-4439-a14c-adbe9f29531a
2019-04-30T08:00:00.000+08:00,"Biotech News Recap: Merck Boasts Another Impressive Quarter, Keytruda Dominance Highlighted",LLY,https://seekingalpha.com/article/4258335-biotech-news-recap-merck-boasts-another-impressive-quarter-keytruda-dominance-highlighted?source=partner_benzinga,Seeking Alpha,,,,0,0,1a84c89a-b9c6-42c1-9049-5fefb6e9b3a6
2019-04-30T08:00:00.000+08:00,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q1 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4258185-eli-lilly-companys-lly-ceo-dave-ricks-q1-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,6d7691d3-fcb9-4f27-b671-70f983dbd5e9
2019-04-30T08:00:00.000+08:00,3 Tech Stocks for Growth Investors to Buy Right Now,LLY,http://www.zacks.com/stock/news/406067/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-BENZ-FT-406067,Zacks,,,,0,0,78b6275b-33ab-4aaa-860c-908a85c806ff
2019-04-30T08:00:00.000+08:00,Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut,LLY,http://www.zacks.com/stock/news/406076/lilly-lly-down-despite-q1-earnings-beat-on-sales-view-cut?cid=CS-BENZ-FT-406076,Zacks,,,,0,0,7b225c9e-f917-4cab-92c4-00c7e6e67d78
2019-04-30T08:00:00.000+08:00,Eli Lilly and Company 2019 Q1 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4257970-eli-lilly-company-2019-q1-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,0,0,b02a032a-82a1-45ed-92d1-540a5f23e737
2019-04-30T08:00:00.000+08:00,Eli Lilly down 2% on Q1 miss and lowered revenue guidance,LLY,https://seekingalpha.com/news/3455995-eli-lilly-2-percent-q1-miss-lowered-revenue-guidance?source=partner_benzinga,Seeking Alpha,,,,0,0,2ad86651-2aec-4bd1-9b6f-617145247ec9
2019-04-30T08:00:00.000+08:00,"Eli Lilly EPS in-line, misses on revenue",LLY,https://seekingalpha.com/news/3455905-eli-lilly-eps-line-misses-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,4591efad-15b8-4a6f-9522-e72ea74c4400
2019-04-30T08:00:00.000+08:00,Eli Lilly And Co shares are trading lower after the the company reported mixed Q1 results and FY19 guidance which was slightly below the consensus estimate.,LLY,https://www.benzinga.com/markets/wiim/19/04/13626512/eli-lilly-and-co-shares-are-trading-lower-after-the-the-company-reported-mixed-q1-results-and-fy19-g,Benzinga Newsdesk,,,,0,0,cbc1b74f-5a35-471b-a753-97f3a83efafe
2019-04-30T08:00:00.000+08:00,30 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/04/13625331/30-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,0,0,25cf51af-a3e1-4a85-a37b-c8509cdc5a1c
2019-04-30T08:00:00.000+08:00,"The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering",LLY,https://www.benzinga.com/general/biotech/19/04/13623920/the-daily-biotech-pulse-earnings-deluge-g1-therapeutics-positive-fda-meeting-mustang-bio-offering,Shanthi Rexaline,,,,0,0,c038d35d-23bb-4fe8-bb67-06979200d399
2019-04-30T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Mixed Ahead Of Earnings, Fed Meeting",LLY,https://www.benzinga.com/news/19/04/13624641/a-peek-into-the-markets-us-stock-futures-mixed-ahead-of-earnings-fed-meeting,Lisa Levin,,,,0,0,939f3e83-2de6-4179-8fc8-f0d2a7f56df5
2019-04-30T08:00:00.000+08:00,"15 Stocks To Watch For April 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/04/13623749/15-stocks-to-watch-for-april-30-2019,Lisa Levin,,,,0,0,a650e4b8-c918-4ca6-8b13-b957e8953b0b
2019-04-30T08:00:00.000+08:00,Eli Lilly Sees FY19 EPS $5.60-$5.70 vs $5.64 Est.,LLY,https://www.benzinga.com/news/19/04/13623520/eli-lilly-sees-fy19-eps-5-60-5-70-vs-5-64-est,Benzinga Newsdesk,,,,0,0,c64daed1-b0c9-4893-abed-2323685279e9
2019-04-30T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.33 Beats $1.26 Estimate, Sales $5.09B Miss $5.11B Estimate",LLY,https://www.benzinga.com/news/earnings/19/04/13623489/eli-lilly-q1-adj-eps-1-33-beats-1-26-estimate-sales-5-09b-miss-5-11b-estimate,Benzinga Newsdesk,,,,0,0,ba50ab90-f524-462c-9ec2-2622f933fdfc
2019-04-30T08:00:00.000+08:00,"Earnings Scheduled For April 30, 2019",LLY,https://www.benzinga.com/news/earnings/19/04/13623421/earnings-scheduled-for-april-30-2019,Lisa Levin,,,,0,0,3f848825-3152-4871-9c8a-507f5860bc3e
2019-04-30T08:00:00.000+08:00,"Biotech News Recap: Merck Boasts Another Impressive Quarter, Keytruda Dominance Highlighted",LLY,https://seekingalpha.com/article/4258335-biotech-news-recap-merck-boasts-another-impressive-quarter-keytruda-dominance-highlighted?source=partner_benzinga,Seeking Alpha,,,,0,0,0a1207d0-840b-4a85-ae9f-a5c14f130780
2019-04-30T08:00:00.000+08:00,Eli Lilly and Company's (LLY) CEO Dave Ricks on Q1 2019 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4258185-eli-lilly-companys-lly-ceo-dave-ricks-q1-2019-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,630cd298-0caa-4050-b64b-a06d72441c6f
2019-04-30T08:00:00.000+08:00,3 Tech Stocks for Growth Investors to Buy Right Now,LLY,http://www.zacks.com/stock/news/406067/3-tech-stocks-for-growth-investors-to-buy-right-now?cid=CS-BENZ-FT-406067,Zacks,,,,0,0,5a378f66-2748-4002-a3cc-7b1fc8f460fc
2019-04-30T08:00:00.000+08:00,Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut,LLY,http://www.zacks.com/stock/news/406076/lilly-lly-down-despite-q1-earnings-beat-on-sales-view-cut?cid=CS-BENZ-FT-406076,Zacks,,,,0,0,b7e60f99-6997-453e-bee5-be56d569834d
2019-04-30T08:00:00.000+08:00,Eli Lilly and Company 2019 Q1 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4257970-eli-lilly-company-2019-q1-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,0,0,6cecc1ac-8802-458e-88e8-574d15d2bbcd
2019-04-30T08:00:00.000+08:00,Eli Lilly down 2% on Q1 miss and lowered revenue guidance,LLY,https://seekingalpha.com/news/3455995-eli-lilly-2-percent-q1-miss-lowered-revenue-guidance?source=partner_benzinga,Seeking Alpha,,,,0,0,60bec88a-93ae-4643-a0c3-369479367614
2019-04-30T08:00:00.000+08:00,"Eli Lilly EPS in-line, misses on revenue",LLY,https://seekingalpha.com/news/3455905-eli-lilly-eps-line-misses-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,b54c5d8a-b395-4a1e-a6db-30b25d2f6c7c
2019-04-29T08:00:00.000+08:00,"Market At New Highs, But Healthcare And Biotechs Feel The Heat",LLY,https://seekingalpha.com/article/4257727-market-new-highs-healthcare-biotechs-feel-heat?source=partner_benzinga,Seeking Alpha,,,,0,0,cfa59c88-0090-4972-bb7d-052b25565009
2019-04-29T08:00:00.000+08:00,New migraine meds face tough price talks with PBMs,LLY,https://seekingalpha.com/news/3455418-new-migraine-meds-face-tough-price-talks-pbms?source=partner_benzinga,Seeking Alpha,,,,0,0,9af5b223-1cfc-40e0-b0bd-0d6081e9b38d
2019-04-29T08:00:00.000+08:00,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice,LLY,http://www.zacks.com/stock/news/404799/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-BENZ-FT-404799,Zacks,,,,0,0,8fceba65-4725-4a4e-9ab8-8962367504d6
2019-04-29T08:00:00.000+08:00,"Market At New Highs, But Healthcare And Biotechs Feel The Heat",LLY,https://seekingalpha.com/article/4257727-market-new-highs-healthcare-biotechs-feel-heat?source=partner_benzinga,Seeking Alpha,,,,0,0,f3f3af4f-998a-4aa2-aea0-2ebed05b2632
2019-04-29T08:00:00.000+08:00,New migraine meds face tough price talks with PBMs,LLY,https://seekingalpha.com/news/3455418-new-migraine-meds-face-tough-price-talks-pbms?source=partner_benzinga,Seeking Alpha,,,,0,0,a7df06ee-23e6-4f0a-9a04-82a3cec355b3
2019-04-29T08:00:00.000+08:00,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice,LLY,http://www.zacks.com/stock/news/404799/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-BENZ-FT-404799,Zacks,,,,0,0,791b5c3f-7ff0-4069-8b42-915d4419635a
2019-04-28T08:00:00.000+08:00,5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates,LLY,http://www.zacks.com/stock/news/405274/5-drug-biotech-stocks-poised-to-beat-q1-earnings-estimates?cid=CS-BENZ-FT-405274,Zacks,,,,0,0,23d67de8-a112-47d9-9399-0f346f82c1cc
2019-04-28T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 74,LLY,https://seekingalpha.com/article/4257568-bulletproof-investing-performance-update-week-74?source=partner_benzinga,Seeking Alpha,,,,0,0,2791f916-0d75-438b-987c-1c89dbf6a552
2019-04-28T08:00:00.000+08:00,Week In Review: Eddingpharm To Pay $375 Million For 2 Lilly Antibiotics And A Suzhou Manufacturing Facility,LLY,https://seekingalpha.com/article/4257491-week-review-eddingpharm-pay-375-million-2-lilly-antibiotics-suzhou-manufacturing-facility?source=partner_benzinga,Seeking Alpha,,,,0,0,7d742c07-e5cf-4a7a-94e4-ad9e5be1a79f
2019-04-28T08:00:00.000+08:00,Summers Value Partners Q1 2019 Investor Letter,LLY,https://seekingalpha.com/article/4257456-summers-value-partners-q1-2019-investor-letter?source=partner_benzinga,Seeking Alpha,,,,0,0,5033de7f-7c7e-44ae-9925-db4d8ac39036
2019-04-28T08:00:00.000+08:00,5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates,LLY,http://www.zacks.com/stock/news/405274/5-drug-biotech-stocks-poised-to-beat-q1-earnings-estimates?cid=CS-BENZ-FT-405274,Zacks,,,,0,0,62f3967f-0bb4-434a-9720-63cad29cff05
2019-04-28T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 74,LLY,https://seekingalpha.com/article/4257568-bulletproof-investing-performance-update-week-74?source=partner_benzinga,Seeking Alpha,,,,0,0,58fb0ba9-e7c1-42dc-aed9-34e0728e0621
2019-04-28T08:00:00.000+08:00,Week In Review: Eddingpharm To Pay $375 Million For 2 Lilly Antibiotics And A Suzhou Manufacturing Facility,LLY,https://seekingalpha.com/article/4257491-week-review-eddingpharm-pay-375-million-2-lilly-antibiotics-suzhou-manufacturing-facility?source=partner_benzinga,Seeking Alpha,,,,0,0,720a90e1-99ed-453b-9d4e-a76283e0fc47
2019-04-28T08:00:00.000+08:00,Summers Value Partners Q1 2019 Investor Letter,LLY,https://seekingalpha.com/article/4257456-summers-value-partners-q1-2019-investor-letter?source=partner_benzinga,Seeking Alpha,,,,0,0,17cb6626-2e65-4171-a589-ac76df233a53
2019-04-27T08:00:00.000+08:00,Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility,LLY,https://www.benzinga.com/node/13612300,TalkMarkets,,,,0,0,2330b680-f422-48e0-9201-5b0ed90a9ef1
2019-04-27T08:00:00.000+08:00,Week In Review: Eddingpharm To Pay $375 Million For Two Lilly Antibiotics And A Suzhou Manufacturing Facility,LLY,https://www.benzinga.com/node/13612300,TalkMarkets,,,,0,0,9cd52f51-6dfb-498e-bffc-be7cb64bdebc
2019-04-26T08:00:00.000+08:00,Recommends Withdrawal Of Marketing Authorisation For Eli Lilly's Cancer Medicine Lartruvo,LLY,https://www.benzinga.com/general/biotech/19/04/13607710/recommends-withdrawal-of-marketing-authorisation-for-eli-lillys-cancer-medicine-lartruvo,Benzinga Newsdesk,,,,0,0,6f711054-c628-4447-bccd-b601bbf92354
2019-04-26T08:00:00.000+08:00,US Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/general/biotech/19/04/13607590/us-court-of-appeals-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Benzinga Newsdesk,,,,0,0,4664d86f-1f62-4e65-924a-07a4e32dd673
2019-04-26T08:00:00.000+08:00,"Arrow Financial Corp Buys Occidental Petroleum Corp, iShares National Muni Bond, Air Products ...",LLY,http://www.gurufocus.com/news/864119/arrow-financial-corp-buys-occidental-petroleum-corp-ishares-national-muni-bond-air-products--chemicals-inc-sells-goldman-sachs-group-inc-nvidia-corp-caterpillar-inc,GuruFocus,,,,0,0,da517471-31f6-463a-8028-6bb96aedecaa
2019-04-26T08:00:00.000+08:00,Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short,LLY,https://seekingalpha.com/article/4257146-biotech-news-recap-gilead-sciences-stellar-data-falls-short?source=partner_benzinga,Seeking Alpha,,,,0,0,24c29af7-9111-40da-b960-54e00e2a35ba
2019-04-26T08:00:00.000+08:00,Lilly prevails in Alimta patent appeal,LLY,https://seekingalpha.com/news/3455012-lilly-prevails-alimta-patent-appeal?source=partner_benzinga,Seeking Alpha,,,,0,0,66dbeeed-ce72-4a47-aabe-ca1d50584ec7
2019-04-26T08:00:00.000+08:00,European advisory group backs withdrawal of Lilly's Lartruvo,LLY,https://seekingalpha.com/news/3455006-european-advisory-group-backs-withdrawal-lillys-lartruvo?source=partner_benzinga,Seeking Alpha,,,,0,0,549e7525-fe92-4f12-9122-57d0c26bbde1
2019-04-26T08:00:00.000+08:00,"AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales",LLY,http://www.zacks.com/stock/news/404479/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales?cid=CS-BENZ-FT-404479,Zacks,,,,0,0,5d5c8d9e-03ef-45e7-925a-a173abaef5be
2019-04-26T08:00:00.000+08:00,Recommends Withdrawal Of Marketing Authorisation For Eli Lilly's Cancer Medicine Lartruvo,LLY,https://www.benzinga.com/general/biotech/19/04/13607710/recommends-withdrawal-of-marketing-authorisation-for-eli-lillys-cancer-medicine-lartruvo,Benzinga Newsdesk,,,,0,0,5b756f6a-18b3-4fec-8bf7-4c18b4539cbd
2019-04-26T08:00:00.000+08:00,US Court Of Appeals Rules In Favor Of Lilly In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/general/biotech/19/04/13607590/us-court-of-appeals-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Benzinga Newsdesk,,,,0,0,cfb40594-2295-4b3e-a2eb-ce3923fbca7f
2019-04-26T08:00:00.000+08:00,"Arrow Financial Corp Buys Occidental Petroleum Corp, iShares National Muni Bond, Air Products ...",LLY,http://www.gurufocus.com/news/864119/arrow-financial-corp-buys-occidental-petroleum-corp-ishares-national-muni-bond-air-products--chemicals-inc-sells-goldman-sachs-group-inc-nvidia-corp-caterpillar-inc,GuruFocus,,,,0,0,67599f54-8b7b-4bef-982e-66c275eb08ca
2019-04-26T08:00:00.000+08:00,Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short,LLY,https://seekingalpha.com/article/4257146-biotech-news-recap-gilead-sciences-stellar-data-falls-short?source=partner_benzinga,Seeking Alpha,,,,0,0,fbf3a492-3b41-4a1a-ae99-9282df0d7bcd
2019-04-26T08:00:00.000+08:00,Lilly prevails in Alimta patent appeal,LLY,https://seekingalpha.com/news/3455012-lilly-prevails-alimta-patent-appeal?source=partner_benzinga,Seeking Alpha,,,,0,0,8de56829-2192-4599-a5c5-06e61647d2e1
2019-04-26T08:00:00.000+08:00,European advisory group backs withdrawal of Lilly's Lartruvo,LLY,https://seekingalpha.com/news/3455006-european-advisory-group-backs-withdrawal-lillys-lartruvo?source=partner_benzinga,Seeking Alpha,,,,0,0,70277674-7a59-43b1-b7e9-2bed50b03654
2019-04-26T08:00:00.000+08:00,"AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales",LLY,http://www.zacks.com/stock/news/404479/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales?cid=CS-BENZ-FT-404479,Zacks,,,,0,0,77f417c2-9480-4742-be41-065a9a760ce9
2019-04-25T08:00:00.000+08:00,Lilly Prepares To Withdraw Lartruvo From Global Market,LLY,https://www.benzinga.com/general/biotech/19/04/13593927/lilly-prepares-to-withdraw-lartruvo-from-global-market,Benzinga Newsdesk,,,,0,0,fba0eded-fa80-4201-8df7-3e1b77067d17
2019-04-25T08:00:00.000+08:00,MannKind up 2% on new Afrezza data,LLY,https://seekingalpha.com/news/3454280-mannkind-2-percent-new-afrezza-data?source=partner_benzinga,Seeking Alpha,,,,0,0,91a69cd0-3b2b-45bc-8a77-fc08b4dc830a
2019-04-25T08:00:00.000+08:00,"Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y",LLY,http://www.zacks.com/stock/news/403595/bayer-bayry-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-BENZ-FT-403595,Zacks,,,,0,0,25736931-ff6c-46c6-9c7d-917cbef4d983
2019-04-25T08:00:00.000+08:00,Lilly pulling Lartruvo from market after failed late-stage study,LLY,https://seekingalpha.com/news/3454062-lilly-pulling-lartruvo-market-failed-late-stage-study?source=partner_benzinga,Seeking Alpha,,,,0,0,9f2249fa-31f0-462b-b17b-a82121bae42a
2019-04-25T08:00:00.000+08:00,Eli Lilly Receives Approval For Hard-To-Detect Inflammatory Arthritis,LLY,https://seekingalpha.com/article/4256557-eli-lilly-receives-approval-hard-detect-inflammatory-arthritis?source=partner_benzinga,Seeking Alpha,,,,0,0,5338b3ec-3f04-4592-930d-1c50bf764c0e
2019-04-25T08:00:00.000+08:00,Lilly Prepares To Withdraw Lartruvo From Global Market,LLY,https://www.benzinga.com/general/biotech/19/04/13593927/lilly-prepares-to-withdraw-lartruvo-from-global-market,Benzinga Newsdesk,,,,0,0,4aecdc24-feab-401c-9ac5-32df223e0b38
2019-04-25T08:00:00.000+08:00,MannKind up 2% on new Afrezza data,LLY,https://seekingalpha.com/news/3454280-mannkind-2-percent-new-afrezza-data?source=partner_benzinga,Seeking Alpha,,,,0,0,cd04faa2-d232-4e97-bef2-126736402db3
2019-04-25T08:00:00.000+08:00,"Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y",LLY,http://www.zacks.com/stock/news/403595/bayer-bayry-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-BENZ-FT-403595,Zacks,,,,0,0,88786305-9f47-46b8-aa74-934623b886d9
2019-04-25T08:00:00.000+08:00,Lilly pulling Lartruvo from market after failed late-stage study,LLY,https://seekingalpha.com/news/3454062-lilly-pulling-lartruvo-market-failed-late-stage-study?source=partner_benzinga,Seeking Alpha,,,,0,0,963f1860-abf9-497b-a05b-b5341265cf1f
2019-04-25T08:00:00.000+08:00,Eli Lilly Receives Approval For Hard-To-Detect Inflammatory Arthritis,LLY,https://seekingalpha.com/article/4256557-eli-lilly-receives-approval-hard-detect-inflammatory-arthritis?source=partner_benzinga,Seeking Alpha,,,,0,0,04f31510-521f-4028-bab4-659294887ca8
2019-04-24T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 24, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/04/13587104/benzingas-top-upgrades-downgrades-for-april-24-2019,Lisa Levin,,,,0,0,713597f9-6303-4715-be00-fb049ce03830
2019-04-24T08:00:00.000+08:00,Edward Jones Upgrades Eli Lilly and Company Common Stock to Buy,LLY,https://www.benzinga.com/news/19/04/13584536/edward-jones-upgrades-eli-lilly-and-company-common-stock-to-buy,Vick Meyer,,,,0,0,917a31d9-3614-4a9e-a42c-dc295bf52fa0
2019-04-24T08:00:00.000+08:00,Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity,LLY,https://seekingalpha.com/article/4256389-eli-lilly-looks-tap-potential-groundbreaking-technology-avidity?source=partner_benzinga,Seeking Alpha,,,,0,0,0de6cffa-4daa-4de0-b4d3-4d7ff6577653
2019-04-24T08:00:00.000+08:00,Needham likes Zimmer Biomet in premarket analyst action,LLY,https://seekingalpha.com/news/3453345-needham-likes-zimmer-biomet-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,b6939322-eea1-479c-9646-d1d144886ed4
2019-04-24T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 24, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/04/13587104/benzingas-top-upgrades-downgrades-for-april-24-2019,Lisa Levin,,,,0,0,5a7a2e80-f7ff-4874-a74b-55fef56c9d29
2019-04-24T08:00:00.000+08:00,Edward Jones Upgrades Eli Lilly and Company Common Stock to Buy,LLY,https://www.benzinga.com/news/19/04/13584536/edward-jones-upgrades-eli-lilly-and-company-common-stock-to-buy,Vick Meyer,,,,0,0,4c5c18f0-dcb7-4e3b-830b-fe7907a76db2
2019-04-24T08:00:00.000+08:00,Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity,LLY,https://seekingalpha.com/article/4256389-eli-lilly-looks-tap-potential-groundbreaking-technology-avidity?source=partner_benzinga,Seeking Alpha,,,,0,0,d6fbbcdb-a078-4890-ab25-587238441849
2019-04-24T08:00:00.000+08:00,Needham likes Zimmer Biomet in premarket analyst action,LLY,https://seekingalpha.com/news/3453345-needham-likes-zimmer-biomet-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,376d75a1-06d3-4f63-9f82-e45247619c8e
2019-04-23T08:00:00.000+08:00,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",LLY,https://www.benzinga.com/markets/wiim/19/04/13579798/shares-of-several-healthcare-stocks-are-trading-higher-in-a-potential-rebound-from-last-weeks-sellof,Benzinga Newsdesk,,,,0,0,ed0739ff-7d1f-40c7-966a-87774061b2fb
2019-04-23T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",LLY,https://www.benzinga.com/general/biotech/19/04/13575392/the-daily-biotech-pulse-fda-accepts-alders-migraine-drug-application-gritstone-offering-lillys-ch,Shanthi Rexaline,,,,0,0,ff8feee1-a136-4863-9ef7-faf8580169d3
2019-04-23T08:00:00.000+08:00,Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China for $375M,LLY,https://www.benzinga.com/news/19/04/13575956/lilly-announces-sale-of-legacy-antibiotics-brands-and-manufacturing-facility-in-china-for-375m,Charles Gross,,,,0,0,e21435e1-8b33-4c4c-b0e1-ab69985025d0
2019-04-23T08:00:00.000+08:00,Futures Tepid As Investors Await Earnings Jolt (Wall Street Breakfast Podcast),LLY,https://seekingalpha.com/article/4255866-futures-tepid-investors-await-earnings-jolt-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,0d5f53d4-9c42-4ffc-a693-6cf2ecb826b3
2019-04-23T08:00:00.000+08:00,Wall Street Breakfast: Futures Tepid As Investors Await Earnings Jolt,LLY,https://seekingalpha.com/article/4255863-wall-street-breakfast-futures-tepid-investors-await-earnings-jolt?source=partner_benzinga,Seeking Alpha,,,,0,0,2fbf2bd5-ba2a-48f5-88fc-0181879824a5
2019-04-23T08:00:00.000+08:00,"Lilly to sell two antibiotics, plant in China for $375M",LLY,https://seekingalpha.com/news/3452661-lilly-sell-two-antibiotics-plant-china-375m?source=partner_benzinga,Seeking Alpha,,,,0,0,6887a1dd-6e77-41e8-bccf-450bb58efa4a
2019-04-23T08:00:00.000+08:00,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",LLY,https://www.benzinga.com/markets/wiim/19/04/13579798/shares-of-several-healthcare-stocks-are-trading-higher-in-a-potential-rebound-from-last-weeks-sellof,Benzinga Newsdesk,,,,0,0,33752eb9-d6aa-4f33-a237-de64ec1fcb03
2019-04-23T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale",LLY,https://www.benzinga.com/general/biotech/19/04/13575392/the-daily-biotech-pulse-fda-accepts-alders-migraine-drug-application-gritstone-offering-lillys-ch,Shanthi Rexaline,,,,0,0,4ccf6d94-6c2f-4701-bd35-1d9c1989c252
2019-04-23T08:00:00.000+08:00,Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China for $375M,LLY,https://www.benzinga.com/news/19/04/13575956/lilly-announces-sale-of-legacy-antibiotics-brands-and-manufacturing-facility-in-china-for-375m,Charles Gross,,,,0,0,c60b0237-3110-4d32-bd87-28e470361d0d
2019-04-23T08:00:00.000+08:00,Futures Tepid As Investors Await Earnings Jolt (Wall Street Breakfast Podcast),LLY,https://seekingalpha.com/article/4255866-futures-tepid-investors-await-earnings-jolt-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,4a9f2bba-9210-4068-9bdb-d6e029777d2b
2019-04-23T08:00:00.000+08:00,Wall Street Breakfast: Futures Tepid As Investors Await Earnings Jolt,LLY,https://seekingalpha.com/article/4255863-wall-street-breakfast-futures-tepid-investors-await-earnings-jolt?source=partner_benzinga,Seeking Alpha,,,,0,0,618001e7-5004-49c2-95bc-ceb94acdaa57
2019-04-23T08:00:00.000+08:00,"Lilly to sell two antibiotics, plant in China for $375M",LLY,https://seekingalpha.com/news/3452661-lilly-sell-two-antibiotics-plant-china-375m?source=partner_benzinga,Seeking Alpha,,,,0,0,e2a74fd8-c417-4271-9610-03316e9fbcce
2019-04-22T08:00:00.000+08:00,"Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns",LLY,https://www.benzinga.com/general/biotech/19/04/13570340/eli-lilly-pfizers-non-opioid-painkiller-faces-safety-efficacy-concerns,Shanthi Rexaline,,,,0,0,24002e27-1945-4dbe-9d1f-e1620db4fd06
2019-04-22T08:00:00.000+08:00,"Pfizer, Eli Lilly Late Thurs. Announced Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis",LLY,https://www.benzinga.com/news/19/04/13570231/pfizer-eli-lilly-late-thurs-announced-top-line-results-from-long-term-phase-3-study-of-tanezumab-in,Benzinga Newsdesk,,,,0,0,71f1609e-cf3c-4ab8-8a53-07e9c6976869
2019-04-22T08:00:00.000+08:00,Eli Lilly Says its COAST-X Study of Taltz Met its Primary and Key Secondary Endpoints,LLY,https://www.benzinga.com/news/19/04/13569523/eli-lilly-says-its-coast-x-study-of-taltz-met-its-primary-and-key-secondary-endpoints,Benzinga Newsdesk,,,,0,0,ed3e5a8e-b6ee-4a62-8751-a2e510061464
2019-04-22T08:00:00.000+08:00,"Eli Lilly Announces Research and Licensing Collaboration with Avidity Biosciences to Pursue Therapeutics Targets Focused on Immunology, Eli Lilly to Pay $20M Upfront and Make a $15M Investment in Avidity",LLY,https://www.benzinga.com/news/19/04/13569477/eli-lilly-announces-research-and-licensing-collaboration-with-avidity-biosciences-to-pursue-therapeu,Benzinga Newsdesk,,,,0,0,55dcb5f8-eb7e-4473-b31c-2873cbce35b5
2019-04-22T08:00:00.000+08:00,"First National Bank Sioux Falls Buys Boeing Co, iShares MSCI EAFE, 'M Co, Sells Vectren Corp, ...",LLY,http://www.gurufocus.com/news/859663/first-national-bank-sioux-falls-buys-boeing-co-ishares-msci-eafe-3m-co-sells-vectren-corp-southern-co,GuruFocus,,,,0,0,7a736924-376d-42cf-9620-70e54c7a884f
2019-04-22T08:00:00.000+08:00,Biotech News Recap: Pressure On Shares Of Novartis Continues Following Zolgensma Patient Death,LLY,https://seekingalpha.com/article/4255742-biotech-news-recap-pressure-shares-novartis-continues-following-zolgensma-patient-death?source=partner_benzinga,Seeking Alpha,,,,0,0,62bac2ee-4a59-4c8b-a82d-bbbebda828a5
2019-04-22T08:00:00.000+08:00,Lilly's Taltz successful in late-stage study in axial skeleton arthritis,LLY,https://seekingalpha.com/news/3452281-lillys-taltz-successful-late-stage-study-axial-skeleton-arthritis?source=partner_benzinga,Seeking Alpha,,,,0,0,9dc74a21-617b-4572-b834-ff09f7df1ec6
2019-04-22T08:00:00.000+08:00,Lilly teams up with Avidity Bio to develop new medicines,LLY,https://seekingalpha.com/news/3452269-lilly-teams-avidity-bio-develop-new-medicines?source=partner_benzinga,Seeking Alpha,,,,0,0,7dd72451-27ab-4a2d-a849-b1b0ce9dd3e1
2019-04-22T08:00:00.000+08:00,"Eli Lilly-Pfizer's Non-Opioid Painkiller Faces Safety, Efficacy Concerns",LLY,https://www.benzinga.com/general/biotech/19/04/13570340/eli-lilly-pfizers-non-opioid-painkiller-faces-safety-efficacy-concerns,Shanthi Rexaline,,,,0,0,c3fc47b2-5080-4721-9974-9069cd8a551e
2019-04-22T08:00:00.000+08:00,"Pfizer, Eli Lilly Late Thurs. Announced Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis",LLY,https://www.benzinga.com/news/19/04/13570231/pfizer-eli-lilly-late-thurs-announced-top-line-results-from-long-term-phase-3-study-of-tanezumab-in,Benzinga Newsdesk,,,,0,0,92c7e19f-7e85-498b-971d-0f5d354962d7
2019-04-22T08:00:00.000+08:00,Eli Lilly Says its COAST-X Study of Taltz Met its Primary and Key Secondary Endpoints,LLY,https://www.benzinga.com/news/19/04/13569523/eli-lilly-says-its-coast-x-study-of-taltz-met-its-primary-and-key-secondary-endpoints,Benzinga Newsdesk,,,,0,0,25d68290-32d2-4cde-8b76-2578ab1b06a0
2019-04-22T08:00:00.000+08:00,"Eli Lilly Announces Research and Licensing Collaboration with Avidity Biosciences to Pursue Therapeutics Targets Focused on Immunology, Eli Lilly to Pay $20M Upfront and Make a $15M Investment in Avidity",LLY,https://www.benzinga.com/news/19/04/13569477/eli-lilly-announces-research-and-licensing-collaboration-with-avidity-biosciences-to-pursue-therapeu,Benzinga Newsdesk,,,,0,0,cd5f05f3-2821-4129-b7a1-365515508151
2019-04-22T08:00:00.000+08:00,"First National Bank Sioux Falls Buys Boeing Co, iShares MSCI EAFE, 'M Co, Sells Vectren Corp, ...",LLY,http://www.gurufocus.com/news/859663/first-national-bank-sioux-falls-buys-boeing-co-ishares-msci-eafe-3m-co-sells-vectren-corp-southern-co,GuruFocus,,,,0,0,335b7ef7-e7b8-4c6b-8f7c-72ed7be70a0d
2019-04-22T08:00:00.000+08:00,Biotech News Recap: Pressure On Shares Of Novartis Continues Following Zolgensma Patient Death,LLY,https://seekingalpha.com/article/4255742-biotech-news-recap-pressure-shares-novartis-continues-following-zolgensma-patient-death?source=partner_benzinga,Seeking Alpha,,,,0,0,1ec59378-f609-490b-b677-d8d2cf02716f
2019-04-22T08:00:00.000+08:00,Lilly's Taltz successful in late-stage study in axial skeleton arthritis,LLY,https://seekingalpha.com/news/3452281-lillys-taltz-successful-late-stage-study-axial-skeleton-arthritis?source=partner_benzinga,Seeking Alpha,,,,0,0,123e558d-ed0d-4aab-ae54-95f484cf020b
2019-04-22T08:00:00.000+08:00,Lilly teams up with Avidity Bio to develop new medicines,LLY,https://seekingalpha.com/news/3452269-lilly-teams-avidity-bio-develop-new-medicines?source=partner_benzinga,Seeking Alpha,,,,0,0,1ee42ad3-0ab0-4bad-90d5-d2f6d03ee7d7
2019-04-19T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 73,LLY,https://seekingalpha.com/article/4255427-bulletproof-investing-performance-update-week-73?source=partner_benzinga,Seeking Alpha,,,,0,0,996eea79-fa17-4022-a62c-f2b1f9e84cb2
2019-04-19T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 73,LLY,https://seekingalpha.com/article/4255427-bulletproof-investing-performance-update-week-73?source=partner_benzinga,Seeking Alpha,,,,0,0,a494f715-5f16-4157-b371-0692a34210d0
2019-04-18T08:00:00.000+08:00,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,LLY,https://www.benzinga.com/markets/wiim/19/04/13561029/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,,,,0,0,083df0fe-ea72-446b-8bba-268f08332dc0
2019-04-18T08:00:00.000+08:00,Lilly and Pfizer's tanezumab shows mixed results in late-stage osteoarthritis study,LLY,https://seekingalpha.com/news/3452164-lilly-pfizers-tanezumab-shows-mixed-results-late-stage-osteoarthritis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,1c764b9d-0b78-4dcc-abb8-3bb1a9c1796a
2019-04-18T08:00:00.000+08:00,Pfizer-Lilly painkiller in lower dose misses main goals in Phase 3 study,LLY,https://seekingalpha.com/news/3452158-pfizer-lilly-painkiller-lower-dose-misses-main-goals-phase-3-study?source=partner_benzinga,Seeking Alpha,,,,0,0,53b54ed0-504c-4e59-8a92-da882a3889ce
2019-04-18T08:00:00.000+08:00,Realty Income: Final Performance,LLY,https://seekingalpha.com/article/4255232-realty-income-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,a5ff07e9-a1ba-476b-bf0b-c53c2baef7ea
2019-04-18T08:00:00.000+08:00,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline,LLY,http://www.zacks.com/stock/news/386713/novo-nordisks-nvo-share-price-rises-ytd-on-strong-pipeline?cid=CS-BENZ-FT-386713,Zacks,,,,0,0,82d213f8-9f95-4bc2-a689-728a698c7fa8
2019-04-18T08:00:00.000+08:00,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline,LLY,http://www.zacks.com/stock/news/386713/novo-nordisks-nvo-share-price-rises-ytd-on-strong-pipeline?cid=CS-BENZ-FT-386713,Zacks,,,,0,0,eccc6048-26fe-44d7-bcaa-b95cedc4018a
2019-04-18T08:00:00.000+08:00,Is Healthcare Berning?,LLY,https://seekingalpha.com/article/4255169-healthcare-berning?source=partner_benzinga,Seeking Alpha,,,,0,0,89c76565-a52f-4556-884c-40f9ccb3d2e0
2019-04-18T08:00:00.000+08:00,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,LLY,https://www.benzinga.com/markets/wiim/19/04/13561029/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,,,,0,0,e3faab31-28bc-4bce-b3d0-8417cabdfb18
2019-04-18T08:00:00.000+08:00,Lilly and Pfizer's tanezumab shows mixed results in late-stage osteoarthritis study,LLY,https://seekingalpha.com/news/3452164-lilly-pfizers-tanezumab-shows-mixed-results-late-stage-osteoarthritis-study?source=partner_benzinga,Seeking Alpha,,,,0,0,4a0c427a-8d57-4494-b174-fb81ff3c3343
2019-04-18T08:00:00.000+08:00,Pfizer-Lilly painkiller in lower dose misses main goals in Phase 3 study,LLY,https://seekingalpha.com/news/3452158-pfizer-lilly-painkiller-lower-dose-misses-main-goals-phase-3-study?source=partner_benzinga,Seeking Alpha,,,,0,0,16b89fef-6601-46f5-8452-a6a036259826
2019-04-18T08:00:00.000+08:00,Realty Income: Final Performance,LLY,https://seekingalpha.com/article/4255232-realty-income-final-performance?source=partner_benzinga,Seeking Alpha,,,,0,0,d85be1ff-c39e-4468-88dd-259e9197ed40
2019-04-18T08:00:00.000+08:00,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline,LLY,http://www.zacks.com/stock/news/386713/novo-nordisks-nvo-share-price-rises-ytd-on-strong-pipeline?cid=CS-BENZ-FT-386713,Zacks,,,,0,0,71890491-f237-428e-86d4-18eea7354577
2019-04-18T08:00:00.000+08:00,Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline,LLY,http://www.zacks.com/stock/news/386713/novo-nordisks-nvo-share-price-rises-ytd-on-strong-pipeline?cid=CS-BENZ-FT-386713,Zacks,,,,0,0,e9b60844-d0ac-48b5-90e3-a1d59a1ded8f
2019-04-18T08:00:00.000+08:00,Is Healthcare Berning?,LLY,https://seekingalpha.com/article/4255169-healthcare-berning?source=partner_benzinga,Seeking Alpha,,,,0,0,39b46584-2248-469e-937c-238cd0dac340
2019-04-17T08:00:00.000+08:00,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,LLY,https://www.benzinga.com/markets/wiim/19/04/13552551/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,,,,0,0,5ef5052f-255e-450c-97f5-193f6e045f5c
2019-04-17T08:00:00.000+08:00,Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement,LLY,https://seekingalpha.com/article/4255101-johnson-and-johnson-looks-help-type-2-diabetes-patients-key-advancement?source=partner_benzinga,Seeking Alpha,,,,0,0,ac22a98b-ff6d-4323-b29e-31504c1d960f
2019-04-17T08:00:00.000+08:00,The Great Biotech Massacre As The Ghost Of Drug Pricing Past Return,LLY,https://www.benzinga.com/node/13556598,TalkMarkets,,,,0,0,4f5e5657-047c-4614-a62d-e330e616f8e3
2019-04-17T08:00:00.000+08:00,"Chesapeake Wealth Management Buys The Communication Services Select Sector SPDR Fund, Comcast ...",LLY,http://www.gurufocus.com/news/856567/chesapeake-wealth-management-buys-the-communication-services-select-sector-spdr-fund-comcast-corp-cocacola-co-sells-eog-resources-inc-cintas-corp-integrated-device-technology-inc,GuruFocus,,,,0,0,dfc86727-abdf-4c8c-be9c-6b6ba32cb073
2019-04-17T08:00:00.000+08:00,Drugmaker selloff intensifies on D.C. pricing headwinds,LLY,https://seekingalpha.com/news/3451536-drugmaker-selloff-intensifies-d-c-pricing-headwinds?source=partner_benzinga,Seeking Alpha,,,,0,0,048ce825-f82f-4c26-8614-7de185bdbba4
2019-04-17T08:00:00.000+08:00,Cortexyme Files For U.S. IPO,LLY,https://seekingalpha.com/article/4254979-cortexyme-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,e4d9b78d-3a60-4a1a-95ef-6a2c2a95f7ef
2019-04-17T08:00:00.000+08:00,Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.,LLY,https://www.benzinga.com/markets/wiim/19/04/13552551/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,,,,0,0,9292da54-3f7f-47e6-bd26-0cdafdbf29fa
2019-04-17T08:00:00.000+08:00,Johnson & Johnson Looks To Help Type 2 Diabetes Patients With Key Advancement,LLY,https://seekingalpha.com/article/4255101-johnson-and-johnson-looks-help-type-2-diabetes-patients-key-advancement?source=partner_benzinga,Seeking Alpha,,,,0,0,82fab57c-2d19-41c1-af47-eb0b5173d69f
2019-04-17T08:00:00.000+08:00,The Great Biotech Massacre As The Ghost Of Drug Pricing Past Return,LLY,https://www.benzinga.com/node/13556598,TalkMarkets,,,,0,0,fd5ea3a5-6af4-4f13-96d6-745c4988e7e2
2019-04-17T08:00:00.000+08:00,"Chesapeake Wealth Management Buys The Communication Services Select Sector SPDR Fund, Comcast ...",LLY,http://www.gurufocus.com/news/856567/chesapeake-wealth-management-buys-the-communication-services-select-sector-spdr-fund-comcast-corp-cocacola-co-sells-eog-resources-inc-cintas-corp-integrated-device-technology-inc,GuruFocus,,,,0,0,15e33378-1611-442b-984a-dba3b475273b
2019-04-17T08:00:00.000+08:00,Drugmaker selloff intensifies on D.C. pricing headwinds,LLY,https://seekingalpha.com/news/3451536-drugmaker-selloff-intensifies-d-c-pricing-headwinds?source=partner_benzinga,Seeking Alpha,,,,0,0,84e85d19-be25-4e5e-a1cb-19ddfb28d418
2019-04-17T08:00:00.000+08:00,Cortexyme Files For U.S. IPO,LLY,https://seekingalpha.com/article/4254979-cortexyme-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,eeee91f1-b87d-4414-be77-976ff67ba5af
2019-04-16T08:00:00.000+08:00,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,LLY,https://www.benzinga.com/markets/wiim/19/04/13547205/shares-of-several-drug-companies-are-trading-lower-weakness-may-be-tied-to-uncertainty-over-healthca,Benzinga Newsdesk,,,,0,0,ba2b7a46-80f1-4e0c-9151-b5b957ac0307
2019-04-16T08:00:00.000+08:00,Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales,LLY,http://www.zacks.com/stock/news/382384/radius-health-rdus-rallies-334-ytd-on-robust-tymlos-sales?cid=CS-BENZ-FT-382384,Zacks,,,,0,0,7d495813-e375-4375-a058-a1daba07d51e
2019-04-16T08:00:00.000+08:00,Johnson & Johnson's Legal Troubles Eat Into Earnings,LLY,http://www.gurufocus.com/news/855111/johnson--johnsons-legal-troubles-eat-into-earnings,GuruFocus,,,,0,0,7c9ed815-7baf-4b52-9405-0197dfa51550
2019-04-16T08:00:00.000+08:00,"Amgen prices Evenity at $1,825 per month",LLY,https://seekingalpha.com/news/3451100-amgen-prices-evenity-1825-per-month?source=partner_benzinga,Seeking Alpha,,,,0,0,f7d2298e-2833-443b-86b5-ed9329bda6ac
2019-04-16T08:00:00.000+08:00,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,LLY,https://www.benzinga.com/markets/wiim/19/04/13547205/shares-of-several-drug-companies-are-trading-lower-weakness-may-be-tied-to-uncertainty-over-healthca,Benzinga Newsdesk,,,,0,0,49c63b08-5b22-4a69-a6d0-8c18c2c4b0e2
2019-04-16T08:00:00.000+08:00,Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales,LLY,http://www.zacks.com/stock/news/382384/radius-health-rdus-rallies-334-ytd-on-robust-tymlos-sales?cid=CS-BENZ-FT-382384,Zacks,,,,0,0,a30f167b-3a05-4c86-83ee-5d4e40be7901
2019-04-16T08:00:00.000+08:00,Johnson & Johnson's Legal Troubles Eat Into Earnings,LLY,http://www.gurufocus.com/news/855111/johnson--johnsons-legal-troubles-eat-into-earnings,GuruFocus,,,,0,0,e630938f-325a-469c-b724-f7a19026af52
2019-04-16T08:00:00.000+08:00,"Amgen prices Evenity at $1,825 per month",LLY,https://seekingalpha.com/news/3451100-amgen-prices-evenity-1825-per-month?source=partner_benzinga,Seeking Alpha,,,,0,0,4dd1c2bc-a315-4845-ab07-e20bc38d64e8
2019-04-15T08:00:00.000+08:00,J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer,LLY,http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-BENZ-FT-380671,Zacks,,,,0,0,20cc3851-68b2-4aa0-8bd4-465fb091a538
2019-04-15T08:00:00.000+08:00,J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer,LLY,http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-BENZ-FT-380671,Zacks,,,,0,0,154a45ca-075e-4715-8049-73c17f7abcea
2019-04-12T08:00:00.000+08:00,"Jones Collombin Investment Counsel Inc Buys Eli Lilly and Co, Visa Inc, New Relic Inc, Sells ...",LLY,http://www.gurufocus.com/news/852818/jones-collombin-investment-counsel-inc-buys-eli-lilly-and-co-visa-inc-new-relic-inc-sells-pfizer-inc-brookfield-asset-management-inc-aon-plc,GuruFocus,,,,0,0,76810179-883b-4aff-adbf-032f1483a235
2019-04-12T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 72,LLY,https://seekingalpha.com/article/4254153-bulletproof-investing-performance-update-week-72?source=partner_benzinga,Seeking Alpha,,,,0,0,8d11c374-fa28-4a4a-be5c-66ace4cfc21c
2019-04-12T08:00:00.000+08:00,"Jones Collombin Investment Counsel Inc Buys Eli Lilly and Co, Visa Inc, New Relic Inc, Sells ...",LLY,http://www.gurufocus.com/news/852818/jones-collombin-investment-counsel-inc-buys-eli-lilly-and-co-visa-inc-new-relic-inc-sells-pfizer-inc-brookfield-asset-management-inc-aon-plc,GuruFocus,,,,0,0,7826dd1e-d56b-440c-a3dd-808bef213618
2019-04-12T08:00:00.000+08:00,Bulletproof Investing Performance Update: Week 72,LLY,https://seekingalpha.com/article/4254153-bulletproof-investing-performance-update-week-72?source=partner_benzinga,Seeking Alpha,,,,0,0,7ff987ab-ffbb-4fd5-b65f-11676c42f2af
2019-04-11T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 11, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/04/13522338/benzingas-top-upgrades-downgrades-for-april-11-2019,Lisa Levin,,,,0,0,1d1956b8-a452-4674-b2db-7f92592a3e20
2019-04-11T08:00:00.000+08:00,Guggenheim Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/19/04/13520931/guggenheim-downgrades-eli-lilly-to-neutral,Vick Meyer,,,,0,0,6a3e3952-77ec-48f3-93bf-fbac819933c0
2019-04-11T08:00:00.000+08:00,"AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come",LLY,https://seekingalpha.com/article/4254083-abbvies-psoriasis-drug-approved-japan-main-event-yet-come?source=partner_benzinga,Seeking Alpha,,,,0,0,850d249a-7301-42ff-b98f-9acdeb3ade8d
2019-04-11T08:00:00.000+08:00,Biotechnology Market on a Tear: 5 ETFs in Spotlight,LLY,http://www.zacks.com/stock/news/379335/biotechnology-market-on-a-tear-5-etfs-in-spotlight?cid=CS-BENZ-FT-379335,Zacks,,,,0,0,40384b6d-5bc5-43d1-aa0a-ce6c47b35b02
2019-04-11T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors",LLY,http://www.zacks.com/stock/news/379194/the-zacks-analyst-blog-highlights-eli-lilly-altria-becton-dickinson-t-mobile-and-general-motors?cid=CS-BENZ-FT-379194,Zacks,,,,0,0,5349fb96-a062-4cbc-8c9e-07ae6797a736
2019-04-11T08:00:00.000+08:00,This Is Why Stocks Are Poised To Surge Higher on April 11,LLY,https://www.benzinga.com/node/13522579,TalkMarkets,,,,0,0,46ef6f6f-d431-4773-8738-6fb342cb4777
2019-04-11T08:00:00.000+08:00,Stifel neutral on Incyte in premarket analyst action,LLY,https://seekingalpha.com/news/3449953-stifel-neutral-incyte-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,3440b7fb-9cc7-4af4-ae23-4fd76884163b
2019-04-11T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 11, 2019",LLY,https://www.benzinga.com/analyst-ratings/upgrades/19/04/13522338/benzingas-top-upgrades-downgrades-for-april-11-2019,Lisa Levin,,,,0,0,cb6098d2-24bc-4afb-91e3-b44fd0e51fbd
2019-04-11T08:00:00.000+08:00,Guggenheim Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/19/04/13520931/guggenheim-downgrades-eli-lilly-to-neutral,Vick Meyer,,,,0,0,ec8da821-6738-41fa-920d-b6d41fbfc056
2019-04-11T08:00:00.000+08:00,"AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come",LLY,https://seekingalpha.com/article/4254083-abbvies-psoriasis-drug-approved-japan-main-event-yet-come?source=partner_benzinga,Seeking Alpha,,,,0,0,3a9856d9-916f-49d2-bced-4c35a40caecb
2019-04-11T08:00:00.000+08:00,Biotechnology Market on a Tear: 5 ETFs in Spotlight,LLY,http://www.zacks.com/stock/news/379335/biotechnology-market-on-a-tear-5-etfs-in-spotlight?cid=CS-BENZ-FT-379335,Zacks,,,,0,0,8ee8d260-2935-45a9-8f88-fa1b9a3230bc
2019-04-11T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Altria, Becton, Dickinson, T-Mobile and General Motors",LLY,http://www.zacks.com/stock/news/379194/the-zacks-analyst-blog-highlights-eli-lilly-altria-becton-dickinson-t-mobile-and-general-motors?cid=CS-BENZ-FT-379194,Zacks,,,,0,0,f878be04-8f2d-4267-8028-077a8f6b79db
2019-04-11T08:00:00.000+08:00,This Is Why Stocks Are Poised To Surge Higher on April 11,LLY,https://www.benzinga.com/node/13522579,TalkMarkets,,,,0,0,2f6a96d3-4b2c-4d02-a312-ede808a6b9bf
2019-04-11T08:00:00.000+08:00,Stifel neutral on Incyte in premarket analyst action,LLY,https://seekingalpha.com/news/3449953-stifel-neutral-incyte-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,7e34bddd-3a1a-4626-af55-63321b2323d4
2019-04-10T08:00:00.000+08:00,"BKD Wealth Advisors, LLC Buys iShares S&P 5…… Growth, Eli Lilly and Co, Vanguard ...",LLY,http://www.gurufocus.com/news/845762/bkd-wealth-advisors-llc-buys-ishares-sp-500-growth-eli-lilly-and-co-vanguard-taxexempt-bond-sells-ishares-sp-500-value-ishares-national-muni-bond-ishares-core-us-aggregate-bond,GuruFocus,,,,0,0,733582bd-4c13-4ea4-b5d6-3e2c659b7e50
2019-04-10T08:00:00.000+08:00,"Top Stock Reports for Eli Lilly, Altria & Becton Dickinson",LLY,http://www.zacks.com/research-daily/376965/top-stock-reports-for-eli-lilly-altria-becton-dickinson?cid=CS-BENZ-FT-376965,Zacks,,,,0,0,96c2ff68-a2b7-4689-9be0-0e02145b2bef
2019-04-10T08:00:00.000+08:00,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice,LLY,http://www.zacks.com/stock/news/376711/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-BENZ-FT-376711,Zacks,,,,0,0,d90eae39-7b74-4607-ae22-a9828cf84ed3
2019-04-10T08:00:00.000+08:00,Managing Biotech Investing Risk With Jonathan Faison (Podcast),LLY,https://seekingalpha.com/article/4253247-managing-biotech-investing-risk-jonathan-faison-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,6e72b8a9-2b86-4aa0-b71f-55c4670a0ba5
2019-04-10T08:00:00.000+08:00,"BKD Wealth Advisors, LLC Buys iShares S&P 5…… Growth, Eli Lilly and Co, Vanguard ...",LLY,http://www.gurufocus.com/news/845762/bkd-wealth-advisors-llc-buys-ishares-sp-500-growth-eli-lilly-and-co-vanguard-taxexempt-bond-sells-ishares-sp-500-value-ishares-national-muni-bond-ishares-core-us-aggregate-bond,GuruFocus,,,,0,0,4d046266-a8e8-4e84-970b-abb3839208c3
2019-04-10T08:00:00.000+08:00,"Top Stock Reports for Eli Lilly, Altria & Becton Dickinson",LLY,http://www.zacks.com/research-daily/376965/top-stock-reports-for-eli-lilly-altria-becton-dickinson?cid=CS-BENZ-FT-376965,Zacks,,,,0,0,e8d24166-60dc-484a-a324-86b9f2c88537
2019-04-10T08:00:00.000+08:00,Looking for a Growth Stock? 3 Reasons Why Lilly (LLY) is a Solid Choice,LLY,http://www.zacks.com/stock/news/376711/looking-for-a-growth-stock-3-reasons-why-lilly-lly-is-a-solid-choice?cid=CS-BENZ-FT-376711,Zacks,,,,0,0,8a128102-de63-45c2-a706-9e7490f5d658
2019-04-10T08:00:00.000+08:00,Managing Biotech Investing Risk With Jonathan Faison (Podcast),LLY,https://seekingalpha.com/article/4253247-managing-biotech-investing-risk-jonathan-faison-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,36297146-2b4a-459b-a841-1b091d9fffa7
2019-04-09T08:00:00.000+08:00,Enbridge: Halftime Report,LLY,https://seekingalpha.com/article/4253528-enbridge-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,3ebae007-21f5-491b-8939-c1930ae79223
2019-04-09T08:00:00.000+08:00,Enbridge: Halftime Report,LLY,https://seekingalpha.com/article/4253528-enbridge-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,c2d0ff7b-ca73-4b03-9584-a376f1bdebad
2019-04-08T08:00:00.000+08:00,"Indiana Trust & Investment Management CO Buys Eli Lilly and Co, Amazon. ...",LLY,http://www.gurufocus.com/news/844171/indiana-trust--investment-management-co-buys-eli-lilly-and-co-amazoncom-inc-duke-energy-corp-sells-pnc-financial-services-group-inc-amgen-inc-bank-of-america-corporation,GuruFocus,,,,0,0,24794d95-ac08-4254-8795-f4d5557868ab
2019-04-08T08:00:00.000+08:00,"XR Securities LLC Buys VanEck Vectors Gold Miners, SPDR S&P 5……, VanEck Vectors Junior ...",LLY,http://www.gurufocus.com/news/844173/xr-securities-llc-buys-vaneck-vectors-gold-miners-spdr-sp-500-vaneck-vectors-junior-gold-miners-sells-johnson--johnson-ishares-china-largecap-ishares-msci-emerging-index-fund,GuruFocus,,,,0,0,07fb88a7-82a2-4899-9bbe-8cf0725fa12a
2019-04-08T08:00:00.000+08:00,"Indiana Trust & Investment Management CO Buys Eli Lilly and Co, Amazon. ...",LLY,http://www.gurufocus.com/news/844171/indiana-trust--investment-management-co-buys-eli-lilly-and-co-amazoncom-inc-duke-energy-corp-sells-pnc-financial-services-group-inc-amgen-inc-bank-of-america-corporation,GuruFocus,,,,0,0,33a0ec28-ea44-4314-a62a-d8859fdc2a95
2019-04-08T08:00:00.000+08:00,"XR Securities LLC Buys VanEck Vectors Gold Miners, SPDR S&P 5……, VanEck Vectors Junior ...",LLY,http://www.gurufocus.com/news/844173/xr-securities-llc-buys-vaneck-vectors-gold-miners-spdr-sp-500-vaneck-vectors-junior-gold-miners-sells-johnson--johnson-ishares-china-largecap-ishares-msci-emerging-index-fund,GuruFocus,,,,0,0,cae38717-1b8f-49cc-98fe-0e5219acc485
2019-04-07T08:00:00.000+08:00,Disney+ And Bank Majors Step Out (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4253136-disney-bank-majors-step-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,aad4e294-2051-49fa-bae9-12bbea5b472f
2019-04-07T08:00:00.000+08:00,Disney+ And Bank Majors Step Out (Stocks To Watch Podcast),LLY,https://seekingalpha.com/article/4253136-disney-bank-majors-step-stocks-watch-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,9fed7128-d10c-4c82-ba5e-36adb682b210
2019-04-06T08:00:00.000+08:00,Stocks To Watch: Disney+ And Bank Majors Step Out,LLY,https://seekingalpha.com/article/4253106-stocks-watch-disney-bank-majors-step?source=partner_benzinga,Seeking Alpha,,,,0,0,f93d138c-7eb3-4130-bcb3-fd915d301473
2019-04-06T08:00:00.000+08:00,Stocks To Watch: Disney+ And Bank Majors Step Out,LLY,https://seekingalpha.com/article/4253106-stocks-watch-disney-bank-majors-step?source=partner_benzinga,Seeking Alpha,,,,0,0,1ed9af16-cd75-4e65-9152-59ba3d413f4f
2019-04-05T08:00:00.000+08:00,Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men,LLY,http://www.zacks.com/stock/news/371728/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-BENZ-FT-371728,Zacks,,,,0,0,5d36720f-ae86-4f19-8355-f63b0c4f2e4b
2019-04-05T08:00:00.000+08:00,Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig,LLY,http://www.zacks.com/stock/news/371493/novartis-amgen-in-legal-dispute-over-migraine-drug-aimovig?cid=CS-BENZ-FT-371493,Zacks,,,,0,0,d3b3d651-57ab-4fff-83b0-2235341e2013
2019-04-05T08:00:00.000+08:00,Pfizer's Ibrance Gets FDA Approval for Breast Cancer in Men,LLY,http://www.zacks.com/stock/news/371728/pfizers-ibrance-gets-fda-approval-for-breast-cancer-in-men?cid=CS-BENZ-FT-371728,Zacks,,,,0,0,bd8e6cfe-f8fc-401d-9347-fa1869b5b80a
2019-04-05T08:00:00.000+08:00,Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig,LLY,http://www.zacks.com/stock/news/371493/novartis-amgen-in-legal-dispute-over-migraine-drug-aimovig?cid=CS-BENZ-FT-371493,Zacks,,,,0,0,f3dc4876-ceab-4614-b720-37c861d78118
2019-04-04T08:00:00.000+08:00,"Tibra Equities Europe Ltd Buys Union Pacific Corp, Walmart Inc, SPDR Select Sector Fund - ...",LLY,http://www.gurufocus.com/news/842745/tibra-equities-europe-ltd-buys-union-pacific-corp-walmart-inc-spdr-select-sector-fund--consumer-staples-sells-spdr-sp-oil--gas-explor--product-oracle-corp-apple-inc,GuruFocus,,,,0,0,bd1d944c-15c5-4d0e-a5f2-2b4de358b70f
2019-04-04T08:00:00.000+08:00,"Tibra Equities Europe Ltd Buys Union Pacific Corp, Walmart Inc, SPDR Select Sector Fund - ...",LLY,http://www.gurufocus.com/news/842745/tibra-equities-europe-ltd-buys-union-pacific-corp-walmart-inc-spdr-select-sector-fund--consumer-staples-sells-spdr-sp-oil--gas-explor--product-oracle-corp-apple-inc,GuruFocus,,,,0,0,0546e9d5-a6ea-4616-b77d-eebc9c0e6a52
2019-04-03T08:00:00.000+08:00,"Cox Capital Co LLC Buys American Tower Corp, Crown Castle International Corp, Community ...",LLY,http://www.gurufocus.com/news/842155/cox-capital-co-llc-buys-american-tower-corp-crown-castle-international-corp-community-healthcare-trust-inc-sells-abbott-laboratories-amdocs,GuruFocus,,,,0,0,28ab8d78-6882-426e-836d-cffc24246a2e
2019-04-03T08:00:00.000+08:00,Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003,LLY,http://www.zacks.com/stock/news/370084/alector-alec-initiates-phase-i-alzheimers-study-on-al003?cid=CS-BENZ-FT-370084,Zacks,,,,0,0,f7c9c888-8cdf-483f-9e42-c84d369231df
2019-04-03T08:00:00.000+08:00,"Cox Capital Co LLC Buys American Tower Corp, Crown Castle International Corp, Community ...",LLY,http://www.gurufocus.com/news/842155/cox-capital-co-llc-buys-american-tower-corp-crown-castle-international-corp-community-healthcare-trust-inc-sells-abbott-laboratories-amdocs,GuruFocus,,,,0,0,035c1f1a-4de4-45ce-8d4f-fc62771cf863
2019-04-03T08:00:00.000+08:00,Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003,LLY,http://www.zacks.com/stock/news/370084/alector-alec-initiates-phase-i-alzheimers-study-on-al003?cid=CS-BENZ-FT-370084,Zacks,,,,0,0,4361719c-60ed-4e60-bec4-dc8a747a15c4
2019-04-02T08:00:00.000+08:00,Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe,LLY,http://www.zacks.com/stock/news/369262/tevas-anti-cgrp-injection-ajovy-gets-approval-in-europe?cid=CS-BENZ-FT-369262,Zacks,,,,0,0,5eaab772-87fb-4964-8c76-2a7d478e1c03
2019-04-02T08:00:00.000+08:00,Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe,LLY,http://www.zacks.com/stock/news/369262/tevas-anti-cgrp-injection-ajovy-gets-approval-in-europe?cid=CS-BENZ-FT-369262,Zacks,,,,0,0,ab59f26c-0122-4d17-b574-32cd4eff003f
2019-04-01T08:00:00.000+08:00,Arteaus Sold its Royalty Interest on Future Global Net Sales of Eli Lilly's Emgality to Royalty Pharma for $260M,LLY,https://www.benzinga.com/news/19/04/13455989/arteaus-sold-its-royalty-interest-on-future-global-net-sales-of-eli-lillys-emgal,Charles Gross,,,,0,0,b08d872d-0cc4-4c84-8c5a-903b4ed5cf15
2019-04-01T08:00:00.000+08:00,3 Big Pharma Stocks to Add to Your Portfolio This April,LLY,http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-BENZ-FT-368171,Zacks,,,,0,0,6fc197e1-5760-4207-b5fb-50c703f5b975
2019-04-01T08:00:00.000+08:00,Arteaus Therapeutics sells Emgality royalty for $260M,LLY,https://seekingalpha.com/news/3447155-arteaus-therapeutics-sells-emgality-royalty-260m?source=partner_benzinga,Seeking Alpha,,,,0,0,bdf0e2ef-58e2-4db0-80b1-d34f16d2e7b8
2019-04-01T08:00:00.000+08:00,Arteaus Sold its Royalty Interest on Future Global Net Sales of Eli Lilly's Emgality to Royalty Pharma for $260M,LLY,https://www.benzinga.com/news/19/04/13455989/arteaus-sold-its-royalty-interest-on-future-global-net-sales-of-eli-lillys-emgal,Charles Gross,,,,0,0,a91e2ca5-9f4b-4336-aa78-459a63f018ef
2019-04-01T08:00:00.000+08:00,3 Big Pharma Stocks to Add to Your Portfolio This April,LLY,http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-BENZ-FT-368171,Zacks,,,,0,0,989c16d8-e45a-4f39-abaf-f7960458d140
2019-04-01T08:00:00.000+08:00,Arteaus Therapeutics sells Emgality royalty for $260M,LLY,https://seekingalpha.com/news/3447155-arteaus-therapeutics-sells-emgality-royalty-260m?source=partner_benzinga,Seeking Alpha,,,,0,0,2a7f290a-c4ba-4f5b-a2cf-aaee5692f3d7
2019-03-30T08:00:00.000+08:00,How To Retire: Don't Go To College,LLY,https://seekingalpha.com/article/4251934-retire-go-college?source=partner_benzinga,Seeking Alpha,,,,0,0,0d523e3d-3e50-404a-ac1e-d8530df3a469
2019-03-30T08:00:00.000+08:00,How To Retire: Don't Go To College,LLY,https://seekingalpha.com/article/4251934-retire-go-college?source=partner_benzinga,Seeking Alpha,,,,0,0,d6b274c1-b656-4d7b-b862-d2d4473c4949
2019-03-29T08:00:00.000+08:00,"Jim Cramer Advised His Viewers On Canopy Growth, DowDuPont And More",LLY,https://www.benzinga.com/media/19/03/13446672/jim-cramer-advised-his-viewers-on-canopy-growth-dowdupont-and-more,Craig Jones,,,,0,0,99b6fd65-47e4-4000-9e69-a5ff8bee9216
2019-03-29T08:00:00.000+08:00,"Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals",LLY,http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-BENZ-FT-367176,Zacks,,,,0,0,12189c6a-0e19-40e5-9e30-7dfe1740ec32
2019-03-29T08:00:00.000+08:00,Filgotinib worth as much as $6/share to Gilead - Leerink,LLY,https://seekingalpha.com/news/3446798-filgotinib-worth-much-6-share-gilead-leerink?source=partner_benzinga,Seeking Alpha,,,,0,0,32bcff87-883e-4392-b5b9-14cc54cfa45f
2019-03-29T08:00:00.000+08:00,"Jim Cramer Advised His Viewers On Canopy Growth, DowDuPont And More",LLY,https://www.benzinga.com/media/19/03/13446672/jim-cramer-advised-his-viewers-on-canopy-growth-dowdupont-and-more,Craig Jones,,,,0,0,1f0325d6-6a3d-4be3-be65-bbb0abc82868
2019-03-29T08:00:00.000+08:00,"Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals",LLY,http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-BENZ-FT-367176,Zacks,,,,0,0,b97bddf1-611b-4447-88b5-2fc9acfc8089
2019-03-29T08:00:00.000+08:00,Filgotinib worth as much as $6/share to Gilead - Leerink,LLY,https://seekingalpha.com/news/3446798-filgotinib-worth-much-6-share-gilead-leerink?source=partner_benzinga,Seeking Alpha,,,,0,0,d83903b4-aa86-4fe9-ac1c-d622222eeb0f
2019-03-27T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",LLY,https://www.benzinga.com/general/biotech/19/03/13429944/the-daily-biotech-pulse-fda-nod-for-novartis-jazz-positive-late-stage,Shanthi Rexaline,,,,0,0,41ec89f5-4051-4d0a-b069-f82c6f0565f8
2019-03-27T08:00:00.000+08:00,"Eli Lilly, EOG, McDonald's, Gold Miners ETF: 'Fast Money' Picks For March 27",LLY,https://www.benzinga.com/media/19/03/13429455/eli-lilly-eog-mcdonalds-gold-miners-etf-fast-money-picks-for-march-27,Craig Jones,,,,0,0,e1b125cb-b61b-4df7-8a98-e37bba23a95b
2019-03-27T08:00:00.000+08:00,5 Cancer-Fighting Stocks to Boost Portfolio Gains,LLY,http://www.zacks.com/stock/news/365746/5-cancer-fighting-stocks-to-boost-portfolio-gains?cid=CS-BENZ-FT-365746,Zacks,,,,0,0,a6bfeb83-6beb-45e2-97dd-e09b49fd386e
2019-03-27T08:00:00.000+08:00,Turning Point Therapeutics Files For U.S. IPO,LLY,https://seekingalpha.com/article/4251329-turning-point-therapeutics-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,80017bb5-da70-4099-b306-34fa808917bb
2019-03-27T08:00:00.000+08:00,Lilly (LLY) Signs New Immunology Deal With Private Biotech,LLY,http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-BENZ-FT-365638,Zacks,,,,0,0,9d844265-dd50-493f-9706-cdba508580d4
2019-03-27T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",LLY,https://www.benzinga.com/general/biotech/19/03/13429944/the-daily-biotech-pulse-fda-nod-for-novartis-jazz-positive-late-stage,Shanthi Rexaline,,,,0,0,b8e111b3-bfe5-4976-83e8-dbb31dc64113
2019-03-27T08:00:00.000+08:00,"Eli Lilly, EOG, McDonald's, Gold Miners ETF: 'Fast Money' Picks For March 27",LLY,https://www.benzinga.com/media/19/03/13429455/eli-lilly-eog-mcdonalds-gold-miners-etf-fast-money-picks-for-march-27,Craig Jones,,,,0,0,6bf6ac3a-b839-45cf-b9c9-a0d877e34d12
2019-03-27T08:00:00.000+08:00,5 Cancer-Fighting Stocks to Boost Portfolio Gains,LLY,http://www.zacks.com/stock/news/365746/5-cancer-fighting-stocks-to-boost-portfolio-gains?cid=CS-BENZ-FT-365746,Zacks,,,,0,0,67b2a8a4-3f21-418a-bc04-5bf909831af1
2019-03-27T08:00:00.000+08:00,Turning Point Therapeutics Files For U.S. IPO,LLY,https://seekingalpha.com/article/4251329-turning-point-therapeutics-files-u-s-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,b9006d4c-b900-4f10-82f0-dd7909c0eac6
2019-03-27T08:00:00.000+08:00,Lilly (LLY) Signs New Immunology Deal With Private Biotech,LLY,http://www.zacks.com/stock/news/365638/lilly-lly-signs-new-immunology-deal-with-private-biotech?cid=CS-BENZ-FT-365638,Zacks,,,,0,0,08154caf-daa0-4575-acf1-7d29a15501dd
2019-03-26T08:00:00.000+08:00,"Eli Lilly Announces Collaboration with ImmuNext to Develop Medicines for Autoimmune Diseases, Eli Lilly to Make a $40M Upfront Payment",LLY,https://www.benzinga.com/news/19/03/13427756/eli-lilly-announces-collaboration-with-immunext-to-develop-medicines-for-autoimm,Benzinga Newsdesk,,,,0,0,ac2ab862-8404-4657-b196-9e319fffae1a
2019-03-26T08:00:00.000+08:00,Lilly teams up with ImmuNext in autoimmune diseases,LLY,https://seekingalpha.com/news/3445892-lilly-teams-immunext-autoimmune-diseases?source=partner_benzinga,Seeking Alpha,,,,0,0,785d3913-5112-4515-ab40-5a98e6a2ea48
2019-03-26T08:00:00.000+08:00,Trump reaches across the aisle on drug prices,LLY,https://seekingalpha.com/news/3445775-trump-reaches-across-aisle-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,322978df-7b73-4a04-a10e-1ff2255f619c
2019-03-26T08:00:00.000+08:00,"Eli Lilly Announces Collaboration with ImmuNext to Develop Medicines for Autoimmune Diseases, Eli Lilly to Make a $40M Upfront Payment",LLY,https://www.benzinga.com/news/19/03/13427756/eli-lilly-announces-collaboration-with-immunext-to-develop-medicines-for-autoimm,Benzinga Newsdesk,,,,0,0,ac2bc55a-eee9-4ada-af1b-471c58c0c0ec
2019-03-26T08:00:00.000+08:00,Lilly teams up with ImmuNext in autoimmune diseases,LLY,https://seekingalpha.com/news/3445892-lilly-teams-immunext-autoimmune-diseases?source=partner_benzinga,Seeking Alpha,,,,0,0,331aec3a-09ce-4649-a326-3cb976495530
2019-03-26T08:00:00.000+08:00,Trump reaches across the aisle on drug prices,LLY,https://seekingalpha.com/news/3445775-trump-reaches-across-aisle-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,303f21d4-5fcc-4544-98df-d922f04fa0b2
2019-03-25T08:00:00.000+08:00,"Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash ...",LLY,http://www.gurufocus.com/news/836961/recent-analysis-shows-mastercard-halliburton-keysight-technologies-eli-lilly-wabash-national-and-regeneron-pharmaceuticals-market-influences--renewed-outlook-key-drivers-of-growth,GuruFocus,,,,0,0,b4aaa839-8e30-4def-be95-fe7870fe5267
2019-03-25T08:00:00.000+08:00,What Will Provide Gilead The Growth Needed For Multiple Expansion?,LLY,https://seekingalpha.com/article/4250764-will-provide-gilead-growth-needed-multiple-expansion?source=partner_benzinga,Seeking Alpha,,,,0,0,74647289-d4db-480d-8060-8b86b1603b54
2019-03-25T08:00:00.000+08:00,"Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash ...",LLY,http://www.gurufocus.com/news/836961/recent-analysis-shows-mastercard-halliburton-keysight-technologies-eli-lilly-wabash-national-and-regeneron-pharmaceuticals-market-influences--renewed-outlook-key-drivers-of-growth,GuruFocus,,,,0,0,c370aa03-a99d-44b5-a6e2-f80c3962ec16
2019-03-25T08:00:00.000+08:00,What Will Provide Gilead The Growth Needed For Multiple Expansion?,LLY,https://seekingalpha.com/article/4250764-will-provide-gilead-growth-needed-multiple-expansion?source=partner_benzinga,Seeking Alpha,,,,0,0,5b21a72b-a24e-4b05-b254-7fb08e834e52
2019-03-24T08:00:00.000+08:00,Lilly Says Net Price for Humalog Insulin Declines 8.1% from 2014-2018,LLY,https://www.benzinga.com/news/19/03/13413633/lilly-says-net-price-for-humalog-insulin-declines-8-1-from-2014-2018,Charles Gross,,,,0,0,dd6bfbf3-2927-48a2-8e40-6995d3a6fa23
2019-03-24T08:00:00.000+08:00,Lilly Says Net Price for Humalog Insulin Declines 8.1% from 2014-2018,LLY,https://www.benzinga.com/news/19/03/13413633/lilly-says-net-price-for-humalog-insulin-declines-8-1-from-2014-2018,Charles Gross,,,,0,0,8c75000c-ca89-4342-a54e-470753a3876a
2019-03-22T08:00:00.000+08:00,Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know,LLY,http://www.zacks.com/stock/news/363545/eli-lilly-lly-stock-moves-001-what-you-should-know?cid=CS-BENZ-FT-363545,Zacks,,,,0,0,68aeab86-fe0a-4cef-948d-8f1202296b1b
2019-03-22T08:00:00.000+08:00,Bull of the Day: DexCom (DXCM),LLY,http://www.zacks.com/commentary/362906/bull-of-the-day-dexcom-dxcm?cid=CS-BENZ-FT-362906,Zacks,,,,0,0,05f12569-8711-4378-8857-9911626ddc79
2019-03-22T08:00:00.000+08:00,Eli Lilly (LLY) Stock Moves -0.01%: What You Should Know,LLY,http://www.zacks.com/stock/news/363545/eli-lilly-lly-stock-moves-001-what-you-should-know?cid=CS-BENZ-FT-363545,Zacks,,,,0,0,dc38d5aa-9827-4b2a-98c6-d09b777a63a6
2019-03-22T08:00:00.000+08:00,Bull of the Day: DexCom (DXCM),LLY,http://www.zacks.com/commentary/362906/bull-of-the-day-dexcom-dxcm?cid=CS-BENZ-FT-362906,Zacks,,,,0,0,52058c69-ece7-4e19-a2e2-78c188d4766a
2019-03-20T08:00:00.000+08:00,"National Comprehensive Cancer Network Announces Its Oncology Research Program, Eli Lilly To Take On 6 Projects Aimed To Improve Delivery Of Gastric, Gastroesophageal Junction Cancer Care In US",LLY,https://www.benzinga.com/news/19/03/13393886/national-comprehensive-cancer-network-announces-its-oncology-research-program-el,Benzinga Newsdesk,,,,0,0,81099208-cb75-4dc6-aa31-b0aeba664838
2019-03-20T08:00:00.000+08:00,"National Comprehensive Cancer Network Announces Its Oncology Research Program, Eli Lilly To Take On 6 Projects Aimed To Improve Delivery Of Gastric, Gastroesophageal Junction Cancer Care In US",LLY,https://www.benzinga.com/news/19/03/13393886/national-comprehensive-cancer-network-announces-its-oncology-research-program-el,Benzinga Newsdesk,,,,0,0,07648fc7-6ffb-4ed5-b9ce-ef3686b85455
2019-03-19T08:00:00.000+08:00,IPO Update: Precision BioSciences Readies Plan For IPO,LLY,https://seekingalpha.com/article/4249820-ipo-update-precision-biosciences-readies-plan-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,2c460d00-ce83-4c22-add5-a29abec3afbb
2019-03-19T08:00:00.000+08:00,Why The Future Looks Bright For Incyte Pharmaceuticals,LLY,http://www.investors.com/stock-lists/stock-spotlight/top-stocks-incyte-pharmaceuticals-biotech-sector/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,c8ffedd5-bd98-44c7-ab55-d5f25c10aabd
2019-03-19T08:00:00.000+08:00,IPO Update: Precision BioSciences Readies Plan For IPO,LLY,https://seekingalpha.com/article/4249820-ipo-update-precision-biosciences-readies-plan-ipo?source=partner_benzinga,Seeking Alpha,,,,0,0,ee24bf19-74c8-4aab-a57f-eb6470660db8
2019-03-19T08:00:00.000+08:00,Why The Future Looks Bright For Incyte Pharmaceuticals,LLY,http://www.investors.com/stock-lists/stock-spotlight/top-stocks-incyte-pharmaceuticals-biotech-sector/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,165c9b45-6bf1-449b-a73c-706169b5ca21
2019-03-15T08:00:00.000+08:00,Microsoft Portfolio: Halftime Report,LLY,https://seekingalpha.com/article/4249101-microsoft-portfolio-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,5b3647d1-7dce-4ee0-a2b2-ff17ed69207c
2019-03-15T08:00:00.000+08:00,"Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others",LLY,http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-BENZ-FT-359854,Zacks,,,,0,0,dae71423-7cb2-4843-80e1-51030da1cd47
2019-03-15T08:00:00.000+08:00,Microsoft Portfolio: Halftime Report,LLY,https://seekingalpha.com/article/4249101-microsoft-portfolio-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,55779bcd-2a4f-4211-aca1-72fcda965550
2019-03-15T08:00:00.000+08:00,"Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others",LLY,http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-BENZ-FT-359854,Zacks,,,,0,0,d1d496ff-ab0a-4943-b2d1-61294db1fb44
2019-03-14T08:00:00.000+08:00,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering",LLY,https://www.benzinga.com/general/biotech/19/03/13357435/the-daily-biotech-pulse-arsanis-completes-x4-merger-ec-nod-for-roche-,Shanthi Rexaline,,,,0,0,938d0fd2-0e01-40eb-ac56-ec05ba82704b
2019-03-14T08:00:00.000+08:00,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering",LLY,https://www.benzinga.com/general/biotech/19/03/13357435/the-daily-biotech-pulse-arsanis-completes-x4-merger-ec-nod-for-roche-,Shanthi Rexaline,,,,0,0,9ef8c015-68f6-4666-898e-2c417c12c6e8
2019-03-13T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, March 13",LLY,https://www.benzinga.com/node/13353793,TalkMarkets,,,,0,0,0d5105d2-c4bd-4a7e-b723-795106f39bfb
2019-03-13T08:00:00.000+08:00,Lilly's Cyramza Successful in Phase III First-Line NSCLC Study,LLY,http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-BENZ-FT-359294,Zacks,,,,0,0,9fcb9d8e-12d1-4412-b3c2-e9680726cc55
2019-03-13T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, March 13",LLY,https://www.benzinga.com/node/13353793,TalkMarkets,,,,0,0,75db1b78-dfdf-41d0-be05-e0aff5b3a6f7
2019-03-13T08:00:00.000+08:00,Lilly's Cyramza Successful in Phase III First-Line NSCLC Study,LLY,http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-BENZ-FT-359294,Zacks,,,,0,0,fd350384-f0d5-49bb-867a-3d475abcb6f9
2019-03-12T08:00:00.000+08:00,"Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/03/13344113/eli-lilly-could-sustain-industry-leading-growth-says-bu,Priya Nigam,,,,0,0,0b410086-e765-40e4-8f1e-a06ff0a75850
2019-03-12T08:00:00.000+08:00,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",LLY,https://www.benzinga.com/general/biotech/19/03/13341010/the-daily-biotech-pulse-zafgen-wont-file-ind-for-metabolic-disorder-d,Shanthi Rexaline,,,,0,0,a1fbf9cb-f0ab-4a4f-853e-d4b1e46d4e30
2019-03-12T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint In Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/general/biotech/19/03/13341449/lilly-announces-cyramza-phase-3-relay-trial-met-primary-endpoint-in-p,Benzinga Newsdesk,,,,0,0,df9fed98-9bd9-4e2d-9930-767957856c4a
2019-03-12T08:00:00.000+08:00,Eli Lilly (LLY) Flat As Market Gains: What You Should Know,LLY,http://www.zacks.com/stock/news/359060/eli-lilly-lly-flat-as-market-gains-what-you-should-know?cid=CS-BENZ-FT-359060,Zacks,,,,0,0,a2ef71c3-bb42-41fe-9e17-61bbf7094f53
2019-03-12T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, March 12",LLY,https://www.benzinga.com/node/13347950,TalkMarkets,,,,0,0,97419c27-799b-4fe1-85e9-92593661cbad
2019-03-12T08:00:00.000+08:00,Trump 2020 drug pricing initiatives - part 2,LLY,https://seekingalpha.com/news/3441977-trump-2020-drug-pricing-initiatives-part-2?source=partner_benzinga,Seeking Alpha,,,,0,0,66c78cfc-89f3-49a8-a147-9fe15c6e494d
2019-03-12T08:00:00.000+08:00,Trump aiming to rein in drug cost with range of proposals,LLY,https://seekingalpha.com/news/3441957-trump-aiming-rein-drug-cost-range-proposals?source=partner_benzinga,Seeking Alpha,,,,0,0,e5f5df5c-c903-46b5-9328-a297ca9eab50
2019-03-12T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, March 12",LLY,https://www.benzinga.com/node/13345182,TalkMarkets,,,,0,0,13d08ed8-58b4-4944-8ec2-6c9d92d0ec20
2019-03-12T08:00:00.000+08:00,Allergan Announces FDA Acceptance of Migraine Candidate NDA,LLY,http://www.zacks.com/stock/news/358972/allergan-announces-fda-acceptance-of-migraine-candidate-nda?cid=CS-BENZ-FT-358972,Zacks,,,,0,0,cf480975-a7b9-403b-a4cb-cd6cad64efe0
2019-03-12T08:00:00.000+08:00,Lilly's Cyramza shows positive effect in first-line lung cancer,LLY,https://seekingalpha.com/news/3441763-lillys-cyramza-shows-positive-effect-first-line-lung-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,b27f5e11-a6ce-4f85-bef6-414c495441a7
2019-03-12T08:00:00.000+08:00,"Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/03/13344113/eli-lilly-could-sustain-industry-leading-growth-says-bu,Priya Nigam,,,,0,0,cc4fa26c-577b-487e-b399-cdd99c9ccc0c
2019-03-12T08:00:00.000+08:00,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",LLY,https://www.benzinga.com/general/biotech/19/03/13341010/the-daily-biotech-pulse-zafgen-wont-file-ind-for-metabolic-disorder-d,Shanthi Rexaline,,,,0,0,51811894-1352-4136-94a5-c2a3e50a7ee1
2019-03-12T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint In Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer,LLY,https://www.benzinga.com/general/biotech/19/03/13341449/lilly-announces-cyramza-phase-3-relay-trial-met-primary-endpoint-in-p,Benzinga Newsdesk,,,,0,0,d7d42114-399e-4c6a-bd2e-fedb54d240c9
2019-03-12T08:00:00.000+08:00,Eli Lilly (LLY) Flat As Market Gains: What You Should Know,LLY,http://www.zacks.com/stock/news/359060/eli-lilly-lly-flat-as-market-gains-what-you-should-know?cid=CS-BENZ-FT-359060,Zacks,,,,0,0,9a11998e-220c-465d-903d-e84173e63e5f
2019-03-12T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, March 12",LLY,https://www.benzinga.com/node/13347950,TalkMarkets,,,,0,0,22b030c1-2a05-440f-9167-2fc9304abc84
2019-03-12T08:00:00.000+08:00,Trump 2020 drug pricing initiatives - part 2,LLY,https://seekingalpha.com/news/3441977-trump-2020-drug-pricing-initiatives-part-2?source=partner_benzinga,Seeking Alpha,,,,0,0,3423529c-fc33-4b05-a871-47e7e2758976
2019-03-12T08:00:00.000+08:00,Trump aiming to rein in drug cost with range of proposals,LLY,https://seekingalpha.com/news/3441957-trump-aiming-rein-drug-cost-range-proposals?source=partner_benzinga,Seeking Alpha,,,,0,0,c2d9d56c-ecd1-4306-b09b-2ea9cf16a5c4
2019-03-12T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, March 12",LLY,https://www.benzinga.com/node/13345182,TalkMarkets,,,,0,0,0ddbb2b2-25a3-43e2-88fa-7f9531b722f3
2019-03-12T08:00:00.000+08:00,Allergan Announces FDA Acceptance of Migraine Candidate NDA,LLY,http://www.zacks.com/stock/news/358972/allergan-announces-fda-acceptance-of-migraine-candidate-nda?cid=CS-BENZ-FT-358972,Zacks,,,,0,0,1105fab1-f735-42d9-af51-92d9cb14526f
2019-03-12T08:00:00.000+08:00,Lilly's Cyramza shows positive effect in first-line lung cancer,LLY,https://seekingalpha.com/news/3441763-lillys-cyramza-shows-positive-effect-first-line-lung-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,a99d9abd-e0df-4c72-84c0-5d7000a514eb
2019-03-11T08:00:00.000+08:00,Elanco Animal Health Begins Trading After Eli Lilly Split,LLY,https://www.benzinga.com/news/19/03/13335982/elanco-animal-health-begins-trading-after-eli-lilly-split,Jayson Derrick,,,,0,0,e66303a7-4725-4e97-8f68-aaa3a4008f8e
2019-03-11T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents at Cowen and Company 39th Annual Health Care Conference (Transcript),LLY,https://seekingalpha.com/article/4247895-eli-lilly-company-lly-presents-cowen-company-39th-annual-health-care-conference-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,0750e03f-7206-4b37-85cc-95579ca3d128
2019-03-11T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, March 11",LLY,https://www.benzinga.com/node/13339349,TalkMarkets,,,,0,0,838fc721-ee6d-43d0-9ce5-3b6d3e3c16b1
2019-03-11T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 11",LLY,https://www.benzinga.com/node/13336924,TalkMarkets,,,,0,0,bfa1bd0f-1fc1-4e5e-96f9-1c61dde26b30
2019-03-11T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 11",LLY,https://www.benzinga.com/node/13336925,TalkMarkets,,,,0,0,23bbcb79-c59d-4278-9232-fc7949c686a3
2019-03-11T08:00:00.000+08:00,Elanco Animal Health Begins Trading After Eli Lilly Split,LLY,https://www.benzinga.com/news/19/03/13335982/elanco-animal-health-begins-trading-after-eli-lilly-split,Jayson Derrick,,,,0,0,d6c208d7-1dbf-4752-9978-39733d511466
2019-03-11T08:00:00.000+08:00,Eli Lilly and Company (LLY) Presents at Cowen and Company 39th Annual Health Care Conference (Transcript),LLY,https://seekingalpha.com/article/4247895-eli-lilly-company-lly-presents-cowen-company-39th-annual-health-care-conference-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,09e108d3-d7c0-409e-a5a0-fac7e32bbcb6
2019-03-11T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, March 11",LLY,https://www.benzinga.com/node/13339349,TalkMarkets,,,,0,0,4a42ab5e-d441-4ad3-b4d1-b40e6442163c
2019-03-11T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 11",LLY,https://www.benzinga.com/node/13336924,TalkMarkets,,,,0,0,f64f91d2-55dc-4e2f-b88b-6084be051d4e
2019-03-11T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 11",LLY,https://www.benzinga.com/node/13336925,TalkMarkets,,,,0,0,71d6b136-690a-4158-953b-298f6615fe75
2019-03-08T08:00:00.000+08:00,"Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs",LLY,http://www.zacks.com/stock/news/358431/pharma-stock-roundup-fda-oks-jj-antidepressant-chmp-recommends-several-drugs?cid=CS-BENZ-FT-358431,Zacks,,,,0,0,8969de70-f39f-4970-bd93-50f70e6aef7c
2019-03-08T08:00:00.000+08:00,"Biotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review",LLY,https://seekingalpha.com/article/4247372-biotech-analysis-central-pharma-news-evokes-mishap-immunogens-struggle-eli-lillys-priority?source=partner_benzinga,Seeking Alpha,,,,0,0,3fc159a9-f0bd-4ed2-b3a5-7eb4382dc1ea
2019-03-08T08:00:00.000+08:00,"Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat",LLY,http://www.zacks.com/stock/news/358423/celldex-cldx-q4-loss-narrower-than-expected-sales-beat?cid=CS-BENZ-FT-358423,Zacks,,,,0,0,371dd647-8f8c-49a0-8f8f-971dc2ebc585
2019-03-08T08:00:00.000+08:00,Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?,LLY,http://www.zacks.com/stock/news/358352/lilly-lly-up-75-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-358352,Zacks,,,,0,0,7958cce7-23ff-45fb-b178-4d8992142c65
2019-03-08T08:00:00.000+08:00,"Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs",LLY,http://www.zacks.com/stock/news/358431/pharma-stock-roundup-fda-oks-jj-antidepressant-chmp-recommends-several-drugs?cid=CS-BENZ-FT-358431,Zacks,,,,0,0,c0881b9e-6f51-49e1-80ff-6e50598b2ffe
2019-03-08T08:00:00.000+08:00,"Biotech Analysis Central Pharma News: Evoke's Mishap, ImmunoGen's Struggle, Eli Lilly's Priority Review",LLY,https://seekingalpha.com/article/4247372-biotech-analysis-central-pharma-news-evokes-mishap-immunogens-struggle-eli-lillys-priority?source=partner_benzinga,Seeking Alpha,,,,0,0,22269bdf-9b46-49fd-a33b-44787bf65221
2019-03-08T08:00:00.000+08:00,"Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat",LLY,http://www.zacks.com/stock/news/358423/celldex-cldx-q4-loss-narrower-than-expected-sales-beat?cid=CS-BENZ-FT-358423,Zacks,,,,0,0,b65708cd-3832-4795-ae70-c5168dae1b01
2019-03-08T08:00:00.000+08:00,Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?,LLY,http://www.zacks.com/stock/news/358352/lilly-lly-up-75-since-last-earnings-report-can-it-continue?cid=CS-BENZ-FT-358352,Zacks,,,,0,0,a9823a92-dc8c-4d23-9d36-637bb007757f
2019-03-07T08:00:00.000+08:00,Eli Lilly Reports Final Exchange Ratio OF 4.5121 Shares For Elanco,LLY,https://www.benzinga.com/news/19/03/13316398/eli-lilly-reports-final-exchange-ratio-of-4-5121-shares-for-elanco,Benzinga Newsdesk,,,,0,0,907f28c0-ad20-4440-954f-db4ea619ec30
2019-03-07T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, March 7",LLY,https://www.benzinga.com/node/13323125,TalkMarkets,,,,0,0,e09c2383-69dd-45a4-9b8f-dda3102628bc
2019-03-07T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, March 7",LLY,https://www.benzinga.com/node/13320531,TalkMarkets,,,,0,0,6ef5a835-5a65-42ad-8ab4-7992c99db6a5
2019-03-07T08:00:00.000+08:00,Xeris: Looking For Entry Before PDUFA,LLY,https://seekingalpha.com/article/4246895-xeris-looking-entry-pdufa?source=partner_benzinga,Seeking Alpha,,,,0,0,68c02207-689c-4f81-b4bb-00a4998abef6
2019-03-07T08:00:00.000+08:00,"Allergan's Depression Candidate Fails in Studies, Stock Down",LLY,http://www.zacks.com/stock/news/358070/allergans-depression-candidate-fails-in-studies-stock-down?cid=CS-BENZ-FT-358070,Zacks,,,,0,0,4f2d6d4a-cc22-49cb-8be9-63cb40f5c941
2019-03-07T08:00:00.000+08:00,Lilly announces final exchange offering for Elanco shares,LLY,https://seekingalpha.com/news/3440638-lilly-announces-final-exchange-offering-elanco-shares?source=partner_benzinga,Seeking Alpha,,,,0,0,71e5f438-5cfb-4e25-a597-b398702eead0
2019-03-07T08:00:00.000+08:00,Eli Lilly Reports Final Exchange Ratio OF 4.5121 Shares For Elanco,LLY,https://www.benzinga.com/news/19/03/13316398/eli-lilly-reports-final-exchange-ratio-of-4-5121-shares-for-elanco,Benzinga Newsdesk,,,,0,0,95d2b40e-034f-4036-9900-a72b7f015449
2019-03-07T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, March 7",LLY,https://www.benzinga.com/node/13323125,TalkMarkets,,,,0,0,2192e835-e9fd-4316-af0d-85f57a02c40b
2019-03-07T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, March 7",LLY,https://www.benzinga.com/node/13320531,TalkMarkets,,,,0,0,4d7b67f4-6bcb-4057-8758-296ed1729d23
2019-03-07T08:00:00.000+08:00,Xeris: Looking For Entry Before PDUFA,LLY,https://seekingalpha.com/article/4246895-xeris-looking-entry-pdufa?source=partner_benzinga,Seeking Alpha,,,,0,0,c7f1fc81-1aee-4b42-917c-6282fb529caf
2019-03-07T08:00:00.000+08:00,"Allergan's Depression Candidate Fails in Studies, Stock Down",LLY,http://www.zacks.com/stock/news/358070/allergans-depression-candidate-fails-in-studies-stock-down?cid=CS-BENZ-FT-358070,Zacks,,,,0,0,32c94a1a-0263-4312-990c-6975ea4de346
2019-03-07T08:00:00.000+08:00,Lilly announces final exchange offering for Elanco shares,LLY,https://seekingalpha.com/news/3440638-lilly-announces-final-exchange-offering-elanco-shares?source=partner_benzinga,Seeking Alpha,,,,0,0,1df806b2-1e1b-45e6-b434-32d05c265a02
2019-03-06T08:00:00.000+08:00,"Cigna Says In Discussions With Lilly About Humalog Authorized Alternative, And If The Net Cost Is Lowest For Plans, Will Add It To Flex Formulary",LLY,https://www.benzinga.com/general/health-care/19/03/13312083/cigna-says-in-discussions-with-lilly-about-humalog-authorized-alt,Benzinga Newsdesk,,,,0,0,a183df5a-a503-4dec-a840-4c5dfc69f6b1
2019-03-06T08:00:00.000+08:00,FDA Approves Major Novel Depression Drug For First Time In 3 Decades,LLY,https://www.benzinga.com/general/biotech/19/03/13309108/fda-approves-major-novel-depression-drug-for-first-time-in-3-decades,Shanthi Rexaline,,,,0,0,528785d9-af95-4495-beab-d7a0079c4a83
2019-03-06T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, March 6",LLY,https://www.benzinga.com/node/13313973,TalkMarkets,,,,0,0,c4282884-51c5-4a3e-b0e2-f4dd40770ab1
2019-03-06T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, March 6",LLY,https://www.benzinga.com/node/13311573,TalkMarkets,,,,0,0,a584e7da-56f8-4d16-98c6-17f38e4f07b6
2019-03-06T08:00:00.000+08:00,J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression,LLY,http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-BENZ-FT-357836,Zacks,,,,0,0,5a129afe-264b-45bd-a433-756a30b28f2d
2019-03-06T08:00:00.000+08:00,"Cigna Says In Discussions With Lilly About Humalog Authorized Alternative, And If The Net Cost Is Lowest For Plans, Will Add It To Flex Formulary",LLY,https://www.benzinga.com/general/health-care/19/03/13312083/cigna-says-in-discussions-with-lilly-about-humalog-authorized-alt,Benzinga Newsdesk,,,,0,0,948123bc-da6e-4caa-a295-43c29c7344e7
2019-03-06T08:00:00.000+08:00,FDA Approves Major Novel Depression Drug For First Time In 3 Decades,LLY,https://www.benzinga.com/general/biotech/19/03/13309108/fda-approves-major-novel-depression-drug-for-first-time-in-3-decades,Shanthi Rexaline,,,,0,0,edfc71a5-3f65-4a0b-88f9-7148fbae854b
2019-03-06T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, March 6",LLY,https://www.benzinga.com/node/13313973,TalkMarkets,,,,0,0,609867e2-0944-40a3-b40f-99b1a5c6b207
2019-03-06T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, March 6",LLY,https://www.benzinga.com/node/13311573,TalkMarkets,,,,0,0,64af7453-8006-430a-892d-50876f833f92
2019-03-06T08:00:00.000+08:00,J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression,LLY,http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-BENZ-FT-357836,Zacks,,,,0,0,a74a15cd-a029-4e0f-b1e2-e0078127671c
2019-03-05T08:00:00.000+08:00,Lilly Receives FDA Priority Review Designation For Emgality Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults,LLY,https://www.benzinga.com/news/19/03/13297342/lilly-receives-fda-priority-review-designation-for-emgality-injection-for-the-pr,Benzinga Newsdesk,,,,0,0,1f3dca40-d683-48e1-9c02-ebd90b11c101
2019-03-05T08:00:00.000+08:00,"If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?",LLY,https://seekingalpha.com/article/4246517-celgene-deal-fails-buy-bristol-myers-squibb?source=partner_benzinga,Seeking Alpha,,,,0,0,cb85a216-1776-43fe-9869-fa4ea8c28c89
2019-03-05T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, March 5",LLY,https://www.benzinga.com/node/13304453,TalkMarkets,,,,0,0,8034a5dd-0bba-43b6-be5d-3b0bc2faf988
2019-03-05T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, March 5",LLY,https://www.benzinga.com/node/13301692,TalkMarkets,,,,0,0,9540e2b6-a8c5-4b58-b875-b35a61754ebc
2019-03-05T08:00:00.000+08:00,Lilly to Bring Half-Priced Version of Popular Humalog Insulin,LLY,http://www.zacks.com/stock/news/357718/lilly-to-bring-half-priced-version-of-popular-humalog-insulin?cid=CS-BENZ-FT-357718,Zacks,,,,0,0,18ae5ad6-e893-4827-8efd-5ff1766e92f8
2019-03-05T08:00:00.000+08:00,Lilly nabs accelerated review for Emgality injection,LLY,https://seekingalpha.com/news/3439731-lilly-nabs-accelerated-review-emgality-injection?source=partner_benzinga,Seeking Alpha,,,,0,0,b801c1dc-6575-43ea-ba7b-936d5dc9194f
2019-03-05T08:00:00.000+08:00,Lilly Receives FDA Priority Review Designation For Emgality Injection For The Preventive Treatment Of Episodic Cluster Headache In Adults,LLY,https://www.benzinga.com/news/19/03/13297342/lilly-receives-fda-priority-review-designation-for-emgality-injection-for-the-pr,Benzinga Newsdesk,,,,0,0,0d5ef446-4821-4a2c-ad50-aa09417fcb63
2019-03-05T08:00:00.000+08:00,"If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?",LLY,https://seekingalpha.com/article/4246517-celgene-deal-fails-buy-bristol-myers-squibb?source=partner_benzinga,Seeking Alpha,,,,0,0,48924f74-46ee-47ac-9826-20a4c84a4c17
2019-03-05T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, March 5",LLY,https://www.benzinga.com/node/13304453,TalkMarkets,,,,0,0,69035cf4-dde4-4e07-bf61-4d0c86c94603
2019-03-05T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, March 5",LLY,https://www.benzinga.com/node/13301692,TalkMarkets,,,,0,0,390d0a5a-f8ec-4506-bad3-4c7cba1f0f36
2019-03-05T08:00:00.000+08:00,Lilly to Bring Half-Priced Version of Popular Humalog Insulin,LLY,http://www.zacks.com/stock/news/357718/lilly-to-bring-half-priced-version-of-popular-humalog-insulin?cid=CS-BENZ-FT-357718,Zacks,,,,0,0,1c97dfb1-4a94-41af-b966-c1a5737519a3
2019-03-05T08:00:00.000+08:00,Lilly nabs accelerated review for Emgality injection,LLY,https://seekingalpha.com/news/3439731-lilly-nabs-accelerated-review-emgality-injection?source=partner_benzinga,Seeking Alpha,,,,0,0,812d2027-0caf-4fbd-8d82-c45030e9307e
2019-03-04T08:00:00.000+08:00,Eli Lilly Announces the Launch of Lower Priced Insulin,LLY,https://www.benzinga.com/news/19/03/13287406/eli-lilly-announces-the-launch-of-lower-priced-insulin,Benzinga Newsdesk,,,,0,0,cebd7b62-244c-4ab8-a44c-703decf15186
2019-03-04T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, March 4",LLY,https://www.benzinga.com/node/13294376,TalkMarkets,,,,0,0,6e93278e-023e-426d-9b17-9eef1947c24a
2019-03-04T08:00:00.000+08:00,"\"Senate committee \"\"looking into\"\" high insulin prices\"",LLY,https://seekingalpha.com/news/3439568-senate-committee-looking-high-insulin-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,eda71e11-5a02-40c4-86b4-0ea79975d413
2019-03-04T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 4",LLY,https://www.benzinga.com/node/13291619,TalkMarkets,,,,0,0,ad8df215-7ecd-4cc3-b661-012a0920adf6
2019-03-04T08:00:00.000+08:00,Lilly to launch lower-priced insulin in U.S.,LLY,https://seekingalpha.com/news/3439383-lilly-launch-lower-priced-insulin-u-s?source=partner_benzinga,Seeking Alpha,,,,0,0,c10b3ee0-3b0f-4718-a259-f72ae28bbf51
2019-03-04T08:00:00.000+08:00,Eli Lilly Announces the Launch of Lower Priced Insulin,LLY,https://www.benzinga.com/news/19/03/13287406/eli-lilly-announces-the-launch-of-lower-priced-insulin,Benzinga Newsdesk,,,,0,0,217944ea-c643-45f6-8250-0caa16199529
2019-03-04T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, March 4",LLY,https://www.benzinga.com/node/13294376,TalkMarkets,,,,0,0,6a9cd2fc-39aa-412d-a319-fdad0cbfadc2
2019-03-04T08:00:00.000+08:00,"\"Senate committee \"\"looking into\"\" high insulin prices\"",LLY,https://seekingalpha.com/news/3439568-senate-committee-looking-high-insulin-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,7bbb5a25-85e5-4e9a-babd-4763cda2644a
2019-03-04T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, March 4",LLY,https://www.benzinga.com/node/13291619,TalkMarkets,,,,0,0,d86a25c1-5ad2-48bf-8ee7-60f2168190ef
2019-03-04T08:00:00.000+08:00,Lilly to launch lower-priced insulin in U.S.,LLY,https://seekingalpha.com/news/3439383-lilly-launch-lower-priced-insulin-u-s?source=partner_benzinga,Seeking Alpha,,,,0,0,34a257e5-85f1-4b70-a2bd-941e5e1b7d50
2019-03-01T08:00:00.000+08:00,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",LLY,https://www.benzinga.com/general/biotech/19/03/13276510/the-daily-biotech-pulse-puma-biotech-earnings-mersana-offering-orphan,Shanthi Rexaline,,,,0,0,6da721e3-dec4-4ca5-85fc-0ac8dedbcd68
2019-03-01T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, March 1",LLY,https://www.benzinga.com/node/13284656,TalkMarkets,,,,0,0,0e973a2b-424d-411f-9afd-65e55e5bcb43
2019-03-01T08:00:00.000+08:00,Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales,LLY,http://www.zacks.com/stock/news/357476/radius-rdus-posts-narrower-q4-loss-on-robust-tymlos-sales?cid=CS-BENZ-FT-357476,Zacks,,,,0,0,e2db03e8-cc6a-4599-9f5f-81b223ef4793
2019-03-01T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Friday, March 1",LLY,https://www.benzinga.com/node/13281376,TalkMarkets,,,,0,0,b871fb05-ab28-4da9-bf10-ddbab7b37855
2019-03-01T08:00:00.000+08:00,Dividend Champions For March 2019,LLY,https://seekingalpha.com/article/4245611-dividend-champions-march-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,0e0b4928-c795-4f54-b55a-ded3457ee8ec
2019-03-01T08:00:00.000+08:00,"The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis",LLY,https://www.benzinga.com/general/biotech/19/03/13276510/the-daily-biotech-pulse-puma-biotech-earnings-mersana-offering-orphan,Shanthi Rexaline,,,,0,0,b914b9d6-e928-44b8-bc4b-3d3ba5e43d3c
2019-03-01T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, March 1",LLY,https://www.benzinga.com/node/13284656,TalkMarkets,,,,0,0,20c6e522-ec4b-4d91-a123-49a2334388a9
2019-03-01T08:00:00.000+08:00,Radius (RDUS) Posts Narrower Q4 Loss on Robust Tymlos Sales,LLY,http://www.zacks.com/stock/news/357476/radius-rdus-posts-narrower-q4-loss-on-robust-tymlos-sales?cid=CS-BENZ-FT-357476,Zacks,,,,0,0,fb38ff27-8b8d-4023-948d-82c591072063
2019-03-01T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Friday, March 1",LLY,https://www.benzinga.com/node/13281376,TalkMarkets,,,,0,0,d9eea400-5878-4e90-8209-0b3faef539c2
2019-03-01T08:00:00.000+08:00,Dividend Champions For March 2019,LLY,https://seekingalpha.com/article/4245611-dividend-champions-march-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,34b609f6-31ea-4d25-a1d9-b3205146f49f
2019-02-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",LLY,https://www.benzinga.com/general/biotech/19/02/13265063/the-daily-biotech-pulse-bristol-myers-squibb-celgene-deal-faces-setba,Shanthi Rexaline,,,,0,0,713cb966-ff5e-40f1-9779-f10311922b23
2019-02-28T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 28",LLY,https://www.benzinga.com/node/13273507,TalkMarkets,,,,0,0,131c63a9-f022-4e35-a1bc-30cca21cfed7
2019-02-28T08:00:00.000+08:00,Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates,LLY,http://www.zacks.com/stock/news/357341/aduro-adro-q4-earnings-and-revenues-fall-shy-of-estimates?cid=CS-BENZ-FT-357341,Zacks,,,,0,0,14c717f5-862d-4038-a912-c2f32c8b8987
2019-02-28T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 28",LLY,https://www.benzinga.com/node/13270080,TalkMarkets,,,,0,0,6fdc3233-1ad2-44da-a9f2-a2e42404302d
2019-02-28T08:00:00.000+08:00,Pfenex expands PF708 deal with Alvogen,LLY,https://seekingalpha.com/news/3438575-pfenex-expands-pf708-deal-alvogen?source=partner_benzinga,Seeking Alpha,,,,0,0,7e50375e-69c9-44cf-9cbb-97ce02cbd0b5
2019-02-28T08:00:00.000+08:00,United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates,LLY,http://www.zacks.com/stock/news/357300/united-therapeutics-uthr-q4-earnings-sales-beat-estimates?cid=CS-BENZ-FT-357300,Zacks,,,,0,0,be254ff6-317e-4a4a-9ecb-c1186692d655
2019-02-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",LLY,https://www.benzinga.com/general/biotech/19/02/13265063/the-daily-biotech-pulse-bristol-myers-squibb-celgene-deal-faces-setba,Shanthi Rexaline,,,,0,0,95d793b0-b663-4beb-a577-950dfc46ad64
2019-02-28T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 28",LLY,https://www.benzinga.com/node/13273507,TalkMarkets,,,,0,0,d7458fed-6ff7-44c1-9c58-4e17c93363eb
2019-02-28T08:00:00.000+08:00,Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates,LLY,http://www.zacks.com/stock/news/357341/aduro-adro-q4-earnings-and-revenues-fall-shy-of-estimates?cid=CS-BENZ-FT-357341,Zacks,,,,0,0,d2255fd3-e67a-419d-80a5-b37c76e5c11f
2019-02-28T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 28",LLY,https://www.benzinga.com/node/13270080,TalkMarkets,,,,0,0,80c8c1fa-6f78-4140-a798-9714a4bfa32d
2019-02-28T08:00:00.000+08:00,Pfenex expands PF708 deal with Alvogen,LLY,https://seekingalpha.com/news/3438575-pfenex-expands-pf708-deal-alvogen?source=partner_benzinga,Seeking Alpha,,,,0,0,6507440f-0e78-4d08-aadb-0889891a7b6d
2019-02-28T08:00:00.000+08:00,United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates,LLY,http://www.zacks.com/stock/news/357300/united-therapeutics-uthr-q4-earnings-sales-beat-estimates?cid=CS-BENZ-FT-357300,Zacks,,,,0,0,0955ea06-7af4-4770-abfa-115e94fc9829
2019-02-27T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",LLY,https://www.benzinga.com/general/biotech/19/02/13254225/the-daily-biotech-pulse-fda-panel-vote-sinks-karyopharm-refuse-to-fil,Shanthi Rexaline,,,,0,0,c0d93fe4-6888-44d8-b6e2-673d8e60490c
2019-02-27T08:00:00.000+08:00,Eli Lilly and Company (LLY) Management Presents at Leerink Partners Global Healthcare Conference (Transcript),LLY,https://seekingalpha.com/article/4244976-eli-lilly-company-lly-management-presents-leerink-partners-global-healthcare-conference?source=partner_benzinga,Seeking Alpha,,,,0,0,42073e7f-28d3-4f2b-bf1a-11a6b57144d7
2019-02-27T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 27",LLY,https://www.benzinga.com/node/13261452,TalkMarkets,,,,0,0,765143f2-d550-45b1-8777-85c00fedf435
2019-02-27T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 27",LLY,https://www.benzinga.com/node/13258484,TalkMarkets,,,,0,0,032e6940-887d-464d-828a-e3c084a05e37
2019-02-27T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings",LLY,https://www.benzinga.com/general/biotech/19/02/13254225/the-daily-biotech-pulse-fda-panel-vote-sinks-karyopharm-refuse-to-fil,Shanthi Rexaline,,,,0,0,c7716a1d-640f-4904-b01c-25ecb75377c1
2019-02-27T08:00:00.000+08:00,Eli Lilly and Company (LLY) Management Presents at Leerink Partners Global Healthcare Conference (Transcript),LLY,https://seekingalpha.com/article/4244976-eli-lilly-company-lly-management-presents-leerink-partners-global-healthcare-conference?source=partner_benzinga,Seeking Alpha,,,,0,0,51b11d03-84cd-4d43-9bfa-13fae2d16451
2019-02-27T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 27",LLY,https://www.benzinga.com/node/13261452,TalkMarkets,,,,0,0,cb1376f5-d8b9-4b2f-a70d-b5ae3672313f
2019-02-27T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 27",LLY,https://www.benzinga.com/node/13258484,TalkMarkets,,,,0,0,ceb235aa-6a97-480e-8645-a0a988b37f69
2019-02-26T08:00:00.000+08:00,FDA rejects Adamis Pharma's application for sublingual tadalafil; shares down 13% after hours,LLY,https://seekingalpha.com/news/3437549-fda-rejects-adamis-pharmas-application-sublingual-tadalafil-shares-13-percent-hours?source=partner_benzinga,Seeking Alpha,,,,0,0,46bef6b8-41a7-4b40-aa7c-2d57d21fea06
2019-02-26T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 26",LLY,https://www.benzinga.com/node/13251186,TalkMarkets,,,,0,0,b1a1a59f-f0ae-4698-8ae8-6d9acbbc258c
2019-02-26T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 26",LLY,https://www.benzinga.com/node/13248215,TalkMarkets,,,,0,0,218b92ae-75e2-4919-b5bf-d489d682f071
2019-02-26T08:00:00.000+08:00,FDA rejects Adamis Pharma's application for sublingual tadalafil; shares down 13% after hours,LLY,https://seekingalpha.com/news/3437549-fda-rejects-adamis-pharmas-application-sublingual-tadalafil-shares-13-percent-hours?source=partner_benzinga,Seeking Alpha,,,,0,0,9a923bcd-0080-4229-aa7c-e18ea1da0935
2019-02-26T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 26",LLY,https://www.benzinga.com/node/13251186,TalkMarkets,,,,0,0,37d2da24-02e7-46c0-92fe-d5c34928deef
2019-02-26T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 26",LLY,https://www.benzinga.com/node/13248215,TalkMarkets,,,,0,0,684fe26f-a076-4678-8914-27f069384836
2019-02-25T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, Feb. 25",LLY,https://www.benzinga.com/node/13240623,TalkMarkets,,,,0,0,1cd3fa31-ab91-4023-bd6b-8dbb2fd5bb97
2019-02-25T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, Feb. 25",LLY,https://www.benzinga.com/node/13238053,TalkMarkets,,,,0,0,c223b6f4-9545-4e99-94fc-e3c39aeed678
2019-02-25T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft",LLY,http://www.zacks.com/stock/news/356845/the-zacks-analyst-blog-highlights-walmart-pfizer-eli-lilly-merck-and-microsoft?cid=CS-BENZ-FT-356845,Zacks,,,,0,0,0c0044d4-757f-4eb4-9f04-4a1e1535abfe
2019-02-25T08:00:00.000+08:00,According To Sources: Scandal In The Chicken And Pork Industries (Podcast),LLY,https://seekingalpha.com/article/4243811-according-sources-scandal-chicken-pork-industries-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,0605dcb5-96df-483d-a83b-5625002b3d75
2019-02-25T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, Feb. 25",LLY,https://www.benzinga.com/node/13240623,TalkMarkets,,,,0,0,38495922-1250-415d-8fd1-3f159633939f
2019-02-25T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Monday, Feb. 25",LLY,https://www.benzinga.com/node/13238053,TalkMarkets,,,,0,0,ccffd1c7-620c-44df-8397-dfc2acae8ebf
2019-02-25T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft",LLY,http://www.zacks.com/stock/news/356845/the-zacks-analyst-blog-highlights-walmart-pfizer-eli-lilly-merck-and-microsoft?cid=CS-BENZ-FT-356845,Zacks,,,,0,0,91083b90-a0ec-4371-953d-2f04035d5623
2019-02-25T08:00:00.000+08:00,According To Sources: Scandal In The Chicken And Pork Industries (Podcast),LLY,https://seekingalpha.com/article/4243811-according-sources-scandal-chicken-pork-industries-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,98dcf9f4-5255-4a33-9836-59267730a2a2
2019-02-24T08:00:00.000+08:00,"Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers",LLY,http://www.gurufocus.com/news/821833/biogen-biomarin-lilly-and-bristolmyers-could-be-in-crosshairs-of-acquirers,GuruFocus,,,,0,0,c6380922-fbde-4fb7-b249-d4cac49a273b
2019-02-24T08:00:00.000+08:00,"Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers",LLY,http://www.gurufocus.com/news/821833/biogen-biomarin-lilly-and-bristolmyers-could-be-in-crosshairs-of-acquirers,GuruFocus,,,,0,0,297315f1-16ba-436c-a3d8-8b930132e61a
2019-02-22T08:00:00.000+08:00,"US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi",LLY,https://www.benzinga.com/news/19/02/13230342/us-senate-finance-committee-launches-bipartisan-investigation-into-rising-insuli,Benzinga Newsdesk,,,,0,0,ac121ace-9b2c-4f52-b18e-5067aed5e9f8
2019-02-22T08:00:00.000+08:00,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",LLY,https://www.benzinga.com/general/biotech/19/02/13225988/the-daily-biotech-pulse-biomarin-slips-on-earnings-therapeuticsmd-pos,Shanthi Rexaline,,,,0,0,a5651023-28b6-49f8-94ad-060e1889742b
2019-02-22T08:00:00.000+08:00,Merck to Buy Immunotherapy Developer Immune Design for $300M,LLY,http://www.zacks.com/stock/news/356654/merck-to-buy-immunotherapy-developer-immune-design-for-%24300m?cid=CS-BENZ-FT-356654,Zacks,,,,0,0,67bf913b-8fd5-4590-b0be-74d1f4086d18
2019-02-22T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb 22",LLY,https://www.benzinga.com/node/13230648,TalkMarkets,,,,0,0,44eff1ed-cb7d-45cf-af9b-07e1fcd6003a
2019-02-22T08:00:00.000+08:00,"Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates",LLY,http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-BENZ-FT-356445,Zacks,,,,0,0,aef0f485-21e9-4efb-84de-d02e979c80d9
2019-02-22T08:00:00.000+08:00,"New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, ...",LLY,http://www.gurufocus.com/news/820916/new-research-coverage-highlights-fedex-honeywell-international-nielsen-holdings-plc-changyou-jb-hunt-transport-services-and-eli-lilly--consolidated-revenues-company-growth-and-expectations-for-2019,GuruFocus,,,,0,0,762ecc4a-8ae2-4f37-80ff-101be2420061
2019-02-22T08:00:00.000+08:00,"Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review",LLY,http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-BENZ-FT-356394,Zacks,,,,0,0,5a133791-32a5-49ab-ab59-98b52b436907
2019-02-22T08:00:00.000+08:00,"US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi",LLY,https://www.benzinga.com/news/19/02/13230342/us-senate-finance-committee-launches-bipartisan-investigation-into-rising-insuli,Benzinga Newsdesk,,,,0,0,940d0e5d-1cc7-427a-96cd-744989018f77
2019-02-22T08:00:00.000+08:00,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",LLY,https://www.benzinga.com/general/biotech/19/02/13225988/the-daily-biotech-pulse-biomarin-slips-on-earnings-therapeuticsmd-pos,Shanthi Rexaline,,,,0,0,1b1d3901-116e-4513-b09b-71f07f0d802d
2019-02-22T08:00:00.000+08:00,Merck to Buy Immunotherapy Developer Immune Design for $300M,LLY,http://www.zacks.com/stock/news/356654/merck-to-buy-immunotherapy-developer-immune-design-for-%24300m?cid=CS-BENZ-FT-356654,Zacks,,,,0,0,563baaa1-9246-4cef-b86b-2256803ce610
2019-02-22T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb 22",LLY,https://www.benzinga.com/node/13230648,TalkMarkets,,,,0,0,b3d6ba8c-bfa9-4acf-9ffa-176611956aaf
2019-02-22T08:00:00.000+08:00,"Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates",LLY,http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-BENZ-FT-356445,Zacks,,,,0,0,b0ef82da-0d21-44d4-a8ad-3aa896a546e7
2019-02-22T08:00:00.000+08:00,"New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, ...",LLY,http://www.gurufocus.com/news/820916/new-research-coverage-highlights-fedex-honeywell-international-nielsen-holdings-plc-changyou-jb-hunt-transport-services-and-eli-lilly--consolidated-revenues-company-growth-and-expectations-for-2019,GuruFocus,,,,0,0,78916303-32ce-4c76-a113-38940ca4d9e7
2019-02-22T08:00:00.000+08:00,"Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review",LLY,http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-BENZ-FT-356394,Zacks,,,,0,0,5d048d13-458d-4a00-aa0f-889acbc0bd59
2019-02-21T08:00:00.000+08:00,Merck To Buy Immune Design For $300M,LLY,https://www.benzinga.com/general/biotech/19/02/13218686/merck-to-buy-immune-design-for-300m,Shanthi Rexaline,,,,0,0,33ee8373-97cf-4066-93d1-04a40df5e06c
2019-02-21T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 21",LLY,https://www.benzinga.com/node/13223942,TalkMarkets,,,,0,0,a49071cb-2b4e-4fe7-bb40-1f8b7786848e
2019-02-21T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 21",LLY,https://www.benzinga.com/node/13220998,TalkMarkets,,,,0,0,0eca65ca-beb3-4eec-8bf1-3b7203821828
2019-02-21T08:00:00.000+08:00,Philip Morris International: Halftime Report,LLY,https://seekingalpha.com/article/4242862-philip-morris-international-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,2abedf71-a43f-4dd9-8a9a-896e17bb3b3e
2019-02-21T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/356081/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-356081,Zacks,,,,0,0,95548866-4ddc-49ca-9b1c-735d3909bfaf
2019-02-21T08:00:00.000+08:00,U.S. healthcare spending to rise 5.5% per annum over next decade,LLY,https://seekingalpha.com/news/3435547-u-s-healthcare-spending-rise-5_5-percent-per-annum-next-decade?source=partner_benzinga,Seeking Alpha,,,,0,0,fcc8abf9-4070-43dd-a857-8b93aec53f5f
2019-02-21T08:00:00.000+08:00,Merck To Buy Immune Design For $300M,LLY,https://www.benzinga.com/general/biotech/19/02/13218686/merck-to-buy-immune-design-for-300m,Shanthi Rexaline,,,,0,0,ea912a8b-9678-4f7e-895f-9c0f727e4935
2019-02-21T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 21",LLY,https://www.benzinga.com/node/13223942,TalkMarkets,,,,0,0,9018df3c-d69b-4922-8725-9f1ff538251a
2019-02-21T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 21",LLY,https://www.benzinga.com/node/13220998,TalkMarkets,,,,0,0,91f1a069-f79e-4729-ba79-5657384803a9
2019-02-21T08:00:00.000+08:00,Philip Morris International: Halftime Report,LLY,https://seekingalpha.com/article/4242862-philip-morris-international-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,180de2d1-25e1-4850-8f74-2435f44e2ae1
2019-02-21T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/356081/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-356081,Zacks,,,,0,0,f2bdaf79-3aea-4f0f-aec0-b0f6f5577351
2019-02-21T08:00:00.000+08:00,U.S. healthcare spending to rise 5.5% per annum over next decade,LLY,https://seekingalpha.com/news/3435547-u-s-healthcare-spending-rise-5_5-percent-per-annum-next-decade?source=partner_benzinga,Seeking Alpha,,,,0,0,148dc33c-f3c5-4319-96fc-b0f682b48aea
2019-02-20T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 20",LLY,https://www.benzinga.com/node/13213916,TalkMarkets,,,,0,0,563922f7-f363-4079-8cd7-fdb9d66f151e
2019-02-20T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 20",LLY,https://www.benzinga.com/node/13211402,TalkMarkets,,,,0,0,110fe80d-60ed-412a-b0a7-026a81b0132b
2019-02-20T08:00:00.000+08:00,Allergan Responds to Investor's Call for CEO/Chair Role Split,LLY,http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-BENZ-FT-355578,Zacks,,,,0,0,8cfa4ac4-6508-4125-ac9c-fe8b428a874b
2019-02-20T08:00:00.000+08:00,Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study,LLY,http://www.zacks.com/stock/news/355538/pfizer-lillys-pain-candidate-succeeds-in-back-pain-study?cid=CS-BENZ-FT-355538,Zacks,,,,0,0,314ef8fc-e862-4fcb-aeeb-1833898bda24
2019-02-20T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 20",LLY,https://www.benzinga.com/node/13213916,TalkMarkets,,,,0,0,2a840700-5330-4d3b-b4b8-b6d5f573270b
2019-02-20T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 20",LLY,https://www.benzinga.com/node/13211402,TalkMarkets,,,,0,0,bdba5a9c-bf48-4e17-bdcd-204513891cd1
2019-02-20T08:00:00.000+08:00,Allergan Responds to Investor's Call for CEO/Chair Role Split,LLY,http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-BENZ-FT-355578,Zacks,,,,0,0,8d1c8031-7bb5-4bc5-8766-bf570e96747d
2019-02-20T08:00:00.000+08:00,Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study,LLY,http://www.zacks.com/stock/news/355538/pfizer-lillys-pain-candidate-succeeds-in-back-pain-study?cid=CS-BENZ-FT-355538,Zacks,,,,0,0,66dc5ecc-3710-4e68-90ab-70a07e16ed24
2019-02-19T08:00:00.000+08:00,S&P Downgrades Eli Lilly Credit Rating From AA- To A+; Outlook Raised From Credit Watch Negative To Stable,LLY,https://www.benzinga.com/news/19/02/13203173/s-p-downgrades-eli-lilly-credit-rating-from-aa-to-a-outlook-raised-from-credit-w,Benzinga Newsdesk,,,,0,0,f12a66c1-6d38-4953-acec-f34254f7bb56
2019-02-19T08:00:00.000+08:00,"Eli Lilly Files For Mixed Shelf Offering, Size Not Disclosed",LLY,https://www.benzinga.com/news/19/02/13202602/eli-lilly-files-for-mixed-shelf-offering-size-not-disclosed,Benzinga Newsdesk,,,,0,0,50f38b26-a398-4490-9cd8-af40acb9860f
2019-02-19T08:00:00.000+08:00,"Eli Lilly 10-K Just Recently Out; 1 Highlight: Co. Employed ~38,680 Employees At End Of 2018",LLY,https://www.benzinga.com/news/19/02/13201130/eli-lilly-10-k-just-recently-out-1-highlight-co-employed-38-680-employees-at-end,Benzinga Newsdesk,,,,0,0,5d0f2098-4c9e-40de-8efc-081a0e9d6ee6
2019-02-19T08:00:00.000+08:00,"Supreme Court Rejects Maryland's Bid To Revive A Law Aimed At Preventing Price Gouging By Pharmaceutical Companies, Reuters Reports",LLY,https://www.benzinga.com/general/biotech/19/02/13200385/supreme-court-rejects-marylands-bid-to-revive-a-law-aimed-at-preventi,Benzinga Newsdesk,,,,0,0,8e1dd77f-e562-4bd2-90e7-382be489a01d
2019-02-19T08:00:00.000+08:00,Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain; Tanezumab Met Primary Endpoint,LLY,https://www.benzinga.com/general/biotech/19/02/13197642/pfizer-and-lilly-announce-top-line-results-from-phase-3-study-of-tane,Benzinga Newsdesk,,,,0,0,ba14f891-7a56-4f85-9b6c-5f0a39505c17
2019-02-19T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 19",LLY,https://www.benzinga.com/node/13204775,TalkMarkets,,,,0,0,6b6cce88-da74-4777-9c6d-5b29ca31e68a
2019-02-19T08:00:00.000+08:00,Lilly files for mixed shelf offering,LLY,https://seekingalpha.com/news/3434620-lilly-files-mixed-shelf-offering?source=partner_benzinga,Seeking Alpha,,,,0,0,2b3f8534-0c20-44ff-8c54-9b7d65bac175
2019-02-19T08:00:00.000+08:00,Lilly wins review of Teva migraine patents in U.S.,LLY,https://seekingalpha.com/news/3434551-lilly-wins-review-teva-migraine-patents-u-s?source=partner_benzinga,Seeking Alpha,,,,0,0,6c80f91d-c6ad-4d75-b202-9a1adc061ee0
2019-02-19T08:00:00.000+08:00,Maryland strikes out in reviving drug price-gouging law,LLY,https://seekingalpha.com/news/3434544-maryland-strikes-reviving-drug-price-gouging-law?source=partner_benzinga,Seeking Alpha,,,,0,0,9e03cd61-ff15-431d-9aaa-5a46a7e5dadb
2019-02-19T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 19",LLY,https://www.benzinga.com/node/13202013,TalkMarkets,,,,0,0,c7cd8739-2b74-4f7d-b483-f009903617c3
2019-02-19T08:00:00.000+08:00,"Merger Arbitrage Mondays - February 18, 2019",LLY,https://seekingalpha.com/article/4242039-merger-arbitrage-mondays-february-18-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,33e04f4f-e6a8-4cce-b19d-22c282bb44dd
2019-02-19T08:00:00.000+08:00,Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo,LLY,http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-BENZ-FT-355437,Zacks,,,,0,0,ae8e7a7d-1474-4b1f-b8c4-da2c36330c7e
2019-02-19T08:00:00.000+08:00,Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why,LLY,http://www.zacks.com/stock/news/355423/mercks-mrk-stock-up-almost-50-in-a-year-heres-why?cid=CS-BENZ-FT-355423,Zacks,,,,0,0,65e43645-981e-4944-ad3f-266861db9200
2019-02-19T08:00:00.000+08:00,Lilly and Pfizer's tanezumab successful in late-stage back pain study,LLY,https://seekingalpha.com/news/3434316-lilly-pfizers-tanezumab-successful-late-stage-back-pain-study?source=partner_benzinga,Seeking Alpha,,,,0,0,da07ecc3-27ed-4aeb-8d31-cb62a7570f57
2019-02-19T08:00:00.000+08:00,Teva: Reasons To Avoid It In Favor Of Innovative Biotechs,LLY,https://seekingalpha.com/article/4242001-teva-reasons-avoid-favor-innovative-biotechs?source=partner_benzinga,Seeking Alpha,,,,0,0,94a5ee77-e2de-46b0-b0a3-8a384c6710df
2019-02-19T08:00:00.000+08:00,S&P Downgrades Eli Lilly Credit Rating From AA- To A+; Outlook Raised From Credit Watch Negative To Stable,LLY,https://www.benzinga.com/news/19/02/13203173/s-p-downgrades-eli-lilly-credit-rating-from-aa-to-a-outlook-raised-from-credit-w,Benzinga Newsdesk,,,,0,0,5560c2ed-6820-4401-a063-b77ec1bb9cdf
2019-02-19T08:00:00.000+08:00,"Eli Lilly Files For Mixed Shelf Offering, Size Not Disclosed",LLY,https://www.benzinga.com/news/19/02/13202602/eli-lilly-files-for-mixed-shelf-offering-size-not-disclosed,Benzinga Newsdesk,,,,0,0,fa3448eb-93cd-40ac-a03a-db28c41af3e7
2019-02-19T08:00:00.000+08:00,"Eli Lilly 10-K Just Recently Out; 1 Highlight: Co. Employed ~38,680 Employees At End Of 2018",LLY,https://www.benzinga.com/news/19/02/13201130/eli-lilly-10-k-just-recently-out-1-highlight-co-employed-38-680-employees-at-end,Benzinga Newsdesk,,,,0,0,706b43af-83e3-4f6f-9e84-74d302aea000
2019-02-19T08:00:00.000+08:00,"Supreme Court Rejects Maryland's Bid To Revive A Law Aimed At Preventing Price Gouging By Pharmaceutical Companies, Reuters Reports",LLY,https://www.benzinga.com/general/biotech/19/02/13200385/supreme-court-rejects-marylands-bid-to-revive-a-law-aimed-at-preventi,Benzinga Newsdesk,,,,0,0,14edbc7e-95a4-4786-8e3d-3b9329774c67
2019-02-19T08:00:00.000+08:00,Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain; Tanezumab Met Primary Endpoint,LLY,https://www.benzinga.com/general/biotech/19/02/13197642/pfizer-and-lilly-announce-top-line-results-from-phase-3-study-of-tane,Benzinga Newsdesk,,,,0,0,d60ebcd2-0eae-4939-a4e8-10cc1b1b7c8b
2019-02-19T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 19",LLY,https://www.benzinga.com/node/13204775,TalkMarkets,,,,0,0,37a1e2a3-2872-4c6b-88f9-a2e5a3745fb2
2019-02-19T08:00:00.000+08:00,Lilly files for mixed shelf offering,LLY,https://seekingalpha.com/news/3434620-lilly-files-mixed-shelf-offering?source=partner_benzinga,Seeking Alpha,,,,0,0,498f5415-eaf5-4c4e-bbca-b811425f490e
2019-02-19T08:00:00.000+08:00,Lilly wins review of Teva migraine patents in U.S.,LLY,https://seekingalpha.com/news/3434551-lilly-wins-review-teva-migraine-patents-u-s?source=partner_benzinga,Seeking Alpha,,,,0,0,e130eb5e-4091-4e62-91a7-6546fe6f419d
2019-02-19T08:00:00.000+08:00,Maryland strikes out in reviving drug price-gouging law,LLY,https://seekingalpha.com/news/3434544-maryland-strikes-reviving-drug-price-gouging-law?source=partner_benzinga,Seeking Alpha,,,,0,0,4580e1e1-9752-4ef8-bea7-db771aeedae0
2019-02-19T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 19",LLY,https://www.benzinga.com/node/13202013,TalkMarkets,,,,0,0,3a921119-a1ff-4390-9d8c-f9109bcfe26b
2019-02-19T08:00:00.000+08:00,"Merger Arbitrage Mondays - February 18, 2019",LLY,https://seekingalpha.com/article/4242039-merger-arbitrage-mondays-february-18-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,98b2f7c9-8c21-4d9b-95b0-2734514e17ea
2019-02-19T08:00:00.000+08:00,Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo,LLY,http://www.zacks.com/stock/news/355437/bayer-obtains-full-rights-to-vitrakvi-from-lillys-loxo?cid=CS-BENZ-FT-355437,Zacks,,,,0,0,8353072b-84a3-4ddb-97ad-61cdd58a045c
2019-02-19T08:00:00.000+08:00,Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why,LLY,http://www.zacks.com/stock/news/355423/mercks-mrk-stock-up-almost-50-in-a-year-heres-why?cid=CS-BENZ-FT-355423,Zacks,,,,0,0,99be9d70-a06e-4e0d-91cf-8a5475f5d91f
2019-02-19T08:00:00.000+08:00,Lilly and Pfizer's tanezumab successful in late-stage back pain study,LLY,https://seekingalpha.com/news/3434316-lilly-pfizers-tanezumab-successful-late-stage-back-pain-study?source=partner_benzinga,Seeking Alpha,,,,0,0,3018da19-4702-4172-a00d-20f0dc71c6a2
2019-02-19T08:00:00.000+08:00,Teva: Reasons To Avoid It In Favor Of Innovative Biotechs,LLY,https://seekingalpha.com/article/4242001-teva-reasons-avoid-favor-innovative-biotechs?source=partner_benzinga,Seeking Alpha,,,,0,0,a5d27f20-0147-4872-92e1-e3b4aca8f683
2019-02-18T08:00:00.000+08:00,Novo Nordisk: Solid Performance Marred By Currency Fluctuations,LLY,https://seekingalpha.com/article/4241865-novo-nordisk-solid-performance-marred-currency-fluctuations?source=partner_benzinga,Seeking Alpha,,,,0,0,c823786a-db2b-4322-95b3-1d037e6ef9d9
2019-02-18T08:00:00.000+08:00,How To Retire: Kill The TV,LLY,https://seekingalpha.com/article/4241728-retire-kill-tv?source=partner_benzinga,Seeking Alpha,,,,0,0,264f7a4f-981c-4c2f-8078-8fe11b114d19
2019-02-18T08:00:00.000+08:00,Novo Nordisk: Solid Performance Marred By Currency Fluctuations,LLY,https://seekingalpha.com/article/4241865-novo-nordisk-solid-performance-marred-currency-fluctuations?source=partner_benzinga,Seeking Alpha,,,,0,0,5f2cd1a6-3d55-489b-8423-e689cd44eaa6
2019-02-18T08:00:00.000+08:00,How To Retire: Kill The TV,LLY,https://seekingalpha.com/article/4241728-retire-kill-tv?source=partner_benzinga,Seeking Alpha,,,,0,0,5b1eaf96-7839-4143-a941-5ad392fc09dd
2019-02-15T08:00:00.000+08:00,"Bayer To Obtain Full Rights To Global Development And Commercialization Of Oncology Compounds VITRAKVI And AND BAY 2731954, Will Be Solely Responsible For Global Development And Commercialization Of Both",LLY,https://www.benzinga.com/general/biotech/19/02/13188321/bayer-to-obtain-full-rights-to-global-development-and-commercializati,Benzinga Newsdesk,,,,0,0,7b0b7c74-d8ad-403b-8d84-80ac1c215b5f
2019-02-15T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb. 15",LLY,https://www.benzinga.com/node/13192791,TalkMarkets,,,,0,0,76d4f63d-d42c-42b4-9660-84454ebb7682
2019-02-15T08:00:00.000+08:00,FDA creates new accelerated review pathway for generic drug applications,LLY,https://seekingalpha.com/news/3433986-fda-creates-new-accelerated-review-pathway-generic-drug-applications?source=partner_benzinga,Seeking Alpha,,,,0,0,241b3128-ada5-4b01-8afe-d8e1fd9c4e2b
2019-02-15T08:00:00.000+08:00,Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates,LLY,http://www.zacks.com/stock/news/355111/alkermes-alks-q4-earnings-revenues-surpass-estimates?cid=CS-BENZ-FT-355111,Zacks,,,,0,0,c1c07307-e0d2-421e-8491-007fec506a81
2019-02-15T08:00:00.000+08:00,Bayer in-licenses Loxo's Vitrakvi and LOXO-195,LLY,https://seekingalpha.com/news/3433965-bayer-licenses-loxos-vitrakvi-loxominus-195?source=partner_benzinga,Seeking Alpha,,,,0,0,ef85fb78-81fb-4a24-b794-41d1db59de49
2019-02-15T08:00:00.000+08:00,Lilly finalizes Loxo buy,LLY,https://seekingalpha.com/news/3433947-lilly-finalizes-loxo-buy?source=partner_benzinga,Seeking Alpha,,,,0,0,668cc79a-7e63-49ed-a343-d7efb826ef94
2019-02-15T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/355011/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-355011,Zacks,,,,0,0,b8b27517-e8c2-4617-8e35-918903a4106b
2019-02-15T08:00:00.000+08:00,"Bayer To Obtain Full Rights To Global Development And Commercialization Of Oncology Compounds VITRAKVI And AND BAY 2731954, Will Be Solely Responsible For Global Development And Commercialization Of Both",LLY,https://www.benzinga.com/general/biotech/19/02/13188321/bayer-to-obtain-full-rights-to-global-development-and-commercializati,Benzinga Newsdesk,,,,0,0,2c9f42ee-02e8-401b-9a79-ebcf663fbd08
2019-02-15T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb. 15",LLY,https://www.benzinga.com/node/13192791,TalkMarkets,,,,0,0,9a5c43cf-fee5-438c-8627-143c07cebbb9
2019-02-15T08:00:00.000+08:00,FDA creates new accelerated review pathway for generic drug applications,LLY,https://seekingalpha.com/news/3433986-fda-creates-new-accelerated-review-pathway-generic-drug-applications?source=partner_benzinga,Seeking Alpha,,,,0,0,a55cde43-ab6b-4829-97cf-7ed42a30a9f8
2019-02-15T08:00:00.000+08:00,Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates,LLY,http://www.zacks.com/stock/news/355111/alkermes-alks-q4-earnings-revenues-surpass-estimates?cid=CS-BENZ-FT-355111,Zacks,,,,0,0,40ee3281-a69f-42f1-bff2-886e1cf22bc0
2019-02-15T08:00:00.000+08:00,Bayer in-licenses Loxo's Vitrakvi and LOXO-195,LLY,https://seekingalpha.com/news/3433965-bayer-licenses-loxos-vitrakvi-loxominus-195?source=partner_benzinga,Seeking Alpha,,,,0,0,0b17f9c7-44a9-4e17-ba13-e1a6e560ddff
2019-02-15T08:00:00.000+08:00,Lilly finalizes Loxo buy,LLY,https://seekingalpha.com/news/3433947-lilly-finalizes-loxo-buy?source=partner_benzinga,Seeking Alpha,,,,0,0,00d910f3-fb52-4523-8336-8de6280da4b1
2019-02-15T08:00:00.000+08:00,Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice,LLY,http://www.zacks.com/stock/news/355011/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-BENZ-FT-355011,Zacks,,,,0,0,46df42b9-8536-4f8d-b385-7101ddde10c6
2019-02-14T08:00:00.000+08:00,"Stocks Trading Ex Dividend For Thurs., Feb. 14, 2019",LLY,https://www.benzinga.com/news/19/02/13176454/stocks-trading-ex-dividend-for-thurs-feb-14-2019,Benzinga Newsdesk,,,,0,0,32b52917-0acc-4bd9-95eb-38d03502ce6f
2019-02-14T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report CAROLINA Trial Of Tradjenta Met Primary Endpoint, Showed 'no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk'",LLY,https://www.benzinga.com/news/19/02/13170784/eli-lilly-boehringer-ingelheim-report-carolina-trial-of-tradjenta-met-primary-en,Benzinga Newsdesk,,,,0,0,5da60313-818a-4df9-aed9-2ceb39d4a8f9
2019-02-14T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 14",LLY,https://www.benzinga.com/node/13182578,TalkMarkets,,,,0,0,ad036ff6-7e98-4fa0-8b20-7e63e1287f87
2019-02-14T08:00:00.000+08:00,"Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat",LLY,http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-BENZ-FT-354853,Zacks,,,,0,0,4c0186ea-43ee-45a9-9819-1108e32b8dc3
2019-02-14T08:00:00.000+08:00,5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings,LLY,http://www.zacks.com/stock/news/354851/5-drug-biotech-stocks-set-to-beat-estimates-in-q4-earnings?cid=CS-BENZ-FT-354851,Zacks,,,,0,0,e4930083-264b-4602-8af8-87c5126ec92b
2019-02-14T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 14",LLY,https://www.benzinga.com/node/13177411,TalkMarkets,,,,0,0,a01d5325-3377-4937-b854-8e83367607aa
2019-02-14T08:00:00.000+08:00,"Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down",LLY,http://www.zacks.com/stock/news/354559/teva-teva-q4-earnings-miss19-view-weak-shares-down?cid=CS-BENZ-FT-354559,Zacks,,,,0,0,996376e6-8a50-4e8b-ada3-2c0db2a8aaa2
2019-02-14T08:00:00.000+08:00,Eli Lilly and Boehringer Ingelheim's Tradjenta successful in CV outcomes study,LLY,https://seekingalpha.com/news/3433257-eli-lilly-boehringer-ingelheims-tradjenta-successful-cv-outcomes-study?source=partner_benzinga,Seeking Alpha,,,,0,0,6173cc73-a2d7-43ec-b81d-4c74258562d1
2019-02-14T08:00:00.000+08:00,"Stocks Trading Ex Dividend For Thurs., Feb. 14, 2019",LLY,https://www.benzinga.com/news/19/02/13176454/stocks-trading-ex-dividend-for-thurs-feb-14-2019,Benzinga Newsdesk,,,,0,0,89668c45-057c-43e9-9fa7-6b972abe4bab
2019-02-14T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report CAROLINA Trial Of Tradjenta Met Primary Endpoint, Showed 'no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk'",LLY,https://www.benzinga.com/news/19/02/13170784/eli-lilly-boehringer-ingelheim-report-carolina-trial-of-tradjenta-met-primary-en,Benzinga Newsdesk,,,,0,0,2876ab34-4911-48a9-b929-d9de3902fc23
2019-02-14T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Feb. 14",LLY,https://www.benzinga.com/node/13182578,TalkMarkets,,,,0,0,98a93998-7718-442e-8deb-f412dcd896e7
2019-02-14T08:00:00.000+08:00,"Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat",LLY,http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-BENZ-FT-354853,Zacks,,,,0,0,a437c221-aa52-44ce-9a57-0abd0962e87c
2019-02-14T08:00:00.000+08:00,5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings,LLY,http://www.zacks.com/stock/news/354851/5-drug-biotech-stocks-set-to-beat-estimates-in-q4-earnings?cid=CS-BENZ-FT-354851,Zacks,,,,0,0,16376236-aa7a-4267-9ef0-4303d0c845c6
2019-02-14T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Feb. 14",LLY,https://www.benzinga.com/node/13177411,TalkMarkets,,,,0,0,9b0e7db3-014b-4b54-ba03-d8a25363bbb7
2019-02-14T08:00:00.000+08:00,"Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down",LLY,http://www.zacks.com/stock/news/354559/teva-teva-q4-earnings-miss19-view-weak-shares-down?cid=CS-BENZ-FT-354559,Zacks,,,,0,0,55bf8527-bfda-433f-8d36-feb103f131ce
2019-02-14T08:00:00.000+08:00,Eli Lilly and Boehringer Ingelheim's Tradjenta successful in CV outcomes study,LLY,https://seekingalpha.com/news/3433257-eli-lilly-boehringer-ingelheims-tradjenta-successful-cv-outcomes-study?source=partner_benzinga,Seeking Alpha,,,,0,0,bcfc7f56-3bc2-4fc0-a28c-5fbd5517f646
2019-02-13T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 13",LLY,https://www.benzinga.com/node/13167628,TalkMarkets,,,,0,0,9987ecea-cdd5-483d-8d30-3bc9848e47b4
2019-02-13T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 13",LLY,https://www.benzinga.com/node/13163977,TalkMarkets,,,,0,0,3c2547dd-92fe-4f9b-9137-1ee430729f7d
2019-02-13T08:00:00.000+08:00,5 Tiny Biotech Stocks With Superb Growth Potential,LLY,http://www.zacks.com/stock/news/354140/5-tiny-biotech-stocks-with-superb-growth-potential?cid=CS-BENZ-FT-354140,Zacks,,,,0,0,bf648145-e1ad-4018-969f-f6eefd26e174
2019-02-13T08:00:00.000+08:00,"Hot Options Report For End Of Day - Wednesday, Feb. 13",LLY,https://www.benzinga.com/node/13167628,TalkMarkets,,,,0,0,0c10b688-b281-40b6-938c-0a0d3d476863
2019-02-13T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Wednesday, Feb. 13",LLY,https://www.benzinga.com/node/13163977,TalkMarkets,,,,0,0,522c9427-a270-45c4-9ee0-51fee7b60303
2019-02-13T08:00:00.000+08:00,5 Tiny Biotech Stocks With Superb Growth Potential,LLY,http://www.zacks.com/stock/news/354140/5-tiny-biotech-stocks-with-superb-growth-potential?cid=CS-BENZ-FT-354140,Zacks,,,,0,0,369611e8-3a67-40e7-9ab9-ce465a377780
2019-02-12T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 12",LLY,https://www.benzinga.com/node/13155620,TalkMarkets,,,,0,0,d3058a88-5921-4709-aafa-f2efa2e13490
2019-02-12T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 12",LLY,https://www.benzinga.com/node/13152044,TalkMarkets,,,,0,0,fb16d987-7043-4bea-97d0-baeb3d3f6b91
2019-02-12T08:00:00.000+08:00,Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials,LLY,https://seekingalpha.com/news/3432086-boehringer-ingelheim-teams-ibm-explore-use-blockchain-clinical-trials?source=partner_benzinga,Seeking Alpha,,,,0,0,cf012ec6-af20-4086-baae-1a4f53de0305
2019-02-12T08:00:00.000+08:00,"Hot Options Report For End Of Day - Tuesday, Feb. 12",LLY,https://www.benzinga.com/node/13155620,TalkMarkets,,,,0,0,6e3b832b-4977-4cd2-829f-504be5d259c9
2019-02-12T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Tuesday, Feb. 12",LLY,https://www.benzinga.com/node/13152044,TalkMarkets,,,,0,0,55e4b610-42dc-4f24-a518-94da45131a6d
2019-02-12T08:00:00.000+08:00,Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials,LLY,https://seekingalpha.com/news/3432086-boehringer-ingelheim-teams-ibm-explore-use-blockchain-clinical-trials?source=partner_benzinga,Seeking Alpha,,,,0,0,002d5e59-db3e-40d3-9262-4f0c18831f9f
2019-02-11T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, Feb. 11",LLY,https://www.benzinga.com/node/13144295,TalkMarkets,,,,0,0,a0da869b-c8bd-42dd-8d2e-adfe55db14e3
2019-02-11T08:00:00.000+08:00,Alkermes Is Still An Attractive Pick,LLY,https://seekingalpha.com/article/4239938-alkermes-still-attractive-pick?source=partner_benzinga,Seeking Alpha,,,,0,0,a22056d1-450f-4d0a-b55f-27bb1479a55f
2019-02-11T08:00:00.000+08:00,Regeneron: Cheap Enough To Look Past The Eylea Valley,LLY,https://seekingalpha.com/article/4239839-regeneron-cheap-enough-look-past-eylea-valley?source=partner_benzinga,Seeking Alpha,,,,0,0,ce6d2c3b-7165-4d46-9691-30dc0bb7719d
2019-02-11T08:00:00.000+08:00,Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake,LLY,http://www.zacks.com/stock/news/353577/lilly-to-begin-exchange-offer-for-sale-of-balance-elanco-stake?cid=CS-BENZ-FT-353577,Zacks,,,,0,0,d7cd0547-9632-4dfd-91f5-f4185e616cce
2019-02-11T08:00:00.000+08:00,"Hot Options Report For End Of Day - Monday, Feb. 11",LLY,https://www.benzinga.com/node/13144295,TalkMarkets,,,,0,0,331c7bc8-55ef-4e45-a9eb-388d05b9949b
2019-02-11T08:00:00.000+08:00,Alkermes Is Still An Attractive Pick,LLY,https://seekingalpha.com/article/4239938-alkermes-still-attractive-pick?source=partner_benzinga,Seeking Alpha,,,,0,0,dfd80cda-0273-470a-96ef-93d95e5895fd
2019-02-11T08:00:00.000+08:00,Regeneron: Cheap Enough To Look Past The Eylea Valley,LLY,https://seekingalpha.com/article/4239839-regeneron-cheap-enough-look-past-eylea-valley?source=partner_benzinga,Seeking Alpha,,,,0,0,c5d74503-3ae3-4943-9520-5ac09dd52b6e
2019-02-11T08:00:00.000+08:00,Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake,LLY,http://www.zacks.com/stock/news/353577/lilly-to-begin-exchange-offer-for-sale-of-balance-elanco-stake?cid=CS-BENZ-FT-353577,Zacks,,,,0,0,bb50bd60-bc4f-4c67-9800-09fa8a884a62
2019-02-08T08:00:00.000+08:00,Eli Lilly Reports Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health,LLY,https://www.benzinga.com/news/19/02/13127520/eli-lilly-reports-will-initiate-divestiture-of-its-remaining-interest-in-elanco-,Benzinga Newsdesk,,,,0,0,12c68318-03af-4b56-b741-cdbaa29c576c
2019-02-08T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb. 8",LLY,https://www.benzinga.com/node/13133347,TalkMarkets,,,,0,0,2af4fbfa-1eef-4111-b552-79ed3b408a0e
2019-02-08T08:00:00.000+08:00,Incyte Down as FDA Extends Review Period of Jakafi for GVHD,LLY,http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-BENZ-FT-353405,Zacks,,,,0,0,4e34e711-c339-4214-9825-3bbbc06eb5e4
2019-02-08T08:00:00.000+08:00,Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition,LLY,https://seekingalpha.com/article/4239475-lilly-q4-looking-low-verzenio-sales-loxo-oncology-acquisition?source=partner_benzinga,Seeking Alpha,,,,0,0,d97816b0-729a-42d9-9eb6-94790d67f28f
2019-02-08T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Friday, Feb. 8",LLY,https://www.benzinga.com/node/13131230,TalkMarkets,,,,0,0,0cd6a50c-df6c-4ae7-8124-e3ec31673604
2019-02-08T08:00:00.000+08:00,The Diabetes Landscape Is Changing — Can This Stock Lead The Pack?,LLY,http://www.investors.com/research/the-new-america/diabetes-treatment-dexcom-stock/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,202301ad-4e95-4986-84c1-ba622d3dc9b9
2019-02-08T08:00:00.000+08:00,Lilly launches exchange offer for Elanco shares,LLY,https://seekingalpha.com/news/3431261-lilly-launches-exchange-offer-elanco-shares?source=partner_benzinga,Seeking Alpha,,,,0,0,91d9ca28-a7db-4879-aeb0-376563ec4e54
2019-02-08T08:00:00.000+08:00,Eli Lilly Reports Will Initiate Divestiture Of Its Remaining Interest In Elanco Animal Health,LLY,https://www.benzinga.com/news/19/02/13127520/eli-lilly-reports-will-initiate-divestiture-of-its-remaining-interest-in-elanco-,Benzinga Newsdesk,,,,0,0,fc50dea8-423b-4102-888a-231297eb4149
2019-02-08T08:00:00.000+08:00,"Hot Options Report For End Of Day - Friday, Feb. 8",LLY,https://www.benzinga.com/node/13133347,TalkMarkets,,,,0,0,01f5abdb-d18b-4d3a-8676-59da19efcc7f
2019-02-08T08:00:00.000+08:00,Incyte Down as FDA Extends Review Period of Jakafi for GVHD,LLY,http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-BENZ-FT-353405,Zacks,,,,0,0,8dfe52be-eb84-4d49-971f-d0782944a03d
2019-02-08T08:00:00.000+08:00,Lilly Q4: Looking At Low Verzenio Sales And The Loxo Oncology Acquisition,LLY,https://seekingalpha.com/article/4239475-lilly-q4-looking-low-verzenio-sales-loxo-oncology-acquisition?source=partner_benzinga,Seeking Alpha,,,,0,0,251d4933-1931-4da0-a1bb-5d13e25c5f6e
2019-02-08T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Friday, Feb. 8",LLY,https://www.benzinga.com/node/13131230,TalkMarkets,,,,0,0,866b1ea2-f141-46ac-9e50-5694065ed81e
2019-02-08T08:00:00.000+08:00,The Diabetes Landscape Is Changing — Can This Stock Lead The Pack?,LLY,http://www.investors.com/research/the-new-america/diabetes-treatment-dexcom-stock/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,8d49774e-a094-4c69-a537-b14058addc86
2019-02-08T08:00:00.000+08:00,Lilly launches exchange offer for Elanco shares,LLY,https://seekingalpha.com/news/3431261-lilly-launches-exchange-offer-elanco-shares?source=partner_benzinga,Seeking Alpha,,,,0,0,eeb58182-6d6c-43c0-b376-aad000745723
2019-02-07T08:00:00.000+08:00,Vertex: Shareholders Might Have Reason To Breathe More Easily,LLY,https://seekingalpha.com/article/4239272-vertex-shareholders-might-reason-breathe-easily?source=partner_benzinga,Seeking Alpha,,,,0,0,893eda59-afc3-456b-8405-8b9e4779e7fa
2019-02-07T08:00:00.000+08:00,Is Big Pharma Poised For A 2019 Buying Spree In Biotech Stocks?,LLY,http://www.investors.com/research/industry-snapshot/biotech-stocks-pharmaceutical-companies/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,3080398d-1c93-4c99-9838-c21dd52b010f
2019-02-07T08:00:00.000+08:00,Array BioPharma: Fairly Valued After Q2 Report,LLY,https://seekingalpha.com/article/4239030-array-biopharma-fairly-valued-q2-report?source=partner_benzinga,Seeking Alpha,,,,0,0,6c639cb4-eff5-4f7d-b018-ece7824db920
2019-02-07T08:00:00.000+08:00,"Stock Market News For Feb 7, 2019",LLY,http://www.zacks.com/stock/news/352868/stock-market-news-for-feb-7-2019?cid=CS-BENZ-FT-352868,Zacks,,,,0,0,379f06f0-526d-4b07-b0b4-35de02f4274a
2019-02-07T08:00:00.000+08:00,Vertex: Shareholders Might Have Reason To Breathe More Easily,LLY,https://seekingalpha.com/article/4239272-vertex-shareholders-might-reason-breathe-easily?source=partner_benzinga,Seeking Alpha,,,,0,0,d045a71a-9240-4475-ae11-1972756a9e15
2019-02-07T08:00:00.000+08:00,Is Big Pharma Poised For A 2019 Buying Spree In Biotech Stocks?,LLY,http://www.investors.com/research/industry-snapshot/biotech-stocks-pharmaceutical-companies/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,98004334-6444-4ff3-bfbf-cf76e0809c67
2019-02-07T08:00:00.000+08:00,Array BioPharma: Fairly Valued After Q2 Report,LLY,https://seekingalpha.com/article/4239030-array-biopharma-fairly-valued-q2-report?source=partner_benzinga,Seeking Alpha,,,,0,0,b6058e23-2b1e-40ce-a30e-e0e53d6ecae1
2019-02-07T08:00:00.000+08:00,"Stock Market News For Feb 7, 2019",LLY,http://www.zacks.com/stock/news/352868/stock-market-news-for-feb-7-2019?cid=CS-BENZ-FT-352868,Zacks,,,,0,0,1bfb1b47-7678-4b54-ac6a-5a2a2bf553ca
2019-02-06T08:00:00.000+08:00,"After State Of the Union, Focus Turns Again To Earnings News, Geopolitics, Fed",LLY,https://www.benzinga.com/news/earnings/19/02/13111084/after-state-of-the-union-focus-turns-again-to-earnings-news-geopolitics,JJ Kinahan,,,,0,0,9c2f23f5-ef6e-44d7-8e31-bff5f0a3c654
2019-02-06T08:00:00.000+08:00,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",LLY,https://www.benzinga.com/general/biotech/19/02/13108115/the-daily-biotech-pulse-paratek-launches-antibiotic-in-us-eli-lilly-e,Shanthi Rexaline,,,,0,0,1e7dde96-1d02-4319-b0e2-333930625a11
2019-02-06T08:00:00.000+08:00,Eli Lilly Guides FY19 EPS Of $5.55-5.65 vs $5.77 Est; Lowers FY19 Revenue Guidance From $25.3-25.8 Bln To $25.1-25.6 Bln vs $25.27 Bln Est,LLY,https://www.benzinga.com/news/earnings/19/02/13108640/eli-lilly-guides-fy19-eps-of-5-55-5-65-vs-5-77-est-lowers-fy19-revenue-,Benzinga_Newsdesk,,,,0,0,add22c74-f007-4dd4-a234-c71ac67f0eff
2019-02-06T08:00:00.000+08:00,"Lilly Q4 EPS $1.33 Misses $1.34 Est, Sales $6.438B Beat $6.28B Est.",LLY,https://www.benzinga.com/news/earnings/19/02/13108626/lilly-reports-q4-1-33share-vs-1-34-est-reports-q4-revenues-of-6-438-bln,Benzinga_Newsdesk,,,,0,0,91dd3fd2-2eb6-4d1f-af19-bca6ca9e671b
2019-02-06T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings,LLY,https://www.benzinga.com/news/earnings/19/02/13108605/a-peek-into-the-markets-us-stock-futures-down-ahead-of-earnings,Lisa Levin,,,,0,0,7b5344e2-b2bf-4b18-8cdd-76b3562ddcb8
2019-02-06T08:00:00.000+08:00,"13 Stocks To Watch For February 6, 2019",LLY,https://www.benzinga.com/news/earnings/19/02/13108221/13-stocks-to-watch-for-february-6-2019,Lisa Levin,,,,0,0,8db7af7e-e6f6-461f-bcd8-0fdda288e8ea
2019-02-06T08:00:00.000+08:00,"Earnings Scheduled For February 6, 2019",LLY,https://www.benzinga.com/news/earnings/19/02/13108178/earnings-scheduled-for-february-6-2019,Lisa Levin,,,,0,0,a1fe022e-804a-4789-a6e3-cbc434cb65bc
2019-02-06T08:00:00.000+08:00,This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag,LLY,http://www.investors.com/research/ibd-industry-themes/eli-lilly-earnings-eli-lilly-stock-glaxo-earnings-q4-2018/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,25bee80a-34ab-44af-a691-535f2b5137ec
2019-02-06T08:00:00.000+08:00,Array: Poised For Growth,LLY,https://seekingalpha.com/article/4238737-array-poised-growth?source=partner_benzinga,Seeking Alpha,,,,0,0,7fddaab9-e389-420b-9ac8-cb145d257d50
2019-02-06T08:00:00.000+08:00,Lilly bails on BTK inhibitor LY3337641,LLY,https://seekingalpha.com/news/3430381-lilly-bails-btk-inhibitor-ly3337641?source=partner_benzinga,Seeking Alpha,,,,0,0,61e56a19-8f19-44b7-b44f-9540ac7f8d83
2019-02-06T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4238673-eli-lilly-company-lly-ceo-dave-ricks-q4-2018-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,f85310e5-797e-41b1-a5e3-e4ba77f2e613
2019-02-06T08:00:00.000+08:00,"Elanco down 5% after Q4 report, Lilly plan to divest remaining shares",LLY,https://seekingalpha.com/news/3430266-elanco-5-percent-q4-report-lilly-plan-divest-remaining-shares?source=partner_benzinga,Seeking Alpha,,,,0,0,e23abc2d-8fea-4e14-834a-af0b668f18d3
2019-02-06T08:00:00.000+08:00,"Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down",LLY,http://www.zacks.com/stock/news/352494/lilly-lly-lags-q4-earnings-lowers-2019-view-stock-down?cid=CS-BENZ-FT-352494,Zacks,,,,0,0,74112aa2-d611-474c-b830-ffc9d3359370
2019-02-06T08:00:00.000+08:00,"Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View",LLY,http://www.zacks.com/stock/news/352407/eli-lilly-lly-lags-q4-earnings-tops-sales-cuts-2019-view?cid=CS-BENZ-FT-352407,Zacks,,,,0,0,b507300a-4d10-45cf-bff8-addc40f4e8d9
2019-02-06T08:00:00.000+08:00,Eli Lilly and Company 2018 Q4 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4238540-eli-lilly-company-2018-q4-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,0,0,9d09d651-85a8-4c67-80f3-b988fd578138
2019-02-06T08:00:00.000+08:00,"Eli Lilly misses by $0.01, beats on revenue",LLY,https://seekingalpha.com/news/3430040-eli-lilly-misses-0_01-beats-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,0c9fa6e2-cb3a-4db7-bbd3-f8c0b9ebfc22
2019-02-06T08:00:00.000+08:00,"After State Of the Union, Focus Turns Again To Earnings News, Geopolitics, Fed",LLY,https://www.benzinga.com/news/earnings/19/02/13111084/after-state-of-the-union-focus-turns-again-to-earnings-news-geopolitics,JJ Kinahan,,,,0,0,54dcd947-57e9-4b5b-8212-44088b1ba7c3
2019-02-06T08:00:00.000+08:00,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",LLY,https://www.benzinga.com/general/biotech/19/02/13108115/the-daily-biotech-pulse-paratek-launches-antibiotic-in-us-eli-lilly-e,Shanthi Rexaline,,,,0,0,822d7de1-f7ed-40f7-b11a-c597cdbe39dd
2019-02-06T08:00:00.000+08:00,Eli Lilly Guides FY19 EPS Of $5.55-5.65 vs $5.77 Est; Lowers FY19 Revenue Guidance From $25.3-25.8 Bln To $25.1-25.6 Bln vs $25.27 Bln Est,LLY,https://www.benzinga.com/news/earnings/19/02/13108640/eli-lilly-guides-fy19-eps-of-5-55-5-65-vs-5-77-est-lowers-fy19-revenue-,Benzinga_Newsdesk,,,,0,0,c1016991-8758-41dd-9b24-8f85c796fd1c
2019-02-06T08:00:00.000+08:00,"Lilly Q4 EPS $1.33 Misses $1.34 Est, Sales $6.438B Beat $6.28B Est.",LLY,https://www.benzinga.com/news/earnings/19/02/13108626/lilly-reports-q4-1-33share-vs-1-34-est-reports-q4-revenues-of-6-438-bln,Benzinga_Newsdesk,,,,0,0,5cfd2f18-a59a-4b99-9a73-90ae0585a834
2019-02-06T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings,LLY,https://www.benzinga.com/news/earnings/19/02/13108605/a-peek-into-the-markets-us-stock-futures-down-ahead-of-earnings,Lisa Levin,,,,0,0,ea39d02c-cf09-4e6a-ba97-7cdf3da1fec4
2019-02-06T08:00:00.000+08:00,"13 Stocks To Watch For February 6, 2019",LLY,https://www.benzinga.com/news/earnings/19/02/13108221/13-stocks-to-watch-for-february-6-2019,Lisa Levin,,,,0,0,e977c3d3-bf53-422b-b0eb-211009227857
2019-02-06T08:00:00.000+08:00,"Earnings Scheduled For February 6, 2019",LLY,https://www.benzinga.com/news/earnings/19/02/13108178/earnings-scheduled-for-february-6-2019,Lisa Levin,,,,0,0,aa20abed-360f-4310-b838-efb001a7aae4
2019-02-06T08:00:00.000+08:00,This Top Pharma Stock Undercut A Buy Point On Its Earnings Lag,LLY,http://www.investors.com/research/ibd-industry-themes/eli-lilly-earnings-eli-lilly-stock-glaxo-earnings-q4-2018/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,43988501-ffb6-4d84-894a-3455fb069e4a
2019-02-06T08:00:00.000+08:00,Array: Poised For Growth,LLY,https://seekingalpha.com/article/4238737-array-poised-growth?source=partner_benzinga,Seeking Alpha,,,,0,0,964b3100-62fe-464b-959e-2bfadd8358ed
2019-02-06T08:00:00.000+08:00,Lilly bails on BTK inhibitor LY3337641,LLY,https://seekingalpha.com/news/3430381-lilly-bails-btk-inhibitor-ly3337641?source=partner_benzinga,Seeking Alpha,,,,0,0,473f169e-61c3-4070-b23d-8d16a91ea4c3
2019-02-06T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2018 Results - Earnings Call Transcript,LLY,https://seekingalpha.com/article/4238673-eli-lilly-company-lly-ceo-dave-ricks-q4-2018-results-earnings-call-transcript?source=partner_benzinga,Seeking Alpha,,,,0,0,4a3b6cb4-618f-4616-9545-0e3e274f8b2e
2019-02-06T08:00:00.000+08:00,"Elanco down 5% after Q4 report, Lilly plan to divest remaining shares",LLY,https://seekingalpha.com/news/3430266-elanco-5-percent-q4-report-lilly-plan-divest-remaining-shares?source=partner_benzinga,Seeking Alpha,,,,0,0,6365cb56-e5ad-4504-85c5-78ed4df576f5
2019-02-06T08:00:00.000+08:00,"Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down",LLY,http://www.zacks.com/stock/news/352494/lilly-lly-lags-q4-earnings-lowers-2019-view-stock-down?cid=CS-BENZ-FT-352494,Zacks,,,,0,0,cce0928c-c911-4052-a174-ccccac5fd449
2019-02-06T08:00:00.000+08:00,"Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View",LLY,http://www.zacks.com/stock/news/352407/eli-lilly-lly-lags-q4-earnings-tops-sales-cuts-2019-view?cid=CS-BENZ-FT-352407,Zacks,,,,0,0,e61d7880-a2e6-4068-9d6f-e6838b6da3a8
2019-02-06T08:00:00.000+08:00,Eli Lilly and Company 2018 Q4 - Results - Earnings Call Slides,LLY,https://seekingalpha.com/article/4238540-eli-lilly-company-2018-q4-results-earnings-call-slides?source=partner_benzinga,Seeking Alpha,,,,0,0,b6da99e2-3c49-47b7-b071-f4e783c84275
2019-02-06T08:00:00.000+08:00,"Eli Lilly misses by $0.01, beats on revenue",LLY,https://seekingalpha.com/news/3430040-eli-lilly-misses-0_01-beats-revenue?source=partner_benzinga,Seeking Alpha,,,,0,0,9f6d4376-a272-45ea-9f45-82c46d983b31
2019-02-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",LLY,https://www.benzinga.com/general/biotech/19/02/13098290/the-daily-biotech-pulse-gilead-earnings-codexis-sings-pact-with-merck,Shanthi Rexaline,,,,0,0,2e74d057-2d63-4612-ac3b-73d8a083723c
2019-02-05T08:00:00.000+08:00,Selling Roche: Sector And Company-Specific Reasons,LLY,https://seekingalpha.com/article/4238279-selling-roche-sector-company-specific-reasons?source=partner_benzinga,Seeking Alpha,,,,0,0,a41a99fd-8ec1-4c40-a2c5-06792b036e49
2019-02-05T08:00:00.000+08:00,Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer,LLY,http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-BENZ-FT-352085,Zacks,,,,0,0,71d5d556-588c-4cf9-aaf5-4efcd43eb277
2019-02-05T08:00:00.000+08:00,Roche Submits sBLA to FDA for Label Expansion of Kadcyla,LLY,http://www.zacks.com/stock/news/352051/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla?cid=CS-BENZ-FT-352051,Zacks,,,,0,0,be605333-5b64-4880-8441-cb55cc0b74dd
2019-02-05T08:00:00.000+08:00,Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies,LLY,http://www.zacks.com/stock/news/351997/lilly-incytes-olumiant-meets-endpoint-in-eczema-studies?cid=CS-BENZ-FT-351997,Zacks,,,,0,0,dda9d653-2a69-44fe-8757-68769aa33778
2019-02-05T08:00:00.000+08:00,Lilly's baricitinib successful in late-stage dermatitis studies,LLY,https://seekingalpha.com/news/3429471-lillys-baricitinib-successful-late-stage-dermatitis-studies?source=partner_benzinga,Seeking Alpha,,,,0,0,3e7d7d66-0af9-4231-9a01-08eb6636a904
2019-02-05T08:00:00.000+08:00,"The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results",LLY,https://www.benzinga.com/general/biotech/19/02/13098290/the-daily-biotech-pulse-gilead-earnings-codexis-sings-pact-with-merck,Shanthi Rexaline,,,,0,0,54d40abb-1b0c-4bc0-858e-65729068cc16
2019-02-05T08:00:00.000+08:00,Selling Roche: Sector And Company-Specific Reasons,LLY,https://seekingalpha.com/article/4238279-selling-roche-sector-company-specific-reasons?source=partner_benzinga,Seeking Alpha,,,,0,0,db5d3fcb-41ae-43ce-bc50-fa2c40e5db2f
2019-02-05T08:00:00.000+08:00,Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer,LLY,http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-BENZ-FT-352085,Zacks,,,,0,0,f3942928-2144-4d7a-961d-93514a86973f
2019-02-05T08:00:00.000+08:00,Roche Submits sBLA to FDA for Label Expansion of Kadcyla,LLY,http://www.zacks.com/stock/news/352051/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla?cid=CS-BENZ-FT-352051,Zacks,,,,0,0,a3d1855e-4763-4a30-865d-902a268bd8a8
2019-02-05T08:00:00.000+08:00,Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies,LLY,http://www.zacks.com/stock/news/351997/lilly-incytes-olumiant-meets-endpoint-in-eczema-studies?cid=CS-BENZ-FT-351997,Zacks,,,,0,0,2f5a6251-5ca4-4fd9-b63f-1365b653b5e1
2019-02-05T08:00:00.000+08:00,Lilly's baricitinib successful in late-stage dermatitis studies,LLY,https://seekingalpha.com/news/3429471-lillys-baricitinib-successful-late-stage-dermatitis-studies?source=partner_benzinga,Seeking Alpha,,,,0,0,6c54e223-958f-497c-a166-9d8956e25416
2019-02-04T08:00:00.000+08:00,Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints,LLY,https://www.benzinga.com/news/19/02/13089677/eli-lilly-announces-two-phase-3-trials-of-baricitinib-met-their-primary-endpoint,Benzinga Newsdesk,,,,0,0,2f392179-7d19-4fe5-9ebd-2b312ea7094f
2019-02-04T08:00:00.000+08:00,Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy,LLY,http://www.zacks.com/stock/news/351848/teva-gains-positive-chmp-opinion-for-migraine-drug-ajovy?cid=CS-BENZ-FT-351848,Zacks,,,,0,0,1d521a98-ce93-4f07-8fc0-ebf9c5333031
2019-02-04T08:00:00.000+08:00,"Merger Arbitrage Mondays - February 4, 2019",LLY,https://seekingalpha.com/article/4237780-merger-arbitrage-mondays-february-4-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,62613adc-b05b-4b9f-97c0-da96a44e169d
2019-02-04T08:00:00.000+08:00,Eli Lilly Announces Two Phase 3 Trials of Baricitinib Met Their Primary Endpoints,LLY,https://www.benzinga.com/news/19/02/13089677/eli-lilly-announces-two-phase-3-trials-of-baricitinib-met-their-primary-endpoint,Benzinga Newsdesk,,,,0,0,f96b58e7-a7e1-4f31-8ed3-d51c2750b600
2019-02-04T08:00:00.000+08:00,Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy,LLY,http://www.zacks.com/stock/news/351848/teva-gains-positive-chmp-opinion-for-migraine-drug-ajovy?cid=CS-BENZ-FT-351848,Zacks,,,,0,0,d58d91cd-8401-4c23-bc49-ac531938151e
2019-02-04T08:00:00.000+08:00,"Merger Arbitrage Mondays - February 4, 2019",LLY,https://seekingalpha.com/article/4237780-merger-arbitrage-mondays-february-4-2019?source=partner_benzinga,Seeking Alpha,,,,0,0,fb2e5234-077b-4b48-9818-082eacabe7cd
2019-02-01T08:00:00.000+08:00,Trump At State Of The Union Will Ask For Drug Pricing Cuts,LLY,https://www.benzinga.com/news/19/02/13086160/trump-at-state-of-the-union-will-ask-for-drug-pricing-cuts,Benzinga Newsdesk,,,,0,0,5d1e78da-16c0-49d2-b6d1-6a80dbc90b67
2019-02-01T08:00:00.000+08:00,"Optum To Cover Amgen, Eli Lilly Migraine Drugs, Exclude Teva",LLY,https://www.benzinga.com/general/health-care/19/02/13083644/optum-to-cover-amgen-eli-lilly-migraine-drugs-exclude-teva,Benzinga Newsdesk,,,,0,0,55e90b4b-ff0e-4ea7-95f1-8c8addda872a
2019-02-01T08:00:00.000+08:00,Pharma Catches Another Case Of M&A Fever,LLY,https://www.benzinga.com/general/biotech/19/02/13083455/pharma-catches-another-case-of-m-a-fever,Chris Dier-Scalise,,,,0,0,55c829f2-190d-4b0a-9273-a84be37fc220
2019-02-01T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant",LLY,https://www.benzinga.com/general/biotech/19/02/13080524/the-daily-biotech-pulse-merck-earnings-positive-relaunch-of-titans-op,Shanthi Rexaline,,,,0,0,728d74ed-8ecc-49c5-92ef-f55bc61a1fba
2019-02-01T08:00:00.000+08:00,"Eli Lilly, Loxo Oncology Reports Expiration Of Hart-Scott-Rodino Antitrust Act Waiting Period For Proposed Deal",LLY,https://www.benzinga.com/news/19/02/13081295/eli-lilly-loxo-oncology-reports-expiration-of-hart-scott-rodino-antitrust-act-wa,Benzinga Newsdesk,,,,0,0,5d262f3e-da39-4913-9a4e-8193ef8bd686
2019-02-01T08:00:00.000+08:00,"Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat",LLY,http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-BENZ-FT-351653,Zacks,,,,0,0,b6171190-e0c6-424f-a380-a979cbbcefbf
2019-02-01T08:00:00.000+08:00,"UnitedHealth's Optum to cover Amgen and Lilly migraine meds, Teva excluded",LLY,https://seekingalpha.com/news/3428735-unitedhealths-optum-cover-amgen-lilly-migraine-meds-teva-excluded?source=partner_benzinga,Seeking Alpha,,,,0,0,f9a4bdab-b0af-43a4-aad4-16973c086cbd
2019-02-01T08:00:00.000+08:00,"Lilly (LLY) Hits 52-Week High, Can the Run Continue?",LLY,http://www.zacks.com/stock/news/351514/lilly-lly-hits-52-week-high-can-the-run-continue?cid=CS-BENZ-FT-351514,Zacks,,,,0,0,419eac93-d303-4176-b1e9-24ccad597dd7
2019-02-01T08:00:00.000+08:00,"Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY",LLY,http://www.zacks.com/stock/news/351448/pharma-stock-roundup-q4-earnings-pipeline-updates-at-pfe-rhhby?cid=CS-BENZ-FT-351448,Zacks,,,,0,0,1c709b3d-6a65-4918-9bd5-1fd60c176647
2019-02-01T08:00:00.000+08:00,Trump At State Of The Union Will Ask For Drug Pricing Cuts,LLY,https://www.benzinga.com/news/19/02/13086160/trump-at-state-of-the-union-will-ask-for-drug-pricing-cuts,Benzinga Newsdesk,,,,0,0,cdd2f908-b6e9-4ac4-916c-4782cbdac12f
2019-02-01T08:00:00.000+08:00,"Optum To Cover Amgen, Eli Lilly Migraine Drugs, Exclude Teva",LLY,https://www.benzinga.com/general/health-care/19/02/13083644/optum-to-cover-amgen-eli-lilly-migraine-drugs-exclude-teva,Benzinga Newsdesk,,,,0,0,9d77cf8e-6c27-4cf3-967e-a30d826a4c96
2019-02-01T08:00:00.000+08:00,Pharma Catches Another Case Of M&A Fever,LLY,https://www.benzinga.com/general/biotech/19/02/13083455/pharma-catches-another-case-of-m-a-fever,Chris Dier-Scalise,,,,0,0,f79d88ef-8579-4cd8-b81c-a6e0725a963a
2019-02-01T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant",LLY,https://www.benzinga.com/general/biotech/19/02/13080524/the-daily-biotech-pulse-merck-earnings-positive-relaunch-of-titans-op,Shanthi Rexaline,,,,0,0,5da08234-144c-4fc8-95c6-20906c282895
2019-02-01T08:00:00.000+08:00,"Eli Lilly, Loxo Oncology Reports Expiration Of Hart-Scott-Rodino Antitrust Act Waiting Period For Proposed Deal",LLY,https://www.benzinga.com/news/19/02/13081295/eli-lilly-loxo-oncology-reports-expiration-of-hart-scott-rodino-antitrust-act-wa,Benzinga Newsdesk,,,,0,0,7d98e037-1eb5-45ae-8dce-c00ed30be8cd
2019-02-01T08:00:00.000+08:00,"Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat",LLY,http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-BENZ-FT-351653,Zacks,,,,0,0,d9309518-0085-49d1-9023-050d69075e45
2019-02-01T08:00:00.000+08:00,"UnitedHealth's Optum to cover Amgen and Lilly migraine meds, Teva excluded",LLY,https://seekingalpha.com/news/3428735-unitedhealths-optum-cover-amgen-lilly-migraine-meds-teva-excluded?source=partner_benzinga,Seeking Alpha,,,,0,0,8128e601-b54b-43fc-8a4a-19817ccd13c2
2019-02-01T08:00:00.000+08:00,"Lilly (LLY) Hits 52-Week High, Can the Run Continue?",LLY,http://www.zacks.com/stock/news/351514/lilly-lly-hits-52-week-high-can-the-run-continue?cid=CS-BENZ-FT-351514,Zacks,,,,0,0,9f5e8f0d-3504-4b74-9349-98483b6c11ac
2019-02-01T08:00:00.000+08:00,"Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY",LLY,http://www.zacks.com/stock/news/351448/pharma-stock-roundup-q4-earnings-pipeline-updates-at-pfe-rhhby?cid=CS-BENZ-FT-351448,Zacks,,,,0,0,5fdde8e7-9d5d-493e-b086-65c69b39a8ec
2019-01-31T08:00:00.000+08:00,"Earnings, Volatility, Brexit Are Key Topics Heading Into February",LLY,https://www.benzinga.com/government/19/01/13077426/earnings-volatility-brexit-are-key-topics-heading-into-february,JJ Kinahan,,,,0,0,95d3f94e-ba37-45d5-8c79-9c0f37b8887f
2019-01-31T08:00:00.000+08:00,"Eli Lilly Reports FDA Expanded ALIMTA's Label To Combine KEYTRUDA, Platinum Chemotherapy For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lunch Cancer",LLY,https://www.benzinga.com/news/19/01/13071823/eli-lilly-reports-fda-expanded-alimtas-label-to-combine-keytruda-platinum-chemot,Benzinga Newsdesk,,,,0,0,274f07b1-a640-40ff-bc8b-ec141a96e85b
2019-01-31T08:00:00.000+08:00,J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study,LLY,http://www.zacks.com/stock/news/351417/jjs-erleada-meets-both-primary-endpoints-in-late-stage-study?cid=CS-BENZ-FT-351417,Zacks,,,,0,0,8a4e91a8-967e-4540-99b0-2e5dab3cfa14
2019-01-31T08:00:00.000+08:00,Entera Bio advancing osteoporosis candidate EB-613; shares up 3%,LLY,https://seekingalpha.com/news/3428239-entera-bio-advancing-osteoporosis-candidate-ebminus-613-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,5ff04747-844d-4381-8857-fba416b1782c
2019-01-31T08:00:00.000+08:00,Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?,LLY,http://www.zacks.com/stock/news/351124/eli-lilly-lly-q4-earnings-coming-up-whats-in-the-cards?cid=CS-BENZ-FT-351124,Zacks,,,,0,0,599be444-b39a-426c-96e8-b00fd58d139a
2019-01-31T08:00:00.000+08:00,FDA OKs new use for Lilly's Alimta,LLY,https://seekingalpha.com/news/3428023-fda-oks-new-use-lillys-alimta?source=partner_benzinga,Seeking Alpha,,,,0,0,86dfa99e-3838-45d8-8b75-03321fc7d633
2019-01-31T08:00:00.000+08:00,Another Alzheimer's Antibody Fails. There Will Be More,LLY,https://seekingalpha.com/article/4236924-another-alzheimers-antibody-fails-will?source=partner_benzinga,Seeking Alpha,,,,0,0,a22769ff-a2e2-49f2-bcc8-eb53e34e392b
2019-01-31T08:00:00.000+08:00,"Earnings, Volatility, Brexit Are Key Topics Heading Into February",LLY,https://www.benzinga.com/government/19/01/13077426/earnings-volatility-brexit-are-key-topics-heading-into-february,JJ Kinahan,,,,0,0,325cb83b-9b4c-4782-aea2-41a79e846db7
2019-01-31T08:00:00.000+08:00,"Eli Lilly Reports FDA Expanded ALIMTA's Label To Combine KEYTRUDA, Platinum Chemotherapy For First-Line Treatment Of Metastatic Nonsquamous Non-Small Cell Lunch Cancer",LLY,https://www.benzinga.com/news/19/01/13071823/eli-lilly-reports-fda-expanded-alimtas-label-to-combine-keytruda-platinum-chemot,Benzinga Newsdesk,,,,0,0,4ed9aa1a-9c95-47ad-af7f-1b40929a17c0
2019-01-31T08:00:00.000+08:00,J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study,LLY,http://www.zacks.com/stock/news/351417/jjs-erleada-meets-both-primary-endpoints-in-late-stage-study?cid=CS-BENZ-FT-351417,Zacks,,,,0,0,ba8a5968-e0d9-4bde-8b54-4905f66309e1
2019-01-31T08:00:00.000+08:00,Entera Bio advancing osteoporosis candidate EB-613; shares up 3%,LLY,https://seekingalpha.com/news/3428239-entera-bio-advancing-osteoporosis-candidate-ebminus-613-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,60bd2986-1383-47fe-bab9-5c84ad7fc2be
2019-01-31T08:00:00.000+08:00,Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?,LLY,http://www.zacks.com/stock/news/351124/eli-lilly-lly-q4-earnings-coming-up-whats-in-the-cards?cid=CS-BENZ-FT-351124,Zacks,,,,0,0,93040d67-134b-40dd-9a35-3501af2813e6
2019-01-31T08:00:00.000+08:00,FDA OKs new use for Lilly's Alimta,LLY,https://seekingalpha.com/news/3428023-fda-oks-new-use-lillys-alimta?source=partner_benzinga,Seeking Alpha,,,,0,0,64e4ace0-6004-4d44-bfa2-4376accdc6ad
2019-01-31T08:00:00.000+08:00,Another Alzheimer's Antibody Fails. There Will Be More,LLY,https://seekingalpha.com/article/4236924-another-alzheimers-antibody-fails-will?source=partner_benzinga,Seeking Alpha,,,,0,0,8ae8d4de-42ca-475a-83ef-9032197bcf77
2019-01-30T08:00:00.000+08:00,Stocks Going Ex-Dividend In February 2019,LLY,https://www.benzinga.com/node/13069106,TalkMarkets,,,,0,0,741675b7-9e76-412a-9a0f-6d7a9dfee1fe
2019-01-30T08:00:00.000+08:00,Stocks Going Ex-Dividend In February 2019,LLY,https://www.benzinga.com/node/13069106,TalkMarkets,,,,0,0,6540639d-b3bf-4fbc-8c6e-0e01745dd8ef
2019-01-29T08:00:00.000+08:00,Pfizer And Lilly Announce Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain Met All Three Co-Primary Endpoints At 24 Weeks,LLY,https://www.benzinga.com/general/biotech/19/01/13053531/pfizer-and-lilly-announce-second-phase-3-study-of-tanezumab-in-osteoa,Benzinga Newsdesk,,,,0,0,46215676-cec5-4d06-bd6c-882fdf87b1e2
2019-01-29T08:00:00.000+08:00,Tiny Israeli firm touts cancer cure,LLY,https://seekingalpha.com/news/3427030-tiny-israeli-firm-touts-cancer-cure?source=partner_benzinga,Seeking Alpha,,,,0,0,db8b2039-3c10-4b79-8509-c6f5ee1bd6a0
2019-01-29T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/350252/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-350252,Zacks,,,,0,0,5634d204-41f8-4cb4-940d-1a5b37da63fb
2019-01-29T08:00:00.000+08:00,Pfizer and Lilly's tanezumab successful in second late-stage study,LLY,https://seekingalpha.com/news/3426829-pfizer-lillys-tanezumab-successful-second-late-stage-study?source=partner_benzinga,Seeking Alpha,,,,0,0,56b8f2bd-4372-4d72-a706-f0149e728ded
2019-01-29T08:00:00.000+08:00,Pfizer And Lilly Announce Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain Met All Three Co-Primary Endpoints At 24 Weeks,LLY,https://www.benzinga.com/general/biotech/19/01/13053531/pfizer-and-lilly-announce-second-phase-3-study-of-tanezumab-in-osteoa,Benzinga Newsdesk,,,,0,0,ff16d74a-6529-4bfd-ac59-8e6b1fe11c11
2019-01-29T08:00:00.000+08:00,Tiny Israeli firm touts cancer cure,LLY,https://seekingalpha.com/news/3427030-tiny-israeli-firm-touts-cancer-cure?source=partner_benzinga,Seeking Alpha,,,,0,0,53592bb5-38b2-4ee6-a637-b27012bea551
2019-01-29T08:00:00.000+08:00,Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?,LLY,http://www.zacks.com/stock/news/350252/should-you-invest-in-the-vaneck-vectors-pharmaceutical-etf-pph?cid=CS-BENZ-FT-350252,Zacks,,,,0,0,710ea14f-3f57-4496-b99b-68152d58246a
2019-01-29T08:00:00.000+08:00,Pfizer and Lilly's tanezumab successful in second late-stage study,LLY,https://seekingalpha.com/news/3426829-pfizer-lillys-tanezumab-successful-second-late-stage-study?source=partner_benzinga,Seeking Alpha,,,,0,0,86571ae4-9bf7-436b-900d-3728104f4306
2019-01-28T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus",LLY,https://www.benzinga.com/news/19/01/13045164/a-peek-into-the-markets-us-stock-futures-down-caterpillar-earnings-in-focus,Lisa Levin,,,,0,0,ec7db654-0ece-4341-9dcd-f8b0384fafb4
2019-01-28T08:00:00.000+08:00,111 and Eli Lilly to Collaborate on Pharmaceutical Distribution With a Focus on Big Data and E-Prescriptions,LLY,https://www.benzinga.com/news/19/01/13045031/111-and-eli-lilly-to-collaborate-on-pharmaceutical-distribution-with-a-focus-on-,Benzinga Newsdesk,,,,0,0,d1c54ddb-cba4-4bbd-8d19-8d4c5ec23cb6
2019-01-28T08:00:00.000+08:00,Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?,LLY,http://www.zacks.com/stock/news/350151/dr-reddys-rdy-to-report-q3-earnings-whats-in-store?cid=CS-BENZ-FT-350151,Zacks,,,,0,0,1674095c-470d-43ab-ba77-6930add707c0
2019-01-28T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update,LLY,https://seekingalpha.com/article/4236060-tracking-ken-fishers-fisher-asset-management-portfolio-q4-2018-update?source=partner_benzinga,Seeking Alpha,,,,0,0,b66ef413-ac09-485b-8044-2dd49d3be1f1
2019-01-28T08:00:00.000+08:00,Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results,LLY,http://www.zacks.com/stock/news/350112/allergan-hikes-quarterly-dividend-by-28-ahead-of-q4-results?cid=CS-BENZ-FT-350112,Zacks,,,,0,0,2a3fad70-6ec2-46f6-839c-59d351d46489
2019-01-28T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck",LLY,http://www.zacks.com/stock/news/350036/the-zacks-analyst-blog-highlights-jj-bristol-myers-lilly-abbvie-and-merck?cid=CS-BENZ-FT-350036,Zacks,,,,0,0,3d97ddbc-2ff7-4fe6-a19b-a4f0933241c8
2019-01-28T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Down, Caterpillar Earnings In Focus",LLY,https://www.benzinga.com/news/19/01/13045164/a-peek-into-the-markets-us-stock-futures-down-caterpillar-earnings-in-focus,Lisa Levin,,,,0,0,b68e859d-0656-430d-9ca5-38d14ad89b2d
2019-01-28T08:00:00.000+08:00,111 and Eli Lilly to Collaborate on Pharmaceutical Distribution With a Focus on Big Data and E-Prescriptions,LLY,https://www.benzinga.com/news/19/01/13045031/111-and-eli-lilly-to-collaborate-on-pharmaceutical-distribution-with-a-focus-on-,Benzinga Newsdesk,,,,0,0,4b031331-a47f-483c-8a56-1bfc5604ce43
2019-01-28T08:00:00.000+08:00,Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?,LLY,http://www.zacks.com/stock/news/350151/dr-reddys-rdy-to-report-q3-earnings-whats-in-store?cid=CS-BENZ-FT-350151,Zacks,,,,0,0,b8757b41-08ee-48a4-b77d-5a5d9dc64157
2019-01-28T08:00:00.000+08:00,Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2018 Update,LLY,https://seekingalpha.com/article/4236060-tracking-ken-fishers-fisher-asset-management-portfolio-q4-2018-update?source=partner_benzinga,Seeking Alpha,,,,0,0,1c9b7528-c7c0-403e-9c7a-1d369c64f9a0
2019-01-28T08:00:00.000+08:00,Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results,LLY,http://www.zacks.com/stock/news/350112/allergan-hikes-quarterly-dividend-by-28-ahead-of-q4-results?cid=CS-BENZ-FT-350112,Zacks,,,,0,0,73a7ed07-1ada-4db7-bf05-4cdf17391a6e
2019-01-28T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck",LLY,http://www.zacks.com/stock/news/350036/the-zacks-analyst-blog-highlights-jj-bristol-myers-lilly-abbvie-and-merck?cid=CS-BENZ-FT-350036,Zacks,,,,0,0,fa06bb2a-efcb-4182-acc5-08877570c178
2019-01-27T08:00:00.000+08:00,AbbVie: Not Driving Via The Rearview Mirror,LLY,https://seekingalpha.com/article/4235824-abbvie-driving-via-rearview-mirror?source=partner_benzinga,Seeking Alpha,,,,0,0,8d193b77-d039-4017-9ed2-cf8808368d03
2019-01-27T08:00:00.000+08:00,AbbVie: Not Driving Via The Rearview Mirror,LLY,https://seekingalpha.com/article/4235824-abbvie-driving-via-rearview-mirror?source=partner_benzinga,Seeking Alpha,,,,0,0,2f77af6e-af0e-41da-9772-40036fd19e72
2019-01-25T08:00:00.000+08:00,"CVS Says Puts New Migraine Drugs From Teva And Eli Lilly On List Of Covered Medicines, Excludes Amgen's AIMOVIG",LLY,https://www.benzinga.com/news/19/01/13041549/cvs-says-puts-new-migraine-drugs-from-teva-and-eli-lilly-on-list-of-covered-medi,Benzinga Newsdesk,,,,0,0,29a89e8b-b67d-49b9-a049-25d121e895ff
2019-01-25T08:00:00.000+08:00,Amgen's Aimovig reportedly excluded from CVS plans,LLY,https://seekingalpha.com/news/3426166-amgens-aimovig-reportedly-excluded-cvs-plans?source=partner_benzinga,Seeking Alpha,,,,0,0,c52257de-4182-4cd6-9742-cafe885bb133
2019-01-25T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV",LLY,http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-BENZ-FT-349786,Zacks,,,,0,0,ec9efcc7-f739-4f91-9d70-e140950444f6
2019-01-25T08:00:00.000+08:00,Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds,LLY,http://www.zacks.com/stock/news/349760/merck-kgaa-gives-vertex-rights-to-two-gene-editing-compounds?cid=CS-BENZ-FT-349760,Zacks,,,,0,0,538b3c6c-5ceb-410d-813b-43fbd3e36a79
2019-01-25T08:00:00.000+08:00,"CVS Says Puts New Migraine Drugs From Teva And Eli Lilly On List Of Covered Medicines, Excludes Amgen's AIMOVIG",LLY,https://www.benzinga.com/news/19/01/13041549/cvs-says-puts-new-migraine-drugs-from-teva-and-eli-lilly-on-list-of-covered-medi,Benzinga Newsdesk,,,,0,0,8e830021-bcb0-49f9-9f42-daa44d48b4ba
2019-01-25T08:00:00.000+08:00,Amgen's Aimovig reportedly excluded from CVS plans,LLY,https://seekingalpha.com/news/3426166-amgens-aimovig-reportedly-excluded-cvs-plans?source=partner_benzinga,Seeking Alpha,,,,0,0,c49c56c4-31e9-433c-b70f-df617dc552cd
2019-01-25T08:00:00.000+08:00,"Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV",LLY,http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-BENZ-FT-349786,Zacks,,,,0,0,862ade79-9842-4829-8536-c40966c51e2e
2019-01-25T08:00:00.000+08:00,Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds,LLY,http://www.zacks.com/stock/news/349760/merck-kgaa-gives-vertex-rights-to-two-gene-editing-compounds?cid=CS-BENZ-FT-349760,Zacks,,,,0,0,2ff04ecd-a089-496d-876b-cf11bd9cffda
2019-01-24T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Jan. 24",LLY,https://www.benzinga.com/node/13036569,TalkMarkets,,,,0,0,c83d7568-de3d-4c2e-ad82-b3e5a179a7bb
2019-01-24T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Jan. 24",LLY,https://www.benzinga.com/node/13033560,TalkMarkets,,,,0,0,68e0d27c-da7c-433b-8274-3c9a818c414a
2019-01-24T08:00:00.000+08:00,Early Q4 reports weigh on large cap drug makers,LLY,https://seekingalpha.com/news/3425685-early-q4-reports-weigh-large-cap-drug-makers?source=partner_benzinga,Seeking Alpha,,,,0,0,61738b5b-f1af-4091-bde7-7fa6919d8a16
2019-01-24T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston",LLY,http://www.zacks.com/stock/news/349486/the-zacks-analyst-blog-highlights-archer-daniels-midland-molina-healthcare-eli-lilly-spark-energy-and-lamb-weston?cid=CS-BENZ-FT-349486,Zacks,,,,0,0,7edd6dae-7232-48f0-b7a1-b11f61064b1a
2019-01-24T08:00:00.000+08:00,Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids,LLY,http://www.zacks.com/stock/news/349470/sanofis-sny-influenza-vaccine-gets-fda-approval-for-kids?cid=CS-BENZ-FT-349470,Zacks,,,,0,0,3dd13e5c-39c4-4234-8951-549779b5fb2e
2019-01-24T08:00:00.000+08:00,"Hot Options Report For End Of Day - Thursday, Jan. 24",LLY,https://www.benzinga.com/node/13036569,TalkMarkets,,,,0,0,6d891f3a-ab19-4ec8-9c74-30ab670720b6
2019-01-24T08:00:00.000+08:00,"Most Active Equity Options And Strikes For Midday - Thursday, Jan. 24",LLY,https://www.benzinga.com/node/13033560,TalkMarkets,,,,0,0,0f9e0e0f-c10c-4a8b-9a4a-20ce6a7a7105
2019-01-24T08:00:00.000+08:00,Early Q4 reports weigh on large cap drug makers,LLY,https://seekingalpha.com/news/3425685-early-q4-reports-weigh-large-cap-drug-makers?source=partner_benzinga,Seeking Alpha,,,,0,0,2583609f-e7ec-4b8c-b623-45e3f3ba27cb
2019-01-24T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Archer Daniels Midland, Molina Healthcare, Eli Lilly, Spark Energy and Lamb Weston",LLY,http://www.zacks.com/stock/news/349486/the-zacks-analyst-blog-highlights-archer-daniels-midland-molina-healthcare-eli-lilly-spark-energy-and-lamb-weston?cid=CS-BENZ-FT-349486,Zacks,,,,0,0,b4900236-cc80-48e8-8065-500fc0636fe5
2019-01-24T08:00:00.000+08:00,Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids,LLY,http://www.zacks.com/stock/news/349470/sanofis-sny-influenza-vaccine-gets-fda-approval-for-kids?cid=CS-BENZ-FT-349470,Zacks,,,,0,0,40f41006-f060-4d43-80d1-10c012c9e2ac
2019-01-23T08:00:00.000+08:00,European Medicines Agency Says No New Patients Should Start Treatment With Lilly's Lartruvo After Study Shows Cancer Medicine Does Not Prolong Life,LLY,https://www.benzinga.com/general/biotech/19/01/13023766/european-medicines-agency-says-no-new-patients-should-start-treatment,Benzinga Newsdesk,,,,0,0,b6271d1e-1033-4b76-bd46-b87fe591cff7
2019-01-23T08:00:00.000+08:00,UBS Initiates Coverage On Eli Lilly with Buy Rating,LLY,https://www.benzinga.com/news/19/01/13023247/ubs-initiates-coverage-on-eli-lilly-with-buy-rating,Benzinga_Newsdesk,,,,0,0,24ae09f7-9770-4ac1-9de8-bb4ad8b0b684
2019-01-23T08:00:00.000+08:00,5 Best Biotech Bets Likely to Outperform Estimates in Q4,LLY,http://www.zacks.com/stock/news/349155/5-best-biotech-bets-likely-to-outperform-estimates-in-q4?cid=CS-BENZ-FT-349155,Zacks,,,,0,0,fea1ac03-eca5-4262-be89-479b137540c5
2019-01-23T08:00:00.000+08:00,UBS likes Lilly in premarket analyst action,LLY,https://seekingalpha.com/news/3425002-ubs-likes-lilly-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,7cee3c5b-cfef-47dc-826f-4f16593a74b5
2019-01-23T08:00:00.000+08:00,6 Stocks to Prepare for a Global Economic Slowdown,LLY,http://www.zacks.com/stock/news/348943/6-stocks-to-prepare-for-a-global-economic-slowdown?cid=CS-BENZ-FT-348943,Zacks,,,,0,0,d6311566-1a4b-44d4-81d2-3bddf24a7a0c
2019-01-23T08:00:00.000+08:00,Teva up 3% premarket on bullish call at UBS,LLY,https://seekingalpha.com/news/3425050-teva-3-percent-premarket-bullish-call-ubs?source=partner_benzinga,Seeking Alpha,,,,0,0,6315692c-ceaa-4ba9-acd4-785d85e2b911
2019-01-23T08:00:00.000+08:00,Treatment with Lilly's Lartruvo to cease in Europe,LLY,https://seekingalpha.com/news/3425041-treatment-lillys-lartruvo-cease-europe?source=partner_benzinga,Seeking Alpha,,,,0,0,c55a9290-4b02-46f5-95fc-94d4916671b6
2019-01-23T08:00:00.000+08:00,Insulin costs in U.S. doubled from 2012 - 2016,LLY,https://seekingalpha.com/news/3424992-insulin-costs-u-s-doubled-2012-2016?source=partner_benzinga,Seeking Alpha,,,,0,0,213f0d7e-942f-49b1-945d-47a9a5986290
2019-01-23T08:00:00.000+08:00,European Medicines Agency Says No New Patients Should Start Treatment With Lilly's Lartruvo After Study Shows Cancer Medicine Does Not Prolong Life,LLY,https://www.benzinga.com/general/biotech/19/01/13023766/european-medicines-agency-says-no-new-patients-should-start-treatment,Benzinga Newsdesk,,,,0,0,4bb101cd-12bb-47f0-9d46-292692e9f0cb
2019-01-23T08:00:00.000+08:00,UBS Initiates Coverage On Eli Lilly with Buy Rating,LLY,https://www.benzinga.com/news/19/01/13023247/ubs-initiates-coverage-on-eli-lilly-with-buy-rating,Benzinga_Newsdesk,,,,0,0,2c7f6b66-983b-46d8-83ec-bc27bf3d00ee
2019-01-23T08:00:00.000+08:00,5 Best Biotech Bets Likely to Outperform Estimates in Q4,LLY,http://www.zacks.com/stock/news/349155/5-best-biotech-bets-likely-to-outperform-estimates-in-q4?cid=CS-BENZ-FT-349155,Zacks,,,,0,0,4e9fbd05-0089-4d8f-9445-4348c47d1c17
2019-01-23T08:00:00.000+08:00,UBS likes Lilly in premarket analyst action,LLY,https://seekingalpha.com/news/3425002-ubs-likes-lilly-premarket-analyst-action?source=partner_benzinga,Seeking Alpha,,,,0,0,87aa8ca6-ac46-4536-900c-24ad9b881100
2019-01-23T08:00:00.000+08:00,6 Stocks to Prepare for a Global Economic Slowdown,LLY,http://www.zacks.com/stock/news/348943/6-stocks-to-prepare-for-a-global-economic-slowdown?cid=CS-BENZ-FT-348943,Zacks,,,,0,0,5f595982-8b79-4b10-a1ba-6b938b120d17
2019-01-23T08:00:00.000+08:00,Teva up 3% premarket on bullish call at UBS,LLY,https://seekingalpha.com/news/3425050-teva-3-percent-premarket-bullish-call-ubs?source=partner_benzinga,Seeking Alpha,,,,0,0,52cc00c2-9f74-4c5a-9742-b08b9eb3bf48
2019-01-23T08:00:00.000+08:00,Treatment with Lilly's Lartruvo to cease in Europe,LLY,https://seekingalpha.com/news/3425041-treatment-lillys-lartruvo-cease-europe?source=partner_benzinga,Seeking Alpha,,,,0,0,c0d0755c-8ecb-45c2-8237-2515729ed62e
2019-01-23T08:00:00.000+08:00,Insulin costs in U.S. doubled from 2012 - 2016,LLY,https://seekingalpha.com/news/3424992-insulin-costs-u-s-doubled-2012-2016?source=partner_benzinga,Seeking Alpha,,,,0,0,d0716745-01c3-4be0-8c0b-a1b3afe1931f
2019-01-22T08:00:00.000+08:00,Johnson & Johnson Shares Fall on Disappointing —…–9 Outlook,LLY,http://www.gurufocus.com/news/803452/johnson--johnson-shares-fall-on-disappointing-2019-outlook-,GuruFocus,,,,0,0,2642ba3d-668e-4c42-b96b-04ce6718c648
2019-01-22T08:00:00.000+08:00,"Company News For Jan 22, 2019",LLY,http://www.zacks.com/stock/news/348839/company-news-for-jan-22-2019?cid=CS-BENZ-FT-348839,Zacks,,,,0,0,e1c3e99c-2daa-472d-a850-f70bc0609719
2019-01-22T08:00:00.000+08:00,Johnson & Johnson Shares Fall on Disappointing —…–9 Outlook,LLY,http://www.gurufocus.com/news/803452/johnson--johnson-shares-fall-on-disappointing-2019-outlook-,GuruFocus,,,,0,0,4acbcf62-9aaf-426b-abae-28d9fda7ad3c
2019-01-22T08:00:00.000+08:00,"Company News For Jan 22, 2019",LLY,http://www.zacks.com/stock/news/348839/company-news-for-jan-22-2019?cid=CS-BENZ-FT-348839,Zacks,,,,0,0,7365a9ee-e797-4372-89f1-dcc039a37033
2019-01-18T08:00:00.000+08:00,Eli Lilly shares are trading lower after the company announced the Phase 3 study of LARTRUVO did not meet its primary endpoint.,LLY,https://www.benzinga.com/markets/wiim/19/01/13006253/eli-lilly-shares-are-trading-lower-after-the-company-announced-the-phase,Hal Lindon,,,,0,0,788b4626-438b-4878-8336-12ce6f49a359
2019-01-18T08:00:00.000+08:00,40 Stocks Moving In Friday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/01/13005824/40-stocks-moving-in-fridays-pre-market-session,Lisa Levin,,,,0,0,0d40866d-c636-4929-aaec-1874422c0fc9
2019-01-18T08:00:00.000+08:00,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",LLY,https://www.benzinga.com/general/biotech/19/01/13004869/the-daily-biotech-pulse-regulatory-roadblock-for-immunomedics-adcom-s,Shanthi Rexaline,,,,0,0,1e1c6ffb-4b54-4d80-92f1-5f12ca7da690
2019-01-18T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/19/01/13005404/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,0,0,18ab402b-914b-49f1-9c71-fca7430e15f5
2019-01-18T08:00:00.000+08:00,Eli Lilly's Phase 3 Study of LARTRUVO Did Not Meet Its Primary Endpoint,LLY,https://www.benzinga.com/news/19/01/13005262/eli-lillys-phase-3-study-of-lartruvo-did-not-meet-its-primary-endpoint,Benzinga Newsdesk,,,,0,0,ebd4a4e0-3dc9-4a0a-ace2-d2661d1473dc
2019-01-18T08:00:00.000+08:00,Realty Income: Halftime Report,LLY,https://seekingalpha.com/article/4234336-realty-income-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,4ab01082-bfd9-4b2c-9f05-e6bf695cdb45
2019-01-18T08:00:00.000+08:00,Eli Lilly to stop promoting Lartruvo after Phase 3 flop; shares down 3%,LLY,https://seekingalpha.com/news/3424279-eli-lilly-stop-promoting-lartruvo-phase-3-flop-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,364f826e-9641-43ea-b200-33a195057b8c
2019-01-18T08:00:00.000+08:00,"Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY",LLY,http://www.zacks.com/stock/news/348355/pharma-stock-roundup-regulatory-updates-in-focus-at-pfe-bmy-rhhby-sny?cid=CS-BENZ-FT-348355,Zacks,,,,0,0,24273fc5-88d1-4af9-ac01-d40e6645f960
2019-01-18T08:00:00.000+08:00,Lilly's olaratumab flunks late-stage soft tissue sarcoma study,LLY,https://seekingalpha.com/news/3424174-lillys-olaratumab-flunks-late-stage-soft-tissue-sarcoma-study?source=partner_benzinga,Seeking Alpha,,,,0,0,86016ae9-99de-40fe-92f7-03d0f1762aab
2019-01-18T08:00:00.000+08:00,Zymeworks earns $8M milestone from licensee Lilly,LLY,https://seekingalpha.com/news/3424166-zymeworks-earns-8m-milestone-licensee-lilly?source=partner_benzinga,Seeking Alpha,,,,0,0,c95a9951-2e5a-4c1b-9e57-5c23d1a7587b
2019-01-18T08:00:00.000+08:00,Eli Lilly shares are trading lower after the company announced the Phase 3 study of LARTRUVO did not meet its primary endpoint.,LLY,https://www.benzinga.com/markets/wiim/19/01/13006253/eli-lilly-shares-are-trading-lower-after-the-company-announced-the-phase,Hal Lindon,,,,0,0,95b79ae0-02b1-4740-88c4-090eb24432f5
2019-01-18T08:00:00.000+08:00,40 Stocks Moving In Friday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/01/13005824/40-stocks-moving-in-fridays-pre-market-session,Lisa Levin,,,,0,0,814271f1-c60b-4baf-9706-4957d3473ed7
2019-01-18T08:00:00.000+08:00,"The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug",LLY,https://www.benzinga.com/general/biotech/19/01/13004869/the-daily-biotech-pulse-regulatory-roadblock-for-immunomedics-adcom-s,Shanthi Rexaline,,,,0,0,26e2d2db-4d0a-4168-a827-b991f32cb433
2019-01-18T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/19/01/13005404/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,0,0,61d63fc0-83a3-45f9-8715-9f7915639ae9
2019-01-18T08:00:00.000+08:00,Eli Lilly's Phase 3 Study of LARTRUVO Did Not Meet Its Primary Endpoint,LLY,https://www.benzinga.com/news/19/01/13005262/eli-lillys-phase-3-study-of-lartruvo-did-not-meet-its-primary-endpoint,Benzinga Newsdesk,,,,0,0,166b0c26-c1ca-4bbb-9a1a-6b3d95533f80
2019-01-18T08:00:00.000+08:00,Realty Income: Halftime Report,LLY,https://seekingalpha.com/article/4234336-realty-income-halftime-report?source=partner_benzinga,Seeking Alpha,,,,0,0,74fb912a-f25c-48cb-8467-2f02eb891ea6
2019-01-18T08:00:00.000+08:00,Eli Lilly to stop promoting Lartruvo after Phase 3 flop; shares down 3%,LLY,https://seekingalpha.com/news/3424279-eli-lilly-stop-promoting-lartruvo-phase-3-flop-shares-3-percent?source=partner_benzinga,Seeking Alpha,,,,0,0,bc2a4c0c-b38c-4be3-ba65-fe40158a56d2
2019-01-18T08:00:00.000+08:00,"Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY",LLY,http://www.zacks.com/stock/news/348355/pharma-stock-roundup-regulatory-updates-in-focus-at-pfe-bmy-rhhby-sny?cid=CS-BENZ-FT-348355,Zacks,,,,0,0,4d0403bb-af50-46bc-9339-499d8ac84a92
2019-01-18T08:00:00.000+08:00,Lilly's olaratumab flunks late-stage soft tissue sarcoma study,LLY,https://seekingalpha.com/news/3424174-lillys-olaratumab-flunks-late-stage-soft-tissue-sarcoma-study?source=partner_benzinga,Seeking Alpha,,,,0,0,ce48ec14-5eb6-49ed-82f1-5579da26caa3
2019-01-18T08:00:00.000+08:00,Zymeworks earns $8M milestone from licensee Lilly,LLY,https://seekingalpha.com/news/3424166-zymeworks-earns-8m-milestone-licensee-lilly?source=partner_benzinga,Seeking Alpha,,,,0,0,8ae05e1a-e533-4b71-97c8-d37e78f44e17
2019-01-17T08:00:00.000+08:00,Zymeworks to Receive an 8M Milestone Payment from Eli Lilly,LLY,https://www.benzinga.com/news/19/01/13003543/zymeworks-to-receive-an-8m-milestone-payment-from-eli-lilly,Benzinga Newsdesk,,,,0,0,e73f5fb2-6675-429f-91e9-2b49dbb816c0
2019-01-17T08:00:00.000+08:00,Eli Lilly And Ablexis Announces Expansion Of Non-Exclusive Perpetual License Agreement; Expanded Rights To Allow For Broader Use Of ALIVAMAB Mouse Platform,LLY,https://www.benzinga.com/general/biotech/19/01/12998311/eli-lilly-and-ablexis-announces-expansion-of-non-exclusive-perpetual-,Benzinga Newsdesk,,,,0,0,996a1c09-216b-4426-81bc-12c2aa403920
2019-01-17T08:00:00.000+08:00,Ligand (LGND) Takes a Hit on Citron's Negative Research Report,LLY,http://www.zacks.com/stock/news/348173/ligand-lgnd-takes-a-hit-on-citrons-negative-research-report?cid=CS-BENZ-FT-348173,Zacks,,,,0,0,ebcc6bd7-dc9c-4cd9-bb51-25ceed1d4b25
2019-01-17T08:00:00.000+08:00,Eli Lilly: An Update,LLY,https://seekingalpha.com/article/4233901-eli-lilly-update?source=partner_benzinga,Seeking Alpha,,,,0,0,5f33d75d-c5a5-4b73-adf4-a271a49249e6
2019-01-17T08:00:00.000+08:00,Zymeworks to Receive an 8M Milestone Payment from Eli Lilly,LLY,https://www.benzinga.com/news/19/01/13003543/zymeworks-to-receive-an-8m-milestone-payment-from-eli-lilly,Benzinga Newsdesk,,,,0,0,b02f6955-5806-42e3-b70e-d8125beeec78
2019-01-17T08:00:00.000+08:00,Eli Lilly And Ablexis Announces Expansion Of Non-Exclusive Perpetual License Agreement; Expanded Rights To Allow For Broader Use Of ALIVAMAB Mouse Platform,LLY,https://www.benzinga.com/general/biotech/19/01/12998311/eli-lilly-and-ablexis-announces-expansion-of-non-exclusive-perpetual-,Benzinga Newsdesk,,,,0,0,43391b2b-68d8-4699-8bfb-7a2e598fd034
2019-01-17T08:00:00.000+08:00,Ligand (LGND) Takes a Hit on Citron's Negative Research Report,LLY,http://www.zacks.com/stock/news/348173/ligand-lgnd-takes-a-hit-on-citrons-negative-research-report?cid=CS-BENZ-FT-348173,Zacks,,,,0,0,b3d9f679-9416-427d-9c28-10bd9e16c7de
2019-01-17T08:00:00.000+08:00,Eli Lilly: An Update,LLY,https://seekingalpha.com/article/4233901-eli-lilly-update?source=partner_benzinga,Seeking Alpha,,,,0,0,ef0074a0-b483-4bff-a4f2-4cd65c9a11a8
2019-01-16T08:00:00.000+08:00,Eli Lilly Form 4 From Lilly Endowment Shows Open Market Sale Of ~51.8K Shares At $117.744/Share,LLY,https://www.benzinga.com/news/19/01/12995122/eli-lilly-form-4-from-lilly-endowment-shows-open-market-sale-of-51-8k-shares-at-,Benzinga Newsdesk,,,,0,0,09e4dff2-16b7-491d-9874-d69c3d2090ab
2019-01-16T08:00:00.000+08:00,Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings,LLY,http://www.zacks.com/stock/news/347859/kitov-pharmas-stock-up-on-anti-cancer-candidate-findings?cid=CS-BENZ-FT-347859,Zacks,,,,0,0,db8f5902-8cf8-488b-a687-170bd403af16
2019-01-16T08:00:00.000+08:00,Intrexon Signs Licensing Agreement with Next Green Wave,LLY,http://www.zacks.com/stock/news/347858/intrexon-signs-licensing-agreement-with-next-green-wave?cid=CS-BENZ-FT-347858,Zacks,,,,0,0,a77e019f-d883-40de-8b58-d9db7951b030
2019-01-16T08:00:00.000+08:00,Hospitals squeezed by high drug costs,LLY,https://seekingalpha.com/news/3423552-hospitals-squeezed-high-drug-costs?source=partner_benzinga,Seeking Alpha,,,,0,0,27373954-6746-4c4d-a4f6-4b3ed8ef6ae4
2019-01-16T08:00:00.000+08:00,Biopharma firms under pressure on Brexit uncertainty,LLY,https://seekingalpha.com/news/3423533-biopharma-firms-pressure-brexit-uncertainty?source=partner_benzinga,Seeking Alpha,,,,0,0,e832cc31-55b2-491c-a6a0-fe510372bcd1
2019-01-16T08:00:00.000+08:00,6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019,LLY,http://www.zacks.com/stock/news/347690/6-reasons-why-you-should-buy-eli-lilly-lly-stock-in-2019?cid=CS-BENZ-FT-347690,Zacks,,,,0,0,cdd96703-4dd0-4177-9dc4-245fe23f20b2
2019-01-16T08:00:00.000+08:00,Eli Lilly Form 4 From Lilly Endowment Shows Open Market Sale Of ~51.8K Shares At $117.744/Share,LLY,https://www.benzinga.com/news/19/01/12995122/eli-lilly-form-4-from-lilly-endowment-shows-open-market-sale-of-51-8k-shares-at-,Benzinga Newsdesk,,,,0,0,9531c8b3-f453-4d73-99bf-e7feb15d2529
2019-01-16T08:00:00.000+08:00,Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings,LLY,http://www.zacks.com/stock/news/347859/kitov-pharmas-stock-up-on-anti-cancer-candidate-findings?cid=CS-BENZ-FT-347859,Zacks,,,,0,0,4e97a0ca-aabc-4bbb-90d7-9db0873014e4
2019-01-16T08:00:00.000+08:00,Intrexon Signs Licensing Agreement with Next Green Wave,LLY,http://www.zacks.com/stock/news/347858/intrexon-signs-licensing-agreement-with-next-green-wave?cid=CS-BENZ-FT-347858,Zacks,,,,0,0,3d30c1be-50ff-47b5-b9be-9944ed6c00fb
2019-01-16T08:00:00.000+08:00,Hospitals squeezed by high drug costs,LLY,https://seekingalpha.com/news/3423552-hospitals-squeezed-high-drug-costs?source=partner_benzinga,Seeking Alpha,,,,0,0,844d5673-81a4-48ff-96f1-b218cf4d443f
2019-01-16T08:00:00.000+08:00,Biopharma firms under pressure on Brexit uncertainty,LLY,https://seekingalpha.com/news/3423533-biopharma-firms-pressure-brexit-uncertainty?source=partner_benzinga,Seeking Alpha,,,,0,0,2b968bb6-f14b-4818-967d-0fd9dfc52cf7
2019-01-16T08:00:00.000+08:00,6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019,LLY,http://www.zacks.com/stock/news/347690/6-reasons-why-you-should-buy-eli-lilly-lly-stock-in-2019?cid=CS-BENZ-FT-347690,Zacks,,,,0,0,2906f500-433b-4d2c-af7b-4e9a9d6d8f32
2019-01-15T08:00:00.000+08:00,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding ...",LLY,http://www.gurufocus.com/news/800508/shareholder-alert-levi--korsinsky-llp-reminds-investors-of-an-investigation-regarding-whether-the-sale-of-loxo-oncology-inc-to-eli-lilly-and-company-is-fair-to-shareholders,GuruFocus,,,,0,0,a2ed16f3-93d1-445e-8952-8bd7bdc64e60
2019-01-15T08:00:00.000+08:00,FDA to beef up cell and gene therapy staff,LLY,https://seekingalpha.com/news/3423193-fda-beef-cell-gene-therapy-staff?source=partner_benzinga,Seeking Alpha,,,,0,0,8bbf5919-3a68-4c93-80ee-af2c510a4834
2019-01-15T08:00:00.000+08:00,FDA Commish touts advances/successes,LLY,https://seekingalpha.com/news/3423185-fda-commish-touts-advances-successes?source=partner_benzinga,Seeking Alpha,,,,0,0,f959987c-3644-4979-832f-8dda3e7b3df8
2019-01-15T08:00:00.000+08:00,Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer,LLY,http://www.zacks.com/stock/news/347471/bristol-myers-drug-combination-gets-eu-nod-for-renal-cancer?cid=CS-BENZ-FT-347471,Zacks,,,,0,0,e16c3736-f795-4d87-8b55-3d10a70ccba1
2019-01-15T08:00:00.000+08:00,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding ...",LLY,http://www.gurufocus.com/news/800508/shareholder-alert-levi--korsinsky-llp-reminds-investors-of-an-investigation-regarding-whether-the-sale-of-loxo-oncology-inc-to-eli-lilly-and-company-is-fair-to-shareholders,GuruFocus,,,,0,0,98bede78-d07f-4723-baaf-ddb74f952ae2
2019-01-15T08:00:00.000+08:00,FDA to beef up cell and gene therapy staff,LLY,https://seekingalpha.com/news/3423193-fda-beef-cell-gene-therapy-staff?source=partner_benzinga,Seeking Alpha,,,,0,0,121e8181-fca6-4013-8c85-5eac917417b8
2019-01-15T08:00:00.000+08:00,FDA Commish touts advances/successes,LLY,https://seekingalpha.com/news/3423185-fda-commish-touts-advances-successes?source=partner_benzinga,Seeking Alpha,,,,0,0,9a305053-5b83-4597-aae8-8cc33d0dfd9b
2019-01-15T08:00:00.000+08:00,Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer,LLY,http://www.zacks.com/stock/news/347471/bristol-myers-drug-combination-gets-eu-nod-for-renal-cancer?cid=CS-BENZ-FT-347471,Zacks,,,,0,0,398c52f3-8490-4362-92e2-78bf101e6f0d
2019-01-14T08:00:00.000+08:00,"Merger Arbitrage Mondays - January 14, 2018",LLY,https://seekingalpha.com/article/4233349-merger-arbitrage-mondays-january-14-2018?source=partner_benzinga,Seeking Alpha,,,,0,0,3033b2f5-44b1-445d-ac18-65bcdf783874
2019-01-14T08:00:00.000+08:00,Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know,LLY,http://www.zacks.com/stock/news/347317/eli-lilly-lly-dips-more-than-broader-markets-what-you-should-know?cid=CS-BENZ-FT-347317,Zacks,,,,0,0,0618fb83-788d-4603-b485-e76035eed8b7
2019-01-14T08:00:00.000+08:00,"Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene",LLY,https://seekingalpha.com/article/4233282-eli-lilly-loxo-make-sense-bristol-myers-celgene?source=partner_benzinga,Seeking Alpha,,,,0,0,d4535fb6-2ed6-4e86-8fef-b7f250ae792b
2019-01-14T08:00:00.000+08:00,Rep. Cummings opens investigation into drug prices,LLY,https://seekingalpha.com/news/3422823-rep-cummings-opens-investigation-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,3a348a74-b9c2-4742-8bbd-c7cd3be1a40b
2019-01-14T08:00:00.000+08:00,A Planned Spinoff Of Cancer Vaccines At Generex,LLY,https://seekingalpha.com/article/4233211-planned-spinoff-cancer-vaccines-generex?source=partner_benzinga,Seeking Alpha,,,,0,0,707d341b-5837-4aaa-8aba-3b66bcf06eb4
2019-01-14T08:00:00.000+08:00,"Merger Arbitrage Mondays - January 14, 2018",LLY,https://seekingalpha.com/article/4233349-merger-arbitrage-mondays-january-14-2018?source=partner_benzinga,Seeking Alpha,,,,0,0,a50f3cff-f63b-455c-9a66-d673e377a6b0
2019-01-14T08:00:00.000+08:00,Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know,LLY,http://www.zacks.com/stock/news/347317/eli-lilly-lly-dips-more-than-broader-markets-what-you-should-know?cid=CS-BENZ-FT-347317,Zacks,,,,0,0,90289b8e-3891-45cf-9cab-e1b779a1bc40
2019-01-14T08:00:00.000+08:00,"Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene",LLY,https://seekingalpha.com/article/4233282-eli-lilly-loxo-make-sense-bristol-myers-celgene?source=partner_benzinga,Seeking Alpha,,,,0,0,4c4c1cce-a981-4a42-a359-3a90fd5df33f
2019-01-14T08:00:00.000+08:00,Rep. Cummings opens investigation into drug prices,LLY,https://seekingalpha.com/news/3422823-rep-cummings-opens-investigation-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,0d7956e0-60df-447d-956d-6a73721f7272
2019-01-14T08:00:00.000+08:00,A Planned Spinoff Of Cancer Vaccines At Generex,LLY,https://seekingalpha.com/article/4233211-planned-spinoff-cancer-vaccines-generex?source=partner_benzinga,Seeking Alpha,,,,0,0,4deaf21e-90d4-4906-b0de-64593e535da4
2019-01-13T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",LLY,https://www.benzinga.com/general/biotech/19/01/12960202/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trials,Shanthi Rexaline,,,,0,0,335d9919-b0a0-4c86-b35b-77668665f0d8
2019-01-13T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",LLY,https://www.benzinga.com/general/biotech/19/01/12960202/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trials,Shanthi Rexaline,,,,0,0,c787a8c5-31a3-4737-936b-d6fa23de8c6e
2019-01-12T08:00:00.000+08:00,"Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development",LLY,https://seekingalpha.com/article/4232947-alector-ipo-abbvie-helping-early-stage-development?source=partner_benzinga,Seeking Alpha,,,,0,0,1cd693b6-5337-4d4e-94d6-5aad66e27db6
2019-01-12T08:00:00.000+08:00,"Alector IPO: AbbVie Is Helping, But It Is At Early Stage Of Development",LLY,https://seekingalpha.com/article/4232947-alector-ipo-abbvie-helping-early-stage-development?source=partner_benzinga,Seeking Alpha,,,,0,0,9eaf3e86-8a47-4b8c-85e8-f1395193a0c5
2019-01-11T08:00:00.000+08:00,4 Biotech Pipeline Areas To Keep An Eye On In 2019,LLY,https://www.benzinga.com/general/biotech/19/01/12970244/4-biotech-pipeline-areas-to-keep-an-eye-on-in-2019,Zacks,,,,0,0,18ea11a2-9d1e-4c7d-b20b-97416b74559a
2019-01-11T08:00:00.000+08:00,5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019,LLY,http://www.zacks.com/stock/news/347065/5-reasons-why-investors-should-buy-novo-nordisk-nvo-in-2019?cid=CS-BENZ-FT-347065,Zacks,,,,0,0,779222ff-725f-4ce2-9521-06aa702bdda7
2019-01-11T08:00:00.000+08:00,Composite Rating For Eli Lilly Jumps To 98,LLY,http://www.investors.com/ibd-data-stories/composite-rating-for-eli-lilly-jumps-to-98/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,e29d0b7e-5309-4e5e-9a50-7a85ad1a6201
2019-01-11T08:00:00.000+08:00,Dem lawmakers introduce bill to lower U.S. drug prices,LLY,https://seekingalpha.com/news/3422438-dem-lawmakers-introduce-bill-lower-u-s-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,70d29578-48f8-467a-802b-16181f419e1e
2019-01-11T08:00:00.000+08:00,Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why,LLY,http://www.zacks.com/stock/news/347050/puma-biotech-pbyi-down-more-than-40-in-90-days-heres-why?cid=CS-BENZ-FT-347050,Zacks,,,,0,0,924418b0-49c8-4c82-a6af-ab2efad5aeb5
2019-01-11T08:00:00.000+08:00,"Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet",LLY,http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-BENZ-FT-347005,Zacks,,,,0,0,60590d2e-d18a-480b-b231-100046af15f5
2019-01-11T08:00:00.000+08:00,4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019,LLY,http://www.zacks.com/stock/news/346884/4-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2019?cid=CS-BENZ-FT-346884,Zacks,,,,0,0,debe8396-fed6-4fd8-9609-938447aecb77
2019-01-11T08:00:00.000+08:00,4 Biotech Pipeline Areas To Keep An Eye On In 2019,LLY,https://www.benzinga.com/general/biotech/19/01/12970244/4-biotech-pipeline-areas-to-keep-an-eye-on-in-2019,Zacks,,,,0,0,ef97ea20-c492-45ae-a46a-88f49557c089
2019-01-11T08:00:00.000+08:00,5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019,LLY,http://www.zacks.com/stock/news/347065/5-reasons-why-investors-should-buy-novo-nordisk-nvo-in-2019?cid=CS-BENZ-FT-347065,Zacks,,,,0,0,87550475-d8cd-4f96-9790-a6951f3a6b5f
2019-01-11T08:00:00.000+08:00,Composite Rating For Eli Lilly Jumps To 98,LLY,http://www.investors.com/ibd-data-stories/composite-rating-for-eli-lilly-jumps-to-98/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,4c6d2c41-9410-4396-80d8-c341ac179d13
2019-01-11T08:00:00.000+08:00,Dem lawmakers introduce bill to lower U.S. drug prices,LLY,https://seekingalpha.com/news/3422438-dem-lawmakers-introduce-bill-lower-u-s-drug-prices?source=partner_benzinga,Seeking Alpha,,,,0,0,37851a53-09fe-4420-92dd-02782f9b4dc1
2019-01-11T08:00:00.000+08:00,Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why,LLY,http://www.zacks.com/stock/news/347050/puma-biotech-pbyi-down-more-than-40-in-90-days-heres-why?cid=CS-BENZ-FT-347050,Zacks,,,,0,0,785e8370-b208-4615-bf1b-cc205087632a
2019-01-11T08:00:00.000+08:00,"Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet",LLY,http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-BENZ-FT-347005,Zacks,,,,0,0,998d095c-8ead-4f9f-ad49-ad17ae8e2188
2019-01-11T08:00:00.000+08:00,4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019,LLY,http://www.zacks.com/stock/news/346884/4-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2019?cid=CS-BENZ-FT-346884,Zacks,,,,0,0,03a32c5c-a23b-4c4e-a8d9-9545be4c4cac
2019-01-10T08:00:00.000+08:00,2018 In The Numbers And What It Means For 2019 - Part I: Stocks,LLY,https://seekingalpha.com/article/4232736-2018-numbers-means-2019-part-stocks?source=partner_benzinga,Seeking Alpha,,,,0,0,07dae80c-3616-4d29-a922-54aeeb56d0f3
2019-01-10T08:00:00.000+08:00,Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting,LLY,http://www.zacks.com/stock/news/346748/big-pharma-ceos-indicate-more-ma-deals-at-jp-morgan-meeting?cid=CS-BENZ-FT-346748,Zacks,,,,0,0,fab3928b-6bc9-40bb-bfa0-ee6179414703
2019-01-10T08:00:00.000+08:00,Drug applications take back seat to safety surveillance at FDA during shutdown,LLY,https://seekingalpha.com/news/3421978-drug-applications-take-back-seat-safety-surveillance-fda-shutdown?source=partner_benzinga,Seeking Alpha,,,,0,0,1c38c707-3a7e-4b80-a6dc-f712b76f811b
2019-01-10T08:00:00.000+08:00,2018 In The Numbers And What It Means For 2019 - Part I: Stocks,LLY,https://seekingalpha.com/article/4232736-2018-numbers-means-2019-part-stocks?source=partner_benzinga,Seeking Alpha,,,,0,0,a1be82f9-676e-467e-957a-b1788aa023ca
2019-01-10T08:00:00.000+08:00,Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting,LLY,http://www.zacks.com/stock/news/346748/big-pharma-ceos-indicate-more-ma-deals-at-jp-morgan-meeting?cid=CS-BENZ-FT-346748,Zacks,,,,0,0,ca1eeb51-41eb-44c4-a3b0-09f9e1e96033
2019-01-10T08:00:00.000+08:00,Drug applications take back seat to safety surveillance at FDA during shutdown,LLY,https://seekingalpha.com/news/3421978-drug-applications-take-back-seat-safety-surveillance-fda-shutdown?source=partner_benzinga,Seeking Alpha,,,,0,0,f457ddc0-8ae5-4f81-b8d4-116403cf6a26
2019-01-09T08:00:00.000+08:00,Building A Bulletproof Portfolio Around Enbridge,LLY,https://seekingalpha.com/article/4232358-building-bulletproof-portfolio-around-enbridge?source=partner_benzinga,Seeking Alpha,,,,0,0,077268f4-36f6-418c-8c5a-5a2f4dc2b891
2019-01-09T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo",LLY,http://www.zacks.com/stock/news/346426/the-zacks-analyst-blog-highlights-bristol-myers-celgene-lilly-and-glaxo?cid=CS-BENZ-FT-346426,Zacks,,,,0,0,85bf6ccb-f967-4624-b7d9-5adc372b995e
2019-01-09T08:00:00.000+08:00,NantKwest launches mid-stage study of triplet therapy for rare skin cancer,LLY,https://seekingalpha.com/news/3421732-nantkwest-launches-mid-stage-study-triplet-therapy-rare-skin-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,be21e860-3481-465b-a2b3-3b464c050602
2019-01-09T08:00:00.000+08:00,Novartis' Crizanlizumab Gets Breakthrough Therapy Status,LLY,http://www.zacks.com/stock/news/346407/novartis-crizanlizumab-gets-breakthrough-therapy-status?cid=CS-BENZ-FT-346407,Zacks,,,,0,0,eab5b269-8675-4a91-bedd-e83f9180d20f
2019-01-09T08:00:00.000+08:00,"Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, ...",LLY,http://www.gurufocus.com/news/797021/report-exploring-fundamental-drivers-behind-virtusa-eli-lilly-cree-newjersey-resources-getty-realty-and-pennantpark-investment--new-horizons-emerging-trends-and-upcoming-developments,GuruFocus,,,,0,0,f2c4e5f8-5b6f-467f-98e5-e0adfdcc7f1a
2019-01-09T08:00:00.000+08:00,Where Will M&A Strike Next Across Biotech?,LLY,https://seekingalpha.com/article/4232266-will-m-strike-next-across-biotech?source=partner_benzinga,Seeking Alpha,,,,0,0,00d66896-f2b6-4bd9-b540-cca2c6f5a89d
2019-01-09T08:00:00.000+08:00,Building A Bulletproof Portfolio Around Enbridge,LLY,https://seekingalpha.com/article/4232358-building-bulletproof-portfolio-around-enbridge?source=partner_benzinga,Seeking Alpha,,,,0,0,fa85f7de-b69d-484c-8be9-f5a36a7abdae
2019-01-09T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo",LLY,http://www.zacks.com/stock/news/346426/the-zacks-analyst-blog-highlights-bristol-myers-celgene-lilly-and-glaxo?cid=CS-BENZ-FT-346426,Zacks,,,,0,0,ce54aef8-1341-4f5f-8c42-db247612cce2
2019-01-09T08:00:00.000+08:00,NantKwest launches mid-stage study of triplet therapy for rare skin cancer,LLY,https://seekingalpha.com/news/3421732-nantkwest-launches-mid-stage-study-triplet-therapy-rare-skin-cancer?source=partner_benzinga,Seeking Alpha,,,,0,0,210bc767-5010-4053-9fda-e06e115653dc
2019-01-09T08:00:00.000+08:00,Novartis' Crizanlizumab Gets Breakthrough Therapy Status,LLY,http://www.zacks.com/stock/news/346407/novartis-crizanlizumab-gets-breakthrough-therapy-status?cid=CS-BENZ-FT-346407,Zacks,,,,0,0,796d08f0-d1f4-4d3f-bf90-c3eb6ee8ba4b
2019-01-09T08:00:00.000+08:00,"Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, ...",LLY,http://www.gurufocus.com/news/797021/report-exploring-fundamental-drivers-behind-virtusa-eli-lilly-cree-newjersey-resources-getty-realty-and-pennantpark-investment--new-horizons-emerging-trends-and-upcoming-developments,GuruFocus,,,,0,0,3d7b91b4-f2e6-4f50-9f34-2dd6ca3a87eb
2019-01-09T08:00:00.000+08:00,Where Will M&A Strike Next Across Biotech?,LLY,https://seekingalpha.com/article/4232266-will-m-strike-next-across-biotech?source=partner_benzinga,Seeking Alpha,,,,0,0,873672b5-703a-46ab-9696-ce7c340f46a1
2019-01-08T08:00:00.000+08:00,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",LLY,https://www.benzinga.com/general/biotech/19/01/12948270/the-daily-biotech-pulse-amgen-slashes-cholesterol-drug-device-prices-,Shanthi Rexaline,,,,0,0,af14bbd0-1b82-4227-af63-c1fc0383037f
2019-01-08T08:00:00.000+08:00,65 Biggest Movers From Yesterday,LLY,https://www.benzinga.com/news/19/01/12948364/65-biggest-movers-from-yesterday,Lisa Levin,,,,0,0,e58aa7d8-367a-406f-aa95-28c2beb6fddd
2019-01-08T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO David Ricks presents at 37th Annual JPMorgan Healthcare Conference (Transcript),LLY,https://seekingalpha.com/article/4232218-eli-lilly-company-lly-ceo-david-ricks-presents-37th-annual-jpmorgan-healthcare-conference?source=partner_benzinga,Seeking Alpha,,,,0,0,d611e34b-b780-4855-be75-83bed3ecb75e
2019-01-08T08:00:00.000+08:00,"Eli Lilly Buys Loxo, This Year Looks To Be An M&A Year To Never Forget",LLY,https://seekingalpha.com/article/4232154-eli-lilly-buys-loxo-year-looks-m-year-never-forget?source=partner_benzinga,Seeking Alpha,,,,0,0,0122b8f1-a1cd-4a52-9f44-4574c420df29
2019-01-08T08:00:00.000+08:00,Eli Lilly: Loxo To Drive Growth?,LLY,https://seekingalpha.com/article/4232119-eli-lilly-loxo-drive-growth?source=partner_benzinga,Seeking Alpha,,,,0,0,9b8db2a8-e180-4aab-ad5a-8bab969f1c9a
2019-01-08T08:00:00.000+08:00,Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?,LLY,http://www.zacks.com/stock/news/346269/eli-lilly-lly-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-346269,Zacks,,,,0,0,3b67dd03-4756-48f5-a37d-93faa3686b16
2019-01-08T08:00:00.000+08:00,Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo,LLY,http://www.zacks.com/stock/news/346271/lilly-offers-%248b-to-acquire-cancer-focused-small-biotech-loxo?cid=CS-BENZ-FT-346271,Zacks,,,,0,0,2f0d2646-1278-4021-aa10-de72d941fc0f
2019-01-08T08:00:00.000+08:00,Crowded Cancer Space Triggers Big M&A Deals: More in Store?,LLY,http://www.zacks.com/stock/news/346265/crowded-cancer-space-triggers-big-ma-deals-more-in-store?cid=CS-BENZ-FT-346265,Zacks,,,,0,0,155fea56-d810-435e-8264-6be6a88a8116
2019-01-08T08:00:00.000+08:00,"Company News For Jan 8, 2019",LLY,http://www.zacks.com/stock/news/346224/company-news-for-jan-8-2019?cid=CS-BENZ-FT-346224,Zacks,,,,0,0,206e1fe8-4bb7-4c46-903e-4be662715264
2019-01-08T08:00:00.000+08:00,U.S.-China Wrap Up Trade Meeting (Wall Street Breakfast Podcast),LLY,https://seekingalpha.com/article/4231992-u-s-china-wrap-trade-meeting-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,6f50953c-eeb7-4500-971b-21fe1a20e289
2019-01-08T08:00:00.000+08:00,Wall Street Breakfast: U.S.-China Wrap Up Trade Meeting,LLY,https://seekingalpha.com/article/4231987-wall-street-breakfast-u-s-china-wrap-trade-meeting?source=partner_benzinga,Seeking Alpha,,,,0,0,9ed7beff-53bc-47e2-b8c8-5b803cb84443
2019-01-08T08:00:00.000+08:00,"The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase",LLY,https://www.benzinga.com/general/biotech/19/01/12948270/the-daily-biotech-pulse-amgen-slashes-cholesterol-drug-device-prices-,Shanthi Rexaline,,,,0,0,1c1c83ac-db44-4260-8237-9e79147aff76
2019-01-08T08:00:00.000+08:00,65 Biggest Movers From Yesterday,LLY,https://www.benzinga.com/news/19/01/12948364/65-biggest-movers-from-yesterday,Lisa Levin,,,,0,0,084ee684-867b-438a-b677-ceb920dcf725
2019-01-08T08:00:00.000+08:00,Eli Lilly and Company (LLY) CEO David Ricks presents at 37th Annual JPMorgan Healthcare Conference (Transcript),LLY,https://seekingalpha.com/article/4232218-eli-lilly-company-lly-ceo-david-ricks-presents-37th-annual-jpmorgan-healthcare-conference?source=partner_benzinga,Seeking Alpha,,,,0,0,a9b382a1-b170-464a-b455-2890229bc2eb
2019-01-08T08:00:00.000+08:00,"Eli Lilly Buys Loxo, This Year Looks To Be An M&A Year To Never Forget",LLY,https://seekingalpha.com/article/4232154-eli-lilly-buys-loxo-year-looks-m-year-never-forget?source=partner_benzinga,Seeking Alpha,,,,0,0,7c18d0b5-ca4d-4cc3-85ba-8b73f461e2c0
2019-01-08T08:00:00.000+08:00,Eli Lilly: Loxo To Drive Growth?,LLY,https://seekingalpha.com/article/4232119-eli-lilly-loxo-drive-growth?source=partner_benzinga,Seeking Alpha,,,,0,0,6138558a-8ff4-40dd-a343-2de34e281613
2019-01-08T08:00:00.000+08:00,Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?,LLY,http://www.zacks.com/stock/news/346269/eli-lilly-lly-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-346269,Zacks,,,,0,0,ed8c8acd-cebd-4e6a-b839-3c72f3ef6c9d
2019-01-08T08:00:00.000+08:00,Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo,LLY,http://www.zacks.com/stock/news/346271/lilly-offers-%248b-to-acquire-cancer-focused-small-biotech-loxo?cid=CS-BENZ-FT-346271,Zacks,,,,0,0,242cb3ae-6a98-46a6-b18e-82e61b0b9e76
2019-01-08T08:00:00.000+08:00,Crowded Cancer Space Triggers Big M&A Deals: More in Store?,LLY,http://www.zacks.com/stock/news/346265/crowded-cancer-space-triggers-big-ma-deals-more-in-store?cid=CS-BENZ-FT-346265,Zacks,,,,0,0,81a17e08-2d43-4e59-bcac-cce8ad22d2e9
2019-01-08T08:00:00.000+08:00,"Company News For Jan 8, 2019",LLY,http://www.zacks.com/stock/news/346224/company-news-for-jan-8-2019?cid=CS-BENZ-FT-346224,Zacks,,,,0,0,e95f4840-fd88-485e-81ae-2d91b464b0a8
2019-01-08T08:00:00.000+08:00,U.S.-China Wrap Up Trade Meeting (Wall Street Breakfast Podcast),LLY,https://seekingalpha.com/article/4231992-u-s-china-wrap-trade-meeting-wall-street-breakfast-podcast?source=partner_benzinga,Seeking Alpha,,,,0,0,2ec91bf3-48f9-4e7e-a8e8-3978c2811d85
2019-01-08T08:00:00.000+08:00,Wall Street Breakfast: U.S.-China Wrap Up Trade Meeting,LLY,https://seekingalpha.com/article/4231987-wall-street-breakfast-u-s-china-wrap-trade-meeting?source=partner_benzinga,Seeking Alpha,,,,0,0,43d758e3-c926-47bc-b347-61c32d4568c0
2019-01-07T08:00:00.000+08:00,Mid-Afternoon Market Update: Dow Up 125 Points; Axsome Therapeutics Shares Spike Higher,LLY,https://www.benzinga.com/news/19/01/12945702/mid-afternoon-market-update-dow-up-125-points-axsome-therapeutics-shares-spike-h,Lisa Levin,,,,0,0,9fe74e1d-3766-48d6-96a5-c4618684088c
2019-01-07T08:00:00.000+08:00,42 Stocks Moving In Monday's Mid-Day Session,LLY,https://www.benzinga.com/news/19/01/12945226/42-stocks-moving-in-mondays-mid-day-session,Lisa Levin,,,,0,0,6c1b54a2-5a3d-4100-aecb-57fe7fd69278
2019-01-07T08:00:00.000+08:00,Mid-Day Market Update: Luxoft Jumps On Acquisition News; PG&E Shares Tumble,LLY,https://www.benzinga.com/news/19/01/12944918/mid-day-market-update-luxoft-jumps-on-acquisition-news-pg-e-shares-tumble,Lisa Levin,,,,0,0,17627142-112c-465d-bd5b-49124bba59eb
2019-01-07T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mixed; Commercial Metals Misses Q1 Views,LLY,https://www.benzinga.com/news/19/01/12943620/mid-morning-market-update-markets-mixed-commercial-metals-misses-q1-views,Lisa Levin,,,,0,0,39d3c668-d0c1-4123-b88d-2433580a7e8e
2019-01-07T08:00:00.000+08:00,Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise,LLY,https://www.benzinga.com/general/biotech/19/01/12942435/eli-lilly-agrees-to-buy-loxo-for-8b-in-bid-to-expand-oncology-franchi,Shanthi Rexaline,,,,0,0,8e969fcc-8819-46eb-b569-4e0e68676ca6
2019-01-07T08:00:00.000+08:00,Eli Lilly Says it Will Limit Share Buybacks to $3.5M in 1H 2019,LLY,https://www.benzinga.com/news/19/01/12942537/eli-lilly-says-it-will-limit-share-buybacks-to-3-5m-in-1h-2019,Benzinga Newsdesk,,,,0,0,db7e3661-2690-4d71-bd74-3d2b049563d4
2019-01-07T08:00:00.000+08:00,21 Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/01/12942028/21-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,56772712-6e9d-4efc-9c48-ab0d1c334814
2019-01-07T08:00:00.000+08:00,Loxo Oncology to be Acquired by Eli Lilly For $235/Share Cash in Deal Worth $8B,LLY,https://www.benzinga.com/news/19/01/12941025/loxo-oncology-to-be-acquired-by-eli-lilly-for-235share-cash-in-deal-worth-8b,Benzinga Newsdesk,,,,0,0,48ccc2ba-994d-49b3-b7c0-ad42f8ec089e
2019-01-07T08:00:00.000+08:00,"Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. ...",LLY,http://www.gurufocus.com/news/796107/bragar-eagel--squire-pc-is-investigating-the-board-of-directors-of-loxo-oncology-inc-loxo-on-behalf-of-stockholders-and-encourages-loxo-investors-to-contact-the-firm,GuruFocus,,,,0,0,fd1256be-766a-4ac7-a8c2-a64494ed2db8
2019-01-07T08:00:00.000+08:00,Eli Lilly (LLY) Gains But Lags Market: What You Should Know,LLY,http://www.zacks.com/stock/news/346099/eli-lilly-lly-gains-but-lags-market-what-you-should-know?cid=CS-BENZ-FT-346099,Zacks,,,,0,0,da4cc2e8-701f-44f9-8c4a-347eb075dd37
2019-01-07T08:00:00.000+08:00,"Stock Market News: Nasdaq Leads Up Session, Helped By Biotech Stocks",LLY,http://www.investors.com/market-trend/stock-market-today/stock-market-news-biotechs-amazon-netflix/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,544dac09-b802-4583-9e06-bfca4b5f9a08
2019-01-07T08:00:00.000+08:00,Tech Stocks Set The Pace; This FANG Stock Is At A Critical Level,LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-stock-market-amazon-stock/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,3840b9bc-c97c-4ff4-a97f-9a79c1e48dd4
2019-01-07T08:00:00.000+08:00,Eli Lilly to acquire Loxo Oncology for $8B,LLY,https://seekingalpha.com/news/3420898-eli-lilly-acquire-loxo-oncology-8b?source=partner_benzinga,Seeking Alpha,,,,0,0,a8416770-e958-45a0-a1d4-9d5aa690b799
2019-01-07T08:00:00.000+08:00,3 Things To Watch For Monday In Biotech Land,LLY,https://seekingalpha.com/article/4231737-3-things-watch-monday-biotech-land?source=partner_benzinga,Seeking Alpha,,,,0,0,70e11248-cd05-4d07-98fa-9ded28d01958
2019-01-07T08:00:00.000+08:00,What The Celgene Deal Means For The Biotech Sector,LLY,https://seekingalpha.com/article/4231701-celgene-deal-means-biotech-sector?source=partner_benzinga,Seeking Alpha,,,,0,0,0a59d626-dc1e-41aa-a9b0-fcff7913daab
2019-01-07T08:00:00.000+08:00,Mid-Afternoon Market Update: Dow Up 125 Points; Axsome Therapeutics Shares Spike Higher,LLY,https://www.benzinga.com/news/19/01/12945702/mid-afternoon-market-update-dow-up-125-points-axsome-therapeutics-shares-spike-h,Lisa Levin,,,,0,0,d546632d-9b9b-4890-a846-835d801053d1
2019-01-07T08:00:00.000+08:00,42 Stocks Moving In Monday's Mid-Day Session,LLY,https://www.benzinga.com/news/19/01/12945226/42-stocks-moving-in-mondays-mid-day-session,Lisa Levin,,,,0,0,cb4cc82b-87f5-4b04-ad3a-d7480fc68ffa
2019-01-07T08:00:00.000+08:00,Mid-Day Market Update: Luxoft Jumps On Acquisition News; PG&E Shares Tumble,LLY,https://www.benzinga.com/news/19/01/12944918/mid-day-market-update-luxoft-jumps-on-acquisition-news-pg-e-shares-tumble,Lisa Levin,,,,0,0,3d570085-6d2f-438f-a4f5-d5a629c07af5
2019-01-07T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mixed; Commercial Metals Misses Q1 Views,LLY,https://www.benzinga.com/news/19/01/12943620/mid-morning-market-update-markets-mixed-commercial-metals-misses-q1-views,Lisa Levin,,,,0,0,353d8510-7754-4aec-8406-d5138ebd59bc
2019-01-07T08:00:00.000+08:00,Eli Lilly Agrees To Buy Loxo For $8B In Bid To Expand Oncology Franchise,LLY,https://www.benzinga.com/general/biotech/19/01/12942435/eli-lilly-agrees-to-buy-loxo-for-8b-in-bid-to-expand-oncology-franchi,Shanthi Rexaline,,,,0,0,a2868e54-c6f5-418d-8431-4c56930c8952
2019-01-07T08:00:00.000+08:00,Eli Lilly Says it Will Limit Share Buybacks to $3.5M in 1H 2019,LLY,https://www.benzinga.com/news/19/01/12942537/eli-lilly-says-it-will-limit-share-buybacks-to-3-5m-in-1h-2019,Benzinga Newsdesk,,,,0,0,d4339185-1ba7-4b55-89e6-d6e300a2385f
2019-01-07T08:00:00.000+08:00,21 Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/19/01/12942028/21-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,4bbe81e6-9b77-45e7-9c5f-69c376ff8de7
2019-01-07T08:00:00.000+08:00,Loxo Oncology to be Acquired by Eli Lilly For $235/Share Cash in Deal Worth $8B,LLY,https://www.benzinga.com/news/19/01/12941025/loxo-oncology-to-be-acquired-by-eli-lilly-for-235share-cash-in-deal-worth-8b,Benzinga Newsdesk,,,,0,0,93bc77b0-fed0-4b6d-b537-899b1b1bf73a
2019-01-07T08:00:00.000+08:00,"Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. ...",LLY,http://www.gurufocus.com/news/796107/bragar-eagel--squire-pc-is-investigating-the-board-of-directors-of-loxo-oncology-inc-loxo-on-behalf-of-stockholders-and-encourages-loxo-investors-to-contact-the-firm,GuruFocus,,,,0,0,4e61b69a-6c34-44be-af26-81e72aed18dc
2019-01-07T08:00:00.000+08:00,Eli Lilly (LLY) Gains But Lags Market: What You Should Know,LLY,http://www.zacks.com/stock/news/346099/eli-lilly-lly-gains-but-lags-market-what-you-should-know?cid=CS-BENZ-FT-346099,Zacks,,,,0,0,8d3e599e-f8d2-4bf3-8f35-bbf3e12af1b7
2019-01-07T08:00:00.000+08:00,"Stock Market News: Nasdaq Leads Up Session, Helped By Biotech Stocks",LLY,http://www.investors.com/market-trend/stock-market-today/stock-market-news-biotechs-amazon-netflix/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,2ce50307-a6a6-4e5e-9af2-d1b6ddb0b623
2019-01-07T08:00:00.000+08:00,Tech Stocks Set The Pace; This FANG Stock Is At A Critical Level,LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-stock-market-amazon-stock/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,b07485b6-49eb-4a5c-a28d-26ca1b005d99
2019-01-07T08:00:00.000+08:00,Eli Lilly to acquire Loxo Oncology for $8B,LLY,https://seekingalpha.com/news/3420898-eli-lilly-acquire-loxo-oncology-8b?source=partner_benzinga,Seeking Alpha,,,,0,0,e36fb727-31ba-48af-93a3-6cb0e233a515
2019-01-07T08:00:00.000+08:00,3 Things To Watch For Monday In Biotech Land,LLY,https://seekingalpha.com/article/4231737-3-things-watch-monday-biotech-land?source=partner_benzinga,Seeking Alpha,,,,0,0,63ff0742-fc99-4d7c-9dcd-48ce5a154aea
2019-01-07T08:00:00.000+08:00,What The Celgene Deal Means For The Biotech Sector,LLY,https://seekingalpha.com/article/4231701-celgene-deal-means-biotech-sector?source=partner_benzinga,Seeking Alpha,,,,0,0,e34a570d-6712-4046-bb68-ececd9c9ba61
2019-01-06T08:00:00.000+08:00,"Dow Jones Futures: Stock Market Rally Picks Up Steam, But This Is Missing",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-2019-stock-market-rally-top-stocks/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,0eb4b9c7-93ed-47c7-8285-d4686d271863
2019-01-06T08:00:00.000+08:00,"Dow Jones Futures: Stock Market Rally Picks Up Steam, But This Is Missing",LLY,http://www.investors.com/market-trend/stock-market-today/dow-jones-futures-2019-stock-market-rally-top-stocks/?src=A00237A&ven=BenzingaCP&src=AURLAAM,Investor's Business Daily,,,,0,0,c69afe1c-2398-443d-9c18-411f072a3d31
2019-01-04T08:00:00.000+08:00,"Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate",LLY,http://www.zacks.com/stock/news/345809/pharma-stock-roundup-bmy-to-buy-celg-for-%2474b-mrk-gets-rights-to-nash-candidate?cid=CS-BENZ-FT-345809,Zacks,,,,0,0,85cb868c-c6a1-4ea3-ba24-b1d95a5609b6
2019-01-04T08:00:00.000+08:00,"Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration",LLY,http://www.zacks.com/stock/news/345747/nektar-imaginab-enter-into-immuno-oncology-collaboration?cid=CS-BENZ-FT-345747,Zacks,,,,0,0,9fff4bfa-cda9-4a30-bbb6-dd25a816dd3d
2019-01-04T08:00:00.000+08:00,"Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate",LLY,http://www.zacks.com/stock/news/345809/pharma-stock-roundup-bmy-to-buy-celg-for-%2474b-mrk-gets-rights-to-nash-candidate?cid=CS-BENZ-FT-345809,Zacks,,,,0,0,92fe7647-db6d-47a0-98f5-b3068b5689aa
2019-01-04T08:00:00.000+08:00,"Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration",LLY,http://www.zacks.com/stock/news/345747/nektar-imaginab-enter-into-immuno-oncology-collaboration?cid=CS-BENZ-FT-345747,Zacks,,,,0,0,ded8468b-490b-4277-a3c3-c8e996926edf
2019-01-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily",LLY,http://www.zacks.com/stock/news/345489/the-zacks-analyst-blog-highlights-tripadvisor-advance-auto-red-hat-salesforce-and-eli-lily?cid=CS-BENZ-FT-345489,Zacks,,,,0,0,d497ed9a-8063-4596-b983-181e677e3342
2019-01-03T08:00:00.000+08:00,Japan OKs five new indications for Merck's Keytruda,LLY,https://seekingalpha.com/news/3420246-japan-oks-five-new-indications-mercks-keytruda?source=partner_benzinga,Seeking Alpha,,,,0,0,d11ca94f-0111-4bee-9f06-4be2353c44d5
2019-01-03T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily",LLY,http://www.zacks.com/stock/news/345489/the-zacks-analyst-blog-highlights-tripadvisor-advance-auto-red-hat-salesforce-and-eli-lily?cid=CS-BENZ-FT-345489,Zacks,,,,0,0,a86ccc57-4248-49ce-a9e8-dce0a745e603
2019-01-03T08:00:00.000+08:00,Japan OKs five new indications for Merck's Keytruda,LLY,https://seekingalpha.com/news/3420246-japan-oks-five-new-indications-mercks-keytruda?source=partner_benzinga,Seeking Alpha,,,,0,0,3cd214cc-a552-4bc8-8c80-0fcd43f93226
2019-01-02T08:00:00.000+08:00,"Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/01/12918090/adamis-has-favorable-pipeline-setup-says-bullish-raymon,Shanthi Rexaline,,,,0,0,35e7156d-1caf-4d49-9cfe-ecc52f4b4615
2019-01-02T08:00:00.000+08:00,The Best Performing Stocks Of 2018,LLY,https://www.benzinga.com/node/12920772,TalkMarkets,,,,0,0,ee9521c1-2a06-4161-aa46-7d04b985fa33
2019-01-02T08:00:00.000+08:00,Drug makers OK with price inclusion in TV ads if done fairly,LLY,https://seekingalpha.com/news/3420056-drug-makers-ok-price-inclusion-tv-ads-done-fairly?source=partner_benzinga,Seeking Alpha,,,,0,0,8e882fa6-b91a-40fd-9bdc-2a8c0b706914
2019-01-02T08:00:00.000+08:00,Eli Lilly Looks To Newly Acquired Assets For Pain Market,LLY,https://seekingalpha.com/article/4231044-eli-lilly-looks-newly-acquired-assets-pain-market?source=partner_benzinga,Seeking Alpha,,,,0,0,2a0fe81a-946f-456d-9179-7edd5a2a53d9
2019-01-02T08:00:00.000+08:00,5 Great S&P 500 Stocks to Buy in 2019,LLY,http://www.zacks.com/stock/news/345316/5-great-sp-500-stocks-to-buy-in-2019?cid=CS-BENZ-FT-345316,Zacks,,,,0,0,f7ff987c-5447-4d34-ba5d-9976144066f6
2019-01-02T08:00:00.000+08:00,"Adamis Has 'Favorable' Pipeline Setup, Says Bullish Raymond James",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/19/01/12918090/adamis-has-favorable-pipeline-setup-says-bullish-raymon,Shanthi Rexaline,,,,0,0,7dc549ca-0e4f-4544-88dc-fe7510951b63
2019-01-02T08:00:00.000+08:00,The Best Performing Stocks Of 2018,LLY,https://www.benzinga.com/node/12920772,TalkMarkets,,,,0,0,0a1d5eaa-3b86-485c-a243-f042dd01cab6
2019-01-02T08:00:00.000+08:00,Drug makers OK with price inclusion in TV ads if done fairly,LLY,https://seekingalpha.com/news/3420056-drug-makers-ok-price-inclusion-tv-ads-done-fairly?source=partner_benzinga,Seeking Alpha,,,,0,0,f44f3b38-b60b-4ceb-9075-424611f0db94
2019-01-02T08:00:00.000+08:00,Eli Lilly Looks To Newly Acquired Assets For Pain Market,LLY,https://seekingalpha.com/article/4231044-eli-lilly-looks-newly-acquired-assets-pain-market?source=partner_benzinga,Seeking Alpha,,,,0,0,def8f8b0-b8f6-4dd9-ae1d-2f3c39c2ac5e
2019-01-02T08:00:00.000+08:00,5 Great S&P 500 Stocks to Buy in 2019,LLY,http://www.zacks.com/stock/news/345316/5-great-sp-500-stocks-to-buy-in-2019?cid=CS-BENZ-FT-345316,Zacks,,,,0,0,55ef8773-b635-469c-98b8-29594cde4b65
2019-01-01T08:00:00.000+08:00,Biotech Bonanza: 2019 Outlook,LLY,https://www.benzinga.com/node/12916141,TalkMarkets,,,,0,0,a372012e-c65c-447a-86db-733853cbf63b
2019-01-01T08:00:00.000+08:00,Biotech Bonanza: 2019 Outlook,LLY,https://www.benzinga.com/node/12916141,TalkMarkets,,,,0,0,4997d352-2ee6-4e15-9461-d033d2c812c7
2018-12-31T08:00:00.000+08:00,"Centene finishes first, Coty last on S&P 500 for 2018",LLY,https://seekingalpha.com/news/3419833-centene-finishes-first-coty-last-s-and-p-500-2018?source=partner_benzinga,Seeking Alpha,,,,0,0,2aa33300-29aa-47dd-950d-c2819bc4e9d6
2018-12-31T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/345212/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-345212,Zacks,,,,0,0,2405b08e-2e58-44c4-871a-d0509c8807ff
2018-12-31T08:00:00.000+08:00,Adamis Pharma files U.S. marketing application for fast-dissolving sublingual tadalafil tablet for ED,LLY,https://seekingalpha.com/news/3419670-adamis-pharma-files-u-s-marketing-application-fast-dissolving-sublingual-tadalafil-tablet-ed?source=partner_benzinga,Seeking Alpha,,,,0,0,994a7547-a338-4da2-934b-a91849f9fbc7
2018-12-31T08:00:00.000+08:00,"Centene finishes first, Coty last on S&P 500 for 2018",LLY,https://seekingalpha.com/news/3419833-centene-finishes-first-coty-last-s-and-p-500-2018?source=partner_benzinga,Seeking Alpha,,,,0,0,15dd7893-9c7c-4c21-b24c-7c788355c16f
2018-12-31T08:00:00.000+08:00,Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?,LLY,http://www.zacks.com/stock/news/345212/has-eli-lilly-and-lly-outpaced-other-medical-stocks-this-year?cid=CS-BENZ-FT-345212,Zacks,,,,0,0,9a2971df-70e8-4dbb-b976-965bc329daf0
2018-12-31T08:00:00.000+08:00,Adamis Pharma files U.S. marketing application for fast-dissolving sublingual tadalafil tablet for ED,LLY,https://seekingalpha.com/news/3419670-adamis-pharma-files-u-s-marketing-application-fast-dissolving-sublingual-tadalafil-tablet-ed?source=partner_benzinga,Seeking Alpha,,,,0,0,654922a2-2a62-40d9-9b77-7fd18f99c0f4
2018-12-29T08:00:00.000+08:00,Week In Review: Shanghai Industrial To Start $7.3 Billion Biomedical Fund In 2019,LLY,https://www.benzinga.com/node/12911936,TalkMarkets,,,,0,0,d67daa15-0a3d-4363-a399-43def463a858
2018-12-29T08:00:00.000+08:00,Week In Review: Shanghai Industrial To Start $7.3 Billion Biomedical Fund In 2019,LLY,https://www.benzinga.com/node/12911936,TalkMarkets,,,,0,0,22841d19-5659-40ce-af8e-8350b09b089d
2018-12-27T08:00:00.000+08:00,Lilly Announces China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt for Hodgkin's Lymphoma,LLY,https://www.benzinga.com/news/18/12/12902413/lilly-announces-chinas-nmpa-approves-innovents-anti-pd-1-antibody-tyvyt-for-hodg,Charles Gross,,,,0,0,12b3278f-f708-4334-a0be-95d5442ed28f
2018-12-27T08:00:00.000+08:00,Teva Stock Rises on Patent Settlement With Neos Therapeutics,LLY,http://www.zacks.com/stock/news/344759/teva-stock-rises-on-patent-settlement-with-neos-therapeutics?cid=CS-BENZ-FT-344759,Zacks,,,,0,0,52711cbc-27b7-4b4b-b743-b4debd9e13b0
2018-12-27T08:00:00.000+08:00,"Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019",LLY,http://www.zacks.com/stock/news/344663/forget-jj-buy-these-3-big-drug-stocks-instead-in-2019?cid=CS-BENZ-FT-344663,Zacks,,,,0,0,2fe25056-4852-4e0a-8f93-dfc7d5188770
2018-12-27T08:00:00.000+08:00,Lilly Announces China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt for Hodgkin's Lymphoma,LLY,https://www.benzinga.com/news/18/12/12902413/lilly-announces-chinas-nmpa-approves-innovents-anti-pd-1-antibody-tyvyt-for-hodg,Charles Gross,,,,0,0,18a3c29b-a4f3-40d5-85fd-6e77df2d2527
2018-12-27T08:00:00.000+08:00,Teva Stock Rises on Patent Settlement With Neos Therapeutics,LLY,http://www.zacks.com/stock/news/344759/teva-stock-rises-on-patent-settlement-with-neos-therapeutics?cid=CS-BENZ-FT-344759,Zacks,,,,0,0,8421c176-adde-4a73-865e-de45f1a5fa34
2018-12-27T08:00:00.000+08:00,"Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019",LLY,http://www.zacks.com/stock/news/344663/forget-jj-buy-these-3-big-drug-stocks-instead-in-2019?cid=CS-BENZ-FT-344663,Zacks,,,,0,0,6c102765-0e29-48d4-bccc-4b54bdbf7e6e
2018-12-26T08:00:00.000+08:00,Bayer (BAYRY) Faces Generic Threat & Rising Competition,LLY,http://www.zacks.com/stock/news/344595/bayer-bayry-faces-generic-threat-rising-competition?cid=CS-BENZ-FT-344595,Zacks,,,,0,0,86998108-5d1f-4d87-b98f-86220c79a2aa
2018-12-26T08:00:00.000+08:00,Bayer (BAYRY) Faces Generic Threat & Rising Competition,LLY,http://www.zacks.com/stock/news/344595/bayer-bayry-faces-generic-threat-rising-competition?cid=CS-BENZ-FT-344595,Zacks,,,,0,0,723ad7f1-edae-43df-bf68-3bc432d76dfd
2018-12-24T08:00:00.000+08:00,"Dividend Increases: December 17-21, 2018",LLY,https://seekingalpha.com/article/4229902-dividend-increases-december-17minus-21-2018?source=partner_benzinga,Seeking Alpha,,,,0,0,f954cdfa-f93d-4566-b0a3-96eb7e68d726
2018-12-24T08:00:00.000+08:00,"Dividend Increases: December 17-21, 2018",LLY,https://seekingalpha.com/article/4229902-dividend-increases-december-17minus-21-2018?source=partner_benzinga,Seeking Alpha,,,,0,0,b9613350-c454-407d-a1bc-8d15f5293b38
2018-12-21T08:00:00.000+08:00,Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study,LLY,http://www.zacks.com/stock/news/344168/pfizer-xtandi-succeeds-in-late-stage-prostate-cancer-study?cid=CS-BENZ-FT-344168,Zacks,,,,0,0,981126e2-42e3-4889-aae8-b81dda738bc5
2018-12-21T08:00:00.000+08:00,Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study,LLY,http://www.zacks.com/stock/news/344168/pfizer-xtandi-succeeds-in-late-stage-prostate-cancer-study?cid=CS-BENZ-FT-344168,Zacks,,,,0,0,d928da87-4514-4ad7-a4f0-6a532eae484b
2018-12-20T08:00:00.000+08:00,Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake,LLY,https://www.benzinga.com/news/18/12/12884561/dicerna-pharma-13d-filing-from-eli-lilly-shows-new-8-6-stake,Benzinga Newsdesk,,,,0,0,defe8a16-2474-48b9-b543-7acf8d04f653
2018-12-20T08:00:00.000+08:00,Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company,LLY,https://www.benzinga.com/news/18/12/12879162/chi-med-announces-amendment-to-the-2013-license-collaboration-agreement-on-fruqu,Charles Gross,,,,0,0,e97f86bc-0883-482c-ae8b-aa73615dada2
2018-12-20T08:00:00.000+08:00,"Lilly's Shares Rise on Robust 2019 View, Dividend Hike",LLY,http://www.zacks.com/stock/news/343999/lillys-shares-rise-on-robust-2019-view-dividend-hike?cid=CS-BENZ-FT-343999,Zacks,,,,0,0,cc8c6734-3a7c-4fcf-99b8-0e1f861196f2
2018-12-20T08:00:00.000+08:00,"Allergan Drops, Stops Textured Breast Implant Sales in Europe",LLY,http://www.zacks.com/stock/news/343980/allergan-drops-stops-textured-breast-implant-sales-in-europe?cid=CS-BENZ-FT-343980,Zacks,,,,0,0,04ca3cb5-5160-412f-b164-5bfa625686d7
2018-12-20T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab",LLY,http://www.zacks.com/stock/news/343959/the-zacks-analyst-blog-highlights-eli-lilly-mitsubishi-ufj-thermo-fisher-oracle-and-ecolab?cid=CS-BENZ-FT-343959,Zacks,,,,0,0,b4784a5b-3961-404d-8b55-570259f94731
2018-12-20T08:00:00.000+08:00,Dicerna Pharma 13D Filing From Eli Lilly Shows New 8.6% Stake,LLY,https://www.benzinga.com/news/18/12/12884561/dicerna-pharma-13d-filing-from-eli-lilly-shows-new-8-6-stake,Benzinga Newsdesk,,,,0,0,253d5b48-a069-4aa5-9210-3809a4f0ab48
2018-12-20T08:00:00.000+08:00,Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company,LLY,https://www.benzinga.com/news/18/12/12879162/chi-med-announces-amendment-to-the-2013-license-collaboration-agreement-on-fruqu,Charles Gross,,,,0,0,53977d8f-7c22-458a-b0b0-6087048f1a85
2018-12-20T08:00:00.000+08:00,"Lilly's Shares Rise on Robust 2019 View, Dividend Hike",LLY,http://www.zacks.com/stock/news/343999/lillys-shares-rise-on-robust-2019-view-dividend-hike?cid=CS-BENZ-FT-343999,Zacks,,,,0,0,b941cdff-531c-49a9-a9d5-309bbb11f59d
2018-12-20T08:00:00.000+08:00,"Allergan Drops, Stops Textured Breast Implant Sales in Europe",LLY,http://www.zacks.com/stock/news/343980/allergan-drops-stops-textured-breast-implant-sales-in-europe?cid=CS-BENZ-FT-343980,Zacks,,,,0,0,d58bf2da-fcf5-4841-9770-85c606657134
2018-12-20T08:00:00.000+08:00,"The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab",LLY,http://www.zacks.com/stock/news/343959/the-zacks-analyst-blog-highlights-eli-lilly-mitsubishi-ufj-thermo-fisher-oracle-and-ecolab?cid=CS-BENZ-FT-343959,Zacks,,,,0,0,6111f36b-95c0-4321-84db-267b92e10db2
2018-12-19T08:00:00.000+08:00,Eli Lilly shares are trading up after the company reaffirmed strong guidance for FY18 and FY19 and raised its quarterly dividend.,LLY,https://www.benzinga.com/markets/wiim/18/12/12874700/eli-lilly-shares-are-trading-up-after-the-company-reaffirmed-strong-guid,Benzinga Newsdesk,,,,0,0,1202a6b1-9bf3-4d0f-8a19-b393891c876b
2018-12-19T08:00:00.000+08:00,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",LLY,https://www.benzinga.com/general/biotech/18/12/12871984/the-daily-biotech-pulse-pfizer-glaxo-set-up-consumer-health-care-vent,Shanthi Rexaline,,,,0,0,11a35414-a9db-477a-bc66-43d636303611
2018-12-19T08:00:00.000+08:00,Eli Lilly Reaffirms FY18 Sales Guidance $24.3B-$24.5B vs $24.43B Estimate,LLY,https://www.benzinga.com/news/18/12/12872490/eli-lilly-reaffirms-fy18-sales-guidance-24-3b-24-5b-vs-24-43b-estimate,Benzinga Newsdesk,,,,0,0,05ffb650-89dc-4555-b1eb-23cca15abdaa
2018-12-19T08:00:00.000+08:00,Eli Lilly Sees FY19 Sales $25.3B-$25.8B vs $24.77B Estimate,LLY,https://www.benzinga.com/news/18/12/12872489/eli-lilly-sees-fy19-sales-25-3b-25-8b-vs-24-77b-estimate,Benzinga Newsdesk,,,,0,0,dade4611-2ca9-4226-93d3-a781ffd55d8c
2018-12-19T08:00:00.000+08:00,Eli Lilly Reaffirms FY18 Adj. EPS Guidance $5.55-$5.60 vs $5.58 Estimate,LLY,https://www.benzinga.com/news/18/12/12872478/eli-lilly-reaffirms-fy18-adj-eps-guidance-5-55-5-60-vs-5-58-estimate,Benzinga Newsdesk,,,,0,0,2c875eca-10b8-4d0e-9e6d-998a167c8c1b
2018-12-19T08:00:00.000+08:00,Eli Lilly Sees FY19 Adj. EPS $5.90-$6 vs $5.82 Estimate,LLY,https://www.benzinga.com/news/18/12/12872475/eli-lilly-sees-fy19-adj-eps-5-90-6-vs-5-82-estimate,Benzinga Newsdesk,,,,0,0,cd6b36b6-7764-4b54-a6e9-bafef640651a
2018-12-19T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.5625 To $0.645/Share,LLY,https://www.benzinga.com/news/18/12/12872448/eli-lilly-raises-qtr-dividend-from-0-5625-to-0-645share,Benzinga Newsdesk,,,,0,0,5cb3bcc8-dacc-43f1-b694-872eb3f9e231
2018-12-19T08:00:00.000+08:00,Eli Lilly shares are trading up after the company reaffirmed strong guidance for FY18 and FY19 and raised its quarterly dividend.,LLY,https://www.benzinga.com/markets/wiim/18/12/12874700/eli-lilly-shares-are-trading-up-after-the-company-reaffirmed-strong-guid,Benzinga Newsdesk,,,,0,0,4ca7a432-388e-4022-a932-a3dfe8ac29db
2018-12-19T08:00:00.000+08:00,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",LLY,https://www.benzinga.com/general/biotech/18/12/12871984/the-daily-biotech-pulse-pfizer-glaxo-set-up-consumer-health-care-vent,Shanthi Rexaline,,,,0,0,7b1d1ffb-fbb1-40a4-ab71-ea89382388e4
2018-12-19T08:00:00.000+08:00,Eli Lilly Reaffirms FY18 Sales Guidance $24.3B-$24.5B vs $24.43B Estimate,LLY,https://www.benzinga.com/news/18/12/12872490/eli-lilly-reaffirms-fy18-sales-guidance-24-3b-24-5b-vs-24-43b-estimate,Benzinga Newsdesk,,,,0,0,d45f5b68-ef6c-45d8-9c45-0fa74038a2c6
2018-12-19T08:00:00.000+08:00,Eli Lilly Sees FY19 Sales $25.3B-$25.8B vs $24.77B Estimate,LLY,https://www.benzinga.com/news/18/12/12872489/eli-lilly-sees-fy19-sales-25-3b-25-8b-vs-24-77b-estimate,Benzinga Newsdesk,,,,0,0,e68f6f15-bdb0-48ee-9dfc-951d66342aa1
2018-12-19T08:00:00.000+08:00,Eli Lilly Reaffirms FY18 Adj. EPS Guidance $5.55-$5.60 vs $5.58 Estimate,LLY,https://www.benzinga.com/news/18/12/12872478/eli-lilly-reaffirms-fy18-adj-eps-guidance-5-55-5-60-vs-5-58-estimate,Benzinga Newsdesk,,,,0,0,e1599785-dde4-4c81-8fed-4c18a27624b0
2018-12-19T08:00:00.000+08:00,Eli Lilly Sees FY19 Adj. EPS $5.90-$6 vs $5.82 Estimate,LLY,https://www.benzinga.com/news/18/12/12872475/eli-lilly-sees-fy19-adj-eps-5-90-6-vs-5-82-estimate,Benzinga Newsdesk,,,,0,0,292da3ba-ab1e-480a-84fc-7d4b6b17aca8
2018-12-19T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.5625 To $0.645/Share,LLY,https://www.benzinga.com/news/18/12/12872448/eli-lilly-raises-qtr-dividend-from-0-5625-to-0-645share,Benzinga Newsdesk,,,,0,0,2a026901-7ee2-4f7b-aaf3-ce38a0c58a88
2018-12-18T08:00:00.000+08:00,"UPDATE: Aduro Will Be Eligible For Development, Commercial Milestones Up To ~$620M/Product",LLY,https://www.benzinga.com/news/18/12/12869690/update-aduro-will-be-eligible-for-development-commercial-milestones-up-to-620mpr,Benzinga Newsdesk,,,,0,0,c171b9e8-d52f-4288-bbd2-ae91c4266d59
2018-12-18T08:00:00.000+08:00,UPDATE: Aduro To Receive Upfront Payment Of $12M,LLY,https://www.benzinga.com/news/18/12/12869687/update-aduro-to-receive-upfront-payment-of-12m,Benzinga Newsdesk,,,,0,0,44afec4d-c3b9-4c97-8211-e0aced19bb1d
2018-12-18T08:00:00.000+08:00,"Eli Lilly, Aduro Biotech Report Research Collaboration, Exclusive License Deal For Aduro's cGAS-STRING Pathway Inhibitor Program",LLY,https://www.benzinga.com/news/18/12/12869683/eli-lilly-aduro-biotech-report-research-collaboration-exclusive-license-deal-for,Benzinga Newsdesk,,,,0,0,4ab5a93b-a629-41ea-9111-19fe89b456f4
2018-12-18T08:00:00.000+08:00,Lilly Highlights Publication Of Analysis Showing Benefit Of The Addition Of Verzenio In Certain Breast Cancer Patients,LLY,https://www.benzinga.com/general/biotech/18/12/12864693/lilly-highlights-publication-of-analysis-showing-benefit-of-the-addit,Benzinga Newsdesk,,,,0,0,4bd8d2f7-0609-42cd-8285-21e6adbdf2f8
2018-12-18T08:00:00.000+08:00,"UPDATE: Aduro Will Be Eligible For Development, Commercial Milestones Up To ~$620M/Product",LLY,https://www.benzinga.com/news/18/12/12869690/update-aduro-will-be-eligible-for-development-commercial-milestones-up-to-620mpr,Benzinga Newsdesk,,,,0,0,ec92256f-1f67-44ff-b0b6-880789763c60
2018-12-18T08:00:00.000+08:00,UPDATE: Aduro To Receive Upfront Payment Of $12M,LLY,https://www.benzinga.com/news/18/12/12869687/update-aduro-to-receive-upfront-payment-of-12m,Benzinga Newsdesk,,,,0,0,eceb6c3a-f4f4-4784-91b1-89c37f6b45cd
2018-12-18T08:00:00.000+08:00,"Eli Lilly, Aduro Biotech Report Research Collaboration, Exclusive License Deal For Aduro's cGAS-STRING Pathway Inhibitor Program",LLY,https://www.benzinga.com/news/18/12/12869683/eli-lilly-aduro-biotech-report-research-collaboration-exclusive-license-deal-for,Benzinga Newsdesk,,,,0,0,503d6c99-d1d4-44c3-8de6-d6ace4b680fb
2018-12-18T08:00:00.000+08:00,Lilly Highlights Publication Of Analysis Showing Benefit Of The Addition Of Verzenio In Certain Breast Cancer Patients,LLY,https://www.benzinga.com/general/biotech/18/12/12864693/lilly-highlights-publication-of-analysis-showing-benefit-of-the-addit,Benzinga Newsdesk,,,,0,0,41cf11bb-8937-4df9-ab9a-b749da4994b7
2018-12-17T08:00:00.000+08:00,Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.,LLY,https://www.benzinga.com/markets/wiim/18/12/12859979/health-insurers-and-healthcare-providers-are-trading-down-today-after-a-,Benzinga_Newsdesk,,,,0,0,1b9d20d6-8f6b-408f-9b95-7cc5fefc699e
2018-12-17T08:00:00.000+08:00,"Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints",LLY,https://www.benzinga.com/news/18/12/12857511/eli-lilly-says-taltz-in-a-superiority-study-vs-abbvies-humira-in-patients-with-a,Benzinga Newsdesk,,,,0,0,48f1cb61-87cd-40f4-b3dd-39e8b284d517
2018-12-17T08:00:00.000+08:00,Health insurers and healthcare providers are trading down today after a Texas court ruled that ObamaCare was unconstitutional.,LLY,https://www.benzinga.com/markets/wiim/18/12/12859979/health-insurers-and-healthcare-providers-are-trading-down-today-after-a-,Benzinga_Newsdesk,,,,0,0,c59c0155-5c34-4d26-95ed-39b4f1babda8
2018-12-17T08:00:00.000+08:00,"Eli Lilly Says Taltz, in a Superiority Study Vs AbbVie's Humira, in Patients with Active Psoriatic Arthritis Met All Primary and Major Secondary Endpoints",LLY,https://www.benzinga.com/news/18/12/12857511/eli-lilly-says-taltz-in-a-superiority-study-vs-abbvies-humira-in-patients-with-a,Benzinga Newsdesk,,,,0,0,05d9e436-415c-4706-8857-b2b08738cbd0
2018-12-14T08:00:00.000+08:00,"Eli Lilly Reports Purchase Of Pre-Clinical Pain Program From Hydra Biosciences, No Terms Disclosed",LLY,https://www.benzinga.com/news/18/12/12854132/eli-lilly-reports-purchase-of-pre-clinical-pain-program-from-hydra-biosciences-n,Benzinga Newsdesk,,,,0,0,3be25f2b-57af-4a01-b43f-d78db28fa920
2018-12-14T08:00:00.000+08:00,Eli Lilly Reports Expansion Of Collaboration With Evidation Health For Andromeda Data Platform,LLY,https://www.benzinga.com/news/18/12/12850880/eli-lilly-reports-expansion-of-collaboration-with-evidation-health-for-andromeda,Benzinga Newsdesk,,,,0,0,4e4a0863-1fd5-48f1-aaec-b44a36731464
2018-12-14T08:00:00.000+08:00,"Eli Lilly Reports Purchase Of Pre-Clinical Pain Program From Hydra Biosciences, No Terms Disclosed",LLY,https://www.benzinga.com/news/18/12/12854132/eli-lilly-reports-purchase-of-pre-clinical-pain-program-from-hydra-biosciences-n,Benzinga Newsdesk,,,,0,0,a0047d1b-7218-4428-9305-bdabf6641279
2018-12-14T08:00:00.000+08:00,Eli Lilly Reports Expansion Of Collaboration With Evidation Health For Andromeda Data Platform,LLY,https://www.benzinga.com/news/18/12/12850880/eli-lilly-reports-expansion-of-collaboration-with-evidation-health-for-andromeda,Benzinga Newsdesk,,,,0,0,f3af6867-4d2e-4668-9f79-b31d7c1e94e0
2018-12-13T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Jobless Claims, Import Prices Data",LLY,https://www.benzinga.com/news/18/12/12843937/a-peek-into-the-markets-us-stock-futures-edge-higher-ahead-of-jobless-claims-imp,Lisa Levin,,,,0,0,b5337c44-b0b2-44a4-bc94-1bb5e749574c
2018-12-13T08:00:00.000+08:00,Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus,LLY,https://www.benzinga.com/news/18/12/12843783/eli-lilly-reports-fast-track-designation-to-baricitinib-development-program-for-,Benzinga Newsdesk,,,,0,0,d98450c3-1315-4f80-b310-45e7693ef93d
2018-12-13T08:00:00.000+08:00,"Eli Lilly Announces Co. Boehringer Ingelheim Partner With Duke Clinical Research Institute To Advance Multidisciplinary Care For People With Type-2 Diabetes, Cardiovascular Disease",LLY,https://www.benzinga.com/news/18/12/12843723/eli-lilly-announces-co-boehringer-ingelheim-partner-with-duke-clinical-research-,Benzinga Newsdesk,,,,0,0,19e0a159-2b6f-44df-92c9-fcb5aae06757
2018-12-13T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Jobless Claims, Import Prices Data",LLY,https://www.benzinga.com/news/18/12/12843937/a-peek-into-the-markets-us-stock-futures-edge-higher-ahead-of-jobless-claims-imp,Lisa Levin,,,,0,0,c0e4e8b7-3dc8-480b-9dcf-0fab3559ecf6
2018-12-13T08:00:00.000+08:00,Eli Lilly Reports Fast Track Designation To Baricitinib Development Program For Treatment Of Systemic Lupus Erythematosus,LLY,https://www.benzinga.com/news/18/12/12843783/eli-lilly-reports-fast-track-designation-to-baricitinib-development-program-for-,Benzinga Newsdesk,,,,0,0,47685cc2-4883-4b51-8e73-d0d4c21cc86a
2018-12-13T08:00:00.000+08:00,"Eli Lilly Announces Co. Boehringer Ingelheim Partner With Duke Clinical Research Institute To Advance Multidisciplinary Care For People With Type-2 Diabetes, Cardiovascular Disease",LLY,https://www.benzinga.com/news/18/12/12843723/eli-lilly-announces-co-boehringer-ingelheim-partner-with-duke-clinical-research-,Benzinga Newsdesk,,,,0,0,c6926a13-3af7-42fe-81e4-25f915365767
2018-12-12T08:00:00.000+08:00,Lilly And AC Immune Announce License And Collaboration Agreement To Focus On Potential Alzheimers Treatment; AC Immune To Receive CHF80M Upfront And IS Eligible For Additional Milestones While Lilly Will Purchase A $50M Note Convertible Equity Position,LLY,https://www.benzinga.com/general/biotech/18/12/12836467/lilly-and-ac-immune-announce-license-and-collaboration-agreement-to-f,Benzinga Newsdesk,,,,0,0,d3c7c2c5-ea8a-45c4-9631-e9130c7a42f4
2018-12-12T08:00:00.000+08:00,Lilly And AC Immune Announce License And Collaboration Agreement To Focus On Potential Alzheimers Treatment; AC Immune To Receive CHF80M Upfront And IS Eligible For Additional Milestones While Lilly Will Purchase A $50M Note Convertible Equity Position,LLY,https://www.benzinga.com/general/biotech/18/12/12836467/lilly-and-ac-immune-announce-license-and-collaboration-agreement-to-f,Benzinga Newsdesk,,,,0,0,5cd92727-d5f7-4522-9064-a4bce3564dcf
2018-12-07T08:00:00.000+08:00,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",LLY,https://www.benzinga.com/markets/cannabis/18/12/12818199/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we,Javier Hasse,,,,0,0,015f8911-eeff-4aaf-b603-65fd2848c65a
2018-12-07T08:00:00.000+08:00,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",LLY,https://www.benzinga.com/markets/cannabis/18/12/12818199/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we,Javier Hasse,,,,0,0,85eddf68-6cab-404f-91c4-dadd6eb8b7a7
2018-12-06T08:00:00.000+08:00,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",LLY,https://www.benzinga.com/general/biotech/18/12/12805307/the-daily-biotech-pulse-abbvie-halts-lung-cancer-trial-oncomed-merges,Shanthi Rexaline,,,,0,0,26018cc6-2ad2-476a-ac03-5400a6cfcd96
2018-12-06T08:00:00.000+08:00,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",LLY,https://www.benzinga.com/general/biotech/18/12/12805307/the-daily-biotech-pulse-abbvie-halts-lung-cancer-trial-oncomed-merges,Shanthi Rexaline,,,,0,0,7911f8e2-7b31-41e6-99dd-9ac8c7f61f42
2018-12-04T08:00:00.000+08:00,"Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details",LLY,https://www.benzinga.com/news/18/12/12795841/ahead-of-mid-week-pause-investors-fret-over-trade-pact-details,JJ Kinahan,,,,0,0,d670356c-b773-4973-a58a-2a2c913412dc
2018-12-04T08:00:00.000+08:00,"Ahead Of Mid-Week Pause, Investors Fret Over Trade Pact Details",LLY,https://www.benzinga.com/news/18/12/12795841/ahead-of-mid-week-pause-investors-fret-over-trade-pact-details,JJ Kinahan,,,,0,0,ce091f73-f05c-44bb-8606-d61318a3c5f6
2018-11-30T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",LLY,https://www.benzinga.com/news/18/11/12779656/stocks-which-set-new-52-week-high-yesterday-thurs-nov-29-2018,Benzinga Newsdesk,,,,0,0,1e29996f-f2fc-4aaa-a945-79c1366722dc
2018-11-30T08:00:00.000+08:00,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",LLY,https://www.benzinga.com/general/biotech/18/11/12777751/the-daily-biotech-pulse-ec-nod-for-shire-mirati-gets-fda-clearance-fo,Shanthi Rexaline,,,,0,0,f8defce9-0dbc-403b-b984-f63f00055236
2018-11-30T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",LLY,https://www.benzinga.com/news/18/11/12779656/stocks-which-set-new-52-week-high-yesterday-thurs-nov-29-2018,Benzinga Newsdesk,,,,0,0,ddb00db5-8ce6-47d6-9aa4-566e6b56b97b
2018-11-30T08:00:00.000+08:00,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",LLY,https://www.benzinga.com/general/biotech/18/11/12777751/the-daily-biotech-pulse-ec-nod-for-shire-mirati-gets-fda-clearance-fo,Shanthi Rexaline,,,,0,0,ebefbc2a-53d2-451a-b151-51b0a96c6dac
2018-11-29T08:00:00.000+08:00,Eli Lilly Highlights Will Present Data For Verzenio At San Antonio Breast Cancer Symposium Dec. 4-8,LLY,https://www.benzinga.com/news/18/11/12770572/eli-lilly-highlights-will-present-data-for-verzenio-at-san-antonio-breast-cancer,Benzinga Newsdesk,,,,0,0,89710c1f-b273-4c54-ae05-7a2f45a2bf25
2018-11-29T08:00:00.000+08:00,Eli Lilly Highlights Will Present Data For Verzenio At San Antonio Breast Cancer Symposium Dec. 4-8,LLY,https://www.benzinga.com/news/18/11/12770572/eli-lilly-highlights-will-present-data-for-verzenio-at-san-antonio-breast-cancer,Benzinga Newsdesk,,,,0,0,114eaa91-73e8-4121-9ec2-a6ec7c5f4bea
2018-11-26T08:00:00.000+08:00,Expert Consensus Decision Pathway Issued By American College Of Cardiology Recommended Lilly's Jardiance As Preferred SGLT2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease,LLY,https://www.benzinga.com/general/biotech/18/11/12751645/expert-consensus-decision-pathway-issued-by-american-college-of-cardi,Benzinga Newsdesk,,,,0,0,55e41323-ff31-42b0-8132-50ad0767bc60
2018-11-26T08:00:00.000+08:00,"Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way",LLY,https://www.benzinga.com/news/18/11/12749682/data-dive-trade-talks-and-powell-busy-post-holiday-week-on-the-way,JJ Kinahan,,,,0,0,182ba401-834d-44e0-ab7a-0a436ddc213a
2018-11-26T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For November 26, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/11/12749415/benzingas-top-upgrades-downgrades-for-november-26-2018,Lisa Levin,,,,0,0,85ceb07c-84d5-4329-8d2c-00049f32a225
2018-11-26T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Surge, Dow Futures Up Over 250 Points",LLY,https://www.benzinga.com/news/18/11/12748416/a-peek-into-the-markets-us-stock-futures-surge-dow-futures-up-over-250-points,Lisa Levin,,,,0,0,07545d40-03c3-4bad-8ef9-49de8e635910
2018-11-26T08:00:00.000+08:00,Citigroup Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/11/12748319/citigroup-downgrades-eli-lilly-to-neutral,Benzinga Newsdesk,,,,0,0,50a6db4c-4617-4ed6-b52c-206736d1e104
2018-11-26T08:00:00.000+08:00,Expert Consensus Decision Pathway Issued By American College Of Cardiology Recommended Lilly's Jardiance As Preferred SGLT2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease,LLY,https://www.benzinga.com/general/biotech/18/11/12751645/expert-consensus-decision-pathway-issued-by-american-college-of-cardi,Benzinga Newsdesk,,,,0,0,55daff71-ca2d-4c92-b961-60e5dfbd1da9
2018-11-26T08:00:00.000+08:00,"Data Dive, Trade Talks And Powell: Busy Post-Holiday Week On The Way",LLY,https://www.benzinga.com/news/18/11/12749682/data-dive-trade-talks-and-powell-busy-post-holiday-week-on-the-way,JJ Kinahan,,,,0,0,93548422-e346-41e9-b4b8-2a7f566e400c
2018-11-26T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For November 26, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/11/12749415/benzingas-top-upgrades-downgrades-for-november-26-2018,Lisa Levin,,,,0,0,6825940c-f536-4b67-9e9b-6cf8119ab300
2018-11-26T08:00:00.000+08:00,"A Peek Into The Markets: US Stock Futures Surge, Dow Futures Up Over 250 Points",LLY,https://www.benzinga.com/news/18/11/12748416/a-peek-into-the-markets-us-stock-futures-surge-dow-futures-up-over-250-points,Lisa Levin,,,,0,0,6fab8ee7-ce8a-4dad-b7dd-d8201750d7e1
2018-11-26T08:00:00.000+08:00,Citigroup Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/11/12748319/citigroup-downgrades-eli-lilly-to-neutral,Benzinga Newsdesk,,,,0,0,345a1197-cdc3-4346-b31e-1f1a6e1dd4e7
2018-11-16T08:00:00.000+08:00,"'Eli Lilly Considers Sale of China Assets to Raise Cash' -Bloomberg, Citing Sources",LLY,https://www.benzinga.com/news/18/11/12715079/eli-lilly-considers-sale-of-china-assets-to-raise-cash-bloomberg-citing-sources,Benzinga Newsdesk,,,,0,0,f8ad190d-8172-4c41-8680-baac2f49100a
2018-11-16T08:00:00.000+08:00,"'Eli Lilly Considers Sale of China Assets to Raise Cash' -Bloomberg, Citing Sources",LLY,https://www.benzinga.com/news/18/11/12715079/eli-lilly-considers-sale-of-china-assets-to-raise-cash-bloomberg-citing-sources,Benzinga Newsdesk,,,,0,0,1ac2fb91-6ee1-4e48-ab68-dc736553b60c
2018-11-14T08:00:00.000+08:00,"Eli Lilly Reports Submission Of New Drug Application For Lasmiditan For Acute Treatment Of Migraine, Receives Breakthrough Designation For Emgality For Preventation Of Episodic Cluster Headache",LLY,https://www.benzinga.com/news/18/11/12694503/eli-lilly-reports-submission-of-new-drug-application-for-lasmiditan-for-acute-tr,Benzinga Newsdesk,,,,0,0,2743b4ee-7e4c-4d05-bdad-9e2ff3c33542
2018-11-14T08:00:00.000+08:00,"Eli Lilly Reports Submission Of New Drug Application For Lasmiditan For Acute Treatment Of Migraine, Receives Breakthrough Designation For Emgality For Preventation Of Episodic Cluster Headache",LLY,https://www.benzinga.com/news/18/11/12694503/eli-lilly-reports-submission-of-new-drug-application-for-lasmiditan-for-acute-tr,Benzinga Newsdesk,,,,0,0,6a3fcc1c-eb3e-4b68-b87c-31734a3681d5
2018-11-06T08:00:00.000+08:00,Long Wait Is Over: Election Day Dawns With Markets Under Light Pressure,LLY,https://www.benzinga.com/news/earnings/18/11/12640101/long-wait-is-over-election-day-dawns-with-markets-under-light-pressure,JJ Kinahan,,,,0,0,c60d03f3-9a2c-4451-9d41-76e85fda35a3
2018-11-06T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings,LLY,https://www.benzinga.com/news/18/11/12638083/a-peek-into-the-markets-us-stock-futures-drop-ahead-of-earnings,Lisa Levin,,,,0,0,b06d7b01-87f2-424e-9b12-0f9b69138181
2018-11-06T08:00:00.000+08:00,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",LLY,https://www.benzinga.com/general/biotech/18/11/12637056/the-daily-biotech-pulse-eyepoint-licenses-eye-inflammation-drug-insys,Shanthi Rexaline,,,,0,0,bccf1e1a-2e6f-413f-8cff-118a7d4f2b71
2018-11-06T08:00:00.000+08:00,UPDATE: Eli Lilly Raises FY18 Adj. EPS Guidance From $5.40-$5.50 To $5.55-$5.60 vs $5.48 Estimate,LLY,https://www.benzinga.com/news/18/11/12637390/update-eli-lilly-raises-fy18-adj-eps-guidance-from-5-40-5-50-to-5-55-5-60-vs-5-4,Benzinga Newsdesk,,,,0,0,d90a5e28-6dfa-47d8-a24f-fbe370b132b8
2018-11-06T08:00:00.000+08:00,"Eli Lilly Q3 EPS $1.39 Beats $1.36 Estimate, Sales $6.062B Beat $6.02B Estimate; Raises Guidance",LLY,https://www.benzinga.com/news/earnings/18/11/12637388/eli-lilly-q3-eps-1-39-beats-1-36-estimate-sales-6-062b-beat-6-02b-estim,Benzinga Newsdesk,,,,0,0,9727b2a8-023f-44ab-bc0a-16e8c82e02fc
2018-11-06T08:00:00.000+08:00,"10 Stocks To Watch For November 6, 2018",LLY,https://www.benzinga.com/news/earnings/18/11/12637058/10-stocks-to-watch-for-november-6-2018,Lisa Levin,,,,0,0,329de12c-fa73-4e21-bc01-afd30f8312ce
2018-11-06T08:00:00.000+08:00,"Earnings Scheduled For November 6, 2018",LLY,https://www.benzinga.com/news/earnings/18/11/12637030/earnings-scheduled-for-november-6-2018,Lisa Levin,,,,0,0,4444965a-ae30-4252-8883-67b0263547a3
2018-11-06T08:00:00.000+08:00,Long Wait Is Over: Election Day Dawns With Markets Under Light Pressure,LLY,https://www.benzinga.com/news/earnings/18/11/12640101/long-wait-is-over-election-day-dawns-with-markets-under-light-pressure,JJ Kinahan,,,,0,0,93dcc7f5-6dde-4024-80a5-6c75db0d5860
2018-11-06T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings,LLY,https://www.benzinga.com/news/18/11/12638083/a-peek-into-the-markets-us-stock-futures-drop-ahead-of-earnings,Lisa Levin,,,,0,0,9ce50fc0-a561-4032-b1be-8fcf1c75c326
2018-11-06T08:00:00.000+08:00,"The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering",LLY,https://www.benzinga.com/general/biotech/18/11/12637056/the-daily-biotech-pulse-eyepoint-licenses-eye-inflammation-drug-insys,Shanthi Rexaline,,,,0,0,bcdc3c61-021a-49a0-9b85-3111234d21e3
2018-11-06T08:00:00.000+08:00,UPDATE: Eli Lilly Raises FY18 Adj. EPS Guidance From $5.40-$5.50 To $5.55-$5.60 vs $5.48 Estimate,LLY,https://www.benzinga.com/news/18/11/12637390/update-eli-lilly-raises-fy18-adj-eps-guidance-from-5-40-5-50-to-5-55-5-60-vs-5-4,Benzinga Newsdesk,,,,0,0,e1e8f9cd-5ae9-42cc-bb89-8c1001cabbea
2018-11-06T08:00:00.000+08:00,"Eli Lilly Q3 EPS $1.39 Beats $1.36 Estimate, Sales $6.062B Beat $6.02B Estimate; Raises Guidance",LLY,https://www.benzinga.com/news/earnings/18/11/12637388/eli-lilly-q3-eps-1-39-beats-1-36-estimate-sales-6-062b-beat-6-02b-estim,Benzinga Newsdesk,,,,0,0,94244b6f-0e26-4c92-a6e7-5cd8285a6cb3
2018-11-06T08:00:00.000+08:00,"10 Stocks To Watch For November 6, 2018",LLY,https://www.benzinga.com/news/earnings/18/11/12637058/10-stocks-to-watch-for-november-6-2018,Lisa Levin,,,,0,0,8a2ee7b8-12e7-42e5-8811-148f34ecfe04
2018-11-06T08:00:00.000+08:00,"Earnings Scheduled For November 6, 2018",LLY,https://www.benzinga.com/news/earnings/18/11/12637030/earnings-scheduled-for-november-6-2018,Lisa Levin,,,,0,0,6e7d23e0-e30c-4fe5-885f-0ebb1adc9946
2018-11-05T08:00:00.000+08:00,"Eli Lilly, NextCure Report Collaboration To Discover, Develop Novel Immuno-Oncology Medicines; NextCure To Receive Upfront Payment Of $25M, Lilly Has Made $15M Equity Investment In NextCure",LLY,https://www.benzinga.com/news/18/11/12634476/eli-lilly-nextcure-report-collaboration-to-discover-develop-novel-immuno-oncolog,Benzinga Newsdesk,,,,0,0,62cfe535-3edd-4317-ae06-b44429181e71
2018-11-05T08:00:00.000+08:00,Eli Lilly shares are trading up 3.8% after the company reported positive early results from a study of jardiance; The company also reported its trulicity demonstrated a 'superior' reduction of cardiovascular events in type 2 diabetes patients.,LLY,https://www.benzinga.com/markets/wiim/18/11/12633381/eli-lilly-shares-are-trading-up-3-8-after-the-company-reported-positive-,Benzinga Newsdesk,,,,0,0,87261bc6-7c21-44fa-a01e-f8f8595b4652
2018-11-05T08:00:00.000+08:00,Eli Lilly Gets Ready For First Report Post-Elanco IPO,LLY,https://www.benzinga.com/news/earnings/18/11/12632088/eli-lilly-gets-ready-for-first-report-post-elanco-ipo,JJ Kinahan,,,,0,0,c966d4c4-e000-4ee8-adfb-a0ba50a02cf9
2018-11-05T08:00:00.000+08:00,Eli Lilly Says Trulicity Demonstrates a Superior Reduction of Cardiovascular Events for People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/11/12631667/eli-lilly-says-trulicity-demonstrates-a-superior-reduction-of-cardiovascular-eve,Benzinga Newsdesk,,,,0,0,d2acaed1-21d2-404e-aeed-3909f5e66b68
2018-11-05T08:00:00.000+08:00,Rally Fizzles As Apple's Guidance Seen Weak; Mixed Signals On China Keep Market Buzzing,LLY,https://www.benzinga.com/news/earnings/18/11/12630536/rally-fizzles-as-apples-guidance-seen-weak-mixed-signals-on-china-keep-,JJ Kinahan,,,,0,0,a50138b7-035f-4152-b91e-46d8f0878d89
2018-11-05T08:00:00.000+08:00,Eli Lilly Announces Positive Early Results From a Study of the First 5 Years of Jardiance Use,LLY,https://www.benzinga.com/news/18/11/12628962/eli-lilly-announces-positive-early-results-from-a-study-of-the-first-5-years-of-,Benzinga Newsdesk,,,,0,0,618efa1a-afcb-4d94-a49e-1ec508e0d8fd
2018-11-05T08:00:00.000+08:00,"Eli Lilly, NextCure Report Collaboration To Discover, Develop Novel Immuno-Oncology Medicines; NextCure To Receive Upfront Payment Of $25M, Lilly Has Made $15M Equity Investment In NextCure",LLY,https://www.benzinga.com/news/18/11/12634476/eli-lilly-nextcure-report-collaboration-to-discover-develop-novel-immuno-oncolog,Benzinga Newsdesk,,,,0,0,03a3fb9d-b6b8-4131-af8e-ad9be0be4579
2018-11-05T08:00:00.000+08:00,Eli Lilly shares are trading up 3.8% after the company reported positive early results from a study of jardiance; The company also reported its trulicity demonstrated a 'superior' reduction of cardiovascular events in type 2 diabetes patients.,LLY,https://www.benzinga.com/markets/wiim/18/11/12633381/eli-lilly-shares-are-trading-up-3-8-after-the-company-reported-positive-,Benzinga Newsdesk,,,,0,0,59aecc5b-9d70-4755-94aa-6ed47263ca8f
2018-11-05T08:00:00.000+08:00,Eli Lilly Gets Ready For First Report Post-Elanco IPO,LLY,https://www.benzinga.com/news/earnings/18/11/12632088/eli-lilly-gets-ready-for-first-report-post-elanco-ipo,JJ Kinahan,,,,0,0,e2674f5e-60dd-48f5-bd54-9c90539e326c
2018-11-05T08:00:00.000+08:00,Eli Lilly Says Trulicity Demonstrates a Superior Reduction of Cardiovascular Events for People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/11/12631667/eli-lilly-says-trulicity-demonstrates-a-superior-reduction-of-cardiovascular-eve,Benzinga Newsdesk,,,,0,0,9c4f2305-1788-4446-9252-a7585f473887
2018-11-05T08:00:00.000+08:00,Rally Fizzles As Apple's Guidance Seen Weak; Mixed Signals On China Keep Market Buzzing,LLY,https://www.benzinga.com/news/earnings/18/11/12630536/rally-fizzles-as-apples-guidance-seen-weak-mixed-signals-on-china-keep-,JJ Kinahan,,,,0,0,3f45ce1a-05da-40eb-b717-5a84dd06db7a
2018-11-05T08:00:00.000+08:00,Eli Lilly Announces Positive Early Results From a Study of the First 5 Years of Jardiance Use,LLY,https://www.benzinga.com/news/18/11/12628962/eli-lilly-announces-positive-early-results-from-a-study-of-the-first-5-years-of-,Benzinga Newsdesk,,,,0,0,f177885a-4270-4a7a-9944-3e8ff3d1661a
2018-11-04T08:00:00.000+08:00,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/11/12615052/the-week-ahead-in-biotech-earnings-conferences-pdufa-dates-clinical-t,Shanthi Rexaline,,,,0,0,95af5be1-48ae-42e5-a42c-55528c371846
2018-11-04T08:00:00.000+08:00,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/11/12615052/the-week-ahead-in-biotech-earnings-conferences-pdufa-dates-clinical-t,Shanthi Rexaline,,,,0,0,9549c7ea-8e4c-49b6-9060-0c2381b50026
2018-11-01T08:00:00.000+08:00,SIGA Technologies Reports Sale of Medical Countermeasures Priority Review Voucher to Eli Lilly for $80M,LLY,https://www.benzinga.com/news/18/11/12610119/siga-technologies-reports-sale-of-medical-countermeasures-priority-review-vouche,Charles Gross,,,,0,0,7a5f3d3c-2e92-4de3-b897-e26fdd35fa84
2018-11-01T08:00:00.000+08:00,SIGA Technologies Reports Sale of Medical Countermeasures Priority Review Voucher to Eli Lilly for $80M,LLY,https://www.benzinga.com/news/18/11/12610119/siga-technologies-reports-sale-of-medical-countermeasures-priority-review-vouche,Charles Gross,,,,0,0,bc667f9f-10c1-4fc4-a2f9-e2c0817ff2c5
2018-10-31T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 31, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12601454/benzingas-top-upgrades-downgrades-for-october-31-2018,Lisa Levin,,,,0,0,2c26f4da-65ef-4f0f-97cc-0b8dac6bacc9
2018-10-31T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/10/12600305/credit-suisse-upgrades-eli-lilly-to-neutral,Vick Meyer,,,,0,0,96c974df-02d8-4225-b9d4-6ac4e76d2e57
2018-10-31T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 31, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12601454/benzingas-top-upgrades-downgrades-for-october-31-2018,Lisa Levin,,,,0,0,6a653245-a560-4fb6-8a6e-b01864674050
2018-10-31T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/10/12600305/credit-suisse-upgrades-eli-lilly-to-neutral,Vick Meyer,,,,0,0,5c32813f-cd0f-4ad1-937d-311a06437c71
2018-10-30T08:00:00.000+08:00,"Eli Lilly, Lowe's, Macy's, XLU: 'Fast Money' Picks For October 30",LLY,https://www.benzinga.com/media/18/10/12588760/eli-lilly-lowes-macys-xlu-fast-money-picks-for-october-30,Craig Jones,,,,0,0,d4dd4e6d-6668-4eb2-bb74-e93a0ed5be98
2018-10-30T08:00:00.000+08:00,"Eli Lilly, Lowe's, Macy's, XLU: 'Fast Money' Picks For October 30",LLY,https://www.benzinga.com/media/18/10/12588760/eli-lilly-lowes-macys-xlu-fast-money-picks-for-october-30,Craig Jones,,,,0,0,8c49c184-ed33-4ddf-b0a7-3ffe1a1e3b3d
2018-10-29T08:00:00.000+08:00,"Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",LLY,https://www.benzinga.com/general/biotech/18/10/12582501/dicerna-soars-after-eli-lilly-invests-100m-in-licensing-research-deal,Shanthi Rexaline,,,,0,0,6c23a819-c0ba-4104-b4c2-33da722646f6
2018-10-29T08:00:00.000+08:00,"Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain",LLY,https://www.benzinga.com/news/18/10/12580835/dicerna-pharma-announces-licensing-and-research-collaboration-with-eli-lilly-for,Benzinga Newsdesk,,,,0,0,f67f52bb-31e5-4697-86d8-3f0b79b4be5f
2018-10-29T08:00:00.000+08:00,"Dicerna Soars After Eli Lilly Invests $100M In Licensing, Research Deal",LLY,https://www.benzinga.com/general/biotech/18/10/12582501/dicerna-soars-after-eli-lilly-invests-100m-in-licensing-research-deal,Shanthi Rexaline,,,,0,0,4fa3b902-2a6c-45cb-b986-d4781a50099d
2018-10-29T08:00:00.000+08:00,"Dicerna Pharma Announces Licensing and Research Collaboration with Eli Lilly for Development and Commercialization of New Medicines in Cardio-Metabolic Disease, Neurodegeneration and Pain",LLY,https://www.benzinga.com/news/18/10/12580835/dicerna-pharma-announces-licensing-and-research-collaboration-with-eli-lilly-for,Benzinga Newsdesk,,,,0,0,a70f39dd-4469-45eb-9960-695972ad87de
2018-10-24T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 24, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12557064/benzingas-top-upgrades-downgrades-for-october-24-2018,Lisa Levin,,,,0,0,e95eedf9-5151-4a95-83a3-b42e06d9d677
2018-10-24T08:00:00.000+08:00,"Wolfe Research Initiates Coverage On Eli Lilly with Peer Perform Rating, Announces $119 Price Target",LLY,https://www.benzinga.com/news/18/10/12555261/wolfe-research-initiates-coverage-on-eli-lilly-with-peer-perform-rating-announce,Vick Meyer,,,,0,0,87a1991f-a6f7-422d-9e85-18c7fc5b6e80
2018-10-24T08:00:00.000+08:00,"Pfizer, Lilly Announce Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients",LLY,https://www.benzinga.com/news/18/10/12554734/pfizer-lilly-announce-complete-results-from-first-study-in-ongoing-phase-3-progr,Charles Gross,,,,0,0,938c2033-e450-403d-9720-67bb73336166
2018-10-24T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 24, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12557064/benzingas-top-upgrades-downgrades-for-october-24-2018,Lisa Levin,,,,0,0,b7f13a47-3b80-4a12-83d0-ca5f0794b848
2018-10-24T08:00:00.000+08:00,"Wolfe Research Initiates Coverage On Eli Lilly with Peer Perform Rating, Announces $119 Price Target",LLY,https://www.benzinga.com/news/18/10/12555261/wolfe-research-initiates-coverage-on-eli-lilly-with-peer-perform-rating-announce,Vick Meyer,,,,0,0,1b77f627-1e20-449f-ac34-5681215a1353
2018-10-24T08:00:00.000+08:00,"Pfizer, Lilly Announce Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients",LLY,https://www.benzinga.com/news/18/10/12554734/pfizer-lilly-announce-complete-results-from-first-study-in-ongoing-phase-3-progr,Charles Gross,,,,0,0,acac7de3-eb86-48cb-b4fd-96d3a68f6784
2018-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2018",LLY,https://www.benzinga.com/news/earnings/18/10/12546405/earnings-scheduled-for-october-23-2018,Lisa Levin,,,,0,0,2c93f947-a707-441e-bff1-3fb5811371aa
2018-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2018",LLY,https://www.benzinga.com/news/earnings/18/10/12546405/earnings-scheduled-for-october-23-2018,Lisa Levin,,,,0,0,1d9825ac-7049-4f78-9082-a1649e9a6336
2018-10-22T08:00:00.000+08:00,Eli Lilly Reports Results For 2 Phase 3 Studies Of Taltz In Ankylosing Spondylitis: 'COAST-V is the first successful AS trial to use ASAS40 as the primary endpoint',LLY,https://www.benzinga.com/news/18/10/12544009/eli-lilly-reports-results-for-2-phase-3-studies-of-taltz-in-ankylosing-spondylit,Benzinga Newsdesk,,,,0,0,aecf17b6-1096-45d6-a79c-e5b4c21d98b9
2018-10-22T08:00:00.000+08:00,A Preview Of Eli Lilly's Q3 Earnings,LLY,https://www.benzinga.com/news/earnings-previews/18/10/12543573/a-preview-of-eli-lillys-earnings,Benzinga Newsdesk,,,,0,0,24941bd8-2601-4c30-aac1-7912a3dd694b
2018-10-22T08:00:00.000+08:00,Eli Lilly Reports Results For 2 Phase 3 Studies Of Taltz In Ankylosing Spondylitis: 'COAST-V is the first successful AS trial to use ASAS40 as the primary endpoint',LLY,https://www.benzinga.com/news/18/10/12544009/eli-lilly-reports-results-for-2-phase-3-studies-of-taltz-in-ankylosing-spondylit,Benzinga Newsdesk,,,,0,0,8741987b-5235-48a5-b400-e7d28d974e24
2018-10-22T08:00:00.000+08:00,A Preview Of Eli Lilly's Q3 Earnings,LLY,https://www.benzinga.com/news/earnings-previews/18/10/12543573/a-preview-of-eli-lillys-earnings,Benzinga Newsdesk,,,,0,0,3d542524-871d-4a4d-a03f-922dc2a4e134
2018-10-16T08:00:00.000+08:00,"Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices",LLY,https://www.benzinga.com/news/18/10/12515662/sanofi-novo-nordisk-lilly-shares-unaffected-amid-report-state-of-minnesota-filed,Benzinga Newsdesk,,,,0,0,8c023864-8817-4d37-8db3-cf438d727fb8
2018-10-16T08:00:00.000+08:00,"Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices",LLY,https://www.benzinga.com/news/18/10/12515662/sanofi-novo-nordisk-lilly-shares-unaffected-amid-report-state-of-minnesota-filed,Benzinga Newsdesk,,,,0,0,bd1c6db5-2dd6-4d26-9055-47515f1a048f
2018-10-14T08:00:00.000+08:00,4 Major Market Opportunities For The Cannabis Industry,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12479521/4-major-market-opportunities-for-the-cannabis-industry,Hannah Genig,,,,0,0,06580ff0-2009-4c39-8788-2cee27cc3a8b
2018-10-14T08:00:00.000+08:00,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/10/12487249/the-week-ahead-in-biotech-esmo-conference-pdufa-dates-clinical-trial-,Shanthi Rexaline,,,,0,0,3d9c4849-d322-4f2a-a6db-31e4e19aeb6f
2018-10-14T08:00:00.000+08:00,4 Major Market Opportunities For The Cannabis Industry,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12479521/4-major-market-opportunities-for-the-cannabis-industry,Hannah Genig,,,,0,0,ce8c1caa-8d0f-4d67-83e3-7253f3f7540a
2018-10-14T08:00:00.000+08:00,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/10/12487249/the-week-ahead-in-biotech-esmo-conference-pdufa-dates-clinical-trial-,Shanthi Rexaline,,,,0,0,a418a4d2-d902-496e-b9ea-346b59ea0de1
2018-10-12T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $120",LLY,https://www.benzinga.com/news/18/10/12498448/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-120,Vick Meyer,,,,0,0,76323d7c-4ed6-4cfd-b7af-05032e49f250
2018-10-12T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $120",LLY,https://www.benzinga.com/news/18/10/12498448/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-120,Vick Meyer,,,,0,0,fc25e814-2915-41b6-8d99-5374dcdaf99b
2018-10-10T08:00:00.000+08:00,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/10/12482335/the-daily-biotech-pulse-novartis-blood-disorder-drug-improves-patient,Shanthi Rexaline,,,,0,0,3d9744b8-8bcf-4166-8d62-5213934be349
2018-10-10T08:00:00.000+08:00,"The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/10/12482335/the-daily-biotech-pulse-novartis-blood-disorder-drug-improves-patient,Shanthi Rexaline,,,,0,0,0115d685-da6d-44f0-8d39-bf78f3076ca2
2018-10-09T08:00:00.000+08:00,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines',LLY,https://www.benzinga.com/news/18/10/12478199/fda-commissioner-scott-gottlieb-issues-statement-on-new-efforts-to-advance-the-d,Benzinga Newsdesk,,,,0,0,25c4f36a-3fa8-492f-a703-30fe3de70dff
2018-10-09T08:00:00.000+08:00,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial",LLY,https://www.benzinga.com/general/biotech/18/10/12474171/the-daily-biotech-pulse-affimeds-cancer-drug-placed-on-clinical-hold-,Shanthi Rexaline,,,,0,0,36702149-5440-45f6-b9d7-8d02422c9072
2018-10-09T08:00:00.000+08:00,FDA Commissioner Scott Gottlieb Issues Statement On 'new efforts to advance the development of generic copies of complex drugs to improve patient access to medicines',LLY,https://www.benzinga.com/news/18/10/12478199/fda-commissioner-scott-gottlieb-issues-statement-on-new-efforts-to-advance-the-d,Benzinga Newsdesk,,,,0,0,2c3b32ce-b10a-42d2-8be3-067526598753
2018-10-09T08:00:00.000+08:00,"The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial",LLY,https://www.benzinga.com/general/biotech/18/10/12474171/the-daily-biotech-pulse-affimeds-cancer-drug-placed-on-clinical-hold-,Shanthi Rexaline,,,,0,0,0531c375-5710-4263-8f0d-566238db6650
2018-10-08T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ameren, Pfizer, Eli Lilly, Envision Healthcare, AES, McCormick, Archer-Daniels Midland, and Ball Corp.",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12472827/stocks-that-made-new-52-week-highs-so-far-today-include-amer,Benzinga Newsdesk,,,,0,0,621ae91f-d32b-4c01-9dbc-8af152862b47
2018-10-08T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ameren, Pfizer, Eli Lilly, Envision Healthcare, AES, McCormick, Archer-Daniels Midland, and Ball Corp.",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12472827/stocks-that-made-new-52-week-highs-so-far-today-include-amer,Benzinga Newsdesk,,,,0,0,15066c8d-9e3a-4e86-94d7-234b71ed7dbe
2018-10-05T08:00:00.000+08:00,3 Screens That Hint At Which Stocks May Outperform In Q4,LLY,https://www.benzinga.com/fintech/18/10/12465725/3-screens-that-hint-at-which-stocks-may-outperform-in-q4,Chris Dier-Scalise,,,,0,0,870d45a4-e991-43c8-9084-0ffb4ee73058
2018-10-05T08:00:00.000+08:00,10 Biggest Price Target Changes For Friday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/10/12464630/10-biggest-price-target-changes-for-friday,Lisa Levin,,,,0,0,a9933683-0b4f-4e9f-ad51-7f7b1722b63b
2018-10-05T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 5, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12464568/benzingas-top-upgrades-downgrades-for-october-5-2018,Lisa Levin,,,,0,0,419a82c5-cf65-46e6-91bf-fd775ab67512
2018-10-05T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 4th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12464408/stocks-which-set-new-52-week-high-yesterday-october-4th,Benzinga Newsdesk,,,,0,0,59294fc2-c18f-4e09-9030-a8babfd9de75
2018-10-05T08:00:00.000+08:00,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",LLY,https://www.benzinga.com/general/biotech/18/10/12463117/the-daily-biotech-pulse-medicinova-gets-orphan-drug-status-kempharm-t,Shanthi Rexaline,,,,0,0,fdcb3347-c12c-45db-93b1-ebcb175c35b3
2018-10-05T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly to Outperform, Raises Price Target to $130",LLY,https://www.benzinga.com/news/18/10/12463136/bmo-capital-upgrades-eli-lilly-to-outperform-raises-price-target-to-130,Benzinga Newsdesk,,,,0,0,423960ff-2120-4a60-b138-129896d1f291
2018-10-05T08:00:00.000+08:00,3 Screens That Hint At Which Stocks May Outperform In Q4,LLY,https://www.benzinga.com/fintech/18/10/12465725/3-screens-that-hint-at-which-stocks-may-outperform-in-q4,Chris Dier-Scalise,,,,0,0,f0fe8a44-1542-40cf-955a-94a8e3980f6e
2018-10-05T08:00:00.000+08:00,10 Biggest Price Target Changes For Friday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/10/12464630/10-biggest-price-target-changes-for-friday,Lisa Levin,,,,0,0,1092c4cd-9c95-46a3-a48c-fd2cf9ad7299
2018-10-05T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 5, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/10/12464568/benzingas-top-upgrades-downgrades-for-october-5-2018,Lisa Levin,,,,0,0,01fe079c-8289-44b8-83d6-0354ad0472bf
2018-10-05T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 4th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12464408/stocks-which-set-new-52-week-high-yesterday-october-4th,Benzinga Newsdesk,,,,0,0,6a29e51c-8683-427e-8208-198d7a02351b
2018-10-05T08:00:00.000+08:00,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",LLY,https://www.benzinga.com/general/biotech/18/10/12463117/the-daily-biotech-pulse-medicinova-gets-orphan-drug-status-kempharm-t,Shanthi Rexaline,,,,0,0,33cd533a-89d2-43a3-9929-7bbedde98f1c
2018-10-05T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly to Outperform, Raises Price Target to $130",LLY,https://www.benzinga.com/news/18/10/12463136/bmo-capital-upgrades-eli-lilly-to-outperform-raises-price-target-to-130,Benzinga Newsdesk,,,,0,0,cdb615bc-a5a7-4804-afb7-ebd503076583
2018-10-04T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ball Corp, CF Industries, Jacobs Engineering, Mosaic, CME Group, and Eli Lilly",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12460628/stocks-that-made-new-52-week-highs-so-far-today-include-ball,Benzinga Newsdesk,,,,0,0,42c5bf64-d598-4399-a6d8-cb8ec84adcf7
2018-10-04T08:00:00.000+08:00,Eli Lilly shares are up 2.8% to $111.68 after the company earlier reported its empagliflozin in a Phase III trial met its primary efficacy endpoint.,LLY,https://www.benzinga.com/markets/wiim/18/10/12459709/eli-lilly-shares-are-up-2-8-to-111-68-after-the-company-earlier-reported,Benzinga_Newsdesk,,,,0,0,901227be-ace4-4831-b5e7-f7a3faf00053
2018-10-04T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 3rd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12459146/stocks-which-set-new-52-week-high-yesterday-october-3rd,Benzinga Newsdesk,,,,0,0,2857d03d-e3e6-4c8f-b541-aa1838803b1e
2018-10-04T08:00:00.000+08:00,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut",LLY,https://www.benzinga.com/general/biotech/18/10/12455944/the-daily-biotech-pulse-atricures-guidance-guardant-health-and-kodiak,Shanthi Rexaline,,,,0,0,bf221702-fa2f-46ff-a6b5-449327e82622
2018-10-04T08:00:00.000+08:00,"Boehringer Ingelheim, Eli Lilly Report Empagliflozin In Phase III Trial Met Primary Efficacy Endpoint",LLY,https://www.benzinga.com/news/18/10/12456485/boehringer-ingelheim-eli-lilly-report-empagliflozin-in-phase-iii-trial-met-prima,Benzinga Newsdesk,,,,0,0,6843596e-7928-41c3-bebf-78a34d4eb28c
2018-10-04T08:00:00.000+08:00,"Eli Lilly Reports Investigational Dual GIP, GLP-1 Receptor Agonist Showed Reduction In HbA1c, Body Weight In People With Type 2 Diabetes",LLY,https://www.benzinga.com/news/18/10/12456383/eli-lilly-reports-investigational-dual-gip-glp-1-receptor-agonist-showed-reducti,Benzinga Newsdesk,,,,0,0,1a84e7d9-4b5e-4902-84dd-51333968eebf
2018-10-04T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ball Corp, CF Industries, Jacobs Engineering, Mosaic, CME Group, and Eli Lilly",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12460628/stocks-that-made-new-52-week-highs-so-far-today-include-ball,Benzinga Newsdesk,,,,0,0,0a6bd8a5-cef4-48fc-813f-a8c1102c7509
2018-10-04T08:00:00.000+08:00,Eli Lilly shares are up 2.8% to $111.68 after the company earlier reported its empagliflozin in a Phase III trial met its primary efficacy endpoint.,LLY,https://www.benzinga.com/markets/wiim/18/10/12459709/eli-lilly-shares-are-up-2-8-to-111-68-after-the-company-earlier-reported,Benzinga_Newsdesk,,,,0,0,f2e6f235-3292-4b9e-9de1-a0cda2bd0902
2018-10-04T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 3rd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12459146/stocks-which-set-new-52-week-high-yesterday-october-3rd,Benzinga Newsdesk,,,,0,0,1dee8b88-bdd2-4a57-8c62-4da22b99df4b
2018-10-04T08:00:00.000+08:00,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut",LLY,https://www.benzinga.com/general/biotech/18/10/12455944/the-daily-biotech-pulse-atricures-guidance-guardant-health-and-kodiak,Shanthi Rexaline,,,,0,0,a3d9415b-8994-4963-9f07-803df5d26bb2
2018-10-04T08:00:00.000+08:00,"Boehringer Ingelheim, Eli Lilly Report Empagliflozin In Phase III Trial Met Primary Efficacy Endpoint",LLY,https://www.benzinga.com/news/18/10/12456485/boehringer-ingelheim-eli-lilly-report-empagliflozin-in-phase-iii-trial-met-prima,Benzinga Newsdesk,,,,0,0,e72d98fc-41c4-4f82-9fa8-965004b7fe16
2018-10-04T08:00:00.000+08:00,"Eli Lilly Reports Investigational Dual GIP, GLP-1 Receptor Agonist Showed Reduction In HbA1c, Body Weight In People With Type 2 Diabetes",LLY,https://www.benzinga.com/news/18/10/12456383/eli-lilly-reports-investigational-dual-gip-glp-1-receptor-agonist-showed-reducti,Benzinga Newsdesk,,,,0,0,e2297bf9-2c62-45d9-b669-934c144046e8
2018-10-03T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 2nd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12451979/stocks-which-set-new-52-week-high-yesterday-october-2nd,Benzinga Newsdesk,,,,0,0,bdfb2840-892c-42d1-8f01-7cc55908ab3c
2018-10-03T08:00:00.000+08:00,10 Biggest Price Target Changes For Wednesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/10/12450241/10-biggest-price-target-changes-for-wednesday,Lisa Levin,,,,0,0,6ee56d3a-022e-4771-b080-cafd9bf0b72b
2018-10-03T08:00:00.000+08:00,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/10/12448229/the-daily-biotech-pulse-endologixs-q3-sales-obsevas-positive-trial-re,Shanthi Rexaline,,,,0,0,fe361209-54c0-45dd-9152-1a08bcdafe7f
2018-10-03T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $107",LLY,https://www.benzinga.com/news/18/10/12448689/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-107,Vick Meyer,,,,0,0,83954d9a-0580-4373-8f44-02bc6517f89c
2018-10-03T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, October 2nd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/10/12451979/stocks-which-set-new-52-week-high-yesterday-october-2nd,Benzinga Newsdesk,,,,0,0,1586d2f6-c514-4e9f-90b0-b864b75fa379
2018-10-03T08:00:00.000+08:00,10 Biggest Price Target Changes For Wednesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/10/12450241/10-biggest-price-target-changes-for-wednesday,Lisa Levin,,,,0,0,3c3c1de9-ae07-4e19-957c-1549ccfb4a85
2018-10-03T08:00:00.000+08:00,"The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/10/12448229/the-daily-biotech-pulse-endologixs-q3-sales-obsevas-positive-trial-re,Shanthi Rexaline,,,,0,0,889a65e1-d692-42ce-8efa-59d721ff605b
2018-10-03T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $107",LLY,https://www.benzinga.com/news/18/10/12448689/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-107,Vick Meyer,,,,0,0,dc2ec312-298e-4707-aa9f-25fc1bbd11de
2018-10-02T08:00:00.000+08:00,Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/18/10/12439121/results-from-two-phase-3-studies-show-lillys-ultra-rapid-lispro-urli-,Benzinga_Newsdesk,,,,0,0,ba940167-a4fd-42eb-95d5-88d1bcbf90cb
2018-10-02T08:00:00.000+08:00,Results From Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint In People With Type 1 And Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/18/10/12439121/results-from-two-phase-3-studies-show-lillys-ultra-rapid-lispro-urli-,Benzinga_Newsdesk,,,,0,0,29e2f5e9-8c59-4b67-892f-e7e3be01492c
2018-10-01T08:00:00.000+08:00,Leerink: Improving Fundamentals Drive Teva Upgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12432584/leerink-improving-fundamentals-drive-teva-upgrade,Hannah Genig,,,,0,0,05d6a24e-5cc7-4067-b9a4-41e2be91b044
2018-10-01T08:00:00.000+08:00,Leerink: Improving Fundamentals Drive Teva Upgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12432584/leerink-improving-fundamentals-drive-teva-upgrade,Hannah Genig,,,,0,0,c5687391-2492-472c-8557-c9e3ffb25154
2018-09-28T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",LLY,https://www.benzinga.com/general/biotech/18/09/12423355/the-daily-biotech-pulse-fda-nods-for-adamis-eli-lilly-pfizer-spero-ob,Shanthi Rexaline,,,,0,0,b434e340-1953-4d0e-acf5-0a004d4fb563
2018-09-28T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",LLY,https://www.benzinga.com/general/biotech/18/09/12423355/the-daily-biotech-pulse-fda-nods-for-adamis-eli-lilly-pfizer-spero-ob,Shanthi Rexaline,,,,0,0,cd70201b-82c4-4a2b-90d4-e3fcef056be4
2018-09-27T08:00:00.000+08:00,Lilly's Emgality Receives FDA Approval for the Preventive Treatment of Migraine in Adults,LLY,https://www.benzinga.com/news/18/09/12422436/lillys-emgality-receives-fda-approval-for-the-preventive-treatment-of-migraine-i,Charles Gross,,,,0,0,e43e1b68-8cb2-4405-a0b4-39263532ce9b
2018-09-27T08:00:00.000+08:00,US Judge Has Dismissed Patent Suits By Teva Against Eli Lilly Related To Its Migraine Drug,LLY,https://www.benzinga.com/news/18/09/12420070/us-judge-has-dismissed-patent-suits-by-teva-against-eli-lilly-related-to-its-mig,Benzinga Newsdesk,,,,0,0,cd342f22-f69f-4572-bdb3-50a97f70a041
2018-09-27T08:00:00.000+08:00,"The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron",LLY,https://www.benzinga.com/general/biotech/18/09/12415125/the-daily-biotech-pulse-hologic-goes-shopping-johnson-johnson-snaps-t,Shanthi Rexaline,,,,0,0,8ffd4112-2f4d-4f7a-91e9-2ca68bc6e8b9
2018-09-27T08:00:00.000+08:00,Lilly's Emgality Receives FDA Approval for the Preventive Treatment of Migraine in Adults,LLY,https://www.benzinga.com/news/18/09/12422436/lillys-emgality-receives-fda-approval-for-the-preventive-treatment-of-migraine-i,Charles Gross,,,,0,0,5483c4c2-6c88-401f-bcfc-a3021fca8210
2018-09-27T08:00:00.000+08:00,US Judge Has Dismissed Patent Suits By Teva Against Eli Lilly Related To Its Migraine Drug,LLY,https://www.benzinga.com/news/18/09/12420070/us-judge-has-dismissed-patent-suits-by-teva-against-eli-lilly-related-to-its-mig,Benzinga Newsdesk,,,,0,0,1f84dccd-3814-4bea-8a3d-dc51b78d6d1f
2018-09-27T08:00:00.000+08:00,"The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron",LLY,https://www.benzinga.com/general/biotech/18/09/12415125/the-daily-biotech-pulse-hologic-goes-shopping-johnson-johnson-snaps-t,Shanthi Rexaline,,,,0,0,82b90579-04a8-411d-9252-16be3d003ea5
2018-09-26T08:00:00.000+08:00,JPMorgan Resumes Coverage Of Eli Lilly: 'One Of The Best-Positioned Names In Our Group',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12410874/jpmorgan-resumes-coverage-of-eli-lilly-one-of-the-best-,Shanthi Rexaline,,,,0,0,ac37a425-4d9c-4885-9dca-3f50bf0dd58e
2018-09-26T08:00:00.000+08:00,"From Earlier, JP Morgan Reinstated Eli Lilly at Overweight, Announces $117 Price Target",LLY,https://www.benzinga.com/news/18/09/12412239/from-earlier-jp-morgan-reinstated-eli-lilly-at-overweight-announces-117-price-ta,Benzinga Newsdesk,,,,0,0,327f174a-7881-4c59-866d-7efa28d5402c
2018-09-26T08:00:00.000+08:00,JPMorgan Resumes Coverage Of Eli Lilly: 'One Of The Best-Positioned Names In Our Group',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12410874/jpmorgan-resumes-coverage-of-eli-lilly-one-of-the-best-,Shanthi Rexaline,,,,0,0,1157a0e1-0bd6-4b53-a219-ddb061b04ea9
2018-09-26T08:00:00.000+08:00,"From Earlier, JP Morgan Reinstated Eli Lilly at Overweight, Announces $117 Price Target",LLY,https://www.benzinga.com/news/18/09/12412239/from-earlier-jp-morgan-reinstated-eli-lilly-at-overweight-announces-117-price-ta,Benzinga Newsdesk,,,,0,0,78ce7434-42ce-4305-9962-a6c6bed2b809
2018-09-21T08:00:00.000+08:00,Lilly Receives Positive CHMP Opinion for Emgality for the Prophylaxis of Migraine in Adults,LLY,https://www.benzinga.com/news/18/09/12388457/lilly-receives-positive-chmp-opinion-for-emgality-for-the-prophylaxis-of-migrain,Benzinga_Newsdesk,,,,0,0,62941e78-7902-4901-ae80-5f93a3f53f6f
2018-09-21T08:00:00.000+08:00,Lilly Receives Positive CHMP Opinion for Emgality for the Prophylaxis of Migraine in Adults,LLY,https://www.benzinga.com/news/18/09/12388457/lilly-receives-positive-chmp-opinion-for-emgality-for-the-prophylaxis-of-migrain,Benzinga_Newsdesk,,,,0,0,58420b16-f327-4003-8ef5-40723f562f4d
2018-09-20T08:00:00.000+08:00,Elanco Animal Health Shares Indicated $26 on 750K Shares; IPO Priced at $24/Share,LLY,https://www.benzinga.com/news/18/09/12383300/elanco-animal-health-shares-indicated-26-on-750k-shares-ipo-priced-at-24share,Benzinga Newsdesk,,,,0,0,9a5823ac-1ec6-4cf8-a55b-6b4eb043f9b2
2018-09-20T08:00:00.000+08:00,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",LLY,https://www.benzinga.com/general/biotech/18/09/12381811/the-daily-biotech-pulse-adverum-snags-fast-track-designation-crispr-t,Shanthi Rexaline,,,,0,0,46f1674b-61e6-4237-a337-75fd6d447e0a
2018-09-20T08:00:00.000+08:00,Elanco Animal Health Prices $62.9M Share IPO @$24/Share,LLY,https://www.benzinga.com/news/18/09/12381007/elanco-animal-health-prices-62-9m-share-ipo-24share,Charles Gross,,,,0,0,9ddf95e8-a529-4100-8d64-a1676dbd42ef
2018-09-20T08:00:00.000+08:00,Elanco Animal Health Shares Indicated $26 on 750K Shares; IPO Priced at $24/Share,LLY,https://www.benzinga.com/news/18/09/12383300/elanco-animal-health-shares-indicated-26-on-750k-shares-ipo-priced-at-24share,Benzinga Newsdesk,,,,0,0,e5370d49-9904-43a3-8d48-cb04e3458e61
2018-09-20T08:00:00.000+08:00,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",LLY,https://www.benzinga.com/general/biotech/18/09/12381811/the-daily-biotech-pulse-adverum-snags-fast-track-designation-crispr-t,Shanthi Rexaline,,,,0,0,6518da36-1333-4bde-838d-6956fefe8874
2018-09-20T08:00:00.000+08:00,Elanco Animal Health Prices $62.9M Share IPO @$24/Share,LLY,https://www.benzinga.com/news/18/09/12381007/elanco-animal-health-prices-62-9m-share-ipo-24share,Charles Gross,,,,0,0,d8094eea-90ed-4dc9-868d-5200481b7b9c
2018-09-19T08:00:00.000+08:00,"Eli Lilly And Company Subsidiary, Elanco, Prices IPO Of 62.9M Shares At $24/Share; Shares Expected To Open For Trade Thursday On NYSE Under Symbol 'ELAn'",LLY,https://www.benzinga.com/news/18/09/12379857/eli-lilly-and-company-subsidiary-elanco-prices-ipo-of-62-9m-shares-at-24share-sh,Benzinga_Newsdesk,,,,0,0,c28bafd5-f7b9-4273-902b-c979f1a4099b
2018-09-19T08:00:00.000+08:00,"Eli Lilly And Company Subsidiary, Elanco, Prices IPO Of 62.9M Shares At $24/Share; Shares Expected To Open For Trade Thursday On NYSE Under Symbol 'ELAn'",LLY,https://www.benzinga.com/news/18/09/12379857/eli-lilly-and-company-subsidiary-elanco-prices-ipo-of-62-9m-shares-at-24share-sh,Benzinga_Newsdesk,,,,0,0,51bb9da8-e5e7-47db-9d63-2aefd75a7c2e
2018-09-18T08:00:00.000+08:00,10 Biggest Price Target Changes For Tuesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/09/12370398/10-biggest-price-target-changes-for-tuesday,Lisa Levin,,,,0,0,dc287f4e-5157-47dc-a438-7af271d850f9
2018-09-18T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $112",LLY,https://www.benzinga.com/news/18/09/12368272/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-112,Vick Meyer,,,,0,0,acf5e58e-61f8-47a6-ae98-30f2b16aee22
2018-09-18T08:00:00.000+08:00,10 Biggest Price Target Changes For Tuesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/09/12370398/10-biggest-price-target-changes-for-tuesday,Lisa Levin,,,,0,0,79e52bcb-0b61-4281-991f-69301f5691cf
2018-09-18T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $112",LLY,https://www.benzinga.com/news/18/09/12368272/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-112,Vick Meyer,,,,0,0,50bda519-8e30-4e5a-bb16-ba37eb72e6c3
2018-09-17T08:00:00.000+08:00,"Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12363642/credit-suisse-lifts-teva-price-target-says-execution-is,Shanthi Rexaline,,,,0,0,3cf36339-3f03-4361-841f-8b6819d61940
2018-09-17T08:00:00.000+08:00,Teva's Preventive Migraine Treatment Approved By FDA,LLY,https://www.benzinga.com/general/biotech/18/09/12362386/tevas-preventive-migraine-treatment-approved-by-fda,Shanthi Rexaline,,,,0,0,a71ca18c-a0d4-4593-8f9a-bf38aa2421b4
2018-09-17T08:00:00.000+08:00,"Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12363642/credit-suisse-lifts-teva-price-target-says-execution-is,Shanthi Rexaline,,,,0,0,f7a82b74-f927-4eb7-aaa1-8417371f9671
2018-09-17T08:00:00.000+08:00,Teva's Preventive Migraine Treatment Approved By FDA,LLY,https://www.benzinga.com/general/biotech/18/09/12362386/tevas-preventive-migraine-treatment-approved-by-fda,Shanthi Rexaline,,,,0,0,165125b5-d29b-4cbf-baf4-e50fb85af741
2018-09-16T08:00:00.000+08:00,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/09/12351792/the-week-ahead-in-biotech-sept-16-22-conferences-pdufa-dates-clinical,Shanthi Rexaline,,,,0,0,3873e33e-3045-41c4-953d-580e3e2303e4
2018-09-16T08:00:00.000+08:00,"The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs",LLY,https://www.benzinga.com/general/biotech/18/09/12351792/the-week-ahead-in-biotech-sept-16-22-conferences-pdufa-dates-clinical,Shanthi Rexaline,,,,0,0,ce93b53b-d2a1-4e47-9883-f562dcb4a203
2018-09-14T08:00:00.000+08:00,"The IPO Outlook For The Week: Eventbrite, Animal Health And Luxury Fashion",LLY,https://www.benzinga.com/news/18/09/12355696/the-ipo-outlook-for-the-week-eventbrite-animal-health-and-luxury-fashion,Elizabeth Balboa,,,,0,0,ea5922fd-f621-4e7a-b08f-ed65115a52db
2018-09-14T08:00:00.000+08:00,"The IPO Outlook For The Week: Eventbrite, Animal Health And Luxury Fashion",LLY,https://www.benzinga.com/news/18/09/12355696/the-ipo-outlook-for-the-week-eventbrite-animal-health-and-luxury-fashion,Elizabeth Balboa,,,,0,0,1259215c-a108-4ba6-9a93-80022a527988
2018-09-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",LLY,https://www.benzinga.com/general/biotech/18/09/12333621/the-daily-biotech-pulse-advaxis-posts-narrower-loss-endocyte-announce,Shanthi Rexaline,,,,0,0,633cdd25-ac79-4667-aaec-1a5c83b0662a
2018-09-11T08:00:00.000+08:00,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",LLY,https://www.benzinga.com/general/biotech/18/09/12333621/the-daily-biotech-pulse-advaxis-posts-narrower-loss-endocyte-announce,Shanthi Rexaline,,,,0,0,3fdfcdd3-bf89-4317-b463-3828b78a5055
2018-09-10T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Friday, September 7th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/09/12332289/stocks-which-set-new-52-week-high-friday-september-7th,Benzinga Newsdesk,,,,0,0,657564fc-0654-4f43-be81-b37e16bb1730
2018-09-10T08:00:00.000+08:00,Eli Lilly Initiates IXORA-R Head-To-Head Clinical Trial Comparing Taltz And Tremfya,LLY,https://www.benzinga.com/news/18/09/12328380/eli-lilly-initiates-ixora-r-head-to-head-clinical-trial-comparing-taltz-and-trem,Benzinga_Newsdesk,,,,0,0,5cb8d7ac-7070-4c69-9726-472c0da15b5f
2018-09-10T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Friday, September 7th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/09/12332289/stocks-which-set-new-52-week-high-friday-september-7th,Benzinga Newsdesk,,,,0,0,7ec781dc-686e-46ac-a59e-e122a108ba0f
2018-09-10T08:00:00.000+08:00,Eli Lilly Initiates IXORA-R Head-To-Head Clinical Trial Comparing Taltz And Tremfya,LLY,https://www.benzinga.com/news/18/09/12328380/eli-lilly-initiates-ixora-r-head-to-head-clinical-trial-comparing-taltz-and-trem,Benzinga_Newsdesk,,,,0,0,c3bca1e9-2696-4327-9e14-de24a75aa5f6
2018-09-07T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $107",LLY,https://www.benzinga.com/news/18/09/12320597/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-107,Vick Meyer,,,,0,0,7e940889-ac46-4b40-b464-b33761fc226f
2018-09-07T08:00:00.000+08:00,"Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $107",LLY,https://www.benzinga.com/news/18/09/12320597/barclays-maintains-overweight-on-eli-lilly-raises-price-target-to-107,Vick Meyer,,,,0,0,1afbfca0-f761-45fe-a20c-0a90cdcf94b9
2018-09-06T08:00:00.000+08:00,New Class of Migraine Drug Creates Four-Way Pharma Development Race,LLY,https://www.benzinga.com/general/biotech/18/09/12284580/new-class-of-migraine-drug-creates-four-way-pharma-development-race,Shanthi Rexaline,,,,0,0,e1601876-565a-4918-8abb-a91237853332
2018-09-06T08:00:00.000+08:00,Eli Lilly's Elanco Sets IPO Of 62.9M Shares In $20-$23/Share Range,LLY,https://www.benzinga.com/news/18/09/12312848/eli-lillys-elanco-sets-ipo-of-62-9m-shares-in-20-23share-range,luke@benzinga.com,,,,0,0,23c27498-3e83-44dc-800d-7333b1097862
2018-09-06T08:00:00.000+08:00,New Class of Migraine Drug Creates Four-Way Pharma Development Race,LLY,https://www.benzinga.com/general/biotech/18/09/12284580/new-class-of-migraine-drug-creates-four-way-pharma-development-race,Shanthi Rexaline,,,,0,0,2bd10520-0741-472d-9a4d-7a274873b5d1
2018-09-06T08:00:00.000+08:00,Eli Lilly's Elanco Sets IPO Of 62.9M Shares In $20-$23/Share Range,LLY,https://www.benzinga.com/news/18/09/12312848/eli-lillys-elanco-sets-ipo-of-62-9m-shares-in-20-23share-range,luke@benzinga.com,,,,0,0,4790a5ce-a251-4dd1-880e-4b8851186bbf
2018-09-05T08:00:00.000+08:00,Eli Lilly Says Phase 3 Results In Flortaucipir PET Imaging Agent Showed That Flortaucipir Demonstrated Statistically Significant Sensitivity And specificity For Detecting A High Level Of Total Alzheimer's Disease Neuropathologic Change,LLY,https://www.benzinga.com/news/18/09/12309274/eli-lilly-says-phase-3-results-in-flortaucipir-pet-imaging-agent-showed-that-flo,Benzinga_Newsdesk,,,,0,0,83c7c0dd-1f3b-4771-bbf1-2060a1cb9cbb
2018-09-05T08:00:00.000+08:00,Eli Lilly Says Phase 3 Results In Flortaucipir PET Imaging Agent Showed That Flortaucipir Demonstrated Statistically Significant Sensitivity And specificity For Detecting A High Level Of Total Alzheimer's Disease Neuropathologic Change,LLY,https://www.benzinga.com/news/18/09/12309274/eli-lilly-says-phase-3-results-in-flortaucipir-pet-imaging-agent-showed-that-flo,Benzinga_Newsdesk,,,,0,0,d8322761-664d-4a4e-a6bf-7e8f5ced4855
2018-09-04T08:00:00.000+08:00,Zymeworks Reports IND-Submission Milestone Achieved In Eli Lilly Collaboration; Co. Will Receive $2M Milestone Payment For Eli Lily's Submission Of IND Application For Bispecific Antibody Enabled By Zymeworks' Azymetric Platform,LLY,https://www.benzinga.com/general/biotech/18/09/12302894/zymeworks-reports-ind-submission-milestone-achieved-in-eli-lilly-coll,Benzinga_Newsdesk,,,,0,0,615e444c-f89d-4183-b0d0-5185a25683fa
2018-09-04T08:00:00.000+08:00,Zymeworks Reports IND-Submission Milestone Achieved In Eli Lilly Collaboration; Co. Will Receive $2M Milestone Payment For Eli Lily's Submission Of IND Application For Bispecific Antibody Enabled By Zymeworks' Azymetric Platform,LLY,https://www.benzinga.com/general/biotech/18/09/12302894/zymeworks-reports-ind-submission-milestone-achieved-in-eli-lilly-coll,Benzinga_Newsdesk,,,,0,0,ef6e21a0-9b72-4098-9b23-13cd56b12c70
2018-08-31T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/18/08/12265004/attention-biotech-investors-mark-your-calendar-for-these-september-pd,Shanthi Rexaline,,,,0,0,0372ea14-065c-4069-b732-48194745bee2
2018-08-31T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/18/08/12265004/attention-biotech-investors-mark-your-calendar-for-these-september-pd,Shanthi Rexaline,,,,0,0,f2091741-9780-4ce6-93c4-6c69dafb9770
2018-08-30T08:00:00.000+08:00,"UPDATE: Adocia Notes Eli Lilly Filed Counterclaims Against Co. Seeking ~$188M, Including Prejudgment Interest",LLY,https://www.benzinga.com/news/18/08/12285393/update-adocia-notes-eli-lilly-filed-counterclaims-against-co-seeking-188m-includ,luke@benzinga.com,,,,0,0,56c9cc7d-e815-4685-8bac-9a4667bdea28
2018-08-30T08:00:00.000+08:00,"French Biopharma Co. Focused On Treatment For Diabetes, Etc, Adocia, Issues Press Release Highlighting Update To Amount Of Damages In Case Against Eli Lilly To ~$1.8B",LLY,https://www.benzinga.com/news/18/08/12285388/french-biopharma-co-focused-on-treatment-for-diabetes-etc-adocia-issues-press-re,luke@benzinga.com,,,,0,0,211ba633-32b6-4e8b-ad7e-706ab38e04ca
2018-08-30T08:00:00.000+08:00,"UPDATE: Adocia Notes Eli Lilly Filed Counterclaims Against Co. Seeking ~$188M, Including Prejudgment Interest",LLY,https://www.benzinga.com/news/18/08/12285393/update-adocia-notes-eli-lilly-filed-counterclaims-against-co-seeking-188m-includ,luke@benzinga.com,,,,0,0,d3142e4c-3810-4ecf-9ae4-90474c45cf61
2018-08-30T08:00:00.000+08:00,"French Biopharma Co. Focused On Treatment For Diabetes, Etc, Adocia, Issues Press Release Highlighting Update To Amount Of Damages In Case Against Eli Lilly To ~$1.8B",LLY,https://www.benzinga.com/news/18/08/12285388/french-biopharma-co-focused-on-treatment-for-diabetes-etc-adocia-issues-press-re,luke@benzinga.com,,,,0,0,48990151-75f0-416a-9e06-3f9ab4fe48aa
2018-08-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",LLY,https://www.benzinga.com/general/biotech/18/08/12267407/the-daily-biotech-pulse-regulatory-roadblock-for-akcea-ionis-affimeds,Shanthi Rexaline,,,,0,0,379f332f-b3a4-42a4-bb63-50f4661c202f
2018-08-28T08:00:00.000+08:00,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",LLY,https://www.benzinga.com/general/biotech/18/08/12267407/the-daily-biotech-pulse-regulatory-roadblock-for-akcea-ionis-affimeds,Shanthi Rexaline,,,,0,0,26e0b324-bc80-475b-8ff3-8d1531340efd
2018-08-27T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: IHS Markit, Cooper Cos., IDEXX Labs, Motorola Solutions, Emerson, Sherwin-Williams, Kansas City Southern, Norfolk Southern, Archer-Daniels, Verisk, Illumina, CSX, AMD, Eli Lilly, & Union Pacific",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12264607/stocks-that-made-new-52-week-highs-so-far-today-include-ihs-,Benzinga Newsdesk,,,,0,0,700e2a7c-77d5-46a8-a49f-1e1bae2a71a9
2018-08-27T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: IHS Markit, Cooper Cos., IDEXX Labs, Motorola Solutions, Emerson, Sherwin-Williams, Kansas City Southern, Norfolk Southern, Archer-Daniels, Verisk, Illumina, CSX, AMD, Eli Lilly, & Union Pacific",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12264607/stocks-that-made-new-52-week-highs-so-far-today-include-ihs-,Benzinga Newsdesk,,,,0,0,a819914d-38f2-4ec0-9223-2120db521aa4
2018-08-25T08:00:00.000+08:00,"Barron's Picks And Pans: Electronic Arts, GlaxoSmithKline, Microsoft, Tesla And More",LLY,https://www.benzinga.com/media/18/08/12260491/barrons-picks-and-pans-electronic-arts-glaxosmithkline-microsoft-tesla-and-more,Nelson Hem,,,,0,0,9d4f21f6-542e-4fba-a454-41ddd0ac0a53
2018-08-25T08:00:00.000+08:00,"Barron's Picks And Pans: Electronic Arts, GlaxoSmithKline, Microsoft, Tesla And More",LLY,https://www.benzinga.com/media/18/08/12260491/barrons-picks-and-pans-electronic-arts-glaxosmithkline-microsoft-tesla-and-more,Nelson Hem,,,,0,0,3dc0b6eb-cf35-468d-a360-d52269259660
2018-08-21T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",LLY,https://www.benzinga.com/general/biotech/18/08/12235573/the-daily-biotech-pulse-mercks-keytruda-secures-approval-for-expanded,Shanthi Rexaline,,,,0,0,e9ff7ac7-afd0-47b4-b4a1-275722ff779f
2018-08-21T08:00:00.000+08:00,"The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows",LLY,https://www.benzinga.com/general/biotech/18/08/12235573/the-daily-biotech-pulse-mercks-keytruda-secures-approval-for-expanded,Shanthi Rexaline,,,,0,0,050a760a-e50b-4747-84c3-78e585a5b807
2018-08-17T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 16th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12224603/stocks-which-set-new-52-week-high-yesterday-august-16th,Benzinga Newsdesk,,,,0,0,92c2e01d-25fa-49b9-9f46-18e6280b28de
2018-08-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",LLY,https://www.benzinga.com/general/biotech/18/08/12222856/the-daily-biotech-pulse-aveo-slips-on-stock-offering-fda-greenlights-,Shanthi Rexaline,,,,0,0,0ecaff57-0dcb-4ff1-9932-6ab149011a96
2018-08-17T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 16th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12224603/stocks-which-set-new-52-week-high-yesterday-august-16th,Benzinga Newsdesk,,,,0,0,c46cafec-9921-44ad-8ef3-934667aec3d8
2018-08-17T08:00:00.000+08:00,"The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns",LLY,https://www.benzinga.com/general/biotech/18/08/12222856/the-daily-biotech-pulse-aveo-slips-on-stock-offering-fda-greenlights-,Shanthi Rexaline,,,,0,0,6c5d1121-df95-4024-be31-3e545bd39f11
2018-08-16T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ingersoll-Rand, Dollar General, Progressive, SunTrust Banks, Eli Lilly, Express Scripts, CenturyLink, Cintas, Fastenal, Aetna, O'Reilly Automotive, Darden Restaurants, Chipotle, and Centene",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12218948/stocks-that-made-new-52-week-highs-so-far-today-include-inge,Benzinga Newsdesk,,,,0,0,ac5f0e04-8eae-4969-8782-242a0d3ac449
2018-08-16T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs So Far Today Include: Ingersoll-Rand, Dollar General, Progressive, SunTrust Banks, Eli Lilly, Express Scripts, CenturyLink, Cintas, Fastenal, Aetna, O'Reilly Automotive, Darden Restaurants, Chipotle, and Centene",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12218948/stocks-that-made-new-52-week-highs-so-far-today-include-inge,Benzinga Newsdesk,,,,0,0,ffd2f40f-ffad-4e93-a395-4180b9639df2
2018-08-14T08:00:00.000+08:00,"Stocks Trading Ex Dividend Today, August 14th",LLY,https://www.benzinga.com/news/18/08/12199631/stocks-trading-ex-dividend-today-august-14th,Benzinga Newsdesk,,,,0,0,2bd76d94-c003-435f-9157-f8244640ac4c
2018-08-14T08:00:00.000+08:00,"Stocks Trading Ex Dividend Today, August 14th",LLY,https://www.benzinga.com/news/18/08/12199631/stocks-trading-ex-dividend-today-august-14th,Benzinga Newsdesk,,,,0,0,8b8fbd4c-5f1f-417c-b9fa-ae5eab74339d
2018-08-13T08:00:00.000+08:00,"Stocks That Will Be Trading Ex Dividend Tomorrow, August 14th",LLY,https://www.benzinga.com/news/18/08/12193922/stocks-that-will-be-trading-ex-dividend-tomorrow-august-14th,Benzinga Newsdesk,,,,0,0,6c9d0f02-67a0-47f8-b8a2-29fc77403c4e
2018-08-13T08:00:00.000+08:00,"Stocks That Will Be Trading Ex Dividend Tomorrow, August 14th",LLY,https://www.benzinga.com/news/18/08/12193922/stocks-that-will-be-trading-ex-dividend-tomorrow-august-14th,Benzinga Newsdesk,,,,0,0,9533e421-ce3f-4d21-b37b-dd689c6f6154
2018-08-08T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 7th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12165578/stocks-which-set-new-52-week-high-yesterday-august-7th,Benzinga Newsdesk,,,,0,0,7eacef8f-ed94-4b33-b740-77652d947931
2018-08-08T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",LLY,https://www.benzinga.com/general/biotech/18/08/12162539/the-daily-biotech-pulse-fda-panel-backs-insmed-eidos-maiden-earnings-,Shanthi Rexaline,,,,0,0,56064242-422c-458a-a92d-ed8ce7986c0b
2018-08-08T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 7th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12165578/stocks-which-set-new-52-week-high-yesterday-august-7th,Benzinga Newsdesk,,,,0,0,6bc1d8d2-7427-4f78-95fc-2b8547f7fbc2
2018-08-08T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",LLY,https://www.benzinga.com/general/biotech/18/08/12162539/the-daily-biotech-pulse-fda-panel-backs-insmed-eidos-maiden-earnings-,Shanthi Rexaline,,,,0,0,0243d0d4-5afd-4088-b9c7-c03491c74d3a
2018-08-07T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12155877/stocks-that-made-new-52-week-highs-earlier-today-include-sl-,Benzinga Newsdesk,,,,0,0,996e9300-e46e-45a8-b3e4-bebda6068ebc
2018-08-07T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 6th",LLY,https://www.benzinga.com/trading-ideas/small-cap-analysis/18/08/12155686/stocks-which-set-new-52-week-high-yesterday-august-6,Benzinga Newsdesk,,,,0,0,c0d45b1a-c103-4a12-b544-53571449a05c
2018-08-07T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",LLY,https://www.benzinga.com/general/biotech/18/08/12152105/the-daily-biotech-pulse-fda-snub-for-gemphire-ligand-earnings-insmeds,Shanthi Rexaline,,,,0,0,0d7bfd58-1dc8-4d1d-800b-4c1c985561bf
2018-08-07T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12155877/stocks-that-made-new-52-week-highs-earlier-today-include-sl-,Benzinga Newsdesk,,,,0,0,52e02072-9627-406e-82a0-b8a9cdd5fefe
2018-08-07T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 6th",LLY,https://www.benzinga.com/trading-ideas/small-cap-analysis/18/08/12155686/stocks-which-set-new-52-week-high-yesterday-august-6,Benzinga Newsdesk,,,,0,0,da7a7d37-5d92-4649-86dd-9f8ed9059e79
2018-08-07T08:00:00.000+08:00,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",LLY,https://www.benzinga.com/general/biotech/18/08/12152105/the-daily-biotech-pulse-fda-snub-for-gemphire-ligand-earnings-insmeds,Shanthi Rexaline,,,,0,0,b3290843-4fb3-4849-b6d1-cd645007ba82
2018-08-06T08:00:00.000+08:00,"Stocks Which Set New 52-Week Highs Friday, August 3rd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12147637/stocks-which-set-new-52-week-highs-friday-august-3rd,Benzinga Newsdesk,,,,0,0,7bf64897-481e-4740-8bd4-64737541498d
2018-08-06T08:00:00.000+08:00,"Stocks Which Set New 52-Week Highs Friday, August 3rd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12147637/stocks-which-set-new-52-week-highs-friday-august-3rd,Benzinga Newsdesk,,,,0,0,83caf638-6652-42dc-9919-925dbd94600d
2018-08-03T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 2nd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12138981/stocks-which-set-new-52-week-high-yesterday-august-2nd,Benzinga Newsdesk,,,,0,0,221506a3-dd24-4c15-a28e-476c6a2a44aa
2018-08-03T08:00:00.000+08:00,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",LLY,https://www.benzinga.com/general/biotech/18/08/12136788/the-daily-biotech-pulse-zafgen-executive-departs-adamas-acceleron-acc,Shanthi Rexaline,,,,0,0,2ca3e85f-ee96-45d8-9241-963fbe9643a5
2018-08-03T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 2nd",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12138981/stocks-which-set-new-52-week-high-yesterday-august-2nd,Benzinga Newsdesk,,,,0,0,2fd16286-2540-41ea-af70-5b68c9c70a7b
2018-08-03T08:00:00.000+08:00,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",LLY,https://www.benzinga.com/general/biotech/18/08/12136788/the-daily-biotech-pulse-zafgen-executive-departs-adamas-acceleron-acc,Shanthi Rexaline,,,,0,0,8860dce2-543e-4e58-9d96-1a6a4b8e269c
2018-08-02T08:00:00.000+08:00,Elanco Animal Health F-1 Shows Registration For $100M IPO; Co. Planning To List On NYSE Under Symbol 'ELAN'; BZ NOTE: Co. Is Eli Lilly's Animal Health Unit,LLY,https://www.benzinga.com/news/18/08/12134479/elanco-animal-health-f-1-shows-registration-for-100m-ipo-co-planning-to-list-on-,Benzinga Newsdesk,,,,0,0,ba5ccafd-8ba4-478d-80a3-ef12c93553e4
2018-08-02T08:00:00.000+08:00,"Stocks That Made New 52 Week Highs So Far Today Include: PerkinElmer, Eli Lilly, Zoetis, Apple, Simon Property Group, Global Payments, and Church & Dwight",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12129601/stocks-that-made-new-52-week-highs-so-far-today-include-perk,Benzinga Newsdesk,,,,0,0,af8038d5-66ad-48cc-a726-d10827276455
2018-08-02T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 1st",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12129448/stocks-which-set-new-52-week-high-yesterday-august-1st,Benzinga Newsdesk,,,,0,0,447dc7eb-0d24-42f9-a9fc-5c354f5ba1c8
2018-08-02T08:00:00.000+08:00,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",LLY,https://www.benzinga.com/general/biotech/18/08/12125416/the-daily-biotech-pulse-denalis-parkinsons-candidate-clears-early-sta,Shanthi Rexaline,,,,0,0,3296c085-4d70-4377-a059-ce8a5743bd10
2018-08-02T08:00:00.000+08:00,Elanco Animal Health F-1 Shows Registration For $100M IPO; Co. Planning To List On NYSE Under Symbol 'ELAN'; BZ NOTE: Co. Is Eli Lilly's Animal Health Unit,LLY,https://www.benzinga.com/news/18/08/12134479/elanco-animal-health-f-1-shows-registration-for-100m-ipo-co-planning-to-list-on-,Benzinga Newsdesk,,,,0,0,6f20e561-7580-4378-8a8c-f5b010a96510
2018-08-02T08:00:00.000+08:00,"Stocks That Made New 52 Week Highs So Far Today Include: PerkinElmer, Eli Lilly, Zoetis, Apple, Simon Property Group, Global Payments, and Church & Dwight",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12129601/stocks-that-made-new-52-week-highs-so-far-today-include-perk,Benzinga Newsdesk,,,,0,0,7d5219d5-204f-4f88-8a22-77aae65f2e51
2018-08-02T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, August 1st",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12129448/stocks-which-set-new-52-week-high-yesterday-august-1st,Benzinga Newsdesk,,,,0,0,bc6faccb-2e12-4d1c-804f-6e66e2f92166
2018-08-02T08:00:00.000+08:00,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",LLY,https://www.benzinga.com/general/biotech/18/08/12125416/the-daily-biotech-pulse-denalis-parkinsons-candidate-clears-early-sta,Shanthi Rexaline,,,,0,0,ed2f7c85-1781-4000-a11f-150d361e9d4a
2018-08-01T08:00:00.000+08:00,"Stocks That Have Made New 52 Week Highs Thus Far Today Include: Robert Half, Eli Lilly, Pfizer, Phillips 66, Humana, HCA Healthcare, Genworth, Republic Services, Illumina, Aflac, Medtronic, Waste Management, and Apple",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12119888/stocks-that-have-made-new-52-week-highs-thus-far-today-inclu,Benzinga Newsdesk,,,,0,0,8c18eacc-d13e-493a-a691-61b795cf0224
2018-08-01T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 31",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12119145/stocks-which-set-new-52-week-high-yesterday-july-31,Benzinga Newsdesk,,,,0,0,7357eae1-0809-4152-ae1f-20c8847c6072
2018-08-01T08:00:00.000+08:00,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",LLY,https://www.benzinga.com/general/biotech/18/08/12114456/benzingas-biotech-pulse-pfizers-xeljanz-gets-eu-nod-newlink-losses-na,Shanthi Rexaline,,,,0,0,ae7e9b62-2df8-4f48-b5a8-4c91fd480afb
2018-08-01T08:00:00.000+08:00,Dan Nathan Sees Unusual Options Activity In Eli Lilly,LLY,https://www.benzinga.com/markets/options/18/08/12113952/dan-nathan-sees-unusual-options-activity-in-eli-lilly,Craig Jones,,,,0,0,d82087d7-65a6-435f-b5d0-14a43f09b450
2018-08-01T08:00:00.000+08:00,"Stocks That Have Made New 52 Week Highs Thus Far Today Include: Robert Half, Eli Lilly, Pfizer, Phillips 66, Humana, HCA Healthcare, Genworth, Republic Services, Illumina, Aflac, Medtronic, Waste Management, and Apple",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12119888/stocks-that-have-made-new-52-week-highs-thus-far-today-inclu,Benzinga Newsdesk,,,,0,0,fb7550ea-ea05-4281-acc1-65ec0b5cb152
2018-08-01T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 31",LLY,https://www.benzinga.com/trading-ideas/technicals/18/08/12119145/stocks-which-set-new-52-week-high-yesterday-july-31,Benzinga Newsdesk,,,,0,0,13da3d7f-e4d0-401c-b910-745d655a963d
2018-08-01T08:00:00.000+08:00,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",LLY,https://www.benzinga.com/general/biotech/18/08/12114456/benzingas-biotech-pulse-pfizers-xeljanz-gets-eu-nod-newlink-losses-na,Shanthi Rexaline,,,,0,0,9db84954-cc6e-4b02-8863-ca86873cfed5
2018-08-01T08:00:00.000+08:00,Dan Nathan Sees Unusual Options Activity In Eli Lilly,LLY,https://www.benzinga.com/markets/options/18/08/12113952/dan-nathan-sees-unusual-options-activity-in-eli-lilly,Craig Jones,,,,0,0,42224aad-2a41-422b-8370-98dd4fe143a2
2018-07-31T08:00:00.000+08:00,"Morgan Stanley Maintains Equal-Weight on Eli Lilly, Raises Price Target to $102",LLY,https://www.benzinga.com/news/18/07/12107653/morgan-stanley-maintains-equal-weight-on-eli-lilly-raises-price-target-to-102,Vick Meyer,,,,0,0,9244ecf7-2cb8-46af-b915-2accef2720cd
2018-07-31T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 30th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12107459/stocks-which-set-new-52-week-high-yesterday-july-30th,Benzinga Newsdesk,,,,0,0,f77f8d3a-6aee-4892-9f07-6f8ce9da49b6
2018-07-31T08:00:00.000+08:00,"Morgan Stanley Maintains Equal-Weight on Eli Lilly, Raises Price Target to $102",LLY,https://www.benzinga.com/news/18/07/12107653/morgan-stanley-maintains-equal-weight-on-eli-lilly-raises-price-target-to-102,Vick Meyer,,,,0,0,1496c7ec-c1f3-4add-bf84-8df01886c966
2018-07-31T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 30th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12107459/stocks-which-set-new-52-week-high-yesterday-july-30th,Benzinga Newsdesk,,,,0,0,760fc487-7709-4d3b-9ff8-6a6ca733ca01
2018-07-30T08:00:00.000+08:00,"Stocks That Made New 52 Week Highs So Far Today Include: AMD, Ingersoll-Rand, Aflac, Fortiv, Kansas City Southern, Union Pacific, HCA Healthcare, ConocoPhillips, Waste Management, and EOG Resources",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12100261/stocks-that-made-new-52-week-highs-so-far-today-include-amd-,Benzinga Newsdesk,,,,0,0,9658d666-ef28-4bb4-94fb-983dcf68ef3f
2018-07-30T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Friday, July 27th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12099824/stocks-which-set-new-52-week-high-friday-july-27th,Benzinga Newsdesk,,,,0,0,d7f989de-17c5-47f8-9985-9c817cd43701
2018-07-30T08:00:00.000+08:00,Eli Lilly Announces a 3 Year Extension of its Cancer Research Collaboration with Dana-Farber Cancer Institute,LLY,https://www.benzinga.com/news/18/07/12096843/eli-lilly-announces-a-3-year-extension-of-its-cancer-research-collaboration-with,Benzinga Newsdesk,,,,0,0,eedea2d8-1b4b-45f6-954b-ab7a9ac31614
2018-07-30T08:00:00.000+08:00,"Stocks That Made New 52 Week Highs So Far Today Include: AMD, Ingersoll-Rand, Aflac, Fortiv, Kansas City Southern, Union Pacific, HCA Healthcare, ConocoPhillips, Waste Management, and EOG Resources",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12100261/stocks-that-made-new-52-week-highs-so-far-today-include-amd-,Benzinga Newsdesk,,,,0,0,3fcd0af2-f58d-4b83-9002-b0f39c505faf
2018-07-30T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Friday, July 27th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12099824/stocks-which-set-new-52-week-high-friday-july-27th,Benzinga Newsdesk,,,,0,0,a781b2f8-c063-4e4c-804e-d77ac3b60675
2018-07-30T08:00:00.000+08:00,Eli Lilly Announces a 3 Year Extension of its Cancer Research Collaboration with Dana-Farber Cancer Institute,LLY,https://www.benzinga.com/news/18/07/12096843/eli-lilly-announces-a-3-year-extension-of-its-cancer-research-collaboration-with,Benzinga Newsdesk,,,,0,0,4ac6a8ae-3783-4265-b958-73418b248b8c
2018-07-29T08:00:00.000+08:00,"Barron's Picks And Pans: Amazon, Eli Lilly, Fiat Chrysler And More",LLY,https://www.benzinga.com/media/18/07/12095539/barrons-picks-and-pans-amazon-eli-lilly-fiat-chrysler-and-more,Nelson Hem,,,,0,0,bace536d-0dd0-404e-8db8-aec386d0b8e6
2018-07-29T08:00:00.000+08:00,"Barron's Picks And Pans: Amazon, Eli Lilly, Fiat Chrysler And More",LLY,https://www.benzinga.com/media/18/07/12095539/barrons-picks-and-pans-amazon-eli-lilly-fiat-chrysler-and-more,Nelson Hem,,,,0,0,5b3fde50-feda-4823-897e-da6f5e47662f
2018-07-28T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",LLY,https://www.benzinga.com/general/biotech/18/07/12083481/the-week-ahead-in-biotech-conferences-pdufa-dates-earnings-and-ipos,Shanthi Rexaline,,,,0,0,0caa595e-916c-40bd-912b-776513fa0161
2018-07-28T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",LLY,https://www.benzinga.com/general/biotech/18/07/12083481/the-week-ahead-in-biotech-conferences-pdufa-dates-earnings-and-ipos,Shanthi Rexaline,,,,0,0,0f809a59-f115-42c1-bc23-918792ecda20
2018-07-27T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 26th:",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12091145/stocks-which-set-new-52-week-high-yesterday-july-26th,Benzinga Newsdesk,,,,0,0,d3f948ec-9eac-4f6a-9154-aacaca71f836
2018-07-27T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 26th:",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12091145/stocks-which-set-new-52-week-high-yesterday-july-26th,Benzinga Newsdesk,,,,0,0,2b0ba32a-6534-470e-bbc5-b84b7e46dc96
2018-07-26T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 25th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12082507/stocks-which-set-new-52-week-high-yesterday-july-25th,Benzinga Newsdesk,,,,0,0,97c6fdcb-8a68-4169-985c-f18970bb6c1f
2018-07-26T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",LLY,https://www.benzinga.com/general/biotech/18/07/12078445/benzingas-daily-biotech-pulse-biogen-ac-immune-slip-despite-positive-,Shanthi Rexaline,,,,0,0,a3d699b8-4446-46dd-8291-02a461efb924
2018-07-26T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 25th",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12082507/stocks-which-set-new-52-week-high-yesterday-july-25th,Benzinga Newsdesk,,,,0,0,81e79ab7-1045-477d-95a9-87ceb9b35800
2018-07-26T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",LLY,https://www.benzinga.com/general/biotech/18/07/12078445/benzingas-daily-biotech-pulse-biogen-ac-immune-slip-despite-positive-,Shanthi Rexaline,,,,0,0,e1dbd801-d53c-44d2-9bd3-293ef7f0e690
2018-07-25T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12073985/stocks-that-made-new-52-week-highs-earlier-include-adobe-s-p,Benzinga Newsdesk,,,,0,0,8f11d0b0-4610-47bd-a891-9a2265f4f7d6
2018-07-25T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 24th:",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12073898/stocks-which-set-new-52-week-high-yesterday-july-24th,Benzinga Newsdesk,,,,0,0,63ba7f8a-cdc2-4f3e-97cc-e469cf2d0e42
2018-07-25T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $90",LLY,https://www.benzinga.com/news/18/07/12072711/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-90,Vick Meyer,,,,0,0,bae4e7b4-346e-4545-bf7a-b96e188e5aea
2018-07-25T08:00:00.000+08:00,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $86",LLY,https://www.benzinga.com/news/18/07/12072560/credit-suisse-maintains-underperform-on-eli-lilly-raises-price-target-to-86,Vick Meyer,,,,0,0,b0235fdc-7b1f-4935-bd2b-0fcf51f8b3fa
2018-07-25T08:00:00.000+08:00,"Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report",LLY,https://www.benzinga.com/news/earnings/18/07/12072376/concerns-about-trade-picture-overshadowing-earnings-as-gm-boeing-report,JJ Kinahan,,,,0,0,33a9ad9f-564d-4199-a563-411c4d57422f
2018-07-25T08:00:00.000+08:00,10 Biggest Price Target Changes For Wednesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/07/12072351/10-biggest-price-target-changes-for-wednesday,Lisa Levin,,,,0,0,a2694e3f-eca7-41af-82c8-94a06933bf8b
2018-07-25T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For July 25, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/07/12071901/benzingas-top-upgrades-downgrades-for-july-25-2018,Lisa Levin,,,,0,0,2a7d7df2-9bad-47ce-b659-a579b2641d7a
2018-07-25T08:00:00.000+08:00,Berenberg Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/18/07/12071311/berenberg-downgrades-eli-lilly-to-hold,Benzinga_Newsdesk,,,,0,0,2927c6de-a477-4569-9297-dc6119177299
2018-07-25T08:00:00.000+08:00,"Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $110",LLY,https://www.benzinga.com/news/18/07/12070765/cantor-fitzgerald-maintains-overweight-on-eli-lilly-raises-price-target-to-110,Vick Meyer,,,,0,0,1914aa1c-0c58-4cbe-8ceb-c876e324f290
2018-07-25T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12073985/stocks-that-made-new-52-week-highs-earlier-include-adobe-s-p,Benzinga Newsdesk,,,,0,0,cf75acc2-e33d-4ee2-8c71-38aec65688fe
2018-07-25T08:00:00.000+08:00,"Stocks Which Set New 52-Week High Yesterday, July 24th:",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12073898/stocks-which-set-new-52-week-high-yesterday-july-24th,Benzinga Newsdesk,,,,0,0,b48c3f09-85e6-49a2-95ff-ca784d7faba0
2018-07-25T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $90",LLY,https://www.benzinga.com/news/18/07/12072711/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-90,Vick Meyer,,,,0,0,9c78706d-dabd-4e11-8b7e-b7be7ba96aa1
2018-07-25T08:00:00.000+08:00,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $86",LLY,https://www.benzinga.com/news/18/07/12072560/credit-suisse-maintains-underperform-on-eli-lilly-raises-price-target-to-86,Vick Meyer,,,,0,0,afd1bc96-eb40-4a0c-ae88-e767c1a2a809
2018-07-25T08:00:00.000+08:00,"Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report",LLY,https://www.benzinga.com/news/earnings/18/07/12072376/concerns-about-trade-picture-overshadowing-earnings-as-gm-boeing-report,JJ Kinahan,,,,0,0,7fae5a73-75ad-4789-bd18-540a6da1231b
2018-07-25T08:00:00.000+08:00,10 Biggest Price Target Changes For Wednesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/18/07/12072351/10-biggest-price-target-changes-for-wednesday,Lisa Levin,,,,0,0,9c9453cb-8f80-4775-b295-8bd35ddf8f18
2018-07-25T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For July 25, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/07/12071901/benzingas-top-upgrades-downgrades-for-july-25-2018,Lisa Levin,,,,0,0,5b8bda4e-1b58-4912-8408-f63d5a1134d3
2018-07-25T08:00:00.000+08:00,Berenberg Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/18/07/12071311/berenberg-downgrades-eli-lilly-to-hold,Benzinga_Newsdesk,,,,0,0,bf163578-1384-421c-ad2e-6243c80943b8
2018-07-25T08:00:00.000+08:00,"Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $110",LLY,https://www.benzinga.com/news/18/07/12070765/cantor-fitzgerald-maintains-overweight-on-eli-lilly-raises-price-target-to-110,Vick Meyer,,,,0,0,f2ea98f2-cb76-40fc-b931-0b29cb47a7fa
2018-07-24T08:00:00.000+08:00,Earnings Season Optimism Seems To Help Lift Market,LLY,https://www.benzinga.com/news/earnings/18/07/12065019/earnings-season-optimism-seems-to-help-lift-market,JJ Kinahan,,,,0,0,fbb16b7e-bb87-450f-8ad3-f57683022acb
2018-07-24T08:00:00.000+08:00,"From Eli Lilly Q2 Earnings Conference Call, Co. Says It Is 'Preparing For All Scenarios' Regarding Trump Administration's Plans To Address Rising Healthcare Costs",LLY,https://www.benzinga.com/news/18/07/12064280/from-eli-lilly-q2-earnings-conference-call-co-says-it-is-preparing-for-all-scena,Benzinga Newsdesk,,,,0,0,535aede4-894b-4d5e-bafe-3b7113e75ef3
2018-07-24T08:00:00.000+08:00,Benzinga Pro's 5 Stocks To Watch Today,LLY,https://www.benzinga.com/news/18/07/12064091/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,,,,0,0,5e53e453-afb4-49cb-bdfb-e19f9fd0713d
2018-07-24T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",LLY,https://www.benzinga.com/general/biotech/18/07/12061774/benzingas-daily-biotech-pulse-celgenes-lymphoma-trial-meets-endpoint-,Shanthi Rexaline,,,,0,0,49d155d3-5b8f-4663-84dc-7748f0d41c7c
2018-07-24T08:00:00.000+08:00,25 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/07/12063230/25-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,0,0,38a05c2d-da02-4ace-8372-acb8ef452c5c
2018-07-24T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings,LLY,https://www.benzinga.com/news/18/07/12062662/a-peek-into-the-markets-us-stock-futures-rise-ahead-of-earnings,Lisa Levin,,,,0,0,2603ce44-5b61-4352-b134-502a9010e3ab
2018-07-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Sales Outlook From $23.7B-$24.2B To $24.0B-$24.5B vs $23.99B Est.,LLY,https://www.benzinga.com/news/18/07/12062340/eli-lilly-raises-fy18-sales-outlook-from-23-7b-24-2b-to-24-0b-24-5b-vs-23-99b-es,Benzinga Newsdesk,,,,0,0,99d72b5c-e75e-4bc1-897d-71a276b1d533
2018-07-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Adj. EPS Outlook From $5.10-$5.20 To $5.40-$5.50 vs $5.15 Est.,LLY,https://www.benzinga.com/news/18/07/12062329/eli-lilly-raises-fy18-adj-eps-outlook-from-5-10-5-20-to-5-40-5-50-vs-5-15-est,Benzinga Newsdesk,,,,0,0,ba690ab6-687f-4da0-aaa6-631a50149b58
2018-07-24T08:00:00.000+08:00,Eli Lilly Revises FY18 Outlook,LLY,https://www.benzinga.com/news/18/07/12062324/eli-lilly-revises-fy18-outlook,Benzinga Newsdesk,,,,0,0,35dbf4cc-4253-4ccd-9be6-9eb88aa53054
2018-07-24T08:00:00.000+08:00,"Eli Lilly Q2 Adj. EPS $1.50 Beats $1.30 Estimate, Sales $6.36B Beat $6.05B Estimate",LLY,https://www.benzinga.com/news/earnings/18/07/12062321/eli-lilly-q2-adj-eps-1-50-beats-1-30-estimate-sales-6-36b-beat-6-05b-es,Benzinga Newsdesk,,,,0,0,d280c331-c1f7-47e5-93a3-25fc74f7e2bc
2018-07-24T08:00:00.000+08:00,"Lilly to Separate Elanco Animal Health with IPO, Offering Is Expected To Represent An Ownership Stake Of Less Than 20% And Process Will Be Complete During Second Half Of 2018",LLY,https://www.benzinga.com/news/18/07/12062312/lilly-to-separate-elanco-animal-health-with-ipo-offering-is-expected-to-represen,Benzinga_Newsdesk,,,,0,0,92b5b603-56d8-46d9-b1c0-f3686bda7a25
2018-07-24T08:00:00.000+08:00,"12 Stocks To Watch For July 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/07/12062019/12-stocks-to-watch-for-july-24-2018,Lisa Levin,,,,0,0,898bc7d4-f127-4b57-bda8-286eac2ec705
2018-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/07/12061930/earnings-scheduled-for-july-24-2018,Lisa Levin,,,,0,0,42a293c2-07ba-488b-8b73-77a831739496
2018-07-24T08:00:00.000+08:00,Earnings Season Optimism Seems To Help Lift Market,LLY,https://www.benzinga.com/news/earnings/18/07/12065019/earnings-season-optimism-seems-to-help-lift-market,JJ Kinahan,,,,0,0,e5914aae-4f8e-4b9a-aa4e-d4237258d0bb
2018-07-24T08:00:00.000+08:00,"From Eli Lilly Q2 Earnings Conference Call, Co. Says It Is 'Preparing For All Scenarios' Regarding Trump Administration's Plans To Address Rising Healthcare Costs",LLY,https://www.benzinga.com/news/18/07/12064280/from-eli-lilly-q2-earnings-conference-call-co-says-it-is-preparing-for-all-scena,Benzinga Newsdesk,,,,0,0,db33ba62-c7bf-4bd4-bb9a-8acec6389ae8
2018-07-24T08:00:00.000+08:00,Benzinga Pro's 5 Stocks To Watch Today,LLY,https://www.benzinga.com/news/18/07/12064091/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,,,,0,0,e4a02f93-5df9-4861-9306-e6fcbd374109
2018-07-24T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",LLY,https://www.benzinga.com/general/biotech/18/07/12061774/benzingas-daily-biotech-pulse-celgenes-lymphoma-trial-meets-endpoint-,Shanthi Rexaline,,,,0,0,76cd2594-68fa-4147-b668-a4a5202f5af3
2018-07-24T08:00:00.000+08:00,25 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/07/12063230/25-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,0,0,d3e75203-1d0f-4eac-8a6c-53b969b94f7b
2018-07-24T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings,LLY,https://www.benzinga.com/news/18/07/12062662/a-peek-into-the-markets-us-stock-futures-rise-ahead-of-earnings,Lisa Levin,,,,0,0,ff650bc9-12bf-486c-880f-c3513e106c62
2018-07-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Sales Outlook From $23.7B-$24.2B To $24.0B-$24.5B vs $23.99B Est.,LLY,https://www.benzinga.com/news/18/07/12062340/eli-lilly-raises-fy18-sales-outlook-from-23-7b-24-2b-to-24-0b-24-5b-vs-23-99b-es,Benzinga Newsdesk,,,,0,0,d47d7a4b-8917-4d5a-a47c-3bc5cdb44c48
2018-07-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Adj. EPS Outlook From $5.10-$5.20 To $5.40-$5.50 vs $5.15 Est.,LLY,https://www.benzinga.com/news/18/07/12062329/eli-lilly-raises-fy18-adj-eps-outlook-from-5-10-5-20-to-5-40-5-50-vs-5-15-est,Benzinga Newsdesk,,,,0,0,b3031508-ddda-4113-8449-3cab0e748788
2018-07-24T08:00:00.000+08:00,Eli Lilly Revises FY18 Outlook,LLY,https://www.benzinga.com/news/18/07/12062324/eli-lilly-revises-fy18-outlook,Benzinga Newsdesk,,,,0,0,714974e7-ad8b-4bd4-a95c-c73700581727
2018-07-24T08:00:00.000+08:00,"Eli Lilly Q2 Adj. EPS $1.50 Beats $1.30 Estimate, Sales $6.36B Beat $6.05B Estimate",LLY,https://www.benzinga.com/news/earnings/18/07/12062321/eli-lilly-q2-adj-eps-1-50-beats-1-30-estimate-sales-6-36b-beat-6-05b-es,Benzinga Newsdesk,,,,0,0,d49d976b-7651-466a-b3df-9840b78ac27b
2018-07-24T08:00:00.000+08:00,"Lilly to Separate Elanco Animal Health with IPO, Offering Is Expected To Represent An Ownership Stake Of Less Than 20% And Process Will Be Complete During Second Half Of 2018",LLY,https://www.benzinga.com/news/18/07/12062312/lilly-to-separate-elanco-animal-health-with-ipo-offering-is-expected-to-represen,Benzinga_Newsdesk,,,,0,0,62c117f8-4237-4302-9bd9-c2fc22012905
2018-07-24T08:00:00.000+08:00,"12 Stocks To Watch For July 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/07/12062019/12-stocks-to-watch-for-july-24-2018,Lisa Levin,,,,0,0,6f391fa4-600a-41f1-ab01-dccfaa9c5b5d
2018-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/07/12061930/earnings-scheduled-for-july-24-2018,Lisa Levin,,,,0,0,ffa19e0a-7a12-4c45-a6b1-2d94a683e496
2018-07-23T08:00:00.000+08:00,Eli Lilly's Q2 Earnings Preview,LLY,https://www.benzinga.com/news/earnings-previews/18/07/12059076/eli-lillys-earnings-preview,Benzinga Newsdesk,,,,0,0,e8adbab6-d6ce-437d-bd7c-cf9b3a0db04f
2018-07-23T08:00:00.000+08:00,Eli Lilly's Q2 Earnings Preview,LLY,https://www.benzinga.com/news/earnings-previews/18/07/12059076/eli-lillys-earnings-preview,Benzinga Newsdesk,,,,0,0,2e1b4a14-ee0f-4c32-9388-af1c13d9f8c4
2018-07-22T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",LLY,https://www.benzinga.com/general/biotech/18/07/12038223/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-resu,Shanthi Rexaline,,,,0,0,71cda6b1-809b-42c2-b2de-5bb0c7f93e0e
2018-07-22T08:00:00.000+08:00,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",LLY,https://www.benzinga.com/general/biotech/18/07/12038223/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-resu,Shanthi Rexaline,,,,0,0,cacd695f-5bda-4871-9386-66430857f4c9
2018-07-20T08:00:00.000+08:00,Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet,LLY,https://www.benzinga.com/general/biotech/18/07/12050508/eli-lilly-and-incyte-late-thursday-announced-study-results-showing-be,Benzinga Newsdesk,,,,0,0,c370fb64-5480-4934-98cc-60886d7a2f17
2018-07-20T08:00:00.000+08:00,Eli Lilly And Incyte Late Thursday Announced Study Results Showing Benefit Of Baricitinib 4 mg For Treatment Of Systemic Lupus Erythematosus (SLE) Were Published In The Lancet,LLY,https://www.benzinga.com/general/biotech/18/07/12050508/eli-lilly-and-incyte-late-thursday-announced-study-results-showing-be,Benzinga Newsdesk,,,,0,0,17539f0c-18b8-4f1d-96d2-52bd3a45425a
2018-07-19T08:00:00.000+08:00,Boehringer Ingelheim and Lilly Announce Tradjenta's CARMELINA Outcome Trial Meets Primary Endpoint,LLY,https://www.benzinga.com/news/18/07/12043218/boehringer-ingelheim-and-lilly-announce-tradjentas-carmelina-outcome-trial-meets,Benzinga_Newsdesk,,,,0,0,cb238b4b-3231-45c0-8216-5d2ef180aa7a
2018-07-19T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $80",LLY,https://www.benzinga.com/news/18/07/12043200/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-80,Vick Meyer,,,,0,0,4f6357db-ba78-4b3a-ab7b-cb80b6a1ea90
2018-07-19T08:00:00.000+08:00,"Eli Lilly Reports Once-Weekly Trulicity Label Updated To Include Data Showing Benefits For Adults With Type 2 Diabetes, Chronic Kidney Disease",LLY,https://www.benzinga.com/news/18/07/12042569/eli-lilly-reports-once-weekly-trulicity-label-updated-to-include-data-showing-be,Benzinga Newsdesk,,,,0,0,0c9bc491-0b04-42b6-b365-c95d5b300c92
2018-07-19T08:00:00.000+08:00,Boehringer Ingelheim and Lilly Announce Tradjenta's CARMELINA Outcome Trial Meets Primary Endpoint,LLY,https://www.benzinga.com/news/18/07/12043218/boehringer-ingelheim-and-lilly-announce-tradjentas-carmelina-outcome-trial-meets,Benzinga_Newsdesk,,,,0,0,aae9e6c0-f894-476b-b923-5a00c98d77b2
2018-07-19T08:00:00.000+08:00,"BMO Capital Maintains Market Perform on Eli Lilly, Raises Price Target to $80",LLY,https://www.benzinga.com/news/18/07/12043200/bmo-capital-maintains-market-perform-on-eli-lilly-raises-price-target-to-80,Vick Meyer,,,,0,0,fcacb9c3-45ba-4986-b4d6-09ac1403ca95
2018-07-19T08:00:00.000+08:00,"Eli Lilly Reports Once-Weekly Trulicity Label Updated To Include Data Showing Benefits For Adults With Type 2 Diabetes, Chronic Kidney Disease",LLY,https://www.benzinga.com/news/18/07/12042569/eli-lilly-reports-once-weekly-trulicity-label-updated-to-include-data-showing-be,Benzinga Newsdesk,,,,0,0,82806dbf-532f-4c58-bc3c-9b87c7dd997f
2018-07-18T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Today Include: Alphabet (Both Classes), Facebook, Amazon, Eli Lilly, Intercontinental Exchange, Adobe, TripAdvisor, Darden Restaurants, Citrix, Marsh & McLennan, Norfolk Southern, Motorola, TJX, Intuit, Visa, and CSX",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12039238/stocks-that-made-new-52-week-highs-today-include-alphabet-bo,Benzinga Newsdesk,,,,0,0,f390e3c7-61bd-4efe-a04b-e082e3b803b4
2018-07-18T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/07/12035427/benzingas-daily-biotech-pulse-novartis-earnings-j-js-hiv-cocktail-cle,Shanthi Rexaline,,,,0,0,7f139927-6a00-4147-bb39-eeddf7ea7354
2018-07-18T08:00:00.000+08:00,"PFizer, Eli Lilly Report Phase 3 Trial Of Tanezumab Met All Thre Co-Primary Endpoints",LLY,https://www.benzinga.com/news/18/07/12035761/pfizer-eli-lilly-report-phase-3-trial-of-tanezumab-met-all-thre-co-primary-endpo,Benzinga_Newsdesk,,,,0,0,ea8b3ced-7d47-4824-9e36-3a8f204ee545
2018-07-18T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Today Include: Alphabet (Both Classes), Facebook, Amazon, Eli Lilly, Intercontinental Exchange, Adobe, TripAdvisor, Darden Restaurants, Citrix, Marsh & McLennan, Norfolk Southern, Motorola, TJX, Intuit, Visa, and CSX",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12039238/stocks-that-made-new-52-week-highs-today-include-alphabet-bo,Benzinga Newsdesk,,,,0,0,3be60471-d2c4-4dc8-b734-8b52658e6ea6
2018-07-18T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares",LLY,https://www.benzinga.com/general/biotech/18/07/12035427/benzingas-daily-biotech-pulse-novartis-earnings-j-js-hiv-cocktail-cle,Shanthi Rexaline,,,,0,0,c33afb73-195f-4bf1-8b02-fb6c14188fa3
2018-07-18T08:00:00.000+08:00,"PFizer, Eli Lilly Report Phase 3 Trial Of Tanezumab Met All Thre Co-Primary Endpoints",LLY,https://www.benzinga.com/news/18/07/12035761/pfizer-eli-lilly-report-phase-3-trial-of-tanezumab-met-all-thre-co-primary-endpo,Benzinga_Newsdesk,,,,0,0,32c7054a-0d03-4e8a-a294-f759d267261c
2018-07-17T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12032289/stocks-that-made-new-52-week-highs-today-include-citrix-trip,Benzinga Newsdesk,,,,0,0,89d588fb-3c59-4ae4-90de-8c758bc54844
2018-07-17T08:00:00.000+08:00,"Stocks That Made New 52-Week Highs Today Include: Citrix, TripAdvisor, Microsoft, Alphabet (Both Classes), Medtronic, Accenture, Facebook, NetApp, S&P Global, Amazon, VeriSign, Motorola Solutions, Marsh & McLennan, IDEXX Labs, Eli Lilly, Sysco, and VF",LLY,https://www.benzinga.com/trading-ideas/technicals/18/07/12032289/stocks-that-made-new-52-week-highs-today-include-citrix-trip,Benzinga Newsdesk,,,,0,0,7f199520-0df0-401a-abb8-452f07827d7c
2018-07-09T08:00:00.000+08:00,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports,LLY,https://www.benzinga.com/news/earnings/18/07/11994014/health-care-sector-outlook-checking-in-ahead-of-q2-earnings-reports,JJ Kinahan,,,,0,0,54b50e69-771e-4445-aa59-f6a3a472f6fc
2018-07-09T08:00:00.000+08:00,Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports,LLY,https://www.benzinga.com/news/earnings/18/07/11994014/health-care-sector-outlook-checking-in-ahead-of-q2-earnings-reports,JJ Kinahan,,,,0,0,401cf737-11cc-4b3b-b9e2-6da207aecf87
2018-07-05T08:00:00.000+08:00,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,LLY,https://www.benzinga.com/general/biotech/18/07/11955951/a-look-at-biotech-in-2018-and-the-biggest-catalysts-coming-up-in-the-,Shanthi Rexaline,,,,0,0,29fd8fb3-0e71-462a-bbe8-0ff0bbe07723
2018-07-05T08:00:00.000+08:00,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,LLY,https://www.benzinga.com/general/biotech/18/07/11955951/a-look-at-biotech-in-2018-and-the-biggest-catalysts-coming-up-in-the-,Shanthi Rexaline,,,,0,0,f8adaadc-0f5a-41da-b052-d70f1715713d
2018-06-29T08:00:00.000+08:00,"UPDATE: Lilly Will Engage 40K People With Migraine In US Over Next 2 Years, Will Be Conducted By Kantar Health On Behalf Of Co.",LLY,https://www.benzinga.com/news/fda/18/06/11956348/update-lilly-will-engage-40k-people-with-migraine-in-us-over-next-2-years-wi,Benzinga Newsdesk,,,,0,0,e63b44dc-1d32-4d10-8ebf-d8a4d6e44e60
2018-06-29T08:00:00.000+08:00,"Eli Lilly Reports Initiation Of OVERCOME Study To Advance Understanding Of Burden, Impact, Epidemiology Of Migraine",LLY,https://www.benzinga.com/news/fda/18/06/11956347/eli-lilly-reports-initiation-of-overcome-study-to-advance-understanding-of-b,Benzinga Newsdesk,,,,0,0,c82072dc-8b57-4ce4-9576-777115c41009
2018-06-29T08:00:00.000+08:00,"UPDATE: Lilly Will Engage 40K People With Migraine In US Over Next 2 Years, Will Be Conducted By Kantar Health On Behalf Of Co.",LLY,https://www.benzinga.com/news/fda/18/06/11956348/update-lilly-will-engage-40k-people-with-migraine-in-us-over-next-2-years-wi,Benzinga Newsdesk,,,,0,0,b3c1588e-924d-4c3c-b324-b5afb241b51a
2018-06-29T08:00:00.000+08:00,"Eli Lilly Reports Initiation Of OVERCOME Study To Advance Understanding Of Burden, Impact, Epidemiology Of Migraine",LLY,https://www.benzinga.com/news/fda/18/06/11956347/eli-lilly-reports-initiation-of-overcome-study-to-advance-understanding-of-b,Benzinga Newsdesk,,,,0,0,cf0cb31f-222c-46e9-87be-1c2a1426e1aa
2018-06-28T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",LLY,https://www.benzinga.com/general/biotech/18/06/11947397/benzingas-daily-biotech-pulse-eli-lilly-edge-therapeutics-bioxcel-rep,Shanthi Rexaline,,,,0,0,8d4e49ca-5c9d-4dbc-a081-46f9867bed87
2018-06-28T08:00:00.000+08:00,Eli Lilly Reports Taltz Met Primary and Secondary Endpoints in a Phase 3 Study,LLY,https://www.benzinga.com/news/18/06/11948093/eli-lilly-reports-taltz-met-primary-and-secondary-endpoints-in-a-phase-3-study,Benzinga Newsdesk,,,,0,0,7985bb91-10d1-49ab-8488-acd048299d13
2018-06-28T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",LLY,https://www.benzinga.com/general/biotech/18/06/11947397/benzingas-daily-biotech-pulse-eli-lilly-edge-therapeutics-bioxcel-rep,Shanthi Rexaline,,,,0,0,9d1cd1e4-00cf-441f-b8df-aa2361eb076d
2018-06-28T08:00:00.000+08:00,Eli Lilly Reports Taltz Met Primary and Secondary Endpoints in a Phase 3 Study,LLY,https://www.benzinga.com/news/18/06/11948093/eli-lilly-reports-taltz-met-primary-and-secondary-endpoints-in-a-phase-3-study,Benzinga Newsdesk,,,,0,0,0ecd24dc-9376-4db8-bdff-5f51e06adbc8
2018-06-27T08:00:00.000+08:00,Eli Lilly Reports Intended Brand Name For Episodic Cluster Headache Treatment Approved As Emgality,LLY,https://www.benzinga.com/news/18/06/11945795/eli-lilly-reports-intended-brand-name-for-episodic-cluster-headache-treatment-ap,Benzinga Newsdesk,,,,0,0,b0c3c3d8-4fea-429d-b625-59e567d0cfdc
2018-06-27T08:00:00.000+08:00,Eli Lilly Announces Results Of Phase 3 Study Of Emgailty Which Met Primary and Secondary Endpoint,LLY,https://www.benzinga.com/general/biotech/18/06/11945793/eli-lilly-announces-results-of-phase-3-study-of-emgailty-which-met-pr,Benzinga Newsdesk,,,,0,0,9720d286-679d-424e-b202-2b04d0a3a2da
2018-06-27T08:00:00.000+08:00,Eli Lilly Reports Intended Brand Name For Episodic Cluster Headache Treatment Approved As Emgality,LLY,https://www.benzinga.com/news/18/06/11945795/eli-lilly-reports-intended-brand-name-for-episodic-cluster-headache-treatment-ap,Benzinga Newsdesk,,,,0,0,a291f57f-422f-4536-a0ed-663212d9237a
2018-06-27T08:00:00.000+08:00,Eli Lilly Announces Results Of Phase 3 Study Of Emgailty Which Met Primary and Secondary Endpoint,LLY,https://www.benzinga.com/general/biotech/18/06/11945793/eli-lilly-announces-results-of-phase-3-study-of-emgailty-which-met-pr,Benzinga Newsdesk,,,,0,0,4996d862-fcd3-448d-9ea6-342749b04229
2018-06-25T08:00:00.000+08:00,Boehringer Ingelheim and Lilly Report EASE Phase III Program Met Primary Endpoint For All Investigated Doses Of empagliflozin,LLY,https://www.benzinga.com/news/18/06/11927084/boehringer-ingelheim-and-lilly-report-ease-phase-iii-program-met-primary-endpoin,Benzinga Newsdesk,,,,0,0,0926fed4-17f5-40aa-b7ee-27cb19ed6b0f
2018-06-25T08:00:00.000+08:00,Boehringer Ingelheim and Lilly Report EASE Phase III Program Met Primary Endpoint For All Investigated Doses Of empagliflozin,LLY,https://www.benzinga.com/news/18/06/11927084/boehringer-ingelheim-and-lilly-report-ease-phase-iii-program-met-primary-endpoin,Benzinga Newsdesk,,,,0,0,22efc895-ccfa-49e3-9702-55f9107ef84f
2018-06-23T08:00:00.000+08:00,Lilly Announces Investigational Doses of Once-Weekly Trulicity Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes at #ADA2018,LLY,https://www.benzinga.com/news/18/06/11925333/lilly-announces-investigational-doses-of-once-weekly-trulicity-show-promise-in-d,Benzinga Newdesk,,,,0,0,b582f9ff-874c-4f63-bd4b-2d8e380bd44b
2018-06-23T08:00:00.000+08:00,Lily Announces Jardiance Reduced Risk of Kidney Disease Progression in Adults With Type 2 Diabetes and Established Cardiovascular (Cv) Disease Independent of Control of Conventional Cv Risk Factors,LLY,https://www.benzinga.com/news/18/06/11925321/lily-announces-jardiance-reduced-risk-of-kidney-disease-progression-in-adults-wi,Benzinga Newdesk,,,,0,0,c0a73127-3ed4-4df7-8318-7ff8fb08b34f
2018-06-23T08:00:00.000+08:00,Lilly Announces New Data Presented at #ADA2018 Reinforce Potential of Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/06/11925320/lilly-announces-new-data-presented-at-ada2018-reinforce-potential-of-ultra-rapid,Benzinga Newdesk,,,,0,0,ce1e9f4b-6325-4491-ad8e-946cbce5e72b
2018-06-23T08:00:00.000+08:00,Lilly Announces Investigational Doses of Once-Weekly Trulicity Show Promise in Delivering Powerful Efficacy in People with Type 2 Diabetes at #ADA2018,LLY,https://www.benzinga.com/news/18/06/11925333/lilly-announces-investigational-doses-of-once-weekly-trulicity-show-promise-in-d,Benzinga Newdesk,,,,0,0,6682bad7-014e-4940-8c8f-6fe911918fb6
2018-06-23T08:00:00.000+08:00,Lily Announces Jardiance Reduced Risk of Kidney Disease Progression in Adults With Type 2 Diabetes and Established Cardiovascular (Cv) Disease Independent of Control of Conventional Cv Risk Factors,LLY,https://www.benzinga.com/news/18/06/11925321/lily-announces-jardiance-reduced-risk-of-kidney-disease-progression-in-adults-wi,Benzinga Newdesk,,,,0,0,d226dc20-f119-44a9-af68-e6a3e33af453
2018-06-23T08:00:00.000+08:00,Lilly Announces New Data Presented at #ADA2018 Reinforce Potential of Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/06/11925320/lilly-announces-new-data-presented-at-ada2018-reinforce-potential-of-ultra-rapid,Benzinga Newdesk,,,,0,0,65b57a25-79ae-49a7-9f5c-0999722d51cc
2018-06-22T08:00:00.000+08:00,"UPDATE: In Separate Decision June 15th District Court Ruled In Favor Of Eli Lilly Against Dr. Reddy's and Hospira, Preventing Them From Launching Alternative Salt Forms Of Pemetrexed Until Lilly's Patent Expires",LLY,https://www.benzinga.com/news/18/06/11923238/update-in-separate-decision-june-15th-district-court-ruled-in-favor-of-eli-lilly,Benzinga Newsdesk,,,,0,0,d12c66e5-ee06-4b3f-bf5f-b7caa145de94
2018-06-22T08:00:00.000+08:00,U.S. District Court Rules In Favor Of Eli Lilly Against Dr. Reddy's Laboratories In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/general/biotech/18/06/11923214/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-,Benzinga Newsdesk,,,,0,0,fc89e862-6715-43d2-81a1-bc4c2c3144cf
2018-06-22T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For June 22, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/06/11920459/benzingas-top-upgrades-downgrades-for-june-22-2018,Lisa Levin,,,,0,0,2f463067-f6ad-4f80-9a4c-5215934ade91
2018-06-22T08:00:00.000+08:00,"The Market In 5 Minutes: Stress Test Results, More Trade Talks, Viacom's Unexpected Risk",LLY,https://www.benzinga.com/markets/cryptocurrency/18/06/11920224/the-market-in-5-minutes-stress-test-results-more-trade-talks-v,Benzinga Newsdesk,,,,0,0,228d7f95-6d6d-495e-9e18-14ee178a206c
2018-06-22T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/18/06/11919824/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,0,0,96378876-cbea-4626-9aae-e7023024886b
2018-06-22T08:00:00.000+08:00,DZ Bank Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/18/06/11919663/dz-bank-downgrades-eli-lilly-to-hold,Benzinga Newsdesk,,,,0,0,0f329d9c-fa27-483a-8927-7435450b2d38
2018-06-22T08:00:00.000+08:00,"UPDATE: In Separate Decision June 15th District Court Ruled In Favor Of Eli Lilly Against Dr. Reddy's and Hospira, Preventing Them From Launching Alternative Salt Forms Of Pemetrexed Until Lilly's Patent Expires",LLY,https://www.benzinga.com/news/18/06/11923238/update-in-separate-decision-june-15th-district-court-ruled-in-favor-of-eli-lilly,Benzinga Newsdesk,,,,0,0,3c52deb5-085f-46f0-af12-8901c3120653
2018-06-22T08:00:00.000+08:00,U.S. District Court Rules In Favor Of Eli Lilly Against Dr. Reddy's Laboratories In Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/general/biotech/18/06/11923214/u-s-district-court-rules-in-favor-of-lilly-in-alimta-vitamin-regimen-,Benzinga Newsdesk,,,,0,0,ff1933d9-a798-4f85-85c6-639b5e106179
2018-06-22T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For June 22, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/06/11920459/benzingas-top-upgrades-downgrades-for-june-22-2018,Lisa Levin,,,,0,0,ddcac5a8-dd75-4672-b79a-55f4cada2043
2018-06-22T08:00:00.000+08:00,"The Market In 5 Minutes: Stress Test Results, More Trade Talks, Viacom's Unexpected Risk",LLY,https://www.benzinga.com/markets/cryptocurrency/18/06/11920224/the-market-in-5-minutes-stress-test-results-more-trade-talks-v,Benzinga Newsdesk,,,,0,0,c219b524-50e1-439e-a432-9ba675090ff1
2018-06-22T08:00:00.000+08:00,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/18/06/11919824/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,0,0,cf0f13ea-cb92-41c3-bd48-e68a798ca67e
2018-06-22T08:00:00.000+08:00,DZ Bank Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/18/06/11919663/dz-bank-downgrades-eli-lilly-to-hold,Benzinga Newsdesk,,,,0,0,b00bc214-4637-4b5b-b70b-cd805d0fa5ba
2018-06-21T08:00:00.000+08:00,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $84",LLY,https://www.benzinga.com/news/18/06/11913332/credit-suisse-maintains-underperform-on-eli-lilly-raises-price-target-to-84,Vick Meyer,,,,0,0,f0b5434d-c947-4705-9688-70e917005f67
2018-06-21T08:00:00.000+08:00,"Credit Suisse Maintains Underperform on Eli Lilly, Raises Price Target to $84",LLY,https://www.benzinga.com/news/18/06/11913332/credit-suisse-maintains-underperform-on-eli-lilly-raises-price-target-to-84,Vick Meyer,,,,0,0,e1087a8d-8e28-4414-b625-8c69148ea666
2018-06-13T08:00:00.000+08:00,Pop Star Pink Confronts SeaWorld On PETA's Behalf During Shareholder Meeting,LLY,https://www.benzinga.com/news/18/06/11876187/pop-star-pink-confronts-seaworld-on-petas-behalf-during-shareholder-meeting,Elizabeth Balboa,,,,0,0,f667fe53-c50b-4760-ab38-1a118635f2e3
2018-06-13T08:00:00.000+08:00,Pop Star Pink Confronts SeaWorld On PETA's Behalf During Shareholder Meeting,LLY,https://www.benzinga.com/news/18/06/11876187/pop-star-pink-confronts-seaworld-on-petas-behalf-during-shareholder-meeting,Elizabeth Balboa,,,,0,0,4a0074cf-ff52-46c4-935d-7e6d063abd5f
2018-06-12T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",LLY,https://www.benzinga.com/general/biotech/18/06/11863705/benzingas-daily-biotech-pulse-galmed-rips-higher-on-positive-nash-dat,Shanthi Rexaline,,,,0,0,5342c526-547d-443c-8a42-6e45044634c8
2018-06-12T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat",LLY,https://www.benzinga.com/news/18/06/11863702/eli-lilly-astrazeneca-discontinuing-global-phase-3-clinical-trials-of-lanabecest,Benzinga Newdesk,,,,0,0,50aa0921-bbbc-4701-b852-23541d19d13e
2018-06-12T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",LLY,https://www.benzinga.com/general/biotech/18/06/11863705/benzingas-daily-biotech-pulse-galmed-rips-higher-on-positive-nash-dat,Shanthi Rexaline,,,,0,0,cb46c3a2-5c70-4d8f-aaf8-52f9da4f7f8d
2018-06-12T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Discontinuing Global Phase 3 Clinical Trials of Lanabecestat",LLY,https://www.benzinga.com/news/18/06/11863702/eli-lilly-astrazeneca-discontinuing-global-phase-3-clinical-trials-of-lanabecest,Benzinga Newdesk,,,,0,0,67bc0e7e-aa17-4b19-be5c-43c3cbe580a6
2018-06-11T08:00:00.000+08:00,"Eli Lilly Division, Elanco Animal Health, Introduces New Respiratory PRRS Vaccine",LLY,https://www.benzinga.com/news/18/06/11857880/eli-lilly-division-elanco-animal-health-introduces-new-respiratory-prrs-vaccine,Benzinga Newsdesk,,,,0,0,7baa99af-dd58-453e-a8f7-a6aea0faf2e6
2018-06-11T08:00:00.000+08:00,Eli Lilly Reports Its Elanco Animal Health Unit Received Licensing Of Prevacent PRRS By USDA Shown To Be Effective In Reducing PRRS In Piglets 2 Weeks Or Older,LLY,https://www.benzinga.com/news/fda/18/06/11857852/eli-lilly-reports-its-elanco-animal-health-unit-received-licensing-of-prevac,Benzinga Newsdesk,,,,0,0,36c92bb1-ed82-4763-98d3-4093d13179da
2018-06-11T08:00:00.000+08:00,"Eli Lilly Division, Elanco Animal Health, Introduces New Respiratory PRRS Vaccine",LLY,https://www.benzinga.com/news/18/06/11857880/eli-lilly-division-elanco-animal-health-introduces-new-respiratory-prrs-vaccine,Benzinga Newsdesk,,,,0,0,26781a48-860d-45a1-b938-f42391016bb8
2018-06-11T08:00:00.000+08:00,Eli Lilly Reports Its Elanco Animal Health Unit Received Licensing Of Prevacent PRRS By USDA Shown To Be Effective In Reducing PRRS In Piglets 2 Weeks Or Older,LLY,https://www.benzinga.com/news/fda/18/06/11857852/eli-lilly-reports-its-elanco-animal-health-unit-received-licensing-of-prevac,Benzinga Newsdesk,,,,0,0,c6ce4fb2-03ab-41a3-914f-12d78c18cf8e
2018-06-08T08:00:00.000+08:00,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More",LLY,https://www.benzinga.com/general/biotech/18/06/11853189/pharma-stock-roundup-merck-eli-lilly-abbvie-and-more,Zacks,,,,0,0,29f6bd5d-09ce-4d75-b25a-8ad9948144e6
2018-06-08T08:00:00.000+08:00,"The Market In 5 Minutes: China, ZTE, McDonald's And More",LLY,https://www.benzinga.com/news/18/06/11852066/the-market-in-5-minutes-china-zte-mcdonalds-and-more,Benzinga Newsdesk,,,,0,0,da9bc50f-6027-4f92-b655-24fcce639ed2
2018-06-08T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For June 8, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/06/11852140/benzingas-top-upgrades-downgrades-for-june-8-2018,Lisa Levin,,,,0,0,7655ac03-14e2-4779-a0a7-5a05160f4188
2018-06-08T08:00:00.000+08:00,"Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces $100 Price Target",LLY,https://www.benzinga.com/news/18/06/11851455/cantor-fitzgerald-initiates-coverage-on-eli-lilly-with-overweight-rating-announc,Benzinga Newsdesk,,,,0,0,532adbf6-179a-4e6e-a143-43f5ce6229c7
2018-06-08T08:00:00.000+08:00,"Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And More",LLY,https://www.benzinga.com/general/biotech/18/06/11853189/pharma-stock-roundup-merck-eli-lilly-abbvie-and-more,Zacks,,,,0,0,736d9dca-6649-4c53-ab9b-72caa1f7daf2
2018-06-08T08:00:00.000+08:00,"The Market In 5 Minutes: China, ZTE, McDonald's And More",LLY,https://www.benzinga.com/news/18/06/11852066/the-market-in-5-minutes-china-zte-mcdonalds-and-more,Benzinga Newsdesk,,,,0,0,bdaf9aa2-14aa-4def-b22e-05adb28b1394
2018-06-08T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For June 8, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/06/11852140/benzingas-top-upgrades-downgrades-for-june-8-2018,Lisa Levin,,,,0,0,17339be0-8cf2-4f62-a166-75e6f5d60605
2018-06-08T08:00:00.000+08:00,"Cantor Fitzgerald Initiates Coverage On Eli Lilly with Overweight Rating, Announces $100 Price Target",LLY,https://www.benzinga.com/news/18/06/11851455/cantor-fitzgerald-initiates-coverage-on-eli-lilly-with-overweight-rating-announc,Benzinga Newsdesk,,,,0,0,daf86325-31b0-48ac-b39f-721a4ccdcc40
2018-06-07T08:00:00.000+08:00,"Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care",LLY,https://www.benzinga.com/general/biotech/18/06/11848847/eli-lilly-ceo-calls-for-uniform-prices-better-use-of-technology-in-he,Dustin Blitchok,,,,0,0,30ab34fb-59a5-42d5-a227-e52878b15558
2018-06-07T08:00:00.000+08:00,"Lilly CEO Ricks, When Asked If Co. Will Participate In Right-To-Try Initiative, Tells Benzinga, Co. Has Supplied Medication To That Patient Population 'For Years,' Notes Co. Was Full Participant In Expanded Access Program, But Does Not Answer Directly",LLY,https://www.benzinga.com/news/18/06/11847698/lilly-ceo-ricks-when-asked-if-co-will-participate-in-right-to-try-initiative-tel,Benzinga Newsdesk,,,,0,0,5873f54a-89b2-4ab3-af4d-d107ea0ec480
2018-06-07T08:00:00.000+08:00,"Lilly CEO Ricks Positive On JP Morgan, Berkshire, Amazon Health Care Coalition, Says 'If these 3 large cos. can use their scale, technology to create real change and move to value-based payments, it could move [health care] system forward'",LLY,https://www.benzinga.com/news/18/06/11847458/lilly-ceo-ricks-positive-on-jp-morgan-berkshire-amazon-health-care-coalition-say,Benzinga Newsdesk,,,,0,0,58acaaf5-84e5-4b56-980c-57eb07841c54
2018-06-07T08:00:00.000+08:00,"Eli Lilly CEO David Ricks Currently Speaking At Detroit Economic Club, Highlights Co. Launching Recently-Approved RA Drug Olumiant At 60% Discount To Competitors",LLY,https://www.benzinga.com/news/18/06/11847379/eli-lilly-ceo-david-ricks-currently-speaking-at-detroit-economic-club-highlights,Benzinga Newsdesk,,,,0,0,f69ff31e-7dc7-4917-930c-193537a33b8d
2018-06-07T08:00:00.000+08:00,"Eli Lilly CEO Calls For Uniform Prices, Better Use Of Technology In Health Care",LLY,https://www.benzinga.com/general/biotech/18/06/11848847/eli-lilly-ceo-calls-for-uniform-prices-better-use-of-technology-in-he,Dustin Blitchok,,,,0,0,5a2d3f29-b0d5-4ff0-b27c-64183334383a
2018-06-07T08:00:00.000+08:00,"Lilly CEO Ricks, When Asked If Co. Will Participate In Right-To-Try Initiative, Tells Benzinga, Co. Has Supplied Medication To That Patient Population 'For Years,' Notes Co. Was Full Participant In Expanded Access Program, But Does Not Answer Directly",LLY,https://www.benzinga.com/news/18/06/11847698/lilly-ceo-ricks-when-asked-if-co-will-participate-in-right-to-try-initiative-tel,Benzinga Newsdesk,,,,0,0,67f614c8-f2c5-4f66-a152-075d573290dd
2018-06-07T08:00:00.000+08:00,"Lilly CEO Ricks Positive On JP Morgan, Berkshire, Amazon Health Care Coalition, Says 'If these 3 large cos. can use their scale, technology to create real change and move to value-based payments, it could move [health care] system forward'",LLY,https://www.benzinga.com/news/18/06/11847458/lilly-ceo-ricks-positive-on-jp-morgan-berkshire-amazon-health-care-coalition-say,Benzinga Newsdesk,,,,0,0,85069539-9272-4fe0-9130-e9d32ae3f315
2018-06-07T08:00:00.000+08:00,"Eli Lilly CEO David Ricks Currently Speaking At Detroit Economic Club, Highlights Co. Launching Recently-Approved RA Drug Olumiant At 60% Discount To Competitors",LLY,https://www.benzinga.com/news/18/06/11847379/eli-lilly-ceo-david-ricks-currently-speaking-at-detroit-economic-club-highlights,Benzinga Newsdesk,,,,0,0,97bcfeb4-caaf-4564-9ce0-d847fcae3038
2018-06-05T08:00:00.000+08:00,UPDATE: Eli Lilly Reports Will Initiate Phase 3 Trial In Moderate To Severe Ulcerative Colitis In 2018,LLY,https://www.benzinga.com/news/fda/18/06/11830896/update-eli-lilly-reports-will-initiate-phase-3-trial-in-moderate-to-severe-u,Benzinga Newsdesk,,,,0,0,b62b345b-7a93-4f4e-9c41-d6489bbf271d
2018-06-05T08:00:00.000+08:00,"Eli Lilly Offers New Safety, Efficacy Data From Phase 2 Study Evaluating Mirikizumab In Patients With Moderate To Severe Ulcerative Colitis: Showed Achivement Of Greater Rates Of Clinical Remission At 12 Weeks vs Placebo",LLY,https://www.benzinga.com/news/fda/18/06/11830886/eli-lilly-offers-new-safety-efficacy-data-from-phase-2-study-evaluating-miri,Benzinga Newsdesk,,,,0,0,7bf9fd7c-456d-4bc9-839f-4a8051a73fd3
2018-06-05T08:00:00.000+08:00,"FDA Expands Eli Lilly's ALIMTA (pemetrexed) Label To Include Combination With KEYTRUDA (pembrolizumab) And Carboplatin As First-Line Treatment For Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective Of PD-L1 Expression",LLY,https://www.benzinga.com/general/biotech/18/06/11828515/fda-expands-eli-lillys-alimta-pemetrexed-label-to-include-combination,Benzinga Newsdesk,,,,0,0,2616afd2-4d2d-4847-876e-cfb7e9d704e2
2018-06-05T08:00:00.000+08:00,UPDATE: Eli Lilly Reports Will Initiate Phase 3 Trial In Moderate To Severe Ulcerative Colitis In 2018,LLY,https://www.benzinga.com/news/fda/18/06/11830896/update-eli-lilly-reports-will-initiate-phase-3-trial-in-moderate-to-severe-u,Benzinga Newsdesk,,,,0,0,3bd06e67-501d-4ea4-b3e6-55e39a0c19c2
2018-06-05T08:00:00.000+08:00,"Eli Lilly Offers New Safety, Efficacy Data From Phase 2 Study Evaluating Mirikizumab In Patients With Moderate To Severe Ulcerative Colitis: Showed Achivement Of Greater Rates Of Clinical Remission At 12 Weeks vs Placebo",LLY,https://www.benzinga.com/news/fda/18/06/11830886/eli-lilly-offers-new-safety-efficacy-data-from-phase-2-study-evaluating-miri,Benzinga Newsdesk,,,,0,0,bc2531ac-9724-4671-8eb1-6ecd5cd82bbe
2018-06-05T08:00:00.000+08:00,"FDA Expands Eli Lilly's ALIMTA (pemetrexed) Label To Include Combination With KEYTRUDA (pembrolizumab) And Carboplatin As First-Line Treatment For Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective Of PD-L1 Expression",LLY,https://www.benzinga.com/general/biotech/18/06/11828515/fda-expands-eli-lillys-alimta-pemetrexed-label-to-include-combination,Benzinga Newsdesk,,,,0,0,de43ab3f-8d5b-4cd0-b16c-dc7e9ece78fb
2018-06-04T08:00:00.000+08:00,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'",LLY,https://www.benzinga.com/news/18/06/11821277/donald-trump-tweets-we-had-repeal-replace-done-and-the-saving-to-our-country-of-,Benzinga Newsdesk,,,,0,0,6467d056-c5c1-4da8-ad4f-5b50a96854b7
2018-06-04T08:00:00.000+08:00,"Donald Trump Tweets: 'We had Repeal & Replace done (and the saving to our country of one trillion dollars) except for one person, but it is getting done anyway'...'less expensive plans will be announced this month. Drug prices coming down & Right to Try!'",LLY,https://www.benzinga.com/news/18/06/11821277/donald-trump-tweets-we-had-repeal-replace-done-and-the-saving-to-our-country-of-,Benzinga Newsdesk,,,,0,0,453e05c5-a3ce-4028-9b9c-5c06919039b3
2018-06-03T08:00:00.000+08:00,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,LLY,https://www.benzinga.com/general/biotech/18/06/11806828/the-week-ahead-in-biotech-asco-presentations-dominate-the-headlines,Shanthi Rexaline,,,,0,0,cd2d9c23-7655-4622-a0b5-06c4aa81d5e3
2018-06-03T08:00:00.000+08:00,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,LLY,https://www.benzinga.com/general/biotech/18/06/11806828/the-week-ahead-in-biotech-asco-presentations-dominate-the-headlines,Shanthi Rexaline,,,,0,0,8eeeb9a7-6e0e-4b8b-9e6b-8cf05213a54c
2018-06-01T08:00:00.000+08:00,Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant,LLY,https://www.benzinga.com/news/fda/18/06/11814901/eli-lilly-pr-confirms-earlier-news-of-fda-approval-for-olumiant,Eddie Staley,,,,0,0,7092ae75-324a-49a8-a9f7-e664083e9e7e
2018-06-01T08:00:00.000+08:00,Eli Lilly And Co.'s Olumiant Wins FDA Approval,LLY,https://www.benzinga.com/news/fda/18/06/11814500/eli-lilly-and-co-s-olumiant-wins-fda-approval,Eddie Staley,,,,0,0,67e5bb18-0ff6-4cc6-b200-2145b5d55e52
2018-06-01T08:00:00.000+08:00,Eli Lilly Says Will Present New Data Evaluating Mirikizumab Fro Treatment Of Moderate To Severe Ulcerative Colitis At Digestive Disease Week Jun. 2-5,LLY,https://www.benzinga.com/news/18/06/11812268/eli-lilly-says-will-present-new-data-evaluating-mirikizumab-fro-treatment-of-mod,Paul Quintaro,,,,0,0,83f6eda9-d0c1-45dd-b11c-ce289453ef28
2018-06-01T08:00:00.000+08:00,Eli Lilly Press Release Confirms Earlier News Of FDA Approval For Olumiant,LLY,https://www.benzinga.com/news/fda/18/06/11814901/eli-lilly-pr-confirms-earlier-news-of-fda-approval-for-olumiant,Eddie Staley,,,,0,0,a5ad106a-370a-4920-95b3-4587629cfe04
2018-06-01T08:00:00.000+08:00,Eli Lilly And Co.'s Olumiant Wins FDA Approval,LLY,https://www.benzinga.com/news/fda/18/06/11814500/eli-lilly-and-co-s-olumiant-wins-fda-approval,Eddie Staley,,,,0,0,5867e305-53fa-4e4f-b9d2-24807dffe8f4
2018-06-01T08:00:00.000+08:00,Eli Lilly Says Will Present New Data Evaluating Mirikizumab Fro Treatment Of Moderate To Severe Ulcerative Colitis At Digestive Disease Week Jun. 2-5,LLY,https://www.benzinga.com/news/18/06/11812268/eli-lilly-says-will-present-new-data-evaluating-mirikizumab-fro-treatment-of-mod,Paul Quintaro,,,,0,0,17fa9e13-a215-4611-adb3-a443a6065782
2018-05-22T08:00:00.000+08:00,Eli Lilly Announces FDA Approval for its Taltz to Include Psoriasis Involving the Genital Area on its Label,LLY,https://www.benzinga.com/news/18/05/11755511/eli-lilly-announces-fda-approval-for-its-taltz-to-include-psoriasis-involving-th,Benzinga Newsdesk,,,,0,0,91a79229-b000-466c-9cba-b758aa81531d
2018-05-22T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) Receives First U.S. FDA Approval For Label Update To Include Data For Psoriasis Involving Genital Area,LLY,https://www.benzinga.com/news/18/05/11755507/lillys-taltz-ixekizumab-receives-first-u-s-fda-approval-for-label-update-to-incl,Benzinga Newsdesk,,,,0,0,d294021b-97c4-4b27-8836-80ce59951bd3
2018-05-22T08:00:00.000+08:00,Eli Lilly Announces FDA Approval for its Taltz to Include Psoriasis Involving the Genital Area on its Label,LLY,https://www.benzinga.com/news/18/05/11755511/eli-lilly-announces-fda-approval-for-its-taltz-to-include-psoriasis-involving-th,Benzinga Newsdesk,,,,0,0,248ada6f-838a-4571-a28f-e171e4814462
2018-05-22T08:00:00.000+08:00,Lilly's Taltz® (ixekizumab) Receives First U.S. FDA Approval For Label Update To Include Data For Psoriasis Involving Genital Area,LLY,https://www.benzinga.com/news/18/05/11755507/lillys-taltz-ixekizumab-receives-first-u-s-fda-approval-for-label-update-to-incl,Benzinga Newsdesk,,,,0,0,2bf0a038-bd08-4ccc-a0f0-a1a61eea7496
2018-05-14T08:00:00.000+08:00,"Eli Lilly To Buy AurKa Pharma For $110M Upfront Payment, Plus Eligibility To Receive Up To $465M In Regulatory, Sales Milestones Related To AK-01",LLY,https://www.benzinga.com/news/m-a/18/05/11702671/eli-lilly-to-buy-aurka-pharma-for-110m-upfront-payment-plus-eligibility-to-r,Benzinga Newsdesk,,,,0,0,016a5b15-f828-467e-aeaf-2d73cdc5c34d
2018-05-14T08:00:00.000+08:00,"Eli Lilly To Buy AurKa Pharma For $110M Upfront Payment, Plus Eligibility To Receive Up To $465M In Regulatory, Sales Milestones Related To AK-01",LLY,https://www.benzinga.com/news/m-a/18/05/11702671/eli-lilly-to-buy-aurka-pharma-for-110m-upfront-payment-plus-eligibility-to-r,Benzinga Newsdesk,,,,0,0,b3a1a565-9212-40b7-8737-1d43727afa32
2018-05-11T08:00:00.000+08:00,55 Biggest Movers From Yesterday,LLY,https://www.benzinga.com/news/18/05/11693478/55-biggest-movers-from-yesterday,Lisa Levin,,,,0,0,aa2d5d92-60b8-4057-82d9-94c16aeda377
2018-05-11T08:00:00.000+08:00,UPDATE: Eli Lilly Announces Tender Offer for HBM-Portfolio Company ARMO BioSciences for $1.6B,LLY,https://www.benzinga.com/news/m-a/18/05/11693426/update-eli-lilly-announces-tender-offer-for-hbm-portfolio-company-armo-biosc,Charles Gross,,,,0,0,34ebf7d7-9b5c-409b-b96d-d6688fc019a8
2018-05-11T08:00:00.000+08:00,55 Biggest Movers From Yesterday,LLY,https://www.benzinga.com/news/18/05/11693478/55-biggest-movers-from-yesterday,Lisa Levin,,,,0,0,f6b52fa2-d174-431a-abc5-44ac5c095023
2018-05-11T08:00:00.000+08:00,UPDATE: Eli Lilly Announces Tender Offer for HBM-Portfolio Company ARMO BioSciences for $1.6B,LLY,https://www.benzinga.com/news/m-a/18/05/11693426/update-eli-lilly-announces-tender-offer-for-hbm-portfolio-company-armo-biosc,Charles Gross,,,,0,0,05ade9b3-5a80-4b36-87bb-c849ba2cff70
2018-05-10T08:00:00.000+08:00,Mid-Afternoon Market Update: Prestige Brands Gains On Earnings Beat; MDC Partners Shares Slide,LLY,https://www.benzinga.com/news/18/05/11688608/mid-afternoon-market-update-prestige-brands-gains-on-earnings-beat-mdc-partners-,Lisa Levin,,,,0,0,1fb4a610-0a52-4a30-8f25-d8c48ae1899f
2018-05-10T08:00:00.000+08:00,40 Stocks Moving In Thursday's Mid-Day Session,LLY,https://www.benzinga.com/news/18/05/11687704/40-stocks-moving-in-thursdays-mid-day-session,Lisa Levin,,,,0,0,f1a58a30-9b20-4cd5-b755-e2664825d082
2018-05-10T08:00:00.000+08:00,Mid-Day Market Update: Dow Rises 150 Points; Hudson Technologies Shares Plunge,LLY,https://www.benzinga.com/news/18/05/11687433/mid-day-market-update-dow-rises-150-points-hudson-technologies-shares-plunge,Lisa Levin,,,,0,0,cf53737d-ccd6-4775-9797-bf9c0ead14a6
2018-05-10T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Magna Tops Q1 Views,LLY,https://www.benzinga.com/news/18/05/11686239/mid-morning-market-update-markets-open-higher-markets-magna-tops-q1-views,Lisa Levin,,,,0,0,5e6c39da-5a80-40cb-a7e4-4ef6a4313448
2018-05-10T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",LLY,https://www.benzinga.com/general/biotech/18/05/11682938/benzingas-daily-biotech-pulse-armo-skyrockets-on-eli-lilly-deal-akcea,Shanthi Rexaline,,,,0,0,f7a71a55-009f-45c1-99b1-2ffa650780cd
2018-05-10T08:00:00.000+08:00,32 Stocks Moving In Thursday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/05/11684612/32-stocks-moving-in-thursdays-pre-market-session,Lisa Levin,,,,0,0,716941b9-2c6c-4272-b145-3e47245d806f
2018-05-10T08:00:00.000+08:00,Lilly Announces Agreement To Acquire ARMO BioSciences For $50/Share Or ~$1.6B,LLY,https://www.benzinga.com/news/18/05/11684092/lilly-announces-agreement-to-acquire-armo-biosciences-for-50share-or-1-6b,Eddie Staley,,,,0,0,dab7dc98-139f-4396-b96e-31e3e844c2a4
2018-05-10T08:00:00.000+08:00,Mid-Afternoon Market Update: Prestige Brands Gains On Earnings Beat; MDC Partners Shares Slide,LLY,https://www.benzinga.com/news/18/05/11688608/mid-afternoon-market-update-prestige-brands-gains-on-earnings-beat-mdc-partners-,Lisa Levin,,,,0,0,e4b6906c-6bc8-44d4-b4ac-7e32be666363
2018-05-10T08:00:00.000+08:00,40 Stocks Moving In Thursday's Mid-Day Session,LLY,https://www.benzinga.com/news/18/05/11687704/40-stocks-moving-in-thursdays-mid-day-session,Lisa Levin,,,,0,0,baa761e5-8912-41c8-a2c1-d73f792f0c91
2018-05-10T08:00:00.000+08:00,Mid-Day Market Update: Dow Rises 150 Points; Hudson Technologies Shares Plunge,LLY,https://www.benzinga.com/news/18/05/11687433/mid-day-market-update-dow-rises-150-points-hudson-technologies-shares-plunge,Lisa Levin,,,,0,0,bf73237a-af32-4d06-8600-40c22280f6b9
2018-05-10T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Higher; Magna Tops Q1 Views,LLY,https://www.benzinga.com/news/18/05/11686239/mid-morning-market-update-markets-open-higher-markets-magna-tops-q1-views,Lisa Levin,,,,0,0,59035f96-6610-4793-b2e2-450b8f3ca514
2018-05-10T08:00:00.000+08:00,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",LLY,https://www.benzinga.com/general/biotech/18/05/11682938/benzingas-daily-biotech-pulse-armo-skyrockets-on-eli-lilly-deal-akcea,Shanthi Rexaline,,,,0,0,f85ed433-50da-43b0-b8f0-2710fab74ffc
2018-05-10T08:00:00.000+08:00,32 Stocks Moving In Thursday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/05/11684612/32-stocks-moving-in-thursdays-pre-market-session,Lisa Levin,,,,0,0,8e7d0ab6-3f31-42a6-83de-d29ea42926d6
2018-05-10T08:00:00.000+08:00,Lilly Announces Agreement To Acquire ARMO BioSciences For $50/Share Or ~$1.6B,LLY,https://www.benzinga.com/news/18/05/11684092/lilly-announces-agreement-to-acquire-armo-biosciences-for-50share-or-1-6b,Eddie Staley,,,,0,0,22c14de0-5e1c-4564-b316-461cc1079aa0
2018-05-07T08:00:00.000+08:00,What's In Store For Radius Health In Q1 Earnings?,LLY,https://www.benzinga.com/general/biotech/18/05/11656510/whats-in-store-for-radius-health-in-q1-earnings,Zacks,,,,0,0,5ccedf6f-5aea-40df-ba94-fb1b44ecdcff
2018-05-07T08:00:00.000+08:00,What's In Store For Radius Health In Q1 Earnings?,LLY,https://www.benzinga.com/general/biotech/18/05/11656510/whats-in-store-for-radius-health-in-q1-earnings,Zacks,,,,0,0,e453c5ac-8e0a-4a96-92c1-aa1a1bf79c11
2018-04-25T08:00:00.000+08:00,Eli Lilly and NCCD of China Collaborate to Advance Care for People Living with Diabetes and Cardiovascular Disease,LLY,https://www.benzinga.com/news/18/04/11571630/eli-lilly-and-nccd-of-china-collaborate-to-advance-care-for-people-living-with-d,Paul Quintaro,,,,0,0,acecdb5e-d93d-43a8-8b5a-b473390c0f24
2018-04-25T08:00:00.000+08:00,Eli Lilly and NCCD of China Collaborate to Advance Care for People Living with Diabetes and Cardiovascular Disease,LLY,https://www.benzinga.com/news/18/04/11571630/eli-lilly-and-nccd-of-china-collaborate-to-advance-care-for-people-living-with-d,Paul Quintaro,,,,0,0,fc33c3cd-666b-4874-9dad-74f774abe625
2018-04-24T08:00:00.000+08:00,19 Companies Google Could Buy With Its $102 Billion In Cash,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/04/11567157/19-companies-google-could-buy-with-its-102-billion-in-cash,Elizabeth Balboa,,,,0,0,c5db531e-6c92-499b-b469-b585e37de9bb
2018-04-24T08:00:00.000+08:00,Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11565763/goldman-sachs-neutral-on-alder-biopharma-as-launch-of-m,Elizabeth Balboa,,,,0,0,64466205-5d29-4dea-804a-bf98a85b58c4
2018-04-24T08:00:00.000+08:00,"Eli Lilly Says It Is Looking To Do More Deals In Oncology, Including Immuno-Oncology And Other Cancer Drugs",LLY,https://www.benzinga.com/news/18/04/11565365/eli-lilly-says-it-is-looking-to-do-more-deals-in-oncology-including-immuno-oncol,Eddie Staley,,,,0,0,afa82b01-c7eb-4429-b74f-3d4a99103e77
2018-04-24T08:00:00.000+08:00,28 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/04/11563983/28-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,0,0,50d114ba-f49d-4751-9d44-e4828853ea35
2018-04-24T08:00:00.000+08:00,"UPDATE: Eli Lilly Raises FY18 Adj. EPS Outlook From $4.81-$4.91 To $5.10-$5.20 vs $4.88 Est., Sales From $23B-$23.5B To $23.7B-$24.2B vs $23.4B Est.",LLY,https://www.benzinga.com/news/guidance/18/04/11563044/update-eli-lilly-raises-fy18-adj-eps-outlook-from-4-81-4-91-to-5-10-5-2,Paul Quintaro,,,,0,0,c87d0ca0-137c-421b-ae11-c8f1c6a6ffca
2018-04-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Outlook,LLY,https://www.benzinga.com/news/guidance/18/04/11563041/eli-lilly-raises-fy18-outlook,Paul Quintaro,,,,0,0,c649062a-1dbd-499c-8d02-132c4a07a815
2018-04-24T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.34 Beats $1.14 Est., Sales $5.7B Beats $5.49B Est.",LLY,https://www.benzinga.com/news/earnings/18/04/11563040/eli-lilly-q1-adj-eps-1-34-beats-1-14-est-sales-5-7b-beats-5-49b-est,Paul Quintaro,,,,0,0,287bc644-d20b-43a6-9067-187a20b8046a
2018-04-24T08:00:00.000+08:00,Lilly Reports Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies at #AAN2018,LLY,https://www.benzinga.com/news/18/04/11562844/lilly-reports-galcanezumab-significantly-reduced-monthly-migraine-headache-days-,Charles Gross,,,,0,0,355b0d47-6199-49d6-9db8-a52c811d928b
2018-04-24T08:00:00.000+08:00,"12 Stocks To Watch For April 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/04/11562671/12-stocks-to-watch-for-april-24-2018,Lisa Levin,,,,0,0,4c012fe9-0db0-491b-9b12-715fdc1802eb
2018-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/04/11562595/earnings-scheduled-for-april-24-2018,Lisa Levin,,,,0,0,52233713-5723-4e6c-aa04-5b1904e0040c
2018-04-24T08:00:00.000+08:00,"Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA",LLY,https://www.benzinga.com/news/18/04/11562553/lilly-incyte-announce-fda-advisory-committee-recommends-approval-of-baricitinib-,Charles Gross,,,,0,0,b83b88ff-f9c6-4ebe-a6d0-8813ed82cc1c
2018-04-24T08:00:00.000+08:00,19 Companies Google Could Buy With Its $102 Billion In Cash,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/04/11567157/19-companies-google-could-buy-with-its-102-billion-in-cash,Elizabeth Balboa,,,,0,0,4b12f94a-8ca3-4f1a-8581-4f8e2833dc0b
2018-04-24T08:00:00.000+08:00,Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11565763/goldman-sachs-neutral-on-alder-biopharma-as-launch-of-m,Elizabeth Balboa,,,,0,0,d8339c79-3e8f-4695-be14-2aa5f5409402
2018-04-24T08:00:00.000+08:00,"Eli Lilly Says It Is Looking To Do More Deals In Oncology, Including Immuno-Oncology And Other Cancer Drugs",LLY,https://www.benzinga.com/news/18/04/11565365/eli-lilly-says-it-is-looking-to-do-more-deals-in-oncology-including-immuno-oncol,Eddie Staley,,,,0,0,25422692-a14a-40fd-992d-380dbec274c4
2018-04-24T08:00:00.000+08:00,28 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/18/04/11563983/28-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,,,,0,0,609ddc83-ba3e-43a5-b6be-e687098160cf
2018-04-24T08:00:00.000+08:00,"UPDATE: Eli Lilly Raises FY18 Adj. EPS Outlook From $4.81-$4.91 To $5.10-$5.20 vs $4.88 Est., Sales From $23B-$23.5B To $23.7B-$24.2B vs $23.4B Est.",LLY,https://www.benzinga.com/news/guidance/18/04/11563044/update-eli-lilly-raises-fy18-adj-eps-outlook-from-4-81-4-91-to-5-10-5-2,Paul Quintaro,,,,0,0,7d36b170-5c8b-4951-a1e7-030b101877c6
2018-04-24T08:00:00.000+08:00,Eli Lilly Raises FY18 Outlook,LLY,https://www.benzinga.com/news/guidance/18/04/11563041/eli-lilly-raises-fy18-outlook,Paul Quintaro,,,,0,0,521615d2-5fec-409e-9f25-392c0b76c4be
2018-04-24T08:00:00.000+08:00,"Eli Lilly Q1 Adj. EPS $1.34 Beats $1.14 Est., Sales $5.7B Beats $5.49B Est.",LLY,https://www.benzinga.com/news/earnings/18/04/11563040/eli-lilly-q1-adj-eps-1-34-beats-1-14-est-sales-5-7b-beats-5-49b-est,Paul Quintaro,,,,0,0,3eba9891-5545-4901-aa74-e20b3f1d86a7
2018-04-24T08:00:00.000+08:00,Lilly Reports Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies at #AAN2018,LLY,https://www.benzinga.com/news/18/04/11562844/lilly-reports-galcanezumab-significantly-reduced-monthly-migraine-headache-days-,Charles Gross,,,,0,0,9c1b49b9-7485-4177-baae-840248fda85a
2018-04-24T08:00:00.000+08:00,"12 Stocks To Watch For April 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/04/11562671/12-stocks-to-watch-for-april-24-2018,Lisa Levin,,,,0,0,e575053a-23b7-4d2d-82fb-d4337aff7a6b
2018-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2018",LLY,https://www.benzinga.com/news/earnings/18/04/11562595/earnings-scheduled-for-april-24-2018,Lisa Levin,,,,0,0,bec2825a-33c9-4180-93f4-3a57e5bd5cc2
2018-04-24T08:00:00.000+08:00,"Lilly, Incyte Announce FDA Advisory Committee Recommends Approval of Baricitinib 2mg, Not 4mg, for Treatment of Moderately-to-Severely Active RA",LLY,https://www.benzinga.com/news/18/04/11562553/lilly-incyte-announce-fda-advisory-committee-recommends-approval-of-baricitinib-,Charles Gross,,,,0,0,4c84795d-3f95-4e90-be3f-67e04d1de67e
2018-04-23T08:00:00.000+08:00,"Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/04/11560145/top-ideas-from-the-2018-sohn-conference-box-bitcoin-facebook,Elizabeth Balboa,,,,0,0,c1e109ff-70c8-45e7-a959-f6f8d56d8cd0
2018-04-23T08:00:00.000+08:00,Earnings Preview: Verizon And AT&T Report Q1 Results This Week,LLY,https://www.benzinga.com/news/earnings/18/04/11559193/earnings-preview-verizon-and-at-t-report-q1-results-this-week,JJ Kinahan,,,,0,0,42e34a99-376f-4dc7-bc43-2ee7a9bd5c4b
2018-04-23T08:00:00.000+08:00,"Upcoming Earnings: CAT, LLY And BA Report This Week",LLY,https://www.benzinga.com/news/earnings/18/04/11558746/upcoming-earnings-cat-lly-and-ba-report-this-week,JJ Kinahan,,,,0,0,cc0ac04e-12f1-42fb-af3b-7912dd3d0e8b
2018-04-23T08:00:00.000+08:00,"From Sohn Conference: Ecor1's Nodelman On Ascendis Pharma Highlighted 10 Potential Buyers Of Co., Including Eli Lilly, Pfizer",LLY,https://www.benzinga.com/news/18/04/11558189/from-sohn-conference-ecor1s-noodleman-on-ascendis-pharma-highlighted-10-potentia,Paul Quintaro,,,,0,0,0368f20f-3e0f-4974-947d-5dcc494206fd
2018-04-23T08:00:00.000+08:00,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO",LLY,https://www.benzinga.com/news/earnings/18/04/11557960/the-week-ahead-sohn-conference-fang-earnings-docusign-ipo,Taylor Cox,,,,0,0,3cccf53f-109f-4832-a94d-1302d8088633
2018-04-23T08:00:00.000+08:00,REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today,LLY,https://www.benzinga.com/general/biotech/18/04/11556096/reminder-eli-lilly-and-incyte-have-fda-adcom-meeting-for-baricitinib-,Hal Lindon,,,,0,0,059ddd6b-6a36-440a-8423-21ac065ddc58
2018-04-23T08:00:00.000+08:00,"Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More",LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/04/11560145/top-ideas-from-the-2018-sohn-conference-box-bitcoin-facebook,Elizabeth Balboa,,,,0,0,a1d470bd-1fb2-4fb0-a3c3-6d6364501b70
2018-04-23T08:00:00.000+08:00,Earnings Preview: Verizon And AT&T Report Q1 Results This Week,LLY,https://www.benzinga.com/news/earnings/18/04/11559193/earnings-preview-verizon-and-at-t-report-q1-results-this-week,JJ Kinahan,,,,0,0,a7e5dd80-3c25-4a60-ad98-77bb297463a1
2018-04-23T08:00:00.000+08:00,"Upcoming Earnings: CAT, LLY And BA Report This Week",LLY,https://www.benzinga.com/news/earnings/18/04/11558746/upcoming-earnings-cat-lly-and-ba-report-this-week,JJ Kinahan,,,,0,0,3cfed6e2-5f91-4c85-a687-f1cd136dccba
2018-04-23T08:00:00.000+08:00,"From Sohn Conference: Ecor1's Nodelman On Ascendis Pharma Highlighted 10 Potential Buyers Of Co., Including Eli Lilly, Pfizer",LLY,https://www.benzinga.com/news/18/04/11558189/from-sohn-conference-ecor1s-noodleman-on-ascendis-pharma-highlighted-10-potentia,Paul Quintaro,,,,0,0,c453e755-afb8-4259-b66e-4bc4066cc25f
2018-04-23T08:00:00.000+08:00,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO",LLY,https://www.benzinga.com/news/earnings/18/04/11557960/the-week-ahead-sohn-conference-fang-earnings-docusign-ipo,Taylor Cox,,,,0,0,b400cd8a-a9e4-4af6-846b-e557ca83df53
2018-04-23T08:00:00.000+08:00,REMINDER: Eli Lilly and Incyte Have FDA AdCom Meeting For Baricitinib Today,LLY,https://www.benzinga.com/general/biotech/18/04/11556096/reminder-eli-lilly-and-incyte-have-fda-adcom-meeting-for-baricitinib-,Hal Lindon,,,,0,0,8d91ea62-dd0d-44db-83e7-71ae3afe103e
2018-04-20T08:00:00.000+08:00,"Eli Lilly Reports Add'l Topline Results From CYRAMZA Phase 3 RANGE Study, Positive Trend Seen In Secondary Endpoint But Did Not Reach Statistical Significance",LLY,https://www.benzinga.com/general/biotech/18/04/11552703/eli-lilly-reports-addl-toplien-results-from-cyramza-phase-3-range-stu,Hal Lindon,,,,0,0,2a44f18b-5c59-4983-8c49-0a60005b0e37
2018-04-20T08:00:00.000+08:00,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",LLY,https://www.benzinga.com/general/biotech/18/04/11545276/the-week-ahead-in-biotech-pdufa-dates-ipos-and-more,Shanthi Rexaline,,,,0,0,7e3c16fd-b7d1-4384-9af0-3399e5b44afc
2018-04-20T08:00:00.000+08:00,"Eli Lilly Reports Add'l Topline Results From CYRAMZA Phase 3 RANGE Study, Positive Trend Seen In Secondary Endpoint But Did Not Reach Statistical Significance",LLY,https://www.benzinga.com/general/biotech/18/04/11552703/eli-lilly-reports-addl-toplien-results-from-cyramza-phase-3-range-stu,Hal Lindon,,,,0,0,2f520947-67a4-4f06-8054-4095cef520bd
2018-04-20T08:00:00.000+08:00,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",LLY,https://www.benzinga.com/general/biotech/18/04/11545276/the-week-ahead-in-biotech-pdufa-dates-ipos-and-more,Shanthi Rexaline,,,,0,0,febaadcd-7d53-4442-8ef6-9e55151d2ef9
2018-04-19T08:00:00.000+08:00,"FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose",LLY,https://www.benzinga.com/news/fda/18/04/11542112/fda-staff-review-of-eli-lillys-rheumatoid-arthritis-treatment-says-supportiv,Paul Quintaro,,,,0,0,21505871-4372-47ed-af00-86d6564cfaa9
2018-04-19T08:00:00.000+08:00,"FDA Staff Review Of Eli Lilly's Rheumatoid Arthritis Treatment Says Supportive Of 2mg Dose, But Not 4mg Dose",LLY,https://www.benzinga.com/news/fda/18/04/11542112/fda-staff-review-of-eli-lillys-rheumatoid-arthritis-treatment-says-supportiv,Paul Quintaro,,,,0,0,c2bea36c-e648-4880-81f4-93bdeeb298ec
2018-04-16T08:00:00.000+08:00,"Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More",LLY,https://www.benzinga.com/trading-ideas/18/04/11519182/benzingas-bulls-bears-of-the-week-caterpillar-facebook-starbucks-tesla-,Nelson Hem,,,,0,0,03aa52d3-dc10-45b1-9f1a-2174867bb2ca
2018-04-16T08:00:00.000+08:00,"Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More",LLY,https://www.benzinga.com/trading-ideas/18/04/11519182/benzingas-bulls-bears-of-the-week-caterpillar-facebook-starbucks-tesla-,Nelson Hem,,,,0,0,29e5c68b-208d-4427-996c-bc27ab87d76f
2018-04-13T08:00:00.000+08:00,"Benzinga's Top Analyst Calls From April 13, 2018",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11516373/benzingas-top-analyst-calls-from-april-13-2018,Bill Haddad,,,,0,0,502b83cf-8b53-456c-9d85-18c105a6d35a
2018-04-13T08:00:00.000+08:00,BMO's Bearish Stance On Eli Lilly Comes To An End,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11515585/bmos-bearish-stance-on-eli-lilly-comes-to-an-end,Jayson Derrick,,,,0,0,a877ae3d-5eb9-4ce9-a056-e3a144c08735
2018-04-13T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 13, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/04/11515178/benzingas-top-upgrades-downgrades-for-april-13-2018,Lisa Levin,,,,0,0,2f98f8e5-b0cf-46ea-8c02-90d9f1f396ed
2018-04-13T08:00:00.000+08:00,BMO Capital Upgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/18/04/11514504/bmo-capital-upgrades-eli-lilly-to-market-perform,Eddie Staley,,,,0,0,510960dd-f674-4c23-8d8e-86f858299fed
2018-04-13T08:00:00.000+08:00,"Benzinga's Top Analyst Calls From April 13, 2018",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11516373/benzingas-top-analyst-calls-from-april-13-2018,Bill Haddad,,,,0,0,63bc33d6-f42f-4258-92ad-d711edd3f528
2018-04-13T08:00:00.000+08:00,BMO's Bearish Stance On Eli Lilly Comes To An End,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11515585/bmos-bearish-stance-on-eli-lilly-comes-to-an-end,Jayson Derrick,,,,0,0,a74c075b-4836-4e89-bb4d-2865473b7055
2018-04-13T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 13, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/04/11515178/benzingas-top-upgrades-downgrades-for-april-13-2018,Lisa Levin,,,,0,0,7e2e653e-125b-441a-886e-84cf00d19a24
2018-04-13T08:00:00.000+08:00,BMO Capital Upgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/18/04/11514504/bmo-capital-upgrades-eli-lilly-to-market-perform,Eddie Staley,,,,0,0,5f2cef9a-f6b1-4be9-a6c4-1823cf8c48db
2018-04-04T08:00:00.000+08:00,"Eli Lilly To Report Q1 Earnings On Tues., Apr. 24 Before Market Open",LLY,https://www.benzinga.com/news/earnings/18/04/11472753/eli-lilly-to-report-q1-earnings-on-tues-apr-24-before-market-open,Paul Quintaro,,,,0,0,278e66ac-1b72-4cbf-9f45-5f4f7b2b8a3a
2018-04-04T08:00:00.000+08:00,"UPDATE: As A Result Of Lilly's Transaction, The Co. Will Incur An Acquired In-Process Research And Development Charge To Earnings Of ~$0.05/Share In Q2",LLY,https://www.benzinga.com/news/contracts/18/04/11467583/update-as-a-result-of-lillys-transaction-the-co-will-incur-an-acquired,Eddie Staley,,,,0,0,defa74a4-8cd2-467a-a139-79495aa685ec
2018-04-04T08:00:00.000+08:00,"Lilly, Sigilon Therapeutics Report Strategic Partnership to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes; Sigilon To Receive $63M Up Front And Lilly To Make An Undisclosed Equity Investment In Sigilon",LLY,https://www.benzinga.com/news/contracts/18/04/11467581/lilly-sigilon-therapeutics-report-strategic-partnership-to-develop-enc,Eddie Staley,,,,0,0,cdea6372-5ec3-4416-8f9c-a68bc390c8d4
2018-04-04T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase 3 Reach-2 Study Met Overall Survival Endpoint And Secondary Endpoint Of Progression-Free Survival,LLY,https://www.benzinga.com/news/18/04/11467482/lilly-announces-cyramza-phase-3-reach-2-study-met-overall-survival-endpoint-and-,Eddie Staley,,,,0,0,2764173d-8276-4d82-941a-eeda54163f0f
2018-04-04T08:00:00.000+08:00,Terns Pharmaceutical Acquires Global Exclusive Rights To Develop And Commercialize 3 NASH Assets From Eli Lilly,LLY,https://www.benzinga.com/news/contracts/18/04/11467361/terns-pharmaceutical-acquires-global-exclusive-rights-to-develop-and-c,Eddie Staley,,,,0,0,aeed4728-e887-4440-bdb3-e158d30e8582
2018-04-04T08:00:00.000+08:00,"Eli Lilly To Report Q1 Earnings On Tues., Apr. 24 Before Market Open",LLY,https://www.benzinga.com/news/earnings/18/04/11472753/eli-lilly-to-report-q1-earnings-on-tues-apr-24-before-market-open,Paul Quintaro,,,,0,0,5c688883-bfcb-48ad-ae06-7de92ded507a
2018-04-04T08:00:00.000+08:00,"UPDATE: As A Result Of Lilly's Transaction, The Co. Will Incur An Acquired In-Process Research And Development Charge To Earnings Of ~$0.05/Share In Q2",LLY,https://www.benzinga.com/news/contracts/18/04/11467583/update-as-a-result-of-lillys-transaction-the-co-will-incur-an-acquired,Eddie Staley,,,,0,0,9c762bd0-4c47-4b02-afe5-6f2ecc5c0b92
2018-04-04T08:00:00.000+08:00,"Lilly, Sigilon Therapeutics Report Strategic Partnership to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes; Sigilon To Receive $63M Up Front And Lilly To Make An Undisclosed Equity Investment In Sigilon",LLY,https://www.benzinga.com/news/contracts/18/04/11467581/lilly-sigilon-therapeutics-report-strategic-partnership-to-develop-enc,Eddie Staley,,,,0,0,292d1ba6-f277-44ad-bc3f-3b839e1c19ae
2018-04-04T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase 3 Reach-2 Study Met Overall Survival Endpoint And Secondary Endpoint Of Progression-Free Survival,LLY,https://www.benzinga.com/news/18/04/11467482/lilly-announces-cyramza-phase-3-reach-2-study-met-overall-survival-endpoint-and-,Eddie Staley,,,,0,0,3ea79aa9-e1f5-4523-ba9f-8f3ffd92bab8
2018-04-04T08:00:00.000+08:00,Terns Pharmaceutical Acquires Global Exclusive Rights To Develop And Commercialize 3 NASH Assets From Eli Lilly,LLY,https://www.benzinga.com/news/contracts/18/04/11467361/terns-pharmaceutical-acquires-global-exclusive-rights-to-develop-and-c,Eddie Staley,,,,0,0,fd171cb6-7fdb-43c6-9fcd-b0802c203b8c
2018-04-03T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/18/04/11422065/attention-biotech-investors-mark-your-calendar-for-these-april-pdufa-,Shanthi Rexaline,,,,0,0,ed558236-f5c1-4938-969e-94a7c65bf2c2
2018-04-03T08:00:00.000+08:00,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/18/04/11422065/attention-biotech-investors-mark-your-calendar-for-these-april-pdufa-,Shanthi Rexaline,,,,0,0,d1cf9adb-8a10-4e17-bfb5-60e302d16ef3
2018-03-20T08:00:00.000+08:00,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season,LLY,https://www.benzinga.com/general/biotech/18/03/11390687/checking-in-on-the-healthcare-sector-ahead-of-q1-earnings-season,JJ Kinahan,,,,0,0,1dcc2f36-d9be-4098-8df2-eaaacb829937
2018-03-20T08:00:00.000+08:00,Checking In On The Healthcare Sector Ahead Of Q1 Earnings Season,LLY,https://www.benzinga.com/general/biotech/18/03/11390687/checking-in-on-the-healthcare-sector-ahead-of-q1-earnings-season,JJ Kinahan,,,,0,0,febf1ae1-7d5e-4a4a-a09d-de05a0613cc2
2018-03-15T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On Merck, Five Below And More",LLY,https://www.benzinga.com/media/18/03/11364192/jim-cramer-shares-his-thoughts-on-merck-five-below-and-more,Craig Jones,,,,0,0,7cb304ad-ec36-4599-9400-80ac24b974e9
2018-03-15T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On Merck, Five Below And More",LLY,https://www.benzinga.com/media/18/03/11364192/jim-cramer-shares-his-thoughts-on-merck-five-below-and-more,Craig Jones,,,,0,0,b699f079-4e1b-41eb-8c09-58247e9a1988
2018-03-14T08:00:00.000+08:00,"Citigroup, Eli Lilly, Square, Target: 'Fast Money' Picks For March 14",LLY,https://www.benzinga.com/media/18/03/11356773/citigroup-eli-lilly-square-target-fast-money-picks-for-march-14,Craig Jones,,,,0,0,8f126989-fc71-445d-b630-15db7fb3224d
2018-03-14T08:00:00.000+08:00,"Citigroup, Eli Lilly, Square, Target: 'Fast Money' Picks For March 14",LLY,https://www.benzinga.com/media/18/03/11356773/citigroup-eli-lilly-square-target-fast-money-picks-for-march-14,Craig Jones,,,,0,0,50d0a76a-8ee9-44e8-8161-4bd256b53556
2018-03-07T08:00:00.000+08:00,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11320275/height-casts-65-odds-that-congress-rolls-back-pharma-di,Elizabeth Balboa,,,,0,0,edd41194-9196-46a9-bb6d-bd4febe87aaf
2018-03-07T08:00:00.000+08:00,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11320275/height-casts-65-odds-that-congress-rolls-back-pharma-di,Elizabeth Balboa,,,,0,0,dcc3fee2-b72e-47a6-a331-4b3f311e2b10
2018-03-06T08:00:00.000+08:00,Dear Activists: Buying Stock Can Effect More Change Than Selling It,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/03/11291102/dear-activists-buying-stock-can-effect-more-change-than-sell,Elizabeth Balboa,,,,0,0,18fb8cb8-b7ec-4359-86bc-f5f9745264df
2018-03-06T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly Expand Their Heart Failure Program for Jardiance with New Exercise Capacity Trials,LLY,https://www.benzinga.com/news/18/03/11311288/boehringer-ingelheim-and-eli-lilly-expand-their-heart-failure-program-for-jardia,Hal Lindon,,,,0,0,451d1c2c-668b-482e-a9c9-9064742596e3
2018-03-06T08:00:00.000+08:00,Dear Activists: Buying Stock Can Effect More Change Than Selling It,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/03/11291102/dear-activists-buying-stock-can-effect-more-change-than-sell,Elizabeth Balboa,,,,0,0,a9a83699-84c8-49b9-8631-e9eee5038eaa
2018-03-06T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly Expand Their Heart Failure Program for Jardiance with New Exercise Capacity Trials,LLY,https://www.benzinga.com/news/18/03/11311288/boehringer-ingelheim-and-eli-lilly-expand-their-heart-failure-program-for-jardia,Hal Lindon,,,,0,0,d5234412-52d5-46d2-9729-619544168c6c
2018-02-27T08:00:00.000+08:00,Benzinga Pro's 5 Stocks To Watch Today,LLY,https://www.benzinga.com/news/18/02/11265713/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,,,,0,0,3cdfc595-2cfd-41ee-a803-1f3627630b45
2018-02-27T08:00:00.000+08:00,Benzinga Pro's 5 Stocks To Watch Today,LLY,https://www.benzinga.com/news/18/02/11265713/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,,,,0,0,e55904d1-d1fc-4746-a5be-f4c0e3783dbd
2018-02-26T08:00:00.000+08:00,"UPDATE: Eli Lilly Says 'New indication based on MONARCH 3 trial can help more women living with HR+, HER2- advanced breast cancer'",LLY,https://www.benzinga.com/news/fda/18/02/11262614/update-eli-lilly-says-new-indication-based-on-monarch-3-trial-can-help-more-,Paul Quintaro,,,,0,0,d665dc8c-bb06-4e41-aa4f-5a897dd70ca8
2018-02-26T08:00:00.000+08:00,Eli Lilly Reports Received Added FDA Approval For Verzenio As Initial Treatment For Advanced Breast Cancer,LLY,https://www.benzinga.com/news/fda/18/02/11262599/eli-lilly-reports-received-added-fda-approval-for-verzenio-as-initial-treatm,Paul Quintaro,,,,0,0,39837ab1-026b-4943-bdda-615cf2ed2cca
2018-02-26T08:00:00.000+08:00,Eli Lilly's Says Trulicity in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/02/11256652/eli-lillys-says-trulicity-in-combination-with-an-sglt-2-inhibitor-improves-blood,Paul Quintaro,,,,0,0,3aea94a8-21eb-40d8-990f-3875ade9639b
2018-02-26T08:00:00.000+08:00,"UPDATE: Eli Lilly Says 'New indication based on MONARCH 3 trial can help more women living with HR+, HER2- advanced breast cancer'",LLY,https://www.benzinga.com/news/fda/18/02/11262614/update-eli-lilly-says-new-indication-based-on-monarch-3-trial-can-help-more-,Paul Quintaro,,,,0,0,7d2b6f2e-de40-44f4-a961-40d0eb66ae58
2018-02-26T08:00:00.000+08:00,Eli Lilly Reports Received Added FDA Approval For Verzenio As Initial Treatment For Advanced Breast Cancer,LLY,https://www.benzinga.com/news/fda/18/02/11262599/eli-lilly-reports-received-added-fda-approval-for-verzenio-as-initial-treatm,Paul Quintaro,,,,0,0,2ada73d2-15dc-4d0d-9d60-813b3819c5ac
2018-02-26T08:00:00.000+08:00,Eli Lilly's Says Trulicity in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/18/02/11256652/eli-lillys-says-trulicity-in-combination-with-an-sglt-2-inhibitor-improves-blood,Paul Quintaro,,,,0,0,49adda24-a447-416a-882b-db8c26f5d870
2018-02-22T08:00:00.000+08:00,"Eli Lilly Shares Near Session Highs, Up 0.4%; Traders Circulating Takeover Chatter Out Of Chat",LLY,https://www.benzinga.com/news/18/02/11242697/eli-lilly-shares-near-session-highs-up-0-4-traders-circulating-takeover-chatter-,Paul Quintaro,,,,0,0,83bb157b-deac-4a33-ac90-46cdd4d2ec7d
2018-02-22T08:00:00.000+08:00,"Eli Lilly Shares Near Session Highs, Up 0.4%; Traders Circulating Takeover Chatter Out Of Chat",LLY,https://www.benzinga.com/news/18/02/11242697/eli-lilly-shares-near-session-highs-up-0-4-traders-circulating-takeover-chatter-,Paul Quintaro,,,,0,0,cf2f0b3f-5496-42c6-b460-b7ee9eff10f1
2018-02-13T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Down; Crude Oil Falls,LLY,https://www.benzinga.com/news/18/02/11184126/a-peek-into-the-markets-u-s-stock-futures-down-crude-oil-falls,Lisa Levin,,,,0,0,4aa87ec6-d669-45d1-9798-874b3c797c6c
2018-02-13T08:00:00.000+08:00,Eli Lilly Says its Top-Line Phase 3 Study of Taltz Met the Primary and All Key Secondary Endpoints,LLY,https://www.benzinga.com/news/18/02/11183860/eli-lilly-says-its-top-line-phase-3-study-of-taltz-met-the-primary-and-all-key-s,Paul Quintaro,,,,0,0,c6fae863-8441-4c95-940d-8e184814ae6b
2018-02-13T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Down; Crude Oil Falls,LLY,https://www.benzinga.com/news/18/02/11184126/a-peek-into-the-markets-u-s-stock-futures-down-crude-oil-falls,Lisa Levin,,,,0,0,20367771-1123-492b-8fdd-69187fb9e174
2018-02-13T08:00:00.000+08:00,Eli Lilly Says its Top-Line Phase 3 Study of Taltz Met the Primary and All Key Secondary Endpoints,LLY,https://www.benzinga.com/news/18/02/11183860/eli-lilly-says-its-top-line-phase-3-study-of-taltz-met-the-primary-and-all-key-s,Paul Quintaro,,,,0,0,d4d1cbd5-c3f0-4e35-9458-477f0848d1b9
2018-02-08T08:00:00.000+08:00,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,LLY,https://www.benzinga.com/general/biotech/18/02/11011808/the-alzheimers-drug-pipeline-high-failure-rates-in-research-on-an-inc,Shanthi Rexaline,,,,0,0,1991fff2-45f3-4c73-9328-f3e9a9fe8ec3
2018-02-08T08:00:00.000+08:00,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,LLY,https://www.benzinga.com/general/biotech/18/02/11011808/the-alzheimers-drug-pipeline-high-failure-rates-in-research-on-an-inc,Shanthi Rexaline,,,,0,0,3092120c-2585-4238-bd3d-66d8b1f2458a
2018-02-07T08:00:00.000+08:00,Array's Melanoma Combo Shows Positive Overall Survival Data,LLY,https://www.benzinga.com/general/biotech/18/02/11150091/arrays-melanoma-combo-shows-positive-overall-survival-data,Zacks,,,,0,0,127d01f3-a144-4757-909e-94511106c0dd
2018-02-07T08:00:00.000+08:00,Array's Melanoma Combo Shows Positive Overall Survival Data,LLY,https://www.benzinga.com/general/biotech/18/02/11150091/arrays-melanoma-combo-shows-positive-overall-survival-data,Zacks,,,,0,0,3316f378-6fa1-4e98-aaae-03d92f8e0dc1
2018-01-31T08:00:00.000+08:00,"Treasury Bounce, Boeing Results Appear To Give Slumping Market New Life",LLY,https://www.benzinga.com/news/earnings/18/01/11109382/treasury-bounce-boeing-results-appear-to-give-slumping-market-new-life,JJ Kinahan,,,,0,0,77fe97c9-c0f4-4a2b-8836-3203f7382d04
2018-01-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus,LLY,https://www.benzinga.com/news/18/01/11107803/a-peek-into-the-markets-u-s-stock-futures-rise-fed-decision-in-focus,Lisa Levin,,,,0,0,ad826695-37cf-49c0-ae18-92d9b1696853
2018-01-31T08:00:00.000+08:00,"Eli Lilly Raises FY18 Adj. EPS Guidance From $4.60-$4.70 to $4.81-$4.91 vs $4.68 Est., Reaffirms Sales Guidance",LLY,https://www.benzinga.com/news/guidance/18/01/11107399/eli-lilly-raises-fy18-adj-eps-guidance-from-4-60-4-70-to-4-81-4-91-vs-4,Paul Quintaro,,,,0,0,cc438a49-2275-4170-8b8c-2161a39549f6
2018-01-31T08:00:00.000+08:00,"Eli Lilly Reports Q4 Adj. EPS $1.14 vs $1.07 Est., Sales $6.16B vs $5.94B Est.",LLY,https://www.benzinga.com/news/earnings/18/01/11107398/eli-lilly-reports-q4-adj-eps-1-14-vs-1-07-est-sales-6-16b-vs-5-94b-est,Paul Quintaro,,,,0,0,b42e5546-5362-4037-993b-7d3a02d3fd88
2018-01-31T08:00:00.000+08:00,"15 Stocks To Watch For January 31, 2018",LLY,https://www.benzinga.com/news/earnings/18/01/11107068/15-stocks-to-watch-for-january-31-2018,Lisa Levin,,,,0,0,d786355d-f8d2-4db0-90b0-281ea02f37a6
2018-01-31T08:00:00.000+08:00,"Earnings Scheduled For January 31, 2018",LLY,https://www.benzinga.com/news/earnings/18/01/11107039/earnings-scheduled-for-january-31-2018,Lisa Levin,,,,0,0,c284a70c-564d-486c-b1f3-a1edb24db8d2
2018-01-31T08:00:00.000+08:00,"Treasury Bounce, Boeing Results Appear To Give Slumping Market New Life",LLY,https://www.benzinga.com/news/earnings/18/01/11109382/treasury-bounce-boeing-results-appear-to-give-slumping-market-new-life,JJ Kinahan,,,,0,0,9b2805d4-3d67-4047-9c8d-5cef8f8d90bc
2018-01-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus,LLY,https://www.benzinga.com/news/18/01/11107803/a-peek-into-the-markets-u-s-stock-futures-rise-fed-decision-in-focus,Lisa Levin,,,,0,0,fe6fd0e9-5039-4c03-8844-e40ce32fcfce
2018-01-31T08:00:00.000+08:00,"Eli Lilly Raises FY18 Adj. EPS Guidance From $4.60-$4.70 to $4.81-$4.91 vs $4.68 Est., Reaffirms Sales Guidance",LLY,https://www.benzinga.com/news/guidance/18/01/11107399/eli-lilly-raises-fy18-adj-eps-guidance-from-4-60-4-70-to-4-81-4-91-vs-4,Paul Quintaro,,,,0,0,f4c34ff1-219f-4363-a5ee-e64f62040450
2018-01-31T08:00:00.000+08:00,"Eli Lilly Reports Q4 Adj. EPS $1.14 vs $1.07 Est., Sales $6.16B vs $5.94B Est.",LLY,https://www.benzinga.com/news/earnings/18/01/11107398/eli-lilly-reports-q4-adj-eps-1-14-vs-1-07-est-sales-6-16b-vs-5-94b-est,Paul Quintaro,,,,0,0,6ed60911-2602-41d9-9992-ebe8b8dc3727
2018-01-31T08:00:00.000+08:00,"15 Stocks To Watch For January 31, 2018",LLY,https://www.benzinga.com/news/earnings/18/01/11107068/15-stocks-to-watch-for-january-31-2018,Lisa Levin,,,,0,0,4449dc18-02cc-4461-a7b1-b36cbc2448c4
2018-01-31T08:00:00.000+08:00,"Earnings Scheduled For January 31, 2018",LLY,https://www.benzinga.com/news/earnings/18/01/11107039/earnings-scheduled-for-january-31-2018,Lisa Levin,,,,0,0,5acc649c-68f7-43cc-a0e0-7f0ddd0d929b
2018-01-30T08:00:00.000+08:00,Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses,LLY,https://www.benzinga.com/news/18/01/11101992/hang-on-rate-fears-in-focus-as-futures-point-lower-after-mondays-big-losses,JJ Kinahan,,,,0,0,1925aa49-7bd9-4996-b8c3-6fd4e4af2139
2018-01-30T08:00:00.000+08:00,Hang On: Rate Fears In Focus As Futures Point Lower After Monday's Big Losses,LLY,https://www.benzinga.com/news/18/01/11101992/hang-on-rate-fears-in-focus-as-futures-point-lower-after-mondays-big-losses,JJ Kinahan,,,,0,0,299f5a08-9b60-41dc-a1ae-c76168c00632
2018-01-29T08:00:00.000+08:00,"The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines",LLY,https://www.benzinga.com/news/earnings/18/01/11094350/the-week-ahead-big-tech-earnings-fed-rate-decision-likely-to-dominate-h,Taylor Cox,,,,0,0,07793b62-b08c-4a19-8357-089e858b78b1
2018-01-29T08:00:00.000+08:00,"Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11093344/analyst-radius-health-could-advance-50-with-osteoporosi,Shanthi Rexaline,,,,0,0,b49dfd32-2596-4e58-8a74-29be867e56f6
2018-01-29T08:00:00.000+08:00,"PFE, LLY, MRK Write Up 'Scripts For Q4",LLY,https://www.benzinga.com/news/earnings/18/01/11094446/pfe-lly-mrk-write-up-scripts-for-q4,JJ Kinahan,,,,0,0,49c188da-737c-4a80-8ead-b58ab6f300b5
2018-01-29T08:00:00.000+08:00,"Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data",LLY,https://www.benzinga.com/news/earnings/18/01/11093826/fed-earnings-are-meaty-filling-between-slices-of-job-price-data,JJ Kinahan,,,,0,0,4b841b9d-16ab-410d-81f7-fe6f81da4f28
2018-01-29T08:00:00.000+08:00,"The Week Ahead: Big Tech Earnings, Fed Rate Decision Likely To Dominate Headlines",LLY,https://www.benzinga.com/news/earnings/18/01/11094350/the-week-ahead-big-tech-earnings-fed-rate-decision-likely-to-dominate-h,Taylor Cox,,,,0,0,dae82937-004c-4c36-8c4a-486a1d6546e1
2018-01-29T08:00:00.000+08:00,"Analyst: Radius Health Could Advance 50% With Osteoporosis Treatment, Breast Cancer Pipeline",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11093344/analyst-radius-health-could-advance-50-with-osteoporosi,Shanthi Rexaline,,,,0,0,e25bf634-23f1-403a-a75c-f39c86ae5146
2018-01-29T08:00:00.000+08:00,"PFE, LLY, MRK Write Up 'Scripts For Q4",LLY,https://www.benzinga.com/news/earnings/18/01/11094446/pfe-lly-mrk-write-up-scripts-for-q4,JJ Kinahan,,,,0,0,4c578d04-476c-4e17-acc8-3ceaa7905b49
2018-01-29T08:00:00.000+08:00,"Fed, Earnings Are Meaty Filling Between Slices Of Job, Price Data",LLY,https://www.benzinga.com/news/earnings/18/01/11093826/fed-earnings-are-meaty-filling-between-slices-of-job-price-data,JJ Kinahan,,,,0,0,90d2f020-5210-4a09-92d0-1bdff8096959
2018-01-26T08:00:00.000+08:00,Jefferies On Gilead: 'We See Better Days Ahead',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11087168/jefferies-on-gilead-we-see-better-days-ahead,Elizabeth Balboa,,,,0,0,558652f6-99ad-445f-a8a0-e76890a14f64
2018-01-26T08:00:00.000+08:00,Jefferies On Gilead: 'We See Better Days Ahead',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11087168/jefferies-on-gilead-we-see-better-days-ahead,Elizabeth Balboa,,,,0,0,49c84c0f-8a68-44ad-b53b-9d8a47b674c4
2018-01-25T08:00:00.000+08:00,Lilly receives EU Marketing Authorisation for Taltz for the Treatment of Active Psoriatic Arthritis,LLY,https://www.benzinga.com/news/18/01/11077489/lilly-receives-eu-marketing-authorisation-for-taltz-for-the-treatment-of-active-,Charles Gross,,,,0,0,5564e0ac-72e7-4306-b208-97cdaf34a2cf
2018-01-25T08:00:00.000+08:00,Lilly receives EU Marketing Authorisation for Taltz for the Treatment of Active Psoriatic Arthritis,LLY,https://www.benzinga.com/news/18/01/11077489/lilly-receives-eu-marketing-authorisation-for-taltz-for-the-treatment-of-active-,Charles Gross,,,,0,0,55f85465-40fd-4c72-9890-d41e4eecff60
2018-01-22T08:00:00.000+08:00,Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11059871/eli-lillys-challenges-leaves-credit-suisse-with-a-sour-,Jayson Derrick,,,,0,0,01e9d388-9a08-4705-a385-c295eb140d69
2018-01-22T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For January 22, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/01/11059799/benzingas-top-upgrades-downgrades-for-january-22-2018,Lisa Levin,,,,0,0,6ce8d22b-bb01-4389-871a-8c31ecb99355
2018-01-22T08:00:00.000+08:00,"The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl",LLY,https://www.benzinga.com/news/18/01/11058793/the-market-in-5-minutes-celgene-buys-juno-netflix-earnings-preview-eagles-and-pa,Benzinga Newsdesk,,,,0,0,72e5c048-4a25-4f99-bee5-ddcb14d4f606
2018-01-22T08:00:00.000+08:00,Eli Lilly Announces FDA Approval of Credelio to Treat and Protect Against Ticks and Fleas,LLY,https://www.benzinga.com/news/18/01/11058673/eli-lilly-announces-fda-approval-of-credelio-to-treat-and-protect-against-ticks-,Paul Quintaro,,,,0,0,4e809dc9-0fff-4a74-8ee0-d056734a69c2
2018-01-22T08:00:00.000+08:00,Credit Suisse Downgrades Eli Lilly to Underperform,LLY,https://www.benzinga.com/news/18/01/11058296/credit-suisse-downgrades-eli-lilly-to-underperform,Paul Quintaro,,,,0,0,91e4853b-10b5-4921-907a-1634663b4b87
2018-01-22T08:00:00.000+08:00,Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11059871/eli-lillys-challenges-leaves-credit-suisse-with-a-sour-,Jayson Derrick,,,,0,0,a4416308-8018-4ebf-b59b-f105bc91abb4
2018-01-22T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For January 22, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/01/11059799/benzingas-top-upgrades-downgrades-for-january-22-2018,Lisa Levin,,,,0,0,ba1a500d-019f-4dd3-8193-c4e9d505630f
2018-01-22T08:00:00.000+08:00,"The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl",LLY,https://www.benzinga.com/news/18/01/11058793/the-market-in-5-minutes-celgene-buys-juno-netflix-earnings-preview-eagles-and-pa,Benzinga Newsdesk,,,,0,0,78b530c6-708f-4442-841f-5a9568b8e818
2018-01-22T08:00:00.000+08:00,Eli Lilly Announces FDA Approval of Credelio to Treat and Protect Against Ticks and Fleas,LLY,https://www.benzinga.com/news/18/01/11058673/eli-lilly-announces-fda-approval-of-credelio-to-treat-and-protect-against-ticks-,Paul Quintaro,,,,0,0,3bfba2ae-15f8-4898-8fff-8a34d9c743ad
2018-01-22T08:00:00.000+08:00,Credit Suisse Downgrades Eli Lilly to Underperform,LLY,https://www.benzinga.com/news/18/01/11058296/credit-suisse-downgrades-eli-lilly-to-underperform,Paul Quintaro,,,,0,0,49f2d07d-250a-4ff1-bb73-a5febb8db347
2018-01-20T08:00:00.000+08:00,"Benzinga's Weekly Bulls & Bears: Apple, Eli Lilly, GE, Nike And More",LLY,https://www.benzinga.com/trading-ideas/18/01/11057025/benzingas-weekly-bulls-bears-apple-eli-lilly-ge-nike-and-more,Nelson Hem,,,,0,0,cdf7cd84-ad03-4821-b84d-7b4d7535b1d3
2018-01-20T08:00:00.000+08:00,"Benzinga's Weekly Bulls & Bears: Apple, Eli Lilly, GE, Nike And More",LLY,https://www.benzinga.com/trading-ideas/18/01/11057025/benzingas-weekly-bulls-bears-apple-eli-lilly-ge-nike-and-more,Nelson Hem,,,,0,0,2ecacc17-8028-44b5-94e7-94284223932f
2018-01-19T08:00:00.000+08:00,The Top 10 Value Stocks In The S&P 500,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/01/11053516/the-top-10-value-stocks-in-the-s-p-500,Matt Hogan - Finbox.io,,,,0,0,6c07b311-58d7-42db-8613-2b27125db366
2018-01-19T08:00:00.000+08:00,The Top 10 Value Stocks In The S&P 500,LLY,https://www.benzinga.com/trading-ideas/long-ideas/18/01/11053516/the-top-10-value-stocks-in-the-s-p-500,Matt Hogan - Finbox.io,,,,0,0,63581df1-0c7f-48a2-b35e-1ea87bec54fb
2018-01-16T08:00:00.000+08:00,"Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11034244/eli-lillys-risks-could-be-underappreciated-goldman-sach,Jayson Derrick,,,,0,0,98621df4-4b78-48b9-b831-109afc289fa7
2018-01-16T08:00:00.000+08:00,Goldman Sachs Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/01/11032947/goldman-sachs-downgrades-eli-lilly-to-neutral,Eddie Staley,,,,0,0,f4b1a131-b528-4149-a0b0-2b7f3ba2cc60
2018-01-16T08:00:00.000+08:00,Innventure and Eli Lilly's Elanco Announce Strategic Initiative to Commercialize Disruptive Technologies for Animal Health,LLY,https://www.benzinga.com/news/contracts/18/01/11032593/innventure-and-eli-lillys-elanco-announce-strategic-initiative-to-comm,Eddie Staley,,,,0,0,f6a5f91f-2b8b-44d2-9272-685915b1ecca
2018-01-16T08:00:00.000+08:00,"Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11034244/eli-lillys-risks-could-be-underappreciated-goldman-sach,Jayson Derrick,,,,0,0,b8101fa1-cfdc-47d5-b014-30e9a3ebd28c
2018-01-16T08:00:00.000+08:00,Goldman Sachs Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/18/01/11032947/goldman-sachs-downgrades-eli-lilly-to-neutral,Eddie Staley,,,,0,0,0825a224-116f-4ca7-b06b-b44f6228ed82
2018-01-16T08:00:00.000+08:00,Innventure and Eli Lilly's Elanco Announce Strategic Initiative to Commercialize Disruptive Technologies for Animal Health,LLY,https://www.benzinga.com/news/contracts/18/01/11032593/innventure-and-eli-lillys-elanco-announce-strategic-initiative-to-comm,Eddie Staley,,,,0,0,4a9a0bd8-4b7e-48cb-ae5b-14b9ff78b001
2018-01-11T08:00:00.000+08:00,"BZ NOTE: Eli Lilly's PDUFA Date For Amemaciclib-MONARCH 1 & 2 Estimated At Jan. 10 By Biotech Research Site; However, That NDA Was Approved Oct. 4, Separate NDA For This Drug Remains Under Review With Estimated Action In April",LLY,https://www.benzinga.com/general/biotech/18/01/11021042/bz-note-eli-lillys-pdufa-date-for-amemaciclib-monarch-1-2-estimated-a,Hal Lindon,,,,0,0,2231f5f5-1398-4cc6-92ab-039ebf3c988b
2018-01-11T08:00:00.000+08:00,"BZ NOTE: Eli Lilly's PDUFA Date For Amemaciclib-MONARCH 1 & 2 Estimated At Jan. 10 By Biotech Research Site; However, That NDA Was Approved Oct. 4, Separate NDA For This Drug Remains Under Review With Estimated Action In April",LLY,https://www.benzinga.com/general/biotech/18/01/11021042/bz-note-eli-lillys-pdufa-date-for-amemaciclib-monarch-1-2-estimated-a,Hal Lindon,,,,0,0,2c4c7fd3-5801-41f6-9959-bb59057c4905
2018-01-08T08:00:00.000+08:00,Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area,LLY,https://www.benzinga.com/general/biotech/18/01/11000497/alzheimers-takes-another-hit-as-pfizer-ends-research-in-the-area,Zacks,,,,0,0,e03886cb-2ed5-4cd5-b20b-9aef4fd3e112
2018-01-08T08:00:00.000+08:00,"The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In",LLY,https://www.benzinga.com/news/18/01/11001477/the-week-ahead-conferences-take-center-stage-earnings-begin-to-trickle-in,Taylor Cox,,,,0,0,892f00ec-66f3-47b7-9207-2f9d2c05a119
2018-01-08T08:00:00.000+08:00,Alzheimer's Takes Another Hit As Pfizer Ends Research In The Area,LLY,https://www.benzinga.com/general/biotech/18/01/11000497/alzheimers-takes-another-hit-as-pfizer-ends-research-in-the-area,Zacks,,,,0,0,cc9fd3b5-6d14-4ce6-a665-0037716b2a59
2018-01-08T08:00:00.000+08:00,"The Week Ahead: Conferences Take Center Stage, Earnings Begin To Trickle In",LLY,https://www.benzinga.com/news/18/01/11001477/the-week-ahead-conferences-take-center-stage-earnings-begin-to-trickle-in,Taylor Cox,,,,0,0,1ce381b9-0dca-4849-9bea-43481c83e32c
2018-01-05T08:00:00.000+08:00,"Argus Shares Eli Lilly's Optimism, Upgrades To Buy",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/10995058/argus-shares-eli-lillys-optimism-upgrades-to-buy,Elizabeth Balboa,,,,0,0,76e77f3b-f155-434f-9c07-17e60d51cfbe
2018-01-05T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For January 5, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/01/10993786/benzingas-top-upgrades-downgrades-for-january-5-2018,Lisa Levin,,,,0,0,95b6b68a-710f-404e-a634-f27568087ab1
2018-01-05T08:00:00.000+08:00,"Eli Lilly To Report Q4 Earnings On Wed., Jan. 31 Before Market Open",LLY,https://www.benzinga.com/news/earnings/18/01/10993723/eli-lilly-to-report-q4-earnings-on-wed-jan-31-before-market-open,Paul Quintaro,,,,0,0,bde219b4-36d6-48bd-962b-03ab6b9ef759
2018-01-05T08:00:00.000+08:00,Argus Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/18/01/10993237/argus-upgrades-eli-lilly-to-buy,Eddie Staley,,,,0,0,ef378b6c-878d-40a8-9bdb-23ffe1e9e5ef
2018-01-05T08:00:00.000+08:00,"Argus Shares Eli Lilly's Optimism, Upgrades To Buy",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/10995058/argus-shares-eli-lillys-optimism-upgrades-to-buy,Elizabeth Balboa,,,,0,0,f2e1859d-6116-43bb-b594-898b2899a620
2018-01-05T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For January 5, 2018",LLY,https://www.benzinga.com/analyst-ratings/upgrades/18/01/10993786/benzingas-top-upgrades-downgrades-for-january-5-2018,Lisa Levin,,,,0,0,89e69c40-3909-44b4-88cf-d0cf0d23a05b
2018-01-05T08:00:00.000+08:00,"Eli Lilly To Report Q4 Earnings On Wed., Jan. 31 Before Market Open",LLY,https://www.benzinga.com/news/earnings/18/01/10993723/eli-lilly-to-report-q4-earnings-on-wed-jan-31-before-market-open,Paul Quintaro,,,,0,0,f35ee7bc-0754-4ddc-813c-8d87ac41dfd2
2018-01-05T08:00:00.000+08:00,Argus Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/18/01/10993237/argus-upgrades-eli-lilly-to-buy,Eddie Staley,,,,0,0,24295a88-271c-4c3a-9d22-ff84895d01b8
2018-01-04T08:00:00.000+08:00,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam",LLY,https://www.benzinga.com/general/biotech/18/01/10985998/goldman-sachs-healthcare-ceos-unscripted-conference-taking-place-toda,Hal Lindon,,,,0,0,53831a44-a435-4e0a-8c31-1eb3a80f8217
2018-01-04T08:00:00.000+08:00,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam",LLY,https://www.benzinga.com/general/biotech/18/01/10985998/goldman-sachs-healthcare-ceos-unscripted-conference-taking-place-toda,Hal Lindon,,,,0,0,defc9adc-c10a-4572-a8c8-14f40848ac17
2017-12-21T08:00:00.000+08:00,"PETA Leverages Shareholder Power, Calls On SeaWorld To End All Animal Breeding",LLY,https://www.benzinga.com/news/17/12/10938703/peta-leverages-shareholder-power-calls-on-seaworld-to-end-all-animal-breeding,Elizabeth Balboa,,,,0,0,e0fe4af6-e22c-4b49-97c5-3a72b720343e
2017-12-21T08:00:00.000+08:00,"PETA Leverages Shareholder Power, Calls On SeaWorld To End All Animal Breeding",LLY,https://www.benzinga.com/news/17/12/10938703/peta-leverages-shareholder-power-calls-on-seaworld-to-end-all-animal-breeding,Elizabeth Balboa,,,,0,0,db4d9112-91f6-4afc-b673-7333b9b46672
2017-12-20T08:00:00.000+08:00,3 Biotech Pipeline Areas To Keep An Eye On In 2018,LLY,https://www.benzinga.com/general/biotech/17/12/10939349/3-biotech-pipeline-areas-to-keep-an-eye-on-in-2018,Zacks,,,,0,0,df37cafa-a214-4602-b7cb-3e7fdeae3612
2017-12-20T08:00:00.000+08:00,3 Biotech Pipeline Areas To Keep An Eye On In 2018,LLY,https://www.benzinga.com/general/biotech/17/12/10939349/3-biotech-pipeline-areas-to-keep-an-eye-on-in-2018,Zacks,,,,0,0,d2c6ec13-8bb2-4bce-bb07-4dd932a5f2a6
2017-12-19T08:00:00.000+08:00,Entrega to Receive $5M Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides,LLY,https://www.benzinga.com/news/17/12/10931579/entrega-to-receive-5m-investment-from-lilly-to-advance-proprietary-oral-delivery,Charles Gross,,,,0,0,e02d921b-94ca-4da7-8214-a2134660cec7
2017-12-19T08:00:00.000+08:00,Entrega to Receive $5M Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides,LLY,https://www.benzinga.com/news/17/12/10931579/entrega-to-receive-5m-investment-from-lilly-to-advance-proprietary-oral-delivery,Charles Gross,,,,0,0,dee0723e-6017-4e96-86e9-6a86aa6391c7
2017-12-18T08:00:00.000+08:00,Eli Lilly Shares Volatile Over Last Few Mins. As Traders Circulate Chatter Co. Hired Bankers Related To Consideration Of Alternatives For Its Animal Health Unit,LLY,https://www.benzinga.com/news/17/12/10927456/eli-lilly-shares-volatile-over-last-few-mins-as-traders-circulate-chatter-co-hir,Paul Quintaro,,,,0,0,9fde0c42-9c5a-4f12-aedb-20a5c7fb8b89
2017-12-18T08:00:00.000+08:00,Eli Lilly Shares Volatile Over Last Few Mins. As Traders Circulate Chatter Co. Hired Bankers Related To Consideration Of Alternatives For Its Animal Health Unit,LLY,https://www.benzinga.com/news/17/12/10927456/eli-lilly-shares-volatile-over-last-few-mins-as-traders-circulate-chatter-co-hir,Paul Quintaro,,,,0,0,efceba18-0ebb-4867-88d2-63a8087d60cf
2017-12-15T08:00:00.000+08:00,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",LLY,https://www.benzinga.com/media/cnbc/17/12/10919102/lightning-round-jim-cramer-shares-his-thoughts-on-t-mobile-electronic-arts,Craig Jones,,,,0,0,d01be9f2-06d3-4f99-b962-904448de3436
2017-12-15T08:00:00.000+08:00,"Lightning Round: Jim Cramer Shares His Thoughts On T-Mobile, Electronic Arts, And More",LLY,https://www.benzinga.com/media/cnbc/17/12/10919102/lightning-round-jim-cramer-shares-his-thoughts-on-t-mobile-electronic-arts,Craig Jones,,,,0,0,d69fc393-4d77-4c14-aa95-f8569eea73c0
2017-12-14T08:00:00.000+08:00,"Eli Lilly Issues Guidance For 2018, New Drugs To Drive Top Line",LLY,https://www.benzinga.com/general/biotech/17/12/10915878/eli-lilly-issues-guidance-for-2018-new-drugs-to-drive-top-line,Zacks,,,,0,0,2e510082-2a04-4a51-bb32-87aa7ce8614d
2017-12-14T08:00:00.000+08:00,"Eli Lilly Issues Guidance For 2018, New Drugs To Drive Top Line",LLY,https://www.benzinga.com/general/biotech/17/12/10915878/eli-lilly-issues-guidance-for-2018-new-drugs-to-drive-top-line,Zacks,,,,0,0,7663ef35-6c70-4910-ad70-ea5d5e891c96
2017-12-13T08:00:00.000+08:00,Eli Lilly Sees FY2018 EPS $4.60-4.70 vs $4.64 Est; Sees Sales $23.0B-23.50B vs $23.10B Est,LLY,https://www.benzinga.com/news/17/12/10907977/eli-lilly-sees-fy2018-eps-4-60-4-70-vs-4-64-est-sees-sales-23-0b-23-50b-vs-23-10,Hal Lindon,,,,0,0,057df460-5757-458b-8ab2-dc08b763e58f
2017-12-13T08:00:00.000+08:00,Eli Lilly Sees FY2017 EPS $4.15-4.25 vs $4.21 Est,LLY,https://www.benzinga.com/news/17/12/10907976/eli-lilly-sees-fy2017-eps-4-15-4-25-vs-4-21-est,Hal Lindon,,,,0,0,f2721ef7-b03e-44ad-86c1-3819de90b745
2017-12-13T08:00:00.000+08:00,Eli Lilly Sees FY2018 EPS $4.60-4.70 vs $4.64 Est; Sees Sales $23.0B-23.50B vs $23.10B Est,LLY,https://www.benzinga.com/news/17/12/10907977/eli-lilly-sees-fy2018-eps-4-60-4-70-vs-4-64-est-sees-sales-23-0b-23-50b-vs-23-10,Hal Lindon,,,,0,0,3a012c0f-ad37-40a7-9a18-3e3502af7ae7
2017-12-13T08:00:00.000+08:00,Eli Lilly Sees FY2017 EPS $4.15-4.25 vs $4.21 Est,LLY,https://www.benzinga.com/news/17/12/10907976/eli-lilly-sees-fy2017-eps-4-15-4-25-vs-4-21-est,Hal Lindon,,,,0,0,0a29a9ff-0882-41ae-9994-fe368a0e4e05
2017-12-11T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.52/Share to $0.5625/Share,LLY,https://www.benzinga.com/trading-ideas/dividends/17/12/10899169/eli-lilly-raises-qtr-dividend-from-0-52share-to-0-5625share,Hal Lindon,,,,0,0,4e479e85-6dd5-4af0-8c6c-cafa1e76a117
2017-12-11T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/17/12/10895964/a-peek-into-the-markets-u-s-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,0,0,1f8c1b23-b9b3-42b3-ac9f-2365aac962e5
2017-12-11T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted BLA For Galcanezumab Review For Prevention Of Migraine In Adults,LLY,https://www.benzinga.com/news/fda/17/12/10895775/eli-lilly-reports-fda-accepted-bla-for-galcanezumab-review-for-prevention-of,Paul Quintaro,,,,0,0,a985dc53-49a2-4d73-a963-39c1929959e2
2017-12-11T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend From $0.52/Share to $0.5625/Share,LLY,https://www.benzinga.com/trading-ideas/dividends/17/12/10899169/eli-lilly-raises-qtr-dividend-from-0-52share-to-0-5625share,Hal Lindon,,,,0,0,909e3c3b-d1b3-4753-890c-cb019b5d965b
2017-12-11T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/17/12/10895964/a-peek-into-the-markets-u-s-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,,,,0,0,78fb708f-b426-4335-bc1e-887239100d88
2017-12-11T08:00:00.000+08:00,Eli Lilly Reports FDA Accepted BLA For Galcanezumab Review For Prevention Of Migraine In Adults,LLY,https://www.benzinga.com/news/fda/17/12/10895775/eli-lilly-reports-fda-accepted-bla-for-galcanezumab-review-for-prevention-of,Paul Quintaro,,,,0,0,f9f1d2bf-6f13-4a3d-9a1a-57c9726feb4f
2017-12-08T08:00:00.000+08:00,"Eli Lilly Reports Top-Line Results From CYRAMZA Phase 3 Study: Met Endpoint Of PFS, But Did Not Improve A Secondary Endpoint Of Overall Survival",LLY,https://www.benzinga.com/news/fda/17/12/10893730/eli-lilly-reports-top-line-results-from-cyramza-phase-3-study-met-endpoint-o,Paul Quintaro,,,,0,0,2c98a163-82ff-4dcc-ba53-b1c50db7a0be
2017-12-08T08:00:00.000+08:00,"Eli Lilly Reports Top-Line Results From CYRAMZA Phase 3 Study: Met Endpoint Of PFS, But Did Not Improve A Secondary Endpoint Of Overall Survival",LLY,https://www.benzinga.com/news/fda/17/12/10893730/eli-lilly-reports-top-line-results-from-cyramza-phase-3-study-met-endpoint-o,Paul Quintaro,,,,0,0,60a50e20-92d3-4e88-b8fb-2068fda6244e
2017-12-06T08:00:00.000+08:00,"Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition",LLY,https://www.benzinga.com/news/contracts/17/12/10878747/juno-therapeutics-signs-licensing-agreements-with-lilly-oncotracker-an,Eddie Staley,,,,0,0,51141346-231e-4c9d-89ec-7134d87e2b71
2017-12-06T08:00:00.000+08:00,"Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition",LLY,https://www.benzinga.com/news/contracts/17/12/10878747/juno-therapeutics-signs-licensing-agreements-with-lilly-oncotracker-an,Eddie Staley,,,,0,0,cf10f312-65bf-4fbf-bce3-8f70e894c41c
2017-12-04T08:00:00.000+08:00,Eli Lilly's Taltz Gets Approval For Label Expansion in US,LLY,https://www.benzinga.com/general/biotech/17/12/10866077/eli-lillys-taltz-gets-approval-for-label-expansion-in-us,Zacks,,,,0,0,7b9061c8-3bc4-4074-a587-c5b112297f58
2017-12-04T08:00:00.000+08:00,Eli Lilly's Taltz Gets Approval For Label Expansion in US,LLY,https://www.benzinga.com/general/biotech/17/12/10866077/eli-lillys-taltz-gets-approval-for-label-expansion-in-us,Zacks,,,,0,0,c6376155-93ce-4e44-8eb8-97b1db3cb9ed
2017-12-01T08:00:00.000+08:00,Eli Lilly Receives FDA Approval For Taltz,LLY,https://www.benzinga.com/general/biotech/17/12/10862229/eli-lilly-receives-fda-approval-for-taltz,Hal Lindon,,,,0,0,32096147-f2ef-4b44-82f0-7690fb332ff0
2017-12-01T08:00:00.000+08:00,Eli Lilly Receives FDA Approval For Taltz,LLY,https://www.benzinga.com/general/biotech/17/12/10862229/eli-lilly-receives-fda-approval-for-taltz,Hal Lindon,,,,0,0,796350ab-f9d9-4a16-82a1-6f39cec34c94
2017-11-27T08:00:00.000+08:00,Lilly Option Alert: Dec 15 $81 Calls Sweep (27) at the Ask: 639 @ $3.847 vs 0 OI; Ref=$84.7,LLY,https://www.benzinga.com/markets/options/17/11/10833716/lilly-option-alert-dec-15-81-calls-sweep-27-at-the-ask-639-3-847-vs-0,Charles Gross,,,,0,0,6a05f3ee-a97f-4516-b966-fe6d22b1b13c
2017-11-27T08:00:00.000+08:00,Lilly Option Alert: Dec 15 $81 Calls Sweep (27) at the Ask: 639 @ $3.847 vs 0 OI; Ref=$84.7,LLY,https://www.benzinga.com/markets/options/17/11/10833716/lilly-option-alert-dec-15-81-calls-sweep-27-at-the-ask-639-3-847-vs-0,Charles Gross,,,,0,0,8809377a-8bc4-4245-8efb-cef87f5e9c28
2017-11-21T08:00:00.000+08:00,"Morgan Stanley Earlier Maintained Equal-Weight Rating on Eli Lilly, Raised Price Target from $86.00 to $90.00",LLY,https://www.benzinga.com/news/17/11/10819373/morgan-stanley-earlier-maintained-equal-weight-rating-on-eli-lilly-raised-price-,Paul Quintaro,,,,0,0,896ecf6d-ac97-4903-babf-c2c88fbca313
2017-11-21T08:00:00.000+08:00,Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem,LLY,https://www.benzinga.com/news/17/11/10817894/dexcom-reports-development-agreement-with-lilly-to-integrate-dexcom-cgm-into-con,Eddie Staley,,,,0,0,5d4f8595-3326-48c2-b1f0-46e0de65ef64
2017-11-21T08:00:00.000+08:00,"Morgan Stanley Earlier Maintained Equal-Weight Rating on Eli Lilly, Raised Price Target from $86.00 to $90.00",LLY,https://www.benzinga.com/news/17/11/10819373/morgan-stanley-earlier-maintained-equal-weight-rating-on-eli-lilly-raised-price-,Paul Quintaro,,,,0,0,5f8e1555-0082-42a2-aab2-bca6bdd1570f
2017-11-21T08:00:00.000+08:00,Dexcom Reports Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem,LLY,https://www.benzinga.com/news/17/11/10817894/dexcom-reports-development-agreement-with-lilly-to-integrate-dexcom-cgm-into-con,Eddie Staley,,,,0,0,74ee4d70-56cd-489d-800d-b50f5d39ca42
2017-11-14T08:00:00.000+08:00,Who Is The Former Pharma Exec Trump Nominated To Lead HHS?,LLY,https://www.benzinga.com/news/17/11/10780202/who-is-the-former-pharma-exec-trump-nominated-to-lead-hhs,Jayson Derrick,,,,0,0,a1c74b8e-e2c7-4bfb-8aef-333e479f33cc
2017-11-14T08:00:00.000+08:00,Who Is The Former Pharma Exec Trump Nominated To Lead HHS?,LLY,https://www.benzinga.com/news/17/11/10780202/who-is-the-former-pharma-exec-trump-nominated-to-lead-hhs,Jayson Derrick,,,,0,0,7bd7cc2d-6e2a-470a-9c99-13a383a1a78a
2017-11-13T08:00:00.000+08:00,Stocks Going Ex Dividend The Third Week of November,LLY,https://www.benzinga.com/news/17/11/10766231/stocks-going-ex-dividend-the-third-week-of-november,Fred Fuld,,,,0,0,f0570037-66c5-462c-a800-8b9a92548260
2017-11-13T08:00:00.000+08:00,Stocks Going Ex Dividend The Third Week of November,LLY,https://www.benzinga.com/news/17/11/10766231/stocks-going-ex-dividend-the-third-week-of-november,Fred Fuld,,,,0,0,76c816f4-d3a9-41ac-92e8-178b7d926563
2017-11-10T08:00:00.000+08:00,Eli Lilly Thursday Reported Positive New Data On FORTEO Showing Statistically Significant Reduced Risk For Fractures,LLY,https://www.benzinga.com/general/biotech/17/11/10763761/eli-lilly-thursday-reported-positive-new-data-on-forteo-showing-stati,Hal Lindon,,,,0,0,0df93594-5df0-4d1e-99bc-f688d9af77ce
2017-11-10T08:00:00.000+08:00,Eli Lilly Thursday Reported Positive New Data On FORTEO Showing Statistically Significant Reduced Risk For Fractures,LLY,https://www.benzinga.com/general/biotech/17/11/10763761/eli-lilly-thursday-reported-positive-new-data-on-forteo-showing-stati,Hal Lindon,,,,0,0,1a9c5af9-b9fe-4d0f-aadc-6a9adbd825c6
2017-11-09T08:00:00.000+08:00,Pharma ETFs Down Post Q3 Earnings,LLY,https://www.benzinga.com/general/biotech/17/11/10757139/pharma-etfs-down-post-q3-earnings,Zacks,,,,0,0,f5848ff4-eb83-4cdc-9d4b-e334b61d5674
2017-11-09T08:00:00.000+08:00,Pharma ETFs Down Post Q3 Earnings,LLY,https://www.benzinga.com/general/biotech/17/11/10757139/pharma-etfs-down-post-q3-earnings,Zacks,,,,0,0,f493d3cf-ae15-4b4c-846e-67c32c8ddb50
2017-11-08T08:00:00.000+08:00,Eli Lilly Says Taltz Demonstrated Improvement In Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors; Also Showed Improvements In Secondary Measures At 52 Week Mark,LLY,https://www.benzinga.com/news/fda/17/11/10745999/eli-lilly-says-taltz-demonstrated-improvement-in-psoriatic-arthritis-for-pat,Paul Quintaro,,,,0,0,70b12359-865f-40cf-8316-1e27ef148b52
2017-11-08T08:00:00.000+08:00,Eli Lilly Says Taltz Demonstrated Improvement In Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors; Also Showed Improvements In Secondary Measures At 52 Week Mark,LLY,https://www.benzinga.com/news/fda/17/11/10745999/eli-lilly-says-taltz-demonstrated-improvement-in-psoriatic-arthritis-for-pat,Paul Quintaro,,,,0,0,d8cf306e-7d60-4d59-9cdc-701fa8d20fd0
2017-10-25T08:00:00.000+08:00,"Evercore Out With A Note Saying Teva Is Suing Eli Lilly, Firm Says They Found A Lawsuit Where Teva Believes Other CGRP Mabs Like Lilly Are Infringing On Its Intellectual Property",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10225463/evercore-out-with-a-note-saying-teva-is-suing-eli-lilly,Paul Quintaro,,,,0,0,ab06f40c-0d50-4f2d-82c8-cf091416b944
2017-10-25T08:00:00.000+08:00,"Evercore Out With A Note Saying Teva Is Suing Eli Lilly, Firm Says They Found A Lawsuit Where Teva Believes Other CGRP Mabs Like Lilly Are Infringing On Its Intellectual Property",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10225463/evercore-out-with-a-note-saying-teva-is-suing-eli-lilly,Paul Quintaro,,,,0,0,67072b1a-41f4-49e7-8e8a-6771283e130d
2017-10-24T08:00:00.000+08:00,14 Technical Levels Discussed On Tuesday's PreMarket Prep,LLY,https://www.benzinga.com/trading-ideas/technicals/17/10/10217298/14-technical-levels-discussed-on-tuesdays-premarket-prep,Spencer Israel,,,,0,0,2aa7c4c2-ab68-4f3e-a8ea-d27f8c7832c1
2017-10-24T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus",LLY,https://www.benzinga.com/news/17/10/10215835/a-peek-into-the-markets-u-s-stock-futures-gain-mcdonalds-general-motors-earnings,Lisa Levin,,,,0,0,b9d5aa56-4364-4037-b5bd-19451c326067
2017-10-24T08:00:00.000+08:00,"Eli Lilly Says it is Considering Strategic Alternatives for its Elanco Animal Health Unit, Including IPO or Sale",LLY,https://www.benzinga.com/news/17/10/10215500/eli-lilly-says-it-is-considering-strategic-alternatives-for-its-elanco-animal-he,Paul Quintaro,,,,0,0,64dab388-6eb2-4b18-9e9e-ccc54ba77837
2017-10-24T08:00:00.000+08:00,"Eli Lilly Q3 EPS $1.05 vs $1.03 Est., Sales $5.66B vs $5.52B Est.",LLY,https://www.benzinga.com/news/earnings/17/10/10215495/eli-lilly-q3-eps-1-05-vs-1-03-est-sales-5-66b-vs-5-52b-est,Paul Quintaro,,,,0,0,7a54a861-4767-4179-ba68-8668a3253907
2017-10-24T08:00:00.000+08:00,"12 Stocks To Watch For October 24, 2017",LLY,https://www.benzinga.com/news/earnings/17/10/10215244/12-stocks-to-watch-for-october-24-2017,Lisa Levin,,,,0,0,78f7ed37-f09e-4594-9910-d816475635d8
2017-10-24T08:00:00.000+08:00,"Earnings Scheduled For October 24, 2017",LLY,https://www.benzinga.com/news/earnings/17/10/10215183/earnings-scheduled-for-october-24-2017,Lisa Levin,,,,0,0,ccac064a-f38d-4091-abc5-dc5d54e087ce
2017-10-24T08:00:00.000+08:00,14 Technical Levels Discussed On Tuesday's PreMarket Prep,LLY,https://www.benzinga.com/trading-ideas/technicals/17/10/10217298/14-technical-levels-discussed-on-tuesdays-premarket-prep,Spencer Israel,,,,0,0,f90cfc5c-39a5-462f-872e-5014cdaaaddf
2017-10-24T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus",LLY,https://www.benzinga.com/news/17/10/10215835/a-peek-into-the-markets-u-s-stock-futures-gain-mcdonalds-general-motors-earnings,Lisa Levin,,,,0,0,6648f480-3fca-42c5-9417-17499c4a1738
2017-10-24T08:00:00.000+08:00,"Eli Lilly Says it is Considering Strategic Alternatives for its Elanco Animal Health Unit, Including IPO or Sale",LLY,https://www.benzinga.com/news/17/10/10215500/eli-lilly-says-it-is-considering-strategic-alternatives-for-its-elanco-animal-he,Paul Quintaro,,,,0,0,6261bebe-7391-4d4f-babe-9ace1701c966
2017-10-24T08:00:00.000+08:00,"Eli Lilly Q3 EPS $1.05 vs $1.03 Est., Sales $5.66B vs $5.52B Est.",LLY,https://www.benzinga.com/news/earnings/17/10/10215495/eli-lilly-q3-eps-1-05-vs-1-03-est-sales-5-66b-vs-5-52b-est,Paul Quintaro,,,,0,0,9f85c36f-af9e-496e-a0e9-73a60d57a12a
2017-10-24T08:00:00.000+08:00,"12 Stocks To Watch For October 24, 2017",LLY,https://www.benzinga.com/news/earnings/17/10/10215244/12-stocks-to-watch-for-october-24-2017,Lisa Levin,,,,0,0,8d4a068f-92b8-45a0-9d92-b3556453df42
2017-10-24T08:00:00.000+08:00,"Earnings Scheduled For October 24, 2017",LLY,https://www.benzinga.com/news/earnings/17/10/10215183/earnings-scheduled-for-october-24-2017,Lisa Levin,,,,0,0,fb049f0f-3f3f-4c9d-80b6-cb580bf621d2
2017-10-23T08:00:00.000+08:00,Buy Sierra Oncology Ahead Of A 2018 Full Of Catalysts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10211724/buy-sierra-oncology-ahead-of-a-2018-full-of-catalysts,Shanthi Rexaline,,,,0,0,98790386-9cf7-4259-b675-14d40dbe686f
2017-10-23T08:00:00.000+08:00,The Week Ahead: Earnings Season Starts In Earnest,LLY,https://www.benzinga.com/news/17/10/10210048/the-week-ahead-earnings-season-starts-in-earnest,Brent Slava,,,,0,0,c999a721-1490-4282-bfed-c92e3ba4b2a4
2017-10-23T08:00:00.000+08:00,Eli Lilly Announces a $72M Investment in Insulin Manufacturing in Indianapolis,LLY,https://www.benzinga.com/news/17/10/10209639/eli-lilly-announces-a-72m-investment-in-insulin-manufacturing-in-indianapolis,Paul Quintaro,,,,0,0,4788fd2d-a8e2-4969-b468-8f03c1035722
2017-10-23T08:00:00.000+08:00,Buy Sierra Oncology Ahead Of A 2018 Full Of Catalysts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10211724/buy-sierra-oncology-ahead-of-a-2018-full-of-catalysts,Shanthi Rexaline,,,,0,0,4d22d0b0-90ff-4c47-af5f-2cc85b95edaa
2017-10-23T08:00:00.000+08:00,The Week Ahead: Earnings Season Starts In Earnest,LLY,https://www.benzinga.com/news/17/10/10210048/the-week-ahead-earnings-season-starts-in-earnest,Brent Slava,,,,0,0,c7d209ca-3942-4951-915f-14bb8d4ce753
2017-10-23T08:00:00.000+08:00,Eli Lilly Announces a $72M Investment in Insulin Manufacturing in Indianapolis,LLY,https://www.benzinga.com/news/17/10/10209639/eli-lilly-announces-a-72m-investment-in-insulin-manufacturing-in-indianapolis,Paul Quintaro,,,,0,0,fc75f46e-38ca-4512-b965-bb04c49aa4d9
2017-10-20T08:00:00.000+08:00,Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday,LLY,https://www.benzinga.com/news/earnings/17/10/10206691/upcoming-earnings-heavy-equipment-maker-caterpillar-and-pharma-giant-el,JJ Kinahan,,,,0,0,7b00cc8e-0b6b-4b6b-bc0b-ea914d751570
2017-10-20T08:00:00.000+08:00,Upcoming Earnings: Heavy-Equipment Maker Caterpillar And Pharma Giant Eli Lilly Report On Tuesday,LLY,https://www.benzinga.com/news/earnings/17/10/10206691/upcoming-earnings-heavy-equipment-maker-caterpillar-and-pharma-giant-el,JJ Kinahan,,,,0,0,97cd7ef0-8e29-41bf-90f6-23052eee3917
2017-10-18T08:00:00.000+08:00,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10192709/boosted-by-keytruda-citi-upgrades-merck-to-buy-for-the-,Jayson Derrick,,,,0,0,51e40cc2-a5f4-4fba-8455-28f2b0ceb77b
2017-10-18T08:00:00.000+08:00,"Eli Lilly, CureVac Report Global Collaboration For Development Of mRNA Cancer Vaccines",LLY,https://www.benzinga.com/news/17/10/10191892/eli-lilly-curevac-report-global-collaboration-for-development-of-mrna-cancer-vac,Paul Quintaro,,,,0,0,dc1b8c62-89fc-489b-b935-7ab0e2152b91
2017-10-18T08:00:00.000+08:00,"Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10192709/boosted-by-keytruda-citi-upgrades-merck-to-buy-for-the-,Jayson Derrick,,,,0,0,fb3b543f-4024-4b1b-ba06-5c3ca2662dc0
2017-10-18T08:00:00.000+08:00,"Eli Lilly, CureVac Report Global Collaboration For Development Of mRNA Cancer Vaccines",LLY,https://www.benzinga.com/news/17/10/10191892/eli-lilly-curevac-report-global-collaboration-for-development-of-mrna-cancer-vac,Paul Quintaro,,,,0,0,2420d919-f83f-4f6f-bd01-a57412b91aa9
2017-10-16T08:00:00.000+08:00,Eli Lilly Gives an Update on its CYRAMZA Trial,LLY,https://www.benzinga.com/news/17/10/10180082/eli-lilly-gives-an-update-on-its-cyramza-trial,Paul Quintaro,,,,0,0,58b8fe83-6f1d-461e-bd24-97be85b91b11
2017-10-16T08:00:00.000+08:00,Eli Lilly Gives an Update on its CYRAMZA Trial,LLY,https://www.benzinga.com/news/17/10/10180082/eli-lilly-gives-an-update-on-its-cyramza-trial,Paul Quintaro,,,,0,0,b64ef569-5902-4ead-9a41-0230ab0924da
2017-10-13T08:00:00.000+08:00,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback",LLY,https://www.benzinga.com/general/biotech/17/10/10175753/pharma-stock-roundup-pfizer-mulls-options-for-consumer-healthcare-eli,Zacks,,,,0,0,b83a2b75-b05a-4ec0-873a-9827259362ff
2017-10-13T08:00:00.000+08:00,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback",LLY,https://www.benzinga.com/general/biotech/17/10/10175753/pharma-stock-roundup-pfizer-mulls-options-for-consumer-healthcare-eli,Zacks,,,,0,0,ab391e31-ba69-454a-b285-437a69509247
2017-10-12T08:00:00.000+08:00,Eli Lilly Granted Priority Review for Verzenio for Advanced Breast Cancer,LLY,https://www.benzinga.com/news/fda/17/10/10170118/eli-lilly-granted-priority-review-for-verzenio-for-advanced-breast-cancer,Paul Quintaro,,,,0,0,d131cb30-612d-4c7f-8493-2625641475f8
2017-10-12T08:00:00.000+08:00,Eli Lilly Granted Priority Review for Verzenio for Advanced Breast Cancer,LLY,https://www.benzinga.com/news/fda/17/10/10170118/eli-lilly-granted-priority-review-for-verzenio-for-advanced-breast-cancer,Paul Quintaro,,,,0,0,d1253850-194f-4719-abc2-3f345aef257f
2017-10-10T08:00:00.000+08:00,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,LLY,https://www.benzinga.com/general/biotech/17/10/10160332/5-pharma-biotech-stocks-that-could-be-big-winners-in-q3-earnings,Zacks,,,,0,0,e3426ac6-c45d-437b-aedf-39ce1180f827
2017-10-10T08:00:00.000+08:00,7 Catalysts For Eli Lilly Over The Next Year,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10159795/7-catalysts-for-eli-lilly-over-the-next-year,Shanthi Rexaline,,,,0,0,74559c06-dcdc-4d5c-b9f7-d2bdf82f86d5
2017-10-10T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 10, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/10/10159397/benzingas-top-upgrades-downgrades-for-october-10-2017,Lisa Levin,,,,0,0,2f8eca9f-4fb2-4e73-bb18-e127d1a6d69c
2017-10-10T08:00:00.000+08:00,"The Market In 5 Minutes: Nvidia's Drive, Russia And Cryptos, And Carbon Emission Limits",LLY,https://www.benzinga.com/news/17/10/10158860/the-market-in-5-minutes-nvidias-drive-russia-and-cryptos-and-carbon-emission-lim,Benzinga News Desk,,,,0,0,319e6159-761a-40ee-81c5-eabb129f0369
2017-10-10T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Fed Speakers,LLY,https://www.benzinga.com/news/17/10/10158201/a-peek-into-the-markets-u-s-stock-futures-gain-ahead-of-fed-speakers,Lisa Levin,,,,0,0,fffc7fe3-76b8-401a-92f5-e7b8be26ff18
2017-10-10T08:00:00.000+08:00,"UPDATE: Eli Lilly Says 'analysis of the secondary study endpoints of both PFS, ORR showed evidence of monotherapy activity in the abemaciclib arm'",LLY,https://www.benzinga.com/news/fda/17/10/10158024/update-eli-lilly-says-analysis-of-the-secondary-study-endpoints-of-both-pfs-,Paul Quintaro,,,,0,0,5c8baf95-e086-4775-89c1-80fcec8c8013
2017-10-10T08:00:00.000+08:00,Eli Lilly Reports Topline Results From Phase 3 JUNIPER Trial Evaluating Verzenio In KRAS-Mutated Advanced NSCLC: 'did not meet its primary endpoint of overall survival',LLY,https://www.benzinga.com/news/fda/17/10/10158021/eli-lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verz,Paul Quintaro,,,,0,0,385d78f7-087b-42a3-abd4-be291b7fedd4
2017-10-10T08:00:00.000+08:00,Credit Suisse Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/17/10/10157951/credit-suisse-downgrades-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,ae52b9c4-cb21-4e21-9a2d-9d2021b1e274
2017-10-10T08:00:00.000+08:00,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,LLY,https://www.benzinga.com/general/biotech/17/10/10160332/5-pharma-biotech-stocks-that-could-be-big-winners-in-q3-earnings,Zacks,,,,0,0,ff057cff-4341-4ee3-a428-0e7ee4cf45dc
2017-10-10T08:00:00.000+08:00,7 Catalysts For Eli Lilly Over The Next Year,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10159795/7-catalysts-for-eli-lilly-over-the-next-year,Shanthi Rexaline,,,,0,0,9bc978ba-3b67-448e-b5f9-0828d58ee79a
2017-10-10T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For October 10, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/10/10159397/benzingas-top-upgrades-downgrades-for-october-10-2017,Lisa Levin,,,,0,0,a96fa116-9193-47e5-9c01-5edec1799e07
2017-10-10T08:00:00.000+08:00,"The Market In 5 Minutes: Nvidia's Drive, Russia And Cryptos, And Carbon Emission Limits",LLY,https://www.benzinga.com/news/17/10/10158860/the-market-in-5-minutes-nvidias-drive-russia-and-cryptos-and-carbon-emission-lim,Benzinga News Desk,,,,0,0,f9b98f25-bda1-4d48-9e50-30ac70cf2cf2
2017-10-10T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Fed Speakers,LLY,https://www.benzinga.com/news/17/10/10158201/a-peek-into-the-markets-u-s-stock-futures-gain-ahead-of-fed-speakers,Lisa Levin,,,,0,0,aeed574e-a4c0-4837-afa9-8b67d6c42314
2017-10-10T08:00:00.000+08:00,"UPDATE: Eli Lilly Says 'analysis of the secondary study endpoints of both PFS, ORR showed evidence of monotherapy activity in the abemaciclib arm'",LLY,https://www.benzinga.com/news/fda/17/10/10158024/update-eli-lilly-says-analysis-of-the-secondary-study-endpoints-of-both-pfs-,Paul Quintaro,,,,0,0,26164e03-11e2-4e5a-86cd-4f6177984a42
2017-10-10T08:00:00.000+08:00,Eli Lilly Reports Topline Results From Phase 3 JUNIPER Trial Evaluating Verzenio In KRAS-Mutated Advanced NSCLC: 'did not meet its primary endpoint of overall survival',LLY,https://www.benzinga.com/news/fda/17/10/10158021/eli-lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verz,Paul Quintaro,,,,0,0,2a04496a-852d-45a8-813b-219a2356af16
2017-10-10T08:00:00.000+08:00,Credit Suisse Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/17/10/10157951/credit-suisse-downgrades-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,b2ed94ca-2064-4f31-a8ec-411dac5ac63c
2017-10-09T08:00:00.000+08:00,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result,LLY,https://www.benzinga.com/general/biotech/17/10/10156660/health-care-sector-back-in-focus-in-congress-ahead-of-q3-earnings-res,JJ Kinahan,,,,0,0,1b883fe6-94cc-48aa-b5d5-9bdd0d3ee6e5
2017-10-09T08:00:00.000+08:00,Health Care Sector Back In Focus In Congress Ahead Of Q3 Earnings Result,LLY,https://www.benzinga.com/general/biotech/17/10/10156660/health-care-sector-back-in-focus-in-congress-ahead-of-q3-earnings-res,JJ Kinahan,,,,0,0,6de1b77d-a594-4d49-bc54-18bf8a48b739
2017-10-06T08:00:00.000+08:00,"Teva Pharmaceuticals Responds To Patent Office Decision In Eli Lilly's Favor, Tells Benzinga: 'We are disappointed with the court's decision and evaluating our options to appeal'",LLY,https://www.benzinga.com/general/biotech/17/10/10150151/teva-pharmaceuticals-responds-to-patent-office-decision-in-eli-lillys,Hal Lindon,,,,0,0,48569e53-cbda-407d-ae4c-01d78b59ef81
2017-10-06T08:00:00.000+08:00,"Teva Pharmaceuticals Responds To Patent Office Decision In Eli Lilly's Favor, Tells Benzinga: 'We are disappointed with the court's decision and evaluating our options to appeal'",LLY,https://www.benzinga.com/general/biotech/17/10/10150151/teva-pharmaceuticals-responds-to-patent-office-decision-in-eli-lillys,Hal Lindon,,,,0,0,b395a8dc-3a95-4a8f-8d61-a790cb44493a
2017-10-05T08:00:00.000+08:00,Eli Lilly Shares Spike On Patent Victory,LLY,https://www.benzinga.com/news/17/10/10147611/eli-lilly-shares-spike-on-patent-victory,Elizabeth Balboa,,,,0,0,6a09e734-71e8-44a7-8b2c-95d6162f44b2
2017-10-05T08:00:00.000+08:00,Eli Lilly Reports US PTO Ruled In Favor Of Co.'s Alimta Vitamin Regimen Patent,LLY,https://www.benzinga.com/news/17/10/10147909/eli-lilly-reports-us-pto-ruled-in-favor-of-co-s-alimta-vitamin-regimen-patent,Paul Quintaro,,,,0,0,84be581f-96f0-4b86-bf51-18d4a7ec4ada
2017-10-05T08:00:00.000+08:00,UPDATE: Eli Lilly Prevails In IPR Review Of '209 Patent For Alimta,LLY,https://www.benzinga.com/news/legal/17/10/10147144/update-scribd-reports-eli-lilly-prevails-in-ipr-review-of-209-patent-for-a,Hal Lindon,,,,0,0,53c9432a-a6b9-43cb-bb03-09375717cab4
2017-10-05T08:00:00.000+08:00,Watching Shares Of Eli Lilly As Traders Pass Unconfirmed Chatter Of Favorable Patent Case Decision,LLY,https://www.benzinga.com/news/rumors/17/10/10147127/watching-shares-of-eli-lilly-as-traders-pass-unconfirmed-chatter-of-favor,Hal Lindon,,,,0,0,db884df6-cc3f-40ad-bf94-bbb3e3a93a36
2017-10-05T08:00:00.000+08:00,Eli Lilly Shares Spike On Patent Victory,LLY,https://www.benzinga.com/news/17/10/10147611/eli-lilly-shares-spike-on-patent-victory,Elizabeth Balboa,,,,0,0,77e176bd-91bc-475f-806d-4f6c72a2c741
2017-10-05T08:00:00.000+08:00,Eli Lilly Reports US PTO Ruled In Favor Of Co.'s Alimta Vitamin Regimen Patent,LLY,https://www.benzinga.com/news/17/10/10147909/eli-lilly-reports-us-pto-ruled-in-favor-of-co-s-alimta-vitamin-regimen-patent,Paul Quintaro,,,,0,0,23ddea36-4140-4a66-9c92-eb1e8e578183
2017-10-05T08:00:00.000+08:00,UPDATE: Eli Lilly Prevails In IPR Review Of '209 Patent For Alimta,LLY,https://www.benzinga.com/news/legal/17/10/10147144/update-scribd-reports-eli-lilly-prevails-in-ipr-review-of-209-patent-for-a,Hal Lindon,,,,0,0,96367b10-1f56-4bfe-b279-db0f0fa783b5
2017-10-05T08:00:00.000+08:00,Watching Shares Of Eli Lilly As Traders Pass Unconfirmed Chatter Of Favorable Patent Case Decision,LLY,https://www.benzinga.com/news/rumors/17/10/10147127/watching-shares-of-eli-lilly-as-traders-pass-unconfirmed-chatter-of-favor,Hal Lindon,,,,0,0,b0781afb-65ed-446e-9cb7-17acf2bdfb3b
2017-09-28T08:00:00.000+08:00,"Eli Lilly Has Said List Price For Its New Breast Cancer Treatment Verzenio Will Be ~$11K/Month, Will Be Available In US By End Of Oct.",LLY,https://www.benzinga.com/news/17/09/10117028/eli-lilly-has-said-list-price-for-its-new-breast-cancer-treatment-verzenio-will-,Paul Quintaro,,,,0,0,819892f7-03f1-44b6-9829-ea5bbc241dee
2017-09-28T08:00:00.000+08:00,"Eli Lilly Has Said List Price For Its New Breast Cancer Treatment Verzenio Will Be ~$11K/Month, Will Be Available In US By End Of Oct.",LLY,https://www.benzinga.com/news/17/09/10117028/eli-lilly-has-said-list-price-for-its-new-breast-cancer-treatment-verzenio-will-,Paul Quintaro,,,,0,0,37586bb1-458e-42e0-bd3a-5a8646057792
2017-09-20T08:00:00.000+08:00,Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10080961/johnson-johnson-downgraded-on-hefty-valuation-compared-,Jayson Derrick,,,,0,0,c78e48cf-f471-431b-abad-b9813427120c
2017-09-20T08:00:00.000+08:00,Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10080961/johnson-johnson-downgraded-on-hefty-valuation-compared-,Jayson Derrick,,,,0,0,22281cf7-d226-4952-8aa1-7e8fa3a6134f
2017-09-19T08:00:00.000+08:00,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks",LLY,https://www.benzinga.com/news/17/09/10074065/wall-streets-m-a-chatter-from-september-18-walgreesn-rite-aid-northrup-grumman-o,Charles Gross,,,,0,0,0ffeb45c-c4e0-4219-b15c-7d3d369f5d8e
2017-09-19T08:00:00.000+08:00,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks",LLY,https://www.benzinga.com/news/17/09/10074065/wall-streets-m-a-chatter-from-september-18-walgreesn-rite-aid-northrup-grumman-o,Charles Gross,,,,0,0,e98fe2f8-d68f-4fc4-85bc-405dbacd3180
2017-09-14T08:00:00.000+08:00,Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/17/09/10057182/eli-lillys-baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-,Paul Quintaro,,,,0,0,e6056959-8f5a-47b0-9fdd-cc7b928a287d
2017-09-14T08:00:00.000+08:00,Eli Lilly's Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,LLY,https://www.benzinga.com/news/17/09/10057182/eli-lillys-baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-,Paul Quintaro,,,,0,0,c105f076-4499-4128-bb54-487f4a509805
2017-09-12T08:00:00.000+08:00,This Analyst Predicts Bullish Growth Outlook For Incyte,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10044788/this-analyst-predicts-bullish-growth-outlook-for-incyte,Shanthi Rexaline,,,,0,0,dc640bcb-6c48-41a4-9741-ae6c64811dcc
2017-09-12T08:00:00.000+08:00,Eli Lilly Says Jardiance Tablets Reduced the Risk of Cardiovascular Death in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/17/09/10043829/eli-lilly-says-jardiance-tablets-reduced-the-risk-of-cardiovascular-death-in-peo,Paul Quintaro,,,,0,0,5d6af6cb-2463-42d3-aa4f-2a634d831ff7
2017-09-12T08:00:00.000+08:00,This Analyst Predicts Bullish Growth Outlook For Incyte,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10044788/this-analyst-predicts-bullish-growth-outlook-for-incyte,Shanthi Rexaline,,,,0,0,994ff692-ea2c-4278-bdec-8c63bac1b259
2017-09-12T08:00:00.000+08:00,Eli Lilly Says Jardiance Tablets Reduced the Risk of Cardiovascular Death in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/17/09/10043829/eli-lilly-says-jardiance-tablets-reduced-the-risk-of-cardiovascular-death-in-peo,Paul Quintaro,,,,0,0,14d7651d-4348-49dc-aa61-a3b4cba1dbca
2017-09-11T08:00:00.000+08:00,Array BioPharma And Others Shine At The ESMO 2017 Congress,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10040619/array-biopharma-and-others-shine-at-the-esmo-2017-congr,Wayne Duggan,,,,0,0,4164665d-b384-41c3-aa1e-64a30847b5c0
2017-09-11T08:00:00.000+08:00,Array BioPharma And Others Shine At The ESMO 2017 Congress,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10040619/array-biopharma-and-others-shine-at-the-esmo-2017-congr,Wayne Duggan,,,,0,0,56be0514-0c9f-4236-a786-cb552e753467
2017-09-10T08:00:00.000+08:00,Lilly Announces Presentation of Phase 3 RANGE Data for CYRAMZA Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer at ESMO 2017,LLY,https://www.benzinga.com/news/17/09/10037266/lilly-announces-presentation-of-phase-3-range-data-for-cyramza-demonstrating-sup,Charles Gross,,,,0,0,fc316e42-1652-4fbb-a4b6-8177e9836e7c
2017-09-10T08:00:00.000+08:00,Lilly Announces Presentation of Phase 3 RANGE Data for CYRAMZA Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer at ESMO 2017,LLY,https://www.benzinga.com/news/17/09/10037266/lilly-announces-presentation-of-phase-3-range-data-for-cyramza-demonstrating-sup,Charles Gross,,,,0,0,a529d5f0-f561-4c21-ab94-03dce3eae38e
2017-09-09T08:00:00.000+08:00,What Pharmaceuticals Spend On Lobbying To Influence Trump,LLY,https://www.benzinga.com/general/biotech/17/09/10008324/what-pharmaceuticals-spend-on-lobbying-to-influence-trump,Elizabeth Balboa,,,,0,0,5cb0e445-f8c0-4ce3-ab44-6f81d61f6a1a
2017-09-09T08:00:00.000+08:00,Data Showing Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine to be Presented at IHC 2017,LLY,https://www.benzinga.com/news/17/09/10037098/data-showing-lillys-lasmiditan-significantly-reduces-pain-in-patients-with-migra,Charles Gross,,,,0,0,73ddda1e-8c08-424a-8938-2ac643f8053b
2017-09-09T08:00:00.000+08:00,What Pharmaceuticals Spend On Lobbying To Influence Trump,LLY,https://www.benzinga.com/general/biotech/17/09/10008324/what-pharmaceuticals-spend-on-lobbying-to-influence-trump,Elizabeth Balboa,,,,0,0,023d1c11-5c6b-43bd-b756-975e20b452a6
2017-09-09T08:00:00.000+08:00,Data Showing Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine to be Presented at IHC 2017,LLY,https://www.benzinga.com/news/17/09/10037098/data-showing-lillys-lasmiditan-significantly-reduces-pain-in-patients-with-migra,Charles Gross,,,,0,0,e6f508bc-b9c0-4228-ba2d-12290b9cc8fe
2017-09-08T08:00:00.000+08:00,"UPDATE: Eli Lilly Says Galcanezumab Showed 'statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)'",LLY,https://www.benzinga.com/news/17/09/10032182/update-eli-lilly-says-galcanezumab-showed-statistically-significant-reduction-in,Paul Quintaro,,,,0,0,1bf9d6f9-92d0-47fb-b13e-5ec3440e2789
2017-09-08T08:00:00.000+08:00,"Eli Lilly Reports Treatment With Self-Administered Galcanezumab For Up To 12 Months Showed Positive Safety, Tolerability Profile In Patients With Migraine",LLY,https://www.benzinga.com/news/fda/17/09/10032176/eli-lilly-reports-treatment-with-self-administered-galcanezumab-for-up-to-12,Paul Quintaro,,,,0,0,4b5e4220-a076-449a-bfd3-d8563dd8dd39
2017-09-08T08:00:00.000+08:00,"UPDATE: Eli Lilly Says Galcanezumab Showed 'statistically significant reduction in the number of monthly migraine headache days with both doses (5.6 days for 120 mg and 6.5 days for 240 mg, p<0.001 for both dosing groups)'",LLY,https://www.benzinga.com/news/17/09/10032182/update-eli-lilly-says-galcanezumab-showed-statistically-significant-reduction-in,Paul Quintaro,,,,0,0,5183507d-7c93-40b1-ae3c-2eeb96a81df2
2017-09-08T08:00:00.000+08:00,"Eli Lilly Reports Treatment With Self-Administered Galcanezumab For Up To 12 Months Showed Positive Safety, Tolerability Profile In Patients With Migraine",LLY,https://www.benzinga.com/news/fda/17/09/10032176/eli-lilly-reports-treatment-with-self-administered-galcanezumab-for-up-to-12,Paul Quintaro,,,,0,0,034036d7-f44f-4e05-b98d-6b65c098658e
2017-09-07T08:00:00.000+08:00,"UPDATE: Eli Lilly Sees Incurring ~$1.2B Pre-Tax Charge Related to Streamlining Of Operations, Or About $0.80/Share After Tax",LLY,https://www.benzinga.com/news/guidance/17/09/10026977/update-eli-lilly-sees-incurring-1-2b-pre-tax-charge-related-to-streamli,Paul Quintaro,,,,0,0,04199d37-8003-4762-baf6-cb0d2f47d4da
2017-09-07T08:00:00.000+08:00,"UPDATE: Eli Lilly Says Streamlining Of Operations Will Impact ~8% Of Workforce, Or About 3,500 Jobs",LLY,https://www.benzinga.com/news/17/09/10026973/update-eli-lilly-says-streamlining-of-operations-will-impact-8-of-workforce-or-a,Paul Quintaro,,,,0,0,c942a5a2-5ba7-4010-8c8f-c093e1772f07
2017-09-07T08:00:00.000+08:00,"Eli Lilly Unveils Actions To Streamline Operations, Sees Annualized Savings Of ~$500M",LLY,https://www.benzinga.com/news/17/09/10026965/eli-lilly-unveils-actions-to-streamline-operations-sees-annualized-savings-of-50,Paul Quintaro,,,,0,0,30facdd9-9e4d-42ec-b5c1-e26b736f2f85
2017-09-07T08:00:00.000+08:00,"UPDATE: Eli Lilly Sees Incurring ~$1.2B Pre-Tax Charge Related to Streamlining Of Operations, Or About $0.80/Share After Tax",LLY,https://www.benzinga.com/news/guidance/17/09/10026977/update-eli-lilly-sees-incurring-1-2b-pre-tax-charge-related-to-streamli,Paul Quintaro,,,,0,0,8240d287-3a5b-4c97-8e37-3337e0cfd322
2017-09-07T08:00:00.000+08:00,"UPDATE: Eli Lilly Says Streamlining Of Operations Will Impact ~8% Of Workforce, Or About 3,500 Jobs",LLY,https://www.benzinga.com/news/17/09/10026973/update-eli-lilly-says-streamlining-of-operations-will-impact-8-of-workforce-or-a,Paul Quintaro,,,,0,0,2b662a10-cd1f-4c96-8a17-62a205af6fc9
2017-09-07T08:00:00.000+08:00,"Eli Lilly Unveils Actions To Streamline Operations, Sees Annualized Savings Of ~$500M",LLY,https://www.benzinga.com/news/17/09/10026965/eli-lilly-unveils-actions-to-streamline-operations-sees-annualized-savings-of-50,Paul Quintaro,,,,0,0,d5d6f529-0611-4f3f-9ba3-f31746db9e6e
2017-08-30T08:00:00.000+08:00,"UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle",LLY,https://www.benzinga.com/news/fda/17/08/9994372/update-lilly-incyte-expect-fda-to-classify-nda-for-baricitinib-as-class-i-res,Paul Quintaro,,,,0,0,9f2fbde4-06ac-4a59-ab80-279e5951867d
2017-08-30T08:00:00.000+08:00,"Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18",LLY,https://www.benzinga.com/news/17/08/9994366/eli-lilly-incyte-report-will-resubmit-nda-for-baricitinib-before-end-of-jan-18,Paul Quintaro,,,,0,0,797b32a1-07ef-4c89-9510-6a39ab58bced
2017-08-30T08:00:00.000+08:00,"UPDATE: Lilly, Incyte Expect FDA To Classify NDA For Baricitinib As Class I Resubmission, Which Will Start A New 6-Month Review Cycle",LLY,https://www.benzinga.com/news/fda/17/08/9994372/update-lilly-incyte-expect-fda-to-classify-nda-for-baricitinib-as-class-i-res,Paul Quintaro,,,,0,0,e49689f5-7b02-4ce8-932c-586326afb171
2017-08-30T08:00:00.000+08:00,"Eli Lilly, Incyte Report Will Resubmit NDA For Baricitinib Before End Of Jan. '18",LLY,https://www.benzinga.com/news/17/08/9994366/eli-lilly-incyte-report-will-resubmit-nda-for-baricitinib-before-end-of-jan-18,Paul Quintaro,,,,0,0,a7f003e8-4665-4bcf-99c1-5ecc81c0289c
2017-08-16T08:00:00.000+08:00,Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results,LLY,https://www.benzinga.com/news/17/08/9940712/shares-of-lilly-fall-on-positive-novo-nordisk-sustain-7-trial-results,Charles Gross,,,,0,0,e4087d6c-634d-473b-be6b-ac1090ad5eba
2017-08-16T08:00:00.000+08:00,Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results,LLY,https://www.benzinga.com/news/17/08/9940712/shares-of-lilly-fall-on-positive-novo-nordisk-sustain-7-trial-results,Charles Gross,,,,0,0,0e7b1633-74a0-4bf9-8f2a-221336d06f5d
2017-08-14T08:00:00.000+08:00,13F From Farallon Capital Shows Liquidated ~1.6M Share Stake In Eli Lilly,LLY,https://www.benzinga.com/news/17/08/9926914/13f-from-farallon-capital-shows-liquidated-1-6m-share-stake-in-eli-lilly,Paul Quintaro,,,,0,0,bde9c085-cf2b-4cff-8229-b1d34ae2546a
2017-08-14T08:00:00.000+08:00,13F From Farallon Capital Shows Liquidated ~1.6M Share Stake In Eli Lilly,LLY,https://www.benzinga.com/news/17/08/9926914/13f-from-farallon-capital-shows-liquidated-1-6m-share-stake-in-eli-lilly,Paul Quintaro,,,,0,0,3bec1fce-d2ad-4a8c-b0b1-9699ab8628fb
2017-08-04T08:00:00.000+08:00,Eli Lilly Reports Results From Second Phase 3 Study Of Lasmiditan For Acute Treatment Of Migraine; Met Its Primary Endpoint In SPARTAN,LLY,https://www.benzinga.com/news/fda/17/08/9879323/eli-lilly-reports-results-from-second-phase-3-study-of-lasmiditan-for-acute-t,Paul Quintaro,,,,0,0,da32ea65-365c-4346-99d1-e6ae1d96190e
2017-08-04T08:00:00.000+08:00,Eli Lilly Reports Results From Second Phase 3 Study Of Lasmiditan For Acute Treatment Of Migraine; Met Its Primary Endpoint In SPARTAN,LLY,https://www.benzinga.com/news/fda/17/08/9879323/eli-lilly-reports-results-from-second-phase-3-study-of-lasmiditan-for-acute-t,Paul Quintaro,,,,0,0,a10e87a2-8543-463c-9204-017a04b5ffa7
2017-07-28T08:00:00.000+08:00,Eli Lilly Says California and Florida AGs Have Requested Info On Co.'s Insulin Products,LLY,https://www.benzinga.com/news/17/07/9841215/eli-lilly-says-california-and-florida-ags-have-requested-info-on-co-s-insulin-pro,Hal Lindon,,,,0,0,771aab49-1ad5-4751-9e15-35d90ccd313f
2017-07-28T08:00:00.000+08:00,Eli Lilly Says California and Florida AGs Have Requested Info On Co.'s Insulin Products,LLY,https://www.benzinga.com/news/17/07/9841215/eli-lilly-says-california-and-florida-ags-have-requested-info-on-co-s-insulin-pro,Hal Lindon,,,,0,0,28132c5e-403a-42a6-b227-377a9f1defdb
2017-07-27T08:00:00.000+08:00,"On, Wisconsin: University Wins Half Billion In iPhone Patent Suit, Another Sign Schools Are Research Cash Cows",LLY,https://www.benzinga.com/general/biotech/17/07/9832748/on-wisconsin-university-wins-half-billion-in-iphone-patent-suit-anothe,Mark Fritz,,,,0,0,e9623cca-6666-426d-b033-a96d3d2866f5
2017-07-27T08:00:00.000+08:00,"Samsung, Amazon — Everyone Is Getting Into Pharmaceuticals",LLY,https://www.benzinga.com/general/biotech/17/07/9827012/samsung-amazon-everyone-is-getting-into-pharmaceuticals,Elizabeth Balboa,,,,0,0,c7e93faa-2cb7-4c0d-9e9b-39d856a7ec69
2017-07-27T08:00:00.000+08:00,"On, Wisconsin: University Wins Half Billion In iPhone Patent Suit, Another Sign Schools Are Research Cash Cows",LLY,https://www.benzinga.com/general/biotech/17/07/9832748/on-wisconsin-university-wins-half-billion-in-iphone-patent-suit-anothe,Mark Fritz,,,,0,0,727cead0-f409-4e2f-a788-92141aa0445b
2017-07-27T08:00:00.000+08:00,"Samsung, Amazon — Everyone Is Getting Into Pharmaceuticals",LLY,https://www.benzinga.com/general/biotech/17/07/9827012/samsung-amazon-everyone-is-getting-into-pharmaceuticals,Elizabeth Balboa,,,,0,0,7c57764c-2507-4c91-a292-d9cc7f6f585f
2017-07-26T08:00:00.000+08:00,Zoetis Investors May Need Patience To See Bull Thesis Play Out,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824398/zoetis-investors-may-need-patience-to-see-bull-thesis-pl,Jayson Derrick,,,,0,0,38cda867-8fe0-41fc-bdbc-9734ef79de0d
2017-07-26T08:00:00.000+08:00,"Intense Competition Pressures Eli Lilly, Leerink Downgrades",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824628/intense-competition-pressures-eli-lilly-leerink-downgrad,Merrick Weingarten,,,,0,0,166b63c6-237c-44c6-8ab6-3b77cd637cdb
2017-07-26T08:00:00.000+08:00,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824125/19-upside-predicted-for-biogen-goldman-upgrades-on-stren,Mark Fritz,,,,0,0,4f209d82-231b-4ada-b6f8-8c393a3102c8
2017-07-26T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For July 26, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/07/9823964/benzingas-top-upgrades-downgrades-for-july-26-2017,Lisa Levin,,,,0,0,7cd1af5f-ef37-462b-90d0-0b446937149a
2017-07-26T08:00:00.000+08:00,Leerink Swann Downgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/17/07/9822845/leerink-swann-downgrades-eli-lilly-to-market-perform,Paul Quintaro,,,,0,0,fe4d2302-de78-4889-a54d-1eed23a2a973
2017-07-26T08:00:00.000+08:00,Zoetis Investors May Need Patience To See Bull Thesis Play Out,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824398/zoetis-investors-may-need-patience-to-see-bull-thesis-pl,Jayson Derrick,,,,0,0,9b14ff0b-6250-42e0-bdfb-e2ae05a4fc1a
2017-07-26T08:00:00.000+08:00,"Intense Competition Pressures Eli Lilly, Leerink Downgrades",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824628/intense-competition-pressures-eli-lilly-leerink-downgrad,Merrick Weingarten,,,,0,0,cb34f270-ae4e-4cf3-8915-ef29e089f1a3
2017-07-26T08:00:00.000+08:00,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9824125/19-upside-predicted-for-biogen-goldman-upgrades-on-stren,Mark Fritz,,,,0,0,b47a9902-0cba-46a7-adaa-86e62088cc1d
2017-07-26T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For July 26, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/07/9823964/benzingas-top-upgrades-downgrades-for-july-26-2017,Lisa Levin,,,,0,0,f479e5d5-28b8-4410-9a16-6f7ee3b8b3a9
2017-07-26T08:00:00.000+08:00,Leerink Swann Downgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/17/07/9822845/leerink-swann-downgrades-eli-lilly-to-market-perform,Paul Quintaro,,,,0,0,293f5aa6-ea9b-4bad-9d01-2b3c62b45e53
2017-07-25T08:00:00.000+08:00,"Eli Lilly Raises FY 2017 Guidance, Sees EPS $4.10-$4.20 from $4.05-$4.15 vs $4.12 Est., Sees Sales $22.0B-$22.5B from $21.8B-$22.3B vs $22.1B Est.",LLY,https://www.benzinga.com/news/guidance/17/07/9815351/eli-lilly-raises-fy-2017-guidance-sees-eps-4-10-4-20-from-4-05-4-15-vs-4,Paul Quintaro,,,,0,0,7100c3bb-3929-48d9-8383-ccd3f6f6a4ad
2017-07-25T08:00:00.000+08:00,"Eli Lilly Q2 EPS $1.11 vs $1.05 Est., Sales $5.82B vs $5.60B Est.",LLY,https://www.benzinga.com/news/earnings/17/07/9815349/eli-lilly-q2-eps-1-11-vs-1-05-est-sales-5-82b-vs-5-60b-est,Paul Quintaro,,,,0,0,6e7444c0-62af-4dbf-99d4-2e8ba9783b2b
2017-07-25T08:00:00.000+08:00,Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017,LLY,https://www.benzinga.com/news/17/07/9815321/eli-lilly-and-incytes-re-submission-of-a-new-drug-application-to-the-fda-will-be-,Paul Quintaro,,,,0,0,93a40105-65a6-428c-8789-562ade7cfcaf
2017-07-25T08:00:00.000+08:00,"12 Stocks To Watch For July 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/07/9815117/12-stocks-to-watch-for-july-25-2017,Lisa Levin,,,,0,0,bb08c67e-5b4d-4ebd-9746-05ddfe21df48
2017-07-25T08:00:00.000+08:00,"Earnings Scheduled For July 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/07/9815114/earnings-scheduled-for-july-25-2017,Lisa Levin,,,,0,0,e4abd40a-9842-40c5-bc90-1c0f125bb951
2017-07-25T08:00:00.000+08:00,"Eli Lilly Raises FY 2017 Guidance, Sees EPS $4.10-$4.20 from $4.05-$4.15 vs $4.12 Est., Sees Sales $22.0B-$22.5B from $21.8B-$22.3B vs $22.1B Est.",LLY,https://www.benzinga.com/news/guidance/17/07/9815351/eli-lilly-raises-fy-2017-guidance-sees-eps-4-10-4-20-from-4-05-4-15-vs-4,Paul Quintaro,,,,0,0,07e8699c-8d51-4364-915e-9202b9dfff85
2017-07-25T08:00:00.000+08:00,"Eli Lilly Q2 EPS $1.11 vs $1.05 Est., Sales $5.82B vs $5.60B Est.",LLY,https://www.benzinga.com/news/earnings/17/07/9815349/eli-lilly-q2-eps-1-11-vs-1-05-est-sales-5-82b-vs-5-60b-est,Paul Quintaro,,,,0,0,c9d4f389-9ecb-4f0d-8c2b-adeef15d45e1
2017-07-25T08:00:00.000+08:00,Eli Lilly and Incyte's Re-submission of a New Drug Application to the FDA Will be Delayed Beyond 2017,LLY,https://www.benzinga.com/news/17/07/9815321/eli-lilly-and-incytes-re-submission-of-a-new-drug-application-to-the-fda-will-be-,Paul Quintaro,,,,0,0,f8d85b05-ee69-46f2-8daa-e2b98167d8d4
2017-07-25T08:00:00.000+08:00,"12 Stocks To Watch For July 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/07/9815117/12-stocks-to-watch-for-july-25-2017,Lisa Levin,,,,0,0,e8a2681b-8a1c-4a8d-b30f-67e8e9d52b6c
2017-07-25T08:00:00.000+08:00,"Earnings Scheduled For July 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/07/9815114/earnings-scheduled-for-july-25-2017,Lisa Levin,,,,0,0,562d13cd-cc09-45e8-bf2c-4bf5820b28bd
2017-07-24T08:00:00.000+08:00,2 Ways To Trade This Week's Healthcare Earnings,LLY,https://www.benzinga.com/news/earnings/17/07/9776865/2-ways-to-trade-this-weeks-healthcare-earnings,ETF Professor,,,,0,0,5f2fd64e-fb31-4232-9ada-f99d52d89bf8
2017-07-24T08:00:00.000+08:00,Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358,LLY,https://www.benzinga.com/news/17/07/9810074/eli-lilly-and-nektar-therapeutics-to-partner-for-development-and-commercializatio,Paul Quintaro,,,,0,0,a22771af-34d7-42d7-8d6d-e41c63292ea6
2017-07-24T08:00:00.000+08:00,2 Ways To Trade This Week's Healthcare Earnings,LLY,https://www.benzinga.com/news/earnings/17/07/9776865/2-ways-to-trade-this-weeks-healthcare-earnings,ETF Professor,,,,0,0,e5aedd3a-cc69-4f0b-8ae9-e7ae02a8384d
2017-07-24T08:00:00.000+08:00,Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358,LLY,https://www.benzinga.com/news/17/07/9810074/eli-lilly-and-nektar-therapeutics-to-partner-for-development-and-commercializatio,Paul Quintaro,,,,0,0,c548ce5c-7e55-41bb-a524-bc73ba4c50a3
2017-07-18T08:00:00.000+08:00,"Adimab Reports Deal With Eli Lilly To Transfer Co.'s Platform To Lilly For Discovery, Optimization Of Antibody-Based Drugs In Therapeutic Areas",LLY,https://www.benzinga.com/news/fda/17/07/9788329/adimab-reports-deal-with-eli-lilly-to-transfer-co-s-platform-to-lilly-for-dis,Paul Quintaro,,,,0,0,0da5a30d-5c2e-4085-a257-ba2239415a2e
2017-07-18T08:00:00.000+08:00,"Adimab Reports Deal With Eli Lilly To Transfer Co.'s Platform To Lilly For Discovery, Optimization Of Antibody-Based Drugs In Therapeutic Areas",LLY,https://www.benzinga.com/news/fda/17/07/9788329/adimab-reports-deal-with-eli-lilly-to-transfer-co-s-platform-to-lilly-for-dis,Paul Quintaro,,,,0,0,b6efb551-3342-4605-a932-bc5cd28500dd
2017-07-13T08:00:00.000+08:00,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",LLY,https://www.benzinga.com/movers/17/07/9775206/shares-of-eli-lilly-astrazeneca-merck-gilead-abbvie-other-large-cap-biotech-spi,Paul Quintaro,,,,0,0,6a3c27c2-91d6-40b2-9c14-48eac87d64e8
2017-07-13T08:00:00.000+08:00,6 Biggest Price Target Changes For Thursday,LLY,https://www.benzinga.com/analyst-ratings/price-target/17/07/9773573/6-biggest-price-target-changes-for-thursday,Lisa Levin,,,,0,0,d9998993-a3d8-4fff-a36c-24d5271e8191
2017-07-13T08:00:00.000+08:00,"Delta, United, Eli Lilly, General Electric: Fast Money Picks For July 13",LLY,https://www.benzinga.com/media/cnbc/17/07/9771620/delta-united-eli-lilly-general-electric-fast-money-picks-for-july-13,Craig Jones,,,,0,0,9e91d8ac-4a9d-431d-a689-afeff46116fc
2017-07-13T08:00:00.000+08:00,"Shares of Eli Lilly, AstraZeneca, Merck, Gilead, Abbvie, Other Large Cap Biotech Spiking Higher",LLY,https://www.benzinga.com/movers/17/07/9775206/shares-of-eli-lilly-astrazeneca-merck-gilead-abbvie-other-large-cap-biotech-spi,Paul Quintaro,,,,0,0,562b49bd-5453-4d7f-89fe-787fcdfeb209
2017-07-13T08:00:00.000+08:00,6 Biggest Price Target Changes For Thursday,LLY,https://www.benzinga.com/analyst-ratings/price-target/17/07/9773573/6-biggest-price-target-changes-for-thursday,Lisa Levin,,,,0,0,6e86e900-79a6-475f-92b7-d65418d98292
2017-07-13T08:00:00.000+08:00,"Delta, United, Eli Lilly, General Electric: Fast Money Picks For July 13",LLY,https://www.benzinga.com/media/cnbc/17/07/9771620/delta-united-eli-lilly-general-electric-fast-money-picks-for-july-13,Craig Jones,,,,0,0,7d723a28-6e79-4581-a2e5-6c073eb33701
2017-07-12T08:00:00.000+08:00,"Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation, Cialis Exclusivity Expected To End At Earliest On Sept. 27th 2018",LLY,https://www.benzinga.com/news/17/07/9768420/lilly-reaches-settlement-agreement-in-u-s-cialis-patent-litigation-cialis-exclusi,Paul Quintaro,,,,0,0,5c66e6f7-27f7-4730-a5dd-10558a8aac9e
2017-07-12T08:00:00.000+08:00,"Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation, Cialis Exclusivity Expected To End At Earliest On Sept. 27th 2018",LLY,https://www.benzinga.com/news/17/07/9768420/lilly-reaches-settlement-agreement-in-u-s-cialis-patent-litigation-cialis-exclusi,Paul Quintaro,,,,0,0,ba3b69af-a8fa-4c11-8e27-b49c65d9b85b
2017-07-10T08:00:00.000+08:00,Eli Lilly's Abemaciclib is Granted Priority Review by the FDA for the Treatment of Breast Cancer,LLY,https://www.benzinga.com/news/17/07/9756000/eli-lillys-abemaciclib-is-granted-priority-review-by-the-fda-for-the-treatment-of,Paul Quintaro,,,,0,0,050c5862-2c5c-4054-ac1c-9ac19025faa8
2017-07-10T08:00:00.000+08:00,Eli Lilly's Abemaciclib is Granted Priority Review by the FDA for the Treatment of Breast Cancer,LLY,https://www.benzinga.com/news/17/07/9756000/eli-lillys-abemaciclib-is-granted-priority-review-by-the-fda-for-the-treatment-of,Paul Quintaro,,,,0,0,0053b0cb-9dfb-4493-aee4-660f376fa5ff
2017-07-07T08:00:00.000+08:00,"UK Supreme Court Rules In Favor Of Eli Lilly's Alimta Vitamin Regimen Patents, Also Affirmed Indirect Infringement Finding By UK Court Of Appeal",LLY,https://www.benzinga.com/news/17/07/9749773/uk-supreme-court-rules-in-favor-of-eli-lillys-alimta-vitamin-regimen-patents-also,Paul Quintaro,,,,0,0,41b4c198-09d4-40e3-ad85-73f93c5cff3f
2017-07-07T08:00:00.000+08:00,"UK Supreme Court Rules In Favor Of Eli Lilly's Alimta Vitamin Regimen Patents, Also Affirmed Indirect Infringement Finding By UK Court Of Appeal",LLY,https://www.benzinga.com/news/17/07/9749773/uk-supreme-court-rules-in-favor-of-eli-lillys-alimta-vitamin-regimen-patents-also,Paul Quintaro,,,,0,0,25a7ea28-4c72-494c-aef6-e6b3a71fccee
2017-07-06T08:00:00.000+08:00,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies,LLY,https://www.benzinga.com/general/biotech/17/07/9745996/merck-falls-as-fda-puts-hold-on-3-keytruda-myeloma-studies,Zacks,,,,0,0,aea2d2c0-9336-4c02-a444-d1b286983937
2017-07-06T08:00:00.000+08:00,Merck Falls As FDA Puts Hold On 3 Keytruda Myeloma Studies,LLY,https://www.benzinga.com/general/biotech/17/07/9745996/merck-falls-as-fda-puts-hold-on-3-keytruda-myeloma-studies,Zacks,,,,0,0,7f541da3-d80f-42c8-8116-7ef56bab5a09
2017-07-03T08:00:00.000+08:00,UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered $15M Milestone Payment From Lilly To Incyte,LLY,https://www.benzinga.com/news/17/07/9681307/update-lilly-says-japanese-marketing-authorization-of-olumiant-triggered-15m-mile,Paul Quintaro,,,,0,0,4f10ee33-78af-465b-ab52-50af853ec49f
2017-07-03T08:00:00.000+08:00,Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant,LLY,https://www.benzinga.com/news/17/07/9681304/eli-lilly-and-incyte-announce-japans-ministry-of-health-grants-marketing-approval,Paul Quintaro,,,,0,0,89a2d995-9481-4126-aa0f-8da01190f1f3
2017-07-03T08:00:00.000+08:00,UPDATE: Lilly Says Japanese Marketing Authorization Of Olumiant Triggered $15M Milestone Payment From Lilly To Incyte,LLY,https://www.benzinga.com/news/17/07/9681307/update-lilly-says-japanese-marketing-authorization-of-olumiant-triggered-15m-mile,Paul Quintaro,,,,0,0,289b63a4-6d84-4b3b-8187-802139fb2175
2017-07-03T08:00:00.000+08:00,Eli Lilly and Incyte Announce Japan's Ministry of Health Grants Marketing Approval for Olumiant,LLY,https://www.benzinga.com/news/17/07/9681304/eli-lilly-and-incyte-announce-japans-ministry-of-health-grants-marketing-approval,Paul Quintaro,,,,0,0,c6127c37-a78d-4be9-a040-3902c51d9d22
2017-06-28T08:00:00.000+08:00,Alder's Shares Dip Despite Positive Migraine Trial Results,LLY,https://www.benzinga.com/17/06/9665252/alders-shares-dip-despite-positive-migraine-trial-results,Zacks,,,,0,0,b4629a48-4a9d-45f7-adbb-5eab4461e061
2017-06-28T08:00:00.000+08:00,Merck's CETP Inhibitor Reduces CV Risk in Phase III Study,LLY,https://www.benzinga.com/17/06/9664402/mercks-cetp-inhibitor-reduces-cv-risk-in-phase-iii-study,Zacks,,,,0,0,9163d185-8a4b-4235-af32-3253d862da58
2017-06-28T08:00:00.000+08:00,Alder's Shares Dip Despite Positive Migraine Trial Results,LLY,https://www.benzinga.com/17/06/9665252/alders-shares-dip-despite-positive-migraine-trial-results,Zacks,,,,0,0,6a0ad865-1b0b-446d-94a0-1303ee6c26b9
2017-06-28T08:00:00.000+08:00,Merck's CETP Inhibitor Reduces CV Risk in Phase III Study,LLY,https://www.benzinga.com/17/06/9664402/mercks-cetp-inhibitor-reduces-cv-risk-in-phase-iii-study,Zacks,,,,0,0,1bb213d0-6c23-4cea-a7f1-67a69f2ab8c4
2017-06-26T08:00:00.000+08:00,Attention To Details: Neos' ADHD Portfolio,LLY,https://www.benzinga.com/general/biotech/17/06/9634178/attention-to-details-neos-adhd-portfolio,Shanthi Rexaline,,,,0,0,6fdd848e-95d3-4ea8-86ea-e64704a412c5
2017-06-26T08:00:00.000+08:00,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",LLY,https://www.benzinga.com/17/06/9652391/novartis-cardiovascular-drug-positive-nsclc-drug-approved,Zacks,,,,0,0,194090fb-993b-4229-804e-098a2b83b1c8
2017-06-26T08:00:00.000+08:00,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",LLY,https://www.benzinga.com/17/06/9652392/novartis-cardiovascular-drug-positive-nsclc-drug-approved,Zacks,,,,0,0,d42b9f89-0303-46c3-8af5-aa51f8354218
2017-06-26T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On Helmerich & Payne, Tailored Brands And Eli Lilly",LLY,https://www.benzinga.com/media/cnbc/17/06/9650666/jim-cramer-shares-his-thoughts-on-helmerich-payne-tailored-brands-and-eli-l,Craig Jones,,,,0,0,b71b0a8c-c5e2-4b82-9a02-664b289287b1
2017-06-26T08:00:00.000+08:00,Attention To Details: Neos' ADHD Portfolio,LLY,https://www.benzinga.com/general/biotech/17/06/9634178/attention-to-details-neos-adhd-portfolio,Shanthi Rexaline,,,,0,0,bbc92efb-751e-480c-8f9c-df54e27e3ee0
2017-06-26T08:00:00.000+08:00,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",LLY,https://www.benzinga.com/17/06/9652391/novartis-cardiovascular-drug-positive-nsclc-drug-approved,Zacks,,,,0,0,d60636ed-d21b-4c26-b15d-7bddd6daaaa2
2017-06-26T08:00:00.000+08:00,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",LLY,https://www.benzinga.com/17/06/9652392/novartis-cardiovascular-drug-positive-nsclc-drug-approved,Zacks,,,,0,0,3030a017-15c9-468d-9b06-442ee89e5641
2017-06-26T08:00:00.000+08:00,"Jim Cramer Shares His Thoughts On Helmerich & Payne, Tailored Brands And Eli Lilly",LLY,https://www.benzinga.com/media/cnbc/17/06/9650666/jim-cramer-shares-his-thoughts-on-helmerich-payne-tailored-brands-and-eli-l,Craig Jones,,,,0,0,a87dde79-ff84-445e-806b-0767a6c67fab
2017-06-22T08:00:00.000+08:00,Why You Should Add Novo Nordisk Stock to Your Portfolio,LLY,https://www.benzinga.com/17/06/9642489/why-you-should-add-novo-nordisk-stock-to-your-portfolio,Zacks,,,,0,0,ae9de0e4-e06f-4e90-847a-5c9c9d1dafe0
2017-06-22T08:00:00.000+08:00,Merck's Keytruda on a Roll: Can it Retain the Momentum?,LLY,https://www.benzinga.com/17/06/9642216/mercks-keytruda-on-a-roll-can-it-retain-the-momentum,Zacks,,,,0,0,79e99140-5bcf-4664-80db-9bf3c89ea8a3
2017-06-22T08:00:00.000+08:00,Why You Should Add Novo Nordisk Stock to Your Portfolio,LLY,https://www.benzinga.com/17/06/9642489/why-you-should-add-novo-nordisk-stock-to-your-portfolio,Zacks,,,,0,0,98bd01f3-a4a2-4199-b8de-bd35ea1c8892
2017-06-22T08:00:00.000+08:00,Merck's Keytruda on a Roll: Can it Retain the Momentum?,LLY,https://www.benzinga.com/17/06/9642216/mercks-keytruda-on-a-roll-can-it-retain-the-momentum,Zacks,,,,0,0,9debbe9b-5e24-4092-a408-95ce9e4be24e
2017-06-21T08:00:00.000+08:00,Eli Lilly Unveils Expanded Biotechnology Center in San Diego As Part Of $850M U.S. Capital Investment In 2017,LLY,https://www.benzinga.com/news/17/06/9636480/eli-lilly-unveils-expanded-biotechnology-center-in-san-diego-as-part-of-850m-u-s-,Paul Quintaro,,,,0,0,07d20dd3-d62c-4b22-a626-077de0de62ea
2017-06-21T08:00:00.000+08:00,Eli Lilly Unveils Expanded Biotechnology Center in San Diego As Part Of $850M U.S. Capital Investment In 2017,LLY,https://www.benzinga.com/news/17/06/9636480/eli-lilly-unveils-expanded-biotechnology-center-in-san-diego-as-part-of-850m-u-s-,Paul Quintaro,,,,0,0,ed11b649-f88a-44b9-9d5c-54b8e0ebb73e
2017-06-18T08:00:00.000+08:00,Eli Lilly Receives FDA Orphan Designation for Humanized Immunoglobulin G4-Variant Monoclonal Antibody Directed Against P19 Subunit of Interleukin (IL)-23 in Treatment Of UC in Pediatric Patients,LLY,https://www.benzinga.com/news/17/06/9622743/eli-lilly-receives-fda-orphan-designation-for-humanized-immunoglobulin-g4-variant,Charles Gross,,,,0,0,a4463df4-5efc-42c2-a257-f1dcc98d03aa
2017-06-18T08:00:00.000+08:00,Eli Lilly Receives FDA Orphan Designation for Humanized Immunoglobulin G4-Variant Monoclonal Antibody Directed Against P19 Subunit of Interleukin (IL)-23 in Treatment Of UC in Pediatric Patients,LLY,https://www.benzinga.com/news/17/06/9622743/eli-lilly-receives-fda-orphan-designation-for-humanized-immunoglobulin-g4-variant,Charles Gross,,,,0,0,5e3cd5bb-2b4e-4cde-8a5d-3a7b8a934855
2017-06-16T08:00:00.000+08:00,"Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends",LLY,https://www.benzinga.com/17/06/9621758/dow-30-stock-roundup-ge-appoints-flannery-as-ceo-utx-cat-hike-dividends,Zacks,,,,0,0,36aa25c4-efcd-4c4b-ba6c-59edcf5ef208
2017-06-16T08:00:00.000+08:00,"Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused",LLY,https://www.benzinga.com/17/06/9618359/pharma-stock-roundup-j-j-lilly-present-data-merck-keytruda-study-enrolment-paused,Zacks,,,,0,0,a3b485dd-423b-4b26-8d50-5b8506c813fc
2017-06-16T08:00:00.000+08:00,"Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017",LLY,https://www.benzinga.com/news/17/06/9617421/lilly-incyte-announce-results-from-long-term-extension-of-phase-3-studies-show-tr,Charles Gross,,,,0,0,de554c54-6bab-4a71-9678-2e6e881de120
2017-06-16T08:00:00.000+08:00,"Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends",LLY,https://www.benzinga.com/17/06/9621758/dow-30-stock-roundup-ge-appoints-flannery-as-ceo-utx-cat-hike-dividends,Zacks,,,,0,0,ef9fef64-6405-4743-a889-73df070c7afb
2017-06-16T08:00:00.000+08:00,"Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused",LLY,https://www.benzinga.com/17/06/9618359/pharma-stock-roundup-j-j-lilly-present-data-merck-keytruda-study-enrolment-paused,Zacks,,,,0,0,7c6e3bf6-7303-4a4a-b9df-e70752bf84ae
2017-06-16T08:00:00.000+08:00,"Lilly, Incyte Announce Results from Long-term Extension of Phase 3 Studies Show Treatment With Baricitinib Slows Progression of Joint Damage, Controls Disease Activity over 2 Years #EULAR2017",LLY,https://www.benzinga.com/news/17/06/9617421/lilly-incyte-announce-results-from-long-term-extension-of-phase-3-studies-show-tr,Charles Gross,,,,0,0,4bb7871f-88f4-4db2-be6a-bd42cfaaa72c
2017-06-15T08:00:00.000+08:00,"Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy",LLY,https://www.benzinga.com/trading-ideas/technicals/17/06/9615279/regeneron-lower-day-after-8-k-filing-increased-competition-fo,Joel Elconin,,,,0,0,ffaf673f-dfff-4ca6-aaf1-0e51609d4d0d
2017-06-15T08:00:00.000+08:00,Why Is ImmunoGen (IMGN) Stock Up 131% This Year?,LLY,https://www.benzinga.com/17/06/9615572/why-is-immunogen-imgn-stock-up-131-this-year,Zacks,,,,0,0,0a797270-1ea7-48e5-a84f-0697bfe307ad
2017-06-15T08:00:00.000+08:00,"Eli Lilly's Talz Showed Significant Improvements In Disease Signs, Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors",LLY,https://www.benzinga.com/news/fda/17/06/9613634/eli-lillys-talz-showed-significant-improvements-in-disease-signs-symptoms-at-,Hal Lindon,,,,0,0,f774c9e3-ffa4-4792-ac7e-41a5bd6c7ba1
2017-06-15T08:00:00.000+08:00,"Regeneron Lower Day After 8-K Filing, Increased Competition For Pain Remedy",LLY,https://www.benzinga.com/trading-ideas/technicals/17/06/9615279/regeneron-lower-day-after-8-k-filing-increased-competition-fo,Joel Elconin,,,,0,0,ac0769f6-cb6c-4d0c-a2da-8a2622fed7f4
2017-06-15T08:00:00.000+08:00,Why Is ImmunoGen (IMGN) Stock Up 131% This Year?,LLY,https://www.benzinga.com/17/06/9615572/why-is-immunogen-imgn-stock-up-131-this-year,Zacks,,,,0,0,6c314f29-c6d4-4013-9005-7da4ebc058b2
2017-06-15T08:00:00.000+08:00,"Eli Lilly's Talz Showed Significant Improvements In Disease Signs, Symptoms At 24 Weeks Among Patients With Active Psoriatic Arthritis Who Had Prior Inadequate Response Or Intolerance To TNF Inhibitors",LLY,https://www.benzinga.com/news/fda/17/06/9613634/eli-lillys-talz-showed-significant-improvements-in-disease-signs-symptoms-at-,Hal Lindon,,,,0,0,a1917f14-457d-4d1f-a235-df76af5cbd31
2017-06-14T08:00:00.000+08:00,Pfizer & Lilly Get Fast Track Designation for Pain Candidate,LLY,https://www.benzinga.com/17/06/9608357/pfizer-lilly-get-fast-track-designation-for-pain-candidate,Zacks,,,,0,0,71262f17-7856-4e58-9f9b-e5f2c3a3ce7d
2017-06-14T08:00:00.000+08:00,"Company News for June 14, 2017",LLY,https://www.benzinga.com/17/06/9608119/company-news-for-june-14-2017,Zacks,,,,0,0,fa7a938a-2e4b-4d5b-91e3-79d6ff3d16b3
2017-06-14T08:00:00.000+08:00,Pfizer & Lilly Get Fast Track Designation for Pain Candidate,LLY,https://www.benzinga.com/17/06/9608357/pfizer-lilly-get-fast-track-designation-for-pain-candidate,Zacks,,,,0,0,1dd7152e-8c0c-4ce9-a2c1-1de4fa15b814
2017-06-14T08:00:00.000+08:00,"Company News for June 14, 2017",LLY,https://www.benzinga.com/17/06/9608119/company-news-for-june-14-2017,Zacks,,,,0,0,2c0112b3-03c0-41ff-93fb-82f88a98987b
2017-06-13T08:00:00.000+08:00,"Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PsA at #EULAR 2017",LLY,https://www.benzinga.com/news/17/06/9604917/lilly-incyte-announce-presentation-of-new-data-on-olumiant-in-ra-taltz-in-psa-at-,Charles Gross,,,,0,0,6022c31b-6cd1-4fed-8ec2-c7f486d3aaa0
2017-06-13T08:00:00.000+08:00,"UPDATE: Lilly Says 'Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance compared with placebo'",LLY,https://www.benzinga.com/news/fda/17/06/9602969/update-lilly-says-analysis-of-12-500-adults-with-type-2-diabetes-from-19-stud,Paul Quintaro,,,,0,0,69ca314b-3d5c-4286-be33-bdc83fb1afb9
2017-06-13T08:00:00.000+08:00,Eli Lilly Reports Jardiance Analysis Reinforces Established Safety Profile,LLY,https://www.benzinga.com/news/fda/17/06/9602960/eli-lilly-reports-jardiance-analysis-reinforces-established-safety-profile,Paul Quintaro,,,,0,0,f00495ca-6003-47a3-98f0-addfe1cb19d4
2017-06-13T08:00:00.000+08:00,Merck Stalls Enrolment in Two Myeloma Studies of Keytruda,LLY,https://www.benzinga.com/17/06/9601762/merck-stalls-enrolment-in-two-myeloma-studies-of-keytruda,Zacks,,,,0,0,b2b2a02a-748a-432f-9d4b-bd417014ccd8
2017-06-13T08:00:00.000+08:00,Lilly Plans New Outcomes Study to Expand Jardiance Label,LLY,https://www.benzinga.com/17/06/9601421/lilly-plans-new-outcomes-study-to-expand-jardiance-label,Zacks,,,,0,0,dc145202-14c1-4662-a03b-ee53686dd958
2017-06-13T08:00:00.000+08:00,Lilly Plans New Outcomes Study to Expand Jardiance Label,LLY,https://www.benzinga.com/17/06/9601422/lilly-plans-new-outcomes-study-to-expand-jardiance-label,Zacks,,,,0,0,991dc1e6-12e3-4e41-a550-848d19900e08
2017-06-13T08:00:00.000+08:00,"Pfizer, Eli Lilly Report Tanezumab Received FDA Fast Track Designation",LLY,https://www.benzinga.com/news/fda/17/06/9600523/pfizer-eli-lilly-report-tanezumab-received-fda-fast-track-designation,Paul Quintaro,,,,0,0,4480638d-e11f-4541-a922-058ce5f47ad6
2017-06-13T08:00:00.000+08:00,"Lilly, Incyte Announce Presentation of New Data on Olumiant in RA, Taltz in PsA at #EULAR 2017",LLY,https://www.benzinga.com/news/17/06/9604917/lilly-incyte-announce-presentation-of-new-data-on-olumiant-in-ra-taltz-in-psa-at-,Charles Gross,,,,0,0,172f141e-b5d7-4d06-8215-884334b48324
2017-06-13T08:00:00.000+08:00,"UPDATE: Lilly Says 'Analysis of 12,500 adults with type 2 diabetes from 19 studies showed amputations and fractures were not increased with Jardiance compared with placebo'",LLY,https://www.benzinga.com/news/fda/17/06/9602969/update-lilly-says-analysis-of-12-500-adults-with-type-2-diabetes-from-19-stud,Paul Quintaro,,,,0,0,34a4e153-5434-4b5a-8a72-e8e445eae187
2017-06-13T08:00:00.000+08:00,Eli Lilly Reports Jardiance Analysis Reinforces Established Safety Profile,LLY,https://www.benzinga.com/news/fda/17/06/9602960/eli-lilly-reports-jardiance-analysis-reinforces-established-safety-profile,Paul Quintaro,,,,0,0,e8ab3229-9760-41fa-8cf3-87eb2e3f5a83
2017-06-13T08:00:00.000+08:00,Merck Stalls Enrolment in Two Myeloma Studies of Keytruda,LLY,https://www.benzinga.com/17/06/9601762/merck-stalls-enrolment-in-two-myeloma-studies-of-keytruda,Zacks,,,,0,0,a577a529-7439-4157-beb3-132199a042ae
2017-06-13T08:00:00.000+08:00,Lilly Plans New Outcomes Study to Expand Jardiance Label,LLY,https://www.benzinga.com/17/06/9601421/lilly-plans-new-outcomes-study-to-expand-jardiance-label,Zacks,,,,0,0,cceb0a45-80cf-4db0-97c2-e6503398ba2c
2017-06-13T08:00:00.000+08:00,Lilly Plans New Outcomes Study to Expand Jardiance Label,LLY,https://www.benzinga.com/17/06/9601422/lilly-plans-new-outcomes-study-to-expand-jardiance-label,Zacks,,,,0,0,8ef695bb-5224-44d1-bffe-9ea465b9f8f2
2017-06-13T08:00:00.000+08:00,"Pfizer, Eli Lilly Report Tanezumab Received FDA Fast Track Designation",LLY,https://www.benzinga.com/news/fda/17/06/9600523/pfizer-eli-lilly-report-tanezumab-received-fda-fast-track-designation,Paul Quintaro,,,,0,0,36b6f19a-9779-4976-9e1e-981b9aaf3c48
2017-06-12T08:00:00.000+08:00,Novartis Presents Positive Data on CAR-T Cell Therapy Drug,LLY,https://www.benzinga.com/17/06/9598892/novartis-presents-positive-data-on-car-t-cell-therapy-drug,Zacks,,,,0,0,69b8f29c-918f-4590-90a7-34f9e626e161
2017-06-12T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce Plans To Conduct New, Large Clinical Outcomes Trial Investigating Jardance For Treatment Of Chronic Kidney Disease",LLY,https://www.benzinga.com/news/fda/17/06/9594198/eli-lilly-boehringer-ingelheim-announce-plans-to-conduct-new-large-clinical-o,Hal Lindon,,,,0,0,6a3c4e09-c530-4766-9df9-c37c59f32907
2017-06-12T08:00:00.000+08:00,Novartis Presents Positive Data on CAR-T Cell Therapy Drug,LLY,https://www.benzinga.com/17/06/9598892/novartis-presents-positive-data-on-car-t-cell-therapy-drug,Zacks,,,,0,0,5e83b787-7dc6-4952-b0e5-efa7850f976e
2017-06-12T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce Plans To Conduct New, Large Clinical Outcomes Trial Investigating Jardance For Treatment Of Chronic Kidney Disease",LLY,https://www.benzinga.com/news/fda/17/06/9594198/eli-lilly-boehringer-ingelheim-announce-plans-to-conduct-new-large-clinical-o,Hal Lindon,,,,0,0,05f473fe-8298-417e-bfe4-03bd67941c11
2017-06-11T08:00:00.000+08:00,Lilly Announces Results Showing Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine Presented at AHS,LLY,https://www.benzinga.com/news/17/06/9592931/lilly-announces-results-showing-galcanezumab-significantly-reduces-number-of-migr,Charles Gross,,,,0,0,c648f6dc-4fd7-4511-93e7-1e8c4b620c66
2017-06-11T08:00:00.000+08:00,Lilly Announces Results Showing Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine Presented at AHS,LLY,https://www.benzinga.com/news/17/06/9592931/lilly-announces-results-showing-galcanezumab-significantly-reduces-number-of-migr,Charles Gross,,,,0,0,9979fc72-10ea-401e-8f58-119e5df24789
2017-06-09T08:00:00.000+08:00,Eli Lilly and the International Diabetes Federation Announce Second Phase of BRIDGES 2 Program,LLY,https://www.benzinga.com/news/17/06/9587690/eli-lilly-and-the-international-diabetes-federation-announce-second-phase-of-brid,Paul Quintaro,,,,0,0,5da68fc6-d35d-4d5e-a83a-f8036228f473
2017-06-09T08:00:00.000+08:00,Eli Lilly and the International Diabetes Federation Announce Second Phase of BRIDGES 2 Program,LLY,https://www.benzinga.com/news/17/06/9587690/eli-lilly-and-the-international-diabetes-federation-announce-second-phase-of-brid,Paul Quintaro,,,,0,0,59cb899f-58ee-4814-a50d-c27837f3206f
2017-06-08T08:00:00.000+08:00,AbbVie (ABBV) Announced Positive Phase III RA Candidate Data,LLY,https://www.benzinga.com/17/06/9583782/abbvie-abbv-announced-positive-phase-iii-ra-candidate-data,Zacks,,,,0,0,6f4faeb4-3c7b-4ed9-b528-ceed398cef45
2017-06-08T08:00:00.000+08:00,Teva Migraine Candidate Succeeds in Second Phase III Study,LLY,https://www.benzinga.com/17/06/9583468/teva-migraine-candidate-succeeds-in-second-phase-iii-study,Zacks,,,,0,0,cf2776fa-a4db-4552-b7bb-8b7054d7fcad
2017-06-08T08:00:00.000+08:00,Eli Lilly to Collaborate with KeyBioscince on Dual Amylin Calcitonin Receptor Agonists,LLY,https://www.benzinga.com/news/17/06/9581590/eli-lilly-to-collaborate-with-keybioscince-on-dual-amylin-calcitonin-receptor-ago,Paul Quintaro,,,,0,0,40b3fb89-5873-47ba-964d-df33263aa102
2017-06-08T08:00:00.000+08:00,AbbVie (ABBV) Announced Positive Phase III RA Candidate Data,LLY,https://www.benzinga.com/17/06/9583782/abbvie-abbv-announced-positive-phase-iii-ra-candidate-data,Zacks,,,,0,0,61066eef-c7ce-4d4f-a113-853019e46280
2017-06-08T08:00:00.000+08:00,Teva Migraine Candidate Succeeds in Second Phase III Study,LLY,https://www.benzinga.com/17/06/9583468/teva-migraine-candidate-succeeds-in-second-phase-iii-study,Zacks,,,,0,0,f39b3c63-9ceb-410d-880f-eab926b4bb52
2017-06-08T08:00:00.000+08:00,Eli Lilly to Collaborate with KeyBioscince on Dual Amylin Calcitonin Receptor Agonists,LLY,https://www.benzinga.com/news/17/06/9581590/eli-lilly-to-collaborate-with-keybioscince-on-dual-amylin-calcitonin-receptor-ago,Paul Quintaro,,,,0,0,7012404b-001f-4813-bbc1-1893f4db276a
2017-06-03T08:00:00.000+08:00,Lilly Announces Initiation of MonarchE Global Phase 3 Study of Abemaciclib as Adjuvant Therapy in Early Breast Cancer #ASCO17,LLY,https://www.benzinga.com/news/17/06/9560837/lilly-announces-initiation-of-monarche-global-phase-3-study-of-abemaciclib-as-adj,Charles Gross,,,,0,0,bb0840c9-d97b-4e72-ad80-db87de493ac5
2017-06-03T08:00:00.000+08:00,Lilly Announces Initiation of MonarchE Global Phase 3 Study of Abemaciclib as Adjuvant Therapy in Early Breast Cancer #ASCO17,LLY,https://www.benzinga.com/news/17/06/9560837/lilly-announces-initiation-of-monarche-global-phase-3-study-of-abemaciclib-as-adj,Charles Gross,,,,0,0,435fc5ba-924e-482a-bc82-4f414d77e484
2017-06-01T08:00:00.000+08:00,"Eli Lilly Announces Derica Rice to Retire as CFO; Co. is Considering Internal, External Candidates",LLY,https://www.benzinga.com/news/17/06/9548231/eli-lilly-announces-derica-rice-to-retire-as-cfo-co-is-considering-internal-exter,Paul Quintaro,,,,0,0,24d53101-1975-4f45-8a02-a405fe65c593
2017-06-01T08:00:00.000+08:00,"Eli Lilly Announces Derica Rice to Retire as CFO; Co. is Considering Internal, External Candidates",LLY,https://www.benzinga.com/news/17/06/9548231/eli-lilly-announces-derica-rice-to-retire-as-cfo-co-is-considering-internal-exter,Paul Quintaro,,,,0,0,a16087a4-45ec-44aa-9414-d255f58ba9a0
2017-05-31T08:00:00.000+08:00,"Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands",LLY,https://www.benzinga.com/news/events/17/05/9542289/bernstein-strategic-decisions-conference-begins-today-presenters-include-e,Hal Lindon,,,,0,0,2056c1fd-a650-4f3b-99c2-9381de820073
2017-05-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Beige Book,LLY,https://www.benzinga.com/news/earnings/17/05/9541176/a-peek-into-the-markets-u-s-stock-futures-up-ahead-of-beige-book,Lisa Levin,,,,0,0,8a4d6e7f-e808-4cfe-9c8a-080760aec885
2017-05-31T08:00:00.000+08:00,Eli Lilly Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA Meets Primary Endpoint,LLY,https://www.benzinga.com/news/fda/17/05/9540920/eli-lilly-phase-3-range-urothelial-cancer-trial-of-cyramza-meets-primary-endp,Paul Quintaro,,,,0,0,0fe7c8df-6641-4af1-be8a-c0dec2ba847d
2017-05-31T08:00:00.000+08:00,"Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands",LLY,https://www.benzinga.com/news/events/17/05/9542289/bernstein-strategic-decisions-conference-begins-today-presenters-include-e,Hal Lindon,,,,0,0,131d5464-ae45-40df-bde5-33c2c31f8862
2017-05-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Beige Book,LLY,https://www.benzinga.com/news/earnings/17/05/9541176/a-peek-into-the-markets-u-s-stock-futures-up-ahead-of-beige-book,Lisa Levin,,,,0,0,7faf8dd3-cb6d-4fb0-8236-4a8fba974379
2017-05-31T08:00:00.000+08:00,Eli Lilly Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA Meets Primary Endpoint,LLY,https://www.benzinga.com/news/fda/17/05/9540920/eli-lilly-phase-3-range-urothelial-cancer-trial-of-cyramza-meets-primary-endp,Paul Quintaro,,,,0,0,735c8180-f8fa-4951-9138-ec20b785ab29
2017-05-30T08:00:00.000+08:00,Monday's Market In 5 Minutes,LLY,https://www.benzinga.com/news/17/05/9534287/mondays-market-in-5-minutes,Benzinga News Desk,,,,0,0,d9805231-2f06-4de1-b142-14ef234c373a
2017-05-30T08:00:00.000+08:00,Monday's Market In 5 Minutes,LLY,https://www.benzinga.com/news/17/05/9534287/mondays-market-in-5-minutes,Benzinga News Desk,,,,0,0,14f6a3f4-df73-40e6-b1ac-cb95515f02b3
2017-05-25T08:00:00.000+08:00,A Look At Nvidia's Largest Shareholders And What Their Presence Means,LLY,https://www.benzinga.com/trading-ideas/long-ideas/17/05/9514507/a-look-at-nvidias-largest-shareholders-and-what-their-presenc,Wayne Duggan,,,,0,0,91e56a9d-0241-4c99-a162-46a4b5dd1448
2017-05-25T08:00:00.000+08:00,A Look At Nvidia's Largest Shareholders And What Their Presence Means,LLY,https://www.benzinga.com/trading-ideas/long-ideas/17/05/9514507/a-look-at-nvidias-largest-shareholders-and-what-their-presenc,Wayne Duggan,,,,0,0,a997135f-9936-4445-a558-6e30e9fa56a2
2017-05-23T08:00:00.000+08:00,"Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9506563/zymeworks-early-but-compelling-data-large-biopharma-part,Ezra Schwarzbaum,,,,0,0,3fa70c8b-1bec-4e00-ae5d-5271b645b6d3
2017-05-23T08:00:00.000+08:00,"Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9506563/zymeworks-early-but-compelling-data-large-biopharma-part,Ezra Schwarzbaum,,,,0,0,8dc84769-2669-4d82-9f0c-18ca5f563bb6
2017-05-17T08:00:00.000+08:00,Watch These 5 Huge Put Purchases In Wednesday Trade,LLY,https://www.benzinga.com/markets/options/17/05/9477836/watch-these-5-huge-put-purchases-in-wednesday-trade,Lisa Levin,,,,0,0,716b5719-90a8-4552-87fe-7bbf3712597c
2017-05-17T08:00:00.000+08:00,Watch These 5 Huge Put Purchases In Wednesday Trade,LLY,https://www.benzinga.com/markets/options/17/05/9477836/watch-these-5-huge-put-purchases-in-wednesday-trade,Lisa Levin,,,,0,0,cab77d0d-f68d-47e4-994f-f399076d513c
2017-05-16T08:00:00.000+08:00,Benzinga's Option Alert Recap From May 16,LLY,https://www.benzinga.com/news/17/05/9476376/benzingas-option-alert-recap-from-may-16,Javier Hasse,,,,0,0,0a921415-fdcd-4ce0-8f44-783c54b4ed81
2017-05-16T08:00:00.000+08:00,Option Alert: Lilly Jun 77.5 Puts Sweep: 1000 @ ASK $1.008: 4230 traded vs 2903 OI: Earnings 7/25 Before Open $78.97 Ref,LLY,https://www.benzinga.com/markets/options/17/05/9474601/option-alert-lilly-jun-77-5-puts-sweep-1000-ask-1-008-4230-traded-vs-2,Charles Gross,,,,0,0,d2771a48-5687-487d-8f4d-298e80e5144e
2017-05-16T08:00:00.000+08:00,Benzinga's Option Alert Recap From May 16,LLY,https://www.benzinga.com/news/17/05/9476376/benzingas-option-alert-recap-from-may-16,Javier Hasse,,,,0,0,8102f8a7-400d-4701-8ebd-fac797346e86
2017-05-16T08:00:00.000+08:00,Option Alert: Lilly Jun 77.5 Puts Sweep: 1000 @ ASK $1.008: 4230 traded vs 2903 OI: Earnings 7/25 Before Open $78.97 Ref,LLY,https://www.benzinga.com/markets/options/17/05/9474601/option-alert-lilly-jun-77-5-puts-sweep-1000-ask-1-008-4230-traded-vs-2,Charles Gross,,,,0,0,d9be58c2-11f5-4f18-a5e1-02e17c122fb8
2017-05-12T08:00:00.000+08:00,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine,LLY,https://www.benzinga.com/news/17/05/9452714/lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-for-th,Charles Gross,,,,0,0,f54e4377-043e-4f25-b86d-31ea69c34f98
2017-05-12T08:00:00.000+08:00,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine,LLY,https://www.benzinga.com/news/17/05/9452714/lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-for-th,Charles Gross,,,,0,0,00827f25-0025-4ffe-8954-eb3a7b360695
2017-05-04T08:00:00.000+08:00,"Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward",LLY,https://www.benzinga.com/news/17/05/9400795/incyte-lilly-disagree-with-fda-crl-for-baricitinib-expects-lilly-to-engage-with-f,Charles Gross,,,,0,0,faccc3d8-5b83-4b43-964e-452ea6507153
2017-05-04T08:00:00.000+08:00,"Incyte, Lilly Disagree With FDA CRL for Baricitinib; Expects Lilly to Engage With FDA to Discuss Agency's Concerns, Determine Potential Path Forward",LLY,https://www.benzinga.com/news/17/05/9400795/incyte-lilly-disagree-with-fda-crl-for-baricitinib-expects-lilly-to-engage-with-f,Charles Gross,,,,0,0,f00b6bba-5a01-4a48-9267-e53781e2e82e
2017-05-01T08:00:00.000+08:00,"10-K Just Recently Out from Eli Lilly Shows Co. Received CID from State of Washington's Office of AG Related to Pricing of Insulin Products, Relationships with PBMs",LLY,https://www.benzinga.com/news/17/05/9377236/10-k-just-recently-out-from-eli-lilly-shows-co-received-cid-from-state-of-washing,Paul Quintaro,,,,0,0,a123ddd1-d36b-4b9a-be1b-2610a1c76529
2017-05-01T08:00:00.000+08:00,"Companies Holding Shareholder Meetings Today Include: American Express, Dish Network, Eli Lilly, And Zynga",LLY,https://www.benzinga.com/news/events/17/05/9375749/companies-holding-shareholder-meetings-today-include-american-express-dish,Hal Lindon,,,,0,0,7333303e-d5e1-4b78-bf53-d85687275689
2017-05-01T08:00:00.000+08:00,"10-K Just Recently Out from Eli Lilly Shows Co. Received CID from State of Washington's Office of AG Related to Pricing of Insulin Products, Relationships with PBMs",LLY,https://www.benzinga.com/news/17/05/9377236/10-k-just-recently-out-from-eli-lilly-shows-co-received-cid-from-state-of-washing,Paul Quintaro,,,,0,0,b9b687f5-e6e4-4b5b-8196-700af8fb9687
2017-05-01T08:00:00.000+08:00,"Companies Holding Shareholder Meetings Today Include: American Express, Dish Network, Eli Lilly, And Zynga",LLY,https://www.benzinga.com/news/events/17/05/9375749/companies-holding-shareholder-meetings-today-include-american-express-dish,Hal Lindon,,,,0,0,7b12d710-859e-4869-b21e-12dec10c087f
2017-04-27T08:00:00.000+08:00,"Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9356865/analyst-sees-eli-lilly-fairly-valued-at-81-per-share-dow,Jayson Derrick,,,,0,0,401b273a-0846-4b3c-b442-2fbb856ef000
2017-04-27T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 27, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/04/9356456/benzingas-top-upgrades-downgrades-for-april-27-2017,Lisa Levin,,,,0,0,74454ee9-1f70-4247-8304-9d33034fb519
2017-04-27T08:00:00.000+08:00,Argus Research Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/17/04/9355322/argus-research-downgrades-eli-lilly-to-hold,Paul Quintaro,,,,0,0,1c029600-379f-42e6-bbcd-10569300e382
2017-04-27T08:00:00.000+08:00,"Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9356865/analyst-sees-eli-lilly-fairly-valued-at-81-per-share-dow,Jayson Derrick,,,,0,0,1b8cd48f-829b-425b-9ae5-0cf20d9cfee9
2017-04-27T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 27, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/04/9356456/benzingas-top-upgrades-downgrades-for-april-27-2017,Lisa Levin,,,,0,0,794fbdc5-63f9-49e2-a06f-e8ae2235c762
2017-04-27T08:00:00.000+08:00,Argus Research Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/17/04/9355322/argus-research-downgrades-eli-lilly-to-hold,Paul Quintaro,,,,0,0,d2091ced-80ec-4809-9e47-c444eb978a88
2017-04-25T08:00:00.000+08:00,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,LLY,https://www.benzinga.com/general/biotech/17/04/9341495/mark-your-calendar-for-these-days-in-may-to-play-the-volatility-around,Shanthi Rexaline,,,,0,0,9cea074f-8053-4af9-a7ee-8e69807f99a3
2017-04-25T08:00:00.000+08:00,"Eli Lilly Reaffirms FY 2017 Sales Guidance, Sees $21.8b to $22.3B vs $22.1B Est",LLY,https://www.benzinga.com/news/guidance/17/04/9339031/eli-lilly-reaffirms-fy-2017-sales-guidance-sees-21-8b-to-22-3b-vs-22-1b-,Paul Quintaro,,,,0,0,d7473396-169f-4437-acce-5b4a2c6dc05d
2017-04-25T08:00:00.000+08:00,"Eli Lilly Reaffirms FY 2017 Adj EPS Guidance, Sees $4.05 to $4.15 vs $4.11 Est",LLY,https://www.benzinga.com/news/guidance/17/04/9339030/eli-lilly-reaffirms-fy-2017-adj-eps-guidance-sees-4-05-to-4-15-vs-4-11-e,Paul Quintaro,,,,0,0,04d471f2-2b3e-4ddb-9306-c9c6f4655f35
2017-04-25T08:00:00.000+08:00,"Eli Lilly Q1 EPS $0.98 vs $0.96 Est, Sales $5.23B vs $5.21B Est",LLY,https://www.benzinga.com/news/earnings/17/04/9339029/eli-lilly-q1-eps-0-98-vs-0-96-est-sales-5-23b-vs-5-21b-est,Paul Quintaro,,,,0,0,ebc6013f-900c-4b73-95c3-f9eab866cfc3
2017-04-25T08:00:00.000+08:00,"15 Stocks To Watch For April 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/04/9338686/15-stocks-to-watch-for-april-25-2017,Lisa Levin,,,,0,0,83a1b90b-17c5-49f2-90ef-ead62355b99f
2017-04-25T08:00:00.000+08:00,"Earnings Scheduled For April 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/04/9338633/earnings-scheduled-for-april-25-2017,Lisa Levin,,,,0,0,04bedb6d-de05-4396-82d7-2f9d7c27a01b
2017-04-25T08:00:00.000+08:00,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,LLY,https://www.benzinga.com/general/biotech/17/04/9341495/mark-your-calendar-for-these-days-in-may-to-play-the-volatility-around,Shanthi Rexaline,,,,0,0,ce609c2e-e10c-40fa-9f3d-b8a6f4a17b57
2017-04-25T08:00:00.000+08:00,"Eli Lilly Reaffirms FY 2017 Sales Guidance, Sees $21.8b to $22.3B vs $22.1B Est",LLY,https://www.benzinga.com/news/guidance/17/04/9339031/eli-lilly-reaffirms-fy-2017-sales-guidance-sees-21-8b-to-22-3b-vs-22-1b-,Paul Quintaro,,,,0,0,bbed2bbb-efc1-4f49-937a-253437f0b846
2017-04-25T08:00:00.000+08:00,"Eli Lilly Reaffirms FY 2017 Adj EPS Guidance, Sees $4.05 to $4.15 vs $4.11 Est",LLY,https://www.benzinga.com/news/guidance/17/04/9339030/eli-lilly-reaffirms-fy-2017-adj-eps-guidance-sees-4-05-to-4-15-vs-4-11-e,Paul Quintaro,,,,0,0,cd370faa-d9d2-4dff-a548-544e43345ac5
2017-04-25T08:00:00.000+08:00,"Eli Lilly Q1 EPS $0.98 vs $0.96 Est, Sales $5.23B vs $5.21B Est",LLY,https://www.benzinga.com/news/earnings/17/04/9339029/eli-lilly-q1-eps-0-98-vs-0-96-est-sales-5-23b-vs-5-21b-est,Paul Quintaro,,,,0,0,ab9698e7-2175-488b-960e-b851222edce3
2017-04-25T08:00:00.000+08:00,"15 Stocks To Watch For April 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/04/9338686/15-stocks-to-watch-for-april-25-2017,Lisa Levin,,,,0,0,4c3edf26-690a-457e-a77b-fcdea0251ac4
2017-04-25T08:00:00.000+08:00,"Earnings Scheduled For April 25, 2017",LLY,https://www.benzinga.com/news/earnings/17/04/9338633/earnings-scheduled-for-april-25-2017,Lisa Levin,,,,0,0,633c0931-6fa8-4a2d-9803-856b4ebea00d
2017-04-24T08:00:00.000+08:00,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9336445/earnings-caterpillar-lockheed-martin-and-eli-lilly-repor,The Ticker Tape,,,,0,0,2ede0a79-e9be-4272-9d37-9b59cd26be50
2017-04-24T08:00:00.000+08:00,Eli Lilly Announces Phase 3 study Comparing Abemaciclib in Combination with an aromatase Met its Primary Endpoint,LLY,https://www.benzinga.com/news/fda/17/04/9333621/eli-lilly-announces-phase-3-study-comparing-abemaciclib-in-combination-with-a,Paul Quintaro,,,,0,0,2e94407b-f5ba-4f59-9232-ff889edd8f00
2017-04-24T08:00:00.000+08:00,"Earnings: Caterpillar, Lockheed Martin, and Eli Lilly Report Tomorrow",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9336445/earnings-caterpillar-lockheed-martin-and-eli-lilly-repor,The Ticker Tape,,,,0,0,b0bc743f-cac1-49c7-90fd-c58b2a6f5097
2017-04-24T08:00:00.000+08:00,Eli Lilly Announces Phase 3 study Comparing Abemaciclib in Combination with an aromatase Met its Primary Endpoint,LLY,https://www.benzinga.com/news/fda/17/04/9333621/eli-lilly-announces-phase-3-study-comparing-abemaciclib-in-combination-with-a,Paul Quintaro,,,,0,0,3bda9395-1cc7-4d23-b7d4-6e33a556b638
2017-04-20T08:00:00.000+08:00,What Would A $5.8 Billion NIH Cut Look Like? Devastation,LLY,https://www.benzinga.com/news/17/04/9308625/what-would-a-5-8-billion-nih-cut-look-like-devastation,Elizabeth Balboa,,,,0,0,cc29996c-c0ce-4178-9826-11d4ce1e9df6
2017-04-20T08:00:00.000+08:00,What Would A $5.8 Billion NIH Cut Look Like? Devastation,LLY,https://www.benzinga.com/news/17/04/9308625/what-would-a-5-8-billion-nih-cut-look-like-devastation,Elizabeth Balboa,,,,0,0,886da679-1cbc-41d9-a3ce-5724cb46c179
2017-04-17T08:00:00.000+08:00,15 Biggest Mid-Day Losers For Monday,LLY,https://www.benzinga.com/news/17/04/9306429/15-biggest-mid-day-losers-for-monday,Lisa Levin,,,,0,0,45ecb00c-1939-483c-9582-c70d5b81ddcb
2017-04-17T08:00:00.000+08:00,Hearing Leerink Defending Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9305474/hearing-leerink-defending-eli-lilly,Hal Lindon,,,,0,0,9b7acd36-284e-47ef-8beb-4b3ff8f29bc9
2017-04-17T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 17, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/04/9305337/benzingas-top-upgrades-downgrades-for-april-17-2017,Lisa Levin,,,,0,0,3c9b8315-7167-4380-9205-d7aff73ff2e5
2017-04-17T08:00:00.000+08:00,20 Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/17/04/9304944/20-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,b4856a4d-c623-456f-8d5a-8c05e7c7b3fa
2017-04-17T08:00:00.000+08:00,BMO Capital Downgrades Eli Lilly to Underperform,LLY,https://www.benzinga.com/news/17/04/9304923/bmo-capital-downgrades-eli-lilly-to-underperform,Paul Quintaro,,,,0,0,bc622329-b2a0-4a37-83b3-6a9260b16f4f
2017-04-17T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,LLY,https://www.benzinga.com/news/17/04/9304915/morgan-stanley-downgrades-eli-lilly-to-equal-weight,Paul Quintaro,,,,0,0,b4d36a9c-c701-4a50-8f23-037a4d2516e5
2017-04-17T08:00:00.000+08:00,"Eli Lilly -4.7% Premarket @ $81.88, Incyte -12.7% @ $123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant",LLY,https://www.benzinga.com/news/17/04/9304475/eli-lilly-4-7-premarket-81-88-incyte-12-7-123-fda-on-friday-declined-to-approve-l,Charles Gross,,,,0,0,4e1a1892-fb5a-4915-9168-41ea3ef4a460
2017-04-17T08:00:00.000+08:00,15 Biggest Mid-Day Losers For Monday,LLY,https://www.benzinga.com/news/17/04/9306429/15-biggest-mid-day-losers-for-monday,Lisa Levin,,,,0,0,0c6ecca5-6734-4141-991c-0c662fce01c5
2017-04-17T08:00:00.000+08:00,Hearing Leerink Defending Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9305474/hearing-leerink-defending-eli-lilly,Hal Lindon,,,,0,0,fa4a2056-7409-4891-b99c-7b1979294b26
2017-04-17T08:00:00.000+08:00,"Benzinga's Top Upgrades, Downgrades For April 17, 2017",LLY,https://www.benzinga.com/analyst-ratings/upgrades/17/04/9305337/benzingas-top-upgrades-downgrades-for-april-17-2017,Lisa Levin,,,,0,0,4b5df949-ebe2-4938-b770-2ebda4043f3b
2017-04-17T08:00:00.000+08:00,20 Stocks Moving In Monday's Pre-Market Session,LLY,https://www.benzinga.com/news/17/04/9304944/20-stocks-moving-in-mondays-pre-market-session,Lisa Levin,,,,0,0,d3a7bf11-1edf-49d0-b400-4a2e440155ca
2017-04-17T08:00:00.000+08:00,BMO Capital Downgrades Eli Lilly to Underperform,LLY,https://www.benzinga.com/news/17/04/9304923/bmo-capital-downgrades-eli-lilly-to-underperform,Paul Quintaro,,,,0,0,cab65777-7cb7-499d-b4b5-524a6e544325
2017-04-17T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equal-Weight,LLY,https://www.benzinga.com/news/17/04/9304915/morgan-stanley-downgrades-eli-lilly-to-equal-weight,Paul Quintaro,,,,0,0,8a1250c9-7bed-4cac-8ffa-1d4edb664ca3
2017-04-17T08:00:00.000+08:00,"Eli Lilly -4.7% Premarket @ $81.88, Incyte -12.7% @ $123; FDA on Friday Declined to Approve, Lilly, Incyte Arthritis Drug Olumiant",LLY,https://www.benzinga.com/news/17/04/9304475/eli-lilly-4-7-premarket-81-88-incyte-12-7-123-fda-on-friday-declined-to-approve-l,Charles Gross,,,,0,0,0706feac-f883-4459-a681-8e18f207d62e
2017-04-14T08:00:00.000+08:00,"Lilly Reaffirms Financial Guidance for 2017, Mid-term Guidance for Remainder of this Decade",LLY,https://www.benzinga.com/news/earnings/17/04/9302180/lilly-reaffirms-financial-guidance-for-2017-mid-term-guidance-for-remain,Charles Gross,,,,0,0,4ab61aa8-4dc6-4d23-96a4-b9222a1fcdf5
2017-04-14T08:00:00.000+08:00,"Lilly, Incyte Announce FDA Issues CRL for Baricitinib",LLY,https://www.benzinga.com/news/earnings/17/04/9302178/lilly-incyte-announce-fda-issues-crl-for-baricitinib,Charles Gross,,,,0,0,1c2edef0-b414-4f06-bb58-34b6314b0e9e
2017-04-14T08:00:00.000+08:00,"Lilly Reaffirms Financial Guidance for 2017, Mid-term Guidance for Remainder of this Decade",LLY,https://www.benzinga.com/news/earnings/17/04/9302180/lilly-reaffirms-financial-guidance-for-2017-mid-term-guidance-for-remain,Charles Gross,,,,0,0,152dfca7-4d3d-4cd4-8aea-1c247c8bed9b
2017-04-14T08:00:00.000+08:00,"Lilly, Incyte Announce FDA Issues CRL for Baricitinib",LLY,https://www.benzinga.com/news/earnings/17/04/9302178/lilly-incyte-announce-fda-issues-crl-for-baricitinib,Charles Gross,,,,0,0,5a65229b-a13d-4064-b830-a6f84146b61a
2017-04-12T08:00:00.000+08:00,Healthcare Sector Earnings: Making A Comeback In Q1 2017?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9293543/healthcare-sector-earnings-making-a-comeback-in-q1-2017,The Ticker Tape,,,,0,0,dd272edf-fd7f-48aa-bad1-dda3a12def84
2017-04-12T08:00:00.000+08:00,Endpoint Reporter John Carroll Tweets: $LLY spokesperson says they are not disclosing the exact date on bari PDUFA. Really? What's the point of that?,LLY,https://www.benzinga.com/news/fda/17/04/9293422/endpoint-reporter-john-carroll-tweets-lly-spokesperson-says-they-are-not-disc,Hal Lindon,,,,0,0,12319ce5-811b-443d-a7f5-a0c68a4d1935
2017-04-12T08:00:00.000+08:00,Healthcare Sector Earnings: Making A Comeback In Q1 2017?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9293543/healthcare-sector-earnings-making-a-comeback-in-q1-2017,The Ticker Tape,,,,0,0,00b7c38c-a332-4af2-adbf-c9eff02febf9
2017-04-12T08:00:00.000+08:00,Endpoint Reporter John Carroll Tweets: $LLY spokesperson says they are not disclosing the exact date on bari PDUFA. Really? What's the point of that?,LLY,https://www.benzinga.com/news/fda/17/04/9293422/endpoint-reporter-john-carroll-tweets-lly-spokesperson-says-they-are-not-disc,Hal Lindon,,,,0,0,76e53775-d5b1-4d16-8020-6b59c5d7dcab
2017-04-07T08:00:00.000+08:00,FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements,LLY,https://www.benzinga.com/news/17/04/9276350/fda-warns-of-dangerous-hidden-ingredient-in-5-otc-male-sexual-enhancement-supplem,Wayne Duggan,,,,0,0,d34070c0-ab67-4e83-ba3a-3489d20e207d
2017-04-07T08:00:00.000+08:00,FDA Warns Of Dangerous Hidden Ingredient In 5 OTC Male Sexual Enhancement Supplements,LLY,https://www.benzinga.com/news/17/04/9276350/fda-warns-of-dangerous-hidden-ingredient-in-5-otc-male-sexual-enhancement-supplem,Wayne Duggan,,,,0,0,c5ffd7e7-f114-404b-964e-86090ba899cd
2017-04-05T08:00:00.000+08:00,"Eli Lilly Spokesperson, Asked If 3-Month Delay In Baricitinib PDUFA Date Announced Jan. 13 Sets New PDUFA Date At Apr. 13, Tells Benzinga 'We Are Not Disclosing A Specific Date For PDUFA'",LLY,https://www.benzinga.com/general/biotech/17/04/9264950/eli-lilly-spokesperson-asked-if-3-month-delay-in-baricitinib-pdufa-dat,Hal Lindon,,,,0,0,5701a9c8-1549-4986-8628-98b33ed50161
2017-04-05T08:00:00.000+08:00,"Eli Lilly Spokesperson, Asked If 3-Month Delay In Baricitinib PDUFA Date Announced Jan. 13 Sets New PDUFA Date At Apr. 13, Tells Benzinga 'We Are Not Disclosing A Specific Date For PDUFA'",LLY,https://www.benzinga.com/general/biotech/17/04/9264950/eli-lilly-spokesperson-asked-if-3-month-delay-in-baricitinib-pdufa-dat,Hal Lindon,,,,0,0,cc1814bf-b963-46f7-b566-aad55368e17e
2017-03-31T08:00:00.000+08:00,Eli Lilly Endowment Reports Open Market Sale Of 210K Shares Of Common Stock At $84.67 Per SEC Filing,LLY,https://www.benzinga.com/news/insider-trades/17/03/9242733/eli-lilly-endowment-reports-open-market-sale-of-210k-shares-of-com,Paul Quintaro,,,,0,0,8f3f0ced-ced0-40ec-b145-0f61348c5c6b
2017-03-31T08:00:00.000+08:00,Eli Lilly Endowment Reports Open Market Sale Of 210K Shares Of Common Stock At $84.67 Per SEC Filing,LLY,https://www.benzinga.com/news/insider-trades/17/03/9242733/eli-lilly-endowment-reports-open-market-sale-of-210k-shares-of-com,Paul Quintaro,,,,0,0,4b9b1b1b-958c-447e-8d8d-c612d6c4cb2d
2017-03-28T08:00:00.000+08:00,"If Gender Confirmation Becomes A Legal Human Right, Which Corporations Could Benefit?",LLY,https://www.benzinga.com/news/17/03/9224070/if-gender-confirmation-becomes-a-legal-human-right-which-corporations-could-benef,Elizabeth Balboa,,,,0,0,d69adb1e-83e2-47cb-83ca-4a85a053770b
2017-03-28T08:00:00.000+08:00,IntelGenx Reports Eli Lilly Granted Co. VersaFilm an Exclusive License for Tadalafil Film Under ED Dosing Patent,LLY,https://www.benzinga.com/news/17/03/9223249/intelgenx-reports-eli-lilly-granted-co-versafilm-an-exclusive-license-for-tadalaf,Paul Quintaro,,,,0,0,35640389-9477-4f4a-a2e2-e5a6bb405dce
2017-03-28T08:00:00.000+08:00,"If Gender Confirmation Becomes A Legal Human Right, Which Corporations Could Benefit?",LLY,https://www.benzinga.com/news/17/03/9224070/if-gender-confirmation-becomes-a-legal-human-right-which-corporations-could-benef,Elizabeth Balboa,,,,0,0,47daf6e2-947d-4dd0-a3d2-a84bf8e72ff1
2017-03-28T08:00:00.000+08:00,IntelGenx Reports Eli Lilly Granted Co. VersaFilm an Exclusive License for Tadalafil Film Under ED Dosing Patent,LLY,https://www.benzinga.com/news/17/03/9223249/intelgenx-reports-eli-lilly-granted-co-versafilm-an-exclusive-license-for-tadalaf,Paul Quintaro,,,,0,0,cff5010d-41a0-411d-b1bd-32d26d34d5d4
2017-03-24T08:00:00.000+08:00,Eli Lilly Announces Plans To Invest $850M In U.S. Operations In 2017,LLY,https://www.benzinga.com/news/17/03/9212125/eli-lilly-announces-plans-to-invest-850m-in-u-s-operations-in-2017,Paul Quintaro,,,,0,0,a146bb34-aec4-4981-acd9-2c7ba2e2ca09
2017-03-24T08:00:00.000+08:00,Eli Lilly Announces Plans To Invest $850M In U.S. Operations In 2017,LLY,https://www.benzinga.com/news/17/03/9212125/eli-lilly-announces-plans-to-invest-850m-in-u-s-operations-in-2017,Paul Quintaro,,,,0,0,9000a7ce-e0c3-478f-9736-24fb9878b774
2017-03-23T08:00:00.000+08:00,"Ignyta Announces Exploration Of Strategic Options For Taladegib, Enalbed By New License Agreement With Eli Lilly",LLY,https://www.benzinga.com/news/17/03/9210145/ignyta-announces-exploration-of-strategic-options-for-taladegib-enalbed-by-new-li,Hal Lindon,,,,0,0,1abe83fd-ddeb-43e0-8bfc-c40f80540d89
2017-03-23T08:00:00.000+08:00,"Ignyta Announces Exploration Of Strategic Options For Taladegib, Enalbed By New License Agreement With Eli Lilly",LLY,https://www.benzinga.com/news/17/03/9210145/ignyta-announces-exploration-of-strategic-options-for-taladegib-enalbed-by-new-li,Hal Lindon,,,,0,0,561bac28-94c9-4c2c-bbee-ed88de243739
2017-03-20T08:00:00.000+08:00,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9182637/leerink-presents-your-2017-biopharma-catalyst-tracker,Shanthi Rexaline,,,,0,0,cb263d8f-7942-4b83-8b0f-fddad60deefe
2017-03-20T08:00:00.000+08:00,Eli Lilly Announces MONARCH 2 Trial of Abemaciclib Met Primary Endpoint of Progression Free Survival,LLY,https://www.benzinga.com/news/17/03/9189873/eli-lilly-announces-monarch-2-trial-of-abemaciclib-met-primary-endpoint-of-progre,Paul Quintaro,,,,0,0,c595dc85-355a-42fc-b59d-2e90a73543b3
2017-03-20T08:00:00.000+08:00,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9182637/leerink-presents-your-2017-biopharma-catalyst-tracker,Shanthi Rexaline,,,,0,0,29856013-299c-4b8e-a36c-a229518c59c1
2017-03-20T08:00:00.000+08:00,Eli Lilly Announces MONARCH 2 Trial of Abemaciclib Met Primary Endpoint of Progression Free Survival,LLY,https://www.benzinga.com/news/17/03/9189873/eli-lilly-announces-monarch-2-trial-of-abemaciclib-met-primary-endpoint-of-progre,Paul Quintaro,,,,0,0,77c9f7e0-0bea-40cf-8de5-3afaf20befea
2017-03-17T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report 'EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes'",LLY,https://www.benzinga.com/news/fda/17/03/9184772/eli-lilly-boehringer-ingelheim-report-emperor-hf-clinical-trial-program-will-,Paul Quintaro,,,,0,0,79c4599c-037a-486c-b3ee-aa72ea8a867f
2017-03-17T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report 'EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes'",LLY,https://www.benzinga.com/news/fda/17/03/9184772/eli-lilly-boehringer-ingelheim-report-emperor-hf-clinical-trial-program-will-,Paul Quintaro,,,,0,0,64c231ea-649c-40b9-a387-e81334aa47d1
2017-03-16T08:00:00.000+08:00,Lilly Drops to Low of $84.16 on Volume,LLY,https://www.benzinga.com/movers/17/03/9181306/lilly-drops-to-low-of-84-16-on-volume,Charles Gross,,,,0,0,ec1697b2-f8a5-4c45-a2c6-e08464a24a0c
2017-03-16T08:00:00.000+08:00,Lilly Drops to Low of $84.16 on Volume,LLY,https://www.benzinga.com/movers/17/03/9181306/lilly-drops-to-low-of-84-16-on-volume,Charles Gross,,,,0,0,3eebd3d6-61c7-4c56-a229-1dc14296d27f
2017-03-07T08:00:00.000+08:00,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",LLY,https://www.benzinga.com/news/events/17/03/9138971/cowen-annual-healthcare-conference-continues-today-presenters-include-regu,Hal Lindon,,,,0,0,8465723e-0ba6-4bb3-9bd1-3d9d77033ee4
2017-03-07T08:00:00.000+08:00,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",LLY,https://www.benzinga.com/news/events/17/03/9138971/cowen-annual-healthcare-conference-continues-today-presenters-include-regu,Hal Lindon,,,,0,0,eda0ba4a-385b-4c5b-84b7-86ec8354d2a5
2017-03-05T08:00:00.000+08:00,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz vs Stelara in Patients with Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/fintech/17/03/9131060/new-head-to-head-data-shows-significantly-higher-response-rates-for-lillys-tal,Charles Gross,,,,0,0,f65c0202-08d7-4cb7-bba6-21b043c8d2e0
2017-03-05T08:00:00.000+08:00,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz vs Stelara in Patients with Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/fintech/17/03/9131060/new-head-to-head-data-shows-significantly-higher-response-rates-for-lillys-tal,Charles Gross,,,,0,0,2944462c-f790-4f1d-9e08-40bc2237a920
2017-03-03T08:00:00.000+08:00,Chi-Med Announces Positive Top-Line Results for FRESCO Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer,LLY,https://www.benzinga.com/news/17/03/9125280/chi-med-announces-positive-top-line-results-for-fresco-phase-iii-pivotal-registra,Charles Gross,,,,0,0,1451c117-5107-45b2-af0c-8bb676e48cec
2017-03-03T08:00:00.000+08:00,Chi-Med Announces Positive Top-Line Results for FRESCO Phase III Pivotal Registration Trial of Fruquintinib in Patients with Locally Advanced or Metastatic Colorectal Cancer,LLY,https://www.benzinga.com/news/17/03/9125280/chi-med-announces-positive-top-line-results-for-fresco-phase-iii-pivotal-registra,Charles Gross,,,,0,0,20ad0de2-f627-49c1-a53a-a0e49baef62c
2017-02-24T08:00:00.000+08:00,Carl Icahn's Track Record In Big Pharma,LLY,https://www.benzinga.com/general/biotech/17/02/9084990/carl-icahns-track-record-in-big-pharma,Shanthi Rexaline,,,,0,0,414294ef-7415-48a3-823d-c33532711bd5
2017-02-24T08:00:00.000+08:00,Carl Icahn's Track Record In Big Pharma,LLY,https://www.benzinga.com/general/biotech/17/02/9084990/carl-icahns-track-record-in-big-pharma,Shanthi Rexaline,,,,0,0,e8ec0cb0-b62a-4ee3-a784-692606338976
2017-02-16T08:00:00.000+08:00,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?",LLY,https://www.benzinga.com/general/biotech/17/02/9061803/after-merck-stops-study-what-remains-of-the-alzheimers-drug-pipeline,Taylor Cox,,,,0,0,5a82626a-d859-4d63-9f67-6c70b26e0d2e
2017-02-16T08:00:00.000+08:00,Border Tax Polarizes U.S Companies As Exporters Take Side With Trump Team,LLY,https://www.benzinga.com/general/politics/17/02/9054755/border-tax-polarizes-u-s-companies-as-exporters-take-side-with-trump-,Shanthi Rexaline,,,,0,0,effe7460-b1f1-4026-aa9e-0cfe5fd24742
2017-02-16T08:00:00.000+08:00,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?",LLY,https://www.benzinga.com/general/biotech/17/02/9061803/after-merck-stops-study-what-remains-of-the-alzheimers-drug-pipeline,Taylor Cox,,,,0,0,1115977b-addc-4781-b20f-dcd4a4900ce2
2017-02-16T08:00:00.000+08:00,Border Tax Polarizes U.S Companies As Exporters Take Side With Trump Team,LLY,https://www.benzinga.com/general/politics/17/02/9054755/border-tax-polarizes-u-s-companies-as-exporters-take-side-with-trump-,Shanthi Rexaline,,,,0,0,5bec956c-ed2b-4021-9d03-cf7bdf73de4d
2017-02-15T08:00:00.000+08:00,Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine,LLY,https://www.benzinga.com/general/biotech/17/02/9056642/eli-lilly-incyte-announce-addl-results-from-pivotal-ra-beam-study-in-n,Hal Lindon,,,,0,0,e1b6853c-de15-43b6-8cc4-b03f919a570e
2017-02-15T08:00:00.000+08:00,Eli Lilly & Incyte Announce Add'l Results From Pivotal RA-BEAM Study In New England Journal Of Medicine,LLY,https://www.benzinga.com/general/biotech/17/02/9056642/eli-lilly-incyte-announce-addl-results-from-pivotal-ra-beam-study-in-n,Hal Lindon,,,,0,0,ad71e6f7-3a87-47d9-9455-4d1e3b2eadb1
2017-02-13T08:00:00.000+08:00,"UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive $65M Milestone Payment",LLY,https://www.benzinga.com/news/17/02/9037913/update-eli-lilly-says-as-a-result-of-olumiant-approval-by-ec-incyte-becomes-eligi,Paul Quintaro,,,,0,0,f25d916f-187b-40e8-9a57-9bc4f6ae6ada
2017-02-13T08:00:00.000+08:00,Eli Lilly Reports EC Approved Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active RA,LLY,https://www.benzinga.com/news/17/02/9037900/eli-lilly-reports-ec-approved-once-daily-olumiant-tablets-for-treatment-of-adults,Paul Quintaro,,,,0,0,98f6ebfd-3719-4fc9-8577-653ff3e7e70e
2017-02-13T08:00:00.000+08:00,"UPDATE: Eli Lilly Says, As a Result of Olumiant Approval by EC, Incyte Becomes Eligible to Receive $65M Milestone Payment",LLY,https://www.benzinga.com/news/17/02/9037913/update-eli-lilly-says-as-a-result-of-olumiant-approval-by-ec-incyte-becomes-eligi,Paul Quintaro,,,,0,0,93d8631b-3fe7-4ab0-8e28-32f18442091f
2017-02-13T08:00:00.000+08:00,Eli Lilly Reports EC Approved Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active RA,LLY,https://www.benzinga.com/news/17/02/9037900/eli-lilly-reports-ec-approved-once-daily-olumiant-tablets-for-treatment-of-adults,Paul Quintaro,,,,0,0,84637920-af4d-4536-89b6-daf7f4099399
2017-02-08T08:00:00.000+08:00,Eli Lilly Reports Trulicity Label Updated to Include Use in Combo with Basal Insulin for Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/17/02/9010327/eli-lilly-reports-trulicity-label-updated-to-include-use-in-combo-with-basal-insu,Paul Quintaro,,,,0,0,44661fac-90cf-45af-a4dd-0d177ca87cb2
2017-02-08T08:00:00.000+08:00,Eli Lilly Reports Trulicity Label Updated to Include Use in Combo with Basal Insulin for Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/17/02/9010327/eli-lilly-reports-trulicity-label-updated-to-include-use-in-combo-with-basal-insu,Paul Quintaro,,,,0,0,29ab9e5e-74fc-4653-a426-5830d3b75a25
2017-02-02T08:00:00.000+08:00,Eli Lilly Reprots Japan IP High Court Rules In Favor In Invalidation Trials Initiated By Sawai Regarding Vitamin Regimen Patents For Alimta,LLY,https://www.benzinga.com/news/legal/17/02/8985156/eli-lilly-reprots-japan-ip-high-court-rules-in-favor-in-invalidation-trials,Paul Quintaro,,,,0,0,63e4e543-79ed-4542-80ee-11678b8031fd
2017-02-02T08:00:00.000+08:00,Eli Lilly Reprots Japan IP High Court Rules In Favor In Invalidation Trials Initiated By Sawai Regarding Vitamin Regimen Patents For Alimta,LLY,https://www.benzinga.com/news/legal/17/02/8985156/eli-lilly-reprots-japan-ip-high-court-rules-in-favor-in-invalidation-trials,Paul Quintaro,,,,0,0,abfc0e1d-e1ab-4d1f-80da-2a487af170b1
2017-01-31T08:00:00.000+08:00,"Eli Lilly CEO Says Too Early To Say If Amyloid-Beta Hypothesis For Alzheihmer's Is Wrong, Believes BACE Inhibitors Data Will Shed More Light",LLY,https://www.benzinga.com/news/17/01/8972532/eli-lilly-ceo-says-too-early-to-say-if-amyloid-beta-hypothesis-for-alzheihmers-is,Paul Quintaro,,,,0,0,9d529339-f5e5-4fbe-bd29-5906aa643565
2017-01-31T08:00:00.000+08:00,"Eli Lilly CEO Says President Trump Didn't Get Into Collaborative Policy Detail In Terms Of U.S. Pricing Environment, Left Meeting With Confidence In People Who Would Work Closely With Legislation Moving Forward",LLY,https://www.benzinga.com/news/17/01/8972494/eli-lilly-ceo-says-president-trump-didnt-get-into-collaborative-policy-detail-in-,Paul Quintaro,,,,0,0,46f937b5-3048-4e78-b10e-a998a33a02ef
2017-01-31T08:00:00.000+08:00,Eli Lilly Says Quarterly Rev. Growth Led By Volume On Conf. Call,LLY,https://www.benzinga.com/news/17/01/8972402/eli-lilly-says-quarterly-rev-growth-led-by-volume-on-conf-call,Paul Quintaro,,,,0,0,7c768def-60ac-4a8e-a834-0b6be1993fa2
2017-01-31T08:00:00.000+08:00,US Commercial News Managing Editor Mandy Jackson Tweets: $LLY terminated EXPEDITION PRO study in prodromal Alzheimer's disease.,LLY,https://www.benzinga.com/news/17/01/8972323/us-commercial-news-managing-editor-mandy-jackson-tweets-lly-terminated-expedition,Paul Quintaro,,,,0,0,fa4e5553-acf8-49fa-b002-362f3cc18388
2017-01-31T08:00:00.000+08:00,"President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'",LLY,https://www.benzinga.com/general/biotech/17/01/8971909/president-trump-doubles-down-on-healthcare-criticism-says-drug-prices-,Jayson Derrick,,,,0,0,ce337312-d38c-456c-aac2-e77af3be10f4
2017-01-31T08:00:00.000+08:00,"Fed Meeting Starts Today, But Focus Remains On Key Earnings Data",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8971667/fed-meeting-starts-today-but-focus-remains-on-key-earnin,The Ticker Tape,,,,0,0,a9b24e56-b940-47be-93b2-25c4afb457c0
2017-01-31T08:00:00.000+08:00,"CNBC's Meg Tirrell Tweets: $LLY CEO tells Trump tax, deregulation could really help us expand operations",LLY,https://www.benzinga.com/general/politics/17/01/8971432/cnbcs-meg-tirrell-tweets-lly-ceo-tells-trump-tax-deregulation-could-r,Paul Quintaro,,,,0,0,5ca52d7c-7ecc-4ed0-a6b1-7976f6caec36
2017-01-31T08:00:00.000+08:00,"The Market In 5 Minutes: Under Armour's Miss, Apple's Q1 Primer",LLY,https://www.benzinga.com/news/17/01/8970347/the-market-in-5-minutes-under-armours-miss-apples-q1-primer,Benzinga News Desk,,,,0,0,2cd47b6e-4e62-4627-a7ab-90876b41ab94
2017-01-31T08:00:00.000+08:00,"Healthcare Q4: Eli Lilly Beats, Pfizer Misses",LLY,https://www.benzinga.com/general/biotech/17/01/8970589/healthcare-q4-eli-lilly-beats-pfizer-misses,Jayson Derrick,,,,0,0,0097b60d-c556-4880-a612-d6501308c9dd
2017-01-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Down; Apple Earnings In Focus,LLY,https://www.benzinga.com/news/earnings/17/01/8970273/a-peek-into-the-markets-u-s-stock-futures-down-apple-earnings-in-focus,Lisa Levin,,,,0,0,d49a9511-f22c-4728-aa71-bc483d16a5f6
2017-01-31T08:00:00.000+08:00,Lilly Reaffirms FY17 Adj. EPS Outlook $4.05-$4.15 vs $4.10 Est.,LLY,https://www.benzinga.com/news/guidance/17/01/8969884/lilly-reaffirms-fy17-adj-eps-outlook-4-05-4-15-vs-4-10-est,Paul Quintaro,,,,0,0,68a54221-2e23-4180-82d6-b7a36d39563e
2017-01-31T08:00:00.000+08:00,"Eli Lilly Reports Q4 EPS $0.95 vs $0.98 Est., Sales $5.761B vs $5.55B Est.",LLY,https://www.benzinga.com/news/earnings/17/01/8969882/eli-lilly-reports-q4-eps-0-95-vs-0-98-est-sales-5-761b-vs-5-55b-est,Paul Quintaro,,,,0,0,6d92cc48-65f2-4003-bfd1-16badf4408a6
2017-01-31T08:00:00.000+08:00,15 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/17/01/8969608/15-stocks-you-should-be-watching-today,Lisa Levin,,,,0,0,16ff7b30-6061-4e92-a3c5-730398064f12
2017-01-31T08:00:00.000+08:00,Jaguar Animal Health +60% Premarket @$0.85 After Announcement of Deal with Lilly Subsidiary,LLY,https://www.benzinga.com/news/17/01/8969579/jaguar-animal-health-60-premarket-0-85-after-announcement-of-deal-with-lilly-subs,Charles Gross,,,,0,0,800742c4-0b94-4ed7-96af-35ecc8a7e0da
2017-01-31T08:00:00.000+08:00,"Earnings Scheduled For January 31, 2017",LLY,https://www.benzinga.com/news/earnings/17/01/8969578/earnings-scheduled-for-january-31-2017,Lisa Levin,,,,0,0,4531c02f-089f-44b4-acf5-b6f08283d023
2017-01-31T08:00:00.000+08:00,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M",LLY,https://www.benzinga.com/news/17/01/8969575/jaguar-animal-health-elanco-announce-global-collaboration-for-development-co-prom,Charles Gross,,,,0,0,eedc86b1-2732-4d5b-ab4d-07b2aef4cddf
2017-01-31T08:00:00.000+08:00,"Eli Lilly CEO Says Too Early To Say If Amyloid-Beta Hypothesis For Alzheihmer's Is Wrong, Believes BACE Inhibitors Data Will Shed More Light",LLY,https://www.benzinga.com/news/17/01/8972532/eli-lilly-ceo-says-too-early-to-say-if-amyloid-beta-hypothesis-for-alzheihmers-is,Paul Quintaro,,,,0,0,39f690f2-080c-4ba3-a4d4-bdd505c7a0db
2017-01-31T08:00:00.000+08:00,"Eli Lilly CEO Says President Trump Didn't Get Into Collaborative Policy Detail In Terms Of U.S. Pricing Environment, Left Meeting With Confidence In People Who Would Work Closely With Legislation Moving Forward",LLY,https://www.benzinga.com/news/17/01/8972494/eli-lilly-ceo-says-president-trump-didnt-get-into-collaborative-policy-detail-in-,Paul Quintaro,,,,0,0,68dd93d9-ebe3-492f-ae94-a0a52d5f29e8
2017-01-31T08:00:00.000+08:00,Eli Lilly Says Quarterly Rev. Growth Led By Volume On Conf. Call,LLY,https://www.benzinga.com/news/17/01/8972402/eli-lilly-says-quarterly-rev-growth-led-by-volume-on-conf-call,Paul Quintaro,,,,0,0,870a4b20-0c6a-42e8-8ea2-15ad781f1a6a
2017-01-31T08:00:00.000+08:00,US Commercial News Managing Editor Mandy Jackson Tweets: $LLY terminated EXPEDITION PRO study in prodromal Alzheimer's disease.,LLY,https://www.benzinga.com/news/17/01/8972323/us-commercial-news-managing-editor-mandy-jackson-tweets-lly-terminated-expedition,Paul Quintaro,,,,0,0,cc1a56d1-dd74-4673-9715-2fefe19fddc7
2017-01-31T08:00:00.000+08:00,"President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'",LLY,https://www.benzinga.com/general/biotech/17/01/8971909/president-trump-doubles-down-on-healthcare-criticism-says-drug-prices-,Jayson Derrick,,,,0,0,7baf94b7-0b55-4c4e-b48b-ad88c7b6cd08
2017-01-31T08:00:00.000+08:00,"Fed Meeting Starts Today, But Focus Remains On Key Earnings Data",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8971667/fed-meeting-starts-today-but-focus-remains-on-key-earnin,The Ticker Tape,,,,0,0,b446d64d-c860-4804-9b0a-5c116e476f17
2017-01-31T08:00:00.000+08:00,"CNBC's Meg Tirrell Tweets: $LLY CEO tells Trump tax, deregulation could really help us expand operations",LLY,https://www.benzinga.com/general/politics/17/01/8971432/cnbcs-meg-tirrell-tweets-lly-ceo-tells-trump-tax-deregulation-could-r,Paul Quintaro,,,,0,0,3723d243-7afb-4434-81a8-3564ad23703c
2017-01-31T08:00:00.000+08:00,"The Market In 5 Minutes: Under Armour's Miss, Apple's Q1 Primer",LLY,https://www.benzinga.com/news/17/01/8970347/the-market-in-5-minutes-under-armours-miss-apples-q1-primer,Benzinga News Desk,,,,0,0,99a17273-f78a-4743-ac81-39da3ef7c6c5
2017-01-31T08:00:00.000+08:00,"Healthcare Q4: Eli Lilly Beats, Pfizer Misses",LLY,https://www.benzinga.com/general/biotech/17/01/8970589/healthcare-q4-eli-lilly-beats-pfizer-misses,Jayson Derrick,,,,0,0,f1812d12-f4a8-49bc-ab78-917b07d85939
2017-01-31T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Down; Apple Earnings In Focus,LLY,https://www.benzinga.com/news/earnings/17/01/8970273/a-peek-into-the-markets-u-s-stock-futures-down-apple-earnings-in-focus,Lisa Levin,,,,0,0,8987b3be-5a1d-48b5-b0f9-85e240763bac
2017-01-31T08:00:00.000+08:00,Lilly Reaffirms FY17 Adj. EPS Outlook $4.05-$4.15 vs $4.10 Est.,LLY,https://www.benzinga.com/news/guidance/17/01/8969884/lilly-reaffirms-fy17-adj-eps-outlook-4-05-4-15-vs-4-10-est,Paul Quintaro,,,,0,0,6affb08a-4001-498b-bebd-ed62bd348356
2017-01-31T08:00:00.000+08:00,"Eli Lilly Reports Q4 EPS $0.95 vs $0.98 Est., Sales $5.761B vs $5.55B Est.",LLY,https://www.benzinga.com/news/earnings/17/01/8969882/eli-lilly-reports-q4-eps-0-95-vs-0-98-est-sales-5-761b-vs-5-55b-est,Paul Quintaro,,,,0,0,8d8fc707-6121-4a46-9a90-6dc4127aa109
2017-01-31T08:00:00.000+08:00,15 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/17/01/8969608/15-stocks-you-should-be-watching-today,Lisa Levin,,,,0,0,24ec6d6b-02f8-4bdb-ab38-0ec0f2f463e9
2017-01-31T08:00:00.000+08:00,Jaguar Animal Health +60% Premarket @$0.85 After Announcement of Deal with Lilly Subsidiary,LLY,https://www.benzinga.com/news/17/01/8969579/jaguar-animal-health-60-premarket-0-85-after-announcement-of-deal-with-lilly-subs,Charles Gross,,,,0,0,7a2fe447-bf99-40df-bb95-c97098acb227
2017-01-31T08:00:00.000+08:00,"Earnings Scheduled For January 31, 2017",LLY,https://www.benzinga.com/news/earnings/17/01/8969578/earnings-scheduled-for-january-31-2017,Lisa Levin,,,,0,0,32dadd52-5c34-4f7d-8f51-2bed537b5b9c
2017-01-31T08:00:00.000+08:00,"Jaguar Animal Health, Elanco Announce Global Collaboration for Development, Co-Promotion of Canalevia; Jaguar to Receive Upfront Payment of $1.5M",LLY,https://www.benzinga.com/news/17/01/8969575/jaguar-animal-health-elanco-announce-global-collaboration-for-development-co-prom,Charles Gross,,,,0,0,c52874f7-08f0-4495-8572-7c9a50de4935
2017-01-30T08:00:00.000+08:00,"Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin",LLY,https://www.benzinga.com/movers/17/01/8966334/recent-weakness-in-eli-lilly-novo-nordisk-sanofi-due-to-new-york-times-reportin,Paul Quintaro,,,,0,0,3a57b44b-110a-4fbb-9d66-9e60b394bf51
2017-01-30T08:00:00.000+08:00,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail,LLY,https://www.benzinga.com/general/biotech/17/01/8962220/taking-a-clinical-road-less-traveled-neurotrope-hopes-to-succeed-in-al,Taylor Cox,,,,0,0,85867938-2228-4419-847e-8547e49f929f
2017-01-30T08:00:00.000+08:00,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8965539/a-mixed-bag-of-earnings-ahead-eli-lilly-pfizer-exxon-mob,The Ticker Tape,,,,0,0,3c48386a-d5ea-4b35-8ef0-bfaf319b5dd1
2017-01-30T08:00:00.000+08:00,"Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8964318/mixing-it-up-markets-await-host-of-economic-data-key-ear,The Ticker Tape,,,,0,0,814f5430-6e60-4ccc-8dbc-72bda3c31966
2017-01-30T08:00:00.000+08:00,"Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin",LLY,https://www.benzinga.com/movers/17/01/8966334/recent-weakness-in-eli-lilly-novo-nordisk-sanofi-due-to-new-york-times-reportin,Paul Quintaro,,,,0,0,aceb9f3e-e377-4ffa-9039-ea779d5fa97a
2017-01-30T08:00:00.000+08:00,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail,LLY,https://www.benzinga.com/general/biotech/17/01/8962220/taking-a-clinical-road-less-traveled-neurotrope-hopes-to-succeed-in-al,Taylor Cox,,,,0,0,4b8ca2f8-adbe-474c-aad5-0204681cb47b
2017-01-30T08:00:00.000+08:00,"A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8965539/a-mixed-bag-of-earnings-ahead-eli-lilly-pfizer-exxon-mob,The Ticker Tape,,,,0,0,689de748-b14a-4ca1-8b32-7f1934cd7127
2017-01-30T08:00:00.000+08:00,"Mixing It Up: Markets Await Host Of Economic Data, Key Earnings, And Fed Meeting",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8964318/mixing-it-up-markets-await-host-of-economic-data-key-ear,The Ticker Tape,,,,0,0,148b878a-7659-4ee3-ad15-6a46af04af09
2017-01-29T08:00:00.000+08:00,"Barron's Sees Dow At 30,000",LLY,https://www.benzinga.com/media/barrons/17/01/8961927/barrons-sees-dow-at-30-000,Nelson Hem,,,,0,0,ed503f73-b70b-446f-bfb2-8dd299868abb
2017-01-29T08:00:00.000+08:00,"Barron's Sees Dow At 30,000",LLY,https://www.benzinga.com/media/barrons/17/01/8961927/barrons-sees-dow-at-30-000,Nelson Hem,,,,0,0,e90cb03a-c800-4d98-b28c-dfb6b1616983
2017-01-26T08:00:00.000+08:00,Eli Lilly Reports Jardiance Is First Type 2 Diabetes Medicine In EU To Include Cardiovascular Death Reduction Data In Label,LLY,https://www.benzinga.com/news/fda/17/01/8950019/eli-lilly-reports-jardiance-is-first-type-2-diabetes-medicine-in-eu-to-includ,Paul Quintaro,,,,0,0,0ff088af-f38b-4e56-a6d5-d9307233c126
2017-01-26T08:00:00.000+08:00,Eli Lilly Reports Jardiance Is First Type 2 Diabetes Medicine In EU To Include Cardiovascular Death Reduction Data In Label,LLY,https://www.benzinga.com/news/fda/17/01/8950019/eli-lilly-reports-jardiance-is-first-type-2-diabetes-medicine-in-eu-to-includ,Paul Quintaro,,,,0,0,5335204b-0e23-4365-85e4-058698953321
2017-01-25T08:00:00.000+08:00,Which Pharma Players Dominate The Lung Cancer Space?,LLY,https://www.benzinga.com/general/biotech/17/01/8945361/which-pharma-players-dominate-the-lung-cancer-space,Shanthi Rexaline,,,,0,0,fcb3da25-97a7-4dd0-be30-a409e597789c
2017-01-25T08:00:00.000+08:00,Which Pharma Players Dominate The Lung Cancer Space?,LLY,https://www.benzinga.com/general/biotech/17/01/8945361/which-pharma-players-dominate-the-lung-cancer-space,Shanthi Rexaline,,,,0,0,612744c5-8473-4a48-9437-677c8d56e106
2017-01-24T08:00:00.000+08:00,"Elanco Animal Health, A Division of Eli Lilly and Aratana, Announces Galliprant Available For Canine Osteoarthritis",LLY,https://www.benzinga.com/news/17/01/8941384/elanco-animal-health-a-division-of-eli-lilly-and-aratana-announces-galliprant-ava,Paul Quintaro,,,,0,0,074fb105-f987-4152-9dda-1a04e15e3ab2
2017-01-24T08:00:00.000+08:00,"Elanco Animal Health, A Division of Eli Lilly and Aratana, Announces Galliprant Available For Canine Osteoarthritis",LLY,https://www.benzinga.com/news/17/01/8941384/elanco-animal-health-a-division-of-eli-lilly-and-aratana-announces-galliprant-ava,Paul Quintaro,,,,0,0,aac1c523-84fe-45b6-8e3c-52e91ad74abf
2017-01-18T08:00:00.000+08:00,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast,LLY,https://www.benzinga.com/news/earnings/17/01/8918930/mid-afternoon-market-update-crude-oil-down-2-5-gigamon-shares-drop-after,Lisa Levin,,,,0,0,de9350d4-513f-445d-8357-ec52dd86819f
2017-01-18T08:00:00.000+08:00,15 Biggest Mid-Day Gainers For Wednesday,LLY,https://www.benzinga.com/news/17/01/8918442/15-biggest-mid-day-gainers-for-wednesday,Lisa Levin,,,,0,0,0c9b6528-452d-49c6-a201-a301b3884115
2017-01-18T08:00:00.000+08:00,Mid-Day Market Update: CoLucid Jumps On Acquisition News; Pearson Shares Tumble,LLY,https://www.benzinga.com/news/earnings/17/01/8918328/mid-day-market-update-colucid-jumps-on-acquisition-news-pearson-shares-t,Lisa Levin,,,,0,0,3e67a983-331d-4ae5-9d04-4fc3c4be8bff
2017-01-18T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views,LLY,https://www.benzinga.com/news/earnings/17/01/8917585/mid-morning-market-update-markets-mixed-goldman-sachs-profit-beats-views,Lisa Levin,,,,0,0,cad159c1-482f-475b-8b76-3acd98cba8de
2017-01-18T08:00:00.000+08:00,"The Market In 5 Minutes: Goldman Sachs, Chelsea Manning And Jerry Seinfeld",LLY,https://www.benzinga.com/news/17/01/8916391/the-market-in-5-minutes-goldman-sachs-chelsea-manning-and-jerry-seinfeld,Benzinga News Desk,,,,0,0,d4772d70-bff0-4f61-ab38-e3bdbef34e9b
2017-01-18T08:00:00.000+08:00,18 Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/17/01/8916687/18-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,b5a73385-7f03-415d-a40e-b9b70a9baa18
2017-01-18T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Yellen Speech",LLY,https://www.benzinga.com/news/earnings/17/01/8916454/a-peek-into-the-markets-u-s-stock-futures-edge-higher-ahead-of-economic-,Lisa Levin,,,,0,0,521b0f42-cc6a-4037-9f80-2abe0040cc73
2017-01-18T08:00:00.000+08:00,CoLUcid Pharma to be Acquired by Eli Lilly for $46.50/Share Cash,LLY,https://www.benzinga.com/news/m-a/17/01/8916178/colucid-pharma-to-be-acquired-by-eli-lilly-for-46-50share-cash,Paul Quintaro,,,,0,0,a83a255c-16ba-490d-8564-a013ed43d687
2017-01-18T08:00:00.000+08:00,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Gigamon Shares Drop After Issuing Lower Forecast,LLY,https://www.benzinga.com/news/earnings/17/01/8918930/mid-afternoon-market-update-crude-oil-down-2-5-gigamon-shares-drop-after,Lisa Levin,,,,0,0,c8871ed7-336d-4e70-aeb4-b8b4efc5123d
2017-01-18T08:00:00.000+08:00,15 Biggest Mid-Day Gainers For Wednesday,LLY,https://www.benzinga.com/news/17/01/8918442/15-biggest-mid-day-gainers-for-wednesday,Lisa Levin,,,,0,0,a81e7ae6-36af-4db4-86a9-01b4fb9c9ccb
2017-01-18T08:00:00.000+08:00,Mid-Day Market Update: CoLucid Jumps On Acquisition News; Pearson Shares Tumble,LLY,https://www.benzinga.com/news/earnings/17/01/8918328/mid-day-market-update-colucid-jumps-on-acquisition-news-pearson-shares-t,Lisa Levin,,,,0,0,bf2b7b13-f8f1-4dea-8d81-366d0a7d115b
2017-01-18T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mixed; Goldman Sachs Profit Beats Views,LLY,https://www.benzinga.com/news/earnings/17/01/8917585/mid-morning-market-update-markets-mixed-goldman-sachs-profit-beats-views,Lisa Levin,,,,0,0,a9cada26-26e0-48f4-afea-645348526392
2017-01-18T08:00:00.000+08:00,"The Market In 5 Minutes: Goldman Sachs, Chelsea Manning And Jerry Seinfeld",LLY,https://www.benzinga.com/news/17/01/8916391/the-market-in-5-minutes-goldman-sachs-chelsea-manning-and-jerry-seinfeld,Benzinga News Desk,,,,0,0,01866149-8dcf-4648-b287-0c9fb9e0b4c6
2017-01-18T08:00:00.000+08:00,18 Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/17/01/8916687/18-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,73a1c5cf-ca8d-4866-aba3-a345b3df9ce6
2017-01-18T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Yellen Speech",LLY,https://www.benzinga.com/news/earnings/17/01/8916454/a-peek-into-the-markets-u-s-stock-futures-edge-higher-ahead-of-economic-,Lisa Levin,,,,0,0,896eb4ce-60a2-4dd1-8713-513aad66eac3
2017-01-18T08:00:00.000+08:00,CoLUcid Pharma to be Acquired by Eli Lilly for $46.50/Share Cash,LLY,https://www.benzinga.com/news/m-a/17/01/8916178/colucid-pharma-to-be-acquired-by-eli-lilly-for-46-50share-cash,Paul Quintaro,,,,0,0,10fb5a78-058c-45cb-a919-6f04c7ed719d
2017-01-17T08:00:00.000+08:00,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8911012/barictinib-fda-delay-only-a-short-term-setback-for-eli-l,Manikandan Raman,,,,0,0,5f15e9ae-f359-4d2b-99b1-4daf53b09a50
2017-01-17T08:00:00.000+08:00,"Incyte PDUFA Date Pushed Back, JMP Discusses Impact",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8910538/incyte-pdufa-date-pushed-back-jmp-discusses-impact,Jim Swanson,,,,0,0,2ee31a16-6ce7-4053-ad69-7781f646c5cb
2017-01-17T08:00:00.000+08:00,"Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8911012/barictinib-fda-delay-only-a-short-term-setback-for-eli-l,Manikandan Raman,,,,0,0,aded2f3a-5ee9-4876-b472-317c4c90917b
2017-01-17T08:00:00.000+08:00,"Incyte PDUFA Date Pushed Back, JMP Discusses Impact",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8910538/incyte-pdufa-date-pushed-back-jmp-discusses-impact,Jim Swanson,,,,0,0,dac23c49-9c4e-4146-b368-40879a6980d3
2017-01-13T08:00:00.000+08:00,"Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PUDFA Goal Date Has Been Extended By 3 Months",LLY,https://www.benzinga.com/general/biotech/17/01/8906996/eli-lilly-and-incyte-report-fda-has-extended-review-period-for-baricit,Hal Lindon,,,,0,0,959770a4-9f4e-4eec-8617-fc2a7cdc8b0c
2017-01-13T08:00:00.000+08:00,7 Biotech Catalysts Remaining In January,LLY,https://www.benzinga.com/general/biotech/17/01/8905085/7-biotech-catalysts-remaining-in-january,Manikandan Raman,,,,0,0,37d22ef0-8b32-4bc6-a5da-e49b2ac90127
2017-01-13T08:00:00.000+08:00,Watch These 5 Huge Put Purchases In Friday Trade,LLY,https://www.benzinga.com/markets/options/17/01/8903595/watch-these-5-huge-put-purchases-in-friday-trade,Lisa Levin,,,,0,0,805aaa81-8576-40be-b06b-89efb2e75db3
2017-01-13T08:00:00.000+08:00,"Eli Lilly And Incyte Report FDA Has Extended Review Period For Baricitinib, PUDFA Goal Date Has Been Extended By 3 Months",LLY,https://www.benzinga.com/general/biotech/17/01/8906996/eli-lilly-and-incyte-report-fda-has-extended-review-period-for-baricit,Hal Lindon,,,,0,0,dcc47590-4a82-4cbd-bc97-4772b1faa483
2017-01-13T08:00:00.000+08:00,7 Biotech Catalysts Remaining In January,LLY,https://www.benzinga.com/general/biotech/17/01/8905085/7-biotech-catalysts-remaining-in-january,Manikandan Raman,,,,0,0,ae6a5c95-9dbe-46ab-b25b-18632ee5f1c5
2017-01-13T08:00:00.000+08:00,Watch These 5 Huge Put Purchases In Friday Trade,LLY,https://www.benzinga.com/markets/options/17/01/8903595/watch-these-5-huge-put-purchases-in-friday-trade,Lisa Levin,,,,0,0,d8a4efc6-6862-45be-a2d8-604086f09740
2017-01-12T08:00:00.000+08:00,"Eli Lilly Releases PR On Earlier Report, Says U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent",LLY,https://www.benzinga.com/news/legal/17/01/8900010/eli-lilly-releases-pr-on-earlier-report-says-u-s-court-of-appeals-rules-in-,Paul Quintaro,,,,0,0,78571f80-f1fa-4f56-89d4-ca6c4a01cc84
2017-01-12T08:00:00.000+08:00,Teva 'Disappointed' In Court's Patent Decision,LLY,https://www.benzinga.com/news/17/01/8899847/teva-disappointed-in-courts-patent-decision,Elizabeth Balboa,,,,0,0,83bf7feb-964b-48b3-b236-fd89b2642c56
2017-01-12T08:00:00.000+08:00,Option Alert: Lilly Jan 75.0 Puts Sweep: 710 @ ASK $0.54: 740 traded vs 16k OI: Earnings 1/31 Before Open $76.22 Ref,LLY,https://www.benzinga.com/news/17/01/8899699/option-alert-lilly-jan-75-0-puts-sweep-710-ask-0-54-740-traded-vs-16k-oi-earnings,Charles Gross,,,,0,0,2ccf25cd-c459-4006-aec7-9a0d3950be11
2017-01-12T08:00:00.000+08:00,U.S. Appeals Court Rules For Eli Lilly Against Teva In Alimta Patent Case,LLY,https://www.benzinga.com/news/legal/17/01/8899681/u-s-appeals-court-rules-for-eli-lilly-against-teva-in-alimta-patent-case,Paul Quintaro,,,,0,0,02ac63e8-0eb5-4a40-a027-43e2975aa844
2017-01-12T08:00:00.000+08:00,"Eli Lilly Releases PR On Earlier Report, Says U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent",LLY,https://www.benzinga.com/news/legal/17/01/8900010/eli-lilly-releases-pr-on-earlier-report-says-u-s-court-of-appeals-rules-in-,Paul Quintaro,,,,0,0,da96c07a-f897-490a-9eba-1f6c96c86821
2017-01-12T08:00:00.000+08:00,Teva 'Disappointed' In Court's Patent Decision,LLY,https://www.benzinga.com/news/17/01/8899847/teva-disappointed-in-courts-patent-decision,Elizabeth Balboa,,,,0,0,183870ee-c1e5-40c3-bb90-f158786439dd
2017-01-12T08:00:00.000+08:00,Option Alert: Lilly Jan 75.0 Puts Sweep: 710 @ ASK $0.54: 740 traded vs 16k OI: Earnings 1/31 Before Open $76.22 Ref,LLY,https://www.benzinga.com/news/17/01/8899699/option-alert-lilly-jan-75-0-puts-sweep-710-ask-0-54-740-traded-vs-16k-oi-earnings,Charles Gross,,,,0,0,fb6b234d-2fd1-495a-8d01-ecaba116a481
2017-01-12T08:00:00.000+08:00,U.S. Appeals Court Rules For Eli Lilly Against Teva In Alimta Patent Case,LLY,https://www.benzinga.com/news/legal/17/01/8899681/u-s-appeals-court-rules-for-eli-lilly-against-teva-in-alimta-patent-case,Paul Quintaro,,,,0,0,d5db8a03-78b0-46e5-ace2-9a455b13d2e4
2017-01-11T08:00:00.000+08:00,"Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed",LLY,https://www.benzinga.com/news/17/01/8893616/lilly-and-merck-expand-immuno-oncology-collaboration-financial-terms-not-disclose,Paul Quintaro,,,,0,0,dc8ac4d9-d87a-445c-85c8-b62ee04a451e
2017-01-11T08:00:00.000+08:00,"Lilly and Merck Expand Immuno-Oncology Collaboration, Financial Terms Not Disclosed",LLY,https://www.benzinga.com/news/17/01/8893616/lilly-and-merck-expand-immuno-oncology-collaboration-financial-terms-not-disclose,Paul Quintaro,,,,0,0,5440654a-5299-4a28-9a66-5f36747139f1
2017-01-06T08:00:00.000+08:00,The MedTech Group: 2017 Top Picks And Catalysts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8877727/the-medtech-group-2017-top-picks-and-catalysts,Jim Swanson,,,,0,0,6c496d9b-8383-421e-b856-49d0aa26e361
2017-01-06T08:00:00.000+08:00,The MedTech Group: 2017 Top Picks And Catalysts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8877727/the-medtech-group-2017-top-picks-and-catalysts,Jim Swanson,,,,0,0,3c3dcb15-762b-45b5-94c8-422462f103bb
2017-01-05T08:00:00.000+08:00,Zymeworks Announces Successful Achievement of Research Milestone with Lilly in Bispecific Antibody Collaboration,LLY,https://www.benzinga.com/news/17/01/8870150/zymeworks-announces-successful-achievement-of-research-milestone-with-lilly-in-bi,Charles Gross,,,,0,0,2c2b06b3-c635-4237-a60a-adb988db2220
2017-01-05T08:00:00.000+08:00,Zymeworks Announces Successful Achievement of Research Milestone with Lilly in Bispecific Antibody Collaboration,LLY,https://www.benzinga.com/news/17/01/8870150/zymeworks-announces-successful-achievement-of-research-milestone-with-lilly-in-bi,Charles Gross,,,,0,0,4afd0dff-b13f-4dac-95b9-cd22b0a786bb
2017-01-04T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce FDA Approval of sNDA to Include Landmark Data in Product Labels for Synjardy, Synjardy XR, Glyxambi Tablets",LLY,https://www.benzinga.com/news/fda/17/01/8868086/eli-lilly-boehringer-ingelheim-announce-fda-approval-of-snda-to-include-landm,Paul Quintaro,,,,0,0,28ad9d4a-1db6-4b9b-b288-6448ae20216a
2017-01-04T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Announce FDA Approval of sNDA to Include Landmark Data in Product Labels for Synjardy, Synjardy XR, Glyxambi Tablets",LLY,https://www.benzinga.com/news/fda/17/01/8868086/eli-lilly-boehringer-ingelheim-announce-fda-approval-of-snda-to-include-landm,Paul Quintaro,,,,0,0,a4f620d0-6f69-4462-a4ca-d757f1fd3e5f
2016-12-28T08:00:00.000+08:00,"FTC Will Require Boehringer Ingelheim To Make Divestitures To Eli Lilly, Bayer AG As Conditions For Sanofi Deal",LLY,https://www.benzinga.com/news/16/12/8847178/ftc-will-require-boehringer-ingelheim-to-make-divestitures-to-eli-lilly-bayer-ag-,Hal Lindon,,,,0,0,1ba92eda-0c74-47d3-a231-0c3543b08499
2016-12-28T08:00:00.000+08:00,A Preview Of January PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/16/12/8844162/a-preview-of-january-pdufa-dates,Shanthi Rexaline,,,,0,0,f2201c33-da22-4c86-925e-96b029840a26
2016-12-28T08:00:00.000+08:00,"FTC Will Require Boehringer Ingelheim To Make Divestitures To Eli Lilly, Bayer AG As Conditions For Sanofi Deal",LLY,https://www.benzinga.com/news/16/12/8847178/ftc-will-require-boehringer-ingelheim-to-make-divestitures-to-eli-lilly-bayer-ag-,Hal Lindon,,,,0,0,a8785c76-1c14-4686-9c34-b75b766234fb
2016-12-28T08:00:00.000+08:00,A Preview Of January PDUFA Dates,LLY,https://www.benzinga.com/general/biotech/16/12/8844162/a-preview-of-january-pdufa-dates,Shanthi Rexaline,,,,0,0,7e30a493-0e18-4b8e-8b58-da49e8ac8f49
2016-12-27T08:00:00.000+08:00,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,LLY,https://www.benzinga.com/general/biotech/16/12/8843728/expect-availability-of-biogens-newly-approved-spinraza-in-just-one-wee,Manikandan Raman,,,,0,0,967be1da-e00d-4a48-98cc-3e7243fd1634
2016-12-27T08:00:00.000+08:00,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,LLY,https://www.benzinga.com/general/biotech/16/12/8843728/expect-availability-of-biogens-newly-approved-spinraza-in-just-one-wee,Manikandan Raman,,,,0,0,620fdc6c-2c3a-4aad-bb39-5333d024c6fd
2016-12-23T08:00:00.000+08:00,6 Worst Biotech Stocks Of 2016,LLY,https://www.benzinga.com/general/biotech/16/12/8832621/6-worst-biotech-stocks-of-2016,Shanthi Rexaline,,,,0,0,4af3cc0b-247f-4b57-ab53-eef106b3298c
2016-12-23T08:00:00.000+08:00,6 Worst Biotech Stocks Of 2016,LLY,https://www.benzinga.com/general/biotech/16/12/8832621/6-worst-biotech-stocks-of-2016,Shanthi Rexaline,,,,0,0,ed241706-af6e-40c8-a99b-75e25f984d88
2016-12-19T08:00:00.000+08:00,Jefferies' 2017 Global Pharma Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8820515/jefferies-2017-global-pharma-outlook,Jim Swanson,,,,0,0,36be6e61-baa6-4f87-bdc5-56f130ea9484
2016-12-19T08:00:00.000+08:00,Jefferies' 2017 Global Pharma Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8820515/jefferies-2017-global-pharma-outlook,Jim Swanson,,,,0,0,12768a8a-0bc3-4503-9e70-a94ccaa532e7
2016-12-16T08:00:00.000+08:00,"Eli Lilly, Boehringer Welcome New Recommendation For Jardiance Tablets; Includes New Recommendations To consider JARDIANCE Use In People With Type 2 Diabetes and Established Cardiovascular Disease To Reduce Risk Of Cardiovascular Death",LLY,https://www.benzinga.com/news/16/12/8816793/eli-lilly-boehringer-welcome-new-recommendation-for-jardiance-tablets-includes-ne,Paul Quintaro,,,,0,0,bcb26ccf-0935-4964-a45d-062553c725de
2016-12-16T08:00:00.000+08:00,"Eli Lilly Biochaperone Lispro U100 and Humalog Showed SImilar Safety Result, Well Tolerated",LLY,https://www.benzinga.com/news/16/12/8816202/eli-lilly-biochaperone-lispro-u100-and-humalog-showed-similar-safety-result-well-,Paul Quintaro,,,,0,0,de043067-b3a6-43fb-bc0f-253d27c971ce
2016-12-16T08:00:00.000+08:00,"Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8814910/eli-lillys-guidance-supported-by-short-term-boosts-not-b,Jayson Derrick,,,,0,0,134d0718-6660-49fd-8bf5-8f285cfb5a34
2016-12-16T08:00:00.000+08:00,"The Market In 5 Minutes: Adobe, Oracle Take The Earnings Stage",LLY,https://www.benzinga.com/news/16/12/8814600/the-market-in-5-minutes-adobe-oracle-take-the-earnings-stage,Benzinga News Desk,,,,0,0,2f3dc3b1-15d7-4336-afc6-26dc91208e2c
2016-12-16T08:00:00.000+08:00,7 Biggest Price Target Changes For Friday,LLY,https://www.benzinga.com/analyst-ratings/price-target/16/12/8815159/7-biggest-price-target-changes-for-friday,Lisa Levin,,,,0,0,acf92741-293a-4609-9e71-9274c4b789d4
2016-12-16T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Target to $82.00",LLY,https://www.benzinga.com/news/16/12/8814369/morgan-stanley-upgrades-eli-lilly-to-overweight-raises-target-to-82-00,Paul Quintaro,,,,0,0,517eb98a-ca2a-4275-b2c2-5764c7b1d825
2016-12-16T08:00:00.000+08:00,"Eli Lilly, Boehringer Welcome New Recommendation For Jardiance Tablets; Includes New Recommendations To consider JARDIANCE Use In People With Type 2 Diabetes and Established Cardiovascular Disease To Reduce Risk Of Cardiovascular Death",LLY,https://www.benzinga.com/news/16/12/8816793/eli-lilly-boehringer-welcome-new-recommendation-for-jardiance-tablets-includes-ne,Paul Quintaro,,,,0,0,eae160bb-e0b6-4783-8b04-0aae67647c17
2016-12-16T08:00:00.000+08:00,"Eli Lilly Biochaperone Lispro U100 and Humalog Showed SImilar Safety Result, Well Tolerated",LLY,https://www.benzinga.com/news/16/12/8816202/eli-lilly-biochaperone-lispro-u100-and-humalog-showed-similar-safety-result-well-,Paul Quintaro,,,,0,0,e94cc1b4-b5a8-461f-8c50-0209cd6815f5
2016-12-16T08:00:00.000+08:00,"Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8814910/eli-lillys-guidance-supported-by-short-term-boosts-not-b,Jayson Derrick,,,,0,0,03c8ba08-7430-4184-9fe7-dd22d66198b7
2016-12-16T08:00:00.000+08:00,"The Market In 5 Minutes: Adobe, Oracle Take The Earnings Stage",LLY,https://www.benzinga.com/news/16/12/8814600/the-market-in-5-minutes-adobe-oracle-take-the-earnings-stage,Benzinga News Desk,,,,0,0,eeb9eebc-eb4e-4954-b9c0-719ab99d1907
2016-12-16T08:00:00.000+08:00,7 Biggest Price Target Changes For Friday,LLY,https://www.benzinga.com/analyst-ratings/price-target/16/12/8815159/7-biggest-price-target-changes-for-friday,Lisa Levin,,,,0,0,6ef27110-f107-4844-9b48-b427c3745081
2016-12-16T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly to Overweight, Raises Target to $82.00",LLY,https://www.benzinga.com/news/16/12/8814369/morgan-stanley-upgrades-eli-lilly-to-overweight-raises-target-to-82-00,Paul Quintaro,,,,0,0,ea516c40-6c97-4cba-9da3-e56af8d322af
2016-12-15T08:00:00.000+08:00,The Week In Guidance: 4 Companies That Gave Investors Their 2017 Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8811408/the-week-in-guidance-4-companies-that-gave-investors-the,Jayson Derrick,,,,0,0,c960f52e-b84c-41bb-9d25-43bbc0155c76
2016-12-15T08:00:00.000+08:00,18 Biggest Mid-Day Gainers For Thursday,LLY,https://www.benzinga.com/news/16/12/8811357/18-biggest-mid-day-gainers-for-thursday,Lisa Levin,,,,0,0,59cb1a89-a25c-4ec6-b1e8-5531030bc45a
2016-12-15T08:00:00.000+08:00,Hearing Eli Lilly Added To Conviction Buy List At Goldman,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8810923/hearing-eli-lilly-added-to-conviction-buy-list-at-goldma,Hal Lindon,,,,0,0,7e3c21e8-9eb3-4c5a-923f-68a669e90801
2016-12-15T08:00:00.000+08:00,Eli Lilly CFO Says They Do Not See U.S. Healthcare Reform Changes Impacting FY17 Sales,LLY,https://www.benzinga.com/general/biotech/16/12/8810424/eli-lilly-cfo-says-they-do-not-see-u-s-healthcare-reform-changes-impac,Paul Quintaro,,,,0,0,0538aeab-3e80-4df3-854d-5aef87c98acc
2016-12-15T08:00:00.000+08:00,"Eli Lilly Announces Guidance, U.S. Insulin Release",LLY,https://www.benzinga.com/news/16/12/8809798/eli-lilly-announces-guidance-u-s-insulin-release,Jayson Derrick,,,,0,0,4894789c-eccf-419f-93ad-3c71c6c760f3
2016-12-15T08:00:00.000+08:00,Eli Lilly Holding Guidance Call Today 10am EST,LLY,https://www.benzinga.com/news/16/12/8809617/eli-lilly-holding-guidance-call-today-10am-est,Hal Lindon,,,,0,0,42c36dbb-6f9a-45e0-83f2-ae8b5a9a92ed
2016-12-15T08:00:00.000+08:00,18 Stocks Moving In Thursday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/12/8809586/18-stocks-moving-in-thursdays-pre-market-session,Lisa Levin,,,,0,0,373c5744-3aa4-4811-9686-71044b43ae1f
2016-12-15T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data,LLY,https://www.benzinga.com/news/earnings/16/12/8809350/a-peek-into-the-markets-u-s-stock-futures-mixed-ahead-of-economic-data,Lisa Levin,,,,0,0,e43bf77c-2528-4d8e-8f58-01a93908bd2e
2016-12-15T08:00:00.000+08:00,Eli Lilly's Basaglar Now Available in US,LLY,https://www.benzinga.com/news/16/12/8809127/eli-lillys-basaglar-now-available-in-us,Paul Quintaro,,,,0,0,a0090c60-accb-4b2f-9b9e-0c0a06c5b2c3
2016-12-15T08:00:00.000+08:00,Eli Lilly and Company Common Stock Sees FY2017 EPS $4.05-4.15 vs $3.97 Est,LLY,https://www.benzinga.com/news/16/12/8809025/eli-lilly-and-company-common-stock-sees-fy2017-eps-4-05-4-15-vs-3-97-est,Paul Quintaro,,,,0,0,422a0f31-5ad7-4bbf-a6a8-7900c8126650
2016-12-15T08:00:00.000+08:00,Eli Lilly and Company Common Stock Sees FY2016 EPS $3.50-3.60 vs $3.52 Est,LLY,https://www.benzinga.com/news/16/12/8809024/eli-lilly-and-company-common-stock-sees-fy2016-eps-3-50-3-60-vs-3-52-est,Paul Quintaro,,,,0,0,1c39ef38-24a1-4971-9499-060b8a41d820
2016-12-15T08:00:00.000+08:00,The Week In Guidance: 4 Companies That Gave Investors Their 2017 Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8811408/the-week-in-guidance-4-companies-that-gave-investors-the,Jayson Derrick,,,,0,0,889f2ecd-ee29-43f0-9f18-d259efff3479
2016-12-15T08:00:00.000+08:00,18 Biggest Mid-Day Gainers For Thursday,LLY,https://www.benzinga.com/news/16/12/8811357/18-biggest-mid-day-gainers-for-thursday,Lisa Levin,,,,0,0,45264a5a-ccc7-428f-8f8f-ff6696a98013
2016-12-15T08:00:00.000+08:00,Hearing Eli Lilly Added To Conviction Buy List At Goldman,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8810923/hearing-eli-lilly-added-to-conviction-buy-list-at-goldma,Hal Lindon,,,,0,0,f8254401-eb0a-4dad-869d-9d464f9a4c8c
2016-12-15T08:00:00.000+08:00,Eli Lilly CFO Says They Do Not See U.S. Healthcare Reform Changes Impacting FY17 Sales,LLY,https://www.benzinga.com/general/biotech/16/12/8810424/eli-lilly-cfo-says-they-do-not-see-u-s-healthcare-reform-changes-impac,Paul Quintaro,,,,0,0,8277fcfe-8827-4044-b047-22e73e674017
2016-12-15T08:00:00.000+08:00,"Eli Lilly Announces Guidance, U.S. Insulin Release",LLY,https://www.benzinga.com/news/16/12/8809798/eli-lilly-announces-guidance-u-s-insulin-release,Jayson Derrick,,,,0,0,f9c8ce19-e9a3-49f3-96d2-5b95a2e91d29
2016-12-15T08:00:00.000+08:00,Eli Lilly Holding Guidance Call Today 10am EST,LLY,https://www.benzinga.com/news/16/12/8809617/eli-lilly-holding-guidance-call-today-10am-est,Hal Lindon,,,,0,0,102b17f0-0f7e-4dbc-9564-3fd2d741f0ed
2016-12-15T08:00:00.000+08:00,18 Stocks Moving In Thursday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/12/8809586/18-stocks-moving-in-thursdays-pre-market-session,Lisa Levin,,,,0,0,7be83864-2c03-450f-b005-847dd7e485ce
2016-12-15T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data,LLY,https://www.benzinga.com/news/earnings/16/12/8809350/a-peek-into-the-markets-u-s-stock-futures-mixed-ahead-of-economic-data,Lisa Levin,,,,0,0,0a7cdde4-9d0f-4f32-9f30-4d003b237442
2016-12-15T08:00:00.000+08:00,Eli Lilly's Basaglar Now Available in US,LLY,https://www.benzinga.com/news/16/12/8809127/eli-lillys-basaglar-now-available-in-us,Paul Quintaro,,,,0,0,ccff8686-c62c-4083-b291-f6461e664489
2016-12-15T08:00:00.000+08:00,Eli Lilly and Company Common Stock Sees FY2017 EPS $4.05-4.15 vs $3.97 Est,LLY,https://www.benzinga.com/news/16/12/8809025/eli-lilly-and-company-common-stock-sees-fy2017-eps-4-05-4-15-vs-3-97-est,Paul Quintaro,,,,0,0,4761a52b-dbfa-4fbd-bce2-3fc77518f80e
2016-12-15T08:00:00.000+08:00,Eli Lilly and Company Common Stock Sees FY2016 EPS $3.50-3.60 vs $3.52 Est,LLY,https://www.benzinga.com/news/16/12/8809024/eli-lilly-and-company-common-stock-sees-fy2016-eps-3-50-3-60-vs-3-52-est,Paul Quintaro,,,,0,0,ad97c1e1-5477-4f82-8127-31861ef08133
2016-12-13T08:00:00.000+08:00,Heads Up! These 4 Companies Issuing Guidance This Week,LLY,https://www.benzinga.com/news/16/12/8802471/heads-up-these-4-companies-issuing-guidance-this-week,Jayson Derrick,,,,0,0,d68f064f-48b0-4187-a4ed-35cf0efd5537
2016-12-13T08:00:00.000+08:00,Lilly Announces Program to Provide Insulin at Discounted Prices,LLY,https://www.benzinga.com/news/16/12/8800170/lilly-announces-program-to-provide-insulin-at-discounted-prices,Paul Quintaro,,,,0,0,36b5d14e-de53-4997-a379-82edbde16392
2016-12-13T08:00:00.000+08:00,Heads Up! These 4 Companies Issuing Guidance This Week,LLY,https://www.benzinga.com/news/16/12/8802471/heads-up-these-4-companies-issuing-guidance-this-week,Jayson Derrick,,,,0,0,9a969173-9c7b-40d7-9b55-cf8aa683a220
2016-12-13T08:00:00.000+08:00,Lilly Announces Program to Provide Insulin at Discounted Prices,LLY,https://www.benzinga.com/news/16/12/8800170/lilly-announces-program-to-provide-insulin-at-discounted-prices,Paul Quintaro,,,,0,0,104595da-1f33-4693-82d5-9e1fa0cfeb61
2016-12-12T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend from $0.51 to $0.52/Share,LLY,https://www.benzinga.com/trading-ideas/dividends/16/12/8799284/eli-lilly-raises-qtr-dividend-from-0-51-to-0-52share,Paul Quintaro,,,,0,0,c6b26ef6-72e1-43cc-bbf8-07ef49e0563c
2016-12-12T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report FDA Approved Synjardy XR Tablets for Adults with Type-2 Diabetes",LLY,https://www.benzinga.com/news/16/12/8798038/eli-lilly-boehringer-ingelheim-report-fda-approved-synjardy-xr-tablets-for-adults,Paul Quintaro,,,,0,0,b4daaf6d-fffb-4c5d-af88-fd078b8cd12e
2016-12-12T08:00:00.000+08:00,What We Know About Trump's Potential Pick To Head The FDA,LLY,https://www.benzinga.com/news/16/12/8797598/what-we-know-about-trumps-potential-pick-to-head-the-fda,Javier Hasse,,,,0,0,d6d1bdfd-fdfd-4273-8ea7-1b9d758e1421
2016-12-12T08:00:00.000+08:00,AC Immune Out Positive On Crenezumab; What Does It Mean?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8795639/ac-immune-out-positive-on-crenezumab-what-does-it-mean,Jayson Derrick,,,,0,0,9f275c10-64c1-40c1-bf6d-b3576a4af826
2016-12-12T08:00:00.000+08:00,Eli Lilly Raises Qtr. Dividend from $0.51 to $0.52/Share,LLY,https://www.benzinga.com/trading-ideas/dividends/16/12/8799284/eli-lilly-raises-qtr-dividend-from-0-51-to-0-52share,Paul Quintaro,,,,0,0,b9467d2a-d687-4ecf-9425-61c374593826
2016-12-12T08:00:00.000+08:00,"Eli Lilly, Boehringer Ingelheim Report FDA Approved Synjardy XR Tablets for Adults with Type-2 Diabetes",LLY,https://www.benzinga.com/news/16/12/8798038/eli-lilly-boehringer-ingelheim-report-fda-approved-synjardy-xr-tablets-for-adults,Paul Quintaro,,,,0,0,05c77282-a49b-4bf3-b148-978816cf0346
2016-12-12T08:00:00.000+08:00,What We Know About Trump's Potential Pick To Head The FDA,LLY,https://www.benzinga.com/news/16/12/8797598/what-we-know-about-trumps-potential-pick-to-head-the-fda,Javier Hasse,,,,0,0,918f6804-d9af-453a-aa56-68fba9d1ebc3
2016-12-12T08:00:00.000+08:00,AC Immune Out Positive On Crenezumab; What Does It Mean?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8795639/ac-immune-out-positive-on-crenezumab-what-does-it-mean,Jayson Derrick,,,,0,0,7a929019-c5ab-4f68-a922-2f1e18dc4789
2016-12-09T08:00:00.000+08:00,AstraZeneca Higher Off Drug News And Upgrade,LLY,https://www.benzinga.com/general/biotech/16/12/8791572/astrazeneca-higher-off-drug-news-and-upgrade,Joel Elconin,,,,0,0,b37ab76e-c540-4c59-a19e-b4e41762d64c
2016-12-09T08:00:00.000+08:00,Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease,LLY,https://www.benzinga.com/news/fda/16/12/8790139/eli-lilly-and-astrazeneca-to-develop-second-potentially-disease-modifying-tre,Paul Quintaro,,,,0,0,df0b8653-554b-4cdf-9684-443b88d81095
2016-12-09T08:00:00.000+08:00,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met,LLY,https://www.benzinga.com/news/16/12/8789840/lilly-announces-detailed-results-of-solanezumab-phase-3-expedition3-study-at-ctad,Charles Gross,,,,0,0,c2c33eea-54b3-43c6-9ccc-0642c5b3bcd7
2016-12-09T08:00:00.000+08:00,AstraZeneca Higher Off Drug News And Upgrade,LLY,https://www.benzinga.com/general/biotech/16/12/8791572/astrazeneca-higher-off-drug-news-and-upgrade,Joel Elconin,,,,0,0,6de96eca-a070-4c13-a023-65b90c8e1192
2016-12-09T08:00:00.000+08:00,Eli Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease,LLY,https://www.benzinga.com/news/fda/16/12/8790139/eli-lilly-and-astrazeneca-to-develop-second-potentially-disease-modifying-tre,Paul Quintaro,,,,0,0,d82215f7-fe10-46a6-becb-b055f506ba0e
2016-12-09T08:00:00.000+08:00,Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITION3 Study at CTAD 2016 Meeting; Primary Endpoint was Not Met,LLY,https://www.benzinga.com/news/16/12/8789840/lilly-announces-detailed-results-of-solanezumab-phase-3-expedition3-study-at-ctad,Charles Gross,,,,0,0,d7f87265-b142-448a-8c37-4c226805820c
2016-12-08T08:00:00.000+08:00,UPDATE: Lilly Trial Met Primary Endpoint Of KI67 Expression Reduction After 2 Weeks Treatment,LLY,https://www.benzinga.com/news/16/12/8785679/update-lilly-trial-met-primary-endpoint-of-ki67-expression-reduction-after-2-week,Paul Quintaro,,,,0,0,f69a35ff-ada2-46d9-9242-992e0fb43e05
2016-12-08T08:00:00.000+08:00,Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer,LLY,https://www.benzinga.com/news/16/12/8785672/lilly-presents-neomonarch-phase-2-data-on-abemaciclib-in-early-stage-breast-cance,Paul Quintaro,,,,0,0,c42d3618-92d7-4911-b060-1d60d930e4b7
2016-12-08T08:00:00.000+08:00,UPDATE: Lilly Trial Met Primary Endpoint Of KI67 Expression Reduction After 2 Weeks Treatment,LLY,https://www.benzinga.com/news/16/12/8785679/update-lilly-trial-met-primary-endpoint-of-ki67-expression-reduction-after-2-week,Paul Quintaro,,,,0,0,86c89a09-43fb-48a9-96e0-274d5a8795b4
2016-12-08T08:00:00.000+08:00,Lilly Presents neoMONARCH Phase 2 Data on Abemaciclib in Early-Stage Breast Cancer,LLY,https://www.benzinga.com/news/16/12/8785672/lilly-presents-neomonarch-phase-2-data-on-abemaciclib-in-early-stage-breast-cance,Paul Quintaro,,,,0,0,bcf07270-c473-4869-b94c-fc5a4fda0e03
2016-12-07T08:00:00.000+08:00,What If Trump Keeps Badmouthing Drug Pricing?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8781602/what-if-trump-keeps-badmouthing-drug-pricing,Wayne Duggan,,,,0,0,2a3382d3-4c54-4c74-8282-d5090413fba6
2016-12-07T08:00:00.000+08:00,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open",LLY,https://www.benzinga.com/movers/16/12/8780747/pfizer-j-j-other-big-pharma-names-dip-lower-just-after-the-open,Paul Quintaro,,,,0,0,6812f25e-06c0-43c5-899e-218905f99069
2016-12-07T08:00:00.000+08:00,What If Trump Keeps Badmouthing Drug Pricing?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8781602/what-if-trump-keeps-badmouthing-drug-pricing,Wayne Duggan,,,,0,0,8a16e4a6-eced-491e-b1b6-9800ad9eaf89
2016-12-07T08:00:00.000+08:00,"Pfizer, J&J, Other Big Pharma Names Dip Lower Just After the Open",LLY,https://www.benzinga.com/movers/16/12/8780747/pfizer-j-j-other-big-pharma-names-dip-lower-just-after-the-open,Paul Quintaro,,,,0,0,c8a5c0f6-eda9-4bde-84a4-3d50a332adda
2016-12-05T08:00:00.000+08:00,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,LLY,https://www.benzinga.com/general/biotech/16/12/8771991/pressure-biosciences-ceo-on-biological-samples-its-all-about-how-you-b,Javier Hasse,,,,0,0,2bcf876f-a101-4908-9bd3-1e89308b28a5
2016-12-05T08:00:00.000+08:00,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,LLY,https://www.benzinga.com/general/biotech/16/12/8771991/pressure-biosciences-ceo-on-biological-samples-its-all-about-how-you-b,Javier Hasse,,,,0,0,65684183-bb5a-47ef-b7c7-18e8279c02a6
2016-12-02T08:00:00.000+08:00,Eli Lilly Shares Spike Higher as FDA Has Approved Jardiance to Reduce CV Death in Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/12/8765387/eli-lilly-shares-spike-higher-as-fda-has-approved-jardiance-to-reduce-cv-death-in,Paul Quintaro,,,,0,0,7f82af48-080e-48f5-b849-e78ea5d837c7
2016-12-02T08:00:00.000+08:00,Lilly Pops to High of $67.45 on Volume,LLY,https://www.benzinga.com/movers/16/12/8765378/lilly-pops-to-high-of-67-45-on-volume,Charles Gross,,,,0,0,8406deef-7eff-4374-b270-46ec55ff5919
2016-12-02T08:00:00.000+08:00,"Eli Lilly Confirms It Will Provide Updated Guidance In Conf. Call Dec. 15, 10am EST",LLY,https://www.benzinga.com/news/16/12/8764556/eli-lilly-confirms-it-will-provide-updated-guidance-in-conf-call-dec-15-10am-est,Hal Lindon,,,,0,0,5347de96-6d66-47c4-9dbe-254dff1244b0
2016-12-02T08:00:00.000+08:00,Eli Lilly Shares Spike Higher as FDA Has Approved Jardiance to Reduce CV Death in Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/12/8765387/eli-lilly-shares-spike-higher-as-fda-has-approved-jardiance-to-reduce-cv-death-in,Paul Quintaro,,,,0,0,1f2e7828-f107-4c78-87c1-dd17da409654
2016-12-02T08:00:00.000+08:00,Lilly Pops to High of $67.45 on Volume,LLY,https://www.benzinga.com/movers/16/12/8765378/lilly-pops-to-high-of-67-45-on-volume,Charles Gross,,,,0,0,f0034592-016a-4513-acb4-7afce7b5c8c1
2016-12-02T08:00:00.000+08:00,"Eli Lilly Confirms It Will Provide Updated Guidance In Conf. Call Dec. 15, 10am EST",LLY,https://www.benzinga.com/news/16/12/8764556/eli-lilly-confirms-it-will-provide-updated-guidance-in-conf-call-dec-15-10am-est,Hal Lindon,,,,0,0,a1b34d24-ec98-40c7-a755-76aeb65c8608
2016-12-01T08:00:00.000+08:00,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron",LLY,https://www.benzinga.com/news/16/12/8758294/forbes-healthcare-summit-concludes-today-presenters-include-express-scripts-aller,Hal Lindon,,,,0,0,465c1b57-029e-48d0-874e-52bf7bd3066a
2016-12-01T08:00:00.000+08:00,"Forbes Healthcare Summit Concludes Today; Presenters Include Express Scripts, Allergan, IBM, Bristol-Myers Squibb, Merck, Anthem, Eli Lilly, And Regeneron",LLY,https://www.benzinga.com/news/16/12/8758294/forbes-healthcare-summit-concludes-today-presenters-include-express-scripts-aller,Hal Lindon,,,,0,0,79c5aafe-2281-4e65-b79b-2b8026d056bc
2016-11-29T08:00:00.000+08:00,The Difference Between Shareholders And Stakeholders,LLY,https://www.benzinga.com/general/education/16/11/8739519/the-difference-between-shareholders-and-stakeholders,Shanthi Rexaline,,,,0,0,9591988b-3034-4fe8-b1ba-4f4f5be5661a
2016-11-29T08:00:00.000+08:00,The Difference Between Shareholders And Stakeholders,LLY,https://www.benzinga.com/general/education/16/11/8739519/the-difference-between-shareholders-and-stakeholders,Shanthi Rexaline,,,,0,0,d2a330ab-06ea-439b-94ab-fcf44744678b
2016-11-25T08:00:00.000+08:00,"Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8739191/aside-from-the-recent-drug-failure-what-else-is-happenin,Manikandan Raman,,,,0,0,e1ab4ca4-3e41-4602-baa0-9cf6ff4cc87d
2016-11-25T08:00:00.000+08:00,Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8738941/reasons-to-be-optimistic-on-biogens-alzheimers-treatment,Manikandan Raman,,,,0,0,ef4e1c36-c538-4503-855a-de0fd24e59ef
2016-11-25T08:00:00.000+08:00,Atlantic Equities Earlier Downgraded Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/16/11/8739094/atlantic-equities-earlier-downgraded-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,a733dce8-ecd8-4a5b-9876-3252773c2b2c
2016-11-25T08:00:00.000+08:00,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week,LLY,https://www.benzinga.com/news/16/11/8738744/the-market-in-5-minutes-black-friday-closes-shortened-trading-week,Benzinga News Desk,,,,0,0,114f7033-60de-4e8f-8207-bd612ec4c6d1
2016-11-25T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/16/11/8738935/benzingas-top-downgrades,Lisa Levin,,,,0,0,e917cd0e-e525-4383-9f13-75f55eda5d05
2016-11-25T08:00:00.000+08:00,Experts React To Concerning Alzheimer's News From Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8736227/experts-react-to-concerning-alzheimers-news-from-lilly,Shanthi Rexaline,,,,0,0,c0ff91db-0b9e-473c-ac13-4bcebafcca01
2016-11-25T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain On Black Friday,LLY,https://www.benzinga.com/news/earnings/16/11/8738678/a-peek-into-the-markets-u-s-stock-futures-gain-on-black-friday,Lisa Levin,,,,0,0,3cddb046-5863-474e-ac31-1cd6744b6af0
2016-11-25T08:00:00.000+08:00,"BMO Capital Downgrades Eli Lilly to Market Perform, Lowers Target to $64.00",LLY,https://www.benzinga.com/news/16/11/8738593/bmo-capital-downgrades-eli-lilly-to-market-perform-lowers-target-to-64-00,Paul Quintaro,,,,0,0,ec99c741-3d15-4927-9a38-31368160d8e3
2016-11-25T08:00:00.000+08:00,"Must Watch Stocks for November 25, 2016",LLY,https://www.benzinga.com/news/earnings/16/11/8738412/must-watch-stocks-for-november-25-2016,Lisa Levin,,,,0,0,0ef5f06f-2234-4ca7-b5c2-6fd866640e4d
2016-11-25T08:00:00.000+08:00,"Aside From The Recent Drug Failure, What Else Is Happening With Eli Lilly?",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8739191/aside-from-the-recent-drug-failure-what-else-is-happenin,Manikandan Raman,,,,0,0,bf838cc4-b61b-4d7e-a4f7-e1b160df4372
2016-11-25T08:00:00.000+08:00,Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8738941/reasons-to-be-optimistic-on-biogens-alzheimers-treatment,Manikandan Raman,,,,0,0,e4e3f77b-251d-4c6c-b8a3-59180a24baaf
2016-11-25T08:00:00.000+08:00,Atlantic Equities Earlier Downgraded Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/16/11/8739094/atlantic-equities-earlier-downgraded-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,d7fa0ef0-d262-4f07-a661-5701afc16298
2016-11-25T08:00:00.000+08:00,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week,LLY,https://www.benzinga.com/news/16/11/8738744/the-market-in-5-minutes-black-friday-closes-shortened-trading-week,Benzinga News Desk,,,,0,0,a8898309-985e-4399-bdd2-8bdc1efec631
2016-11-25T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/16/11/8738935/benzingas-top-downgrades,Lisa Levin,,,,0,0,992a63c8-f325-4cc6-860a-9fd5c2f4c032
2016-11-25T08:00:00.000+08:00,Experts React To Concerning Alzheimer's News From Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8736227/experts-react-to-concerning-alzheimers-news-from-lilly,Shanthi Rexaline,,,,0,0,4ee41cf8-660f-48e2-b142-e63c87e2e3ed
2016-11-25T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain On Black Friday,LLY,https://www.benzinga.com/news/earnings/16/11/8738678/a-peek-into-the-markets-u-s-stock-futures-gain-on-black-friday,Lisa Levin,,,,0,0,2427fd12-8908-475a-8260-16a4928cb324
2016-11-25T08:00:00.000+08:00,"BMO Capital Downgrades Eli Lilly to Market Perform, Lowers Target to $64.00",LLY,https://www.benzinga.com/news/16/11/8738593/bmo-capital-downgrades-eli-lilly-to-market-perform-lowers-target-to-64-00,Paul Quintaro,,,,0,0,e0df44ed-0b3d-40fd-8803-798e18d2e00e
2016-11-25T08:00:00.000+08:00,"Must Watch Stocks for November 25, 2016",LLY,https://www.benzinga.com/news/earnings/16/11/8738412/must-watch-stocks-for-november-25-2016,Lisa Levin,,,,0,0,96edf9af-4929-4763-9778-3e53f1529bf7
2016-11-23T08:00:00.000+08:00,A Tough Day For Some Biotech Bulls,LLY,https://www.benzinga.com/general/biotech/16/11/8735459/a-tough-day-for-some-biotech-bulls,Wayne Duggan,,,,0,0,38af399d-3fc2-473e-9493-8cec490a446f
2016-11-23T08:00:00.000+08:00,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock,LLY,https://www.benzinga.com/general/biotech/16/11/8735076/eli-lillys-solanezumab-failure-alzheimers-treatment-space-feels-afters,Bryan Finnigan,,,,0,0,1ee91334-8ed2-4e75-94a8-5d46f25ca5ea
2016-11-23T08:00:00.000+08:00,18 Biggest Mid-Day Losers For Wednesday,LLY,https://www.benzinga.com/news/16/11/8735535/18-biggest-mid-day-losers-for-wednesday,Lisa Levin,,,,0,0,b2de34f8-c514-41de-9031-0e67a4a174cd
2016-11-23T08:00:00.000+08:00,"Baird Analayst Says No Change To Axovant Sciences on Lilly's solanezumab Failure, Intepirdine Commercial Opportunity In AD Is Multiple Billions per Year",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8735421/baird-analayst-says-no-change-to-axovant-sciences-on-lil,Paul Quintaro,,,,0,0,24ca7d88-090a-41e9-bddc-1a7c819fd605
2016-11-23T08:00:00.000+08:00,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise,LLY,https://www.benzinga.com/news/earnings/16/11/8735174/mid-day-market-update-eli-lilly-tumbles-after-alzheimers-study-fails-to-,Lisa Levin,,,,0,0,4adafb4b-aadc-4010-ac99-1cc4293decbe
2016-11-23T08:00:00.000+08:00,Stocks Hitting 52-Week Lows,LLY,https://www.benzinga.com/news/16/11/8734565/stocks-hitting-52-week-lows,Lisa Levin,,,,0,0,5395ae7c-0621-473b-8eed-3d5ecd8a15b7
2016-11-23T08:00:00.000+08:00,Adam Feuerstein Tweets: Check out @AF_biotech tweets laying out bear thesis on $PRTA as collateral damage from $LLY sola blowup. He knows his stuff.,LLY,https://www.benzinga.com/news/16/11/8734422/adam-feuerstein-tweets-check-out-af-biotech-tweets-laying-out-bear-thesis-on-prta,Paul Quintaro,,,,0,0,07bcd9b4-79df-4a6b-8780-38d6d8cbc9a1
2016-11-23T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views,LLY,https://www.benzinga.com/news/earnings/16/11/8734398/mid-morning-market-update-markets-mostly-lower-deere-tops-q4-views,Lisa Levin,,,,0,0,76b6dbca-59cd-4629-bba4-27a62db7749e
2016-11-23T08:00:00.000+08:00,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%",LLY,https://www.benzinga.com/news/16/11/8734362/biotech-down-in-early-trading-pdl-biopharma-15-eli-lilly-13-biogen-6-cellectis-in,Paul Quintaro,,,,0,0,2ffe22b7-3219-4dbd-90ed-c02c4dfe39c6
2016-11-23T08:00:00.000+08:00,Neurotrope Issues Statement On Eli Lilly's Solanezumab,LLY,https://www.benzinga.com/news/16/11/8734206/neurotrope-issues-statement-on-eli-lillys-solanezumab,Paul Quintaro,,,,0,0,ebd50c4c-256c-46aa-ace1-d48d50b90a88
2016-11-23T08:00:00.000+08:00,"Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734123/credit-suisse-says-hard-to-get-strong-read-through-concl,Paul Quintaro,,,,0,0,c7f6ece8-e110-44ae-a13d-c10f7bbb72c2
2016-11-23T08:00:00.000+08:00,"JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734116/jp-morgan-highlighting-downside-in-biogen-shares-this-mo,Paul Quintaro,,,,0,0,47233b6d-c1cc-4a22-beaa-7acf33008aca
2016-11-23T08:00:00.000+08:00,Eli Lilly's Solanezumab Failure Is Bad News For Biogen,LLY,https://www.benzinga.com/general/biotech/16/11/8733840/eli-lillys-solanezumab-failure-is-bad-news-for-biogen,Shanthi Rexaline,,,,0,0,3435fbe4-6526-4ff1-845a-a8510e9afd07
2016-11-23T08:00:00.000+08:00,"AC Immune Shares Down 20% Amid Concerning Alzheimer Drug Data from Lilly; BZ NOTE: In an Oct. 18 Note, Leerink Estimated AC Immune Shares Could Be Down 60% if Data was Not Favorable",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734021/ac-immune-shares-down-20-amid-concerning-alzheimer-drug-,Paul Quintaro,,,,0,0,42872e9d-f468-4dad-9278-2a421e374321
2016-11-23T08:00:00.000+08:00,"Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733961/morgan-stanley-calling-for-biogen-to-end-the-day-flat-to,Paul Quintaro,,,,0,0,e97b46bd-343d-41d3-8c0c-5145d8843063
2016-11-23T08:00:00.000+08:00,Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733897/raymond-james-out-saying-they-would-be-buyers-of-biogen-,Paul Quintaro,,,,0,0,66b5d122-8982-43b0-9c15-5995eb95a5e0
2016-11-23T08:00:00.000+08:00,20 Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/11/8733809/20-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,d07bbc26-1481-4c8a-9e62-9c9d51823bb4
2016-11-23T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data, Fed Minutes",LLY,https://www.benzinga.com/news/earnings/16/11/8733667/a-peek-into-the-markets-u-s-stock-futures-mixed-ahead-of-economic-data-f,Lisa Levin,,,,0,0,6f6ed2e7-2e1e-44d7-9d24-7aa7b9a94661
2016-11-23T08:00:00.000+08:00,Eli Lilly Plunges 15% After Alzheimer's Study Fails To Meet Goals,LLY,https://www.benzinga.com/news/16/11/8733559/eli-lilly-plunges-15-after-alzheimers-study-fails-to-meet-goals,Manikandan Raman,,,,0,0,4db63119-1ce5-4bb4-b992-c7e9ad390dba
2016-11-23T08:00:00.000+08:00,Can You Guess This Chart?,LLY,https://www.benzinga.com/general/16/11/8733554/can-you-guess-this-chart,Benzinga News Desk,,,,0,0,0d3e615e-9737-4386-b8a8-cc3139e7fbc1
2016-11-23T08:00:00.000+08:00,"Adam Feuerstein Tweets: Worst thing: $LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, $BIIB",LLY,https://www.benzinga.com/news/16/11/8733507/adam-feuerstein-tweets-worst-thing-lly-gamed-sola-study-to-win-but-still-failed-b,Paul Quintaro,,,,0,0,ff64b6ac-c5b6-4788-9834-3e07f2836a92
2016-11-23T08:00:00.000+08:00,Lilly -15% Premarket @$64.75 Following Report that Solanezumab Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/16/11/8733456/lilly-15-premarket-64-75-following-report-that-solanezumab-did-not-meet-primary-e,Charles Gross,,,,0,0,ee96ab35-aa02-4dab-aff3-2ef5df554ba5
2016-11-23T08:00:00.000+08:00,"Adam Feuerstein @adamfeuerstein Tweet: $LLY Alzheimer's drug fails key clinical trial thestreet.com/story/13903616… Very quick news hit, back with more perspective later.",LLY,https://www.benzinga.com/news/16/11/8733438/adam-feuerstein-adamfeuerstein-tweet-lly-alzheimers-drug-fails-key-clinical-trial,Charles Gross,,,,0,0,75968900-1ad8-40a7-bd45-3d1241e4fc14
2016-11-23T08:00:00.000+08:00,UPDATE: Lilly EXPEDITION 3 Study Outcome Expected To Result In Q4 Charge Of ~$150M or ~$0.09,LLY,https://www.benzinga.com/news/16/11/8733380/update-lilly-expedition-3-study-outcome-expected-to-result-in-q4-charge-of-150m-o,Paul Quintaro,,,,0,0,447912bc-6294-40ff-8402-cac3097940c9
2016-11-23T08:00:00.000+08:00,"Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, Did Not Meet Primary Endpoint",LLY,https://www.benzinga.com/news/16/11/8733377/lilly-announces-top-line-results-of-solanezumab-phase-3-clinical-trial-did-not-me,Paul Quintaro,,,,0,0,eef15cac-df76-4452-81d2-3f9840d25c71
2016-11-23T08:00:00.000+08:00,A Tough Day For Some Biotech Bulls,LLY,https://www.benzinga.com/general/biotech/16/11/8735459/a-tough-day-for-some-biotech-bulls,Wayne Duggan,,,,0,0,81f9abaa-ba1e-42c6-82dd-f328efd8010c
2016-11-23T08:00:00.000+08:00,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock,LLY,https://www.benzinga.com/general/biotech/16/11/8735076/eli-lillys-solanezumab-failure-alzheimers-treatment-space-feels-afters,Bryan Finnigan,,,,0,0,c5486093-6b77-451b-9481-00153e54475b
2016-11-23T08:00:00.000+08:00,18 Biggest Mid-Day Losers For Wednesday,LLY,https://www.benzinga.com/news/16/11/8735535/18-biggest-mid-day-losers-for-wednesday,Lisa Levin,,,,0,0,77ec0cec-b6a7-4365-a212-8f7ece733bb5
2016-11-23T08:00:00.000+08:00,"Baird Analayst Says No Change To Axovant Sciences on Lilly's solanezumab Failure, Intepirdine Commercial Opportunity In AD Is Multiple Billions per Year",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8735421/baird-analayst-says-no-change-to-axovant-sciences-on-lil,Paul Quintaro,,,,0,0,420d4427-d73c-4a3a-88db-30af51eb5bfc
2016-11-23T08:00:00.000+08:00,Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise,LLY,https://www.benzinga.com/news/earnings/16/11/8735174/mid-day-market-update-eli-lilly-tumbles-after-alzheimers-study-fails-to-,Lisa Levin,,,,0,0,bbc5308b-b9d3-4950-ab98-0164422205c9
2016-11-23T08:00:00.000+08:00,Stocks Hitting 52-Week Lows,LLY,https://www.benzinga.com/news/16/11/8734565/stocks-hitting-52-week-lows,Lisa Levin,,,,0,0,baf896e7-2e8b-43d8-8962-9faddfb5688b
2016-11-23T08:00:00.000+08:00,Adam Feuerstein Tweets: Check out @AF_biotech tweets laying out bear thesis on $PRTA as collateral damage from $LLY sola blowup. He knows his stuff.,LLY,https://www.benzinga.com/news/16/11/8734422/adam-feuerstein-tweets-check-out-af-biotech-tweets-laying-out-bear-thesis-on-prta,Paul Quintaro,,,,0,0,4249a533-6711-454f-aa52-b0f9acf38633
2016-11-23T08:00:00.000+08:00,Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views,LLY,https://www.benzinga.com/news/earnings/16/11/8734398/mid-morning-market-update-markets-mostly-lower-deere-tops-q4-views,Lisa Levin,,,,0,0,6ea1eb91-00bf-47a7-b5ce-a77fadb4f48d
2016-11-23T08:00:00.000+08:00,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%",LLY,https://www.benzinga.com/news/16/11/8734362/biotech-down-in-early-trading-pdl-biopharma-15-eli-lilly-13-biogen-6-cellectis-in,Paul Quintaro,,,,0,0,6f165161-a8e8-4a54-af05-db0d30890e84
2016-11-23T08:00:00.000+08:00,Neurotrope Issues Statement On Eli Lilly's Solanezumab,LLY,https://www.benzinga.com/news/16/11/8734206/neurotrope-issues-statement-on-eli-lillys-solanezumab,Paul Quintaro,,,,0,0,7629eccb-4e7e-42d3-a397-b6f62bcd64f5
2016-11-23T08:00:00.000+08:00,"Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734123/credit-suisse-says-hard-to-get-strong-read-through-concl,Paul Quintaro,,,,0,0,509bfe3d-6303-4e02-b322-a4e9dc80c5fb
2016-11-23T08:00:00.000+08:00,"JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734116/jp-morgan-highlighting-downside-in-biogen-shares-this-mo,Paul Quintaro,,,,0,0,e2cd164f-4288-4444-ac2d-2a0000914964
2016-11-23T08:00:00.000+08:00,Eli Lilly's Solanezumab Failure Is Bad News For Biogen,LLY,https://www.benzinga.com/general/biotech/16/11/8733840/eli-lillys-solanezumab-failure-is-bad-news-for-biogen,Shanthi Rexaline,,,,0,0,618c81ab-9ab6-4a89-a1cc-066797b7332e
2016-11-23T08:00:00.000+08:00,"AC Immune Shares Down 20% Amid Concerning Alzheimer Drug Data from Lilly; BZ NOTE: In an Oct. 18 Note, Leerink Estimated AC Immune Shares Could Be Down 60% if Data was Not Favorable",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734021/ac-immune-shares-down-20-amid-concerning-alzheimer-drug-,Paul Quintaro,,,,0,0,9965215c-ef8f-482a-9e56-bc82cd195ea1
2016-11-23T08:00:00.000+08:00,"Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733961/morgan-stanley-calling-for-biogen-to-end-the-day-flat-to,Paul Quintaro,,,,0,0,102f9d7c-6a53-4838-8409-1e6135175615
2016-11-23T08:00:00.000+08:00,Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733897/raymond-james-out-saying-they-would-be-buyers-of-biogen-,Paul Quintaro,,,,0,0,02841949-584b-4a5b-9f19-1a8f5ddbb75a
2016-11-23T08:00:00.000+08:00,20 Stocks Moving In Wednesday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/11/8733809/20-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,,,,0,0,cd449ac9-73b0-439c-b6f1-083e8094c692
2016-11-23T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Economic Data, Fed Minutes",LLY,https://www.benzinga.com/news/earnings/16/11/8733667/a-peek-into-the-markets-u-s-stock-futures-mixed-ahead-of-economic-data-f,Lisa Levin,,,,0,0,8e60ec5b-9716-42e8-b6d1-05d5a8ae4360
2016-11-23T08:00:00.000+08:00,Eli Lilly Plunges 15% After Alzheimer's Study Fails To Meet Goals,LLY,https://www.benzinga.com/news/16/11/8733559/eli-lilly-plunges-15-after-alzheimers-study-fails-to-meet-goals,Manikandan Raman,,,,0,0,f6572793-e0cd-452b-b1dd-924b1eafd5f6
2016-11-23T08:00:00.000+08:00,Can You Guess This Chart?,LLY,https://www.benzinga.com/general/16/11/8733554/can-you-guess-this-chart,Benzinga News Desk,,,,0,0,c880e620-36c5-408c-817b-e376a033c88a
2016-11-23T08:00:00.000+08:00,"Adam Feuerstein Tweets: Worst thing: $LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, $BIIB",LLY,https://www.benzinga.com/news/16/11/8733507/adam-feuerstein-tweets-worst-thing-lly-gamed-sola-study-to-win-but-still-failed-b,Paul Quintaro,,,,0,0,68f3a823-69cf-451d-9f9f-e5ec275f76fc
2016-11-23T08:00:00.000+08:00,Lilly -15% Premarket @$64.75 Following Report that Solanezumab Did Not Meet Primary Endpoint,LLY,https://www.benzinga.com/news/16/11/8733456/lilly-15-premarket-64-75-following-report-that-solanezumab-did-not-meet-primary-e,Charles Gross,,,,0,0,ba21ff4e-946c-4d18-a603-94c58c1e272e
2016-11-23T08:00:00.000+08:00,"Adam Feuerstein @adamfeuerstein Tweet: $LLY Alzheimer's drug fails key clinical trial thestreet.com/story/13903616… Very quick news hit, back with more perspective later.",LLY,https://www.benzinga.com/news/16/11/8733438/adam-feuerstein-adamfeuerstein-tweet-lly-alzheimers-drug-fails-key-clinical-trial,Charles Gross,,,,0,0,a1e829b7-db55-4b83-8668-2ba0e059955b
2016-11-23T08:00:00.000+08:00,UPDATE: Lilly EXPEDITION 3 Study Outcome Expected To Result In Q4 Charge Of ~$150M or ~$0.09,LLY,https://www.benzinga.com/news/16/11/8733380/update-lilly-expedition-3-study-outcome-expected-to-result-in-q4-charge-of-150m-o,Paul Quintaro,,,,0,0,22bc50cf-25cd-4964-b3b4-dddbd6de477c
2016-11-23T08:00:00.000+08:00,"Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, Did Not Meet Primary Endpoint",LLY,https://www.benzinga.com/news/16/11/8733377/lilly-announces-top-line-results-of-solanezumab-phase-3-clinical-trial-did-not-me,Paul Quintaro,,,,0,0,7cf079a4-81ae-4841-88e0-f41d023aa2bd
2016-11-22T08:00:00.000+08:00,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe",LLY,https://www.benzinga.com/news/16/11/8728289/quintilesims-forms-new-collaboration-with-bristol-myers-squibb-lilly-merck-kgaa-d,Paul Quintaro,,,,0,0,b95189ac-d317-4c6c-a84c-a156b8db170b
2016-11-22T08:00:00.000+08:00,"QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to Generate Real World Insights On Usage of Anti-Cancer Therapies Across Europe",LLY,https://www.benzinga.com/news/16/11/8728289/quintilesims-forms-new-collaboration-with-bristol-myers-squibb-lilly-merck-kgaa-d,Paul Quintaro,,,,0,0,10cd8ee6-e934-4f00-bca8-7d84b6bb9fdb
2016-11-21T08:00:00.000+08:00,Intelgenx Technologies Reports Signing Of Term Sheet For Eli Lilly To License Tadalafil Dosing Patent '6943,LLY,https://www.benzinga.com/news/16/11/8723017/intelgenx-technologies-reports-signing-of-term-sheet-for-eli-lilly-to-license-tad,Paul Quintaro,,,,0,0,80c62a97-2491-4a71-a07b-bb2e8552e837
2016-11-21T08:00:00.000+08:00,Intelgenx Technologies Reports Signing Of Term Sheet For Eli Lilly To License Tadalafil Dosing Patent '6943,LLY,https://www.benzinga.com/news/16/11/8723017/intelgenx-technologies-reports-signing-of-term-sheet-for-eli-lilly-to-license-tad,Paul Quintaro,,,,0,0,d3d43cd8-ea16-4e16-9c2e-601b869625f3
2016-11-14T08:00:00.000+08:00,"Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimummab In Patient-Reported Outcomes",LLY,https://www.benzinga.com/news/16/11/8691085/eli-lilly-incyte-corp-report-ra-beam-and-ra-build-patients-early-response-to-bari,Paul Quintaro,,,,0,0,cd669fd1-9601-4142-9b08-b009857b82e5
2016-11-14T08:00:00.000+08:00,"Eli Lilly, Incyte Corp Report RA-BEAM and Ra-BUILD Patients Early Response To Baricitinib Show Significant Improvement Compared To Adalimummab In Patient-Reported Outcomes",LLY,https://www.benzinga.com/news/16/11/8691085/eli-lilly-incyte-corp-report-ra-beam-and-ra-build-patients-early-response-to-bari,Paul Quintaro,,,,0,0,783a1d8d-82a7-4a7c-8d3f-e4b2c74d44ca
2016-11-13T08:00:00.000+08:00,Lilly Announces Jardiance Consistently Reduced the Risk of Cardiovascular Death in Adults With Type 2 Diabetes Regardless of Type of Cardiovascular Disease at Baseline,LLY,https://www.benzinga.com/news/16/11/8688398/lilly-announces-jardiance-consistently-reduced-the-risk-of-cardiovascular-death-i,Charles Gross,,,,0,0,ab899215-09e5-40d7-ae37-e744332fb197
2016-11-13T08:00:00.000+08:00,Lilly Announces Jardiance Consistently Reduced the Risk of Cardiovascular Death in Adults With Type 2 Diabetes Regardless of Type of Cardiovascular Disease at Baseline,LLY,https://www.benzinga.com/news/16/11/8688398/lilly-announces-jardiance-consistently-reduced-the-risk-of-cardiovascular-death-i,Charles Gross,,,,0,0,ebed465e-cfb9-4068-8d3f-d146bae7a263
2016-11-11T08:00:00.000+08:00,"Traders Attributing Drop In Eli Lilly To Humana Dropping Humalog Insulin From 2017 Formulary, Senator Bernie Sanders Attacked Company In Prior Week For 700% Increase In Drug Price",LLY,https://www.benzinga.com/news/16/11/8686688/traders-attributing-drop-in-eli-lilly-to-humana-dropping-humalog-insulin-from-201,Paul Quintaro,,,,0,0,b6849fbf-1981-4e98-bb62-de528a10b490
2016-11-11T08:00:00.000+08:00,"Traders Attributing Drop In Eli Lilly To Humana Dropping Humalog Insulin From 2017 Formulary, Senator Bernie Sanders Attacked Company In Prior Week For 700% Increase In Drug Price",LLY,https://www.benzinga.com/news/16/11/8686688/traders-attributing-drop-in-eli-lilly-to-humana-dropping-humalog-insulin-from-201,Paul Quintaro,,,,0,0,35ff2019-97b3-4102-a90e-743bbd663da0
2016-11-10T08:00:00.000+08:00,"10 Notable Stocks Trading Ex-Dividend Friday, November 11",LLY,https://www.benzinga.com/news/dividends/16/11/8681027/10-notable-stocks-trading-ex-dividend-friday-november-11,Lisa Levin,,,,0,0,87b27e09-69c3-4da5-8eac-4019c92497bb
2016-11-10T08:00:00.000+08:00,"10 Notable Stocks Trading Ex-Dividend Friday, November 11",LLY,https://www.benzinga.com/news/dividends/16/11/8681027/10-notable-stocks-trading-ex-dividend-friday-november-11,Lisa Levin,,,,0,0,6ed63279-81f0-492b-bf78-98e0260e6b3e
2016-11-09T08:00:00.000+08:00,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",LLY,https://www.benzinga.com/movers/16/11/8672426/pharma-stocks-up-post-election-ariad-16-infinity-up-13-allergan-progenics-endo-,Paul Quintaro,,,,0,0,dd849e68-909c-43f5-8b0c-beb2d242da62
2016-11-09T08:00:00.000+08:00,Biotech Is Getting A Big Boost Following Clinton's Loss,LLY,https://www.benzinga.com/general/biotech/16/11/8671658/biotech-is-getting-a-big-boost-following-clintons-loss,R. Chandrasekaran,,,,0,0,9937a6bd-bd4b-4e03-91dd-234197a40295
2016-11-09T08:00:00.000+08:00,"Pharma Stocks Up Post Election: Ariad 16%, Infinity Up 13%, Allergan, Progenics, Endo 10%, Pfizer, Regeneron 8%, AbbVie 7%, Mylan, Medicines Co. 6%, Perrigo, Merck 5%, Bristol-Myers, Eli Lilly, Sanofi, Novartis 3.5%",LLY,https://www.benzinga.com/movers/16/11/8672426/pharma-stocks-up-post-election-ariad-16-infinity-up-13-allergan-progenics-endo-,Paul Quintaro,,,,0,0,ad9d3bd2-538b-4e51-9265-e8f29c61852a
2016-11-09T08:00:00.000+08:00,Biotech Is Getting A Big Boost Following Clinton's Loss,LLY,https://www.benzinga.com/general/biotech/16/11/8671658/biotech-is-getting-a-big-boost-following-clintons-loss,R. Chandrasekaran,,,,0,0,8a501260-c34b-4b6c-8301-dbf13b7c42c9
2016-11-03T08:00:00.000+08:00,"Palatin's Female Arousal Drug Data Impresses, Investors React Positively",LLY,https://www.benzinga.com/general/biotech/16/11/8639557/palatins-female-arousal-drug-data-impresses-investors-react-positively,Manikandan Raman,,,,0,0,5d06fa46-c690-4261-9abe-289c47a8bf10
2016-11-03T08:00:00.000+08:00,"Palatin's Female Arousal Drug Data Impresses, Investors React Positively",LLY,https://www.benzinga.com/general/biotech/16/11/8639557/palatins-female-arousal-drug-data-impresses-investors-react-positively,Manikandan Raman,,,,0,0,e25dd2e2-822b-41c1-8c7a-d4bc021d5c2b
2016-11-02T08:00:00.000+08:00,"Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo",LLY,https://www.benzinga.com/news/16/11/8638669/eli-lilly-incyte-reports-new-data-from-pivotal-ra-beacon-study-showing-significan,Paul Quintaro,,,,0,0,dddca0b1-7bfd-44b5-a6dd-f63d3f00ace2
2016-11-02T08:00:00.000+08:00,"Eli Lilly, Incyte Reports New Data from Pivotal RA-BEACON Study Showing Significant Improvement in Patient-Reported Outcomes in RA Patients Treated with Baricitinib vs Placebo",LLY,https://www.benzinga.com/news/16/11/8638669/eli-lilly-incyte-reports-new-data-from-pivotal-ra-beacon-study-showing-significan,Paul Quintaro,,,,0,0,624788a7-d6d5-4e89-903a-f1d3e7175991
2016-11-01T08:00:00.000+08:00,"Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits.",LLY,https://www.benzinga.com/general/biotech/16/11/8631548/senator-bernie-sanders-tweets-people-are-dying-or-getting-sicker-becau,Paul Quintaro,,,,0,0,ad2602b7-8973-49fd-a866-1775431c2447
2016-11-01T08:00:00.000+08:00,"Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits.",LLY,https://www.benzinga.com/general/biotech/16/11/8631548/senator-bernie-sanders-tweets-people-are-dying-or-getting-sicker-becau,Paul Quintaro,,,,0,0,585f1802-11c7-4e93-8aa4-4ca3cde7ea2f
2016-10-26T08:00:00.000+08:00,"Following Q3 Results, Here's Where Eli Lilly Investors' Focus Is Turning",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8603593/following-q3-results-heres-where-eli-lilly-investors-foc,R. Chandrasekaran,,,,0,0,5e9d7dab-3ebb-45b2-9cb8-7a464961c75b
2016-10-26T08:00:00.000+08:00,"Following Q3 Results, Here's Where Eli Lilly Investors' Focus Is Turning",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8603593/following-q3-results-heres-where-eli-lilly-investors-foc,R. Chandrasekaran,,,,0,0,f567b996-e37c-43ca-a804-69c2eb185105
2016-10-25T08:00:00.000+08:00,6 Big Pharma Companies Left To Report September Quarterly Figures,LLY,https://www.benzinga.com/general/biotech/16/10/8597972/6-big-pharma-companies-left-to-report-september-quarterly-figures,R. Chandrasekaran,,,,0,0,d1c65e65-31c7-4464-b46b-0417e08f17f9
2016-10-25T08:00:00.000+08:00,Epic Earnings: Many US Companies Beating Expectations As Season Continues,LLY,https://www.benzinga.com/news/earnings/16/10/8598230/epic-earnings-many-us-companies-beating-expectations-as-season-continues,The Ticker Tape,,,,0,0,b3ff93b8-6c25-4821-8a65-467eb81f0059
2016-10-25T08:00:00.000+08:00,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind",LLY,https://www.benzinga.com/news/16/10/8595821/the-market-in-5-minutes-ua-gm-p-g-earnings-on-the-streets-mind,Benzinga News Desk,,,,0,0,bd729e9f-f3de-427e-81d7-3093898b8ed6
2016-10-25T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus",LLY,https://www.benzinga.com/news/earnings/16/10/8596085/a-peek-into-the-markets-u-s-stock-futures-rise-gm-apple-earnings-in-focu,Monica Gerson,,,,0,0,6f0bb41a-daa3-480e-ae90-bd723f61cb07
2016-10-25T08:00:00.000+08:00,"Eli Lilly Maintains FY 2016 EPS Guidance, Raises Revenue Outlook from $20.6B - $21.1B to $20.8B - $21.2B vs $21.2B est",LLY,https://www.benzinga.com/news/16/10/8595669/eli-lilly-maintains-fy-2016-eps-guidance-raises-revenue-outlook-from-20-6b-21-1b-,Paul Quintaro,,,,0,0,d3a4b9af-8549-46de-8724-5787fbbf43bf
2016-10-25T08:00:00.000+08:00,"Eli Lilly Q3 EPS $0.88 vs $0.96 Est, Revenue $5.19B vs $5.28B Est",LLY,https://www.benzinga.com/news/earnings/16/10/8595665/eli-lilly-q3-eps-0-88-vs-0-96-est-revenue-5-19b-vs-5-28b-est,Paul Quintaro,,,,0,0,0579f7e4-5d33-4664-aa22-ed8c5b925ff2
2016-10-25T08:00:00.000+08:00,12 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/16/10/8595352/12-stocks-you-should-be-watching-today,Monica Gerson,,,,0,0,d59089a6-fd60-4f74-ade9-4811f24cd975
2016-10-25T08:00:00.000+08:00,"Earnings Scheduled For October 25, 2016",LLY,https://www.benzinga.com/news/earnings/16/10/8595305/earnings-scheduled-for-october-25-2016,Monica Gerson,,,,0,0,6cd54128-d1d8-47be-8579-f99b6cd1e8cc
2016-10-25T08:00:00.000+08:00,6 Big Pharma Companies Left To Report September Quarterly Figures,LLY,https://www.benzinga.com/general/biotech/16/10/8597972/6-big-pharma-companies-left-to-report-september-quarterly-figures,R. Chandrasekaran,,,,0,0,089d9d18-613f-43d2-b536-6a1742541adb
2016-10-25T08:00:00.000+08:00,Epic Earnings: Many US Companies Beating Expectations As Season Continues,LLY,https://www.benzinga.com/news/earnings/16/10/8598230/epic-earnings-many-us-companies-beating-expectations-as-season-continues,The Ticker Tape,,,,0,0,b553afec-f4bf-4ca9-a02d-0a1ab4b7c8c7
2016-10-25T08:00:00.000+08:00,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind",LLY,https://www.benzinga.com/news/16/10/8595821/the-market-in-5-minutes-ua-gm-p-g-earnings-on-the-streets-mind,Benzinga News Desk,,,,0,0,fbadd145-f492-4f3d-ac06-64381fddbef0
2016-10-25T08:00:00.000+08:00,"A Peek Into The Markets: U.S. Stock Futures Rise; GM, Apple Earnings In Focus",LLY,https://www.benzinga.com/news/earnings/16/10/8596085/a-peek-into-the-markets-u-s-stock-futures-rise-gm-apple-earnings-in-focu,Monica Gerson,,,,0,0,409cbb0b-f800-4fbe-805d-8f3b43a5562b
2016-10-25T08:00:00.000+08:00,"Eli Lilly Maintains FY 2016 EPS Guidance, Raises Revenue Outlook from $20.6B - $21.1B to $20.8B - $21.2B vs $21.2B est",LLY,https://www.benzinga.com/news/16/10/8595669/eli-lilly-maintains-fy-2016-eps-guidance-raises-revenue-outlook-from-20-6b-21-1b-,Paul Quintaro,,,,0,0,5834847e-389c-4f58-b60e-e3f8bf22df01
2016-10-25T08:00:00.000+08:00,"Eli Lilly Q3 EPS $0.88 vs $0.96 Est, Revenue $5.19B vs $5.28B Est",LLY,https://www.benzinga.com/news/earnings/16/10/8595665/eli-lilly-q3-eps-0-88-vs-0-96-est-revenue-5-19b-vs-5-28b-est,Paul Quintaro,,,,0,0,e12ce3db-b0dd-4fec-b815-39801dc87cbb
2016-10-25T08:00:00.000+08:00,12 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/16/10/8595352/12-stocks-you-should-be-watching-today,Monica Gerson,,,,0,0,de9480e0-3bd3-4967-85c8-a11761a61372
2016-10-25T08:00:00.000+08:00,"Earnings Scheduled For October 25, 2016",LLY,https://www.benzinga.com/news/earnings/16/10/8595305/earnings-scheduled-for-october-25-2016,Monica Gerson,,,,0,0,a43b7527-19ec-4278-bc1c-fff3083ec625
2016-10-21T08:00:00.000+08:00,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,LLY,https://www.benzinga.com/general/biotech/16/10/8588232/are-the-drugs-working-pharma-giants-eli-lilly-and-merck-to-update-inve,The Ticker Tape,,,,0,0,41f2c7ae-7483-4290-a123-ab70da45d929
2016-10-21T08:00:00.000+08:00,Are The Drugs Working? Pharma Giants Eli Lilly And Merck To Update Investors On Cancer Treatments,LLY,https://www.benzinga.com/general/biotech/16/10/8588232/are-the-drugs-working-pharma-giants-eli-lilly-and-merck-to-update-inve,The Ticker Tape,,,,0,0,628d3bea-548e-45e2-b7c4-cf2e374a5c9e
2016-10-19T08:00:00.000+08:00,FDA Has Granted Accelerated Approval for Eli Lilly's Lartruvo with Doxorubicin for Treatment of Advanced Soft Tissue Sarcoma,LLY,https://www.benzinga.com/news/16/10/8578952/hearing-fda-has-granted-accelerated-approval-for-eli-lillys-lartruvo-with-doxorub,Paul Quintaro,,,,0,0,412e7ac2-1def-414d-a281-611dd205a515
2016-10-19T08:00:00.000+08:00,FDA Has Granted Accelerated Approval for Eli Lilly's Lartruvo with Doxorubicin for Treatment of Advanced Soft Tissue Sarcoma,LLY,https://www.benzinga.com/news/16/10/8578952/hearing-fda-has-granted-accelerated-approval-for-eli-lillys-lartruvo-with-doxorub,Paul Quintaro,,,,0,0,5e2db847-2c55-4fc1-a42a-00f1fa59a1fd
2016-10-18T08:00:00.000+08:00,AC Immune Is An Alzheimer's Pure Play With A Lot On The Line,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8572794/ac-immune-is-an-alzheimers-pure-play-with-a-lot-on-the-l,Shanthi Rexaline,,,,0,0,6732e66c-84e0-46e7-b688-cbe2b3f2f963
2016-10-18T08:00:00.000+08:00,AC Immune Is An Alzheimer's Pure Play With A Lot On The Line,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8572794/ac-immune-is-an-alzheimers-pure-play-with-a-lot-on-the-l,Shanthi Rexaline,,,,0,0,f3d0c6ec-ac57-48ac-aabf-3e7d420cb3f5
2016-10-17T08:00:00.000+08:00,Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative,LLY,https://www.benzinga.com/news/16/10/8568461/lilly-partners-with-the-national-cancer-institute-to-accelerate-cancer-research-t,Paul Quintaro,,,,0,0,a8f0eb62-5008-4c05-a14a-49293264b1ea
2016-10-17T08:00:00.000+08:00,Lilly Partners with the National Cancer Institute to Accelerate Cancer Research through New Program under Cancer Moonshot Initiative,LLY,https://www.benzinga.com/news/16/10/8568461/lilly-partners-with-the-national-cancer-institute-to-accelerate-cancer-research-t,Paul Quintaro,,,,0,0,12e9eb50-5386-4cc7-a5f1-7f141ce5d44b
2016-10-09T08:00:00.000+08:00,New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016,LLY,https://www.benzinga.com/news/16/10/8544704/new-data-on-the-combination-of-lillys-alimta-and-mercks-keytruda-show-a-near-doub,Charles Gross,,,,0,0,20a715b3-d59e-4503-9c57-61865b5c5361
2016-10-09T08:00:00.000+08:00,New Data on the Combination of Lilly's ALIMTA and Merck's KEYTRUDA Show a Near-Doubling of Objective Response Rate Compared to Standard of Care Alone in First-Line Metastatic NSCLC Presented at ESMO 2016,LLY,https://www.benzinga.com/news/16/10/8544704/new-data-on-the-combination-of-lillys-alimta-and-mercks-keytruda-show-a-near-doub,Charles Gross,,,,0,0,c6743fb4-aaff-4dd2-842d-f29c07f4b267
2016-10-05T08:00:00.000+08:00,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8532707/anavex-life-sciences-joins-the-club-of-stocks-moving-hig,Jayson Derrick,,,,0,0,147e05ac-800b-497e-bb17-ed9099a75ccc
2016-10-05T08:00:00.000+08:00,"Eli Lilly Announces Elanco US Subsidiary Has Entered Deal to Buy Boehringer Ingelheim Vetmedica's US Feline, Canine, Rabies Vaccines Portfolio for $885M",LLY,https://www.benzinga.com/news/16/10/8531059/eli-lilly-announces-elanco-us-subsidiary-has-entered-deal-to-buy-boehringer-ingel,Paul Quintaro,,,,0,0,1e1c7a92-49b3-47fa-b448-dab8bc9fccb1
2016-10-05T08:00:00.000+08:00,Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8532707/anavex-life-sciences-joins-the-club-of-stocks-moving-hig,Jayson Derrick,,,,0,0,4aeb7a60-407e-4445-8aba-a3f0a4d1478b
2016-10-05T08:00:00.000+08:00,"Eli Lilly Announces Elanco US Subsidiary Has Entered Deal to Buy Boehringer Ingelheim Vetmedica's US Feline, Canine, Rabies Vaccines Portfolio for $885M",LLY,https://www.benzinga.com/news/16/10/8531059/eli-lilly-announces-elanco-us-subsidiary-has-entered-deal-to-buy-boehringer-ingel,Paul Quintaro,,,,0,0,9c566b83-54a4-4796-afa5-58716ba5f211
2016-10-03T08:00:00.000+08:00,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8521018/in-one-experts-view-eli-lillys-alzheimer-drug-trial-has-,Wayne Duggan,,,,0,0,c6601945-be55-4149-87d0-022fd6b3f68c
2016-10-03T08:00:00.000+08:00,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8521040/a-possible-trading-opportunity-presents-itself-in-biogen,Manikandan Raman,,,,0,0,a2fbb4f1-2cba-417b-851f-902202f4cfe8
2016-10-03T08:00:00.000+08:00,"In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8521018/in-one-experts-view-eli-lillys-alzheimer-drug-trial-has-,Wayne Duggan,,,,0,0,d8ea2f60-2157-4c56-a726-f84a122c4a42
2016-10-03T08:00:00.000+08:00,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8521040/a-possible-trading-opportunity-presents-itself-in-biogen,Manikandan Raman,,,,0,0,5e27730c-f5f5-4942-85a0-aa187a4ee044
2016-09-27T08:00:00.000+08:00,The Drug Price Increase Debate: Separating The Winners From The Losers,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8499775/goldman-on-the-drug-price-increase-debate-separating-the,Jim Swanson,,,,0,0,feac8e5c-11ff-4351-a019-866dff3ca9e9
2016-09-27T08:00:00.000+08:00,7 Biggest Price Target Changes For Tuesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/16/09/8499957/7-biggest-price-target-changes-for-tuesday,Lisa Levin,,,,0,0,1b026c70-1395-43ec-bba6-7b990025213b
2016-09-27T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/09/8499491/benzingas-top-upgrades,Monica Gerson,,,,0,0,bf715b75-3a77-48d1-8a03-5ab278c7a2ad
2016-09-27T08:00:00.000+08:00,"The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed",LLY,https://www.benzinga.com/news/16/09/8499111/the-market-in-5-minutes-debates-oil-keep-stocks-mixed,Benzinga News Desk,,,,0,0,2e8cfa32-be35-42a1-a5a5-b09a45ce8467
2016-09-27T08:00:00.000+08:00,Eli Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8499117/lilly-is-entering-a-period-of-accelerated-growth-goldman,Monica Gerson,,,,0,0,c9e251d0-c7a1-4853-bd50-4307007a75c1
2016-09-27T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Data,LLY,https://www.benzinga.com/news/earnings/16/09/8498946/a-peek-into-the-markets-u-s-stock-futures-gain-ahead-of-economic-data,Monica Gerson,,,,0,0,d38a57c3-b996-44d9-afdd-9829131fef80
2016-09-27T08:00:00.000+08:00,"Goldman Sachs Upgrades Eli Lilly to Buy, Raises PT to $95.00",LLY,https://www.benzinga.com/news/16/09/8498722/goldman-sachs-upgrades-eli-lilly-to-buy-raises-pt-to-95-00,Paul Quintaro,,,,0,0,86f9f072-2047-422d-ab85-025c946ffddb
2016-09-27T08:00:00.000+08:00,The Drug Price Increase Debate: Separating The Winners From The Losers,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8499775/goldman-on-the-drug-price-increase-debate-separating-the,Jim Swanson,,,,0,0,1ca7d9e6-7830-435a-ae42-af0d5f64aeb1
2016-09-27T08:00:00.000+08:00,7 Biggest Price Target Changes For Tuesday,LLY,https://www.benzinga.com/analyst-ratings/price-target/16/09/8499957/7-biggest-price-target-changes-for-tuesday,Lisa Levin,,,,0,0,5bb82e9c-ed30-4274-ae80-2501336bab6e
2016-09-27T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/09/8499491/benzingas-top-upgrades,Monica Gerson,,,,0,0,f3e88c1f-b0ed-4e52-ab48-21c5e930b21a
2016-09-27T08:00:00.000+08:00,"The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed",LLY,https://www.benzinga.com/news/16/09/8499111/the-market-in-5-minutes-debates-oil-keep-stocks-mixed,Benzinga News Desk,,,,0,0,a7fd5dff-8c16-4259-8421-c4780942f343
2016-09-27T08:00:00.000+08:00,Eli Lilly Is Entering A Period Of Accelerated Growth; Goldman Upgrades Stock To Buy,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8499117/lilly-is-entering-a-period-of-accelerated-growth-goldman,Monica Gerson,,,,0,0,99b7cc31-85af-4d15-9138-af34032e955c
2016-09-27T08:00:00.000+08:00,A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Data,LLY,https://www.benzinga.com/news/earnings/16/09/8498946/a-peek-into-the-markets-u-s-stock-futures-gain-ahead-of-economic-data,Monica Gerson,,,,0,0,f7fc0fb6-dfec-42f3-9b12-967f265b0011
2016-09-27T08:00:00.000+08:00,"Goldman Sachs Upgrades Eli Lilly to Buy, Raises PT to $95.00",LLY,https://www.benzinga.com/news/16/09/8498722/goldman-sachs-upgrades-eli-lilly-to-buy-raises-pt-to-95-00,Paul Quintaro,,,,0,0,b9f15031-3667-4094-a901-b355ca279692
2016-09-26T08:00:00.000+08:00,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8494801/vtv-therapeutics-shares-initiated-with-buy-rating-13-tar,Manikandan Raman,,,,0,0,d38b085f-19ac-4598-861a-b724ec961cc8
2016-09-26T08:00:00.000+08:00,Cerecor Reports Acquisition of TARP-γ8-AMPA Receptor Antagonist from Eli Lilly,LLY,https://www.benzinga.com/news/16/09/8494523/cerecor-reports-acquisition-of-tarp-8-ampa-receptor-antagonist-from-eli-lilly,Paul Quintaro,,,,0,0,1ac8abc7-15f5-4bd2-ade1-122e1803bf27
2016-09-26T08:00:00.000+08:00,First Trust Gets Smart With New Sector ETFs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/16/09/8493047/first-trust-gets-smart-with-new-sector-etfs,ETF Professor,,,,0,0,6f6b1e4d-c7e3-4bdb-9b59-272faa50f378
2016-09-26T08:00:00.000+08:00,"vTv Therapeutics Shares Initiated With Buy Rating, $13 Target",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8494801/vtv-therapeutics-shares-initiated-with-buy-rating-13-tar,Manikandan Raman,,,,0,0,241d38a7-dea0-48c0-9c4d-708f11e3866d
2016-09-26T08:00:00.000+08:00,Cerecor Reports Acquisition of TARP-γ8-AMPA Receptor Antagonist from Eli Lilly,LLY,https://www.benzinga.com/news/16/09/8494523/cerecor-reports-acquisition-of-tarp-8-ampa-receptor-antagonist-from-eli-lilly,Paul Quintaro,,,,0,0,6460c3dc-f01e-4c55-96eb-e326066a7672
2016-09-26T08:00:00.000+08:00,First Trust Gets Smart With New Sector ETFs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/16/09/8493047/first-trust-gets-smart-with-new-sector-etfs,ETF Professor,,,,0,0,09669f63-2fed-4088-90e2-f92b8f465801
2016-09-21T08:00:00.000+08:00,Chasing Takeover Rumors Can Be Hazardous To Your Portfolio,LLY,https://www.benzinga.com/node/8482768,Joel Elconin,,,,0,0,2ddfddd3-f6cc-4fa3-864e-c852c07076c4
2016-09-21T08:00:00.000+08:00,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen",LLY,https://www.benzinga.com/news/16/09/8480831/the-market-in-5-minutes-were-waiting-for-you-mrs-yellen,Benzinga News Desk,,,,0,0,cc9901b2-6159-4c48-8c06-6ac053481f21
2016-09-21T08:00:00.000+08:00,Clovis Upgraded At Credit Suisse Following Acquisition Rumor,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8480898/clovis-upgraded-at-credit-suisse-following-acquisition-r,Monica Gerson,,,,0,0,763f7398-d172-4c91-8ce0-a4a0a6d8b2fb
2016-09-21T08:00:00.000+08:00,Chasing Takeover Rumors Can Be Hazardous To Your Portfolio,LLY,https://www.benzinga.com/node/8482768,Joel Elconin,,,,0,0,91af8b19-417b-4bc8-9890-3ebe2a73d558
2016-09-21T08:00:00.000+08:00,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen",LLY,https://www.benzinga.com/news/16/09/8480831/the-market-in-5-minutes-were-waiting-for-you-mrs-yellen,Benzinga News Desk,,,,0,0,19e859d7-af23-4c4b-9243-4333950b746d
2016-09-21T08:00:00.000+08:00,Clovis Upgraded At Credit Suisse Following Acquisition Rumor,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8480898/clovis-upgraded-at-credit-suisse-following-acquisition-r,Monica Gerson,,,,0,0,42daec70-4a59-4382-9ec1-6ab86b323391
2016-09-20T08:00:00.000+08:00,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8479674/some-traders-attributing-after-hours-upside-in-clovis-to,Paul Quintaro,,,,0,0,4fb197d9-97b6-4a5e-a707-64c035b28453
2016-09-20T08:00:00.000+08:00,"Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors",LLY,https://www.benzinga.com/node/8478906,Paul Quintaro,,,,0,0,79a29f2d-8090-4c75-ada9-307de80d76e3
2016-09-20T08:00:00.000+08:00,Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest,LLY,https://www.benzinga.com/news/16/09/8478767/traders-attributing-spike-higher-in-clovis-oncology-to-unconfirmed-chatter-of-lil,Paul Quintaro,,,,0,0,d6b7ccf4-f8a7-476a-8319-6e75106b50d1
2016-09-20T08:00:00.000+08:00,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8479674/some-traders-attributing-after-hours-upside-in-clovis-to,Paul Quintaro,,,,0,0,97984261-77b7-4ff8-a466-e5200d04e582
2016-09-20T08:00:00.000+08:00,"Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors",LLY,https://www.benzinga.com/node/8478906,Paul Quintaro,,,,0,0,f5e62c9f-bffa-441a-bf0a-62bb85a97069
2016-09-20T08:00:00.000+08:00,Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest,LLY,https://www.benzinga.com/news/16/09/8478767/traders-attributing-spike-higher-in-clovis-oncology-to-unconfirmed-chatter-of-lil,Paul Quintaro,,,,0,0,44ca5b63-52ad-4ad9-9bb9-f350362ddbf9
2016-09-16T08:00:00.000+08:00,3 Pharma Companies Receive Positive EU Opinions,LLY,https://www.benzinga.com/general/biotech/16/09/8465083/3-pharma-companies-receive-positive-eu-opinions,R. Chandrasekaran,,,,0,0,a54cb8f0-1714-4083-8c04-dab92fc28576
2016-09-16T08:00:00.000+08:00,Eli Lilly Reports CHMP Recommended Approval of Co.'s Olaratumab in Combo with Doxorubicin for Advanced Soft Tissue Sarcoma,LLY,https://www.benzinga.com/news/16/09/8464972/eli-lilly-reports-chmp-recommended-approval-of-co-s-olaratumab-in-combo-with-doxo,Paul Quintaro,,,,0,0,48cd5c6a-d166-4359-a900-54ecc543d776
2016-09-16T08:00:00.000+08:00,3 Pharma Companies Receive Positive EU Opinions,LLY,https://www.benzinga.com/general/biotech/16/09/8465083/3-pharma-companies-receive-positive-eu-opinions,R. Chandrasekaran,,,,0,0,baa68150-2ed9-4691-808e-ec971bd6f882
2016-09-16T08:00:00.000+08:00,Eli Lilly Reports CHMP Recommended Approval of Co.'s Olaratumab in Combo with Doxorubicin for Advanced Soft Tissue Sarcoma,LLY,https://www.benzinga.com/news/16/09/8464972/eli-lilly-reports-chmp-recommended-approval-of-co-s-olaratumab-in-combo-with-doxo,Paul Quintaro,,,,0,0,ba21ba23-219b-4d29-a43d-770a4e90e2ef
2016-09-08T08:00:00.000+08:00,New Upside Potential Drives JPMorgan's Eli Lilly Upgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8436629/new-upside-potential-drives-jpmorgans-eli-lilly-upgrade,Manikandan Raman,,,,0,0,6ba83bc6-9bb0-40bb-9619-8712668ffe0b
2016-09-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/09/8435965/benzingas-top-upgrades,Monica Gerson,,,,0,0,c938f7c8-521c-455c-92e0-ef382ec32110
2016-09-08T08:00:00.000+08:00,The Market In 5 Minutes: iPhone 7 Arrives,LLY,https://www.benzinga.com/news/16/09/8435362/the-market-in-5-minutes-iphone-7-arrives,Benzinga News Desk,,,,0,0,8d0ff812-d14d-40d4-85e5-36dcf685cdf7
2016-09-08T08:00:00.000+08:00,JP Morgan Upgrades Eli Lilly to Overweight,LLY,https://www.benzinga.com/news/16/09/8434693/jp-morgan-upgrades-eli-lilly-to-overweight,Paul Quintaro,,,,0,0,fb7383d9-bfd4-4502-a25c-8a7dd007e251
2016-09-08T08:00:00.000+08:00,New Upside Potential Drives JPMorgan's Eli Lilly Upgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8436629/new-upside-potential-drives-jpmorgans-eli-lilly-upgrade,Manikandan Raman,,,,0,0,525d5060-a15e-46b6-844e-e96973aae58e
2016-09-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/09/8435965/benzingas-top-upgrades,Monica Gerson,,,,0,0,f9f6dfe3-00ba-40a9-85d1-60469d8f8d39
2016-09-08T08:00:00.000+08:00,The Market In 5 Minutes: iPhone 7 Arrives,LLY,https://www.benzinga.com/news/16/09/8435362/the-market-in-5-minutes-iphone-7-arrives,Benzinga News Desk,,,,0,0,f42024b9-4215-41c0-b24d-1cc1d75235e2
2016-09-08T08:00:00.000+08:00,JP Morgan Upgrades Eli Lilly to Overweight,LLY,https://www.benzinga.com/news/16/09/8434693/jp-morgan-upgrades-eli-lilly-to-overweight,Paul Quintaro,,,,0,0,05de7512-579b-4eb6-808a-b609dda9d98b
2016-09-07T08:00:00.000+08:00,"Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7",LLY,https://www.benzinga.com/media/cnbc/16/09/8428800/apple-eli-lilly-u-s-steel-fast-money-picks-for-september-7,Craig Jones,,,,0,0,a342e057-6fb2-4466-8798-15bb0f432dd0
2016-09-07T08:00:00.000+08:00,"Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7",LLY,https://www.benzinga.com/media/cnbc/16/09/8428800/apple-eli-lilly-u-s-steel-fast-money-picks-for-september-7,Craig Jones,,,,0,0,2167d09a-ea0b-47fe-b49d-386bf0b43ede
2016-09-06T08:00:00.000+08:00,"Adam Feuerstein @adamfeuerstein Tweet: $LLY - Cowen analyst Steve Scala goes all in on sola, predicting 99% likelihood of hitting ph3 ADAS-Cog14 primary endpoint. 99%! Yowza.",LLY,https://www.benzinga.com/news/16/09/8425884/adam-feuerstein-adamfeuerstein-tweet-lly-cowen-analyst-steve-scala-goes-all-in-on,Charles Gross,,,,0,0,9229eaa8-e566-41d5-be6a-c47b60a09401
2016-09-06T08:00:00.000+08:00,"Adam Feuerstein @adamfeuerstein Tweet: $LLY - Cowen analyst Steve Scala goes all in on sola, predicting 99% likelihood of hitting ph3 ADAS-Cog14 primary endpoint. 99%! Yowza.",LLY,https://www.benzinga.com/news/16/09/8425884/adam-feuerstein-adamfeuerstein-tweet-lly-cowen-analyst-steve-scala-goes-all-in-on,Charles Gross,,,,0,0,bbdacd94-6dc9-4312-86d6-57faf2a83c31
2016-08-30T08:00:00.000+08:00,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8405933/janney-initiates-galapagos-at-buy-sees-fair-value-of-sha,Manikandan Raman,,,,0,0,6d348df1-cffb-4050-a09b-2a6ba1672142
2016-08-30T08:00:00.000+08:00,"Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8405933/janney-initiates-galapagos-at-buy-sees-fair-value-of-sha,Manikandan Raman,,,,0,0,7b96d30f-0439-4100-96e4-d8756739156f
2016-08-29T08:00:00.000+08:00,Novogen Names Gordon Hirsch as Chief Medical Officer,LLY,https://www.benzinga.com/news/16/08/8399344/novogen-names-gordon-hirsch-as-chief-medical-officer,Charles Gross,,,,0,0,393e4e20-d65c-4c2a-a25f-baa44d29d41b
2016-08-29T08:00:00.000+08:00,Novogen Names Gordon Hirsch as Chief Medical Officer,LLY,https://www.benzinga.com/news/16/08/8399344/novogen-names-gordon-hirsch-as-chief-medical-officer,Charles Gross,,,,0,0,81f7f5b4-22d9-4226-8843-b346dccf6720
2016-08-22T08:00:00.000+08:00,Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293,LLY,https://www.benzinga.com/news/16/08/8376571/lilly-and-astrazeneca-receive-fda-fast-track-designation-for-azd3293,Paul Quintaro,,,,0,0,9eaaebaa-5d17-440f-a6f6-e749bd41150c
2016-08-22T08:00:00.000+08:00,Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293,LLY,https://www.benzinga.com/news/16/08/8376571/lilly-and-astrazeneca-receive-fda-fast-track-designation-for-azd3293,Paul Quintaro,,,,0,0,5982746b-47d6-49d0-9551-79f33c26ff04
2016-08-11T08:00:00.000+08:00,"Lilly Announces Health Canada Approves New Indication for Jardiance Tablets for Adults With Type 2 Diabetes, Established Cardiovascular Disease",LLY,https://www.benzinga.com/news/16/08/8337214/lilly-announces-health-canada-approves-new-indication-for-jardiance-tablets-for-a,Charles Gross,,,,0,0,e09085c9-5e51-498f-b48c-421817f948a1
2016-08-11T08:00:00.000+08:00,"Lilly Announces Health Canada Approves New Indication for Jardiance Tablets for Adults With Type 2 Diabetes, Established Cardiovascular Disease",LLY,https://www.benzinga.com/news/16/08/8337214/lilly-announces-health-canada-approves-new-indication-for-jardiance-tablets-for-a,Charles Gross,,,,0,0,c09b6ab1-2259-40b7-af2f-e501f562b420
2016-08-10T08:00:00.000+08:00,Lilly Volume Spike,LLY,https://www.benzinga.com/news/16/08/8332627/lilly-volume-spike,Charles Gross,,,,0,0,d9914005-e301-40d5-a7cf-8de159dd61ae
2016-08-10T08:00:00.000+08:00,Eli Lilly Update on MONARCH 2 Phase 3 Trial Recommended to Continue As Planned By Independent Committee as Interim Efficacy Criteria Not Met,LLY,https://www.benzinga.com/news/16/08/8330854/eli-lilly-update-on-monarch-2-phase-3-trial-recommended-to-continue-as-planned-by,Paul Quintaro,,,,0,0,6a3853b7-afcd-46ae-86aa-4aef27a511ac
2016-08-10T08:00:00.000+08:00,Lilly Volume Spike,LLY,https://www.benzinga.com/news/16/08/8332627/lilly-volume-spike,Charles Gross,,,,0,0,c6402881-7f98-4d02-afcd-e50c04f904dc
2016-08-10T08:00:00.000+08:00,Eli Lilly Update on MONARCH 2 Phase 3 Trial Recommended to Continue As Planned By Independent Committee as Interim Efficacy Criteria Not Met,LLY,https://www.benzinga.com/news/16/08/8330854/eli-lilly-update-on-monarch-2-phase-3-trial-recommended-to-continue-as-planned-by,Paul Quintaro,,,,0,0,770dad8a-6202-4166-b644-33139418cb36
2016-07-28T08:00:00.000+08:00,UPDATE: Lilly in 10Q Says Received Civil Investigative Demand from U.S. Attorney's Office for the Southern District of New York,LLY,https://www.benzinga.com/news/16/07/8273137/update-lilly-in-10q-says-received-civil-investigative-demand-from-u-s-attorneys-o,Charles Gross,,,,0,0,db653e03-1c49-43c2-ac97-a0ba88163acf
2016-07-28T08:00:00.000+08:00,"Eli Lilly Says DOJ Requested Documents, Information Relating to Relationships With Pharmacy-Benefit Managers - DJ",LLY,https://www.benzinga.com/news/16/07/8273124/eli-lilly-says-doj-requested-documents-information-relating-to-relationships-with,Charles Gross,,,,0,0,fd10c489-746d-43a9-a8d7-849746bc6e56
2016-07-28T08:00:00.000+08:00,UPDATE: Lilly in 10Q Says Received Civil Investigative Demand from U.S. Attorney's Office for the Southern District of New York,LLY,https://www.benzinga.com/news/16/07/8273137/update-lilly-in-10q-says-received-civil-investigative-demand-from-u-s-attorneys-o,Charles Gross,,,,0,0,7118e17b-e414-4833-8d6e-f8a3868cc88e
2016-07-28T08:00:00.000+08:00,"Eli Lilly Says DOJ Requested Documents, Information Relating to Relationships With Pharmacy-Benefit Managers - DJ",LLY,https://www.benzinga.com/news/16/07/8273124/eli-lilly-says-doj-requested-documents-information-relating-to-relationships-with,Charles Gross,,,,0,0,96e3ebec-882a-48c2-8965-cfab26ab5c91
2016-07-27T08:00:00.000+08:00,New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease,LLY,https://www.benzinga.com/news/16/07/8267566/new-studies-suggest-relationship-between-tau-pathology-and-progression-of-alzheim,Paul Quintaro,,,,0,0,ed068157-2b19-4d0f-a627-3ca59f197154
2016-07-27T08:00:00.000+08:00,"John Lechleiter To Step Down From Lilly CEO, David Ricks To Take Position",LLY,https://www.benzinga.com/news/16/07/8262781/john-lechleiter-to-step-down-from-lilly-ceo-david-ricks-to-take-position,Paul Quintaro,,,,0,0,6b7ea6e6-1dbd-4997-9b11-54e23af44d6e
2016-07-27T08:00:00.000+08:00,New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease,LLY,https://www.benzinga.com/news/16/07/8267566/new-studies-suggest-relationship-between-tau-pathology-and-progression-of-alzheim,Paul Quintaro,,,,0,0,95884de7-0a02-438e-a1c0-0a840073cac6
2016-07-27T08:00:00.000+08:00,"John Lechleiter To Step Down From Lilly CEO, David Ricks To Take Position",LLY,https://www.benzinga.com/news/16/07/8262781/john-lechleiter-to-step-down-from-lilly-ceo-david-ricks-to-take-position,Paul Quintaro,,,,0,0,2a25690a-6d29-4c0e-ae5f-419cfc57ce6c
2016-07-26T08:00:00.000+08:00,Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report,LLY,https://www.benzinga.com/trading-ideas/technicals/16/07/8259383/technical-alert-eli-lilly-unchanged-after-wild-ride-following,Eddie Staley,,,,0,0,fb8d3370-7242-4206-b3d2-816c76530bf5
2016-07-26T08:00:00.000+08:00,"Lilly Sees FY 2016 EPS $3.50 to $3.60 vs $3.56 est, Revenue $20.6B to $21.1B vs $20.9B est",LLY,https://www.benzinga.com/news/16/07/8256302/lilly-sees-fy-2016-eps-3-50-to-3-60-vs-3-56-est-revenue-20-6b-to-21-1b-vs-20-9b-e,Paul Quintaro,,,,0,0,38882ab7-b938-4c9f-ae50-2e5a0c65334f
2016-07-26T08:00:00.000+08:00,"Lilly Q2 EPS $0.86 vs $0.86 est, Revenue $5.4B vs $5.2B est",LLY,https://www.benzinga.com/news/earnings/16/07/8256298/lilly-q2-eps-0-86-vs-0-86-est-revenue-5-4b-vs-5-2b-est,Paul Quintaro,,,,0,0,7f758082-df9d-439b-a646-41aaf31d6391
2016-07-26T08:00:00.000+08:00,"Earnings Scheduled For July 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/07/8255995/earnings-scheduled-for-july-26-2016,Monica Gerson,,,,0,0,037e6b1c-0b53-4d64-81a6-41f97e34e76d
2016-07-26T08:00:00.000+08:00,Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report,LLY,https://www.benzinga.com/trading-ideas/technicals/16/07/8259383/technical-alert-eli-lilly-unchanged-after-wild-ride-following,Eddie Staley,,,,0,0,d1248962-2b06-4127-8018-712beb36e5b1
2016-07-26T08:00:00.000+08:00,"Lilly Sees FY 2016 EPS $3.50 to $3.60 vs $3.56 est, Revenue $20.6B to $21.1B vs $20.9B est",LLY,https://www.benzinga.com/news/16/07/8256302/lilly-sees-fy-2016-eps-3-50-to-3-60-vs-3-56-est-revenue-20-6b-to-21-1b-vs-20-9b-e,Paul Quintaro,,,,0,0,0eb05ae9-3371-4da1-8808-2346264dc3b2
2016-07-26T08:00:00.000+08:00,"Lilly Q2 EPS $0.86 vs $0.86 est, Revenue $5.4B vs $5.2B est",LLY,https://www.benzinga.com/news/earnings/16/07/8256298/lilly-q2-eps-0-86-vs-0-86-est-revenue-5-4b-vs-5-2b-est,Paul Quintaro,,,,0,0,a4697687-0084-44c0-8db5-40ad6a39dc81
2016-07-26T08:00:00.000+08:00,"Earnings Scheduled For July 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/07/8255995/earnings-scheduled-for-july-26-2016,Monica Gerson,,,,0,0,4d2c74be-5a25-423d-886c-3b058e574706
2016-07-25T08:00:00.000+08:00,Can MCD Feed Higher Sales with More than Breakfast?,LLY,https://www.benzinga.com/news/earnings/16/07/8253048/can-mcd-feed-higher-sales-with-more-than-breakfast,The Ticker Tape,,,,0,0,e132b00e-fd22-402b-85f1-1984dc5081f7
2016-07-25T08:00:00.000+08:00,"Week Ahead: It's Not Just Earnings This Time, as GDP, Fed Also on Tap",LLY,https://www.benzinga.com/news/earnings/16/07/8252276/week-ahead-its-not-just-earnings-this-time-as-gdp-fed-also-on-tap,The Ticker Tape,,,,0,0,e513bf31-f470-4388-a279-a97d21cad906
2016-07-25T08:00:00.000+08:00,Can MCD Feed Higher Sales with More than Breakfast?,LLY,https://www.benzinga.com/news/earnings/16/07/8253048/can-mcd-feed-higher-sales-with-more-than-breakfast,The Ticker Tape,,,,0,0,ccd42123-0db9-47dc-9381-541911db6ee2
2016-07-25T08:00:00.000+08:00,"Week Ahead: It's Not Just Earnings This Time, as GDP, Fed Also on Tap",LLY,https://www.benzinga.com/news/earnings/16/07/8252276/week-ahead-its-not-just-earnings-this-time-as-gdp-fed-also-on-tap,The Ticker Tape,,,,0,0,19b3a3c0-7a92-438a-81c6-a38d31fdb540
2016-07-19T08:00:00.000+08:00,Eli Lilly Gets FDA Expanded Indication For Type 2 Diabetes Treatment Synjardy To Add Treatment-Naïve Adults,LLY,https://www.benzinga.com/general/biotech/16/07/8231550/eli-lilly-gets-fda-expanded-indication-for-type-2-diabetes-treatment-s,R. Chandrasekaran,,,,0,0,40e0611b-ca92-4b57-8194-65acd4d3107b
2016-07-19T08:00:00.000+08:00,Eli Lilly Reports U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults,LLY,https://www.benzinga.com/news/16/07/8231138/eli-lilly-reports-u-s-fda-expands-indication-for-type-2-diabetes-treatment-synjar,Paul Quintaro,,,,0,0,d714be17-b710-4da7-bed3-a10abeda37b2
2016-07-19T08:00:00.000+08:00,Eli Lilly Gets FDA Expanded Indication For Type 2 Diabetes Treatment Synjardy To Add Treatment-Naïve Adults,LLY,https://www.benzinga.com/general/biotech/16/07/8231550/eli-lilly-gets-fda-expanded-indication-for-type-2-diabetes-treatment-s,R. Chandrasekaran,,,,0,0,1b8c4d3d-1f70-4f47-8cd7-9ed818dbb657
2016-07-19T08:00:00.000+08:00,Eli Lilly Reports U.S. FDA expands indication for type 2 diabetes treatment Synjardy to include treatment-naïve adults,LLY,https://www.benzinga.com/news/16/07/8231138/eli-lilly-reports-u-s-fda-expands-indication-for-type-2-diabetes-treatment-synjar,Paul Quintaro,,,,0,0,78f2d8fe-b3d1-481b-b86d-c1620a9eecd3
2016-07-18T08:00:00.000+08:00,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/07/8227554/bmo-analysts-say-mercks-fundamentals-dont-justify-its-va,Manikandan Raman,,,,0,0,bdac1867-5057-4480-9db2-3ef5cf5ea341
2016-07-18T08:00:00.000+08:00,BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/07/8227554/bmo-analysts-say-mercks-fundamentals-dont-justify-its-va,Manikandan Raman,,,,0,0,58876c41-21ff-4ee7-ae93-ff7d14f9aac0
2016-07-13T08:00:00.000+08:00,Eli Lilly Reports Clinical Trial Collaboration Deal with Ingelheim for Metastatic Breast Cancer,LLY,https://www.benzinga.com/news/16/07/8212419/eli-lilly-reports-clinical-trial-collaboration-deal-with-ingelheim-for-metastatic,Paul Quintaro,,,,0,0,2545ec7f-d136-4ffc-a92f-bdf1682ab3a1
2016-07-13T08:00:00.000+08:00,Eli Lilly Reports Clinical Trial Collaboration Deal with Ingelheim for Metastatic Breast Cancer,LLY,https://www.benzinga.com/news/16/07/8212419/eli-lilly-reports-clinical-trial-collaboration-deal-with-ingelheim-for-metastatic,Paul Quintaro,,,,0,0,6db1e14c-fdff-47dd-bcb8-c092a12d7488
2016-07-06T08:00:00.000+08:00,"Watch for Near-Term Profit Taking in Lilly Shares Following Spike Higher as Traders Passing Around Vague, Unconfirmed Chatter on Co.",LLY,https://www.benzinga.com/news/16/07/8189473/watch-for-near-term-profit-taking-in-lilly-shares-following-spike-higher-as-trade,Paul Quintaro,,,,0,0,69c0f6e5-3b59-4017-8932-02bf696e5b56
2016-07-06T08:00:00.000+08:00,Eli Lilly Shares Spiking Higher,LLY,https://www.benzinga.com/movers/16/07/8189464/eli-lilly-shares-spiking-higher,Paul Quintaro,,,,0,0,b8994e24-251d-4bd5-b1aa-9b03f7905cec
2016-07-06T08:00:00.000+08:00,"Watch for Near-Term Profit Taking in Lilly Shares Following Spike Higher as Traders Passing Around Vague, Unconfirmed Chatter on Co.",LLY,https://www.benzinga.com/news/16/07/8189473/watch-for-near-term-profit-taking-in-lilly-shares-following-spike-higher-as-trade,Paul Quintaro,,,,0,0,c17dbbb5-2d86-425f-91f2-ebca499ba8ac
2016-07-06T08:00:00.000+08:00,Eli Lilly Shares Spiking Higher,LLY,https://www.benzinga.com/movers/16/07/8189464/eli-lilly-shares-spiking-higher,Paul Quintaro,,,,0,0,701b3195-d66b-4180-9ecf-3a9b078c89d4
2016-06-30T08:00:00.000+08:00,"Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company",LLY,https://www.benzinga.com/news/16/06/8170340/regen-biopharma-inc-enters-into-open-innovation-drug-discovery-program-agreement-,Paul Quintaro,,,,0,0,95a76845-3764-45a5-b7e2-0d66b9ff9abe
2016-06-30T08:00:00.000+08:00,"Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company",LLY,https://www.benzinga.com/news/16/06/8170340/regen-biopharma-inc-enters-into-open-innovation-drug-discovery-program-agreement-,Paul Quintaro,,,,0,0,a1743a14-64d9-4026-a46c-df59f0a63b28
2016-06-21T08:00:00.000+08:00,Eli Lilly Canada Granted Approval For Taltz In Treatment Of Moderate-To-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/06/8135931/eli-lilly-canada-granted-approval-for-taltz-in-treatment-of-moderate-to-severe-pl,Eddie Staley,,,,0,0,f51eeaef-0689-4ed6-81f8-44d14e7933b6
2016-06-21T08:00:00.000+08:00,Eli Lilly Canada Granted Approval For Taltz In Treatment Of Moderate-To-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/06/8135931/eli-lilly-canada-granted-approval-for-taltz-in-treatment-of-moderate-to-severe-pl,Eddie Staley,,,,0,0,4f8f6af0-6713-4315-bf3a-331938fd3eaf
2016-06-14T08:00:00.000+08:00,German Supreme Court Grants Lilly Appeal in Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/16/06/8111785/german-supreme-court-grants-lilly-appeal-in-alimta-vitamin-regimen-patent-lawsuit,Charles Gross,,,,0,0,c0045965-86c0-47fa-a4c5-5407f88028ed
2016-06-14T08:00:00.000+08:00,Jefferies Shares Pharma Stock Catalyst Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8110237/jefferies-shares-pharma-stock-catalyst-outlook,Javier Hasse,,,,0,0,d43b2d6e-c4d8-45bd-a0d6-0b50bbd2b4d1
2016-06-14T08:00:00.000+08:00,Eli Lilly Says JARDIANCE Significantly Reduced Risk of Progressive Kidney Disease in Adults with Type-2 Diabetes with Established CV Disease,LLY,https://www.benzinga.com/news/16/06/8108899/eli-lilly-says-jardiance-significantly-reduced-risk-of-progressive-kidney-disease,Paul Quintaro,,,,0,0,71c4c20d-ee38-4869-93f7-a3a1dd2c099d
2016-06-14T08:00:00.000+08:00,German Supreme Court Grants Lilly Appeal in Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/16/06/8111785/german-supreme-court-grants-lilly-appeal-in-alimta-vitamin-regimen-patent-lawsuit,Charles Gross,,,,0,0,76eb7795-e88b-43be-8cc9-733ad33758cb
2016-06-14T08:00:00.000+08:00,Jefferies Shares Pharma Stock Catalyst Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8110237/jefferies-shares-pharma-stock-catalyst-outlook,Javier Hasse,,,,0,0,8c91b6af-57de-4a16-b100-6018fee0cb01
2016-06-14T08:00:00.000+08:00,Eli Lilly Says JARDIANCE Significantly Reduced Risk of Progressive Kidney Disease in Adults with Type-2 Diabetes with Established CV Disease,LLY,https://www.benzinga.com/news/16/06/8108899/eli-lilly-says-jardiance-significantly-reduced-risk-of-progressive-kidney-disease,Paul Quintaro,,,,0,0,5b89c8b8-b5e8-432f-84f6-2b37ede5a25d
2016-06-13T08:00:00.000+08:00,"SunTrust Highlights Upcoming Pharma Calendar, Favorite Names",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8105042/suntrust-highlights-upcoming-pharma-calendar-favorite-na,Amy Weingarden,,,,0,0,9955812f-ac3a-4aa3-a2e7-81267984488a
2016-06-13T08:00:00.000+08:00,"SunTrust Highlights Upcoming Pharma Calendar, Favorite Names",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8105042/suntrust-highlights-upcoming-pharma-calendar-favorite-na,Amy Weingarden,,,,0,0,e52e8da3-957e-4c72-a734-c590afce71ce
2016-06-12T08:00:00.000+08:00,Lilly Announces New Jardiance Data Show Reduced Risk for Cardiovascular Death Was Consistent Across Age Groups in Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/06/8101683/lilly-announces-new-jardiance-data-show-reduced-risk-for-cardiovascular-death-was,Charles Gross,,,,0,0,2bc465da-cc05-46f0-b2d9-eec083bafdf8
2016-06-12T08:00:00.000+08:00,Lilly Presents New Data Showing Once-Weekly Trulicity in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes at 6th American Diabetes Association Scientific Sessions,LLY,https://www.benzinga.com/news/16/06/8101680/lilly-presents-new-data-showing-once-weekly-trulicity-in-combination-with-insulin,Charles Gross,,,,0,0,3a9cd873-c998-4416-abd5-a3a826b2ccb2
2016-06-12T08:00:00.000+08:00,Lilly Announces New Study Results Show Tradjenta Reduces Blood Sugar in Adults With Type 2 Diabetes at Risk for Kidney Impairment,LLY,https://www.benzinga.com/news/16/06/8101559/lilly-announces-new-study-results-show-tradjenta-reduces-blood-sugar-in-adults-wi,Charles Gross,,,,0,0,592d8c3d-076a-4088-9614-564640fe4cd5
2016-06-12T08:00:00.000+08:00,Lilly Announces New Jardiance Data Show Reduced Risk for Cardiovascular Death Was Consistent Across Age Groups in Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/06/8101683/lilly-announces-new-jardiance-data-show-reduced-risk-for-cardiovascular-death-was,Charles Gross,,,,0,0,52c6404b-fcc7-40b7-a43b-12c42bf4960d
2016-06-12T08:00:00.000+08:00,Lilly Presents New Data Showing Once-Weekly Trulicity in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes at 6th American Diabetes Association Scientific Sessions,LLY,https://www.benzinga.com/news/16/06/8101680/lilly-presents-new-data-showing-once-weekly-trulicity-in-combination-with-insulin,Charles Gross,,,,0,0,34d5b537-6176-4ef1-a2bc-d0e8f426e8b1
2016-06-12T08:00:00.000+08:00,Lilly Announces New Study Results Show Tradjenta Reduces Blood Sugar in Adults With Type 2 Diabetes at Risk for Kidney Impairment,LLY,https://www.benzinga.com/news/16/06/8101559/lilly-announces-new-study-results-show-tradjenta-reduces-blood-sugar-in-adults-wi,Charles Gross,,,,0,0,7d2cdb1c-2f52-48a0-8580-183ce91e3f30
2016-06-09T08:00:00.000+08:00,Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results,LLY,https://www.benzinga.com/news/16/06/8091888/eli-lilly-and-incyte-say-two-phase-3-trials-for-arthritis-have-positive-results,Paul Quintaro,,,,0,0,8580e154-a82b-45b1-aff5-4692589262d2
2016-06-09T08:00:00.000+08:00,Eli Lilly and Incyte Say Two Phase 3 Trials For Arthritis Have Positive Results,LLY,https://www.benzinga.com/news/16/06/8091888/eli-lilly-and-incyte-say-two-phase-3-trials-for-arthritis-have-positive-results,Paul Quintaro,,,,0,0,2f5f8cc8-23ff-4ad8-a97e-70b3946dbc75
2016-06-08T08:00:00.000+08:00,Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks,LLY,https://www.benzinga.com/news/16/06/8090415/studies-demonstrate-lillys-taltz-ixekizumab-maintained-or-achieved-high-levels-of,Paul Quintaro,,,,0,0,ebcbef1f-b2f2-4e26-8c5b-45fb0964453a
2016-06-08T08:00:00.000+08:00,Option Alert: LLY Fri 6/10 76.5 Calls (Wkly) Sweep: 801 @ ASK $0.13: 900 traded vs 320 OI: Earnings 7/26 Before Open $74.80 Ref,LLY,https://www.benzinga.com/markets/options/16/06/8089044/option-alert-lly-fri-610-76-5-calls-wkly-sweep-801-ask-0-13-900-traded,Charles Gross,,,,0,0,7ac4f023-5037-4184-b80e-48c62416270c
2016-06-08T08:00:00.000+08:00,Studies Demonstrate Lilly's Taltz® (ixekizumab) Maintained or Achieved High Levels of Skin Clearance for Patients with Moderate-to-Severe Plaque Psoriasis through 60 Weeks,LLY,https://www.benzinga.com/news/16/06/8090415/studies-demonstrate-lillys-taltz-ixekizumab-maintained-or-achieved-high-levels-of,Paul Quintaro,,,,0,0,56e9c56a-0fba-41ac-a16d-1a7c29b5f819
2016-06-08T08:00:00.000+08:00,Option Alert: LLY Fri 6/10 76.5 Calls (Wkly) Sweep: 801 @ ASK $0.13: 900 traded vs 320 OI: Earnings 7/26 Before Open $74.80 Ref,LLY,https://www.benzinga.com/markets/options/16/06/8089044/option-alert-lly-fri-610-76-5-calls-wkly-sweep-801-ask-0-13-900-traded,Charles Gross,,,,0,0,e80c1d79-e821-4229-a1aa-ad545e1619e0
2016-06-07T08:00:00.000+08:00,"Eli Lilly Reports Results of Clinical, Patient-Reported Outcomes Data for Baricitinib in Patients with RA",LLY,https://www.benzinga.com/news/16/06/8077730/eli-lilly-reports-results-of-clinical-patient-reported-outcomes-data-for-bariciti,Paul Quintaro,,,,0,0,11c3a7d7-cbc6-416d-a973-052bbaa21429
2016-06-07T08:00:00.000+08:00,"Eli Lilly Reports Results of Clinical, Patient-Reported Outcomes Data for Baricitinib in Patients with RA",LLY,https://www.benzinga.com/news/16/06/8077730/eli-lilly-reports-results-of-clinical-patient-reported-outcomes-data-for-bariciti,Paul Quintaro,,,,0,0,8a7006a6-b9b0-4871-9a23-cb86dc3ac0a0
2016-06-06T08:00:00.000+08:00,4 Key Takeaways From ASCO,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8076107/4-key-takeaways-from-asco,Javier Hasse,,,,0,0,077a7996-5f7f-4100-97ec-de16fc06bff6
2016-06-06T08:00:00.000+08:00,4 Key Takeaways From ASCO,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8076107/4-key-takeaways-from-asco,Javier Hasse,,,,0,0,2a245cd8-4bee-4eb8-ba6c-1587e8db7d25
2016-06-05T08:00:00.000+08:00,Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16,LLY,https://www.benzinga.com/news/16/06/8071138/lilly-announces-encouraging-data-of-early-phase-immuno-oncology-studies-of-alimta,Charles Gross,,,,0,0,50f015b0-93fc-4786-aa32-73406456cc84
2016-06-05T08:00:00.000+08:00,Lilly Announces Encouraging Data of Early-Phase Immuno-Oncology Studies of ALIMTA and CYRAMZA with Merck's KEYTRUDA in NSCLC Presented at #ASCO16,LLY,https://www.benzinga.com/news/16/06/8071138/lilly-announces-encouraging-data-of-early-phase-immuno-oncology-studies-of-alimta,Charles Gross,,,,0,0,113db9c3-3abd-4e79-80c9-bd915d70d8d0
2016-06-03T08:00:00.000+08:00,Negative Alimta News Disappointing For Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8068589/negative-alimta-news-disappointing-for-eli-lilly,Manikandan Raman,,,,0,0,a9cfea98-db28-44cd-86f9-c02ac5ee1bd8
2016-06-03T08:00:00.000+08:00,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions",LLY,https://www.benzinga.com/news/16/06/8068298/ouch-jobs-report-miss-sends-rate-hike-odds-down-raises-questions,The Ticker Tape,,,,0,0,a8a89fed-7e49-42fa-9486-3263bf132139
2016-06-03T08:00:00.000+08:00,"Eli Lilly Shares Selling Off, Hearing Co's Patent On Alimta To be Reviewed At US Patent Office",LLY,https://www.benzinga.com/news/16/06/8067849/eli-lilly-shares-selling-off-hearing-cos-patent-on-alimta-to-be-reviewed-at-us-pa,Paul Quintaro,,,,0,0,5afad9f7-9484-42aa-b532-f057762b6d63
2016-06-03T08:00:00.000+08:00,"Morgan Stanley Negative On Eli Lilly, Says 'Negative AlimtaIPR news disappointing since patent was upheld in District Court last year'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8067770/morgan-stanley-negative-on-eli-lilly-says-negative-alimt,Paul Quintaro,,,,0,0,45b65958-4962-4fe0-9695-9f4759631204
2016-06-03T08:00:00.000+08:00,Negative Alimta News Disappointing For Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8068589/negative-alimta-news-disappointing-for-eli-lilly,Manikandan Raman,,,,0,0,8f709ee3-59e3-4136-ab9c-96095c1c878b
2016-06-03T08:00:00.000+08:00,"Ouch! Jobs Report Miss Sends Rate Hike Odds Down, Raises Questions",LLY,https://www.benzinga.com/news/16/06/8068298/ouch-jobs-report-miss-sends-rate-hike-odds-down-raises-questions,The Ticker Tape,,,,0,0,50e44c43-9a8e-4038-a5b7-f229e9abd168
2016-06-03T08:00:00.000+08:00,"Eli Lilly Shares Selling Off, Hearing Co's Patent On Alimta To be Reviewed At US Patent Office",LLY,https://www.benzinga.com/news/16/06/8067849/eli-lilly-shares-selling-off-hearing-cos-patent-on-alimta-to-be-reviewed-at-us-pa,Paul Quintaro,,,,0,0,eef39128-ea32-4dad-a46c-361ef7a6bd21
2016-06-03T08:00:00.000+08:00,"Morgan Stanley Negative On Eli Lilly, Says 'Negative AlimtaIPR news disappointing since patent was upheld in District Court last year'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8067770/morgan-stanley-negative-on-eli-lilly-says-negative-alimt,Paul Quintaro,,,,0,0,965081b5-01b2-4212-a759-a046f615bd8d
2016-05-31T08:00:00.000+08:00,"Adocia, Lilly Reports Positive Topline Results From Phase 1 Study Of BioChaperone Lispro U100 In Healthy Japanese Subjects, No New Or Unexpected Safety Findings Were Observed",LLY,https://www.benzinga.com/news/16/05/8049442/adocia-lilly-reports-positive-topline-results-from-phase-1-study-of-biochaperone-,Paul Quintaro,,,,0,0,8fb74da0-ef27-4d71-af4b-162120cfd95c
2016-05-31T08:00:00.000+08:00,Eli Lilly Gets FDA Approval For Its Jentadueto XR For Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/16/05/8049224/eli-lilly-gets-fda-approval-for-its-jentadueto-xr-for-adults-with-type,R. Chandrasekaran,,,,0,0,3a20f35a-f2a9-4e34-8429-1108862cd65e
2016-05-31T08:00:00.000+08:00,U.S. FDA Approves Once-daily Jentadueto XR Tablets for Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/05/8048674/u-s-fda-approves-once-daily-jentadueto-xr-tablets-for-adults-with-type-2-diabetes,Paul Quintaro,,,,0,0,888cbd0c-7eb2-453f-9441-ae9e32f59881
2016-05-31T08:00:00.000+08:00,"Adocia, Lilly Reports Positive Topline Results From Phase 1 Study Of BioChaperone Lispro U100 In Healthy Japanese Subjects, No New Or Unexpected Safety Findings Were Observed",LLY,https://www.benzinga.com/news/16/05/8049442/adocia-lilly-reports-positive-topline-results-from-phase-1-study-of-biochaperone-,Paul Quintaro,,,,0,0,e8e9371b-7e09-4182-9838-c6a4346ba27c
2016-05-31T08:00:00.000+08:00,Eli Lilly Gets FDA Approval For Its Jentadueto XR For Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/general/biotech/16/05/8049224/eli-lilly-gets-fda-approval-for-its-jentadueto-xr-for-adults-with-type,R. Chandrasekaran,,,,0,0,44705527-3901-4100-9029-cb000240ab71
2016-05-31T08:00:00.000+08:00,U.S. FDA Approves Once-daily Jentadueto XR Tablets for Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/16/05/8048674/u-s-fda-approves-once-daily-jentadueto-xr-tablets-for-adults-with-type-2-diabetes,Paul Quintaro,,,,0,0,0d4689ed-3fff-4be0-bcc5-36347dd785a8
2016-05-24T08:00:00.000+08:00,Eli Lilly Says It Will Launch 20 New Products Through 2023,LLY,https://www.benzinga.com/general/biotech/16/05/8023341/eli-lilly-says-it-will-launch-20-new-products-through-2023,Jayson Derrick,,,,0,0,b414d361-0979-4035-934f-ce628bb0193e
2016-05-24T08:00:00.000+08:00,Eli Lilly Offers Outline of Potential to Launch 20 New Products in 10 Years,LLY,https://www.benzinga.com/news/16/05/8022495/eli-lilly-offers-outline-of-potential-to-launch-20-new-products-in-10-years,Paul Quintaro,,,,0,0,f3394675-64e4-4010-a8a0-b5a9fe865855
2016-05-24T08:00:00.000+08:00,Eli Lilly Says It Will Launch 20 New Products Through 2023,LLY,https://www.benzinga.com/general/biotech/16/05/8023341/eli-lilly-says-it-will-launch-20-new-products-through-2023,Jayson Derrick,,,,0,0,4e11bbd4-cc42-4ced-853d-f7b56e6a5426
2016-05-24T08:00:00.000+08:00,Eli Lilly Offers Outline of Potential to Launch 20 New Products in 10 Years,LLY,https://www.benzinga.com/news/16/05/8022495/eli-lilly-offers-outline-of-potential-to-launch-20-new-products-in-10-years,Paul Quintaro,,,,0,0,b48a2c0b-9705-4e84-bbc8-46640db44325
2016-05-23T08:00:00.000+08:00,"H.C. Wainwright Initiates Radius Health At Buy, $55 Target",LLY,https://www.benzinga.com/node/8017397,Andrew Efimoff,,,,0,0,8fe0380f-2088-426b-8201-d0a4f2fe4a95
2016-05-23T08:00:00.000+08:00,"H.C. Wainwright Initiates Radius Health At Buy, $55 Target",LLY,https://www.benzinga.com/node/8017397,Andrew Efimoff,,,,0,0,58712421-56a7-4bf3-8f42-d3f82afa5d44
2016-05-19T08:00:00.000+08:00,JPMorgan's Take On Big Pharma's New ASCO Abstracts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/8006813/jpmorgans-take-on-big-pharmas-new-asco-abstracts,Wayne Duggan,,,,0,0,6a068028-65e8-4804-af8f-24c3c42b379a
2016-05-19T08:00:00.000+08:00,JPMorgan's Take On Big Pharma's New ASCO Abstracts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/8006813/jpmorgans-take-on-big-pharmas-new-asco-abstracts,Wayne Duggan,,,,0,0,7e691010-eacd-4233-a024-cb33072ce397
2016-05-18T08:00:00.000+08:00,"Lilly Highlights ASCO Data Underscores Co.'s Diverse Oncology Pipeline, Portfolio",LLY,https://www.benzinga.com/news/16/05/8001681/lilly-highlights-asco-data-underscores-co-s-diverse-oncology-pipeline-portfolio,Paul Quintaro,,,,0,0,28f3a698-d3de-426f-b0ae-2f707876cc55
2016-05-18T08:00:00.000+08:00,"Lilly Highlights ASCO Data Underscores Co.'s Diverse Oncology Pipeline, Portfolio",LLY,https://www.benzinga.com/news/16/05/8001681/lilly-highlights-asco-data-underscores-co-s-diverse-oncology-pipeline-portfolio,Paul Quintaro,,,,0,0,9bfc1319-ec2c-45d5-9c07-53c9f4619604
2016-05-17T08:00:00.000+08:00,Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7997997/fitch-says-drug-approvals-are-driving-targeted-acquisiti,Dhiraj Surapaneni,,,,0,0,bbe9c82a-e0f2-45ed-b21a-166fbda34e12
2016-05-17T08:00:00.000+08:00,"Eli Lilly Now A Strong Buy, Run-Up To Continue, Vetr Top Raters Say",LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/05/7996612/eli-lilly-now-a-strong-buy-run-up-to-continue-vetr-top-raters,Javier Hasse,,,,0,0,70c72a35-9fef-405c-854a-ab587a6ba15d
2016-05-17T08:00:00.000+08:00,Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7997997/fitch-says-drug-approvals-are-driving-targeted-acquisiti,Dhiraj Surapaneni,,,,0,0,a5906e94-768e-430c-a5c7-f1c04cebe9de
2016-05-17T08:00:00.000+08:00,"Eli Lilly Now A Strong Buy, Run-Up To Continue, Vetr Top Raters Say",LLY,https://www.benzinga.com/analyst-ratings/upgrades/16/05/7996612/eli-lilly-now-a-strong-buy-run-up-to-continue-vetr-top-raters,Javier Hasse,,,,0,0,5b0896d6-f199-4cc8-9142-33690320a5eb
2016-05-11T08:00:00.000+08:00,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7966287/jefferies-updates-price-targets-in-global-pharma-sees-ri,Wayne Duggan,,,,0,0,782374af-dcb3-41d9-9abd-256c5134a834
2016-05-11T08:00:00.000+08:00,The Market In 5 Minutes: Don't Stop Me Now,LLY,https://www.benzinga.com/news/16/05/7965189/the-market-in-5-minutes-dont-stop-me-now,Benzinga News Desk,,,,0,0,4d00ea74-80fa-48df-9620-9ba497697064
2016-05-11T08:00:00.000+08:00,"Jefferies Updates Price Targets In Global Pharma, Sees 'Rich Catalyst Environment' Ahead",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7966287/jefferies-updates-price-targets-in-global-pharma-sees-ri,Wayne Duggan,,,,0,0,93479175-3b90-4c3f-8914-f3dd550751df
2016-05-11T08:00:00.000+08:00,The Market In 5 Minutes: Don't Stop Me Now,LLY,https://www.benzinga.com/news/16/05/7965189/the-market-in-5-minutes-dont-stop-me-now,Benzinga News Desk,,,,0,0,5ba844ae-7abb-4695-830b-eb72627ba119
2016-05-10T08:00:00.000+08:00,FDA Says Will Add New Warning to Labels for All Olanzapine-Containing Products; Watch Eli Lilly Shares,LLY,https://www.benzinga.com/news/16/05/7959917/fda-says-will-add-new-warning-to-labels-for-all-olanzapine-containing-products-wa,Paul Quintaro,,,,0,0,fcae79a0-3cc5-490f-814e-10cbf446eff0
2016-05-10T08:00:00.000+08:00,FDA Says Will Add New Warning to Labels for All Olanzapine-Containing Products; Watch Eli Lilly Shares,LLY,https://www.benzinga.com/news/16/05/7959917/fda-says-will-add-new-warning-to-labels-for-all-olanzapine-containing-products-wa,Paul Quintaro,,,,0,0,d715e575-3112-4cd3-b815-b708de202d28
2016-05-04T08:00:00.000+08:00,"FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma",LLY,https://www.benzinga.com/news/16/05/7927630/fda-grants-priority-review-for-lillys-olaratumab-an-investigational-medicine-for-,Paul Quintaro,,,,0,0,651bbb75-619f-4a91-bd08-64d93b486c85
2016-05-04T08:00:00.000+08:00,"FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma",LLY,https://www.benzinga.com/news/16/05/7927630/fda-grants-priority-review-for-lillys-olaratumab-an-investigational-medicine-for-,Paul Quintaro,,,,0,0,9a565e06-9711-416e-9f2d-03735d0bebab
2016-05-02T08:00:00.000+08:00,Eli Lilly's Taltz Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/05/7915217/eli-lillys-taltz-now-available-in-the-u-s-for-the-treatment-of-moderate-to-severe,Paul Quintaro,,,,0,0,76411436-766c-4ae8-8120-188cbacbe933
2016-05-02T08:00:00.000+08:00,GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just $0.36,LLY,https://www.benzinga.com/news/16/05/7914112/geoinvesting-says-anavex-life-sciences-stock-has-a-book-value-of-just-0-36,Jayson Derrick,,,,0,0,cbfa8ee0-3788-40ec-9716-aa7c04b5aef6
2016-05-02T08:00:00.000+08:00,Eli Lilly's Taltz Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/05/7915217/eli-lillys-taltz-now-available-in-the-u-s-for-the-treatment-of-moderate-to-severe,Paul Quintaro,,,,0,0,60406a61-04d4-46ef-bda8-e76a37e0c885
2016-05-02T08:00:00.000+08:00,GeoInvesting Says Anavex Life Sciences' Stock Has A Book Value Of Just $0.36,LLY,https://www.benzinga.com/news/16/05/7914112/geoinvesting-says-anavex-life-sciences-stock-has-a-book-value-of-just-0-36,Jayson Derrick,,,,0,0,59b24aa6-7503-405a-856a-8c6cfffb7a18
2016-04-27T08:00:00.000+08:00,"Adocia, Lilly ReportPositive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes",LLY,https://www.benzinga.com/news/16/04/7891650/adocia-lilly-reportpositive-topline-results-from-a-phase-1b-study-of-repeated-adm,Paul Quintaro,,,,0,0,76a05edd-0156-42cc-bc39-10405986c04c
2016-04-27T08:00:00.000+08:00,"Adocia, Lilly ReportPositive Topline Results from a Phase 1b Study of Repeated Administration of Ultra-Rapid BioChaperone Lispro U100 in People with Type 2 Diabetes",LLY,https://www.benzinga.com/news/16/04/7891650/adocia-lilly-reportpositive-topline-results-from-a-phase-1b-study-of-repeated-adm,Paul Quintaro,,,,0,0,4bd9e2ce-5b89-4564-bb74-a86859e3efa5
2016-04-26T08:00:00.000+08:00,10 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/04/7883462/10-stocks-moving-in-tuesdays-pre-market-session,Monica Gerson,,,,0,0,875c751b-ad5f-4345-ae8b-35f0e31b43d9
2016-04-26T08:00:00.000+08:00,Eli Lilly's Q1 EPS Disappoints,LLY,https://www.benzinga.com/news/earnings/16/04/7882697/eli-lillys-q1-eps-disappoints,R. Chandrasekaran,,,,0,0,42de443a-a9c5-4ca3-91e8-bae667ff02ec
2016-04-26T08:00:00.000+08:00,"Eli Lilly Raises FY 2016 Guidance; Sees EPS $3.50 to $3.60 vs $3.54 est, Revenue $20.6B to $21.1B vs $20.7B est",LLY,https://www.benzinga.com/news/16/04/7882567/eli-lilly-raises-fy-2016-guidance-sees-eps-3-50-to-3-60-vs-3-54-est-revenue-20-6b,Paul Quintaro,,,,0,0,b089155a-a0c4-44f6-a86f-e12dc20201a9
2016-04-26T08:00:00.000+08:00,"Eli Lilly Q1 EPS $0.83 vs $0.85 est, Revenue $4.87B vs $4.82B est",LLY,https://www.benzinga.com/news/earnings/16/04/7882563/eli-lilly-q1-eps-0-83-vs-0-85-est-revenue-4-87b-vs-4-82b-est,Paul Quintaro,,,,0,0,4afa28c9-142b-42f5-bbfb-a169dd945e52
2016-04-26T08:00:00.000+08:00,"Keep an Eye on These 12 Stocks for April 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/04/7882108/keep-an-eye-on-these-12-stocks-for-april-26-2016,Monica Gerson,,,,0,0,a157a410-7ebd-4141-9525-a1dfe5f43585
2016-04-26T08:00:00.000+08:00,"Earnings Scheduled For April 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/04/7882015/earnings-scheduled-for-april-26-2016,Monica Gerson,,,,0,0,3ded0a53-c1d1-4b91-a602-9f5c03c34184
2016-04-26T08:00:00.000+08:00,10 Stocks Moving In Tuesday's Pre-Market Session,LLY,https://www.benzinga.com/news/16/04/7883462/10-stocks-moving-in-tuesdays-pre-market-session,Monica Gerson,,,,0,0,6bc14e83-e3a3-4762-ada2-2e5c63cc6cb7
2016-04-26T08:00:00.000+08:00,Eli Lilly's Q1 EPS Disappoints,LLY,https://www.benzinga.com/news/earnings/16/04/7882697/eli-lillys-q1-eps-disappoints,R. Chandrasekaran,,,,0,0,d06fd145-ecf7-4928-a1c9-69668c756414
2016-04-26T08:00:00.000+08:00,"Eli Lilly Raises FY 2016 Guidance; Sees EPS $3.50 to $3.60 vs $3.54 est, Revenue $20.6B to $21.1B vs $20.7B est",LLY,https://www.benzinga.com/news/16/04/7882567/eli-lilly-raises-fy-2016-guidance-sees-eps-3-50-to-3-60-vs-3-54-est-revenue-20-6b,Paul Quintaro,,,,0,0,49b0ffab-5099-417c-8758-9029c0dc0aea
2016-04-26T08:00:00.000+08:00,"Eli Lilly Q1 EPS $0.83 vs $0.85 est, Revenue $4.87B vs $4.82B est",LLY,https://www.benzinga.com/news/earnings/16/04/7882563/eli-lilly-q1-eps-0-83-vs-0-85-est-revenue-4-87b-vs-4-82b-est,Paul Quintaro,,,,0,0,a8f118a8-157a-42d2-9fa6-14ea91f00a6b
2016-04-26T08:00:00.000+08:00,"Keep an Eye on These 12 Stocks for April 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/04/7882108/keep-an-eye-on-these-12-stocks-for-april-26-2016,Monica Gerson,,,,0,0,8bb573d4-cec2-4493-8722-c2a3d6cc170a
2016-04-26T08:00:00.000+08:00,"Earnings Scheduled For April 26, 2016",LLY,https://www.benzinga.com/news/earnings/16/04/7882015/earnings-scheduled-for-april-26-2016,Monica Gerson,,,,0,0,f33b5ffc-93f6-40ff-b88f-2b912e864bc8
2016-04-25T08:00:00.000+08:00,"Aratana, Eli Lilly Team Create 'Watershed Contract' For Pet Biotech Sector",LLY,https://www.benzinga.com/general/biotech/16/04/7881082/aratana-eli-lilly-team-create-watershed-contract-for-pet-biotech-secto,Nicholas Donato,,,,0,0,c23d98b9-daa7-459f-9d03-e4e254825398
2016-04-25T08:00:00.000+08:00,"Aratana, Elanco Announce Global Strategic Collaboration, $45 Up Front Payment To Aratana, & Up To $83M",LLY,https://www.benzinga.com/news/16/04/7880194/aratana-elanco-announce-global-strategic-collaboration-45-up-front-payment-to-ara,Paul Quintaro,,,,0,0,6a03d6b9-402d-4c30-bbab-4d7c5c96826d
2016-04-25T08:00:00.000+08:00,"Transition Therapeutics Reports Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 , Will Trigger $500K Milestone Payment To Eli Lilly",LLY,https://www.benzinga.com/news/16/04/7880126/transition-therapeutics-reports-dosing-of-first-patient-in-phase-2-study-of-drug-,Paul Quintaro,,,,0,0,b76c0944-20ef-4076-95ed-f30397a09c7c
2016-04-25T08:00:00.000+08:00,"The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7878887/the-heart-of-major-pharma-q1-earnings-season-eli-lilly-a,Wayne Duggan,,,,0,0,3db8926b-56df-4fc6-8516-9d03add6e9a3
2016-04-25T08:00:00.000+08:00,"The Market In 5 Minutes: Monday, April 25, 2016",LLY,https://www.benzinga.com/news/16/04/7877761/the-market-in-5-minutes-monday-april-25-2016,Benzinga Newsdesk,,,,0,0,402ab6f0-be3f-49cb-b481-35764f9f3b86
2016-04-25T08:00:00.000+08:00,"Aratana, Eli Lilly Team Create 'Watershed Contract' For Pet Biotech Sector",LLY,https://www.benzinga.com/general/biotech/16/04/7881082/aratana-eli-lilly-team-create-watershed-contract-for-pet-biotech-secto,Nicholas Donato,,,,0,0,0bddd489-cfdb-4a72-bd96-ef8704ce3dff
2016-04-25T08:00:00.000+08:00,"Aratana, Elanco Announce Global Strategic Collaboration, $45 Up Front Payment To Aratana, & Up To $83M",LLY,https://www.benzinga.com/news/16/04/7880194/aratana-elanco-announce-global-strategic-collaboration-45-up-front-payment-to-ara,Paul Quintaro,,,,0,0,293e22ee-d4f0-4c74-9bf6-accf81aa6322
2016-04-25T08:00:00.000+08:00,"Transition Therapeutics Reports Dosing of First Patient in Phase 2 Study of Drug Candidate TT701 , Will Trigger $500K Milestone Payment To Eli Lilly",LLY,https://www.benzinga.com/news/16/04/7880126/transition-therapeutics-reports-dosing-of-first-patient-in-phase-2-study-of-drug-,Paul Quintaro,,,,0,0,6573896c-6bd3-4ab2-a43a-52094050b3bf
2016-04-25T08:00:00.000+08:00,"The Heart Of Major Pharma Q1 Earnings Season: Eli Lilly, AbbVie, Bristol-Myers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7878887/the-heart-of-major-pharma-q1-earnings-season-eli-lilly-a,Wayne Duggan,,,,0,0,45bb137e-dda6-4701-9041-500e89e7ce3c
2016-04-25T08:00:00.000+08:00,"The Market In 5 Minutes: Monday, April 25, 2016",LLY,https://www.benzinga.com/news/16/04/7877761/the-market-in-5-minutes-monday-april-25-2016,Benzinga Newsdesk,,,,0,0,e21e64dc-9cae-48a0-a2a8-2b0b8fbbb70b
2016-04-19T08:00:00.000+08:00,Eli Lilly And Boehringer Reveals Study On Jardiance For Treatment Heart Failure,LLY,https://www.benzinga.com/news/16/04/7854782/eli-lilly-and-boehringer-reveals-study-on-jardiance-for-treatment-heart-failure,R. Chandrasekaran,,,,0,0,42394cec-f79e-4a87-b059-88b5e63ea350
2016-04-19T08:00:00.000+08:00,"Lilly, Boehringer Ingelheim Announce Jardiance to be Studied to Treat People With Chronic Heart Failure",LLY,https://www.benzinga.com/news/16/04/7854602/lilly-boehringer-ingelheim-announce-jardiance-to-be-studied-to-treatment-people-w,Charles Gross,,,,0,0,b82f9234-2a5f-4676-947b-875944e68097
2016-04-19T08:00:00.000+08:00,Eli Lilly And Boehringer Reveals Study On Jardiance For Treatment Heart Failure,LLY,https://www.benzinga.com/news/16/04/7854782/eli-lilly-and-boehringer-reveals-study-on-jardiance-for-treatment-heart-failure,R. Chandrasekaran,,,,0,0,826ddbf0-1f8b-4bf9-9cdb-c99d5527ebf9
2016-04-19T08:00:00.000+08:00,"Lilly, Boehringer Ingelheim Announce Jardiance to be Studied to Treat People With Chronic Heart Failure",LLY,https://www.benzinga.com/news/16/04/7854602/lilly-boehringer-ingelheim-announce-jardiance-to-be-studied-to-treatment-people-w,Charles Gross,,,,0,0,95f281c9-1f61-42ff-b1df-0b2dd770b996
2016-04-18T08:00:00.000+08:00,Mid-Afternoon Market Update: Chiasma Tumbles Following FDA Review; Cvent Shares Spike Higher,LLY,https://www.benzinga.com/news/earnings/16/04/7852329/mid-afternoon-market-update-chiasma-tumbles-following-fda-review-cvent-s,Lisa Levin,,,,0,0,ede50b21-4ece-4f45-a378-f34913120ee4
2016-04-18T08:00:00.000+08:00,Mid-Day Market Update: US Stocks Turn Positive; Hasbro Shares Gain Following Earnings Beat,LLY,https://www.benzinga.com/news/earnings/16/04/7851616/mid-day-market-update-us-stocks-turn-positive-hasbro-shares-gain-followi,Lisa Levin,,,,0,0,40462f2c-8722-4f4d-aea0-3f0442e07c22
2016-04-18T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Q1 Profit Beats Expectations,LLY,https://www.benzinga.com/news/earnings/16/04/7850856/mid-morning-market-update-markets-open-lower-morgan-stanley-q1-profit-be,Monica Gerson,,,,0,0,344c794d-6ba0-49d1-83b1-4b07d384376b
2016-04-18T08:00:00.000+08:00,Transition Therapeutics Says Partner Eli Lily Will Not Advance TT401 into Phase 3 Development,LLY,https://www.benzinga.com/news/16/04/7849507/transition-therapeutics-says-partner-eli-lily-will-not-advance-tt401-into-phase-3,Hal Lindon,,,,0,0,aa120915-4c02-419e-916b-be54dd0ae4bc
2016-04-18T08:00:00.000+08:00,Mid-Afternoon Market Update: Chiasma Tumbles Following FDA Review; Cvent Shares Spike Higher,LLY,https://www.benzinga.com/news/earnings/16/04/7852329/mid-afternoon-market-update-chiasma-tumbles-following-fda-review-cvent-s,Lisa Levin,,,,0,0,15a5b9af-8e03-4ae2-a8d1-344a71b77dc8
2016-04-18T08:00:00.000+08:00,Mid-Day Market Update: US Stocks Turn Positive; Hasbro Shares Gain Following Earnings Beat,LLY,https://www.benzinga.com/news/earnings/16/04/7851616/mid-day-market-update-us-stocks-turn-positive-hasbro-shares-gain-followi,Lisa Levin,,,,0,0,025eab6e-ea8f-43fd-840b-df4e07f37548
2016-04-18T08:00:00.000+08:00,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Q1 Profit Beats Expectations,LLY,https://www.benzinga.com/news/earnings/16/04/7850856/mid-morning-market-update-markets-open-lower-morgan-stanley-q1-profit-be,Monica Gerson,,,,0,0,ba72d8e2-4da6-48f8-b194-06e0b0af123e
2016-04-18T08:00:00.000+08:00,Transition Therapeutics Says Partner Eli Lily Will Not Advance TT401 into Phase 3 Development,LLY,https://www.benzinga.com/news/16/04/7849507/transition-therapeutics-says-partner-eli-lily-will-not-advance-tt401-into-phase-3,Hal Lindon,,,,0,0,66b25cbc-5d61-4bc2-9386-ed1116f565ab
2016-04-08T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data",LLY,https://www.benzinga.com/news/16/04/7818685/eli-lilly-astrazeneca-report-continuation-of-pivotal-trial-for-people-with-early-,Paul Quintaro,,,,0,0,92908037-9b13-4f89-a424-524beced1468
2016-04-08T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Report Continuation of Pivotal Trial for People with Early Alzheimer's Disease; Will Continue to Phase 3 After Positive Interim Safety Data",LLY,https://www.benzinga.com/news/16/04/7818685/eli-lilly-astrazeneca-report-continuation-of-pivotal-trial-for-people-with-early-,Paul Quintaro,,,,0,0,9a0bd9f0-b84b-4ec0-994b-61663914f565
2016-04-06T08:00:00.000+08:00,SocGen Picks New Favorites In Big Pharma,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7810497/socgen-picks-new-favorites-in-big-pharma,Manikandan Raman,,,,0,0,07138d6e-f4de-4140-8e4b-fce0414a14ca
2016-04-06T08:00:00.000+08:00,Societe Generale Initiates Coverage on Eli Lilly at Hold,LLY,https://www.benzinga.com/news/16/04/7810187/societe-generale-initiates-coverage-on-eli-lilly-at-hold,Eddie Staley,,,,0,0,6f423db7-00c3-4bcc-a747-2b002ae063ae
2016-04-06T08:00:00.000+08:00,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib",LLY,https://www.benzinga.com/news/16/04/7808622/incyte-acquires-rights-to-devlop-and-commercialize-ruxolitinib-from-lilly-will-ma,Hal Lindon,,,,0,0,96444ebf-9eb8-46e0-83a0-863ba52f4fdc
2016-04-06T08:00:00.000+08:00,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP,LLY,https://www.benzinga.com/news/16/04/7808154/who-says-number-of-adults-with-diabetes-has-quadrupled-since-1980-afp,Charles Gross,,,,0,0,d289b040-d200-43a4-8440-f46edf22d3ac
2016-04-06T08:00:00.000+08:00,SocGen Picks New Favorites In Big Pharma,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7810497/socgen-picks-new-favorites-in-big-pharma,Manikandan Raman,,,,0,0,1bea87fe-11a7-4fe1-9f96-e31e7a34864b
2016-04-06T08:00:00.000+08:00,Societe Generale Initiates Coverage on Eli Lilly at Hold,LLY,https://www.benzinga.com/news/16/04/7810187/societe-generale-initiates-coverage-on-eli-lilly-at-hold,Eddie Staley,,,,0,0,5d2f2337-76ab-4541-8da4-5ca8ef2d6edd
2016-04-06T08:00:00.000+08:00,"Incyte Acquires Rights To Devlop and Commercialize Ruxolitinib From Lilly, Will Make $35M Upfront Payment As Well As Additional Potential Payments Contingent On Certain Regulatory Milestones; Novartis Granted Right To Develop & Commercialize Ruxolitinib",LLY,https://www.benzinga.com/news/16/04/7808622/incyte-acquires-rights-to-devlop-and-commercialize-ruxolitinib-from-lilly-will-ma,Hal Lindon,,,,0,0,90da7022-9bb2-44a7-840e-74861e3f8564
2016-04-06T08:00:00.000+08:00,WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP,LLY,https://www.benzinga.com/news/16/04/7808154/who-says-number-of-adults-with-diabetes-has-quadrupled-since-1980-afp,Charles Gross,,,,0,0,52514298-6ddc-4f5c-b7ca-aa3299c62775
2016-04-04T08:00:00.000+08:00,This Data Signals The End For Merck's Anacetrapib,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7796690/this-data-signals-the-end-for-mercks-anacetrapib,Monica Gerson,,,,0,0,1984ee24-1c82-4ca3-9d1a-3da6a7007b53
2016-04-04T08:00:00.000+08:00,This Data Signals The End For Merck's Anacetrapib,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7796690/this-data-signals-the-end-for-mercks-anacetrapib,Monica Gerson,,,,0,0,f02a5def-a0f1-4c32-9448-f3b0f8a30efd
2016-03-31T08:00:00.000+08:00,Eli Lilly's Says ACC/AHA U.S. Guideline Says It's Reasonable To Chosose Effient Over Clopidogrel For Certain ACS-PCI Patients,LLY,https://www.benzinga.com/news/16/03/7785232/eli-lillys-says-accaha-u-s-guideline-says-its-reasonable-to-chosose-effient-over-,Hal Lindon,,,,0,0,09cd41a1-c16e-4c31-8a56-7d6d9ea3dc4b
2016-03-31T08:00:00.000+08:00,"Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint",LLY,https://www.benzinga.com/news/16/03/7782201/eli-lilly-phase-3-show-baricitinib-treatment-with-patients-in-rheumatoid-arthriti,Hal Lindon,,,,0,0,5f0ef0ef-d69c-4b65-936d-249572e12d29
2016-03-31T08:00:00.000+08:00,Eli Lilly's Says ACC/AHA U.S. Guideline Says It's Reasonable To Chosose Effient Over Clopidogrel For Certain ACS-PCI Patients,LLY,https://www.benzinga.com/news/16/03/7785232/eli-lillys-says-accaha-u-s-guideline-says-its-reasonable-to-chosose-effient-over-,Hal Lindon,,,,0,0,d1b3da87-9efa-441f-a54b-09ad8e58d0d3
2016-03-31T08:00:00.000+08:00,"Eli Lilly Phase 3 Show Baricitinib Treatment With Patients In Rheumatoid Arthritis Show Significant Improvements, Met Primary Endpoint",LLY,https://www.benzinga.com/news/16/03/7782201/eli-lilly-phase-3-show-baricitinib-treatment-with-patients-in-rheumatoid-arthriti,Hal Lindon,,,,0,0,b1a207d3-34ba-4665-a04f-fa3dc550e1cb
2016-03-29T08:00:00.000+08:00,Citi Downgrades Novartis Following SAG Investigation,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7769264/citi-downgrades-novartis-following-sag-investigation,Manikandan Raman,,,,0,0,86929d29-bb46-46b1-9089-7ab71dabd1b0
2016-03-29T08:00:00.000+08:00,Citi Downgrades Novartis Following SAG Investigation,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7769264/citi-downgrades-novartis-following-sag-investigation,Manikandan Raman,,,,0,0,10ef6952-a251-426a-b8ee-b5fa09c7aaf8
2016-03-28T08:00:00.000+08:00,"Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading",LLY,https://www.benzinga.com/news/16/03/7764033/biopharma-names-lly-pfe-mrk-and-more-popping-higher-following-reports-china-fda-t,Paul Quintaro,,,,0,0,d02c8ac8-8f39-4dbf-aa03-63377746c26a
2016-03-28T08:00:00.000+08:00,"Biopharma Names LLY, PFE, MRK, And More Popping Higher Following Reports China FDA To Investigate Improper Vaccine Trading",LLY,https://www.benzinga.com/news/16/03/7764033/biopharma-names-lly-pfe-mrk-and-more-popping-higher-following-reports-china-fda-t,Paul Quintaro,,,,0,0,8204de16-3865-42a6-a2ba-e2cfadb1129a
2016-03-22T08:00:00.000+08:00,Adam Feuerstein Tweets: '$LLY FDA approves ixekizumab to treat adults with moderate-to-severe plaque psoriasis. Brand name Taltz.',LLY,https://www.benzinga.com/news/16/03/7746881/adam-feuerstein-tweets-lly-fda-approves-ixekizumab-to-treat-adults-with-moderate-,Paul Quintaro,,,,0,0,bf72fccf-0550-462b-bab7-c7fed858a893
2016-03-22T08:00:00.000+08:00,Adam Feuerstein Tweets: '$LLY FDA approves ixekizumab to treat adults with moderate-to-severe plaque psoriasis. Brand name Taltz.',LLY,https://www.benzinga.com/news/16/03/7746881/adam-feuerstein-tweets-lly-fda-approves-ixekizumab-to-treat-adults-with-moderate-,Paul Quintaro,,,,0,0,e9dae063-bf93-40a5-abc2-d76a746a5527
2016-03-17T08:00:00.000+08:00,Option Alert: LLY May16 70.0 Calls Sweep: 1500 @ ASK $2.76: 1500 traded vs 55 OI: Earnings 4/26 Before Open $69.58 Ref,LLY,https://www.benzinga.com/markets/options/16/03/7728081/option-alert-lly-may16-70-0-calls-sweep-1500-ask-2-76-1500-traded-vs-5,Charles Gross,,,,0,0,a3ace797-81dd-42c4-adbb-29ccd868effc
2016-03-17T08:00:00.000+08:00,Option Alert: LLY May16 70.0 Calls Sweep: 1500 @ ASK $2.76: 1500 traded vs 55 OI: Earnings 4/26 Before Open $69.58 Ref,LLY,https://www.benzinga.com/markets/options/16/03/7728081/option-alert-lly-may16-70-0-calls-sweep-1500-ask-2-76-1500-traded-vs-5,Charles Gross,,,,0,0,a451d5eb-fdd0-4f3c-96da-61768f50ca20
2016-03-15T08:00:00.000+08:00,"Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study, Instead Of Co-Primary Endpoints Of Cognition & Function, The Amended Trial Will Include Single Primary Endpoint Of Cognition",LLY,https://www.benzinga.com/news/16/03/7712214/lilly-announces-change-to-primary-endpoint-of-expedition3-study-instead-of-co-pri,Hal Lindon,,,,0,0,bf52247b-2eb5-4c8a-9625-1a63566f6842
2016-03-15T08:00:00.000+08:00,"Lilly Announces Change to Primary Endpoint of EXPEDITION3 Study, Instead Of Co-Primary Endpoints Of Cognition & Function, The Amended Trial Will Include Single Primary Endpoint Of Cognition",LLY,https://www.benzinga.com/news/16/03/7712214/lilly-announces-change-to-primary-endpoint-of-expedition3-study-instead-of-co-pri,Hal Lindon,,,,0,0,aa843042-5d12-43f1-8f73-bd047554cfac
2016-03-14T08:00:00.000+08:00,Adocia & Lilly Announce Topline Results: 'BioChaperone Lispro U100 demonstrated a statistically significant 31 percent reduction in blood glucose',LLY,https://www.benzinga.com/news/16/03/7706809/adocia-lilly-announce-topline-results-biochaperone-lispro-u100-demonstrated-a-sta,Paul Quintaro,,,,0,0,de22d2c0-7da8-4f91-ace3-20679325b8c0
2016-03-14T08:00:00.000+08:00,Adocia And Lilly Announce Positive Topline Results From A Phase 1B Study Of Repeated Admin Of Ultra-Rapid BioChaperone Lispro In Patients With Type 1 Diabetes,LLY,https://www.benzinga.com/news/16/03/7706801/adocia-and-lilly-announce-positive-topline-results-from-a-phase-1b-study-of-repea,Charles Gross,,,,0,0,7c555256-00ad-46b5-bef3-80c7f3d7d05b
2016-03-14T08:00:00.000+08:00,Adocia & Lilly Announce Topline Results: 'BioChaperone Lispro U100 demonstrated a statistically significant 31 percent reduction in blood glucose',LLY,https://www.benzinga.com/news/16/03/7706809/adocia-lilly-announce-topline-results-biochaperone-lispro-u100-demonstrated-a-sta,Paul Quintaro,,,,0,0,e415d4e7-e7ff-4224-86dc-24b254f27a99
2016-03-14T08:00:00.000+08:00,Adocia And Lilly Announce Positive Topline Results From A Phase 1B Study Of Repeated Admin Of Ultra-Rapid BioChaperone Lispro In Patients With Type 1 Diabetes,LLY,https://www.benzinga.com/news/16/03/7706801/adocia-and-lilly-announce-positive-topline-results-from-a-phase-1b-study-of-repea,Charles Gross,,,,0,0,52db20ce-d2bc-4545-b991-4def3409c376
2016-03-07T08:00:00.000+08:00,Eli Lilly Studies Show Ixekizumab Improved Work Productivity for Patients W/ Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/03/7325981/eli-lilly-studies-show-ixekizumab-improved-work-productivity-for-patients-w-moder,Paul Quintaro,,,,0,0,45e338ed-8a68-43f4-adea-6af3c75a5352
2016-03-07T08:00:00.000+08:00,PeptiDream to License PDPS Technology to Lilly,LLY,https://www.benzinga.com/news/16/03/7203359/peptidream-to-license-pdps-technology-to-lilly,Charles Gross,,,,0,0,7decc94c-cd07-4965-a3bf-73d47d552e96
2016-03-07T08:00:00.000+08:00,Eli Lilly Studies Show Ixekizumab Improved Work Productivity for Patients W/ Moderate-to-Severe Plaque Psoriasis,LLY,https://www.benzinga.com/news/16/03/7325981/eli-lilly-studies-show-ixekizumab-improved-work-productivity-for-patients-w-moder,Paul Quintaro,,,,0,0,985a7efd-77e4-400d-8ca0-339961706354
2016-03-07T08:00:00.000+08:00,PeptiDream to License PDPS Technology to Lilly,LLY,https://www.benzinga.com/news/16/03/7203359/peptidream-to-license-pdps-technology-to-lilly,Charles Gross,,,,0,0,8ee4b2ce-dc2e-4019-b7b2-678ca930179e
2016-03-03T08:00:00.000+08:00,"Bernstein Cuts LLY FY 2017 EPS From $4.23 To $4.07, Cuts NVS FY 2017 EPS From $5.21 To %5.17",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/6796936/bernstein-cuts-lly-fy-2017-eps-from-4-23-to-4-07-cuts-nv,Paul Quintaro,,,,0,0,aa1de706-dac7-4118-9130-9ca78ddb726e
2016-03-03T08:00:00.000+08:00,"Bernstein Cuts LLY FY 2017 EPS From $4.23 To $4.07, Cuts NVS FY 2017 EPS From $5.21 To %5.17",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/6796936/bernstein-cuts-lly-fy-2017-eps-from-4-23-to-4-07-cuts-nv,Paul Quintaro,,,,0,0,317d714d-54fc-4f24-97ac-da805146dc05
2016-03-02T08:00:00.000+08:00,Option Alert: LLY Fri 4/8 70.0 Puts (Wkly) Sweep: 1050 @ ASK $1.15: 1050 traded vs 0 OI: $73.54 Ref,LLY,https://www.benzinga.com/markets/options/16/03/6785516/option-alert-lly-fri-48-70-0-puts-wkly-sweep-1050-ask-1-15-1050-traded,Charles Gross,,,,0,0,7a8db880-b745-498e-878d-3c2dd5b16c8b
2016-03-02T08:00:00.000+08:00,Option Alert: LLY Fri 4/8 70.0 Puts (Wkly) Sweep: 1050 @ ASK $1.15: 1050 traded vs 0 OI: $73.54 Ref,LLY,https://www.benzinga.com/markets/options/16/03/6785516/option-alert-lly-fri-48-70-0-puts-wkly-sweep-1050-ask-1-15-1050-traded,Charles Gross,,,,0,0,5e4c3fd6-c602-40b2-a6e1-1798afb298ec
2016-03-01T08:00:00.000+08:00,Lilly To Present Phase 3 Ixekizumab Data At 74th AAD Conference Taking Place Mar. 4-8th,LLY,https://www.benzinga.com/news/16/03/6760428/lilly-to-present-phase-3-ixekizumab-data-at-74th-aad-conference-taking-place-mar-,Hal Lindon,,,,0,0,d0b12276-0307-4f1e-9f63-38b7cbe4478c
2016-03-01T08:00:00.000+08:00,Lilly To Present Phase 3 Ixekizumab Data At 74th AAD Conference Taking Place Mar. 4-8th,LLY,https://www.benzinga.com/news/16/03/6760428/lilly-to-present-phase-3-ixekizumab-data-at-74th-aad-conference-taking-place-mar-,Hal Lindon,,,,0,0,8db9933e-0bb1-4bdf-a7a1-d24c9f1269f6
2016-02-26T08:00:00.000+08:00,EMA Recommends Against Approval of Eli Lilly's Psoriasis Treatment Lxekizumab ‍,LLY,https://www.benzinga.com/news/16/02/6692644/ema-recommends-against-approval-of-eli-lillys-psoriasis-treatment-lxekizumab,Charles Gross,,,,0,0,47bd55c6-0d44-4e4d-9aa0-1c65ecd907fc
2016-02-26T08:00:00.000+08:00,EMA Recommends Against Approval of Eli Lilly's Psoriasis Treatment Lxekizumab ‍,LLY,https://www.benzinga.com/news/16/02/6692644/ema-recommends-against-approval-of-eli-lillys-psoriasis-treatment-lxekizumab,Charles Gross,,,,0,0,50c01f54-185e-47bd-a10d-b7b35be908b6
2016-02-22T08:00:00.000+08:00,"Eli Lilly Files Auto Shelf For Mixed Offering, Size Not Disclosed",LLY,https://www.benzinga.com/news/16/02/6501807/eli-lilly-files-auto-shelf-for-mixed-offering-size-not-disclosed,Paul Quintaro,,,,0,0,db785bce-2fc8-43a6-b55e-4d21779983c7
2016-02-22T08:00:00.000+08:00,"Radius Health Shares Up 29% Following Data from Amgen, UCB's Romosozumab Showing Failed Achievement on One of Two Secondary Endpoints",LLY,https://www.benzinga.com/news/16/02/6495221/radius-health-shares-up-29-following-data-from-amgen-ucbs-romosozumab-showing-fai,Paul Quintaro,,,,0,0,6c6b3be2-2f35-49bc-9590-7ca6e44a6875
2016-02-22T08:00:00.000+08:00,"Eli Lilly Files Auto Shelf For Mixed Offering, Size Not Disclosed",LLY,https://www.benzinga.com/news/16/02/6501807/eli-lilly-files-auto-shelf-for-mixed-offering-size-not-disclosed,Paul Quintaro,,,,0,0,d4d3eacc-9f54-452c-88c3-2e15e3d05d37
2016-02-22T08:00:00.000+08:00,"Radius Health Shares Up 29% Following Data from Amgen, UCB's Romosozumab Showing Failed Achievement on One of Two Secondary Endpoints",LLY,https://www.benzinga.com/news/16/02/6495221/radius-health-shares-up-29-following-data-from-amgen-ucbs-romosozumab-showing-fai,Paul Quintaro,,,,0,0,597ed8d5-bf02-4c31-8d8a-8d11aad53d2f
2016-02-16T08:00:00.000+08:00,Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6307372/biotech-conference-suggests-tempering-expectations-for-e,Rebecca Sheppard,,,,0,0,c244a49f-18a5-4b51-9544-0dd6bd999143
2016-02-16T08:00:00.000+08:00,Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6307372/biotech-conference-suggests-tempering-expectations-for-e,Rebecca Sheppard,,,,0,0,406504ea-7d0a-4768-bf46-f1e618cba57c
2016-02-12T08:00:00.000+08:00,"13G Filing Shows Eli Lilly Holder Primecap Mgmt Co Holds Amended 5.20% Stake As Of Dec 31, Held 5.17% Stake on Sept 30 2015",LLY,https://www.benzinga.com/general/hedge-funds/16/02/6254781/13g-filing-shows-eli-lilly-holder-primecap-mgmt-co-holds-amended-5,Paul Quintaro,,,,0,0,f2421d35-bfcc-483d-93fc-792990ecf283
2016-02-12T08:00:00.000+08:00,Eli Lilly Announces Alimta Not Infringed By Actavis Marketing Pemetrexed Trometamol,LLY,https://www.benzinga.com/news/16/02/6254773/eli-lilly-announces-alimta-not-infringed-by-actavis-marketing-pemetrexed-trometam,Hal Lindon,,,,0,0,f6bfc2d4-aaed-4158-b6bd-317033bd62b3
2016-02-12T08:00:00.000+08:00,"13G Filing Shows Eli Lilly Holder Primecap Mgmt Co Holds Amended 5.20% Stake As Of Dec 31, Held 5.17% Stake on Sept 30 2015",LLY,https://www.benzinga.com/general/hedge-funds/16/02/6254781/13g-filing-shows-eli-lilly-holder-primecap-mgmt-co-holds-amended-5,Paul Quintaro,,,,0,0,53cfcf3d-4890-49d6-b9e2-04efad337947
2016-02-12T08:00:00.000+08:00,Eli Lilly Announces Alimta Not Infringed By Actavis Marketing Pemetrexed Trometamol,LLY,https://www.benzinga.com/news/16/02/6254773/eli-lilly-announces-alimta-not-infringed-by-actavis-marketing-pemetrexed-trometam,Hal Lindon,,,,0,0,a15991f1-dc66-41bf-bde7-0205b5c830bc
2016-02-08T08:00:00.000+08:00,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6228983/most-of-credit-suisses-top-investment-ideas-for-2016-in-,Amy Weingarden,,,,0,0,cddfccf3-390a-4721-be4d-90d576a2ed5e
2016-02-08T08:00:00.000+08:00,Most Of Credit Suisse's Top Investment Ideas For 2016...In One Place,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6228983/most-of-credit-suisses-top-investment-ideas-for-2016-in-,Amy Weingarden,,,,0,0,934958a2-da85-471f-aa12-1e58e4fc1c91
2016-02-05T08:00:00.000+08:00,"Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6221815/credit-suisse-global-focus-list-update-toyota-out-agnico,Wayne Duggan,,,,0,0,a0383579-be12-4068-9a8a-7e81b912d16a
2016-02-05T08:00:00.000+08:00,"Credit Suisse Global Focus List Update: Toyota Out, Agnico Eagle In",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6221815/credit-suisse-global-focus-list-update-toyota-out-agnico,Wayne Duggan,,,,0,0,0a2cc49e-e9e0-4002-913e-2162c9e54263
2016-01-28T08:00:00.000+08:00,Earnings Recap For January 28,LLY,https://www.benzinga.com/news/earnings/16/01/6182803/earnings-recap-for-january-28,Javier Hasse,,,,0,0,ccc58817-ccf6-4874-9f9a-abd83d0ee8fb
2016-01-28T08:00:00.000+08:00,Eli Lilly Punished For Inline Report,LLY,https://www.benzinga.com/trading-ideas/technicals/16/01/6180042/eli-lilly-punished-for-inline-report,Joel Elconin,,,,0,0,8026646a-fc78-4be2-93b3-2258ceef6352
2016-01-28T08:00:00.000+08:00,"Eli Lilly Sees FY EPS $2.83 to $2.93 est vs $3.43 est, Revenue $20.2B to $20.7B vs $20.8B est",LLY,https://www.benzinga.com/news/16/01/6177562/eli-lilly-sees-fy-eps-2-83-to-2-93-est-vs-3-43-est-revenue-20-2b-to-20-7b-vs-20-8,Paul Quintaro,,,,0,0,eedf4193-0cb6-4664-9479-cf623aa0b8c5
2016-01-28T08:00:00.000+08:00,"Eli Lilly Q4 EPS $0.78 vs $0.78 est, Revenue $5.38B vs $5.32B est",LLY,https://www.benzinga.com/news/earnings/16/01/6177559/eli-lilly-q4-eps-0-78-vs-0-78-est-revenue-5-38b-vs-5-32b-est,Paul Quintaro,,,,0,0,60ed28b2-3d49-4152-8f11-3fcd0c44163e
2016-01-28T08:00:00.000+08:00,"Earnings Scheduled For January 28, 2016",LLY,https://www.benzinga.com/news/earnings/16/01/6177199/earnings-scheduled-for-january-28-2016,Monica Gerson,,,,0,0,d1d2c1d6-0763-4662-9471-856b9e553c8f
2016-01-28T08:00:00.000+08:00,Earnings Recap For January 28,LLY,https://www.benzinga.com/news/earnings/16/01/6182803/earnings-recap-for-january-28,Javier Hasse,,,,0,0,c2cad0c3-41a0-42b6-b511-854e32f69c12
2016-01-28T08:00:00.000+08:00,Eli Lilly Punished For Inline Report,LLY,https://www.benzinga.com/trading-ideas/technicals/16/01/6180042/eli-lilly-punished-for-inline-report,Joel Elconin,,,,0,0,05dc6c08-7a14-4cab-bbf7-2fa53725b64c
2016-01-28T08:00:00.000+08:00,"Eli Lilly Sees FY EPS $2.83 to $2.93 est vs $3.43 est, Revenue $20.2B to $20.7B vs $20.8B est",LLY,https://www.benzinga.com/news/16/01/6177562/eli-lilly-sees-fy-eps-2-83-to-2-93-est-vs-3-43-est-revenue-20-2b-to-20-7b-vs-20-8,Paul Quintaro,,,,0,0,1c41e7f4-8298-4cc1-accf-a911f68046aa
2016-01-28T08:00:00.000+08:00,"Eli Lilly Q4 EPS $0.78 vs $0.78 est, Revenue $5.38B vs $5.32B est",LLY,https://www.benzinga.com/news/earnings/16/01/6177559/eli-lilly-q4-eps-0-78-vs-0-78-est-revenue-5-38b-vs-5-32b-est,Paul Quintaro,,,,0,0,10c1d845-6ab7-4f9f-a38d-063e1f4a6e9e
2016-01-28T08:00:00.000+08:00,"Earnings Scheduled For January 28, 2016",LLY,https://www.benzinga.com/news/earnings/16/01/6177199/earnings-scheduled-for-january-28-2016,Monica Gerson,,,,0,0,fcf945ad-7718-4981-8bce-05f37e6fe476
2016-01-27T08:00:00.000+08:00,"Lilly, Roche Diagnostics to Partner on Alzheimer's Disease Adjunct Diagnostic Tool",LLY,https://www.benzinga.com/news/16/01/6174360/lilly-roche-diagnostics-to-partner-on-alzheimers-disease-adjunct-diagnostic-tool,Hal Lindon,,,,0,0,33f2c3a7-2e8f-40c2-a5a3-cc624d0ff767
2016-01-27T08:00:00.000+08:00,"Lilly, Roche Diagnostics to Partner on Alzheimer's Disease Adjunct Diagnostic Tool",LLY,https://www.benzinga.com/news/16/01/6174360/lilly-roche-diagnostics-to-partner-on-alzheimers-disease-adjunct-diagnostic-tool,Hal Lindon,,,,0,0,9185c041-92c8-4d58-97b2-36a826dce61a
2016-01-25T08:00:00.000+08:00,"JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?",LLY,https://www.benzinga.com/news/earnings/16/01/6166994/jnj-kicks-off-health-care-earnings-what-about-deals-buybacks,The Ticker Tape,,,,0,0,7ae1083b-65e9-4676-a8a8-5af24442f054
2016-01-25T08:00:00.000+08:00,US Big Pharma: What To Watch For In Q4 Results,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6166545/us-big-pharma-what-to-watch-for-in-q4-results,Wayne Duggan,,,,0,0,0932b6d9-9ce5-450a-8594-9238d58211f6
2016-01-25T08:00:00.000+08:00,"Stock Marquee Crowded With Oil, Apple, And The Fed",LLY,https://www.benzinga.com/news/earnings/16/01/6166641/stock-marquee-crowded-with-oil-apple-and-the-fed,The Ticker Tape,,,,0,0,7021b7e8-233d-440c-8a67-7c264594086a
2016-01-25T08:00:00.000+08:00,Eli Lilly Reports FDA Acceptance of Filing of CV Outcomes Data for Jardiance,LLY,https://www.benzinga.com/news/16/01/6166052/eli-lilly-reports-fda-acceptance-of-filing-of-cv-outcomes-data-for-jardiance,Paul Quintaro,,,,0,0,b32a32ef-f0f1-434a-8261-c0e294a2d65e
2016-01-25T08:00:00.000+08:00,"JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?",LLY,https://www.benzinga.com/news/earnings/16/01/6166994/jnj-kicks-off-health-care-earnings-what-about-deals-buybacks,The Ticker Tape,,,,0,0,b03e6b4a-f291-432e-ab11-0c3f8d46ae0a
2016-01-25T08:00:00.000+08:00,US Big Pharma: What To Watch For In Q4 Results,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6166545/us-big-pharma-what-to-watch-for-in-q4-results,Wayne Duggan,,,,0,0,258892b5-86ff-473e-b52d-81257414866f
2016-01-25T08:00:00.000+08:00,"Stock Marquee Crowded With Oil, Apple, And The Fed",LLY,https://www.benzinga.com/news/earnings/16/01/6166641/stock-marquee-crowded-with-oil-apple-and-the-fed,The Ticker Tape,,,,0,0,0033c3a3-8001-4f1e-a221-3fda13b7179f
2016-01-25T08:00:00.000+08:00,Eli Lilly Reports FDA Acceptance of Filing of CV Outcomes Data for Jardiance,LLY,https://www.benzinga.com/news/16/01/6166052/eli-lilly-reports-fda-acceptance-of-filing-of-cv-outcomes-data-for-jardiance,Paul Quintaro,,,,0,0,4a74e22e-cbab-40f2-be79-24dd9c463944
2016-01-21T08:00:00.000+08:00,U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen,LLY,https://www.benzinga.com/news/16/01/6159361/u-s-food-and-drug-administration-approves-humulin-r-u-500-kwikpen,Hal Lindon,,,,0,0,1a86a07d-bffb-4008-adf1-72f6aae4403e
2016-01-21T08:00:00.000+08:00,U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen,LLY,https://www.benzinga.com/news/16/01/6159361/u-s-food-and-drug-administration-approves-humulin-r-u-500-kwikpen,Hal Lindon,,,,0,0,f94be1dd-b299-46ee-a233-42a58979d407
2016-01-19T08:00:00.000+08:00,Eli Lilly Reiterates FY15 Guidance Of $3.45-$3.55 vs. Est. $3.43-DJ,LLY,https://www.benzinga.com/news/16/01/6151234/eli-lilly-reiterates-fy15-guidance-of-3-45-3-55-vs-est-3-43-dj,Hal Lindon,,,,0,0,09056ca3-d6b6-4549-a0fa-241ab8973938
2016-01-19T08:00:00.000+08:00,"Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA",LLY,https://www.benzinga.com/news/16/01/6151199/eli-lilly-incyte-report-submission-of-nda-for-oral-once-daily-baricitinib-for-tre,Paul Quintaro,,,,0,0,e7919aed-ae77-435d-b927-006436efee21
2016-01-19T08:00:00.000+08:00,Eli Lilly Reiterates FY15 Guidance Of $3.45-$3.55 vs. Est. $3.43-DJ,LLY,https://www.benzinga.com/news/16/01/6151234/eli-lilly-reiterates-fy15-guidance-of-3-45-3-55-vs-est-3-43-dj,Hal Lindon,,,,0,0,39ad26ff-f75c-4883-a7d0-5e1973a62af5
2016-01-19T08:00:00.000+08:00,"Eli Lilly, Incyte Report Submission of NDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe RA",LLY,https://www.benzinga.com/news/16/01/6151199/eli-lilly-incyte-report-submission-of-nda-for-oral-once-daily-baricitinib-for-tre,Paul Quintaro,,,,0,0,bdb3d43d-f48f-4413-8c2f-0ebdf595a14b
2016-01-15T08:00:00.000+08:00,"Argus Reiterates $93 Target On Eli Lilly, Highlights 'Strong Late-Stage Pipeline'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6146521/argus-reiterates-93-target-on-eli-lilly-highlights-stron,Jim Swanson,,,,0,0,ee8e169f-9fbd-4e30-b661-2aeaa32d8e67
2016-01-15T08:00:00.000+08:00,"Argus Reiterates $93 Target On Eli Lilly, Highlights 'Strong Late-Stage Pipeline'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6146521/argus-reiterates-93-target-on-eli-lilly-highlights-stron,Jim Swanson,,,,0,0,d4669b94-a167-479e-9bc6-359335435cc1
2016-01-11T08:00:00.000+08:00,"Insulet Enters Agreement With Eli Lilly For OmniPod Delivery Of U200 Concentrated Insulin, Terms Not Dislcosed",LLY,https://www.benzinga.com/news/16/01/6133603/insulet-enters-agreement-with-eli-lilly-for-omnipod-delivery-of-u200-concentrated,Hal Lindon,,,,0,0,363a2cef-5220-4948-b9fe-7b4231a44cc4
2016-01-11T08:00:00.000+08:00,"Insulet Enters Agreement With Eli Lilly For OmniPod Delivery Of U200 Concentrated Insulin, Terms Not Dislcosed",LLY,https://www.benzinga.com/news/16/01/6133603/insulet-enters-agreement-with-eli-lilly-for-omnipod-delivery-of-u200-concentrated,Hal Lindon,,,,0,0,a84547e4-a329-4138-a356-5fc2ec72ac52
2016-01-05T08:00:00.000+08:00,Eli Lilly Shares Lower Following Weaker-Than-Expected 2016 Guidance,LLY,https://www.benzinga.com/news/16/01/6110639/eli-lilly-shares-lower-following-weaker-than-expected-2016-guidance,Jayson Derrick,,,,0,0,253cb8f3-3f6d-4a60-b3b4-b231d5d17b2e
2016-01-05T08:00:00.000+08:00,Eli Lilly Shares Trading Down 2+% to $81 Following Weaker-Than-Expected FY16 Outlook,LLY,https://www.benzinga.com/news/16/01/6110210/eli-lilly-shares-trading-down-2-to-81-following-weaker-than-expected-fy16-outlook,Paul Quintaro,,,,0,0,2bed30e8-2b3f-4102-9421-86f2723d6d8a
2016-01-05T08:00:00.000+08:00,"UPDATE: Eli Lilly Sees FY16 Adj. EPS $3.45-$3.55 vs $3.65 Est., Sales $20.2B-$20.7B vs $21.5B Est.",LLY,https://www.benzinga.com/news/16/01/6109863/update-eli-lilly-sees-fy16-adj-eps-3-45-3-55-vs-3-65-est-sales-20-2b-20-7b-vs-21-,Paul Quintaro,,,,0,0,25f88ee4-cd54-47f4-94fd-ac5c2dcc40c7
2016-01-05T08:00:00.000+08:00,UPDATE: Eli Lilly Reaffirms FY15 Adj. EPS Outlook $3.40-$3.45 vs $3.44 Est.,LLY,https://www.benzinga.com/news/16/01/6109861/update-eli-lilly-reaffirms-fy15-adj-eps-outlook-3-40-3-45-vs-3-44-est,Paul Quintaro,,,,0,0,da62fa52-914b-4e1e-b053-2aa061ce11bf
2016-01-05T08:00:00.000+08:00,Eli Lilly Issues Update to FY15 Outlook; Offers FY16 Guidance,LLY,https://www.benzinga.com/news/16/01/6109858/eli-lilly-issues-update-to-fy15-outlook-offers-fy16-guidance,Paul Quintaro,,,,0,0,dc5ddcbe-012a-480b-9f50-b719f824095f
2016-01-05T08:00:00.000+08:00,Eli Lilly Shares Lower Following Weaker-Than-Expected 2016 Guidance,LLY,https://www.benzinga.com/news/16/01/6110639/eli-lilly-shares-lower-following-weaker-than-expected-2016-guidance,Jayson Derrick,,,,0,0,938a2f79-158d-4be7-800a-d22299777bfe
2016-01-05T08:00:00.000+08:00,Eli Lilly Shares Trading Down 2+% to $81 Following Weaker-Than-Expected FY16 Outlook,LLY,https://www.benzinga.com/news/16/01/6110210/eli-lilly-shares-trading-down-2-to-81-following-weaker-than-expected-fy16-outlook,Paul Quintaro,,,,0,0,e430537e-02d7-421a-8d3a-3a7de9b60248
2016-01-05T08:00:00.000+08:00,"UPDATE: Eli Lilly Sees FY16 Adj. EPS $3.45-$3.55 vs $3.65 Est., Sales $20.2B-$20.7B vs $21.5B Est.",LLY,https://www.benzinga.com/news/16/01/6109863/update-eli-lilly-sees-fy16-adj-eps-3-45-3-55-vs-3-65-est-sales-20-2b-20-7b-vs-21-,Paul Quintaro,,,,0,0,f64dc85f-1a93-4beb-9529-bac07a4782f1
2016-01-05T08:00:00.000+08:00,UPDATE: Eli Lilly Reaffirms FY15 Adj. EPS Outlook $3.40-$3.45 vs $3.44 Est.,LLY,https://www.benzinga.com/news/16/01/6109861/update-eli-lilly-reaffirms-fy15-adj-eps-outlook-3-40-3-45-vs-3-44-est,Paul Quintaro,,,,0,0,9ec2d6c6-8701-4cd1-a8f0-1b3b7a76e8b3
2016-01-05T08:00:00.000+08:00,Eli Lilly Issues Update to FY15 Outlook; Offers FY16 Guidance,LLY,https://www.benzinga.com/news/16/01/6109858/eli-lilly-issues-update-to-fy15-outlook-offers-fy16-guidance,Paul Quintaro,,,,0,0,0d4c91f4-f889-40b1-a0c5-e9c72357f378
2015-12-28T08:00:00.000+08:00,"Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6075841/eli-lillys-2016-guidance-released-next-week-could-disapp,Jim Swanson,,,,0,0,74f229e4-16ea-4ce1-b36b-2b6699d2563e
2015-12-28T08:00:00.000+08:00,Leerink's Fernandez on Eli Lilly Ahead of Expected FY16 Guidance on Jan. 5: 'Much Lower Fx Benefit Makes 2016 Guidance Tough; All Eyes on Sola',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6075811/leerinks-fernandez-on-eli-lilly-ahead-of-expected-fy16-g,Paul Quintaro,,,,0,0,efa3a290-ba7b-436d-ab28-0984129c2ffc
2015-12-28T08:00:00.000+08:00,"Eli Lilly's 2016 Guidance Released Next Week Could Disappoint, Leerink Warns",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6075841/eli-lillys-2016-guidance-released-next-week-could-disapp,Jim Swanson,,,,0,0,8ac68501-f835-4832-a2d2-24b1d59a55b1
2015-12-28T08:00:00.000+08:00,Leerink's Fernandez on Eli Lilly Ahead of Expected FY16 Guidance on Jan. 5: 'Much Lower Fx Benefit Makes 2016 Guidance Tough; All Eyes on Sola',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6075811/leerinks-fernandez-on-eli-lilly-ahead-of-expected-fy16-g,Paul Quintaro,,,,0,0,9c77c8cb-709f-40f2-83e9-dca6b5a8c0f2
2015-12-23T08:00:00.000+08:00,Not All Of Clinton's Policies Are Bad For Pharmaceuticals,LLY,https://www.benzinga.com/general/biotech/15/12/6070719/not-all-of-clintons-policies-are-bad-for-pharmaceuticals,Laura Brodbeck,,,,0,0,5a57040a-6db3-4fba-9d0d-ee5560f8bb44
2015-12-23T08:00:00.000+08:00,Not All Of Clinton's Policies Are Bad For Pharmaceuticals,LLY,https://www.benzinga.com/general/biotech/15/12/6070719/not-all-of-clintons-policies-are-bad-for-pharmaceuticals,Laura Brodbeck,,,,0,0,26534f33-694c-4f20-9676-287a7a918769
2015-12-21T08:00:00.000+08:00,"UPDATE: Halozyme Says Will Receive Initial $25M Payment, Followed by Milestone Payments of Up to $160M for Each of Up to Five Collab Targets",LLY,https://www.benzinga.com/news/15/12/6064738/update-halozyme-says-will-receive-initial-25m-payment-followed-by-milestone-payme,Paul Quintaro,,,,0,0,7117613e-d55a-4fd6-ae7e-404971a245f6
2015-12-21T08:00:00.000+08:00,"Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly",LLY,https://www.benzinga.com/news/15/12/6064722/halozyme-reports-entering-of-global-collab-licensing-deal-with-lilly,Paul Quintaro,,,,0,0,2fb86963-1a29-4709-b15f-943f80f52347
2015-12-21T08:00:00.000+08:00,"UPDATE: Halozyme Says Will Receive Initial $25M Payment, Followed by Milestone Payments of Up to $160M for Each of Up to Five Collab Targets",LLY,https://www.benzinga.com/news/15/12/6064738/update-halozyme-says-will-receive-initial-25m-payment-followed-by-milestone-payme,Paul Quintaro,,,,0,0,f2ad58b4-cc2e-4689-b9ff-13e997e8c7df
2015-12-21T08:00:00.000+08:00,"Halozyme Reports Entering of Global Collab, Licensing Deal with Lilly",LLY,https://www.benzinga.com/news/15/12/6064722/halozyme-reports-entering-of-global-collab-licensing-deal-with-lilly,Paul Quintaro,,,,0,0,0ce28ec8-6562-44ec-bb52-6a57e638764c
2015-12-19T08:00:00.000+08:00,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6061487/credit-suisse-offers-2016-u-s-large-cap-pharma-outlook,Jayson Derrick,,,,0,0,58f945b1-fef1-4f7d-8936-dc855b621dcf
2015-12-19T08:00:00.000+08:00,Credit Suisse Offers 2016 U.S. Large-Cap Pharma Outlook,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6061487/credit-suisse-offers-2016-u-s-large-cap-pharma-outlook,Jayson Derrick,,,,0,0,33393910-4498-4b0f-8265-d0b022befc46
2015-12-18T08:00:00.000+08:00,3 Biotechs Atlantic Equities Loves And 1 It's Avoiding,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6061206/3-biotechs-atlantic-equities-loves-and-1-its-avoiding,Javier Hasse,,,,0,0,0208adad-0d44-4941-82c2-3882360e3cdb
2015-12-18T08:00:00.000+08:00,"Atlantic Equities Initiates Coverage on Eli Lilly at Overweight, Announces $100.00 PT",LLY,https://www.benzinga.com/news/15/12/6060358/atlantic-equities-initiates-coverage-on-eli-lilly-at-overweight-announces-100-00-,Paul Quintaro,,,,0,0,77802038-fa45-4388-a3b5-a31a13c09401
2015-12-18T08:00:00.000+08:00,Lilly's Lung Cancer Drug Necitumumab Receives Positive Opinion from EMA,LLY,https://www.benzinga.com/news/15/12/6060080/lillys-lung-cancer-drug-necitumumab-receives-positive-opinion-from-ema,Charles Gross,,,,0,0,d942b3a6-af4c-4b6e-829a-c5e66d844867
2015-12-18T08:00:00.000+08:00,3 Biotechs Atlantic Equities Loves And 1 It's Avoiding,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6061206/3-biotechs-atlantic-equities-loves-and-1-its-avoiding,Javier Hasse,,,,0,0,7c78ddca-5646-4102-8b84-c4b97704ff44
2015-12-18T08:00:00.000+08:00,"Atlantic Equities Initiates Coverage on Eli Lilly at Overweight, Announces $100.00 PT",LLY,https://www.benzinga.com/news/15/12/6060358/atlantic-equities-initiates-coverage-on-eli-lilly-at-overweight-announces-100-00-,Paul Quintaro,,,,0,0,0c5a4e62-90b5-46ab-a249-848ccd19fae3
2015-12-18T08:00:00.000+08:00,Lilly's Lung Cancer Drug Necitumumab Receives Positive Opinion from EMA,LLY,https://www.benzinga.com/news/15/12/6060080/lillys-lung-cancer-drug-necitumumab-receives-positive-opinion-from-ema,Charles Gross,,,,0,0,de2fc3a9-514b-4ea4-bfa5-39aed4f8db3c
2015-12-17T08:00:00.000+08:00,Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6057167/shares-of-eli-lilly-up-0-6-after-credit-suisse-adds-to-f,Paul Quintaro,,,,0,0,1590826b-4dae-4509-83fd-2865a825cd5a
2015-12-17T08:00:00.000+08:00,Shares of Eli Lilly Up ~0.6% After Credit Suisse Adds to 'Focus List'; Shares of Bristol-Myers Down ~0.7% as Stock Removed from Same List,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6057167/shares-of-eli-lilly-up-0-6-after-credit-suisse-adds-to-f,Paul Quintaro,,,,0,0,0c70b4f0-d334-40c4-a91b-8a3e8cdc46f4
2015-12-12T08:00:00.000+08:00,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6041783/major-pharma-group-outlook-in-2016-fundamentals-to-outwe,Jennifer Lynn,,,,0,0,62a3fad9-e66a-4b67-8446-cd9fef468669
2015-12-12T08:00:00.000+08:00,Major Pharma Group Outlook In 2016: Fundamentals To Outweigh Political Headwinds,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6041783/major-pharma-group-outlook-in-2016-fundamentals-to-outwe,Jennifer Lynn,,,,0,0,84bc68e3-60ab-44bf-ba23-2047cab583d1
2015-12-10T08:00:00.000+08:00,Eli Lilly and Merk Announces Expansion of Immuno Oncology Collaboration,LLY,https://www.benzinga.com/news/15/12/6036228/eli-lilly-and-merk-announces-expansion-of-immuno-oncology-collaboration,Paul Quintaro,,,,0,0,afc2b098-4642-4707-a47e-1f866cc305e5
2015-12-10T08:00:00.000+08:00,Eli Lilly and Merk Announces Expansion of Immuno Oncology Collaboration,LLY,https://www.benzinga.com/news/15/12/6036228/eli-lilly-and-merk-announces-expansion-of-immuno-oncology-collaboration,Paul Quintaro,,,,0,0,c58904f3-3928-4809-a833-20a62de2c715
2015-12-08T08:00:00.000+08:00,Eli Lilly Increases Dividend From $0.50 To $0.51/Share,LLY,https://www.benzinga.com/news/15/12/6029081/eli-lilly-increases-dividend-from-0-50-to-0-51share,Hal Lindon,,,,0,0,44e81583-c47a-4d01-a4bc-6481096c5ec1
2015-12-08T08:00:00.000+08:00,Eli Lilly Increases Dividend From $0.50 To $0.51/Share,LLY,https://www.benzinga.com/news/15/12/6029081/eli-lilly-increases-dividend-from-0-50-to-0-51share,Hal Lindon,,,,0,0,9ea5d355-875a-4c7f-82b7-4e5bab48e820
2015-12-07T08:00:00.000+08:00,Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6026272/eli-lilly-could-make-a-lot-more-from-alzheimers-drug-tha,Monica Gerson,,,,0,0,61130209-21bb-4650-9b1b-264fac281806
2015-12-07T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/12/6025991/benzingas-top-upgrades,Lisa Levin,,,,0,0,64e3c539-38b6-4714-90de-f125840ada00
2015-12-07T08:00:00.000+08:00,"Deutsche Bank Upgrades Eli Lilly to Buy, Raises to $99.00",LLY,https://www.benzinga.com/news/15/12/6025218/deutsche-bank-upgrades-eli-lilly-to-buy-raises-to-99-00,Paul Quintaro,,,,0,0,d7ae1589-4b19-4690-b67b-b1d5d42c23b7
2015-12-07T08:00:00.000+08:00,Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6026272/eli-lilly-could-make-a-lot-more-from-alzheimers-drug-tha,Monica Gerson,,,,0,0,064178eb-c112-48cd-9ede-303c73ad5129
2015-12-07T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/12/6025991/benzingas-top-upgrades,Lisa Levin,,,,0,0,459198da-aa7a-4080-8868-91d91a3270b3
2015-12-07T08:00:00.000+08:00,"Deutsche Bank Upgrades Eli Lilly to Buy, Raises to $99.00",LLY,https://www.benzinga.com/news/15/12/6025218/deutsche-bank-upgrades-eli-lilly-to-buy-raises-to-99-00,Paul Quintaro,,,,0,0,72fcfe27-bd7d-4d8b-b18f-acf5e8ed36bd
2015-12-04T08:00:00.000+08:00,Cautious Stock Rebound as Jobs Data Delivers But Wages Still in Question,LLY,https://www.benzinga.com/news/15/12/6022625/cautious-stock-rebound-as-jobs-data-delivers-but-wages-still-in-question,The Ticker Tape,,,,0,0,484c57a6-8779-4a4a-b749-d44b85128342
2015-12-04T08:00:00.000+08:00,Lilly Ends Basal Insulin Peglispro Development Program,LLY,https://www.benzinga.com/news/15/12/6021994/lilly-ends-basal-insulin-peglispro-development-program,Eddie Staley,,,,0,0,0b1218fc-ca92-42d9-bd0d-1d251a00ff5f
2015-12-04T08:00:00.000+08:00,Cautious Stock Rebound as Jobs Data Delivers But Wages Still in Question,LLY,https://www.benzinga.com/news/15/12/6022625/cautious-stock-rebound-as-jobs-data-delivers-but-wages-still-in-question,The Ticker Tape,,,,0,0,f08d798c-d133-4782-942f-5257cc6705cb
2015-12-04T08:00:00.000+08:00,Lilly Ends Basal Insulin Peglispro Development Program,LLY,https://www.benzinga.com/news/15/12/6021994/lilly-ends-basal-insulin-peglispro-development-program,Eddie Staley,,,,0,0,7f2005b9-2818-4160-acaa-c1427502ee8e
2015-12-01T08:00:00.000+08:00,"New Data Show Lilly's Once-Weekly Trulicity is Effective as Add-on Treatment to Sulfonylurea, Trulicity Primary Endpoint Provided Superior A1C Rduction; Secondary Endpoint Did Not Reach Statistical Significance",LLY,https://www.benzinga.com/news/15/12/6013131/new-data-show-lillys-once-weekly-trulicity-is-effective-as-add-on-treatment-to-su,Hal Lindon,,,,0,0,5a862b8b-fc5c-4911-b85e-89bee651d407
2015-12-01T08:00:00.000+08:00,Barclays' Biopharmaceuticals Blueprint For 2016,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6011335/barclays-biopharmaceuticals-blueprint-for-2016,Jayson Derrick,,,,0,0,78f7017d-c49f-41bb-a5f2-5fedf2391ff6
2015-12-01T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/12/6011813/benzingas-top-upgrades,Lisa Levin,,,,0,0,82657095-f44b-42e0-b32e-420ee720f68c
2015-12-01T08:00:00.000+08:00,"Barclays Upgrades Eli Lilly to Overweight, Raises PT to $95.00",LLY,https://www.benzinga.com/news/15/12/6010816/barclays-upgrades-eli-lilly-to-overweight-raises-pt-to-95-00,Charles Gross,,,,0,0,9e3c4b90-b728-4d7d-9150-19833ca7663d
2015-12-01T08:00:00.000+08:00,"New Data Show Lilly's Once-Weekly Trulicity is Effective as Add-on Treatment to Sulfonylurea, Trulicity Primary Endpoint Provided Superior A1C Rduction; Secondary Endpoint Did Not Reach Statistical Significance",LLY,https://www.benzinga.com/news/15/12/6013131/new-data-show-lillys-once-weekly-trulicity-is-effective-as-add-on-treatment-to-su,Hal Lindon,,,,0,0,4f6648fa-7443-4ec4-b00b-061a2a882095
2015-12-01T08:00:00.000+08:00,Barclays' Biopharmaceuticals Blueprint For 2016,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6011335/barclays-biopharmaceuticals-blueprint-for-2016,Jayson Derrick,,,,0,0,a9440720-2938-4a1e-a523-11a81ea31de7
2015-12-01T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/12/6011813/benzingas-top-upgrades,Lisa Levin,,,,0,0,c9d7f0ad-3e48-4574-b303-dc1e58ded058
2015-12-01T08:00:00.000+08:00,"Barclays Upgrades Eli Lilly to Overweight, Raises PT to $95.00",LLY,https://www.benzinga.com/news/15/12/6010816/barclays-upgrades-eli-lilly-to-overweight-raises-pt-to-95-00,Charles Gross,,,,0,0,b7bbca3f-ba74-491c-9118-3be601e4ecf5
2015-11-30T08:00:00.000+08:00,Health Canada Approves JARDIANCE (Empagliflozin) Tablets For Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/11/6007462/health-canada-approves-jardiance-empagliflozin-tablets-for-adults-with-type-2-dia,Eddie Staley,,,,0,0,16c95ccb-9a87-4a50-a593-fd511b5d3c45
2015-11-30T08:00:00.000+08:00,Health Canada Approves JARDIANCE (Empagliflozin) Tablets For Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/11/6007462/health-canada-approves-jardiance-empagliflozin-tablets-for-adults-with-type-2-dia,Eddie Staley,,,,0,0,839e3051-b68e-4f49-8415-bc6bcbbf20af
2015-11-24T08:00:00.000+08:00,Eli Lilly Release Confirms FDA Approval If Portrazza,LLY,https://www.benzinga.com/news/15/11/5999325/eli-lilly-release-confirms-fda-approval-if-portrazza,Eddie Staley,,,,0,0,1899eecb-bfee-47a4-8c85-f446026d1f76
2015-11-24T08:00:00.000+08:00,FDA Approves Eli Lilly's Portrazza to Treat Advanced Squamous Non-Small Cell Lung Cancer-DJ,LLY,https://www.benzinga.com/news/15/11/5999047/fda-approves-eli-lillys-portrazza-to-treat-advanced-squamous-non-small-cell-lung-,Hal Lindon,,,,0,0,bc115e35-8b96-4036-9a93-75265493ada3
2015-11-24T08:00:00.000+08:00,Eli Lilly Release Confirms FDA Approval If Portrazza,LLY,https://www.benzinga.com/news/15/11/5999325/eli-lilly-release-confirms-fda-approval-if-portrazza,Eddie Staley,,,,0,0,6a4f3807-d982-4406-8a6e-1b01aa172a9e
2015-11-24T08:00:00.000+08:00,FDA Approves Eli Lilly's Portrazza to Treat Advanced Squamous Non-Small Cell Lung Cancer-DJ,LLY,https://www.benzinga.com/news/15/11/5999047/fda-approves-eli-lillys-portrazza-to-treat-advanced-squamous-non-small-cell-lung-,Hal Lindon,,,,0,0,033362ad-2c26-46dd-a7a5-c2ca301f9f11
2015-11-19T08:00:00.000+08:00,US Stock Futures Edge Higher Ahead Of Jobless Claims Report,LLY,https://www.benzinga.com/news/earnings/15/11/5990030/us-stock-futures-edge-higher-ahead-of-jobless-claims-report,Monica Gerson,,,,0,0,2180ad77-60a6-497f-b459-0a21c3615d87
2015-11-19T08:00:00.000+08:00,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial,LLY,https://www.benzinga.com/news/15/11/5989132/lilly-and-merck-expand-immuno-oncology-collaboration-with-phase-iii-nonsquamous-n,Eddie Staley,,,,0,0,29528a08-236c-458e-9d37-957980d58a44
2015-11-19T08:00:00.000+08:00,US Stock Futures Edge Higher Ahead Of Jobless Claims Report,LLY,https://www.benzinga.com/news/earnings/15/11/5990030/us-stock-futures-edge-higher-ahead-of-jobless-claims-report,Monica Gerson,,,,0,0,1f85839d-b300-4138-a1db-7f398c7059f1
2015-11-19T08:00:00.000+08:00,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial,LLY,https://www.benzinga.com/news/15/11/5989132/lilly-and-merck-expand-immuno-oncology-collaboration-with-phase-iii-nonsquamous-n,Eddie Staley,,,,0,0,b7e9b0b9-f7b1-475e-927e-79ee2153fa7f
2015-11-16T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/11/5979841/benzingas-top-upgrades,Lisa Levin,,,,0,0,182bdc63-6b8b-488f-b304-4c0216b99f61
2015-11-16T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly to Outperform, Raises PT to $100.00",LLY,https://www.benzinga.com/news/15/11/5979322/bmo-capital-upgrades-eli-lilly-to-outperform-raises-pt-to-100-00,Paul Quintaro,,,,0,0,686aa08e-38f3-4b49-b0c1-26b5439def73
2015-11-16T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/11/5979841/benzingas-top-upgrades,Lisa Levin,,,,0,0,efa42152-1308-4384-9310-25af51e6156a
2015-11-16T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly to Outperform, Raises PT to $100.00",LLY,https://www.benzinga.com/news/15/11/5979322/bmo-capital-upgrades-eli-lilly-to-outperform-raises-pt-to-100-00,Paul Quintaro,,,,0,0,545cb910-ef7e-4217-bb7c-c6c0e9347b3d
2015-11-10T08:00:00.000+08:00,"WuXi, Lilly Report Strategic Collaboration to Develop Novel Therapeutic in China",LLY,https://www.benzinga.com/news/15/11/5972639/wuxi-lilly-report-strategic-collaboration-to-develop-novel-therapeutic-in-china,Paul Quintaro,,,,0,0,c0a7252b-597b-43b5-913f-564f9edfd115
2015-11-10T08:00:00.000+08:00,"WuXi, Lilly Report Strategic Collaboration to Develop Novel Therapeutic in China",LLY,https://www.benzinga.com/news/15/11/5972639/wuxi-lilly-report-strategic-collaboration-to-develop-novel-therapeutic-in-china,Paul Quintaro,,,,0,0,91b5838f-37f9-4acd-94e6-cdec2fa089b5
2015-11-09T08:00:00.000+08:00,"UPDATE: Eli Lilly Release Shows New Data on JARDIANCE Showed Reduction to Risk of Rates Endpoint of Hospitalization for Heart Failure, Death from Heart Failure by 39% vs Placebo",LLY,https://www.benzinga.com/news/15/11/5969221/update-eli-lilly-release-shows-new-data-on-jardiance-showed-reduction-to-risk-of-,Paul Quintaro,,,,0,0,e593ff59-cdce-4172-892d-c19b101c7438
2015-11-09T08:00:00.000+08:00,New Jardiance data show improved CV outcomes regardless of heart failure status at baseline,LLY,https://www.benzinga.com/news/15/11/5969217/new-jardiance-data-show-improved-cv-outcomes-regardless-of-heart-failure-status-a,Hal Lindon,,,,0,0,82f7817e-a9fc-4db4-8c2b-bb9328421568
2015-11-09T08:00:00.000+08:00,"UPDATE: Eli Lilly Release Shows New Data on JARDIANCE Showed Reduction to Risk of Rates Endpoint of Hospitalization for Heart Failure, Death from Heart Failure by 39% vs Placebo",LLY,https://www.benzinga.com/news/15/11/5969221/update-eli-lilly-release-shows-new-data-on-jardiance-showed-reduction-to-risk-of-,Paul Quintaro,,,,0,0,1fb23ca7-aae6-4960-a07a-caa753c2c1c7
2015-11-09T08:00:00.000+08:00,New Jardiance data show improved CV outcomes regardless of heart failure status at baseline,LLY,https://www.benzinga.com/news/15/11/5969217/new-jardiance-data-show-improved-cv-outcomes-regardless-of-heart-failure-status-a,Hal Lindon,,,,0,0,6608013e-e92d-4d8d-86ea-bfc9500d6159
2015-11-08T08:00:00.000+08:00,"Ignyta Acquires Exclusive Rights to Taladegib Oncology Program from Lilly for $2M, ~1.2M Ignyta Shares",LLY,https://www.benzinga.com/news/15/11/5967717/ignyta-acquires-exclusive-rights-to-taladegib-oncology-program-from-lilly-for-2m-,Charles Gross,,,,0,0,10b4ea4c-3f99-40d0-bb4e-21dac982f41a
2015-11-08T08:00:00.000+08:00,"Ignyta Acquires Exclusive Rights to Taladegib Oncology Program from Lilly for $2M, ~1.2M Ignyta Shares",LLY,https://www.benzinga.com/news/15/11/5967717/ignyta-acquires-exclusive-rights-to-taladegib-oncology-program-from-lilly-for-2m-,Charles Gross,,,,0,0,bfe79c6c-2211-44a4-b287-8b9a0f047fde
2015-11-07T08:00:00.000+08:00,"Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA",LLY,https://www.benzinga.com/news/15/11/5967515/lilly-incyte-announce-data-demonstrate-baricitinib-superiority-to-adalimumab-in-i,Charles Gross,,,,0,0,e0334280-1b38-4f8a-be0b-5d61f2829ed7
2015-11-07T08:00:00.000+08:00,"Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms of RA",LLY,https://www.benzinga.com/news/15/11/5967515/lilly-incyte-announce-data-demonstrate-baricitinib-superiority-to-adalimumab-in-i,Charles Gross,,,,0,0,b2d8396a-e8c1-45f5-a63a-ecc69700c8d5
2015-11-06T08:00:00.000+08:00,"Eli Lilly Spokesperson Confirms Disclosure of DoJ Inquiry Was In Filing A Week Ago, Notes News 'did not generate much media interest until today.'",LLY,https://www.benzinga.com/news/15/11/5966759/eli-lilly-spokesperson-confirms-disclosure-of-doj-inquiry-was-in-filing-a-week-ag,Paul Quintaro,,,,0,0,e6867413-2b53-48f9-8fd3-5dea993b087d
2015-11-06T08:00:00.000+08:00,"Eli Lilly Moving Off DoJ Inquiry, But News Is Old",LLY,https://www.benzinga.com/news/15/11/5966717/eli-lilly-moving-off-doj-inquiry-but-news-is-old,Javier Hasse,,,,0,0,a62aa715-d65f-492a-83a5-30cdaf1871c7
2015-11-06T08:00:00.000+08:00,Eli Lilly Spokesperson Says Will Soon Be Providing Statement Related to DoJ Inquiry/Disclosure Related to Wholesalers,LLY,https://www.benzinga.com/exclusives/15/11/5966728/eli-lilly-spokesperson-says-will-soon-be-providing-statement-related-to-doj,Paul Quintaro,,,,0,0,c4aa18ca-1fb2-4005-a721-8fc15598b33d
2015-11-06T08:00:00.000+08:00,BZ NOTE: Eli Lilly Comments on DoJ Inquiry on Wholesalers Came from 10-Q FIled on Oct. 30; News Should Have Been Priced Into the Stock Several Days Ago,LLY,https://www.benzinga.com/news/15/11/5966680/bz-note-eli-lilly-comments-on-doj-inquiry-on-wholesalers-came-from-10-q-filed-on-,Paul Quintaro,,,,0,0,ecfd4321-c4cb-4db4-a12d-f7f780483495
2015-11-06T08:00:00.000+08:00,"UPDATE: Eli Lilly Shares Plunge $1 Over Last Few Mins, Stock Now Down ~2.5% for Session",LLY,https://www.benzinga.com/movers/15/11/5966637/update-eli-lilly-shares-plunge-1-over-last-few-mins-stock-now-down-2-5-for-sess,Paul Quintaro,,,,0,0,3708b659-3a8c-4329-a390-727c873fbce0
2015-11-06T08:00:00.000+08:00,Lilly Says DoJ Conducting Inquiry Of Agreements With Wholesalers -DJ,LLY,https://www.benzinga.com/news/15/11/5966636/lilly-says-doj-conducting-inquiry-of-agreements-with-wholesalers-dj,Charles Gross,,,,0,0,a05f94ab-d28a-4640-906c-2d840be56c8b
2015-11-06T08:00:00.000+08:00,Eli Lilly Shares Falling,LLY,https://www.benzinga.com/movers/15/11/5966633/eli-lilly-shares-falling,Hal Lindon,,,,0,0,9ac763bc-3aba-4777-9c24-b4f4dc803ddb
2015-11-06T08:00:00.000+08:00,"Eli Lilly Spokesperson Confirms Disclosure of DoJ Inquiry Was In Filing A Week Ago, Notes News 'did not generate much media interest until today.'",LLY,https://www.benzinga.com/news/15/11/5966759/eli-lilly-spokesperson-confirms-disclosure-of-doj-inquiry-was-in-filing-a-week-ag,Paul Quintaro,,,,0,0,57f7cb15-1463-4c74-b895-dd0d32c58863
2015-11-06T08:00:00.000+08:00,"Eli Lilly Moving Off DoJ Inquiry, But News Is Old",LLY,https://www.benzinga.com/news/15/11/5966717/eli-lilly-moving-off-doj-inquiry-but-news-is-old,Javier Hasse,,,,0,0,42d8d3a1-46d6-406f-b1aa-2bc7154cef56
2015-11-06T08:00:00.000+08:00,Eli Lilly Spokesperson Says Will Soon Be Providing Statement Related to DoJ Inquiry/Disclosure Related to Wholesalers,LLY,https://www.benzinga.com/exclusives/15/11/5966728/eli-lilly-spokesperson-says-will-soon-be-providing-statement-related-to-doj,Paul Quintaro,,,,0,0,c3c77d00-fe36-4a9e-a27d-1a2970d28a03
2015-11-06T08:00:00.000+08:00,BZ NOTE: Eli Lilly Comments on DoJ Inquiry on Wholesalers Came from 10-Q FIled on Oct. 30; News Should Have Been Priced Into the Stock Several Days Ago,LLY,https://www.benzinga.com/news/15/11/5966680/bz-note-eli-lilly-comments-on-doj-inquiry-on-wholesalers-came-from-10-q-filed-on-,Paul Quintaro,,,,0,0,f5d160ec-3ab2-44bc-81ab-1c6de117e41b
2015-11-06T08:00:00.000+08:00,"UPDATE: Eli Lilly Shares Plunge $1 Over Last Few Mins, Stock Now Down ~2.5% for Session",LLY,https://www.benzinga.com/movers/15/11/5966637/update-eli-lilly-shares-plunge-1-over-last-few-mins-stock-now-down-2-5-for-sess,Paul Quintaro,,,,0,0,d852ecf0-e6ad-4cf4-80fc-3eadc2d5b638
2015-11-06T08:00:00.000+08:00,Lilly Says DoJ Conducting Inquiry Of Agreements With Wholesalers -DJ,LLY,https://www.benzinga.com/news/15/11/5966636/lilly-says-doj-conducting-inquiry-of-agreements-with-wholesalers-dj,Charles Gross,,,,0,0,2691cefb-f503-430f-94f4-65e0e22d433a
2015-11-06T08:00:00.000+08:00,Eli Lilly Shares Falling,LLY,https://www.benzinga.com/movers/15/11/5966633/eli-lilly-shares-falling,Hal Lindon,,,,0,0,5ecebb68-33df-472d-a0d9-68aa1414a036
2015-10-27T08:00:00.000+08:00,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data,LLY,https://www.benzinga.com/press-releases/15/10/5945308/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-3-data,Paul Quintaro,,,,0,0,00e92c9a-84bf-4570-8f4e-4b666fbb6a05
2015-10-27T08:00:00.000+08:00,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data,LLY,https://www.benzinga.com/press-releases/15/10/5945308/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-3-data,Paul Quintaro,,,,0,0,50b423a4-289b-419e-8c8c-3514482f9048
2015-10-22T08:00:00.000+08:00,"US Stock Futures Gain Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/15/10/5935702/us-stock-futures-gain-ahead-of-earnings-economic-data,Monica Gerson,,,,0,0,4d07134a-79f1-4311-8d91-a91c7c36b465
2015-10-22T08:00:00.000+08:00,"Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast",LLY,https://www.benzinga.com/news/earnings/15/10/5935628/eli-lilly-posts-upbeat-q3-earnings-raises-forecast,Monica Gerson,,,,0,0,8084cfb1-be39-41ab-bf37-a761fb7b6cb7
2015-10-22T08:00:00.000+08:00,"Eli Lilly Raises FY 2015 EPS $3.40-$3.45 Vs Est $3.28, Had Seen $3.20-$3.30 & Revs $19.7B-$20B Vs Est $19.93B",LLY,https://www.benzinga.com/news/15/10/5935490/eli-lilly-raises-fy-2015-eps-3-40-3-45-vs-est-3-28-had-seen-3-20-3-30-revs-19-7b-,Paul Quintaro,,,,0,0,1c1711dc-eed8-47dc-96b3-9b5d93df1731
2015-10-22T08:00:00.000+08:00,"Eli Lilly Q3 EPS $0.89 vs $0.75 est, Revenue $4.96B vs $4.99B est",LLY,https://www.benzinga.com/news/earnings/15/10/5935489/eli-lilly-q3-eps-0-89-vs-0-75-est-revenue-4-96b-vs-4-99b-est,Paul Quintaro,,,,0,0,281f795b-ef39-4fdf-99c1-ffa25e4b985f
2015-10-22T08:00:00.000+08:00,"Earnings Scheduled For October 22, 2015",LLY,https://www.benzinga.com/news/earnings/15/10/5935259/earnings-scheduled-for-october-22-2015,Monica Gerson,,,,0,0,f5499b1e-0184-4886-a206-68ba918916bc
2015-10-22T08:00:00.000+08:00,"US Stock Futures Gain Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/15/10/5935702/us-stock-futures-gain-ahead-of-earnings-economic-data,Monica Gerson,,,,0,0,7a0df8c3-6ec0-4004-a513-851773d81594
2015-10-22T08:00:00.000+08:00,"Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast",LLY,https://www.benzinga.com/news/earnings/15/10/5935628/eli-lilly-posts-upbeat-q3-earnings-raises-forecast,Monica Gerson,,,,0,0,f5a6695f-03cf-4b96-bdaf-03f06c5341f6
2015-10-22T08:00:00.000+08:00,"Eli Lilly Raises FY 2015 EPS $3.40-$3.45 Vs Est $3.28, Had Seen $3.20-$3.30 & Revs $19.7B-$20B Vs Est $19.93B",LLY,https://www.benzinga.com/news/15/10/5935490/eli-lilly-raises-fy-2015-eps-3-40-3-45-vs-est-3-28-had-seen-3-20-3-30-revs-19-7b-,Paul Quintaro,,,,0,0,c0f97ea4-5564-48f5-8c27-000707ae8ea4
2015-10-22T08:00:00.000+08:00,"Eli Lilly Q3 EPS $0.89 vs $0.75 est, Revenue $4.96B vs $4.99B est",LLY,https://www.benzinga.com/news/earnings/15/10/5935489/eli-lilly-q3-eps-0-89-vs-0-75-est-revenue-4-96b-vs-4-99b-est,Paul Quintaro,,,,0,0,77b617ce-84c5-4325-9daa-227e24f4ad4a
2015-10-22T08:00:00.000+08:00,"Earnings Scheduled For October 22, 2015",LLY,https://www.benzinga.com/news/earnings/15/10/5935259/earnings-scheduled-for-october-22-2015,Monica Gerson,,,,0,0,c6dc916d-c7fc-4878-9960-2235344af4a6
2015-10-21T08:00:00.000+08:00,"Global Growth Temperature Likely Captured In Caterpillar, McDonald's And Under Armour Earnings",LLY,https://www.benzinga.com/trading-ideas/previews/15/10/5932997/global-growth-temperature-likely-captured-in-caterpillar-mcdona,The Ticker Tape,,,,0,0,f02c4235-8bd6-404b-9210-2ecb4152d891
2015-10-21T08:00:00.000+08:00,Lilly supports global Dementia Discovery Fund,LLY,https://www.benzinga.com/news/15/10/5930964/lilly-supports-global-dementia-discovery-fund,Paul Quintaro,,,,0,0,fd5c2b89-db68-46cf-ae27-cc65d3babb2d
2015-10-21T08:00:00.000+08:00,"Global Growth Temperature Likely Captured In Caterpillar, McDonald's And Under Armour Earnings",LLY,https://www.benzinga.com/trading-ideas/previews/15/10/5932997/global-growth-temperature-likely-captured-in-caterpillar-mcdona,The Ticker Tape,,,,0,0,1c665db0-121d-4800-841e-8676c13cd592
2015-10-21T08:00:00.000+08:00,Lilly supports global Dementia Discovery Fund,LLY,https://www.benzinga.com/news/15/10/5930964/lilly-supports-global-dementia-discovery-fund,Paul Quintaro,,,,0,0,f5e43b2e-0578-4c1a-8b2f-db5654b93ef5
2015-10-20T08:00:00.000+08:00,Yabao Pharmaceuticals Enters 2nd Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment,LLY,https://www.benzinga.com/news/15/10/5927985/yabao-pharmaceuticals-enters-2nd-innovative-collaboration-with-eli-lilly-and-comp,Hal Lindon,,,,0,0,1b729c7d-96e4-4591-9bc8-b2c6e0468a01
2015-10-20T08:00:00.000+08:00,Yabao Pharmaceuticals Enters 2nd Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment,LLY,https://www.benzinga.com/news/15/10/5927985/yabao-pharmaceuticals-enters-2nd-innovative-collaboration-with-eli-lilly-and-comp,Hal Lindon,,,,0,0,03ba3a7d-22b4-4787-b5fd-5c8351ab87a0
2015-10-18T08:00:00.000+08:00,Google Stands Out Amid Low Earnings Expectations,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5922170/google-stands-out-amid-low-earnings-expectations,Nelson Hem,,,,0,0,2c7d6172-eb73-434e-9e96-911f31daee44
2015-10-18T08:00:00.000+08:00,Google Stands Out Amid Low Earnings Expectations,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5922170/google-stands-out-amid-low-earnings-expectations,Nelson Hem,,,,0,0,a17cbe86-16f6-44cd-b32f-dd45f789ded0
2015-10-14T08:00:00.000+08:00,New Type 2 Diabetes Treatment Synjardy Tablets Now Available in U.S. Pharmacies,LLY,https://www.benzinga.com/news/15/10/5911779/new-type-2-diabetes-treatment-synjardy-tablets-now-available-in-u-s-pharmacies,Hal Lindon,,,,0,0,bef0e54e-0827-490b-ad6f-e9139ea79935
2015-10-14T08:00:00.000+08:00,Incyte and Eli Lilly Announce Baricitnib Results,LLY,https://www.benzinga.com/news/15/10/5911278/incyte-and-eli-lilly-announce-baricitnib-results,Paul Quintaro,,,,0,0,47f25c62-53ac-4d6e-9f22-c5f72d3329de
2015-10-14T08:00:00.000+08:00,New Type 2 Diabetes Treatment Synjardy Tablets Now Available in U.S. Pharmacies,LLY,https://www.benzinga.com/news/15/10/5911779/new-type-2-diabetes-treatment-synjardy-tablets-now-available-in-u-s-pharmacies,Hal Lindon,,,,0,0,df3efafc-2bdd-4d22-85ce-0329c7543613
2015-10-14T08:00:00.000+08:00,Incyte and Eli Lilly Announce Baricitnib Results,LLY,https://www.benzinga.com/news/15/10/5911278/incyte-and-eli-lilly-announce-baricitnib-results,Paul Quintaro,,,,0,0,7b4ea058-2aca-4d3f-b9ac-3db5fdd2611a
2015-10-13T08:00:00.000+08:00,"JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5907490/jmp-analyst-says-eli-lillys-cetp-failure-positive-for-es,Hal Lindon,,,,0,0,207ef015-ede6-422b-8181-bef0c3434b59
2015-10-13T08:00:00.000+08:00,US Stock Futures Down; JPMorgan Earnings In Focus,LLY,https://www.benzinga.com/news/15/10/5907418/us-stock-futures-down-jpmorgan-earnings-in-focus,Monica Gerson,,,,0,0,25e9393b-3a86-4f20-8285-9f24d1b401cd
2015-10-13T08:00:00.000+08:00,"Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, no terms",LLY,https://www.benzinga.com/news/15/10/5907277/lilly-and-imaginab-announce-preclinical-immuno-oncology-collaboration-no-terms,Paul Quintaro,,,,0,0,f3f4f564-f8fd-4a51-ae1d-3bdb83aa2855
2015-10-13T08:00:00.000+08:00,Fast Money Traders Share Their Thoughts On Eli Lilly and And The Restaurant Sector,LLY,https://www.benzinga.com/media/cnbc/15/10/5906585/fast-money-traders-share-their-thoughts-on-eli-lilly-and-and-the-restaurant,Craig Jones,,,,0,0,1dc53561-1cc4-4f52-bd70-0bcba8a7990e
2015-10-13T08:00:00.000+08:00,Fast Money Picks For October 13,LLY,https://www.benzinga.com/media/cnbc/15/10/5906571/fast-money-picks-for-october-13,Craig Jones,,,,0,0,4dfaa0fc-7ff4-4ba4-a96b-945726968234
2015-10-13T08:00:00.000+08:00,"JMP Analyst Says Eli Lilly's CETP Failure Positive For Esperion Therapeutics ETC-1002 Oral Candidate, States Strategic Value Of Asset Has Increased",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5907490/jmp-analyst-says-eli-lillys-cetp-failure-positive-for-es,Hal Lindon,,,,0,0,046e0d68-32d2-41b0-99fc-5f9a633c3d0c
2015-10-13T08:00:00.000+08:00,US Stock Futures Down; JPMorgan Earnings In Focus,LLY,https://www.benzinga.com/news/15/10/5907418/us-stock-futures-down-jpmorgan-earnings-in-focus,Monica Gerson,,,,0,0,582650ab-7abc-49fe-8a24-2d6c20e10fab
2015-10-13T08:00:00.000+08:00,"Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, no terms",LLY,https://www.benzinga.com/news/15/10/5907277/lilly-and-imaginab-announce-preclinical-immuno-oncology-collaboration-no-terms,Paul Quintaro,,,,0,0,04ca5649-d3ef-4108-a358-fc7bfbf020d9
2015-10-13T08:00:00.000+08:00,Fast Money Traders Share Their Thoughts On Eli Lilly and And The Restaurant Sector,LLY,https://www.benzinga.com/media/cnbc/15/10/5906585/fast-money-traders-share-their-thoughts-on-eli-lilly-and-and-the-restaurant,Craig Jones,,,,0,0,33f5eef1-4409-4d6e-b83c-554b643aad19
2015-10-13T08:00:00.000+08:00,Fast Money Picks For October 13,LLY,https://www.benzinga.com/media/cnbc/15/10/5906571/fast-money-picks-for-october-13,Craig Jones,,,,0,0,7dbeeda8-2180-4c55-ac85-3bdcf0e7333a
2015-10-12T08:00:00.000+08:00,"UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5905636/update-chardans-amusa-highlights-bull-vs-bear-case-for-e,Paul Quintaro,,,,0,0,4858f3ab-c349-4c2c-9615-306e491fc7ec
2015-10-12T08:00:00.000+08:00,"Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5905630/chardan-capitals-amusa-on-esperion-following-evacetrapib,Paul Quintaro,,,,0,0,1f5da5a1-948b-4a35-a650-83e3ac18a263
2015-10-12T08:00:00.000+08:00,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives,LLY,https://www.benzinga.com/general/biotech/15/10/5905059/eli-lilly-discontinues-evacetrapib-investors-move-bets-to-alternatives,Wayne Duggan,,,,0,0,1e72f89c-6b56-4c03-b56b-2ab893409ccc
2015-10-12T08:00:00.000+08:00,"Regeneron Trading Up To $517/Share Up 2.6% Premarket On Eli Lilly Evacetraqib Development Discontinuation, Watch Regenron Partner Sanofi",LLY,https://www.benzinga.com/movers/15/10/5904624/regeneron-trading-up-to-517share-up-2-6-premarket-on-eli-lilly-evacetraqib-deve,Hal Lindon,,,,0,0,40671ff3-2bb8-41a4-af95-8390a895b93b
2015-10-12T08:00:00.000+08:00,UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904582/update-shares-of-esperion-therapeutics-trading-up-14-following-discontinuation-of,Paul Quintaro,,,,0,0,f0145713-298f-49a9-b36c-127b422d1cdb
2015-10-12T08:00:00.000+08:00,"UPDATE: Shares of Eli Lilly Trading Down ~8%, Now Under $80 at $79.49",LLY,https://www.benzinga.com/movers/15/10/5904581/update-shares-of-eli-lilly-trading-down-8-now-under-80-at-79-49,Paul Quintaro,,,,0,0,98a75ab5-c5ca-46a1-b2a8-be23cefda382
2015-10-12T08:00:00.000+08:00,TheStreet's Adam Feuerstein Recently Tweets: 'Watch $ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904572/thestreets-adam-feuerstein-recently-tweets-watch-espr-on-the-heels-of-eli-lilly-d,Paul Quintaro,,,,0,0,986dd0ca-caf2-4a0a-86ac-0ef773c57d5f
2015-10-12T08:00:00.000+08:00,"Esperion Shares Trading Higher To $28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetraqib",LLY,https://www.benzinga.com/movers/15/10/5904564/esperion-shares-trading-higher-to-28-50share-up-14-9-premarket-following-eli-li,Hal Lindon,,,,0,0,4dc74346-e2cb-4816-86d8-a9648c4bee85
2015-10-12T08:00:00.000+08:00,Shares of Eli Lilly Resume; Now Trading Down ~$83,LLY,https://www.benzinga.com/news/15/10/5904561/shares-of-eli-lilly-resume-now-trading-down-83,Paul Quintaro,,,,0,0,89cd1cfe-d0a7-431e-87a7-c756f6eaa428
2015-10-12T08:00:00.000+08:00,UPDATE: Eli Lilly Evacetraqib Devlopment Discontinuation Expected To Result In Q4 Charge Of $90M or $0.05 After-Tax,LLY,https://www.benzinga.com/news/15/10/5904548/update-eli-lilly-evacetraqib-devlopment-discontinuation-expected-to-result-in-q4-,Hal Lindon,,,,0,0,49483c4a-e5b9-4b59-91f7-c78751f7a7eb
2015-10-12T08:00:00.000+08:00,"UPDATE: Eli Discontinuing Evacetraqib Development Due To Low Probability Of Study TO Achieve Primary Endpoint Based On Results To Date, Not Being Stopped Due To Safety Findings",LLY,https://www.benzinga.com/news/15/10/5904540/update-eli-discontinuing-evacetraqib-development-due-to-low-probability-of-study-,Hal Lindon,,,,0,0,c8a1ce6e-b146-46fc-bb56-c4e3ea799f17
2015-10-12T08:00:00.000+08:00,"UPDATE: Lilly Will Terminate Phase 3 Trial of Evacetrapib, Cites Insufficient Efficacy",LLY,https://www.benzinga.com/news/15/10/5904532/update-lilly-will-terminate-phase-3-trial-of-evacetrapib-cites-insufficient-effic,Paul Quintaro,,,,0,0,3042240b-f4e4-48b8-9283-7dce6df826c9
2015-10-12T08:00:00.000+08:00,Lilly Announces Will Discontinue Development of Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904443/lilly-announces-will-discontinue-development-of-evacetrapib,Paul Quintaro,,,,0,0,7a1d957e-caf9-421b-9a28-ce33ba866e83
2015-10-12T08:00:00.000+08:00,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt,LLY,https://www.benzinga.com/general/biotech/15/10/5904403/watching-volatility-in-other-big-pharma-names-amid-eli-lilly-halt,Hal Lindon,,,,0,0,34d13f1d-4a4c-40d1-bc04-7b6b1c833f70
2015-10-12T08:00:00.000+08:00,Eli Lilly Shares Halted News Pending,LLY,https://www.benzinga.com/news/15/10/5904398/eli-lilly-shares-halted-news-pending,Paul Quintaro,,,,0,0,d01d5d0e-7a9e-4c94-9bb3-26b2c945a561
2015-10-12T08:00:00.000+08:00,US Stock Futures Flat Ahead Of Fed Speakers,LLY,https://www.benzinga.com/news/15/10/5904212/us-stock-futures-flat-ahead-of-fed-speakers,Monica Gerson,,,,0,0,c07e8812-a5ea-4a17-b1b0-34d74656845e
2015-10-12T08:00:00.000+08:00,"UPDATE: Chardan's Amusa Highlights Bull vs Bear Case for Esperion, Sees the Latter as 'More Important'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5905636/update-chardans-amusa-highlights-bull-vs-bear-case-for-e,Paul Quintaro,,,,0,0,8abcba45-700a-49c3-88dc-1d1490ef472d
2015-10-12T08:00:00.000+08:00,"Chardan Capital's Amusa on Esperion Following Evacetrapib Discontinuation: '...by increasing the likelihood of regulatory scrutiny on ETC-1002, the evacetrapib failure reduces the chance ETC-1002 gets there...'",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5905630/chardan-capitals-amusa-on-esperion-following-evacetrapib,Paul Quintaro,,,,0,0,15661534-902d-46af-b95e-389e25391fe7
2015-10-12T08:00:00.000+08:00,Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives,LLY,https://www.benzinga.com/general/biotech/15/10/5905059/eli-lilly-discontinues-evacetrapib-investors-move-bets-to-alternatives,Wayne Duggan,,,,0,0,734b10d8-42e4-4634-b273-a66295297a73
2015-10-12T08:00:00.000+08:00,"Regeneron Trading Up To $517/Share Up 2.6% Premarket On Eli Lilly Evacetraqib Development Discontinuation, Watch Regenron Partner Sanofi",LLY,https://www.benzinga.com/movers/15/10/5904624/regeneron-trading-up-to-517share-up-2-6-premarket-on-eli-lilly-evacetraqib-deve,Hal Lindon,,,,0,0,5e2a6c7d-2d2b-41b2-a11f-eaa4e96f9260
2015-10-12T08:00:00.000+08:00,UPDATE: Shares of Esperion Therapeutics Trading Up ~14% Following Discontinuation of Lilly's Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904582/update-shares-of-esperion-therapeutics-trading-up-14-following-discontinuation-of,Paul Quintaro,,,,0,0,72557701-a618-4ba4-aa3c-8502fec34329
2015-10-12T08:00:00.000+08:00,"UPDATE: Shares of Eli Lilly Trading Down ~8%, Now Under $80 at $79.49",LLY,https://www.benzinga.com/movers/15/10/5904581/update-shares-of-eli-lilly-trading-down-8-now-under-80-at-79-49,Paul Quintaro,,,,0,0,f0f8a7a0-ea4f-45ec-b8cb-15fdade1c5b5
2015-10-12T08:00:00.000+08:00,TheStreet's Adam Feuerstein Recently Tweets: 'Watch $ESPR' on the Heels of Eli Lilly Discontinuation of Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904572/thestreets-adam-feuerstein-recently-tweets-watch-espr-on-the-heels-of-eli-lilly-d,Paul Quintaro,,,,0,0,2e280626-793e-43fa-83a4-930c68249e07
2015-10-12T08:00:00.000+08:00,"Esperion Shares Trading Higher To $28.50/Share, Up 14.9% Premarket Following Eli Lilly Development Discontinuation For Evacetraqib",LLY,https://www.benzinga.com/movers/15/10/5904564/esperion-shares-trading-higher-to-28-50share-up-14-9-premarket-following-eli-li,Hal Lindon,,,,0,0,2d788dda-0463-4ba7-8340-4af15a401795
2015-10-12T08:00:00.000+08:00,Shares of Eli Lilly Resume; Now Trading Down ~$83,LLY,https://www.benzinga.com/news/15/10/5904561/shares-of-eli-lilly-resume-now-trading-down-83,Paul Quintaro,,,,0,0,6f2dfd24-5399-4efb-8cf1-33ac8057248b
2015-10-12T08:00:00.000+08:00,UPDATE: Eli Lilly Evacetraqib Devlopment Discontinuation Expected To Result In Q4 Charge Of $90M or $0.05 After-Tax,LLY,https://www.benzinga.com/news/15/10/5904548/update-eli-lilly-evacetraqib-devlopment-discontinuation-expected-to-result-in-q4-,Hal Lindon,,,,0,0,4baecf26-3847-4677-bb4f-9de64d1c5110
2015-10-12T08:00:00.000+08:00,"UPDATE: Eli Discontinuing Evacetraqib Development Due To Low Probability Of Study TO Achieve Primary Endpoint Based On Results To Date, Not Being Stopped Due To Safety Findings",LLY,https://www.benzinga.com/news/15/10/5904540/update-eli-discontinuing-evacetraqib-development-due-to-low-probability-of-study-,Hal Lindon,,,,0,0,a3aceb33-6712-405e-9c42-ae6b9a4239d8
2015-10-12T08:00:00.000+08:00,"UPDATE: Lilly Will Terminate Phase 3 Trial of Evacetrapib, Cites Insufficient Efficacy",LLY,https://www.benzinga.com/news/15/10/5904532/update-lilly-will-terminate-phase-3-trial-of-evacetrapib-cites-insufficient-effic,Paul Quintaro,,,,0,0,48827e55-cf87-4517-a11a-21b34fed6656
2015-10-12T08:00:00.000+08:00,Lilly Announces Will Discontinue Development of Evacetrapib,LLY,https://www.benzinga.com/news/15/10/5904443/lilly-announces-will-discontinue-development-of-evacetrapib,Paul Quintaro,,,,0,0,021fdfc2-5b81-4721-96f4-6b894c9ab249
2015-10-12T08:00:00.000+08:00,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt,LLY,https://www.benzinga.com/general/biotech/15/10/5904403/watching-volatility-in-other-big-pharma-names-amid-eli-lilly-halt,Hal Lindon,,,,0,0,d66286b3-0091-419a-959c-446d368f4172
2015-10-12T08:00:00.000+08:00,Eli Lilly Shares Halted News Pending,LLY,https://www.benzinga.com/news/15/10/5904398/eli-lilly-shares-halted-news-pending,Paul Quintaro,,,,0,0,ea8668e0-917e-4ba8-879e-c01064a52657
2015-10-12T08:00:00.000+08:00,US Stock Futures Flat Ahead Of Fed Speakers,LLY,https://www.benzinga.com/news/15/10/5904212/us-stock-futures-flat-ahead-of-fed-speakers,Monica Gerson,,,,0,0,3a916f3f-bd60-4898-9e8d-00d3ad351206
2015-10-11T08:00:00.000+08:00,"Lilly, Innovent Biologics Expand Their Strategic Alliance",LLY,https://www.benzinga.com/news/15/10/5903735/lilly-innovent-biologics-expand-their-strategic-alliance,Charles Gross,,,,0,0,ee2f195e-9a88-4ea0-8892-5a7283b26a69
2015-10-11T08:00:00.000+08:00,"Lilly, Innovent Biologics Expand Their Strategic Alliance",LLY,https://www.benzinga.com/news/15/10/5903735/lilly-innovent-biologics-expand-their-strategic-alliance,Charles Gross,,,,0,0,89f22a7a-de4d-427b-b06f-7f8dc039b009
2015-10-09T08:00:00.000+08:00,Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions; Terms Not Disclosed,LLY,https://www.benzinga.com/news/15/10/5902720/lilly-acquires-phase-iii-intranasal-glucagon-from-locemia-solutions-terms-not-dis,Hal Lindon,,,,0,0,00ea03f4-d0f9-45cc-8e4b-ea75ff541b69
2015-10-09T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/10/5901507/benzingas-top-upgrades,Lisa Levin,,,,0,0,febbae5e-cc36-4675-8e2e-5bbc76bd2284
2015-10-09T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly; Likes Jardiance For Short-Term And Pipeline For Long-Term,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5901399/credit-suisse-upgrades-eli-lilly-likes-jardiance-for-sho,Monica Gerson,,,,0,0,eaf96bf0-3f09-45d1-a821-fdbe9b542942
2015-10-09T08:00:00.000+08:00,"Credit Suisse Upgrades Eli Lilly to Outperform, Raises PT to $105.00",LLY,https://www.benzinga.com/news/15/10/5901004/credit-suisse-upgrades-eli-lilly-to-outperform-raises-pt-to-105-00,Paul Quintaro,,,,0,0,78ba0afc-7cb4-4d79-b0af-204f042d6719
2015-10-09T08:00:00.000+08:00,Lilly Acquires Phase III Intranasal Glucagon from Locemia Solutions; Terms Not Disclosed,LLY,https://www.benzinga.com/news/15/10/5902720/lilly-acquires-phase-iii-intranasal-glucagon-from-locemia-solutions-terms-not-dis,Hal Lindon,,,,0,0,32b43ff8-399d-4c0e-a582-284edde9d316
2015-10-09T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/10/5901507/benzingas-top-upgrades,Lisa Levin,,,,0,0,25577380-7ab3-4141-a18a-41b3f49a9f07
2015-10-09T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly; Likes Jardiance For Short-Term And Pipeline For Long-Term,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5901399/credit-suisse-upgrades-eli-lilly-likes-jardiance-for-sho,Monica Gerson,,,,0,0,19f3e5d3-f356-4dad-b8eb-126e4bc38dc9
2015-10-09T08:00:00.000+08:00,"Credit Suisse Upgrades Eli Lilly to Outperform, Raises PT to $105.00",LLY,https://www.benzinga.com/news/15/10/5901004/credit-suisse-upgrades-eli-lilly-to-outperform-raises-pt-to-105-00,Paul Quintaro,,,,0,0,1bf5da50-67d1-4b59-a4be-2631f7f33274
2015-10-08T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer,LLY,https://www.benzinga.com/news/15/10/5897301/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib-a-cdk-4-and-6,Paul Quintaro,,,,0,0,374edba8-e919-471c-b2cd-045dce974673
2015-10-08T08:00:00.000+08:00,Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib - a CDK 4 and 6 Inhibitor - in Advanced Breast Cancer,LLY,https://www.benzinga.com/news/15/10/5897301/lilly-receives-fda-breakthrough-therapy-designation-for-abemaciclib-a-cdk-4-and-6,Paul Quintaro,,,,0,0,3887f582-8e4e-41ed-8d33-0fa12fb16b0a
2015-10-02T08:00:00.000+08:00,US Insurers Cautious on Lilly's Diabetes Drug Jardiance -Reuters,LLY,https://www.benzinga.com/news/15/10/5884154/us-insurers-cautious-on-lillys-diabetes-drug-jardiance-reuters,Charles Gross,,,,0,0,055505d5-bc8b-4bbd-913e-9fc1de82163c
2015-10-02T08:00:00.000+08:00,US Insurers Cautious on Lilly's Diabetes Drug Jardiance -Reuters,LLY,https://www.benzinga.com/news/15/10/5884154/us-insurers-cautious-on-lillys-diabetes-drug-jardiance-reuters,Charles Gross,,,,0,0,3c013fb0-a655-4f78-9e12-b7c1a0cad8dd
2015-10-01T08:00:00.000+08:00,10 Defensive Stock Ideas From Bank Of America,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5881648/10-defensive-stock-ideas-from-bank-of-america,Jayson Derrick,,,,0,0,219d18c0-866a-4cbb-826a-210c949b6845
2015-10-01T08:00:00.000+08:00,10 Defensive Stock Ideas From Bank Of America,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5881648/10-defensive-stock-ideas-from-bank-of-america,Jayson Derrick,,,,0,0,df57aca4-c2b7-4431-8a0b-13af7142419f
2015-09-29T08:00:00.000+08:00,Stocks Hitting 52-Week Lows,LLY,https://www.benzinga.com/news/15/09/5872882/stocks-hitting-52-week-lows,Lisa Levin,,,,0,0,777d8911-01b9-4b8b-aff8-0d03a7a1405a
2015-09-29T08:00:00.000+08:00,Morning Market Losers,LLY,https://www.benzinga.com/news/15/09/5872776/morning-market-losers,Lisa Levin,,,,0,0,b37e4fd5-7b84-40f9-aa55-b60b26cc333f
2015-09-29T08:00:00.000+08:00,Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results,LLY,https://www.benzinga.com/news/15/09/5871582/eli-lilly-and-incyte-announce-positive-top-line-phase-3-baricitnib-results,Paul Quintaro,,,,0,0,c74d47ea-60bb-47b3-8148-eebcbcae39ff
2015-09-29T08:00:00.000+08:00,Stocks Hitting 52-Week Lows,LLY,https://www.benzinga.com/news/15/09/5872882/stocks-hitting-52-week-lows,Lisa Levin,,,,0,0,a333f8b7-8064-47c4-8c17-701226d05e2d
2015-09-29T08:00:00.000+08:00,Morning Market Losers,LLY,https://www.benzinga.com/news/15/09/5872776/morning-market-losers,Lisa Levin,,,,0,0,637df5cf-fd0e-41d8-a451-9080ac4f7468
2015-09-29T08:00:00.000+08:00,Eli Lilly and Incyte Announce Positive Top Line Phase 3 Baricitnib Results,LLY,https://www.benzinga.com/news/15/09/5871582/eli-lilly-and-incyte-announce-positive-top-line-phase-3-baricitnib-results,Paul Quintaro,,,,0,0,f3620f94-275a-497a-ab33-89c7bf89418e
2015-09-28T08:00:00.000+08:00,"Lilly, Sanofi Reach Settlement Agreement On Insulin Glargine Litigation In U.S.; Lilly To Have Ability To Launch Basaglar In 2016, Further Details Confidential",LLY,https://www.benzinga.com/news/15/09/5868975/lilly-sanofi-reach-settlement-agreement-on-insulin-glargine-litigation-in-u-s-lil,Hal Lindon,,,,0,0,4b2bda2c-f7fb-4bdc-bf7c-ce5ea1a4ac9c
2015-09-28T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial,LLY,https://www.benzinga.com/news/15/09/5868322/lillys-cyramza-ramucirumab-significantly-improves-progression-free-survival-in-ph,Paul Quintaro,,,,0,0,0e5e6a1d-5eab-4327-969e-f9aab8371fea
2015-09-28T08:00:00.000+08:00,"Lilly, Sanofi Reach Settlement Agreement On Insulin Glargine Litigation In U.S.; Lilly To Have Ability To Launch Basaglar In 2016, Further Details Confidential",LLY,https://www.benzinga.com/news/15/09/5868975/lilly-sanofi-reach-settlement-agreement-on-insulin-glargine-litigation-in-u-s-lil,Hal Lindon,,,,0,0,e738a357-8b69-427d-b6e9-01178fa600b6
2015-09-28T08:00:00.000+08:00,Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free Survival in Phase II Bladder Cancer Trial,LLY,https://www.benzinga.com/news/15/09/5868322/lillys-cyramza-ramucirumab-significantly-improves-progression-free-survival-in-ph,Paul Quintaro,,,,0,0,6dab35c0-b7ee-4be7-8541-6760f75c3fbd
2015-09-21T08:00:00.000+08:00,"Forget The 2016 Election Candidates, CEOs Are Driving Change",LLY,https://www.benzinga.com/news/15/09/5851638/forget-the-2016-election-candidates-ceos-are-driving-change,Laura Brodbeck,,,,0,0,03652f2b-61b0-4fde-9fdc-2c06e5f1a6b6
2015-09-21T08:00:00.000+08:00,"Forget The 2016 Election Candidates, CEOs Are Driving Change",LLY,https://www.benzinga.com/news/15/09/5851638/forget-the-2016-election-candidates-ceos-are-driving-change,Laura Brodbeck,,,,0,0,dba90dc8-3e82-4d5f-a289-8edc7cc44749
2015-09-18T08:00:00.000+08:00,Bank Of America: New Eli Lilly Data Is 'Game-Changing',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5849914/bank-of-america-new-eli-lilly-data-is-game-changing,Jayson Derrick,,,,0,0,c696e410-6c98-44a4-98cf-5fb4ce289832
2015-09-18T08:00:00.000+08:00,"Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5849393/eli-lillys-home-run-is-jardiance-says-morgan-stanley,J.D. Singh,,,,0,0,1e40ca86-0283-4506-8233-fe1fbb85cf2f
2015-09-18T08:00:00.000+08:00,Bank Of America: New Eli Lilly Data Is 'Game-Changing',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5849914/bank-of-america-new-eli-lilly-data-is-game-changing,Jayson Derrick,,,,0,0,13cd6b7a-2df0-4e46-9a60-c34f87608d23
2015-09-18T08:00:00.000+08:00,"Eli Lilly's 'Home Run' Is Jardiance, Says Morgan Stanley",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5849393/eli-lillys-home-run-is-jardiance-says-morgan-stanley,J.D. Singh,,,,0,0,28d50587-3f00-4033-8fcf-40191af617f3
2015-09-17T08:00:00.000+08:00,"Boehringer Ingelheim Pharma, Eli Lilly Announce Jardiance Significantly Reduced Risk of Combined Endpoint of CV Death, Non-Fatal Heart Attack, Stroke",LLY,https://www.benzinga.com/news/15/09/5847206/boehringer-ingelheim-pharma-eli-lilly-announce-jardiance-significantly-reduced-ri,Paul Quintaro,,,,0,0,02a9f0be-f919-4e4f-b8f6-02bd80137dd7
2015-09-17T08:00:00.000+08:00,"Boehringer Ingelheim Pharma, Eli Lilly Announce Jardiance Significantly Reduced Risk of Combined Endpoint of CV Death, Non-Fatal Heart Attack, Stroke",LLY,https://www.benzinga.com/news/15/09/5847206/boehringer-ingelheim-pharma-eli-lilly-announce-jardiance-significantly-reduced-ri,Paul Quintaro,,,,0,0,00328884-4d9e-4c54-a9f1-0222cf068d9d
2015-09-15T08:00:00.000+08:00,Eli Lilly Says Abasaglar Showed Similar Safety to Lantus - Reuters,LLY,https://www.benzinga.com/news/15/09/5838008/eli-lilly-says-abasaglar-showed-similar-safety-to-lantus-reuters,Paul Quintaro,,,,0,0,96dd0952-1dda-4949-a450-fdaecd176ae7
2015-09-15T08:00:00.000+08:00,Eli Lilly Says Abasaglar Showed Similar Safety to Lantus - Reuters,LLY,https://www.benzinga.com/news/15/09/5838008/eli-lilly-says-abasaglar-showed-similar-safety-to-lantus-reuters,Paul Quintaro,,,,0,0,460be15a-53a3-419d-9748-e940afd484a5
2015-08-27T08:00:00.000+08:00,U.S. FDA approves Synjardy tablets for adults with type 2 diabetes,LLY,https://www.benzinga.com/news/15/08/5796737/u-s-fda-approves-synjardy-tablets-for-adults-with-type-2-diabetes,Hal Lindon,,,,0,0,8555a7e9-a3e1-4c9a-b8aa-2df8e1dd65af
2015-08-27T08:00:00.000+08:00,Benzinga's Top Initiations,LLY,https://www.benzinga.com/analyst-ratings/initiation/15/08/5796522/benzingas-top-initiations,Lisa Levin,,,,0,0,2cd3d91a-6079-4bc0-a227-ae831630a729
2015-08-27T08:00:00.000+08:00,"Berenberg Initiates Coverage on Eli Lilly at Buy, Announces $100.00 PT",LLY,https://www.benzinga.com/news/15/08/5795879/berenberg-initiates-coverage-on-eli-lilly-at-buy-announces-100-00-pt,Paul Quintaro,,,,0,0,01ff8a2a-5844-4ad0-9b76-34ea2e895c8c
2015-08-27T08:00:00.000+08:00,U.S. FDA approves Synjardy tablets for adults with type 2 diabetes,LLY,https://www.benzinga.com/news/15/08/5796737/u-s-fda-approves-synjardy-tablets-for-adults-with-type-2-diabetes,Hal Lindon,,,,0,0,f594451b-eb01-4c7a-88e0-f3108a95893e
2015-08-27T08:00:00.000+08:00,Benzinga's Top Initiations,LLY,https://www.benzinga.com/analyst-ratings/initiation/15/08/5796522/benzingas-top-initiations,Lisa Levin,,,,0,0,2a1b8481-6fd9-4f91-bf99-8a048313f974
2015-08-27T08:00:00.000+08:00,"Berenberg Initiates Coverage on Eli Lilly at Buy, Announces $100.00 PT",LLY,https://www.benzinga.com/news/15/08/5795879/berenberg-initiates-coverage-on-eli-lilly-at-buy-announces-100-00-pt,Paul Quintaro,,,,0,0,6bea4d8b-9ac8-4c8c-9435-3ffb0cc0e573
2015-08-25T08:00:00.000+08:00,U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent,LLY,https://www.benzinga.com/news/15/08/5791011/u-s-district-court-rules-in-lillys-favor-on-alimta-vitamin-regimen-patent,Paul Quintaro,,,,0,0,34a39114-aec5-4f49-887e-b8925f32d454
2015-08-25T08:00:00.000+08:00,U.S. District Court Rules in Lilly's Favor on Alimta Vitamin Regimen Patent,LLY,https://www.benzinga.com/news/15/08/5791011/u-s-district-court-rules-in-lillys-favor-on-alimta-vitamin-regimen-patent,Paul Quintaro,,,,0,0,913c0a2e-7f29-4303-a34b-fe90887b1da0
2015-08-20T08:00:00.000+08:00,Benzinga's Volume Movers,LLY,https://www.benzinga.com/news/15/08/5780843/benzingas-volume-movers,Lisa Levin,,,,0,0,bdf6ea9a-ae4b-4e41-8400-e6dc23a3e52e
2015-08-20T08:00:00.000+08:00,Lily +3% on Positive Jardiance Results,LLY,https://www.benzinga.com/news/15/08/5780049/lily-3-on-positive-jardiance-results,Charles Gross,,,,0,0,3d1a45d3-9c73-4eab-9355-15395b0b367c
2015-08-20T08:00:00.000+08:00,Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events,LLY,https://www.benzinga.com/news/15/08/5779292/jardiance-demonstrated-cardiovascular-risk-reduction-in-people-with-type-2-diabet,Hal Lindon,,,,0,0,1ad5276a-c1f5-407a-aa52-42580b608331
2015-08-20T08:00:00.000+08:00,Benzinga's Volume Movers,LLY,https://www.benzinga.com/news/15/08/5780843/benzingas-volume-movers,Lisa Levin,,,,0,0,4c850fea-99f7-4d70-b7d4-a1925bf35c33
2015-08-20T08:00:00.000+08:00,Lily +3% on Positive Jardiance Results,LLY,https://www.benzinga.com/news/15/08/5780049/lily-3-on-positive-jardiance-results,Charles Gross,,,,0,0,d22d6f16-a1a5-44da-8248-4e24e7c735ab
2015-08-20T08:00:00.000+08:00,Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events,LLY,https://www.benzinga.com/news/15/08/5779292/jardiance-demonstrated-cardiovascular-risk-reduction-in-people-with-type-2-diabet,Hal Lindon,,,,0,0,57791279-1bc6-411e-b32f-70dac2a63e48
2015-08-16T08:00:00.000+08:00,Eli Lilly CEO: Recent Events In China Don't Change Much,LLY,https://www.benzinga.com/general/biotech/15/08/5767116/eli-lilly-ceo-recent-events-in-china-dont-change-much,Ritesh Anan,,,,0,0,8f648ddc-24de-4e09-bd58-cda3b749a7c8
2015-08-16T08:00:00.000+08:00,Eli Lilly CEO: Recent Events In China Don't Change Much,LLY,https://www.benzinga.com/general/biotech/15/08/5767116/eli-lilly-ceo-recent-events-in-china-dont-change-much,Ritesh Anan,,,,0,0,63dfbebd-eb5f-463c-bca8-7dd965d9ac12
2015-08-15T08:00:00.000+08:00,Here's A Look At Eli Lilly's Future Pipeline,LLY,https://www.benzinga.com/general/biotech/15/08/5767069/heres-a-look-at-eli-lillys-future-pipeline,Zoheb Sait,,,,0,0,a3da1676-08e2-49ef-8d7e-91b080cc60a2
2015-08-15T08:00:00.000+08:00,Here's A Look At Eli Lilly's Future Pipeline,LLY,https://www.benzinga.com/general/biotech/15/08/5767069/heres-a-look-at-eli-lillys-future-pipeline,Zoheb Sait,,,,0,0,d5ac9aec-93df-479d-bd78-e2493e3b91a1
2015-07-27T08:00:00.000+08:00,Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16,LLY,https://www.benzinga.com/news/15/07/5704861/lilly-issues-update-on-evacetrapib-phase-3-trial-last-patient-visit-in-accelerate,Paul Quintaro,,,,0,0,161c1861-0a2e-4e3d-9afa-3d7d65ed0960
2015-07-27T08:00:00.000+08:00,Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16,LLY,https://www.benzinga.com/news/15/07/5704861/lilly-issues-update-on-evacetrapib-phase-3-trial-last-patient-visit-in-accelerate,Paul Quintaro,,,,0,0,53d91f29-4617-466b-a9d6-c069cfa13ee4
2015-07-23T08:00:00.000+08:00,"Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5698873/analysts-key-takeaways-from-eli-lilly-bristol-myer-squib,Jayson Derrick,,,,0,0,e50f3132-cec3-49e5-b246-1173196f1c07
2015-07-23T08:00:00.000+08:00,Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat,LLY,https://www.benzinga.com/general/biotech/15/07/5697796/eli-lilly-ceo-explains-the-reasons-behind-the-0-16-eps-beat,Santhosh Naikar,,,,0,0,5c82699d-c08d-4ed5-be90-6f662dd52017
2015-07-23T08:00:00.000+08:00,Lilly CEO Says Bubble in Prices of Smaller Biotech Cos -Reuters,LLY,https://www.benzinga.com/news/15/07/5697835/lilly-ceo-says-bubble-in-prices-of-smaller-biotech-cos-reuters,Charles Gross,,,,0,0,55f8ecbf-48c5-499c-ae2c-bce3342bf227
2015-07-23T08:00:00.000+08:00,Eli Lilly Sees FY15 Adj. EPS $3.20-$3.30 vs $3.18 Est.,LLY,https://www.benzinga.com/news/15/07/5696333/eli-lilly-sees-fy15-adj-eps-3-20-3-30-vs-3-18-est,Paul Quintaro,,,,0,0,eda1b785-2baf-412e-b8f6-d323438cfa7a
2015-07-23T08:00:00.000+08:00,"Eli Lilly Reports Q1 Adj. EPS $0.90 Vs Est $0.74, Sales $4.98B Vs Est $4.91B",LLY,https://www.benzinga.com/news/earnings/15/07/5696332/eli-lilly-reports-q1-adj-eps-0-90-vs-est-0-74-sales-4-98b-vs-est-4-91b,Eddie Staley,,,,0,0,015b9c84-6bb2-4c88-a222-2a4bfb6c32f2
2015-07-23T08:00:00.000+08:00,"Earnings Scheduled For July 23, 2015",LLY,https://www.benzinga.com/news/earnings/15/07/5696128/earnings-scheduled-for-july-23-2015,Monica Gerson,,,,0,0,b94b6f38-2273-4348-9152-9726a81ff89a
2015-07-23T08:00:00.000+08:00,"Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5698873/analysts-key-takeaways-from-eli-lilly-bristol-myer-squib,Jayson Derrick,,,,0,0,7c5d6509-c58a-4783-99ef-40daa60843df
2015-07-23T08:00:00.000+08:00,Eli Lilly CEO Explains The Reasons Behind The $0.16 EPS Beat,LLY,https://www.benzinga.com/general/biotech/15/07/5697796/eli-lilly-ceo-explains-the-reasons-behind-the-0-16-eps-beat,Santhosh Naikar,,,,0,0,dcf468c4-aa99-40a6-916b-680cc456b124
2015-07-23T08:00:00.000+08:00,Lilly CEO Says Bubble in Prices of Smaller Biotech Cos -Reuters,LLY,https://www.benzinga.com/news/15/07/5697835/lilly-ceo-says-bubble-in-prices-of-smaller-biotech-cos-reuters,Charles Gross,,,,0,0,381a2287-07e5-4c9c-9d24-2174ec476533
2015-07-23T08:00:00.000+08:00,Eli Lilly Sees FY15 Adj. EPS $3.20-$3.30 vs $3.18 Est.,LLY,https://www.benzinga.com/news/15/07/5696333/eli-lilly-sees-fy15-adj-eps-3-20-3-30-vs-3-18-est,Paul Quintaro,,,,0,0,eb9e58fd-4f0a-4373-a514-05747a07ef1c
2015-07-23T08:00:00.000+08:00,"Eli Lilly Reports Q1 Adj. EPS $0.90 Vs Est $0.74, Sales $4.98B Vs Est $4.91B",LLY,https://www.benzinga.com/news/earnings/15/07/5696332/eli-lilly-reports-q1-adj-eps-0-90-vs-est-0-74-sales-4-98b-vs-est-4-91b,Eddie Staley,,,,0,0,c0fd0eb9-b07a-4d07-b243-500df453d2f3
2015-07-23T08:00:00.000+08:00,"Earnings Scheduled For July 23, 2015",LLY,https://www.benzinga.com/news/earnings/15/07/5696128/earnings-scheduled-for-july-23-2015,Monica Gerson,,,,0,0,4411bfef-5956-482a-a9e6-ee3d34edd36b
2015-07-22T08:00:00.000+08:00,What's Coming For Large-Cap Pharma Stocks This Earnings Season?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5693254/whats-coming-for-large-cap-pharma-stocks-this-earnings-s,Wayne Duggan,,,,0,0,c35b9a74-704b-4411-b1a3-1aa762ee0372
2015-07-22T08:00:00.000+08:00,"Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5694244/did-mcdonalds-caterpillar-amazon-lose-sizzle-to-strong-d,TD Ameritrade,,,,0,0,e17dfac6-2996-411e-aa36-3806d07c53c2
2015-07-22T08:00:00.000+08:00,Evercore ISI's Mark Schoenebaum: New Eli Lilly Data 'Incrementally Positive',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5693489/evercore-isis-mark-schoenebaum-new-eli-lilly-data-increm,Monica Gerson,,,,0,0,fcf7adb2-6132-4123-8ca7-d616343f6a6a
2015-07-22T08:00:00.000+08:00,Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/15/07/5692153/data-using-new-delayed-start-methodology-suggested-benefit-of-early-treatment-wit,Eddie Staley,,,,0,0,091e979e-7c06-4470-b487-01c793242edb
2015-07-22T08:00:00.000+08:00,Data Utilizing New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/15/07/5692146/data-utilizing-new-delayed-start-methodology-suggested-benefit-of-early-treatment,Hal Lindon,,,,0,0,5758c598-eefc-449c-9bf2-ee41bf185cd1
2015-07-22T08:00:00.000+08:00,What's Coming For Large-Cap Pharma Stocks This Earnings Season?,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5693254/whats-coming-for-large-cap-pharma-stocks-this-earnings-s,Wayne Duggan,,,,0,0,139ab76a-3eb1-413a-b550-ff60708de547
2015-07-22T08:00:00.000+08:00,"Did McDonald's, Caterpillar & Amazon Lose Sizzle To Strong Dollar?",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5694244/did-mcdonalds-caterpillar-amazon-lose-sizzle-to-strong-d,TD Ameritrade,,,,0,0,7cb251f7-28ae-47f8-8c97-4accac1cae81
2015-07-22T08:00:00.000+08:00,Evercore ISI's Mark Schoenebaum: New Eli Lilly Data 'Incrementally Positive',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5693489/evercore-isis-mark-schoenebaum-new-eli-lilly-data-increm,Monica Gerson,,,,0,0,5af96c2d-87ca-41f6-a147-c3cef8bfa390
2015-07-22T08:00:00.000+08:00,Data Using New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/15/07/5692153/data-using-new-delayed-start-methodology-suggested-benefit-of-early-treatment-wit,Eddie Staley,,,,0,0,2ff9a8d3-220d-40b7-b923-5a03f87b2fd2
2015-07-22T08:00:00.000+08:00,Data Utilizing New Delayed-Start Methodology Suggested Benefit of Early Treatment with Solanezumab in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/15/07/5692146/data-utilizing-new-delayed-start-methodology-suggested-benefit-of-early-treatment,Hal Lindon,,,,0,0,94700cf3-966e-4a4e-acef-b74679c9c6c6
2015-07-21T08:00:00.000+08:00,New Alzheimer's Trials Could Produce The Most Important Drugs In History,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5689606/new-alzheimers-trials-could-produce-the-most-important-d,Leigh Drogen,,,,0,0,b135973a-012f-44ca-bfe2-95359bbab1b6
2015-07-21T08:00:00.000+08:00,Fast Money Picks For July 21,LLY,https://www.benzinga.com/media/cnbc/15/07/5686983/fast-money-picks-for-july-21,Craig Jones,,,,0,0,f6ae9402-b829-43f9-bdbb-79b52fbeeaad
2015-07-21T08:00:00.000+08:00,New Alzheimer's Trials Could Produce The Most Important Drugs In History,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5689606/new-alzheimers-trials-could-produce-the-most-important-d,Leigh Drogen,,,,0,0,3f614129-0c81-4f7f-beaf-d05c0f9b6c09
2015-07-21T08:00:00.000+08:00,Fast Money Picks For July 21,LLY,https://www.benzinga.com/media/cnbc/15/07/5686983/fast-money-picks-for-july-21,Craig Jones,,,,0,0,fbfba442-8640-4eac-9e91-e2073674e384
2015-07-20T08:00:00.000+08:00,Has Eli Lilly Found A Cure For Alzheimer's?,LLY,https://www.benzinga.com/news/15/07/5683636/has-eli-lilly-found-a-cure-for-alzheimers,Laura Brodbeck,,,,0,0,713eeef7-5a52-433e-9df7-2a9e5445f0e5
2015-07-20T08:00:00.000+08:00,"Stifel, JMP Securities Discuss What To Expect From AAIC Conference",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5684214/stifel-jmp-securities-discuss-what-to-expect-from-aaic-c,Jayson Derrick,,,,0,0,d6df46c1-4e65-43bc-afed-2f613e0de848
2015-07-20T08:00:00.000+08:00,Has Eli Lilly Found A Cure For Alzheimer's?,LLY,https://www.benzinga.com/news/15/07/5683636/has-eli-lilly-found-a-cure-for-alzheimers,Laura Brodbeck,,,,0,0,061743f9-1b38-4284-bcda-d04792f97151
2015-07-20T08:00:00.000+08:00,"Stifel, JMP Securities Discuss What To Expect From AAIC Conference",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5684214/stifel-jmp-securities-discuss-what-to-expect-from-aaic-c,Jayson Derrick,,,,0,0,1de3e294-37e8-45ab-bd71-87e7bc2483a0
2015-07-15T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/15/07/5673731/benzingas-top-downgrades,Lisa Levin,,,,0,0,d05492c2-cceb-42b9-8fad-7663312d8eca
2015-07-15T08:00:00.000+08:00,"Morgan Stanley Cuts Eli Lilly: Says Downgraded Not Related to Negative Call on Alzheimer's Data, Sees Current Share Price Factoring 'in pipelineenthusiasm for two blockbuster candidates:' Solanezumab, Evacetrapib",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5673474/morgan-stanley-cuts-eli-lilly-says-downgraded-not-relate,Paul Quintaro,,,,0,0,2eb10dbe-f816-445f-85f8-f0bc01087428
2015-07-15T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equalweight,LLY,https://www.benzinga.com/news/15/07/5672850/morgan-stanley-downgrades-eli-lilly-to-equalweight,Hal Lindon,,,,0,0,88896b71-6b97-4a96-ace3-2e6b883edc53
2015-07-15T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/15/07/5673731/benzingas-top-downgrades,Lisa Levin,,,,0,0,1fbbee20-6d49-4405-9a1b-c69342206bae
2015-07-15T08:00:00.000+08:00,"Morgan Stanley Cuts Eli Lilly: Says Downgraded Not Related to Negative Call on Alzheimer's Data, Sees Current Share Price Factoring 'in pipelineenthusiasm for two blockbuster candidates:' Solanezumab, Evacetrapib",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5673474/morgan-stanley-cuts-eli-lilly-says-downgraded-not-relate,Paul Quintaro,,,,0,0,b6b63c25-5bb9-42ad-9f99-b087514966cd
2015-07-15T08:00:00.000+08:00,Morgan Stanley Downgrades Eli Lilly to Equalweight,LLY,https://www.benzinga.com/news/15/07/5672850/morgan-stanley-downgrades-eli-lilly-to-equalweight,Hal Lindon,,,,0,0,72116bbd-3fa6-4162-8033-3348342117f1
2015-07-13T08:00:00.000+08:00,Stocks Hitting 52-Week Highs,LLY,https://www.benzinga.com/news/15/07/5667030/stocks-hitting-52-week-highs,Lisa Levin,,,,0,0,e6a48f64-f369-47ad-9124-83a5952aff0d
2015-07-13T08:00:00.000+08:00,Stocks Hitting 52-Week Highs,LLY,https://www.benzinga.com/news/15/07/5667030/stocks-hitting-52-week-highs,Lisa Levin,,,,0,0,11039c9a-d581-4210-af4d-f9f1bca9a8a8
2015-07-09T08:00:00.000+08:00,"Eli Lilly Issues Statement Regarding FDA Panel Review of Necitumumab: 'Encouraged' by Committee's Constructuive Discussion, Working Closely with FDA to Continue Review",LLY,https://www.benzinga.com/news/15/07/5661905/eli-lilly-issues-statement-regarding-fda-panel-review-of-necitumumab-encouraged-b,Paul Quintaro,,,,0,0,c0e49926-ca67-417c-b0c6-1e898876bb11
2015-07-09T08:00:00.000+08:00,Fast Money Picks For July 9,LLY,https://www.benzinga.com/media/cnbc/15/07/5659284/fast-money-picks-for-july-9,Craig Jones,,,,0,0,50d89a31-132f-4643-8607-a0351821e5aa
2015-07-09T08:00:00.000+08:00,"Eli Lilly Issues Statement Regarding FDA Panel Review of Necitumumab: 'Encouraged' by Committee's Constructuive Discussion, Working Closely with FDA to Continue Review",LLY,https://www.benzinga.com/news/15/07/5661905/eli-lilly-issues-statement-regarding-fda-panel-review-of-necitumumab-encouraged-b,Paul Quintaro,,,,0,0,b9d92e7b-6497-4735-bff0-4d1a9651d334
2015-07-09T08:00:00.000+08:00,Fast Money Picks For July 9,LLY,https://www.benzinga.com/media/cnbc/15/07/5659284/fast-money-picks-for-july-9,Craig Jones,,,,0,0,217264df-d45d-4366-8975-f348e1373cb4
2015-07-07T08:00:00.000+08:00,Fast Money Picks For July 7,LLY,https://www.benzinga.com/media/cnbc/15/07/5651262/fast-money-picks-for-july-7,Craig Jones,,,,0,0,8827b004-7a1b-4eba-899a-b4f56fb17be1
2015-07-07T08:00:00.000+08:00,Fast Money Picks For July 7,LLY,https://www.benzinga.com/media/cnbc/15/07/5651262/fast-money-picks-for-july-7,Craig Jones,,,,0,0,78b1d103-b97f-442d-ba15-27abdca19971
2015-07-03T08:00:00.000+08:00,"AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5647375/aaic-is-coming-heres-what-to-expect-biogen-and-eli-lilly,Zoheb Sait,,,,0,0,766a4d90-526f-467e-a556-ee16fdb15582
2015-07-03T08:00:00.000+08:00,"AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5647375/aaic-is-coming-heres-what-to-expect-biogen-and-eli-lilly,Zoheb Sait,,,,0,0,a57ae61d-e774-4d69-8d8a-974c3ef629dc
2015-06-29T08:00:00.000+08:00,"Lilly, Immunocore Report Immunotherapy-based Clinical Trial Collaboration in Melanoma",LLY,https://www.benzinga.com/news/15/06/5631264/lilly-immunocore-report-immunotherapy-based-clinical-trial-collaboration-in-melan,Hal Lindon,,,,0,0,c12c0ec1-69b7-4d56-9d5c-8827a7593f61
2015-06-29T08:00:00.000+08:00,"Lilly, Immunocore Report Immunotherapy-based Clinical Trial Collaboration in Melanoma",LLY,https://www.benzinga.com/news/15/06/5631264/lilly-immunocore-report-immunotherapy-based-clinical-trial-collaboration-in-melan,Hal Lindon,,,,0,0,080d9f66-5c56-493a-bea2-84e121ca5b20
2015-06-25T08:00:00.000+08:00,Eli Lilly Shares Go Parabolic,LLY,https://www.benzinga.com/trading-ideas/technicals/15/06/5625001/eli-lilly-shares-go-parabolic,Joel Elconin,,,,0,0,96e047f6-eea2-43e4-bc58-3fa7929b9e7a
2015-06-25T08:00:00.000+08:00,Bank of America Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/15/06/5623660/bank-of-america-upgrades-eli-lilly-to-buy,Hal Lindon,,,,0,0,51f33bf9-1ca3-406b-9cd4-f0b986f0fa7b
2015-06-25T08:00:00.000+08:00,\Eli Lilly Announces UK Court Has Ruled in Favor of Co. in Alimta Vitamin Regimen Patent Suit,LLY,https://www.benzinga.com/news/15/06/5623532/eli-lilly-announces-uk-court-has-ruled-in-favor-of-co-in-alimta-vitamin-regimen-p,Paul Quintaro,,,,0,0,60f79290-308c-412f-8284-25141ea66120
2015-06-25T08:00:00.000+08:00,Eli Lilly Shares Go Parabolic,LLY,https://www.benzinga.com/trading-ideas/technicals/15/06/5625001/eli-lilly-shares-go-parabolic,Joel Elconin,,,,0,0,c52417ca-09cd-4729-ad21-b427581dcc25
2015-06-25T08:00:00.000+08:00,Bank of America Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/15/06/5623660/bank-of-america-upgrades-eli-lilly-to-buy,Hal Lindon,,,,0,0,efa500c0-3ad5-45be-8f08-3973a43a5ddc
2015-06-25T08:00:00.000+08:00,\Eli Lilly Announces UK Court Has Ruled in Favor of Co. in Alimta Vitamin Regimen Patent Suit,LLY,https://www.benzinga.com/news/15/06/5623532/eli-lilly-announces-uk-court-has-ruled-in-favor-of-co-in-alimta-vitamin-regimen-p,Paul Quintaro,,,,0,0,b830c806-7913-4276-95f3-96ce286b5c68
2015-06-24T08:00:00.000+08:00,"Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5621334/sales-of-this-eli-lilly-drug-could-nearly-double-wall-st,Jim Swanson,,,,0,0,8a6d19cb-90ea-4351-afa0-98de8adb586b
2015-06-24T08:00:00.000+08:00,"Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5621334/sales-of-this-eli-lilly-drug-could-nearly-double-wall-st,Jim Swanson,,,,0,0,fd23f859-8f32-4a0c-b94c-300e9eb942c2
2015-06-22T08:00:00.000+08:00,"Ken Langone's Top Stock Picks: Schlumberger, Eli Lilly And Facebook",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5612627/ken-langones-top-stock-picks-schlumberger-eli-lilly-and-,Ritesh Anan,,,,0,0,9f52b962-18d1-4385-9eed-03823ae46e7d
2015-06-22T08:00:00.000+08:00,"Ken Langone's Top Stock Picks: Schlumberger, Eli Lilly And Facebook",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5612627/ken-langones-top-stock-picks-schlumberger-eli-lilly-and-,Ritesh Anan,,,,0,0,f10a9810-701b-4dfc-96b9-cf5e3f07a366
2015-06-19T08:00:00.000+08:00,CYRAMZA Hepatocellular Carcinoma Data Published by The Lancet Oncology,LLY,https://www.benzinga.com/news/15/06/5608057/cyramza-hepatocellular-carcinoma-data-published-by-the-lancet-oncology,Hal Lindon,,,,0,0,d1bace50-ed38-4870-81a5-9b1f304f494d
2015-06-19T08:00:00.000+08:00,CYRAMZA Hepatocellular Carcinoma Data Published by The Lancet Oncology,LLY,https://www.benzinga.com/news/15/06/5608057/cyramza-hepatocellular-carcinoma-data-published-by-the-lancet-oncology,Hal Lindon,,,,0,0,a015a48b-62ce-4587-bb27-b19c9caf8c28
2015-06-18T08:00:00.000+08:00,Eli Lilly Price Target Hiked To $92 At Argus; Here's Why,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5606161/eli-lilly-price-target-hiked-to-92-at-argus-heres-why,Jim Swanson,,,,0,0,f0479d7e-84bd-44a8-b205-aa1a01ff6fe5
2015-06-18T08:00:00.000+08:00,Eli Lilly Price Target Hiked To $92 At Argus; Here's Why,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5606161/eli-lilly-price-target-hiked-to-92-at-argus-heres-why,Jim Swanson,,,,0,0,45712dce-e057-450f-b76c-bca26e4c23d5
2015-06-17T08:00:00.000+08:00,The Note Moving Pharma Giants Today,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5603207/the-note-moving-pharma-giants-today,John Seward,,,,0,0,78ccc54d-3238-41d6-9076-9a633ec7451c
2015-06-17T08:00:00.000+08:00,Lilly's investigational migraine prevention medicine met primary endpoint in a Phase 2b study,LLY,https://www.benzinga.com/news/15/06/5602740/lillys-investigational-migraine-prevention-medicine-met-primary-endpoint-in-a-pha,Hal Lindon,,,,0,0,a500c8a5-018e-418c-8fd8-21064250bf4c
2015-06-17T08:00:00.000+08:00,Benzinga's Top Initiations,LLY,https://www.benzinga.com/analyst-ratings/initiation/15/06/5602006/benzingas-top-initiations,Lisa Levin,,,,0,0,cb5c0e78-50f1-4b7b-a474-7c048951a405
2015-06-17T08:00:00.000+08:00,"Eli Lilly, Dana-Farber Announce Research Collaboration For New Medicines To Fight Cancer",LLY,https://www.benzinga.com/news/15/06/5601491/eli-lilly-dana-farber-announce-research-collaboration-for-new-medicines-to-fight-,Hal Lindon,,,,0,0,eba3de6e-cbe0-46f3-9bc0-344c5f8c01ca
2015-06-17T08:00:00.000+08:00,"Eli Lilly, Sara Cannon Research Institute Enter Collaboration To Develop Investigational Oncology Therapy",LLY,https://www.benzinga.com/news/15/06/5601453/eli-lilly-sara-cannon-research-institute-enter-collaboration-to-develop-investiga,Hal Lindon,,,,0,0,cb6c8ae8-9dcf-4050-971f-862514a646dd
2015-06-17T08:00:00.000+08:00,"Piper Jaffray Initiates Coverage on Eli Lilly at Overweight, Announces $97.00 PT",LLY,https://www.benzinga.com/news/15/06/5600995/piper-jaffray-initiates-coverage-on-eli-lilly-at-overweight-announces-97-00-pt,Eddie Staley,,,,0,0,fc71487b-efdf-4a65-943f-4bcd895ff7d4
2015-06-17T08:00:00.000+08:00,The Note Moving Pharma Giants Today,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5603207/the-note-moving-pharma-giants-today,John Seward,,,,0,0,d2043bea-ebac-4bfb-9c77-19b1a6b9667c
2015-06-17T08:00:00.000+08:00,Lilly's investigational migraine prevention medicine met primary endpoint in a Phase 2b study,LLY,https://www.benzinga.com/news/15/06/5602740/lillys-investigational-migraine-prevention-medicine-met-primary-endpoint-in-a-pha,Hal Lindon,,,,0,0,d939d923-cf8a-4dfd-8693-618e6f942f27
2015-06-17T08:00:00.000+08:00,Benzinga's Top Initiations,LLY,https://www.benzinga.com/analyst-ratings/initiation/15/06/5602006/benzingas-top-initiations,Lisa Levin,,,,0,0,b6dbdc54-256b-43c0-9d0e-b21e51ac5526
2015-06-17T08:00:00.000+08:00,"Eli Lilly, Dana-Farber Announce Research Collaboration For New Medicines To Fight Cancer",LLY,https://www.benzinga.com/news/15/06/5601491/eli-lilly-dana-farber-announce-research-collaboration-for-new-medicines-to-fight-,Hal Lindon,,,,0,0,44ea0898-cbca-4a68-b1b0-d1ca5ac0535b
2015-06-17T08:00:00.000+08:00,"Eli Lilly, Sara Cannon Research Institute Enter Collaboration To Develop Investigational Oncology Therapy",LLY,https://www.benzinga.com/news/15/06/5601453/eli-lilly-sara-cannon-research-institute-enter-collaboration-to-develop-investiga,Hal Lindon,,,,0,0,b5917c21-7c04-4676-a892-5ed1b8e6de0d
2015-06-17T08:00:00.000+08:00,"Piper Jaffray Initiates Coverage on Eli Lilly at Overweight, Announces $97.00 PT",LLY,https://www.benzinga.com/news/15/06/5600995/piper-jaffray-initiates-coverage-on-eli-lilly-at-overweight-announces-97-00-pt,Eddie Staley,,,,0,0,561db965-d450-476a-8df9-e7587832e6bd
2015-06-16T08:00:00.000+08:00,New Report: Abbvie Is Jefferies' Top Global Pharma Stock,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5599077/new-report-abbvie-is-jefferies-top-global-pharma-stock,Wayne Duggan,,,,0,0,5fccc51a-fe44-4947-be79-a3c811688b34
2015-06-16T08:00:00.000+08:00,New Report: Abbvie Is Jefferies' Top Global Pharma Stock,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5599077/new-report-abbvie-is-jefferies-top-global-pharma-stock,Wayne Duggan,,,,0,0,1be9bb10-a426-4d3a-9ffc-ef82caa64909
2015-06-12T08:00:00.000+08:00,UPDATE: Alzheimers Association Says Release of Data Under Embargo to Conference Participants Might have Influenced Lily Share Price,LLY,https://www.benzinga.com/news/15/06/5591696/update-alzheimers-association-says-release-of-data-under-embargo-to-conference-pa,Charles Gross,,,,0,0,149f039c-eed3-40c4-b655-d6be7a32dcb0
2015-06-12T08:00:00.000+08:00,Alzheimer's Group Says May Not Offer Early Look At Highly Sought Data On Lilly Drug -Reuters,LLY,https://www.benzinga.com/news/15/06/5591693/alzheimers-group-says-may-not-offer-early-look-at-highly-sought-data-on-lilly-dru,Charles Gross,,,,0,0,9afe5624-0fba-40ea-ba9b-6ddfd4ff5c46
2015-06-12T08:00:00.000+08:00,UPDATE: Alzheimers Association Says Release of Data Under Embargo to Conference Participants Might have Influenced Lily Share Price,LLY,https://www.benzinga.com/news/15/06/5591696/update-alzheimers-association-says-release-of-data-under-embargo-to-conference-pa,Charles Gross,,,,0,0,0d2e290f-1ffe-461d-b0c1-6f6d928d61bb
2015-06-12T08:00:00.000+08:00,Alzheimer's Group Says May Not Offer Early Look At Highly Sought Data On Lilly Drug -Reuters,LLY,https://www.benzinga.com/news/15/06/5591693/alzheimers-group-says-may-not-offer-early-look-at-highly-sought-data-on-lilly-dru,Charles Gross,,,,0,0,b7fe0bcf-261f-4aa4-8c7f-34fdc440c2df
2015-06-10T08:00:00.000+08:00,"Studies Report Psoriasis Patients Achieved Significant Levels of Skin Clearance, Improved Quality of Life after 12 Weeks of Ixekizumab Treatment",LLY,https://www.benzinga.com/news/15/06/5584295/studies-report-psoriasis-patients-achieved-significant-levels-of-skin-clearance-i,Paul Quintaro,,,,0,0,23e58c1f-0414-43fe-a167-7551de18ec08
2015-06-10T08:00:00.000+08:00,Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis,LLY,https://www.benzinga.com/news/15/06/5582938/lilly-and-incyte-unveil-detailed-data-on-two-pivotal-studies-of-baricitinib-in-rh,Eddie Staley,,,,0,0,40dddda0-663c-4400-bce7-4ae772c7a8f5
2015-06-10T08:00:00.000+08:00,Fast Money Picks For June 10,LLY,https://www.benzinga.com/media/cnbc/15/06/5582100/fast-money-picks-for-june-10,Craig Jones,,,,0,0,a5d9b6ee-964a-4b12-be93-c82eda3e7e8d
2015-06-10T08:00:00.000+08:00,"Studies Report Psoriasis Patients Achieved Significant Levels of Skin Clearance, Improved Quality of Life after 12 Weeks of Ixekizumab Treatment",LLY,https://www.benzinga.com/news/15/06/5584295/studies-report-psoriasis-patients-achieved-significant-levels-of-skin-clearance-i,Paul Quintaro,,,,0,0,f7fdd0c9-018a-48e9-836e-de47b738bd5a
2015-06-10T08:00:00.000+08:00,Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis,LLY,https://www.benzinga.com/news/15/06/5582938/lilly-and-incyte-unveil-detailed-data-on-two-pivotal-studies-of-baricitinib-in-rh,Eddie Staley,,,,0,0,986e522f-b44d-4110-8d7a-ac6c6ea30c5e
2015-06-10T08:00:00.000+08:00,Fast Money Picks For June 10,LLY,https://www.benzinga.com/media/cnbc/15/06/5582100/fast-money-picks-for-june-10,Craig Jones,,,,0,0,94cfb22e-2c0b-4ab6-a9e0-2269c15dc362
2015-06-09T08:00:00.000+08:00,Lily Shares Spike to All-Time High,LLY,https://www.benzinga.com/news/15/06/5581168/lily-shares-spike-to-all-time-high,Charles Gross,,,,0,0,5494855e-07e2-4dc1-8f06-795f6f632767
2015-06-09T08:00:00.000+08:00,Lily Shares Spike to High; Weekly Jun 12 $79.5 Call Active,LLY,https://www.benzinga.com/news/15/06/5580891/lily-shares-spike-to-high-weekly-jun-12-79-5-call-active,Charles Gross,,,,0,0,2b9f2b43-54ce-4206-9bef-15de8b70a0f8
2015-06-09T08:00:00.000+08:00,Lily Shares Spike to All-Time High,LLY,https://www.benzinga.com/news/15/06/5581168/lily-shares-spike-to-all-time-high,Charles Gross,,,,0,0,fcb53e93-8cb7-4d5a-8ae6-84dc6ae36967
2015-06-09T08:00:00.000+08:00,Lily Shares Spike to High; Weekly Jun 12 $79.5 Call Active,LLY,https://www.benzinga.com/news/15/06/5580891/lily-shares-spike-to-high-weekly-jun-12-79-5-call-active,Charles Gross,,,,0,0,0de17005-5fab-4b95-8a51-cc60dc0b330f
2015-06-08T08:00:00.000+08:00,"This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5576612/this-technology-could-disrupt-u-s-pharma-stocks-credit-s,John Seward,,,,0,0,356ab812-af5e-4004-a8f6-0d685d6e8b59
2015-06-08T08:00:00.000+08:00,New Data Show Enhanced Effects of Lilly's Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/06/5575490/new-data-show-enhanced-effects-of-lillys-once-weekly-trulicity-dulaglutide-to-lan,Hal Lindon,,,,0,0,a2322cc2-4c5e-4b37-8e7b-71861ce5ffde
2015-06-08T08:00:00.000+08:00,"This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5576612/this-technology-could-disrupt-u-s-pharma-stocks-credit-s,John Seward,,,,0,0,b4fb2476-eacc-4262-981c-3f78f3020c42
2015-06-08T08:00:00.000+08:00,New Data Show Enhanced Effects of Lilly's Once-Weekly Trulicity (dulaglutide) to Lantus (insulin glargine) in Patients with Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/06/5575490/new-data-show-enhanced-effects-of-lillys-once-weekly-trulicity-dulaglutide-to-lan,Hal Lindon,,,,0,0,188bf340-1a7e-4888-a2ef-c374b3025b96
2015-06-07T08:00:00.000+08:00,Lily Presents Study Indicating Once-Weekly Trulicity More Effective than Once-Daily Victoza in Japanese Patients after 52 Weeks,LLY,https://www.benzinga.com/news/15/06/5573876/lily-presents-study-indicating-once-weekly-trulicity-more-effective-than-once-dai,Charles Gross,,,,0,0,b66adbf6-36fd-4655-9928-146e149941a7
2015-06-07T08:00:00.000+08:00,Lilly's Basal Insulin Peglispro Shows Superiority to Glargine in Reducing HbA1c in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/06/5573869/lillys-basal-insulin-peglispro-shows-superiority-to-glargine-in-reducing-hba1c-in,Charles Gross,,,,0,0,06a0eb2e-aad0-420f-84eb-3e550d02af92
2015-06-07T08:00:00.000+08:00,Lilly's Basal Insulin Peglispro Studies Demonstrate Superiority to Glargine in People with Type 1 Diabetes,LLY,https://www.benzinga.com/news/15/06/5573867/lillys-basal-insulin-peglispro-studies-demonstrate-superiority-to-glargine-in-peo,Charles Gross,,,,0,0,7271d07e-146f-40eb-b473-0e7b7efce872
2015-06-07T08:00:00.000+08:00,Lily Presents Study Indicating Once-Weekly Trulicity More Effective than Once-Daily Victoza in Japanese Patients after 52 Weeks,LLY,https://www.benzinga.com/news/15/06/5573876/lily-presents-study-indicating-once-weekly-trulicity-more-effective-than-once-dai,Charles Gross,,,,0,0,6fc366c6-b4e0-4fdd-b467-a09cff05c049
2015-06-07T08:00:00.000+08:00,Lilly's Basal Insulin Peglispro Shows Superiority to Glargine in Reducing HbA1c in People with Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/06/5573869/lillys-basal-insulin-peglispro-shows-superiority-to-glargine-in-reducing-hba1c-in,Charles Gross,,,,0,0,248ebb60-f3b6-4fe4-bd82-4dbcdc8d3c8a
2015-06-07T08:00:00.000+08:00,Lilly's Basal Insulin Peglispro Studies Demonstrate Superiority to Glargine in People with Type 1 Diabetes,LLY,https://www.benzinga.com/news/15/06/5573867/lillys-basal-insulin-peglispro-studies-demonstrate-superiority-to-glargine-in-peo,Charles Gross,,,,0,0,24ae536f-2e71-4965-b379-f034c44b5809
2015-06-04T08:00:00.000+08:00,Lilly to Report Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology,LLY,https://www.benzinga.com/news/15/06/5568186/lilly-to-report-pivotal-phase-3-study-results-for-investigational-psoriasis-treat,Hal Lindon,,,,0,0,37788992-6e75-48c4-8f8e-f5be9be96eca
2015-06-04T08:00:00.000+08:00,Lilly to Report Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology,LLY,https://www.benzinga.com/news/15/06/5568186/lilly-to-report-pivotal-phase-3-study-results-for-investigational-psoriasis-treat,Hal Lindon,,,,0,0,65f727b5-65fb-4d82-b157-025cda1ef445
2015-06-01T08:00:00.000+08:00,16 Biotech Stocks Moving Off The ASCO Conference,LLY,https://www.benzinga.com/general/biotech/15/06/5557758/16-biotech-stocks-moving-off-the-asco-conference,Javier Hasse,,,,0,0,aa35f841-4995-4d7f-b7cb-dce309ded7c5
2015-06-01T08:00:00.000+08:00,16 Biotech Stocks Moving Off The ASCO Conference,LLY,https://www.benzinga.com/general/biotech/15/06/5557758/16-biotech-stocks-moving-off-the-asco-conference,Javier Hasse,,,,0,0,bcd23fd0-0c74-44b2-9fde-0b64f8702315
2015-05-29T08:00:00.000+08:00,"Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors",LLY,https://www.benzinga.com/news/15/05/5551419/lilly-astrazeneca-to-partner-on-immuno-oncology-combination-clinical-trial-in-sol,Hal Lindon,,,,0,0,6845b0dc-7635-4da3-ac69-c1562aa4b5f9
2015-05-29T08:00:00.000+08:00,"Lilly, AstraZeneca to Partner on Immuno-Oncology Combination Clinical Trial in Solid Tumors",LLY,https://www.benzinga.com/news/15/05/5551419/lilly-astrazeneca-to-partner-on-immuno-oncology-combination-clinical-trial-in-sol,Hal Lindon,,,,0,0,6bca1a0e-99f9-42ac-bb6f-a99e175bdcf6
2015-05-28T08:00:00.000+08:00,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data,LLY,https://www.benzinga.com/news/15/05/5548917/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-iii-data,Paul Quintaro,,,,0,0,71b0f4df-2f60-4229-898f-a1db8fe8204e
2015-05-28T08:00:00.000+08:00,Eli Lilly Reports Results Of Cash Tender Offer,LLY,https://www.benzinga.com/news/15/05/5547402/eli-lilly-reports-results-of-cash-tender-offer,Hal Lindon,,,,0,0,86458945-18e1-48d8-b9a1-f8c1145007b8
2015-05-28T08:00:00.000+08:00,Eli Lilly Reports Will Present CYRAMZA Data at ASCO Meeting: Will Submit to Japanese Regulatory Authorities,LLY,https://www.benzinga.com/news/15/05/5547396/eli-lilly-reports-will-present-cyramza-data-at-asco-meeting-will-submit-to-japane,Paul Quintaro,,,,0,0,cb5f0095-bedf-43c7-9ac9-68d895902525
2015-05-28T08:00:00.000+08:00,Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data,LLY,https://www.benzinga.com/news/15/05/5548917/lilly-and-incyte-announce-webcast-to-discuss-baricitinib-phase-iii-data,Paul Quintaro,,,,0,0,d22dcd4e-d9b0-402a-9fef-5f9ffc7af2ed
2015-05-28T08:00:00.000+08:00,Eli Lilly Reports Results Of Cash Tender Offer,LLY,https://www.benzinga.com/news/15/05/5547402/eli-lilly-reports-results-of-cash-tender-offer,Hal Lindon,,,,0,0,1948532a-2994-4e65-a3ab-c2c7fef8af52
2015-05-28T08:00:00.000+08:00,Eli Lilly Reports Will Present CYRAMZA Data at ASCO Meeting: Will Submit to Japanese Regulatory Authorities,LLY,https://www.benzinga.com/news/15/05/5547396/eli-lilly-reports-will-present-cyramza-data-at-asco-meeting-will-submit-to-japane,Paul Quintaro,,,,0,0,59b60e61-32da-4fe1-bd0d-9869b943be98
2015-05-27T08:00:00.000+08:00,Eli Lilly Announces FDA Approves Humalog,LLY,https://www.benzinga.com/news/15/05/5543248/eli-lilly-announces-fda-approves-humalog,Hal Lindon,,,,0,0,e716fdc3-eaf9-4341-8160-516526b6a89c
2015-05-27T08:00:00.000+08:00,Lilly to Present New Clinical Data at 75th American Diabetes Association Scientific Sessions,LLY,https://www.benzinga.com/news/15/05/5542840/lilly-to-present-new-clinical-data-at-75th-american-diabetes-association-scientif,Eddie Staley,,,,0,0,bde3b79b-6a8c-4bc6-bc75-a8b1e3606471
2015-05-27T08:00:00.000+08:00,Eli Lilly Announces FDA Approves Humalog,LLY,https://www.benzinga.com/news/15/05/5543248/eli-lilly-announces-fda-approves-humalog,Hal Lindon,,,,0,0,b5c46841-8b23-41f6-a556-66414d64fc96
2015-05-27T08:00:00.000+08:00,Lilly to Present New Clinical Data at 75th American Diabetes Association Scientific Sessions,LLY,https://www.benzinga.com/news/15/05/5542840/lilly-to-present-new-clinical-data-at-75th-american-diabetes-association-scientif,Eddie Staley,,,,0,0,7c132ec6-81ec-4a61-b4dd-4c5071cfcaa9
2015-05-14T08:00:00.000+08:00,"Lilly, Sanford-Burnham Collaborate to Investigate Immunological Therapies",LLY,https://www.benzinga.com/news/15/05/5509634/lilly-sanford-burnham-collaborate-to-investigate-immunological-therapies,Charles Gross,,,,0,0,2f7caeed-7954-470a-ae38-8c4636f0a66b
2015-05-14T08:00:00.000+08:00,"Lilly, Sanford-Burnham Collaborate to Investigate Immunological Therapies",LLY,https://www.benzinga.com/news/15/05/5509634/lilly-sanford-burnham-collaborate-to-investigate-immunological-therapies,Charles Gross,,,,0,0,efd9d5d4-2fc9-4ef9-9917-d2145cdb3938
2015-05-12T08:00:00.000+08:00,Lilly Announces Cash Tender Offer for Up to $1.6Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016,LLY,https://www.benzinga.com/news/15/05/5501447/lilly-announces-cash-tender-offer-for-up-to-1-6aggregate-principal-amount-of-its-,Eddie Staley,,,,0,0,1a1b6a9f-87e1-4a81-94d2-199cd6ba3d78
2015-05-12T08:00:00.000+08:00,Lilly Announces Cash Tender Offer for Up to $1.6Aggregate Principal Amount of Its Outstanding Debt Securities and the Redemption of Its 6.57% Notes due 2016,LLY,https://www.benzinga.com/news/15/05/5501447/lilly-announces-cash-tender-offer-for-up-to-1-6aggregate-principal-amount-of-its-,Eddie Staley,,,,0,0,45cda4eb-2567-44fa-8a98-4565b61979ee
2015-05-11T08:00:00.000+08:00,"Lilly, BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies",LLY,https://www.benzinga.com/news/15/05/5498678/lilly-biontech-announce-research-collaboration-on-novel-cancer-immunotherapies,Charles Gross,,,,0,0,c66d7147-dfc3-4b04-bf39-abf1891c0d5a
2015-05-11T08:00:00.000+08:00,"Lilly, BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies",LLY,https://www.benzinga.com/news/15/05/5498678/lilly-biontech-announce-research-collaboration-on-novel-cancer-immunotherapies,Charles Gross,,,,0,0,72bc89eb-b121-449f-b91d-cc1583a48445
2015-05-05T08:00:00.000+08:00,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/05/5476290/credit-suisse-we-prefer-pfizer-bristol-over-pharma-peers,Mark Meadows,,,,0,0,190aa129-e9d7-416b-9195-2cea0621059f
2015-05-05T08:00:00.000+08:00,"Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/05/5476290/credit-suisse-we-prefer-pfizer-bristol-over-pharma-peers,Mark Meadows,,,,0,0,6cf1eb36-f0b7-48a2-a5f5-0eea6342ad2a
2015-05-01T08:00:00.000+08:00,Shares Of Lilly Spike Lower Momentarily To $71.25 Before Rebounding To $73,LLY,https://www.benzinga.com/news/15/05/5468614/shares-of-lilly-spike-lower-momentarily-to-71-25-before-rebounding-to-73,Paul Quintaro,,,,0,0,e168963f-f940-4e7a-b7f1-a1d4e15e9b9b
2015-05-01T08:00:00.000+08:00,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly,LLY,https://www.benzinga.com/news/15/05/5467343/hearing-unconfirmed-market-chatter-of-potential-merck-bid-for-lilly,Charles Gross,,,,0,0,d3e3ef72-4a57-4a41-924e-dd2f31dbe9cd
2015-05-01T08:00:00.000+08:00,Shares Of Lilly Spike Lower Momentarily To $71.25 Before Rebounding To $73,LLY,https://www.benzinga.com/news/15/05/5468614/shares-of-lilly-spike-lower-momentarily-to-71-25-before-rebounding-to-73,Paul Quintaro,,,,0,0,7e066ca1-18d9-44ae-a744-6d8a54fe27ae
2015-05-01T08:00:00.000+08:00,Hearing Unconfirmed Market Chatter of Potential Merck Bid for Lilly,LLY,https://www.benzinga.com/news/15/05/5467343/hearing-unconfirmed-market-chatter-of-potential-merck-bid-for-lilly,Charles Gross,,,,0,0,01b2ba19-b413-4598-9e38-51a0bbc6224e
2015-04-29T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/04/5456013/benzingas-top-upgrades,Lisa Levin,,,,0,0,e1c54b82-5e25-4ef3-b694-1c6146d6a770
2015-04-29T08:00:00.000+08:00,Citigroup Upgrades Eli Lilly To Buy,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/04/5455619/citigroup-upgrades-eli-lilly-to-buy,Monica Gerson,,,,0,0,fa63d368-2f58-4eb9-a8e6-e7415ad6174f
2015-04-29T08:00:00.000+08:00,IPO Outlook: CoLucid Offers Hope For Migraine Sufferers,LLY,https://www.benzinga.com/general/biotech/15/04/5451948/ipo-outlook-colucid-offers-hope-for-migraine-sufferers,Charles Enser,,,,0,0,576ef5bb-8252-4dc9-8f53-f5e18750c6d9
2015-04-29T08:00:00.000+08:00,Citigroup Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/15/04/5454745/citigroup-upgrades-eli-lilly-to-buy,Hal Lindon,,,,0,0,cd331644-1226-4fc0-b453-1742f0fd300f
2015-04-29T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/04/5456013/benzingas-top-upgrades,Lisa Levin,,,,0,0,bf7ddecf-da65-4ecc-a61e-f1697ff8690b
2015-04-29T08:00:00.000+08:00,Citigroup Upgrades Eli Lilly To Buy,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/04/5455619/citigroup-upgrades-eli-lilly-to-buy,Monica Gerson,,,,0,0,13f7e630-06a5-420a-adff-7827d874d7a6
2015-04-29T08:00:00.000+08:00,IPO Outlook: CoLucid Offers Hope For Migraine Sufferers,LLY,https://www.benzinga.com/general/biotech/15/04/5451948/ipo-outlook-colucid-offers-hope-for-migraine-sufferers,Charles Enser,,,,0,0,3f1bb87c-95c9-476f-9843-8d96b3949ee6
2015-04-29T08:00:00.000+08:00,Citigroup Upgrades Eli Lilly to Buy,LLY,https://www.benzinga.com/news/15/04/5454745/citigroup-upgrades-eli-lilly-to-buy,Hal Lindon,,,,0,0,1f3faaa3-02ca-4073-bb59-1fc5548fc209
2015-04-28T08:00:00.000+08:00,BofA Sees Many Catalysts On Eli Lilly's Horizon,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5453175/bofa-sees-many-catalysts-on-eli-lillys-horizon,Monica Gerson,,,,0,0,3432622c-eea0-4fb8-8df7-6e82dd2760ba
2015-04-28T08:00:00.000+08:00,BofA Sees Many Catalysts On Eli Lilly's Horizon,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5453175/bofa-sees-many-catalysts-on-eli-lillys-horizon,Monica Gerson,,,,0,0,e9806a13-ac23-43f7-b4b7-87c7b0f3d1c2
2015-04-24T08:00:00.000+08:00,Lilly's CYRAMZA Receives Approval For Use With FOLFIRI In Second-Line Treatment Of Metastatic Colorectal Cancer,LLY,https://www.benzinga.com/news/15/04/5442461/lillys-cyramza-receives-approval-for-use-with-folfiri-in-second-line-treatment-of,Paul Quintaro,,,,0,0,79b95145-196c-475a-8501-408e81a27690
2015-04-24T08:00:00.000+08:00,Eli Lilly CFO: Solid Underlying Performance Despite FX Headwind,LLY,https://www.benzinga.com/media/cnbc/15/04/5438000/eli-lilly-cfo-solid-underlying-performance-despite-fx-headwind,Ritesh Anan,,,,0,0,06754ca5-7685-446b-ad74-6cc0aa5111d2
2015-04-24T08:00:00.000+08:00,BMO's Updated Eli Lilly Model Following Earnings,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5441265/bmos-updated-eli-lilly-model-following-earnings,Javier Hasse,,,,0,0,89e562d9-321a-42ae-9ecc-d0d07a2457fc
2015-04-24T08:00:00.000+08:00,Lilly's CYRAMZA Receives Approval For Use With FOLFIRI In Second-Line Treatment Of Metastatic Colorectal Cancer,LLY,https://www.benzinga.com/news/15/04/5442461/lillys-cyramza-receives-approval-for-use-with-folfiri-in-second-line-treatment-of,Paul Quintaro,,,,0,0,7740ed86-64b9-45c9-96ba-2e18c0512c0b
2015-04-24T08:00:00.000+08:00,Eli Lilly CFO: Solid Underlying Performance Despite FX Headwind,LLY,https://www.benzinga.com/media/cnbc/15/04/5438000/eli-lilly-cfo-solid-underlying-performance-despite-fx-headwind,Ritesh Anan,,,,0,0,0add9186-0d48-4fc5-839f-f4ad3043d960
2015-04-24T08:00:00.000+08:00,BMO's Updated Eli Lilly Model Following Earnings,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5441265/bmos-updated-eli-lilly-model-following-earnings,Javier Hasse,,,,0,0,8f1878b6-8b04-4d01-b1af-2a6d9adb80a1
2015-04-23T08:00:00.000+08:00,"US Stock Futures Down Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/15/04/5435801/us-stock-futures-down-ahead-of-earnings-economic-data,Monica Gerson,,,,0,0,3c136d3a-67e8-4bcf-abf6-920d4b19fd95
2015-04-23T08:00:00.000+08:00,Eli Lilly Tops Q1 Views,LLY,https://www.benzinga.com/news/earnings/15/04/5435387/eli-lilly-tops-q1-views,Monica Gerson,,,,0,0,2d4efe8d-e972-4be9-8fa6-ee88eca1a65e
2015-04-23T08:00:00.000+08:00,Lilly Q1 EPS $4.65B vs $4.62B est,LLY,https://www.benzinga.com/news/15/04/5435084/lilly-q1-eps-4-65b-vs-4-62b-est,Paul Quintaro,,,,0,0,e0370c0f-5e6a-4ec3-8f47-cbcb4235763f
2015-04-23T08:00:00.000+08:00,Lilly Confirms FY Guidance,LLY,https://www.benzinga.com/news/15/04/5435081/lilly-confirms-fy-guidance,Paul Quintaro,,,,0,0,4309382e-e9b4-4fd8-8584-d749323acfc2
2015-04-23T08:00:00.000+08:00,Lilly Q1 EPS $0.87 vs $0.77 est,LLY,https://www.benzinga.com/news/earnings/15/04/5435079/lilly-q1-eps-0-87-vs-0-77-est,Paul Quintaro,,,,0,0,4dd7e2cb-5840-4f1d-9957-3081574d07c0
2015-04-23T08:00:00.000+08:00,"Earnings Scheduled For April 23, 2015",LLY,https://www.benzinga.com/news/earnings/15/04/5434811/earnings-scheduled-for-april-23-2015,Monica Gerson,,,,0,0,aeb877e3-d10a-4b0b-8ed4-195b54f064f3
2015-04-23T08:00:00.000+08:00,"US Stock Futures Down Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/15/04/5435801/us-stock-futures-down-ahead-of-earnings-economic-data,Monica Gerson,,,,0,0,90e3a1af-7f1c-48ae-b26b-f984053ef19a
2015-04-23T08:00:00.000+08:00,Eli Lilly Tops Q1 Views,LLY,https://www.benzinga.com/news/earnings/15/04/5435387/eli-lilly-tops-q1-views,Monica Gerson,,,,0,0,afe0e0bb-21cf-4c24-9bd3-b54959543902
2015-04-23T08:00:00.000+08:00,Lilly Q1 EPS $4.65B vs $4.62B est,LLY,https://www.benzinga.com/news/15/04/5435084/lilly-q1-eps-4-65b-vs-4-62b-est,Paul Quintaro,,,,0,0,43315814-6c02-4527-9227-6cd240ef0ce9
2015-04-23T08:00:00.000+08:00,Lilly Confirms FY Guidance,LLY,https://www.benzinga.com/news/15/04/5435081/lilly-confirms-fy-guidance,Paul Quintaro,,,,0,0,5199ea13-0d71-437f-aaae-d69a799655ec
2015-04-23T08:00:00.000+08:00,Lilly Q1 EPS $0.87 vs $0.77 est,LLY,https://www.benzinga.com/news/earnings/15/04/5435079/lilly-q1-eps-0-87-vs-0-77-est,Paul Quintaro,,,,0,0,9f1e80bc-3738-4327-8d7c-8871c61a67d1
2015-04-23T08:00:00.000+08:00,"Earnings Scheduled For April 23, 2015",LLY,https://www.benzinga.com/news/earnings/15/04/5434811/earnings-scheduled-for-april-23-2015,Monica Gerson,,,,0,0,b55c2b4b-c43c-468a-8800-dd5a549d6292
2015-04-22T08:00:00.000+08:00,Eli Lilly Partner Deciphera Pharma Announces Data Highlighting Kinase Inhibitor Pipeline at AACR Meeting,LLY,https://www.benzinga.com/news/15/04/5430900/eli-lilly-partner-deciphera-pharma-announces-data-highlighting-kinase-inhibitor-p,Paul Quintaro,,,,0,0,44691054-b0e1-4ebc-9cbf-dc589558a13c
2015-04-22T08:00:00.000+08:00,Eli Lilly Partner Deciphera Pharma Announces Data Highlighting Kinase Inhibitor Pipeline at AACR Meeting,LLY,https://www.benzinga.com/news/15/04/5430900/eli-lilly-partner-deciphera-pharma-announces-data-highlighting-kinase-inhibitor-p,Paul Quintaro,,,,0,0,04813708-9d6b-49cc-aa3d-898be058b9bb
2015-04-20T08:00:00.000+08:00,Lilly's Ixekizumab Meets Primary Endpoint in a Phase 3 Study Investigating Treatment of Psoriatic Arthritis,LLY,https://www.benzinga.com/news/15/04/5421562/lillys-ixekizumab-meets-primary-endpoint-in-a-phase-3-study-investigating-treatme,Hal Lindon,,,,0,0,47d2d60a-0c39-4d6a-a8ff-d34d96c032ca
2015-04-20T08:00:00.000+08:00,Lilly's Ixekizumab Meets Primary Endpoint in a Phase 3 Study Investigating Treatment of Psoriatic Arthritis,LLY,https://www.benzinga.com/news/15/04/5421562/lillys-ixekizumab-meets-primary-endpoint-in-a-phase-3-study-investigating-treatme,Hal Lindon,,,,0,0,da6a2aa0-96a6-4b16-9cea-4cf60fd3359f
2015-04-16T08:00:00.000+08:00,"Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales",LLY,https://www.benzinga.com/news/15/04/5415298/lilly-bristol-myers-squibb-restructure-erbitux-pact-in-north-america-lilly-gets-f,Paul Quintaro,,,,0,0,c28e52d2-4cdf-4b04-b731-d90b85102d2a
2015-04-16T08:00:00.000+08:00,"Lilly, Bristol-Myers Squibb Restructure Erbitux Pact In North America; Lilly Gets Full Commercialization Rights While Bristol-Myers Gets Tiered Royalties On Product Sales",LLY,https://www.benzinga.com/news/15/04/5415298/lilly-bristol-myers-squibb-restructure-erbitux-pact-in-north-america-lilly-gets-f,Paul Quintaro,,,,0,0,1e5f80a7-7fa9-4cbc-8d55-f383918f62e4
2015-04-15T08:00:00.000+08:00,SunTrust's Latest Comments On Merck,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5411600/suntrusts-latest-comments-on-merck,Jayson Derrick,,,,0,0,e15a08d8-8100-4b5d-9f07-f62792a68ff7
2015-04-15T08:00:00.000+08:00,SunTrust's Latest Comments On Merck,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5411600/suntrusts-latest-comments-on-merck,Jayson Derrick,,,,0,0,db9dad40-b658-4a52-9274-b43bb7cd9a48
2015-04-14T08:00:00.000+08:00,Morgan Stanley's Major Pharma Q1 Preview,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5407829/morgan-stanleys-major-pharma-q1-preview,Kevin Riley,,,,0,0,8f903df3-0205-4869-abfa-cdf71330dc71
2015-04-14T08:00:00.000+08:00,Morgan Stanley's Major Pharma Q1 Preview,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5407829/morgan-stanleys-major-pharma-q1-preview,Kevin Riley,,,,0,0,6e18de90-a86f-488f-8b69-f24905021601
2015-04-13T08:00:00.000+08:00,7 Trends Drug Investors Should Know,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5403186/7-trends-drug-investors-should-know,John Seward,,,,0,0,36c796b7-7306-4d35-854f-7b4a0f752b18
2015-04-13T08:00:00.000+08:00,7 Trends Drug Investors Should Know,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5403186/7-trends-drug-investors-should-know,John Seward,,,,0,0,fb75c7b7-3ed8-4509-ad67-239ce1c111c0
2015-04-01T08:00:00.000+08:00,8 Companies That Are Fighting Indiana's 'Religious Freedom' Law,LLY,https://www.benzinga.com/news/15/04/5374706/8-companies-that-are-fighting-indianas-religious-freedom-law,Laura Brodbeck,,,,0,0,9e730272-db27-4214-91a2-1de274769d0e
2015-04-01T08:00:00.000+08:00,8 Companies That Are Fighting Indiana's 'Religious Freedom' Law,LLY,https://www.benzinga.com/news/15/04/5374706/8-companies-that-are-fighting-indianas-religious-freedom-law,Laura Brodbeck,,,,0,0,09d73bbc-bc75-4306-ad57-85971d1119d0
2015-03-27T08:00:00.000+08:00,"EMA Recommends Approval of Eli Lilly, Boehringer Ingelheim's Empagliflozin Plus Metformin",LLY,https://www.benzinga.com/news/15/03/5362511/ema-recommends-approval-of-eli-lilly-boehringer-ingelheims-empagliflozin-plus-met,Charles Gross,,,,0,0,7eef48d8-f7df-4b53-8091-3515ad9c2b97
2015-03-27T08:00:00.000+08:00,"EMA Recommends Approval of Eli Lilly, Boehringer Ingelheim's Empagliflozin Plus Metformin",LLY,https://www.benzinga.com/news/15/03/5362511/ema-recommends-approval-of-eli-lilly-boehringer-ingelheims-empagliflozin-plus-met,Charles Gross,,,,0,0,42a70700-4d74-4945-bdbd-6f75878a1513
2015-03-23T08:00:00.000+08:00,Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5349889/analyst-heres-why-eli-lilly-is-worth-more-than-it-used-t,Monica Gerson,,,,0,0,70401384-6141-4362-be34-9c566aa9d544
2015-03-23T08:00:00.000+08:00,"FDA Concludes 2 Year Zyprexa Relprevv Review Of Two Deaths Related To Schizophrenia Drug, FDA Says No New Warnings Needed",LLY,https://www.benzinga.com/news/15/03/5349188/fda-concludes-2-year-zyprexa-relprevv-review-of-two-deaths-related-to-schizophren,Paul Quintaro,,,,0,0,f4bab6ff-227d-4923-a6a6-8dfe679672fd
2015-03-23T08:00:00.000+08:00,"Pfizer, Lilly To Resume Phase 3 Chronic Pain Program For Tanezumab",LLY,https://www.benzinga.com/news/15/03/5348944/pfizer-lilly-to-resume-phase-3-chronic-pain-program-for-tanezumab,Paul Quintaro,,,,0,0,e2a259f6-a78f-4c5c-a746-ecf197b2a1c1
2015-03-23T08:00:00.000+08:00,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5348881/suntrust-names-eli-lilly-merck-bristol-myers-as-favorite,Mark Meadows,,,,0,0,1ba2a291-fd45-45b5-938b-ebee06dabbe7
2015-03-23T08:00:00.000+08:00,"Pfizer, Eli Lilly Announce Preparing of Resumption for Phase 3 Chronic Pain Program for Tanezumab",LLY,https://www.benzinga.com/news/15/03/5347402/pfizer-eli-lilly-announce-preparing-of-resumption-for-phase-3-chronic-pain-progra,Paul Quintaro,,,,0,0,cd218734-6547-49f5-b6f5-e4734ae659f8
2015-03-23T08:00:00.000+08:00,Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5349889/analyst-heres-why-eli-lilly-is-worth-more-than-it-used-t,Monica Gerson,,,,0,0,55a6e2c3-0d3b-4c33-9006-f5442fc2a140
2015-03-23T08:00:00.000+08:00,"FDA Concludes 2 Year Zyprexa Relprevv Review Of Two Deaths Related To Schizophrenia Drug, FDA Says No New Warnings Needed",LLY,https://www.benzinga.com/news/15/03/5349188/fda-concludes-2-year-zyprexa-relprevv-review-of-two-deaths-related-to-schizophren,Paul Quintaro,,,,0,0,25eba5da-9856-4828-af87-69f2b93d23ad
2015-03-23T08:00:00.000+08:00,"Pfizer, Lilly To Resume Phase 3 Chronic Pain Program For Tanezumab",LLY,https://www.benzinga.com/news/15/03/5348944/pfizer-lilly-to-resume-phase-3-chronic-pain-program-for-tanezumab,Paul Quintaro,,,,0,0,0e7f3fbe-64fe-4f74-be89-5c5899179741
2015-03-23T08:00:00.000+08:00,"SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5348881/suntrust-names-eli-lilly-merck-bristol-myers-as-favorite,Mark Meadows,,,,0,0,e9382d66-8ed4-43a3-b81f-de52144d966e
2015-03-23T08:00:00.000+08:00,"Pfizer, Eli Lilly Announce Preparing of Resumption for Phase 3 Chronic Pain Program for Tanezumab",LLY,https://www.benzinga.com/news/15/03/5347402/pfizer-eli-lilly-announce-preparing-of-resumption-for-phase-3-chronic-pain-progra,Paul Quintaro,,,,0,0,51f0cd92-5b67-41d6-8530-165a63f097c0
2015-03-20T08:00:00.000+08:00,Eli Lilly Just Unveiled A Major Biotech Collaboration In China,LLY,https://www.benzinga.com/general/biotech/15/03/5344535/eli-lilly-just-unveiled-a-major-biotech-collaboration-in-china,John Seward,,,,0,0,98abc735-e248-4d5d-9a05-1e7d8d290e8e
2015-03-20T08:00:00.000+08:00,"UPDATE: Lilly Says Innovent Will Get Upfront Payment of $56M, Could Get Future Payments $400M+",LLY,https://www.benzinga.com/news/15/03/5343870/update-lilly-says-innovent-will-get-upfront-payment-of-56m-could-get-future-payme,Paul Quintaro,,,,0,0,c9d433cf-e2d1-4ee4-9b6c-4fb09aaeca2a
2015-03-20T08:00:00.000+08:00,Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World,LLY,https://www.benzinga.com/news/15/03/5343861/lilly-and-innovent-biologics-announce-a-strategic-alliance-to-bring-potential-onc,Eddie Staley,,,,0,0,51cef08c-bd2d-4ece-821d-c3d4f27cf1d2
2015-03-20T08:00:00.000+08:00,Eli Lilly Just Unveiled A Major Biotech Collaboration In China,LLY,https://www.benzinga.com/general/biotech/15/03/5344535/eli-lilly-just-unveiled-a-major-biotech-collaboration-in-china,John Seward,,,,0,0,58abcddd-2a87-414d-a294-642033b2d947
2015-03-20T08:00:00.000+08:00,"UPDATE: Lilly Says Innovent Will Get Upfront Payment of $56M, Could Get Future Payments $400M+",LLY,https://www.benzinga.com/news/15/03/5343870/update-lilly-says-innovent-will-get-upfront-payment-of-56m-could-get-future-payme,Paul Quintaro,,,,0,0,8d8d6877-4ded-40ad-a4a3-6219482e4d55
2015-03-20T08:00:00.000+08:00,Lilly and Innovent Biologics Announce a Strategic Alliance to Bring Potential Oncology Therapies to Patients in China and Around the World,LLY,https://www.benzinga.com/news/15/03/5343861/lilly-and-innovent-biologics-announce-a-strategic-alliance-to-bring-potential-onc,Eddie Staley,,,,0,0,0ca753a9-3c81-45c2-a5bd-a4594b48d68f
2015-03-19T08:00:00.000+08:00,"Eli Lilly, Hanmi Report Exclusive License Deal for Development, Commercialization of Immunological Therapy",LLY,https://www.benzinga.com/news/15/03/5340194/eli-lilly-hanmi-report-exclusive-license-deal-for-development-commercialization-o,Paul Quintaro,,,,0,0,fef05612-8dd1-4e88-84a5-96429794d041
2015-03-19T08:00:00.000+08:00,"Eli Lilly, Hanmi Report Exclusive License Deal for Development, Commercialization of Immunological Therapy",LLY,https://www.benzinga.com/news/15/03/5340194/eli-lilly-hanmi-report-exclusive-license-deal-for-development-commercialization-o,Paul Quintaro,,,,0,0,e811944c-bb6c-48a7-af9e-8679848968f2
2015-03-10T08:00:00.000+08:00,8 Healthcare Names Cowen & Co Are Talking About,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5315206/8-healthcare-names-cowen-co-are-talking-about,Monica Gerson,,,,0,0,7e876aa3-14c6-4e3a-80c9-fcece91a9352
2015-03-10T08:00:00.000+08:00,8 Healthcare Names Cowen & Co Are Talking About,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5315206/8-healthcare-names-cowen-co-are-talking-about,Monica Gerson,,,,0,0,470bfcb9-293f-4f6e-9306-6f9c32797bcd
2015-03-06T08:00:00.000+08:00,German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/15/03/5304800/german-court-rules-against-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Eddie Staley,,,,0,0,3f7eb351-e88f-443d-8191-dc5e55cd61d2
2015-03-06T08:00:00.000+08:00,German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit,LLY,https://www.benzinga.com/news/15/03/5304800/german-court-rules-against-lilly-in-alimta-vitamin-regimen-patent-lawsuit,Eddie Staley,,,,0,0,4d38046b-f909-430d-b061-32efd91ddb2c
2015-03-03T08:00:00.000+08:00,Denovo Biopharma Announces It Has Exclusively Licensed Pomaglumetad Methionil From Eli Lily & Co.,LLY,https://www.benzinga.com/general/biotech/15/03/5292109/denovo-biopharma-announces-it-has-exclusively-licensed-pomaglumetad-me,Hal Lindon,,,,0,0,a3cc7170-d60a-414e-831e-24bedda7bd6e
2015-03-03T08:00:00.000+08:00,Denovo Biopharma Announces It Has Exclusively Licensed Pomaglumetad Methionil From Eli Lily & Co.,LLY,https://www.benzinga.com/general/biotech/15/03/5292109/denovo-biopharma-announces-it-has-exclusively-licensed-pomaglumetad-me,Hal Lindon,,,,0,0,e6576d78-0a74-49db-8208-25125051552d
2015-02-23T08:00:00.000+08:00,5 'Key Pipeline Catalysts' To Watch At Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/02/5266196/5-key-pipeline-catalysts-to-watch-at-eli-lilly,Monica Gerson,,,,0,0,bd3bfdd8-342a-45cc-9322-e7f70ab99305
2015-02-23T08:00:00.000+08:00,Lilly Announces Delay In Submission For Basal Insulin Peglispro To Regulatory Agencies,LLY,https://www.benzinga.com/news/15/02/5263752/lilly-announces-delay-in-submission-for-basal-insulin-peglispro-to-regulatory-age,Hal Lindon,,,,0,0,8c45504f-202a-4992-b3a1-b8f2960cbfd5
2015-02-23T08:00:00.000+08:00,Eli Lilly Reports Delay on Regulatory Submission Timing for Basal Insulin Peglispro,LLY,https://www.benzinga.com/news/15/02/5263713/eli-lilly-reports-delay-on-regulatory-submission-timing-for-basal-insulin-peglisp,Paul Quintaro,,,,0,0,d2f44085-ec4a-4230-a6d7-deec8b15376a
2015-02-23T08:00:00.000+08:00,Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity,LLY,https://www.benzinga.com/news/15/02/5263220/eli-lilly-reports-baricitinib-found-superior-to-placebo-for-reducing-ra-disease-a,Paul Quintaro,,,,0,0,64b7c1a6-fe67-4933-928b-f1ec5ec36bbd
2015-02-23T08:00:00.000+08:00,"Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study",LLY,https://www.benzinga.com/news/15/02/5263188/lilly-incyte-report-baricitinib-superior-to-placebo-in-reducing-ra-disease-activi,Charles Gross,,,,0,0,6db19af8-3420-4db1-b991-4bede4c0e543
2015-02-23T08:00:00.000+08:00,5 'Key Pipeline Catalysts' To Watch At Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/02/5266196/5-key-pipeline-catalysts-to-watch-at-eli-lilly,Monica Gerson,,,,0,0,25e2b95f-bb37-4aff-b4ac-9b25439230ff
2015-02-23T08:00:00.000+08:00,Lilly Announces Delay In Submission For Basal Insulin Peglispro To Regulatory Agencies,LLY,https://www.benzinga.com/news/15/02/5263752/lilly-announces-delay-in-submission-for-basal-insulin-peglispro-to-regulatory-age,Hal Lindon,,,,0,0,7fa7ae88-0e9a-45aa-98a4-4bcfdf98ec8b
2015-02-23T08:00:00.000+08:00,Eli Lilly Reports Delay on Regulatory Submission Timing for Basal Insulin Peglispro,LLY,https://www.benzinga.com/news/15/02/5263713/eli-lilly-reports-delay-on-regulatory-submission-timing-for-basal-insulin-peglisp,Paul Quintaro,,,,0,0,53168003-c642-4648-8b36-0e8626240f83
2015-02-23T08:00:00.000+08:00,Eli Lilly Reports Baricitinib Found Superior to Placebo for Reducing RA Disease Activity,LLY,https://www.benzinga.com/news/15/02/5263220/eli-lilly-reports-baricitinib-found-superior-to-placebo-for-reducing-ra-disease-a,Paul Quintaro,,,,0,0,c3ae32ea-f39f-4ab6-86d6-57122476ac4d
2015-02-23T08:00:00.000+08:00,"Lilly, Incyte Report Baricitinib Superior to Placebo in Reducing RA Disease Activity in Second Phase 3 Study",LLY,https://www.benzinga.com/news/15/02/5263188/lilly-incyte-report-baricitinib-superior-to-placebo-in-reducing-ra-disease-activi,Charles Gross,,,,0,0,58e53c15-b3fb-40cc-abbf-184df5f44bd5
2015-02-19T08:00:00.000+08:00,Lilly Provides Phase 3 Trial Update On Evacetrapib,LLY,https://www.benzinga.com/news/15/02/5255050/lilly-provides-phase-3-trial-update-on-evacetrapib,Hal Lindon,,,,0,0,4ed98e1f-fbbf-4456-818e-c2e56bcb1f55
2015-02-19T08:00:00.000+08:00,Lilly Provides Phase 3 Trial Update On Evacetrapib,LLY,https://www.benzinga.com/news/15/02/5255050/lilly-provides-phase-3-trial-update-on-evacetrapib,Hal Lindon,,,,0,0,1ce86817-0b90-4ee9-b6d0-1042628a2dbd
2015-02-11T08:00:00.000+08:00,"UPDATE: Lilly Says China, Parts of Asia Most Profitable of Emerging Markets, Parts of India Subcontinent Least Profitable",LLY,https://www.benzinga.com/news/15/02/5231133/update-lilly-says-china-parts-of-asia-most-profitable-of-emerging-markets-parts-o,Charles Gross,,,,0,0,aafe4816-9209-422f-a041-c27e6c947f62
2015-02-11T08:00:00.000+08:00,Lilly Says Still Room to Grow Business in China,LLY,https://www.benzinga.com/news/15/02/5231123/lilly-says-still-room-to-grow-business-in-china,Charles Gross,,,,0,0,18ddd6e7-d51c-463e-97a0-6df5bcf448b6
2015-02-11T08:00:00.000+08:00,Lilly Currently Presenting at Leerink Global Healthcare Conference,LLY,https://www.benzinga.com/news/15/02/5231099/lilly-currently-presenting-at-leerink-global-healthcare-conference,Charles Gross,,,,0,0,12212fb5-569e-48cc-8c27-62df5af2145c
2015-02-11T08:00:00.000+08:00,"UPDATE: Lilly Says China, Parts of Asia Most Profitable of Emerging Markets, Parts of India Subcontinent Least Profitable",LLY,https://www.benzinga.com/news/15/02/5231133/update-lilly-says-china-parts-of-asia-most-profitable-of-emerging-markets-parts-o,Charles Gross,,,,0,0,3d94d108-2b24-4760-baea-0fa78c9e85d6
2015-02-11T08:00:00.000+08:00,Lilly Says Still Room to Grow Business in China,LLY,https://www.benzinga.com/news/15/02/5231123/lilly-says-still-room-to-grow-business-in-china,Charles Gross,,,,0,0,bd938a12-cbc2-48ea-b7e9-adb69c28d1cd
2015-02-11T08:00:00.000+08:00,Lilly Currently Presenting at Leerink Global Healthcare Conference,LLY,https://www.benzinga.com/news/15/02/5231099/lilly-currently-presenting-at-leerink-global-healthcare-conference,Charles Gross,,,,0,0,9d1a7820-879e-4718-b9f5-d18e23d5b48c
2015-02-06T08:00:00.000+08:00,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",LLY,https://www.benzinga.com/general/education/15/02/5220037/after-a-blockbuster-2014-what-will-2015-hold-for-pharmaceutical-m-a,Steve Sapletal,,,,0,0,0e6fc04c-aefe-4a19-a81f-a45ccaf099c8
2015-02-06T08:00:00.000+08:00,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",LLY,https://www.benzinga.com/general/education/15/02/5220037/after-a-blockbuster-2014-what-will-2015-hold-for-pharmaceutical-m-a,Steve Sapletal,,,,0,0,7df2c6a7-4b4d-42fb-aa4b-2ab46308b682
2015-02-05T08:00:00.000+08:00,IPO Alert: Biotech Investors Should Watch Advanced Accelerator's New Drug Lineup,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/02/5214143/ipo-alert-biotech-investors-should-watch-advanced-accelerator,Charles Enser,,,,0,0,bb14cb63-f9e6-4149-951c-a20e4b46d6ee
2015-02-05T08:00:00.000+08:00,IPO Alert: Biotech Investors Should Watch Advanced Accelerator's New Drug Lineup,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/02/5214143/ipo-alert-biotech-investors-should-watch-advanced-accelerator,Charles Enser,,,,0,0,006d8233-0f1e-432f-b6fc-309d0172f313
2015-02-02T08:00:00.000+08:00,UBS: Eli Lilly's 'Outlook Continuing To Improve',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/02/5200436/ubs-eli-lillys-outlook-continuing-to-improve,Anthony Sanfilippo,,,,0,0,e5acd3e0-b434-4ce8-a783-559bd8cd22d3
2015-02-02T08:00:00.000+08:00,Lilly Announces FDA Approves First-in-class Glyxambi Tablets for Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/02/5199947/lilly-announces-fda-approves-first-in-class-glyxambi-tablets-for-adults-with-type,Charles Gross,,,,0,0,6e4c35fd-0903-4d35-bc88-ad1cc8d4399f
2015-02-02T08:00:00.000+08:00,Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance On Back Of Strengthening Dollar,LLY,https://www.benzinga.com/media/cnbc/15/02/5198463/eli-lilly-ceo-explains-the-reasons-behind-not-changing-2015-guidance-on-bac,Ritesh Anan,,,,0,0,1db66afd-8fc9-43e6-8d99-9faa3f6fc420
2015-02-02T08:00:00.000+08:00,UBS: Eli Lilly's 'Outlook Continuing To Improve',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/02/5200436/ubs-eli-lillys-outlook-continuing-to-improve,Anthony Sanfilippo,,,,0,0,90b23888-baaa-4177-8313-552bdbc45957
2015-02-02T08:00:00.000+08:00,Lilly Announces FDA Approves First-in-class Glyxambi Tablets for Adults With Type 2 Diabetes,LLY,https://www.benzinga.com/news/15/02/5199947/lilly-announces-fda-approves-first-in-class-glyxambi-tablets-for-adults-with-type,Charles Gross,,,,0,0,c4b252f1-d7cb-4f8d-9e61-492daa7208cc
2015-02-02T08:00:00.000+08:00,Eli Lilly CEO Explains The Reasons Behind Not Changing 2015 Guidance On Back Of Strengthening Dollar,LLY,https://www.benzinga.com/media/cnbc/15/02/5198463/eli-lilly-ceo-explains-the-reasons-behind-not-changing-2015-guidance-on-bac,Ritesh Anan,,,,0,0,e5165247-b344-4f02-853e-9fc9a6408fe7
2015-01-30T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline",LLY,https://www.benzinga.com/news/earnings/15/01/5195086/update-eli-lilly-posts-upbeat-q4-profit-sales-decline,Monica Gerson,,,,0,0,c41be22d-874c-4e50-b253-3a801af9e9d0
2015-01-30T08:00:00.000+08:00,"Eli Lilly Guides FY 2015 Lower, Expects $19.5B to $20B",LLY,https://www.benzinga.com/news/15/01/5194897/eli-lilly-guides-fy-2015-lower-expects-19-5b-to-20b,Paul Quintaro,,,,0,0,4de1d3f9-3e6a-4ff4-a94c-3d55615ce0f5
2015-01-30T08:00:00.000+08:00,"Eli Lilly Q4 EPS $0.75, $0.73 Est",LLY,https://www.benzinga.com/news/earnings/15/01/5194894/eli-lilly-q4-eps-0-75-0-73-est,Paul Quintaro,,,,0,0,fba00e22-cebd-4d98-9c0d-0af5b9583f2c
2015-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2015",LLY,https://www.benzinga.com/news/earnings/15/01/5194708/earnings-scheduled-for-january-30-2015,Monica Gerson,,,,0,0,82237304-b1d0-4f52-9973-99b9c1d239b3
2015-01-30T08:00:00.000+08:00,10 Must Watch Stocks for Today,LLY,https://www.benzinga.com/news/earnings/15/01/5194673/10-must-watch-stocks-for-today,Monica Gerson,,,,0,0,382e6138-18d3-4aaa-ba05-991f09e973e6
2015-01-30T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Sales Decline",LLY,https://www.benzinga.com/news/earnings/15/01/5195086/update-eli-lilly-posts-upbeat-q4-profit-sales-decline,Monica Gerson,,,,0,0,c22e937c-9054-4ade-84c5-0c58418725b1
2015-01-30T08:00:00.000+08:00,"Eli Lilly Guides FY 2015 Lower, Expects $19.5B to $20B",LLY,https://www.benzinga.com/news/15/01/5194897/eli-lilly-guides-fy-2015-lower-expects-19-5b-to-20b,Paul Quintaro,,,,0,0,eccf80f6-47c0-4634-837e-457eb82ea8d5
2015-01-30T08:00:00.000+08:00,"Eli Lilly Q4 EPS $0.75, $0.73 Est",LLY,https://www.benzinga.com/news/earnings/15/01/5194894/eli-lilly-q4-eps-0-75-0-73-est,Paul Quintaro,,,,0,0,0813f934-03bc-4cba-8383-ad71d1613308
2015-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2015",LLY,https://www.benzinga.com/news/earnings/15/01/5194708/earnings-scheduled-for-january-30-2015,Monica Gerson,,,,0,0,70d76d57-2807-48d6-8c13-adc70aa5fae3
2015-01-30T08:00:00.000+08:00,10 Must Watch Stocks for Today,LLY,https://www.benzinga.com/news/earnings/15/01/5194673/10-must-watch-stocks-for-today,Monica Gerson,,,,0,0,69d76b91-3c79-4035-965d-9e8032eea6ee
2015-01-15T08:00:00.000+08:00,A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5151534/here-is-goldman-sachs-potential-pair-trade-for-2-drug-gi,Javier Hasse,,,,0,0,a36f4e4d-de1b-4884-9310-b36137943fa5
2015-01-15T08:00:00.000+08:00,10 Biotech Stories You Might've Missed This Week,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5151323/10-biotech-stories-you-mightve-missed-this-week,Kyle Dennis,,,,0,0,12ce9581-cf8e-4c52-8f97-f4533f5e472e
2015-01-15T08:00:00.000+08:00,Goldman Sachs Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/15/01/5149456/goldman-sachs-upgrades-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,ce48c30a-7bda-459f-b4f2-0d8c6b273781
2015-01-15T08:00:00.000+08:00,A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5151534/here-is-goldman-sachs-potential-pair-trade-for-2-drug-gi,Javier Hasse,,,,0,0,cd3e5d3e-7392-4ddf-bf23-21b404d0c8bc
2015-01-15T08:00:00.000+08:00,10 Biotech Stories You Might've Missed This Week,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5151323/10-biotech-stories-you-mightve-missed-this-week,Kyle Dennis,,,,0,0,7a2f0a60-baea-452c-971b-f7461758072c
2015-01-15T08:00:00.000+08:00,Goldman Sachs Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/15/01/5149456/goldman-sachs-upgrades-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,0075a506-4e21-4f1c-bb93-d197ab65b05d
2015-01-13T08:00:00.000+08:00,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel',LLY,https://www.benzinga.com/opinion/15/01/5141858/notes-from-the-street-flashback-oil-going-to-200barrel,Kenny Polcari,,,,0,0,31d13736-f183-4b1d-ab4e-173c89457957
2015-01-13T08:00:00.000+08:00,Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial,LLY,https://www.benzinga.com/news/15/01/5141737/merck-and-eli-lilly-announce-agreement-for-collaboration-on-cancer-clinical-trial,Paul Quintaro,,,,0,0,7719af85-6ec5-4d98-b272-1769fe6d3360
2015-01-13T08:00:00.000+08:00,Notes From The Street: 'FLASHBACK....Oil Going To $200/Barrel',LLY,https://www.benzinga.com/opinion/15/01/5141858/notes-from-the-street-flashback-oil-going-to-200barrel,Kenny Polcari,,,,0,0,589e0403-629a-4818-a89e-b8e519f19bb7
2015-01-13T08:00:00.000+08:00,Merck and Eli Lilly Announce Agreement For Collaboration on Cancer Clinical Trial,LLY,https://www.benzinga.com/news/15/01/5141737/merck-and-eli-lilly-announce-agreement-for-collaboration-on-cancer-clinical-trial,Paul Quintaro,,,,0,0,75a06477-f7b5-45f7-9e4e-11165562dc4e
2015-01-12T08:00:00.000+08:00,'FDA stops import of Lilly's Cialis from Australia',LLY,https://www.benzinga.com/news/15/01/5140427/fda-stops-import-of-lillys-cialis-from-australia,Paul Quintaro,,,,0,0,46fd3f81-4f74-474a-9bf4-000522864347
2015-01-12T08:00:00.000+08:00,"Eil Lilly CEO Talks New Product Launches, Pricing Pressure From Other Companies",LLY,https://www.benzinga.com/media/cnbc/15/01/5138491/eil-lilly-ceo-talks-new-product-launches-pricing-pressure-from-other-compan,Ritesh Anan,,,,0,0,89cb2505-7c6f-4425-b7c8-a8f1532b64e1
2015-01-12T08:00:00.000+08:00,FDA Issues Import Block On Eli Lilly's Cialis,LLY,https://www.benzinga.com/news/15/01/5138518/fda-issues-import-block-on-eli-lillys-cialis,Kevin Riley,,,,0,0,2b1e1510-8958-4294-b507-78ed32dc7f94
2015-01-12T08:00:00.000+08:00,FDA issues Import Block Alert On Lilly's Cialis,LLY,https://www.benzinga.com/news/15/01/5138494/fda-issues-import-block-alert-on-lillys-cialis,Paul Quintaro,,,,0,0,12d7ec62-d31e-4760-b20f-05bb0a2b0aa5
2015-01-12T08:00:00.000+08:00,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5136446/biotechs-presenting-at-the-j-p-morgan-healthcare-conference-d,Kyle Dennis,,,,0,0,d99c73e1-d2cf-48ea-984a-14063a886d9a
2015-01-12T08:00:00.000+08:00,From CNBC: Eli Lilly CEO 'Anticipates 2015 Drug Price Increases; Remains Interested In Smaller M&A Deals',LLY,https://www.benzinga.com/news/15/01/5138448/from-cnbc-eli-lilly-ceo-anticipates-2015-drug-price-increases-remains-interested-,Paul Quintaro,,,,0,0,4b705f95-eb81-4173-b1ff-ef92d6516e59
2015-01-12T08:00:00.000+08:00,"Fast Money Picks For January 12: Twitter, Eli Lilly, Lions Gate",LLY,https://www.benzinga.com/media/cnbc/15/01/5135993/fast-money-picks-for-january-12-twitter-eli-lilly-lions-gate,Craig Jones,,,,0,0,43eef1d6-fd2f-48f4-9f55-f78b0b0dcb5d
2015-01-12T08:00:00.000+08:00,'FDA stops import of Lilly's Cialis from Australia',LLY,https://www.benzinga.com/news/15/01/5140427/fda-stops-import-of-lillys-cialis-from-australia,Paul Quintaro,,,,0,0,59aec797-4fa9-4c08-94f3-f0c21b3ccf82
2015-01-12T08:00:00.000+08:00,"Eil Lilly CEO Talks New Product Launches, Pricing Pressure From Other Companies",LLY,https://www.benzinga.com/media/cnbc/15/01/5138491/eil-lilly-ceo-talks-new-product-launches-pricing-pressure-from-other-compan,Ritesh Anan,,,,0,0,af228b7b-bd97-4c03-95fd-f5489930714b
2015-01-12T08:00:00.000+08:00,FDA Issues Import Block On Eli Lilly's Cialis,LLY,https://www.benzinga.com/news/15/01/5138518/fda-issues-import-block-on-eli-lillys-cialis,Kevin Riley,,,,0,0,b6babf12-d3e5-4a88-930d-3605dea5e7ef
2015-01-12T08:00:00.000+08:00,FDA issues Import Block Alert On Lilly's Cialis,LLY,https://www.benzinga.com/news/15/01/5138494/fda-issues-import-block-alert-on-lillys-cialis,Paul Quintaro,,,,0,0,95aee35d-ccb5-4723-8b03-8c0b30a1269d
2015-01-12T08:00:00.000+08:00,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5136446/biotechs-presenting-at-the-j-p-morgan-healthcare-conference-d,Kyle Dennis,,,,0,0,9e8f89ac-87d0-46e0-afb8-b2babcd4d6a7
2015-01-12T08:00:00.000+08:00,From CNBC: Eli Lilly CEO 'Anticipates 2015 Drug Price Increases; Remains Interested In Smaller M&A Deals',LLY,https://www.benzinga.com/news/15/01/5138448/from-cnbc-eli-lilly-ceo-anticipates-2015-drug-price-increases-remains-interested-,Paul Quintaro,,,,0,0,cc168eaf-56c9-47a7-88fb-5469b9e9431e
2015-01-12T08:00:00.000+08:00,"Fast Money Picks For January 12: Twitter, Eli Lilly, Lions Gate",LLY,https://www.benzinga.com/media/cnbc/15/01/5135993/fast-money-picks-for-january-12-twitter-eli-lilly-lions-gate,Craig Jones,,,,0,0,2f5a7624-82bc-4d02-ae8b-d0e1e230b3ec
2015-01-09T08:00:00.000+08:00,Bank of America Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/15/01/5133767/bank-of-america-downgrades-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,4aae7a3d-84f0-457c-ad7d-44a22a70c695
2015-01-09T08:00:00.000+08:00,Bank of America Downgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/news/15/01/5133767/bank-of-america-downgrades-eli-lilly-to-neutral,Paul Quintaro,,,,0,0,8cdd9da3-afe5-4ed7-adb1-8b0f76af5ee9
2015-01-08T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Higher,LLY,https://www.benzinga.com/general/movers-shakers/15/01/5131996/premarket-prep-technical-update-eli-lilly-higher,Hal Lindon,,,,0,0,cc61e7f7-d2fe-401b-9b46-ba2ce6842c59
2015-01-08T08:00:00.000+08:00,"Deutsche Bank, Stifel Differ On Outlook For Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5131674/deutsche-bank-stifel-differ-on-outlook-for-eli-lilly,Kevin Riley,,,,0,0,06c0c3b2-ba24-4050-a526-04048bbe09c3
2015-01-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/01/5130698/benzingas-top-upgrades,Lisa Levin,,,,0,0,de394c08-2faf-4d48-8873-af302a01beb7
2015-01-08T08:00:00.000+08:00,Jefferies Upgrades Eli Lilly To Buy,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/01/5130413/jefferies-upgrades-eli-lilly-to-buy,Monica Gerson,,,,0,0,e5b8b759-6b60-483a-9aaa-50771fa97ebe
2015-01-08T08:00:00.000+08:00,"UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, Modest Upside",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5130061/update-deutsche-bank-downgrades-eli-lilly-on-positive-ou,Dwight Einhorn,,,,0,0,dcff91fa-ad74-4223-b6a7-0771963f12c7
2015-01-08T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly to Buy, Raises PT to $80.00",LLY,https://www.benzinga.com/news/15/01/5129698/jefferies-upgrades-eli-lilly-to-buy-raises-pt-to-80-00,Charles Gross,,,,0,0,f2cfb166-34fb-48b6-a1aa-66fd9c851fa2
2015-01-08T08:00:00.000+08:00,Deutsche Bank Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/15/01/5129666/deutsche-bank-downgrades-eli-lilly-to-hold,Charles Gross,,,,0,0,6dbfa427-41c5-47f0-b160-e9b1f4f0a28a
2015-01-08T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Higher,LLY,https://www.benzinga.com/general/movers-shakers/15/01/5131996/premarket-prep-technical-update-eli-lilly-higher,Hal Lindon,,,,0,0,83797931-e19b-4ee2-ba3d-2fc8812a560b
2015-01-08T08:00:00.000+08:00,"Deutsche Bank, Stifel Differ On Outlook For Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5131674/deutsche-bank-stifel-differ-on-outlook-for-eli-lilly,Kevin Riley,,,,0,0,731ea827-1a0c-46ce-8bac-087f08c822d6
2015-01-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/01/5130698/benzingas-top-upgrades,Lisa Levin,,,,0,0,2f3b5f74-847e-4553-a5fd-9681d3acc0ad
2015-01-08T08:00:00.000+08:00,Jefferies Upgrades Eli Lilly To Buy,LLY,https://www.benzinga.com/analyst-ratings/upgrades/15/01/5130413/jefferies-upgrades-eli-lilly-to-buy,Monica Gerson,,,,0,0,98e274ce-941d-43f8-9b9b-4f9b5a512696
2015-01-08T08:00:00.000+08:00,"UPDATE: Deutsche Bank Downgrades Eli Lilly On Positive Outlook, Modest Upside",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5130061/update-deutsche-bank-downgrades-eli-lilly-on-positive-ou,Dwight Einhorn,,,,0,0,f566e508-0bd0-4fe2-980e-8e781b0c8f3d
2015-01-08T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly to Buy, Raises PT to $80.00",LLY,https://www.benzinga.com/news/15/01/5129698/jefferies-upgrades-eli-lilly-to-buy-raises-pt-to-80-00,Charles Gross,,,,0,0,fbcc4dd8-1bcc-42f6-b64a-5dcea7dba6ca
2015-01-08T08:00:00.000+08:00,Deutsche Bank Downgrades Eli Lilly to Hold,LLY,https://www.benzinga.com/news/15/01/5129666/deutsche-bank-downgrades-eli-lilly-to-hold,Charles Gross,,,,0,0,13b91966-a668-4141-bd3d-65b1bc40f124
2015-01-07T08:00:00.000+08:00,4 Stocks Trending On Social Media This Wednesday,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5127925/4-stocks-trending-on-social-media-this-wednesday,Garrett Cook,,,,0,0,9aefa52d-be43-425c-9fb5-98edc23b9ed1
2015-01-07T08:00:00.000+08:00,Eli Lilly Moves Higher Following FY 2014 & 2015 Outlook,LLY,https://www.benzinga.com/news/15/01/5126839/eli-lilly-moves-higher-following-fy-2014-2015-outlook,Kevin Riley,,,,0,0,e01fea05-a399-41f4-a2ef-72cf9fd5ca22
2015-01-07T08:00:00.000+08:00,"From Eli Lilly Guidance Conference Call: Mgmt Still Expecting FY14 Sales in $19.4-$19.8B Range, vs $19.7B Analyst Est.",LLY,https://www.benzinga.com/news/15/01/5126972/from-eli-lilly-guidance-conference-call-mgmt-still-expecting-fy14-sales-in-19-4-1,Paul Quintaro,,,,0,0,7536b708-71ba-462e-89b4-4994571b7c21
2015-01-07T08:00:00.000+08:00,Benzinga's Top #PreMarket Losers,LLY,https://www.benzinga.com/news/15/01/5126569/benzingas-top-premarket-losers,Monica Gerson,,,,0,0,d3118342-8098-4037-a52b-1d8ea468224b
2015-01-07T08:00:00.000+08:00,Eli Lilly Sees FY2014 EPS $2.72-2.80,LLY,https://www.benzinga.com/news/15/01/5126307/eli-lilly-sees-fy2014-eps-2-72-2-80,Eddie Staley,,,,0,0,6c81a4de-513e-4360-afea-f5b4da38ee81
2015-01-07T08:00:00.000+08:00,Eli Lilly Sees FY2015 EPS $3.10-3.20; Sees Sales $20.30B-20.80B,LLY,https://www.benzinga.com/news/15/01/5126305/eli-lilly-sees-fy2015-eps-3-10-3-20-sees-sales-20-30b-20-80b,Eddie Staley,,,,0,0,1a418659-2a15-4bb9-b6a5-f87d2c711f2c
2015-01-07T08:00:00.000+08:00,4 Stocks Trending On Social Media This Wednesday,LLY,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5127925/4-stocks-trending-on-social-media-this-wednesday,Garrett Cook,,,,0,0,fd1ae7ea-1526-48e7-9778-a2876d7753a8
2015-01-07T08:00:00.000+08:00,Eli Lilly Moves Higher Following FY 2014 & 2015 Outlook,LLY,https://www.benzinga.com/news/15/01/5126839/eli-lilly-moves-higher-following-fy-2014-2015-outlook,Kevin Riley,,,,0,0,b21918bd-9f97-4767-8980-04ad819057dc
2015-01-07T08:00:00.000+08:00,"From Eli Lilly Guidance Conference Call: Mgmt Still Expecting FY14 Sales in $19.4-$19.8B Range, vs $19.7B Analyst Est.",LLY,https://www.benzinga.com/news/15/01/5126972/from-eli-lilly-guidance-conference-call-mgmt-still-expecting-fy14-sales-in-19-4-1,Paul Quintaro,,,,0,0,4ce552a5-f1ee-4802-acbc-63862aebeba6
2015-01-07T08:00:00.000+08:00,Benzinga's Top #PreMarket Losers,LLY,https://www.benzinga.com/news/15/01/5126569/benzingas-top-premarket-losers,Monica Gerson,,,,0,0,53d0ac72-ce4d-4f0c-87ae-3609ecdf2712
2015-01-07T08:00:00.000+08:00,Eli Lilly Sees FY2014 EPS $2.72-2.80,LLY,https://www.benzinga.com/news/15/01/5126307/eli-lilly-sees-fy2014-eps-2-72-2-80,Eddie Staley,,,,0,0,ace20d99-b428-41f3-8c9c-596da61722ce
2015-01-07T08:00:00.000+08:00,Eli Lilly Sees FY2015 EPS $3.10-3.20; Sees Sales $20.30B-20.80B,LLY,https://www.benzinga.com/news/15/01/5126305/eli-lilly-sees-fy2015-eps-3-10-3-20-sees-sales-20-30b-20-80b,Eddie Staley,,,,0,0,62813d2c-c696-4f12-b22a-f203dcf25324
2015-01-06T08:00:00.000+08:00,Fast Money Halftime Report Final Trade From January 6,LLY,https://www.benzinga.com/media/cnbc/15/01/5124655/fast-money-halftime-report-final-trade-from-january-6,Craig Jones,,,,0,0,e4605716-5061-429b-86f1-e68d0e134fef
2015-01-06T08:00:00.000+08:00,Fast Money Halftime Report Final Trade From January 6,LLY,https://www.benzinga.com/media/cnbc/15/01/5124655/fast-money-halftime-report-final-trade-from-january-6,Craig Jones,,,,0,0,aef787b6-b54c-4330-a42d-2933eec46df3
2015-01-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/15/01/5116117/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,fb7655bf-914b-4610-96d4-18858e8c4610
2015-01-02T08:00:00.000+08:00,US Stock Futures Surge Ahead Of Manufacturing Data,LLY,https://www.benzinga.com/news/15/01/5115018/us-stock-futures-surge-ahead-of-manufacturing-data,Monica Gerson,,,,0,0,379f50dd-949a-488f-a9dc-2b60abb9bcad
2015-01-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/15/01/5116117/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,09741fb5-8b5d-4967-b16b-609c40caf668
2015-01-02T08:00:00.000+08:00,US Stock Futures Surge Ahead Of Manufacturing Data,LLY,https://www.benzinga.com/news/15/01/5115018/us-stock-futures-surge-ahead-of-manufacturing-data,Monica Gerson,,,,0,0,00971722-106f-4341-bf86-d28f54d9231b
2015-01-01T08:00:00.000+08:00,Lilly Completes Acquisition of Novartis Animal Health,LLY,https://www.benzinga.com/news/15/01/5114528/lilly-completes-acquisition-of-novartis-animal-health,Charles Gross,,,,0,0,f2625b96-d395-4911-8222-4949a35dd1ef
2015-01-01T08:00:00.000+08:00,Lilly Completes Acquisition of Novartis Animal Health,LLY,https://www.benzinga.com/news/15/01/5114528/lilly-completes-acquisition-of-novartis-animal-health,Charles Gross,,,,0,0,95706424-b250-4afe-87d4-47ca5e410d3e
2014-12-22T08:00:00.000+08:00,FTC Places Conditions on Lilly's Proposed Deal to Divest Sentinel to Virbac SA,LLY,https://www.benzinga.com/news/14/12/5100018/ftc-places-conditions-on-lillys-proposed-deal-to-divest-sentinel-to-virbac-sa,Paul Quintaro,,,,0,0,b3d50e02-2a3d-44ff-925c-be11855b645e
2014-12-22T08:00:00.000+08:00,FTC Places Conditions on Lilly's Proposed Deal to Divest Sentinel to Virbac SA,LLY,https://www.benzinga.com/news/14/12/5100018/ftc-places-conditions-on-lillys-proposed-deal-to-divest-sentinel-to-virbac-sa,Paul Quintaro,,,,0,0,a223cff4-c0c1-4b61-a300-57b13bf30b84
2014-12-19T08:00:00.000+08:00,"Lilly, Adocia Announce Alliance to Co-Develop BioChaperone Lispro",LLY,https://www.benzinga.com/news/14/12/5095540/lilly-adocia-announce-alliance-to-co-develop-biochaperone-lispro,Charles Gross,,,,0,0,f1b2d21e-9dd6-44c1-aa66-edc3cb707727
2014-12-19T08:00:00.000+08:00,"Lilly, Adocia Announce Alliance to Co-Develop BioChaperone Lispro",LLY,https://www.benzinga.com/news/14/12/5095540/lilly-adocia-announce-alliance-to-co-develop-biochaperone-lispro,Charles Gross,,,,0,0,44d0d379-93cb-4363-b096-3f4f13176d4b
2014-12-16T08:00:00.000+08:00,7 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/14/12/5082669/7-stocks-you-should-be-watching-today,Monica Gerson,,,,0,0,aff590c2-f9b3-426f-9f63-2d63cdab667d
2014-12-16T08:00:00.000+08:00,7 Stocks You Should Be Watching Today,LLY,https://www.benzinga.com/news/earnings/14/12/5082669/7-stocks-you-should-be-watching-today,Monica Gerson,,,,0,0,4007fd08-c94d-46ff-8687-260359960465
2014-12-15T08:00:00.000+08:00,Lilly Announces Dividend Increase From $0.49 To $0.50/share,LLY,https://www.benzinga.com/news/14/12/5081768/lilly-announces-dividend-increase-from-0-49-to-0-50share,Hal Lindon,,,,0,0,55c07f18-fcd8-4cce-96d0-e2d7e1c2dc78
2014-12-15T08:00:00.000+08:00,Lilly Announces Dividend Increase From $0.49 To $0.50/share,LLY,https://www.benzinga.com/news/14/12/5081768/lilly-announces-dividend-increase-from-0-49-to-0-50share,Hal Lindon,,,,0,0,7855d7c1-39a3-4d2c-932c-b61df12bbe96
2014-12-12T08:00:00.000+08:00,UPDATE: FDA Expands Approval For Cyramza,LLY,https://www.benzinga.com/news/14/12/5077610/update-fda-expands-approval-for-cyramza,Paul Quintaro,,,,0,0,a3f2cf59-1ff5-42dc-9f7c-2faa29cf878f
2014-12-12T08:00:00.000+08:00,Eli Lilly's Cyramza Receives Expanded FDA Approval,LLY,https://www.benzinga.com/news/14/12/5077608/eli-lillys-cyramza-receives-expanded-fda-approval,Paul Quintaro,,,,0,0,6e9c5569-9b1b-4421-ae54-f5f5969c602c
2014-12-12T08:00:00.000+08:00,UPDATE: FDA Expands Approval For Cyramza,LLY,https://www.benzinga.com/news/14/12/5077610/update-fda-expands-approval-for-cyramza,Paul Quintaro,,,,0,0,4c9a69a6-be88-430f-a8e0-4cb9d71eb936
2014-12-12T08:00:00.000+08:00,Eli Lilly's Cyramza Receives Expanded FDA Approval,LLY,https://www.benzinga.com/news/14/12/5077608/eli-lillys-cyramza-receives-expanded-fda-approval,Paul Quintaro,,,,0,0,6a554738-0ed5-483e-b860-11688b358db3
2014-12-11T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly and Company to Overweight, Raises PT to $85.00",LLY,https://www.benzinga.com/news/14/12/5074029/morgan-stanley-upgrades-eli-lilly-and-company-to-overweight-raises-pt-to-85-00,Eddie Staley,,,,0,0,1763707a-de46-471e-9ad3-f4866362c22f
2014-12-11T08:00:00.000+08:00,"Morgan Stanley Upgrades Eli Lilly and Company to Overweight, Raises PT to $85.00",LLY,https://www.benzinga.com/news/14/12/5074029/morgan-stanley-upgrades-eli-lilly-and-company-to-overweight-raises-pt-to-85-00,Eddie Staley,,,,0,0,96ffa31d-e84c-45c1-8e66-525c3c21bf5c
2014-12-09T08:00:00.000+08:00,"Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint",LLY,https://www.benzinga.com/news/14/12/5066369/lilly-incyte-announce-phase-3-trial-of-baricitinib-in-moderate-to-severe-rheumato,Charles Gross,,,,0,0,cc1fa107-93fd-4d9d-a454-1d4ca443cedc
2014-12-09T08:00:00.000+08:00,"Lilly, Incyte Announce Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis Met Primary Endpoint",LLY,https://www.benzinga.com/news/14/12/5066369/lilly-incyte-announce-phase-3-trial-of-baricitinib-in-moderate-to-severe-rheumato,Charles Gross,,,,0,0,9a3078b8-0b84-40a1-9e9d-f3498f109da4
2014-12-08T08:00:00.000+08:00,"Eli Lilly, Anthem, Inc. and HealthCore Create Research Collaboration",LLY,https://www.benzinga.com/news/14/12/5063097/eli-lilly-anthem-inc-and-healthcore-create-research-collaboration,Hal Lindon,,,,0,0,942100da-f52c-4716-982b-1ef825c6e1d5
2014-12-08T08:00:00.000+08:00,"Eli Lilly, Anthem, Inc. and HealthCore Create Research Collaboration",LLY,https://www.benzinga.com/news/14/12/5063097/eli-lilly-anthem-inc-and-healthcore-create-research-collaboration,Hal Lindon,,,,0,0,371dfefd-a971-4b97-9c13-34059f2f5913
2014-12-04T08:00:00.000+08:00,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $5.00",LLY,https://www.benzinga.com/news/14/12/5056734/jefferies-maintains-hold-on-eli-lilly-and-company-raises-pt-to-5-00,Eddie Staley,,,,0,0,d0c1ca67-6844-4995-af55-cc7cd54d01b2
2014-12-04T08:00:00.000+08:00,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $5.00",LLY,https://www.benzinga.com/news/14/12/5056734/jefferies-maintains-hold-on-eli-lilly-and-company-raises-pt-to-5-00,Eddie Staley,,,,0,0,77ccaecd-f343-4ad5-be78-1dc028c4e926
2014-12-02T08:00:00.000+08:00,Zosano Pharma and Eli Lilly and Company Enter Into Exclusive Licensing Agreement for Zosano's ZP-PTH Product Candidate,LLY,https://www.benzinga.com/news/14/12/5049674/zosano-pharma-and-eli-lilly-and-company-enter-into-exclusive-licensing-agreement-,Eddie Staley,,,,0,0,7f084669-01c7-4371-9891-74c019d30f6b
2014-12-02T08:00:00.000+08:00,Zosano Pharma and Eli Lilly and Company Enter Into Exclusive Licensing Agreement for Zosano's ZP-PTH Product Candidate,LLY,https://www.benzinga.com/news/14/12/5049674/zosano-pharma-and-eli-lilly-and-company-enter-into-exclusive-licensing-agreement-,Eddie Staley,,,,0,0,cbe46c03-df5d-4a17-bf85-39deb50aec8c
2014-12-01T08:00:00.000+08:00,Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH,LLY,https://www.benzinga.com/news/14/12/5045611/lilly-announces-co-astrazeneca-report-enrollment-of-first-patient-into-amaranth,Paul Quintaro,,,,0,0,b6f97386-869d-4beb-a3df-7f906e4c49a0
2014-12-01T08:00:00.000+08:00,Lilly Announces Co. AstraZeneca Report Enrollment of First Patient Into AMARANTH,LLY,https://www.benzinga.com/news/14/12/5045611/lilly-announces-co-astrazeneca-report-enrollment-of-first-patient-into-amaranth,Paul Quintaro,,,,0,0,c0558083-b1b2-46f1-89a9-7f13b38c1058
2014-11-24T08:00:00.000+08:00,From 13G: Eli Lilly Company Reports 9.1% Stake In Coherus BioSciences Inc.,LLY,https://www.benzinga.com/news/14/11/5034405/from-13g-eli-lilly-company-reports-9-1-stake-in-coherus-biosciences-inc,Paul Quintaro,,,,0,0,b8d9b4ed-9c3b-444b-b714-a73b28b24566
2014-11-24T08:00:00.000+08:00,From 13G: Eli Lilly Company Reports 9.1% Stake In Coherus BioSciences Inc.,LLY,https://www.benzinga.com/news/14/11/5034405/from-13g-eli-lilly-company-reports-9-1-stake-in-coherus-biosciences-inc,Paul Quintaro,,,,0,0,329baa2c-e3ee-4f92-b1cf-bc76648c9402
2014-11-21T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/11/5030739/premarket-prep-technical-update-eli-lilly-higher,Hal Lindon,,,,0,0,912e5fd3-9718-4938-81f2-a5c6cdbaeecb
2014-11-21T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/11/5030739/premarket-prep-technical-update-eli-lilly-higher,Hal Lindon,,,,0,0,4aaf2c8e-1660-4337-98ac-8902f27998bd
2014-11-17T08:00:00.000+08:00,"Eli Lilly Reports New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight, Markers of Abdominal Fat in Adults with Type 2 Diabetes",LLY,https://www.benzinga.com/news/14/11/5016446/eli-lilly-reports-new-retrospective-data-showed-empagliflozin-reduced-a1c-body-we,Paul Quintaro,,,,0,0,2d6fc8c1-04c0-483d-9ce3-5a4e8713fa6e
2014-11-17T08:00:00.000+08:00,"Eli Lilly Reports New Retrospective Data Showed Empagliflozin Reduced A1C, Body Weight, Markers of Abdominal Fat in Adults with Type 2 Diabetes",LLY,https://www.benzinga.com/news/14/11/5016446/eli-lilly-reports-new-retrospective-data-showed-empagliflozin-reduced-a1c-body-we,Paul Quintaro,,,,0,0,93292595-82f7-4d27-bc68-95e57f4c0273
2014-11-11T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,LLY,https://www.benzinga.com/general/movers-shakers/14/11/5000617/premarket-prep-technical-update-eli-lilly-makes-multi-year-high,Hal Lindon,,,,0,0,e272000d-a7e6-40ef-b65d-423e61d6dc62
2014-11-11T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,LLY,https://www.benzinga.com/general/movers-shakers/14/11/5000617/premarket-prep-technical-update-eli-lilly-makes-multi-year-high,Hal Lindon,,,,0,0,c93bf546-0df4-41dd-9e87-dbe7760d55d6
2014-11-05T08:00:00.000+08:00,FDA Approves Ramcirumab In Combination With Paclitaxel For Gastric Cancer,LLY,https://www.benzinga.com/news/14/11/4984623/fda-approves-ramcirumab-in-combination-with-paclitaxel-for-gastric-cancer,Paul Quintaro,,,,0,0,3dceb702-997f-44b8-abd9-ea6a4fd259d2
2014-11-05T08:00:00.000+08:00,FDA Approves Ramcirumab In Combination With Paclitaxel For Gastric Cancer,LLY,https://www.benzinga.com/news/14/11/4984623/fda-approves-ramcirumab-in-combination-with-paclitaxel-for-gastric-cancer,Paul Quintaro,,,,0,0,fb93c1d2-d020-46dc-a9c6-b5b17a118978
2014-11-03T08:00:00.000+08:00,Credit Suisse Raises Eli Lilly Price Target,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/11/4975142/credit-suisse-raises-eli-lilly-price-target,James McIntosh,,,,0,0,4f3fcaaa-ea3c-4125-b053-94b0f173566a
2014-11-03T08:00:00.000+08:00,Credit Suisse Raises Eli Lilly Price Target,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/11/4975142/credit-suisse-raises-eli-lilly-price-target,James McIntosh,,,,0,0,4483b597-9a8f-4c70-9340-e9dccfd694e2
2014-10-29T08:00:00.000+08:00,"Eli Lilly Recently Filed 10-Q; Seeing FY14 EPS Expected in $2.36-$2.44 Range Amid Revisions on Boehringer Deal, Facility Closing",LLY,https://www.benzinga.com/news/14/10/4963437/eli-lilly-recently-filed-10-q-seeing-fy14-eps-expected-in-2-36-2-44-range-amid-re,Paul Quintaro,,,,0,0,4e31362c-97cc-4149-b08d-c538b0e47cae
2014-10-29T08:00:00.000+08:00,"Lilly, Boehringer Ingelheim Changing Structure of Diabetes Alliance In Certain Countries",LLY,https://www.benzinga.com/news/14/10/4961487/lilly-boehringer-ingelheim-changing-structure-of-diabetes-alliance-in-certain-cou,Charles Gross,,,,0,0,17199ca1-4131-4ae4-80f6-76a81e16b07e
2014-10-29T08:00:00.000+08:00,"Eli Lilly Recently Filed 10-Q; Seeing FY14 EPS Expected in $2.36-$2.44 Range Amid Revisions on Boehringer Deal, Facility Closing",LLY,https://www.benzinga.com/news/14/10/4963437/eli-lilly-recently-filed-10-q-seeing-fy14-eps-expected-in-2-36-2-44-range-amid-re,Paul Quintaro,,,,0,0,77ae594e-7e8a-4c94-b0a2-27f0e728bab3
2014-10-29T08:00:00.000+08:00,"Lilly, Boehringer Ingelheim Changing Structure of Diabetes Alliance In Certain Countries",LLY,https://www.benzinga.com/news/14/10/4961487/lilly-boehringer-ingelheim-changing-structure-of-diabetes-alliance-in-certain-cou,Charles Gross,,,,0,0,41bba308-6757-4d94-973b-1324a7de7875
2014-10-27T08:00:00.000+08:00,"Lilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda",LLY,https://www.benzinga.com/news/14/10/4955900/lilly-responds-to-decision-in-case-of-terrence-allen-et-al-v-takeda,Charles Gross,,,,0,0,25da7652-4d66-48b3-9014-89542343e2ea
2014-10-27T08:00:00.000+08:00,UPDATE: Judge Cut $9B Award To Eli Lilly & Takeda Pharma To $36.8M,LLY,https://www.benzinga.com/news/14/10/4955077/update-judge-cut-9b-award-to-eli-lilly-takeda-pharma-to-36-8m,Paul Quintaro,,,,0,0,43b972a1-2f42-4e4e-bb62-188909c0c548
2014-10-27T08:00:00.000+08:00,"Takeda, Lilly Receive $9B Actos Award To $36.8M",LLY,https://www.benzinga.com/news/14/10/4955072/takeda-lilly-receive-9b-actos-award-to-36-8m,Paul Quintaro,,,,0,0,22414316-93cd-44d2-9930-95c3eb170e38
2014-10-27T08:00:00.000+08:00,Virbac to Acquire US Veterinary Assets from Eli Lilly,LLY,https://www.benzinga.com/news/14/10/4952719/virbac-to-acquire-us-veterinary-assets-from-eli-lilly,Charles Gross,,,,0,0,32e149b8-89f9-4434-bbfe-3e405670d4b9
2014-10-27T08:00:00.000+08:00,"Lilly Responds to Decision in Case of Terrence Allen, et al. v. Takeda",LLY,https://www.benzinga.com/news/14/10/4955900/lilly-responds-to-decision-in-case-of-terrence-allen-et-al-v-takeda,Charles Gross,,,,0,0,ee37a9a5-d09f-419c-b687-abf3457333e3
2014-10-27T08:00:00.000+08:00,UPDATE: Judge Cut $9B Award To Eli Lilly & Takeda Pharma To $36.8M,LLY,https://www.benzinga.com/news/14/10/4955077/update-judge-cut-9b-award-to-eli-lilly-takeda-pharma-to-36-8m,Paul Quintaro,,,,0,0,0c957e2f-d1a6-4e86-ae4c-4b0ca3c7327b
2014-10-27T08:00:00.000+08:00,"Takeda, Lilly Receive $9B Actos Award To $36.8M",LLY,https://www.benzinga.com/news/14/10/4955072/takeda-lilly-receive-9b-actos-award-to-36-8m,Paul Quintaro,,,,0,0,926e1088-a046-4f54-8f16-e1c21073d604
2014-10-27T08:00:00.000+08:00,Virbac to Acquire US Veterinary Assets from Eli Lilly,LLY,https://www.benzinga.com/news/14/10/4952719/virbac-to-acquire-us-veterinary-assets-from-eli-lilly,Charles Gross,,,,0,0,6131a0ea-ea14-4c80-a64a-e8764d28ce55
2014-10-24T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/10/4951251/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,496ea68e-3e7b-4b47-8929-5de2508105ae
2014-10-24T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/10/4951251/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,1b06f890-d599-4ea3-b46e-66bad2c40ad1
2014-10-23T08:00:00.000+08:00,"US Stock Futures Rise Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/14/10/4946403/us-stock-futures-rise-ahead-of-earnings-economic-data,Monica Gerson,,,,0,0,278f5215-2473-41e5-9e48-aeb4f529272a
2014-10-23T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Lower Q3 Profit,LLY,https://www.benzinga.com/news/earnings/14/10/4946310/update-eli-lilly-posts-lower-q3-profit,Monica Gerson,,,,0,0,d7d982c4-f46e-4b65-95ae-91cdc86f7178
2014-10-23T08:00:00.000+08:00,Eli Lilly and Company Sees FY2014 EPS $2.34-2.42,LLY,https://www.benzinga.com/news/14/10/4946098/eli-lilly-and-company-sees-fy2014-eps-2-34-2-42,Paul Quintaro,,,,0,0,932ee21b-b96f-4d3d-99ff-7bae2dc09748
2014-10-23T08:00:00.000+08:00,Eli Lilly and Company Reports Q3 EPS of $0.66 vs $0.69 Est; Revenue of $4.88B vs $4.83B Est,LLY,https://www.benzinga.com/news/earnings/14/10/4946070/eli-lilly-and-company-reports-q3-eps-of-0-66-vs-0-69-est-revenue-of-4-88,Paul Quintaro,,,,0,0,8ba7979b-0ae2-4043-880f-918a26dff133
2014-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2014",LLY,https://www.benzinga.com/news/earnings/14/10/4945866/earnings-scheduled-for-october-23-2014,Monica Gerson,,,,0,0,0d3dc6b4-4d38-4c75-a2d7-6379a856ec26
2014-10-23T08:00:00.000+08:00,"US Stock Futures Rise Ahead Of Earnings, Economic Data",LLY,https://www.benzinga.com/news/14/10/4946403/us-stock-futures-rise-ahead-of-earnings-economic-data,Monica Gerson,,,,0,0,536b9c42-e007-4918-9641-682222fe9ca2
2014-10-23T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Lower Q3 Profit,LLY,https://www.benzinga.com/news/earnings/14/10/4946310/update-eli-lilly-posts-lower-q3-profit,Monica Gerson,,,,0,0,39b752e8-6734-4293-a415-d536dc1d3a5c
2014-10-23T08:00:00.000+08:00,Eli Lilly and Company Sees FY2014 EPS $2.34-2.42,LLY,https://www.benzinga.com/news/14/10/4946098/eli-lilly-and-company-sees-fy2014-eps-2-34-2-42,Paul Quintaro,,,,0,0,0bd620f2-03e7-46cc-a16d-c377c3c0a103
2014-10-23T08:00:00.000+08:00,Eli Lilly and Company Reports Q3 EPS of $0.66 vs $0.69 Est; Revenue of $4.88B vs $4.83B Est,LLY,https://www.benzinga.com/news/earnings/14/10/4946070/eli-lilly-and-company-reports-q3-eps-of-0-66-vs-0-69-est-revenue-of-4-88,Paul Quintaro,,,,0,0,38b13f2d-f28d-403d-bc51-9bf99df2ce70
2014-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2014",LLY,https://www.benzinga.com/news/earnings/14/10/4945866/earnings-scheduled-for-october-23-2014,Monica Gerson,,,,0,0,81ee3636-8c31-4e46-804f-10f54d08ceaf
2014-10-22T08:00:00.000+08:00,CANDA NK-2 Files Motion To Dismiss Patent Infringement Suit,LLY,https://www.benzinga.com/news/14/10/4945173/canda-nk-2-files-motion-to-dismiss-patent-infringement-suit,Eddie Staley,,,,0,0,53efde55-7cb7-42e8-b401-a1849736c27c
2014-10-22T08:00:00.000+08:00,"Lilly, Zymeworks Announce Expansion Of Strategic Licensing And Collaboration Agreement",LLY,https://www.benzinga.com/news/14/10/4944856/lilly-zymeworks-announce-expansion-of-strategic-licensing-and-collaboration-agree,Eddie Staley,,,,0,0,7f319ef7-6420-49b1-81b7-5a71c6e496af
2014-10-22T08:00:00.000+08:00,CANDA NK-2 Files Motion To Dismiss Patent Infringement Suit,LLY,https://www.benzinga.com/news/14/10/4945173/canda-nk-2-files-motion-to-dismiss-patent-infringement-suit,Eddie Staley,,,,0,0,04c4b2d3-1546-44bf-a809-4363535d6b9a
2014-10-22T08:00:00.000+08:00,"Lilly, Zymeworks Announce Expansion Of Strategic Licensing And Collaboration Agreement",LLY,https://www.benzinga.com/news/14/10/4944856/lilly-zymeworks-announce-expansion-of-strategic-licensing-and-collaboration-agree,Eddie Staley,,,,0,0,33b82866-8055-401d-b959-7efc64b42ce4
2014-10-21T08:00:00.000+08:00,FDA Accepts Filing Of A NDA For Empagliflozin,LLY,https://www.benzinga.com/news/14/10/4938737/fda-accepts-filing-of-a-nda-for-empagliflozin,Hal Lindon,,,,0,0,f3513956-f380-49c5-8440-5e3ba73257a7
2014-10-21T08:00:00.000+08:00,FDA Accepts Filing Of A NDA For Empagliflozin,LLY,https://www.benzinga.com/news/14/10/4938737/fda-accepts-filing-of-a-nda-for-empagliflozin,Hal Lindon,,,,0,0,0d643825-d8a0-4ec2-8a8f-243aef751bf6
2014-10-19T08:00:00.000+08:00,Benzinga Weekly Preview: Earnings Season Is In Full Swing,LLY,https://www.benzinga.com/news/earnings/14/10/4931957/benzinga-weekly-preview-earnings-season-is-in-full-swing,Laura Brodbeck,,,,0,0,f306e184-b6c5-405b-97eb-5bd9d3d9a39c
2014-10-19T08:00:00.000+08:00,Benzinga Weekly Preview: Earnings Season Is In Full Swing,LLY,https://www.benzinga.com/news/earnings/14/10/4931957/benzinga-weekly-preview-earnings-season-is-in-full-swing,Laura Brodbeck,,,,0,0,436744dc-fbd5-46e7-907f-6122ada3f69a
2014-10-16T08:00:00.000+08:00,UPDATE: Lilly To Initiate Efforts To Sell Guayama Site,LLY,https://www.benzinga.com/news/14/10/4929458/update-lilly-to-initiate-efforts-to-sell-guayama-site,Paul Quintaro,,,,0,0,33edcff8-fa41-432f-8111-76c565458734
2014-10-16T08:00:00.000+08:00,Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations,LLY,https://www.benzinga.com/news/14/10/4929452/lilly-announces-plan-to-realign-puerto-rico-manufacturing-operations,Paul Quintaro,,,,0,0,31a407bb-5190-4f7b-818e-68ad113bba30
2014-10-16T08:00:00.000+08:00,UPDATE: Lilly To Initiate Efforts To Sell Guayama Site,LLY,https://www.benzinga.com/news/14/10/4929458/update-lilly-to-initiate-efforts-to-sell-guayama-site,Paul Quintaro,,,,0,0,b83a60fd-d84d-4ba7-91e4-abe7e5df7c96
2014-10-16T08:00:00.000+08:00,Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations,LLY,https://www.benzinga.com/news/14/10/4929452/lilly-announces-plan-to-realign-puerto-rico-manufacturing-operations,Paul Quintaro,,,,0,0,d0bf3e90-bc84-4774-9d39-42d2c43bc195
2014-10-13T08:00:00.000+08:00,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $70.00",LLY,https://www.benzinga.com/news/14/10/4916681/jefferies-maintains-hold-on-eli-lilly-and-company-raises-pt-to-70-00,Eddie Staley,,,,0,0,2f051e8d-1d81-4795-be44-54fabba2ea6b
2014-10-13T08:00:00.000+08:00,"Jefferies Maintains Hold on Eli Lilly and Company, Raises PT to $70.00",LLY,https://www.benzinga.com/news/14/10/4916681/jefferies-maintains-hold-on-eli-lilly-and-company-raises-pt-to-70-00,Eddie Staley,,,,0,0,fb391a9f-ceb3-42c0-a516-edbc96abf6e1
2014-10-10T08:00:00.000+08:00,Eli Lilly's Olaratumab Wins FDA Orphan Drug Designation,LLY,https://www.benzinga.com/news/14/10/4914018/eli-lillys-olaratumab-wins-fda-orphan-drug-designation,Paul Quintaro,,,,0,0,96f00cfe-978a-4193-961f-7c0638e85e0e
2014-10-10T08:00:00.000+08:00,Eli Lilly's Olaratumab Wins FDA Orphan Drug Designation,LLY,https://www.benzinga.com/news/14/10/4914018/eli-lillys-olaratumab-wins-fda-orphan-drug-designation,Paul Quintaro,,,,0,0,8c823607-94f3-485c-ae20-c34ffb3238ee
2014-10-03T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/10/4897896/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,6ccf8033-b08a-4edf-9787-a4136b7273e6
2014-10-03T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/10/4897896/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,da9a61ef-09e0-41e0-9d36-8887cd953c81
2014-10-02T08:00:00.000+08:00,Markets Little Changed Ahead Of Friday's Jobs Report,LLY,https://www.benzinga.com/news/earnings/14/10/4895753/markets-little-changed-ahead-of-fridays-jobs-report,Jayson Derrick,,,,0,0,fc383c69-7570-4720-a001-01e9438aa12f
2014-10-02T08:00:00.000+08:00,Eli Lilly Will Discontinue Tabalumab Development of Efficacy Data,LLY,https://www.benzinga.com/news/14/10/4894006/eli-lilly-will-discontinue-tabalumab-development-of-efficacy-data,Paul Quintaro,,,,0,0,d5166827-7244-4bfc-9504-6db4930a6f9c
2014-10-02T08:00:00.000+08:00,"Guggenheim Securities Initiates Coverage on Eli Lilly and Company at Buy, Announces $80.00 PT",LLY,https://www.benzinga.com/news/14/10/4893395/guggenheim-securities-initiates-coverage-on-eli-lilly-and-company-at-buy-announce,Paul Quintaro,,,,0,0,c1778234-12d6-4a2c-ad60-32ab2f39e5f5
2014-10-02T08:00:00.000+08:00,Markets Little Changed Ahead Of Friday's Jobs Report,LLY,https://www.benzinga.com/news/earnings/14/10/4895753/markets-little-changed-ahead-of-fridays-jobs-report,Jayson Derrick,,,,0,0,7713daed-d787-47d5-bd0a-b4f942daa860
2014-10-02T08:00:00.000+08:00,Eli Lilly Will Discontinue Tabalumab Development of Efficacy Data,LLY,https://www.benzinga.com/news/14/10/4894006/eli-lilly-will-discontinue-tabalumab-development-of-efficacy-data,Paul Quintaro,,,,0,0,68169517-03d6-4784-b296-2c43e971c35b
2014-10-02T08:00:00.000+08:00,"Guggenheim Securities Initiates Coverage on Eli Lilly and Company at Buy, Announces $80.00 PT",LLY,https://www.benzinga.com/news/14/10/4893395/guggenheim-securities-initiates-coverage-on-eli-lilly-and-company-at-buy-announce,Paul Quintaro,,,,0,0,e17c69b7-d959-496a-b59a-3bf2fc82f074
2014-09-22T08:00:00.000+08:00,"Dyax Offers Highlights of Recent Progress in Licensing, Funded-Research Portfolio",LLY,https://www.benzinga.com/news/14/09/4865236/dyax-offers-highlights-of-recent-progress-in-licensing-funded-research-portfolio,Paul Quintaro,,,,0,0,31d49891-4119-47b4-a93a-745ac74c697d
2014-09-22T08:00:00.000+08:00,"Dyax Offers Highlights of Recent Progress in Licensing, Funded-Research Portfolio",LLY,https://www.benzinga.com/news/14/09/4865236/dyax-offers-highlights-of-recent-progress-in-licensing-funded-research-portfolio,Paul Quintaro,,,,0,0,32e3af37-a413-41f0-ac65-2c0156fd64a4
2014-09-18T08:00:00.000+08:00,Lilly Wins Approval From FDA For Diabetes Treatment Trulicity - Bloomberg,LLY,https://www.benzinga.com/news/14/09/4861043/lilly-wins-approval-from-fda-for-diabetes-treatment-trulicity-bloomberg,Paul Quintaro,,,,0,0,5fd741fb-25d7-49e2-9585-dc156363c69c
2014-09-18T08:00:00.000+08:00,Eli Lilly Reports CYRAMZA in Combo with Paclitaxel Showed Significant Improvement in Overall Survival in Second-Line Gastric Cancer Patients,LLY,https://www.benzinga.com/news/14/09/4859270/eli-lilly-reports-cyramza-in-combo-with-paclitaxel-showed-significant-improvement,Paul Quintaro,,,,0,0,489976aa-1f7a-4a66-8c1b-0ac40f75fb23
2014-09-18T08:00:00.000+08:00,Lilly Wins Approval From FDA For Diabetes Treatment Trulicity - Bloomberg,LLY,https://www.benzinga.com/news/14/09/4861043/lilly-wins-approval-from-fda-for-diabetes-treatment-trulicity-bloomberg,Paul Quintaro,,,,0,0,654766d5-8c03-49f5-b13c-7a25bbd66b18
2014-09-18T08:00:00.000+08:00,Eli Lilly Reports CYRAMZA in Combo with Paclitaxel Showed Significant Improvement in Overall Survival in Second-Line Gastric Cancer Patients,LLY,https://www.benzinga.com/news/14/09/4859270/eli-lilly-reports-cyramza-in-combo-with-paclitaxel-showed-significant-improvement,Paul Quintaro,,,,0,0,df9f09e2-f0c9-47e7-b167-3df4063e86c1
2014-09-17T08:00:00.000+08:00,"Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone",LLY,https://www.benzinga.com/news/14/09/4856827/lipocine-inc-halted-feds-eye-safety-efficacy-of-testosterone,John Seward,,,,0,0,80d699ee-4fbf-482b-b6f1-53b5640b0f4e
2014-09-17T08:00:00.000+08:00,"Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone",LLY,https://www.benzinga.com/news/14/09/4856827/lipocine-inc-halted-feds-eye-safety-efficacy-of-testosterone,John Seward,,,,0,0,4dcef026-9ce9-4da4-b6b0-306a9439bc3b
2014-09-16T08:00:00.000+08:00,"Denovo Biopharma Reports Purchase of Enzastaurin from Eli Lilly, Includes Rights to Develop, Manufacture, Commercialize, No Terms Disclosed",LLY,https://www.benzinga.com/news/14/09/4853617/denovo-biopharma-reports-purchase-of-enzastaurin-from-eli-lilly-includes-rights-t,Paul Quintaro,,,,0,0,39a4bad3-4024-431a-811c-aca93eca87de
2014-09-16T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to $500M in Milestones",LLY,https://www.benzinga.com/news/14/09/4851833/eli-lilly-astrazeneca-report-alliance-to-co-develop-potential-treatment-for-alzhe,Paul Quintaro,,,,0,0,f40b2b2d-c51d-4558-9804-5e8107fc2de8
2014-09-16T08:00:00.000+08:00,"Denovo Biopharma Reports Purchase of Enzastaurin from Eli Lilly, Includes Rights to Develop, Manufacture, Commercialize, No Terms Disclosed",LLY,https://www.benzinga.com/news/14/09/4853617/denovo-biopharma-reports-purchase-of-enzastaurin-from-eli-lilly-includes-rights-t,Paul Quintaro,,,,0,0,f0031524-1ce7-406a-8da8-56226e37b3c2
2014-09-16T08:00:00.000+08:00,"Eli Lilly, AstraZeneca Report Alliance to Co-Develop Potential Treatment for Alzheimer's, Lilly to Pay Up to $500M in Milestones",LLY,https://www.benzinga.com/news/14/09/4851833/eli-lilly-astrazeneca-report-alliance-to-co-develop-potential-treatment-for-alzhe,Paul Quintaro,,,,0,0,5d055b59-8909-41ed-8f32-4dea2dd77403
2014-09-12T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival,LLY,https://www.benzinga.com/news/14/09/4845416/lilly-announces-cyramza-phase-iii-second-line-colorectal-cancer-trial-meets-prima,Eddie Staley,,,,0,0,42c472d9-0e1f-45cd-b9ec-37672def15c8
2014-09-12T08:00:00.000+08:00,Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival,LLY,https://www.benzinga.com/news/14/09/4845416/lilly-announces-cyramza-phase-iii-second-line-colorectal-cancer-trial-meets-prima,Eddie Staley,,,,0,0,5f7dd614-7810-4dcd-9862-cad347426090
2014-09-08T08:00:00.000+08:00,What Is A High Risk Market?,LLY,https://www.benzinga.com/general/education/14/09/4829252/what-is-a-high-risk-market,Jim Probasco,,,,0,0,7d11f0e1-fd53-42f5-8519-44378bc9462f
2014-09-08T08:00:00.000+08:00,What Is A High Risk Market?,LLY,https://www.benzinga.com/general/education/14/09/4829252/what-is-a-high-risk-market,Jim Probasco,,,,0,0,25a20edb-f648-4a91-994a-40ca09562731
2014-09-04T08:00:00.000+08:00,"Lilly's Basal Insulin Peglispro Demonstrated Hba1c Superiority Against Lantus in Phase Iii Trials In Patients With Type 1 Diabetes; Expects US, EC Submissions By End of Q1 2015",LLY,https://www.benzinga.com/news/14/09/4825118/lillys-basal-insulin-peglispro-demonstrated-hba1c-superiority-against-lantus-in-p,Charles Gross,,,,0,0,222a60a8-d338-4e0a-bd3f-7b9e5c5e89af
2014-09-04T08:00:00.000+08:00,"Lilly's Basal Insulin Peglispro Demonstrated Hba1c Superiority Against Lantus in Phase Iii Trials In Patients With Type 1 Diabetes; Expects US, EC Submissions By End of Q1 2015",LLY,https://www.benzinga.com/news/14/09/4825118/lillys-basal-insulin-peglispro-demonstrated-hba1c-superiority-against-lantus-in-p,Charles Gross,,,,0,0,44ed65a1-9fb0-4601-8799-857c7eafd77c
2014-08-27T08:00:00.000+08:00,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend,LLY,https://www.benzinga.com/news/earnings/14/08/4809313/markets-little-changed-in-low-volume-and-slow-news-ahead-of-long-weekend,Jayson Derrick,,,,0,0,3ff543f3-f4ef-472a-a6bd-cf3a4f63ccdb
2014-08-27T08:00:00.000+08:00,Deutsche Bank: Eli Lilly At 'Critical Stage' In Its Journey,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/08/4808422/deutsche-bank-eli-lilly-at-critical-stage-in-its-journey,Jayson Derrick,,,,0,0,47cf5e89-f20c-4b6f-8230-6632c01d0b48
2014-08-27T08:00:00.000+08:00,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold",LLY,https://www.benzinga.com/news/14/08/4808624/deutsche-bank-starts-pfizer-lilly-at-buy-merck-bristol-myers-at-hold,Paul Quintaro,,,,0,0,6e919884-9929-4d5d-8bb7-9731014a26ce
2014-08-27T08:00:00.000+08:00,"Deutsche Bank Initiates Coverage on Eli Lilly and Company at Buy, Announces $71.00 PT",LLY,https://www.benzinga.com/news/14/08/4807106/deutsche-bank-initiates-coverage-on-eli-lilly-and-company-at-buy-announces-71-00-,Paul Quintaro,,,,0,0,9a1b412e-a6ae-423a-a813-5be1072d4974
2014-08-27T08:00:00.000+08:00,Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend,LLY,https://www.benzinga.com/news/earnings/14/08/4809313/markets-little-changed-in-low-volume-and-slow-news-ahead-of-long-weekend,Jayson Derrick,,,,0,0,8639f81c-6f59-461d-997b-6f878a36f04c
2014-08-27T08:00:00.000+08:00,Deutsche Bank: Eli Lilly At 'Critical Stage' In Its Journey,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/08/4808422/deutsche-bank-eli-lilly-at-critical-stage-in-its-journey,Jayson Derrick,,,,0,0,1530291b-7578-47dd-9c88-73f74f915582
2014-08-27T08:00:00.000+08:00,"Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold",LLY,https://www.benzinga.com/news/14/08/4808624/deutsche-bank-starts-pfizer-lilly-at-buy-merck-bristol-myers-at-hold,Paul Quintaro,,,,0,0,10ef2dd1-7402-40e1-9af2-5f22f3e8df66
2014-08-27T08:00:00.000+08:00,"Deutsche Bank Initiates Coverage on Eli Lilly and Company at Buy, Announces $71.00 PT",LLY,https://www.benzinga.com/news/14/08/4807106/deutsche-bank-initiates-coverage-on-eli-lilly-and-company-at-buy-announces-71-00-,Paul Quintaro,,,,0,0,b8644285-70df-45c9-a259-d98e8b3af4cd
2014-08-26T08:00:00.000+08:00,New Type 2 Diabetes Treatment Jardiance Tablets For Adults Now Available In U.S. Pharmacies,LLY,https://www.benzinga.com/news/14/08/4804308/new-type-2-diabetes-treatment-jardiance-tablets-for-adults-now-available-in-u-s-p,Eddie Staley,,,,0,0,67fdd62c-f4e4-476b-a584-1d8ad80d63b7
2014-08-26T08:00:00.000+08:00,Eli Lilly Reports New Type 2 Diabetes Treatment Jardiance Tabs Now Available in US Pharmacies,LLY,https://www.benzinga.com/news/14/08/4804300/eli-lilly-reports-new-type-2-diabetes-treatment-jardiance-tabs-now-available-in-u,Paul Quintaro,,,,0,0,5b0bb759-c36c-4cab-a47b-7a55371cbedd
2014-08-26T08:00:00.000+08:00,New Type 2 Diabetes Treatment Jardiance Tablets For Adults Now Available In U.S. Pharmacies,LLY,https://www.benzinga.com/news/14/08/4804308/new-type-2-diabetes-treatment-jardiance-tablets-for-adults-now-available-in-u-s-p,Eddie Staley,,,,0,0,20c82919-ef92-4402-b108-1edd66f29117
2014-08-26T08:00:00.000+08:00,Eli Lilly Reports New Type 2 Diabetes Treatment Jardiance Tabs Now Available in US Pharmacies,LLY,https://www.benzinga.com/news/14/08/4804300/eli-lilly-reports-new-type-2-diabetes-treatment-jardiance-tabs-now-available-in-u,Paul Quintaro,,,,0,0,e3876c20-7043-4709-85b0-c1719983ee2f
2014-08-21T08:00:00.000+08:00,Lilly's Ixekizumab Met all Primary and Key Secondary Objectives,LLY,https://www.benzinga.com/news/14/08/4795075/lillys-ixekizumab-met-all-primary-and-key-secondary-objectives,Charles Gross,,,,0,0,695d89a7-543f-4cb5-9967-e0d621490f01
2014-08-21T08:00:00.000+08:00,"Lilly's Ixekizumab Found Superior to Etanercept, Placebo in Phase 3 Trial, Met All Primary, Key Secondary Endpoints",LLY,https://www.benzinga.com/news/14/08/4795074/lillys-ixekizumab-found-superior-to-etanercept-placebo-in-phase-3-trial-met-all-p,Paul Quintaro,,,,0,0,9d8e3a54-958e-4c52-8236-1bd6bc78145b
2014-08-21T08:00:00.000+08:00,Lilly's Ixekizumab Met all Primary and Key Secondary Objectives,LLY,https://www.benzinga.com/news/14/08/4795075/lillys-ixekizumab-met-all-primary-and-key-secondary-objectives,Charles Gross,,,,0,0,7c4f0baf-20b7-4587-a03e-94b90cd4df3d
2014-08-21T08:00:00.000+08:00,"Lilly's Ixekizumab Found Superior to Etanercept, Placebo in Phase 3 Trial, Met All Primary, Key Secondary Endpoints",LLY,https://www.benzinga.com/news/14/08/4795074/lillys-ixekizumab-found-superior-to-etanercept-placebo-in-phase-3-trial-met-all-p,Paul Quintaro,,,,0,0,a8ca540a-0799-4c5e-8a2f-fe5e0e4edb63
2014-08-18T08:00:00.000+08:00,Eli Lilly reports FDA Granting of Tentative Approval for Basaglar,LLY,https://www.benzinga.com/news/14/08/4787801/eli-lilly-reports-fda-granting-of-tentative-approval-for-basaglar,Paul Quintaro,,,,0,0,7aa25f2e-3191-4b26-94f4-49c77be16cb9
2014-08-18T08:00:00.000+08:00,Eli Lilly reports FDA Granting of Tentative Approval for Basaglar,LLY,https://www.benzinga.com/news/14/08/4787801/eli-lilly-reports-fda-granting-of-tentative-approval-for-basaglar,Paul Quintaro,,,,0,0,1152ca18-97af-42f6-97d3-1adc37448e47
2014-08-11T08:00:00.000+08:00,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments,LLY,https://www.benzinga.com/news/earnings/14/08/4772254/markets-marginally-higher-on-light-volume-and-encouraging-geopolitical-d,Jayson Derrick,,,,0,0,ab61bf26-446a-45ea-9bad-5eee5db216da
2014-08-11T08:00:00.000+08:00,Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments,LLY,https://www.benzinga.com/news/earnings/14/08/4772254/markets-marginally-higher-on-light-volume-and-encouraging-geopolitical-d,Jayson Derrick,,,,0,0,26e6052c-6437-4f4a-963e-cc4202e785a8
2014-08-05T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/08/4757856/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,ad0871d5-293a-4070-94e6-18e8d7a4f638
2014-08-05T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/08/4757856/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,9b65fc2e-fc15-4ca0-b3a6-3c4a80c9aedb
2014-08-02T08:00:00.000+08:00,FDA Approves Jardiance Rempagliflozin Tablets for Adults withType 2 Diabetes,LLY,https://www.benzinga.com/news/14/08/4751561/fda-approves-jardiance-rempagliflozin-tablets-for-adults-withtype-2-diabetes,Charles Gross,,,,0,0,69fb047d-7e79-425a-a5ac-0a9a23fc5327
2014-08-02T08:00:00.000+08:00,FDA Approves Jardiance Rempagliflozin Tablets for Adults withType 2 Diabetes,LLY,https://www.benzinga.com/news/14/08/4751561/fda-approves-jardiance-rempagliflozin-tablets-for-adults-withtype-2-diabetes,Charles Gross,,,,0,0,c49e5168-f859-4442-9ecd-c4dd1c316912
2014-08-01T08:00:00.000+08:00,UPDATE: Tigress Initiates Coverage On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/initiation/14/08/4750945/update-tigress-initiates-coverage-on-eli-lilly,Ali Berri,,,,0,0,e607407f-ec5c-41d7-b947-8d71b9176219
2014-08-01T08:00:00.000+08:00,Tigress Financial Initiates Coverage on Eli Lilly and Company at Buy,LLY,https://www.benzinga.com/news/14/08/4750777/tigress-financial-initiates-coverage-on-eli-lilly-and-company-at-buy,Paul Quintaro,,,,0,0,58b0c5ba-4dc0-443b-92c3-c0d4cee0d27c
2014-08-01T08:00:00.000+08:00,UPDATE: Tigress Initiates Coverage On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/initiation/14/08/4750945/update-tigress-initiates-coverage-on-eli-lilly,Ali Berri,,,,0,0,ffc6c6fb-5327-4343-9d89-8eea388edeb8
2014-08-01T08:00:00.000+08:00,Tigress Financial Initiates Coverage on Eli Lilly and Company at Buy,LLY,https://www.benzinga.com/news/14/08/4750777/tigress-financial-initiates-coverage-on-eli-lilly-and-company-at-buy,Paul Quintaro,,,,0,0,47b1b826-3400-42d9-8a4b-edd65ac79575
2014-07-31T08:00:00.000+08:00,Dow Suffers 300 Point Drop; S&P 500 And NASDAQ Also Tumble,LLY,https://www.benzinga.com/news/earnings/14/07/4748027/dow-suffers-300-point-drop-s-p-500-and-nasdaq-also-tumble,Jayson Derrick,,,,0,0,d352bbf7-450c-40e1-b339-776d38c8d5df
2014-07-31T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/07/4747319/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,842fd235-da91-4887-a54a-b3923ac1308f
2014-07-31T08:00:00.000+08:00,Dow Suffers 300 Point Drop; S&P 500 And NASDAQ Also Tumble,LLY,https://www.benzinga.com/news/earnings/14/07/4748027/dow-suffers-300-point-drop-s-p-500-and-nasdaq-also-tumble,Jayson Derrick,,,,0,0,3412cfc3-2633-4f76-9f8f-89cc6c5e1f3d
2014-07-31T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/07/4747319/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,6bbedbc0-b54d-42cb-a0a6-de67f91376b4
2014-07-29T08:00:00.000+08:00,Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties,LLY,https://www.benzinga.com/news/earnings/14/07/4739183/stocks-lower-as-earnings-season-takes-back-seat-to-geopolitical-uncertai,Jayson Derrick,,,,0,0,2063b1d9-739c-4e92-bc1b-06195f64b361
2014-07-29T08:00:00.000+08:00,Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties,LLY,https://www.benzinga.com/news/earnings/14/07/4739183/stocks-lower-as-earnings-season-takes-back-seat-to-geopolitical-uncertai,Jayson Derrick,,,,0,0,c9eb7fa8-9e73-4ace-ac1c-d0fa4b24b1d9
2014-07-24T08:00:00.000+08:00,Thursday Morning Earnings Reports,LLY,https://www.benzinga.com/news/earnings/14/07/4727432/thursday-morning-earnings-reports,Ali Berri,,,,0,0,79f57d29-db13-4e55-bdfd-b5bdbb0a538b
2014-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 Adjusted EPS of $0.68 vs $0.65 Est; Revenue of $4.94B vs $4.88B Est,LLY,https://www.benzinga.com/news/earnings/14/07/4726147/eli-lilly-and-company-reports-q2-adjusted-eps-of-0-68-vs-0-65-est-revenu,Charles Gross,,,,0,0,67cbfe36-bb12-472c-b053-e893602f7f7e
2014-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2014",LLY,https://www.benzinga.com/news/earnings/14/07/4725954/earnings-scheduled-for-july-24-2014,Monica Gerson,,,,0,0,b54da106-d8d9-41b3-8f45-f1e51fb737b3
2014-07-24T08:00:00.000+08:00,Thursday Morning Earnings Reports,LLY,https://www.benzinga.com/news/earnings/14/07/4727432/thursday-morning-earnings-reports,Ali Berri,,,,0,0,81169fc7-864b-46c3-b46d-74b4b3c73cb2
2014-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 Adjusted EPS of $0.68 vs $0.65 Est; Revenue of $4.94B vs $4.88B Est,LLY,https://www.benzinga.com/news/earnings/14/07/4726147/eli-lilly-and-company-reports-q2-adjusted-eps-of-0-68-vs-0-65-est-revenu,Charles Gross,,,,0,0,f85b0a27-855b-4f66-a781-03915b12c216
2014-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2014",LLY,https://www.benzinga.com/news/earnings/14/07/4725954/earnings-scheduled-for-july-24-2014,Monica Gerson,,,,0,0,6ed891eb-9428-4bb9-862a-971e14a18694
2014-07-18T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/07/4713478/premarket-prep-technical-update-eli-lilly-trading-sharply-highe,Hal Lindon,,,,0,0,f7cf7727-4dfd-46f1-a319-7065ee8d5145
2014-07-18T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/07/4713478/premarket-prep-technical-update-eli-lilly-trading-sharply-highe,Hal Lindon,,,,0,0,fce585bd-3940-4e23-9efc-5a73f5f65779
2014-07-17T08:00:00.000+08:00,"Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results",LLY,https://www.benzinga.com/news/14/07/4707388/alzheimers-rates-falling-but-pharmas-search-for-a-cure-yields-no-results,Bruce Kennedy,,,,0,0,f3c6724c-f677-48c0-b1fb-7ab121ffa64e
2014-07-17T08:00:00.000+08:00,"Alzheimer's Rates Falling, But Pharma's Search For A Cure Yields No Results",LLY,https://www.benzinga.com/news/14/07/4707388/alzheimers-rates-falling-but-pharmas-search-for-a-cure-yields-no-results,Bruce Kennedy,,,,0,0,adca0c2d-b464-4e30-bc0f-90d9a8c1a1f3
2014-07-16T08:00:00.000+08:00,New Study Shows Beta-Amyloid Imaging Is Associated With Altered Diagnosis And Management Of Alzheimer's Disease,LLY,https://www.benzinga.com/news/14/07/4705758/new-study-shows-beta-amyloid-imaging-is-associated-with-altered-diagnosis-and-man,Eddie Staley,,,,0,0,1d39d49b-f884-44e3-8b23-f15204475674
2014-07-16T08:00:00.000+08:00,Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover And Co-Develop Novel Cancer Therapies,LLY,https://www.benzinga.com/news/14/07/4705393/lilly-and-immunocore-enter-immunotherapy-agreement-to-co-discover-and-co-develop-,Eddie Staley,,,,0,0,9002c83b-5beb-435b-8e8f-6712a7e458cc
2014-07-16T08:00:00.000+08:00,New Study Shows Beta-Amyloid Imaging Is Associated With Altered Diagnosis And Management Of Alzheimer's Disease,LLY,https://www.benzinga.com/news/14/07/4705758/new-study-shows-beta-amyloid-imaging-is-associated-with-altered-diagnosis-and-man,Eddie Staley,,,,0,0,c19c62eb-1e20-4e36-80f0-bd1917f4c969
2014-07-16T08:00:00.000+08:00,Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover And Co-Develop Novel Cancer Therapies,LLY,https://www.benzinga.com/news/14/07/4705393/lilly-and-immunocore-enter-immunotherapy-agreement-to-co-discover-and-co-develop-,Eddie Staley,,,,0,0,c69e8b8f-1d38-4937-bc4e-e62376817297
2014-07-15T08:00:00.000+08:00,Benzinga's Top #PreMarket Gainers,LLY,https://www.benzinga.com/news/14/07/4702184/benzingas-top-premarket-gainers,Monica Gerson,,,,0,0,b5acbfc6-d7c4-4575-86db-3ee9c49fb691
2014-07-15T08:00:00.000+08:00,US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings,LLY,https://www.benzinga.com/news/14/07/4701903/us-stock-futures-mostly-higher-ahead-of-goldman-sachs-earnings,Monica Gerson,,,,0,0,f6812ad5-6883-4e5b-9162-fa7d2d27a231
2014-07-15T08:00:00.000+08:00,New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/14/07/4701527/new-data-shows-cognitive-impairment-precedes-and-predicts-subsequent-functional-i,Charles Gross,,,,0,0,4426e183-6f51-487b-9854-49cb8cc94bae
2014-07-15T08:00:00.000+08:00,Benzinga's Top #PreMarket Gainers,LLY,https://www.benzinga.com/news/14/07/4702184/benzingas-top-premarket-gainers,Monica Gerson,,,,0,0,99d01e6b-0193-481f-a22f-edcc7745e564
2014-07-15T08:00:00.000+08:00,US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings,LLY,https://www.benzinga.com/news/14/07/4701903/us-stock-futures-mostly-higher-ahead-of-goldman-sachs-earnings,Monica Gerson,,,,0,0,506c55cc-6b99-4366-8354-7b6a744a5552
2014-07-15T08:00:00.000+08:00,New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimer's Disease,LLY,https://www.benzinga.com/news/14/07/4701527/new-data-shows-cognitive-impairment-precedes-and-predicts-subsequent-functional-i,Charles Gross,,,,0,0,05fc140d-2820-4090-a628-d881cca1004f
2014-07-14T08:00:00.000+08:00,Dow Sets New Intraday High; Citigroup Impresses With Earnings,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4700510/dow-sets-new-intraday-high-citigroup-impresses-with-earn,Jayson Derrick,,,,0,0,c37f2cc2-05b8-4cc5-a08a-026d5d8a6f37
2014-07-14T08:00:00.000+08:00,Dow Sets New Intraday High; Citigroup Impresses With Earnings,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4700510/dow-sets-new-intraday-high-citigroup-impresses-with-earn,Jayson Derrick,,,,0,0,800c8dcf-92ad-4b3a-94c1-d00add8e0550
2014-07-07T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/health-care/14/07/4684198/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,473f9ad1-c7db-435d-a261-670a84f722a5
2014-07-07T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/health-care/14/07/4684198/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,2e316884-4884-4db7-9440-bafd9a41e3c4
2014-07-02T08:00:00.000+08:00,Barclays Downgrades Pharmaceutical Sector,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4678189/barclays-downgrades-pharmaceutical-sector,John Seward,,,,0,0,ffa1d82e-55c6-4983-92ca-0355b5efdb34
2014-07-02T08:00:00.000+08:00,UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4677379/update-barclays-upgrades-eli-lilly-despite-sector-downgr,Eric Niederer,,,,0,0,fbd0506b-6728-4299-9ece-96172b2f7b05
2014-07-02T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/07/4677107/benzingas-top-upgrades,Monica Gerson,,,,0,0,d9aae934-31a5-4afa-ba7f-3bf8744257b8
2014-07-02T08:00:00.000+08:00,"Barclays Upgrades Eli Lilly and Company to Equal-weight, Raises PT to $63.00",LLY,https://www.benzinga.com/news/14/07/4676712/barclays-upgrades-eli-lilly-and-company-to-equal-weight-raises-pt-to-63-00,Paul Quintaro,,,,0,0,04d69dec-36f4-434d-9e8b-af3fce666af3
2014-07-02T08:00:00.000+08:00,Barclays Downgrades Pharmaceutical Sector,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4678189/barclays-downgrades-pharmaceutical-sector,John Seward,,,,0,0,3fb04b12-a321-4c82-abc3-9f7d8425dcc6
2014-07-02T08:00:00.000+08:00,UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4677379/update-barclays-upgrades-eli-lilly-despite-sector-downgr,Eric Niederer,,,,0,0,40b34a88-870a-43a3-971b-31d5deab41e2
2014-07-02T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/07/4677107/benzingas-top-upgrades,Monica Gerson,,,,0,0,2baad802-9d7c-45ec-93f1-462c63ccb3a4
2014-07-02T08:00:00.000+08:00,"Barclays Upgrades Eli Lilly and Company to Equal-weight, Raises PT to $63.00",LLY,https://www.benzinga.com/news/14/07/4676712/barclays-upgrades-eli-lilly-and-company-to-equal-weight-raises-pt-to-63-00,Paul Quintaro,,,,0,0,0f3f26a8-5727-4059-b37e-1c9a22c3e670
2014-06-27T08:00:00.000+08:00,CHMP Issues Positive Report For Lilly's Insulin Glargine Product,LLY,https://www.benzinga.com/news/14/06/4666384/chmp-issues-positive-report-for-lillys-insulin-glargine-product,Paul Quintaro,,,,0,0,beee620a-8a8c-4494-8db2-df3bdc2c9a35
2014-06-27T08:00:00.000+08:00,CHMP Issues Positive Report For Lilly's Insulin Glargine Product,LLY,https://www.benzinga.com/news/14/06/4666384/chmp-issues-positive-report-for-lillys-insulin-glargine-product,Paul Quintaro,,,,0,0,e2dc6be9-e3f0-4281-8c1a-12a9389fb7e7
2014-06-25T08:00:00.000+08:00,Bernstein Analysts Say A Hostile Deal with Eli Lilly Is Unlikely Because of Indiana Law,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4658975/bernstein-analysts-say-a-hostile-deal-with-eli-lilly-is-,Paul Quintaro,,,,0,0,34b3cf16-9026-4109-a5e3-fdf8226418a6
2014-06-25T08:00:00.000+08:00,Bernstein Analysts Say A Hostile Deal with Eli Lilly Is Unlikely Because of Indiana Law,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4658975/bernstein-analysts-say-a-hostile-deal-with-eli-lilly-is-,Paul Quintaro,,,,0,0,b2b2e8b4-53dc-4a01-8fd0-0137b9d915a0
2014-06-20T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4650060/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,f57c137f-6138-43d3-a756-40d19ccddd7c
2014-06-20T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4650060/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,fd69c2b9-0ef5-4793-919a-f17a4dcd469a
2014-06-15T08:00:00.000+08:00,Lilly Reports Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials,LLY,https://www.benzinga.com/news/14/06/4633912/lilly-reports-empagliflozinlinagliptin-combination-tablet-showed-reduction-in-blo,Charles Gross,,,,0,0,a0395211-7c67-4191-b307-51992a60f37a
2014-06-15T08:00:00.000+08:00,Lilly Reports Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials,LLY,https://www.benzinga.com/news/14/06/4633912/lilly-reports-empagliflozinlinagliptin-combination-tablet-showed-reduction-in-blo,Charles Gross,,,,0,0,18aa670a-a200-4a13-aa25-bd1d0cc3a103
2014-06-14T08:00:00.000+08:00,Lilly Announces New Data on Basal Insulin Peglispro Shows Novel Mechanism of Action,LLY,https://www.benzinga.com/news/14/06/4633691/lilly-announces-new-data-on-basal-insulin-peglispro-shows-novel-mechanism-of-acti,Charles Gross,,,,0,0,e6f82077-00fa-4dbf-b761-f3e828be8805
2014-06-14T08:00:00.000+08:00,Studies Show LY2963016 from Lilly and Boehringer Ingelheim has Similar Safety and Efficacy Profile to Lantus®,LLY,https://www.benzinga.com/news/14/06/4633690/studies-show-ly2963016-from-lilly-and-boehringer-ingelheim-has-similar-safety-and,Charles Gross,,,,0,0,4b6a1899-6011-466d-9c02-1935928c883b
2014-06-14T08:00:00.000+08:00,Lilly Announces New Data on Basal Insulin Peglispro Shows Novel Mechanism of Action,LLY,https://www.benzinga.com/news/14/06/4633691/lilly-announces-new-data-on-basal-insulin-peglispro-shows-novel-mechanism-of-acti,Charles Gross,,,,0,0,9346b920-c72e-4cb8-82e4-1e7e65ba8dc5
2014-06-14T08:00:00.000+08:00,Studies Show LY2963016 from Lilly and Boehringer Ingelheim has Similar Safety and Efficacy Profile to Lantus®,LLY,https://www.benzinga.com/news/14/06/4633690/studies-show-ly2963016-from-lilly-and-boehringer-ingelheim-has-similar-safety-and,Charles Gross,,,,0,0,4905d019-8185-41c2-a721-86e1768bed2e
2014-06-11T08:00:00.000+08:00,"Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss",LLY,https://www.benzinga.com/news/earnings/14/06/4626985/market-wrap-for-june-11-momentum-hit-dow-suffers-triple-digit-loss,Jayson Derrick,,,,0,0,8abace2c-fd53-4a0b-9af7-132c26be186d
2014-06-11T08:00:00.000+08:00,"Eli Lilly Announces Top-Line Results oh Phase III Hepatocellular Carcinoma Trial, Says Did Not Meet Primary Endpoint",LLY,https://www.benzinga.com/news/14/06/4624966/eli-lilly-announces-top-line-results-oh-phase-iii-hepatocellular-carcinoma-trial-,Paul Quintaro,,,,0,0,c6904994-cd91-48f1-873e-e6b836595bfc
2014-06-11T08:00:00.000+08:00,"Market Wrap For June 11: Momentum Hit, Dow Suffers Triple Digit Loss",LLY,https://www.benzinga.com/news/earnings/14/06/4626985/market-wrap-for-june-11-momentum-hit-dow-suffers-triple-digit-loss,Jayson Derrick,,,,0,0,bd4564fe-384c-418a-bffe-dbdba2b15b18
2014-06-11T08:00:00.000+08:00,"Eli Lilly Announces Top-Line Results oh Phase III Hepatocellular Carcinoma Trial, Says Did Not Meet Primary Endpoint",LLY,https://www.benzinga.com/news/14/06/4624966/eli-lilly-announces-top-line-results-oh-phase-iii-hepatocellular-carcinoma-trial-,Paul Quintaro,,,,0,0,211b6684-f0a0-4b42-859a-a8e43d95c55a
2014-06-04T08:00:00.000+08:00,ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?,LLY,https://www.benzinga.com/news/14/06/4606298/asco-meeting-day-3-do-more-treatments-equal-a-longer-life,Erika Janowicz,,,,0,0,864d962b-943d-48d3-acf7-1ff0e3cdb38f
2014-06-04T08:00:00.000+08:00,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy,LLY,https://www.benzinga.com/news/14/06/4606039/asco-meeting-day-2-promising-results-from-jnjs-imbruvica-targeted-therapy,Erika Janowicz,,,,0,0,0618d9b8-d9d3-478f-a97f-ac485eac2ae3
2014-06-04T08:00:00.000+08:00,ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?,LLY,https://www.benzinga.com/news/14/06/4606298/asco-meeting-day-3-do-more-treatments-equal-a-longer-life,Erika Janowicz,,,,0,0,6d98850f-4f1f-47cc-81a2-3b61fd192cca
2014-06-04T08:00:00.000+08:00,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy,LLY,https://www.benzinga.com/news/14/06/4606039/asco-meeting-day-2-promising-results-from-jnjs-imbruvica-targeted-therapy,Erika Janowicz,,,,0,0,e319f875-7082-45d3-b3e3-d09a4fabee3b
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Finding Resistance At $60.00,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602067/premarket-prep-technical-update-eli-lilly-finding-resistance-at,Hal Lindon,,,,0,0,8862063b-3254-4ce6-934f-ecb1ba05db07
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602065/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,0,0,4b7a6d00-2355-4a5a-a555-0bd9cd9eb6e4
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602063/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,e963479b-ed59-45bf-8ecf-2b9b726b209e
2014-06-02T08:00:00.000+08:00,UPDATE: Morgan Stanley Reiterates On Eli Lilly & Co. On Lackluster Survival Benefit,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4600908/update-morgan-stanley-reiterates-on-eli-lilly-co-on-lack,Dwight Einhorn,,,,0,0,5e21d37a-7c3e-4ada-9dec-d591e4566108
2014-06-02T08:00:00.000+08:00,Lilly Reports Increased Access to Clinical Trials Data for Qualified Researchers,LLY,https://www.benzinga.com/news/14/06/4600494/lilly-reports-increased-access-to-clinical-trials-data-for-qualified-researchers,Hal Lindon,,,,0,0,fc7b73a8-d21c-486c-94c1-a07d0b433931
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Finding Resistance At $60.00,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602067/premarket-prep-technical-update-eli-lilly-finding-resistance-at,Hal Lindon,,,,0,0,394ebdbd-1413-4652-9fc8-957ee3d8f0a3
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602065/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,0,0,a8db0edf-cad8-47c6-92f7-77fb8172c6f4
2014-06-02T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/06/4602063/premarket-prep-technical-update-eli-lilly-trading-lower,Hal Lindon,,,,0,0,e8b5fb4e-8098-46f0-a8c4-b1738bc7e8a1
2014-06-02T08:00:00.000+08:00,UPDATE: Morgan Stanley Reiterates On Eli Lilly & Co. On Lackluster Survival Benefit,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4600908/update-morgan-stanley-reiterates-on-eli-lilly-co-on-lack,Dwight Einhorn,,,,0,0,66813ffe-b23f-45c5-9f1b-42ab8144b84e
2014-06-02T08:00:00.000+08:00,Lilly Reports Increased Access to Clinical Trials Data for Qualified Researchers,LLY,https://www.benzinga.com/news/14/06/4600494/lilly-reports-increased-access-to-clinical-trials-data-for-qualified-researchers,Hal Lindon,,,,0,0,6e22cc3c-0ac4-4d20-9848-c59e8dbda278
2014-05-30T08:00:00.000+08:00,US Stock Futures Edge Lower Ahead Of Consumer Spending Report,LLY,https://www.benzinga.com/news/14/05/4596217/us-stock-futures-edge-lower-ahead-of-consumer-spending-report,Monica Gerson,,,,0,0,d1a4ba13-7412-4d04-bea5-7b51e38dc1b2
2014-05-30T08:00:00.000+08:00,QIAGEN Announces Collaboration with Lilly,LLY,https://www.benzinga.com/news/14/05/4595994/qiagen-announces-collaboration-with-lilly,Charles Gross,,,,0,0,e9ae574d-dfca-4688-aea8-591410db93fb
2014-05-30T08:00:00.000+08:00,US Stock Futures Edge Lower Ahead Of Consumer Spending Report,LLY,https://www.benzinga.com/news/14/05/4596217/us-stock-futures-edge-lower-ahead-of-consumer-spending-report,Monica Gerson,,,,0,0,0ab87231-c602-4188-852d-71cf1589d004
2014-05-30T08:00:00.000+08:00,QIAGEN Announces Collaboration with Lilly,LLY,https://www.benzinga.com/news/14/05/4595994/qiagen-announces-collaboration-with-lilly,Charles Gross,,,,0,0,ca15acbf-b3d7-4161-b0f5-ecfb71a3e34f
2014-05-28T08:00:00.000+08:00,"Sanofi, Lilly Announce Licensing Agreement for Nonprescription Cialis",LLY,https://www.benzinga.com/news/14/05/4587949/sanofi-lilly-announce-licensing-agreement-for-nonprescription-cialis,Charles Gross,,,,0,0,537829f4-02a7-4563-a47c-a46be5ec57a5
2014-05-28T08:00:00.000+08:00,"Sanofi, Lilly Announce Licensing Agreement for Nonprescription Cialis",LLY,https://www.benzinga.com/news/14/05/4587949/sanofi-lilly-announce-licensing-agreement-for-nonprescription-cialis,Charles Gross,,,,0,0,67891855-66e2-4c2d-aa4d-dfd30e790bcf
2014-05-27T08:00:00.000+08:00,Eli Lilly Announces Will Hold Investor Web Call on Jun. 16th to Discuss Phase III Data for Dulaglutide,LLY,https://www.benzinga.com/news/14/05/4586375/eli-lilly-announces-will-hold-investor-web-call-on-jun-16th-to-discuss-phase-iii-,Hal Lindon,,,,0,0,ab8a46f2-4104-490e-93de-8848806dcc03
2014-05-27T08:00:00.000+08:00,Eli Lilly Announces Will Hold Investor Web Call on Jun. 16th to Discuss Phase III Data for Dulaglutide,LLY,https://www.benzinga.com/news/14/05/4586375/eli-lilly-announces-will-hold-investor-web-call-on-jun-16th-to-discuss-phase-iii-,Hal Lindon,,,,0,0,c4c8b5e9-f105-4e0c-af0c-cd561a54fa57
2014-05-22T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4578583/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,2cd246b5-c4cb-4ec5-9650-46e0782b2b9e
2014-05-22T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading HIgher,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4578583/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,37452c67-5fa8-4ea7-861d-4ece1a767006
2014-05-15T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4560138/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,0,0,279f2c11-c6fc-40e8-bc2a-ab4364a1e95c
2014-05-15T08:00:00.000+08:00,Eli Lilly Announces Linagliptin Positive Results,LLY,https://www.benzinga.com/news/14/05/4560136/eli-lilly-announces-linagliptin-positive-results,Hal Lindon,,,,0,0,9d216e06-b9f5-4ca3-b679-05c4024dc337
2014-05-15T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4560138/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,0,0,050666ff-02de-4272-9652-7c77f75e2c83
2014-05-15T08:00:00.000+08:00,Eli Lilly Announces Linagliptin Positive Results,LLY,https://www.benzinga.com/news/14/05/4560136/eli-lilly-announces-linagliptin-positive-results,Hal Lindon,,,,0,0,2acad809-6e87-4656-b7f6-92f82af73c20
2014-05-14T08:00:00.000+08:00,Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent Activity,LLY,https://www.benzinga.com/news/14/05/4556838/lilly-says-abemaciclib-in-phase-1-study-demonstrated-single-agent-activity,Paul Quintaro,,,,0,0,db5df026-9868-49b7-973b-b4d28579b154
2014-05-14T08:00:00.000+08:00,"Stocks To Watch For May 14, 2014",LLY,https://www.benzinga.com/trading-ideas/technicals/14/05/4552883/stocks-to-watch-for-may-14-2014,António Costa,,,,0,0,accd2970-8d2f-41bf-a1c3-935aa254a29c
2014-05-14T08:00:00.000+08:00,Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent Activity,LLY,https://www.benzinga.com/news/14/05/4556838/lilly-says-abemaciclib-in-phase-1-study-demonstrated-single-agent-activity,Paul Quintaro,,,,0,0,0c245bba-b7a7-4b57-82b9-d2cb7ce4add3
2014-05-14T08:00:00.000+08:00,"Stocks To Watch For May 14, 2014",LLY,https://www.benzinga.com/trading-ideas/technicals/14/05/4552883/stocks-to-watch-for-may-14-2014,António Costa,,,,0,0,0b4f08b7-ed5b-4787-a5ea-6bbea9219749
2014-05-12T08:00:00.000+08:00,Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry,LLY,https://www.benzinga.com/news/14/05/4548238/google-celebrates-dorothy-hodgkin-her-contributions-to-chemistry,Erika Janowicz,,,,0,0,6966d452-18f2-4f73-8469-874ede90fba2
2014-05-12T08:00:00.000+08:00,UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,LLY,https://www.benzinga.com/news/14/05/4546503/update-eli-lilly-announces-peglispro-shows-superiority-compared-to-insulin-glargi,Hal Lindon,,,,0,0,ab0272a0-9306-40f7-9180-b4f90435d543
2014-05-12T08:00:00.000+08:00,Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,LLY,https://www.benzinga.com/news/14/05/4546488/eli-lilly-announces-peglispro-shows-superiority-compared-to-insulin-glargine-in-h,Paul Quintaro,,,,0,0,9e5c86b2-0cc7-4629-910a-454487d997e9
2014-05-12T08:00:00.000+08:00,Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry,LLY,https://www.benzinga.com/news/14/05/4548238/google-celebrates-dorothy-hodgkin-her-contributions-to-chemistry,Erika Janowicz,,,,0,0,2bcec4a4-132f-450f-9636-29d541cf0038
2014-05-12T08:00:00.000+08:00,UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,LLY,https://www.benzinga.com/news/14/05/4546503/update-eli-lilly-announces-peglispro-shows-superiority-compared-to-insulin-glargi,Hal Lindon,,,,0,0,a7215ece-5d70-4d8c-9206-20d5c32d1493
2014-05-12T08:00:00.000+08:00,Eli Lilly Announces Peglispro Shows Superiority Compared to Insulin Glargine in HBA1C,LLY,https://www.benzinga.com/news/14/05/4546488/eli-lilly-announces-peglispro-shows-superiority-compared-to-insulin-glargine-in-h,Paul Quintaro,,,,0,0,66a37d59-0f17-4ceb-b573-e9d4e137f212
2014-05-09T08:00:00.000+08:00,Lilly Strongly Disagrees with Court's Ruling in Brazil Labor Case,LLY,https://www.benzinga.com/news/14/05/4544324/lilly-strongly-disagrees-with-courts-ruling-in-brazil-labor-case,Charles Gross,,,,0,0,7256cf7e-1997-48a7-b18e-ddd574407ea9
2014-05-09T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4543359/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,0,0,7ea291ae-79e3-4a88-bc55-4fe30ffa3f82
2014-05-09T08:00:00.000+08:00,Lilly Strongly Disagrees with Court's Ruling in Brazil Labor Case,LLY,https://www.benzinga.com/news/14/05/4544324/lilly-strongly-disagrees-with-courts-ruling-in-brazil-labor-case,Charles Gross,,,,0,0,9c2a9070-4b69-4c22-a394-0d33adc25111
2014-05-09T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Sharply Lower,LLY,https://www.benzinga.com/general/movers-shakers/14/05/4543359/premarket-prep-technical-update-eli-lilly-trading-sharply-lower,Hal Lindon,,,,0,0,cb3238e9-555d-4310-a582-a7fc742aa1dd
2014-04-29T08:00:00.000+08:00,Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting,LLY,https://www.benzinga.com/news/14/04/4509591/market-wrap-for-april-29-dow-approaches-record-highs-despite-ongoing-ukraine-tens,Jayson Derrick,,,,0,0,6c6d62df-4eb4-4d45-a852-7d7c2dcc53c9
2014-04-29T08:00:00.000+08:00,Market Wrap For April 29: Dow Approaches Record Highs Despite Ongoing Ukraine Tension and Upcoming Fed Meeting,LLY,https://www.benzinga.com/news/14/04/4509591/market-wrap-for-april-29-dow-approaches-record-highs-despite-ongoing-ukraine-tens,Jayson Derrick,,,,0,0,f94660a4-26c6-4dea-a24e-ee6485a56783
2014-04-24T08:00:00.000+08:00,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,LLY,https://www.benzinga.com/news/14/04/4497474/market-wrap-for-april-24-apples-smashing-earnings-overshadowed-by-ukraine-concern,Jayson Derrick,,,,0,0,f65df124-4c60-4c31-8354-c84d46ef77cf
2014-04-24T08:00:00.000+08:00,"Eli Lilly Reports Q1 Adjusted EPS of $0.70, Inline; Revenue of $4.68B vs $4.79B Est",LLY,https://www.benzinga.com/news/earnings/14/04/4494361/eli-lilly-reports-q1-adjusted-eps-of-0-70-inline-revenue-of-4-68b-vs-4-7,Charles Gross,,,,0,0,e5ae8f3e-04d1-4d47-8261-94fb1404c50a
2014-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2014",LLY,https://www.benzinga.com/news/earnings/14/04/4494236/earnings-scheduled-for-april-24-2014,Monica Gerson,,,,0,0,379ad53e-0a2a-438a-aae2-9cea0c8b5a5b
2014-04-24T08:00:00.000+08:00,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,LLY,https://www.benzinga.com/news/14/04/4497474/market-wrap-for-april-24-apples-smashing-earnings-overshadowed-by-ukraine-concern,Jayson Derrick,,,,0,0,997ec34a-d0b2-45b2-89f3-97a7aaa2ae91
2014-04-24T08:00:00.000+08:00,"Eli Lilly Reports Q1 Adjusted EPS of $0.70, Inline; Revenue of $4.68B vs $4.79B Est",LLY,https://www.benzinga.com/news/earnings/14/04/4494361/eli-lilly-reports-q1-adjusted-eps-of-0-70-inline-revenue-of-4-68b-vs-4-7,Charles Gross,,,,0,0,d8757631-104b-4faf-b44f-22f3178e463c
2014-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2014",LLY,https://www.benzinga.com/news/earnings/14/04/4494236/earnings-scheduled-for-april-24-2014,Monica Gerson,,,,0,0,3b846dd3-12fb-4022-8ad6-df60c2686b1a
2014-04-23T08:00:00.000+08:00,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split",LLY,https://www.benzinga.com/news/earnings/14/04/4492955/market-wrap-for-april-23-s-p-500-ends-winning-streak-apple-announces-7-f,Jayson Derrick,,,,0,0,b11f0adb-ccc5-4e9d-9df8-24e3338f5367
2014-04-23T08:00:00.000+08:00,MKM Partners Downgrades Eli Lilly and Company to Neutral,LLY,https://www.benzinga.com/news/14/04/4490412/mkm-partners-downgrades-eli-lilly-and-company-to-neutral,Paul Quintaro,,,,0,0,292b4119-fb21-4162-8dde-ff649a3c7171
2014-04-23T08:00:00.000+08:00,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split",LLY,https://www.benzinga.com/news/earnings/14/04/4492955/market-wrap-for-april-23-s-p-500-ends-winning-streak-apple-announces-7-f,Jayson Derrick,,,,0,0,6b737375-7e0a-4538-972e-1eab5af2a67a
2014-04-23T08:00:00.000+08:00,MKM Partners Downgrades Eli Lilly and Company to Neutral,LLY,https://www.benzinga.com/news/14/04/4490412/mkm-partners-downgrades-eli-lilly-and-company-to-neutral,Paul Quintaro,,,,0,0,63469885-3308-4cd4-ba4f-d472077a479b
2014-04-22T08:00:00.000+08:00,"Benzinga's M&A Chatter for Tuesday April 22, 2014",LLY,https://www.benzinga.com/news/14/04/4489040/benzingas-m-a-chatter-for-tuesday-april-22-2014,Charles Gross,,,,0,0,c8205a22-4a4d-4f89-b14e-70a2083f23bd
2014-04-22T08:00:00.000+08:00,US Stock Futures Edge Higher Ahead Of McDonald's Earnings,LLY,https://www.benzinga.com/news/14/04/4486136/us-stock-futures-edge-higher-ahead-of-mcdonalds-earnings,Monica Gerson,,,,0,0,bdf283a2-c1d3-4950-90a9-aecb97b80172
2014-04-22T08:00:00.000+08:00,Lilly to Acquire Novartis Animal Health for Approximately $5.4B in Cash,LLY,https://www.benzinga.com/news/14/04/4485754/lilly-to-acquire-novartis-animal-health-for-approximately-5-4b-in-cash,Charles Gross,,,,0,0,a8fb0f9b-6656-4d41-885d-c41da3d56d00
2014-04-22T08:00:00.000+08:00,"Benzinga's M&A Chatter for Tuesday April 22, 2014",LLY,https://www.benzinga.com/news/14/04/4489040/benzingas-m-a-chatter-for-tuesday-april-22-2014,Charles Gross,,,,0,0,3cd3456d-b626-4a74-a817-0cbfbd4e123d
2014-04-22T08:00:00.000+08:00,US Stock Futures Edge Higher Ahead Of McDonald's Earnings,LLY,https://www.benzinga.com/news/14/04/4486136/us-stock-futures-edge-higher-ahead-of-mcdonalds-earnings,Monica Gerson,,,,0,0,fd628e46-66f2-452c-b0ac-74d8f6a4b2cf
2014-04-22T08:00:00.000+08:00,Lilly to Acquire Novartis Animal Health for Approximately $5.4B in Cash,LLY,https://www.benzinga.com/news/14/04/4485754/lilly-to-acquire-novartis-animal-health-for-approximately-5-4b-in-cash,Charles Gross,,,,0,0,06dcaedd-bd8d-474a-95fd-c89fce3c3f38
2014-04-21T08:00:00.000+08:00,UPDATE: Lilly's CYRAMZA is First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy,LLY,https://www.benzinga.com/news/14/04/4485121/update-lillys-cyramza-is-first-fda-approved-treatment-for-advanced-gastric-cancer,Charles Gross,,,,0,0,9dad7743-a891-4c4d-b415-6f34d435574d
2014-04-21T08:00:00.000+08:00,FDA Approves Cyramza for Stomach Cancer,LLY,https://www.benzinga.com/news/14/04/4484605/fda-approves-cyramza-for-stomach-cancer,Charles Gross,,,,0,0,4315e38a-69b5-430d-a2dd-1db050df6dcc
2014-04-21T08:00:00.000+08:00,"No Legwork Mondays – Takeda, Eli Lilly And Actos",LLY,https://www.benzinga.com/markets/14/04/4470420/no-legwork-mondays-takeda-eli-lilly-and-actos,Tabitha Jean Naylor,,,,0,0,956254ba-b102-4257-9ebf-b25e17116c95
2014-04-21T08:00:00.000+08:00,UPDATE: Lilly's CYRAMZA is First FDA-Approved Treatment for Advanced Gastric Cancer After Prior Chemotherapy,LLY,https://www.benzinga.com/news/14/04/4485121/update-lillys-cyramza-is-first-fda-approved-treatment-for-advanced-gastric-cancer,Charles Gross,,,,0,0,e3d1526e-e3fa-4e87-8f03-a420b6d43f2f
2014-04-21T08:00:00.000+08:00,FDA Approves Cyramza for Stomach Cancer,LLY,https://www.benzinga.com/news/14/04/4484605/fda-approves-cyramza-for-stomach-cancer,Charles Gross,,,,0,0,72945f24-7864-444e-b9ff-5c735d12969a
2014-04-21T08:00:00.000+08:00,"No Legwork Mondays – Takeda, Eli Lilly And Actos",LLY,https://www.benzinga.com/markets/14/04/4470420/no-legwork-mondays-takeda-eli-lilly-and-actos,Tabitha Jean Naylor,,,,0,0,1215116a-91b0-45f7-9f10-e5153e43b937
2014-04-17T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/trading-ideas/technicals/14/04/4480002/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,0c2a25c0-9525-408f-8d52-2791165b085e
2014-04-17T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/trading-ideas/technicals/14/04/4480002/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,64c51107-8d89-4164-a66e-19ef02a1ca07
2014-04-14T08:00:00.000+08:00,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings",LLY,https://www.benzinga.com/news/14/04/4469346/market-wrap-for-april-14-markets-surge-on-positive-retail-data-citi-earnings,Jayson Derrick,,,,0,0,f55c295d-810a-4528-b538-11e1fcc6bd1b
2014-04-14T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/04/4469026/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,842f0577-08fd-4e1c-a03a-05e215cbd88e
2014-04-14T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $54.00",LLY,https://www.benzinga.com/news/14/04/4467649/jefferies-upgrades-eli-lilly-and-company-to-hold-raises-pt-to-54-00,Hal Lindon,,,,0,0,71eb94df-beb4-4306-a5b3-3f87a1da463a
2014-04-14T08:00:00.000+08:00,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings",LLY,https://www.benzinga.com/news/14/04/4469346/market-wrap-for-april-14-markets-surge-on-positive-retail-data-citi-earnings,Jayson Derrick,,,,0,0,ec990b97-def2-471a-ba9a-d9285689b579
2014-04-14T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Trading Higher,LLY,https://www.benzinga.com/general/movers-shakers/14/04/4469026/premarket-prep-technical-update-eli-lilly-trading-higher,Hal Lindon,,,,0,0,f1c0f0ec-2551-4648-8d56-b431f5f78234
2014-04-14T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $54.00",LLY,https://www.benzinga.com/news/14/04/4467649/jefferies-upgrades-eli-lilly-and-company-to-hold-raises-pt-to-54-00,Hal Lindon,,,,0,0,a6649451-de7a-4652-9997-7b208df821f8
2014-04-10T08:00:00.000+08:00,Eli Lilly to Report First Quarter Results April 24th Before Market Open,LLY,https://www.benzinga.com/news/earnings/14/04/4462889/eli-lilly-to-report-first-quarter-results-april-24th-before-market-open,David Johnson,,,,0,0,ca82a87b-b558-43cc-9340-81c501513724
2014-04-10T08:00:00.000+08:00,Eli Lilly to Report First Quarter Results April 24th Before Market Open,LLY,https://www.benzinga.com/news/earnings/14/04/4462889/eli-lilly-to-report-first-quarter-results-april-24th-before-market-open,David Johnson,,,,0,0,ea7d3aa8-07fc-4132-998e-6951e3f8c352
2014-04-09T08:00:00.000+08:00,Anne Marie Baiynd tweets: 'Careful with $LLY - looks like it is on its way to fill the gap',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4457085/anne-marie-baiynd-tweets-careful-with-lly-looks-like-it-,David Johnson,,,,0,0,899f799c-ebee-495d-af05-2fa29b0970d5
2014-04-09T08:00:00.000+08:00,Anne Marie Baiynd tweets: 'Careful with $LLY - looks like it is on its way to fill the gap',LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4457085/anne-marie-baiynd-tweets-careful-with-lly-looks-like-it-,David Johnson,,,,0,0,ff69607e-356f-46df-9a0c-a281d4f7f3fb
2014-04-08T08:00:00.000+08:00,Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins,LLY,https://www.benzinga.com/news/14/04/4455649/market-wrap-for-april-8-markets-bounce-higher-as-earnings-season-begins,Jayson Derrick,,,,0,0,eee89727-899f-4dc5-a360-c32440fc1709
2014-04-08T08:00:00.000+08:00,Fitch Says Lilly's Ratings Intact Following $9B Actos Jury Verdict,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4454915/fitch-says-lillys-ratings-intact-following-9b-actos-jury,Charles Gross,,,,0,0,f513f878-45b0-4633-a76f-79a7f971b832
2014-04-08T08:00:00.000+08:00,UPDATE: BMO Capital Upgrades Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4454720/update-bmo-capital-upgrades-eli-lilly,Kurt Zuschlag,,,,0,0,1aad4278-f464-4d04-b856-28ad25c197f5
2014-04-08T08:00:00.000+08:00,Mark Schoenebaum Tweet: '$LLY will owe nothing in this lost court case. THEY ARE INDEMNIFIED. yet stock down. weird',LLY,https://www.benzinga.com/news/14/04/4454213/mark-schoenebaum-tweet-lly-will-owe-nothing-in-this-lost-court-case-they-are-inde,Charles Gross,,,,0,0,250844c7-20c7-45f1-a288-1938f5bbbd62
2014-04-08T08:00:00.000+08:00,"Lilly Issues Response to Verdict in Case of Terrence Allen, et al. v. Takeda, Says Lilly Will Be Indemnified for Expenses",LLY,https://www.benzinga.com/news/14/04/4454028/lilly-issues-response-to-verdict-in-case-of-terrence-allen-et-al-v-takeda-says-li,Paul Quintaro,,,,0,0,8af99583-eace-4db3-8f2d-e0bede6e3bb3
2014-04-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/04/4453756/benzingas-top-upgrades,Monica Gerson,,,,0,0,38314119-be36-4e44-8a21-e57a1e3fb45b
2014-04-08T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly and Company to Market Perform, Raises PT to $62.00",LLY,https://www.benzinga.com/news/14/04/4453341/bmo-capital-upgrades-eli-lilly-and-company-to-market-perform-raises-pt-to-62-00,Hal Lindon,,,,0,0,82db7a22-bbef-4f34-9497-4602a04f18d7
2014-04-08T08:00:00.000+08:00,Takeda Responds to $6B Verdict in Diabetes Drug Case,LLY,https://www.benzinga.com/news/14/04/4453097/takeda-responds-to-6b-verdict-in-diabetes-drug-case,Charles Gross,,,,0,0,feb6a63c-1697-49ac-b6dd-5160100c505e
2014-04-08T08:00:00.000+08:00,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/14/04/4452855/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,,,,0,0,e59a6625-5db7-46d0-8aa3-6949ed6fe85a
2014-04-08T08:00:00.000+08:00,Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins,LLY,https://www.benzinga.com/news/14/04/4455649/market-wrap-for-april-8-markets-bounce-higher-as-earnings-season-begins,Jayson Derrick,,,,0,0,b402e675-bd55-4618-9c2c-ecc4ae82419e
2014-04-08T08:00:00.000+08:00,Fitch Says Lilly's Ratings Intact Following $9B Actos Jury Verdict,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4454915/fitch-says-lillys-ratings-intact-following-9b-actos-jury,Charles Gross,,,,0,0,aab49983-942d-494a-93ee-02c77c7902dc
2014-04-08T08:00:00.000+08:00,UPDATE: BMO Capital Upgrades Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4454720/update-bmo-capital-upgrades-eli-lilly,Kurt Zuschlag,,,,0,0,23805160-adf1-471f-800a-d40b76ba3693
2014-04-08T08:00:00.000+08:00,Mark Schoenebaum Tweet: '$LLY will owe nothing in this lost court case. THEY ARE INDEMNIFIED. yet stock down. weird',LLY,https://www.benzinga.com/news/14/04/4454213/mark-schoenebaum-tweet-lly-will-owe-nothing-in-this-lost-court-case-they-are-inde,Charles Gross,,,,0,0,bb5cb871-163f-4543-82dd-3ee802192c48
2014-04-08T08:00:00.000+08:00,"Lilly Issues Response to Verdict in Case of Terrence Allen, et al. v. Takeda, Says Lilly Will Be Indemnified for Expenses",LLY,https://www.benzinga.com/news/14/04/4454028/lilly-issues-response-to-verdict-in-case-of-terrence-allen-et-al-v-takeda-says-li,Paul Quintaro,,,,0,0,d8b4be7d-d0cc-4782-a276-095a809f8c19
2014-04-08T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/04/4453756/benzingas-top-upgrades,Monica Gerson,,,,0,0,4eb921e2-981b-4e23-b453-84bd31a7d81d
2014-04-08T08:00:00.000+08:00,"BMO Capital Upgrades Eli Lilly and Company to Market Perform, Raises PT to $62.00",LLY,https://www.benzinga.com/news/14/04/4453341/bmo-capital-upgrades-eli-lilly-and-company-to-market-perform-raises-pt-to-62-00,Hal Lindon,,,,0,0,bf6a834a-e961-4455-a0a7-fc3ad3d19361
2014-04-08T08:00:00.000+08:00,Takeda Responds to $6B Verdict in Diabetes Drug Case,LLY,https://www.benzinga.com/news/14/04/4453097/takeda-responds-to-6b-verdict-in-diabetes-drug-case,Charles Gross,,,,0,0,34ba0a10-06dd-412e-af75-58ff9b0d8eca
2014-04-08T08:00:00.000+08:00,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/14/04/4452855/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,,,,0,0,c85326c5-58da-4484-a73b-f67952ca045d
2014-04-06T08:00:00.000+08:00,Lilly to Present Early-Stage Data Targeting Key Cancer Pathways at AACR 2014,LLY,https://www.benzinga.com/news/14/04/4449061/lilly-to-present-early-stage-data-targeting-key-cancer-pathways-at-aacr-2014,Charles Gross,,,,0,0,d9aa0fc3-9516-483c-94a0-ce7f73acfa7e
2014-04-06T08:00:00.000+08:00,Lilly to Present Early-Stage Data Targeting Key Cancer Pathways at AACR 2014,LLY,https://www.benzinga.com/news/14/04/4449061/lilly-to-present-early-stage-data-targeting-key-cancer-pathways-at-aacr-2014,Charles Gross,,,,0,0,6f0ce50b-1b1c-4d25-a842-7ed453b8ded0
2014-04-03T08:00:00.000+08:00,Market Wrap For April 3: Markets Winning Streak Fails To Extend To Five Days,LLY,https://www.benzinga.com/news/14/04/4445359/market-wrap-for-april-3-markets-winning-streak-fails-to-extend-to-five-days,Jayson Derrick,,,,0,0,a30c4e1a-3ca1-4c79-adb3-ac4651a29f94
2014-04-03T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,LLY,https://www.benzinga.com/general/movers-shakers/14/04/4444982/premarket-prep-technical-update-eli-lilly-makes-multi-year-high,Hal Lindon,,,,0,0,4ff58bf0-27f2-4adf-88ca-cc4a64071daf
2014-04-03T08:00:00.000+08:00,UPDATE: Cowen & Company Upgrades Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4444784/update-cowen-company-upgrades-eli-lilly,Kurt Zuschlag,,,,0,0,ee47c84a-54d2-46de-a77f-4227a23a2f84
2014-04-03T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/04/4443242/benzingas-top-upgrades,Monica Gerson,,,,0,0,3801f96a-8bcf-4183-bd03-d3a61a6ad83d
2014-04-03T08:00:00.000+08:00,"Cowen &amp; Company Upgrades Eli Lilly and Company to Outperform, Raises PT to $68.00",LLY,https://www.benzinga.com/news/14/04/4443166/cowen-amp-company-upgrades-eli-lilly-and-company-to-outperform-raises-pt-to-68-00,Juan Lopez,,,,0,0,bf5b2d25-92cc-4efb-be16-b689e458405e
2014-04-03T08:00:00.000+08:00,Market Wrap For April 3: Markets Winning Streak Fails To Extend To Five Days,LLY,https://www.benzinga.com/news/14/04/4445359/market-wrap-for-april-3-markets-winning-streak-fails-to-extend-to-five-days,Jayson Derrick,,,,0,0,da513649-f9d8-4487-a1ab-3f3ece64c749
2014-04-03T08:00:00.000+08:00,#Premarket Prep Technical Update - Eli Lilly Makes Multi-Year High And Retreats,LLY,https://www.benzinga.com/general/movers-shakers/14/04/4444982/premarket-prep-technical-update-eli-lilly-makes-multi-year-high,Hal Lindon,,,,0,0,c24e7390-1265-4e9e-a7ce-0b7c87e3544c
2014-04-03T08:00:00.000+08:00,UPDATE: Cowen & Company Upgrades Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4444784/update-cowen-company-upgrades-eli-lilly,Kurt Zuschlag,,,,0,0,3b7d1dd2-bdf0-4af2-b0e6-5b8a01ab4d7d
2014-04-03T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/14/04/4443242/benzingas-top-upgrades,Monica Gerson,,,,0,0,94da8a46-793d-4e3e-b2fb-784736bbddb5
2014-04-03T08:00:00.000+08:00,"Cowen &amp; Company Upgrades Eli Lilly and Company to Outperform, Raises PT to $68.00",LLY,https://www.benzinga.com/news/14/04/4443166/cowen-amp-company-upgrades-eli-lilly-and-company-to-outperform-raises-pt-to-68-00,Juan Lopez,,,,0,0,b455da6c-6d33-4a5b-b0c1-2917437ca982
2014-04-01T08:00:00.000+08:00,Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke,LLY,https://www.benzinga.com/news/14/04/4437774/market-wrap-for-april-1-s-p-500-hitting-new-all-time-high-not-an-april-fools-joke,Jayson Derrick,,,,0,0,9b8df812-3008-4685-96cd-f5e91f529aba
2014-04-01T08:00:00.000+08:00,Moody's Says Alimta Patent Ruling Credit Positive for Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4437053/moodys-says-alimta-patent-ruling-credit-positive-for-lil,Charles Gross,,,,0,0,80cd6423-06a2-4f82-98db-7ad28465fd1c
2014-04-01T08:00:00.000+08:00,"Eli Lilly Expands Authorized Generic Deals with Prasco, Will Market Authorized Generic of Evista in US",LLY,https://www.benzinga.com/news/14/04/4436074/eli-lilly-expands-authorized-generic-deals-with-prasco-will-market-authorized-gen,Paul Quintaro,,,,0,0,01fac9cf-d605-41da-a32f-6655bc9ef032
2014-04-01T08:00:00.000+08:00,UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta Case Ruling,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4435425/update-bank-of-america-reiterates-on-eli-lilly-and-co-fo,Dwight Einhorn,,,,0,0,7187ca82-8800-4ed0-8f60-d9afbb848972
2014-04-01T08:00:00.000+08:00,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $69.00",LLY,https://www.benzinga.com/news/14/04/4435148/bank-of-america-maintains-buy-on-eli-lilly-and-company-raises-po-to-69-00,Juan Lopez,,,,0,0,990f06d8-059a-4469-a826-27c14f26db38
2014-04-01T08:00:00.000+08:00,Market Wrap For April 1: S&P 500 Hitting New All-Time High Not An April Fools' Joke,LLY,https://www.benzinga.com/news/14/04/4437774/market-wrap-for-april-1-s-p-500-hitting-new-all-time-high-not-an-april-fools-joke,Jayson Derrick,,,,0,0,23c4bc3f-a883-408f-9388-8c415c2e042e
2014-04-01T08:00:00.000+08:00,Moody's Says Alimta Patent Ruling Credit Positive for Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4437053/moodys-says-alimta-patent-ruling-credit-positive-for-lil,Charles Gross,,,,0,0,da4c8ffa-e84c-4cca-a9ed-af640fd22a79
2014-04-01T08:00:00.000+08:00,"Eli Lilly Expands Authorized Generic Deals with Prasco, Will Market Authorized Generic of Evista in US",LLY,https://www.benzinga.com/news/14/04/4436074/eli-lilly-expands-authorized-generic-deals-with-prasco-will-market-authorized-gen,Paul Quintaro,,,,0,0,3a984d49-1ac2-455e-bf53-7692e4a62b38
2014-04-01T08:00:00.000+08:00,UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following Alimta Case Ruling,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/04/4435425/update-bank-of-america-reiterates-on-eli-lilly-and-co-fo,Dwight Einhorn,,,,0,0,636911c8-1c73-4084-acbf-a75f43a85dbf
2014-04-01T08:00:00.000+08:00,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $69.00",LLY,https://www.benzinga.com/news/14/04/4435148/bank-of-america-maintains-buy-on-eli-lilly-and-company-raises-po-to-69-00,Juan Lopez,,,,0,0,95c86418-9bc0-43de-8a33-6ac262530307
2014-03-31T08:00:00.000+08:00,UPDATE: Court Upholds Validity of Lilly's Alimta Patent Through 2022,LLY,https://www.benzinga.com/news/14/03/4434125/update-court-upholds-validity-of-lillys-alimta-patent-through-2022,Charles Gross,,,,0,0,54dd9bbc-3b7e-40ea-8b99-6f32ed32ab2a
2014-03-31T08:00:00.000+08:00,Federal Judge Upholds Eli Lilly's Alimta Cancer Drug Patent; Had been Challenged by Generic Makers,LLY,https://www.benzinga.com/news/14/03/4434070/federal-judge-upholds-eli-lillys-alimta-cancer-drug-patent-had-been-challenged-by,Charles Gross,,,,0,0,87584924-9125-48f3-8fd2-da66e9ebffc8
2014-03-31T08:00:00.000+08:00,UPDATE: Court Upholds Validity of Lilly's Alimta Patent Through 2022,LLY,https://www.benzinga.com/news/14/03/4434125/update-court-upholds-validity-of-lillys-alimta-patent-through-2022,Charles Gross,,,,0,0,b88197d2-e44c-44ec-833a-387e24af1238
2014-03-31T08:00:00.000+08:00,Federal Judge Upholds Eli Lilly's Alimta Cancer Drug Patent; Had been Challenged by Generic Makers,LLY,https://www.benzinga.com/news/14/03/4434070/federal-judge-upholds-eli-lillys-alimta-cancer-drug-patent-had-been-challenged-by,Charles Gross,,,,0,0,8c9429a9-a292-4a3f-9994-9b5df2408e48
2014-03-12T08:00:00.000+08:00,Eli Lilly Range Bound,LLY,https://www.benzinga.com/trading-ideas/technicals/14/03/4386031/eli-lilly-range-bound,Hal Lindon,,,,0,0,2c4747b6-62c5-4c3b-b050-cc30ca5faed3
2014-03-12T08:00:00.000+08:00,Eli Lilly Range Bound,LLY,https://www.benzinga.com/trading-ideas/technicals/14/03/4386031/eli-lilly-range-bound,Hal Lindon,,,,0,0,67915239-5080-425b-ae9c-64146380a19e
2014-03-05T08:00:00.000+08:00,Lilly Announces FDA Complete Response Letter for Empagliflozin,LLY,https://www.benzinga.com/news/14/03/4366791/lilly-announces-fda-complete-response-letter-for-empagliflozin,Charles Gross,,,,0,0,e0efd12b-c82c-4f11-a680-7a266728870e
2014-03-05T08:00:00.000+08:00,Lilly Announces FDA Complete Response Letter for Empagliflozin,LLY,https://www.benzinga.com/news/14/03/4366791/lilly-announces-fda-complete-response-letter-for-empagliflozin,Charles Gross,,,,0,0,9fc80d34-ab18-4f41-8b2a-691bcacf8153
2014-03-04T08:00:00.000+08:00,Biotechs vs. Pharmaceuticals: What's the Difference?,LLY,https://www.benzinga.com/general/education/14/03/4361845/biotechs-vs-pharmaceuticals-whats-the-difference,Tim Parker,,,,0,0,4717236e-3f7a-41b7-a9c4-0a5d783e9d19
2014-03-04T08:00:00.000+08:00,Biotechs vs. Pharmaceuticals: What's the Difference?,LLY,https://www.benzinga.com/general/education/14/03/4361845/biotechs-vs-pharmaceuticals-whats-the-difference,Tim Parker,,,,0,0,986d630b-91b8-466c-bf94-a48822a4e9d7
2014-02-25T08:00:00.000+08:00,"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide, Hits Primary Endpoint",LLY,https://www.benzinga.com/news/14/02/4340847/lillys-once-weekly-dulaglutide-shows-non-inferiority-to-liraglutide-hits-primary-,Paul Quintaro,,,,0,0,bdc7a697-f2ac-4bea-a74d-5085b724d70a
2014-02-25T08:00:00.000+08:00,"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide, Hits Primary Endpoint",LLY,https://www.benzinga.com/news/14/02/4340847/lillys-once-weekly-dulaglutide-shows-non-inferiority-to-liraglutide-hits-primary-,Paul Quintaro,,,,0,0,d934599e-ee9c-4c00-af6b-4b0d087af62c
2014-02-24T08:00:00.000+08:00,Elanco Announces Agreement to Acquire Lohmann Animal Health; Lowers FY 2014 Earnings Guidance to $2.72-2.80 on a Non-GAAP Basis,LLY,https://www.benzinga.com/news/14/02/4336478/elanco-announces-agreement-to-acquire-lohmann-animal-health-lowers-fy-2014-earnin,Eddie Staley,,,,0,0,aa455d58-4e5c-46f8-a573-8963186ba4da
2014-02-24T08:00:00.000+08:00,Elanco Announces Agreement to Acquire Lohmann Animal Health; Lowers FY 2014 Earnings Guidance to $2.72-2.80 on a Non-GAAP Basis,LLY,https://www.benzinga.com/news/14/02/4336478/elanco-announces-agreement-to-acquire-lohmann-animal-health-lowers-fy-2014-earnin,Eddie Staley,,,,0,0,13cb3153-1d4f-4d71-b2c7-6353a65a7e60
2014-02-19T08:00:00.000+08:00,"Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak",LLY,https://www.benzinga.com/news/14/02/4321856/market-wrap-for-february-19-stocks-close-lower-nasdaq-ends-winning-streak,Jayson Derrick,,,,0,0,c32d16e2-d2c5-4dd4-9bf1-7a9dccfa6ee1
2014-02-19T08:00:00.000+08:00,Eli Lilly Reports Ramucirumab Phase III Met Primary Endpoint of Overall Survival,LLY,https://www.benzinga.com/news/14/02/4319425/eli-lilly-reports-ramucirumab-phase-iii-met-primary-endpoint-of-overall-survival,Paul Quintaro,,,,0,0,6f74c601-e5ac-4b22-92d2-4a704c0c910d
2014-02-19T08:00:00.000+08:00,"Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends Winning Streak",LLY,https://www.benzinga.com/news/14/02/4321856/market-wrap-for-february-19-stocks-close-lower-nasdaq-ends-winning-streak,Jayson Derrick,,,,0,0,5dd1e702-27ea-46ec-8e28-83e77b1ad585
2014-02-19T08:00:00.000+08:00,Eli Lilly Reports Ramucirumab Phase III Met Primary Endpoint of Overall Survival,LLY,https://www.benzinga.com/news/14/02/4319425/eli-lilly-reports-ramucirumab-phase-iii-met-primary-endpoint-of-overall-survival,Paul Quintaro,,,,0,0,d25f8328-4c4e-4160-886b-683ea5299507
2014-01-31T08:00:00.000+08:00,Market Wrap For January 31: Markets End January On Sour Note,LLY,https://www.benzinga.com/news/14/01/4272196/market-wrap-for-january-31-markets-end-january-on-sour-note,Jayson Derrick,,,,0,0,8fafa2e1-bc55-4ea5-b2e9-1ff1fb7bb333
2014-01-31T08:00:00.000+08:00,Pfizer vs. Eli Lilly - Which Is The Better Investment?,LLY,https://www.benzinga.com/markets/14/01/4269947/pfizer-vs-eli-lily-which-is-the-better-investment,Tabitha Jean Naylor,,,,0,0,eec6e180-1753-4dc3-a87e-1f9877f41647
2014-01-31T08:00:00.000+08:00,"#PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over Into Europe",LLY,https://www.benzinga.com/news/earnings/14/01/4269864/premarket-primer-friday-january-31-emerging-market-turmoil-spills-over-i,Laura Brodbeck,,,,0,0,ffb9b85e-41fd-4ccd-a0c5-a42579d125af
2014-01-31T08:00:00.000+08:00,Market Wrap For January 31: Markets End January On Sour Note,LLY,https://www.benzinga.com/news/14/01/4272196/market-wrap-for-january-31-markets-end-january-on-sour-note,Jayson Derrick,,,,0,0,905ce6f7-8551-4943-b7e6-1ef8b561cecf
2014-01-31T08:00:00.000+08:00,Pfizer vs. Eli Lilly - Which Is The Better Investment?,LLY,https://www.benzinga.com/markets/14/01/4269947/pfizer-vs-eli-lily-which-is-the-better-investment,Tabitha Jean Naylor,,,,0,0,7b65c455-8879-4d13-b4e9-4ba440517b79
2014-01-31T08:00:00.000+08:00,"#PreMarket Primer: Friday, January 31: Emerging Market Turmoil Spills Over Into Europe",LLY,https://www.benzinga.com/news/earnings/14/01/4269864/premarket-primer-friday-january-31-emerging-market-turmoil-spills-over-i,Laura Brodbeck,,,,0,0,a5878d45-147a-4754-b011-d02e47276f74
2014-01-30T08:00:00.000+08:00,"Sanofi Files Suit in US to Defend Lantus, Lantus SoloStar Patent Rights",LLY,https://www.benzinga.com/news/14/01/4268760/sanofi-files-suit-in-us-to-defend-lantus-lantus-solostar-patent-rights,Charles Gross,,,,0,0,60e0ecf0-5ce2-4ba9-bd2e-e7efd7ec91a1
2014-01-30T08:00:00.000+08:00,Market Wrap For January 30: Markets Focus on Good News,LLY,https://www.benzinga.com/news/14/01/4268577/market-wrap-for-january-30-markets-focus-on-good-news,Jayson Derrick,,,,0,0,5a8cbadd-e508-4d50-b115-6e544ca0c75c
2014-01-30T08:00:00.000+08:00,Eli Lilly Declines,LLY,https://www.benzinga.com/trading-ideas/technicals/14/01/4268039/eli-lilly-declines,Hal Lindon,,,,0,0,66c29c92-3f57-46bb-b458-19bd071cc9cb
2014-01-30T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Drop In Q4 Profit,LLY,https://www.benzinga.com/news/earnings/14/01/4266060/update-eli-lilly-posts-drop-in-q4-profit,Monica Gerson,,,,0,0,72a26fc8-90a0-4df6-a8cf-6c5778b63557
2014-01-30T08:00:00.000+08:00,"#PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By Further $10 Billion",LLY,https://www.benzinga.com/news/earnings/14/01/4265520/premarket-primer-thursday-january-30-fed-cut-stimulus-by-further-10-bill,Laura Brodbeck,,,,0,0,d8de850e-2923-4e09-ac15-aaa4572931d9
2014-01-30T08:00:00.000+08:00,"Eli Lilly Reports Q4 Adjusted EPS of $0.74, Inline; Revenue of $5.81B vs $5.45B Est",LLY,https://www.benzinga.com/news/earnings/14/01/4265698/eli-lilly-reports-q4-adjusted-eps-of-0-74-inline-revenue-of-5-81b-vs-5-4,Charles Gross,,,,0,0,873de26d-eeb4-4a47-9891-c1ecb1b40268
2014-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2014",LLY,https://www.benzinga.com/news/earnings/14/01/4265509/earnings-scheduled-for-january-30-2014,Monica Gerson,,,,0,0,99134ff5-0ad3-441b-baed-f19bfa54e9a3
2014-01-30T08:00:00.000+08:00,"Sanofi Files Suit in US to Defend Lantus, Lantus SoloStar Patent Rights",LLY,https://www.benzinga.com/news/14/01/4268760/sanofi-files-suit-in-us-to-defend-lantus-lantus-solostar-patent-rights,Charles Gross,,,,0,0,cfa4f637-785f-4f29-90b6-6cd733fd7b16
2014-01-30T08:00:00.000+08:00,Market Wrap For January 30: Markets Focus on Good News,LLY,https://www.benzinga.com/news/14/01/4268577/market-wrap-for-january-30-markets-focus-on-good-news,Jayson Derrick,,,,0,0,2a395462-8b98-4fb9-bdc0-f372dee7c07c
2014-01-30T08:00:00.000+08:00,Eli Lilly Declines,LLY,https://www.benzinga.com/trading-ideas/technicals/14/01/4268039/eli-lilly-declines,Hal Lindon,,,,0,0,de1f9b9f-c606-4691-b835-d8cd6015389b
2014-01-30T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Drop In Q4 Profit,LLY,https://www.benzinga.com/news/earnings/14/01/4266060/update-eli-lilly-posts-drop-in-q4-profit,Monica Gerson,,,,0,0,abc3b8bc-3eea-4cab-9641-3bbf4362318e
2014-01-30T08:00:00.000+08:00,"#PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By Further $10 Billion",LLY,https://www.benzinga.com/news/earnings/14/01/4265520/premarket-primer-thursday-january-30-fed-cut-stimulus-by-further-10-bill,Laura Brodbeck,,,,0,0,becabf15-f6ab-4b27-bd88-5fecc2d11429
2014-01-30T08:00:00.000+08:00,"Eli Lilly Reports Q4 Adjusted EPS of $0.74, Inline; Revenue of $5.81B vs $5.45B Est",LLY,https://www.benzinga.com/news/earnings/14/01/4265698/eli-lilly-reports-q4-adjusted-eps-of-0-74-inline-revenue-of-5-81b-vs-5-4,Charles Gross,,,,0,0,5067cbb6-e475-45a7-91a0-4786fe1b4b38
2014-01-30T08:00:00.000+08:00,"Earnings Scheduled For January 30, 2014",LLY,https://www.benzinga.com/news/earnings/14/01/4265509/earnings-scheduled-for-january-30-2014,Monica Gerson,,,,0,0,c455e9cc-af35-4224-806d-4e028d88cbf6
2014-01-28T08:00:00.000+08:00,Tug Of War In Ariad Pharmaceuticals,LLY,https://www.benzinga.com/general/movers-shakers/14/01/4259051/tug-of-war-in-ariad-pharmaceuticals,PreMarketInfo,,,,0,0,f9006141-0254-4c3f-8025-0fa17cb6701a
2014-01-28T08:00:00.000+08:00,Tug Of War In Ariad Pharmaceuticals,LLY,https://www.benzinga.com/general/movers-shakers/14/01/4259051/tug-of-war-in-ariad-pharmaceuticals,PreMarketInfo,,,,0,0,06f03d2a-7a9e-49bf-bd91-eaacceffbfd9
2014-01-27T08:00:00.000+08:00,"Benzinga's M&A Chatter for Monday January 27, 2014",LLY,https://www.benzinga.com/news/14/01/4255409/benzingas-m-a-chatter-for-monday-january-27-2014,Charles Gross,,,,0,0,fec14ade-26ca-4155-9b5f-7b3c80b790e7
2014-01-27T08:00:00.000+08:00,"Benzinga's M&A Chatter for Monday January 27, 2014",LLY,https://www.benzinga.com/news/14/01/4255409/benzingas-m-a-chatter-for-monday-january-27-2014,Charles Gross,,,,0,0,9d054642-6e91-45d4-93d0-27983b43b762
2014-01-24T08:00:00.000+08:00,Benzinga Weekly Preview: Tech Sector To Steal The Spotlight,LLY,https://www.benzinga.com/news/earnings/14/01/4250770/benzinga-weekly-preview-tech-sector-to-steal-the-spotlight,Laura Brodbeck,,,,0,0,01f09557-63e3-45b4-a1dc-9ecbd5bb80a2
2014-01-24T08:00:00.000+08:00,Ariad Shares Continue to Surge Amidst Buyout Rumors,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/01/4250914/ariad-shares-continue-to-surge-amidst-buyout-rumors,Erika Janowicz,,,,0,0,3b53f8b3-59ea-49ac-98db-b47783905c10
2014-01-24T08:00:00.000+08:00,Benzinga Weekly Preview: Tech Sector To Steal The Spotlight,LLY,https://www.benzinga.com/news/earnings/14/01/4250770/benzinga-weekly-preview-tech-sector-to-steal-the-spotlight,Laura Brodbeck,,,,0,0,b479bf50-824a-4e63-875e-fe41d4690495
2014-01-24T08:00:00.000+08:00,Ariad Shares Continue to Surge Amidst Buyout Rumors,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/14/01/4250914/ariad-shares-continue-to-surge-amidst-buyout-rumors,Erika Janowicz,,,,0,0,6dfee9cb-520c-43ab-b4ae-12f73755c581
2014-01-23T08:00:00.000+08:00,Top Trending Tickers On StockTwits For January 23,LLY,https://www.benzinga.com/news/14/01/4246422/top-trending-tickers-on-stocktwits-for-january-23,Jayson Derrick,,,,0,0,58f28fbc-9283-40a8-a97f-8c06a847459a
2014-01-23T08:00:00.000+08:00,Top Trending Tickers On StockTwits For January 23,LLY,https://www.benzinga.com/news/14/01/4246422/top-trending-tickers-on-stocktwits-for-january-23,Jayson Derrick,,,,0,0,332fbf54-7308-48b5-8aa6-d129ebcb86d3
2014-01-22T08:00:00.000+08:00,"UK Daily Mail Reports Aria Approached by Big Pharma, Including Lilly",LLY,https://www.benzinga.com/news/14/01/4244358/uk-daily-mail-reports-aria-approached-by-big-pharma-including-lilly,Charles Gross,,,,0,0,2148e205-4576-4ea5-a9b4-196f663d19cd
2014-01-22T08:00:00.000+08:00,"UK Daily Mail Reports Aria Approached by Big Pharma, Including Lilly",LLY,https://www.benzinga.com/news/14/01/4244358/uk-daily-mail-reports-aria-approached-by-big-pharma-including-lilly,Charles Gross,,,,0,0,6069d783-eadd-4cb8-88f2-acd311fa3dc1
2014-01-16T08:00:00.000+08:00,Is The Market On Drugs?,LLY,https://www.benzinga.com/general/movers-shakers/14/01/4230084/is-the-market-on-drugs,PreMarketInfo,,,,0,0,cee283de-9c81-4d8a-85db-3af9f421bbaf
2014-01-16T08:00:00.000+08:00,Is The Market On Drugs?,LLY,https://www.benzinga.com/general/movers-shakers/14/01/4230084/is-the-market-on-drugs,PreMarketInfo,,,,0,0,29526df3-d695-4209-849b-5be7a0b2071d
2014-01-13T08:00:00.000+08:00,Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics,LLY,https://www.benzinga.com/news/14/01/4216815/lilly-acquires-cgrp-antibody-for-migraine-prevention-from-arteaus-therapeutics,Charles Gross,,,,0,0,ee160ac1-67fd-4695-93f2-246b04997fa3
2014-01-13T08:00:00.000+08:00,Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus Therapeutics,LLY,https://www.benzinga.com/news/14/01/4216815/lilly-acquires-cgrp-antibody-for-migraine-prevention-from-arteaus-therapeutics,Charles Gross,,,,0,0,26fd2b41-2524-4b95-a58d-2eef2bf024fc
2014-01-10T08:00:00.000+08:00,"Barclays Downgrades Eli Lilly and Company to Underweight, Lowers PT to $51.00",LLY,https://www.benzinga.com/news/14/01/4208858/barclays-downgrades-eli-lilly-and-company-to-underweight-lowers-pt-to-51-00,Paul Quintaro,,,,0,0,27c37a4b-44fb-48ee-8d76-8d81b9c01727
2014-01-10T08:00:00.000+08:00,"Barclays Downgrades Eli Lilly and Company to Underweight, Lowers PT to $51.00",LLY,https://www.benzinga.com/news/14/01/4208858/barclays-downgrades-eli-lilly-and-company-to-underweight-lowers-pt-to-51-00,Paul Quintaro,,,,0,0,48e7727f-ce9b-42ae-b968-cca2e5a03f3a
2014-01-08T08:00:00.000+08:00,"BMO Capital Downgrades Eli Lilly and Company to Underperform, Maintains $50.00 PT",LLY,https://www.benzinga.com/news/14/01/4201935/bmo-capital-downgrades-eli-lilly-and-company-to-underperform-maintains-50-00-pt,Juan Lopez,,,,0,0,e14ef86c-d91d-446e-84e5-edf71d125344
2014-01-08T08:00:00.000+08:00,"BMO Capital Downgrades Eli Lilly and Company to Underperform, Maintains $50.00 PT",LLY,https://www.benzinga.com/news/14/01/4201935/bmo-capital-downgrades-eli-lilly-and-company-to-underperform-maintains-50-00-pt,Juan Lopez,,,,0,0,e6d841ca-a789-40fc-bc7b-ac94cf3683bb
2014-01-07T08:00:00.000+08:00,Market Wrap For January 7: Markets Reverse 3-Day Slump,LLY,https://www.benzinga.com/news/14/01/4199997/market-wrap-for-january-7-markets-reverse-3-day-slump,Jayson Derrick,,,,0,0,1ed34de9-8220-4c2a-a6df-0aff9798bc93
2014-01-07T08:00:00.000+08:00,Lilly Commited To Maintaining Dividend at Least at Current Level,LLY,https://www.benzinga.com/news/14/01/4197465/lilly-commited-to-maintaining-dividend-at-least-at-current-level,Charles Gross,,,,0,0,4b5dcdc2-ce0d-42c0-9c65-3251fd6a40eb
2014-01-07T08:00:00.000+08:00,Eli Lilly Reconfirms 2013 Expectations; Sees 2014 EPS $2.77-$2.85,LLY,https://www.benzinga.com/news/earnings/14/01/4197456/eli-lilly-reconfirms-2013-expectations-sees-2014-eps-2-77-2-85,Charles Gross,,,,0,0,e4956efd-7dfc-4136-b918-b53fb7289e41
2014-01-07T08:00:00.000+08:00,Market Wrap For January 7: Markets Reverse 3-Day Slump,LLY,https://www.benzinga.com/news/14/01/4199997/market-wrap-for-january-7-markets-reverse-3-day-slump,Jayson Derrick,,,,0,0,ffadcb02-4b30-4964-914a-bd58f2447bd7
2014-01-07T08:00:00.000+08:00,Lilly Commited To Maintaining Dividend at Least at Current Level,LLY,https://www.benzinga.com/news/14/01/4197465/lilly-commited-to-maintaining-dividend-at-least-at-current-level,Charles Gross,,,,0,0,32cb8fdf-1034-42b4-a3e7-14df71c5174b
2014-01-07T08:00:00.000+08:00,Eli Lilly Reconfirms 2013 Expectations; Sees 2014 EPS $2.77-$2.85,LLY,https://www.benzinga.com/news/earnings/14/01/4197456/eli-lilly-reconfirms-2013-expectations-sees-2014-eps-2-77-2-85,Charles Gross,,,,0,0,84702580-bc4a-46cf-ab9c-9724af963c87
2013-12-20T08:00:00.000+08:00,US Stock Futures Gain Ahead Of GDP Data,LLY,https://www.benzinga.com/news/13/12/4172260/us-stock-futures-gain-ahead-of-gdp-data,Monica Gerson,,,,0,0,bfca4a79-ba0e-4685-9a25-21a4b51d3acd
2013-12-20T08:00:00.000+08:00,"PeptiDream Announces Collaboration, License Agreement with Lilly",LLY,https://www.benzinga.com/news/13/12/4172061/peptidream-announces-collaboration-license-agreement-with-lilly,Charles Gross,,,,0,0,d66bb648-f6de-447b-bcc3-2a2d6c3e7747
2013-12-20T08:00:00.000+08:00,US Stock Futures Gain Ahead Of GDP Data,LLY,https://www.benzinga.com/news/13/12/4172260/us-stock-futures-gain-ahead-of-gdp-data,Monica Gerson,,,,0,0,f937ce62-0256-46ec-ba3b-6ab5049d82e0
2013-12-20T08:00:00.000+08:00,"PeptiDream Announces Collaboration, License Agreement with Lilly",LLY,https://www.benzinga.com/news/13/12/4172061/peptidream-announces-collaboration-license-agreement-with-lilly,Charles Gross,,,,0,0,1627b586-ce8e-4a8c-ace1-e6dcb757475a
2013-12-13T08:00:00.000+08:00,ImmunoGen Reporting that Lilly May Extend its Pact With Added Payment,LLY,https://www.benzinga.com/news/13/12/4153669/immunogen-reporting-that-lilly-may-extend-its-pact-with-added-payment,Paul Quintaro,,,,0,0,0858c24b-d573-41b6-a78c-8822a7ea8767
2013-12-13T08:00:00.000+08:00,ImmunoGen Reporting that Lilly May Extend its Pact With Added Payment,LLY,https://www.benzinga.com/news/13/12/4153669/immunogen-reporting-that-lilly-may-extend-its-pact-with-added-payment,Paul Quintaro,,,,0,0,08d93bbd-ac69-4b41-a2cb-44799b6cc28d
2013-12-11T08:00:00.000+08:00,Citron Pharma Launches Generic Cymbalta Delayed Release Capsules,LLY,https://www.benzinga.com/news/13/12/4148698/citron-pharma-launches-generic-cymbalta-delayed-release-capsules,Charles Gross,,,,0,0,cfa79b08-25d6-4698-a816-567a80be6d1f
2013-12-11T08:00:00.000+08:00,FDA Approves First Generic Versions of Antidepressant Drug Cymbalta,LLY,https://www.benzinga.com/news/13/12/4148557/fda-approves-first-generic-versions-of-antidepressant-drug-cymbalta,Charles Gross,,,,0,0,aa7eeccf-6bda-455d-ae72-e391076e375d
2013-12-11T08:00:00.000+08:00,Citron Pharma Launches Generic Cymbalta Delayed Release Capsules,LLY,https://www.benzinga.com/news/13/12/4148698/citron-pharma-launches-generic-cymbalta-delayed-release-capsules,Charles Gross,,,,0,0,030c842a-12d1-4010-8387-50998888d24b
2013-12-11T08:00:00.000+08:00,FDA Approves First Generic Versions of Antidepressant Drug Cymbalta,LLY,https://www.benzinga.com/news/13/12/4148557/fda-approves-first-generic-versions-of-antidepressant-drug-cymbalta,Charles Gross,,,,0,0,a4d7b4e2-56c8-4088-b279-bd1aa18b3ce3
2013-12-05T08:00:00.000+08:00,"Lilly Reports Edivoxetine Did Not Meet Primary Endpoint, Expecting Q4 Charge $0.01/Share",LLY,https://www.benzinga.com/news/13/12/4131925/lilly-reports-edivoxetine-did-not-meet-primary-endpoint-expecting-q4-charge-0-01s,Paul Quintaro,,,,0,0,2639f672-3deb-43d8-a728-d7eaf3cfd4a4
2013-12-05T08:00:00.000+08:00,"Lilly Reports Edivoxetine Did Not Meet Primary Endpoint, Expecting Q4 Charge $0.01/Share",LLY,https://www.benzinga.com/news/13/12/4131925/lilly-reports-edivoxetine-did-not-meet-primary-endpoint-expecting-q4-charge-0-01s,Paul Quintaro,,,,0,0,65ae5038-1b0f-4b41-bb2a-d13ab55b3db3
2013-12-03T08:00:00.000+08:00,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit",LLY,https://www.benzinga.com/news/13/12/4125553/bloomberg-reporting-merck-eli-lilly-rumored-to-be-interested-in-novartis-veterina,Paul Quintaro,,,,0,0,34c959e0-01d0-409d-b0c3-ba59a07e8931
2013-12-03T08:00:00.000+08:00,"Bloomberg Reporting Merck, Eli Lilly Rumored to Be Interested in Novartis' Veterinary Unit",LLY,https://www.benzinga.com/news/13/12/4125553/bloomberg-reporting-merck-eli-lilly-rumored-to-be-interested-in-novartis-veterina,Paul Quintaro,,,,0,0,120609e1-7208-4ba3-95f0-474f5f8ec988
2013-11-18T08:00:00.000+08:00,QIAGEN Announces Agreement to Develop Molecular Companion Diagnostic Paired with Lilly Investigational Cancer Compounds,LLY,https://www.benzinga.com/news/13/11/4087478/qiagen-announces-agreement-to-develop-molecular-companion-diagnostic-paired-with-,Charles Gross,,,,0,0,8cc324ad-1326-478b-8234-94e20cbb4925
2013-11-18T08:00:00.000+08:00,QIAGEN Announces Agreement to Develop Molecular Companion Diagnostic Paired with Lilly Investigational Cancer Compounds,LLY,https://www.benzinga.com/news/13/11/4087478/qiagen-announces-agreement-to-develop-molecular-companion-diagnostic-paired-with-,Charles Gross,,,,0,0,80f84137-af17-4c5b-a558-22cc644c8e70
2013-11-14T08:00:00.000+08:00,"Actavis Confirms Patent Challenge of Generic Axiron, Says Lilly Filed Suit",LLY,https://www.benzinga.com/news/13/11/4080047/actavis-confirms-patent-challenge-of-generic-axiron-says-lilly-filed-suit,Paul Quintaro,,,,0,0,93eeaf1e-8287-4fb7-89a3-c5f83b5f94a4
2013-11-14T08:00:00.000+08:00,US Stock Futures Mixed Ahead of Economic Data,LLY,https://www.benzinga.com/news/13/11/4079696/us-stock-futures-mixed-ahead-of-economic-data,Monica Gerson,,,,0,0,2f1f05f1-5bae-4ded-a1c3-62ed93b7f0cb
2013-11-14T08:00:00.000+08:00,Lilly to Invest $700M to Enhance Global Insulin Manufacturing Capacity,LLY,https://www.benzinga.com/news/13/11/4079436/lilly-to-invest-700m-to-enhance-global-insulin-manufacturing-capacity,Charles Gross,,,,0,0,538b116c-01b3-4ba7-8689-6175dbfafd47
2013-11-14T08:00:00.000+08:00,"Actavis Confirms Patent Challenge of Generic Axiron, Says Lilly Filed Suit",LLY,https://www.benzinga.com/news/13/11/4080047/actavis-confirms-patent-challenge-of-generic-axiron-says-lilly-filed-suit,Paul Quintaro,,,,0,0,3ff5e664-aad6-479f-a8cf-c14755051367
2013-11-14T08:00:00.000+08:00,US Stock Futures Mixed Ahead of Economic Data,LLY,https://www.benzinga.com/news/13/11/4079696/us-stock-futures-mixed-ahead-of-economic-data,Monica Gerson,,,,0,0,97cdc772-6f1e-42c9-9090-6d74ce37d63f
2013-11-14T08:00:00.000+08:00,Lilly to Invest $700M to Enhance Global Insulin Manufacturing Capacity,LLY,https://www.benzinga.com/news/13/11/4079436/lilly-to-invest-700m-to-enhance-global-insulin-manufacturing-capacity,Charles Gross,,,,0,0,f864716e-50e0-4946-9eb3-21c1f1fa3764
2013-11-11T08:00:00.000+08:00,UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/11/4068825/update-goldman-sachs-downgrades-eli-lilly-company-on-rel,Dwight Einhorn,,,,0,0,47c84021-2968-4001-8939-5a819a75f725
2013-11-11T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/13/11/4068178/benzingas-top-downgrades,Monica Gerson,,,,0,0,f8600d92-7197-4e00-a783-a4b0e19a1d4f
2013-11-11T08:00:00.000+08:00,US Stock Futures Mixed After Friday Rally,LLY,https://www.benzinga.com/news/13/11/4068007/us-stock-futures-mixed-after-friday-rally,Monica Gerson,,,,0,0,265ebf09-6dd1-442a-b084-a183e0d86d90
2013-11-11T08:00:00.000+08:00,"Goldman Sachs Downgrades Eli Lilly and Company to Sell, Lowers PT to $48.00",LLY,https://www.benzinga.com/news/13/11/4067895/goldman-sachs-downgrades-eli-lilly-and-company-to-sell-lowers-pt-to-48-00,Juan Lopez,,,,0,0,e159a1c5-4cbe-4420-97f3-153ee6a55efd
2013-11-11T08:00:00.000+08:00,UPDATE: Goldman Sachs Downgrades Eli Lilly & Company on Relative Lack of Differentiation in Pipeline,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/11/4068825/update-goldman-sachs-downgrades-eli-lilly-company-on-rel,Dwight Einhorn,,,,0,0,09378f11-c62e-408d-9d40-9a2e535f326b
2013-11-11T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/13/11/4068178/benzingas-top-downgrades,Monica Gerson,,,,0,0,3b071437-82e9-46a3-880c-412feb9c24b4
2013-11-11T08:00:00.000+08:00,US Stock Futures Mixed After Friday Rally,LLY,https://www.benzinga.com/news/13/11/4068007/us-stock-futures-mixed-after-friday-rally,Monica Gerson,,,,0,0,cf96a8a1-2a28-4865-8c68-194e014250b1
2013-11-11T08:00:00.000+08:00,"Goldman Sachs Downgrades Eli Lilly and Company to Sell, Lowers PT to $48.00",LLY,https://www.benzinga.com/news/13/11/4067895/goldman-sachs-downgrades-eli-lilly-and-company-to-sell-lowers-pt-to-48-00,Juan Lopez,,,,0,0,99ac5d96-2ce0-4722-b313-16edba1d6f53
2013-10-25T08:00:00.000+08:00,UPDATE: FDA Approves Addition to Cialis Product Label,LLY,https://www.benzinga.com/news/13/10/4022594/update-fda-approves-addition-to-cialis-product-label,Eddie Staley,,,,0,0,e4b967f7-d8bd-4431-a8f2-70d35d473db1
2013-10-25T08:00:00.000+08:00,Elli Lilly Says FDA Approves Addition to Cialis Product Label,LLY,https://www.benzinga.com/news/13/10/4022566/elli-lilly-says-fda-approves-addition-to-cialis-product-label,Paul Quintaro,,,,0,0,9997a259-7064-4217-beab-485fa5507c5f
2013-10-25T08:00:00.000+08:00,UPDATE: FDA Approves Addition to Cialis Product Label,LLY,https://www.benzinga.com/news/13/10/4022594/update-fda-approves-addition-to-cialis-product-label,Eddie Staley,,,,0,0,43976ee2-ecba-4211-85b2-1e8c13adcb77
2013-10-25T08:00:00.000+08:00,Elli Lilly Says FDA Approves Addition to Cialis Product Label,LLY,https://www.benzinga.com/news/13/10/4022566/elli-lilly-says-fda-approves-addition-to-cialis-product-label,Paul Quintaro,,,,0,0,df654fb1-e1ab-4478-b019-afafeebc1cf0
2013-10-24T08:00:00.000+08:00,"MKM Partners Upgrades Eli Lilly and Company to Buy, Maintains $59.00 PT",LLY,https://www.benzinga.com/news/13/10/4019636/mkm-partners-upgrades-eli-lilly-and-company-to-buy-maintains-59-00-pt,Paul Quintaro,,,,0,0,28c2ec57-831b-48ee-ba78-bc820a8f64c0
2013-10-24T08:00:00.000+08:00,"MKM Partners Upgrades Eli Lilly and Company to Buy, Maintains $59.00 PT",LLY,https://www.benzinga.com/news/13/10/4019636/mkm-partners-upgrades-eli-lilly-and-company-to-buy-maintains-59-00-pt,Paul Quintaro,,,,0,0,71a94d3a-b859-4ab6-a70d-9402a469f9f1
2013-10-23T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/13/10/4014409/benzingas-top-pre-market-gainers,Monica Gerson,,,,0,0,6b01b1ab-99ae-423b-b454-a5ed267794e7
2013-10-23T08:00:00.000+08:00,US Stock Futures Down Ahead Of Earnings,LLY,https://www.benzinga.com/news/13/10/4014076/us-stock-futures-down-ahead-of-earnings,Monica Gerson,,,,0,0,4ad178b0-82c9-4de8-818d-2d2c334a067a
2013-10-23T08:00:00.000+08:00,UPDATE: Eli Lilly Q3 Profit Drops 9.3%,LLY,https://www.benzinga.com/news/earnings/13/10/4014069/update-eli-lilly-q3-profit-drops-9-3,Monica Gerson,,,,0,0,08d48795-8c01-4314-b9a0-d394bedef485
2013-10-23T08:00:00.000+08:00,Eli Lilly and Company Reports Q3 EPS of $1.11 vs $1.04 Est; Revenue of $5.77B vs $5.76B Est,LLY,https://www.benzinga.com/news/earnings/13/10/4013863/eli-lilly-and-company-reports-q3-eps-of-1-11-vs-1-04-est-revenue-of-5-77,Charles Gross,,,,0,0,9a6d8074-273f-4c8a-95e0-9f322c24c423
2013-10-23T08:00:00.000+08:00,FDA Grants Priority Review to Lilly's Ramucirumab,LLY,https://www.benzinga.com/news/13/10/4013862/fda-grants-priority-review-to-lillys-ramucirumab,Charles Gross,,,,0,0,88debf1e-362f-4874-9fbe-125e46f7d1aa
2013-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2013",LLY,https://www.benzinga.com/news/earnings/13/10/4013617/earnings-scheduled-for-october-23-2013,Monica Gerson,,,,0,0,ea93f439-3b7e-4b0b-a229-611a206021a5
2013-10-23T08:00:00.000+08:00,"Stocks To Watch For October 23, 2013",LLY,https://www.benzinga.com/news/earnings/13/10/4013609/stocks-to-watch-for-october-23-2013,Monica Gerson,,,,0,0,6a8fb7fb-81fc-4588-b79e-f8e8f0930b65
2013-10-23T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/13/10/4014409/benzingas-top-pre-market-gainers,Monica Gerson,,,,0,0,fd4029d0-080d-44a1-a10d-f6c393dedb5f
2013-10-23T08:00:00.000+08:00,US Stock Futures Down Ahead Of Earnings,LLY,https://www.benzinga.com/news/13/10/4014076/us-stock-futures-down-ahead-of-earnings,Monica Gerson,,,,0,0,cf6a8f9a-519a-47e3-825d-8d1eb28aeea8
2013-10-23T08:00:00.000+08:00,UPDATE: Eli Lilly Q3 Profit Drops 9.3%,LLY,https://www.benzinga.com/news/earnings/13/10/4014069/update-eli-lilly-q3-profit-drops-9-3,Monica Gerson,,,,0,0,9818b550-2218-4789-8066-03aea37075bc
2013-10-23T08:00:00.000+08:00,Eli Lilly and Company Reports Q3 EPS of $1.11 vs $1.04 Est; Revenue of $5.77B vs $5.76B Est,LLY,https://www.benzinga.com/news/earnings/13/10/4013863/eli-lilly-and-company-reports-q3-eps-of-1-11-vs-1-04-est-revenue-of-5-77,Charles Gross,,,,0,0,5e267437-d369-4db8-bdaf-916befca3fc3
2013-10-23T08:00:00.000+08:00,FDA Grants Priority Review to Lilly's Ramucirumab,LLY,https://www.benzinga.com/news/13/10/4013862/fda-grants-priority-review-to-lillys-ramucirumab,Charles Gross,,,,0,0,a7d3e53c-fb2a-4124-b512-5768af053a13
2013-10-23T08:00:00.000+08:00,"Earnings Scheduled For October 23, 2013",LLY,https://www.benzinga.com/news/earnings/13/10/4013617/earnings-scheduled-for-october-23-2013,Monica Gerson,,,,0,0,47ed9173-5ab4-43b5-814a-7f68cebc68bd
2013-10-23T08:00:00.000+08:00,"Stocks To Watch For October 23, 2013",LLY,https://www.benzinga.com/news/earnings/13/10/4013609/stocks-to-watch-for-october-23-2013,Monica Gerson,,,,0,0,c2af5dad-7ecb-4470-84d1-36c084ffbffb
2013-10-20T08:00:00.000+08:00,Earnings Expectations For The Week Of October 21: The Crunch Is On,LLY,https://www.benzinga.com/news/earnings/13/10/4004935/earnings-expectations-for-the-week-of-october-21-the-crunch-is-on,Nelson Hem,,,,0,0,5cc35889-91d2-4ff0-b8e7-7430b056c113
2013-10-20T08:00:00.000+08:00,Earnings Expectations For The Week Of October 21: The Crunch Is On,LLY,https://www.benzinga.com/news/earnings/13/10/4004935/earnings-expectations-for-the-week-of-october-21-the-crunch-is-on,Nelson Hem,,,,0,0,f040c968-9786-47e7-9d02-8096b1f3d997
2013-10-11T08:00:00.000+08:00,Fitch Affirms Eli Lilly Rating; Raises Outlook from Negative to Stable,LLY,https://www.benzinga.com/news/13/10/3985376/fitch-affirms-eli-lilly-rating-raises-outlook-from-negative-to-stable,Paul Quintaro,,,,0,0,f7c73a2b-1022-4fae-ae12-273748ed1326
2013-10-11T08:00:00.000+08:00,"Jefferies Downgrades Eli Lilly and Company to Underperform, Lowers PT to $40.00",LLY,https://www.benzinga.com/news/13/10/3984953/jefferies-downgrades-eli-lilly-and-company-to-underperform-lowers-pt-to-40-00,Paul Quintaro,,,,0,0,b74e3344-1952-4b45-bf5e-03298e1446b1
2013-10-11T08:00:00.000+08:00,"Market Primer: Friday, October 11: Budget Showdown Could Be Nearing Its End",LLY,https://www.benzinga.com/news/earnings/13/10/3984727/market-primer-friday-october-11-budget-showdown-could-be-nearing-its-end,Laura Brodbeck,,,,0,0,3ed08a6c-44e7-4ca5-ac9c-fec30d04553c
2013-10-11T08:00:00.000+08:00,Fitch Affirms Eli Lilly Rating; Raises Outlook from Negative to Stable,LLY,https://www.benzinga.com/news/13/10/3985376/fitch-affirms-eli-lilly-rating-raises-outlook-from-negative-to-stable,Paul Quintaro,,,,0,0,f3a0403e-4c07-48cd-b41d-4421725d22cd
2013-10-11T08:00:00.000+08:00,"Jefferies Downgrades Eli Lilly and Company to Underperform, Lowers PT to $40.00",LLY,https://www.benzinga.com/news/13/10/3984953/jefferies-downgrades-eli-lilly-and-company-to-underperform-lowers-pt-to-40-00,Paul Quintaro,,,,0,0,02cefb01-6c1c-4042-9652-e41c8f52c17a
2013-10-11T08:00:00.000+08:00,"Market Primer: Friday, October 11: Budget Showdown Could Be Nearing Its End",LLY,https://www.benzinga.com/news/earnings/13/10/3984727/market-primer-friday-october-11-budget-showdown-could-be-nearing-its-end,Laura Brodbeck,,,,0,0,7d29ed2f-16b6-41d5-917d-67acb33f33fc
2013-10-10T08:00:00.000+08:00,Edward Jones Upgrades Eli Lilly and Company to Sell,LLY,https://www.benzinga.com/news/13/10/3981556/edward-jones-upgrades-eli-lilly-and-company-to-sell,Paul Quintaro,,,,0,0,186f062c-c15e-4568-943a-e002a457e21e
2013-10-10T08:00:00.000+08:00,Edward Jones Upgrades Eli Lilly and Company to Sell,LLY,https://www.benzinga.com/news/13/10/3981556/edward-jones-upgrades-eli-lilly-and-company-to-sell,Paul Quintaro,,,,0,0,3fe86de1-f41a-4ede-a023-4f561362d0f2
2013-10-08T08:00:00.000+08:00,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral",LLY,https://www.benzinga.com/analyst-ratings/price-target/13/10/3976494/credit-suisse-starts-pfizer-bristol-myers-abbvie-allergan,Paul Quintaro,,,,0,0,b9f22f9a-6004-46b7-9884-30ff8abea195
2013-10-08T08:00:00.000+08:00,"Credit Suisse Starts Pfizer, Bristol-Myers, AbbVie, Allergan at Outperform, Merck, Eli Lilly, Forest Labs at Neutral",LLY,https://www.benzinga.com/analyst-ratings/price-target/13/10/3976494/credit-suisse-starts-pfizer-bristol-myers-abbvie-allergan,Paul Quintaro,,,,0,0,cadbf785-6cff-4529-ab1b-e65ab1699b7b
2013-10-03T08:00:00.000+08:00,"PreMarket Info Recap for October 3, 2013: Quiet Markets, Range Bound",LLY,https://www.benzinga.com/markets/commodities/13/10/3964446/premarket-info-recap-for-october-3-2013-quiet-markets-range-bound,PreMarketInfo,,,,0,0,0b9c91e2-2138-4536-8018-6aef9dbc0532
2013-10-03T08:00:00.000+08:00,"Lilly Reaffirms Outlook, Will Buyback Up to $5B in Shares, Maintaining Dividend",LLY,https://www.benzinga.com/news/13/10/3963817/lilly-reaffirms-outlook-will-buyback-up-to-5b-in-shares-maintaining-dividend,Paul Quintaro,,,,0,0,c1ead0f4-356d-4fe4-b373-1320cf56f25b
2013-10-03T08:00:00.000+08:00,"PreMarket Info Recap for October 3, 2013: Quiet Markets, Range Bound",LLY,https://www.benzinga.com/markets/commodities/13/10/3964446/premarket-info-recap-for-october-3-2013-quiet-markets-range-bound,PreMarketInfo,,,,0,0,33882050-adc7-4c0c-ac81-51192be5b370
2013-10-03T08:00:00.000+08:00,"Lilly Reaffirms Outlook, Will Buyback Up to $5B in Shares, Maintaining Dividend",LLY,https://www.benzinga.com/news/13/10/3963817/lilly-reaffirms-outlook-will-buyback-up-to-5b-in-shares-maintaining-dividend,Paul Quintaro,,,,0,0,58167a17-7cef-4d33-b04c-fa44216890f8
2013-10-02T08:00:00.000+08:00,Pharmaceutical Industry Expected To Collect Billions From Obamacare,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/10/3959811/pharmaceutical-industry-expected-to-collect-billions-from-oba,James Ha,,,,0,0,363f3694-d561-431f-bffb-4e53e64e9568
2013-10-02T08:00:00.000+08:00,Pharmaceutical Industry Expected To Collect Billions From Obamacare,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/10/3959811/pharmaceutical-industry-expected-to-collect-billions-from-oba,James Ha,,,,0,0,86cd3a12-e5b6-44ba-b1d5-bc802d2166f2
2013-09-30T08:00:00.000+08:00,Eli Lilly Says Disappointed in Medicare's Decision to Deny Patient Access to Beta-Amyloid Imaging Agents,LLY,https://www.benzinga.com/news/13/09/3951685/eli-lilly-says-disappointed-in-medicares-decision-to-deny-patient-access-to-beta-,Paul Quintaro,,,,0,0,392aa655-4f8a-4d3b-9142-691dafa6989a
2013-09-30T08:00:00.000+08:00,Eli Lilly Says Disappointed in Medicare's Decision to Deny Patient Access to Beta-Amyloid Imaging Agents,LLY,https://www.benzinga.com/news/13/09/3951685/eli-lilly-says-disappointed-in-medicares-decision-to-deny-patient-access-to-beta-,Paul Quintaro,,,,0,0,33054926-69d4-4cdd-a6ee-818baab45552
2013-09-28T08:00:00.000+08:00,"Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid",LLY,https://www.benzinga.com/news/13/09/3949927/lilly-disappointed-in-medicare-decision-to-deny-appropriate-patient-access-to-bet,Charles Gross,,,,0,0,44534272-20dd-4689-98c5-789450b08ff1
2013-09-28T08:00:00.000+08:00,"Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid",LLY,https://www.benzinga.com/news/13/09/3949927/lilly-disappointed-in-medicare-decision-to-deny-appropriate-patient-access-to-bet,Charles Gross,,,,0,0,df6577b6-b9e0-4c43-b598-945850557a38
2013-09-26T08:00:00.000+08:00,Lilly Shows Investigational Dulaglutide Resulted in Improved Indicators,LLY,https://www.benzinga.com/news/13/09/3944283/lilly-shows-investigational-dulaglutide-resulted-in-improved-indicators,Paul Quintaro,,,,0,0,6e8cd5be-c6af-4011-99a8-80b67f592515
2013-09-26T08:00:00.000+08:00,Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,LLY,https://www.benzinga.com/news/13/09/3944264/lilly-says-rainbow-trial-met-primary-endpoint-separate-phase-iii-trial-of-ramucir,Paul Quintaro,,,,0,0,195573a9-2bb9-45b7-b619-9e03ccfa4492
2013-09-26T08:00:00.000+08:00,Eli Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,LLY,https://www.benzinga.com/news/13/09/3944254/eli-lilly-says-rainbow-trial-met-primary-endpoint-separate-phase-iii-trial-of-ram,Paul Quintaro,,,,0,0,f50777c3-7f19-4ced-902d-c9388a7be30b
2013-09-26T08:00:00.000+08:00,Lilly Shows Investigational Dulaglutide Resulted in Improved Indicators,LLY,https://www.benzinga.com/news/13/09/3944283/lilly-shows-investigational-dulaglutide-resulted-in-improved-indicators,Paul Quintaro,,,,0,0,cc0d6a23-59c3-4ccc-862c-24e80f94f13a
2013-09-26T08:00:00.000+08:00,Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,LLY,https://www.benzinga.com/news/13/09/3944264/lilly-says-rainbow-trial-met-primary-endpoint-separate-phase-iii-trial-of-ramucir,Paul Quintaro,,,,0,0,96acee8f-4ed7-4a19-b694-50f4a37bdc96
2013-09-26T08:00:00.000+08:00,Eli Lilly Says RAINBOW Trial Met Primary Endpoint; Separate Phase III Trial of Ramucirumab in Women with ROSE Did Not Meet Endpoint,LLY,https://www.benzinga.com/news/13/09/3944254/eli-lilly-says-rainbow-trial-met-primary-endpoint-separate-phase-iii-trial-of-ram,Paul Quintaro,,,,0,0,613b1267-63cc-4b26-84aa-55a23ee66bdd
2013-09-17T08:00:00.000+08:00,Lilly to Present Data Across Diabetes Portfolio at 49th European Association for Study of Diabetes Annual Meeting,LLY,https://www.benzinga.com/news/13/09/3918659/lilly-to-present-data-across-diabetes-portfolio-at-49th-european-association-for-,Paul Quintaro,,,,0,0,10104538-cae4-4628-8f8d-2d848720db23
2013-09-17T08:00:00.000+08:00,Lilly to Present Data Across Diabetes Portfolio at 49th European Association for Study of Diabetes Annual Meeting,LLY,https://www.benzinga.com/news/13/09/3918659/lilly-to-present-data-across-diabetes-portfolio-at-49th-european-association-for-,Paul Quintaro,,,,0,0,14bc4d4d-49d4-48d6-8b6d-bfeb84ba117f
2013-09-12T08:00:00.000+08:00,Benzinga Market Primer for September 12: Kerry and Lavrov Discuss The Terms Of Syria Resolution At Two Day Meeting,LLY,https://www.benzinga.com/markets/bonds/13/09/3907246/benzinga-market-primer-thursday-september-12-kerry-and-lavrov-discuss-th,Laura Brodbeck,,,,0,0,10e78908-f0d6-46d0-913d-80250f8730a7
2013-09-12T08:00:00.000+08:00,Benzinga Market Primer for September 12: Kerry and Lavrov Discuss The Terms Of Syria Resolution At Two Day Meeting,LLY,https://www.benzinga.com/markets/bonds/13/09/3907246/benzinga-market-primer-thursday-september-12-kerry-and-lavrov-discuss-th,Laura Brodbeck,,,,0,0,5a70c8f7-1a39-467a-a8c5-62139c51b560
2013-08-29T08:00:00.000+08:00,"Humana, Lilly Collaborate on Research to Improve Health Care Outcomes",LLY,https://www.benzinga.com/news/13/08/3874797/humana-lilly-collaborate-on-research-to-improve-health-care-outcomes,Charles Gross,,,,0,0,3ed52bf1-5c13-4da7-a4a6-87310e156b16
2013-08-29T08:00:00.000+08:00,"Humana, Lilly Collaborate on Research to Improve Health Care Outcomes",LLY,https://www.benzinga.com/news/13/08/3874797/humana-lilly-collaborate-on-research-to-improve-health-care-outcomes,Charles Gross,,,,0,0,b5ed3c06-daed-47e2-84e9-e5254e64668a
2013-08-28T08:00:00.000+08:00,Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology,LLY,https://www.benzinga.com/news/13/08/3871986/immunogen-shares-charge-higher-following-news-of-deal-with-lilly-for-tap-technolo,Paul Quintaro,,,,0,0,345aa172-bfae-4746-abbc-2fb12e5a9b67
2013-08-28T08:00:00.000+08:00,UPDATE: Immuogen May Get Up to $200.5M Under Deal with Eli Lilly,LLY,https://www.benzinga.com/news/13/08/3871979/update-immuogen-may-get-up-to-200-5m-under-deal-with-eli-lilly,Paul Quintaro,,,,0,0,e43f0280-3c9c-448c-9689-f775b7117761
2013-08-28T08:00:00.000+08:00,Form 8-K Shows Immunogen Entered into License Deal with Eli Lilly for Targeted Antibody Payload Technology,LLY,https://www.benzinga.com/news/13/08/3871972/form-8-k-shows-immunogen-entered-into-license-deal-with-eli-lilly-for-targeted-an,Paul Quintaro,,,,0,0,787d7df6-ac20-4968-a349-d69d2ff375ba
2013-08-28T08:00:00.000+08:00,Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology,LLY,https://www.benzinga.com/news/13/08/3871986/immunogen-shares-charge-higher-following-news-of-deal-with-lilly-for-tap-technolo,Paul Quintaro,,,,0,0,642efb1f-0adb-4807-9954-2b6aafdb047e
2013-08-28T08:00:00.000+08:00,UPDATE: Immuogen May Get Up to $200.5M Under Deal with Eli Lilly,LLY,https://www.benzinga.com/news/13/08/3871979/update-immuogen-may-get-up-to-200-5m-under-deal-with-eli-lilly,Paul Quintaro,,,,0,0,cd1c4efa-43a6-4fc4-a73b-901bd2dd91c5
2013-08-28T08:00:00.000+08:00,Form 8-K Shows Immunogen Entered into License Deal with Eli Lilly for Targeted Antibody Payload Technology,LLY,https://www.benzinga.com/news/13/08/3871972/form-8-k-shows-immunogen-entered-into-license-deal-with-eli-lilly-for-targeted-an,Paul Quintaro,,,,0,0,be9b2226-adc6-4e0b-a561-52b0ea057eb3
2013-08-22T08:00:00.000+08:00,Eli Lilly Accused of Bribing Doctors in China -WantChinaTimes,LLY,https://www.benzinga.com/news/13/08/3857382/eli-lilly-accused-of-bribing-doctors-in-china-wantchinatimes,Charles Gross,,,,0,0,e0d18903-8d01-4b15-ac3a-a9e8b1abf5eb
2013-08-22T08:00:00.000+08:00,Eli Lilly Accused of Bribing Doctors in China -WantChinaTimes,LLY,https://www.benzinga.com/news/13/08/3857382/eli-lilly-accused-of-bribing-doctors-in-china-wantchinatimes,Charles Gross,,,,0,0,3ab6432c-3196-4bea-9d64-e7974d879993
2013-08-15T08:00:00.000+08:00,Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control,LLY,https://www.benzinga.com/news/13/08/3842282/linagliptin-demonstrated-significant-hba1c-reduction-in-elderly-people-with-type-,James Hunt,,,,0,0,12aabd3b-5484-4464-bc06-ae9d6bf7a9ac
2013-08-15T08:00:00.000+08:00,Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control,LLY,https://www.benzinga.com/news/13/08/3842282/linagliptin-demonstrated-significant-hba1c-reduction-in-elderly-people-with-type-,James Hunt,,,,0,0,c18f4ee0-3ef6-4cc6-aeeb-81830282c2d5
2013-08-13T08:00:00.000+08:00,Eli Lilly Soaring After Positive Cancer Drug Data (LLY),LLY,https://www.benzinga.com/news/13/08/3834345/eli-lilly-soaring-after-positive-cancer-drug-data-lly,Tim Parker,,,,0,0,f240dd0e-2166-4f9e-84f3-4f113433a138
2013-08-13T08:00:00.000+08:00,"Notable Stocks Trading Ex-Dividend Today: DuPont, Kroger, Eli Lilly, Microsoft, TJX",LLY,https://www.benzinga.com/news/13/08/3834157/notable-stocks-trading-ex-dividend-today-dupont-kroger-eli-lilly-microsoft-tjx,Paul Quintaro,,,,0,0,3facda4a-fce9-421d-b464-6907b144b4d3
2013-08-13T08:00:00.000+08:00,Lilly Reports Phase III Necitumumab Study Met Primary Endpoint,LLY,https://www.benzinga.com/news/13/08/3833989/lilly-reports-phase-iii-necitumumab-study-met-primary-endpoint,Paul Quintaro,,,,0,0,79e50fdc-cf1d-42bd-bfda-f0967efd0a3c
2013-08-13T08:00:00.000+08:00,Eli Lilly Soaring After Positive Cancer Drug Data (LLY),LLY,https://www.benzinga.com/news/13/08/3834345/eli-lilly-soaring-after-positive-cancer-drug-data-lly,Tim Parker,,,,0,0,9af508d6-86f1-4d4f-9cf0-97f14ec4d5bf
2013-08-13T08:00:00.000+08:00,"Notable Stocks Trading Ex-Dividend Today: DuPont, Kroger, Eli Lilly, Microsoft, TJX",LLY,https://www.benzinga.com/news/13/08/3834157/notable-stocks-trading-ex-dividend-today-dupont-kroger-eli-lilly-microsoft-tjx,Paul Quintaro,,,,0,0,99fd15c1-21c3-4088-89a9-5e8b8d76fe1f
2013-08-13T08:00:00.000+08:00,Lilly Reports Phase III Necitumumab Study Met Primary Endpoint,LLY,https://www.benzinga.com/news/13/08/3833989/lilly-reports-phase-iii-necitumumab-study-met-primary-endpoint,Paul Quintaro,,,,0,0,27a6d29a-c3c4-4abd-94ea-1a043973e6fd
2013-07-25T08:00:00.000+08:00,"Barclays Maintains Equal-weight on Eli Lilly and Company, Raises PT to $58.00",LLY,https://www.benzinga.com/news/13/07/3783085/barclays-maintains-equal-weight-on-eli-lilly-and-company-raises-pt-to-58-00,Juan Lopez,,,,0,0,61929c91-ead2-4751-bbc5-fcd47356d431
2013-07-25T08:00:00.000+08:00,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown",LLY,https://www.benzinga.com/markets/bonds/13/07/3782015/benzinga-market-primer-thursday-july-25-futures-lower-after-technical-br,Matthew Kanterman,,,,0,0,a9cc2a1c-8a28-448a-9bb4-5a95b255a63d
2013-07-25T08:00:00.000+08:00,"Barclays Maintains Equal-weight on Eli Lilly and Company, Raises PT to $58.00",LLY,https://www.benzinga.com/news/13/07/3783085/barclays-maintains-equal-weight-on-eli-lilly-and-company-raises-pt-to-58-00,Juan Lopez,,,,0,0,9cdf4aed-58c3-46b3-abe9-faeb5f1105b3
2013-07-25T08:00:00.000+08:00,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown",LLY,https://www.benzinga.com/markets/bonds/13/07/3782015/benzinga-market-primer-thursday-july-25-futures-lower-after-technical-br,Matthew Kanterman,,,,0,0,4ff941ad-1194-4a90-b209-531b9b36ee9e
2013-07-24T08:00:00.000+08:00,"Benzinga's PreMarket Info Recap for July 24, 2013: Ford and General Motors Trading at 2-Year Highs!",LLY,https://www.benzinga.com/news/earnings/13/07/3778890/benzingas-premarket-info-recap-for-july-24-2013-ford-and-general-motors-,PreMarketInfo,,,,0,0,4669760e-f686-4945-8708-a3cc6d98d0ff
2013-07-24T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/13/07/3778530/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,504cd891-19ae-430e-8c08-46afa505395d
2013-07-24T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/13/07/3778160/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,cc0485ce-0db6-42e4-aa17-397544563d3f
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Raises FY2013 EPS Guidance from $3.82-3.97 to $4.05-4.15 vs $3.93 Est,LLY,https://www.benzinga.com/news/13/07/3778051/eli-lilly-and-company-raises-fy2013-eps-guidance-from-3-82-3-97-to-4-05-4-15-vs-3,Paul Quintaro,,,,0,0,20df1f75-cb8e-4e40-97b0-3add1ec6d8e2
2013-07-24T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts 31% Rise In Q2 Profit, Lifts Full-Year Outlook",LLY,https://www.benzinga.com/news/earnings/13/07/3778038/update-eli-lilly-posts-31-rise-in-q2-profit-lifts-full-year-outlook,Lisa Levin,,,,0,0,5d9f101d-f1c2-4273-8cb8-b4045be0d3dc
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est; Revenue of $5.92B vs $5.82B Est,LLY,https://www.benzinga.com/news/earnings/13/07/3777867/eli-lilly-and-company-reports-q2-eps-of-1-16-vs-1-01-est-revenue-of-5-92,Charles Gross,,,,0,0,19682913-db22-4674-b3ae-216737b2ec92
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est,LLY,https://www.benzinga.com/news/earnings/13/07/3777866/eli-lilly-and-company-reports-q2-eps-of-1-16-vs-1-01-est,Charles Gross,,,,0,0,c9492cba-a4fe-47a9-b7ce-2cca475f60ee
2013-07-24T08:00:00.000+08:00,"Benzinga Market Primer: Wednesday, July 24: Apple Earnings Beat",LLY,https://www.benzinga.com/markets/bonds/13/07/3777693/benzinga-market-primer-wednesday-july-24-apple-earnings-beat,Matthew Kanterman,,,,0,0,de89aad4-87f0-457d-959d-b8f853c5a2ef
2013-07-24T08:00:00.000+08:00,US Stock Futures Rise After Upbeat Apple Results,LLY,https://www.benzinga.com/news/13/07/3777812/us-stock-futures-rise-after-upbeat-apple-results,Monica Gerson,,,,0,0,7703259c-a6a7-435e-9125-f728ec4d0718
2013-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/07/3777589/earnings-scheduled-for-july-24-2013,Monica Gerson,,,,0,0,3df97930-bf04-4c17-abd7-f6ba53cd8895
2013-07-24T08:00:00.000+08:00,"Benzinga's PreMarket Info Recap for July 24, 2013: Ford and General Motors Trading at 2-Year Highs!",LLY,https://www.benzinga.com/news/earnings/13/07/3778890/benzingas-premarket-info-recap-for-july-24-2013-ford-and-general-motors-,PreMarketInfo,,,,0,0,926fbf19-8e55-4e02-a813-2a4dd36f4073
2013-07-24T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/13/07/3778530/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,853284f7-8baa-4f6a-a454-bec954b4adbd
2013-07-24T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/13/07/3778160/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,16a602cf-4ce7-49de-9f4a-d8f7e4917760
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Raises FY2013 EPS Guidance from $3.82-3.97 to $4.05-4.15 vs $3.93 Est,LLY,https://www.benzinga.com/news/13/07/3778051/eli-lilly-and-company-raises-fy2013-eps-guidance-from-3-82-3-97-to-4-05-4-15-vs-3,Paul Quintaro,,,,0,0,1bcfd00a-2cb9-4b1a-874e-2cac890f8df6
2013-07-24T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts 31% Rise In Q2 Profit, Lifts Full-Year Outlook",LLY,https://www.benzinga.com/news/earnings/13/07/3778038/update-eli-lilly-posts-31-rise-in-q2-profit-lifts-full-year-outlook,Lisa Levin,,,,0,0,47aed8de-5cfd-4e7f-a941-3b0074374d5f
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est; Revenue of $5.92B vs $5.82B Est,LLY,https://www.benzinga.com/news/earnings/13/07/3777867/eli-lilly-and-company-reports-q2-eps-of-1-16-vs-1-01-est-revenue-of-5-92,Charles Gross,,,,0,0,2e9c050a-82c2-4863-a5d1-a52e07d1fb9e
2013-07-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q2 EPS of $1.16 vs $1.01 Est,LLY,https://www.benzinga.com/news/earnings/13/07/3777866/eli-lilly-and-company-reports-q2-eps-of-1-16-vs-1-01-est,Charles Gross,,,,0,0,c636a825-eb85-4fa3-90a0-70c1e8b95c98
2013-07-24T08:00:00.000+08:00,"Benzinga Market Primer: Wednesday, July 24: Apple Earnings Beat",LLY,https://www.benzinga.com/markets/bonds/13/07/3777693/benzinga-market-primer-wednesday-july-24-apple-earnings-beat,Matthew Kanterman,,,,0,0,0f69c158-9228-4d82-bbba-8efe040c0464
2013-07-24T08:00:00.000+08:00,US Stock Futures Rise After Upbeat Apple Results,LLY,https://www.benzinga.com/news/13/07/3777812/us-stock-futures-rise-after-upbeat-apple-results,Monica Gerson,,,,0,0,2fc1ff15-0ca3-42f2-aa71-392810ef0e05
2013-07-24T08:00:00.000+08:00,"Earnings Scheduled For July 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/07/3777589/earnings-scheduled-for-july-24-2013,Monica Gerson,,,,0,0,b65ac8d9-bdde-4ff6-b58d-c98d70ec875d
2013-07-23T08:00:00.000+08:00,Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly,LLY,https://www.benzinga.com/news/13/07/3776476/transition-therapeutics-enters-osteoarthritis-license-and-collaboration-agreement,James Hunt,,,,0,0,866eda4f-6b16-469f-93fb-14dadf7cb990
2013-07-23T08:00:00.000+08:00,Transition Therapeutics Enters Osteoarthritis License and Collaboration Agreement with Lilly,LLY,https://www.benzinga.com/news/13/07/3776476/transition-therapeutics-enters-osteoarthritis-license-and-collaboration-agreement,James Hunt,,,,0,0,400f54b6-1d71-46db-9962-b86ec8215056
2013-07-22T08:00:00.000+08:00,"Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)",LLY,https://www.benzinga.com/news/earnings/13/07/3769106/earnings-expectations-for-the-week-of-july-22-aapl-gm-mcd-nflx,Nelson Hem,,,,0,0,1e2d5e28-1762-4ea1-aaff-412237fb7072
2013-07-22T08:00:00.000+08:00,"Earnings Expectations for the Week of July 22 (AAPL, GM, MCD, NFLX)",LLY,https://www.benzinga.com/news/earnings/13/07/3769106/earnings-expectations-for-the-week-of-july-22-aapl-gm-mcd-nflx,Nelson Hem,,,,0,0,6298f0c4-1882-4720-aa5d-80da1f8a6ef7
2013-07-19T08:00:00.000+08:00,Weekly Preview: Earnings Season Kicks Into Hyperdrive,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3767719/weekly-preview-earnings-season-kicks-into-hyperdrive,Matthew Kanterman,,,,0,0,456766f7-7298-4b51-8bc0-7a6015093847
2013-07-19T08:00:00.000+08:00,Weekly Preview: Earnings Season Kicks Into Hyperdrive,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3767719/weekly-preview-earnings-season-kicks-into-hyperdrive,Matthew Kanterman,,,,0,0,d9ce6297-4cf7-48fd-ba7d-0e84ee283dd2
2013-07-17T08:00:00.000+08:00,"Bloomberg Reporting Eli Lilly Spokesperson Says to Freeze Worker, Exec Pay This Year",LLY,https://www.benzinga.com/news/13/07/3761161/bloomberg-reporting-eli-lilly-spokesperson-says-to-freeze-worker-exec-pay-this-ye,Paul Quintaro,,,,0,0,552c7daf-5cac-417c-8f81-b48b18afeb86
2013-07-17T08:00:00.000+08:00,"Bloomberg Reporting Eli Lilly Spokesperson Says to Freeze Worker, Exec Pay This Year",LLY,https://www.benzinga.com/news/13/07/3761161/bloomberg-reporting-eli-lilly-spokesperson-says-to-freeze-worker-exec-pay-this-ye,Paul Quintaro,,,,0,0,f9abb779-89c4-4f8f-a63a-48f1b19fa786
2013-07-16T08:00:00.000+08:00,Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3756698/eli-lilly-tries-again-with-alzheimers-drug-as-the-race-f,Jim Probasco,,,,0,0,eb3ae12f-ad39-4661-be09-fcbac2077327
2013-07-16T08:00:00.000+08:00,New Study Shows Men Taking Cialis® (tadalafil) Tablets Once Daily Returned to Normal Erectile Function after Incomplete Response to As-Needed PDE5 Inhibitor Therapy,LLY,https://www.benzinga.com/news/13/07/3755577/new-study-shows-men-taking-cialis-tadalafil-tablets-once-daily-returned-to-normal,James Hunt,,,,0,0,4c3b4172-9497-4ca9-94a5-57f7d4c87e9e
2013-07-16T08:00:00.000+08:00,Eli Lilly Tries Again with Alzheimer's Drug as the Race for a Cure Continues (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3756698/eli-lilly-tries-again-with-alzheimers-drug-as-the-race-f,Jim Probasco,,,,0,0,de51daae-68bc-4ac1-82e7-847eeff4e5d2
2013-07-16T08:00:00.000+08:00,New Study Shows Men Taking Cialis® (tadalafil) Tablets Once Daily Returned to Normal Erectile Function after Incomplete Response to As-Needed PDE5 Inhibitor Therapy,LLY,https://www.benzinga.com/news/13/07/3755577/new-study-shows-men-taking-cialis-tadalafil-tablets-once-daily-returned-to-normal,James Hunt,,,,0,0,8b2674e7-ed9f-41d7-8e23-be82153decc8
2013-07-03T08:00:00.000+08:00,Lilly to Host Call Discussing Trial Design of New Solanezumab Phase 3 Study,LLY,https://www.benzinga.com/news/13/07/3727699/lilly-to-host-call-discussing-trial-design-of-new-solanezumab-phase-3-study,Paul Quintaro,,,,0,0,d9426ff6-2bfd-447c-83a0-8a7440fce74f
2013-07-03T08:00:00.000+08:00,Lilly to Host Call Discussing Trial Design of New Solanezumab Phase 3 Study,LLY,https://www.benzinga.com/news/13/07/3727699/lilly-to-host-call-discussing-trial-design-of-new-solanezumab-phase-3-study,Paul Quintaro,,,,0,0,774bdf7b-8934-43d3-966f-b03b9c437a98
2013-06-25T08:00:00.000+08:00,"Boehringer, Lilly Offer Results of CV Post-Hoc Meta-Analysis Examining CV Events in Adults with Type 2 Diabetes Treated with Linagliptin",LLY,https://www.benzinga.com/news/13/06/3703663/boehringer-lilly-offer-results-of-cv-post-hoc-meta-analysis-examining-cv-events-i,Paul Quintaro,,,,0,0,31a49db2-6a2a-4066-986a-bc1b52f93721
2013-06-25T08:00:00.000+08:00,"Boehringer, Lilly Offer Results of CV Post-Hoc Meta-Analysis Examining CV Events in Adults with Type 2 Diabetes Treated with Linagliptin",LLY,https://www.benzinga.com/news/13/06/3703663/boehringer-lilly-offer-results-of-cv-post-hoc-meta-analysis-examining-cv-events-i,Paul Quintaro,,,,0,0,8ede2efe-3885-44a4-954a-df1d364cdd5b
2013-06-22T08:00:00.000+08:00,"Phase 3 Study Shows Empagliflozin Significantly Reduced Blood Glucose in Adults with Type 2 Diabetes, Impaired Kidney Function",LLY,https://www.benzinga.com/news/13/06/3698004/phase-3-study-shows-empagliflozin-significantly-reduced-blood-glucose-in-adults-w,Charles Gross,,,,0,0,09875ce2-cf61-4312-8596-dabc4c4e57be
2013-06-22T08:00:00.000+08:00,Lilly Announces Phase 3 Data Show Empagliflozin Plus Insulin Significantly Reduced HbA1c in Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/13/06/3698001/lilly-announces-phase-3-data-show-empagliflozin-plus-insulin-significantly-reduce,Charles Gross,,,,0,0,04aae31c-20b4-4604-99db-136c0f1949ec
2013-06-22T08:00:00.000+08:00,"Phase 3 Study Shows Empagliflozin Significantly Reduced Blood Glucose in Adults with Type 2 Diabetes, Impaired Kidney Function",LLY,https://www.benzinga.com/news/13/06/3698004/phase-3-study-shows-empagliflozin-significantly-reduced-blood-glucose-in-adults-w,Charles Gross,,,,0,0,5132747e-7d80-4ba4-86a5-220ed4daa2e1
2013-06-22T08:00:00.000+08:00,Lilly Announces Phase 3 Data Show Empagliflozin Plus Insulin Significantly Reduced HbA1c in Adults with Type 2 Diabetes,LLY,https://www.benzinga.com/news/13/06/3698001/lilly-announces-phase-3-data-show-empagliflozin-plus-insulin-significantly-reduce,Charles Gross,,,,0,0,abd8ecdd-98f0-4175-9dfd-0a26e06c7148
2013-06-20T08:00:00.000+08:00,"Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Updates to Prescribing Information for TRADJENTA® (linagliptin) Tablets and JENTADUETO® (linagliptin and metformin hydrochloride) Tablets",LLY,https://www.benzinga.com/press-releases/13/06/3693429/boehringer-ingelheim-pharmaceuticals-inc-and-eli-lilly-and-company-anno,James Hunt,,,,0,0,f9dec2c0-4c91-44c2-b34e-44023db85b7b
2013-06-20T08:00:00.000+08:00,"Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Updates to Prescribing Information for TRADJENTA® (linagliptin) Tablets and JENTADUETO® (linagliptin and metformin hydrochloride) Tablets",LLY,https://www.benzinga.com/press-releases/13/06/3693429/boehringer-ingelheim-pharmaceuticals-inc-and-eli-lilly-and-company-anno,James Hunt,,,,0,0,34fcacc3-01e7-4410-a0b7-e194c9de4b90
2013-06-19T08:00:00.000+08:00,Eli Lilly Issues Alert for Two Illegal Scans Involving Co. Name,LLY,https://www.benzinga.com/news/13/06/3690486/eli-lilly-issues-alert-for-two-illegal-scans-involving-co-name,Paul Quintaro,,,,0,0,6c096af2-815e-4a36-bd6a-bf70ff0a3442
2013-06-19T08:00:00.000+08:00,Eli Lilly Issues Alert for Two Illegal Scans Involving Co. Name,LLY,https://www.benzinga.com/news/13/06/3690486/eli-lilly-issues-alert-for-two-illegal-scans-involving-co-name,Paul Quintaro,,,,0,0,b85c81ff-fcd0-4022-af7e-d8c29a04f57f
2013-06-13T08:00:00.000+08:00,UPDATE: Lilly Doesn't See Charge as Material,LLY,https://www.benzinga.com/news/13/06/3675179/update-lilly-doesnt-see-charge-as-material,Paul Quintaro,,,,0,0,9fe4e07c-9f76-47ac-8464-64989b8d4db5
2013-06-13T08:00:00.000+08:00,"Lilly Issues Release: Voluntarily Terminates Phase II Study of LY2886721, Says Decision Doesn't Affect Other Alzheimer's Compounds, Sees Charge",LLY,https://www.benzinga.com/news/13/06/3675176/lilly-issues-release-voluntarily-terminates-phase-ii-study-of-ly2886721-says-deci,Paul Quintaro,,,,0,0,9d39ec63-2e46-4f75-9319-8513e01b9d50
2013-06-13T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/13/06/3672822/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,8fd24070-ecbc-447e-a917-cf4a1debc383
2013-06-13T08:00:00.000+08:00,"Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis",LLY,https://www.benzinga.com/news/13/06/3672609/lilly-incyte-announce-baricitinib-efficacy-and-safety-data-from-phase-2b-jada-stu,Charles Gross,,,,0,0,ae7594d8-b1ea-4ebb-b951-295e13d80b74
2013-06-13T08:00:00.000+08:00,UPDATE: Lilly Doesn't See Charge as Material,LLY,https://www.benzinga.com/news/13/06/3675179/update-lilly-doesnt-see-charge-as-material,Paul Quintaro,,,,0,0,f2c1da4c-0d44-4133-981a-e8a2f46f345d
2013-06-13T08:00:00.000+08:00,"Lilly Issues Release: Voluntarily Terminates Phase II Study of LY2886721, Says Decision Doesn't Affect Other Alzheimer's Compounds, Sees Charge",LLY,https://www.benzinga.com/news/13/06/3675176/lilly-issues-release-voluntarily-terminates-phase-ii-study-of-ly2886721-says-deci,Paul Quintaro,,,,0,0,93348cfb-e981-4548-b71f-b18c6e1c27de
2013-06-13T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/13/06/3672822/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,cff27560-620e-4e1b-af85-1221bffa156c
2013-06-13T08:00:00.000+08:00,"Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis",LLY,https://www.benzinga.com/news/13/06/3672609/lilly-incyte-announce-baricitinib-efficacy-and-safety-data-from-phase-2b-jada-stu,Charles Gross,,,,0,0,f6509cf0-e227-49d0-a609-3139bd320117
2013-06-06T08:00:00.000+08:00,"Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)",LLY,https://www.benzinga.com/news/13/06/3653822/drug-company-profits-set-to-increase-from-additions-to-dsm-5,Jim Probasco,,,,0,0,034bc397-34f9-4bdb-bc0b-149f4d00f4b7
2013-06-06T08:00:00.000+08:00,"Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE)",LLY,https://www.benzinga.com/news/13/06/3653822/drug-company-profits-set-to-increase-from-additions-to-dsm-5,Jim Probasco,,,,0,0,7a223b64-e021-4314-88be-88dd1bb6fc37
2013-06-03T08:00:00.000+08:00,Lilly Announces PRONOUNCE Trial Did Not Meet Primary Superiority Endpoint,LLY,https://www.benzinga.com/news/13/06/3641076/lilly-announces-pronounce-trial-did-not-meet-primary-superiority-endpoint,Paul Quintaro,,,,0,0,1ec7fa70-6e24-4264-a160-adef9b3da5ff
2013-06-03T08:00:00.000+08:00,Lilly Announces PRONOUNCE Trial Did Not Meet Primary Superiority Endpoint,LLY,https://www.benzinga.com/news/13/06/3641076/lilly-announces-pronounce-trial-did-not-meet-primary-superiority-endpoint,Paul Quintaro,,,,0,0,3202ed7b-1a27-434e-996e-3b320b2a04ec
2013-06-02T08:00:00.000+08:00,"CVR Energy, Warner Chilcott and Other Top Performers in May",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/06/3639582/cvr-energy-warner-chilcott-and-other-top-performers-in-may,Nelson Hem,,,,0,0,dba0dd1b-348d-4133-958f-09a974754b1b
2013-06-02T08:00:00.000+08:00,"CVR Energy, Warner Chilcott and Other Top Performers in May",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/06/3639582/cvr-energy-warner-chilcott-and-other-top-performers-in-may,Nelson Hem,,,,0,0,81d44725-97fe-44b9-8570-2fa43bad1799
2013-05-29T08:00:00.000+08:00,"SunTrust Robinson Humphrey Initiates Coverage on Eli Lilly and Company at Buy, Announces $63.00 PT",LLY,https://www.benzinga.com/news/13/05/3630415/suntrust-robinson-humphrey-initiates-coverage-on-eli-lilly-and-company-at-buy-ann,Paul Quintaro,,,,0,0,f6423c63-a1ae-482c-adeb-c9a2d47dcf41
2013-05-29T08:00:00.000+08:00,New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis,LLY,https://www.benzinga.com/news/13/05/3628114/new-data-on-forteo-teriparatide-rdna-origin-injection-show-increased-bone-mineral,Eddie Staley,,,,0,0,8eae2b2e-f624-46e9-9e50-5893b8ed7855
2013-05-29T08:00:00.000+08:00,"SunTrust Robinson Humphrey Initiates Coverage on Eli Lilly and Company at Buy, Announces $63.00 PT",LLY,https://www.benzinga.com/news/13/05/3630415/suntrust-robinson-humphrey-initiates-coverage-on-eli-lilly-and-company-at-buy-ann,Paul Quintaro,,,,0,0,7de8eafb-e43d-4d4b-b241-6aa0846aa7a7
2013-05-29T08:00:00.000+08:00,New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis,LLY,https://www.benzinga.com/news/13/05/3628114/new-data-on-forteo-teriparatide-rdna-origin-injection-show-increased-bone-mineral,Eddie Staley,,,,0,0,db118bd2-abe8-4da3-8a18-7422bfcc7a5c
2013-05-28T08:00:00.000+08:00,"UPDATE: Jefferies Upgrades Eli Lilly to Hold, Raises PT Following SOTP Analysis",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/05/3624587/update-jefferies-upgrades-eli-lilly-to-hold-raises-pt-fo,Dwight Einhorn,,,,0,0,b789b480-6c44-4343-9bab-dc7245322a3a
2013-05-28T08:00:00.000+08:00,"PreMarket Info Recap for May 28, 2013",LLY,https://www.benzinga.com/news/earnings/13/05/3624297/premarket-info-recap-for-may-28-2013,PreMarketInfo,,,,0,0,c78f99a7-fff5-4e28-aeca-967edefa62fb
2013-05-28T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $49.00",LLY,https://www.benzinga.com/news/13/05/3623663/jefferies-upgrades-eli-lilly-and-company-to-hold-raises-pt-to-49-00,Juan Lopez,,,,0,0,0e611350-1411-4040-92b5-dc6dcfe0b86e
2013-05-28T08:00:00.000+08:00,"UPDATE: Jefferies Upgrades Eli Lilly to Hold, Raises PT Following SOTP Analysis",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/05/3624587/update-jefferies-upgrades-eli-lilly-to-hold-raises-pt-fo,Dwight Einhorn,,,,0,0,4cc4e69a-4444-4f63-b54d-3a491159e71e
2013-05-28T08:00:00.000+08:00,"PreMarket Info Recap for May 28, 2013",LLY,https://www.benzinga.com/news/earnings/13/05/3624297/premarket-info-recap-for-may-28-2013,PreMarketInfo,,,,0,0,15b311a5-68ee-4768-96f9-cf88a9e8b8c6
2013-05-28T08:00:00.000+08:00,"Jefferies Upgrades Eli Lilly and Company to Hold, Raises PT to $49.00",LLY,https://www.benzinga.com/news/13/05/3623663/jefferies-upgrades-eli-lilly-and-company-to-hold-raises-pt-to-49-00,Juan Lopez,,,,0,0,8659ca82-7de0-4d76-9256-fb49ca338f2f
2013-05-18T08:00:00.000+08:00,"U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/05/3601714/u-s-steel-genomic-health-and-other-stocks-insiders-are-buying,Nelson Hem,,,,0,0,5ed5b19e-6592-48e2-8975-a1468e0885e7
2013-05-18T08:00:00.000+08:00,"U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/05/3601714/u-s-steel-genomic-health-and-other-stocks-insiders-are-buying,Nelson Hem,,,,0,0,8094c1dd-6876-4aca-89de-2f5370fa9a1d
2013-05-14T08:00:00.000+08:00,"PreMarket Info Recap for May 14, 2013",LLY,https://www.benzinga.com/news/13/05/3587360/premarket-info-recap-for-may-14-2013,PreMarketInfo,,,,0,0,7f8e6e77-fa3f-4a8f-aefc-17baec856214
2013-05-14T08:00:00.000+08:00,Eli Lillly Says CEO John Lechleiter's Surgery Went as Expected,LLY,https://www.benzinga.com/news/13/05/3587273/eli-lillly-says-ceo-john-lechleiters-surgery-went-as-expected,Paul Quintaro,,,,0,0,c4f0ff69-9c83-467e-9b1d-6d1a7b69f4fd
2013-05-14T08:00:00.000+08:00,"PreMarket Info Recap for May 14, 2013",LLY,https://www.benzinga.com/news/13/05/3587360/premarket-info-recap-for-may-14-2013,PreMarketInfo,,,,0,0,600eb6f2-8ad3-46c1-9b95-7c0822d34ee3
2013-05-14T08:00:00.000+08:00,Eli Lillly Says CEO John Lechleiter's Surgery Went as Expected,LLY,https://www.benzinga.com/news/13/05/3587273/eli-lillly-says-ceo-john-lechleiters-surgery-went-as-expected,Paul Quintaro,,,,0,0,242e23b3-5039-4ddc-b4dc-140ca361c325
2013-05-10T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/13/05/3578792/benzingas-top-pre-market-losers,Monica Gerson,,,,0,0,7ff8fc5f-fef1-4a7d-a4e1-5f416ffc1c91
2013-05-10T08:00:00.000+08:00,Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma,LLY,https://www.benzinga.com/news/13/05/3578660/lilly-announces-enzastaurin-phase-iii-study-did-not-meet-primary-endpoint-in-diff,Eddie Staley,,,,0,0,4bf334c0-97bd-449f-a296-3643bc2f2847
2013-05-10T08:00:00.000+08:00,Lilly Says Enzastaurin Phase III Did Not Meet Primary Endpoint; Reaffirms Outlook,LLY,https://www.benzinga.com/news/13/05/3578633/lilly-says-enzastaurin-phase-iii-did-not-meet-primary-endpoint-reaffirms-outlook,Paul Quintaro,,,,0,0,4ae9b638-765b-4ebb-9ec3-beb42a885290
2013-05-10T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/13/05/3578792/benzingas-top-pre-market-losers,Monica Gerson,,,,0,0,a4ea921d-b633-4838-b41c-5abe8b1b13a7
2013-05-10T08:00:00.000+08:00,Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma,LLY,https://www.benzinga.com/news/13/05/3578660/lilly-announces-enzastaurin-phase-iii-study-did-not-meet-primary-endpoint-in-diff,Eddie Staley,,,,0,0,ca861dae-f384-4ce3-920d-3d88f9da8c3d
2013-05-10T08:00:00.000+08:00,Lilly Says Enzastaurin Phase III Did Not Meet Primary Endpoint; Reaffirms Outlook,LLY,https://www.benzinga.com/news/13/05/3578633/lilly-says-enzastaurin-phase-iii-did-not-meet-primary-endpoint-reaffirms-outlook,Paul Quintaro,,,,0,0,ec90c190-922a-4fce-95c8-ff1a164b635f
2013-05-06T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/13/05/3560669/benzingas-top-pre-market-losers,Lisa Levin,,,,0,0,fc092db8-e7c2-4edb-b998-b683e4681885
2013-05-06T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/13/05/3560669/benzingas-top-pre-market-losers,Lisa Levin,,,,0,0,c66bfd4c-9bf0-4671-b433-d9927bd94700
2013-04-25T08:00:00.000+08:00,"Benzinga Market Primer: Thursday, April 25",LLY,https://www.benzinga.com/markets/bonds/13/04/3528251/benzinga-market-primer-thursday-april-25,Matthew Kanterman,,,,0,0,e8ed4152-01a5-4770-9ac8-39edc18b5167
2013-04-25T08:00:00.000+08:00,"Benzinga Market Primer: Thursday, April 25",LLY,https://www.benzinga.com/markets/bonds/13/04/3528251/benzinga-market-primer-thursday-april-25,Matthew Kanterman,,,,0,0,076f508d-a0ba-4a7f-ac94-004432c146e3
2013-04-24T08:00:00.000+08:00,Eli Lilly Approaching the April 19th low of $56.37; Currently Seen as Intra-Day Support,LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3525181/eli-lilly-approaching-the-april-19th-low-of-56-37-currently-s,bret.kenwell@benzinga.com,,,,0,0,0332c03a-75e4-40d6-a676-9b5c124a062b
2013-04-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q1 EPS of $1.14 vs $1.05 Est; Revenue of $5.60B vs $5.66B Est,LLY,https://www.benzinga.com/news/earnings/13/04/3523672/eli-lilly-and-company-reports-q1-eps-of-1-14-vs-1-05-est-revenue-of-5-60,Charles Gross,,,,0,0,1be08b7f-ad96-459e-a190-9d6ba91fbde2
2013-04-24T08:00:00.000+08:00,US Stock Futures Up Ahead Of Earnings,LLY,https://www.benzinga.com/news/13/04/3523632/us-stock-futures-up-ahead-of-earnings,Monica Gerson,,,,0,0,ce4ac753-406b-4239-a022-9eba324a21cf
2013-04-24T08:00:00.000+08:00,"Stocks To Watch For April 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/04/3523445/stocks-to-watch-for-april-24-2013,Monica Gerson,,,,0,0,df5f2b3b-e6ba-4132-abf7-0a6c2f86f916
2013-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/04/3523440/earnings-scheduled-for-april-24-2013,Monica Gerson,,,,0,0,959b04c7-2410-4913-bfe2-3bd70e027639
2013-04-24T08:00:00.000+08:00,Eli Lilly Approaching the April 19th low of $56.37; Currently Seen as Intra-Day Support,LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3525181/eli-lilly-approaching-the-april-19th-low-of-56-37-currently-s,bret.kenwell@benzinga.com,,,,0,0,8b759eb8-6ed3-4e58-a546-4432df95b427
2013-04-24T08:00:00.000+08:00,Eli Lilly and Company Reports Q1 EPS of $1.14 vs $1.05 Est; Revenue of $5.60B vs $5.66B Est,LLY,https://www.benzinga.com/news/earnings/13/04/3523672/eli-lilly-and-company-reports-q1-eps-of-1-14-vs-1-05-est-revenue-of-5-60,Charles Gross,,,,0,0,963abfcd-23d2-4a23-bc92-0ad03bd543c2
2013-04-24T08:00:00.000+08:00,US Stock Futures Up Ahead Of Earnings,LLY,https://www.benzinga.com/news/13/04/3523632/us-stock-futures-up-ahead-of-earnings,Monica Gerson,,,,0,0,6acb4a2f-ad5b-4d8a-8d49-3ee3f0a29016
2013-04-24T08:00:00.000+08:00,"Stocks To Watch For April 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/04/3523445/stocks-to-watch-for-april-24-2013,Monica Gerson,,,,0,0,5f85488b-23ac-4c61-9928-f4813cc98fe9
2013-04-24T08:00:00.000+08:00,"Earnings Scheduled For April 24, 2013",LLY,https://www.benzinga.com/news/earnings/13/04/3523440/earnings-scheduled-for-april-24-2013,Monica Gerson,,,,0,0,c85fd82f-4e83-4035-a47c-6009710d83e4
2013-04-23T08:00:00.000+08:00,"Eli Lilly Earnings Preview: EPS, Sales Growth Expected",LLY,https://www.benzinga.com/news/earnings/13/04/3521186/eli-lilly-earnings-preview-eps-sales-growth-expected,Nelson Hem,,,,0,0,c93f7554-e82e-49cb-ac0c-647fa4fd1da7
2013-04-23T08:00:00.000+08:00,"Eli Lilly Earnings Preview: EPS, Sales Growth Expected",LLY,https://www.benzinga.com/news/earnings/13/04/3521186/eli-lilly-earnings-preview-eps-sales-growth-expected,Nelson Hem,,,,0,0,6be4b321-3fa5-4b13-92e9-0039c692a295
2013-04-21T08:00:00.000+08:00,Earnings Expectations for the Week of April 22,LLY,https://www.benzinga.com/news/earnings/13/04/3514067/earnings-expectations-for-the-week-of-april-22,Nelson Hem,,,,0,0,c986a4da-a2ef-4213-800c-ec3e3d7e0925
2013-04-21T08:00:00.000+08:00,Earnings Expectations for the Week of April 22,LLY,https://www.benzinga.com/news/earnings/13/04/3514067/earnings-expectations-for-the-week-of-april-22,Nelson Hem,,,,0,0,4fbcc6f7-34d6-46ed-8204-6a4eecdd4297
2013-04-19T08:00:00.000+08:00,"Weekly Preview: Earnings Season Continues, Apple In Focus",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3512062/weekly-preview-earnings-season-continues-apple-in-focus,Matthew Kanterman,,,,0,0,24bd7c35-1bba-4ddb-9ed0-143a81b90c37
2013-04-19T08:00:00.000+08:00,"Weekly Preview: Earnings Season Continues, Apple In Focus",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3512062/weekly-preview-earnings-season-continues-apple-in-focus,Matthew Kanterman,,,,0,0,bcb1d326-cb44-44cf-8223-2308bb9b206e
2013-04-17T08:00:00.000+08:00,Lilly Buys Novel Tau Tangle Diagnostic Progra,LLY,https://www.benzinga.com/news/13/04/3503556/lilly-buys-novel-tau-tangle-diagnostic-progra,Paul Quintaro,,,,0,0,c9d91e45-b9ec-4751-a6ea-5584e22bc1cc
2013-04-17T08:00:00.000+08:00,Lilly Buys Novel Tau Tangle Diagnostic Progra,LLY,https://www.benzinga.com/news/13/04/3503556/lilly-buys-novel-tau-tangle-diagnostic-progra,Paul Quintaro,,,,0,0,d90c4a38-51a0-4ee0-8782-f813743ff344
2013-04-16T08:00:00.000+08:00,Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,LLY,https://www.benzinga.com/news/13/04/3499958/lilly-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-type-2-dia,Paul Quintaro,,,,0,0,1d8b19cc-cc9b-4c92-b39d-7ac4b79ee31a
2013-04-16T08:00:00.000+08:00,Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,LLY,https://www.benzinga.com/news/13/04/3499958/lilly-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-type-2-dia,Paul Quintaro,,,,0,0,70d9cf2a-b98c-4467-bb2c-4971642f3c4b
2013-04-11T08:00:00.000+08:00,ETF Showdown: A Pharma Fight,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/04/3491090/etf-showdown-a-pharma-fight,ETF Professor,,,,0,0,e6aa5273-3e09-4225-863e-d1eb08bd7454
2013-04-11T08:00:00.000+08:00,AP Reporting Eli Lilly Planning to Cut Hundreds from US Sales Force by July 1st,LLY,https://www.benzinga.com/news/13/04/3491071/ap-reporting-eli-lilly-planning-to-cut-hundreds-from-us-sales-force-by-july-1st,Paul Quintaro,,,,0,0,cb1a0cfa-d986-4dd5-9299-a87cfd6f41e7
2013-04-11T08:00:00.000+08:00,ETF Showdown: A Pharma Fight,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/04/3491090/etf-showdown-a-pharma-fight,ETF Professor,,,,0,0,5d42b140-1bdf-475a-97dd-6ee2ca875900
2013-04-11T08:00:00.000+08:00,AP Reporting Eli Lilly Planning to Cut Hundreds from US Sales Force by July 1st,LLY,https://www.benzinga.com/news/13/04/3491071/ap-reporting-eli-lilly-planning-to-cut-hundreds-from-us-sales-force-by-july-1st,Paul Quintaro,,,,0,0,ae668cf0-f7ec-4274-a47d-4b0f4458d868
2013-04-10T08:00:00.000+08:00,UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3486693/update-jefferies-raises-pt-on-eli-lilly-co-as-least-pref,Dwight Einhorn,,,,0,0,1b30f816-5258-4880-b4ae-e6e1c7499645
2013-04-10T08:00:00.000+08:00,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $44.00",LLY,https://www.benzinga.com/news/13/04/3485535/jefferies-maintains-underperform-on-eli-lilly-and-company-raises-pt-to-44-00,Juan Lopez,,,,0,0,e1654e77-53f2-460b-90b2-8040e46daa93
2013-04-10T08:00:00.000+08:00,UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3486693/update-jefferies-raises-pt-on-eli-lilly-co-as-least-pref,Dwight Einhorn,,,,0,0,2422486e-9ddd-4d9b-b59c-1c4da1d2e95b
2013-04-10T08:00:00.000+08:00,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $44.00",LLY,https://www.benzinga.com/news/13/04/3485535/jefferies-maintains-underperform-on-eli-lilly-and-company-raises-pt-to-44-00,Juan Lopez,,,,0,0,eee284f6-ba63-4f23-b87e-ed4ec88f605c
2013-04-09T08:00:00.000+08:00,"Eli Lilly Rejects $57.25 Resistance, 20 EMA Support Lower At $56.04, Breakout In Play",LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3483196/eli-lilly-rejects-57-25-resistance-20-ema-support-lower-at-56,Zack Armstrong,,,,0,0,7d054b19-55fc-4f4d-b674-4cf808362fb9
2013-04-09T08:00:00.000+08:00,"Eli Lilly Rejects $57.25 Resistance, 20 EMA Support Lower At $56.04, Breakout In Play",LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3483196/eli-lilly-rejects-57-25-resistance-20-ema-support-lower-at-56,Zack Armstrong,,,,0,0,24bb35da-2b46-4d83-a8ba-8c0327e6ebfe
2013-04-03T08:00:00.000+08:00,"Eli Lilly Attempting To Breakout Over $57 Resistance, RSI Overbought",LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3468447/eli-lilly-attempting-to-breakout-over-57-resistance-rsi-overb,Zack Armstrong,,,,0,0,d80ce6bf-a3c9-4660-a00c-7c43eccd239d
2013-04-03T08:00:00.000+08:00,"Eli Lilly Attempting To Breakout Over $57 Resistance, RSI Overbought",LLY,https://www.benzinga.com/trading-ideas/technicals/13/04/3468447/eli-lilly-attempting-to-breakout-over-57-resistance-rsi-overb,Zack Armstrong,,,,0,0,1177e2d4-4298-4cfd-9f58-e1474b6cfec3
2013-04-02T08:00:00.000+08:00,Eli Lilly Working with Indianapolis Officials for Proposal to Invest Added $180M in Insulin Manufacturing Ops,LLY,https://www.benzinga.com/news/13/04/3463492/eli-lilly-working-with-indianapolis-officials-for-proposal-to-invest-added-180m-i,Paul Quintaro,,,,0,0,e4f231cf-9367-447b-b17d-2a97829f53e4
2013-04-02T08:00:00.000+08:00,Eli Lilly Working with Indianapolis Officials for Proposal to Invest Added $180M in Insulin Manufacturing Ops,LLY,https://www.benzinga.com/news/13/04/3463492/eli-lilly-working-with-indianapolis-officials-for-proposal-to-invest-added-180m-i,Paul Quintaro,,,,0,0,d9e217af-e840-451b-b3cd-0de86fbdcb8d
2013-03-26T08:00:00.000+08:00,Eli Lilly Isues Statement Re Intention to Cancel Listing of Shares,LLY,https://www.benzinga.com/news/13/03/3447546/eli-lilly-isues-statement-re-intention-to-cancel-listing-of-shares,Paul Quintaro,,,,0,0,85940ef7-f4b3-4d84-8c2a-a342cbfdcd60
2013-03-26T08:00:00.000+08:00,"EMA Accepts Marketing Authorization App for Boehringer, Lilly Empagliflozin",LLY,https://www.benzinga.com/news/13/03/3447482/ema-accepts-marketing-authorization-app-for-boehringer-lilly-empagliflozin,Paul Quintaro,,,,0,0,e04cecfc-98ab-405c-8eb3-f169938c2ba9
2013-03-26T08:00:00.000+08:00,Eli Lilly Isues Statement Re Intention to Cancel Listing of Shares,LLY,https://www.benzinga.com/news/13/03/3447546/eli-lilly-isues-statement-re-intention-to-cancel-listing-of-shares,Paul Quintaro,,,,0,0,df4e6d88-ebeb-4f74-be39-a3a0464a3524
2013-03-26T08:00:00.000+08:00,"EMA Accepts Marketing Authorization App for Boehringer, Lilly Empagliflozin",LLY,https://www.benzinga.com/news/13/03/3447482/ema-accepts-marketing-authorization-app-for-boehringer-lilly-empagliflozin,Paul Quintaro,,,,0,0,b411b397-11f1-4828-870b-98590ef42d9a
2013-03-25T08:00:00.000+08:00,This Dead Money Sector is Leading the S&P This Year,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/03/3442563/this-dead-money-sector-is-leading-the-s-p-this-year,Tim Parker,,,,0,0,a829c555-803d-4302-9e1d-fb1d283ca1b3
2013-03-25T08:00:00.000+08:00,This Dead Money Sector is Leading the S&P This Year,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/03/3442563/this-dead-money-sector-is-leading-the-s-p-this-year,Tim Parker,,,,0,0,41d7681d-0a56-473b-b768-6e85f098d75d
2013-03-22T08:00:00.000+08:00,"Eli Lilly Fails At $55.75 Resistance, 20 EMA Support Lower At $54.83, Breakout Still In Play",LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3439970/eli-lilly-fails-at-55-75-resistance-20-ema-support-lower-at-5,Zack Armstrong,,,,0,0,12543dee-c325-4cd0-8e76-191698e974dd
2013-03-22T08:00:00.000+08:00,"Eli Lilly Fails At $55.75 Resistance, 20 EMA Support Lower At $54.83, Breakout Still In Play",LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3439970/eli-lilly-fails-at-55-75-resistance-20-ema-support-lower-at-5,Zack Armstrong,,,,0,0,a24055d2-6ac8-4d00-a017-16645eee086b
2013-03-18T08:00:00.000+08:00,Lilly Says New Study of Cialis Met Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Hyperlasia,LLY,https://www.benzinga.com/news/13/03/3424958/lilly-says-new-study-of-cialis-met-primary-endpoint-in-men-with-lower-urinary-tra,Paul Quintaro,,,,0,0,5b3fd49e-1c60-45db-bad0-204f6842444d
2013-03-18T08:00:00.000+08:00,Lilly Says New Study of Cialis Met Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Hyperlasia,LLY,https://www.benzinga.com/news/13/03/3424958/lilly-says-new-study-of-cialis-met-primary-endpoint-in-men-with-lower-urinary-tra,Paul Quintaro,,,,0,0,89bf83a4-737e-4014-9c1d-11d67b4ba8e1
2013-03-14T08:00:00.000+08:00,Magnet Trades: The Case of Eli Lilly,LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3417945/magnet-trades-the-case-of-eli-lilly,Dennis Dick,,,,0,0,4620b2c0-85c0-479a-b1be-2c98c0769d1d
2013-03-14T08:00:00.000+08:00,Magnet Trades: The Case of Eli Lilly,LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3417945/magnet-trades-the-case-of-eli-lilly,Dennis Dick,,,,0,0,8552bd98-a81a-4b36-91c0-6abc7b7a56bd
2013-03-11T08:00:00.000+08:00,Are Scientists Edging Closer to a Cure for Alzheimer's?,LLY,https://www.benzinga.com/news/13/03/3404085/are-scientists-edging-closer-to-a-cure-for-alzheimers,Tim Parker,,,,0,0,d27c8f44-dad8-4b94-ba44-a35903e1a889
2013-03-11T08:00:00.000+08:00,Are Scientists Edging Closer to a Cure for Alzheimer's?,LLY,https://www.benzinga.com/news/13/03/3404085/are-scientists-edging-closer-to-a-cure-for-alzheimers,Tim Parker,,,,0,0,02db322f-0a50-4555-8e48-ad11bbbceaf7
2013-03-05T08:00:00.000+08:00,"Eli Lilly Breaks Out Over $55 Resistance To Continue Uptrend, MACD Attempting Bullish Crossover",LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3391697/eli-lilly-breaks-out-over-55-resistance-to-continue-uptrend-m,Zack Armstrong,,,,0,0,db7c72a2-8b2a-4632-a161-4547a1e112d6
2013-03-05T08:00:00.000+08:00,Eli Lilly Sets Date for '13 Diabetes Pipeline Update,LLY,https://www.benzinga.com/news/13/03/3389836/eli-lilly-sets-date-for-13-diabetes-pipeline-update,Paul Quintaro,,,,0,0,2b78b476-a4d8-4a49-825a-15acf56ab726
2013-03-05T08:00:00.000+08:00,"Eli Lilly Breaks Out Over $55 Resistance To Continue Uptrend, MACD Attempting Bullish Crossover",LLY,https://www.benzinga.com/trading-ideas/technicals/13/03/3391697/eli-lilly-breaks-out-over-55-resistance-to-continue-uptrend-m,Zack Armstrong,,,,0,0,51b35a5f-a052-4abf-8650-00359844307a
2013-03-05T08:00:00.000+08:00,Eli Lilly Sets Date for '13 Diabetes Pipeline Update,LLY,https://www.benzinga.com/news/13/03/3389836/eli-lilly-sets-date-for-13-diabetes-pipeline-update,Paul Quintaro,,,,0,0,51b90336-2d17-4bc5-86cc-04fdc4aa4b8f
2013-03-01T08:00:00.000+08:00,Eli Lilly Files Automatic Mixed Securities Shelf,LLY,https://www.benzinga.com/news/13/03/3381184/eli-lilly-files-automatic-mixed-securities-shelf,Paul Quintaro,,,,0,0,2a5c54fe-fa2c-4f4c-832a-2c217a832fa8
2013-03-01T08:00:00.000+08:00,Eli Lilly Files Automatic Mixed Securities Shelf,LLY,https://www.benzinga.com/news/13/03/3381184/eli-lilly-files-automatic-mixed-securities-shelf,Paul Quintaro,,,,0,0,ae2c1682-b3b5-4e60-8b3a-19efbf50b3e2
2013-02-28T08:00:00.000+08:00,"If The Market Falls, Try These Low Beta ETFs",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/02/3379576/if-the-market-falls-try-these-low-beta-etfs,ETF Professor,,,,0,0,f0077ede-0d98-4989-8d6f-41420f2fc22a
2013-02-28T08:00:00.000+08:00,"If The Market Falls, Try These Low Beta ETFs",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/02/3379576/if-the-market-falls-try-these-low-beta-etfs,ETF Professor,,,,0,0,8ab31f49-842d-4aa1-8931-60ad97b21b08
2013-02-27T08:00:00.000+08:00,Eli Lilly Issues Statement Related to Intention to Cancel Listing of London Stock Exchange Shares,LLY,https://www.benzinga.com/news/13/02/3373257/eli-lilly-issues-statement-related-to-intention-to-cancel-listing-of-london-stock,Paul Quintaro,,,,0,0,281393dc-7652-4766-b24f-1d4e945a5ddf
2013-02-27T08:00:00.000+08:00,UPDATE: Credit Suisse Raises PT to $68 on Eli Lilly on Patent Ruling Confidence,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/02/3372680/update-credit-suisse-raises-pt-to-68-on-eli-lilly-on-pat,David Johnson,,,,0,0,38d1a343-fd0e-4150-b404-6609957e712a
2013-02-27T08:00:00.000+08:00,Eli Lilly Issues Statement Related to Intention to Cancel Listing of London Stock Exchange Shares,LLY,https://www.benzinga.com/news/13/02/3373257/eli-lilly-issues-statement-related-to-intention-to-cancel-listing-of-london-stock,Paul Quintaro,,,,0,0,e6aa0992-95a8-4055-a253-a4d481217cb5
2013-02-27T08:00:00.000+08:00,UPDATE: Credit Suisse Raises PT to $68 on Eli Lilly on Patent Ruling Confidence,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/02/3372680/update-credit-suisse-raises-pt-to-68-on-eli-lilly-on-pat,David Johnson,,,,0,0,483d9bc3-c0d6-4998-9d80-d3bbe17ac565
2013-02-20T08:00:00.000+08:00,Eli Lilly Continues Advance After Breakout Over $54 Resistance,LLY,https://www.benzinga.com/trading-ideas/technicals/13/02/3349768/eli-lilly-continues-advance-after-breakout-over-54-resistance,Zack Armstrong,,,,0,0,a54f4998-813e-44d6-a35d-94d12c9a42ed
2013-02-20T08:00:00.000+08:00,Eli Lilly Continues Advance After Breakout Over $54 Resistance,LLY,https://www.benzinga.com/trading-ideas/technicals/13/02/3349768/eli-lilly-continues-advance-after-breakout-over-54-resistance,Zack Armstrong,,,,0,0,bdcb3a30-4309-4357-873d-61eab77ec869
2013-02-07T08:00:00.000+08:00,Eli Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab,LLY,https://www.benzinga.com/news/13/02/3313229/eli-lilly-discontinues-phase-3-rheumatoid-arthritis-program-for-tabalumab,Paul Quintaro,,,,0,0,0b269641-d70d-47de-82c8-1b56b73bd532
2013-02-07T08:00:00.000+08:00,Eli Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab,LLY,https://www.benzinga.com/news/13/02/3313229/eli-lilly-discontinues-phase-3-rheumatoid-arthritis-program-for-tabalumab,Paul Quintaro,,,,0,0,d84ecdf4-97a0-46be-854d-fceea0d9921a
2013-02-06T08:00:00.000+08:00,Eli Lilly Re-testing Breakout Over $53.50,LLY,https://www.benzinga.com/trading-ideas/dividends/13/02/3311390/eli-lilly-re-testing-breakout-over-53-50,Zack Armstrong,,,,0,0,152f1191-6f40-4f7d-aae3-2112ad734382
2013-02-06T08:00:00.000+08:00,Eli Lilly Re-testing Breakout Over $53.50,LLY,https://www.benzinga.com/trading-ideas/dividends/13/02/3311390/eli-lilly-re-testing-breakout-over-53-50,Zack Armstrong,,,,0,0,9484e9e1-9279-4dd6-9751-2e233572b9dd
2013-01-30T08:00:00.000+08:00,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Eli Lilly & Company",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3289155/update-goldman-sachs-reiterates-neutral-rating-raises-pt,Dwight Einhorn,,,,0,0,feb7c5fa-a9f6-4b35-a7e8-37b7158aca7f
2013-01-30T08:00:00.000+08:00,UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3288937/update-citigroup-raises-eli-lilly-pt-to-60-on-eli-lilly-,David Johnson,,,,0,0,d6ad022a-0b2d-4e04-aa59-ddd7ed6bd59d
2013-01-30T08:00:00.000+08:00,"Goldman Sachs Maintains Neutral on Eli Lilly and Company, Raises PT to $56.00",LLY,https://www.benzinga.com/news/13/01/3288031/goldman-sachs-maintains-neutral-on-eli-lilly-and-company-raises-pt-to-56-00,Juan Lopez,,,,0,0,0c8a6ff4-21d7-4649-84b7-67295e953af2
2013-01-30T08:00:00.000+08:00,"Citigroup Maintains Buy on Eli Lilly and Company, Raises PT to $60.00",LLY,https://www.benzinga.com/news/13/01/3288015/citigroup-maintains-buy-on-eli-lilly-and-company-raises-pt-to-60-00,Juan Lopez,,,,0,0,0b565a7c-d72f-4052-95c7-56d91a8821e0
2013-01-30T08:00:00.000+08:00,"UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Eli Lilly & Company",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3289155/update-goldman-sachs-reiterates-neutral-rating-raises-pt,Dwight Einhorn,,,,0,0,f1e0a53f-982a-4c81-9b1b-7b50e1479ed5
2013-01-30T08:00:00.000+08:00,UPDATE: Citigroup Raises Eli Lilly PT to $60 on Eli Lilly on Potential Upside,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3288937/update-citigroup-raises-eli-lilly-pt-to-60-on-eli-lilly-,David Johnson,,,,0,0,a9da0fee-9a98-474d-a5d4-81d7122934eb
2013-01-30T08:00:00.000+08:00,"Goldman Sachs Maintains Neutral on Eli Lilly and Company, Raises PT to $56.00",LLY,https://www.benzinga.com/news/13/01/3288031/goldman-sachs-maintains-neutral-on-eli-lilly-and-company-raises-pt-to-56-00,Juan Lopez,,,,0,0,55cd01b4-fc56-4586-8bae-a54fe96d6f3b
2013-01-30T08:00:00.000+08:00,"Citigroup Maintains Buy on Eli Lilly and Company, Raises PT to $60.00",LLY,https://www.benzinga.com/news/13/01/3288015/citigroup-maintains-buy-on-eli-lilly-and-company-raises-pt-to-60-00,Juan Lopez,,,,0,0,8064f62f-7133-4d78-b828-6a641a951f0b
2013-01-29T08:00:00.000+08:00,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg,LLY,https://www.benzinga.com/news/13/01/3284158/novo-spokesperson-says-will-introduce-tresiba-in-some-eu-countries-in-first-half-,Paul Quintaro,,,,0,0,ba586187-9d0b-409e-a851-e97ffd12a962
2013-01-29T08:00:00.000+08:00,Lilly Planning Five New Drug Regulatory Filings in 2013,LLY,https://www.benzinga.com/news/13/01/3283502/lilly-planning-five-new-drug-regulatory-filings-in-2013,Paul Quintaro,,,,0,0,c6dbaeaa-750c-4f5e-a5fa-0ae3018db6ac
2013-01-29T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Lifts FY13 Forecast",LLY,https://www.benzinga.com/news/earnings/13/01/3282838/update-eli-lilly-posts-upbeat-q4-profit-lifts-fy13-forecast,Lisa Levin,,,,0,0,fc6a5b47-0e68-4ab4-975f-4499e59eaa22
2013-01-29T08:00:00.000+08:00,Eli Lilly & Co Reports Q4 EPS of $0.85 vs $0.82 Est; Revenue $5.96B vs $5.78B Est,LLY,https://www.benzinga.com/news/earnings/13/01/3282458/eli-lilly-co-reports-q4-eps-of-0-85-vs-0-82-est-revenue-5-96b-vs-5-78b-e,Charles Gross,,,,0,0,25013bda-852a-4b73-a240-56e1d342ab0a
2013-01-29T08:00:00.000+08:00,"US Stock Futures Slightly Lower Ahead Of Ford Earnings, Consumer Confidence Data",LLY,https://www.benzinga.com/news/13/01/3282302/us-stock-futures-slightly-lower-ahead-of-ford-earnings-consumer-confidence-data,Monica Gerson,,,,0,0,2053bb33-0f24-4e09-8c03-5e490221a2da
2013-01-29T08:00:00.000+08:00,"Earnings Scheduled For January 29, 2013",LLY,https://www.benzinga.com/news/earnings/13/01/3282117/earnings-scheduled-for-january-29-2013,Monica Gerson,,,,0,0,79e56f08-961f-4dc5-b4a9-72324e2ee385
2013-01-29T08:00:00.000+08:00,Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg,LLY,https://www.benzinga.com/news/13/01/3284158/novo-spokesperson-says-will-introduce-tresiba-in-some-eu-countries-in-first-half-,Paul Quintaro,,,,0,0,ec963f8c-f845-4d17-8b39-98f6a7db85ee
2013-01-29T08:00:00.000+08:00,Lilly Planning Five New Drug Regulatory Filings in 2013,LLY,https://www.benzinga.com/news/13/01/3283502/lilly-planning-five-new-drug-regulatory-filings-in-2013,Paul Quintaro,,,,0,0,6d122075-e466-4cd1-8eff-a74c5c419659
2013-01-29T08:00:00.000+08:00,"UPDATE: Eli Lilly Posts Upbeat Q4 Profit, Lifts FY13 Forecast",LLY,https://www.benzinga.com/news/earnings/13/01/3282838/update-eli-lilly-posts-upbeat-q4-profit-lifts-fy13-forecast,Lisa Levin,,,,0,0,878782a2-844d-4ff4-8b45-08cf27ae41df
2013-01-29T08:00:00.000+08:00,Eli Lilly & Co Reports Q4 EPS of $0.85 vs $0.82 Est; Revenue $5.96B vs $5.78B Est,LLY,https://www.benzinga.com/news/earnings/13/01/3282458/eli-lilly-co-reports-q4-eps-of-0-85-vs-0-82-est-revenue-5-96b-vs-5-78b-e,Charles Gross,,,,0,0,1012f832-3bb4-4b52-907a-db11cfa396fc
2013-01-29T08:00:00.000+08:00,"US Stock Futures Slightly Lower Ahead Of Ford Earnings, Consumer Confidence Data",LLY,https://www.benzinga.com/news/13/01/3282302/us-stock-futures-slightly-lower-ahead-of-ford-earnings-consumer-confidence-data,Monica Gerson,,,,0,0,07f6e4de-7acc-4268-81c4-3ff1a5db7802
2013-01-29T08:00:00.000+08:00,"Earnings Scheduled For January 29, 2013",LLY,https://www.benzinga.com/news/earnings/13/01/3282117/earnings-scheduled-for-january-29-2013,Monica Gerson,,,,0,0,7348b022-c4cf-4fcd-9609-36d704b34968
2013-01-26T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3276790/short-interest-swings-in-biotech-stocks-biib-celg-vvus,Nelson Hem,,,,0,0,da80745c-169a-4c09-aa91-5d08647238dd
2013-01-26T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3276790/short-interest-swings-in-biotech-stocks-biib-celg-vvus,Nelson Hem,,,,0,0,ce9d481d-59a8-4cc0-8877-c065e819c66b
2013-01-25T08:00:00.000+08:00,"The Week Ahead: Earnings from Facebook, Ford, Caterpillar; US Jobs Report",LLY,https://www.benzinga.com/news/earnings/13/01/3276171/the-week-ahead-earnings-from-facebook-ford-caterpillar-us-jobs-report,Sam Mattera,,,,0,0,9c2f0637-2a76-417e-8679-59b001c97244
2013-01-25T08:00:00.000+08:00,"The Week Ahead: Earnings from Facebook, Ford, Caterpillar; US Jobs Report",LLY,https://www.benzinga.com/news/earnings/13/01/3276171/the-week-ahead-earnings-from-facebook-ford-caterpillar-us-jobs-report,Sam Mattera,,,,0,0,7cc492df-7c46-465a-a854-f7664e96f706
2013-01-17T08:00:00.000+08:00,"CLSA Initiates Coverage on Eli Lilly and Company at Sell, Announces $47.00 PT",LLY,https://www.benzinga.com/news/13/01/3251597/clsa-initiates-coverage-on-eli-lilly-and-company-at-sell-announces-47-00-pt,Juan Lopez,,,,0,0,270be2aa-fb83-4730-890a-26a7053b12cd
2013-01-17T08:00:00.000+08:00,"CLSA Initiates Coverage on Eli Lilly and Company at Sell, Announces $47.00 PT",LLY,https://www.benzinga.com/news/13/01/3251597/clsa-initiates-coverage-on-eli-lilly-and-company-at-sell-announces-47-00-pt,Juan Lopez,,,,0,0,ec4c201f-2f45-4fa3-a6d6-7bd186d3fc5e
2013-01-16T08:00:00.000+08:00,"UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3248011/update-jefferies-company-reiterates-underperform-rating-,Dwight Einhorn,,,,0,0,52e29b16-ab58-4243-90aa-842c968d2f46
2013-01-16T08:00:00.000+08:00,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $43.00",LLY,https://www.benzinga.com/news/13/01/3247857/jefferies-maintains-underperform-on-eli-lilly-and-company-raises-pt-to-43-00,Juan Lopez,,,,0,0,4e094a60-080c-4329-9222-f6279a5ef8d9
2013-01-16T08:00:00.000+08:00,"UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3248011/update-jefferies-company-reiterates-underperform-rating-,Dwight Einhorn,,,,0,0,cd93065a-1420-411e-bf41-7da4781f3ef3
2013-01-16T08:00:00.000+08:00,"Jefferies Maintains Underperform on Eli Lilly and Company, Raises PT to $43.00",LLY,https://www.benzinga.com/news/13/01/3247857/jefferies-maintains-underperform-on-eli-lilly-and-company-raises-pt-to-43-00,Juan Lopez,,,,0,0,867a526e-227b-434e-9ee6-5bf8b2b63ae9
2013-01-15T08:00:00.000+08:00,Lily's Amyvid Approved in EU for Patients with Cognitive Impairment Being Evaluated for Alzheimer's,LLY,https://www.benzinga.com/news/13/01/3245709/lilys-amyvid-approved-in-eu-for-patients-with-cognitive-impairment-being-evaluate,Paul Quintaro,,,,0,0,7882fe5b-428e-431c-9ffe-07656ad21b37
2013-01-15T08:00:00.000+08:00,Lily's Amyvid Approved in EU for Patients with Cognitive Impairment Being Evaluated for Alzheimer's,LLY,https://www.benzinga.com/news/13/01/3245709/lilys-amyvid-approved-in-eu-for-patients-with-cognitive-impairment-being-evaluate,Paul Quintaro,,,,0,0,0469a723-faef-428a-b188-1a97fe805d07
2013-01-09T08:00:00.000+08:00,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3229062/update-bank-of-america-merrill-lynch-reiterates-buy-rati,Dwight Einhorn,,,,0,0,624522f4-14d6-42f7-ac51-4c8fe7a9775f
2013-01-09T08:00:00.000+08:00,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $60.00",LLY,https://www.benzinga.com/news/13/01/3228628/bank-of-america-maintains-buy-on-eli-lilly-and-company-raises-po-to-60-00,Juan Lopez,,,,0,0,e106c76f-2ded-4c86-9581-9ee4c5b55098
2013-01-09T08:00:00.000+08:00,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3229062/update-bank-of-america-merrill-lynch-reiterates-buy-rati,Dwight Einhorn,,,,0,0,71023d99-269c-4cc4-b3e9-57cce6e6a6d6
2013-01-09T08:00:00.000+08:00,"Bank of America Maintains Buy on Eli Lilly and Company, Raises PO to $60.00",LLY,https://www.benzinga.com/news/13/01/3228628/bank-of-america-maintains-buy-on-eli-lilly-and-company-raises-po-to-60-00,Juan Lopez,,,,0,0,52ac248a-8acb-46f8-88ba-b36801a65f87
2013-01-08T08:00:00.000+08:00,Goldman Sachs and Others That May Beat Earnings,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3225028/goldman-sachs-and-others-that-may-beat-earnings,Nelson Hem,,,,0,0,25a36310-9bb9-446c-99ed-094ab69dd991
2013-01-08T08:00:00.000+08:00,Goldman Sachs and Others That May Beat Earnings,LLY,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3225028/goldman-sachs-and-others-that-may-beat-earnings,Nelson Hem,,,,0,0,a4297307-1e8a-4ab1-a543-32ea8fdda72a
2013-01-07T08:00:00.000+08:00,"UBS Maintains Neutral on Eli Lilly and Company, Raises PT to $51.00",LLY,https://www.benzinga.com/news/13/01/3220708/ubs-maintains-neutral-on-eli-lilly-and-company-raises-pt-to-51-00,Juan Lopez,,,,0,0,eb6f4b55-adda-472c-a997-04663c000bbd
2013-01-07T08:00:00.000+08:00,"UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3219991/update-bmo-capital-markets-reiterates-market-perform-rat,Dwight Einhorn,,,,0,0,7fd524c4-5bfd-4494-9e88-4b2635a6d9d8
2013-01-07T08:00:00.000+08:00,"Eli Lilly Reassumes Sole Worldwide Development, Commercialization Role for Novel Basal Insulin Analog",LLY,https://www.benzinga.com/news/13/01/3218919/eli-lilly-reassumes-sole-worldwide-development-commercialization-role-for-novel-b,Paul Quintaro,,,,0,0,d357b2bf-be85-43fd-b4c8-cf9d1c21b403
2013-01-07T08:00:00.000+08:00,"Stocks To Watch For January 7, 2013",LLY,https://www.benzinga.com/news/earnings/13/01/3217926/stocks-to-watch-for-january-7-2013,Monica Gerson,,,,0,0,f2ce6416-7098-4055-b7da-2c7b5df6f863
2013-01-07T08:00:00.000+08:00,"UBS Maintains Neutral on Eli Lilly and Company, Raises PT to $51.00",LLY,https://www.benzinga.com/news/13/01/3220708/ubs-maintains-neutral-on-eli-lilly-and-company-raises-pt-to-51-00,Juan Lopez,,,,0,0,6e3e28d0-cb58-41d2-a1ee-0d64190a54fc
2013-01-07T08:00:00.000+08:00,"UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3219991/update-bmo-capital-markets-reiterates-market-perform-rat,Dwight Einhorn,,,,0,0,51d70e38-9533-4c0b-ac7f-a40a238d9150
2013-01-07T08:00:00.000+08:00,"Eli Lilly Reassumes Sole Worldwide Development, Commercialization Role for Novel Basal Insulin Analog",LLY,https://www.benzinga.com/news/13/01/3218919/eli-lilly-reassumes-sole-worldwide-development-commercialization-role-for-novel-b,Paul Quintaro,,,,0,0,0f9d6e04-00af-4520-876d-b7a40e6e4d68
2013-01-07T08:00:00.000+08:00,"Stocks To Watch For January 7, 2013",LLY,https://www.benzinga.com/news/earnings/13/01/3217926/stocks-to-watch-for-january-7-2013,Monica Gerson,,,,0,0,0b748392-cc49-48a6-ab65-9bb3702ae094
2013-01-04T08:00:00.000+08:00,Eli Lilly Offers Solid FY13 EPS Outlook; Shares Slightly Higher,LLY,https://www.benzinga.com/news/13/01/3215088/eli-lilly-offers-solid-fy13-eps-outlook-shares-slightly-higher,Paul Quintaro,,,,0,0,ae0ea54b-e583-418b-9340-0b948bba45cb
2013-01-04T08:00:00.000+08:00,Eli Lilly Offers Solid FY13 EPS Outlook; Shares Slightly Higher,LLY,https://www.benzinga.com/news/13/01/3215088/eli-lilly-offers-solid-fy13-eps-outlook-shares-slightly-higher,Paul Quintaro,,,,0,0,6783d0d1-030f-4e49-8f69-4a3d03f7c40c
2012-12-20T08:00:00.000+08:00,Eli Lilly to Pay $29.4M to Settle SEC Foreign Bribery Case,LLY,https://www.benzinga.com/news/12/12/3191061/eli-lilly-to-pay-29-4m-to-settle-sec-foreign-bribery-case,Paul Quintaro,,,,0,0,590fc43b-112f-408a-994f-8931568120a3
2012-12-20T08:00:00.000+08:00,Eli Lilly to Pay $29.4M to Settle SEC Foreign Bribery Case,LLY,https://www.benzinga.com/news/12/12/3191061/eli-lilly-to-pay-29-4m-to-settle-sec-foreign-bribery-case,Paul Quintaro,,,,0,0,9426b327-1ed5-4696-87dd-e74527c1f04f
2012-12-18T08:00:00.000+08:00,"Benzinga Market Primer, Tuesday, December 18",LLY,https://www.benzinga.com/news/12/12/3181502/benzinga-market-primer-tuesday-december-18,Sam Mattera,,,,0,0,358be530-e432-4d4f-b8f4-a8fe87e978b6
2012-12-18T08:00:00.000+08:00,"Benzinga Market Primer, Tuesday, December 18",LLY,https://www.benzinga.com/news/12/12/3181502/benzinga-market-primer-tuesday-december-18,Sam Mattera,,,,0,0,2a8abf63-04fd-4d24-a168-fdb4d6f523d9
2012-12-17T08:00:00.000+08:00,"Eli Lilly Authorizes $1.5B Buyback Plan, Declares $0.49/Share Qtr. Dividend",LLY,https://www.benzinga.com/news/12/12/3180346/eli-lilly-authorizes-1-5b-buyback-plan-declares-0-49share-qtr-dividend,Paul Quintaro,,,,0,0,ade7a215-bcfb-4caf-a6ff-82df09e9ab6a
2012-12-17T08:00:00.000+08:00,"Eli Lilly Authorizes $1.5B Buyback Plan, Declares $0.49/Share Qtr. Dividend",LLY,https://www.benzinga.com/news/12/12/3180346/eli-lilly-authorizes-1-5b-buyback-plan-declares-0-49share-qtr-dividend,Paul Quintaro,,,,0,0,8217b12d-3202-4d8d-b9f5-659d182e0a0e
2012-12-13T08:00:00.000+08:00,"Eli Lilly Reaffirms FY12 Outlook; Sees Q4 Charge of $20-35M Pretax, or ~$0.02/Share",LLY,https://www.benzinga.com/news/12/12/3170277/eli-lilly-reaffirms-fy12-outlook-sees-q4-charge-of-20-35m-pretax-or-0-02share,Paul Quintaro,,,,0,0,52012b7d-8fc0-483d-907e-9c1e5dbccbb5
2012-12-13T08:00:00.000+08:00,"Eli Lilly Reaffirms FY12 Outlook; Sees Q4 Charge of $20-35M Pretax, or ~$0.02/Share",LLY,https://www.benzinga.com/news/12/12/3170277/eli-lilly-reaffirms-fy12-outlook-sees-q4-charge-of-20-35m-pretax-or-0-02share,Paul Quintaro,,,,0,0,b424bc60-8dcc-449b-91bd-95713d6fe8d2
2012-12-12T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3167675/short-interest-swings-in-biotech-stocks-biib-celg-vvus,Nelson Hem,,,,0,0,e3009722-59ab-4cbb-8041-dd4e5b73adb6
2012-12-12T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/12/12/3166290/benzingas-top-pre-market-losers,Lisa Levin,,,,0,0,101f18d4-4dc5-4c5f-9f80-c78c76edf42c
2012-12-12T08:00:00.000+08:00,Eli Lilly Discusses Next Steps for Solanezumab,LLY,https://www.benzinga.com/news/12/12/3166274/eli-lilly-discusses-next-steps-for-solanezumab,Paul Quintaro,,,,0,0,97e98324-c8af-4ede-a766-1ed45fc46505
2012-12-12T08:00:00.000+08:00,Lilly Provides Update on Solanezumab Phase 3 Study,LLY,https://www.benzinga.com/news/12/12/3165927/lilly-provides-update-on-solanezumab-phase-3-study,Charles Gross,,,,0,0,b38b5c66-5d42-46c0-8296-4555c46802b3
2012-12-12T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3167675/short-interest-swings-in-biotech-stocks-biib-celg-vvus,Nelson Hem,,,,0,0,03c9b0bc-b61c-4030-8ec3-1d02e6f87565
2012-12-12T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/12/12/3166290/benzingas-top-pre-market-losers,Lisa Levin,,,,0,0,8711f122-ed98-476d-a744-de6084e5ca31
2012-12-12T08:00:00.000+08:00,Eli Lilly Discusses Next Steps for Solanezumab,LLY,https://www.benzinga.com/news/12/12/3166274/eli-lilly-discusses-next-steps-for-solanezumab,Paul Quintaro,,,,0,0,7082b831-a1ae-40ea-888a-13d9fcdda5e5
2012-12-12T08:00:00.000+08:00,Lilly Provides Update on Solanezumab Phase 3 Study,LLY,https://www.benzinga.com/news/12/12/3165927/lilly-provides-update-on-solanezumab-phase-3-study,Charles Gross,,,,0,0,e74f11ed-f40c-4750-9906-7ded2118cd82
2012-12-10T08:00:00.000+08:00,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3159940/three-more-defensive-stock-picks-for-2013-lly-pfe-vtr,Nelson Hem,,,,0,0,6aa7c018-165a-43d1-9443-552493a0cb4b
2012-12-10T08:00:00.000+08:00,"Three More Defensive Stock Picks for 2013 (LLY, PFE, VTR)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3159940/three-more-defensive-stock-picks-for-2013-lly-pfe-vtr,Nelson Hem,,,,0,0,3251ee3b-7cba-43bf-a838-fed31c4617d9
2012-11-30T08:00:00.000+08:00,"Citigroup Initiates Coverage on Eli Lilly and Company at Buy, Annoucnes $55.00 PT",LLY,https://www.benzinga.com/news/12/11/3135439/citigroup-initiates-coverage-on-eli-lilly-and-company-at-buy-annoucnes-55-00-pt,Paul Quintaro,,,,0,0,7fda3e63-7dbc-4a5d-985b-daf3174d9b09
2012-11-30T08:00:00.000+08:00,"Citigroup Initiates Coverage on Eli Lilly and Company at Buy, Annoucnes $55.00 PT",LLY,https://www.benzinga.com/news/12/11/3135439/citigroup-initiates-coverage-on-eli-lilly-and-company-at-buy-annoucnes-55-00-pt,Paul Quintaro,,,,0,0,dbee2f6b-eee3-4bd7-8812-ff70016e23c4
2012-11-29T08:00:00.000+08:00,"Citi Reiterates Buy on Eli Lilly and Company, Maintains $55.00 PT",LLY,https://www.benzinga.com/news/12/11/3132161/citi-reiterates-buy-on-eli-lilly-and-company-maintains-55-00-pt,Paul Quintaro,,,,0,0,37b8af7c-b7e1-43e5-9e1b-1d1141e8399c
2012-11-29T08:00:00.000+08:00,"Citi Reiterates Buy on Eli Lilly and Company, Maintains $55.00 PT",LLY,https://www.benzinga.com/news/12/11/3132161/citi-reiterates-buy-on-eli-lilly-and-company-maintains-55-00-pt,Paul Quintaro,,,,0,0,5dcb30f5-3756-4b91-9286-2452cfa299d7
2012-11-21T08:00:00.000+08:00,Eli Lilly's Tabalumab Receives Orphan Drug Designation for Multiple Myeloma Treatment,LLY,https://www.benzinga.com/news/12/11/3111645/eli-lillys-tabalumab-receives-orphan-drug-designation-for-multiple-myeloma-treatm,Paul Quintaro,,,,0,0,0288f94c-1759-4119-aafd-aa94617a961f
2012-11-21T08:00:00.000+08:00,Eli Lilly's Tabalumab Receives Orphan Drug Designation for Multiple Myeloma Treatment,LLY,https://www.benzinga.com/news/12/11/3111645/eli-lillys-tabalumab-receives-orphan-drug-designation-for-multiple-myeloma-treatm,Paul Quintaro,,,,0,0,678bc5e6-0197-4d96-a259-0fcd9691f36b
2012-11-13T08:00:00.000+08:00,"Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials",LLY,https://www.benzinga.com/news/12/11/3086353/lilly-and-incyte-announce-additional-phase-iib-baricitinib-data-advance-into-phas,Eddie Staley,,,,0,0,2b70c852-61ea-428c-9c69-33f1d7aedcfc
2012-11-13T08:00:00.000+08:00,"Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Advance into Phase III Trials",LLY,https://www.benzinga.com/news/12/11/3086353/lilly-and-incyte-announce-additional-phase-iib-baricitinib-data-advance-into-phas,Eddie Staley,,,,0,0,81b49430-9a2c-4eaa-a2e3-760e0284ff3d
2012-11-09T08:00:00.000+08:00,Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases,LLY,https://www.benzinga.com/news/12/11/3075054/lilly-to-present-phase-ii-rheumatoid-arthritis-and-biomarker-data-at-acr-for-two-,Paul Quintaro,,,,0,0,04a12752-3d1a-4bd0-8b44-fc3d90fcb967
2012-11-09T08:00:00.000+08:00,Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases,LLY,https://www.benzinga.com/news/12/11/3075054/lilly-to-present-phase-ii-rheumatoid-arthritis-and-biomarker-data-at-acr-for-two-,Paul Quintaro,,,,0,0,d09a3a76-9374-4fdb-954a-127ec45f2219
2012-10-30T08:00:00.000+08:00,Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations,LLY,https://www.benzinga.com/news/12/10/3038947/lilly-to-announce-expansion-of-indianapolis-insulin-manufacturing-operations,Paul Quintaro,,,,0,0,22002868-0fb5-4882-a993-e5ea225ce15d
2012-10-30T08:00:00.000+08:00,European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia,LLY,https://www.benzinga.com/news/12/10/3037813/european-commission-approves-lillys-cialis-for-benign-prostatic-hyperplasia,Charles Gross,,,,0,0,5c938aec-0f42-4934-9e83-fa6eacfc48b8
2012-10-30T08:00:00.000+08:00,Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations,LLY,https://www.benzinga.com/news/12/10/3038947/lilly-to-announce-expansion-of-indianapolis-insulin-manufacturing-operations,Paul Quintaro,,,,0,0,1c38a578-7336-4509-981e-026a1fece9ba
2012-10-30T08:00:00.000+08:00,European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia,LLY,https://www.benzinga.com/news/12/10/3037813/european-commission-approves-lillys-cialis-for-benign-prostatic-hyperplasia,Charles Gross,,,,0,0,36eec4fd-ad58-4b5c-8706-39fd534d245f
2012-10-26T08:00:00.000+08:00,"BMO Capital Markets Maintains Eli Lilly & at Market Perform, Lowers PT from $50 to $47",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/3030232/bmo-capital-markets-maintains-eli-lilly-at-market-perform,Juan Lopez,,,,0,0,d4491f95-596a-4ef7-9710-380dbb0a5dfb
2012-10-26T08:00:00.000+08:00,"BMO Capital Markets Maintains Eli Lilly & at Market Perform, Lowers PT from $50 to $47",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/3030232/bmo-capital-markets-maintains-eli-lilly-at-market-perform,Juan Lopez,,,,0,0,afda7c9e-5ef9-4a3a-9718-7e4b9fae72b7
2012-10-25T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/10/3027401/short-interest-swings-in-biotech-stocks-biib-gild-vvus,Nelson Hem,,,,0,0,30ae11cc-073c-4847-92da-b63ba7fa1340
2012-10-25T08:00:00.000+08:00,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/10/3027401/short-interest-swings-in-biotech-stocks-biib-gild-vvus,Nelson Hem,,,,0,0,accc49fc-ecd5-4b22-ade7-86360939b76a
2012-10-24T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Downbeat Q3 Profit,LLY,https://www.benzinga.com/news/earnings/12/10/3020117/update-eli-lilly-posts-downbeat-q3-profit,Lisa Levin,,,,0,0,ade47abc-9556-4938-bc6d-5bbfcd79a0be
2012-10-24T08:00:00.000+08:00,Eli Lilly & Reports Q3 EPS $0.79 vs $0.83 Est; Revenues $5.62B vs $5.62B Est,LLY,https://www.benzinga.com/news/earnings/12/10/3020018/eli-lilly-reports-q3-eps-0-79-vs-0-83-est-revenues-5-62b-vs-5-62b-est,Allie Wickman,,,,0,0,17568ba4-9f2c-4bfa-bb25-88567b38a4de
2012-10-24T08:00:00.000+08:00,"Earnings Scheduled For October 24, 2012",LLY,https://www.benzinga.com/news/earnings/12/10/3019635/earnings-scheduled-for-october-24-2012,Monica Gerson,,,,0,0,9a68ff7b-34c7-450c-9389-e197be2ff105
2012-10-24T08:00:00.000+08:00,UPDATE: Eli Lilly Posts Downbeat Q3 Profit,LLY,https://www.benzinga.com/news/earnings/12/10/3020117/update-eli-lilly-posts-downbeat-q3-profit,Lisa Levin,,,,0,0,f2ee62dc-fa47-44ab-bb9f-334043f798b4
2012-10-24T08:00:00.000+08:00,Eli Lilly & Reports Q3 EPS $0.79 vs $0.83 Est; Revenues $5.62B vs $5.62B Est,LLY,https://www.benzinga.com/news/earnings/12/10/3020018/eli-lilly-reports-q3-eps-0-79-vs-0-83-est-revenues-5-62b-vs-5-62b-est,Allie Wickman,,,,0,0,0471ea09-935c-4cd2-974d-b18734b70180
2012-10-24T08:00:00.000+08:00,"Earnings Scheduled For October 24, 2012",LLY,https://www.benzinga.com/news/earnings/12/10/3019635/earnings-scheduled-for-october-24-2012,Monica Gerson,,,,0,0,b194330b-46cb-4e71-9340-89c7c980ad8b
2012-10-23T08:00:00.000+08:00,Eli Lilly Releases Data From Two Retrospective Studies,LLY,https://www.benzinga.com/news/12/10/3018695/eli-lilly-releases-data-from-two-retrospective-studies,Eddie Staley,,,,0,0,3084d3da-4408-44c1-8557-c13a97ac4533
2012-10-23T08:00:00.000+08:00,New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient or Plavix Presented at TCT,LLY,https://www.benzinga.com/news/12/10/3018685/new-retrospective-studies-of-hospital-readmission-rates-for-subsequent-heart-atta,Paul Quintaro,,,,0,0,960d3ff0-96a2-4645-99e0-6fb6250128f8
2012-10-23T08:00:00.000+08:00,Eli Lilly Releases Data From Two Retrospective Studies,LLY,https://www.benzinga.com/news/12/10/3018695/eli-lilly-releases-data-from-two-retrospective-studies,Eddie Staley,,,,0,0,dd4516ff-dace-4877-9fd7-dff9e5e42471
2012-10-23T08:00:00.000+08:00,New Retrospective Studies of Hospital Readmission Rates for Subsequent Heart Attack and Initial Hospitalization Costs in ACS-PCI Patients Treated with Effient or Plavix Presented at TCT,LLY,https://www.benzinga.com/news/12/10/3018685/new-retrospective-studies-of-hospital-readmission-rates-for-subsequent-heart-atta,Paul Quintaro,,,,0,0,dac5f37f-9a9d-4c2b-988c-77f911187a45
2012-10-22T08:00:00.000+08:00,Eli Lilly Says Got Positive Data for Phase III on Type 2 Diabetes Drug,LLY,https://www.benzinga.com/news/12/10/3013941/eli-lilly-says-got-positive-data-for-phase-iii-on-type-2-diabetes-drug,Paul Quintaro,,,,0,0,48cef0c7-ae42-46aa-b9d5-13fe97f0c558
2012-10-22T08:00:00.000+08:00,Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,LLY,https://www.benzinga.com/news/12/10/3013699/lilly-diabetes-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-t,Eddie Staley,,,,0,0,8ad64aa7-9043-45ca-b839-8157c3ba7819
2012-10-22T08:00:00.000+08:00,Earnings Expectations for the Week of October 22,LLY,https://www.benzinga.com/news/earnings/12/10/3012252/earnings-expectations-for-the-week-of-october-22,Nelson Hem,,,,0,0,fbd2ced0-8e88-4305-a570-3c8548733884
2012-10-22T08:00:00.000+08:00,Eli Lilly Says Got Positive Data for Phase III on Type 2 Diabetes Drug,LLY,https://www.benzinga.com/news/12/10/3013941/eli-lilly-says-got-positive-data-for-phase-iii-on-type-2-diabetes-drug,Paul Quintaro,,,,0,0,e918e5ca-55f4-4eb5-a29e-25108910fe9c
2012-10-22T08:00:00.000+08:00,Lilly Diabetes Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes,LLY,https://www.benzinga.com/news/12/10/3013699/lilly-diabetes-announces-positive-results-of-phase-iii-trials-of-dulaglutide-in-t,Eddie Staley,,,,0,0,1f1b2f48-de57-4bd7-b144-c1d5504b182f
2012-10-22T08:00:00.000+08:00,Earnings Expectations for the Week of October 22,LLY,https://www.benzinga.com/news/earnings/12/10/3012252/earnings-expectations-for-the-week-of-october-22,Nelson Hem,,,,0,0,390e6b6f-49c3-466d-a048-b1a9a242b258
2012-10-19T08:00:00.000+08:00,Amyvid Recommended for Approval in Europe,LLY,https://www.benzinga.com/news/12/10/3010245/amyvid-recommended-for-approval-in-europe,Paul Quintaro,,,,0,0,f6aedb4f-52ac-4879-9a63-75c5790dc465
2012-10-19T08:00:00.000+08:00,EU Recommends Approval of Lilly's Brain Plaque Test,LLY,https://www.benzinga.com/news/12/10/3009806/eu-recommends-approval-of-lillys-brain-plaque-test,Eddie Staley,,,,0,0,ee24e269-f77b-4a11-a307-257a6bc28b08
2012-10-19T08:00:00.000+08:00,Amyvid Recommended for Approval in Europe,LLY,https://www.benzinga.com/news/12/10/3010245/amyvid-recommended-for-approval-in-europe,Paul Quintaro,,,,0,0,1cd248f3-caed-4e29-ba5c-5ce06e722da3
2012-10-19T08:00:00.000+08:00,EU Recommends Approval of Lilly's Brain Plaque Test,LLY,https://www.benzinga.com/news/12/10/3009806/eu-recommends-approval-of-lillys-brain-plaque-test,Eddie Staley,,,,0,0,5b9b8e74-d2d8-466c-97d5-f8354598c87e
2012-10-17T08:00:00.000+08:00,ALIMTA Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients,LLY,https://www.benzinga.com/node/3003546,Eddie Staley,,,,0,0,30895893-55ea-43f5-8b84-d32f3b52e0cc
2012-10-17T08:00:00.000+08:00,ALIMTA Extends Survival in Continuation Maintenance Setting for Specific Lung Cancer Patients,LLY,https://www.benzinga.com/node/3003546,Eddie Staley,,,,0,0,f29640db-fc2f-459b-b14d-f953d4603d95
2012-10-15T08:00:00.000+08:00,Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO and Zoledronic Acid,LLY,https://www.benzinga.com/news/12/10/2994551/lilly-announces-new-data-further-exploring-mechanistic-differences-between-forteo,Eddie Staley,,,,0,0,d4dd0084-720d-49af-87cb-4a3679fddf59
2012-10-15T08:00:00.000+08:00,Leerink Swan Upgrades Eli Lilly & from Market Perform to Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2994017/leerink-swan-upgrades-eli-lilly-from-market-perform-to-outper,Paul Quintaro,,,,0,0,47dc97a7-0a14-415f-822b-bc787b51d19b
2012-10-15T08:00:00.000+08:00,Lilly Announces Ramucirumab Showed Prolonged Progression-Free Survival in Gastric Cancer Treatment,LLY,https://www.benzinga.com/news/12/10/2993329/lilly-announces-ramucirumab-showed-prolonged-progression-free-survival-in-gastric,Paul Quintaro,,,,0,0,761ff4d2-1c34-4ce9-b013-ee2be71ec44c
2012-10-15T08:00:00.000+08:00,Lilly Announces New Data Further Exploring Mechanistic Differences Between FORTEO and Zoledronic Acid,LLY,https://www.benzinga.com/news/12/10/2994551/lilly-announces-new-data-further-exploring-mechanistic-differences-between-forteo,Eddie Staley,,,,0,0,47ae3e96-4e9c-4e7a-a183-18a1384e0f33
2012-10-15T08:00:00.000+08:00,Leerink Swan Upgrades Eli Lilly & from Market Perform to Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2994017/leerink-swan-upgrades-eli-lilly-from-market-perform-to-outper,Paul Quintaro,,,,0,0,72ba73ea-248b-468e-ac69-50d908cd41b4
2012-10-15T08:00:00.000+08:00,Lilly Announces Ramucirumab Showed Prolonged Progression-Free Survival in Gastric Cancer Treatment,LLY,https://www.benzinga.com/news/12/10/2993329/lilly-announces-ramucirumab-showed-prolonged-progression-free-survival-in-gastric,Paul Quintaro,,,,0,0,f8462099-e7e6-47dd-b986-38c193c3915e
2012-10-12T08:00:00.000+08:00,Cowen Downgrades Eli Lilly & from Neutral to Underperform,LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/10/2989837/cowen-downgrades-eli-lilly-from-neutral-to-underperform,Paul Quintaro,,,,0,0,65bf6fee-c0aa-4099-b352-eb6a28a60a17
2012-10-12T08:00:00.000+08:00,"Jefferies & Company Maintains Eli Lilly & at Underperform, Raises PT from $35 to $36",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2989403/jefferies-company-maintains-eli-lilly-at-underperform-rai,Juan Lopez,,,,0,0,80a6313f-5de0-4b1e-bbb9-01ae85efcf90
2012-10-12T08:00:00.000+08:00,Cowen Downgrades Eli Lilly & from Neutral to Underperform,LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/10/2989837/cowen-downgrades-eli-lilly-from-neutral-to-underperform,Paul Quintaro,,,,0,0,23a656c1-4853-4beb-a779-49d2b27b93ca
2012-10-12T08:00:00.000+08:00,"Jefferies & Company Maintains Eli Lilly & at Underperform, Raises PT from $35 to $36",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2989403/jefferies-company-maintains-eli-lilly-at-underperform-rai,Juan Lopez,,,,0,0,11cfe37a-500b-4c28-b58b-9c7447e77bad
2012-10-11T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $52 to $57",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2985584/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,Juan Lopez,,,,0,0,098f7421-29d6-49f0-96fe-bc069cea9926
2012-10-11T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $52 to $57",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2985584/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,Juan Lopez,,,,0,0,a8c8d885-c51e-444f-86bf-62452e5852d4
2012-10-09T08:00:00.000+08:00,Part I: Must Know ETFs For Q3 Earnings,LLY,https://www.benzinga.com/markets/bonds/12/10/2979411/part-i-must-know-etfs-for-q3-earnings,ETF Professor,,,,0,0,31ef3cc2-954c-4bcd-b58b-560a995d3c81
2012-10-09T08:00:00.000+08:00,UPDATE: Goldman Sachs Upgrades Eli Lilly & Co. to Neutral on Sola Data,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/2979535/update-goldman-sachs-upgrades-eli-lilly-co-to-neutral-on,David Johnson,,,,0,0,b70c5eb3-02dd-4134-9969-fd6160d27b0b
2012-10-09T08:00:00.000+08:00,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $45 to $49",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2978995/ubs-maintains-eli-lilly-at-neutral-raises-pt-from-45-to-4,Juan Lopez,,,,0,0,1c607aba-2312-4b9b-bf6d-68b266fce682
2012-10-09T08:00:00.000+08:00,Lilly Crosses $52 on Heavy Volume,LLY,https://www.benzinga.com/news/12/10/2978551/lilly-crosses-52-on-heavy-volume,Charles Gross,,,,0,0,bf621216-d683-4b3c-97f2-465a0c287036
2012-10-09T08:00:00.000+08:00,"Lilly Hits 52-Week High Following Monday's Positive Phase 3 Results, $51.80",LLY,https://www.benzinga.com/news/12/10/2978519/lilly-hits-52-week-high-following-mondays-positive-phase-3-results-51-80,Charles Gross,,,,0,0,7a0caec2-37f7-4e3b-8ec2-0c3cdb4da53b
2012-10-09T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/10/2977465/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,cfe02024-f3fe-44f4-b009-f3add903af7b
2012-10-09T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2977429/benzingas-top-upgrades,Monica Gerson,,,,0,0,0061012c-76ef-4d6d-acb9-6a17cd8c29d6
2012-10-09T08:00:00.000+08:00,"Goldman Sachs Upgrades Eli Lilly & from Sell to Neutral, Raises PT from $42 to $54",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2977094/goldman-sachs-upgrades-eli-lilly-from-sell-to-neutral-raises-,Juan Lopez,,,,0,0,3642c2c3-12a6-4100-a3c6-01bcd632f03b
2012-10-09T08:00:00.000+08:00,Part I: Must Know ETFs For Q3 Earnings,LLY,https://www.benzinga.com/markets/bonds/12/10/2979411/part-i-must-know-etfs-for-q3-earnings,ETF Professor,,,,0,0,f93395bd-b2f7-425d-ba04-bc399d341942
2012-10-09T08:00:00.000+08:00,UPDATE: Goldman Sachs Upgrades Eli Lilly & Co. to Neutral on Sola Data,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/2979535/update-goldman-sachs-upgrades-eli-lilly-co-to-neutral-on,David Johnson,,,,0,0,632c1e18-57be-4067-a3b7-a27aaa4dec42
2012-10-09T08:00:00.000+08:00,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $45 to $49",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2978995/ubs-maintains-eli-lilly-at-neutral-raises-pt-from-45-to-4,Juan Lopez,,,,0,0,b02a2722-a219-4ac0-abbf-e7706b9f3ff9
2012-10-09T08:00:00.000+08:00,Lilly Crosses $52 on Heavy Volume,LLY,https://www.benzinga.com/news/12/10/2978551/lilly-crosses-52-on-heavy-volume,Charles Gross,,,,0,0,d6c4bb1d-54e9-4c61-9828-28c554ece21c
2012-10-09T08:00:00.000+08:00,"Lilly Hits 52-Week High Following Monday's Positive Phase 3 Results, $51.80",LLY,https://www.benzinga.com/news/12/10/2978519/lilly-hits-52-week-high-following-mondays-positive-phase-3-results-51-80,Charles Gross,,,,0,0,4c21fd06-2501-4cf0-b58d-d52e3c1e986c
2012-10-09T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/10/2977465/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,5141d03a-0964-4eaa-bf55-ede551e98814
2012-10-09T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2977429/benzingas-top-upgrades,Monica Gerson,,,,0,0,8d70e904-9730-44b6-83aa-522d192c7fe6
2012-10-09T08:00:00.000+08:00,"Goldman Sachs Upgrades Eli Lilly & from Sell to Neutral, Raises PT from $42 to $54",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/10/2977094/goldman-sachs-upgrades-eli-lilly-from-sell-to-neutral-raises-,Juan Lopez,,,,0,0,85cdb03a-9dda-40d1-8448-bca05cc4ccd4
2012-10-08T08:00:00.000+08:00,Hearing BMO Making Cautious Comments on Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/2975769/hearing-bmo-making-cautious-comments-on-lilly,Charles Gross,,,,0,0,3b37b1bb-0b01-404f-824b-4eb8a2727b39
2012-10-08T08:00:00.000+08:00,Lilly Hits $50 Following Positive Phase 3 Results,LLY,https://www.benzinga.com/news/12/10/2975649/lilly-hits-50-following-positive-phase-3-results,Charles Gross,,,,0,0,1ba6c00a-77e7-4804-8490-ea2020928c1a
2012-10-08T08:00:00.000+08:00,"Lilly Hits 52-Week High on Phase 3 Results, $49.38",LLY,https://www.benzinga.com/news/12/10/2975518/lilly-hits-52-week-high-on-phase-3-results-49-38,Charles Gross,,,,0,0,1d71f749-76ce-4c81-b299-63ecbd97cf0c
2012-10-08T08:00:00.000+08:00,Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant,LLY,https://www.benzinga.com/news/12/10/2975514/eli-lilly-reports-phase-3-results-of-solanezumab-decline-in-expedition1-study-not,Paul Quintaro,,,,0,0,d368cc99-737d-46d5-affe-b90810120699
2012-10-08T08:00:00.000+08:00,Lilly Spiking Higher,LLY,https://www.benzinga.com/news/12/10/2975513/lilly-spiking-higher,Charles Gross,,,,0,0,e53263bb-c669-4a0a-a02c-a2bf0d03ac26
2012-10-08T08:00:00.000+08:00,Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide,LLY,https://www.benzinga.com/news/12/10/2974797/eli-lilly-says-ending-partnership-with-amylin-wasnt-easy-broad-diabetes-pipeline-,Paul Quintaro,,,,0,0,d730809e-71e7-4007-a161-03ea3a71b531
2012-10-08T08:00:00.000+08:00,Hearing BMO Making Cautious Comments on Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/2975769/hearing-bmo-making-cautious-comments-on-lilly,Charles Gross,,,,0,0,2101c3e1-87f3-4096-91b8-ced154e49814
2012-10-08T08:00:00.000+08:00,Lilly Hits $50 Following Positive Phase 3 Results,LLY,https://www.benzinga.com/news/12/10/2975649/lilly-hits-50-following-positive-phase-3-results,Charles Gross,,,,0,0,5557155a-0638-45d0-adbc-8d6d2181108b
2012-10-08T08:00:00.000+08:00,"Lilly Hits 52-Week High on Phase 3 Results, $49.38",LLY,https://www.benzinga.com/news/12/10/2975518/lilly-hits-52-week-high-on-phase-3-results-49-38,Charles Gross,,,,0,0,2185a0d3-8149-4259-9f2a-18140d7aff0c
2012-10-08T08:00:00.000+08:00,Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant,LLY,https://www.benzinga.com/news/12/10/2975514/eli-lilly-reports-phase-3-results-of-solanezumab-decline-in-expedition1-study-not,Paul Quintaro,,,,0,0,e6367cc4-5d6f-4cdd-970f-7308e6c91920
2012-10-08T08:00:00.000+08:00,Lilly Spiking Higher,LLY,https://www.benzinga.com/news/12/10/2975513/lilly-spiking-higher,Charles Gross,,,,0,0,80c9ac88-c844-4660-a4ff-977072ca34d9
2012-10-08T08:00:00.000+08:00,Eli Lilly Says Ending Partnership with Amylin Wasn't Easy; Broad Diabetes Pipeline is Advantage; End of Amylin Deal Was Bet on Dulaglutide,LLY,https://www.benzinga.com/news/12/10/2974797/eli-lilly-says-ending-partnership-with-amylin-wasnt-easy-broad-diabetes-pipeline-,Paul Quintaro,,,,0,0,b46f16b5-4a0e-41a8-94de-f09424580fd9
2012-10-02T08:00:00.000+08:00,From Earlier: Lilly and Boehringer Say Linagliptin Treatment Shows Significance,LLY,https://www.benzinga.com/news/12/10/2958910/from-earlier-lilly-and-boehringer-say-linagliptin-treatment-shows-significance,Paul Quintaro,,,,0,0,da3ae2f5-8bc4-4ccb-8c6e-f5317c176554
2012-10-02T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/10/2958453/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,598c58e6-b2b4-442f-8a7f-4a272c437b59
2012-10-02T08:00:00.000+08:00,Eli Lilly Reports on SGLT-2 Trials,LLY,https://www.benzinga.com/news/12/10/2958278/eli-lilly-reports-on-sglt-2-trials,Charles Gross,,,,0,0,70fae4fc-d40c-4349-a58b-b1f908e0c02d
2012-10-02T08:00:00.000+08:00,From Earlier: Lilly and Boehringer Say Linagliptin Treatment Shows Significance,LLY,https://www.benzinga.com/news/12/10/2958910/from-earlier-lilly-and-boehringer-say-linagliptin-treatment-shows-significance,Paul Quintaro,,,,0,0,b63a96a0-75ff-4650-834b-86b9511f950d
2012-10-02T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/10/2958453/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,dada36dd-88ef-4550-9d7b-b039f4836fe5
2012-10-02T08:00:00.000+08:00,Eli Lilly Reports on SGLT-2 Trials,LLY,https://www.benzinga.com/news/12/10/2958278/eli-lilly-reports-on-sglt-2-trials,Charles Gross,,,,0,0,261af6e9-6079-486a-98fa-19b03f309e65
2012-10-01T08:00:00.000+08:00,Deutsche Bank Suspends Coverage on Eli Lilly &,LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2956750/deutsche-bank-suspends-coverage-on-eli-lilly,Juan Lopez,,,,0,0,a4f582e5-3b74-4827-8f2f-f105f2ab2b90
2012-10-01T08:00:00.000+08:00,"Eli Lilly Releases Data from Phase 2 Ramucirumab Trials, Says Indicate May be Beneficial to Patients with Non-Small Cell Lung Cancer",LLY,https://www.benzinga.com/news/12/10/2955561/eli-lilly-releases-data-from-phase-2-ramucirumab-trials-says-indicate-may-be-bene,Paul Quintaro,,,,0,0,160ee1eb-4779-4522-a7b7-b22357abf689
2012-10-01T08:00:00.000+08:00,Deutsche Bank Suspends Coverage on Eli Lilly &,LLY,https://www.benzinga.com/analyst-ratings/price-target/12/10/2956750/deutsche-bank-suspends-coverage-on-eli-lilly,Juan Lopez,,,,0,0,8244ce8d-f0f8-4310-8300-d97799e5602e
2012-10-01T08:00:00.000+08:00,"Eli Lilly Releases Data from Phase 2 Ramucirumab Trials, Says Indicate May be Beneficial to Patients with Non-Small Cell Lung Cancer",LLY,https://www.benzinga.com/news/12/10/2955561/eli-lilly-releases-data-from-phase-2-ramucirumab-trials-says-indicate-may-be-bene,Paul Quintaro,,,,0,0,e36f7a3d-85c7-4964-aa2f-95fc4d92253d
2012-09-29T08:00:00.000+08:00,Lilly Presents Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer,LLY,https://www.benzinga.com/news/12/09/2952144/lilly-presents-phase-ii-results-for-monoclonal-antibody-ramucirumab-in-lung-cance,Charles Gross,,,,0,0,362a4dd5-5733-4c60-b393-372cba30a68d
2012-09-29T08:00:00.000+08:00,Lilly Presents Phase II Results for Monoclonal Antibody Ramucirumab in Lung Cancer,LLY,https://www.benzinga.com/news/12/09/2952144/lilly-presents-phase-ii-results-for-monoclonal-antibody-ramucirumab-in-lung-cance,Charles Gross,,,,0,0,166bbebc-b33e-4173-9e35-1765c8b9c6d5
2012-09-26T08:00:00.000+08:00,McCormick Appoints Jacques Tapiero to Board of Directors,LLY,https://www.benzinga.com/news/12/09/2941278/mccormick-appoints-jacques-tapiero-to-board-of-directors,Eddie Staley,,,,0,0,9df4e21f-f358-4480-bb75-d4053846d16e
2012-09-26T08:00:00.000+08:00,McCormick Appoints Jacques Tapiero to Board of Directors,LLY,https://www.benzinga.com/news/12/09/2941278/mccormick-appoints-jacques-tapiero-to-board-of-directors,Eddie Staley,,,,0,0,0a104c08-537c-4a04-bcfc-a528c4693ab1
2012-09-21T08:00:00.000+08:00,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $42 to $45",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2930331/ubs-maintains-eli-lilly-at-neutral-raises-pt-from-42-to-4,Juan Lopez,,,,0,0,500d7ee5-bf01-4aec-9ab1-d7a71eaae2e0
2012-09-21T08:00:00.000+08:00,Cialis Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union,LLY,https://www.benzinga.com/news/12/09/2930030/cialis-tablets-recommended-for-approval-for-the-treatment-of-the-signs-and-sympto,Eddie Staley,,,,0,0,4d4e039f-ba29-46e7-b76c-385930fec198
2012-09-21T08:00:00.000+08:00,"UBS Maintains Eli Lilly & at Neutral, Raises PT from $42 to $45",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2930331/ubs-maintains-eli-lilly-at-neutral-raises-pt-from-42-to-4,Juan Lopez,,,,0,0,a165aa0d-71bc-442c-b56d-347c3b36cdc6
2012-09-21T08:00:00.000+08:00,Cialis Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the European Union,LLY,https://www.benzinga.com/news/12/09/2930030/cialis-tablets-recommended-for-approval-for-the-treatment-of-the-signs-and-sympto,Eddie Staley,,,,0,0,5a9db520-5bd5-4ec2-b145-0cdfcd033019
2012-09-14T08:00:00.000+08:00,"UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/09/2912158/update-goldman-sachs-reiterates-sell-rating-raises-pt-on,Dwight Einhorn,,,,0,0,71fe6def-065a-452b-a7d9-62b3a2768f4f
2012-09-14T08:00:00.000+08:00,"Goldman Sachs Maintains Eli Lilly & at Sell, Raises PT from $39 to $42",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2910893/goldman-sachs-maintains-eli-lilly-at-sell-raises-pt-from-,Juan Lopez,,,,0,0,e046faff-f549-404a-a79b-c7503209a1e6
2012-09-14T08:00:00.000+08:00,"UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Eli Lilly & Co.",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/09/2912158/update-goldman-sachs-reiterates-sell-rating-raises-pt-on,Dwight Einhorn,,,,0,0,0c10d5f1-61a4-4912-809b-857ff666d481
2012-09-14T08:00:00.000+08:00,"Goldman Sachs Maintains Eli Lilly & at Sell, Raises PT from $39 to $42",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2910893/goldman-sachs-maintains-eli-lilly-at-sell-raises-pt-from-,Juan Lopez,,,,0,0,1d9a92ab-5cee-43b4-a3b2-721ce87962ac
2012-09-06T08:00:00.000+08:00,Seven Cheap Large-Caps Yielding Over 4%,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/09/2889501/seven-cheap-large-caps-yielding-over-4,Scott Rubin,,,,0,0,a05acc61-1497-474c-b67a-380a3aed7a09
2012-09-06T08:00:00.000+08:00,Eli Lilly Says Phase III Study on Pointbreak Did Not Meet Primary Endpoint of Improved Overall Survival,LLY,https://www.benzinga.com/news/12/09/2888379/eli-lilly-says-phase-iii-study-on-pointbreak-did-not-meet-primary-endpoint-of-imp,Eddie Staley,,,,0,0,e17142cf-88fe-4996-b97c-dd8cea5a2cd0
2012-09-06T08:00:00.000+08:00,Seven Cheap Large-Caps Yielding Over 4%,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/09/2889501/seven-cheap-large-caps-yielding-over-4,Scott Rubin,,,,0,0,9ee74e74-db2f-4b6d-8e2e-e87c4071e3a5
2012-09-06T08:00:00.000+08:00,Eli Lilly Says Phase III Study on Pointbreak Did Not Meet Primary Endpoint of Improved Overall Survival,LLY,https://www.benzinga.com/news/12/09/2888379/eli-lilly-says-phase-iii-study-on-pointbreak-did-not-meet-primary-endpoint-of-imp,Eddie Staley,,,,0,0,0ed3c35c-5a38-44c9-a31f-8cbe5ef14320
2012-09-05T08:00:00.000+08:00,"Sanford C. Bernstein Upgraded Eli Lilly & from Market Perform to Outperform, Announced PT to $52",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2884564/sanford-c-bernstein-upgraded-eli-lilly-from-market-perfor,Juan Lopez,,,,0,0,14b25e44-185c-485f-a4c0-b1c1f5175c44
2012-09-05T08:00:00.000+08:00,"Sanford C. Bernstein Upgraded Eli Lilly & from Market Perform to Outperform, Announced PT to $52",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/09/2884564/sanford-c-bernstein-upgraded-eli-lilly-from-market-perfor,Juan Lopez,,,,0,0,f6b6f9ee-d5b1-422c-8b8c-1b82e9e17664
2012-08-29T08:00:00.000+08:00,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2869106/update-bank-of-america-merrill-lynch-reiterates-buy-rati,Dwight Einhorn,,,,0,0,29453acb-be93-4ba2-9fe7-da711ccb2569
2012-08-29T08:00:00.000+08:00,"Lilly Stops Phase 3 Development on Schizophrenia Treatment, Sees $0.02 Charge, Forecast for FY12 Unchanged",LLY,https://www.benzinga.com/news/12/08/2868041/lilly-stops-phase-3-development-on-schizophrenia-treatment-sees-0-02-charge-forec,Paul Quintaro,,,,0,0,82b34836-5841-40d6-88ba-6bbfa53da03a
2012-08-29T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $46 to $52",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/08/2867719/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,Juan Lopez,,,,0,0,10071df7-d13b-498a-bd49-9ae2b0b524a4
2012-08-29T08:00:00.000+08:00,"UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2869106/update-bank-of-america-merrill-lynch-reiterates-buy-rati,Dwight Einhorn,,,,0,0,cad6bcbf-b3ee-4cc5-a982-351698855a22
2012-08-29T08:00:00.000+08:00,"Lilly Stops Phase 3 Development on Schizophrenia Treatment, Sees $0.02 Charge, Forecast for FY12 Unchanged",LLY,https://www.benzinga.com/news/12/08/2868041/lilly-stops-phase-3-development-on-schizophrenia-treatment-sees-0-02-charge-forec,Paul Quintaro,,,,0,0,f86377af-69e1-44ff-8db0-aeed197e85b3
2012-08-29T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly & at Buy, Raises PO from $46 to $52",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/08/2867719/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,Juan Lopez,,,,0,0,cdba07b5-8fe6-49fc-9732-ffc733abba53
2012-08-28T08:00:00.000+08:00,"Atlantic Equities Upgrades Eli Lilly & from Underweight to Overweight, Announces PT of $49",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2864257/atlantic-equities-upgrades-eli-lilly-from-underweight-to-over,Juan Lopez,,,,0,0,02f9f244-11fe-45d8-9ece-5257c47737de
2012-08-28T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2864233/benzingas-top-upgrades,Lisa Levin,,,,0,0,2782c668-15fd-4f9b-ac75-bc3f72ae6b99
2012-08-28T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/08/2864109/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,badf9772-293c-40b8-934b-6e614f3f7ad5
2012-08-28T08:00:00.000+08:00,"Atlantic Equities Upgrades Eli Lilly & from Underweight to Overweight, Announces PT of $49",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2864257/atlantic-equities-upgrades-eli-lilly-from-underweight-to-over,Juan Lopez,,,,0,0,745dd96f-5dea-4762-b53f-dc575ddcacc4
2012-08-28T08:00:00.000+08:00,Benzinga's Top Upgrades,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2864233/benzingas-top-upgrades,Lisa Levin,,,,0,0,55a45e21-4e63-45aa-adc7-c14f09fc0bf9
2012-08-28T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/08/2864109/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,88df7a2c-6481-47d3-b5b3-4ba8eaddf0d1
2012-08-27T08:00:00.000+08:00,Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure,LLY,https://www.benzinga.com/news/12/08/2860547/daiichi-sankyo-and-lilly-announce-trilogy-acs-results-regarding-effient-prasugrel,Charles Gross,,,,0,0,e2382a53-8000-4536-b73b-58776174544a
2012-08-27T08:00:00.000+08:00,Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed Medically without an Artery-Opening Procedure,LLY,https://www.benzinga.com/news/12/08/2860547/daiichi-sankyo-and-lilly-announce-trilogy-acs-results-regarding-effient-prasugrel,Charles Gross,,,,0,0,87ac56cc-cae2-49c1-b349-4fa56955be36
2012-08-24T08:00:00.000+08:00,Eli Lilly Alzheimer's Drug Misses Goals,LLY,https://www.benzinga.com/news/12/08/2858605/eli-lilly-alzheimers-drug-misses-goals,Brett Callwood,,,,0,0,0e90c3a0-fd7a-4b41-a238-7e83754a6609
2012-08-24T08:00:00.000+08:00,U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent,LLY,https://www.benzinga.com/news/12/08/2858432/u-s-court-of-appeals-upholds-validity-of-lillys-alimta-compound-patent,Paul Quintaro,,,,0,0,421c3261-d900-4c2c-adf7-45f65df466e6
2012-08-24T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly & Co. from Neutral to Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2858334/credit-suisse-upgrades-eli-lilly-co-from-neutral-to-outperfor,Juan Lopez,,,,0,0,63e1edb6-600f-453b-a4ba-74affcbd5ae9
2012-08-24T08:00:00.000+08:00,Teva Loses Bid to Invalidate Patent on Lily's Alimata Drug -Bloomberg,LLY,https://www.benzinga.com/news/12/08/2858324/teva-loses-bid-to-invalidate-patent-on-lilys-alimata-drug-bloomberg,Paul Quintaro,,,,0,0,9b96ecdd-160d-44ce-bde9-1efda245b94a
2012-08-24T08:00:00.000+08:00,UPDATE: Eli Lilly's Conference Call on Solanezumab Ends,LLY,https://www.benzinga.com/news/12/08/2858142/update-eli-lillys-conference-call-on-solanezumab-ends,Paul Quintaro,,,,0,0,184ebafb-fd28-47c8-904a-1d87109540ce
2012-08-24T08:00:00.000+08:00,UPDATE: Eli Lilly Says Doesn't See Solanezumab Results Affecting Financial View,LLY,https://www.benzinga.com/news/12/08/2858011/update-eli-lilly-says-doesnt-see-solanezumab-results-affecting-financial-view,Paul Quintaro,,,,0,0,87c23cd7-d2d7-45fb-93bc-75781666d951
2012-08-24T08:00:00.000+08:00,Jefferies Maintains Underperform on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2857961/jefferies-maintains-underperform-on-eli-lilly,Joe Young,,,,0,0,1dada193-048a-45ba-ba44-061a47eb290b
2012-08-24T08:00:00.000+08:00,"Lilly Rises 9.5% Pre-Market as Alzheimer's Drug Fails to Meet Primary Endpoints, But Slows Progression of Disease",LLY,https://www.benzinga.com/news/12/08/2857769/lilly-rises-9-5-pre-market-as-alzheimers-drug-fails-to-meet-primary-endpoints-but,Charles Gross,,,,0,0,9fad7b1a-3961-4582-a7ab-ebb04211a003
2012-08-24T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/08/2857750/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,7f9c4100-7b5f-4430-b219-fed3e9ee2a05
2012-08-24T08:00:00.000+08:00,Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial,LLY,https://www.benzinga.com/news/12/08/2857688/eli-lilly-announces-negative-results-of-solanezumab-phase-3-trial,Paul Quintaro,,,,0,0,d421b5dd-384a-4bf8-95f6-fff6a29b9c2a
2012-08-24T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/08/2857613/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,066c471d-ceaa-441e-ab7e-10c183d2c97a
2012-08-24T08:00:00.000+08:00,Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease,LLY,https://www.benzinga.com/news/12/08/2857568/eli-lilly-and-company-announces-top-line-results-on-solanezumab-phase-3-clinical-,Charles Gross,,,,0,0,629edd2d-5f54-46f0-82b7-bb1b38e314b1
2012-08-24T08:00:00.000+08:00,Eli Lilly Alzheimer's Drug Misses Goals,LLY,https://www.benzinga.com/news/12/08/2858605/eli-lilly-alzheimers-drug-misses-goals,Brett Callwood,,,,0,0,95d35d05-229c-414f-b13c-6f85520db1d9
2012-08-24T08:00:00.000+08:00,U.S. Court of Appeals Upholds Validity of Lilly's Alimta Compound Patent,LLY,https://www.benzinga.com/news/12/08/2858432/u-s-court-of-appeals-upholds-validity-of-lillys-alimta-compound-patent,Paul Quintaro,,,,0,0,07b4875d-ecdf-4a06-94dd-108c62fb6c4b
2012-08-24T08:00:00.000+08:00,Credit Suisse Upgrades Eli Lilly & Co. from Neutral to Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/08/2858334/credit-suisse-upgrades-eli-lilly-co-from-neutral-to-outperfor,Juan Lopez,,,,0,0,89265846-c338-41d1-bd12-8e19d1359d3e
2012-08-24T08:00:00.000+08:00,Teva Loses Bid to Invalidate Patent on Lily's Alimata Drug -Bloomberg,LLY,https://www.benzinga.com/news/12/08/2858324/teva-loses-bid-to-invalidate-patent-on-lilys-alimata-drug-bloomberg,Paul Quintaro,,,,0,0,4663a1b0-a8d7-4896-86e7-e88c7bc12ac9
2012-08-24T08:00:00.000+08:00,UPDATE: Eli Lilly's Conference Call on Solanezumab Ends,LLY,https://www.benzinga.com/news/12/08/2858142/update-eli-lillys-conference-call-on-solanezumab-ends,Paul Quintaro,,,,0,0,1340f238-4742-4227-9fc6-a2cc2c224949
2012-08-24T08:00:00.000+08:00,UPDATE: Eli Lilly Says Doesn't See Solanezumab Results Affecting Financial View,LLY,https://www.benzinga.com/news/12/08/2858011/update-eli-lilly-says-doesnt-see-solanezumab-results-affecting-financial-view,Paul Quintaro,,,,0,0,1dee5a81-8fe2-48db-b386-ff2d1a54c9d3
2012-08-24T08:00:00.000+08:00,Jefferies Maintains Underperform on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2857961/jefferies-maintains-underperform-on-eli-lilly,Joe Young,,,,0,0,5b868ff8-0084-4a8a-9a7a-31ea0c0646a7
2012-08-24T08:00:00.000+08:00,"Lilly Rises 9.5% Pre-Market as Alzheimer's Drug Fails to Meet Primary Endpoints, But Slows Progression of Disease",LLY,https://www.benzinga.com/news/12/08/2857769/lilly-rises-9-5-pre-market-as-alzheimers-drug-fails-to-meet-primary-endpoints-but,Charles Gross,,,,0,0,c5e64f22-ec01-4c85-a0b1-09cc7902b4e9
2012-08-24T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/08/2857750/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,42cd8783-510b-48f9-ba5a-f6eb5c7e6b05
2012-08-24T08:00:00.000+08:00,Eli Lilly Announces Negative Results of Solanezumab Phase 3 Trial,LLY,https://www.benzinga.com/news/12/08/2857688/eli-lilly-announces-negative-results-of-solanezumab-phase-3-trial,Paul Quintaro,,,,0,0,435ec150-20bd-4530-b53c-6d0cef010eeb
2012-08-24T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/12/08/2857613/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,bb89d610-c34f-4acd-ae1f-0496f2715899
2012-08-24T08:00:00.000+08:00,Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer's Disease,LLY,https://www.benzinga.com/news/12/08/2857568/eli-lilly-and-company-announces-top-line-results-on-solanezumab-phase-3-clinical-,Charles Gross,,,,0,0,9baa766b-e3fc-4370-acfa-41cb2500de8f
2012-08-17T08:00:00.000+08:00,FDA Approves Prescribing Eli Lilly's Tradjenta Tablets,LLY,https://www.benzinga.com/news/12/08/2842042/fda-approves-prescribing-eli-lillys-tradjenta-tablets,Paul Quintaro,,,,0,0,643ccce7-8b31-4702-82e2-63c40057008e
2012-08-17T08:00:00.000+08:00,FDA Approves Prescribing Eli Lilly's Tradjenta Tablets,LLY,https://www.benzinga.com/news/12/08/2842042/fda-approves-prescribing-eli-lillys-tradjenta-tablets,Paul Quintaro,,,,0,0,a1f50bac-3278-43bb-963c-0299f946f2dc
2012-08-12T08:00:00.000+08:00,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/12/08/2825817/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,,,,0,0,8a05682b-eae7-4675-9520-367b8258210b
2012-08-12T08:00:00.000+08:00,Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/12/08/2825817/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,,,,0,0,4c318d74-4344-46e4-ba3f-ff3ed2324fcf
2012-08-07T08:00:00.000+08:00,"UPDATE: Lilly Says Fewer Forteo Patients Had Worsening Back Pain; Says had 9 Deaths in Study, 4 in Forteo Group and 5 in Risedronate Group",LLY,https://www.benzinga.com/news/12/08/2810951/update-lilly-says-fewer-forteo-patients-had-worsening-back-pain-says-had-9-deaths,Paul Quintaro,,,,0,0,116883a7-ecf0-40c6-9426-b8ecd2347e77
2012-08-07T08:00:00.000+08:00,Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures,LLY,https://www.benzinga.com/news/12/08/2810908/lilly-announces-study-results-regarding-postmenopausal-women-with-back-pain-cause,Paul Quintaro,,,,0,0,ec8183fd-c023-412b-96a7-ec5afad88f75
2012-08-07T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/12/08/2810517/benzingas-top-pre-market-losers,Lisa Levin,,,,0,0,c18c74e4-3b0a-4fc9-bb9c-a1abebabd8c8
2012-08-07T08:00:00.000+08:00,"UPDATE: Lilly Says Fewer Forteo Patients Had Worsening Back Pain; Says had 9 Deaths in Study, 4 in Forteo Group and 5 in Risedronate Group",LLY,https://www.benzinga.com/news/12/08/2810951/update-lilly-says-fewer-forteo-patients-had-worsening-back-pain-says-had-9-deaths,Paul Quintaro,,,,0,0,e48d2cc6-26f4-48aa-9f08-532c631b2fd5
2012-08-07T08:00:00.000+08:00,Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures,LLY,https://www.benzinga.com/news/12/08/2810908/lilly-announces-study-results-regarding-postmenopausal-women-with-back-pain-cause,Paul Quintaro,,,,0,0,581b003b-8452-4914-9a06-1452fdf1f39e
2012-08-07T08:00:00.000+08:00,Benzinga's Top Pre-Market Losers,LLY,https://www.benzinga.com/news/12/08/2810517/benzingas-top-pre-market-losers,Lisa Levin,,,,0,0,d5e4bc4e-fbdf-40d9-82e2-9ca5715820a5
2012-07-30T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for July 30, 2012",LLY,https://www.benzinga.com/markets/bonds/12/07/2785682/financial-breakfast-morning-news-summary-for-july-30-2012,James Hunter,,,,0,0,7a7413bf-85ad-4e03-ae61-224c1db1f613
2012-07-30T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/07/2785603/benzingas-top-downgrades,Lisa Levin,,,,0,0,32eb7732-43a4-4cb4-92e6-5a164fe8016b
2012-07-30T08:00:00.000+08:00,"Jefferies & Company Downgrades Eli Lilly & from Hold to Underperform, Lowers PT from $37 to $35",LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/07/2785370/jefferies-company-downgrades-eli-lilly-from-hold-to-underpe,Juan Lopez,,,,0,0,1508d176-43d5-47ca-9ce1-2015af4986f6
2012-07-30T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for July 30, 2012",LLY,https://www.benzinga.com/markets/bonds/12/07/2785682/financial-breakfast-morning-news-summary-for-july-30-2012,James Hunter,,,,0,0,c9063d98-421b-4bb3-b3ae-f5209d7adbec
2012-07-30T08:00:00.000+08:00,Benzinga's Top Downgrades,LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/07/2785603/benzingas-top-downgrades,Lisa Levin,,,,0,0,ab65cad0-440f-4172-be95-014470617505
2012-07-30T08:00:00.000+08:00,"Jefferies & Company Downgrades Eli Lilly & from Hold to Underperform, Lowers PT from $37 to $35",LLY,https://www.benzinga.com/analyst-ratings/downgrades/12/07/2785370/jefferies-company-downgrades-eli-lilly-from-hold-to-underpe,Juan Lopez,,,,0,0,26f2acd2-eb57-42a4-bb33-61a94c2f9ad7
2012-07-27T08:00:00.000+08:00,UPDATE: Morgan Stanley Raises PT on Eli Lily & Co. from $39 to $41,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/07/2782644/update-morgan-stanley-raises-pt-on-eli-lily-co-from-39-t,Viktor Puskorius,,,,0,0,af738640-6996-4031-8b3a-83dfd2264331
2012-07-27T08:00:00.000+08:00,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $39 to $41",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2781737/morgan-stanley-maintains-eli-lilly-at-underweight-raises-,Juan Lopez,,,,0,0,d7a667c2-efc8-4229-83a1-74c0d6b083c9
2012-07-27T08:00:00.000+08:00,UPDATE: Morgan Stanley Raises PT on Eli Lily & Co. from $39 to $41,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/07/2782644/update-morgan-stanley-raises-pt-on-eli-lily-co-from-39-t,Viktor Puskorius,,,,0,0,18fe3da0-11a8-4d16-a4b2-aa81748e68ba
2012-07-27T08:00:00.000+08:00,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $39 to $41",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2781737/morgan-stanley-maintains-eli-lilly-at-underweight-raises-,Juan Lopez,,,,0,0,695e5aea-5ff2-4391-acbb-105f2bb7246e
2012-07-25T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly and Company Announced Jentadueto tablets Receive Approval for the Treatment of Adults with Type 2 Diabetes in Europe,LLY,https://www.benzinga.com/news/12/07/2773875/boehringer-ingelheim-and-eli-lilly-and-company-announced-jentadueto-tablets-recei,Eddie Staley,,,,0,0,55508ba0-cde7-4892-8455-bf4b8a25531e
2012-07-25T08:00:00.000+08:00,UPDATE: Eli Lilly Sees $250M Generics Effect on Emerging Market Sales,LLY,https://www.benzinga.com/news/12/07/2773705/update-eli-lilly-sees-250m-generics-effect-on-emerging-market-sales,Paul Quintaro,,,,0,0,0819cfae-951f-4187-bea8-f5920e2086bc
2012-07-25T08:00:00.000+08:00,Eli Lilly Says Will Buy Back 420M Shares By the End of the Year,LLY,https://www.benzinga.com/news/12/07/2773666/eli-lilly-says-will-buy-back-420m-shares-by-the-end-of-the-year,Paul Quintaro,,,,0,0,7b9832ee-890c-428d-984d-e7fa2dd4f896
2012-07-25T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for July 25, 2012",LLY,https://www.benzinga.com/markets/bonds/12/07/2772930/financial-breakfast-morning-news-summary-for-july-25-2012,James Hunter,,,,0,0,db27feff-4004-42d0-87c7-1c56ccaccbb4
2012-07-25T08:00:00.000+08:00,"Benzinga Market Primer, Wednesday July 25",LLY,https://www.benzinga.com/markets/bonds/12/07/2772668/benzinga-market-primer-wednesday-july-25,Matthew Kanterman,,,,0,0,2c2f326f-86c6-41f4-91be-804f5ebf3ff8
2012-07-25T08:00:00.000+08:00,Eli Lilly & Reports Q2 EPS $0.83 vs $0.77 Est; Revenues $5.6B vs $5.59B Est,LLY,https://www.benzinga.com/news/earnings/12/07/2772602/eli-lilly-reports-q2-eps-0-83-vs-0-77-est-revenues-5-6b-vs-5-59b-est,Allie Wickman,,,,0,0,2ef2dffa-84b3-4ba7-a60c-ab0232a6b62d
2012-07-25T08:00:00.000+08:00,US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading,LLY,https://www.benzinga.com/news/12/07/2772595/us-stock-futures-mixed-apple-shares-drop-in-pre-market-trading,Monica Gerson,,,,0,0,11c26c7c-1e33-4341-8d75-6d883e3c28fd
2012-07-25T08:00:00.000+08:00,Earnings Scheduled For July 25,LLY,https://www.benzinga.com/news/earnings/12/07/2772332/earnings-scheduled-for-july-25,Monica Gerson,,,,0,0,2414590b-8822-4159-a20e-13866d862b3d
2012-07-25T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly and Company Announced Jentadueto tablets Receive Approval for the Treatment of Adults with Type 2 Diabetes in Europe,LLY,https://www.benzinga.com/news/12/07/2773875/boehringer-ingelheim-and-eli-lilly-and-company-announced-jentadueto-tablets-recei,Eddie Staley,,,,0,0,669c1d70-118f-48ff-9add-775e03bcf9c1
2012-07-25T08:00:00.000+08:00,UPDATE: Eli Lilly Sees $250M Generics Effect on Emerging Market Sales,LLY,https://www.benzinga.com/news/12/07/2773705/update-eli-lilly-sees-250m-generics-effect-on-emerging-market-sales,Paul Quintaro,,,,0,0,699f854d-6ffa-4e2e-8e3c-0372a0c2c628
2012-07-25T08:00:00.000+08:00,Eli Lilly Says Will Buy Back 420M Shares By the End of the Year,LLY,https://www.benzinga.com/news/12/07/2773666/eli-lilly-says-will-buy-back-420m-shares-by-the-end-of-the-year,Paul Quintaro,,,,0,0,f255d962-5a90-49b9-bfdf-840a78170597
2012-07-25T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for July 25, 2012",LLY,https://www.benzinga.com/markets/bonds/12/07/2772930/financial-breakfast-morning-news-summary-for-july-25-2012,James Hunter,,,,0,0,3234135d-56e3-4913-b696-e2129036868a
2012-07-25T08:00:00.000+08:00,"Benzinga Market Primer, Wednesday July 25",LLY,https://www.benzinga.com/markets/bonds/12/07/2772668/benzinga-market-primer-wednesday-july-25,Matthew Kanterman,,,,0,0,76edebe9-68ad-4ac9-8274-6d4055a8e67e
2012-07-25T08:00:00.000+08:00,Eli Lilly & Reports Q2 EPS $0.83 vs $0.77 Est; Revenues $5.6B vs $5.59B Est,LLY,https://www.benzinga.com/news/earnings/12/07/2772602/eli-lilly-reports-q2-eps-0-83-vs-0-77-est-revenues-5-6b-vs-5-59b-est,Allie Wickman,,,,0,0,47af71de-4ba3-432e-ac63-16adb2ce75b3
2012-07-25T08:00:00.000+08:00,US Stock Futures Mixed; Apple Shares Drop In Pre-Market Trading,LLY,https://www.benzinga.com/news/12/07/2772595/us-stock-futures-mixed-apple-shares-drop-in-pre-market-trading,Monica Gerson,,,,0,0,85613045-8eee-471d-b538-656fdeb09d1a
2012-07-25T08:00:00.000+08:00,Earnings Scheduled For July 25,LLY,https://www.benzinga.com/news/earnings/12/07/2772332/earnings-scheduled-for-july-25,Monica Gerson,,,,0,0,fbb2a401-7903-4e26-92dc-626e4fb0c4b4
2012-07-24T08:00:00.000+08:00,What You Need in Order to Retire Before Age 60,LLY,https://www.benzinga.com/general/topics/12/07/2766077/what-you-need-in-order-to-retire-before-age-60,Minyanville,,,,0,0,043e941d-6cd8-46d7-a403-ec5ac6d4ec18
2012-07-24T08:00:00.000+08:00,What You Need in Order to Retire Before Age 60,LLY,https://www.benzinga.com/general/topics/12/07/2766077/what-you-need-in-order-to-retire-before-age-60,Minyanville,,,,0,0,16a57233-3ca1-443d-9c5f-9a392424d03b
2012-07-23T08:00:00.000+08:00,From Earlier: Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers,LLY,https://www.benzinga.com/news/12/07/2764558/from-earlier-pharmacokinetic-study-results-released-evaluating-interactions-betwe,Eddie Staley,,,,0,0,394ca6d0-a203-41fd-90bc-83a9ba4cdf35
2012-07-23T08:00:00.000+08:00,Earnings Expectations for the Week of July 23,LLY,https://www.benzinga.com/news/earnings/12/07/2763770/earnings-expectations-for-the-week-of-july-23,Nelson Hem,,,,0,0,229cc6c9-2f73-4b96-8b7f-b5156b29bc53
2012-07-23T08:00:00.000+08:00,From Earlier: Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers,LLY,https://www.benzinga.com/news/12/07/2764558/from-earlier-pharmacokinetic-study-results-released-evaluating-interactions-betwe,Eddie Staley,,,,0,0,78114a2a-943c-474d-a1b2-fc089e7b50e3
2012-07-23T08:00:00.000+08:00,Earnings Expectations for the Week of July 23,LLY,https://www.benzinga.com/news/earnings/12/07/2763770/earnings-expectations-for-the-week-of-july-23,Nelson Hem,,,,0,0,81d08aab-5fec-4e07-8963-ce0327380a30
2012-07-22T08:00:00.000+08:00,Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers,LLY,https://www.benzinga.com/news/12/07/2763844/pharmacokinetic-study-results-released-evaluating-interactions-between-livalo-and,Charles Gross,,,,0,0,1e21120b-95a2-4296-931d-4855709bc900
2012-07-22T08:00:00.000+08:00,Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO and Protease Inhibitor Combination in Healthy Volunteers,LLY,https://www.benzinga.com/news/12/07/2763844/pharmacokinetic-study-results-released-evaluating-interactions-between-livalo-and,Charles Gross,,,,0,0,65eb651d-8283-4825-ae3c-1b4199567d7f
2012-07-18T08:00:00.000+08:00,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $35 to $39",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2752833/morgan-stanley-maintains-eli-lilly-at-underweight-raises-,Juan Lopez,,,,0,0,92598e6e-d692-437c-94bb-bf483ab608d2
2012-07-18T08:00:00.000+08:00,"Morgan Stanley Maintains Eli Lilly & at Underweight, Raises PT from $35 to $39",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2752833/morgan-stanley-maintains-eli-lilly-at-underweight-raises-,Juan Lopez,,,,0,0,dfa339ca-7f70-4039-b0e7-2539dbad5f45
2012-07-13T08:00:00.000+08:00,3 New Bets by a Biotech Hedge Fund,LLY,https://www.benzinga.com/news/12/07/2743392/3-new-bets-by-a-biotech-hedge-fund,Insider Monkey,,,,0,0,35726b85-9b40-4944-84e5-4228e4eebc62
2012-07-13T08:00:00.000+08:00,"Jefferies & Company Maintains Eli Lilly & at Hold, Raises PT from $36 to $37",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2741560/jefferies-company-maintains-eli-lilly-at-hold-raises-pt-f,Juan Lopez,,,,0,0,05e36599-3ee9-4928-b81c-9189af4a220b
2012-07-13T08:00:00.000+08:00,3 New Bets by a Biotech Hedge Fund,LLY,https://www.benzinga.com/news/12/07/2743392/3-new-bets-by-a-biotech-hedge-fund,Insider Monkey,,,,0,0,f373dd8d-e4aa-4f6d-a932-e40200c8109d
2012-07-13T08:00:00.000+08:00,"Jefferies & Company Maintains Eli Lilly & at Hold, Raises PT from $36 to $37",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/07/2741560/jefferies-company-maintains-eli-lilly-at-hold-raises-pt-f,Juan Lopez,,,,0,0,6ad6978a-5309-4c34-b600-577089885bc0
2012-07-11T08:00:00.000+08:00,Lilly's Schizophrenia Drug as Effective as Placebo -IBD,LLY,https://www.benzinga.com/news/12/07/2735535/lillys-schizophrenia-drug-as-effective-as-placebo-ibd,Charles Gross,,,,0,0,1302b217-6e61-45d2-b8b2-bd266af54203
2012-07-11T08:00:00.000+08:00,Eli Lilly Announces Negative Clinical Trial Results From Schizophrenia Study,LLY,https://www.benzinga.com/news/12/07/2734749/eli-lilly-announces-negative-clinical-trial-results-from-schizophrenia-study,Allie Wickman,,,,0,0,71d13597-456c-4f15-8586-feade11a836c
2012-07-11T08:00:00.000+08:00,Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study,LLY,https://www.benzinga.com/news/12/07/2734421/lilly-announces-pomaglumetad-methionil-did-not-meet-primary-endpoint-of-clinical-,Allie Wickman,,,,0,0,d56fbf6c-c5f8-4b28-aabd-9236dd88592b
2012-07-11T08:00:00.000+08:00,Lilly's Schizophrenia Drug as Effective as Placebo -IBD,LLY,https://www.benzinga.com/news/12/07/2735535/lillys-schizophrenia-drug-as-effective-as-placebo-ibd,Charles Gross,,,,0,0,2c70f42d-93d6-4e9a-a32c-c96223d45893
2012-07-11T08:00:00.000+08:00,Eli Lilly Announces Negative Clinical Trial Results From Schizophrenia Study,LLY,https://www.benzinga.com/news/12/07/2734749/eli-lilly-announces-negative-clinical-trial-results-from-schizophrenia-study,Allie Wickman,,,,0,0,c01113ff-0906-4e7d-9296-68a78ffdf277
2012-07-11T08:00:00.000+08:00,Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study,LLY,https://www.benzinga.com/news/12/07/2734421/lilly-announces-pomaglumetad-methionil-did-not-meet-primary-endpoint-of-clinical-,Allie Wickman,,,,0,0,9ecb8ed9-3656-4e01-b94d-4333e2e3c017
2012-07-10T08:00:00.000+08:00,"Immigrants: Restless Dreamers, Economic Pillars",LLY,https://www.benzinga.com/general/entrepreneurship/12/07/2731818/immigrants-restless-dreamers-economic-pillars,Marcus Goncalves,,,,0,0,c2ed00e5-3b2b-473d-bb7f-1929c1a6c39e
2012-07-10T08:00:00.000+08:00,"Immigrants: Restless Dreamers, Economic Pillars",LLY,https://www.benzinga.com/general/entrepreneurship/12/07/2731818/immigrants-restless-dreamers-economic-pillars,Marcus Goncalves,,,,0,0,87334562-96ff-4c2c-ba52-19bc5971e627
2012-07-06T08:00:00.000+08:00,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl),LLY,https://www.benzinga.com/news/12/07/2722715/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta-duloxetine-hcl,Eddie Staley,,,,0,0,5e26c9c0-5b18-4356-85a4-168cb963c9bc
2012-07-06T08:00:00.000+08:00,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl),LLY,https://www.benzinga.com/news/12/07/2722706/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta-duloxetine-hcl,Eddie Staley,,,,0,0,110eb3a7-b2cd-4736-b9d2-a3468b33f57d
2012-07-06T08:00:00.000+08:00,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl),LLY,https://www.benzinga.com/news/12/07/2722715/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta-duloxetine-hcl,Eddie Staley,,,,0,0,6c4c4952-ad49-4996-93a4-012d52b8e374
2012-07-06T08:00:00.000+08:00,Lilly Obtains Six Months U.S. Pediatric Exclusivity for Cymbalta (duloxetine HCl),LLY,https://www.benzinga.com/news/12/07/2722706/lilly-obtains-six-months-u-s-pediatric-exclusivity-for-cymbalta-duloxetine-hcl,Eddie Staley,,,,0,0,f6bba038-a747-404d-9324-fa5e9e41bf5d
2012-07-02T08:00:00.000+08:00,Bristol-Myers to Acquire Amylin,LLY,https://www.benzinga.com/news/12/07/2714085/bristol-myers-to-acquire-amylin,Brett Callwood,,,,0,0,d0ea7e9a-35ea-4b77-b931-daa86cff7faa
2012-07-02T08:00:00.000+08:00,Bristol-Myers to Acquire Amylin,LLY,https://www.benzinga.com/news/12/07/2714085/bristol-myers-to-acquire-amylin,Brett Callwood,,,,0,0,62292901-d333-4c33-832d-cdee655369c4
2012-06-28T08:00:00.000+08:00,Lilly Statement on Affordable Care Act Ruling by Supreme Court,LLY,https://www.benzinga.com/news/12/06/2705869/lilly-statement-on-affordable-care-act-ruling-by-supreme-court,Paul Quintaro,,,,0,0,cd511660-f90b-454c-acb4-c8bc43599f79
2012-06-28T08:00:00.000+08:00,Lilly Statement on Affordable Care Act Ruling by Supreme Court,LLY,https://www.benzinga.com/news/12/06/2705869/lilly-statement-on-affordable-care-act-ruling-by-supreme-court,Paul Quintaro,,,,0,0,6e9ec1d7-4b81-4487-945c-63250f6e1c6f
2012-06-27T08:00:00.000+08:00,UPDATE: Goldman Sachs Raises PT on Eli Lily & Company to $38,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/06/2701418/update-goldman-sachs-raises-pt-on-eli-lily-company-to-38,Joe Young,,,,0,0,d666528e-a7b6-406e-9c8e-41fa64f1bf5a
2012-06-27T08:00:00.000+08:00,"Goldman Sachs Maintains Eli Lilly & Company at Sell, Raises PT from $35 to $38",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/06/2700552/goldman-sachs-maintains-eli-lilly-company-at-sell-raises-,Juan Lopez,,,,0,0,161b0da3-9488-4902-847f-9ad35b4cc10a
2012-06-27T08:00:00.000+08:00,UPDATE: Goldman Sachs Raises PT on Eli Lily & Company to $38,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/06/2701418/update-goldman-sachs-raises-pt-on-eli-lily-company-to-38,Joe Young,,,,0,0,e5bf1e18-ccbf-4f6e-ae24-9d327ce12f22
2012-06-27T08:00:00.000+08:00,"Goldman Sachs Maintains Eli Lilly & Company at Sell, Raises PT from $35 to $38",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/06/2700552/goldman-sachs-maintains-eli-lilly-company-at-sell-raises-,Juan Lopez,,,,0,0,ba91e535-9c92-4d88-b9d5-3cfa7f934f92
2012-06-26T08:00:00.000+08:00,Lilly Puts Statement Out on Pdufa Vote,LLY,https://www.benzinga.com/news/12/06/2699330/lilly-puts-statement-out-on-pdufa-vote,Paul Quintaro,,,,0,0,723eae31-e946-44cf-9395-c970f5df5073
2012-06-26T08:00:00.000+08:00,Lilly Puts Statement Out on Pdufa Vote,LLY,https://www.benzinga.com/news/12/06/2699330/lilly-puts-statement-out-on-pdufa-vote,Paul Quintaro,,,,0,0,f1a11e32-0cbd-4b7b-85eb-a1ebf1d43ae4
2012-06-19T08:00:00.000+08:00,"Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program",LLY,https://www.benzinga.com/news/12/06/2678818/lilly-declares-third-quarter-2012-dividend-resumes-share-repurchase-program,Allie Wickman,,,,0,0,6491e868-caeb-4257-af29-2bb2a01381a4
2012-06-19T08:00:00.000+08:00,"Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program",LLY,https://www.benzinga.com/news/12/06/2678818/lilly-declares-third-quarter-2012-dividend-resumes-share-repurchase-program,Allie Wickman,,,,0,0,1be344fc-508a-4885-9e2b-82c720379b41
2012-06-11T08:00:00.000+08:00,"Lilly Releases Data on Diabetes Drug, Patients Lost Weight on Lilly's Drug, Gained on Sanofi's",LLY,https://www.benzinga.com/news/12/06/2659370/lilly-releases-data-on-diabetes-drug-patients-lost-weight-on-lillys-drug-gained-o,Paul Quintaro,,,,0,0,c65c69d3-63bc-4eb4-947f-2e0096f61867
2012-06-11T08:00:00.000+08:00,"Lilly Releases Data on Diabetes Drug, Patients Lost Weight on Lilly's Drug, Gained on Sanofi's",LLY,https://www.benzinga.com/news/12/06/2659370/lilly-releases-data-on-diabetes-drug-patients-lost-weight-on-lillys-drug-gained-o,Paul Quintaro,,,,0,0,75e0c3f3-5f6c-46e4-bab1-c0b4004f6df2
2012-06-08T08:00:00.000+08:00,"UPDATE: Lilly Says 1 Serious Adverse Event in 8 MG Group, 4 Serious Adverse Events in 2 MG Group, No Deaths or Opportunistic Infection in Active Treatment Group",LLY,https://www.benzinga.com/news/12/06/2654225/update-lilly-says-1-serious-adverse-event-in-8-mg-group-4-serious-adverse-events-,Paul Quintaro,,,,0,0,e5b4e7a3-b4f8-4e99-aa69-14064aa87ce2
2012-06-08T08:00:00.000+08:00,"Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis",LLY,https://www.benzinga.com/news/12/06/2654224/lilly-and-incytes-oral-jak1-and-jak2-inhibitor-baricitinib-showed-positive-result,Allie Wickman,,,,0,0,95af3855-9c47-43cc-b7b0-ab050e596f83
2012-06-08T08:00:00.000+08:00,"UPDATE: Lilly Says 1 Serious Adverse Event in 8 MG Group, 4 Serious Adverse Events in 2 MG Group, No Deaths or Opportunistic Infection in Active Treatment Group",LLY,https://www.benzinga.com/news/12/06/2654225/update-lilly-says-1-serious-adverse-event-in-8-mg-group-4-serious-adverse-events-,Paul Quintaro,,,,0,0,96ee5106-50a2-495f-8a97-a1682cedb640
2012-06-08T08:00:00.000+08:00,"Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis",LLY,https://www.benzinga.com/news/12/06/2654224/lilly-and-incytes-oral-jak1-and-jak2-inhibitor-baricitinib-showed-positive-result,Allie Wickman,,,,0,0,30172664-2326-4f1a-9e93-b2707065291a
2012-06-06T08:00:00.000+08:00,Eli Lilly's CEO Says No Large Pharma Deals Coming -WSJ,LLY,https://www.benzinga.com/news/12/06/2648591/eli-lillys-ceo-says-no-large-pharma-deals-coming-wsj,Paul Quintaro,,,,0,0,78a28691-e1fc-4e97-860a-328b8749b81b
2012-06-06T08:00:00.000+08:00,Eli Lilly's CEO Says No Large Pharma Deals Coming -WSJ,LLY,https://www.benzinga.com/news/12/06/2648591/eli-lillys-ceo-says-no-large-pharma-deals-coming-wsj,Paul Quintaro,,,,0,0,47fe515e-c975-4fe1-b16d-b2f1a9ed9703
2012-06-04T08:00:00.000+08:00,Eli Lilly Announces Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation,LLY,https://www.benzinga.com/news/12/06/2639368/eli-lilly-announces-lung-cancer-study-showed-encouraging-results-for-alimta-based,Eddie Staley,,,,0,0,6a4244a4-e293-4771-8acb-94285f790c3b
2012-06-04T08:00:00.000+08:00,Eli Lilly Announces Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy,LLY,https://www.benzinga.com/news/12/06/2639303/eli-lilly-announces-patients-with-most-common-type-of-lung-cancer-lived-longer-wi,Eddie Staley,,,,0,0,87005e0c-9fd8-45fe-973e-e927a9895f77
2012-06-04T08:00:00.000+08:00,Eli Lilly Announces Lung Cancer Study Showed Encouraging Results For ALIMTA-based Regimens And Full-dose Radiation,LLY,https://www.benzinga.com/news/12/06/2639368/eli-lilly-announces-lung-cancer-study-showed-encouraging-results-for-alimta-based,Eddie Staley,,,,0,0,03c635ef-4989-4025-92bb-cd43b220b3de
2012-06-04T08:00:00.000+08:00,Eli Lilly Announces Patients With Most Common Type Of Lung Cancer Lived Longer With ALIMTA-Based Continuation Maintenance Therapy,LLY,https://www.benzinga.com/news/12/06/2639303/eli-lilly-announces-patients-with-most-common-type-of-lung-cancer-lived-longer-wi,Eddie Staley,,,,0,0,eda3b40b-0540-43df-83d8-03859db58917
2012-06-01T08:00:00.000+08:00,Eli Lilly Says Amyvid Now Available in Select US Markets,LLY,https://www.benzinga.com/news/12/06/2635635/eli-lilly-says-amyvid-now-available-in-select-us-markets,Paul Quintaro,,,,0,0,3b167577-1614-457e-a09c-82d67a4a05b4
2012-06-01T08:00:00.000+08:00,"Cardinal Health to Manufacture, Distribute Eli Lilly and Company's Brain Imaging Agent Amyvid",LLY,https://www.benzinga.com/news/12/06/2635310/cardinal-health-to-manufacture-distribute-eli-lilly-and-companys-brain-imaging-ag,Eddie Staley,,,,0,0,ec8f331d-25f5-40c0-ad08-4a27d8d82303
2012-06-01T08:00:00.000+08:00,Eli Lilly Says Amyvid Now Available in Select US Markets,LLY,https://www.benzinga.com/news/12/06/2635635/eli-lilly-says-amyvid-now-available-in-select-us-markets,Paul Quintaro,,,,0,0,23b3830b-8e63-4266-bdbb-a661a17634dd
2012-06-01T08:00:00.000+08:00,"Cardinal Health to Manufacture, Distribute Eli Lilly and Company's Brain Imaging Agent Amyvid",LLY,https://www.benzinga.com/news/12/06/2635310/cardinal-health-to-manufacture-distribute-eli-lilly-and-companys-brain-imaging-ag,Eddie Staley,,,,0,0,23546718-773f-47b0-9e54-8db8ce26fcbf
2012-05-31T08:00:00.000+08:00,15 Great Stocks with Great Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/12/05/2633305/15-great-stocks-with-great-yield,Matthew Kanterman,,,,0,0,43da27a8-9a25-4e80-b786-a1e0586fe71f
2012-05-31T08:00:00.000+08:00,Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?,LLY,https://www.benzinga.com/personal-finance/financial-advisors/12/05/2632730/vivus-qnexa-is-not-guaranteed-approval-remember-pr,Ross Drew,,,,0,0,f1ad4e3c-0c99-4073-8947-127dde934711
2012-05-31T08:00:00.000+08:00,Lily: New Data Showed LIVALO Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin,LLY,https://www.benzinga.com/news/12/05/2630739/lily-new-data-showed-livalo-met-primary-endpoint-of-ldl-c-reduction-when-compared,Allie Wickman,,,,0,0,bdadc30f-df41-45d1-9b04-90d0397de432
2012-05-31T08:00:00.000+08:00,15 Great Stocks with Great Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/12/05/2633305/15-great-stocks-with-great-yield,Matthew Kanterman,,,,0,0,717c2358-edff-4f4e-a21c-d3c47d39b1aa
2012-05-31T08:00:00.000+08:00,Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?,LLY,https://www.benzinga.com/personal-finance/financial-advisors/12/05/2632730/vivus-qnexa-is-not-guaranteed-approval-remember-pr,Ross Drew,,,,0,0,38ab2c5e-1d1e-4ec9-a90c-72a740172773
2012-05-31T08:00:00.000+08:00,Lily: New Data Showed LIVALO Met Primary Endpoint of LDL-C Reduction When Compared with Pravastatin,LLY,https://www.benzinga.com/news/12/05/2630739/lily-new-data-showed-livalo-met-primary-endpoint-of-ldl-c-reduction-when-compared,Allie Wickman,,,,0,0,c95849d6-dc69-4ff1-86fa-3ec85c3f33b8
2012-05-29T08:00:00.000+08:00,Eli Lilly Announces Jentadueto Tablets Recommended for Approval in Treatment of Adults with Type 2 Diabetes in Europe,LLY,https://www.benzinga.com/news/12/05/2625014/eli-lilly-announces-jentadueto-tablets-recommended-for-approval-in-treatment-of-a,Eddie Staley,,,,0,0,88a20336-44b2-4a19-abac-f321eca069c7
2012-05-29T08:00:00.000+08:00,Eli Lilly Announces Jentadueto Tablets Recommended for Approval in Treatment of Adults with Type 2 Diabetes in Europe,LLY,https://www.benzinga.com/news/12/05/2625014/eli-lilly-announces-jentadueto-tablets-recommended-for-approval-in-treatment-of-a,Eddie Staley,,,,0,0,a3cc43f7-12ec-44b5-ab99-24c98b663bb9
2012-05-24T08:00:00.000+08:00,FDA Fee Bill Gets Enough Support for Passage as Vote Continues -Bloomberg,LLY,https://www.benzinga.com/news/12/05/2617193/fda-fee-bill-gets-enough-support-for-passage-as-vote-continues-bloomberg,Paul Quintaro,,,,0,0,f7f71730-4913-4b25-9b76-11da0d3d4c3b
2012-05-24T08:00:00.000+08:00,New Phase 3 data for Tradjenta,LLY,https://www.benzinga.com/news/12/05/2615591/new-phase-3-data-for-tradjenta,Paul Quintaro,,,,0,0,eeda4c50-3599-459a-a38e-481fede2eb85
2012-05-24T08:00:00.000+08:00,FDA Fee Bill Gets Enough Support for Passage as Vote Continues -Bloomberg,LLY,https://www.benzinga.com/news/12/05/2617193/fda-fee-bill-gets-enough-support-for-passage-as-vote-continues-bloomberg,Paul Quintaro,,,,0,0,dca3ba72-b8ed-47b6-a467-b4899dda0d78
2012-05-24T08:00:00.000+08:00,New Phase 3 data for Tradjenta,LLY,https://www.benzinga.com/news/12/05/2615591/new-phase-3-data-for-tradjenta,Paul Quintaro,,,,0,0,9e13345a-c464-4043-9340-4a88c469c10a
2012-05-18T08:00:00.000+08:00,"BMO Capital Markets Initiates Coverage on Eli Lilly & at Market Perform, Announces PT of $38",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/05/2600591/bmo-capital-markets-initiates-coverage-on-eli-lilly-at-ma,webmaster,,,,0,0,d1a16a3e-4e12-48af-aeb7-7aac82588f31
2012-05-18T08:00:00.000+08:00,"BMO Capital Markets Initiates Coverage on Eli Lilly & at Market Perform, Announces PT of $38",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/05/2600591/bmo-capital-markets-initiates-coverage-on-eli-lilly-at-ma,webmaster,,,,0,0,fc23668d-f83e-4d77-bd26-c030e1d65f4f
2012-05-17T08:00:00.000+08:00,Eli Lilly Receives Positive Mad Money/Jim Cramer Mention -CNBC,LLY,https://www.benzinga.com/media/cnbc/12/05/2599685/eli-lilly-receives-positive-mad-moneyjim-cramer-mention-cnbc,Charles Gross,,,,0,0,2083346e-17f4-48a3-b08d-03c775987912
2012-05-17T08:00:00.000+08:00,Eli Lilly Receives Positive Mad Money/Jim Cramer Mention -CNBC,LLY,https://www.benzinga.com/media/cnbc/12/05/2599685/eli-lilly-receives-positive-mad-moneyjim-cramer-mention-cnbc,Charles Gross,,,,0,0,6b62beed-ac12-40f1-a73e-0c8ba27f91ba
2012-05-10T08:00:00.000+08:00,Option Alert: Heavy Volume in Lilly Calls,LLY,https://www.benzinga.com/markets/options/12/05/2578275/option-alert-heavy-volume-in-lilly-calls,Charles Gross,,,,0,0,28c28f07-0fa5-4299-89ac-654413ecbcf1
2012-05-10T08:00:00.000+08:00,Option Alert: Heavy Volume in Lilly Calls,LLY,https://www.benzinga.com/markets/options/12/05/2578275/option-alert-heavy-volume-in-lilly-calls,Charles Gross,,,,0,0,fdc591b3-9dbe-494c-92a2-c7b9ff48c05f
2012-05-07T08:00:00.000+08:00,UPDATE: Bank of America Increases PO on Eli Lilly & Co to $46,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/05/2563156/update-bank-of-america-increases-po-on-eli-lilly-co-to-4,Dwight Einhorn,,,,0,0,f268d8fc-06cd-417e-b256-dccec2cd0483
2012-05-07T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly at Buy, Raises PO from $43 to $46",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/05/2562943/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,webmaster,,,,0,0,cc62d243-8749-4441-a3d1-35dbcb036f26
2012-05-07T08:00:00.000+08:00,UPDATE: Bank of America Increases PO on Eli Lilly & Co to $46,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/05/2563156/update-bank-of-america-increases-po-on-eli-lilly-co-to-4,Dwight Einhorn,,,,0,0,5a83041b-4a57-4684-aed9-d02b07f7d4f8
2012-05-07T08:00:00.000+08:00,"Bank of America Maintains Eli Lilly at Buy, Raises PO from $43 to $46",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/05/2562943/bank-of-america-maintains-eli-lilly-at-buy-raises-po-from,webmaster,,,,0,0,e8012807-64b4-4266-bcff-88091ce3fb0d
2012-05-04T08:00:00.000+08:00,"Option Alert: Eli Lilly July 42 Call; Block Trade: 6,000 Contracts; Currently $41.20",LLY,https://www.benzinga.com/markets/options/12/05/2560452/option-alert-eli-lilly-july-42-call-block-trade-6-000-contracts-curren,Charles Gross,,,,0,0,ee9ae926-2666-4be0-b444-32053f029c35
2012-05-04T08:00:00.000+08:00,"Option Alert: Eli Lilly July 42 Call; Block Trade: 6,000 Contracts; Currently $41.20",LLY,https://www.benzinga.com/markets/options/12/05/2560452/option-alert-eli-lilly-july-42-call-block-trade-6-000-contracts-curren,Charles Gross,,,,0,0,a5d8cab4-9f00-4d6e-ab09-90a2361e72da
2012-04-30T08:00:00.000+08:00,FDA Considering Letting Patients Purchase Drugs Without Prescriptions,LLY,https://www.benzinga.com/news/12/04/2541492/fda-considering-letting-patients-purchase-drugs-without-prescriptions,Marco Rabinowitz,,,,0,0,ee8ca5f8-9666-448d-a180-0d47ecbf4c92
2012-04-30T08:00:00.000+08:00,FDA Considering Letting Patients Purchase Drugs Without Prescriptions,LLY,https://www.benzinga.com/news/12/04/2541492/fda-considering-letting-patients-purchase-drugs-without-prescriptions,Marco Rabinowitz,,,,0,0,fb268ea3-0c68-4d63-aa74-15e9ad9ff89f
2012-04-25T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for April 25, 2012",LLY,https://www.benzinga.com/markets/bonds/12/04/2526765/financial-breakfast-morning-news-summary-for-april-25-2012,Allie Wickman,,,,0,0,0cf37ea4-3d54-46b6-ae64-b8f711ca811f
2012-04-25T08:00:00.000+08:00,Eli Lilly &amp; Reports Q1 EPS $0.92 vs $0.79 Est; Revenues $5.6B vs $5.35B Est,LLY,https://www.benzinga.com/news/earnings/12/04/2526430/eli-lilly-amp-reports-q1-eps-0-92-vs-0-79-est-revenues-5-6b-vs-5-35b-est,webmaster,,,,0,0,9e046e71-90c4-4c39-8cd4-0d6ca975d0ce
2012-04-25T08:00:00.000+08:00,Earnings Scheduled For April 25,LLY,https://www.benzinga.com/news/earnings/12/04/2525743/earnings-scheduled-for-april-25,Monica Gerson,,,,0,0,d11f9b79-2a0b-4c2d-acf7-26e861ae4a26
2012-04-25T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for April 25, 2012",LLY,https://www.benzinga.com/markets/bonds/12/04/2526765/financial-breakfast-morning-news-summary-for-april-25-2012,Allie Wickman,,,,0,0,cc85d15c-612c-4f30-be92-906ffb94be42
2012-04-25T08:00:00.000+08:00,Eli Lilly &amp; Reports Q1 EPS $0.92 vs $0.79 Est; Revenues $5.6B vs $5.35B Est,LLY,https://www.benzinga.com/news/earnings/12/04/2526430/eli-lilly-amp-reports-q1-eps-0-92-vs-0-79-est-revenues-5-6b-vs-5-35b-est,webmaster,,,,0,0,b990c6a6-8a29-4605-9453-9743b2ac971d
2012-04-25T08:00:00.000+08:00,Earnings Scheduled For April 25,LLY,https://www.benzinga.com/news/earnings/12/04/2525743/earnings-scheduled-for-april-25,Monica Gerson,,,,0,0,fd01f95f-f30b-426d-9a19-1054371dd64c
2012-04-22T08:00:00.000+08:00,"Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)",LLY,https://www.benzinga.com/news/earnings/12/04/2517141/earnings-expectations-for-the-week-of-april-23-aapl-xom-ups,Nelson Hem,,,,0,0,953d7bf9-f191-4f69-add8-458f28c525e0
2012-04-22T08:00:00.000+08:00,"Earnings Expectations for the Week of April 23 (AAPL, XOM, UPS)",LLY,https://www.benzinga.com/news/earnings/12/04/2517141/earnings-expectations-for-the-week-of-april-23-aapl-xom-ups,Nelson Hem,,,,0,0,63b2e93d-cd54-4e49-b490-659fbcd1133d
2012-04-18T08:00:00.000+08:00,Why our portfolio is John Deere green,LLY,https://www.benzinga.com/markets/12/04/2506146/why-our-portfolio-is-john-deere-green,Covestor,,,,0,0,34b88db0-9bdd-4e11-b318-ae08279749b9
2012-04-18T08:00:00.000+08:00,Why our portfolio is John Deere green,LLY,https://www.benzinga.com/markets/12/04/2506146/why-our-portfolio-is-john-deere-green,Covestor,,,,0,0,68c958a7-f521-4c80-b893-1ddaf325c73e
2012-04-16T08:00:00.000+08:00,How I approach biotech investing,LLY,https://www.benzinga.com/markets/12/04/2501106/how-i-approach-biotech-investing,Covestor,,,,0,0,d543a803-0ca6-4b90-b12b-5d0fa36d7368
2012-04-16T08:00:00.000+08:00,How I approach biotech investing,LLY,https://www.benzinga.com/markets/12/04/2501106/how-i-approach-biotech-investing,Covestor,,,,0,0,12333a2f-e9c4-4b5d-8e7f-50dea67be42a
2012-04-12T08:00:00.000+08:00,Why we added biotech stock Sequenom to the lineup,LLY,https://www.benzinga.com/markets/12/04/2493883/why-we-added-biotech-stock-sequenom-to-the-lineup,Covestor,,,,0,0,f69b09b8-0cae-4b5c-9c72-0e3b4bfe0c81
2012-04-12T08:00:00.000+08:00,Lilly's CEO on CNBC Says Hopes to Offset Decline Due to Patent Expiration,LLY,https://www.benzinga.com/media/cnbc/12/04/2492316/lillys-ceo-on-cnbc-says-hopes-to-offset-decline-due-to-patent-expiration,Paul Quintaro,,,,0,0,ea1a6926-7d1a-4834-a1d3-74c9e833e049
2012-04-12T08:00:00.000+08:00,Why we added biotech stock Sequenom to the lineup,LLY,https://www.benzinga.com/markets/12/04/2493883/why-we-added-biotech-stock-sequenom-to-the-lineup,Covestor,,,,0,0,46b1f3c8-5972-4200-b345-4dd25c3fc344
2012-04-12T08:00:00.000+08:00,Lilly's CEO on CNBC Says Hopes to Offset Decline Due to Patent Expiration,LLY,https://www.benzinga.com/media/cnbc/12/04/2492316/lillys-ceo-on-cnbc-says-hopes-to-offset-decline-due-to-patent-expiration,Paul Quintaro,,,,0,0,ed608343-ed80-41be-ae5f-021788e6edb0
2012-04-10T08:00:00.000+08:00,Safeguard Scientifics Will Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharma,LLY,https://www.benzinga.com/news/12/04/2484028/safeguard-scientifics-will-realize-additional-proceeds-from-eli-lillys-acquisitio,Paul Quintaro,,,,0,0,b34ce3ba-ceb5-466c-a15f-946ec763ebbb
2012-04-10T08:00:00.000+08:00,Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals,LLY,https://www.benzinga.com/news/12/04/2484026/safeguard-scientifics-to-realize-additional-proceeds-from-eli-lillys-acquisition-,Allie Wickman,,,,0,0,0e4d4d20-dfe7-4563-a29f-fcd6716c0e51
2012-04-10T08:00:00.000+08:00,Safeguard Scientifics Will Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharma,LLY,https://www.benzinga.com/news/12/04/2484028/safeguard-scientifics-will-realize-additional-proceeds-from-eli-lillys-acquisitio,Paul Quintaro,,,,0,0,d9d16853-51dc-493b-b657-4451363a196b
2012-04-10T08:00:00.000+08:00,Safeguard Scientifics to Realize Additional Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals,LLY,https://www.benzinga.com/news/12/04/2484026/safeguard-scientifics-to-realize-additional-proceeds-from-eli-lillys-acquisition-,Allie Wickman,,,,0,0,8d0fb746-7ad1-4811-bc92-3b8c67994064
2012-04-09T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/04/2480326/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,df8f12ea-2c77-4c9f-9414-707a7630ae85
2012-04-09T08:00:00.000+08:00,Eli Lilly Announces FDA Approves Amyvid for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline,LLY,https://www.benzinga.com/news/12/04/2480069/eli-lilly-announces-fda-approves-amyvid-for-use-in-patients-being-evaluated-for-a,Eddie Staley,,,,0,0,11a89d28-0246-45db-9eb3-e99742d8b6ab
2012-04-09T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/04/2480326/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,31f1478d-4fb5-4e56-85a6-6dd2764515e1
2012-04-09T08:00:00.000+08:00,Eli Lilly Announces FDA Approves Amyvid for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline,LLY,https://www.benzinga.com/news/12/04/2480069/eli-lilly-announces-fda-approves-amyvid-for-use-in-patients-being-evaluated-for-a,Eddie Staley,,,,0,0,20a3fb50-cbad-4820-bcbf-bd93897de8d4
2012-04-03T08:00:00.000+08:00,Where the Rubber Meets the Road for Obamacare,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/04/2469605/where-the-rubber-meets-the-road-for-obamacare,Marco Rabinowitz,,,,0,0,12c9cb07-6c30-4cc9-852b-f3ea07507987
2012-04-03T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/04/2468272/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,68924c2c-6da5-40db-b607-e5aac98aa098
2012-04-03T08:00:00.000+08:00,Where the Rubber Meets the Road for Obamacare,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/04/2469605/where-the-rubber-meets-the-road-for-obamacare,Marco Rabinowitz,,,,0,0,15403ec3-c0f0-4cba-aa89-c863dd6da596
2012-04-03T08:00:00.000+08:00,Benzinga's Top Pre-Market Gainers,LLY,https://www.benzinga.com/news/12/04/2468272/benzingas-top-pre-market-gainers,Lisa Levin,,,,0,0,c1baaa61-bdb9-43e7-a9a4-2960a03e4ebd
2012-03-28T08:00:00.000+08:00,ImmunoCellular's Intellectual Property Steadily Increases,LLY,https://www.benzinga.com/news/fda/12/03/2452222/immunocellulars-intellectual-property-steadily-increases,Chemistfrog,,,,0,0,ad653867-7ac8-4a6c-8c5f-70ed109dcf70
2012-03-28T08:00:00.000+08:00,"Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis",LLY,https://www.benzinga.com/news/12/03/2452099/lillys-anti-il-17-monoclonal-antibody-ixekizumab-met-primary-endpoint-in-phase-ii,Charles Gross,,,,0,0,eb3871cd-8cc4-4b1e-887a-a8c23847209e
2012-03-28T08:00:00.000+08:00,Amylin Rejected $3.5 Billion Offer; Stock Soars,LLY,https://www.benzinga.com/news/12/03/2451652/amylin-rejected-3-5-billion-offer-stock-soars,Scott Rubin,,,,0,0,93eaf3a4-935b-421d-b871-91c90c7b9680
2012-03-28T08:00:00.000+08:00,ImmunoCellular's Intellectual Property Steadily Increases,LLY,https://www.benzinga.com/news/fda/12/03/2452222/immunocellulars-intellectual-property-steadily-increases,Chemistfrog,,,,0,0,a36ed5db-220e-483f-a579-cafa2e959f7c
2012-03-28T08:00:00.000+08:00,"Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque Psoriasis",LLY,https://www.benzinga.com/news/12/03/2452099/lillys-anti-il-17-monoclonal-antibody-ixekizumab-met-primary-endpoint-in-phase-ii,Charles Gross,,,,0,0,75628d14-43d2-4abd-af1d-79f14b783cc1
2012-03-28T08:00:00.000+08:00,Amylin Rejected $3.5 Billion Offer; Stock Soars,LLY,https://www.benzinga.com/news/12/03/2451652/amylin-rejected-3-5-billion-offer-stock-soars,Scott Rubin,,,,0,0,0f459824-72ac-4438-9d53-f03c83d955d7
2012-03-23T08:00:00.000+08:00,Amylin Pharmaceuticals Announces BYETTA Approved for Use with Basal Insulin in Europe,LLY,https://www.benzinga.com/news/12/03/2444804/amylin-pharmaceuticals-announces-byetta-approved-for-use-with-basal-insulin-in-eu,Eddie Staley,,,,0,0,812d7cfe-9bdc-4a8a-b323-11a070eb7f2f
2012-03-23T08:00:00.000+08:00,Amylin Pharmaceuticals Announces BYETTA Approved for Use with Basal Insulin in Europe,LLY,https://www.benzinga.com/news/12/03/2444804/amylin-pharmaceuticals-announces-byetta-approved-for-use-with-basal-insulin-in-eu,Eddie Staley,,,,0,0,5d1279ab-35d7-428b-958e-52adf11edcef
2012-03-21T08:00:00.000+08:00,"Benzinga's M&A Chatter for Wednesday March 21, 2012",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2442482/benzingas-m-a-chatter-for-wednesday-march-21-2012,Charles Gross,,,,0,0,198d2ba1-9e34-4375-8fb1-81b968544577
2012-03-21T08:00:00.000+08:00,"Forest Labs Spiking Higher on Takeover Chatter, Lilly Rumored Buyer",LLY,https://www.benzinga.com/news/12/03/2441463/forest-labs-spiking-higher-on-takeover-chatter-lilly-rumored-buyer,Charles Gross,,,,0,0,0ea061c3-bcfd-46e9-a446-4cd63609f75c
2012-03-21T08:00:00.000+08:00,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2440492/st-jude-novo-nordisk-and-other-health-care-stocks-worth-a-loo,Nelson Hem,,,,0,0,ce99f103-2a2e-42c5-85a5-a4ed2368f000
2012-03-21T08:00:00.000+08:00,"Benzinga's M&A Chatter for Wednesday March 21, 2012",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2442482/benzingas-m-a-chatter-for-wednesday-march-21-2012,Charles Gross,,,,0,0,a3870b61-4448-4655-b2e2-eeb3e3578c5c
2012-03-21T08:00:00.000+08:00,"Forest Labs Spiking Higher on Takeover Chatter, Lilly Rumored Buyer",LLY,https://www.benzinga.com/news/12/03/2441463/forest-labs-spiking-higher-on-takeover-chatter-lilly-rumored-buyer,Charles Gross,,,,0,0,2718f79a-6e86-4d5f-97d7-260107f62c11
2012-03-21T08:00:00.000+08:00,"St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2440492/st-jude-novo-nordisk-and-other-health-care-stocks-worth-a-loo,Nelson Hem,,,,0,0,a570249c-0109-47d4-bb0e-a326f2f3be59
2012-03-15T08:00:00.000+08:00,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2427762/a-look-at-the-new-russell-high-yield-etf-hdiv-abt-kft,ETF Professor,,,,0,0,aaf7f038-4797-4d3d-9848-a93dc62276bb
2012-03-15T08:00:00.000+08:00,"A Look At The New Russell High Yield ETF (HDIV, ABT, KFT)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2427762/a-look-at-the-new-russell-high-yield-etf-hdiv-abt-kft,ETF Professor,,,,0,0,2727d322-da0c-42c5-9581-04bb355dda6c
2012-03-09T08:00:00.000+08:00,S&P Indices Announces Changes to U.S. Index,LLY,https://www.benzinga.com/news/12/03/2412847/s-p-indices-announces-changes-to-u-s-index,Charles Gross,,,,0,0,6b025fce-0eeb-4ce1-b4f1-6fe961cd4a8f
2012-03-09T08:00:00.000+08:00,S&P Indices Announces Changes to U.S. Index,LLY,https://www.benzinga.com/news/12/03/2412847/s-p-indices-announces-changes-to-u-s-index,Charles Gross,,,,0,0,946f78b9-9fbc-4e6b-b22b-fa8fe36b173d
2012-03-08T08:00:00.000+08:00,"Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2407015/fresh-del-monte-blackrock-and-other-stocks-insiders-are-buyin,Nelson Hem,,,,0,0,0eb3737a-cb19-4ef3-bc35-95d266e947cd
2012-03-08T08:00:00.000+08:00,"Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2407015/fresh-del-monte-blackrock-and-other-stocks-insiders-are-buyin,Nelson Hem,,,,0,0,b1968189-ff4b-477f-876b-ba49a231bd57
2012-03-07T08:00:00.000+08:00,"Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto tablets, now available in U.S. pharmacies",LLY,https://www.benzinga.com/news/12/03/2403574/boehringer-ingelheim-and-lillys-new-oral-type-2-diabetes-treatment-for-adults-jen,Eddie Staley,,,,0,0,383d52cf-a99e-444b-8290-d2072c14adc4
2012-03-07T08:00:00.000+08:00,"Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto tablets, now available in U.S. pharmacies",LLY,https://www.benzinga.com/news/12/03/2403574/boehringer-ingelheim-and-lillys-new-oral-type-2-diabetes-treatment-for-adults-jen,Eddie Staley,,,,0,0,d6c7deb1-8f9d-4dc7-88d5-312a58c18c06
2012-03-02T08:00:00.000+08:00,UPDATE: JP Morgan Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/03/2392473/update-jp-morgan-upgrades-eli-lilly-to-neutral,David Johnson,,,,0,0,5f0518f1-0316-416c-9fc7-ccd93a33a8d6
2012-03-02T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for March 2, 2012",LLY,https://www.benzinga.com/markets/bonds/12/03/2391807/financial-breakfast-morning-news-summary-for-march-2-2012,Allie Wickman,,,,0,0,47ffccbe-7abe-4590-a0b8-42c707469c3c
2012-03-02T08:00:00.000+08:00,"JP Morgan Upgrades Eli Lilly from Underweight to Neutral, Maintains PT at $40",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/03/2391645/jp-morgan-upgrades-eli-lilly-from-underweight-to-neutral-main,webmaster,,,,0,0,fc83c13c-c24d-4d91-90d8-fe88fbe16477
2012-03-02T08:00:00.000+08:00,UPDATE: JP Morgan Upgrades Eli Lilly to Neutral,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/12/03/2392473/update-jp-morgan-upgrades-eli-lilly-to-neutral,David Johnson,,,,0,0,498db961-6a3e-4dcc-93de-3ac0f58deb60
2012-03-02T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for March 2, 2012",LLY,https://www.benzinga.com/markets/bonds/12/03/2391807/financial-breakfast-morning-news-summary-for-march-2-2012,Allie Wickman,,,,0,0,9c297de3-376d-4383-97a6-8cad48db23a0
2012-03-02T08:00:00.000+08:00,"JP Morgan Upgrades Eli Lilly from Underweight to Neutral, Maintains PT at $40",LLY,https://www.benzinga.com/analyst-ratings/upgrades/12/03/2391645/jp-morgan-upgrades-eli-lilly-from-underweight-to-neutral-main,webmaster,,,,0,0,30566151-033e-48a3-8e94-a472b04ab38d
2012-02-17T08:00:00.000+08:00,CHMP Recommends Approval of BYETTA for Use With Basal Insulin,LLY,https://www.benzinga.com/news/12/02/2353416/chmp-recommends-approval-of-byetta-for-use-with-basal-insulin,Matthew Kennedy,,,,0,0,e1d7b352-cf9b-49b7-92c2-bbddd8a08ae8
2012-02-17T08:00:00.000+08:00,CHMP Recommends Approval of BYETTA for Use With Basal Insulin,LLY,https://www.benzinga.com/news/12/02/2353416/chmp-recommends-approval-of-byetta-for-use-with-basal-insulin,Matthew Kennedy,,,,0,0,c731562e-0daf-4ba4-bf21-a174696d168d
2012-02-07T08:00:00.000+08:00,Stocks Going Ex-Dividend the Third Week of February 2012,LLY,https://www.benzinga.com/markets/12/02/2325637/stocks-going-ex-dividend-the-third-week-of-february-2012,Fred Fuld,,,,0,0,3c4b7289-dcab-43c3-bdfa-3d435ca65207
2012-02-07T08:00:00.000+08:00,New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia,LLY,https://www.benzinga.com/news/12/02/2322652/new-study-evaluates-cialis-in-parallel-with-tamsulosin-in-men-with-signs-and-symp,Eddie Staley,,,,0,0,d7e6b170-b271-4831-a1fa-40c71024c2ed
2012-02-07T08:00:00.000+08:00,Eli Lilly Says Cialis Data Met Primary Endpoint,LLY,https://www.benzinga.com/news/12/02/2322593/eli-lilly-says-cialis-data-met-primary-endpoint,Matthew Kennedy,,,,0,0,f87c1087-746c-47dd-be23-dbfd707478c4
2012-02-07T08:00:00.000+08:00,Stocks Going Ex-Dividend the Third Week of February 2012,LLY,https://www.benzinga.com/markets/12/02/2325637/stocks-going-ex-dividend-the-third-week-of-february-2012,Fred Fuld,,,,0,0,87456a55-c75c-47e7-aa64-19370087bc44
2012-02-07T08:00:00.000+08:00,New Study Evaluates Cialis in parallel with Tamsulosin in Men with Signs and Symptoms Suggestive of Benign Prostatic Hyperplasia,LLY,https://www.benzinga.com/news/12/02/2322652/new-study-evaluates-cialis-in-parallel-with-tamsulosin-in-men-with-signs-and-symp,Eddie Staley,,,,0,0,242f31b7-feda-4d30-8bbe-e72589e6e683
2012-02-07T08:00:00.000+08:00,Eli Lilly Says Cialis Data Met Primary Endpoint,LLY,https://www.benzinga.com/news/12/02/2322593/eli-lilly-says-cialis-data-met-primary-endpoint,Matthew Kennedy,,,,0,0,74283e7f-57ef-49fe-94f2-cc0d1838464e
2012-02-02T08:00:00.000+08:00,Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/02/2313085/amylin-pharmaceuticals-continues-to-soar-in-wake-of-bydureon-,Scott Rubin,,,,0,0,6946858d-0402-4bf8-aaf6-f740856757ef
2012-02-02T08:00:00.000+08:00,Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval,LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/02/2313085/amylin-pharmaceuticals-continues-to-soar-in-wake-of-bydureon-,Scott Rubin,,,,0,0,a32e2474-f0cc-492a-bc42-76a89b94e61d
2012-01-31T08:00:00.000+08:00,Earnings Roundup,LLY,https://www.benzinga.com/news/earnings/12/01/2302855/earnings-roundup,Lisa Levin,,,,0,0,ead9f2ee-b423-49bb-9df2-450f4d7fc6ae
2012-01-31T08:00:00.000+08:00,FDA Approves Lilly & Co's Jentadueto Tablets,LLY,https://www.benzinga.com/news/12/01/2302679/fda-approves-lilly-cos-jentadueto-tablets,Matthew Kennedy,,,,0,0,213e4e2b-9430-4e98-920b-7f7615e330f6
2012-01-31T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for January 31, 2012",LLY,https://www.benzinga.com/news/earnings/12/01/2302337/financial-breakfast-morning-news-summary-for-january-31-2012,Allie Wickman,,,,0,0,15e829db-44e5-4b29-94f3-a7f681923e63
2012-01-31T08:00:00.000+08:00,UPDATE: Eli Lilly Reports 27% Decline In Q4 Profit,LLY,https://www.benzinga.com/news/earnings/12/01/2302160/update-eli-lilly-reports-27-decline-in-q4-profit,Monica Gerson,,,,0,0,25170517-296b-4d9e-a14e-c6b224752df3
2012-01-31T08:00:00.000+08:00,From Earlier: FDA Approves Lilly's Jentadueto Tablets for the Treatment of Adult Patients with Type 2 Diabetes,LLY,https://www.benzinga.com/news/12/01/2302063/from-earlier-fda-approves-lillys-jentadueto-tablets-for-the-treatment-of-adult-pa,Eddie Staley,,,,0,0,9c046780-a3ea-4291-9437-88b7e7712761
2012-01-31T08:00:00.000+08:00,Eli Lilly & Reports Q4 EPS $0.87 vs $0.81 Est; Revenues $6.05B vs $5.90B Est,LLY,https://www.benzinga.com/news/earnings/12/01/2302017/eli-lilly-reports-q4-eps-0-87-vs-0-81-est-revenues-6-05b-vs-5-90b-est,Allie Wickman,,,,0,0,954511cf-342d-41dd-b4ef-2d0761d0e533
2012-01-31T08:00:00.000+08:00,US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/12/01/2301996/us-stock-futures-signal-higher-start-on-wall-street,Monica Gerson,,,,0,0,b8b99f6b-4e2c-4f3e-8cbc-f24578b7eb07
2012-01-31T08:00:00.000+08:00,Earnings Scheduled For January 31,LLY,https://www.benzinga.com/news/earnings/12/01/2301396/earnings-scheduled-for-january-31,Monica Gerson,,,,0,0,56d7c880-cc35-41f6-948f-489df31d0355
2012-01-31T08:00:00.000+08:00,Earnings Roundup,LLY,https://www.benzinga.com/news/earnings/12/01/2302855/earnings-roundup,Lisa Levin,,,,0,0,12069d75-31e8-4deb-8165-0d4ecf1e78cf
2012-01-31T08:00:00.000+08:00,FDA Approves Lilly & Co's Jentadueto Tablets,LLY,https://www.benzinga.com/news/12/01/2302679/fda-approves-lilly-cos-jentadueto-tablets,Matthew Kennedy,,,,0,0,ea92047d-05d6-4ede-a779-ca2c07df06b6
2012-01-31T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for January 31, 2012",LLY,https://www.benzinga.com/news/earnings/12/01/2302337/financial-breakfast-morning-news-summary-for-january-31-2012,Allie Wickman,,,,0,0,f22c33d8-fb4c-4e12-a02e-99aac000bcd1
2012-01-31T08:00:00.000+08:00,UPDATE: Eli Lilly Reports 27% Decline In Q4 Profit,LLY,https://www.benzinga.com/news/earnings/12/01/2302160/update-eli-lilly-reports-27-decline-in-q4-profit,Monica Gerson,,,,0,0,c22ba776-349d-483a-abea-886d7021e482
2012-01-31T08:00:00.000+08:00,From Earlier: FDA Approves Lilly's Jentadueto Tablets for the Treatment of Adult Patients with Type 2 Diabetes,LLY,https://www.benzinga.com/news/12/01/2302063/from-earlier-fda-approves-lillys-jentadueto-tablets-for-the-treatment-of-adult-pa,Eddie Staley,,,,0,0,d4c6d6d4-4bc3-43c3-b4ca-88c05d7e0ce1
2012-01-31T08:00:00.000+08:00,Eli Lilly & Reports Q4 EPS $0.87 vs $0.81 Est; Revenues $6.05B vs $5.90B Est,LLY,https://www.benzinga.com/news/earnings/12/01/2302017/eli-lilly-reports-q4-eps-0-87-vs-0-81-est-revenues-6-05b-vs-5-90b-est,Allie Wickman,,,,0,0,ca1aa75f-eb4d-4278-9049-f04479068b34
2012-01-31T08:00:00.000+08:00,US Stock Futures Signal Higher Start On Wall Street,LLY,https://www.benzinga.com/news/12/01/2301996/us-stock-futures-signal-higher-start-on-wall-street,Monica Gerson,,,,0,0,438b4c9c-a87f-41cb-b286-3454ff0f58a0
2012-01-31T08:00:00.000+08:00,Earnings Scheduled For January 31,LLY,https://www.benzinga.com/news/earnings/12/01/2301396/earnings-scheduled-for-january-31,Monica Gerson,,,,0,0,a3971b3b-bdc0-4e68-b766-55bcaf43b56d
2012-01-29T08:00:00.000+08:00,Earnings Expectations for the Week of January 30,LLY,https://www.benzinga.com/news/earnings/12/01/2297577/earnings-expectations-for-the-week-of-january-30,Nelson Hem,,,,0,0,81ed52d4-2f1f-43b2-9612-53746fca2da1
2012-01-29T08:00:00.000+08:00,Earnings Expectations for the Week of January 30,LLY,https://www.benzinga.com/news/earnings/12/01/2297577/earnings-expectations-for-the-week-of-january-30,Nelson Hem,,,,0,0,a9a9e748-8f4f-454f-a3a6-36a71981bc01
2012-01-24T08:00:00.000+08:00,Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp; Terms Not Disclosed,LLY,https://www.benzinga.com/news/12/01/2285216/elanco-animal-health-announces-lillys-agreement-to-acquire-chemgen-corp-terms-not,Eddie Staley,,,,0,0,56a20c6f-1f6c-4002-9090-6666f42885dd
2012-01-24T08:00:00.000+08:00,Elanco Animal Health Announces Lilly's Agreement to Acquire ChemGen Corp; Terms Not Disclosed,LLY,https://www.benzinga.com/news/12/01/2285216/elanco-animal-health-announces-lillys-agreement-to-acquire-chemgen-corp-terms-not,Eddie Staley,,,,0,0,bb518d88-6eb9-4f37-9e6e-aaf56b5b05a9
2012-01-17T08:00:00.000+08:00,"Benzinga's M&A Chatter for Tuesday January 17, 2012",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2269076/benzingas-m-a-chatter-for-tuesday-january-17-2012,Charles Gross,,,,0,0,1fe0b318-122c-4b1c-be1b-d137f1cf3a8a
2012-01-17T08:00:00.000+08:00,"UPDATE: Deutsche Bank Raises PT to $40, Maintains Hold on Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/01/2266699/update-deutsche-bank-raises-pt-to-40-maintains-hold-on-el,David Johnson,,,,0,0,f8b58a1b-d104-43f3-8b42-af4e9507fe61
2012-01-17T08:00:00.000+08:00,"Benzinga's M&A Chatter for Tuesday January 17, 2012",LLY,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2269076/benzingas-m-a-chatter-for-tuesday-january-17-2012,Charles Gross,,,,0,0,2d36e7de-75df-4ede-b1df-ba5299ac18de
2012-01-17T08:00:00.000+08:00,"UPDATE: Deutsche Bank Raises PT to $40, Maintains Hold on Eli Lilly",LLY,https://www.benzinga.com/analyst-ratings/price-target/12/01/2266699/update-deutsche-bank-raises-pt-to-40-maintains-hold-on-el,David Johnson,,,,0,0,e7664c0c-0bf7-4e45-94f2-31ee8f2fc3c1
2012-01-10T08:00:00.000+08:00,ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline,LLY,https://www.benzinga.com/news/12/01/2252048/shangpharma-announces-opening-of-new-facility-to-support-lillys-pipeline,Eddie Staley,,,,0,0,ac20d4a2-f70d-47f1-8deb-fc4f9592d193
2012-01-10T08:00:00.000+08:00,ShangPharma Announces Opening of New Facility to Support Lilly's Pipeline,LLY,https://www.benzinga.com/news/12/01/2252048/shangpharma-announces-opening-of-new-facility-to-support-lillys-pipeline,Eddie Staley,,,,0,0,d5947714-733f-4c32-8e8d-ffada682376b
2012-01-05T08:00:00.000+08:00,UPDATE: Eli Lilly Says Decline in 2012 Guidance Reflects Zyprexa Patent Expiration,LLY,https://www.benzinga.com/news/12/01/2241544/update-eli-lilly-says-decline-in-2012-guidance-reflects-zyprexa-patent-expiration,Matthew Kennedy,,,,0,0,d4940f6f-1f40-4dec-bb05-2277292a1305
2012-01-05T08:00:00.000+08:00,Eli Lilly Guides 2012 EPS $3.10-3.20 vs $3.67 Est,LLY,https://www.benzinga.com/news/12/01/2241532/eli-lilly-guides-2012-eps-3-10-3-20-vs-3-67-est,Matthew Kennedy,,,,0,0,459ac75d-df9d-44fb-82a9-d4f9629dc5cb
2012-01-05T08:00:00.000+08:00,UPDATE: Eli Lilly Says Decline in 2012 Guidance Reflects Zyprexa Patent Expiration,LLY,https://www.benzinga.com/news/12/01/2241544/update-eli-lilly-says-decline-in-2012-guidance-reflects-zyprexa-patent-expiration,Matthew Kennedy,,,,0,0,62e91c4e-63d9-4a01-a63c-a021dd5b95e2
2012-01-05T08:00:00.000+08:00,Eli Lilly Guides 2012 EPS $3.10-3.20 vs $3.67 Est,LLY,https://www.benzinga.com/news/12/01/2241532/eli-lilly-guides-2012-eps-3-10-3-20-vs-3-67-est,Matthew Kennedy,,,,0,0,5f412400-26cb-4c09-a785-a4f40b8edff6
2012-01-03T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.97,LLY,https://www.benzinga.com/intraday-update/12/01/2236264/eli-lilly-hits-52-week-high-of-41-97,Benzinga Staff,,,,0,0,c4194380-0faf-4b71-9ef4-e233e555b511
2012-01-03T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.97,LLY,https://www.benzinga.com/intraday-update/12/01/2236264/eli-lilly-hits-52-week-high-of-41-97,Benzinga Staff,,,,0,0,4068a1b1-0224-42c2-9a40-6a9db4957ddf
2011-12-30T08:00:00.000+08:00,ETF Showdown: Fun With Pharma,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2233813/etf-showdown-fun-with-pharma,ETF Professor,,,,0,0,56925b43-af63-47ca-b0d1-b19d64a753f2
2011-12-30T08:00:00.000+08:00,ETF Showdown: Fun With Pharma,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2233813/etf-showdown-fun-with-pharma,ETF Professor,,,,0,0,a3088115-46d2-46bb-8d57-61b8ea6194f5
2011-12-27T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.87,LLY,https://www.benzinga.com/intraday-update/11/12/2229518/eli-lilly-hits-52-week-high-of-41-87,Benzinga Staff,,,,0,0,af6d9c82-bff3-4ff5-b286-7ef02fcf87bc
2011-12-27T08:00:00.000+08:00,Best Biotech Stocks of 2011,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2229504/best-biotech-stocks-of-2011,Nelson Hem,,,,0,0,ec18cb38-67e4-44ff-a4e8-c27caca5d78e
2011-12-27T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.87,LLY,https://www.benzinga.com/intraday-update/11/12/2229518/eli-lilly-hits-52-week-high-of-41-87,Benzinga Staff,,,,0,0,229b6267-4c8b-4bc4-b2ed-144871130ba7
2011-12-27T08:00:00.000+08:00,Best Biotech Stocks of 2011,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2229504/best-biotech-stocks-of-2011,Nelson Hem,,,,0,0,63243168-74db-4ca7-9f34-de5a2c15ab1a
2011-12-22T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.85,LLY,https://www.benzinga.com/intraday-update/11/12/2224883/eli-lilly-hits-52-week-high-of-41-85,Benzinga Staff,,,,0,0,4bcd0c48-72ab-46e6-ad43-f535eae8dafa
2011-12-22T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.85,LLY,https://www.benzinga.com/intraday-update/11/12/2224883/eli-lilly-hits-52-week-high-of-41-85,Benzinga Staff,,,,0,0,c40ca866-6109-4b60-8d0a-9a0f999e7efb
2011-12-21T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.44,LLY,https://www.benzinga.com/intraday-update/11/12/2222032/eli-lilly-hits-52-week-high-of-41-44,Benzinga Staff,,,,0,0,08c8dd85-bb79-411a-b35f-2a9c456d3c72
2011-12-21T08:00:00.000+08:00,Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed,LLY,https://www.benzinga.com/news/11/12/2221601/ligand-enters-into-platform-captisol-license-and-supply-agreements-with-lilly-ter,Allie Wickman,,,,0,0,975ff892-c9cc-4ac8-afae-4e8e7f6fa4e4
2011-12-21T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $41.44,LLY,https://www.benzinga.com/intraday-update/11/12/2222032/eli-lilly-hits-52-week-high-of-41-44,Benzinga Staff,,,,0,0,36d90f36-cbc4-4603-8f9a-77b683340450
2011-12-21T08:00:00.000+08:00,Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed,LLY,https://www.benzinga.com/news/11/12/2221601/ligand-enters-into-platform-captisol-license-and-supply-agreements-with-lilly-ter,Allie Wickman,,,,0,0,d1a407a0-9a30-42ec-80d0-7fde01811baf
2011-12-20T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for December 20, 2011",LLY,https://www.benzinga.com/news/earnings/11/12/2218382/financial-breakfast-morning-news-summary-for-december-20-2011,Allie Wickman,,,,0,0,8ea56e43-b5f2-4fc4-9b94-9964c75709a8
2011-12-20T08:00:00.000+08:00,"ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly",LLY,https://www.benzinga.com/news/11/12/2218340/immunogen-inc-announces-antibody-drug-conjugate-collaboration-with-lilly,Allie Wickman,,,,0,0,a9c6de75-1eb3-46ce-8ca4-165af333402b
2011-12-20T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for December 20, 2011",LLY,https://www.benzinga.com/news/earnings/11/12/2218382/financial-breakfast-morning-news-summary-for-december-20-2011,Allie Wickman,,,,0,0,a2ece0fb-3b01-4a7d-8d1f-fb1898415b44
2011-12-20T08:00:00.000+08:00,"ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With Lilly",LLY,https://www.benzinga.com/news/11/12/2218340/immunogen-inc-announces-antibody-drug-conjugate-collaboration-with-lilly,Allie Wickman,,,,0,0,98fc06d1-9280-4272-9574-ebf6a7713f9f
2011-12-15T08:00:00.000+08:00,"Fast Money Picks For December 16th (AET, M, MANT, ETR, COV, LLY, ADBE)",LLY,https://www.benzinga.com/media/cnbc/11/12/2211590/fast-money-picks-for-december-16th-aet-m-mant-etr-cov-lly-adbe,Craig Jones,,,,0,0,83535e4c-4cad-45f7-9724-3fd8f8ab15d5
2011-12-15T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.49,LLY,https://www.benzinga.com/intraday-update/11/12/2209095/eli-lilly-hits-52-week-high-of-40-49,Benzinga Staff,,,,0,0,6001e4b6-8bd2-4db9-b519-46ec2f1d2629
2011-12-15T08:00:00.000+08:00,"Fast Money Picks For December 16th (AET, M, MANT, ETR, COV, LLY, ADBE)",LLY,https://www.benzinga.com/media/cnbc/11/12/2211590/fast-money-picks-for-december-16th-aet-m-mant-etr-cov-lly-adbe,Craig Jones,,,,0,0,f92a9145-8690-4475-ac15-3c3b5d00b64a
2011-12-15T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.49,LLY,https://www.benzinga.com/intraday-update/11/12/2209095/eli-lilly-hits-52-week-high-of-40-49,Benzinga Staff,,,,0,0,0d35c025-e2cd-4fd3-aaf6-128d9ef360f5
2011-12-14T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.25,LLY,https://www.benzinga.com/intraday-update/11/12/2204887/eli-lilly-hits-52-week-high-of-40-25,Benzinga Staff,,,,0,0,1442e4a6-cd66-4ea0-a923-5cfef0017f3f
2011-12-14T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.25,LLY,https://www.benzinga.com/intraday-update/11/12/2204887/eli-lilly-hits-52-week-high-of-40-25,Benzinga Staff,,,,0,0,7a1539ff-55be-4c12-89d1-eda57bd8837a
2011-12-13T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.13,LLY,https://www.benzinga.com/intraday-update/11/12/2200750/eli-lilly-hits-52-week-high-of-40-13,Benzinga Staff,,,,0,0,d17a6940-f184-4590-9a66-84cdcf1a17f5
2011-12-13T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $40.13,LLY,https://www.benzinga.com/intraday-update/11/12/2200750/eli-lilly-hits-52-week-high-of-40-13,Benzinga Staff,,,,0,0,25b5daa1-a03b-4f8f-8590-9ee30e604953
2011-12-12T08:00:00.000+08:00,Katherine Baicker Elected to Lilly Board of Directors,LLY,https://www.benzinga.com/news/11/12/2197077/katherine-baicker-elected-to-lilly-board-of-directors,Eddie Staley,,,,0,0,2a599523-45a1-48d1-9f01-469404fe23f0
2011-12-12T08:00:00.000+08:00,"From Earlier, Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting",LLY,https://www.benzinga.com/news/11/12/2197071/from-earlier-lilly-oncology-reveals-findings-from-study-of-jak2-inhibitor-for-blo,Allie Wickman,,,,0,0,ef57bc94-b0ef-40a2-859b-5abe97097a03
2011-12-12T08:00:00.000+08:00,Katherine Baicker Elected to Lilly Board of Directors,LLY,https://www.benzinga.com/news/11/12/2197077/katherine-baicker-elected-to-lilly-board-of-directors,Eddie Staley,,,,0,0,cb4fe2cd-eb13-40ee-a165-c4ec4c1bd105
2011-12-12T08:00:00.000+08:00,"From Earlier, Lilly Oncology Reveals Findings From Study of JAK2 Inhibitor for Blood Cancers at ASH Meeting",LLY,https://www.benzinga.com/news/11/12/2197071/from-earlier-lilly-oncology-reveals-findings-from-study-of-jak2-inhibitor-for-blo,Allie Wickman,,,,0,0,823a404b-104c-4eba-b7ff-1db846f8a9e6
2011-12-07T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $39.79,LLY,https://www.benzinga.com/intraday-update/11/12/2183781/eli-lilly-hits-52-week-high-of-39-79,Benzinga Staff,,,,0,0,6e068843-694a-4c4e-989e-cd6218cfede9
2011-12-07T08:00:00.000+08:00,Eli Lilly & Hits 52-Week High of $39.79,LLY,https://www.benzinga.com/intraday-update/11/12/2183781/eli-lilly-hits-52-week-high-of-39-79,Benzinga Staff,,,,0,0,ade9e613-8316-4fb1-b06d-f690c1d2b66e
2011-12-06T08:00:00.000+08:00,"3M, Eli Lily, General Electric Receive Positive Mad Money/Jim Cramer Mention -CNBC",LLY,https://www.benzinga.com/media/cnbc/11/12/2181787/3m-eli-lily-general-electric-receive-positive-mad-moneyjim-cramer-mention-c,Charles Gross,,,,0,0,24a9fa87-6a3f-475c-b311-83d933377b56
2011-12-06T08:00:00.000+08:00,"3M, Eli Lily, General Electric Receive Positive Mad Money/Jim Cramer Mention -CNBC",LLY,https://www.benzinga.com/media/cnbc/11/12/2181787/3m-eli-lily-general-electric-receive-positive-mad-moneyjim-cramer-mention-c,Charles Gross,,,,0,0,39d6a976-f3c6-4db1-89a5-5dd292d0e4dd
2011-12-01T08:00:00.000+08:00,"Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment",LLY,https://www.benzinga.com/news/11/12/2166511/lilly-announces-first-and-only-international-prospective-observational-study-desi,Eddie Staley,,,,0,0,8895c889-243f-41da-bc81-a944f24383a6
2011-12-01T08:00:00.000+08:00,"Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment",LLY,https://www.benzinga.com/news/11/12/2166511/lilly-announces-first-and-only-international-prospective-observational-study-desi,Eddie Staley,,,,0,0,4efe2d84-505b-47d7-bcc3-d3f3bba91de6
2011-11-22T08:00:00.000+08:00,Eli Lilly Spokesperson Says the Company does Not Comment on Rumors; Response to Chatter Lilly is Pursuing Acquisition of Forest Laboratories,LLY,https://www.benzinga.com/news/11/11/2145579/eli-lilly-spokesperson-says-the-company-does-not-comment-on-rumors-response-to-ch,Charles Gross,,,,0,0,d77ff148-6f9c-4ad1-b287-7768d60200e3
2011-11-22T08:00:00.000+08:00,Forest Laboratories Moving Higher; May be Attributed to Takeover Chatter,LLY,https://www.benzinga.com/news/11/11/2145546/forest-laboratories-moving-higher-may-be-attributed-to-takeover-chatter,Charles Gross,,,,0,0,bb4ae2a6-78e2-47a0-9558-3ad426c6cfee
2011-11-22T08:00:00.000+08:00,Eli Lilly Spokesperson Says the Company does Not Comment on Rumors; Response to Chatter Lilly is Pursuing Acquisition of Forest Laboratories,LLY,https://www.benzinga.com/news/11/11/2145579/eli-lilly-spokesperson-says-the-company-does-not-comment-on-rumors-response-to-ch,Charles Gross,,,,0,0,92fecf33-01a7-4de0-82ea-c1a3e958b5f1
2011-11-22T08:00:00.000+08:00,Forest Laboratories Moving Higher; May be Attributed to Takeover Chatter,LLY,https://www.benzinga.com/news/11/11/2145546/forest-laboratories-moving-higher-may-be-attributed-to-takeover-chatter,Charles Gross,,,,0,0,b8353448-a595-4ae4-9c63-7b6a6da0b931
2011-11-16T08:00:00.000+08:00,New Analysis of Data Presented at AHA Regarding Effect of Effient on Cardiovascular Events in STEMI Patients According to Timing of PCI,LLY,https://www.benzinga.com/news/11/11/2135187/new-analysis-of-data-presented-at-aha-regarding-effect-of-effient-on-cardiovascul,Eddie Staley,,,,0,0,60172fd9-e740-4490-9997-18b56edb0117
2011-11-16T08:00:00.000+08:00,Kenexa Announces Partnership With Eli Lilly and Company,LLY,https://www.benzinga.com/news/11/11/2132807/kenexa-announces-partnership-with-eli-lilly-and-company,Eddie Staley,,,,0,0,853f7026-cfa7-47f0-b7c6-fad06c3d00e8
2011-11-16T08:00:00.000+08:00,New Analysis of Data Presented at AHA Regarding Effect of Effient on Cardiovascular Events in STEMI Patients According to Timing of PCI,LLY,https://www.benzinga.com/news/11/11/2135187/new-analysis-of-data-presented-at-aha-regarding-effect-of-effient-on-cardiovascul,Eddie Staley,,,,0,0,1bfdbac5-52b8-4aee-9d31-d3b568c6a8d8
2011-11-16T08:00:00.000+08:00,Kenexa Announces Partnership With Eli Lilly and Company,LLY,https://www.benzinga.com/news/11/11/2132807/kenexa-announces-partnership-with-eli-lilly-and-company,Eddie Staley,,,,0,0,84b5156b-1a62-4290-8c98-a80d131076de
2011-11-10T08:00:00.000+08:00,Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region,LLY,https://www.benzinga.com/news/11/11/2116583/lilly-ceo-lechleiter-outlines-opportunities-for-improved-health-and-economic-grow,Allie Wickman,,,,0,0,811ccbc9-d550-4e44-8300-c7ec21fee028
2011-11-10T08:00:00.000+08:00,Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region,LLY,https://www.benzinga.com/news/11/11/2116583/lilly-ceo-lechleiter-outlines-opportunities-for-improved-health-and-economic-grow,Allie Wickman,,,,0,0,61ca0f90-85c7-4740-898f-bd56bdc5656c
2011-11-08T08:00:00.000+08:00,From Earlier: Amylin to End Diabetes Drug Deal with Lilly,LLY,https://www.benzinga.com/news/11/11/2107467/from-earlier-amylin-to-end-diabetes-drug-deal-with-lilly,Matthew Kennedy,,,,0,0,811012b0-1eb9-4676-a908-a3431cc40c6c
2011-11-08T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/11/2105587/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,c8b71f4c-706f-4340-bdd1-479e9fd6628f
2011-11-08T08:00:00.000+08:00,Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin,LLY,https://www.benzinga.com/news/11/11/2105283/lilly-and-amylin-mutually-agree-to-end-diabetes-alliance-and-transition-exenatide,Eddie Staley,,,,0,0,6d804d0d-39dd-4753-b56d-fe02f0b87d17
2011-11-08T08:00:00.000+08:00,From Earlier: Amylin to End Diabetes Drug Deal with Lilly,LLY,https://www.benzinga.com/news/11/11/2107467/from-earlier-amylin-to-end-diabetes-drug-deal-with-lilly,Matthew Kennedy,,,,0,0,8fe1a7f6-b3cf-4c63-a0b0-19cc70a2f256
2011-11-08T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/11/2105587/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,d3497013-3ced-416a-a828-a76d64ce4de2
2011-11-08T08:00:00.000+08:00,Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin,LLY,https://www.benzinga.com/news/11/11/2105283/lilly-and-amylin-mutually-agree-to-end-diabetes-alliance-and-transition-exenatide,Eddie Staley,,,,0,0,724de0ab-8ace-4638-9766-04ddafe075f2
2011-11-07T08:00:00.000+08:00,Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly's Molecular Imaging Agent,LLY,https://www.benzinga.com/news/11/11/2101884/siemens-petnet-solutions-signs-nationwide-commercial-agreement-to-manufacture-and,Eddie Staley,,,,0,0,004f202f-4823-4363-bb62-ac016f299aa6
2011-11-07T08:00:00.000+08:00,Siemens PETNET Solutions Signs Nationwide Commercial Agreement to Manufacture and Distribute Lilly's Molecular Imaging Agent,LLY,https://www.benzinga.com/news/11/11/2101884/siemens-petnet-solutions-signs-nationwide-commercial-agreement-to-manufacture-and,Eddie Staley,,,,0,0,11a890d4-f64d-4ad0-86f4-0101bb828552
2011-11-03T08:00:00.000+08:00,Fitch Downgrades Eli Lilly's Bank Loan Rating To 'A' From 'A+',LLY,https://www.benzinga.com/news/11/11/2092411/fitch-downgrades-eli-lillys-bank-loan-rating-to-a-from-a,Allie Wickman,,,,0,0,13d4a8a8-63a6-4462-8557-f0329691e081
2011-11-03T08:00:00.000+08:00,Fitch Downgrades Eli Lilly's Bank Loan Rating To 'A' From 'A+',LLY,https://www.benzinga.com/news/11/11/2092411/fitch-downgrades-eli-lillys-bank-loan-rating-to-a-from-a,Allie Wickman,,,,0,0,71e4d243-a9f6-4c6e-ab46-74894bc7288e
2011-10-31T08:00:00.000+08:00,Watch for YM BioSciences' Upcoming Clinical Data Catalyst,LLY,https://www.benzinga.com/general/topics/11/10/2079938/watch-for-ym-biosciences-upcoming-clinical-data-catalyst,M.E. Garza,,,,0,0,ce7efc76-11ba-4f65-87d5-6174a36c8013
2011-10-31T08:00:00.000+08:00,Watch for YM BioSciences' Upcoming Clinical Data Catalyst,LLY,https://www.benzinga.com/general/topics/11/10/2079938/watch-for-ym-biosciences-upcoming-clinical-data-catalyst,M.E. Garza,,,,0,0,58b48797-7eb5-45d2-8bf6-749bd6b35b99
2011-10-28T08:00:00.000+08:00,UPDATE: First Global Upgrades Eli Lilly to Moderate Outperform,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2022356/update-first-global-upgrades-eli-lilly-to-moderate-outpe,Phil Marsh,,,,0,0,9dddf00a-8c07-4872-8210-0a553f3b97b1
2011-10-28T08:00:00.000+08:00,Lilly's ALIMTA Receives EC Approval,LLY,https://www.benzinga.com/news/11/10/2022155/lillys-alimta-receives-ec-approval,Matthew Kennedy,,,,0,0,7a3159a9-78ce-479b-be1c-785c013323c6
2011-10-28T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for October 28, 2011",LLY,https://www.benzinga.com/news/earnings/11/10/2021852/financial-breakfast-morning-news-summary-for-october-28-2011,Allie Wickman,,,,0,0,953761c8-3218-41c2-bc4b-7da9f5a79051
2011-10-28T08:00:00.000+08:00,Eli Lilly Announces ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer,LLY,https://www.benzinga.com/news/11/10/2021722/eli-lilly-announces-alimta-first-chemotherapy-approved-in-europe-as-continuation-,Eddie Staley,,,,0,0,d5489744-7660-4ee3-a482-44b786e39fae
2011-10-28T08:00:00.000+08:00,First Global Upgrades Eli Lilly from Market Perform to Market Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/10/2021589/first-global-upgrades-eli-lilly-from-market-perform-to-market,Joe Young,,,,0,0,c1991880-8223-4063-8a38-2cef66bec466
2011-10-28T08:00:00.000+08:00,UPDATE: First Global Upgrades Eli Lilly to Moderate Outperform,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2022356/update-first-global-upgrades-eli-lilly-to-moderate-outpe,Phil Marsh,,,,0,0,232bdef9-6afc-4bb5-be31-3f8647057245
2011-10-28T08:00:00.000+08:00,Lilly's ALIMTA Receives EC Approval,LLY,https://www.benzinga.com/news/11/10/2022155/lillys-alimta-receives-ec-approval,Matthew Kennedy,,,,0,0,b5fcd5ff-3783-4a82-bc51-418dc2dffcd9
2011-10-28T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for October 28, 2011",LLY,https://www.benzinga.com/news/earnings/11/10/2021852/financial-breakfast-morning-news-summary-for-october-28-2011,Allie Wickman,,,,0,0,329fe49e-c3f2-4206-b9cc-8ac3f990fed6
2011-10-28T08:00:00.000+08:00,Eli Lilly Announces ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer,LLY,https://www.benzinga.com/news/11/10/2021722/eli-lilly-announces-alimta-first-chemotherapy-approved-in-europe-as-continuation-,Eddie Staley,,,,0,0,a7c984b7-4dfb-4d28-a9c2-3c0a87b13f96
2011-10-28T08:00:00.000+08:00,First Global Upgrades Eli Lilly from Market Perform to Market Outperform,LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/10/2021589/first-global-upgrades-eli-lilly-from-market-perform-to-market,Joe Young,,,,0,0,33cfdc17-7b98-487c-87fa-05c95e21faf5
2011-10-25T08:00:00.000+08:00,Lilly Cuts 2011 Financial Guidance Due to Xigris Withdrawal; Expects $3.84-$3.89 vs $4.33 Est and $4.30-$4.35 Prior,LLY,https://www.benzinga.com/news/11/10/2010278/lilly-cuts-2011-financial-guidance-due-to-xigris-withdrawal-expects-3-84-3-89-vs-,Allie Wickman,,,,0,0,9628081e-79ee-40b1-8c2c-d1095b7b4af5
2011-10-25T08:00:00.000+08:00,UPDATE: Lilly Sees Charge $0.75-0.95 Pretax; Reaffirms Forecast Adj EPS 2011,LLY,https://www.benzinga.com/news/11/10/2010277/update-lilly-sees-charge-0-75-0-95-pretax-reaffirms-forecast-adj-eps-2011,Matthew Kennedy,,,,0,0,fbbef948-cd8d-4efe-8db1-1a851c085333
2011-10-25T08:00:00.000+08:00,Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results,LLY,https://www.benzinga.com/news/11/10/2010184/lilly-announces-withdrawal-of-xigris-following-recent-clinical-trial-results,Allie Wickman,,,,0,0,30034680-46dc-4c2d-adde-f9b0fffa1700
2011-10-25T08:00:00.000+08:00,Lilly Cuts 2011 Financial Guidance Due to Xigris Withdrawal; Expects $3.84-$3.89 vs $4.33 Est and $4.30-$4.35 Prior,LLY,https://www.benzinga.com/news/11/10/2010278/lilly-cuts-2011-financial-guidance-due-to-xigris-withdrawal-expects-3-84-3-89-vs-,Allie Wickman,,,,0,0,580dd3ab-2725-4cb0-8425-88487695e906
2011-10-25T08:00:00.000+08:00,UPDATE: Lilly Sees Charge $0.75-0.95 Pretax; Reaffirms Forecast Adj EPS 2011,LLY,https://www.benzinga.com/news/11/10/2010277/update-lilly-sees-charge-0-75-0-95-pretax-reaffirms-forecast-adj-eps-2011,Matthew Kennedy,,,,0,0,463f1183-a25c-4064-8804-7f100a38b36c
2011-10-25T08:00:00.000+08:00,Lilly Announces Withdrawal of Xigris® Following Recent Clinical Trial Results,LLY,https://www.benzinga.com/news/11/10/2010184/lilly-announces-withdrawal-of-xigris-following-recent-clinical-trial-results,Allie Wickman,,,,0,0,01db6188-265b-419f-b71b-09d14fe9d5ea
2011-10-24T08:00:00.000+08:00,"Eli Lilly: FDA Approves First Generic Olanzapine To Treat Schizophrenia, Bipolar Disorder",LLY,https://www.benzinga.com/news/11/10/2008385/eli-lilly-fda-approves-first-generic-olanzapine-to-treat-schizophrenia-bipolar-di,Allie Wickman,,,,0,0,4536dbc5-2adc-453a-8787-19a7e10d7667
2011-10-24T08:00:00.000+08:00,UPDATE: Jefferies Lowers PT on Eli LIlly to $33,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2006785/update-jefferies-lowers-pt-on-eli-lilly-to-33,Phil Marsh,,,,0,0,6074af13-6e5d-494e-bf4d-6e820d97331c
2011-10-24T08:00:00.000+08:00,Jefferies Lowers PT on Eli Lilly to $33,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/10/2006338/jefferies-lowers-pt-on-eli-lilly-to-33,Joe Young,,,,0,0,5ac81a12-845d-47a5-8dd8-b44b5d747783
2011-10-24T08:00:00.000+08:00,"Eli Lilly: FDA Approves First Generic Olanzapine To Treat Schizophrenia, Bipolar Disorder",LLY,https://www.benzinga.com/news/11/10/2008385/eli-lilly-fda-approves-first-generic-olanzapine-to-treat-schizophrenia-bipolar-di,Allie Wickman,,,,0,0,fcf5ac0e-d2ed-4054-8786-029e9eaccc8f
2011-10-24T08:00:00.000+08:00,UPDATE: Jefferies Lowers PT on Eli LIlly to $33,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2006785/update-jefferies-lowers-pt-on-eli-lilly-to-33,Phil Marsh,,,,0,0,06ce42bb-c707-44c8-9b5b-c3917ef49beb
2011-10-24T08:00:00.000+08:00,Jefferies Lowers PT on Eli Lilly to $33,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/10/2006338/jefferies-lowers-pt-on-eli-lilly-to-33,Joe Young,,,,0,0,de6337b2-099b-4514-ba62-36862963484f
2011-10-20T08:00:00.000+08:00,Earnings Roundup,LLY,https://www.benzinga.com/news/earnings/11/10/2000402/earnings-roundup,Lisa Levin,,,,0,0,b98d2e33-27a2-4d22-bc82-c7fbc5b9ce95
2011-10-20T08:00:00.000+08:00,Eli Lilly Sees Zyprexa Expiration to Significantly Hurt Sales,LLY,https://www.benzinga.com/news/earnings/11/10/2000232/eli-lilly-sees-zyprexa-expiration-to-significantly-hurt-sales,Matthew Kennedy,,,,0,0,88d0a18e-5c09-4584-b76d-f56b10ff4cc0
2011-10-20T08:00:00.000+08:00,UPDATE: Eli Lilly Reports Decline In Q3 Net Profit,LLY,https://www.benzinga.com/news/earnings/11/10/2000063/update-eli-lilly-reports-decline-in-q3-net-profit,Lisa Levin,,,,0,0,e6164e19-9153-4e9e-9aba-2330df0cf6d9
2011-10-20T08:00:00.000+08:00,Eli Lilly Reports Q3 EPS $1.13 vs $1.13 Est; Revenues $6.15B vs $6.06B Est,LLY,https://www.benzinga.com/news/earnings/11/10/2000061/eli-lilly-reports-q3-eps-1-13-vs-1-13-est-revenues-6-15b-vs-6-06b-est,Matthew Kennedy,,,,0,0,98ac2ad0-7da3-4f8c-830b-03dc458cfd6e
2011-10-20T08:00:00.000+08:00,Eli Lilly and Company's Profit Falls,LLY,https://www.benzinga.com/news/earnings/11/10/1999660/eli-lilly-and-companys-profit-falls,Benzinga Staff Writer,,,,0,0,65523c18-a2c1-4453-a5c6-83f54b2fe3ab
2011-10-20T08:00:00.000+08:00,Earnings Scheduled For October 20,LLY,https://www.benzinga.com/news/earnings/11/10/1999160/earnings-scheduled-for-october-20,Monica Gerson,,,,0,0,3c054bf4-d0c9-4c6a-b46d-78b54a31fc9e
2011-10-20T08:00:00.000+08:00,Earnings Roundup,LLY,https://www.benzinga.com/news/earnings/11/10/2000402/earnings-roundup,Lisa Levin,,,,0,0,1ad2b079-9f4e-46d3-83ff-a289ea6b2703
2011-10-20T08:00:00.000+08:00,Eli Lilly Sees Zyprexa Expiration to Significantly Hurt Sales,LLY,https://www.benzinga.com/news/earnings/11/10/2000232/eli-lilly-sees-zyprexa-expiration-to-significantly-hurt-sales,Matthew Kennedy,,,,0,0,25ab4c0b-3434-48e9-94ed-10f8c01e5627
2011-10-20T08:00:00.000+08:00,UPDATE: Eli Lilly Reports Decline In Q3 Net Profit,LLY,https://www.benzinga.com/news/earnings/11/10/2000063/update-eli-lilly-reports-decline-in-q3-net-profit,Lisa Levin,,,,0,0,73add187-2049-474a-9a61-3dafb69212b0
2011-10-20T08:00:00.000+08:00,Eli Lilly Reports Q3 EPS $1.13 vs $1.13 Est; Revenues $6.15B vs $6.06B Est,LLY,https://www.benzinga.com/news/earnings/11/10/2000061/eli-lilly-reports-q3-eps-1-13-vs-1-13-est-revenues-6-15b-vs-6-06b-est,Matthew Kennedy,,,,0,0,cbbedaab-f90d-40a7-8fb7-7bd31d4b5833
2011-10-20T08:00:00.000+08:00,Eli Lilly and Company's Profit Falls,LLY,https://www.benzinga.com/news/earnings/11/10/1999660/eli-lilly-and-companys-profit-falls,Benzinga Staff Writer,,,,0,0,efa595a7-daab-422f-be2e-726cda7486a6
2011-10-20T08:00:00.000+08:00,Earnings Scheduled For October 20,LLY,https://www.benzinga.com/news/earnings/11/10/1999160/earnings-scheduled-for-october-20,Monica Gerson,,,,0,0,d06aa84a-3a6a-43da-83da-93e5ae4dc6fb
2011-10-17T08:00:00.000+08:00,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",LLY,https://www.benzinga.com/news/earnings/11/10/1990058/eli-lilly-earnings-preview-analysts-expect-rising-revenue-falling-eps,Benzinga Staff Writer,,,,0,0,b3371b87-ab6a-414d-948e-cbbc3c7cc63d
2011-10-17T08:00:00.000+08:00,"Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS",LLY,https://www.benzinga.com/news/earnings/11/10/1990058/eli-lilly-earnings-preview-analysts-expect-rising-revenue-falling-eps,Benzinga Staff Writer,,,,0,0,3cf9d5a1-1d37-4547-9609-c487cb03682c
2011-10-14T08:00:00.000+08:00,Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/11/10/1985660/top-4-stocks-in-the-drug-manufacturers-major-industry-with-the,Monica Gerson,,,,0,0,a7f8f05b-fcb7-4ae6-a1e8-89354e8ed663
2011-10-14T08:00:00.000+08:00,Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield,LLY,https://www.benzinga.com/trading-ideas/dividends/11/10/1985660/top-4-stocks-in-the-drug-manufacturers-major-industry-with-the,Monica Gerson,,,,0,0,79f9b8e3-1f99-41eb-8820-47867e778eb8
2011-10-12T08:00:00.000+08:00,New Study Shows Cialis Significantly Improved Study Endpoints in Men,LLY,https://www.benzinga.com/news/11/10/1981047/new-study-shows-cialis-significantly-improved-study-endpoints-in-men,Matthew Kennedy,,,,0,0,c4d61ebb-af06-4340-9a12-52f03e4a0d5b
2011-10-12T08:00:00.000+08:00,New Study Shows Cialis Significantly Improved Study Endpoints in Men,LLY,https://www.benzinga.com/news/11/10/1981047/new-study-shows-cialis-significantly-improved-study-endpoints-in-men,Matthew Kennedy,,,,0,0,49cee712-f821-45f2-ac92-4cb4e00d6fa3
2011-10-07T08:00:00.000+08:00,Will Earnings Be a Catalyst?,LLY,https://www.benzinga.com/11/10/1973558/will-earnings-be-a-catalyst,optionsXpress,,,,0,0,3d4bb188-17d8-4016-b51c-6fa86a7ffe02
2011-10-07T08:00:00.000+08:00,Notable Call Options Activity in Eli Lilly,LLY,https://www.benzinga.com/markets/options/11/10/1973347/notable-call-options-activity-in-eli-lilly,Michael J. Zerinskas,,,,0,0,35b573e6-c9ea-41a5-a472-fded63c74ed1
2011-10-07T08:00:00.000+08:00,Resistance 10-07-2011,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/10/1973244/resistance-10-07-2011,optionsXpress,,,,0,0,f286228e-f5fa-489a-be1a-1b906f90fd47
2011-10-07T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for October 7, 2011",LLY,https://www.benzinga.com/news/11/10/1972040/financial-breakfast-morning-news-summary-for-october-7-2011,Allie Wickman,,,,0,0,fe615f6b-ccdb-4340-9f4d-8ca8c63d24fa
2011-10-07T08:00:00.000+08:00,Cialis for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Men With Both Erectile Dysfunction and Signs and Symptoms of BPH,LLY,https://www.benzinga.com/news/11/10/1971917/cialis-for-once-daily-use-now-fda-approved-to-treat-men-with-signs-and-symptoms-o,Eddie Staley,,,,0,0,11bc7f2a-ca2f-453e-b46e-75c5b987bb6b
2011-10-07T08:00:00.000+08:00,Will Earnings Be a Catalyst?,LLY,https://www.benzinga.com/11/10/1973558/will-earnings-be-a-catalyst,optionsXpress,,,,0,0,1792d71e-c018-404f-91be-b0d1e6ca3c34
2011-10-07T08:00:00.000+08:00,Notable Call Options Activity in Eli Lilly,LLY,https://www.benzinga.com/markets/options/11/10/1973347/notable-call-options-activity-in-eli-lilly,Michael J. Zerinskas,,,,0,0,41156ff1-82fb-4345-8ae7-e897ca6df309
2011-10-07T08:00:00.000+08:00,Resistance 10-07-2011,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/10/1973244/resistance-10-07-2011,optionsXpress,,,,0,0,8e51883f-730b-4802-8757-6e0df3d605bd
2011-10-07T08:00:00.000+08:00,"Financial Breakfast: Morning News Summary for October 7, 2011",LLY,https://www.benzinga.com/news/11/10/1972040/financial-breakfast-morning-news-summary-for-october-7-2011,Allie Wickman,,,,0,0,3aca217c-f1f2-4af8-8bb5-203f2c91ff1f
2011-10-07T08:00:00.000+08:00,Cialis for Once Daily Use Now FDA-Approved to Treat Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Men With Both Erectile Dysfunction and Signs and Symptoms of BPH,LLY,https://www.benzinga.com/news/11/10/1971917/cialis-for-once-daily-use-now-fda-approved-to-treat-men-with-signs-and-symptoms-o,Eddie Staley,,,,0,0,84018b9c-a353-451e-976f-35e1e3809341
2011-10-06T08:00:00.000+08:00,Lilly's Cialis is Approved for Treatment of Enlarged Prostates,LLY,https://www.benzinga.com/news/11/10/1971009/lillys-cialis-is-approved-for-treatment-of-enlarged-prostates,Matthew Kennedy,,,,0,0,56f906b0-91ea-4941-87c1-9f48ab49e6d6
2011-10-06T08:00:00.000+08:00,Lilly's Cialis is Approved for Treatment of Enlarged Prostates,LLY,https://www.benzinga.com/news/11/10/1971009/lillys-cialis-is-approved-for-treatment-of-enlarged-prostates,Matthew Kennedy,,,,0,0,f3b5d76e-8bdc-4e6f-a968-a08a0c6299d6
2011-10-05T08:00:00.000+08:00,Lilly CEO Says Not Interested in Pfizer Nutrition Business,LLY,https://www.benzinga.com/news/11/10/1967659/lilly-ceo-says-not-interested-in-pfizer-nutrition-business,Matthew Kennedy,,,,0,0,23a5adf2-e6cf-487b-9ed4-872204a54c49
2011-10-05T08:00:00.000+08:00,Lilly CEO Wants Better Chance to Win Worker Green Cards,LLY,https://www.benzinga.com/news/11/10/1966932/lilly-ceo-wants-better-chance-to-win-worker-green-cards,Matthew Kennedy,,,,0,0,37276a02-259b-449e-9f20-290df5014ce9
2011-10-05T08:00:00.000+08:00,Lilly CEO Says Not Interested in Pfizer Nutrition Business,LLY,https://www.benzinga.com/news/11/10/1967659/lilly-ceo-says-not-interested-in-pfizer-nutrition-business,Matthew Kennedy,,,,0,0,310685a7-2082-4fd0-9aed-6341ddfe3e0a
2011-10-05T08:00:00.000+08:00,Lilly CEO Wants Better Chance to Win Worker Green Cards,LLY,https://www.benzinga.com/news/11/10/1966932/lilly-ceo-wants-better-chance-to-win-worker-green-cards,Matthew Kennedy,,,,0,0,24052a68-83e9-425c-ad6c-fffa16477e23
2011-09-26T08:00:00.000+08:00,Eli Lilly Announces ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients,LLY,https://www.benzinga.com/news/11/09/1944389/eli-lilly-announces-alimta-helped-keep-most-common-form-of-lung-cancer-at-bay-in-,Eddie Staley,,,,0,0,c22baf3d-f584-4c63-bd68-b593bc1a5e52
2011-09-26T08:00:00.000+08:00,ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer,LLY,https://www.benzinga.com/news/11/09/1943232/alimta-receives-positive-opinion-from-chmp-as-continuation-maintenance-therapy-fo,Matthew Kennedy,,,,0,0,9aa18f3e-2e88-4f4b-9b96-77f01e73aba2
2011-09-26T08:00:00.000+08:00,Eli Lilly Announces ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients,LLY,https://www.benzinga.com/news/11/09/1944389/eli-lilly-announces-alimta-helped-keep-most-common-form-of-lung-cancer-at-bay-in-,Eddie Staley,,,,0,0,00d4efde-3d10-4659-8edc-32a0a197d1af
2011-09-26T08:00:00.000+08:00,ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer,LLY,https://www.benzinga.com/news/11/09/1943232/alimta-receives-positive-opinion-from-chmp-as-continuation-maintenance-therapy-fo,Matthew Kennedy,,,,0,0,6ddf041b-b2e7-4585-b613-d0c6332ab74d
2011-09-13T08:00:00.000+08:00,Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases,LLY,https://www.benzinga.com/news/11/09/1914100/lilly-invests-30-million-in-partnership-to-address-non-communicable-diseases,Matthew Kennedy,,,,0,0,981e0cc3-b853-437c-8243-fde23c18da14
2011-09-13T08:00:00.000+08:00,Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases,LLY,https://www.benzinga.com/news/11/09/1914100/lilly-invests-30-million-in-partnership-to-address-non-communicable-diseases,Matthew Kennedy,,,,0,0,610f799d-4bfe-4749-baa4-2b7b134a0c5e
2011-09-12T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/09/1911749/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,58d39c3a-e649-4ab2-87d1-db6bfc8dbc7e
2011-09-12T08:00:00.000+08:00,"Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors",LLY,https://www.benzinga.com/news/11/09/1911646/amylin-pharmaceuticals-eli-lilly-and-alkermes-announce-analyses-find-type-2-diabe,Eddie Staley,,,,0,0,a8736828-55da-4187-bc21-15dffc349fa7
2011-09-12T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/09/1911749/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,82e909bd-5667-4f60-8994-eebc6a272808
2011-09-12T08:00:00.000+08:00,"Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors",LLY,https://www.benzinga.com/news/11/09/1911646/amylin-pharmaceuticals-eli-lilly-and-alkermes-announce-analyses-find-type-2-diabe,Eddie Staley,,,,0,0,7220cd20-0d4e-4476-8d6b-fb2c152889cc
2011-09-07T08:00:00.000+08:00,Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations,LLY,https://www.benzinga.com/news/11/09/1904416/boehringer-ingelheim-and-lilly-to-feature-type-2-diabetes-research-in-presentatio,Abe Raymond,,,,0,0,391f7db1-e182-4a12-87a4-c941afd03210
2011-09-07T08:00:00.000+08:00,Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations,LLY,https://www.benzinga.com/news/11/09/1904416/boehringer-ingelheim-and-lilly-to-feature-type-2-diabetes-research-in-presentatio,Abe Raymond,,,,0,0,94341f2c-20fe-41fa-8945-c114257bd371
2011-09-01T08:00:00.000+08:00,"Mustafa Nevzat Could Attract Other Suitors, Ultimately Be Sold For About $1B - WSJ",LLY,https://www.benzinga.com/news/11/09/1897134/mustafa-nevzat-could-attract-other-suitors-ultimately-be-sold-for-about-1b-wsj,Allie Wickman,,,,0,0,82304abd-ecf2-4fbe-aad0-ca01c6784297
2011-09-01T08:00:00.000+08:00,"Mustafa Nevzat Could Attract Other Suitors, Ultimately Be Sold For About $1B - WSJ",LLY,https://www.benzinga.com/news/11/09/1897134/mustafa-nevzat-could-attract-other-suitors-ultimately-be-sold-for-about-1b-wsj,Allie Wickman,,,,0,0,e0173294-9f4c-4f58-ba1f-ce9dfe106fe8
2011-08-25T08:00:00.000+08:00,Eli Lilly Announces Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes,LLY,https://www.benzinga.com/news/11/08/1884300/eli-lilly-announces-linagliptin-receives-approval-in-europe-for-the-treatment-of-,Eddie Staley,,,,0,0,cdd2327d-6ec1-4ee2-bd14-99c0e8f17870
2011-08-25T08:00:00.000+08:00,Eli Lilly Announces Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes,LLY,https://www.benzinga.com/news/11/08/1884300/eli-lilly-announces-linagliptin-receives-approval-in-europe-for-the-treatment-of-,Eddie Staley,,,,0,0,9dbe3699-7e65-49be-8130-6befeb2bbe0c
2011-08-15T08:00:00.000+08:00,Effient Showed Significant 26% Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study,LLY,https://www.benzinga.com/news/11/08/1857293/effient-showed-significant-26-reduction-in-cardiovascular-events-over-clopidogrel,Eddie Staley,,,,0,0,2f356a1a-e529-4390-bea6-7d0dd40bc8d0
2011-08-15T08:00:00.000+08:00,Effient Showed Significant 26% Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study,LLY,https://www.benzinga.com/news/11/08/1857293/effient-showed-significant-26-reduction-in-cardiovascular-events-over-clopidogrel,Eddie Staley,,,,0,0,d0649f72-859c-46ab-8ce2-6f32ff024441
2011-08-10T08:00:00.000+08:00,"Bydureon FDA Action Date Set For January 28, 2012",LLY,https://www.benzinga.com/news/11/08/1849139/bydureon-fda-action-date-set-for-january-28-2012,Allie Wickman,,,,0,0,b75042fa-005b-4097-8808-49320deab5f5
2011-08-10T08:00:00.000+08:00,"Bydureon FDA Action Date Set For January 28, 2012",LLY,https://www.benzinga.com/news/11/08/1849139/bydureon-fda-action-date-set-for-january-28-2012,Allie Wickman,,,,0,0,6bd38bd5-dd1c-4040-9901-dc11e56147d8
2011-08-09T08:00:00.000+08:00,Eli Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion,LLY,https://www.benzinga.com/news/11/08/1844270/eli-lilly-announces-review-of-data-on-long-term-raloxifene-treatment-for-postmeno,Eddie Staley,,,,0,0,09f224fc-ee3c-4a39-870e-e449f75c9255
2011-08-09T08:00:00.000+08:00,Eli Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion,LLY,https://www.benzinga.com/news/11/08/1844270/eli-lilly-announces-review-of-data-on-long-term-raloxifene-treatment-for-postmeno,Eddie Staley,,,,0,0,dc2f9eb3-d5ba-4886-b280-7adff452e0f6
2011-08-01T08:00:00.000+08:00,Leerink Swann Upgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/11/08/1820940/leerink-swann-upgrades-eli-lilly-to-market-perform,BenzingaStaffT,,,,0,0,f9507692-3088-4257-8a0b-3331b76ee1c1
2011-08-01T08:00:00.000+08:00,Leerink Swann Upgrades Eli Lilly to Market Perform,LLY,https://www.benzinga.com/news/11/08/1820940/leerink-swann-upgrades-eli-lilly-to-market-perform,BenzingaStaffT,,,,0,0,61333933-d468-4682-b014-f541f2b5f5e1
2011-07-29T08:00:00.000+08:00,U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent,LLY,https://www.benzinga.com/news/11/07/1817664/u-s-court-of-appeals-affirms-validity-of-lillys-strattera-patent,Eddie Staley,,,,0,0,4c748252-ceb3-4c48-9669-11145207621c
2011-07-29T08:00:00.000+08:00,Bank of America Comments on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1816199/bank-of-america-comments-on-eli-lilly,Lydia Davidson,,,,0,0,95bff5c7-c39b-4026-b364-421af60e4093
2011-07-29T08:00:00.000+08:00,U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent,LLY,https://www.benzinga.com/news/11/07/1817664/u-s-court-of-appeals-affirms-validity-of-lillys-strattera-patent,Eddie Staley,,,,0,0,b289bfe9-3b32-4b62-a263-f5ae1d08899a
2011-07-29T08:00:00.000+08:00,Bank of America Comments on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1816199/bank-of-america-comments-on-eli-lilly,Lydia Davidson,,,,0,0,65391195-a527-43ed-9172-d605f3b7bc0f
2011-07-28T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of August,LLY,https://www.benzinga.com/11/07/1814889/stocks-going-ex-dividend-the-second-week-of-august,Fred Fuld,,,,0,0,9d5608a0-e55c-46b8-9c77-666b29978e33
2011-07-28T08:00:00.000+08:00,BYDUREON™ Reply Submitted to FDA,LLY,https://www.benzinga.com/news/11/07/1811607/bydureon-reply-submitted-to-fda,Allie Wickman,,,,0,0,00d697f3-e89d-4af6-b709-3b5684257157
2011-07-28T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of August,LLY,https://www.benzinga.com/11/07/1814889/stocks-going-ex-dividend-the-second-week-of-august,Fred Fuld,,,,0,0,673bc9e2-e4f1-438f-a99d-c22b86b62dce
2011-07-28T08:00:00.000+08:00,BYDUREON™ Reply Submitted to FDA,LLY,https://www.benzinga.com/news/11/07/1811607/bydureon-reply-submitted-to-fda,Allie Wickman,,,,0,0,efe8a0c3-c297-4217-b0d1-bf6928a29d90
2011-07-27T08:00:00.000+08:00,Hearing Supreme Court Asked to Overturn Obama's Health Care Reform,LLY,https://www.benzinga.com/news/11/07/1809176/hearing-supreme-court-asked-to-overturn-obamas-health-care-reform,Paul Quintaro,,,,0,0,6a4a90d7-ccdf-4fc1-b40c-ce98c731eb35
2011-07-27T08:00:00.000+08:00,Hearing Supreme Court Asked to Overturn Obama's Health Care Reform,LLY,https://www.benzinga.com/news/11/07/1809176/hearing-supreme-court-asked-to-overturn-obamas-health-care-reform,Paul Quintaro,,,,0,0,0e254a75-5007-4847-a12f-8e35aba7bb05
2011-07-22T08:00:00.000+08:00,"EMA Gives Negative Opinion on Ariclaim, Cymbalta, Xeristar Extensions",LLY,https://www.benzinga.com/news/11/07/1792845/ema-gives-negative-opinion-on-ariclaim-cymbalta-xeristar-extensions,Paul Quintaro,,,,0,0,35a16b2b-4078-4fb1-8d18-000c99652bea
2011-07-22T08:00:00.000+08:00,"EMA Gives Negative Opinion on Ariclaim, Cymbalta, Xeristar Extensions",LLY,https://www.benzinga.com/news/11/07/1792845/ema-gives-negative-opinion-on-ariclaim-cymbalta-xeristar-extensions,Paul Quintaro,,,,0,0,47d0343f-8bee-4a53-8195-1c6e4732b27f
2011-07-21T08:00:00.000+08:00,"Deutsche Bank Maintains Eli Lilly Hold, $38.50 PT",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1791044/deutsche-bank-maintains-eli-lilly-hold-38-50-pt,Hilary Farrell,,,,0,0,11862d76-fa38-4309-9ed5-28d6c853848d
2011-07-21T08:00:00.000+08:00,Fifteen Health Care ETFs Trading Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1790212/fifteen-health-care-etfs-trading-near-52-week-highs,Nelson Hem,,,,0,0,43598080-06e4-46e6-9b92-3d2fd56a212b
2011-07-21T08:00:00.000+08:00,Earnings Roundup For July 21,LLY,https://www.benzinga.com/news/earnings/11/07/1788800/earnings-roundup-for-july-21,Monica Gerson,,,,0,0,a972eec3-4ca0-4313-ae1d-cd5a396d4a2c
2011-07-21T08:00:00.000+08:00,"News Summary for July 20, 2011",LLY,https://www.benzinga.com/etfs/commodities/11/07/1787811/news-summary-for-july-20-2011,Allie Wickman,,,,0,0,62d3fc6a-309f-4faf-8f95-3776a1307818
2011-07-21T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/07/1787761/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,ab57d30f-c65d-44a0-af4e-83f5a0e900b6
2011-07-21T08:00:00.000+08:00,"Lilly Sees Year EPS $4.25-4.35, Had Seen $4.15-4.30",LLY,https://www.benzinga.com/news/11/07/1787730/lilly-sees-year-eps-4-25-4-35-had-seen-4-15-4-30,Paul Quintaro,,,,0,0,f14c8631-a6f7-46cb-a34b-44f55467f55c
2011-07-21T08:00:00.000+08:00,UPDATE: Eli Lilly Reports 11% Drop In Q2 Earnings,LLY,https://www.benzinga.com/news/earnings/11/07/1787367/update-eli-lilly-reports-11-drop-in-q2-earnings,Monica Gerson,,,,0,0,fbb97410-94f6-4da0-8a2f-fd5c365e380e
2011-07-21T08:00:00.000+08:00,US Stock Futures Down As Investors Await Earnings Reports,LLY,https://www.benzinga.com/news/11/07/1787175/us-stock-futures-down-as-investors-await-earnings-reports,Monica Gerson,,,,0,0,b985da86-7834-4cea-842b-2b97a0a2d4a8
2011-07-21T08:00:00.000+08:00,Earnings Scheduled For July 21,LLY,https://www.benzinga.com/news/earnings/11/07/1786911/earnings-scheduled-for-july-21,Monica Gerson,,,,0,0,e954d628-9eee-4939-ad65-78741c5605d1
2011-07-21T08:00:00.000+08:00,"Deutsche Bank Maintains Eli Lilly Hold, $38.50 PT",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1791044/deutsche-bank-maintains-eli-lilly-hold-38-50-pt,Hilary Farrell,,,,0,0,13886f5c-7299-44c1-b0fa-633ff6b4cfc8
2011-07-21T08:00:00.000+08:00,Fifteen Health Care ETFs Trading Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1790212/fifteen-health-care-etfs-trading-near-52-week-highs,Nelson Hem,,,,0,0,02764493-fa79-46d9-8159-4a28ef92d874
2011-07-21T08:00:00.000+08:00,Earnings Roundup For July 21,LLY,https://www.benzinga.com/news/earnings/11/07/1788800/earnings-roundup-for-july-21,Monica Gerson,,,,0,0,4d1cdb43-3d29-4424-802e-55e6f4ed363c
2011-07-21T08:00:00.000+08:00,"News Summary for July 20, 2011",LLY,https://www.benzinga.com/etfs/commodities/11/07/1787811/news-summary-for-july-20-2011,Allie Wickman,,,,0,0,aaa7400f-c001-4a51-a606-01ac96418eb1
2011-07-21T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/07/1787761/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,f617c13f-dc58-4db5-92a6-1add3820fb21
2011-07-21T08:00:00.000+08:00,"Lilly Sees Year EPS $4.25-4.35, Had Seen $4.15-4.30",LLY,https://www.benzinga.com/news/11/07/1787730/lilly-sees-year-eps-4-25-4-35-had-seen-4-15-4-30,Paul Quintaro,,,,0,0,88005c32-bae3-4674-8086-43e19c17be68
2011-07-21T08:00:00.000+08:00,UPDATE: Eli Lilly Reports 11% Drop In Q2 Earnings,LLY,https://www.benzinga.com/news/earnings/11/07/1787367/update-eli-lilly-reports-11-drop-in-q2-earnings,Monica Gerson,,,,0,0,ea211c11-361e-44b2-9633-acf048e66c0b
2011-07-21T08:00:00.000+08:00,US Stock Futures Down As Investors Await Earnings Reports,LLY,https://www.benzinga.com/news/11/07/1787175/us-stock-futures-down-as-investors-await-earnings-reports,Monica Gerson,,,,0,0,a1724389-03e5-4aac-ad26-fb7a9f80fe91
2011-07-21T08:00:00.000+08:00,Earnings Scheduled For July 21,LLY,https://www.benzinga.com/news/earnings/11/07/1786911/earnings-scheduled-for-july-21,Monica Gerson,,,,0,0,2a56682f-4393-4d28-859f-2aa4c5f57650
2011-07-18T08:00:00.000+08:00,Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter,LLY,https://www.benzinga.com/11/07/1775111/eli-lilly-earnings-preview-analysts-predict-higher-earnings-over-prior-quarter,Benzinga Staff Writer,,,,0,0,ccfa15ba-b5a4-4a50-bc58-e6e1154bcd9d
2011-07-18T08:00:00.000+08:00,Citi Comments on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1773155/citi-comments-on-eli-lilly,BenzingaStaffT,,,,0,0,1378e49c-5d6c-4da6-98f6-7a3214f4e7d3
2011-07-18T08:00:00.000+08:00,Eli Lilly Announces New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy,LLY,https://www.benzinga.com/news/11/07/1772753/eli-lilly-announces-new-data-showed-minimal-potential-for-drug-interaction-betwee,Eddie Staley,,,,0,0,4c9ad402-ca67-44be-b17d-3c1100b8f209
2011-07-18T08:00:00.000+08:00,Jefferies Raises PT On Eli Lilly To $34,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/07/1772738/jefferies-raises-pt-on-eli-lilly-to-34,Joe Young,,,,0,0,9ef4fada-c146-47f9-b5c2-0d1159692cc5
2011-07-18T08:00:00.000+08:00,Jefferies Raises PT On Eli Lilly To $34,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/07/1772736/jefferies-raises-pt-on-eli-lilluy,Joe Young,,,,0,0,31647030-b4d6-4a12-bda4-0a6f66398009
2011-07-18T08:00:00.000+08:00,Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter,LLY,https://www.benzinga.com/11/07/1775111/eli-lilly-earnings-preview-analysts-predict-higher-earnings-over-prior-quarter,Benzinga Staff Writer,,,,0,0,1a75ea1c-f2dc-4dc7-8a6e-9390d3ea5664
2011-07-18T08:00:00.000+08:00,Citi Comments on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1773155/citi-comments-on-eli-lilly,BenzingaStaffT,,,,0,0,1893356a-4c2b-41c5-842a-e65e7ec7d122
2011-07-18T08:00:00.000+08:00,Eli Lilly Announces New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO and a Common Antiretroviral Therapy,LLY,https://www.benzinga.com/news/11/07/1772753/eli-lilly-announces-new-data-showed-minimal-potential-for-drug-interaction-betwee,Eddie Staley,,,,0,0,b3529dab-1077-4910-b206-68dd2664caa0
2011-07-18T08:00:00.000+08:00,Jefferies Raises PT On Eli Lilly To $34,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/07/1772738/jefferies-raises-pt-on-eli-lilly-to-34,Joe Young,,,,0,0,b0ccd353-26ae-4656-a3bd-7c96f3dd3ea9
2011-07-18T08:00:00.000+08:00,Jefferies Raises PT On Eli Lilly To $34,LLY,https://www.benzinga.com/analyst-ratings/price-target/11/07/1772736/jefferies-raises-pt-on-eli-lilluy,Joe Young,,,,0,0,a3c6386f-7a52-48bb-a745-9b74a010bffe
2011-07-17T08:00:00.000+08:00,Earnings Expectations for the Week of July 18,LLY,https://www.benzinga.com/news/earnings/11/07/1771585/earnings-expectations-for-the-week-of-july-18,Nelson Hem,,,,0,0,e9858130-ae30-4abd-987a-04a400fa8f08
2011-07-17T08:00:00.000+08:00,Earnings Expectations for the Week of July 18,LLY,https://www.benzinga.com/news/earnings/11/07/1771585/earnings-expectations-for-the-week-of-july-18,Nelson Hem,,,,0,0,2cf04e07-4b60-49ab-a713-fd47bdff8b62
2011-07-13T08:00:00.000+08:00,Twelve Health Care ETFs Trading Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1761358/twelve-health-care-etfs-trading-near-52-week-highs,Nelson Hem,,,,0,0,235d7b52-41b3-4dd5-8841-7535ef40f788
2011-07-13T08:00:00.000+08:00,Twelve Health Care ETFs Trading Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1761358/twelve-health-care-etfs-trading-near-52-week-highs,Nelson Hem,,,,0,0,5f2113bc-75f7-40b4-a61a-b9ff1951801e
2011-07-08T08:00:00.000+08:00,Citi Reiterates Hold and PT of $38 on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/reiteration/11/07/1748861/citi-reiterates-hold-and-pt-of-38-on-eli-lilly,Emily Austin,,,,0,0,c6ad26b2-105e-48d1-a088-228c4adba631
2011-07-08T08:00:00.000+08:00,Citi Reiterates Hold and PT of $38 on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/reiteration/11/07/1748861/citi-reiterates-hold-and-pt-of-38-on-eli-lilly,Emily Austin,,,,0,0,4ca3d117-6904-4243-8fc8-8819f5e0f115
2011-07-01T08:00:00.000+08:00,Sideline Money Flows In 07-01-2011,LLY,https://www.benzinga.com/11/07/1221874/sideline-money-flows-in-07-01-2011,optionsXpress,,,,0,0,1b20b701-7206-4408-8a98-9da8f6b8957a
2011-07-01T08:00:00.000+08:00,Wells Fargo Maintains Market Perform on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1220335/wells-fargo-maintains-market-perform-on-eli-lilly,BenzingaStaffJ,,,,0,0,bac171c0-6b9e-4cb6-ae30-65a50338685f
2011-07-01T08:00:00.000+08:00,J.P. Morgan Comments On Eli Lilly Investor Day,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1219784/j-p-morgan-comments-on-eli-lilly-investor-day,BenzingaStaffB,,,,0,0,c5440196-56c0-4bf8-9257-89f8804799cc
2011-07-01T08:00:00.000+08:00,Deutsche Bank Discusses Eli Lilly Investor Meeting,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1219781/deutsche-bank-discusses-eli-lilly-investor-meeting,Jonathan Chen,,,,0,0,56ef3b98-3e49-46ee-b5ec-f6990e88f3c5
2011-07-01T08:00:00.000+08:00,Sideline Money Flows In 07-01-2011,LLY,https://www.benzinga.com/11/07/1221874/sideline-money-flows-in-07-01-2011,optionsXpress,,,,0,0,aee51511-c62f-4b8b-816c-244bcf90f203
2011-07-01T08:00:00.000+08:00,Wells Fargo Maintains Market Perform on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1220335/wells-fargo-maintains-market-perform-on-eli-lilly,BenzingaStaffJ,,,,0,0,e42dae7d-5234-47e1-b5b7-77389cc3ae43
2011-07-01T08:00:00.000+08:00,J.P. Morgan Comments On Eli Lilly Investor Day,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1219784/j-p-morgan-comments-on-eli-lilly-investor-day,BenzingaStaffB,,,,0,0,a66fbd10-5b30-4633-a87a-61ff3c5618f1
2011-07-01T08:00:00.000+08:00,Deutsche Bank Discusses Eli Lilly Investor Meeting,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1219781/deutsche-bank-discusses-eli-lilly-investor-meeting,Jonathan Chen,,,,0,0,5fae1109-80c1-4068-a32a-3164eda9b290
2011-06-29T08:00:00.000+08:00,Citi Maintains Hold Rating On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1211165/citi-maintains-hold-rating-on-eli-lilly,BenzingaStaffB,,,,0,0,4acdfe06-672b-48f0-9c51-af9027e0e902
2011-06-29T08:00:00.000+08:00,Citi Maintains Hold Rating On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1211165/citi-maintains-hold-rating-on-eli-lilly,BenzingaStaffB,,,,0,0,04a34b45-9e0a-4966-9e27-ae0916c7223f
2011-06-28T08:00:00.000+08:00,"Fast Money Picks For June 29th (LULU, XHB, BAC, LLY)",LLY,https://www.benzinga.com/media/cnbc/11/06/1209847/fast-money-picks-for-june-29th-lulu-xhb-bac-lly,Craig Jones,,,,0,0,8eb37b18-cf2b-4787-922e-3a8ed64671b4
2011-06-28T08:00:00.000+08:00,Eli Lilly: Newly Published Study Showed Axiron Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men,LLY,https://www.benzinga.com/news/11/06/1207695/eli-lilly-newly-published-study-showed-axiron-topical-solution-restored-testoster,Allie Wickman,,,,0,0,0a04c488-c903-4606-98e9-401b64694825
2011-06-28T08:00:00.000+08:00,Eli Lilly Announces New Investment to Boost Its Biotechnology Capabilities,LLY,https://www.benzinga.com/news/11/06/1206345/eli-lilly-announces-new-investment-to-boost-its-biotechnology-capabilities,Eddie Staley,,,,0,0,370d0009-c3e9-4892-a93f-cc6e827dd556
2011-06-28T08:00:00.000+08:00,"Fast Money Picks For June 29th (LULU, XHB, BAC, LLY)",LLY,https://www.benzinga.com/media/cnbc/11/06/1209847/fast-money-picks-for-june-29th-lulu-xhb-bac-lly,Craig Jones,,,,0,0,81e27e3f-4dfa-41f4-a97f-f76b8a12a1cc
2011-06-28T08:00:00.000+08:00,Eli Lilly: Newly Published Study Showed Axiron Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men,LLY,https://www.benzinga.com/news/11/06/1207695/eli-lilly-newly-published-study-showed-axiron-topical-solution-restored-testoster,Allie Wickman,,,,0,0,3943d8a7-adbc-454d-a946-e0751d0e0a0a
2011-06-28T08:00:00.000+08:00,Eli Lilly Announces New Investment to Boost Its Biotechnology Capabilities,LLY,https://www.benzinga.com/news/11/06/1206345/eli-lilly-announces-new-investment-to-boost-its-biotechnology-capabilities,Eddie Staley,,,,0,0,70d4bfd0-3c57-4b2c-8ffa-e9cac1016d0c
2011-06-27T08:00:00.000+08:00,Citi Maintains Hold Rating on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/reiteration/11/06/1202059/citi-maintains-hold-rating-on-eli-lilly,BenzingaStaffL,,,,0,0,1131f512-962d-49cd-a714-f7d8e4a05e93
2011-06-27T08:00:00.000+08:00,Jefferies Maintains Buy on Amylin Pharmaceuticals,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1202018/jefferies-maintains-buy-on-amylin-pharmaceuticals,BenzingaStaffJ,,,,0,0,ac2f5ca3-cb76-4011-a6bb-ec448612acd5
2011-06-27T08:00:00.000+08:00,Citi Maintains Hold Rating on Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/reiteration/11/06/1202059/citi-maintains-hold-rating-on-eli-lilly,BenzingaStaffL,,,,0,0,d2a4df23-21d8-4a79-8814-382a89531623
2011-06-27T08:00:00.000+08:00,Jefferies Maintains Buy on Amylin Pharmaceuticals,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1202018/jefferies-maintains-buy-on-amylin-pharmaceuticals,BenzingaStaffJ,,,,0,0,a709a062-a44d-4e07-aaa5-52cd84dfc4ae
2011-06-24T08:00:00.000+08:00,Eli Lilly: Linagliptin Recommended For Approval In The Treatment Of Type 2 Diabetes In Europe,LLY,https://www.benzinga.com/news/11/06/1197748/eli-lilly-linagliptin-recommended-for-approval-in-the-treatment-of-type-2-diabete,Allie Wickman,,,,0,0,7fae05b0-07bf-4946-8f04-a724cb6d2317
2011-06-24T08:00:00.000+08:00,Eli Lilly: Linagliptin Recommended For Approval In The Treatment Of Type 2 Diabetes In Europe,LLY,https://www.benzinga.com/news/11/06/1197748/eli-lilly-linagliptin-recommended-for-approval-in-the-treatment-of-type-2-diabete,Allie Wickman,,,,0,0,bd523611-e754-4bfa-a069-05b33eb28114
2011-06-23T08:00:00.000+08:00,Forest Labs and Watson Pharma to Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1195494/forest-labs-and-watson-pharma-to-open-near-52-week-highs,Nelson Hem,,,,0,0,22ee85bf-358f-4f7c-8b71-d839e75ce8f0
2011-06-23T08:00:00.000+08:00,Deutsche Bank Sees No Catalyst At Eli Lilly Investor Meeting,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1195168/deutsche-bank-sees-no-catalyst-at-eli-lilly-investor-mee,Jonathan Chen,,,,0,0,3311b298-649a-4f25-9c6a-e497c2e882fe
2011-06-23T08:00:00.000+08:00,Forest Labs and Watson Pharma to Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1195494/forest-labs-and-watson-pharma-to-open-near-52-week-highs,Nelson Hem,,,,0,0,b67d6adb-b386-4bf4-b331-00966a26481c
2011-06-23T08:00:00.000+08:00,Deutsche Bank Sees No Catalyst At Eli Lilly Investor Meeting,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1195168/deutsche-bank-sees-no-catalyst-at-eli-lilly-investor-mee,Jonathan Chen,,,,0,0,35325a0a-74e9-406e-99c7-2fd67c6a07dd
2011-06-22T08:00:00.000+08:00,Goldman Sachs Suggests Buying Put Spreads on Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1191905/goldman-sachs-suggests-buying-put-spreads-on-eli-lilly-and-company,Michael J. Zerinskas,,,,0,0,5bf19f59-751b-479a-923e-4f2546bde5a9
2011-06-22T08:00:00.000+08:00,Goldman Sachs Suggests Buying Put Spreads on Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1191905/goldman-sachs-suggests-buying-put-spreads-on-eli-lilly-and-company,Michael J. Zerinskas,,,,0,0,96fa252f-4e6a-4894-b1ab-41c612eab41e
2011-06-21T08:00:00.000+08:00,Colgate and Forest Labs to Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1186875/colgate-and-forest-labs-to-open-near-52-week-highs,Nelson Hem,,,,0,0,ff311acc-a029-4581-851e-b4d77df8ad37
2011-06-21T08:00:00.000+08:00,"News Summary for June 21, 2011",LLY,https://www.benzinga.com/etfs/commodities/11/06/1186746/news-summary-for-june-21-2011,Allie Wickman,,,,0,0,5ab2943b-db71-4f39-a071-a750632cfc19
2011-06-21T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/06/1186469/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,94de3548-2bf4-4e3e-9c18-67822d355413
2011-06-21T08:00:00.000+08:00,Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe,LLY,https://www.benzinga.com/news/11/06/1186219/eli-lilly-and-amylin-pharmaceuticals-announces-bydureon-receives-marketing-author,Benzinga Staff,,,,0,0,e32cb447-b136-4576-8a32-0f7fe801337d
2011-06-21T08:00:00.000+08:00,Colgate and Forest Labs to Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1186875/colgate-and-forest-labs-to-open-near-52-week-highs,Nelson Hem,,,,0,0,d40be36c-4cea-4f76-9ddd-c685b8741b8a
2011-06-21T08:00:00.000+08:00,"News Summary for June 21, 2011",LLY,https://www.benzinga.com/etfs/commodities/11/06/1186746/news-summary-for-june-21-2011,Allie Wickman,,,,0,0,ce608c3b-0b15-48ae-be6e-cf4a49925b0b
2011-06-21T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/06/1186469/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,,,,0,0,2ba50911-e8e0-4406-a292-10d332567bf6
2011-06-21T08:00:00.000+08:00,Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe,LLY,https://www.benzinga.com/news/11/06/1186219/eli-lilly-and-amylin-pharmaceuticals-announces-bydureon-receives-marketing-author,Benzinga Staff,,,,0,0,827a2006-996e-47e1-a6cc-01b0bad7e321
2011-06-20T08:00:00.000+08:00,Lilly Declares Third-Quarter 2011 Dividend of $0.49/Share,LLY,https://www.benzinga.com/news/11/06/1184774/lilly-declares-third-quarter-2011-dividend-of-0-49share,Allie Wickman,,,,0,0,d5586d2f-f77b-4f49-b8bb-a7301c764ab3
2011-06-20T08:00:00.000+08:00,Lilly Declares Third-Quarter 2011 Dividend of $0.49/Share,LLY,https://www.benzinga.com/news/11/06/1184774/lilly-declares-third-quarter-2011-dividend-of-0-49share,Allie Wickman,,,,0,0,c3b09b32-e24e-4ebd-a542-f01981cd35b2
2011-06-15T08:00:00.000+08:00,Options Brief: Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1172064/options-brief-eli-lilly-and-company,Michael J. Zerinskas,,,,0,0,8408a8ae-53fa-4c85-8cdc-cd3587f36aa4
2011-06-15T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly's New Type 2 Diabetes Treatment Tradjenta Tablets for Adults Now Available in U.S. Pharmacies,LLY,https://www.benzinga.com/news/fda/11/06/1170407/boehringer-ingelheim-and-eli-lillys-new-type-2-diabetes-treatment-tradjenta-t,Benzinga Staff,,,,0,0,8d4b0575-a12b-4a86-8312-665a9ea873ef
2011-06-15T08:00:00.000+08:00,Options Brief: Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1172064/options-brief-eli-lilly-and-company,Michael J. Zerinskas,,,,0,0,82cfd78a-4b7e-443e-9c5d-a2ace1a5b322
2011-06-15T08:00:00.000+08:00,Boehringer Ingelheim and Eli Lilly's New Type 2 Diabetes Treatment Tradjenta Tablets for Adults Now Available in U.S. Pharmacies,LLY,https://www.benzinga.com/news/fda/11/06/1170407/boehringer-ingelheim-and-eli-lillys-new-type-2-diabetes-treatment-tradjenta-t,Benzinga Staff,,,,0,0,33c04d55-1b1a-4135-b619-e18d5339f11a
2011-06-10T08:00:00.000+08:00,CIGNA and Forest Laboratories Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1157166/cigna-and-forest-laboratories-open-near-52-week-highs,Nelson Hem,,,,0,0,83e0f59a-83c7-4e92-b852-efcb2b0e228e
2011-06-10T08:00:00.000+08:00,CIGNA and Forest Laboratories Open Near 52-Week Highs,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/06/1157166/cigna-and-forest-laboratories-open-near-52-week-highs,Nelson Hem,,,,0,0,526b1a4d-f6ce-4f23-85b2-739a5a41668d
2011-06-09T08:00:00.000+08:00,Synthes and Eli Lilly Sign Development and Collaboration Agreement,LLY,https://www.benzinga.com/news/contracts/11/06/1154159/synthes-and-eli-lilly-sign-development-and-collaboration-agreement,Benzinga Staff,,,,0,0,0ce15e6a-4b3f-49e6-afc0-bfff036a9a20
2011-06-09T08:00:00.000+08:00,Synthes and Eli Lilly Sign Development and Collaboration Agreement,LLY,https://www.benzinga.com/news/contracts/11/06/1154159/synthes-and-eli-lilly-sign-development-and-collaboration-agreement,Benzinga Staff,,,,0,0,1483c2b9-9da3-427b-9b5c-834b17bade96
2011-06-08T08:00:00.000+08:00,UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order,LLY,https://www.benzinga.com/news/legal/11/06/1151354/update-amylin-pharmaceuticals-issues-statement-regarding-u-s-district-court,Benzinga Staff,,,,0,0,334775c3-1d8f-4454-942f-5c1afb2870c3
2011-06-08T08:00:00.000+08:00,U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation,LLY,https://www.benzinga.com/news/legal/11/06/1151229/u-s-district-court-rules-in-favor-of-eli-lilly-in-amylin-litigation,Benzinga Staff,,,,0,0,3fc558af-468f-46d9-bab7-cffa79188643
2011-06-08T08:00:00.000+08:00,FDA Approves Updates to Lilly's HumalogLabel,LLY,https://www.benzinga.com/news/fda/11/06/1148694/fda-approves-updates-to-lillys-humaloglabel,Benzinga Staff,,,,0,0,56a59337-507e-44ab-8bb3-1d601f61e6ab
2011-06-08T08:00:00.000+08:00,UPDATE: Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order,LLY,https://www.benzinga.com/news/legal/11/06/1151354/update-amylin-pharmaceuticals-issues-statement-regarding-u-s-district-court,Benzinga Staff,,,,0,0,c78838a0-0537-46e5-95da-ce2901a77e08
2011-06-08T08:00:00.000+08:00,U.S. District Court Rules in Favor of Eli Lilly in Amylin Litigation,LLY,https://www.benzinga.com/news/legal/11/06/1151229/u-s-district-court-rules-in-favor-of-eli-lilly-in-amylin-litigation,Benzinga Staff,,,,0,0,112ebd98-ec94-4afe-ba51-af5b7d6bcddb
2011-06-08T08:00:00.000+08:00,FDA Approves Updates to Lilly's HumalogLabel,LLY,https://www.benzinga.com/news/fda/11/06/1148694/fda-approves-updates-to-lillys-humaloglabel,Benzinga Staff,,,,0,0,a7f83732-4c7c-4fbd-bd76-ebf73437f070
2011-06-06T08:00:00.000+08:00,Will Prozac Murder Trial Doom Eli Lilly Stock?,LLY,https://www.benzinga.com/news/global/11/06/1142243/will-prozac-murder-trial-doom-eli-lilly-stock,Luci Morland,,,,0,0,871b2937-fdd4-4c30-944e-79db2de2f2fd
2011-06-06T08:00:00.000+08:00,Will Prozac Murder Trial Doom Eli Lilly Stock?,LLY,https://www.benzinga.com/news/global/11/06/1142243/will-prozac-murder-trial-doom-eli-lilly-stock,Luci Morland,,,,0,0,dd9d3028-d85f-4822-a72e-b379ce5c6732
2011-06-02T08:00:00.000+08:00,Options Brief: Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1132491/options-brief-eli-lilly-and-company,Michael J. Zerinskas,,,,0,0,18361888-96eb-4427-8984-c8123f8304b1
2011-06-02T08:00:00.000+08:00,Options Brief: Eli Lilly and Company,LLY,https://www.benzinga.com/options/11/06/1132491/options-brief-eli-lilly-and-company,Michael J. Zerinskas,,,,0,0,5c8daf9e-2ff8-4bec-bea2-40c553db3cc8
2011-06-01T08:00:00.000+08:00,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",LLY,https://www.benzinga.com/analyst-ratings/11/06/1128490/hapoalim-securities-terminates-healthcare-coverage-including-bristol-m,BenzingaStaffL,,,,0,0,9cdbc608-31b5-45a1-852a-48a0e94f43d0
2011-06-01T08:00:00.000+08:00,Hapoalim Cutting Ocverage On Multitude Of Names,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1128380/hapoalim-cutting-ocverage-on-multitude-of-names,Jonathan Chen,,,,0,0,fc8fa1fd-6bdb-4359-9827-d37b6d96bae6
2011-06-01T08:00:00.000+08:00,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE,LLY,https://www.benzinga.com/markets/11/06/1125693/top-4-large-cap-stocks-in-the-drug-manufacturers-major-industry-with-the-highe,Monica Gerson,,,,0,0,cf1cad8d-0857-4eba-a7ae-5c8caba7cae1
2011-06-01T08:00:00.000+08:00,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",LLY,https://www.benzinga.com/analyst-ratings/11/06/1128490/hapoalim-securities-terminates-healthcare-coverage-including-bristol-m,BenzingaStaffL,,,,0,0,29aa2547-8932-4f9b-94e8-08b4ee44635f
2011-06-01T08:00:00.000+08:00,Hapoalim Cutting Ocverage On Multitude Of Names,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1128380/hapoalim-cutting-ocverage-on-multitude-of-names,Jonathan Chen,,,,0,0,12f86c48-40a2-4d62-a3f2-e84af8dbd836
2011-06-01T08:00:00.000+08:00,Top 4 Large-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest ROE,LLY,https://www.benzinga.com/markets/11/06/1125693/top-4-large-cap-stocks-in-the-drug-manufacturers-major-industry-with-the-highe,Monica Gerson,,,,0,0,04c68f4d-5e27-4b8b-a0bc-c4dd6a2473ee
2011-05-24T08:00:00.000+08:00,Diabetes Device Market to Reach $24 Billion by 2017,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/05/1107925/diabetes-device-market-to-reach-24-billion-by-2017,Allie Wickman,,,,0,0,1a671e4b-10dd-4bf6-b840-773789e42708
2011-05-24T08:00:00.000+08:00,Diabetes Device Market to Reach $24 Billion by 2017,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/05/1107925/diabetes-device-market-to-reach-24-billion-by-2017,Allie Wickman,,,,0,0,23357637-cb1a-401f-a285-5ce60e52b132
2011-05-23T08:00:00.000+08:00,"Eli Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement",LLY,https://www.benzinga.com/news/contracts/11/05/1106075/eli-lilly-and-investor-group-form-new-critical-care-company-biocritica-,Benzinga Staff,,,,0,0,9425bd03-0c95-46fc-9d77-12949458d4a6
2011-05-23T08:00:00.000+08:00,"Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement",LLY,https://www.benzinga.com/news/contracts/11/05/1104830/lilly-and-investor-group-form-new-critical-care-company-biocritica-sign,Allie Wickman,,,,0,0,df49c0f2-e8cf-4a96-9261-32c88e328349
2011-05-23T08:00:00.000+08:00,"Eli Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement",LLY,https://www.benzinga.com/news/contracts/11/05/1106075/eli-lilly-and-investor-group-form-new-critical-care-company-biocritica-,Benzinga Staff,,,,0,0,e5e574b3-0e32-44db-8d79-db3768122425
2011-05-23T08:00:00.000+08:00,"Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement",LLY,https://www.benzinga.com/news/contracts/11/05/1104830/lilly-and-investor-group-form-new-critical-care-company-biocritica-sign,Allie Wickman,,,,0,0,bc13f9a2-1fc1-42c8-97c4-ca6c341f8bb4
2011-05-22T08:00:00.000+08:00,Top Healthcare and Major Drugs stocks to watch- Sector Performance,LLY,https://www.benzinga.com/11/05/1103086/top-healthcare-and-major-drugs-stocks-to-watch-sector-performance,CEO World,,,,0,0,e1696b83-a4a6-4cac-9f9f-d9c97c2aac58
2011-05-22T08:00:00.000+08:00,Top Healthcare and Major Drugs stocks to watch- Sector Performance,LLY,https://www.benzinga.com/11/05/1103086/top-healthcare-and-major-drugs-stocks-to-watch-sector-performance,CEO World,,,,0,0,8126e1ff-51da-4c1b-a47e-1bcd9c1c1a46
2011-05-19T08:00:00.000+08:00,A Mega Cap ETF Joins the First Trust AlphaDEX Lineup,LLY,https://www.benzinga.com/11/05/1098726/a-mega-cap-etf-joins-the-first-trust-alphadex-lineup,Invest With An Edge,,,,0,0,49d5345f-aa53-4f4b-b33b-fff185254d9e
2011-05-19T08:00:00.000+08:00,Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients,LLY,https://www.benzinga.com/news/fda/11/05/1096707/eli-lilly-announces-study-determined-best-dose-and-showed-55-response-rate-wi,Benzinga Staff,,,,0,0,6bc7737d-6b18-4259-82b7-3dca1bd6677a
2011-05-19T08:00:00.000+08:00,ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma,LLY,https://www.benzinga.com/news/fda/11/05/1096701/eli-lilly-presents-data-on-cixutumumab-in-five-subtypes-of-sarcoma,Benzinga Staff,,,,0,0,db5c8515-4394-4dad-a81d-d3b6fb82fb3e
2011-05-19T08:00:00.000+08:00,A Mega Cap ETF Joins the First Trust AlphaDEX Lineup,LLY,https://www.benzinga.com/11/05/1098726/a-mega-cap-etf-joins-the-first-trust-alphadex-lineup,Invest With An Edge,,,,0,0,5f0b058e-bfd9-4230-b0a6-ed3b19b2bd63
2011-05-19T08:00:00.000+08:00,Eli Lilly Announces Study Determined Best Dose and Showed 55% Response Rate With Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients,LLY,https://www.benzinga.com/news/fda/11/05/1096707/eli-lilly-announces-study-determined-best-dose-and-showed-55-response-rate-wi,Benzinga Staff,,,,0,0,f6885304-fb18-4c58-a813-e74fff76f802
2011-05-19T08:00:00.000+08:00,ELi Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma,LLY,https://www.benzinga.com/news/fda/11/05/1096701/eli-lilly-presents-data-on-cixutumumab-in-five-subtypes-of-sarcoma,Benzinga Staff,,,,0,0,7dc978f2-c033-4e66-b60d-f6192f102e20
2011-05-18T08:00:00.000+08:00,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,LLY,https://www.benzinga.com/11/05/1092918/glaxosmithkline-and-isis-pharmaceuticals-partnership-shouldnt-be-overlooked-as-a-long-,CEO World,,,,0,0,063a0c3a-7bad-4bb1-86ae-c1aeecb0e548
2011-05-18T08:00:00.000+08:00,GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term,LLY,https://www.benzinga.com/11/05/1092918/glaxosmithkline-and-isis-pharmaceuticals-partnership-shouldnt-be-overlooked-as-a-long-,CEO World,,,,0,0,ddc45d47-c324-4c6d-ae68-044d465c0c6c
2011-05-16T08:00:00.000+08:00,Eli Lilly Provides Its Perspective in Response to Amylin Lawsuit,LLY,https://www.benzinga.com/news/legal/11/05/1087453/eli-lilly-provides-its-perspective-in-response-to-amylin-lawsuit,Benzinga Staff,,,,0,0,ecfea770-aae0-4efe-aff1-91f9b9d44167
2011-05-16T08:00:00.000+08:00,"Lilly Says Suit Is Without Merit, Will Vigorously Defend Position",LLY,https://www.benzinga.com/news/legal/11/05/1086529/lilly-says-suit-is-without-merit-will-vigorously-defend-position,Theo Kratz,,,,0,0,c652cf52-cc5c-410e-9922-93025761cb56
2011-05-16T08:00:00.000+08:00,Lilly Rejected By U.S. Supreme Court On Gemzar Patent -Bloomberg,LLY,https://www.benzinga.com/news/legal/11/05/1086386/lilly-rejected-by-u-s-supreme-court-on-gemzar-patent-bloomberg,Theo Kratz,,,,0,0,2ee1f110-4566-4f86-a730-95ba4d05ee40
2011-05-16T08:00:00.000+08:00,Lilly Provides Statement in Response to Amylin Lawsuit,LLY,https://www.benzinga.com/news/legal/11/05/1086356/lilly-provides-statement-in-response-to-amylin-lawsuit,Benzinga Staff,,,,0,0,73fcb16d-fffe-4819-9b5b-dde4ee7ff67f
2011-05-16T08:00:00.000+08:00,Bank Of America Raising PT On LLY To $43,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1085632/bank-of-america-raising-pt-on-lly-to-43,BenzingaStaffT,,,,0,0,2277e93a-a297-4ed7-8262-c64aa0d62640
2011-05-16T08:00:00.000+08:00,Amylin Pharmaceuticals Files Suit Against Eli Lilly,LLY,https://www.benzinga.com/news/legal/11/05/1085504/amylin-pharmaceuticals-files-suit-against-eli-lilly,Benzinga Staff,,,,0,0,707a4460-03f4-490d-b4cd-d215e27596ae
2011-05-16T08:00:00.000+08:00,Eli Lilly Provides Its Perspective in Response to Amylin Lawsuit,LLY,https://www.benzinga.com/news/legal/11/05/1087453/eli-lilly-provides-its-perspective-in-response-to-amylin-lawsuit,Benzinga Staff,,,,0,0,a1e04253-e375-4549-a409-241d30a49b8c
2011-05-16T08:00:00.000+08:00,"Lilly Says Suit Is Without Merit, Will Vigorously Defend Position",LLY,https://www.benzinga.com/news/legal/11/05/1086529/lilly-says-suit-is-without-merit-will-vigorously-defend-position,Theo Kratz,,,,0,0,ba8ba440-0386-4a1d-b75c-e988e6ea19ea
2011-05-16T08:00:00.000+08:00,Lilly Rejected By U.S. Supreme Court On Gemzar Patent -Bloomberg,LLY,https://www.benzinga.com/news/legal/11/05/1086386/lilly-rejected-by-u-s-supreme-court-on-gemzar-patent-bloomberg,Theo Kratz,,,,0,0,413356e9-f0a0-4f58-a4ce-78d5a09266d8
2011-05-16T08:00:00.000+08:00,Lilly Provides Statement in Response to Amylin Lawsuit,LLY,https://www.benzinga.com/news/legal/11/05/1086356/lilly-provides-statement-in-response-to-amylin-lawsuit,Benzinga Staff,,,,0,0,def601d1-2b0a-43b7-8184-daac4cbf5540
2011-05-16T08:00:00.000+08:00,Bank Of America Raising PT On LLY To $43,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1085632/bank-of-america-raising-pt-on-lly-to-43,BenzingaStaffT,,,,0,0,8e0cc536-3aa4-4da2-a96e-4df76689908d
2011-05-16T08:00:00.000+08:00,Amylin Pharmaceuticals Files Suit Against Eli Lilly,LLY,https://www.benzinga.com/news/legal/11/05/1085504/amylin-pharmaceuticals-files-suit-against-eli-lilly,Benzinga Staff,,,,0,0,73d18857-348c-4548-9c92-89407833e168
2011-05-12T08:00:00.000+08:00,Going Large: First Trust Introduces Mega-Cap ETF,LLY,https://www.benzinga.com/etfs/broad-u-s-equity-etfs/11/05/1080403/going-large-first-trust-introduces-mega-cap-etf,ETF Professor,,,,0,0,bb58be46-8c48-43c6-93e5-d3b65a9aca55
2011-05-12T08:00:00.000+08:00,Going Large: First Trust Introduces Mega-Cap ETF,LLY,https://www.benzinga.com/etfs/broad-u-s-equity-etfs/11/05/1080403/going-large-first-trust-introduces-mega-cap-etf,ETF Professor,,,,0,0,af4bb4d3-357b-4a39-83c8-35018a59f765
2011-05-10T08:00:00.000+08:00,Using the Euro as a Barometer 05-10-2011,LLY,https://www.benzinga.com/11/05/1072884/using-the-euro-as-a-barometer-05-10-2011,optionsXpress,,,,0,0,13938c49-a488-49d4-918b-05109717f12f
2011-05-10T08:00:00.000+08:00,Using the Euro as a Barometer 05-10-2011,LLY,https://www.benzinga.com/11/05/1072884/using-the-euro-as-a-barometer-05-10-2011,optionsXpress,,,,0,0,334fb437-ca67-4fc5-b96e-011772c2b310
2011-05-03T08:00:00.000+08:00,"Defense, Defense 05-03-2011",LLY,https://www.benzinga.com/11/05/1053661/defense-defense-05-03-2011,optionsXpress,,,,0,0,a0ca5118-00d2-4672-8a05-9dc057a3f923
2011-05-03T08:00:00.000+08:00,"Defense, Defense 05-03-2011",LLY,https://www.benzinga.com/11/05/1053661/defense-defense-05-03-2011,optionsXpress,,,,0,0,ce3f2ca7-5b07-48fc-858c-dbbb7b0e0d7a
2011-05-02T08:00:00.000+08:00,UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY),LLY,https://www.benzinga.com/news/fda/11/05/1049748/update-fda-approves-tradjenta%E2%84%A2-tablets-for-the-treatment-of-type-2-diabetes-l,Theo Kratz,,,,0,0,73660ab6-460c-4e8e-adb3-af46cbb05a0a
2011-05-02T08:00:00.000+08:00,UPDATE: FDA Approves New Treatment for Type 2 Diabetes; Marketed by Eli Lilly,LLY,https://www.benzinga.com/news/fda/11/05/1049361/update-fda-approves-new-treatment-for-type-2-diabetes-marketed-by-eli-lilly,Benzinga Staff,,,,0,0,4124a700-da2b-44b0-b301-965d53ff05d5
2011-05-02T08:00:00.000+08:00,"Lilly, Boehringer Win FDA Approval For Diabetes Drug, Bloomberg (LLY)",LLY,https://www.benzinga.com/news/fda/11/05/1049275/lilly-boehringer-win-fda-approval-for-diabetes-drug-bloomberg-lly,Benzinga Staff,,,,0,0,1588afdf-de93-4123-96d6-5c3b7b35303b
2011-05-02T08:00:00.000+08:00,UPDATE: FDA Approves Tradjenta™ Tablets for the Treatment of Type 2 Diabetes (LLY),LLY,https://www.benzinga.com/news/fda/11/05/1049748/update-fda-approves-tradjenta%E2%84%A2-tablets-for-the-treatment-of-type-2-diabetes-l,Theo Kratz,,,,0,0,24d2cc1a-b9cc-4da4-a1af-4f6ec9ba8c5c
2011-05-02T08:00:00.000+08:00,UPDATE: FDA Approves New Treatment for Type 2 Diabetes; Marketed by Eli Lilly,LLY,https://www.benzinga.com/news/fda/11/05/1049361/update-fda-approves-new-treatment-for-type-2-diabetes-marketed-by-eli-lilly,Benzinga Staff,,,,0,0,5ed56c12-86cc-4a51-acc0-541424937d8b
2011-05-02T08:00:00.000+08:00,"Lilly, Boehringer Win FDA Approval For Diabetes Drug, Bloomberg (LLY)",LLY,https://www.benzinga.com/news/fda/11/05/1049275/lilly-boehringer-win-fda-approval-for-diabetes-drug-bloomberg-lly,Benzinga Staff,,,,0,0,42ca3929-4c47-4409-8f58-dc2c483a4ac0
2011-04-30T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of May,LLY,https://www.benzinga.com/11/04/1046145/stocks-going-ex-dividend-the-second-week-of-may,Fred Fuld,,,,0,0,0595a36f-ad3d-405d-8172-08751e5f9b82
2011-04-30T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of May,LLY,https://www.benzinga.com/11/04/1046145/stocks-going-ex-dividend-the-second-week-of-may,Fred Fuld,,,,0,0,b1a21e88-e79c-4e3d-8531-e1440cce436f
2011-04-29T08:00:00.000+08:00,Lilly In Advanced Talks To Resolve SEC Foreign Bribery Probe -DJ (LLY),LLY,https://www.benzinga.com/news/legal/11/04/1044930/lilly-in-advanced-talks-to-resolve-sec-foreign-bribery-probe-dj-lly,Benzinga Staff,,,,0,0,22aa4963-6e91-4724-82d8-74d6dd5fedd9
2011-04-29T08:00:00.000+08:00,New Treatment For Chronic Low Back Pain Approved by Health Canada (LLY),LLY,https://www.benzinga.com/news/fda/11/04/1044686/new-treatment-for-chronic-low-back-pain-approved-by-health-canada-lly,Theo Kratz,,,,0,0,85a3fb84-2c08-40ae-b3db-f351eddc8b8e
2011-04-29T08:00:00.000+08:00,Lilly In Advanced Talks To Resolve SEC Foreign Bribery Probe -DJ (LLY),LLY,https://www.benzinga.com/news/legal/11/04/1044930/lilly-in-advanced-talks-to-resolve-sec-foreign-bribery-probe-dj-lly,Benzinga Staff,,,,0,0,13e2a205-ac90-4d41-a79f-898becfc7eac
2011-04-29T08:00:00.000+08:00,New Treatment For Chronic Low Back Pain Approved by Health Canada (LLY),LLY,https://www.benzinga.com/news/fda/11/04/1044686/new-treatment-for-chronic-low-back-pain-approved-by-health-canada-lly,Theo Kratz,,,,0,0,ff3199fc-b857-4d1c-9dfd-d95e9d3d3bf9
2011-04-27T08:00:00.000+08:00,U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY),LLY,https://www.benzinga.com/news/legal/11/04/1038056/u-s-district-court-order-maintains-patent-exclusivity-for-lillys-cymbalta-l,Benzinga Staff,,,,0,0,615dc4a9-25cc-4089-9c45-7d212452e17d
2011-04-27T08:00:00.000+08:00,"Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)",LLY,https://www.benzinga.com/markets/11/04/1037789/biotech-pharma-stocks-snapshot-technology-and-medical-devices-on-the-rise-with,Investor Ideas,,,,0,0,f0769728-4afc-4dfa-860b-806fbc8575cc
2011-04-27T08:00:00.000+08:00,U.S. District Court Order Maintains Patent Exclusivity for Lilly's Cymbalta (LLY),LLY,https://www.benzinga.com/news/legal/11/04/1038056/u-s-district-court-order-maintains-patent-exclusivity-for-lillys-cymbalta-l,Benzinga Staff,,,,0,0,3d8baff9-d19b-4e21-89e4-2200c494eb5f
2011-04-27T08:00:00.000+08:00,"Biotech /Pharma Stocks Snapshot; Technology and Medical Devices on the Rise Within Healthcare; Aethlon Medical, ELI Lilly (LLY), Medtronic (MDT), Pfizer (PFE), Apple (AAPL)",LLY,https://www.benzinga.com/markets/11/04/1037789/biotech-pharma-stocks-snapshot-technology-and-medical-devices-on-the-rise-with,Investor Ideas,,,,0,0,9d2027cc-e0db-44ef-91c2-a9696fbf0d80
2011-04-26T08:00:00.000+08:00,Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease,LLY,https://www.benzinga.com/news/11/04/1031961/lilly-and-medtronic-announce-drug-device-collaboration-for-parkinsons-disease,Benzinga Staff,,,,0,0,e9ade7b5-83df-4209-91a8-a52e81908274
2011-04-26T08:00:00.000+08:00,Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease,LLY,https://www.benzinga.com/news/11/04/1031961/lilly-and-medtronic-announce-drug-device-collaboration-for-parkinsons-disease,Benzinga Staff,,,,0,0,dc5d76bd-5cc1-43a9-b44f-90bd57e6abf5
2011-04-20T08:00:00.000+08:00,"Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized",LLY,https://www.benzinga.com/life/politics/11/04/1019527/five-stocks-that-may-end-up-umm-higher-if-marijuana-is-legalized,Gary Cassady,,,,0,0,912328fd-b287-4c90-a476-1fb8309296ae
2011-04-20T08:00:00.000+08:00,"Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized",LLY,https://www.benzinga.com/life/politics/11/04/1019527/five-stocks-that-may-end-up-umm-higher-if-marijuana-is-legalized,Gary Cassady,,,,0,0,2ba43a18-19c2-47e0-900f-b4aac19520ce
2011-04-19T08:00:00.000+08:00,"Hapoalim Upgrades LLY From Hold To Buy, Raises PT To $39",LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/04/1015547/hapoalim-upgrades-lly-from-hold-to-buy-raises-pt-to-39,BenzingaStaffL,,,,0,0,a75299d5-d0a9-4997-8fd6-a56b48d14ada
2011-04-19T08:00:00.000+08:00,Deutsche Bank Maintains Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1014883/deutsche-bank-maintains-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,20e64444-7256-4fde-bff4-27a538cefb71
2011-04-19T08:00:00.000+08:00,"CEOWORLD Daily Business Roundup- BP, GS, GM, RIMM, YHOO, TXN, IBM, YHOO, C, INTC, WMT, AAPL…",LLY,https://www.benzinga.com/11/04/1019160/ceoworld-daily-business-roundup-bp-gs-gm-rimm-yhoo-txn-ibm-yhoo-c-intc-wmt-aapl%E2%80%A6,CEO World,,,,0,0,c1144184-0bd4-4375-8848-34db13386d3e
2011-04-19T08:00:00.000+08:00,"Hapoalim Upgrades LLY From Hold To Buy, Raises PT To $39",LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/04/1015547/hapoalim-upgrades-lly-from-hold-to-buy-raises-pt-to-39,BenzingaStaffL,,,,0,0,a710942e-f146-42ce-8e0e-b15f3027bb30
2011-04-19T08:00:00.000+08:00,Deutsche Bank Maintains Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1014883/deutsche-bank-maintains-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,753083ea-9d5b-4bb1-a67c-7dba45057121
2011-04-19T08:00:00.000+08:00,"CEOWORLD Daily Business Roundup- BP, GS, GM, RIMM, YHOO, TXN, IBM, YHOO, C, INTC, WMT, AAPL…",LLY,https://www.benzinga.com/11/04/1019160/ceoworld-daily-business-roundup-bp-gs-gm-rimm-yhoo-txn-ibm-yhoo-c-intc-wmt-aapl%E2%80%A6,CEO World,,,,0,0,b6adec99-f415-4aa4-a7f0-34327e2dbbeb
2011-04-18T08:00:00.000+08:00,Jefferies Maintains Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1010875/jefferies-maintains-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,7bf895e5-f634-4cd3-a105-5a46d0098c92
2011-04-18T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/markets/futures/11/04/1010216/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,9196aab2-9e56-4780-9363-d553a79345d5
2011-04-18T08:00:00.000+08:00,Eli Lilly Reports Upbeat Q1 Earnings,LLY,https://www.benzinga.com/news/11/04/1010013/eli-lilly-reports-upbeat-q1-earnings,Lisa Levin,,,,0,0,10a4d9fe-99ee-4b68-a8d2-93c4d2626f08
2011-04-18T08:00:00.000+08:00,US Stock Futures Down As Investors Await Citigroup Earnings,LLY,https://www.benzinga.com/markets/futures/11/04/1009937/us-stock-futures-down-as-investors-await-citigroup-earnings,Lisa Levin,,,,0,0,ddbaccaa-6a66-4a88-a1c2-56388758c58a
2011-04-18T08:00:00.000+08:00,Jefferies Maintains Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1010875/jefferies-maintains-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,e8a1aeea-41d7-4519-83eb-e9b8029855c4
2011-04-18T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/markets/futures/11/04/1010216/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,c875edd0-c792-4cde-b759-688b645c4fd1
2011-04-18T08:00:00.000+08:00,Eli Lilly Reports Upbeat Q1 Earnings,LLY,https://www.benzinga.com/news/11/04/1010013/eli-lilly-reports-upbeat-q1-earnings,Lisa Levin,,,,0,0,1caa2d3d-6ee8-4c89-9796-a399217cb314
2011-04-18T08:00:00.000+08:00,US Stock Futures Down As Investors Await Citigroup Earnings,LLY,https://www.benzinga.com/markets/futures/11/04/1009937/us-stock-futures-down-as-investors-await-citigroup-earnings,Lisa Levin,,,,0,0,7ecf32d9-507c-4b56-8d9d-6a255362637c
2011-04-17T08:00:00.000+08:00,"Earnings Scheduled For April 18 (AMTD, TXN, KEY, C, LLY, GCI, HAL, MTB, BRO, AMLN, ZION, CR)",LLY,https://www.benzinga.com/news/earnings/11/04/1009581/earnings-scheduled-for-april-18-amtd-txn-key-c-lly-gci-hal-mtb-bro-amln-,Lisa Levin,,,,0,0,5da71c2a-cef2-4551-8838-fca5c5354d6c
2011-04-17T08:00:00.000+08:00,"Stocks To Watch For April 18 (C, TXN, JNJ, HAL, LLY)",LLY,https://www.benzinga.com/news/11/04/1009576/stocks-to-watch-for-april-18-c-txn-jnj-hal-lly,Lisa Levin,,,,0,0,4d0a75ec-7e10-468a-b7ea-b0134f87ae6c
2011-04-17T08:00:00.000+08:00,Monday's Economic and Earnings Schedule,LLY,https://www.benzinga.com/news/11/04/1009538/mondays-economic-and-earnings-schedule,Nick Smith,,,,0,0,75ddd197-9d0c-472d-b77c-748dc488260b
2011-04-17T08:00:00.000+08:00,"Earnings Scheduled For April 18 (AMTD, TXN, KEY, C, LLY, GCI, HAL, MTB, BRO, AMLN, ZION, CR)",LLY,https://www.benzinga.com/news/earnings/11/04/1009581/earnings-scheduled-for-april-18-amtd-txn-key-c-lly-gci-hal-mtb-bro-amln-,Lisa Levin,,,,0,0,bd19da5d-3012-44bd-8699-3efab25a111c
2011-04-17T08:00:00.000+08:00,"Stocks To Watch For April 18 (C, TXN, JNJ, HAL, LLY)",LLY,https://www.benzinga.com/news/11/04/1009576/stocks-to-watch-for-april-18-c-txn-jnj-hal-lly,Lisa Levin,,,,0,0,aa0435a4-7140-4873-a8d1-853bfc4280b8
2011-04-17T08:00:00.000+08:00,Monday's Economic and Earnings Schedule,LLY,https://www.benzinga.com/news/11/04/1009538/mondays-economic-and-earnings-schedule,Nick Smith,,,,0,0,f6c18726-3e51-418a-ad81-aa2694ef41a0
2011-04-16T08:00:00.000+08:00,"CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO…",LLY,https://www.benzinga.com/11/04/1019162/ceoworld-daily-business-roundup-jnj-chk-amd-t-axp-aapl-intc-jpm-goog-lly-csco%E2%80%A6,CEO World,,,,0,0,b285d271-f959-4fea-a846-618cf0832eed
2011-04-16T08:00:00.000+08:00,"CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO…",LLY,https://www.benzinga.com/11/04/1019162/ceoworld-daily-business-roundup-jnj-chk-amd-t-axp-aapl-intc-jpm-goog-lly-csco%E2%80%A6,CEO World,,,,0,0,539c95a3-c4fe-483c-9771-99ecd9743735
2011-04-15T08:00:00.000+08:00,"Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/04/1007106/top-percentage-gainers-and-losers-as-of-10am-41511-ago-opxa-m,Benjamin Lee,,,,0,0,437a1e11-564a-4f55-8873-3ff469d2e075
2011-04-15T08:00:00.000+08:00,"BYDUREON Recommended For Approval In Europe (LLY, ALKS)",LLY,https://www.benzinga.com/news/11/04/1006905/bydureon-recommended-for-approval-in-europe-lly-alks,Franklin Price,,,,0,0,53276bd1-0cfc-430c-8579-c2a34c51e6f2
2011-04-15T08:00:00.000+08:00,"Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe",LLY,https://www.benzinga.com/news/11/04/1006514/eli-lilly-amylin-pharmaceuticals-and-alkermes-announce-bydureon-recommended-for-a,Benzinga Staff,,,,0,0,f4fd4cda-0854-456a-afff-fe9bf8b87904
2011-04-15T08:00:00.000+08:00,"Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/04/1007106/top-percentage-gainers-and-losers-as-of-10am-41511-ago-opxa-m,Benjamin Lee,,,,0,0,101e4794-c97b-4d13-aeab-e4b644b74588
2011-04-15T08:00:00.000+08:00,"BYDUREON Recommended For Approval In Europe (LLY, ALKS)",LLY,https://www.benzinga.com/news/11/04/1006905/bydureon-recommended-for-approval-in-europe-lly-alks,Franklin Price,,,,0,0,fd9d6144-cc13-40b7-a3ca-aec1defd13b8
2011-04-15T08:00:00.000+08:00,"Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe",LLY,https://www.benzinga.com/news/11/04/1006514/eli-lilly-amylin-pharmaceuticals-and-alkermes-announce-bydureon-recommended-for-a,Benzinga Staff,,,,0,0,51a52261-9533-4769-a6ac-8687f252b195
2011-04-14T08:00:00.000+08:00,Jefferies: LLY Q1 Earnings Could Be Under Pressure,LLY,https://www.benzinga.com/analyst-ratings/11/04/1003652/jefferies-lly-q1-earnings-could-be-under-pressure,BenzingaStaffL,,,,0,0,d78d68be-914d-43c9-a95f-219ddf80418b
2011-04-14T08:00:00.000+08:00,Jefferies: LLY Q1 Earnings Could Be Under Pressure,LLY,https://www.benzinga.com/analyst-ratings/11/04/1003652/jefferies-lly-q1-earnings-could-be-under-pressure,BenzingaStaffL,,,,0,0,dc471e57-456c-4cce-aac9-6135274908a3
2011-04-07T08:00:00.000+08:00,Market Holds Its Ground 04-07-2011,LLY,https://www.benzinga.com/11/04/988099/market-holds-its-ground-04-07-2011,optionsXpress,,,,0,0,e5f245ee-b041-4836-83cb-95f2d1ce396c
2011-04-07T08:00:00.000+08:00,Market Holds Its Ground 04-07-2011,LLY,https://www.benzinga.com/11/04/988099/market-holds-its-ground-04-07-2011,optionsXpress,,,,0,0,f699d663-e340-4a9e-befa-9f1ac61f646b
2011-04-04T08:00:00.000+08:00,Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer,LLY,https://www.benzinga.com/news/11/04/976203/two-novel-lilly-molecules-target-genetic-mutations-that-can-lead-to-cancer,Benzinga Staff,,,,0,0,94edb26d-65c3-4667-838c-cae601f1f4e6
2011-04-04T08:00:00.000+08:00,Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer,LLY,https://www.benzinga.com/news/11/04/976203/two-novel-lilly-molecules-target-genetic-mutations-that-can-lead-to-cancer,Benzinga Staff,,,,0,0,07115aae-7e2a-4483-b90e-798cf7f6a115
2011-04-01T08:00:00.000+08:00,Axiron Topical Solution CIII Now Available in Pharmacies,LLY,https://www.benzinga.com/news/11/04/972011/axiron-topical-solution-ciii-now-available-in-pharmacies,Benzinga Staff,,,,0,0,3aa6ece0-ac87-4fb2-8614-9e91d7a42b22
2011-04-01T08:00:00.000+08:00,Axiron Topical Solution CIII Now Available in Pharmacies,LLY,https://www.benzinga.com/news/11/04/972011/axiron-topical-solution-ciii-now-available-in-pharmacies,Benzinga Staff,,,,0,0,87ef6355-72c0-4125-8f79-ce366cdbeed5
2011-03-29T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Likes Gentex, Micron Technology (AES, CHS, ASNA, BTU, WLT, LLY, LYG, GNTX, MSFT, INTC, CSCO, MU)",LLY,https://www.benzinga.com/media/cnbc/11/03/958281/mad-money-lightning-round-cramer-likes-gentex-micron-technology-aes-chs-asna,Lisa Levin,,,,0,0,9ab114f8-5382-44fe-9d20-24c924f33010
2011-03-29T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Likes Gentex, Micron Technology (AES, CHS, ASNA, BTU, WLT, LLY, LYG, GNTX, MSFT, INTC, CSCO, MU)",LLY,https://www.benzinga.com/media/cnbc/11/03/958281/mad-money-lightning-round-cramer-likes-gentex-micron-technology-aes-chs-asna,Lisa Levin,,,,0,0,2a256a12-be27-4bed-9127-5026cbba29a9
2011-03-18T08:00:00.000+08:00,Lilly and Avid Receive Complete Response Letter from FDA for Amyvid,LLY,https://www.benzinga.com/news/11/03/935436/lilly-and-avid-receive-complete-response-letter-from-fda-for-amyvid,Benzinga Staff,,,,0,0,709c5653-1d86-415f-a396-41fca42de359
2011-03-18T08:00:00.000+08:00,Jefferies Comments On Eli Lilly Strattera Appeal,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/03/935425/jefferies-comments-on-eli-lilly-strattera-appeal,Benzinga Staff,,,,0,0,90ab3757-eddc-4ee8-bbad-2f1cefaef364
2011-03-18T08:00:00.000+08:00,Lilly and Avid Receive Complete Response Letter from FDA for Amyvid,LLY,https://www.benzinga.com/news/11/03/935436/lilly-and-avid-receive-complete-response-letter-from-fda-for-amyvid,Benzinga Staff,,,,0,0,78162fb1-efea-4550-a9f0-b2b7110b4b52
2011-03-18T08:00:00.000+08:00,Jefferies Comments On Eli Lilly Strattera Appeal,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/03/935425/jefferies-comments-on-eli-lilly-strattera-appeal,Benzinga Staff,,,,0,0,00c83d65-3df0-4bfd-aebe-0542efd6dbf8
2011-03-17T08:00:00.000+08:00,Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group,LLY,https://www.benzinga.com/news/11/03/934210/lilly-announces-important-action-regarding-recall-of-alcohol-prep-pads-made-by-tri,Benzinga Staff,,,,0,0,81976c21-dce2-4563-8ebe-1e5a7acc3056
2011-03-17T08:00:00.000+08:00,Lilly Announces Important Action Regarding Recall of Alcohol Prep Pads Made by Triad Group,LLY,https://www.benzinga.com/news/11/03/934210/lilly-announces-important-action-regarding-recall-of-alcohol-prep-pads-made-by-tri,Benzinga Staff,,,,0,0,f7913e40-c62f-44d2-9b56-b4bbd66f20bc
2011-03-15T08:00:00.000+08:00,Citi Maintains Hold Rating On LLY,LLY,https://www.benzinga.com/analyst-ratings/11/03/926646/citi-maintains-hold-rating-on-lly,BenzingaStaffL,,,,0,0,ca1c6626-5bb3-4118-94d1-8d05b8a2b690
2011-03-15T08:00:00.000+08:00,Citi Maintains Hold Rating On LLY,LLY,https://www.benzinga.com/analyst-ratings/11/03/926646/citi-maintains-hold-rating-on-lly,BenzingaStaffL,,,,0,0,917c99ef-b2c5-4bfc-8327-2f3e54efd640
2011-03-14T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/03/922785/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,3cdae2a1-b4f5-41b4-a962-147cd8cab302
2011-03-14T08:00:00.000+08:00,Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health,LLY,https://www.benzinga.com/news/11/03/922669/lilly-makes-an-irrevocable-offer-to-acquire-janssen-animal-health,Benzinga Staff,,,,0,0,df114c64-6a10-4266-8552-ad9ef25fcf45
2011-03-14T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/news/11/03/922785/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,91545508-ec55-4dad-bce6-70e1aa23ee49
2011-03-14T08:00:00.000+08:00,Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health,LLY,https://www.benzinga.com/news/11/03/922669/lilly-makes-an-irrevocable-offer-to-acquire-janssen-animal-health,Benzinga Staff,,,,0,0,2d1efdc7-43ce-44c9-b3cd-2677c609a92f
2011-03-10T08:00:00.000+08:00,Health Insurers Triple S&P 500 Returns,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/03/917642/health-insurers-triple-s-p-500-returns,Minyanville,,,,0,0,675f9b89-fba7-44cd-89bf-912b4fff3eef
2011-03-10T08:00:00.000+08:00,Health Insurers Triple S&P 500 Returns,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/03/917642/health-insurers-triple-s-p-500-returns,Minyanville,,,,0,0,05de6e95-8bb5-493b-870b-b16066061b5a
2011-03-09T08:00:00.000+08:00,"Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/03/915528/stocks-to-watch-when-human-genome-sciences-reopens-after-benly,Jonathan Chen,,,,0,0,7de3ef15-4d24-4c2b-950b-675104526ac2
2011-03-09T08:00:00.000+08:00,"Stocks To Watch When Human Genome Sciences Reopens After Benlysta Approval (HGSI, GSK, LJPC, ANTH, CEPH)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/03/915528/stocks-to-watch-when-human-genome-sciences-reopens-after-benly,Jonathan Chen,,,,0,0,fa5c35f7-f08f-4a43-b2cc-34cbefe1713d
2011-03-08T08:00:00.000+08:00,Citi Comments On LLY 10-K,LLY,https://www.benzinga.com/analyst-ratings/11/03/910658/citi-comments-on-lly-10-k,BenzingaStaffL,,,,0,0,08e79dd8-e61a-4f92-9365-39fb05b63f3a
2011-03-08T08:00:00.000+08:00,Citi Comments On LLY 10-K,LLY,https://www.benzinga.com/analyst-ratings/11/03/910658/citi-comments-on-lly-10-k,BenzingaStaffL,,,,0,0,455af009-a8f3-46fc-b651-0fbd10b54e66
2011-03-03T08:00:00.000+08:00,"Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study",LLY,https://www.benzinga.com/news/11/03/900231/amylin-pharmaceuticals-eli-lilly-and-alkermes-announce-top-line-results-from-durat,Benzinga Staff,,,,0,0,942ade62-b629-4b75-a565-d5009432e3b6
2011-03-03T08:00:00.000+08:00,"Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study",LLY,https://www.benzinga.com/news/11/03/900231/amylin-pharmaceuticals-eli-lilly-and-alkermes-announce-top-line-results-from-durat,Benzinga Staff,,,,0,0,0b7cbc0a-a243-4ba2-9fe3-5e9a9c7e2e9f
2011-02-11T08:00:00.000+08:00,Two ETFs for the Recovery in Big Pharma,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/02/855024/two-etfs-for-the-recovery-in-big-pharma,Charles Lewis Sizemore CFA,,,,0,0,c56d6f48-e38d-4bfc-a634-d7ada2ca9ac3
2011-02-11T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/853373/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,b50cef2b-47bc-454e-bbd8-1d576b9d207e
2011-02-11T08:00:00.000+08:00,Eli Lilly Announces Senior Leadership Changes,LLY,https://www.benzinga.com/news/11/02/853269/eli-lilly-announces-senior-leadership-changes,Benzinga Staff,,,,0,0,efe986ac-858b-4021-b934-efc40dd57c86
2011-02-11T08:00:00.000+08:00,Two ETFs for the Recovery in Big Pharma,LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/02/855024/two-etfs-for-the-recovery-in-big-pharma,Charles Lewis Sizemore CFA,,,,0,0,b1293fbd-08eb-444e-99bc-e0354f8b2ac8
2011-02-11T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/853373/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,206eb332-bbad-494b-b0c1-03f805c77171
2011-02-11T08:00:00.000+08:00,Eli Lilly Announces Senior Leadership Changes,LLY,https://www.benzinga.com/news/11/02/853269/eli-lilly-announces-senior-leadership-changes,Benzinga Staff,,,,0,0,ab303359-8e21-4847-b31f-a1fd106fbe68
2011-02-04T08:00:00.000+08:00,Jefferies Updates Estimates on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/835131/jefferies-updates-estimates-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,bdd76c9a-4a01-4194-aef9-82dcd5bfee08
2011-02-04T08:00:00.000+08:00,Jefferies Updates Estimates on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/835131/jefferies-updates-estimates-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,c8fa8d93-7f67-4abe-b369-d703543f2ffa
2011-02-03T08:00:00.000+08:00,Roche Misses on Tamiflu Decline - Analyst Blog,LLY,https://www.benzinga.com/11/02/831315/roche-misses-on-tamiflu-decline-analyst-blog,Zacks,,,,0,0,508a7b5e-cd02-4b61-a03b-a413fb8345df
2011-02-03T08:00:00.000+08:00,Roche Misses on Tamiflu Decline - Analyst Blog,LLY,https://www.benzinga.com/11/02/831448/roche-misses-on-tamiflu-decline-analyst-blog,webmaster,,,,0,0,e074aca4-a548-4b2a-8f5c-f821feedf069
2011-02-03T08:00:00.000+08:00,Roche Misses on Tamiflu Decline - Analyst Blog,LLY,https://www.benzinga.com/11/02/831315/roche-misses-on-tamiflu-decline-analyst-blog,Zacks,,,,0,0,08f97c10-6c0b-4525-bcd3-fc1af8d409ed
2011-02-03T08:00:00.000+08:00,Roche Misses on Tamiflu Decline - Analyst Blog,LLY,https://www.benzinga.com/11/02/831448/roche-misses-on-tamiflu-decline-analyst-blog,webmaster,,,,0,0,14a825bb-43c9-4886-bbf9-97b788dbbe40
2011-02-02T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of February,LLY,https://www.benzinga.com/11/02/829884/stocks-going-ex-dividend-the-second-week-of-february,Fred Fuld,,,,0,0,09f67ba0-cebd-42a6-a2f7-d772f6482b69
2011-02-02T08:00:00.000+08:00,Hospira Misses; 2011 View Weak - Analyst Blog,LLY,https://www.benzinga.com/11/02/828839/hospira-misses-2011-view-weak-analyst-blog,Zacks,,,,0,0,68e9e5fc-90ea-4971-9bb2-8e2be116977b
2011-02-02T08:00:00.000+08:00,Hospira Misses; 2011 View Weak - Analyst Blog,LLY,https://www.benzinga.com/11/02/828927/hospira-misses-2011-view-weak-analyst-blog,webmaster,,,,0,0,5fd77d20-f6b2-4950-84ad-47d242a0703e
2011-02-02T08:00:00.000+08:00,"Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab",LLY,https://www.benzinga.com/news/11/02/828042/lilly-bristol-myers-squibb-stop-enrollment-in-one-of-two-phase-iii-lung-cancer-tri,Benzinga Staff,,,,0,0,944a20e4-3a26-470a-b421-55c1348c946f
2011-02-02T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of February,LLY,https://www.benzinga.com/11/02/829884/stocks-going-ex-dividend-the-second-week-of-february,Fred Fuld,,,,0,0,f269291b-61b3-4e12-9c9e-3d628450bd40
2011-02-02T08:00:00.000+08:00,Hospira Misses; 2011 View Weak - Analyst Blog,LLY,https://www.benzinga.com/11/02/828839/hospira-misses-2011-view-weak-analyst-blog,Zacks,,,,0,0,2d17cd20-2a45-4558-99f0-6fe8e8dded1d
2011-02-02T08:00:00.000+08:00,Hospira Misses; 2011 View Weak - Analyst Blog,LLY,https://www.benzinga.com/11/02/828927/hospira-misses-2011-view-weak-analyst-blog,webmaster,,,,0,0,fcabf239-9e40-4e3b-b797-c0e3f8fb61aa
2011-02-02T08:00:00.000+08:00,"Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab",LLY,https://www.benzinga.com/news/11/02/828042/lilly-bristol-myers-squibb-stop-enrollment-in-one-of-two-phase-iii-lung-cancer-tri,Benzinga Staff,,,,0,0,c2ba7c4f-e2f6-4f19-a877-1961da081d45
2011-01-31T08:00:00.000+08:00,Earnings Preview: Alkermes - Analyst Blog,LLY,https://www.benzinga.com/11/01/820694/earnings-preview-alkermes-analyst-blog,Zacks,,,,0,0,b106bfd8-8e4a-4d84-8d11-c8e917a8d33e
2011-01-31T08:00:00.000+08:00,Earnings Preview: Alkermes - Analyst Blog,LLY,https://www.benzinga.com/11/01/820709/earnings-preview-alkermes-analyst-blog,webmaster,,,,0,0,68050d22-b954-4072-bbab-f2568822cb0f
2011-01-31T08:00:00.000+08:00,Earnings Preview: Alkermes - Analyst Blog,LLY,https://www.benzinga.com/11/01/820694/earnings-preview-alkermes-analyst-blog,Zacks,,,,0,0,c821b861-d84a-496e-a8e8-1f4282f9235f
2011-01-31T08:00:00.000+08:00,Earnings Preview: Alkermes - Analyst Blog,LLY,https://www.benzinga.com/11/01/820709/earnings-preview-alkermes-analyst-blog,webmaster,,,,0,0,2845c797-dab2-4b09-a79c-35c9055cf4ad
2011-01-28T08:00:00.000+08:00,"Company News for January 28, 2011 - Corporate Summary",LLY,https://www.benzinga.com/11/01/815895/company-news-for-january-28-2011-corporate-summary,Zacks,,,,0,0,07964d24-32c5-4836-b1a4-52733f2c5241
2011-01-28T08:00:00.000+08:00,Hapoalim Reiterates Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/815843/hapoalim-reiterates-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,05055056-3c4d-4576-9b81-b539ce83f0e4
2011-01-28T08:00:00.000+08:00,"Company News for January 28, 2011 - Corporate Summary",LLY,https://www.benzinga.com/11/01/815978/company-news-for-january-28-2011-corporate-summary,webmaster,,,,0,0,2bd722d7-1eb4-484b-a0ae-0507d3f8e3ef
2011-01-28T08:00:00.000+08:00,"Company News for January 28, 2011 - Corporate Summary",LLY,https://www.benzinga.com/11/01/815895/company-news-for-january-28-2011-corporate-summary,Zacks,,,,0,0,a17575d0-ac05-4599-b51b-28bcc897f855
2011-01-28T08:00:00.000+08:00,Hapoalim Reiterates Hold on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/815843/hapoalim-reiterates-hold-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,1478448d-8d7a-45f5-9eed-470659a29672
2011-01-28T08:00:00.000+08:00,"Company News for January 28, 2011 - Corporate Summary",LLY,https://www.benzinga.com/11/01/815978/company-news-for-january-28-2011-corporate-summary,webmaster,,,,0,0,61cba38a-2104-4b52-a46f-29e84771d4a1
2011-01-27T08:00:00.000+08:00,Jefferies Comments on Eli Lilly's FY 2010 Earnings (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/812715/jefferies-comments-on-eli-lillys-fy-2010-earnings-lly,BenzingaStaffJ,,,,0,0,fe3af635-c8f4-4e18-9578-5839f4ef6e17
2011-01-27T08:00:00.000+08:00,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,LLY,https://www.benzinga.com/11/01/812304/eli-lilly-tops-ests-guides-in-line-analyst-blog,Zacks,,,,0,0,c2858db2-b131-43b9-9383-c47f6e2a9293
2011-01-27T08:00:00.000+08:00,Cost Control Helps Amylin Cut Loss - Analyst Blog,LLY,https://www.benzinga.com/11/01/812300/cost-control-helps-amylin-cut-loss-analyst-blog,Zacks,,,,0,0,6e4d1f25-7a4c-4176-b8f4-d73940a0ad29
2011-01-27T08:00:00.000+08:00,Cost Control Helps Amylin Cut Loss - Analyst Blog,LLY,https://www.benzinga.com/11/01/812311/cost-control-helps-amylin-cut-loss-analyst-blog,webmaster,,,,0,0,36e6ed0b-e71d-4616-bebb-bbd72b3643cc
2011-01-27T08:00:00.000+08:00,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,LLY,https://www.benzinga.com/11/01/812315/eli-lilly-tops-ests-guides-in-line-analyst-blog,webmaster,,,,0,0,87bb8af7-9bdf-492a-a2ac-ab087c9e2270
2011-01-27T08:00:00.000+08:00,"Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance",LLY,https://www.benzinga.com/news/11/01/811635/lilly-reports-fourth-quarter-and-full-year-2010-results-provides-2011-financial-gu,Benzinga Staff,,,,0,0,9aab8e37-b531-4358-b3fb-41e300d6623d
2011-01-27T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/811630/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,eca59971-ac4d-4661-a0cc-3c5cfb7c2a42
2011-01-27T08:00:00.000+08:00,Eli Lilly Beats EPS Estimates By 1 Cent (LLY),LLY,https://www.benzinga.com/news/11/01/811344/eli-lilly-beats-eps-estimates-by-1-cent-lly,Daniel Hayden IV,,,,0,0,65444f47-11dd-4a2c-beb6-5796f32faa52
2011-01-27T08:00:00.000+08:00,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)",LLY,https://www.benzinga.com/news/earnings/11/01/810773/earnings-scheduled-for-january-27-cat-msft-pg-t-bmy-lly-amzn-azn-twc-sndk,Lisa Levin,,,,0,0,9fde00b3-ac08-4c86-b823-59a7210c001a
2011-01-27T08:00:00.000+08:00,Jefferies Comments on Eli Lilly's FY 2010 Earnings (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/812715/jefferies-comments-on-eli-lillys-fy-2010-earnings-lly,BenzingaStaffJ,,,,0,0,6d1f4225-e092-4d5d-a019-2623a9c577c5
2011-01-27T08:00:00.000+08:00,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,LLY,https://www.benzinga.com/11/01/812304/eli-lilly-tops-ests-guides-in-line-analyst-blog,Zacks,,,,0,0,e9f35c0f-909b-440b-ad75-1e440cdab153
2011-01-27T08:00:00.000+08:00,Cost Control Helps Amylin Cut Loss - Analyst Blog,LLY,https://www.benzinga.com/11/01/812300/cost-control-helps-amylin-cut-loss-analyst-blog,Zacks,,,,0,0,701569a5-de6a-4513-9e10-4647ecbdcfd3
2011-01-27T08:00:00.000+08:00,Cost Control Helps Amylin Cut Loss - Analyst Blog,LLY,https://www.benzinga.com/11/01/812311/cost-control-helps-amylin-cut-loss-analyst-blog,webmaster,,,,0,0,2580b846-3d5c-4107-8854-9e06407d0d85
2011-01-27T08:00:00.000+08:00,Eli Lilly Tops Ests; Guides In Line - Analyst Blog,LLY,https://www.benzinga.com/11/01/812315/eli-lilly-tops-ests-guides-in-line-analyst-blog,webmaster,,,,0,0,9776c199-52a6-40ff-b10e-442c34f08405
2011-01-27T08:00:00.000+08:00,"Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance",LLY,https://www.benzinga.com/news/11/01/811635/lilly-reports-fourth-quarter-and-full-year-2010-results-provides-2011-financial-gu,Benzinga Staff,,,,0,0,06e0cbcb-6163-4f3c-aa74-7c2def26b958
2011-01-27T08:00:00.000+08:00,A Peek Into The Market Before The Trading Starts,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/811630/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,,,,0,0,86512ceb-0bb9-4145-8d2d-ca979b5bdeef
2011-01-27T08:00:00.000+08:00,Eli Lilly Beats EPS Estimates By 1 Cent (LLY),LLY,https://www.benzinga.com/news/11/01/811344/eli-lilly-beats-eps-estimates-by-1-cent-lly,Daniel Hayden IV,,,,0,0,b9e080cc-19a2-4915-a9ca-14449e52ba56
2011-01-27T08:00:00.000+08:00,"Earnings Scheduled For January 27 (CAT, MSFT, PG, T, BMY, LLY, AMZN, AZN, TWC, SNDK, NOK, CB, JBLU, VRSN, PMCS, CL, MSI, KLAC)",LLY,https://www.benzinga.com/news/earnings/11/01/810773/earnings-scheduled-for-january-27-cat-msft-pg-t-bmy-lly-amzn-azn-twc-sndk,Lisa Levin,,,,0,0,7af484d3-3dc3-4d5f-99d7-d67218d50a6a
2011-01-26T08:00:00.000+08:00,Teva and APP Announce Launch of Generic Gemzar,LLY,https://www.benzinga.com/news/11/01/807844/teva-and-app-announce-launch-of-generic-gemzar,Benzinga Staff,,,,0,0,9a7e6b7b-4339-4afa-b34b-cef8f9ce1d8c
2011-01-26T08:00:00.000+08:00,Teva and APP Announce Launch of Generic Gemzar,LLY,https://www.benzinga.com/news/11/01/807844/teva-and-app-announce-launch-of-generic-gemzar,Benzinga Staff,,,,0,0,f8bd21b2-fb42-4288-bb42-67bad5e1cea2
2011-01-25T08:00:00.000+08:00,Earnings Preview: Eli Lilly - Analyst Blog,LLY,https://www.benzinga.com/11/01/805010/earnings-preview-eli-lilly-analyst-blog,Zacks,,,,0,0,eb41460b-c876-44c0-9f84-cdf6ea1fd940
2011-01-25T08:00:00.000+08:00,Earnings Preview: Eli Lilly - Analyst Blog,LLY,https://www.benzinga.com/11/01/805014/earnings-preview-eli-lilly-analyst-blog,webmaster,,,,0,0,95e44d1a-b893-4e78-960a-2418a202a458
2011-01-25T08:00:00.000+08:00,Earnings Preview: Eli Lilly - Analyst Blog,LLY,https://www.benzinga.com/11/01/805010/earnings-preview-eli-lilly-analyst-blog,Zacks,,,,0,0,4b5af187-bc12-4d7e-b223-ac7d575f995f
2011-01-25T08:00:00.000+08:00,Earnings Preview: Eli Lilly - Analyst Blog,LLY,https://www.benzinga.com/11/01/805014/earnings-preview-eli-lilly-analyst-blog,webmaster,,,,0,0,2232a7f7-f6d2-4a26-8e08-5c14d891b07b
2011-01-24T08:00:00.000+08:00,Citi Increases EPS Estimate on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/Analyst%20Color/11/01/801170/citi-increases-eps-estimate-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,934bd0da-b214-496f-8bcd-0993c32c4601
2011-01-24T08:00:00.000+08:00,Citi Increases EPS Estimate on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/Analyst%20Color/11/01/801170/citi-increases-eps-estimate-on-eli-lilly-lly,BenzingaStaffJ,,,,0,0,d4bfcfc6-8953-4d81-b55a-4856360bb68c
2011-01-21T08:00:00.000+08:00,FDA Panel Reviews Lilly Drug - Analyst Blog,LLY,https://www.benzinga.com/11/01/799127/fda-panel-reviews-lilly-drug-analyst-blog,Zacks,,,,0,0,264e6e76-5930-4aab-9bdd-02948d4300c0
2011-01-21T08:00:00.000+08:00,FDA Panel Reviews Lilly Drug - Analyst Blog,LLY,https://www.benzinga.com/11/01/799214/fda-panel-reviews-lilly-drug-analyst-blog,webmaster,,,,0,0,13c3340f-17c3-4910-8412-9d3fd0879ab0
2011-01-21T08:00:00.000+08:00,FDA Panel Reviews Lilly Drug - Analyst Blog,LLY,https://www.benzinga.com/11/01/799127/fda-panel-reviews-lilly-drug-analyst-blog,Zacks,,,,0,0,1a50abb1-852f-4ead-a08c-e760e947146a
2011-01-21T08:00:00.000+08:00,FDA Panel Reviews Lilly Drug - Analyst Blog,LLY,https://www.benzinga.com/11/01/799214/fda-panel-reviews-lilly-drug-analyst-blog,webmaster,,,,0,0,b18a5e93-bc5c-459e-90c2-dd2c02927166
2011-01-20T08:00:00.000+08:00,Bleeding Risk with MRK's Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/794495/bleeding-risk-with-mrks-candidate-analyst-blog,Zacks,,,,0,0,372e22bf-55e7-49d5-afc4-babe3095caf8
2011-01-20T08:00:00.000+08:00,Bleeding Risk with MRK's Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/794579/bleeding-risk-with-mrks-candidate-analyst-blog,webmaster,,,,0,0,b1388698-f6a7-423f-a2cc-40a430c1e123
2011-01-20T08:00:00.000+08:00,MannKind in Jeopardy - Analyst Blog,LLY,https://www.benzinga.com/11/01/794199/mannkind-in-jeopardy-analyst-blog,Zacks,,,,0,0,e6785ef7-adb8-49fe-96fb-84e92b0fd1d8
2011-01-20T08:00:00.000+08:00,MannKind in Jeopardy - Analyst Blog,LLY,https://www.benzinga.com/11/01/794337/mannkind-in-jeopardy-analyst-blog,webmaster,,,,0,0,8dca515c-a700-4e25-9885-ed97de7273bc
2011-01-20T08:00:00.000+08:00,Bleeding Risk with MRK's Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/794495/bleeding-risk-with-mrks-candidate-analyst-blog,Zacks,,,,0,0,07dfce0a-7283-4ba4-b9b9-e179593b9a7b
2011-01-20T08:00:00.000+08:00,Bleeding Risk with MRK's Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/794579/bleeding-risk-with-mrks-candidate-analyst-blog,webmaster,,,,0,0,156d4be8-d076-4381-a4cb-160d9d188b33
2011-01-20T08:00:00.000+08:00,MannKind in Jeopardy - Analyst Blog,LLY,https://www.benzinga.com/11/01/794199/mannkind-in-jeopardy-analyst-blog,Zacks,,,,0,0,71c9a624-4449-4c69-9e0e-f14af41e18de
2011-01-20T08:00:00.000+08:00,MannKind in Jeopardy - Analyst Blog,LLY,https://www.benzinga.com/11/01/794337/mannkind-in-jeopardy-analyst-blog,webmaster,,,,0,0,cc3e9362-a18f-4b04-bda2-5326d6c65075
2011-01-19T08:00:00.000+08:00,FDA To Review Alzheimer's Brain Scan (LLY),LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/01/789789/fda-to-review-alzheimers-brain-scan-lly,Gary Cassady,,,,0,0,5d767f5b-c3d1-4545-a4b9-7ddc9db22078
2011-01-19T08:00:00.000+08:00,FDA To Review Alzheimer's Brain Scan (LLY),LLY,https://www.benzinga.com/trading-ideas/long-ideas/11/01/789789/fda-to-review-alzheimers-brain-scan-lly,Gary Cassady,,,,0,0,f3466663-5c36-4a90-ac77-9127ca14c3d7
2011-01-17T08:00:00.000+08:00,Community to put Directors in Tenet - Analyst Blog,LLY,https://www.benzinga.com/11/01/784435/community-to-put-directors-in-tenet-analyst-blog,Zacks,,,,0,0,47bf1a0d-3c6d-4609-a35b-f2217d287118
2011-01-17T08:00:00.000+08:00,Community to put Directors in Tenet - Analyst Blog,LLY,https://www.benzinga.com/11/01/784451/community-to-put-directors-in-tenet-analyst-blog,webmaster,,,,0,0,af2055a2-66fd-4179-911e-1743ec6dba39
2011-01-17T08:00:00.000+08:00,Community to put Directors in Tenet - Analyst Blog,LLY,https://www.benzinga.com/11/01/784435/community-to-put-directors-in-tenet-analyst-blog,Zacks,,,,0,0,c9008eb3-d5a8-4bd8-9359-29b60a1f812a
2011-01-17T08:00:00.000+08:00,Community to put Directors in Tenet - Analyst Blog,LLY,https://www.benzinga.com/11/01/784451/community-to-put-directors-in-tenet-analyst-blog,webmaster,,,,0,0,055ff6cd-cbea-4199-84e0-fe97f4482416
2011-01-14T08:00:00.000+08:00,Merck's Blood Thinner in Trouble - Analyst Blog,LLY,https://www.benzinga.com/11/01/781769/mercks-blood-thinner-in-trouble-analyst-blog,Zacks,,,,0,0,48ec3987-303f-418a-8cf7-4a4096871aff
2011-01-14T08:00:00.000+08:00,Merck's Blood Thinner in Trouble - Analyst Blog,LLY,https://www.benzinga.com/11/01/781796/mercks-blood-thinner-in-trouble-analyst-blog,webmaster,,,,0,0,45419733-6ca7-40e9-a7ce-1fa5c8db8ee9
2011-01-14T08:00:00.000+08:00,Merck's Blood Thinner in Trouble - Analyst Blog,LLY,https://www.benzinga.com/11/01/781769/mercks-blood-thinner-in-trouble-analyst-blog,Zacks,,,,0,0,e2208033-510f-49e7-9afe-d48abe946723
2011-01-14T08:00:00.000+08:00,Merck's Blood Thinner in Trouble - Analyst Blog,LLY,https://www.benzinga.com/11/01/781796/mercks-blood-thinner-in-trouble-analyst-blog,webmaster,,,,0,0,40c8c282-6c6e-46e9-aee8-45382f0d9a06
2011-01-13T08:00:00.000+08:00,FDA Panel Rejects LLY's candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/777587/fda-panel-rejects-llys-candidate-analyst-blog,Zacks,,,,0,0,fedaf4b4-dc0d-4515-a064-5fcf8e6e8651
2011-01-13T08:00:00.000+08:00,FDA Panel Rejects LLY's candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/777678/fda-panel-rejects-llys-candidate-analyst-blog,webmaster,,,,0,0,d9849054-5922-4701-b0f9-81f3c55bee15
2011-01-13T08:00:00.000+08:00,FDA Panel Rejects LLY's candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/777587/fda-panel-rejects-llys-candidate-analyst-blog,Zacks,,,,0,0,31122583-2fe5-4b4d-8025-9613b28fc063
2011-01-13T08:00:00.000+08:00,FDA Panel Rejects LLY's candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/777678/fda-panel-rejects-llys-candidate-analyst-blog,webmaster,,,,0,0,fe7757c0-6f78-4f7f-adea-2b28fb1cee7f
2011-01-12T08:00:00.000+08:00,Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application,LLY,https://www.benzinga.com/news/11/01/774888/statement-from-lilly-on-fda-advisory-committee-recommendation-regarding-liprotamas,Benzinga Staff,,,,0,0,56223e74-54c7-4fcb-8aef-36cc517a23bc
2011-01-12T08:00:00.000+08:00,"Benzinga's Top Upgrades (LLY, CPNO, VZ, SLE)",LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/01/773340/benzingas-top-upgrades-lly-cpno-vz-sle,Lisa Levin,,,,0,0,158964ce-3a87-4546-8bc5-139d6ad3959b
2011-01-12T08:00:00.000+08:00,Hapoalim Upgrades Eli Lilly To Hold (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/773123/hapoalim-upgrades-eli-lilly-to-hold-lly,Jonathan Chen,,,,0,0,b7d0177e-65b5-4a04-a052-e2bfe7a8caa0
2011-01-12T08:00:00.000+08:00,Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application,LLY,https://www.benzinga.com/news/11/01/774888/statement-from-lilly-on-fda-advisory-committee-recommendation-regarding-liprotamas,Benzinga Staff,,,,0,0,51fc4589-5bb2-43ed-b15a-aa18899ea405
2011-01-12T08:00:00.000+08:00,"Benzinga's Top Upgrades (LLY, CPNO, VZ, SLE)",LLY,https://www.benzinga.com/analyst-ratings/upgrades/11/01/773340/benzingas-top-upgrades-lly-cpno-vz-sle,Lisa Levin,,,,0,0,ef5a3e14-45a8-4425-bb46-8f33d41e6eca
2011-01-12T08:00:00.000+08:00,Hapoalim Upgrades Eli Lilly To Hold (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/773123/hapoalim-upgrades-eli-lilly-to-hold-lly,Jonathan Chen,,,,0,0,68ef8eb2-3360-49a8-9d7e-9860255193f2
2011-01-07T08:00:00.000+08:00,Data on Sanofi Cancer Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/761923/data-on-sanofi-cancer-candidate-analyst-blog,Zacks,,,,0,0,7b4008ed-d4d2-4c65-b85d-8b1db899bc28
2011-01-07T08:00:00.000+08:00,Data on Sanofi Cancer Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/762034/data-on-sanofi-cancer-candidate-analyst-blog,webmaster,,,,0,0,67501fc4-7693-40a5-a61b-564c7690832c
2011-01-07T08:00:00.000+08:00,Data on Sanofi Cancer Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/761923/data-on-sanofi-cancer-candidate-analyst-blog,Zacks,,,,0,0,648338ad-fd5c-45c8-b0e5-0ad0ec8e6b01
2011-01-07T08:00:00.000+08:00,Data on Sanofi Cancer Candidate - Analyst Blog,LLY,https://www.benzinga.com/11/01/762034/data-on-sanofi-cancer-candidate-analyst-blog,webmaster,,,,0,0,9f17159d-ff39-439e-a468-df5b8f33e73b
2011-01-06T08:00:00.000+08:00,Label Expansion for Roche's Actemra - Analyst Blog,LLY,https://www.benzinga.com/11/01/759651/label-expansion-for-roches-actemra-analyst-blog,Zacks,,,,0,0,187c2df9-d49f-4b2d-8b44-ebb5779d32b7
2011-01-06T08:00:00.000+08:00,Label Expansion for Roche's Actemra - Analyst Blog,LLY,https://www.benzinga.com/11/01/759680/label-expansion-for-roches-actemra-analyst-blog,webmaster,,,,0,0,4df03362-cf9c-4d02-98e0-bdcd02b29026
2011-01-06T08:00:00.000+08:00,Label Expansion for Roche's Actemra - Analyst Blog,LLY,https://www.benzinga.com/11/01/759651/label-expansion-for-roches-actemra-analyst-blog,Zacks,,,,0,0,adb9ccea-431c-4b54-aa4c-80b155434026
2011-01-06T08:00:00.000+08:00,Label Expansion for Roche's Actemra - Analyst Blog,LLY,https://www.benzinga.com/11/01/759680/label-expansion-for-roches-actemra-analyst-blog,webmaster,,,,0,0,f54e8619-cddf-467d-94ad-ae1a3b95f31c
2011-01-04T08:00:00.000+08:00,Bristol-Myers Outlook Mixed - Analyst Blog,LLY,https://www.benzinga.com/11/01/751433/bristol-myers-outlook-mixed-analyst-blog,Zacks,,,,0,0,718967f0-7fa0-4618-a1bf-0a92d1981d19
2011-01-04T08:00:00.000+08:00,Bristol-Myers Outlook Mixed - Analyst Blog,LLY,https://www.benzinga.com/11/01/751451/bristol-myers-outlook-mixed-analyst-blog,webmaster,,,,0,0,56745776-2bdd-4b9d-9efe-3fe00a5ef525
2011-01-04T08:00:00.000+08:00,Citi Comments On Eli Lilly Product Trends,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/749739/citi-comments-on-eli-lilly-product-trends,Benzinga Staff,,,,0,0,de21a7f6-a1bb-4dba-a041-f850808aa817
2011-01-04T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Advises Investors To Buy Baidu (AXL, F, GM, LLY, BIDU, DEO)",LLY,https://www.benzinga.com/media/cnbc/11/01/748853/mad-money-lightning-round-cramer-advises-investors-to-buy-baidu-axl-f-gm-lly,Lisa Levin,,,,0,0,b02139cf-c1ab-40ca-9f6d-0334952ecaea
2011-01-04T08:00:00.000+08:00,Bristol-Myers Outlook Mixed - Analyst Blog,LLY,https://www.benzinga.com/11/01/751433/bristol-myers-outlook-mixed-analyst-blog,Zacks,,,,0,0,c70480e8-f6f4-417f-9c06-f12f93e09215
2011-01-04T08:00:00.000+08:00,Bristol-Myers Outlook Mixed - Analyst Blog,LLY,https://www.benzinga.com/11/01/751451/bristol-myers-outlook-mixed-analyst-blog,webmaster,,,,0,0,e277f486-8bfc-43ca-9e25-60e328d7aad0
2011-01-04T08:00:00.000+08:00,Citi Comments On Eli Lilly Product Trends,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/749739/citi-comments-on-eli-lilly-product-trends,Benzinga Staff,,,,0,0,ef474ab2-6717-4be6-bcc1-33d3532840c0
2011-01-04T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Advises Investors To Buy Baidu (AXL, F, GM, LLY, BIDU, DEO)",LLY,https://www.benzinga.com/media/cnbc/11/01/748853/mad-money-lightning-round-cramer-advises-investors-to-buy-baidu-axl-f-gm-lly,Lisa Levin,,,,0,0,610411d2-27f4-46a7-b79a-ce4a3d60da0d
2011-01-03T08:00:00.000+08:00,'Mad Money Lightning Round': Baidu's Terrific,LLY,https://www.benzinga.com/11/01/748400/mad-money-lightning-round-baidus-terrific,webmaster,,,,0,0,9fcf773f-a84b-464e-8293-1ee2a5c3e6d6
2011-01-03T08:00:00.000+08:00,Xoma: Key Diabetes Drug Study Preview,LLY,https://www.benzinga.com/11/01/748401/xoma-key-diabetes-drug-study-preview,webmaster,,,,0,0,e3fb292e-627d-4148-b370-4cde11cadea5
2011-01-03T08:00:00.000+08:00,'Mad Money Lightning Round': Baidu's Terrific,LLY,https://www.benzinga.com/11/01/748400/mad-money-lightning-round-baidus-terrific,webmaster,,,,0,0,10efa721-8d69-40c5-a476-1659227dd728
2011-01-03T08:00:00.000+08:00,Xoma: Key Diabetes Drug Study Preview,LLY,https://www.benzinga.com/11/01/748401/xoma-key-diabetes-drug-study-preview,webmaster,,,,0,0,1e770801-c9af-46ba-aa7d-6a21f46006fe
2010-12-23T08:00:00.000+08:00,Label Expansion Sought for Byetta - Analyst Blog,LLY,https://www.benzinga.com/10/12/728913/label-expansion-sought-for-byetta-analyst-blog,Zacks,,,,0,0,6f43d708-3376-405f-8372-6c1d4736aa68
2010-12-23T08:00:00.000+08:00,Label Expansion Sought for Byetta - Analyst Blog,LLY,https://www.benzinga.com/10/12/728947/label-expansion-sought-for-byetta-analyst-blog,webmaster,,,,0,0,98eec4dd-62bb-4e12-828d-253dad7026c7
2010-12-23T08:00:00.000+08:00,Label Expansion Sought for Byetta - Analyst Blog,LLY,https://www.benzinga.com/10/12/728913/label-expansion-sought-for-byetta-analyst-blog,Zacks,,,,0,0,43233bdd-c13e-4521-9b59-5ae36c62bc2a
2010-12-23T08:00:00.000+08:00,Label Expansion Sought for Byetta - Analyst Blog,LLY,https://www.benzinga.com/10/12/728947/label-expansion-sought-for-byetta-analyst-blog,webmaster,,,,0,0,d45d8a32-29ed-47c5-b04a-ee04d75bc220
2010-12-22T08:00:00.000+08:00,Amylin and Lilly Seek Expanded Use of BYETTA,LLY,https://www.benzinga.com/news/10/12/727156/amylin-and-lilly-seek-expanded-use-of-byetta,Benzinga Staff,,,,0,0,e36fcd8f-1782-49c6-aaf9-01f688a32b8d
2010-12-22T08:00:00.000+08:00,INCY's INC424 Meets Goal - Analyst Blog,LLY,https://www.benzinga.com/10/12/725713/incys-inc424-meets-goal-analyst-blog,Zacks,,,,0,0,bab9679b-3bc4-4772-8275-8db0374ff5ed
2010-12-22T08:00:00.000+08:00,INCY's INC424 Meets Goal - Analyst Blog,LLY,https://www.benzinga.com/10/12/725777/incys-inc424-meets-goal-analyst-blog,webmaster,,,,0,0,d5986d83-aaca-494d-aed6-b56a13f0e9b8
2010-12-22T08:00:00.000+08:00,Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share,LLY,https://www.benzinga.com/news/m-a/10/12/725156/unconfirmed-rumors-circulate-that-neurocrine-biosciences-inc-nbix-will-be-take,Franklin Price,,,,0,0,7a52bbc2-2f73-4e5e-9e48-6ee94ff5c0a1
2010-12-22T08:00:00.000+08:00,Eli Lilly Acquires Avid - Analyst Blog,LLY,https://www.benzinga.com/10/12/724943/eli-lilly-acquires-avid-analyst-blog,Zacks,,,,0,0,1535fe3f-20f5-4337-8d98-368b5e03e0ba
2010-12-22T08:00:00.000+08:00,Eli Lilly Acquires Avid - Analyst Blog,LLY,https://www.benzinga.com/10/12/725063/eli-lilly-acquires-avid-analyst-blog,webmaster,,,,0,0,fe7f0d47-7629-4119-938d-1078c5104e2f
2010-12-22T08:00:00.000+08:00,Amylin and Lilly Seek Expanded Use of BYETTA,LLY,https://www.benzinga.com/news/10/12/727156/amylin-and-lilly-seek-expanded-use-of-byetta,Benzinga Staff,,,,0,0,43c10f8b-0133-4b10-8fda-d946fe5be42e
2010-12-22T08:00:00.000+08:00,INCY's INC424 Meets Goal - Analyst Blog,LLY,https://www.benzinga.com/10/12/725713/incys-inc424-meets-goal-analyst-blog,Zacks,,,,0,0,184022ee-e535-448d-8aad-56f65d35ecb7
2010-12-22T08:00:00.000+08:00,INCY's INC424 Meets Goal - Analyst Blog,LLY,https://www.benzinga.com/10/12/725777/incys-inc424-meets-goal-analyst-blog,webmaster,,,,0,0,ba350f0c-775e-44de-bcaa-036266bf1242
2010-12-22T08:00:00.000+08:00,Unconfirmed Rumors Circulate that Neurocrine Biosciences Inc. (NBIX) will be taken out by Eli Lilly & Co. (LLY) at $17.00 a share,LLY,https://www.benzinga.com/news/m-a/10/12/725156/unconfirmed-rumors-circulate-that-neurocrine-biosciences-inc-nbix-will-be-take,Franklin Price,,,,0,0,55b4c13c-8c94-4d87-927f-49aed9e7f9e6
2010-12-22T08:00:00.000+08:00,Eli Lilly Acquires Avid - Analyst Blog,LLY,https://www.benzinga.com/10/12/724943/eli-lilly-acquires-avid-analyst-blog,Zacks,,,,0,0,5ea82d43-dbff-40be-afd9-e3533f712033
2010-12-22T08:00:00.000+08:00,Eli Lilly Acquires Avid - Analyst Blog,LLY,https://www.benzinga.com/10/12/725063/eli-lilly-acquires-avid-analyst-blog,webmaster,,,,0,0,0df1aec6-772c-4ba9-9e58-7268381dbce9
2010-12-21T08:00:00.000+08:00,Rolling BLA for AMLN's Metreleptin - Analyst Blog,LLY,https://www.benzinga.com/10/12/720827/rolling-bla-for-amlns-metreleptin-analyst-blog,Zacks,,,,0,0,738b2d45-22fa-44e9-90e3-43cb9fa9af83
2010-12-21T08:00:00.000+08:00,Rolling BLA for AMLN's Metreleptin - Analyst Blog,LLY,https://www.benzinga.com/10/12/720800/rolling-bla-for-amlns-metreleptin-analyst-blog,webmaster,,,,0,0,f769a4aa-f8e5-41ff-80e8-e9d8ce687ebd
2010-12-21T08:00:00.000+08:00,Rolling BLA for AMLN's Metreleptin - Analyst Blog,LLY,https://www.benzinga.com/10/12/720827/rolling-bla-for-amlns-metreleptin-analyst-blog,Zacks,,,,0,0,44951e26-ab32-487e-b373-fc63b6dc27de
2010-12-21T08:00:00.000+08:00,Rolling BLA for AMLN's Metreleptin - Analyst Blog,LLY,https://www.benzinga.com/10/12/720800/rolling-bla-for-amlns-metreleptin-analyst-blog,webmaster,,,,0,0,3a24ab0c-3088-41b8-a338-cf5f5dc752f1
2010-12-20T08:00:00.000+08:00,Safeguard Scientifics to Realize at Least $36M in Initial Sale Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals,LLY,https://www.benzinga.com/news/10/12/718287/safeguard-scientifics-to-realize-at-least-36m-in-initial-sale-proceeds-from-eli-li,Benzinga Staff,,,,0,0,24e6aa62-6552-441a-a8e5-afd2552c431f
2010-12-20T08:00:00.000+08:00,Safeguard Scientifics to Realize at Least $36M in Initial Sale Proceeds from Eli Lilly's Acquisition of Avid Radiopharmaceuticals,LLY,https://www.benzinga.com/news/10/12/718287/safeguard-scientifics-to-realize-at-least-36m-in-initial-sale-proceeds-from-eli-li,Benzinga Staff,,,,0,0,2fecb972-2284-402e-a4c7-173832a3de90
2010-12-17T08:00:00.000+08:00,"Friday's Put/Call Ratio Leaders (PSUN, LO, COCO, LLY, MCHP)",LLY,https://www.benzinga.com/movers/10/12/712175/fridays-putcall-ratio-leaders-psun-lo-coco-lly-mchp,Michael J. Zerinskas,,,,0,0,45b2bc30-c7df-4ac0-994d-172aab82df5d
2010-12-17T08:00:00.000+08:00,"Friday's Put/Call Ratio Leaders (PSUN, LO, COCO, LLY, MCHP)",LLY,https://www.benzinga.com/movers/10/12/712175/fridays-putcall-ratio-leaders-psun-lo-coco-lly-mchp,Michael J. Zerinskas,,,,0,0,55418036-7bbf-491f-a6de-da710de2a5d1
2010-12-14T08:00:00.000+08:00,Lilly Study Stopped on Safety Concerns - Analyst Blog,LLY,https://www.benzinga.com/10/12/700168/lilly-study-stopped-on-safety-concerns-analyst-blog,Zacks,,,,0,0,84cde54c-48b9-4eb7-bbf2-f477901c1c3a
2010-12-14T08:00:00.000+08:00,Lilly Study Stopped on Safety Concerns - Analyst Blog,LLY,https://www.benzinga.com/10/12/700205/lilly-study-stopped-on-safety-concerns-analyst-blog,webmaster,,,,0,0,6bccd053-78e8-46fc-b867-8d77ef31838b
2010-12-14T08:00:00.000+08:00,Lilly Study Stopped on Safety Concerns - Analyst Blog,LLY,https://www.benzinga.com/10/12/700168/lilly-study-stopped-on-safety-concerns-analyst-blog,Zacks,,,,0,0,044abf67-c9fe-4794-818a-54b8e14158fc
2010-12-14T08:00:00.000+08:00,Lilly Study Stopped on Safety Concerns - Analyst Blog,LLY,https://www.benzinga.com/10/12/700205/lilly-study-stopped-on-safety-concerns-analyst-blog,webmaster,,,,0,0,0760ddb6-4a28-4093-8ca8-f2c2c721d5ab
2010-12-13T08:00:00.000+08:00,Loss at BIOD Narrower than Expected - Analyst Blog,LLY,https://www.benzinga.com/10/12/694384/loss-at-biod-narrower-than-expected-analyst-blog,Zacks,,,,0,0,0803b83d-e87f-442c-8e55-e886a1254f00
2010-12-13T08:00:00.000+08:00,Loss at BIOD Narrower than Expected - Analyst Blog,LLY,https://www.benzinga.com/10/12/694430/loss-at-biod-narrower-than-expected-analyst-blog,webmaster,,,,0,0,8a675caa-7ae8-4e9d-bc0a-982de7268f60
2010-12-13T08:00:00.000+08:00,Loss at BIOD Narrower than Expected - Analyst Blog,LLY,https://www.benzinga.com/10/12/694384/loss-at-biod-narrower-than-expected-analyst-blog,Zacks,,,,0,0,87cb67f5-26d7-4acf-b43b-998729e398c0
2010-12-13T08:00:00.000+08:00,Loss at BIOD Narrower than Expected - Analyst Blog,LLY,https://www.benzinga.com/10/12/694430/loss-at-biod-narrower-than-expected-analyst-blog,webmaster,,,,0,0,20af4196-8e72-4af7-a140-249879cf7765
2010-12-10T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)",LLY,https://www.benzinga.com/media/cnbc/10/12/686930/mad-money-lightning-round-cramer-advises-investors-to-buy-blackrock-lly-deck,Lisa Levin,,,,0,0,6e54125e-c371-4391-9b91-5592c80cd0b6
2010-12-10T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Advises Investors To Buy BlackRock (LLY, DECK, CMI, OXPS, AXP, V, MRK, ABT, BLK)",LLY,https://www.benzinga.com/media/cnbc/10/12/686930/mad-money-lightning-round-cramer-advises-investors-to-buy-blackrock-lly-deck,Lisa Levin,,,,0,0,23872963-4751-458e-8954-eb40e958467a
2010-12-09T08:00:00.000+08:00,'Mad Money Lightning Round': Go for BlackRock,LLY,https://www.benzinga.com/10/12/686549/mad-money-lightning-round-go-for-blackrock,webmaster,,,,0,0,cd5bee0d-7442-406f-befd-7a6420eded96
2010-12-09T08:00:00.000+08:00,Best Stocks For Creating A Passive Income Stream,LLY,https://www.benzinga.com/10/12/686102/best-stocks-for-creating-a-passive-income-stream,Mark Riddix,,,,0,0,38fabae2-3d1d-41d9-b31d-bde58455536b
2010-12-09T08:00:00.000+08:00,'Mad Money Lightning Round': Go for BlackRock,LLY,https://www.benzinga.com/10/12/686549/mad-money-lightning-round-go-for-blackrock,webmaster,,,,0,0,acd15742-c2e6-4a54-89b9-5e291ed91281
2010-12-09T08:00:00.000+08:00,Best Stocks For Creating A Passive Income Stream,LLY,https://www.benzinga.com/10/12/686102/best-stocks-for-creating-a-passive-income-stream,Mark Riddix,,,,0,0,d323f4eb-d7ea-4596-9fb8-86c2c1f13308
2010-12-03T08:00:00.000+08:00,Neutral on Incyte - Analyst Blog,LLY,https://www.benzinga.com/10/12/667562/neutral-on-incyte-analyst-blog,Zacks,,,,0,0,65000ce7-70a2-4763-9d44-96d44f7a615e
2010-12-03T08:00:00.000+08:00,Neutral on Incyte - Analyst Blog,LLY,https://www.benzinga.com/10/12/667598/neutral-on-incyte-analyst-blog,webmaster,,,,0,0,9e904eed-88a5-44e1-a92f-ef69d381a3e8
2010-12-03T08:00:00.000+08:00,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,LLY,https://www.benzinga.com/10/12/667408/cbsts-fast-injection-cubicin-okd-analyst-blog,Zacks,,,,0,0,d02b522f-2846-4407-840a-709bac1db9a6
2010-12-03T08:00:00.000+08:00,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,LLY,https://www.benzinga.com/10/12/667491/cbsts-fast-injection-cubicin-okd-analyst-blog,webmaster,,,,0,0,b31d1d33-bb68-410f-b30c-e31da8246238
2010-12-03T08:00:00.000+08:00,Merck Strikes Deal with SmartCells - Analyst Blog,LLY,https://www.benzinga.com/10/12/666201/merck-strikes-deal-with-smartcells-analyst-blog,Zacks,,,,0,0,995bf256-1562-4eb4-99ca-53414e6c2311
2010-12-03T08:00:00.000+08:00,Merck Strikes Deal with SmartCells - Analyst Blog,LLY,https://www.benzinga.com/10/12/666755/merck-strikes-deal-with-smartcells-analyst-blog,webmaster,,,,0,0,731cdc98-d8ca-4c24-9b3d-c17d7fb8ea80
2010-12-03T08:00:00.000+08:00,Neutral on Incyte - Analyst Blog,LLY,https://www.benzinga.com/10/12/667562/neutral-on-incyte-analyst-blog,Zacks,,,,0,0,12f1324d-8192-4d29-a409-0f6521840bf1
2010-12-03T08:00:00.000+08:00,Neutral on Incyte - Analyst Blog,LLY,https://www.benzinga.com/10/12/667598/neutral-on-incyte-analyst-blog,webmaster,,,,0,0,f25405ac-feaa-4644-bd31-3ce413a3c9fb
2010-12-03T08:00:00.000+08:00,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,LLY,https://www.benzinga.com/10/12/667408/cbsts-fast-injection-cubicin-okd-analyst-blog,Zacks,,,,0,0,59d86959-3718-4607-b470-191ff2fda7ac
2010-12-03T08:00:00.000+08:00,CBST's Fast-Injection Cubicin OK'd - Analyst Blog,LLY,https://www.benzinga.com/10/12/667491/cbsts-fast-injection-cubicin-okd-analyst-blog,webmaster,,,,0,0,1da3714c-6cf2-4894-b78f-46401816c642
2010-12-03T08:00:00.000+08:00,Merck Strikes Deal with SmartCells - Analyst Blog,LLY,https://www.benzinga.com/10/12/666201/merck-strikes-deal-with-smartcells-analyst-blog,Zacks,,,,0,0,cbde9235-0a80-453e-9ce7-fb049a3173fc
2010-12-03T08:00:00.000+08:00,Merck Strikes Deal with SmartCells - Analyst Blog,LLY,https://www.benzinga.com/10/12/666755/merck-strikes-deal-with-smartcells-analyst-blog,webmaster,,,,0,0,2f002d19-cf39-4ea7-bfce-bcc273d32344
2010-11-29T08:00:00.000+08:00,Acrux and Eli Lilly Receive FDA Approval for Testosterone Drug,LLY,https://www.benzinga.com/news/10/11/649175/acrux-and-eli-lilly-receive-fda-approval-for-testosterone-drug,Benzinga Staff,,,,0,0,b696af0a-b14f-4bc3-b9ea-1b1077ed3c57
2010-11-29T08:00:00.000+08:00,Acrux and Eli Lilly Receive FDA Approval for Testosterone Drug,LLY,https://www.benzinga.com/news/10/11/649175/acrux-and-eli-lilly-receive-fda-approval-for-testosterone-drug,Benzinga Staff,,,,0,0,891025fe-a318-48fc-abc6-314d7417ed40
2010-11-24T08:00:00.000+08:00,Amylin Stays Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/11/641454/amylin-stays-neutral-analyst-blog,Zacks,,,,0,0,7bc37a4c-0c13-42de-b43b-831a7513fd60
2010-11-24T08:00:00.000+08:00,"Company News for November 24, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/11/640698/company-news-for-november-24-2010-corporate-summary,Zacks,,,,0,0,23c2640e-1639-4bc0-9700-12da5f1bb325
2010-11-24T08:00:00.000+08:00,FDA Approves Axiron - Analyst Blog,LLY,https://www.benzinga.com/10/11/640550/fda-approves-axiron-analyst-blog,Zacks,,,,0,0,a97922a4-e26b-478b-ac0a-1b23a0797a23
2010-11-24T08:00:00.000+08:00,Amylin Stays Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/11/641590/amylin-stays-neutral-analyst-blog,webmaster,,,,0,0,66d387a1-f8f0-4295-aa4a-086c0e9cbd54
2010-11-24T08:00:00.000+08:00,"Company News for November 24, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/11/640738/company-news-for-november-24-2010-corporate-summary,webmaster,,,,0,0,5518156b-64f3-479a-9722-949fa36e890d
2010-11-24T08:00:00.000+08:00,FDA Approves Axiron - Analyst Blog,LLY,https://www.benzinga.com/10/11/640610/fda-approves-axiron-analyst-blog,webmaster,,,,0,0,64925cd0-358e-4322-902d-cd555d5a0c5d
2010-11-24T08:00:00.000+08:00,Amylin Stays Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/11/641454/amylin-stays-neutral-analyst-blog,Zacks,,,,0,0,66ee5b35-ff3c-416f-84d0-c79c9224bd58
2010-11-24T08:00:00.000+08:00,"Company News for November 24, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/11/640698/company-news-for-november-24-2010-corporate-summary,Zacks,,,,0,0,5c598bc5-037e-4a27-8d60-9a8b40352de2
2010-11-24T08:00:00.000+08:00,FDA Approves Axiron - Analyst Blog,LLY,https://www.benzinga.com/10/11/640550/fda-approves-axiron-analyst-blog,Zacks,,,,0,0,2f7e6e07-198c-44ed-8032-5595405db7aa
2010-11-24T08:00:00.000+08:00,Amylin Stays Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/11/641590/amylin-stays-neutral-analyst-blog,webmaster,,,,0,0,81e0589a-5566-4655-bfde-fa6c52940884
2010-11-24T08:00:00.000+08:00,"Company News for November 24, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/11/640738/company-news-for-november-24-2010-corporate-summary,webmaster,,,,0,0,8065eaec-bd1b-4719-b056-4f4bb6aae6fc
2010-11-24T08:00:00.000+08:00,FDA Approves Axiron - Analyst Blog,LLY,https://www.benzinga.com/10/11/640610/fda-approves-axiron-analyst-blog,webmaster,,,,0,0,72994b30-9b60-4ef2-bb7f-65d1dd016f02
2010-11-22T08:00:00.000+08:00,Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta,LLY,https://www.benzinga.com/news/10/11/631930/impax-laboratories-receives-tentative-fda-approval-for-generic-cymbalta,Benzinga Staff,,,,0,0,dfa597e0-455d-4f48-9166-8291b7cc8783
2010-11-22T08:00:00.000+08:00,Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta,LLY,https://www.benzinga.com/news/10/11/631930/impax-laboratories-receives-tentative-fda-approval-for-generic-cymbalta,Benzinga Staff,,,,0,0,d9e038e6-75ec-4a13-a46e-28910590442d
2010-11-19T08:00:00.000+08:00,"Zings Of The Day (GOOG, LLY)",LLY,https://www.benzinga.com/news/10/11/628877/zings-of-the-day-goog-lly,Roger Nachman,,,,0,0,4991dfce-6b8e-4e2f-b696-0081658b25a9
2010-11-19T08:00:00.000+08:00,"Zings Of The Day (GOOG, LLY)",LLY,https://www.benzinga.com/news/10/11/628877/zings-of-the-day-goog-lly,Roger Nachman,,,,0,0,b977ac52-bb35-4486-8296-016284bcb4c3
2010-11-16T08:00:00.000+08:00,Citi Gives Valuation Update On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/614548/citi-gives-valuation-update-on-eli-lilly,Benzinga Staff,,,,0,0,268d1663-674d-4f4a-a6a8-a91428ee4351
2010-11-16T08:00:00.000+08:00,Citi Gives Valuation Update On Eli Lilly,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/614548/citi-gives-valuation-update-on-eli-lilly,Benzinga Staff,,,,0,0,5d68f43a-c90b-412f-86d3-9a197cad7f67
2010-11-15T08:00:00.000+08:00,Hospira Launches Gemcitabine HCL,LLY,https://www.benzinga.com/news/10/11/611457/hospira-launches-gemcitabine-hcl,Benzinga Staff,,,,0,0,9ccc7abb-d8f7-4d24-9b87-06baaabbbd7f
2010-11-15T08:00:00.000+08:00,Hospira Launches Gemcitabine HCL,LLY,https://www.benzinga.com/news/10/11/611457/hospira-launches-gemcitabine-hcl,Benzinga Staff,,,,0,0,f29d168f-4147-4b54-9d29-01660bd2fa1f
2010-11-12T08:00:00.000+08:00,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases",LLY,https://www.benzinga.com/10/11/605894/zacks-analyst-blog-highlights-lions-gate-entertainment-amylin-pharmaceuticals-amylin-ph,Zacks,,,,0,0,5897ac13-23d3-4578-b588-bc7b913943a0
2010-11-12T08:00:00.000+08:00,Eli Lilly's Dividend Security Threatened,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/605424/eli-lillys-dividend-security-threatened,Joe Young,,,,0,0,da886334-9245-473a-81c6-9b4649c60939
2010-11-12T08:00:00.000+08:00,"Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases",LLY,https://www.benzinga.com/10/11/605894/zacks-analyst-blog-highlights-lions-gate-entertainment-amylin-pharmaceuticals-amylin-ph,Zacks,,,,0,0,93582972-081e-4a7b-83bb-c1af31e09fe4
2010-11-12T08:00:00.000+08:00,Eli Lilly's Dividend Security Threatened,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/605424/eli-lillys-dividend-security-threatened,Joe Young,,,,0,0,c603c63f-d373-4df7-8ac4-efc35fd65772
2010-11-11T08:00:00.000+08:00,J.P. Morgan Reiterates Incyte Corporation Rating,LLY,https://www.benzinga.com/analyst-ratings/10/11/601270/j-p-morgan-reiterates-incyte-corporation-rating,BenzingaStaffL,,,,0,0,9b385829-e288-4e81-8d06-78efb5a07bad
2010-11-11T08:00:00.000+08:00,J.P. Morgan Reiterates Incyte Corporation Rating,LLY,https://www.benzinga.com/analyst-ratings/10/11/601270/j-p-morgan-reiterates-incyte-corporation-rating,BenzingaStaffL,,,,0,0,327e9f8a-d290-440b-9ff1-690c034b29ec
2010-11-09T08:00:00.000+08:00,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,LLY,https://www.benzinga.com/10/11/596175/pharma-biotech-industry-outlook-nov-2010-zacks-analyst-interviews,Zacks,,,,0,0,1f4c8aaa-c928-4e05-9d65-43d24b101569
2010-11-09T08:00:00.000+08:00,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,LLY,https://www.benzinga.com/10/11/596174/pharma-biotech-industry-outlook-nov-2010-industry-outlook,Zacks,,,,0,0,8c27fe79-da65-4ae3-8ff8-e9de5a51c64a
2010-11-09T08:00:00.000+08:00,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook,LLY,https://www.benzinga.com/10/11/596170/pharma-and-biotech-industry-outlook-nov-2010-industry-outlook,Zacks,,,,0,0,9a220e03-693d-4d50-a5b8-680bcf28afc1
2010-11-09T08:00:00.000+08:00,LLY's Avid Interest in Alzheimer's - Analyst Blog,LLY,https://www.benzinga.com/10/11/594924/llys-avid-interest-in-alzheimers-analyst-blog,Zacks,,,,0,0,ffa7ac31-5f1f-4fed-ba07-65c0cdfb25f6
2010-11-09T08:00:00.000+08:00,Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews,LLY,https://www.benzinga.com/10/11/596175/pharma-biotech-industry-outlook-nov-2010-zacks-analyst-interviews,Zacks,,,,0,0,f6a54ae1-5a3d-4b4c-9a8c-8f7c8a6bfaf8
2010-11-09T08:00:00.000+08:00,Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook,LLY,https://www.benzinga.com/10/11/596174/pharma-biotech-industry-outlook-nov-2010-industry-outlook,Zacks,,,,0,0,d148987c-c665-4574-86aa-8204a2c00c81
2010-11-09T08:00:00.000+08:00,Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook,LLY,https://www.benzinga.com/10/11/596170/pharma-and-biotech-industry-outlook-nov-2010-industry-outlook,Zacks,,,,0,0,747ebea0-eee7-48a8-abb8-2641994d4bd9
2010-11-09T08:00:00.000+08:00,LLY's Avid Interest in Alzheimer's - Analyst Blog,LLY,https://www.benzinga.com/10/11/594924/llys-avid-interest-in-alzheimers-analyst-blog,Zacks,,,,0,0,d95f2023-9def-4b7f-93ed-b539ce70c45e
2010-11-08T08:00:00.000+08:00,"Eli Lilly Buying Alzheimer's Drug Maker, Is It A Buy? (LLY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/11/588610/eli-lilly-buying-alzheimers-drug-maker-is-it-a-buy-lly,Roger Nachman,,,,0,0,6cffb85a-8a52-4105-8bec-744afadd7ead
2010-11-08T08:00:00.000+08:00,Lilly to Acquire Avid Radiopharmaceuticals for up to $550M,LLY,https://www.benzinga.com/news/10/11/588344/lilly-to-acquire-avid-radiopharmaceuticals-for-up-to-550m,Benzinga Staff,,,,0,0,f97c1c20-7b30-4343-b929-5d557f461065
2010-11-08T08:00:00.000+08:00,"Eli Lilly Buying Alzheimer's Drug Maker, Is It A Buy? (LLY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/11/588610/eli-lilly-buying-alzheimers-drug-maker-is-it-a-buy-lly,Roger Nachman,,,,0,0,f8e13d72-ad6b-4824-ad02-381ac1785d99
2010-11-08T08:00:00.000+08:00,Lilly to Acquire Avid Radiopharmaceuticals for up to $550M,LLY,https://www.benzinga.com/news/10/11/588344/lilly-to-acquire-avid-radiopharmaceuticals-for-up-to-550m,Benzinga Staff,,,,0,0,dc0801ed-c6b3-413e-8982-189bdc9b5f73
2010-10-21T08:00:00.000+08:00,Hapoalim Securities Reiterates Sell Rating on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/541397/hapoalim-securities-reiterates-sell-rating-on-eli-lilly-l,Michael J. Zerinskas,,,,0,0,0cf23a29-0925-407c-a9a1-eb454b0ebb93
2010-10-21T08:00:00.000+08:00,Lilly Beats by a Penny; Ups View - Analyst Blog,LLY,https://www.benzinga.com/10/10/540787/lilly-beats-by-a-penny-ups-view-analyst-blog,Zacks,,,,0,0,6ef5cc11-9e98-4367-ba40-4ac1c3a4ad62
2010-10-21T08:00:00.000+08:00,"Stock Market News for October 21, 2010 - Market News",LLY,https://www.benzinga.com/10/10/540018/stock-market-news-for-october-21-2010-market-news,Zacks,,,,0,0,5f937ddc-ead1-47ba-ab61-cc98b44c29ae
2010-10-21T08:00:00.000+08:00,"Company News for October 21, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/10/540015/company-news-for-october-21-2010-corporate-summary,Zacks,,,,0,0,794c2960-a8b0-4157-a197-74f299504fa1
2010-10-21T08:00:00.000+08:00,"Trading Plan for October 21, 2010",LLY,https://www.benzinga.com/10/10/539085/trading-plan-for-october-21-2010,Ryan Mallory,,,,0,0,0f53fa58-59f1-430d-b7e0-6d8558dd2d82
2010-10-21T08:00:00.000+08:00,"Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)",LLY,https://www.benzinga.com/market-update/10/10/538421/earnings-scheduled-for-october-21-mcd-cat-t-lly-cs-ual-bax-nvs-unp-ups-bb,Monica Gerson,,,,0,0,60246e67-1946-46f0-b465-da5affdbc53f
2010-10-21T08:00:00.000+08:00,Hapoalim Securities Reiterates Sell Rating on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/541397/hapoalim-securities-reiterates-sell-rating-on-eli-lilly-l,Michael J. Zerinskas,,,,0,0,21a7b92c-594b-4a59-8a04-c949aa461a5c
2010-10-21T08:00:00.000+08:00,Lilly Beats by a Penny; Ups View - Analyst Blog,LLY,https://www.benzinga.com/10/10/540787/lilly-beats-by-a-penny-ups-view-analyst-blog,Zacks,,,,0,0,ab0d0a2d-860c-4900-9759-c6134d7795fe
2010-10-21T08:00:00.000+08:00,"Stock Market News for October 21, 2010 - Market News",LLY,https://www.benzinga.com/10/10/540018/stock-market-news-for-october-21-2010-market-news,Zacks,,,,0,0,bd695980-f43c-4916-aa0f-48328249300d
2010-10-21T08:00:00.000+08:00,"Company News for October 21, 2010 - Corporate Summary",LLY,https://www.benzinga.com/10/10/540015/company-news-for-october-21-2010-corporate-summary,Zacks,,,,0,0,bdd1be76-503a-4801-bfa8-7549d9cdb09f
2010-10-21T08:00:00.000+08:00,"Trading Plan for October 21, 2010",LLY,https://www.benzinga.com/10/10/539085/trading-plan-for-october-21-2010,Ryan Mallory,,,,0,0,faab49f7-e353-45f0-952a-26a37d74026a
2010-10-21T08:00:00.000+08:00,"Earnings Scheduled For October 21 (MCD, CAT, T, LLY, CS, UAL, BAX, NVS, UNP, UPS, BBT, PM, RAI, CTXS, SNDK, JBLU, AXP, TRV, LUV, AMZN, STI, HSY, XRX, CB)",LLY,https://www.benzinga.com/market-update/10/10/538421/earnings-scheduled-for-october-21-mcd-cat-t-lly-cs-ual-bax-nvs-unp-ups-bb,Monica Gerson,,,,0,0,706a7a59-890a-4057-9830-6c37da85b3b7
2010-10-20T08:00:00.000+08:00,Viagra Treatment for Muscular Dystrophy,LLY,https://www.benzinga.com/10/10/535843/viagra-treatment-for-muscular-dystrophy,Fred Fuld,,,,0,0,ab6f8d41-4425-4508-8ca3-0fae0532e397
2010-10-20T08:00:00.000+08:00,"\"\"\"Change Of Heart\"\" By FDA For LLY\"",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/534669/change-of-heart-by-fda-for-lly,Joe Young,,,,0,0,941ea5c9-4bff-4ca0-b8b5-252f3e01bcc0
2010-10-20T08:00:00.000+08:00,"Benzinga's Top Downgrades (KOF, LLY, ITW, AMLN)",LLY,https://www.benzinga.com/market-update/10/10/534484/benzingas-top-downgrades-kof-lly-itw-amln,Lisa Levin,,,,0,0,979ac4b9-c3a0-49bc-a95a-fb0e3ddb9ec8
2010-10-20T08:00:00.000+08:00,Amylin Pharmaceuticals Crushed In Pre-Market (AMLN),LLY,https://www.benzinga.com/pre-market-outlook/10/10/534462/amylin-pharmaceuticals-crushed-in-pre-market-amln,Roger Nachman,,,,0,0,e99a82a9-a2b4-4cbd-a9c5-a6edbf32ab88
2010-10-20T08:00:00.000+08:00,Citigroup Downgrades LLY To Hold,LLY,https://www.benzinga.com/market-update/10/10/534441/citigroup-downgrades-lly-to-hold,Lisa Levin,,,,0,0,7a340f19-87d5-4497-b879-6cdd443b834c
2010-10-20T08:00:00.000+08:00,Viagra Treatment for Muscular Dystrophy,LLY,https://www.benzinga.com/10/10/535843/viagra-treatment-for-muscular-dystrophy,Fred Fuld,,,,0,0,69f1a334-9be5-467f-bc86-d70278d41f03
2010-10-20T08:00:00.000+08:00,"\"\"\"Change Of Heart\"\" By FDA For LLY\"",LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/534669/change-of-heart-by-fda-for-lly,Joe Young,,,,0,0,90c5e53b-f4d4-4b30-8f4a-58b083906bdc
2010-10-20T08:00:00.000+08:00,"Benzinga's Top Downgrades (KOF, LLY, ITW, AMLN)",LLY,https://www.benzinga.com/market-update/10/10/534484/benzingas-top-downgrades-kof-lly-itw-amln,Lisa Levin,,,,0,0,56dc4f93-5105-458f-b84e-4501e65235bf
2010-10-20T08:00:00.000+08:00,Amylin Pharmaceuticals Crushed In Pre-Market (AMLN),LLY,https://www.benzinga.com/pre-market-outlook/10/10/534462/amylin-pharmaceuticals-crushed-in-pre-market-amln,Roger Nachman,,,,0,0,d4462ad4-a6c9-423a-890c-0f8543e337dd
2010-10-20T08:00:00.000+08:00,Citigroup Downgrades LLY To Hold,LLY,https://www.benzinga.com/market-update/10/10/534441/citigroup-downgrades-lly-to-hold,Lisa Levin,,,,0,0,57afe229-399d-40ab-bdf9-6b28e8519d34
2010-10-19T08:00:00.000+08:00,"In Core Product Trends Report, Citigroup Rates Eli Lilly High Risk",LLY,https://www.benzinga.com/analyst-ratings/10/10/531902/in-core-product-trends-report-citigroup-rates-eli-lilly-high-risk,BenzingaStaffL,,,,0,0,eec7008c-289d-49f2-ba6e-7b25fd8cbcef
2010-10-19T08:00:00.000+08:00,"In Core Product Trends Report, Citigroup Rates Eli Lilly High Risk",LLY,https://www.benzinga.com/analyst-ratings/10/10/531902/in-core-product-trends-report-citigroup-rates-eli-lilly-high-risk,BenzingaStaffL,,,,0,0,aad699dd-b209-42fd-a7d3-0c6e74202803
2010-10-18T08:00:00.000+08:00,Lilly Declares Fourth-Quarter 2010 Dividend of $.49,LLY,https://www.benzinga.com/news/dividends/10/10/530313/lilly-declares-fourth-quarter-2010-dividend-of-49,Benzinga Staff,,,,0,0,6dfc99e5-0a9e-4186-af73-29c31ce6e8bb
2010-10-18T08:00:00.000+08:00,Lilly Declares Fourth-Quarter 2010 Dividend of $.49,LLY,https://www.benzinga.com/news/dividends/10/10/530313/lilly-declares-fourth-quarter-2010-dividend-of-49,Benzinga Staff,,,,0,0,60eb09cd-9cfb-425f-89b6-28280843a152
2010-10-12T08:00:00.000+08:00,Eli Lilly Product Trends: Increases Across The Board,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/519146/eli-lilly-product-trends-increases-across-the-board,Joe Young,,,,0,0,3dc20531-237d-4072-a673-6babf81bdd9f
2010-10-12T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/10/518907/top-4-nyse-stocks-in-the-healthcare-sector-with-the-highest-di,Lisa Levin,,,,0,0,6773033d-6d3d-4cff-ac8a-d7fa9bce0b59
2010-10-12T08:00:00.000+08:00,Eli Lilly Product Trends: Increases Across The Board,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/519146/eli-lilly-product-trends-increases-across-the-board,Joe Young,,,,0,0,b850b7ae-242b-440e-b513-692e75c11931
2010-10-12T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/10/518907/top-4-nyse-stocks-in-the-healthcare-sector-with-the-highest-di,Lisa Levin,,,,0,0,9be82f0f-3814-4de9-9b78-38e98cd509c2
2010-10-11T08:00:00.000+08:00,Eli Lilly Drug Fails Phase 3 Trial (LLY),LLY,https://www.benzinga.com/news/10/10/517595/eli-lilly-drug-fails-phase-3-trial-lly,Roger Nachman,,,,0,0,d2ab527c-4808-4b3e-966d-076d420dc185
2010-10-11T08:00:00.000+08:00,Eli Lilly Drug Fails Phase 3 Trial (LLY),LLY,https://www.benzinga.com/news/10/10/517595/eli-lilly-drug-fails-phase-3-trial-lly,Roger Nachman,,,,0,0,eab0b3bf-f0ee-4f64-8d08-e7b467546c83
2010-10-07T08:00:00.000+08:00,5 Most Undervalued Stocks in the S&P 500,LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/10/514189/5-most-undervalued-stocks-in-the-s-p-500,Benzinga Staff,,,,0,0,c06b319c-0558-4d0b-82a8-29f051238d06
2010-10-07T08:00:00.000+08:00,5 Most Undervalued Stocks in the S&P 500,LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/10/514189/5-most-undervalued-stocks-in-the-s-p-500,Benzinga Staff,,,,0,0,5c4f700d-78d5-4839-9ccd-1cae37ff62e7
2010-10-06T08:00:00.000+08:00,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) is in talks with Eli Lilly & Co. (LLY) to be acquired in the mid $30s",LLY,https://www.benzinga.com/news/10/10/511391/unconfirmed-rumor-that-amylin-pharmaceuticals-inc-amln-is-in-talks-with-eli-lilly-,Franklin Price,,,,0,0,6d82fc2f-2684-4732-b4a8-f59422f61b2e
2010-10-06T08:00:00.000+08:00,Eli Lilly's Core Product Trends For The Week Ending 9/24,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/510677/eli-lillys-core-product-trends-for-the-week-ending-924,Joe Young,,,,0,0,aef87efd-3281-4831-8a08-14c4d747222b
2010-10-06T08:00:00.000+08:00,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) is in talks with Eli Lilly & Co. (LLY) to be acquired in the mid $30s",LLY,https://www.benzinga.com/news/10/10/511391/unconfirmed-rumor-that-amylin-pharmaceuticals-inc-amln-is-in-talks-with-eli-lilly-,Franklin Price,,,,0,0,0502d97b-6da5-4dda-b7ef-0237f02c2ef9
2010-10-06T08:00:00.000+08:00,Eli Lilly's Core Product Trends For The Week Ending 9/24,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/510677/eli-lillys-core-product-trends-for-the-week-ending-924,Joe Young,,,,0,0,a73a88a7-3de1-409d-a8ef-46aee558ffd1
2010-10-04T08:00:00.000+08:00,J&J-Galapagos in Anti-Cancer Deal - Analyst Blog,LLY,https://www.benzinga.com/10/10/507625/j-j-galapagos-in-anti-cancer-deal-analyst-blog,Zacks,,,,0,0,8ac39ebe-ee9b-478c-99d7-89b5ce9ef9b0
2010-10-04T08:00:00.000+08:00,Bristol Myers at Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/10/507623/bristol-myers-at-neutral-analyst-blog,Zacks,,,,0,0,ef868aac-bf69-4698-b47d-eb70dff3f357
2010-10-04T08:00:00.000+08:00,Male Menopause: Another Treatment for Pharmaceutical Companies,LLY,https://www.benzinga.com/10/10/507557/male-menopause-another-treatment-for-pharmaceutical-companies,Fred Fuld,,,,0,0,d218e805-3c59-4339-88c0-8b7edc69b8b3
2010-10-04T08:00:00.000+08:00,J&J-Galapagos in Anti-Cancer Deal - Analyst Blog,LLY,https://www.benzinga.com/10/10/507625/j-j-galapagos-in-anti-cancer-deal-analyst-blog,Zacks,,,,0,0,2aa6087c-5500-475e-ab7d-e6cf5278eb0d
2010-10-04T08:00:00.000+08:00,Bristol Myers at Neutral - Analyst Blog,LLY,https://www.benzinga.com/10/10/507623/bristol-myers-at-neutral-analyst-blog,Zacks,,,,0,0,8cf46352-46c4-42ee-bcb5-a726f98b3a0d
2010-10-04T08:00:00.000+08:00,Male Menopause: Another Treatment for Pharmaceutical Companies,LLY,https://www.benzinga.com/10/10/507557/male-menopause-another-treatment-for-pharmaceutical-companies,Fred Fuld,,,,0,0,073bd3d9-b4c7-43e8-938f-a7b909727685
2010-09-30T08:00:00.000+08:00,"Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, LLNW, APWR, MNKD)",LLY,https://www.benzinga.com/market-update/10/09/500887/benzingas-top-pre-market-nasdaq-gainers-snts-llnw-apwr-mnkd,Lisa Levin,,,,0,0,92956388-016d-4a9a-be47-2b110db33428
2010-09-30T08:00:00.000+08:00,"Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, LLNW, APWR, MNKD)",LLY,https://www.benzinga.com/market-update/10/09/500887/benzingas-top-pre-market-nasdaq-gainers-snts-llnw-apwr-mnkd,Lisa Levin,,,,0,0,c1b866d9-d07e-4c4a-a2f2-2dbaead9f8b7
2010-09-29T08:00:00.000+08:00,Unconfirmed Rumor that Eli Lilly & Co. (LLY) is readying bid for MannKind Corp. (MNKD) at $12.50 a share,LLY,https://www.benzinga.com/news/10/09/498994/unconfirmed-rumor-that-eli-lilly-co-lly-is-readying-bid-for-mannkind-corp-mnkd-at-,Franklin Price,,,,0,0,ac931b41-5ffc-4f81-8de5-163c92d0f84d
2010-09-29T08:00:00.000+08:00,Unconfirmed Rumor that Eli Lilly & Co. (LLY) is readying bid for MannKind Corp. (MNKD) at $12.50 a share,LLY,https://www.benzinga.com/news/10/09/498994/unconfirmed-rumor-that-eli-lilly-co-lly-is-readying-bid-for-mannkind-corp-mnkd-at-,Franklin Price,,,,0,0,1d5ec0e7-368b-4750-b253-bf1ec394c99b
2010-09-28T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Considers Apple As One Of The Best Stocks Ever, Advises Investors To Buy AT&T And Verizon, Sell A-Power Energy (AAPL, LLY, T, VZ, GOOG, APWR, LDK, ARUN)",LLY,https://www.benzinga.com/media/cnbc/10/09/495771/mad-money-lightning-round-cramer-considers-apple-as-one-of-the-best-stocks-e,Monica Gerson,,,,0,0,30b54ae4-9e22-4b58-904f-6884ea20907b
2010-09-28T08:00:00.000+08:00,"Mad Money Lightning Round: Cramer Considers Apple As One Of The Best Stocks Ever, Advises Investors To Buy AT&T And Verizon, Sell A-Power Energy (AAPL, LLY, T, VZ, GOOG, APWR, LDK, ARUN)",LLY,https://www.benzinga.com/media/cnbc/10/09/495771/mad-money-lightning-round-cramer-considers-apple-as-one-of-the-best-stocks-e,Monica Gerson,,,,0,0,a698b28e-d1c4-4246-ab4f-3f266d347fb3
2010-09-23T08:00:00.000+08:00,Lilly CEO Says Regional Innovation Important to the Nation's Economy (LLY),LLY,https://www.benzinga.com/life/politics/10/09/488801/lilly-ceo-says-regional-innovation-important-to-the-nations-economy-lly,Benzinga Staff,,,,0,0,a8abd285-33a8-446b-ab1d-c688a7e70512
2010-09-23T08:00:00.000+08:00,Yield Versus Yield,LLY,https://www.benzinga.com/10/09/488911/yield-versus-yield,Roger Nusbaum,,,,0,0,22947b8e-0299-42ac-96fa-302f4b18cac6
2010-09-23T08:00:00.000+08:00,Lilly CEO Says Regional Innovation Important to the Nation's Economy (LLY),LLY,https://www.benzinga.com/life/politics/10/09/488801/lilly-ceo-says-regional-innovation-important-to-the-nations-economy-lly,Benzinga Staff,,,,0,0,6ba97673-ecee-4b7d-91fc-70ce9b3c62fb
2010-09-23T08:00:00.000+08:00,Yield Versus Yield,LLY,https://www.benzinga.com/10/09/488911/yield-versus-yield,Roger Nusbaum,,,,0,0,aefd7cf9-db61-40c5-8861-d8ffaf1cd784
2010-09-22T08:00:00.000+08:00,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) will be taken out by Eli Lilly & Co. (LLY) at $32.00",LLY,https://www.benzinga.com/news/10/09/487087/unconfirmed-rumor-that-amylin-pharmaceuticals-inc-amln-will-be-taken-out-by-eli-li,Franklin Price,,,,0,0,bd07ac6d-2160-4db3-adaa-419e63200064
2010-09-22T08:00:00.000+08:00,"Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) will be taken out by Eli Lilly & Co. (LLY) at $32.00",LLY,https://www.benzinga.com/news/10/09/487087/unconfirmed-rumor-that-amylin-pharmaceuticals-inc-amln-will-be-taken-out-by-eli-li,Franklin Price,,,,0,0,b5e78bb2-ebe8-44a8-bd6e-d5921115f25f
2010-09-21T08:00:00.000+08:00,Jeffrey A. Winton Named VP At Eli Lilly And Company (LLY),LLY,https://www.benzinga.com/news/10/09/484545/jeffrey-a-winton-named-vp-at-eli-lilly-and-company-lly,Benzinga Staff,,,,0,0,b26b0f46-ccf6-4d1d-801c-af50bd4d7038
2010-09-21T08:00:00.000+08:00,J.P. Morgan Has Underweight Rating On Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/09/484253/j-p-morgan-has-underweight-rating-on-eli-lilly-lly,Roger Nachman,,,,0,0,404c6fd5-65bd-4a1d-854b-59fcd65a06ca
2010-09-21T08:00:00.000+08:00,Jeffrey A. Winton Named VP At Eli Lilly And Company (LLY),LLY,https://www.benzinga.com/news/10/09/484545/jeffrey-a-winton-named-vp-at-eli-lilly-and-company-lly,Benzinga Staff,,,,0,0,b09369b3-751b-463c-9f8c-503f9eae0123
2010-09-21T08:00:00.000+08:00,J.P. Morgan Has Underweight Rating On Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/09/484253/j-p-morgan-has-underweight-rating-on-eli-lilly-lly,Roger Nachman,,,,0,0,c1c1a833-8632-4f5e-93bd-a065c3d30bbd
2010-09-20T08:00:00.000+08:00,Pipeline Setback for TTHI - Analyst Blog,LLY,https://www.benzinga.com/10/09/483429/pipeline-setback-for-tthi-analyst-blog,Zacks,,,,0,0,15e6a019-2eb7-4ee5-ad72-67a7f04f3332
2010-09-20T08:00:00.000+08:00,Pipeline Setback for TTHI - Analyst Blog,LLY,https://www.benzinga.com/10/09/483429/pipeline-setback-for-tthi-analyst-blog,Zacks,,,,0,0,25ad6e4b-e11c-42fd-9cb6-e1315e96217b
2010-09-17T08:00:00.000+08:00,Thumbs Up for ALKS Drug - Analyst Blog,LLY,https://www.benzinga.com/10/09/480240/thumbs-up-for-alks-drug-analyst-blog,Zacks,,,,0,0,2eff8e4c-d2fc-4d8a-b8c4-dbc2fcc21438
2010-09-17T08:00:00.000+08:00,Thumbs Up for ALKS Drug - Analyst Blog,LLY,https://www.benzinga.com/10/09/480240/thumbs-up-for-alks-drug-analyst-blog,Zacks,,,,0,0,10bfabfc-89c4-4034-86f3-0e2813a1262d
2010-09-15T08:00:00.000+08:00,Pharmaceutical Stocks Worth Owning For The Dividend Alone,LLY,https://www.benzinga.com/10/09/476393/pharmaceutical-stocks-worth-owning-for-the-dividend-alone,Mark Riddix,,,,0,0,b8456e4d-452e-4220-9fab-7c5f81a6d30b
2010-09-15T08:00:00.000+08:00,Pharmaceutical Stocks Worth Owning For The Dividend Alone,LLY,https://www.benzinga.com/10/09/476391/pharmaceutical-stocks-worth-owning-for-the-dividend-alone,Mark Riddix,,,,0,0,063da7b3-57a8-45db-b73f-1626b1a110bb
2010-09-15T08:00:00.000+08:00,Pharmaceutical Stocks Worth Owning For The Dividend Alone,LLY,https://www.benzinga.com/10/09/476393/pharmaceutical-stocks-worth-owning-for-the-dividend-alone,Mark Riddix,,,,0,0,eb360189-4b3b-4fcc-9dc9-3946e0e3ea83
2010-09-15T08:00:00.000+08:00,Pharmaceutical Stocks Worth Owning For The Dividend Alone,LLY,https://www.benzinga.com/10/09/476391/pharmaceutical-stocks-worth-owning-for-the-dividend-alone,Mark Riddix,,,,0,0,f4be8dcb-adcc-466d-a22b-7fb2a98dc28b
2010-09-10T08:00:00.000+08:00,More Unconfirmed Chatter On Vivus Takeover (VVUS),LLY,https://www.benzinga.com/news/m-a/10/09/467374/more-unconfirmed-chatter-on-vivus-takeover-vvus,Roger Nachman,,,,0,0,122e8bd0-52a6-4e0c-ac88-57ea8bb755e1
2010-09-10T08:00:00.000+08:00,More Unconfirmed Chatter On Vivus Takeover (VVUS),LLY,https://www.benzinga.com/news/m-a/10/09/467374/more-unconfirmed-chatter-on-vivus-takeover-vvus,Roger Nachman,,,,0,0,60041edb-2f2c-4081-8d27-7154309cfe18
2010-09-03T08:00:00.000+08:00,PDLI Gives Third-Quarter Outlook - Analyst Blog,LLY,https://www.benzinga.com/10/09/456734/pdli-gives-third-quarter-outlook-analyst-blog,Zacks,,,,0,0,f6e1b60a-7cd1-408a-8c71-b4beffccab3c
2010-09-03T08:00:00.000+08:00,PDLI Gives Third-Quarter Outlook - Analyst Blog,LLY,https://www.benzinga.com/10/09/456734/pdli-gives-third-quarter-outlook-analyst-blog,Zacks,,,,0,0,7417ba45-579f-4725-ac87-ce44d657e976
2010-09-01T08:00:00.000+08:00,U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents (LLY),LLY,https://www.benzinga.com/company-news/10/09/453140/u-s-court-of-appeals-upholds-validity-of-lillys-evista-patents-lly,Benzinga Staff,,,,0,0,dfaee4db-5f32-45dd-afb6-da18c297b9f6
2010-09-01T08:00:00.000+08:00,U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents (LLY),LLY,https://www.benzinga.com/company-news/10/09/453140/u-s-court-of-appeals-upholds-validity-of-lillys-evista-patents-lly,Benzinga Staff,,,,0,0,ee4412b5-8c42-472c-bf79-1da0ccbf04cd
2010-08-30T08:00:00.000+08:00,Incyte Evenly Poised - Analyst Blog,LLY,https://www.benzinga.com/10/08/448427/incyte-evenly-poised-analyst-blog,Zacks,,,,0,0,0c826c13-f492-48f4-839e-bebccb9d9ac9
2010-08-30T08:00:00.000+08:00,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/448162/goldman-sachs-introduces-and-adjusts-estimates-for-major-,Monica Gerson,,,,0,0,ce1dd121-df3d-486b-8e15-78deecf0289b
2010-08-30T08:00:00.000+08:00,Incyte Evenly Poised - Analyst Blog,LLY,https://www.benzinga.com/10/08/448427/incyte-evenly-poised-analyst-blog,Zacks,,,,0,0,66ddd79e-5899-477c-ba44-964fec5ede98
2010-08-30T08:00:00.000+08:00,Goldman Sachs Introduces And Adjusts Estimates For Major Pharmaceuticals,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/448162/goldman-sachs-introduces-and-adjusts-estimates-for-major-,Monica Gerson,,,,0,0,915ae903-ce77-4c98-8d77-3482c90ede5c
2010-08-26T08:00:00.000+08:00,Repros Schedules Meeting with FDA - Analyst Blog,LLY,https://www.benzinga.com/10/08/445043/repros-schedules-meeting-with-fda-analyst-blog,Zacks,,,,0,0,26f03ae3-0a0c-43c1-a384-ea10fe5ec730
2010-08-26T08:00:00.000+08:00,VVUS) Unconfirmed rumor that (LLY) will buy the company for $9.00 Cash,LLY,https://www.benzinga.com/markets/company-news/10/08/444239/vvus-unconfirmed-rumor-that-lly-will-buy-the-company-for-9-00-cash,Franklin Price,,,,0,0,f0c0ceaa-3801-41a9-bac6-561a563f9bf8
2010-08-26T08:00:00.000+08:00,Repros Schedules Meeting with FDA - Analyst Blog,LLY,https://www.benzinga.com/10/08/445043/repros-schedules-meeting-with-fda-analyst-blog,Zacks,,,,0,0,b90469dd-f3b1-45e5-9989-fa8e720c74ca
2010-08-26T08:00:00.000+08:00,VVUS) Unconfirmed rumor that (LLY) will buy the company for $9.00 Cash,LLY,https://www.benzinga.com/markets/company-news/10/08/444239/vvus-unconfirmed-rumor-that-lly-will-buy-the-company-for-9-00-cash,Franklin Price,,,,0,0,02e7bbfa-36f9-43d9-8cdd-7d2db70a8de7
2010-08-20T08:00:00.000+08:00,Jefferies Reiterates Hold Rating on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/437629/jefferies-reiterates-hold-rating-on-eli-lilly-lly,Michael J. Zerinskas,,,,0,0,05afaed2-30c8-40d2-8302-bde41c7f59e7
2010-08-20T08:00:00.000+08:00,Jefferies Reiterates Hold Rating on Eli Lilly (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/437629/jefferies-reiterates-hold-rating-on-eli-lilly-lly,Michael J. Zerinskas,,,,0,0,c746bb6b-1cb1-4dd1-93ed-c0249c8e6599
2010-08-18T08:00:00.000+08:00,FDA Panel to Review Eli Lilly's Cymbalta - Analyst Blog,LLY,https://www.benzinga.com/10/08/434309/fda-panel-to-review-eli-lillys-cymbalta-analyst-blog,Zacks,,,,0,0,656517f4-bbc1-4ac7-8154-40f0974fed1b
2010-08-18T08:00:00.000+08:00,FDA Panel to Review Eli Lilly's Cymbalta - Analyst Blog,LLY,https://www.benzinga.com/10/08/434309/fda-panel-to-review-eli-lillys-cymbalta-analyst-blog,Zacks,,,,0,0,5206b2e6-bd3f-4e13-b002-c0c7917b2b41
2010-08-17T08:00:00.000+08:00,Eli Lilly Halts Development Of Alzheimer Drug (LLY),LLY,https://www.benzinga.com/markets/company-news/10/08/431859/eli-lilly-halts-development-of-alzheimer-drug-lly,Scott Rubin,,,,0,0,7319c888-9c99-4784-bd11-f41f5bb55cea
2010-08-17T08:00:00.000+08:00,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/430766/top-4-large-cap-stocks-in-the-healthcare-sector-with-the-highe,Lisa Levin,,,,0,0,23d8c164-1ad7-43cb-8906-5db4953bf977
2010-08-17T08:00:00.000+08:00,Eli Lilly Halts Development Of Alzheimer Drug (LLY),LLY,https://www.benzinga.com/markets/company-news/10/08/431859/eli-lilly-halts-development-of-alzheimer-drug-lly,Scott Rubin,,,,0,0,718524cf-7fdc-4467-a13b-f9e329d1befe
2010-08-17T08:00:00.000+08:00,"Top 4 Large-Cap Stocks In The Healthcare Sector With The Highest Dividend Yield (LLY, BMY, GSK, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/430766/top-4-large-cap-stocks-in-the-healthcare-sector-with-the-highe,Lisa Levin,,,,0,0,74750494-3fc0-4fd8-84db-f1029d79f39e
2010-08-13T08:00:00.000+08:00,All Is Not Well In The Pharmaceutical Industry,LLY,https://www.benzinga.com/markets/company-news/10/08/427658/all-is-not-well-in-the-pharmaceutical-industry,Monica Gerson,,,,0,0,1e3ff86b-fa65-413f-ae05-3a4ab8f2e53f
2010-08-13T08:00:00.000+08:00,Eli Lilly Cuts Revenue Guidance - Analyst Blog,LLY,https://www.benzinga.com/10/08/427545/eli-lilly-cuts-revenue-guidance-analyst-blog,Zacks,,,,0,0,0735e8a9-d46e-47f6-9da1-d7e200a1008f
2010-08-13T08:00:00.000+08:00,Eli Lilly Loses Strattera Patent Case; Hapoalim Securities Reiterates Sell Rating (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/427398/eli-lilly-loses-strattera-patent-case-hapoalim-securities,Scott Rubin,,,,0,0,741dcf6d-025f-47c9-8139-85d7f8dfcf9c
2010-08-13T08:00:00.000+08:00,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)",LLY,https://www.benzinga.com/markets/company-news/10/08/427275/u-s-probing-pharmaceutical-corruption-gsk-pfe-bmy-lly,Ronald Weisenstein,,,,0,0,51ea9516-299d-4f92-b92b-6f1174771b9b
2010-08-13T08:00:00.000+08:00,All Is Not Well In The Pharmaceutical Industry,LLY,https://www.benzinga.com/markets/company-news/10/08/427658/all-is-not-well-in-the-pharmaceutical-industry,Monica Gerson,,,,0,0,404dfd7b-1288-43d4-8a42-fc6f6c70cda0
2010-08-13T08:00:00.000+08:00,Eli Lilly Cuts Revenue Guidance - Analyst Blog,LLY,https://www.benzinga.com/10/08/427545/eli-lilly-cuts-revenue-guidance-analyst-blog,Zacks,,,,0,0,faed4075-a659-47db-9bd8-40f4054bf277
2010-08-13T08:00:00.000+08:00,Eli Lilly Loses Strattera Patent Case; Hapoalim Securities Reiterates Sell Rating (LLY),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/427398/eli-lilly-loses-strattera-patent-case-hapoalim-securities,Scott Rubin,,,,0,0,5f76de24-97aa-4a7e-9c18-db56ffd6bead
2010-08-13T08:00:00.000+08:00,"U.S. Probing Pharmaceutical Corruption (GSK, PFE, BMY, LLY)",LLY,https://www.benzinga.com/markets/company-news/10/08/427275/u-s-probing-pharmaceutical-corruption-gsk-pfe-bmy-lly,Ronald Weisenstein,,,,0,0,e03cec7f-da02-44ba-8bdc-ce93d39dff96
2010-08-12T08:00:00.000+08:00,Amgen's Vectibix Disappoints - Analyst Blog,LLY,https://www.benzinga.com/10/08/426077/amgens-vectibix-disappoints-analyst-blog,Zacks,,,,0,0,86e44641-6cfd-4f22-9ece-94d77522a5a0
2010-08-12T08:00:00.000+08:00,Amgen's Vectibix Disappoints - Analyst Blog,LLY,https://www.benzinga.com/10/08/426077/amgens-vectibix-disappoints-analyst-blog,Zacks,,,,0,0,d61a4d15-3010-4247-911d-90cb2d19cf89
2010-08-11T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/422556/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Lisa Levin,,,,0,0,3ea312a6-8c75-4dba-a5fa-057bfaaef721
2010-08-11T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (LLY, GSK, BMY, PFE)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/422556/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Lisa Levin,,,,0,0,60c4cd2b-c9b2-439a-8e79-c09b93fbead4
2010-08-09T08:00:00.000+08:00,Revenues Dip at Alkermes - Analyst Blog,LLY,https://www.benzinga.com/10/08/419705/revenues-dip-at-alkermes-analyst-blog,Zacks,,,,0,0,b5955f79-38f1-4bcd-80ea-568fb78d374d
2010-08-09T08:00:00.000+08:00,Finally There Is A Cure For Tobacco Addiction (CIGX),LLY,https://www.benzinga.com/markets/company-news/10/08/418540/finally-there-is-a-cure-for-tobacco-addiction-cigx,Monica Gerson,,,,0,0,3902b328-ddcd-40d1-be85-a2086ea09e2c
2010-08-09T08:00:00.000+08:00,Revenues Dip at Alkermes - Analyst Blog,LLY,https://www.benzinga.com/10/08/419705/revenues-dip-at-alkermes-analyst-blog,Zacks,,,,0,0,9230028a-113e-4068-9a46-84a6164853a4
2010-08-09T08:00:00.000+08:00,Finally There Is A Cure For Tobacco Addiction (CIGX),LLY,https://www.benzinga.com/markets/company-news/10/08/418540/finally-there-is-a-cure-for-tobacco-addiction-cigx,Monica Gerson,,,,0,0,e0d6a3b5-7907-412d-99ca-af4dff07fe92
2010-08-03T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of August 2010,LLY,https://www.benzinga.com/10/08/407524/stocks-going-ex-dividend-the-second-week-of-august-2010,Fred Fuld,,,,0,0,922708ec-52de-4f50-86cb-8ed6d8ca9907
2010-08-03T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of August 2010,LLY,https://www.benzinga.com/10/08/407524/stocks-going-ex-dividend-the-second-week-of-august-2010,Fred Fuld,,,,0,0,24fcf7e7-8a26-4b8c-a0c0-e229a68d9e06
2010-08-02T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/405780/top-4-nyse-stocks-in-the-healthcare-sector-with-the-highest-fr,Monica Gerson,,,,0,0,c7da8f5e-10bb-4bef-9ab9-ae3d8cbee2c3
2010-08-02T08:00:00.000+08:00,"Top 4 NYSE Stocks In The Healthcare Sector With The Highest Free Cash Flow (PFE, JNJ, MRK, LLY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/08/405780/top-4-nyse-stocks-in-the-healthcare-sector-with-the-highest-fr,Monica Gerson,,,,0,0,7826e95b-9604-4e35-97a6-0b29dc454a10
2010-07-30T08:00:00.000+08:00,July Impressive -- S&Ps Up 6.9% 07-30-2010,LLY,https://www.benzinga.com/10/07/404892/july-impressive-s-ps-up-6-9-07-30-2010,optionsXpress,,,,0,0,44ea00ea-e0ca-4e05-a877-ff18780d60b4
2010-07-30T08:00:00.000+08:00,July Impressive -- S&Ps Up 6.9% 07-30-2010,LLY,https://www.benzinga.com/10/07/404892/july-impressive-s-ps-up-6-9-07-30-2010,optionsXpress,,,,0,0,c78a0bd4-af56-4c83-943b-348b43b87005
2010-07-26T08:00:00.000+08:00,Corporate Catalysts For The Week Starting July 26,LLY,https://www.benzinga.com/markets/company-news/10/07/393588/corporate-catalysts-for-the-week-starting-july-26,Monica Gerson,,,,0,0,04c999e7-91fd-4d45-8d84-850a39aacfdf
2010-07-26T08:00:00.000+08:00,Corporate Catalysts For The Week Starting July 26,LLY,https://www.benzinga.com/markets/company-news/10/07/393588/corporate-catalysts-for-the-week-starting-july-26,Monica Gerson,,,,0,0,518b8a7b-df17-4eea-9dcb-13230048da12
2010-07-22T08:00:00.000+08:00,Markets Surge on Strong Corporate Earnings (SPY),LLY,https://www.benzinga.com/global/10/07/390044/markets-surge-on-strong-corporate-earnings-spy,Ronald Weisenstein,,,,0,0,9f3ab463-ead8-404b-9764-aff893b85db3
2010-07-22T08:00:00.000+08:00,"Eli Lilly Beats Estimates, Raises Forecast (LLY)",LLY,https://www.benzinga.com/markets/company-news/10/07/389573/eli-lilly-beats-estimates-raises-forecast-lly,Daniel Hayden IV,,,,0,0,57d1b093-5dc2-4d25-b5c2-fd5313098ece
2010-07-22T08:00:00.000+08:00,"Eli Lilly Reports Strong Sales, Beats on Profit (LLY)",LLY,https://www.benzinga.com/markets/company-news/10/07/389534/eli-lilly-reports-strong-sales-beats-on-profit-lly,Ronald Weisenstein,,,,0,0,4f3dca7c-ac14-4fa3-b04d-22ffa0f2b3e6
2010-07-22T08:00:00.000+08:00,"Eli Lilly Posts Better-Than-Expected Q2 Results, Raises 2010 EPS Guidance",LLY,https://www.benzinga.com/markets/company-news/10/07/389479/eli-lilly-posts-better-than-expected-q2-results-raises-2010-eps-gu,Monica Gerson,,,,0,0,1f2084cb-a2b4-4019-8282-3a92dfb023ed
2010-07-22T08:00:00.000+08:00,Markets Surge on Strong Corporate Earnings (SPY),LLY,https://www.benzinga.com/global/10/07/390044/markets-surge-on-strong-corporate-earnings-spy,Ronald Weisenstein,,,,0,0,59aea553-62e2-45e0-9476-edf6760c2d05
2010-07-22T08:00:00.000+08:00,"Eli Lilly Beats Estimates, Raises Forecast (LLY)",LLY,https://www.benzinga.com/markets/company-news/10/07/389573/eli-lilly-beats-estimates-raises-forecast-lly,Daniel Hayden IV,,,,0,0,e4a0f5d8-3713-4526-9088-74f708cf7ead
2010-07-22T08:00:00.000+08:00,"Eli Lilly Reports Strong Sales, Beats on Profit (LLY)",LLY,https://www.benzinga.com/markets/company-news/10/07/389534/eli-lilly-reports-strong-sales-beats-on-profit-lly,Ronald Weisenstein,,,,0,0,49966763-bdaa-42a7-9a85-d56725a5fcee
2010-07-22T08:00:00.000+08:00,"Eli Lilly Posts Better-Than-Expected Q2 Results, Raises 2010 EPS Guidance",LLY,https://www.benzinga.com/markets/company-news/10/07/389479/eli-lilly-posts-better-than-expected-q2-results-raises-2010-eps-gu,Monica Gerson,,,,0,0,1d5cdba6-b18d-41d7-9520-ab0a3fbccee4
2010-07-06T08:00:00.000+08:00,Lechleiter Says LLY Has The Most Exciting Pipeline,LLY,https://www.benzinga.com/markets/company-news/10/07/363530/lechleiter-says-lly-has-the-most-exciting-pipeline,Monica Gerson,,,,0,0,115c3584-b198-43e4-905b-a6167f3b348b
2010-07-06T08:00:00.000+08:00,"News Summary (LLY, TM)",LLY,https://www.benzinga.com/markets/company-news/10/07/362862/news-summary-lly-tm,Monica Gerson,,,,0,0,da8ffda4-d6cc-41a8-a704-1df88cd9021b
2010-07-06T08:00:00.000+08:00,Lechleiter Says LLY Has The Most Exciting Pipeline,LLY,https://www.benzinga.com/markets/company-news/10/07/363530/lechleiter-says-lly-has-the-most-exciting-pipeline,Monica Gerson,,,,0,0,07c5b7d1-53bc-4e12-bc90-11b5f406dd25
2010-07-06T08:00:00.000+08:00,"News Summary (LLY, TM)",LLY,https://www.benzinga.com/markets/company-news/10/07/362862/news-summary-lly-tm,Monica Gerson,,,,0,0,fbaea16c-0e7a-41a1-a3c0-a0ede37df75c
2010-07-02T08:00:00.000+08:00,Calls Purchased on Eli Lilly & Co. (LLY),LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/07/360666/calls-purchased-on-eli-lilly-co-lly,Michael J. Zerinskas,,,,0,0,87f45571-983c-43c3-a08b-0cfc89a0f20f
2010-07-02T08:00:00.000+08:00,Calls Purchased on Eli Lilly & Co. (LLY),LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/07/360666/calls-purchased-on-eli-lilly-co-lly,Michael J. Zerinskas,,,,0,0,5f95461b-7e96-4319-8e39-81bef6ffbca0
2010-06-30T08:00:00.000+08:00,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/06/355821/top-4-stocks-in-the-drug-manufacturers-major-industry-with-the,Monica Gerson,,,,0,0,8c0c8342-9217-4c21-bae6-0ae5f5a1dd21
2010-06-30T08:00:00.000+08:00,"Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Dividend Yield (AZN, LLY, GSK, BMY)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/10/06/355821/top-4-stocks-in-the-drug-manufacturers-major-industry-with-the,Monica Gerson,,,,0,0,e85daf53-b50c-4a27-be4d-f443fc82f671
2010-06-28T08:00:00.000+08:00,Hapoalim Securities Expects Eli Lilly To Acquire Amylin Pharmaceuticals Post Approval Of AMLN’s Bydureon,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/351319/hapoalim-securities-expects-eli-lilly-to-acquire-amylin-p,Monica Gerson,,,,0,0,a2bda991-264e-401c-8d8c-8485ffee5c31
2010-06-28T08:00:00.000+08:00,Hapoalim Securities Expects Eli Lilly To Acquire Amylin Pharmaceuticals Post Approval Of AMLN’s Bydureon,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/351319/hapoalim-securities-expects-eli-lilly-to-acquire-amylin-p,Monica Gerson,,,,0,0,92569842-628c-48b1-83a2-464299e0c999
2010-06-10T08:00:00.000+08:00,MannKind Corp. Glosses Over FDA Meeting; Hapoalim Balks (MNKD),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/326447/mannkind-corp-glosses-over-fda-meeting-hapoalim-balks-mnk,Benzinga Staff,,,,0,0,c763155e-b4db-448d-8247-7e38f01f633f
2010-06-10T08:00:00.000+08:00,News Summary,LLY,https://www.benzinga.com/markets/company-news/10/06/326430/news-summary,Monica Gerson,,,,0,0,2ae23abd-d90e-4d8a-8b3b-71cb86167eeb
2010-06-10T08:00:00.000+08:00,MannKind Corp. Glosses Over FDA Meeting; Hapoalim Balks (MNKD),LLY,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/326447/mannkind-corp-glosses-over-fda-meeting-hapoalim-balks-mnk,Benzinga Staff,,,,0,0,3713c1eb-9efd-4f20-aac6-a48c714b00f5
2010-06-10T08:00:00.000+08:00,News Summary,LLY,https://www.benzinga.com/markets/company-news/10/06/326430/news-summary,Monica Gerson,,,,0,0,93eed736-9b23-4d90-aabe-d5b14baee313
2010-06-07T08:00:00.000+08:00,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)",LLY,https://www.benzinga.com/markets/company-news/10/06/317702/top-5-large-cap-nyse-stocks-in-the-healthcare-sector-with-the-high,Monica Gerson,,,,0,0,7e56a28b-164d-4974-8837-b7e8bc679433
2010-06-07T08:00:00.000+08:00,"Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)",LLY,https://www.benzinga.com/markets/company-news/10/06/317702/top-5-large-cap-nyse-stocks-in-the-healthcare-sector-with-the-high,Monica Gerson,,,,0,0,3c2272ed-c8ba-4327-92a5-2346dcd9b57d
2010-05-27T08:00:00.000+08:00,"With Interest Rates this low, Should Investors Look to Equity Dividend Yields?",LLY,https://www.benzinga.com/10/05/304265/with-interest-rates-this-low-should-investors-look-to-equity-dividend-yields,Options House,,,,0,0,506e4f0f-6fab-433d-ac57-e499f9f3b712
2010-05-27T08:00:00.000+08:00,"With Interest Rates this low, Should Investors Look to Equity Dividend Yields?",LLY,https://www.benzinga.com/10/05/304265/with-interest-rates-this-low-should-investors-look-to-equity-dividend-yields,Options House,,,,0,0,d57aa554-7653-4af5-a347-dc13ef034197
2010-05-13T08:00:00.000+08:00,Companies Dodge $60 Billion in Taxes,LLY,https://www.benzinga.com/markets/company-news/10/05/280860/companies-dodge-60-billion-in-taxes,Michael J. Zerinskas,,,,0,0,72abb59c-98c1-4ce0-b0c3-62039938be39
2010-05-13T08:00:00.000+08:00,Companies Dodge $60 Billion in Taxes,LLY,https://www.benzinga.com/markets/company-news/10/05/280860/companies-dodge-60-billion-in-taxes,Michael J. Zerinskas,,,,0,0,947755b1-ea2d-4ebe-9729-c35fe2cbd5c9
2010-05-03T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of May,LLY,https://www.benzinga.com/257335/stocks-going-ex-dividend-the-second-week-of-may,Fred Fuld,,,,0,0,f6bd05a5-ea5a-491d-a370-8759eb7195fa
2010-05-03T08:00:00.000+08:00,Stocks Going Ex Dividend the Second Week of May,LLY,https://www.benzinga.com/257335/stocks-going-ex-dividend-the-second-week-of-may,Fred Fuld,,,,0,0,b8ec41a1-4a2b-4929-9257-ce7373dc516e
2010-04-28T08:00:00.000+08:00,"Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)",LLY,https://www.benzinga.com/markets/company-news/249094/whistleblower-gets-rewarded-in-astrazeneca-case-azn-lly,Benzinga Staff 5,,,,0,0,91543285-9f4d-4f93-b96f-b7e1bcf3bfba
2010-04-28T08:00:00.000+08:00,"Whistleblower Gets Rewarded In AstraZeneca Case (AZN, LLY)",LLY,https://www.benzinga.com/markets/company-news/249094/whistleblower-gets-rewarded-in-astrazeneca-case-azn-lly,Benzinga Staff 5,,,,0,0,99f22812-ccc0-4be4-81c1-7914b9965bb0
2010-04-21T08:00:00.000+08:00,"Afternoon-Market Update Abbott Labs (NYSE: ABT), Boeing (NYSE: BA), Tempur-Pedic (NYSE: TPX)",LLY,https://www.benzinga.com/markets/company-news/237003/afternoon-market-update-abbott-labs-nyse-abt-boeing-nyse-ba-tempur-pedic,Monica Gerson,,,,0,0,3bb3c559-e06e-47ed-94fe-f0fa8b8447a8
2010-04-21T08:00:00.000+08:00,"Afternoon-Market Update Abbott Labs (NYSE: ABT), Boeing (NYSE: BA), Tempur-Pedic (NYSE: TPX)",LLY,https://www.benzinga.com/markets/company-news/237003/afternoon-market-update-abbott-labs-nyse-abt-boeing-nyse-ba-tempur-pedic,Monica Gerson,,,,0,0,dd9edff7-252b-4f02-8068-f032480a3e16
2010-04-19T08:00:00.000+08:00,"Company News for April 19, 2010 - Corporate Summary",LLY,https://www.benzinga.com/230041/company-news-for-april-19-2010-corporate-summary,Zacks,,,,0,0,fa89c31e-c449-4730-9458-875a6099d22e
2010-04-19T08:00:00.000+08:00,Eli Lilly Slashes Earnings Guidance (LLY),LLY,https://www.benzinga.com/markets/company-news/229891/eli-lilly-slashes-earnings-guidance-lly,Bud Fox,,,,0,0,4103fea3-e99b-4f4d-8543-4660adf607c4
2010-04-19T08:00:00.000+08:00,Bulls Bet on Eli Lilly,LLY,https://www.benzinga.com/trading-ideas/long-ideas/229651/bulls-bet-on-eli-lilly,Michael J. Zerinskas,,,,0,0,d789e0d0-815b-47cc-9052-f448aef4010a
2010-04-19T08:00:00.000+08:00,US Stock Futures Point To A Weak Opening; Investors Eyeing Citigroup Results,LLY,https://www.benzinga.com/markets/company-news/229516/us-stock-futures-point-to-a-weak-opening-investors-eyeing-citigroup-resu,Monica Gerson,,,,0,0,d44d3d88-bb3e-4887-9c90-136fd17ff5a4
2010-04-19T08:00:00.000+08:00,Eli Lilly & Co. (LLY) Reports A 5% Drop In First-Quarter Profit,LLY,https://www.benzinga.com/markets/company-news/229455/eli-lilly-co-lly-reports-a-5-drop-in-first-quarter-profit,Benzinga Staff 5,,,,0,0,0561e87e-8e93-4ef1-b081-3ea189fd8aa8
2010-04-19T08:00:00.000+08:00,"Stocks To Watch On April 19 (C, HAL, LLY, IBM, ZION)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/229454/stocks-to-watch-on-april-19-c-hal-lly-ibm-zion,Monica Gerson,,,,0,0,2c33be98-67f6-49b3-8e8d-485bb5afcc4d
2010-04-19T08:00:00.000+08:00,"Eli Lilly and Co. (LLY) Profit Falls 5%, As Revenues Climb",LLY,https://www.benzinga.com/markets/company-news/229447/eli-lilly-and-co-lly-profit-falls-5-as-revenues-climb,Daniel Hayden IV,,,,0,0,b30a5fb6-cb1c-4c76-8516-d96092d8dce8
2010-04-19T08:00:00.000+08:00,"Company News for April 19, 2010 - Corporate Summary",LLY,https://www.benzinga.com/230041/company-news-for-april-19-2010-corporate-summary,Zacks,,,,0,0,98586998-9ae8-4429-aec8-f464016b641b
2010-04-19T08:00:00.000+08:00,Eli Lilly Slashes Earnings Guidance (LLY),LLY,https://www.benzinga.com/markets/company-news/229891/eli-lilly-slashes-earnings-guidance-lly,Bud Fox,,,,0,0,016d9cd1-a207-485c-b485-8ca59f431f86
2010-04-19T08:00:00.000+08:00,Bulls Bet on Eli Lilly,LLY,https://www.benzinga.com/trading-ideas/long-ideas/229651/bulls-bet-on-eli-lilly,Michael J. Zerinskas,,,,0,0,beae43fa-1e65-4f6c-87fb-fb73db439a8c
2010-04-19T08:00:00.000+08:00,US Stock Futures Point To A Weak Opening; Investors Eyeing Citigroup Results,LLY,https://www.benzinga.com/markets/company-news/229516/us-stock-futures-point-to-a-weak-opening-investors-eyeing-citigroup-resu,Monica Gerson,,,,0,0,e6416617-f162-49a1-9acb-974e674124ad
2010-04-19T08:00:00.000+08:00,Eli Lilly & Co. (LLY) Reports A 5% Drop In First-Quarter Profit,LLY,https://www.benzinga.com/markets/company-news/229455/eli-lilly-co-lly-reports-a-5-drop-in-first-quarter-profit,Benzinga Staff 5,,,,0,0,cd0ab9c6-4975-49b8-ac54-2b9d6690aec2
2010-04-19T08:00:00.000+08:00,"Stocks To Watch On April 19 (C, HAL, LLY, IBM, ZION)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/229454/stocks-to-watch-on-april-19-c-hal-lly-ibm-zion,Monica Gerson,,,,0,0,31a19820-b905-4869-a796-1df3304ad25d
2010-04-19T08:00:00.000+08:00,"Eli Lilly and Co. (LLY) Profit Falls 5%, As Revenues Climb",LLY,https://www.benzinga.com/markets/company-news/229447/eli-lilly-and-co-lly-profit-falls-5-as-revenues-climb,Daniel Hayden IV,,,,0,0,58902234-7eb4-4bb4-8ed3-9b0d6cd55cd6
2010-04-01T08:00:00.000+08:00,Citigroup Rates Teva Pharmaceutical Industries (TEVA) A Buy After Court Ruling,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/204686/citigroup-rates-teva-pharmaceutical-industries-teva-a-buy-after,Daniel Hayden IV,,,,0,0,d11ca51b-bc18-45f1-8c04-d57cb8b9bc68
2010-04-01T08:00:00.000+08:00,Citigroup Rates Teva Pharmaceutical Industries (TEVA) A Buy After Court Ruling,LLY,https://www.benzinga.com/analyst-ratings/analyst-color/204686/citigroup-rates-teva-pharmaceutical-industries-teva-a-buy-after,Daniel Hayden IV,,,,0,0,af754ff8-9eb8-4c47-9fec-f1bb9d167929
2010-03-29T08:00:00.000+08:00,"There Are Still Some Bargains In The Market; Barron’s (LLY, PFE, GS, MS, CVX)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/197656/there-are-still-some-bargains-in-the-market-barron%E2%80%99s-lly-pfe-gs-ms-c,Benzinga Staff 5,,,,0,0,51855640-0c67-4e6c-99d4-ebcd49135162
2010-03-29T08:00:00.000+08:00,"There Are Still Some Bargains In The Market; Barron’s (LLY, PFE, GS, MS, CVX)",LLY,https://www.benzinga.com/trading-ideas/long-ideas/197656/there-are-still-some-bargains-in-the-market-barron%E2%80%99s-lly-pfe-gs-ms-c,Benzinga Staff 5,,,,0,0,0cd7a1e2-abf3-4af4-b713-95ce642b674d
2010-03-24T08:00:00.000+08:00,Investors Need To Pay More Attention To Dividend ETFs In 2010,LLY,https://www.benzinga.com/190222/investors-need-to-pay-more-attention-to-dividend-etfs-in-2010,David Bettencourt,,,,0,0,792719f7-644b-490b-9325-9c5bbe451cac
2010-03-24T08:00:00.000+08:00,Investors Need To Pay More Attention To Dividend ETFs In 2010,LLY,https://www.benzinga.com/190222/investors-need-to-pay-more-attention-to-dividend-etfs-in-2010,David Bettencourt,,,,0,0,e052e5a1-7e64-4268-b52c-6cac5f996313
2010-03-23T08:00:00.000+08:00,Before Jumping Into A Single Health Care Stock Consider This ETF,LLY,https://www.benzinga.com/188732/before-jumping-into-a-single-health-care-stock-consider-this-etf,David Bettencourt,,,,0,0,ba5b24ba-dccd-4588-ae44-052622138ce0
2010-03-23T08:00:00.000+08:00,Before Jumping Into A Single Health Care Stock Consider This ETF,LLY,https://www.benzinga.com/188732/before-jumping-into-a-single-health-care-stock-consider-this-etf,David Bettencourt,,,,0,0,a15ff6aa-06f1-44d8-a782-ba3949affb05
2010-03-22T08:00:00.000+08:00,Investors Flock To Healthcare ETFs On Historic Reform,LLY,https://www.benzinga.com/185428/investors-flock-to-healthcare-etfs-on-historic-reform,David Bettencourt,,,,0,0,39225b1d-dda5-487c-8c4e-f44d048404c7
2010-03-22T08:00:00.000+08:00,Investors Flock To Healthcare ETFs On Historic Reform,LLY,https://www.benzinga.com/185428/investors-flock-to-healthcare-etfs-on-historic-reform,David Bettencourt,,,,0,0,3d834897-8b21-4836-8aa5-5024d1706667
2010-03-21T08:00:00.000+08:00,How Will Obama-Care Play Into The Markets And ETFs?,LLY,https://www.benzinga.com/183562/how-will-obama-care-play-into-the-markets-and-etfs,David Bettencourt,,,,0,0,993a103b-12c1-4771-9fe6-d4bc95d4bb45
2010-03-21T08:00:00.000+08:00,How Will Obama-Care Play Into The Markets And ETFs?,LLY,https://www.benzinga.com/183562/how-will-obama-care-play-into-the-markets-and-etfs,David Bettencourt,,,,0,0,64a1270e-0bb8-4d83-b209-d892a5faef8f
2010-03-17T08:00:00.000+08:00,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying,LLY,https://www.benzinga.com/178858/this-healthcare-etf-xlv-is-seeing-above-average-call-buying,David Bettencourt,,,,0,0,cc7db17a-c07e-477a-9ff1-96e41eb8dcf3
2010-03-17T08:00:00.000+08:00,This Healthcare ETF (XLV) Is Seeing Above Average Call Buying,LLY,https://www.benzinga.com/178858/this-healthcare-etf-xlv-is-seeing-above-average-call-buying,David Bettencourt,,,,0,0,92d40732-b485-4b17-9f6b-6889c11efd5d
2010-03-15T08:00:00.000+08:00,"Benzinga’s News Roundup (PEP, ALKS, MRK)",LLY,https://www.benzinga.com/markets/company-news/173095/benzinga%E2%80%99s-news-roundup-pep-alks-mrk,BenzingaStaff3,,,,0,0,687b608b-d54e-40be-89cc-c92f7fb7cc62
2010-03-15T08:00:00.000+08:00,"Benzinga’s Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)",LLY,https://www.benzinga.com/pre-market-outlook/173049/benzinga%E2%80%99s-top-pre-market-gainers-pvh-amln-chrd-isis-nvax,BenzingaStaff3,,,,0,0,062ccb32-116d-47dc-ad40-291be3fb2d08
2010-03-15T08:00:00.000+08:00,"Benzinga’s News Roundup (PEP, ALKS, MRK)",LLY,https://www.benzinga.com/markets/company-news/173095/benzinga%E2%80%99s-news-roundup-pep-alks-mrk,BenzingaStaff3,,,,0,0,8d3a4a82-69af-4bd3-8df5-29eb07f8e538
2010-03-15T08:00:00.000+08:00,"Benzinga’s Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)",LLY,https://www.benzinga.com/pre-market-outlook/173049/benzinga%E2%80%99s-top-pre-market-gainers-pvh-amln-chrd-isis-nvax,BenzingaStaff3,,,,0,0,b76e8398-a4f7-4c7e-8e92-72659a10db60
2010-03-08T08:00:00.000+08:00,AMLN Is Waiting For A Decision On Byetta,LLY,https://www.benzinga.com/media/cnbc/163501/amln-is-waiting-for-a-decision-on-byetta,Craig Jones,,,,0,0,3e3e4980-69e3-43f7-abc3-b2f7a1bab8d9
2010-03-08T08:00:00.000+08:00,AMLN Is Waiting For A Decision On Byetta,LLY,https://www.benzinga.com/media/cnbc/163501/amln-is-waiting-for-a-decision-on-byetta,Craig Jones,,,,0,0,88af9e2f-982b-4432-bb74-5277b759d88c
2010-03-03T08:00:00.000+08:00,Transition (TTHI) Secures Licensing Deal With Eli Lilly (LLY),LLY,https://www.benzinga.com/markets/company-news/154809/transition-tthi-secures-licensing-deal-with-eli-lilly-lly,Benzinga Staff 5,,,,0,0,086225a8-7381-4537-a008-538eab78e76e
2010-03-03T08:00:00.000+08:00,Transition (TTHI) Secures Licensing Deal With Eli Lilly (LLY),LLY,https://www.benzinga.com/markets/company-news/154809/transition-tthi-secures-licensing-deal-with-eli-lilly-lly,Benzinga Staff 5,,,,0,0,2b0c3ea7-5746-4472-9ac1-77bb23442c91
2010-02-25T08:00:00.000+08:00,Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY),LLY,https://www.benzinga.com/markets/company-news/144430/eli-lilly-banks-on-its-restructured-development-process-to-offset-sales-,Benzinga Staff 5,,,,0,0,e8f5702b-8c01-4a4e-842f-62f49ab2e080
2010-02-25T08:00:00.000+08:00,Eli Lilly Banks On Its Restructured Development Process To Offset Sales Loss (LLY),LLY,https://www.benzinga.com/markets/company-news/144430/eli-lilly-banks-on-its-restructured-development-process-to-offset-sales-,Benzinga Staff 5,,,,0,0,e3c38be7-16b9-4e81-acbd-a85a376126bb
2010-02-23T08:00:00.000+08:00,"Market Roundup (BAC, JPM, DELL, WAG, LLY)",LLY,https://www.benzinga.com/markets/company-news/138439/market-roundup-bac-jpm-dell-wag-lly,Monica Gerson,,,,0,0,9fe2c2dc-a3a2-44d1-9873-580fafb4a86b
2010-02-23T08:00:00.000+08:00,"Market Roundup (BAC, JPM, DELL, WAG, LLY)",LLY,https://www.benzinga.com/markets/company-news/138439/market-roundup-bac-jpm-dell-wag-lly,Monica Gerson,,,,0,0,be8891b7-1c62-435c-8dfa-cf8daf3b072b
2010-02-18T08:00:00.000+08:00,"Carl Icahn On CNBC (AMLN, GELG, LGM)",LLY,https://www.benzinga.com/media/cnbc/132752/carl-icahn-on-cnbc-amln-gelg-lgm,Bud Fox,,,,0,0,9f380006-1953-4bc5-b5ff-d2a2d200bc50
2010-02-18T08:00:00.000+08:00,"Carl Icahn On CNBC (AMLN, GELG, LGM)",LLY,https://www.benzinga.com/media/cnbc/132752/carl-icahn-on-cnbc-amln-gelg-lgm,Bud Fox,,,,0,0,96db6e93-5e24-4e2e-bd3c-967885be523d
2010-02-05T08:00:00.000+08:00,"Market Round-up (UBS, GOOG¸ AAPL, MOT¸ PG, PFE, MRK, LLY, CVS, WAG)",LLY,https://www.benzinga.com/markets/company-news/115676/market-round-up-ubs-goog%C2%B8-aapl-mot%C2%B8-pg-pfe-mrk-lly-cvs-wag,Monica Gerson,,,,0,0,0746efe1-bc92-4296-acda-d230f90257f5
2010-02-05T08:00:00.000+08:00,"Market Round-up (UBS, GOOG¸ AAPL, MOT¸ PG, PFE, MRK, LLY, CVS, WAG)",LLY,https://www.benzinga.com/markets/company-news/115676/market-round-up-ubs-goog%C2%B8-aapl-mot%C2%B8-pg-pfe-mrk-lly-cvs-wag,Monica Gerson,,,,0,0,807bf57f-344f-4b44-8551-28cbf0231d24
2010-02-03T08:00:00.000+08:00,Pharma Stocks Dive On Missed Expectations,LLY,https://www.benzinga.com/market-update/109642/pharma-stocks-dive-on-missed-expectations,Monica Gerson,,,,0,0,a1859ec0-5a26-4a22-ae2d-0f7da67c9d4d
2010-02-03T08:00:00.000+08:00,Pharma Stocks Dive On Missed Expectations,LLY,https://www.benzinga.com/market-update/109642/pharma-stocks-dive-on-missed-expectations,Monica Gerson,,,,0,0,4362a492-4f5c-4ab2-8bd8-0147829eca34
2010-02-01T08:00:00.000+08:00,"Five Stocks To Buy Since Analysts Hate Them (LLY, CAN, EEP, LXK, PCX)",LLY,https://www.benzinga.com/trading-ideas/10/02/106399/five-stocks-to-buy-since-analysts-hate-them-lly-can-eep-lxk-pcx,Benzinga Staff 5,,,,0,0,cc24ff38-f9b5-47d7-9050-71c2f9f1c28b
2010-02-01T08:00:00.000+08:00,"Five Stocks To Buy Since Analysts Hate Them (LLY, CAN, EEP, LXK, PCX)",LLY,https://www.benzinga.com/trading-ideas/10/02/106399/five-stocks-to-buy-since-analysts-hate-them-lly-can-eep-lxk-pcx,Benzinga Staff 5,,,,0,0,a0e14dd4-d89a-40ae-81dd-63975f9f83fb
2010-01-29T08:00:00.000+08:00,Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC,LLY,https://www.benzinga.com/media/cnbc/104192/eli-lilly-lly-has-a-healthy-pipeline-ceo-tells-cnbc,Benzinga Staff 5,,,,0,0,3e9fcc55-0f84-4d7f-ab0b-d12f3ab45ae9
2010-01-29T08:00:00.000+08:00,Eli Lilly (LLY) Has A Healthy Pipeline : CEO Tells CNBC,LLY,https://www.benzinga.com/media/cnbc/104192/eli-lilly-lly-has-a-healthy-pipeline-ceo-tells-cnbc,Benzinga Staff 5,,,,0,0,36df1dff-3974-4867-b5b4-36b14a29f124
2010-01-28T08:00:00.000+08:00,"Eli Lilly & Co. (LLY) Profits Are Up, But Concerns Remain",LLY,https://www.benzinga.com/markets/company-news/103414/eli-lilly-co-lly-profits-are-up-but-concerns-remain,Daniel Hayden IV,,,,0,0,607d7b0b-bd2f-4394-8a15-029c7f4ddbf7
2010-01-28T08:00:00.000+08:00,"Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute",LLY,https://www.benzinga.com/markets/company-news/103233/bristol-bmy-lilly-lly-up-sales-and-settle-dispute,Benzinga Staff 5,,,,0,0,8e89ce2c-b797-499e-a89f-c4685041f267
2010-01-28T08:00:00.000+08:00,"Benzinga’s Earnings Roundup (TYC, BDX, TWC, BLL, LLY)",LLY,https://www.benzinga.com/markets/company-news/102602/benzinga%E2%80%99s-earnings-roundup-tyc-bdx-twc-bll-lly,BenzingaStaff3,,,,0,0,88e01ef7-c218-42d5-9ae5-5b8f9f2678e9
2010-01-28T08:00:00.000+08:00,"Eli Lilly & Co. (LLY) Profits Are Up, But Concerns Remain",LLY,https://www.benzinga.com/markets/company-news/103414/eli-lilly-co-lly-profits-are-up-but-concerns-remain,Daniel Hayden IV,,,,0,0,d86dcaea-26ad-4222-9a00-3b1b7cda7918
2010-01-28T08:00:00.000+08:00,"Bristol (BMY), Lilly (LLY) Up Sales And Settle Dispute",LLY,https://www.benzinga.com/markets/company-news/103233/bristol-bmy-lilly-lly-up-sales-and-settle-dispute,Benzinga Staff 5,,,,0,0,5734a698-595f-4c51-9972-3838b5b09dfa
2010-01-28T08:00:00.000+08:00,"Benzinga’s Earnings Roundup (TYC, BDX, TWC, BLL, LLY)",LLY,https://www.benzinga.com/markets/company-news/102602/benzinga%E2%80%99s-earnings-roundup-tyc-bdx-twc-bll-lly,BenzingaStaff3,,,,0,0,317d9e8f-15ef-425f-989b-d34436ec4645
2010-01-26T08:00:00.000+08:00,"FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY)",LLY,https://www.benzinga.com/markets/company-news/99276/fda-approval-for-diabetes-drug-lifts-novo-shares-nvo-amln-lly,Benzinga Staff 5,,,,0,0,e9d5c622-1b12-4d65-8fb6-2561e2b097fb
2010-01-26T08:00:00.000+08:00,"FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY)",LLY,https://www.benzinga.com/markets/company-news/99276/fda-approval-for-diabetes-drug-lifts-novo-shares-nvo-amln-lly,Benzinga Staff 5,,,,0,0,e653321e-b28f-4822-997e-e23869d32061
2010-01-05T08:00:00.000+08:00,Eli Lilly (LLY) To Outsource Drug Testing,LLY,https://www.benzinga.com/markets/company-news/76431/eli-lilly-lly-to-outsource-drug-testing,Benzinga Staff 5,,,,0,0,ec7c27fe-fb10-44d9-83f3-ba54f9ff2801
2010-01-05T08:00:00.000+08:00,Eli Lilly (LLY) To Outsource Drug Testing,LLY,https://www.benzinga.com/markets/company-news/76431/eli-lilly-lly-to-outsource-drug-testing,Benzinga Staff 5,,,,0,0,c757fe1d-7b8c-4978-a589-223d037836c3
2009-12-22T08:00:00.000+08:00,Eli Lilly (LLY) Lacks Near Term Upside Drivers,LLY,https://www.benzinga.com/analyst-ratings/price-target/70305/eli-lilly-lly-lacks-near-term-upside-drivers,Benzinga Staff 5,,,,0,0,d9eb3250-ecdc-47cf-9498-44d99ac2791f
2009-12-22T08:00:00.000+08:00,Eli Lilly (LLY) Lacks Near Term Upside Drivers,LLY,https://www.benzinga.com/analyst-ratings/price-target/70305/eli-lilly-lly-lacks-near-term-upside-drivers,Benzinga Staff 5,,,,0,0,18de47f7-5f41-4a33-ae78-bf4d11eb2ef4
2009-12-21T08:00:00.000+08:00,Play Biotech M&A With This ETF (XBI),LLY,https://www.benzinga.com/trading-ideas/long-ideas/69621/play-biotech-m-a-with-this-etf-xbi,ETF Professor,,,,0,0,cc0b5634-cb7e-48fc-b7b9-62d663c28573
2009-12-21T08:00:00.000+08:00,"Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)",LLY,https://www.benzinga.com/markets/company-news/69068/top-gainers-in-nasdaq-chtt-bucy-incy-sblk-mail,Monica Gerson,,,,0,0,df8435d4-6178-4c0a-91f2-120788fe18ef
2009-12-21T08:00:00.000+08:00,Play Biotech M&A With This ETF (XBI),LLY,https://www.benzinga.com/trading-ideas/long-ideas/69621/play-biotech-m-a-with-this-etf-xbi,ETF Professor,,,,0,0,0cec0fb6-5a95-453f-8732-1c033ba97c13
2009-12-21T08:00:00.000+08:00,"Top Gainers in NASDAQ (CHTT, BUCY, INCY, SBLK, MAIL)",LLY,https://www.benzinga.com/markets/company-news/69068/top-gainers-in-nasdaq-chtt-bucy-incy-sblk-mail,Monica Gerson,,,,0,0,abfa9811-2a4d-4a44-9b66-d2e3b1feae58
2009-12-11T08:00:00.000+08:00,Eli Lilly’s EPS Guidance Exceeds Estimates (LLY),LLY,https://www.benzinga.com/markets/company-news/60269/eli-lilly%E2%80%99s-eps-guidance-exceeds-estimates-lly,Benzinga Staff 5,,,,0,0,4b10ae8a-b3cc-489a-afb8-3901c4a9f58d
2009-12-11T08:00:00.000+08:00,LLY Has Strong Product Pipeline,LLY,https://www.benzinga.com/analyst-research/analyst-color/60223/lly-has-strong-product-pipeline,Monica Gerson,,,,0,0,7a272491-9ac1-4f34-a10f-f5bc68088174
2009-12-11T08:00:00.000+08:00,LLY Issues Disappointing Long Term Guidance,LLY,https://www.benzinga.com/analyst-research/analyst-color/60133/lly-issues-disappointing-long-term-guidance,Monica Gerson,,,,0,0,dfdbdc30-14c5-496a-a3bb-86e77dc3393c
2009-12-11T08:00:00.000+08:00,Eli Lilly’s EPS Guidance Exceeds Estimates (LLY),LLY,https://www.benzinga.com/markets/company-news/60269/eli-lilly%E2%80%99s-eps-guidance-exceeds-estimates-lly,Benzinga Staff 5,,,,0,0,92a247b4-fd42-422c-95c1-2c5698066130
2009-12-11T08:00:00.000+08:00,LLY Has Strong Product Pipeline,LLY,https://www.benzinga.com/analyst-research/analyst-color/60223/lly-has-strong-product-pipeline,Monica Gerson,,,,0,0,adced9a0-91b6-4d0f-b483-efdae575b9fa
2009-12-11T08:00:00.000+08:00,LLY Issues Disappointing Long Term Guidance,LLY,https://www.benzinga.com/analyst-research/analyst-color/60133/lly-issues-disappointing-long-term-guidance,Monica Gerson,,,,0,0,e2bee8c1-3d4e-49ad-9e2e-a47bf21314be
2009-12-10T08:00:00.000+08:00,Eli Lilly (LLY) Is Facing Big Challenges,LLY,https://www.benzinga.com/media/cnbc/59647/eli-lilly-lly-is-facing-big-challenges,Craig Jones,,,,0,0,838f602c-9a6b-4106-a66d-efb86f714ef5
2009-12-10T08:00:00.000+08:00,LLY Issues Disappointing Long-term Guidance,LLY,https://www.benzinga.com/analyst-research/analyst-color/59241/lly-issues-disappointing-long-term-guidance,Monica Gerson,,,,0,0,eb5165f3-fb15-456c-a1d1-edb8b751ca24
2009-12-10T08:00:00.000+08:00,SEC On Trail Of Insider Trading Transactions,LLY,https://www.benzinga.com/markets/company-news/58782/sec-on-trail-of-insider-trading-transactions,Benzinga Staff 5,,,,0,0,f6e023d0-d52e-4d21-9286-d6281dd53a4c
2009-12-10T08:00:00.000+08:00,"Benzinga’s Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)",LLY,https://www.benzinga.com/pre-market-outlook/58628/benzinga%E2%80%99s-top-pre-market-losers-cien-lly-osip-prov-cytk-aol-siga,BenzingaStaff3,,,,0,0,eaf5f6aa-5ec3-4698-a4e3-4d02914a79c3
2009-12-10T08:00:00.000+08:00,"Benzinga’s Earnings Roundup (GIL, LLY, COST, UNFI, ROK)",LLY,https://www.benzinga.com/markets/company-news/earnings/58494/benzinga%E2%80%99s-earnings-roundup-gil-lly-cost-unfi-rok,BenzingaStaff3,,,,0,0,47d75e0c-ca81-40ce-b8ab-0865524c7e29
2009-12-10T08:00:00.000+08:00,"Lilly (LLY) Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines",LLY,https://www.benzinga.com/markets/company-news/58489/lilly-lly-outlines-innovation-strategy-reviews-promising-pipeline-of-pote,BenzingaStaff1,,,,0,0,dfd78a79-4f43-4a5b-88af-215c85156e11
2009-12-10T08:00:00.000+08:00,Eli Lilly (LLY) Is Facing Big Challenges,LLY,https://www.benzinga.com/media/cnbc/59647/eli-lilly-lly-is-facing-big-challenges,Craig Jones,,,,0,0,206de2b1-c3d4-46b7-ac7c-0b00b48addb6
2009-12-10T08:00:00.000+08:00,LLY Issues Disappointing Long-term Guidance,LLY,https://www.benzinga.com/analyst-research/analyst-color/59241/lly-issues-disappointing-long-term-guidance,Monica Gerson,,,,0,0,dce6205f-9878-4f0b-9552-826145528e83
2009-12-10T08:00:00.000+08:00,SEC On Trail Of Insider Trading Transactions,LLY,https://www.benzinga.com/markets/company-news/58782/sec-on-trail-of-insider-trading-transactions,Benzinga Staff 5,,,,0,0,12cdc6af-bd5b-48e0-bc36-be59468e7049
2009-12-10T08:00:00.000+08:00,"Benzinga’s Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)",LLY,https://www.benzinga.com/pre-market-outlook/58628/benzinga%E2%80%99s-top-pre-market-losers-cien-lly-osip-prov-cytk-aol-siga,BenzingaStaff3,,,,0,0,26ae8d71-98f9-40a9-899c-1c07d056b42c
2009-12-10T08:00:00.000+08:00,"Benzinga’s Earnings Roundup (GIL, LLY, COST, UNFI, ROK)",LLY,https://www.benzinga.com/markets/company-news/earnings/58494/benzinga%E2%80%99s-earnings-roundup-gil-lly-cost-unfi-rok,BenzingaStaff3,,,,0,0,312cf023-8d04-4a22-b95b-c110805ddb00
2009-12-10T08:00:00.000+08:00,"Lilly (LLY) Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines",LLY,https://www.benzinga.com/markets/company-news/58489/lilly-lly-outlines-innovation-strategy-reviews-promising-pipeline-of-pote,BenzingaStaff1,,,,0,0,a4de084c-9fe1-48ea-84d7-3cfcd0c287a2
2009-12-08T08:00:00.000+08:00,"10 Stocks To Shine In 2010 (C, NYT, LVLT, KBH, LLY)",LLY,https://www.benzinga.com/analyst-research/upgrades/55664/10-stocks-to-shine-in-2010-c-nyt-lvlt-kbh-lly-bsx-moh-dow,Benzinga Staff 5,,,,0,0,e46d499d-7cd8-47fd-916a-313cf5c7a708
2009-12-08T08:00:00.000+08:00,"10 Stocks To Shine In 2010 (C, NYT, LVLT, KBH, LLY)",LLY,https://www.benzinga.com/analyst-research/upgrades/55664/10-stocks-to-shine-in-2010-c-nyt-lvlt-kbh-lly-bsx-moh-dow,Benzinga Staff 5,,,,0,0,43c2270f-dbc1-438d-8cd7-93e0f6c7e36b
2009-12-01T08:00:00.000+08:00,"Company News for December 01, 2009 - Corporate Summary",LLY,https://www.benzinga.com/48404/company-news-for-december-01-2009-corporate-summary,Zacks,,,,0,0,63ac9900-93c0-4bae-b3de-399a9c7d962e
2009-12-01T08:00:00.000+08:00,"Company News for December 01, 2009 - Corporate Summary",LLY,https://www.benzinga.com/48404/company-news-for-december-01-2009-corporate-summary,Zacks,,,,0,0,dbf12af8-79a1-4dee-8732-aaf4c7283045
2009-11-13T08:00:00.000+08:00,Eli Lilly Calls Active (NYSE: LLY),LLY,https://www.benzinga.com/markets/options/41138/eli-lilly-calls-active-nyse-lly,Michael J. Zerinskas,,,,0,0,aad8df97-aca3-4f25-9c71-f2406d6b1ece
2009-11-13T08:00:00.000+08:00,Eli Lilly Calls Active (NYSE: LLY),LLY,https://www.benzinga.com/markets/options/41138/eli-lilly-calls-active-nyse-lly,Michael J. Zerinskas,,,,0,0,954f921a-f0e2-45c5-8f79-e5e10b3dff1e
2009-11-02T08:00:00.000+08:00,"Stocks Running Early (HGSI, VRTX, DNDN, JWN)",LLY,https://www.benzinga.com/pre-market-outlook/33826/stocks-running-early-hgsi-vrtx-dndn-jwn,Benzinga Staff,,,,0,0,e30e3a12-445a-49af-bdea-62533b1a7bea
2009-11-02T08:00:00.000+08:00,"Stocks Running Early (HGSI, VRTX, DNDN, JWN)",LLY,https://www.benzinga.com/pre-market-outlook/33826/stocks-running-early-hgsi-vrtx-dndn-jwn,Benzinga Staff,,,,0,0,4a00d996-6a72-4c8a-9eaa-4db15eecc915
2009-10-21T08:00:00.000+08:00,Eli Lilly Posts Higher Returns than Expected Behind Increased Sales Volumes (NYSE: LLY),LLY,https://www.benzinga.com/general/27608/eli-lilly-posts-higher-returns-than-expected-behind-increased-sales-volumes-nyse-lly,Benzinga Staff15,,,,0,0,dd83eba7-9ca3-4652-b69b-6def9e8580b5
2009-10-21T08:00:00.000+08:00,"Today’s Earnings Preview (BA, MS, WFC, EBAY, LLY, MO)",LLY,https://www.benzinga.com/markets/company-news/earnings/27322/today%E2%80%99s-earnings-preview-ba-ms-wfc-ebay-lly-mo,Benzinga Staff15,,,,0,0,7894eefa-e080-45b5-be07-43684db2e4a3
2009-10-21T08:00:00.000+08:00,Eli Lilly Posts Higher Returns than Expected Behind Increased Sales Volumes (NYSE: LLY),LLY,https://www.benzinga.com/general/27608/eli-lilly-posts-higher-returns-than-expected-behind-increased-sales-volumes-nyse-lly,Benzinga Staff15,,,,0,0,0bebe78f-8a25-4c92-96c1-8f116355c479
2009-10-21T08:00:00.000+08:00,"Today’s Earnings Preview (BA, MS, WFC, EBAY, LLY, MO)",LLY,https://www.benzinga.com/markets/company-news/earnings/27322/today%E2%80%99s-earnings-preview-ba-ms-wfc-ebay-lly-mo,Benzinga Staff15,,,,0,0,5b6e0b88-b62a-487e-865c-2bbf51f1ebb7
2009-10-19T08:00:00.000+08:00,The Week’s Must-Haves and Have-nots According to Jim Cramer,LLY,https://www.benzinga.com/markets/analyst-research/26058/the-week%E2%80%99s-must-haves-and-have-nots,Benzinga Staff 5,,,,0,0,a977b18f-decd-4555-afbb-f14a1449b623
2009-10-19T08:00:00.000+08:00,The Week’s Must-Haves and Have-nots According to Jim Cramer,LLY,https://www.benzinga.com/markets/analyst-research/26058/the-week%E2%80%99s-must-haves-and-have-nots,Benzinga Staff 5,,,,0,0,901077e0-5c7f-4977-b9f4-46c94713f032
2009-09-29T08:00:00.000+08:00,Eli Lilly (LLY) trading in a congestion zone,LLY,https://www.benzinga.com/18416/health-care/eli-lilly-lly-trading-in-a-congestion-zone,Craig Jones,,,,0,0,a5f12df9-87de-476a-9acb-20f99bdd0930
2009-09-29T08:00:00.000+08:00,Eli Lilly (LLY) trading in a congestion zone,LLY,https://www.benzinga.com/18416/health-care/eli-lilly-lly-trading-in-a-congestion-zone,Craig Jones,,,,0,0,e33cc51a-37bd-4206-91d9-96941f4309a6
2009-09-24T08:00:00.000+08:00,Eli Lilly and Company (LLY) Wins Evista Patent Till 2014,LLY,https://www.benzinga.com/16597/health-care/eli-lilly-and-company-lly-wins-evista-patent-till-2014,BenzingaStaff1,,,,0,0,c2f6fda8-8b23-4ca1-a3ec-da9ffdf766b2
2009-09-24T08:00:00.000+08:00,Eli Lilly and Company (LLY) Wins Evista Patent Till 2014,LLY,https://www.benzinga.com/16597/health-care/eli-lilly-and-company-lly-wins-evista-patent-till-2014,BenzingaStaff1,,,,0,0,576318bb-78af-405d-a127-f26120f16911
2009-09-09T08:00:00.000+08:00,Zignals Stock Charts: 7 Divided Elites from TheStockAdvisors,LLY,https://www.benzinga.com/134753/zignals-stock-charts-7-divided-elites-from-thestockadvisors,Zignals,,,,0,0,1668d9ee-f6a0-430d-b224-12b43f5d873f
2009-09-09T08:00:00.000+08:00,Zignals Stock Charts: 7 Divided Elites from TheStockAdvisors,LLY,https://www.benzinga.com/134753/zignals-stock-charts-7-divided-elites-from-thestockadvisors,Zignals,,,,0,0,ab49d759-2f05-43da-8edc-2b39225c0b29
2009-08-31T08:00:00.000+08:00,"Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink",LLY,https://www.benzinga.com/benzingastaff1/2009/8/31/negative-implications-eli-lillys-lly-efficient-says-leerink,BenzingaStaff1,,,,0,0,58a821c0-8411-48aa-b805-70bca742c2fc
2009-08-31T08:00:00.000+08:00,"Negative Implications for Eli Lilly's (LLY) Efficient, Says Leerink",LLY,https://www.benzinga.com/benzingastaff1/2009/8/31/negative-implications-eli-lillys-lly-efficient-says-leerink,BenzingaStaff1,,,,0,0,0257f9af-9fab-4885-a161-a776c0f3899d
